<SEC-DOCUMENT>0001104659-21-080206.txt : 20210611
<SEC-HEADER>0001104659-21-080206.hdr.sgml : 20210611
<ACCEPTANCE-DATETIME>20210611164641
ACCESSION NUMBER:		0001104659-21-080206
CONFORMED SUBMISSION TYPE:	S-1
PUBLIC DOCUMENT COUNT:		69
FILED AS OF DATE:		20210611
DATE AS OF CHANGE:		20210611

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SERA PROGNOSTICS, INC.
		CENTRAL INDEX KEY:			0001534969
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				261911522
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-257038
		FILM NUMBER:		211011921

	BUSINESS ADDRESS:	
		STREET 1:		2749 E. PARLEYS WAY
		STREET 2:		SUITE 200
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84109
		BUSINESS PHONE:		(801) 990-0520

	MAIL ADDRESS:	
		STREET 1:		2749 E. PARLEYS WAY
		STREET 2:		SUITE 200
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84109
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>tm2110724-10_s1.htm
<DESCRIPTION>S-1
<TEXT>
<html>
  <head>
    <title>tm2110724-10_s1 - none - 28.5314571s</title>
  </head>
  <body style="margin-left:auto;margin-right:auto;width:595.31pt;">
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:27pt;width:541.31pt;">
        <div style="text-align:center; width:541.31pt; line-height:11.5pt;font-weight:bold;font-size:9.5pt;">
          <font style="letter-spacing:-0.19pt;">As filed with the Securities and Exchange Commission on June 11, 2021.</font><font style="font-weight:normal;letter-spacing:0.19pt;"> </font>
        </div>
        <div style="margin-top:2pt; text-align:right; width:541.31pt; line-height:10pt;font-weight:bold;">
          <font style="letter-spacing:-0.16pt;">Registration No. 333-&#8199;&#8199;&#8199;&#8199;&#8199;</font>&#8203;</div>
        <div style="margin-top:2.5pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 2.5pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 3pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:4pt; text-align:center; width:541.31pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">UNITED STATES </font>
          <br >
          <font style="letter-spacing:-0.28pt;">SECURITIES AND EXCHANGE COMMISSION</font>
          <br >
          <font style="font-size:8pt;letter-spacing:-0.16pt;">Washington, D.C. 20549</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:6.5pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 43.35%; margin-right: 43.35%; margin-top: 6.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:6pt; text-align:center; width:541.31pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">FORM S-1 </font>
        </div>
        <div style="margin-top:2pt; text-align:center; width:541.31pt; line-height:12pt;font-style:italic;font-weight:bold;font-size:10pt;">
          <font style="font-style:normal;letter-spacing:-0.2pt;">REGISTRATION STATEMENT </font>
          <br >
          <font style="letter-spacing:-0.2pt;">UNDER </font>
          <br >
          <font style="letter-spacing:-0.2pt;">THE SECURITIES ACT OF 1933</font><font style="font-style:normal;font-weight:normal;font-size:14pt;">&#8203;<font style="letter-spacing:0.28pt;"> </font></font>
        </div>
        <div style="margin-top:3pt; text-align:center; width:541.31pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">SERA PROGNOSTICS, INC.</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:1pt; text-align:center; width:541.31pt; line-height:10pt;">
          <font style="letter-spacing:0.16pt;">(Exact name of Registrant as specified in its charter) </font>
        </div>
        <table style="width:541.31pt;height:24.5pt;margin-top:4pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:172.44pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Delaware</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:172.44pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">8071</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:172.43pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">26-1911522 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0.667pt 0pt 0.5pt 0pt; width:172.44pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">(State or other jurisdiction of </font>
                <br >
                <font style="letter-spacing:0.16pt;">incorporation or organization) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0.667pt 0pt 0.5pt 0pt; width:172.44pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">(Primary Standard Industrial </font>
                <br >
                <font style="letter-spacing:0.16pt;">Classification Code Number) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0.667pt 0pt 0.5pt 0pt; width:172.43pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">(I.R.S. Employer </font>
                <br >
                <font style="letter-spacing:0.16pt;">Identification Number)</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:4pt; text-align:center; width:541.31pt; line-height:8.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.16pt;">2749 East Parleys Way</font>
          <br >
          <font style="letter-spacing:-0.16pt;">Suite 200</font>
          <br >
          <font style="letter-spacing:-0.16pt;">Salt Lake City, UT 84109 </font>
          <br >
          <font style="letter-spacing:-0.16pt;">(801) 990-0520 </font>
          <br >
          <font style="font-weight:normal;letter-spacing:0.16pt;">(Address, including zip code, and telephone number, including area code, of Registrant&#8217;s principal executive offices) </font>
        </div>
        <div style="margin-top:4.5pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 43.35%; margin-right: 43.35%; margin-top: 4.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:5pt; text-align:center; width:541.31pt; line-height:8.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.16pt;">Gregory C. Critchfield, M.D., M.S. </font>
          <br >
          <font style="letter-spacing:-0.16pt;">President and Chief Executive Officer </font>
          <br >
          <font style="letter-spacing:-0.16pt;">Sera Prognostics, Inc. </font>
          <br >
          <font style="letter-spacing:-0.16pt;">2749 East Parleys Way</font>
          <br >
          <font style="letter-spacing:-0.16pt;">Suite 200</font>
          <br >
          <font style="letter-spacing:-0.16pt;">Salt Lake City, UT 84109 </font>
          <br >
          <font style="letter-spacing:-0.16pt;">(801) 990-0520 </font>
          <br >
          <font style="font-weight:normal;letter-spacing:0.16pt;">(Name, address, including zip code, and telephone number, including area code, of agent for service) </font>
        </div>
        <div style="margin-top:4.5pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 43.35%; margin-right: 43.35%; margin-top: 4.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:4pt; text-align:center; width:541.31pt; line-height:10pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.16pt;">Copies to:</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.16pt;"> </font>
        </div>
        <table style="width:541.31pt;margin-top:-1pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:264.66pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Jonathan L. Kravetz</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Megan N. Gates</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Daniel H. Follansbee</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C. </font>
                <br >
                <font style="letter-spacing:-0.16pt;">One Financial Center</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Boston, MA 02111</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(617) 542-6000 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:264.65pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Edwin M. O&#8217;Connor</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Seo Salimi </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Goodwin Procter LLP</font>
                <br >
                <font style="letter-spacing:-0.16pt;">620 Eighth Avenue </font>
                <br >
                <font style="letter-spacing:-0.16pt;">New York, New York 10018 </font>
                <br >
                <font style="letter-spacing:-0.16pt;">(212) 813-8800</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:1pt; text-align:center; width:541.31pt; line-height:10pt;">
          <font style="letter-spacing:0.16pt;">Approximate date of commencement of proposed sale to the public: As soon as practicable after this Registration Statement is declared effective. </font>
        </div>
        <div style="text-indent:20pt; margin-top:1pt; width:541.31pt; line-height:8pt;">
          <font style="letter-spacing:0.16pt;">If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule&#160;415 under the Securities Act of 1933, check the following box. &#9744; </font>
        </div>
        <div style="text-indent:20pt; margin-top:1pt; width:541.31pt; line-height:8pt;">
          <font style="letter-spacing:0.16pt;">If this form is filed to register additional securities for an offering pursuant to Rule&#160;462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744; </font>
        </div>
        <div style="text-indent:20pt; margin-top:1pt; width:541.31pt; line-height:8pt;">
          <font style="letter-spacing:0.16pt;">If this form is a post-effective amendment filed pursuant to Rule&#160;462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744; </font>
        </div>
        <div style="text-indent:20pt; margin-top:1pt; width:541.31pt; line-height:8pt;">
          <font style="letter-spacing:0.16pt;">If this form is a post-effective amendment filed pursuant to Rule&#160;462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744; </font>
        </div>
        <div style="text-indent:20pt; margin-top:1pt; width:541.31pt; line-height:8pt;">
          <font style="letter-spacing:0.16pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act. </font>
        </div>
        <table style="width:541.31pt;height:26pt;margin-top:2pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
          <tr style="line-height:7.5pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:397.31pt;">
              <div style=" float:left; line-height:7.5pt; text-align:left; width:84pt;white-space:nowrap;">
                <font style="letter-spacing:0.15pt;">Large accelerated filer</font>
                <br >
              </div>
              <div style=" line-height:7.5pt; text-align:left; margin-left:84pt;">
                <font style="letter-spacing:0.15pt;">&#9744; </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:132pt;">
              <div style=" float:left; line-height:7.5pt; text-align:left; width:108pt;white-space:nowrap;">
                <font style="letter-spacing:0.15pt;">Accelerated filer</font>
                <br >
              </div>
              <div style=" line-height:7.5pt; text-align:left; margin-left:108pt;">
                <font style="letter-spacing:0.15pt;">&#9744; </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.5pt;white-space:normal;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; width:397.31pt;">
              <div style=" float:left; line-height:7.5pt; text-align:left; width:84pt;white-space:nowrap;">
                <font style="letter-spacing:0.15pt;">Non-accelerated filer</font>
                <br >
              </div>
              <div style=" line-height:7.5pt; text-align:left; margin-left:84pt;">
                <font style="letter-spacing:0.15pt;">&#9746; </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; width:132pt;">
              <div style=" float:left; line-height:7.5pt; text-align:left; width:108pt;white-space:nowrap;">
                <font style="letter-spacing:0.15pt;">Smaller reporting company</font>
                <br >
              </div>
              <div style=" line-height:7.5pt; text-align:left; margin-left:108pt;">
                <font style="letter-spacing:0.15pt;">&#9746; </font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.5pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:397.31pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; width:132pt;white-space:normal;">
              <div style=" float:left; line-height:7.5pt; text-align:left; width:108pt;white-space:nowrap;">
                <font style="letter-spacing:0.15pt;">Emerging growth company</font>
                <br >
              </div>
              <div style=" line-height:7.5pt; text-align:left; margin-left:108pt;">
                <font style="letter-spacing:0.15pt;">&#9746;</font>
              </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; width:541.31pt; line-height:8pt;">
          <font style="letter-spacing:0.16pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act. &#9744; </font>
        </div>
        <div style="margin-top:4.5pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 43.35%; margin-right: 43.35%; margin-top: 4.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:4pt; text-align:center; width:541.31pt; line-height:10pt;font-weight:bold;">
          <font style="letter-spacing:-0.16pt;">CALCULATION OF REGISTRATION FEE</font><font style="font-weight:normal;letter-spacing:0.16pt;"> </font>
        </div>
        <table style="width:541.31pt;height:38.5pt;margin-top:-10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7pt;">
          <tr style="line-height:7pt;white-space:nowrap;text-align:left;vertical-align:bottom;">
            <td style="border-bottom:3pt double #000000;padding:0pt 0pt 1pt 0pt; width:0pt;" colspan="12">&#8203;</td>
            <td style="padding:0pt;border-bottom:3pt double #000000; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7pt;">
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 1pt 0pt; width:404.76pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.14pt;">Title of Securities being Registered </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 1pt 0pt; width:59.64pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.14pt;">Proposed Maximum </font>
                <br >
                <font style="letter-spacing:-0.14pt;">Aggregate</font>
                <br >
                <font style="letter-spacing:-0.14pt;">Offering Price</font><font style=" position:relative; bottom:1.5pt;font-size:5.5pt;letter-spacing:-0.11pt;">(</font><font style=" position:relative; bottom:1.5pt;font-size:5.5pt;letter-spacing:-0.11pt;">1</font><font style=" position:relative; bottom:1.5pt;font-size:5.5pt;letter-spacing:-0.11pt;">)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 1pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.14pt;">Amount of </font>
                <br >
                <font style="letter-spacing:-0.14pt;">Registration Fee</font><font style=" position:relative; bottom:1.5pt;font-size:5.5pt;letter-spacing:-0.11pt;">(</font><font style=" position:relative; bottom:1.5pt;font-size:5.5pt;letter-spacing:-0.11pt;">2</font><font style=" position:relative; bottom:1.5pt;font-size:5.5pt;letter-spacing:-0.11pt;">)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:1.25pt 0pt 1pt 0pt; width:404.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.16pt;">Class A Common Stock, $0.0001 par value per share </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.25pt 0pt 1pt 0pt; width:59.64pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">$75,000,000</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.66pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:1.25pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:1.25pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">8,182.50</td>
            <td style="padding:0pt;padding-left:10.66pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:9.5pt; margin-top:1.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:7.5pt;">
          <font style="letter-spacing:0.15pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:1.6pt; margin-bottom:0pt; line-height:9.5pt; text-align:left; margin-left:20pt;font-size:7.5pt;">
          <font style="letter-spacing:0.15pt;">Estimated solely for purposes of computing the amount of the registration fee pursuant to Rule&#160;457(o) under the Securities Act of 1933, as amended. Includes initial public offering price of shares that the underwriters have the option to purchase. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:9.5pt; margin-top:-2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:7.5pt;">
          <font style="letter-spacing:0.15pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:-2pt; margin-bottom:0pt; line-height:9.5pt; text-align:left; margin-left:20pt;font-size:7.5pt;">
          <font style="letter-spacing:0.15pt;">Calculated pursuant to Rule 457(o) under the Securities Act of 1933, as amended, based on an estimate of the proposed maximum aggregate offering price.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:4.333pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 43.35%; margin-right: 43.35%; margin-top: 4.33333333333337pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="text-indent:20pt; margin-top:2pt; width:541.31pt; line-height:7.5pt;font-weight:bold;font-size:7.5pt;">
          <font style="letter-spacing:-0.15pt;">The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section&#160;8(a), may determine.</font><font style="font-weight:normal;letter-spacing:0.15pt;"> </font>
        </div>
        <div style="margin-top:5.333pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 5.33333333333337pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 3pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
      </div>
      <hr >
    </div>
    <div style="position:relative;overflow-x:hidden;min-height:775.71pt;page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="position:absolute;top:738.82pt;left:48.66pt;height:30.03pt;width:706pt;transform-origin:0pt -0pt;transform:rotate(-90deg) translate(0%, 0%);">
        <div style="width:706pt; line-height:10.5pt;color:#E45D50;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
          <font style="letter-spacing:-0.09pt;">The information in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</font><font style="color:#000000;letter-spacing:-0.09pt;"> </font>
          <br >
        </div>
      </div>
      <div style="margin-top:27.85pt;min-height:706pt;margin-left:87.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;color:#E45D50;">
          <font style="letter-spacing:-0.2pt;">SUBJECT TO COMPLETION, DATED JUNE 11, 2021</font><font style="color:#000000;letter-spacing:-0.2pt;"> </font>
        </div>
        <div style="margin-top:6pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">PRELIMINARY PROSPECTUS </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:14pt;font-weight:bold;font-size:12pt;">
          <font style="letter-spacing:-0.24pt;">SHARES</font><font style="font-weight:normal;letter-spacing:0.24pt;"> </font>
        </div>
        <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img src="lg_seraprognostics-4clr.jpg" alt="[MISSING IMAGE: lg_seraprognostics-4clr.jpg]" height="45" width="230" >
        </div>
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14pt;font-weight:bold;font-size:12pt;">
          <font style="letter-spacing:-0.24pt;">CLASS A COMMON STOCK</font><font style="font-weight:normal;letter-spacing:0.24pt;"> </font>
        </div>
        <div style="margin-top:18.833pt; text-align:center; width:456pt;">
          <div style="margin-left: 42.106%; margin-right: 42.106%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">This is an initial public offering of shares of Class A common stock of Sera Prognostics, Inc. We are selling&#160;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares of our Class A common stock. We currently expect that the initial public offering price will be between $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;and $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share of Class A common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">We have granted the underwriters an option for a period of 30&#160;days to purchase up to an additional&#160;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares of Class A common stock to cover over-allotments, if any. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">We have applied to list our Class A common stock on The Nasdaq Global Market under the symbol &#8220;SERA.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Following this offering, we will have two classes of common stock: Class A common stock and Class B common stock. The rights of the holders of Class A common stock and Class B common stock are identical, except with respect to voting and conversion. Each share of Class A common stock will be entitled to one vote and shares of Class B common stock will be non-voting, except as may be required by law. Each share of Class B common stock may be converted at any time into one share of Class A common stock at the option of its holder, subject to the ownership limitations provided for in our amended and restated certificate of incorporation which will be in effect upon the completion of this offering.</font>
        </div>
        <div style="margin-top:17.5pt; text-align:center; width:456pt;">
          <div style="margin-left: 42.106%; margin-right: 42.106%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="text-indent:20pt; margin-top:11pt; width:456pt; line-height:11pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Investing in our Class A common stock involves a high degree of risk. See &#8220;</font><font style=" text-decoration:underline #000000 solid;letter-spacing:-0.2pt;">Risk Factors</font><font style="letter-spacing:-0.2pt;">&#8221; beginning on page <a href="#tRIFA">14</a>.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">We are an &#8220;emerging growth company&#8221; as defined under the federal securities laws and, as such, we have elected to comply with certain reduced reporting requirements for this prospectus and may elect to do so in future filings. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </font>
        </div>
        <div style="margin-top:17.5pt; text-align:center; width:456pt;">
          <div style="margin-left: 42.106%; margin-right: 42.106%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <table style="width:456pt;height:53.5000000000001pt;margin-top:8.5pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:322pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Per Share </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:322pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Initial public offering price </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:322pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Underwriting discounts and commissions</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(1)</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:322pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Proceeds, before expenses, to Sera Prognostics, Inc. </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">See the section titled &#8220;Underwriting&#8221; for additional information regarding compensation payable to the underwriters. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:18.5pt; text-align:center; width:456pt;">
          <div style="margin-left: 42.106%; margin-right: 42.106%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-left:20pt; margin-top:11pt; width:436pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">The underwriters expect to deliver the shares against payment on or about &#8199;&#8199;&#8199;&#8199;&#8199;, 2021. </font>
        </div>
        <div style="margin-top:17.5pt; text-align:center; width:456pt;">
          <div style="margin-left: 42.106%; margin-right: 42.106%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <table style="width:456pt;margin-top:12.5pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:16pt;">
          <tr style="line-height:16pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:16pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:144pt;">Citigroup </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:144pt;text-align:center;">
              <div style="text-align:center;">Cowen </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0.5pt 1pt 0pt; width:144pt;text-align:right;">
              <div style="text-align:right;">William Blair</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:18.5pt; text-align:center; width:456pt;">
          <div style="margin-left: 42.106%; margin-right: 42.106%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:15pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Prospectus dated &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2021.</font>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">TABLE OF CONTENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:330.5pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:427.33pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.305pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Page </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPSF"><font style="letter-spacing:0.2pt;">Prospectus Summary </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPSF">2</a></font> <a href="#tPSF"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tRIFA"><font style="letter-spacing:0.2pt;">Risk Factors </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tRIFA">14</a></font> <a href="#tRIFA"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSNRF"><font style="letter-spacing:0.2pt;">Special Note Regarding Forward-Looking Statements </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSNRF">54</a></font> <a href="#tSNRF"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tMAID"><font style="letter-spacing:0.2pt;">Market and Industry Data </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tMAID">56</a></font> <a href="#tMAID"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUOP"><font style="letter-spacing:0.2pt;">Use of Proceeds </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tUOP">57</a></font> <a href="#tUOP"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDIPO"><font style="letter-spacing:0.2pt;">Dividend Policy </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDIPO">58</a></font> <a href="#tDIPO"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCAP"><font style="letter-spacing:0.2pt;">Capitalization </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCAP">59</a></font> <a href="#tCAP"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDIL"><font style="letter-spacing:0.2pt;">Dilution </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDIL">61</a></font> <a href="#tDIL"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tMDAA"><font style="letter-spacing:0.2pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tMDAA">64</a></font> <a href="#tMDAA"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tBUS"><font style="letter-spacing:0.2pt;">Business </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tBUS">77</a></font> <a href="#tBUS"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tMAN"><font style="letter-spacing:0.2pt;">Management </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tMAN">118</a></font> <a href="#tMAN"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEXCO"><font style="letter-spacing:0.2pt;">Executive Compensation </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tEXCO">128</a></font> <a href="#tEXCO"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDICO"><font style="letter-spacing:0.2pt;">Director Compensation </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDICO">137</a></font> <a href="#tDICO"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCRAR"><font style="letter-spacing:0.2pt;">Certain Relationships and Related Party Transactions </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCRAR">138</a></font> <a href="#tCRAR"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPRST"><font style="letter-spacing:0.2pt;">Principal Stockholders </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPRST">142</a></font> <a href="#tPRST"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOCS"><font style="letter-spacing:0.2pt;">Description of Capital Stock </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOCS">147</a></font> <a href="#tDOCS"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSEFF"><font style="letter-spacing:0.2pt;">Shares Eligible for Future Sale </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSEFF">153</a></font> <a href="#tSEFF"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tMUFI"><font style="letter-spacing:0.2pt;">Material U.S. Federal Income and Estate Tax Consequences to Non-U.S. Holders </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tMUFI">156</a></font> <a href="#tMUFI"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUND"><font style="letter-spacing:0.2pt;">Underwriting </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tUND">160</a></font> <a href="#tUND"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tLEMA"><font style="letter-spacing:0.2pt;">Legal Matters </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tLEMA">168</a></font> <a href="#tLEMA"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEXP"><font style="letter-spacing:0.2pt;">Experts </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tEXP">168</a></font> <a href="#tEXP"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tWYCF"><font style="letter-spacing:0.2pt;">Where You Can Find More Information </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tWYCF">168</a></font> <a href="#tWYCF"></a></td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tITFS"><font style="letter-spacing:0.2pt;">Index to Financial Statements </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tITFS">F-1</a></font>
            </td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We have not, and the underwriters have not, authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses we have prepared. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of shares of our Class A common stock. Our business, financial condition, results of operations and prospects may have changed since that date.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For investors outside of the United States: We have not, and the underwriters have not, done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of Class A common stock and the distribution of this prospectus outside of the United States. </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8220;Sera,&#8221; &#8220;PreTRM,&#8221; &#8220;The Pregnancy Company&#8221; and our logo are our trademarks. All other service marks, trademarks and trade names appearing in this prospectus are the property of their respective owners. We do not intend our use or display of other companies&#8217; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, these other companies. Solely for convenience, trademarks and tradenames referred to in this prospectus may appear without the </font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> or &#8482; symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights, or that the applicable owner will not assert its rights, to these trademarks and tradenames. Unless the context otherwise requires, we use the terms &#8220;Sera,&#8221; &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; in this prospectus to refer to Sera Prognostics, Inc.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">i</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPSF">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">PROSPECTUS SUMMARY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">This summary highlights selected information contained elsewhere in this prospectus and does not contain all of the information that you should consider in making an investment decision. Before investing in our Class A common stock, you should carefully read this entire prospectus, including our financial statements and the related notes thereto and the information set forth under the &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; sections of this prospectus.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Overview</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We are a women&#8217;s health diagnostic company utilizing our proprietary proteomics and bioinformatics platform to discover, develop and commercialize clinically meaningful and economically impactful biomarker tests, with an initial focus on improving pregnancy outcomes. We believe that our method of combining the disciplines of proteomics and bioinformatics with rigorous clinical testing and economic analysis enables us to provide physicians and patients with actionable data and information designed to result in better maternal and neonatal health at lower cost. Our vision is to deliver pivotal and actionable information to pregnant women, their physicians and healthcare payers to significantly improve maternal and neonatal health and to dramatically reduce healthcare costs. We have built an advanced, proprietary and scalable proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are highly accurate predictors of dynamic changes that occur during pregnancy. By incorporating our proprietary technology platform into our rigorous data-driven development process, we have created a differentiated approach for effectively addressing major conditions of pregnancy. We envision that our comprehensive approach will enable us to fully characterize one of the most important periods in the lives of women and children, and will help to improve their well-being. Our goal is to develop and commercialize tests that inform important decisions during all pregnancies. We also believe that the work we perform in pregnancy can ultimately be leveraged more broadly to address other areas in medicine and healthcare. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our first commercial product, the PreTRM test, is the only broadly validated, commercially available blood-based biomarker test to accurately predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 19 or 20 of gestation that provides an accurate prediction of the expectant mother&#8217;s risk of delivering spontaneously before 37 weeks&#8217; gestation. Our commercialization strategy includes conducting clinical trials to demonstrate the health and economic benefits of early and accurate detection of preterm birth risk coupled with well-recognized interventions in higher risk patients. Anthem, Inc., or Anthem, whose health plans cover more than 10% of U.S. pregnancies annually, will make our PreTRM test available to eligible pregnant members as part of this multi-year contract. Anthem is the nation&#8217;s second largest health insurer with greater than 43 million members nationwide. Through this collaboration, a significant number of physicians and patients in the U.S. gain access to early and accurate predictions of preterm birth to enable more informed decision-making during pregnancy. Sera believes that its commercial collaboration with Anthem further validates the clinical and economic value of its PreTRM test and significantly de-risks initial commercialization. Sera further expects this provides a pathway for broader market adoption through subsequent coverage decisions by other major payers. We are actively discovering and developing several additional biomarker tests to predict other major conditions of pregnancy, such as preeclampsia and gestational diabetes, among others, that have the potential to offer significant health benefits to women and their babies. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">There are approximately 140&#160;million births globally each year. Of these, it is estimated that as many as 25% are affected by various complications, including: preterm birth, preeclampsia, fetal growth restriction, stillbirth, hypertension of pregnancy, gestational diabetes and others. In the United States, there are approximately 3.8&#160;million births annually, and over 10% of those pregnancies result in preterm births with profound short- and long-term health consequences to the mother and baby. These health consequences are estimated to lead to associated costs of approximately $25&#160;billion annually in the United States. Traditional methods to detect prematurity risk in time for proactive management have been limited and fail to identify the vast majority of women who will deliver prematurely. We believe our actionable blood-based biomarker test for prematurity risk can enable patients, physicians and payers to more proactively manage and mitigate the complications and associated costs of prematurity. Given that pregnancy is the launch point for the </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">future health of babies and a key determinant in the future health of mothers and babies, we believe this area is ripe for innovation and better tools to improve patient outcomes. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Our Proprietary Technology Platform</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">The complexities of the biological processes occurring during pregnancy have been a major obstacle in developing effective tests for pregnancy-related conditions. We are working to overcome this obstacle through our development of a proprietary technology platform consisting of biobanks, advanced mass spectrometry and other proteomic analytic methods and bioinformatics, which enables superior characterization of the biology of pregnancy and more accurate prediction of pregnancy outcomes, as illustrated below. </font>
          </div>
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Our Proprietary Technology Platform</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
            <img src="tm2110724d3-fc_biobank4c.jpg" alt="[MISSING IMAGE: tm2110724d3-fc_biobank4c.jpg]" height="279" width="605" >
          </div>
          <div style="text-indent:20pt; margin-top:12.01pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">An analysis of protein pathways and expression at various points during pregnancy reveals the constantly evolving and dynamic changes affecting both the mother and the fetus. Earlier detection of changes in protein expression indicating the emergence of adverse pregnancy outcomes can enable proactive management of those conditions. A fundamental component of our platform is our proprietary and continually growing biobank consisting of comprehensive, clinically and demographically annotated blood samples collected from more than 10,500 pregnant U.S. women, representing broad demographic and geographic diversity inherent in the U.S. population. This differentiated resource enables us to develop and broadly validate our predictors. Further biobank diversity is also provided through our scientific collaborations with leading maternal fetal medicine experts around the globe, enabling us to analyze specimens collected from patients in the United States, Europe, Asia and Africa. In strict adherence to the authoritative National Academy of Medicine, or NAM, guidelines, we apply our innovative mass spectrometry and other proteomic analytical methods and our protein information network knowledge to probe biobank samples for meaningful protein expression changes. We then subject the data to detailed bioinformatics analysis and use advanced tools, such as machine learning and artificial intelligence, to find relationships between various proteins and to discover important predictors. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Our Discovery, Development, and Commercialization Approach</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Our product discovery and development approach is based on rigorous science and health-based economic analyses as we discover, develop and commercialize biomarker tests designed to transform pregnancy-related care for patients, doctors and payers. We have initially applied our platform and capabilities to address the problem of preterm birth, given its profound health and economic impacts worldwide. In the future, we may use this technology to develop products for a number of health conditions other than premature births. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We use the following multifaceted approach in our research, development and commercialization efforts: </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-left:12pt;width:456pt;">
          <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Significant Unmet Need.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We select specific conditions of pregnancy that are clinically meaningful and economically important and with significant unmet needs that lack effective solutions. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Proteomic and Bioinformatics Platform.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We utilize our platform to understand the biology underlying selected pregnancy-related conditions in order to discover, verify and broadly validate high-performing predictive biomarker tests. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Demonstrate Health and Economic Impact of Our Test and Treat Strategy.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We believe a critical element of our success will be to demonstrate the beneficial health and economic impacts of using the information provided by our biomarker tests. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Payer-Centric Reimbursement Coverage.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We have adopted what we believe is an innovative payer-centric approach for early commercialization of our biomarker tests, by seeking to leverage the health and economic benefits conferred by our biomarker approach to gain early reimbursement coverage from major health insurance payers. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Broader Market Adoption.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We are capitalizing on our innovative payer-centric reimbursement strategy to facilitate obtaining widespread commercial coverage of our biomarker tests from other healthcare payers. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Our Pipeline</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We are developing a robust pipeline of novel blood-based biomarker tests for a number of major pregnancy related conditions beyond preterm birth by leveraging the biological insights provided by our proprietary technology platform. Our product candidates are designed to accurately predict and enable better management of a range of serious pregnancy-related conditions. We believe these product candidates, if successfully developed, have the potential to address significant unmet needs by providing more accurate detection of these pregnancy-related conditions and providing patients and physicians with earlier opportunities for interventional treatment. We retain worldwide development and commercialization rights to all of our product candidates. </font>
          </div>
          <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our biomarker pregnancy pipeline consists of the following: </font>
          </div>
          <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
            <img src="tm2110724d7-tbl_predictor4c.jpg" alt="[MISSING IMAGE: tm2110724d7-tbl_predictor4c.jpg]" height="301" width="603" >
          </div>
          <div style="margin-top:17pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">The PreTRM Test&#8201;&#8212;&#8201;Our Solution for Preterm Birth</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our first product, the PreTRM test, is the only broadly validated, commercially available blood-based biomarker test to accurately predict the risk of spontaneous preterm birth. Preterm birth, which occurs in approximately 15&#160;million deliveries annually around the world, is defined as any birth before 37 weeks&#8217; gestation and is a leading cause of illness and death in newborns. The 2020 March of Dimes Report Card </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-bottom:56pt; margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">shows that of the approximately 3.8&#160;million babies born annually in the United States, more than one in 10 is born prematurely. Preterm births result in approximately $25&#160;billion in economic costs in the United States per year, largely as a result of profound short- and long-term health consequences to the mother and baby. Major long-term medical complications associated with preterm birth include learning disabilities, cerebral palsy, chronic respiratory illness, intellectual disability, seizures and vision and hearing loss. These complications can generate significant costs throughout the lives of affected children. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The PreTRM test is a non-invasive blood test given to a pregnant woman during week 19 or 20 of gestation. The PreTRM test provides an accurate prediction of the expectant mother&#8217;s individualized risk, expressed as a&#160;percentage, of delivering spontaneously before 37 weeks&#8217; gestation, as well as her relative risk compared to the average population risk. The great majority of single fetus, or singleton, preterm births are spontaneous, where the mother goes into labor and delivers without any apparent known pathology. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The protein biomarkers of preterm birth utilized in our PreTRM test have been extensively validated in multiple maternal fetal medicine centers located in the United States, Europe, Asia and Africa. In addition, we continue to build on our existing data to further demonstrate the clinical and economic benefits of intervening based on PreTRM test results. We believe our comprehensive approach to build evidence for our PreTRM test addresses key elements payers require in order to reimburse testing, including: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:0.2pt;">analytical validation of the testing platform, or measurement validity; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:0.2pt;">clinical validation, or test validity; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:0.2pt;">clinical utility of using validated predictions, or positive health benefit; and </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:0.2pt;">economic utility, or cost effectiveness and healthcare savings. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="text-indent:20pt; margin-top:5pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Underscoring the benefits of the PreTRM test and treat strategy, evidence of the clinical and economic utility of the PreTRM test administered mid-pregnancy has been published by respected independent health economists in a leading maternal fetal medicine journal. </font>
          </div>
          <div style="text-indent:20pt; margin-top:5pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The strength of the data from our studies of the PreTRM test has enabled us to pursue an innovative and accelerated approach to commercialization. We have secured PreTRM test reimbursement through a major strategic payer, Anthem, representing an important step in achieving initial payer acceptance of our rigorous approach to prematurity, which we believe will help the PreTRM test obtain broader insurance coverage adoption. We believe that this collaboration significantly de-risks initial commercialization of the PreTRM test, as it provides reimbursement from a major payer covering more than 10% of U.S. pregnancies annually and provides a pathway for broader market adoption through subsequent coverage decisions by other major payers. The collaboration also enables us to generate more data to demonstrate the value of the PreTRM test and treat approach across diverse patient populations within Anthem&#8217;s insurance plans. In November&#160;2020, we were awarded a unique CPT</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> PLA code by the AMA Editorial Board, specifically for the PreTRM test, which we believe will also help drive payment and coverage decisions for PreTRM testing. </font>
          </div>
          <div style="margin-top:4pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Our Team</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:2pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our team brings extensive experience and expertise in building and running highly profitable molecular diagnostics companies. We are led by Gregory C. Critchfield, M.D., M.S., our Chairman, President and Chief Executive Officer, who previously served as President of Myriad Genetic Laboratories; Douglas Fisher, M.D., our Chief Business Officer; Thomas Garite, M.D., our Vice President, Clinical Sciences, a past president of the Society for Maternal Fetal Medicine; Jay Boniface, Ph.D., our Chief Scientific Officer; and Nadia Altomare, our Chief Commercial Officer, all of whom have extensive leadership experience in the pharmaceutical, device and diagnostic companies. Jay Moyes, our Chief Financial Officer, or CFO, previously served as CFO with Myriad Genetics and has extensive experience in public and private financings, licensing transactions and acquisitions. We are supported by an experienced board of directors and clinical and scientific advisors that are leaders in the fields of maternal fetal medicine, bioinformatics, clinical trials and science-based businesses. </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Our Strengths</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We attribute our success and future growth prospects to the following: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Our differentiated approach to understanding and addressing major conditions of pregnancy.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We take a focused and data-driven approach based on rigorous science to understand the biology of pregnancy and the health and economic impacts of major pregnancy conditions. Our approach involves conducting controlled trials and health economic analyses to demonstrate the beneficial health and economic impacts of using the information provided by our biomarker tests. We also work with leading health economists and organizations to build rigorous models that describe how the application of our tests impacts both health and economic outcomes. Leveraging the demonstrated short- and long-term health and economic benefits of our biomarker approach, we aim to gain early reimbursement coverage from major health insurance payers by working with them to demonstrate the benefits of using our biomarker tests based upon analysis of claims data in their own plans. We intend to capitalize on our innovative payer-centric reimbursement strategy to facilitate obtaining widespread commercial coverage of our biomarker tests from other healthcare payers. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Our proprietary and scalable proteomics and bioinformatics platform technology creates clinically meaningful and economically impactful predictions for pregnancy.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We believe our proprietary proteomic and bioinformatics technology platform has the potential to enable critical advances in the management of pregnancy and its outcomes. Our platform consists of biobanks, advanced mass spectrometry and other proteomic analytic methods and bioinformatics, which enables superior characterization of the biology of pregnancy and accurate prediction of pregnancy outcomes. We believe this platform has the potential to address significant unmet medical needs in the large, underserved market for the prediction of outcomes associated with pregnancy. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">The PreTRM test is the only broadly validated, commercially available blood test proven to predict the risk of an individual woman to deliver prematurely.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The predictive performance of the PreTRM biomarkers has been extensively validated in diverse populations and geographies and enables earlier proactive care addressing higher preterm birth risk that occurs among the 3.8&#160;million annual singleton pregnancies in the United States. We believe that based on our growing body of evidence regarding the clinical and economic benefits of the PreTRM test and our innovative collaboration with Anthem, as greater payer and physician adoption occurs throughout the United States, the PreTRM test has the potential to become an important standard of care for preterm birth. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Innovative and strategic partnership with Anthem.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We have secured early PreTRM test reimbursement through our strategic collaboration with Anthem, which represents an important step in achieving initial payer acceptance of our rigorous approach to prematurity and which we believe will help foster broader insurance coverage adoption. We launched this commercialization process in the first half of 2021, and from which we envision substantial penetration of Anthem&#8217;s network over the next few&#160;years. We believe this collaboration significantly de-risks initial commercialization of our PreTRM test, as it demonstrates reimbursement from a major payer covering more than 10% of U.S. pregnancies annually and provides a pathway for broader market adoption through subsequent coverage decisions by other major payers. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Broad pipeline covering additional significant conditions of pregnancy.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We are also developing a novel pipeline of blood-based biomarker tests for a number of major pregnancy-related conditions beyond preterm birth by leveraging the biological insights provided by our proprietary technology platform. We believe these product candidates, if successfully developed, have the potential to address significant unmet needs by providing more accurate detection of these pregnancy-related conditions and affording patients and physicians earlier opportunities for interventional treatment. We retain worldwide development and commercialization rights to all of our product candidates. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="font-weight:bold;letter-spacing:-0.2pt;">Deeply experienced team in biotechnology and molecular diagnostics test development and commercialization.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Our executive team has decades of experience in building and commercializing molecular diagnostics tests. We have worked to build a first-class scientific organization capable of harnessing and translating our platform technologies into innovative predictive solutions as we strive to deliver pivotal and actionable information to pregnant women, their physicians and </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-left:12pt;width:456pt;">
          <div style="margin-left:40pt; width:416pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">payers to improve the health of patients as well as the economics of healthcare delivery. Our experienced discovery and development team performs rigorous bioinformatics analyses and strictly adheres to the authoritative guidelines published by the NAM on how to reliably develop and validate omics predictions made on complex biological data sets. Adhering to these guidelines, in the case of predicting preterm birth, we have been able to document generalizable biomarker predictive performance across independent cohorts of patients from the United States, Europe, Asia and Africa. Reflective of the scientific rigor of our efforts, our scientists have published best practice recommendations for the analysis of preterm delivery data. We believe this will improve the quality of statistical analysis of research data related to proteomic test development, enabling the broad community of statisticians, researchers, clinicians and regulators to better validate predictions prior to their clinical use. </font>
          </div>
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Our Strategy</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Our vision is to deliver pivotal and actionable information to pregnant women, their physicians and healthcare payers to significantly improve maternal and neonatal health and to dramatically reduce healthcare costs. Our goal as The Pregnancy Company is to discover, develop and commercialize clinically meaningful and economically impactful biomarker tests designed to improve pregnancy outcomes. We believe it is critical to innovate products that will be viewed as cost-effective by payers in order to receive reimbursement for our tests. We aim to accomplish our vision by implementing the following strategies: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:0.2pt;">Accelerate the commercialization of the PreTRM test through our innovative strategic partnership with Anthem. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:0.2pt;">Expand coverage of the PreTRM test to additional payers to maximize the commercial opportunity. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:0.2pt;">Apply our platform capabilities to broaden our pipeline and develop novel and high-performing biomarker tests for pregnancy-related conditions and potentially other health conditions. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:0.2pt;">Continually enhance the value and capabilities of our proprietary technology platform through ongoing expansion and integration of our biobank and our proteomics and bioinformatics databases. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:0.2pt;">Rapidly build a dedicated women&#8217;s health commercial infrastructure. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:0.2pt;">Evaluate strategic partnerships to maximize the value of our product offerings. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Risk Factors</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Our business is subject to a number of risks of which you should be aware before making an investment decision. These risks are discussed more fully in the &#8220;Risk Factors&#8221; section of this prospectus immediately following this prospectus summary. These risks include the following: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:0.2pt;">We have incurred net losses since our inception and we anticipate that we will continue to incur losses for the foreseeable future, which could harm our future business prospects. Operating our business requires a significant amount of cash, and our ability to generate sufficient cash depends on many factors, some of which are beyond our control. We expect to need to raise additional capital after this offering, and if we cannot raise additional capital when needed, we may have to curtail or cease operations. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:0.2pt;">We have derived substantially all of our revenues to date from the PreTRM test, and if our efforts to further increase the use and adoption of the PreTRM test or to develop new products and services in the future do not succeed, our business will be harmed. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:0.2pt;">Our success depends on broad scientific and market acceptance of the PreTRM test, which we may fail to achieve. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:0.2pt;">In the near future, we expect to rely on sales to a limited number of direct customers, primarily Anthem, for a significant portion of our revenue from the sale of the PreTRM test, and the loss of Anthem as a customer could materially harm our business. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:0.2pt;">If our CLIA-certified laboratory facility becomes inoperable, we will be unable to perform our tests and our business will be harmed. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-left:12pt;width:456pt;">
          <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:0.2pt;">Our business would be materially harmed if our proprietary biobank were to become contaminated, lost or destroyed. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:0.2pt;">If we are unable to successfully scale our operations, our business could suffer. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:0.2pt;">The ongoing COVID-19 pandemic could materially affect our operations, as well as the business or operations of third parties with whom we conduct business. Our business could be adversely affected by the effects of other future health epidemics or pandemics in regions where we, or third parties on which we rely, have significant business operations. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:0.2pt;">Our estimates of total addressable market opportunity and forecasts of market growth may prove to be inaccurate, and even if the market in which we compete achieves the forecasted growth, our business could fail to grow at similar rates. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:0.2pt;">If third-party payers do not adequately reimburse for any new tests we may develop, our new tests may not be purchased or used, which may adversely affect our revenue and profits. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:0.2pt;">Our revenues may be adversely impacted if third-party payers withdraw coverage or provide lower levels of reimbursement due to changing policies, billing complexities or other factors. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:0.2pt;">Any failure to obtain, maintain and enforce our intellectual property rights could impair our ability to protect our proprietary technology and our brand. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:0.2pt;">Competition in the life science industry, including companies engaged in molecular diagnostics and proteomics, is intense. If we are unable to compete successfully with respect to our current or future products or services, we may not be able to increase or sustain our revenues or achieve profitability. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Corporate Information</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We were incorporated under the laws of the State of Delaware on January&#160;17, 2008. Our principal executive offices are located at 2749 East Parleys Way, Suite 200, Salt Lake City, UT 84109, and our telephone number is (801) 990-0520. Our website address is </font><font style="font-style:italic;letter-spacing:0.2pt;">https://www.seraprognostics.com/</font>&#8203;<font style="letter-spacing:0.2pt;">. The information contained on, or that can be accessed through, our website is not and shall not be deemed to be part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. Investors should not rely on any such information in deciding whether to purchase our Class A common stock. </font></div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Implications of Being an Emerging Growth Company</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We are an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS Act. We will remain an emerging growth company until the earlier of (1)&#160;the last day of the fiscal year following the fifth anniversary of the completion of this offering, (2)&#160;the last day of the fiscal year in which we have total annual gross revenue of at least $1.07&#160;billion, (3)&#160;the date on which we are deemed to be a &#8220;large accelerated filer&#8221; as defined in Rule&#160;12b-2 under the Securities Exchange Act of 1934, as amended, or the Exchange Act, which would occur if the market value of our Class A common stock and Class B common stock held by non-affiliates exceeded $700.0&#160;million as of the last business day of our most recently completed second fiscal quarter or (4)&#160;the date on which we have issued more than $1.0&#160;billion in non-convertible debt securities during the prior three-year period. An emerging growth company may take advantage of specified reduced reporting requirements and is relieved of certain other significant requirements that are otherwise generally applicable to public companies. As an emerging growth company, </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:0.2pt;">we may present only two&#160;years of audited financial statements, plus unaudited condensed financial statements for any interim period, and related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations in this prospectus; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:0.2pt;">we may avail ourselves of the exemption from the requirement to obtain an attestation and report from our auditors on the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:0.2pt;">we may provide reduced disclosure about our executive compensation arrangements; and </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-bottom:328pt; margin-left:12pt;width:456pt;">
          <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:0.2pt;">we may not require stockholder non-binding advisory votes on executive compensation or golden parachute arrangements. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We have elected to take advantage of certain of the reduced disclosure obligations in the registration statement of which this prospectus is a part and may elect to take advantage of other reduced reporting requirements in future filings. As a result, the information that we provide to our stockholders may be different than you might receive from other public reporting companies in which you hold equity interests.</font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards, delaying the adoption of these accounting standards until they would apply to private companies. We have elected to avail ourselves of this exemption from new or revised accounting standards, and, therefore, we will not be subject to the same new or revised accounting standards at the same time as other public companies that are not emerging growth companies or those that have opted out of using such extended transition period, which may make comparison of our financial statements with such other public companies more difficult. We may take advantage of these reporting exemptions until we no longer qualify as an emerging growth company, or, with respect to adoption of certain new or revised accounting standards, until we irrevocably elect to opt out of using the extended transition period. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting standards as of public company effective dates. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We are also a &#8220;smaller reporting company&#8221; as defined in the Securities Exchange Act of 1934, as amended, or the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our Class A common stock and Class B common stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the most recently completed fiscal year and our Class A common stock and Class B common stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter. </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-bottom:38pt; margin-left:12pt;width:456pt;">
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="text-transform:uppercase;letter-spacing:-0.2pt;">The Offering</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Class A common stock offered by us </font>
            </div>
          </div>
          <div style="margin-left:162pt; margin-top:-12pt; width:294pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares. </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Underwriters&#8217; option to purchase&#160;additional shares of Class A common stock offered by us </font>
            </div>
          </div>
          <div style="margin-left:162pt; margin-top:-12pt; width:294pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares. </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Total Class A and Class B common stock to be outstanding immediately after this offering </font>
            </div>
          </div>
          <div style="margin-left:162pt; margin-top:-12pt; width:294pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares (or &#8199;&#8199;&#8199;&#8199; shares if the underwriters exercise their option to purchase additional shares in full). </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Use of proceeds </font>
            </div>
          </div>
          <div style="margin-left:162pt; margin-top:-12pt; width:294pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We estimate the net proceeds from this offering will be approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million (or $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million if the underwriters exercise their option to purchase additional shares in full), assuming an initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, which is the midpoint of the estimated price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </font>
          </div>
          <div style="margin-left:162pt; margin-top:8pt; width:294pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We intend to use the net proceeds from the offering for the following purposes: (i)&#160;commercialization activities relating to the PreTRM test; (ii)&#160;clinical studies supporting commercialization of the PreTRM test, including the Anthem/PRIME study, and for product discovery and development studies; (iii)&#160;increasing capacity and efficiency of our clinical laboratory and enhancing our information technology infrastructure; (iv)&#160;further development of our proprietary proteomics and bioinformatics platform and our pipeline programs; and (v)&#160;working capital and other general corporate purposes. See the &#8220;Use of Proceeds&#8221; section of this prospectus for additional information. </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Voting Rights </font>
            </div>
          </div>
          <div style="margin-left:162pt; margin-top:-12pt; width:294pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Following this offering, we will have two classes of common stock: Class A common stock and Class B common stock. The rights of the holders of Class A common stock and Class B common stock are identical, except with respect to voting and conversion. Each share of Class A common stock will be entitled to one vote and shares of Class B common stock will be non-voting, except as may be required by law. Each share of Class B common stock may be converted into one share of Class A common stock at the option of its holder, subject to the ownership limitations provided for in our amended and restated certificate of incorporation to be in effect upon the completion of this offering. See the section titled &#8220;Description of Capital Stock&#8221; for additional information. </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Risk factors </font>
            </div>
          </div>
          <div style="margin-left:162pt; margin-top:-12pt; width:294pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">You should read the &#8220;Risk Factors&#8221; section of this prospectus beginning on page <a href="#tRIFA">14</a> and other information included in this prospectus for a discussion of factors to consider carefully before deciding to invest in shares of our common stock. </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Proposed Nasdaq Global Market symbol </font>
            </div>
          </div>
          <div style="margin-left:162pt; margin-top:-12pt; width:294pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">SERA </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-bottom:176pt; margin-left:12pt;width:456pt;">
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The number of shares of our Class A common stock and Class B common stock to be outstanding after this offering is based on 53,682,978 shares of our Class A common stock and Class B common stock outstanding as of March 31, 2021, after giving effect to the conversion of all of our outstanding shares of preferred stock, including the 6,477,458 shares of Series E convertible preferred stock issued in April 2021, into an aggregate of 49,562,136 shares of our Class A common stock and Class B common stock upon the completion of this offering, and excludes the following: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:0.2pt;">10,308,231 shares of our Class A common stock issuable upon the exercise of outstanding stock options as of March 31, 2021, having a weighted-average exercise price of $1.22 per share;</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:0.2pt;">5,700,270 shares of Class A common stock issuable upon the exercise of warrants outstanding as of March 31, 2021, having a weighted-average exercise price of $6.15 per share;</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:0.2pt;">169,533 shares of common stock (on an as-converted basis) issuable upon exercise of warrants to purchase convertible preferred stock as of March 31, 2021, having a weighted average exercise price of $3.46 per share; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:0.2pt;">2,933,549 shares of common stock reserved for issuance pursuant to future awards under our 2011 Equity Incentive Plan, of which options to purchase 1,543,237 shares of Class A common stock having an exercise price of $4.27 per share were granted since March 31, 2021; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199; shares of Class A common stock reserved for issuance pursuant to future awards under our 2021 Equity Incentive Plan, which will become effective upon the completion of this offering; and </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199; shares of Class A common stock reserved for issuance pursuant to future awards under our 2021 Employee Stock Purchase Plan, which will become effective upon the completion of this offering. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Except as otherwise indicated, all information contained in this prospectus assumes or gives effect to: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:0.2pt;">the automatic conversion of all of our outstanding shares of convertible preferred stock into an aggregate of 49,562,136 shares of our Class A common stock and Class B common stock upon the completion of this offering; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:0.2pt;">no exercise by the underwriters of their option purchase up to an additional &#8199;&#8199;&#8199;&#8199;&#8199;shares of our Class A common stock; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:0.2pt;">no exercise of the outstanding options described above; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:0.2pt;">no exercise of the outstanding warrants described above; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:0.2pt;">a one for&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;reverse split of our Class A common stock and Class B common Stock effected on&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;; and </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
            <font style="letter-spacing:0.2pt;">the filing and effectiveness of our amended and restated certificate of incorporation and the adoption of our amended and restated by-laws immediately prior to and upon the completion of this offering. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Summary Financial Data</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">You should read the following summary financial data together with our condensed financial statements and the related notes appearing at the end of this prospectus and the &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; sections of this prospectus. The summary statements of operations data for the three months ended March 31, 2021 and 2020, and the summary balance sheet data as of March 31, 2021 have been derived from the unaudited interim condensed financial statements included elsewhere in this prospectus. We have derived the statement of operations data and balance sheet data for the&#160;years ended December&#160;31, 2020 and 2019 from our audited financial statements appearing elsewhere in this prospectus. The unaudited interim condensed financial statements were prepared on the same basis as our audited financial statements and reflect, in the opinion of management, all adjustments, which include only normal, recurring adjustments that are necessary to present fairly the results for the interim periods presented. Our historical results are not necessarily indicative of the results that may be expected in the future, and our results for any interim period are not necessarily indicative of results that may be expected for any full year. </font>
          </div>
          <table style="width:456pt;height:360.85pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <tr style="line-height:8pt;height:9.84pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:216.34pt;text-align:left;" rowspan="2">&#8203;</td>
              <td style="padding:0pt; width:6pt;" rowspan="2">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt; width:0pt;" colspan="10">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Three Months Ended March&#160;31, </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt; width:0pt;" colspan="10">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Year Ended December&#160;31, </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;height:14.09pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">2021 </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">2020 </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">2020 </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">2019 </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:7.97999999999999pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:216.34pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.253pt 0pt 2.812pt 0pt; width:0pt;text-align:center;" colspan="22">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">(in thousands, except share and per share amounts) </font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:7.97999999999999pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:216.34pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.253pt 0pt 2.812pt 0pt; width:0pt;" colspan="10">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">(unaudited) </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:1.907pt 0pt 0.843pt 0pt; width:216.34pt;text-align:left;">
                <div style="margin-left:10pt; text-indent:-10pt;">
                  <font style="letter-spacing:-0.2pt;">Statements of Operations and Comprehensive Loss </font>
                  <br >
                  <font style="letter-spacing:-0.2pt;">Data:</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.49pt 0pt 1.51pt 0pt; width:216.34pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Revenue </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">13</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">8</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">25</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">36</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.49pt 0pt 1.51pt 0pt; width:216.34pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Operating expenses: </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.49pt 0pt 1.51pt 0pt; width:216.34pt;text-align:left;">
                <div style="margin-left:10pt;">
                  <font style="letter-spacing:0.2pt;">Cost of revenue </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">3</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">11</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">18</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.49pt 0pt 1.51pt 0pt; width:216.34pt;text-align:left;">
                <div style="margin-left:10pt;">
                  <font style="letter-spacing:0.2pt;">Research and development </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2,396</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,050</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">7,782</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">9,353</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.49pt 0pt 1.51pt 0pt; width:216.34pt;text-align:left;">
                <div style="margin-left:10pt;">
                  <font style="letter-spacing:0.2pt;">Selling and marketing </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,350</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">868</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">3,645</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,963</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="border-bottom:1px solid #CCEEFF;padding:3.49pt 0pt 2.5pt 0pt; width:216.34pt;text-align:left;">
                <div style="margin-left:10pt;">
                  <font style="letter-spacing:0.2pt;">General and administrative </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.49pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.49pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">2,287</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.49pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.49pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">1,379</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.49pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.49pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">6,558</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.49pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.49pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">4,278</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:3.24pt 0pt 2.5pt 0pt; width:216.34pt;text-align:left;">
                <div style="margin-left:20pt;">
                  <font style="letter-spacing:0.2pt;">Total operating expenses </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3.24pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.24pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">6,038</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3.24pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.24pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">4,300</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3.24pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.24pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">17,996</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3.24pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.24pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">16,612</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.24pt 0pt 1.51pt 0pt; width:216.34pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Loss from operations </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(6,025<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(4,292<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(17,971<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(16,576<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.49pt 0pt 1.51pt 0pt; width:216.34pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Interest expense </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(307<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(437<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(1,839<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(1,972<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="border-bottom:1px solid #CCEEFF;padding:3.49pt 0pt 2.5pt 0pt; width:216.34pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Other income (expense), net </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.49pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.49pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">(27<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.49pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.49pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">33</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.49pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.49pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">(38<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.49pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.49pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">2,027</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.24pt 0pt 3.25pt 0pt; width:216.34pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Net loss and comprehensive loss </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.24pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.24pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">(6,359<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.24pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.24pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(4,696<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.24pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.24pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">(19,848<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.24pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.24pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(16,521<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:1.407pt 0pt 2.583pt 0pt; width:216.34pt;white-space:normal;text-align:left;">
                <div style="margin-left:10pt; text-indent:-10pt;">
                  <font style="letter-spacing:0.2pt;">Net loss per share attributable to common stockholders, basic and diluted</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#65279;(1)</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:1.407pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:1.407pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">(1.71<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:1.407pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:1.407pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(1.48<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:1.407pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:1.407pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">(6.14<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:1.407pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:1.407pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(5.24<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:1.407pt 0pt 2.583pt 0pt; width:216.34pt;white-space:normal;text-align:left;">
                <div style="margin-left:10pt; text-indent:-10pt;">
                  <font style="letter-spacing:0.2pt;">Weighted-average common shares outstanding, basic and diluted</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#65279;(1)</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:1.407pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.407pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">3,725,328</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:1.407pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.407pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">3,171,251</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:1.407pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.407pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">3,234,476</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:1.407pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.407pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">3,153,654</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:1.407pt 0pt 2.583pt 0pt; width:216.34pt;white-space:normal;text-align:left;">
                <div style="margin-left:10pt; text-indent:-10pt;">
                  <font style="letter-spacing:0.2pt;">Pro&#160;forma net loss per share, basic and diluted (unaudited)</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#65279;(1)</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:1.407pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:1.407pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">(0.17<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:1.407pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:1.407pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">(0.56<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:1.407pt 0pt 2.583pt 0pt; width:216.34pt;white-space:normal;text-align:left;">
                <div style="margin-left:10pt; text-indent:-10pt;">
                  <font style="letter-spacing:0.2pt;">Pro&#160;forma weighted-average common shares outstanding, basic and diluted (unaudited)</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#65279;(1)</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:1.407pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.407pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">37,645,659</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:1.407pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.407pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">35,756,690</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>
          <div style="margin-top:6.2pt; width:456pt;">
            <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
          </div>
          <div style=" float:left; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">(1)</font>
            <br >
          </div>
          <div style=" margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">See Note 13 to our unaudited condensed financial statements and Note 15 to our financial statements appearing elsewhere in this prospectus for details on the calculation of basic and diluted net loss per share attributable to common stockholders. The unaudited pro&#160;forma basic and diluted net loss per share attributable to common stockholders for the three&#160;months ended March&#160;31, 2021 were computed using the weighted-average number of shares of common stock outstanding, including the pro&#160;forma effect of the automatic conversion of all outstanding shares of convertible preferred stock into shares of common stock on the later of January&#160;1, 2021 or the date the equity instruments were issued. The unaudited pro&#160;forma basic and diluted net loss per share attributable to common stockholders for the </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-bottom:58.77pt; margin-left:12pt;width:456pt;">
          <div style="margin-left:20pt; width:436pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">year ended December&#160;31, 2020 were computed using the weighted-average number of shares of common stock outstanding, including the pro&#160;forma effect of the automatic conversion of all outstanding shares of convertible preferred stock into shares of common stock on the later of January&#160;1, 2020 or the date the equity instruments were issued. The unaudited pro&#160;forma basic and diluted net loss per share attributable to common stockholders do not give effect to the issuance and sale of 6,477,458 shares of Series&#160;E convertible preferred stock in April&#160;2021 for aggregate gross proceeds of $38.8&#160;million. </font>
          </div>
          <table style="width:456pt;height:159.64pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <tr style="line-height:8.98pt;height:18.82pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:294.44pt;" rowspan="2">&#8203;</td>
              <td style="padding:0pt; width:6pt;" rowspan="2">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:0pt;text-align:center;" colspan="16">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">As of March&#160;31, 2021</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">(unaudited) </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8.98pt;height:23.07pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.597pt 0pt 2.478pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Actual </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.597pt 0pt 2.478pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Pro&#160;forma</font><font style=" position:relative; bottom:3.25pt;font-size:6pt;letter-spacing:-0.12pt;">(1)</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.597pt 0pt 2.478pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Pro&#160;forma</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">as adjusted</font><font style=" position:relative; bottom:3.25pt;font-size:6pt;letter-spacing:-0.12pt;">(2)</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:7.97999999999999pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:294.44pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.263pt 0pt 2.812pt 0pt; width:0pt;text-align:center;" colspan="16">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">(in thousands) </font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:294.44pt;text-align:left;">
                <font style="letter-spacing:-0.2pt;">Balance Sheet Data:</font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.245pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.245pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:294.44pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Cash and cash equivalents </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">60,016</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">98,816</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.245pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</td>
              <td style="padding:0pt;padding-left:4.245pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:294.44pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Working capital</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(3)</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">56,709</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">95,509</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.245pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;"> </td>
              <td style="padding:0pt;padding-left:4.245pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:294.44pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Total assets </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">62,744</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">101,544</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.245pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;"> </td>
              <td style="padding:0pt;padding-left:4.245pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:294.44pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Convertible preferred stock </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">188,343</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.245pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;"> </td>
              <td style="padding:0pt;padding-left:4.245pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:294.44pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Accumulated deficit </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(137,818<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(137,818<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.245pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;"> </td>
              <td style="padding:0pt;padding-left:4.245pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:294.44pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Total stockholders&#8217; (deficit) equity </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(130,390<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">97,247</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.245pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.245pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>
          <div style="margin-top:12.5pt; width:456pt;">
            <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
          </div>
          <div style=" float:left; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">(1)</font>
            <br >
          </div>
          <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">The pro&#160;forma balance sheet data reflect the actual balance sheet data and give effect to: (i)&#160;the sale and issuance of 6,477,458 shares of our Series&#160;E convertible preferred stock in April&#160;2021 for gross cash proceeds of $38.8&#160;million; (ii)&#160;the filing and effectiveness of our amended and restated certificate of incorporation immediately prior to the completion of this offering; and (iii)&#160;the automatic conversion of all outstanding shares of our convertible preferred stock, including the 6,477,458 shares of Series&#160;E convertible preferred stock issued in April&#160;2021, into an aggregate of 49,562,136 shares of Class&#160;A common stock and Class&#160;B common stock upon the consummation of this offering. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">(2)</font>
            <br >
          </div>
          <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">The pro&#160;forma as adjusted balance sheet data give further effect to (1) above and to the issuance and sale of &#8199;&#8199;&#8199;&#8199;&#8199;&#160;shares of our Class&#160;A common stock in this offering at an assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. The pro&#160;forma as adjusted information discussed above is illustrative only and will change based on the actual initial public offering price and other terms of this offering determined at pricing. A $1.00 increase (decrease) in the assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro&#160;forma as adjusted amount of each of cash and cash equivalents, working capital, total assets and total stockholders&#8217; (deficit) equity by $&#8199;&#8199;&#8199;&#8199; million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. An increase (decrease) of 1,000,000 shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase (decrease) the pro&#160;forma as adjusted amount of each of cash and cash equivalents, working capital, total assets and total stockholders&#8217; (deficit) equity by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming no change in the assumed initial public offering price per share and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">(3)</font>
            <br >
          </div>
          <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
            <font style="letter-spacing:0.2pt;">We define working capital as current assets less current liabilities. See our financial statements and related notes appearing elsewhere in this prospectus for further details regarding our current assets and current liabilities.</font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tRIFA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">RISK FACTORS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:13pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Investing in our Class&#160;A common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below, the section of this prospectus entitled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our financial statements and related notes, before investing in our Class&#160;A common stock. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that affect us. If any of the following risks occur, our business, operating results and prospects could be materially harmed. In that event, the price of our Class&#160;A common stock could decline, and you could lose part or all of your investment.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:6pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Our Financial Position and Need for Additional Capital</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:7pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We have incurred net losses since our inception and we anticipate that we will continue to incur losses for the foreseeable future, which could harm our future business prospects.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have incurred net losses each year since our inception in 2008. To date, we have financed our operations primarily through private placements of our equity and debt securities and bank loans. Our net loss for the&#160;years ended December&#160;31, 2020 and 2019 was $19.8&#160;million and $16.5&#160;million, respectively. As of March&#160;31, 2021, we had an accumulated deficit of $137.8&#160;million. Our losses may continue to increase in the future as we continue to devote a substantial portion of our resources to efforts to increase the adoption of, and reimbursement for, the PreTRM test, make improvements to this product, and research, develop and commercialize new products. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Other than revenues from the sale of the PreTRM test, we do not expect to generate revenues from other sources in the immediate future. It is possible that we will not generate sufficient revenue from the sale of our products to cover our costs, including research and development expenses related to furthering our product pipeline, and achieve or sustain profitability. A significant element of our business strategy is to increase and maintain our in-network coverage with third-party payers; however, the negotiated fees under contracts with third-party payers are typically lower than the list price of our tests, and in some cases the third-party payers with whom we may contract in the future may have negative coverage determinations for the PreTRM test and potential future offerings. Therefore, being in-network with third-party payers may have an adverse impact on our revenues especially if we are unable to increase the adoption of, and obtain favorable coverage reimbursement for, our products. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As there is a possibility that our company, any collaborators and/or licensees may not successfully develop additional products, obtain required regulatory authorizations for such products, manufacture such products at an acceptable cost or with sufficient quality or successfully market and sell such products with desired margins, our expenses may continue to exceed any revenues we may receive. Our operating expenses also will increase as, or if, among other factors: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">our earlier-stage products move into later-stage development, which is generally more expensive than early-stage development; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">we select additional technologies or products for development; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">we increase the number of patents we are prosecuting or otherwise expend additional resources on patent prosecution or defense; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">we acquire or in-license additional technologies, product candidates, products or businesses. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Operating our business requires a significant amount of cash, and our ability to generate sufficient cash depends on many factors, some of which are beyond our control. We expect to need to raise additional capital after this offering, and, if we cannot raise additional capital when needed, we may have to curtail or cease operations.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the future, we expect to incur significant costs in connection with our operations, including, but not limited to, the development, marketing authorization, and commercialization of new tests, and other products. These development activities generally require a substantial investment before we can determine commercial viability, and the proceeds of this offering will not be sufficient to fully fund these activities. We </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">expect to need to raise additional funds through public or private equity or debt financings, collaborations or licensing arrangements to continue to fund or expand our operations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our actual liquidity and capital funding requirements will depend on numerous factors, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">our ability to achieve broad commercial success with the PreTRM test; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the scope and duration of, and expenditures associated with, our discovery efforts and research and development programs, including for our proprietary proteomics and bioinformatics platform; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the costs to fund our commercialization strategies for any product candidates which we launch and to prepare for potential product marketing authorizations, as required; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the costs of any acquisitions of complementary businesses or technologies that we may pursue; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">potential licensing or partnering transactions, if any; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">our facility expenses, which will vary depending on the time and terms of any facility lease or sublease we may enter into, and other operating expenses; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the scope and extent of the expansion of our sales and marketing efforts; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the commercial success of our products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">our ability to obtain more extensive coverage and reimbursement for the PreTRM test and other products, if any; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">our ability to collect our accounts receivable. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The availability of additional capital, whether from private capital sources, such as banks, or the public capital markets, may fluctuate as our financial condition and market conditions in general change. There may be times when the private capital sources and the public capital markets lack sufficient liquidity or when our securities cannot be sold at attractive prices, or at all, in which case we would not be able to access capital from these sources. In addition, any weakening of our financial condition or deterioration in our credit ratings could adversely affect our ability to obtain necessary funds. Even if available, additional financing could be costly or have adverse consequences. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Additional capital, if needed, may not be available on satisfactory terms or at all. Furthermore, any additional capital raised through the sale of equity or equity-linked securities will dilute our stockholders&#8217; ownership interests and may have an adverse effect on the price of our common stock. In addition, the terms of any financing may adversely affect stockholders&#8217; holdings or rights. Debt financing, if available, may include restrictive covenants. To the extent that we raise additional funds through collaborations and licensing arrangements, it may be necessary to relinquish some rights to our technologies or grant licenses on terms that may not be favorable to us. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If we are not able to obtain adequate funding when needed, we may be required to delay development programs or sales and marketing initiatives. If we are unable to raise additional capital in sufficient amounts or on satisfactory terms, we may have to reduce our workforce and may be prevented from continuing our discovery, development and commercialization efforts and leveraging other corporate opportunities. In addition, it may be necessary to work with a partner on one or more of our tests or products under development, which could lower our economic value of those products. Each of the foregoing factors may harm our business, operating results and financial condition and may impact our ability to continue as a going concern. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our quarterly and annual results may fluctuate from period to period, which could adversely impact the value of our Class&#160;A common stock.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our quarterly and annual results of operations, including our revenues, gross margin, net loss and cash flows, may vary from period to period as a result of a variety of factors, many of which are outside of our control, including those listed elsewhere in this &#8220;Risk Factors&#8221; section, and as a result, period-to-period comparisons of our operating results may not be meaningful. Our quarterly and annual results should not be relied upon as an indication of future performance. In addition, to the extent that we continue to spend considerably on our internal sales and marketing and research and development efforts, we expect to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">incur costs in advance of achieving the anticipated benefits of such efforts. We also face competitive pricing and reimbursement pressures, and we may not be able to maintain our premium pricing in the future, which would adversely affect our operating results. Fluctuations in quarterly and annual results and key metrics may cause our results to fall below our financial guidance or other projections or goals, or the expectations of analysts or investors, which could adversely affect the price of our Class&#160;A common stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Our Business and Industry</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:7pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We have derived substantially all of our revenues to date from the PreTRM test, and if our efforts to further increase the use and adoption of the PreTRM test or to develop new products and services in the future do not succeed, our business will be harmed.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We currently receive and expect to continue to receive substantially all of our revenues from the sales of the PreTRM test. We intend to establish early reimbursement coverage for the PreTRM test by collaborating with payers to perform rigorous analysis to demonstrate the health and economic benefits of our biomarker tests based upon their own claims data in their plans, and then leveraging early payer reimbursement coverage determinations to obtain widespread commercial coverage of the PreTRM test from other health care payers and physician practices in the pregnancy market. If we are unable to execute on this commercial strategy and increase our revenues from the sale of the PreTRM test, our business may be materially adversely impacted. Our ability to increase sales of the PreTRM test and establish greater levels of adoption and reimbursement for the PreTRM test is uncertain for many reasons, including, among others: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">we may be unable to demonstrate to clinics, clinicians, physicians, payers and patients that the PreTRM test is superior to alternatives with respect to value, convenience, accuracy, scope of coverage and other factors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">third-party payers may set the amounts of reimbursement at prices that reduce our profit margins or do not allow us to cover our expenses; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">we may not be able to maintain and grow effective sales and marketing capabilities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">our sales and marketing efforts may fail to effectively reach customers or communicate the benefits of the PreTRM test; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">superior alternatives to the PreTRM test may be developed and commercialized; we may not be able to compete against these alternatives; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">we may face competitive pressures; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">we may experience supply constraints, including due to the failure of our key suppliers to provide required sequencing instruments and reagents; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">we may encounter difficulties with transportation logistics and regulations associated with shipping blood samples, including infrastructure conditions and transportation delays; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">U.S. or foreign regulatory or legislative bodies may adopt new regulations or policies or take other actions that impose significant restrictions on our ability to market our products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">we may be unable to compete successfully with respect to our current or future products or services, as a result of which we may not be able to increase or sustain our revenues or achieve profitability; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">we may not be able to protect our intellectual property position. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If our market share for the PreTRM test fails to grow or grows more slowly than expected, our business, operating results and financial condition would be adversely affected. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our success depends on broad scientific and market acceptance of the PreTRM test, which we may fail to achieve.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our ability to achieve and maintain scientific and commercial market acceptance of the PreTRM test will depend on a number of factors. We expect that the PreTRM test will be subject to the market forces and adoption curves common to other new technologies. The market for proteomics and bioinformatics </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">technologies and products is in its early stages of development. If widespread adoption of the PreTRM test or any other products that we commercialize in the future takes longer than anticipated, we will continue to experience operating losses. The success of life sciences technologies and products is due, in large part, to acceptance by the scientific and medical communities and their adoption of certain products in the applicable field of research. The life sciences scientific community is often led by a small number of early adopters and key opinion leaders who significantly influence the rest of the community through publications in peer-reviewed journals. In such journal publications, the researchers will describe their discoveries, and also the methods, and typically the products used, to fuel such discoveries. Mentions in peer-reviewed journal publications may be a driver for the general acceptance of products for the life sciences industry, such as the PreTRM test. In addition, continuing collaborative relationships with opinion leaders will be vital to maintaining any market acceptance we achieve. If too few researchers describe the use of our products, too many researchers shift to a competing product and publish research outlining their use of that product, or too many researchers negatively describe the use of our products in publications, it may drive customers away from our products. Other factors in achieving commercial market acceptance include: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">our ability to market and increase awareness of the capabilities of the PreTRM test; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the ability of the PreTRM test to demonstrate comparable performance in intended use applications broadly in the hands of customers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">our customers&#8217; willingness to adopt new products and workflows; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the PreTRM test&#8217;s ease of use and whether it reliably provides advantages over other alternative technologies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the rate of adoption of the PreTRM test by patients, physicians, payers and the medical community at large; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the prices we charge for the PreTRM test; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">our ability to develop new products and solutions for customers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">whether competitors develop and commercialize products that perform similar functions as the PreTRM test; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the impact of our investments in product innovation and commercial growth. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We cannot assure that we will be successful in addressing each of these criteria or other criteria that might affect the market acceptance of any products we commercialize, particularly the PreTRM test. If we are unsuccessful in achieving and maintaining market acceptance of the PreTRM test, our business, financial condition and results of operations would be adversely affected. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">In the near future, we expect to rely on sales to a limited number of direct customers, primarily Anthem, for a significant portion of our revenue from the sale of the PreTRM test, and the loss of Anthem as a customer could materially harm our business.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We expect that a significant portion of our revenue in the near future will be generated from sales to a limited number of customers, primarily Anthem, the loss of which could adversely affect our business, financial condition and results of operations. Accordingly, we are subject to customer concentration risk. Furthermore, any termination of our relationship with Anthem would also adversely impact our strategy to rapidly accelerate commercialization of the PreTRM test and help incentivize broader market adoption. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we are unable to establish sales and marketing capabilities, we may not be successful in commercializing the PreTRM test.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have limited experience as a company in sales and marketing and our ability to achieve profitability depends on our being able to attract customers for the PreTRM test and our future products, once approved. Although members of our management team have considerable industry experience, we must expand our sales, marketing, distribution and customer service and support capabilities with the appropriate technical expertise in order to successfully commercialize the PreTRM test. To perform sales, marketing, distribution, and customer service and support successfully, we will face a number of risks, including: </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">our ability to attract, retain and manage the sales, marketing and customer service and support force necessary to commercialize and gain market acceptance for our technology; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the time and cost of establishing a specialized sales, marketing and customer service and support force; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">our sales, marketing and customer service and support force may be unable to initiate and execute successful commercialization activities. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may seek to enlist one or more third parties to assist with sales, distribution and customer service and support. There is no guarantee, if we do seek to enter into such arrangements, that we will be successful in attracting desirable sales and distribution partners or that we will be able to enter into such arrangements on favorable terms. If our sales and marketing efforts, or those of any third-party sales and distribution partners, are not successful, the PreTRM test may not gain market acceptance, which could materially impact our business operations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Even if the PreTRM test achieves broad scientific and market acceptance, if we fail to improve it or introduce compelling new products, our future revenues and prospects could be harmed.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Even if we are able to achieve broad scientific and market acceptance for the PreTRM test, our ability to grow our business will depend in large part on our ability both to enhance and improve the PreTRM test and to introduce compelling new products, including for major pregnancy related conditions beyond preterm birth. The success of any enhancement to the PreTRM test or introduction of new products depends on several factors, including completion of certain clinical development requirements, timely completion and delivery of the product, competitive pricing, adequate quality testing, integration with existing technologies, appropriately timed and staged product introductions and overall market acceptance. Any new product or enhancement to the PreTRM test that we develop may not be introduced in a timely or cost-effective manner, may contain defects, errors or vulnerabilities or may not achieve the market acceptance necessary to generate significant revenue. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The typical development cycle of new life sciences products can be lengthy and complicated and may require new scientific discoveries or advancements, considerable resources and complex technology and engineering. Such developments may involve external suppliers and service providers, making the management of development projects complex and subject to risks and uncertainties regarding timing, timely delivery of required components or services and satisfactory technical performance of such components or assembled products. If we do not achieve the required technical specifications or successfully manage new product development processes, or if development work is not performed according to schedule, then such new technologies or products may be adversely impacted. To date, we have only completed the development process for one product. We cannot assure you that we will ever succeed in completing that process for another product, including for major pregnancy related conditions beyond preterm birth, or that even if we do, it will be launched successfully in the market and find commercial acceptance. If we are unable to successfully develop new products, enhance the PreTRM test to meet customer requirements, compete with alternative products or otherwise gain and maintain market acceptance, our business, results of operations and financial condition could be harmed. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Competition in the life science industry, including companies engaged in molecular diagnostics and proteomics, is intense. If we are unable to compete successfully with respect to our current or future products or services, we may not be able to increase or sustain our revenues or achieve profitability.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are a women&#8217;s health diagnostic company utilizing our proprietary proteomics and bioinformatics platform to discover, develop and commercialize biomarker tests, and our first commercial product, the PreTRM test, is designed to accurately predict the risk of premature delivery. The proteomics and bioinformatics industry is characterized by rapid technological changes, frequent new product introductions, reimbursement challenges, emerging competition, intellectual property disputes and litigation, price competition, aggressive marketing practices, evolving industry standards and changing customer preferences. We cannot guarantee that research, discoveries or other advancements by other companies will not render our existing or potential products and services uneconomical or result in products and services that are superior or otherwise preferable to our current or future products and services. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">18</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We face competition with respect to the PreTRM test and expect to face competition with respect to any product candidates that we may seek to develop or commercialize in the future. Many of the companies against which we are competing or may compete against in the future have significantly greater financial resources and expertise in research and development, manufacturing and commercialization. Mergers and acquisitions in our industry may result in even more resources being concentrated among a smaller number of our competitors. Smaller and early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel and conducting clinical trials, as well as in acquiring technologies complementary to, or necessary for, our products and services. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">To remain competitive over time, we will need to continually research and develop improvements to our products and services. However, we cannot assure you that we will be able to develop and commercialize any improvements to our products and services on a timely basis. Our competitors may develop and commercialize competing or alternative products and services and improvements faster than we are able to do so, which would negatively affect our ability to increase or sustain our revenue or achieve profitability. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If our products do not perform as expected, our operating results, reputation and business will suffer.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our success depends on the market&#8217;s confidence that we can provide reliable, high-quality testing results. There is no guarantee that the accuracy and reproducibility we have demonstrated to date will continue as our test volumes continue to increase and our product portfolio continues to expand. We believe that patients that rely on our tests are particularly sensitive to test limitations and errors, including inaccurate test results. As a result, if our tests do not perform as expected or favorably in comparison to competing tests, our operating results, reputation and business will suffer. We may also become subject to legal claims arising from such limitations, errors or inaccuracies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The PreTRM test uses, and our future tests will use, a number of complex and sophisticated proteomic and bioinformatics processes and advanced mass spectrometry techniques, which are highly sensitive to external factors. An operational, technological or other failure in one of these complex processes may result in sensitivity or specificity rates that are lower than we anticipate. In addition, we regularly evaluate and refine our testing processes, and any refinements we make may not improve our tests as we expect and may result in unanticipated issues that may adversely affect our test performance as described above. Such operational, technical and other difficulties adversely affect test performance, may impact the commercial attractiveness of our products and may increase our costs or divert our resources, including management&#8217;s time and attention, from other projects and priorities. Furthermore, any changes to our testing process may require us to use new or different suppliers or materials with whom or which we are unfamiliar, and which may not perform as we anticipate, and could cause delays, downtime or other operational issues. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If our CLIA-certified laboratory facility becomes inoperable, we will be unable to perform our tests and our business will be harmed.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We currently operate a CLIA-certified laboratory facility in Salt Lake City, Utah, which processes the PreTRM test that represents the source of substantially all of our revenues. Our facility could be harmed or rendered inoperable, or our products or other assets could be damaged or destroyed, by natural or manmade disasters, including earthquakes, severe weather, flooding, power outages and contamination, including as a result of the COVID-19 pandemic, which may render it difficult or impossible for us to operate our business and/or perform our tests for some period of time. The inability to perform our tests or the backlog of tests that could develop if our facility is inoperable&#8201;&#8212;&#8201;for even a short period of time&#8201;&#8212;&#8201;may harm our reputation and result in a material adverse effect on our revenues. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The marketing, sale and use of the PreTRM test and any other products that we develop in the future could result in substantial damages arising from product liability or professional liability claims, associated with product recalls or otherwise, that exceed our resources.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The marketing, sale and use of the PreTRM test and any other products that we develop and commercialize in the future could lead to product liability claims against us if someone were to allege that the PreTRM test or any future product failed to perform as it was designed or as claimed in our promotional </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">19</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">materials, was performed pursuant to incorrect or inadequate laboratory procedures, if we delivered incorrect or incomplete test results or if someone were to misinterpret test results. In addition, we may be subject to liability for errors in, a misunderstanding of, or inappropriate reliance upon, the information we provide, or for failure to provide such information, in connection with our marketing and promotional activities or as part of the results generated by the PreTRM test and other future tests. Even though the PreTRM test is highly accurate, it is not 100% accurate, and we may report false results. In such a scenario, the patient or her family may file a lawsuit against us claiming product or professional liability. In addition, any manufacturing or design defects in our products could lead to product recalls, either voluntary or as required by government authorities, which could result in the removal of a product from the market. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A product liability or professional liability claim could result in substantial damages and be costly and time-consuming for us to defend. Although we maintain product and professional liability insurance, our insurance may not fully protect us from the financial impact of defending against product liability or professional liability claims or any judgments, fines or settlement costs arising out of any such claims, or the financial and reputational consequences of a product recall. Any product liability or professional liability claim brought against us, with or without merit, could increase our insurance rates, cause our insurance coverage to be terminated or prevent us from securing insurance coverage in the future. As we attempt to bring new products to market, we may need to increase our product liability coverage, which would be a significant additional expense that we may not be able to afford. Additionally, any product liability or professional liability lawsuit could harm our reputation, result in a cessation of PreTRM testing or cause our partners to terminate our agreements with them, any of which could adversely impact our results of operations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The results of our clinical trials may not support the use of our tests and other product candidates, or may not be replicated in later studies.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have conducted and are currently conducting a variety of observational and interventional studies for the PreTRM test and our other tests in development that involve clinical investigators at multiple sites in the United States. We may need to conduct additional studies for the PreTRM test, as well as other tests we may offer in the future, to drive test adoption in the marketplace and reimbursement. Should we not be able to perform these studies, or should their results not provide clinically meaningful data and value for clinicians, adoption of our tests could be impaired. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The administration of clinical and economic utility studies is expensive and demands significant attention from certain members of our management team. Data collected from these studies may not be positive or consistent with our existing data, or may not be statistically significant or compelling to the medical community or payers. If the results obtained from our ongoing or future studies are inconsistent with certain results obtained from our previous studies, adoption of our products would suffer and our business would be harmed. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Peer-reviewed publications regarding our products and product candidates may be limited by many factors, including delays in the completion of, poor design of, or lack of compelling data from clinical studies, as well as delays in the review, acceptance, and publication process. If our products or product candidates or the technology underlying our current or future products or product candidates do not receive sufficient favorable exposure in peer-reviewed publications, or are not published, the rate of health care provider adoption of our tests and positive reimbursement coverage decisions for our tests and other products could be negatively affected. The publication of clinical data in peer-reviewed journals can be a crucial step in commercializing and obtaining reimbursement for tests, and our inability to control when, if ever, results are published may delay or limit our ability to derive sufficient revenues from any test that is the subject of a study. The performance achieved in published studies may not be repeated in later studies that may be required to obtain U.S. Food and Drug Administration, or FDA, marketing authorizations should we decide to do so for business reasons, or should we be required to submit applications to the FDA or other health authorities seeking such authorizations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, clinical trials must be conducted in accordance with applicable laws and subject to the oversight of Institutional Review Boards, or IRBs, at the medical institutions where the clinical trials are conducted. We rely on clinical trial sites to ensure the proper and timely conduct of our clinical trials and while we have agreements governing their committed activities, we have limited influence over their actual performance. We depend on our collaborators and on medical institutions to conduct our clinical trials in </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">20</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">compliance with applicable human subject protection regulations and Good Clinical Practice, or GCP, requirements. To the extent our collaborators fail to enroll participants for our clinical trials, fail to conduct the study in compliance with applicable law and GCP requirements, or are delayed for a significant time in the execution of trials, including achieving full enrollment, we may be affected by increased costs, program delays, or both. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Interim, top-line and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to confirmation, audit and verification procedures that could result in material changes in the final data.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">From time to time, we may publicly disclose interim, top-line or preliminary data from our clinical trials, which is based on a preliminary analysis of then-available data, and these results and related findings and conclusions may be subject to change following a more comprehensive review of the data. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or have had the opportunity to fully and carefully evaluate all data. As a result, the interim, top-line or preliminary data that we report may differ from future results of the same trials, or different conclusions or considerations may qualify such results once additional data have been received and fully evaluated. Interim data from clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary, interim or top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary top-line data we previously published. As a result, preliminary, interim and top-line data should be viewed with caution until the final data are available. Adverse differences between preliminary, interim and top-line data and final data could significantly harm our business prospects and may cause the price of our common stock to fluctuate or decline. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Further, payers, physicians and others may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could adversely impact the potential of the particular product or program, the prospects for commercialization of any product, and the business prospects of our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is derived from information that is typically extensive, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If the preliminary, interim or top-line data that we report differ from actual results, or if payers, physicians or others disagree with the conclusions reached, our ability to commercialize our product candidates may be significantly impaired, which could materially harm our business, operating results, prospects or financial condition. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our business would be materially harmed if our proprietary biobank were to become contaminated, lost or destroyed.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A fundamental component of our platform is our proprietary and continually growing biobank, consisting of comprehensive, clinically and demographically annotated blood samples collected from more than 10,500 pregnant U.S. women, representing the broad demographic and geographic diversity inherent in the U.S. population. This biobank is maintained at our facility in Salt Lake City, Utah, in a secure environment. If the samples and information contained in the biobank were to become compromised or destroyed, through contamination, theft, a cybersecurity breach, a natural disaster or otherwise, our ability to rely on the data represented in the biobank could be significantly impaired, which could materially harm our business, operating results, prospects or financial condition. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">International expansion of our business will expose us to business, regulatory, political, operational, financial and economic risks associated with doing business outside the United States.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">To the extent that we decide to market our products and services outside the United States, our business will be subject to the risks associated with doing business outside the United States, including an increase in our expenses and diversion of our management&#8217;s attention from the development of future products and services. Accordingly, our business and financial results in the future could be adversely affected due to a variety of factors, including: </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">21</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">multiple, conflicting and changing laws and regulations such as privacy, security and data use regulations, tax laws, export and import restrictions, economic sanctions and embargoes, employment laws, anti-corruption laws, regulatory requirements, reimbursement or payer regimes and other governmental approvals, permits and licenses; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">failure by us or our distributors to obtain any necessary regulatory clearance, authorization or approval for the use of our products and services in various countries; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">additional potentially relevant third-party patent rights; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">complexities and difficulties in obtaining intellectual property protection and maintaining, defending and enforcing our intellectual property outside the United States; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">difficulties in staffing and managing foreign operations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">employment risks related to hiring employees outside the United States; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">complexities associated with managing multiple payer reimbursement regimes, government payers or patient self-pay systems; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">difficulties in negotiating favorable reimbursement negotiations with governmental authorities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">logistics and regulations associated with shipping samples, including infrastructure conditions and transportation delays; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">limits in our ability to penetrate international markets if we are not able to sell our products or conduct services locally; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products and services and exposure to foreign currency exchange rate fluctuations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade and other business restrictions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">regulatory and compliance risks that relate to maintaining accurate information and control over sales and distributors&#8217; activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act, or FCPA, its books and records provisions, or its anti-bribery provisions, or laws similar to the FCPA in other jurisdictions in which we may operate, such as the United Kingdom&#8217;s Bribery Act of 2010, or the U.K. Bribery Act; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">onerous anti-bribery requirements of several member states in the EU, the United Kingdom, Japan, and other countries that are constantly changing and require disclosure of information to which U.S. legal privilege may not extend. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any of these factors could significantly harm our future international expansion and operations and, consequently, our revenue and results of operations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may not be able to obtain and maintain the third-party relationships that are necessary to develop and commercialize some or all of our tests.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We expect to depend on collaborators, partners, licensees and other third parties to support our test development and validation efforts, to deliver needed supplies, and to transport specimens for testing, among other things. Any problems we experience with any of these third parties could delay the development, validation, commercialization, and performance of our testing, which could harm our results of operations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We cannot guarantee that we will be able to successfully negotiate agreements for, or maintain relationships with, collaborators, partners, licensees, and other third parties on favorable terms, if at all. If we are unable to obtain or maintain these agreements, we may not be able to develop, validate, obtain regulatory authorizations for, or commercialize any future tests, which will in turn adversely affect our business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We expect to expend substantial management time and effort to enter into relationships with third parties and, if we successfully enter into such relationships, to manage these relationships. In addition, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">22</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">substantial amounts will be paid to third parties in these relationships. However, we cannot control the amount or timing of resources our future contract partners will devote to our business endeavors, and we cannot guarantee that these parties will fulfill their obligations to us under these arrangements in a timely fashion, if at all. In addition, while we manage the relationships with third parties, we cannot control all of the operations of and protection of intellectual property by such third parties. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We rely on third parties for sample collection, including phlebotomy services, and commercial courier delivery services, and if these services are disrupted, our business will be harmed.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We rely on third parties to perform sample collection, including phlebotomy services, and to transport samples to our laboratory facility in a timely and cost-efficient manner. Disruptions in these services, whether due to any natural or other disasters, pandemics, acts of war or terrorism, shipping embargoes, labor unrest, political instability or similar events could adversely affect specimen integrity and our ability to process samples in a timely manner and to service our customers, and ultimately our reputation and our business. In addition, if we are unable to continue to obtain expedited delivery services on commercially reasonable terms, our operating results may be adversely affected. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, our relationships with these service providers could be scrutinized under federal and state health care laws such as the federal Anti-Kickback Statute and the Stark Law, and their implementing regulations, to the extent, for example, that these services provide a financial benefit to or relieve a financial burden for a potential referral source. If our operations are found to be in violation of any of these laws and regulations, we may be subject to administrative, civil and criminal penalties, damages, fines, individual imprisonment, refunding of payments received by us and curtailment or cessation of our operations, among other potential penalties, any of which could harm our reputation and adversely affect our business, operating results and financial condition. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We rely on a limited number of suppliers or, in some cases, single suppliers, for some of our laboratory instruments and materials and may not be able to find replacements or immediately transition to alternative suppliers on a cost-effective basis, or at all.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We source components of our technology from third parties and certain components are sole sourced. Obtaining substitute components may be difficult or require us to re-design our products. Any natural or other disasters, such as the ongoing COVID-19 pandemic, acts of war or terrorism, shipping embargoes, labor unrest or political instability or similar events at our third-party suppliers&#8217; facilities that cause a loss of manufacturing capacity or a reduction in the quality of the items manufactured would heighten the risks that we face. Changes to, failure to renew or termination of our existing agreements or our inability to enter into new agreements with other suppliers could result in the loss of access to important components of our tests and could impair, delay or suspend our commercialization efforts. Our failure to maintain a continued and cost-effective supply of high-quality components could materially and adversely harm our business, operating results, and financial condition. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we are unable to successfully scale our operations, or to attract and retain highly skilled employees, our business could suffer.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As our test volumes grow and we develop future product offerings, we will need to continue to ramp up our testing capacity and implement increases in scale, such as increased headcount, additional or upgraded equipment, additional qualified laboratory personnel, increased office and laboratory space, expanded customer service capabilities, improved billing and systems processes, enhanced controls and procedures and expanded or internal quality assurance program and technology platform. The value of the PreTRM test and our other testing products that we may develop in the future depends on our ability to perform, and our reputation for performing, the tests on a timely basis and at an exceptionally high standard of quality. Failure to implement necessary procedures, transition to new facilities, equipment or processes or to hire the necessary personnel in a timely and effective manner could result in higher processing costs or an inability to meet market demand or could otherwise affect our operating results. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">To execute our growth plan, we must attract and retain highly qualified personnel. Competition for these personnel is intense, especially for sales, scientific, medical, laboratory, research and development and other technical personnel, and the turnover rate of such personnel can be high. We may, from time to time, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">23</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">experience difficulty in hiring and retaining employees with appropriate qualifications. Many of the companies with which we compete for highly qualified personnel have greater resources than we have. If we hire employees from competitors or other companies, their former employers may attempt to assert that these employees or our company have breached their legal obligations to their former employers, which occurs from time to time. Furthermore, to the extent that we are unable to retain our employees and they leave our company to join one of our competitors, we cannot assure you that any invention, non-disclosure or non-compete agreements we have in place will provide meaningful protection against a departing employee&#8217;s unauthorized use or disclosure of our confidential information. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, our growth may place a significant strain on our operating and financial systems and our management, sales, marketing and administrative resources. As a result of our growth, our operating costs may escalate faster than we anticipate, we may face difficulties in obtaining additional office or laboratory space and some of our internal systems may need to be enhanced or replaced. If we cannot effectively manage our expanding operations and our costs, we may not be able to grow successfully or we may grow at a slower pace, and our business could be adversely affected. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may engage in acquisitions, dispositions or other strategic transactions that could disrupt our business, cause dilution to our stockholders or reduce our financial resources.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">From time to time, we may enter into transactions to acquire or dispose of businesses, products or technologies or to engage in other strategic transactions. Because we have not made any such acquisitions to date, our ability to do so successfully is unproven. Even if we identify suitable transactions, we may not be able to complete such transactions on favorable terms or at all. Any acquisitions or other strategic transactions we consummate may not strengthen our competitive position, and these transactions may be viewed negatively by customers or investors. We may decide to incur debt in connection with an acquisition or issue shares of our common stock or other equity securities to the stockholders of the acquired company, which would cause dilution to our existing stockholders. We could incur losses resulting from such strategic transactions, including undiscovered liabilities of an acquired business that are not covered by any indemnification we may obtain from the seller. In addition, we may not be able to successfully integrate any acquired personnel, technologies and operations into our existing business in an effective, timely and non-disruptive manner. Any dispositions may also cause us to lose revenue and may not strengthen our financial position. Strategic transactions may also divert management attention from day-to-day responsibilities, increase our expenses, result in accounting charges and reduce our cash available for operations and other uses. We cannot predict the number, timing or size of future strategic transactions or the effect that any such transactions might have on our operating results. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may need to raise additional funds through equity or debt financings, corporate collaborations or licensing arrangements to continue to fund or expand our operations. Additional capital, if needed, may not be available on satisfactory terms or at all. Furthermore, any additional capital raised through the sale of equity or equity-linked securities, or grant of equity or equity-linked securities in connection with any debt financing, will dilute stockholders&#8217; ownership interests in us and may have an adverse effect on the price of our common stock. In addition, the terms of any financing may adversely affect stockholders&#8217; holdings or rights. To the extent that we raise capital through collaborations and licensing arrangements, it may be necessary to relinquish some rights to our technologies or grant licenses on terms that may not be favorable to us. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If we are not able to obtain adequate funding when needed, we may have to delay development programs or sales and marketing initiatives. In addition, we may have to work with a partner on one or more of our tests or programs, which could lower the economic value of those programs to our company. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The ongoing COVID-19 pandemic could materially affect our operations, as well as the business or operations of third parties with whom we conduct business. Our business could be adversely affected by the effects of other future health epidemics or pandemics in regions where we, or third parties on which we rely, have significant business operations.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our business and its operations, including, but not limited to, our laboratory operations, sales and marketing efforts, supply chain operations, research and development activities and fundraising activities, could be adversely affected by health epidemics in regions where we have business operations, and such health </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">24</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">epidemics could cause significant disruption in the operations of third parties upon whom we rely. For example, in December&#160;2019, a novel strain of coronavirus, SARS-CoV-2, causing a disease referred to as COVID-19, was reported to have surfaced in Wuhan, China. Since then, COVID-19 has spread to other countries and throughout the United States. In March&#160;2020, the World Health Organization declared the COVID-19 outbreak a pandemic, and the U.S. government imposed restrictions on travel between the United States, Europe, and certain other countries. Since March&#160;2020, numerous state and local jurisdictions, including the jurisdictions where our headquarters and laboratory are located, have imposed, and others in the future may impose, quarantines, shelter-in-place orders, executive orders and similar government orders for their residents to control the spread of COVID-19. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In response to these public health directives and orders, we have implemented work-from-home policies for substantially all of our employees. The effects of the executive orders, the shelter-in-place orders, and our work-from-home policies may negatively impact productivity, disrupt our business and delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. These and similar, and perhaps more severe, disruptions in our operations could negatively impact our business, operating results and financial condition. We continue to monitor state and local quarantine, shelter-in-place orders, executive orders and similar government orders and have begun reopening our offices to allow certain employees to return to the office, as needed, in accordance with our reopening plan, which is based on a phased approach that is appropriately tailored for each of our offices, with a focus on employee safety and optimal work environment. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Quarantines, shelter-in-place orders, executive orders and similar government orders, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, related to COVID-19 or other infectious diseases, could impact personnel at third-party manufacturing facilities, or the availability or cost of materials we use or require to conduct our business, which would disrupt our supply chain. In particular, some of our suppliers of certain materials used in our laboratory operations and research and development activities may be located in areas that are subject to executive orders and shelter-in-place orders. While many of these materials may be obtained from more than one supplier, port closures and other restrictions resulting from the COVID-19 pandemic or future pandemics may disrupt our supply chain or limit our ability to obtain sufficient materials to operate our business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, our clinical trials could be affected by the COVID-19 pandemic. The primary impact to our business has been the early cessation of enrollment in our AVERT PRETERM TRIAL in March&#160;2020, and the delayed commencement of enrollment in our PRIME study until November&#160;2020. If COVID-19 continues to spread in the United States and elsewhere, we may experience additional disruptions that could severely impact our business, preclinical studies and clinical trials. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The spread of COVID-19, which has caused a broad impact globally, may materially affect us economically, including by causing a significant reduction in laboratory testing volumes. In addition, reimbursements for our tests may also be delayed if third-party payers&#8217; processing is impacted by the COVID-19 pandemic and work-from-home policies and other operational limitations mandated by federal, state, and local governments as a result of the pandemic. While the potential economic impact brought by COVID-19, and the duration of such impact, may be difficult to assess or predict, the widespread pandemic has resulted in significant disruption of global financial markets, which could reduce our ability to access capital and negatively affect our future liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 and related government orders and restrictions could materially affect our business and the value of our common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The COVID-19 pandemic continues to evolve rapidly. The ultimate impact of the COVID-19 pandemic or a similar health epidemic is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, health care systems or the global economy as a whole. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We cannot ensure that our employees will fully adhere to compliance policies and procedures.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are in the process of implementing compliance policies and procedures intended to train our sales, billing, marketing and other personnel regarding compliance with state and federal laws applicable to our </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">25</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">business. Our efforts to implement appropriate monitoring of compliance with such policies and procedures are likewise ongoing. Despite our compliance policies and procedures, and related training and monitoring, we may experience situations in which employees may have failed to fully adhere to our policies and applicable laws in the past or in which they fail to adhere to applicable policies and/or laws in the future. Such failures may subject us to administrative, civil, and criminal actions, penalties, damages, fines, individual imprisonment, exclusion from participation in federal healthcare programs, refunding of payments received by us and curtailment or cessation of our operations. In addition, commercial third-party payers may refuse to provide all or any reimbursement for tests administered, seek repayment from us of amounts previously reimbursed and harm our ability to secure network contracts with third-party payers. Any of the foregoing could adversely affect our revenue, cash flow, and financial condition, and reduce our growth prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we lose the services of our Chairman, President and Chief Executive Officer, our Chief Scientific Officer or other members of our senior management team, we may not be able to execute our business strategy.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our success depends in large part upon the continued service of our senior management team. In particular, our Chairman, President and Chief Executive Officer, Gregory C. Critchfield, M.D., M.S., and John J. Boniface, Ph.D., our Chief Scientific Officer, are critical to our vision, strategic direction, culture, products and technology. In addition, we do not maintain key-man insurance for Dr.&#160;Critchfield or any other member of our senior management team. The loss of our Chairman, President and Chief Executive Officer, Chief Scientific Officer or one or more other members of our senior management team could have an adverse effect on our business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have a significant amount of net operating loss, or NOL, carryforwards that can be used to offset potential future taxable income and related income taxes. As of December&#160;31, 2020, we had federal and state NOL carryforwards of approximately $125.1&#160;million, of which, $70.2&#160;million, if not utilized, begin to expire in 2028. Approximately $54.9&#160;million of these federal NOLs can be carried forward indefinitely. Under Section&#160;382 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an &#8220;ownership change&#8221; &#8203;(generally defined as a greater than 50% change, by value, in equity ownership over any three-year period), the corporation&#8217;s ability to use its pre-change NOL carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. We may experience ownership changes in the future as a result of shifts in our stock ownership, some of which may not be within our control. Our ability to use these carryforwards could be limited if we experience an &#8220;ownership change.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our estimates of total addressable market opportunity and forecasts of market growth may prove to be inaccurate, and even if the market in which we compete achieves the forecasted growth, our business could fail to grow at a similar rate.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Total addressable market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates that may not prove to be accurate. Our publicly announced estimates and forecasts relating to the size and expected growth of our market may prove to be inaccurate. Even if the market in which we compete meets our size estimates and forecasted growth, our business could fail to grow at similar rates. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Reimbursement</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:7pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If third-party payers do not adequately reimburse for any new tests we may develop, our new tests may not be purchased or used, which may adversely affect our revenue and profits.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the United States and markets in other countries, patients generally rely on third-party payers to reimburse all or part of the costs associated with their treatment or tests. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payers is critical to new product acceptance. Our business depends on our ability to obtain or maintain adequate reimbursement coverage from third-party payers. We expect third-party payers such as third-party commercial insurers to be our most significant sources of payments in the near future. In particular, we believe that for our company to achieve commercial success, it will be necessary to gain acceptance from third-party payers for the PreTRM test, and to obtain positive coverage determinations and favorable reimbursement </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">26</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">rates from third-party payers for our tests. In addition, we do not yet know whether and to what extent certain of our products, including those under development, will be covered or reimbursed. If we are unable to obtain or maintain coverage or adequate reimbursement from, or achieve in-network status with, third-party payers for our existing or future tests or other products, our ability to generate revenues will be limited. For example, health care providers may be reluctant to order our tests or other products due to the potential of a substantial cost to the patient if coverage or reimbursement is unavailable or insufficient. Such coverage and reimbursement may depend upon a number of factors, including the determination that the test and its use or administration for a particular patient are: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">a covered benefit; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">safe, effective, and medically necessary; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">appropriate for the specific patient; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">supported by guidelines established by the relevant professional college; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">approved in any states where specific assay approval is necessary; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">cost-effective; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">neither experimental nor investigational. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the United States, the principal decisions about reimbursement for new tests may be made by the Centers for Medicare &amp; Medicaid Services, or CMS, an agency within the United States Department of Health and Human Services, or HHS. Third-party payers often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates, and both CMS and other third-party payers may have sufficient market power to demand significant price reductions. Further, due to the COVID-19 pandemic, millions of individuals have lost or will be losing employer-based insurance coverage, which may adversely affect our ability to commercialize our products. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Obtaining coverage and reimbursement approval for a test from each third-party payer is a time-consuming and costly process that could require us to provide to each payer supporting scientific, clinical and related data. We may not be able to provide data sufficient to satisfy third-party payers that the test should be covered and reimbursed. There is substantial uncertainty whether any particular payer will cover and reimburse the use of any test incorporating new technology. Even when a payer determines that a test is eligible for reimbursement, the payer may impose coverage limitations that preclude payment under certain circumstances or for certain patient populations. Moreover, eligibility for coverage does not imply that any test will be reimbursed in all cases or at a rate that allows us to make a profit or even cover our costs. Interim payments for new tests, if applicable, may also not be sufficient to cover our costs and may not be made permanent. In some instances, payment may only be obtained by engaging in lengthy and costly appeals processes. Reimbursement rates may vary, for example, according to the use of the test and the clinical setting in which it is used, and may reflect budgetary constraints and/or imperfections in Medicare, Medicaid or other data used to calculate these rates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">There have been, and we expect that there will continue to be, federal and state proposals to constrain expenditures for health care products and services, which may affect payments for our tests. Governmental and private entities that establish reimbursement policies, including CMS, frequently change coverage policies, product and service codes and payment methodologies and reimbursement values. Due in part to actions by third-party payers, the health care industry is experiencing a trend toward containing or reducing costs through various means, including lowering reimbursement rates and negotiating reduced payment schedules with service providers for certain products and/or services. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our inability to promptly obtain coverage and profitable reimbursement rates from third-party payers for our tests could have a material and adverse effect on our business, operating results and financial condition. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, leading professional societies may recommend alternatives to our tests, which may provide a basis for third-party payers not to cover or reimburse our tests. In making coverage determinations, third-party payers often rely on practice guidelines issued by professional societies. Test-ordering providers may also rely on such guidelines when deciding whether to order testing for their patients. If any relevant </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">27</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">professional societies issue guidelines suggesting, or otherwise make recommendations, that providers not use our tests or instead use alternatives to our tests, payers may make unfavorable coverage and reimbursement decisions and test-ordering providers may not order our tests. Any such outcomes could have a material and adverse effect on our business, operating results, and financial condition. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">New reimbursement methodologies applicable to the PreTRM test, and other future tests, including new CPT codes, may decrease reimbursement rates from third-party payers.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The American Medical Association, or AMA, generally assigns specific billing codes for laboratory tests under a coding system known as Current Procedure Terminology, or CPT, which we must use to bill and receive reimbursement for our tests. Once a CPT code is established, CMS establishes payment levels and coverage rules for that code under Medicare and Medicaid. Commercial insurers likewise establish their own payment rates and coverage rules for that code. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The AMA has issued a unique CPT</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">&#8203;<font style="letter-spacing:0.15pt;"> </font></font><font style="letter-spacing:0.2pt;">PLA code for the PreTRM test. Before the AMA issued a CPT PLA code for the PreTRM test, we submitted claims for reimbursement using CPT codes existing at the time based on the guidance of outside coding experts and legal counsel. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We cannot guarantee that we will be able to negotiate favorable rates for our unique code, nor can we guarantee that we will receive reimbursement at all, especially if we are unable to collect and publish additional data and obtain positive coverage determinations for the PreTRM test or our other future tests. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We do not currently have specific CPT codes assigned for any of our other tests under development and there is a risk that we may not be able to obtain such codes or, if obtained, we may not be able to negotiate favorable rates for such codes. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Finally, third-party payers may not establish positive coverage policies for our tests or adequately reimburse for any CPT code we may use, or seek recoupment for testing previously performed, which is a common occurrence in our industry. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Billing disputes with third-party payers, including disagreement regarding the selection and use of CPT codes when submitting claims, may decrease realized revenue and may lead to requests for recoupment of past amounts paid.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">It is possible that payers could dispute our billing or coding from time to time. Payers may likewise request recoupments of our business, and we expect that these disputes and requests or recoupment may arise. Third-party payers may also decide to deny payment or recoup payment for testing that they contend to have been not medically necessary, against their coverage determinations, or for which they have otherwise overpaid. There is also a risk that the CPT codes we previously submitted, are currently submitting, or will submit in the future on claims will be rejected or withdrawn or that third-party payers will seek refunds of amounts that they claim were inappropriately billed based on, for example, the CPT code used, the modifier attached or the number of&#160;units billed. Claims for recoupment require the time and attention of our management and other key personnel, which can be a distraction from operating our business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If third-party payers deny payment for testing, reimbursement revenue for our testing could decline. If a third-party payer successfully challenges that payment for prior testing was in breach of contract or otherwise contrary to policy or law, they may recoup payment, which amounts could be significant and would impact our operating results and financial condition, and it may decrease reimbursement going forward. We may also decide to negotiate and settle with a third-party payer in order to resolve an allegation of overpayment. Any of these outcomes, including recoupment or reimbursements, might also require us to restate our financials from a prior period, any of which could have a material and adverse effect on our business, operating results, and financial condition. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Failure to comply with laws and regulations related to submission of claims for our services could result in substantial financial penalties and/or potential civil or criminal liability.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are subject to a variety of complex federal and state laws and regulations applicable to the submission of claims for payment for our services. If a third-party payer or a regulatory or enforcement agency, or, in some cases, </font><font style="font-style:italic;letter-spacing:0.2pt;">qui tam</font><font style="letter-spacing:0.2pt;"> relators, believe or allege that we engaged in improper billing practices, including, but not </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">28</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">limited to, submitting improper CPT codes, multipliers or modifiers on our claims, we may be subject to investigation and/or enforcement actions under federal and/or state law. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="font-style:normal;letter-spacing:0.2pt;">Responding to and defending such investigations and/or enforcement actions may require significant time and attention from management and key personnel, include significant expenditures, and result in significant penalties, damages, fees, and reputational harm, all of which could have a material adverse effect on our business, operating results, and financial condition. </font><font style="letter-spacing:0.2pt;">See &#8220;&#8212; Risks Related to Government Regulation&#8201;&#8212;&#8201;If we, or our employees or contractors on our behalf, engage in conduct that violates health care laws, are suspected or accused of engaging in such conduct, or are subject to investigation for actual or alleged such conduct, we could face substantial penalties and damage to our reputation, and our business operations and financial condition could be adversely affected</font><font style="font-style:normal;letter-spacing:0.2pt;">.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#8220;Most favored nation&#8221; provisions in contracts with third-party payers may limit potential for revenue growth and may lead to claims for recoupment.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Some of our contracts with third-party payers may in the future contain &#8220;most favored nation&#8221; provisions, pursuant to which we typically agree that we will not bill the third-party payer more than we bill any other third-party payer. These contract provisions limit the amount we are able to charge for our products and can negatively impact revenue. We monitor our billing and claims submissions for compliance with these contractual requirements with third-party payers. If we do not successfully manage compliance with these most favored nation provisions, we may be required to forego revenues from some third-party payers or reduce the amount we bill to each third-party payer with a most favored nation clause in its contract that is violated, which would adversely affect our business, operating results, and financial condition. This situation could also subject us to claims for recoupment, which could ultimately result in an obligation to repay amounts previously earned. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">When third-party payers deny coverage, we are often unable to collect from the patient or any other source and risk disputes if we attempt to do so.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If a third-party payer denies coverage, or if the patient has a large deductible or co-insurance amount, it may be difficult for us to collect from the patient, and we may not be successful in doing so. If we are in-network, we may be contractually prohibited from seeking payment from the patient. If we are out-of-network, we may be unable to collect the full amount of a patient&#8217;s responsibility, despite our good faith efforts to collect. As a result, we may not always be able to collect the full amount due for our tests if third-party payers deny coverage, cover only a portion of the invoiced amount or the patient has a large deductible, which could cause payers to raise questions regarding our billing policies and patient collection practices. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe that our practices with respect to billing and collecting patient responsibility amounts are compliant with applicable laws; however, we may in the future receive inquiries from third-party payers regarding our practices in these areas. There is no guarantee that we will be successful in addressing such concerns, and if we are unsuccessful, this may result in a third-party payer deciding to reimburse for our tests at a lower rate or not at all, seeking recoupment of amounts previously paid to us, or bringing legal action to seek reimbursement of previous amounts paid. Any of such occurrences could cause reimbursement revenue for our testing, which constitutes the large majority of our revenue, to decline. Additionally, if we were required to make a repayment, such repayment could be significant, which could have a material and adverse effect on our business, operating results, and financial condition. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our revenues may be adversely impacted if third-party payers withdraw coverage or provide lower levels of reimbursement due to changing policies, billing complexities or other factors.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If we become an in-network provider by entering into an agreement with any of the third-party payers from which we receive reimbursement, this means that we will have an agreement that governs approval or payment terms. However, such a contract would not guarantee reimbursement for all testing we perform. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, the terms of any such agreement may require a physician or qualified practitioner&#8217;s signature on test requisitions or require other controls and procedures prior to conducting a test. In particular, third-party payers have been increasingly requiring prior authorization to be obtained prior to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">29</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">conducting a test as a condition to reimbursing for the test. If the payers were to do so for the PreTRM test, it could place a burden on our billing operations and require us to dedicate resources to monitor that these prior authorization requirements are met. To the extent we or the health care providers ordering our tests do not follow the prior authorization requirements, we may be subject to claims for recoupment of reimbursement amounts previously paid to us, or may not receive some or all of the reimbursement payments to which we would otherwise be entitled. This may occur in the future, which could have a material and adverse effect on our business, operating results, and financial condition. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If we are considered to be an out-of-network provider, which we expect to be the case with at least some of the largest third-party payers from which we may receive reimbursement in the future, such third-party payers could withdraw coverage and decline to reimburse for our tests, for any reason. They can also impose prior authorization requirements through the terms of the patients&#8217; health plans. Managing reimbursement on a case-by-case basis is time-consuming and contributes to an increase in the number of days it takes us to collect on accounts, which also increases our risk of non-payment. Negotiating reimbursement on a case-by-case basis also typically results in the receipt of reimbursement at a significant discount to the list price of our tests. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Even if we are being reimbursed for our tests, third-party payers may unilaterally review and adjust the rate of reimbursement, require co-payments from patients or stop paying for our tests. Both government health care programs and private insurers continue to increase their efforts to control the cost, utilization and delivery of health care services by demanding price discounts or rebates and limiting coverage of, and amounts they will pay for, molecular tests. These measures have resulted in reduced payment rates and decreased utilization in the clinical laboratory industry. Because of these cost-containment measures, governmental and commercial insurers&#8201;&#8212;&#8201;including those that may reimburse our tests in the future&#8201;&#8212;&#8201;may reduce, suspend, revoke or discontinue payments or coverage at any time. Reduced reimbursement of our tests may harm our business, operating results, and financial condition. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Billing for clinical laboratory testing services is complex. We perform tests in advance of payment and without certainty as to the outcome of the billing process. In cases where we expect to receive a fixed fee per test due to our reimbursement arrangements, we may nevertheless encounter variable reimbursement, leading to disputes over pricing and billing. Each third-party payer typically has different billing requirements, and the billing requirements of many payers have become increasingly difficult to meet. Among the factors complicating our billing of third-party payers are: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">disparity in coverage among various payers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">disparity in information and billing requirements among payers, including with respect to prior authorization requirements and procedures and establishing medical necessity; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">incorrect or missing billing information, which is required to be provided by the ordering health care provider. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">These risks related to billing complexities, and the associated uncertainty in obtaining payment for our tests, could harm our business, operating results, and financial condition. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Status as an out-of-network provider with a large commercial insurer may cause health care providers to avoid recommending our tests.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may be considered to be an out-of-network provider with respect to the large commercial insurers from which we may receive reimbursement from in the future. Physician groups and other health care providers may view this negatively and may insist upon only using reference laboratories that are in-network with their patients&#8217; insurance companies. These types of decisions could reduce our revenue and harm our financial condition. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Changes in government health care policy could increase our costs and negatively impact coverage and reimbursement for our tests by governmental and other third-party payers.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The U.S. government is pursuing health care reform and aiming to reduce health care costs. Government health care policy has been, and will likely continue to be, a topic of extensive legislative and executive activity in the U.S. federal government and many U.S. state governments. As a result, our business could be </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">30</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">affected by significant and potentially unanticipated changes in government health care policy, which could in turn substantially impact our revenues, increase costs, and divert management attention from our business strategy. We cannot predict the impact of governmental health care policy changes on our future business, operating results, and financial condition. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the United States, the Affordable Care Act, or ACA, was signed into law in March&#160;2010 and significantly impacted the U.S. pharmaceutical and medical device industries, including the diagnostics sector, in a number of ways. The ACA restricts insurers from charging higher premiums or denying coverage to individuals with pre-existing conditions, and requires insurers to cover certain preventative services without charging any copayment or coinsurance, including screening for lung, breast, colorectal and cervical cancers. The ACA also created a new system of health insurance &#8220;exchanges&#8221; designed to make health insurance available to individuals and certain groups through state- or federally-administered marketplaces in addition to existing channels for obtaining health insurance coverage. In connection with such exchanges, certain &#8220;essential health benefits&#8221; are intended to be made more consistent across plans, setting a baseline coverage level. The states (and the federal government) have some discretion in determining the definition of &#8220;essential health benefits&#8221; and we do not know whether our tests or other products will fall into a benefit category deemed &#8220;essential&#8221; for coverage purposes across the plans offered in any or all of the exchanges. If any of our tests are not covered by plans offered in the health insurance exchanges, our business, operating results and financial condition could be adversely affected. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">There have been multiple attempts to repeal the ACA or significantly scale back its applicability, which could negatively impact reimbursement for our testing, adversely affect our test volumes and adversely affect our business, operating results, and financial condition. In December&#160;2018, a U.S. District Court Judge in the Northern District of Texas, or the Texas District Court Judge, ruled that the entire ACA is invalid based primarily on the fact that as part of the 2017 Tax Cuts and Jobs Act, Congress repealed the tax-based shared responsibility payment imposed by the ACA commonly referred to as the &#8220;individual mandate.&#8221; The repeal of this mandate means that fewer consumers will carry insurance coverage and therefore may be less likely to elect to receive our testing because they would be required to pay out of pocket for such tests. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In December&#160;2019, the Fifth Circuit Court of Appeals upheld the Texas District Court&#8217;s ruling that the individual mandate was unconstitutional and remanded the case back to the Texas District Court to determine whether the remaining provisions of the ACA were nonetheless valid. On March&#160;2, 2020, the U.S. Supreme Court granted petitions for writs of certiorari to review this case and oral arguments occurred on November&#160;10, 2020; although it is unclear how the Supreme Court will rule, a decision is expected in Spring 2021. Because it is unclear whether or how the ACA may change, and whether and to what extent clinical laboratory testing may be affected, especially given the new administration, we are uncertain how our business may be impacted. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition to the ACA, various health care reform proposals have also emerged from federal and state governments. The Protecting Access to Medicare Act of 2014, or PAMA, for example, introduced a multi-year pricing program for services payable under the Clinical Laboratory Fee Schedule, or CLFS, that is designed to bring Medicare allowable amounts in line with the amounts paid by private payers. The rule issued by CMS to implement PAMA required certain laboratories to report third-party payer rates and test volumes. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The implementation of Medicare rates pursuant to PAMA has negatively impacted overall pricing and reimbursement for many clinical laboratory testing services and may do so in the future. Since January&#160;1, 2018, the Medicare payment rate for these tests is equal to the weighted median private payer rate reported to CMS, which for many tests is lower than the previous CLFS payment rates due to the often lower negotiated private insurer rates applicable to large commercial laboratories that were required to report data to CMS. Likewise, because private insurers often base their pricing for laboratory testing on a&#160;percentage of the price set on the CLFS, PAMA has in turn affected rates paid by private insurers. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Although we do not presently submit claims to Medicare or other state and federal health care programs, the rates paid by these programs have been the subject of controversy in the industry, including a lawsuit by the American Clinical Laboratory Association, and it is unclear whether and to what extent the new rates may change. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Other legislative changes have been proposed and adopted in the United States since the Affordable Care Act was enacted. In August 2011, the Budget Control Act of 2011, among other things, created </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">31</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers up to 2% per fiscal year, and, due to subsequent legislative amendments, will remain in effect through 2030 unless additional Congressional action is taken. Pursuant to the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, as well as subsequent legislation, these reductions have been suspended from May 1, 2020 through March 31, 2021 due to the COVID-19 pandemic. Proposed legislation, if passed, would extend this suspension until the end of the pandemic.</font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We cannot predict whether future health care initiatives will be implemented at the federal or state level or how any such future legislation, regulation, or initiative may affect us. Current or potential future federal legislation and the expansion of government&#8217;s role in the U.S. health care industry, as well as changes to the reimbursement amounts paid by third-party payers for our current and future tests, may adversely affect our test volumes and adversely affect our business, operating results, and financial condition. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If the validity of an informed consent from a patient is challenged, we could be precluded from billing for such patient&#8217;s testing, be forced to stop performing certain tests, forced to exclude the patient&#8217;s data or samples from clinical trial results or be subject to lawsuits or regulatory enforcement.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are required to ensure that all clinical data and blood samples that we receive have been collected from subjects who have provided appropriate informed consent for us to perform our testing, both commercially and in clinical trials. Among other things, in our consent forms, we seek to ensure that the subjects from whom the data and samples are collected do not retain or have conferred on them any proprietary or commercial rights to the data or any discoveries derived from them. A subject&#8217;s informed consent could be challenged in the future, and the informed consent could prove invalid, unlawful or otherwise inadequate for our purposes. Any such findings against us, or our partners, could deny us access to, or force us to stop, testing samples in a particular territory or could call into question the results of our clinical trials. We could also be precluded from billing third-party payers for tests for which informed consents for such tests are challenged, or we could be requested to refund amounts previously paid by third-party payers for such tests. We could become involved in legal challenges or regulatory enforcement, which could require significant management and financial resources and adversely affect our operating results. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Government Regulation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:7pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may be adversely impacted by changes in laws and regulations, or in their application.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The healthcare industry in which we operate is highly regulated, and failure to comply with applicable regulatory, supervisory, accreditation, registration or licensing requirements may adversely affect our business, operating results and financial condition. The laws and regulations governing our research and marketing efforts are extremely complex and in many instances there are no clear regulatory or judicial interpretations of these laws and regulations, which increases the risk that we may be found to be in violation of these laws. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Furthermore, the industry is growing, and regulatory agencies such as HHS or the FDA may apply heightened scrutiny to new developments. While we have taken steps to ensure compliance with current regulatory frameworks in all material respects as historically enforced by the applicable regulatory agencies, given the highly complex and often unclear guidelines, there could be areas where we are unintentionally and unknowingly noncompliant. Any change in the federal or state laws or regulations relating to our business may require us to implement changes to our business or practices, and we may not be able to do so in a timely or cost-effective manner. Should we be found to be noncompliant with current or future regulatory requirements, we may be subject to sanctions that could include changes to our operations, adverse publicity, substantial financial penalties and criminal proceedings, which may adversely affect our business, operating results and financial condition by increasing our cost of compliance or limiting our ability to develop, market and commercialize our products. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, there has been a recent trend of increased U.S. federal and state regulation of payments made to physicians, which are governed by laws and regulations including the Stark Law, the federal Anti-Kickback Statute, the Physician Payments Sunshine Act, the Eliminating Kickbacks in Recovery Act of 2018 </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">32</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">and the federal False Claims Act, or FCA, as well as state equivalents of such laws. For example, the Stark Law and some state law equivalents include many requirements such as tracking and/or capping non-monetary compensation provided to referring physicians, unless an exception protects that compensation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">While we are implementing a compliance plan intended to address compliance with government laws and regulations, including applicable fraud and abuse laws and regulations such as those described in this risk factor, the evolving commercial compliance environment and the need to build and maintain robust and scalable systems to comply with regulations in multiple jurisdictions with different compliance and reporting requirements increases the possibility that we could inadvertently violate one or more of these requirements. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Changes in the way the FDA regulates the reagents, other consumables and testing equipment we use when developing, validating and performing our tests could result in delay or additional expense in bringing our tests to market or performing such tests for our customers.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Many of the sequencing instruments, reagents, kits and other consumable products used to perform our testing, as well as the instruments and other capital equipment that enable the testing, are offered for sale as analyte specific reagents, or ASRs, or for research use only, or RUO. ASRs are medical devices and must comply with FDA quality system requirements provisions and other device requirements, but most are exempt from premarket review by the FDA as an </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;"> diagnostic product. Products that are intended for RUO and are labeled as RUO are exempt from compliance with most FDA requirements, including the approval or clearance and other product quality requirements for medical devices. A product labeled RUO but which is actually intended for clinical diagnostic use may be viewed by the FDA as adulterated and misbranded under the Federal Food, Drug and Cosmetic Act, or the FD&amp;C Act, and subject to FDA enforcement action. The FDA has said that when determining the intended use of a product labeled RUO, it will consider the totality of the circumstances surrounding distribution and use of the product, including how the product is marketed and to whom. The FDA could disagree with a supplier&#8217;s assessment that the supplier&#8217;s products are RUOs, or could conclude that products labeled as RUO are actually intended for clinical diagnostic use, and could take enforcement action against the supplier, including requiring the supplier to cease offering the product while it seeks appropriate marketing authorization from FDA. Suppliers of ASRs and RUO products that we employ in our tests may cease selling their respective products, and we may be unable to obtain an acceptable substitute on commercially reasonable terms or at all, which could significantly and adversely affect our ability to provide timely testing results to our customers or could significantly increase our costs of conducting business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we fail to comply with federal and/or state laboratory licensing requirements, we could lose the ability to perform our tests or experience disruptions to our business.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are subject to CLIA, a federal law that regulates clinical laboratories that perform testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention or treatment of disease. CLIA regulations require clinical laboratories to obtain a certificate and mandate specific standards in the areas of personnel qualifications, administration, and participation in proficiency testing, patient test management and quality assurance. CLIA certification is also required in order for us to be eligible to bill many commercial insurers for our tests. To renew this certification, we are subject to survey and inspection every two&#160;years. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition to CLIA requirements, we elect to participate in the accreditation program of the College of American Pathologists, or CAP. CMS, which regulates clinical laboratories through CLIA, has deemed CAP standards to be equally or more stringent than CLIA regulations and has approved CAP as a recognized accrediting organization. Inspection by CAP is performed in lieu of inspection by CMS for CAP-accredited laboratories. Because we are accredited by the CAP Laboratory Accreditation Program, we are deemed to also comply with CLIA. Many commercial insurers require CAP accreditation as a condition to contracting with clinical laboratories to cover their tests. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">CMS has the authority to impose a wide range of sanctions, including revocation of the CLIA certification along with a bar on the ownership or operation of a CLIA-certified laboratory by any owners or operators of the deficient laboratory. Any sanction imposed under CLIA and its implementing regulations, including but not limited to those applicable to proficiency testing, or our failure to renew a CLIA certificate, could have a material and adverse effect on our business, operating results and financial condition. If we </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">33</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">were to lose our CLIA certification, we would not be able to operate our clinical laboratory or conduct our testing, which would adversely impact our business, operating results, and financial condition. Failure to maintain CAP accreditation could likewise have a material adverse effect on the sales of our tests and the results of our operations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Moreover, several states require that we hold licenses to test samples from patients in those states. For example, in New York, our PreTRM test must be approved by the New York State Department of Health before it is offered in New York. As part of this process, the State of New York requires validation of our tests. New York State also requires additional regulatory approvals for laboratories producing clinical results through the oversight of the New York State Clinical Laboratory Evaluation Program (NYS-CLEP). We have obtained licenses from states where we believe we are required to be licensed. From time to time, we may become aware of other states that require out-of-state laboratories to obtain licensure in order to accept specimens from the state, and it is possible that other states do have such requirements or will have such requirements in the future. If we identify any other state with such requirements or if we are contacted by any other state advising us of such requirements, we expect to seek to comply with such requirements. However, there is no assurance that we will be able to obtain any such required license for the particular state. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If a clinical laboratory is out of compliance with state laboratory licensure laws and regulations, the state authority may suspend, restrict or revoke the license to operate the clinical laboratory, assess substantial civil money penalties, or impose specific corrective action plans. If we were to lose a required state licensure, we would not be able to operate our clinical laboratory and conduct our tests, in full or in particular states, which would adversely impact our business, operating results and financial condition. Any such actions could materially affect our business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The FDA may undertake rulemaking to regulate Laboratory Developed Tests, or LDTs, or Congress may reform the current legal requirements applicable to LDTs, in which case we may become subject to extensive regulatory requirements and may be required to conduct additional clinical trials prior to continuing to sell our existing tests or launching any other tests we may develop, which may increase the cost of conducting, or otherwise harm, our business.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We currently market the PreTRM test as an LDT and may in the future market other tests as LDTs. The FDA has adopted a policy of enforcement discretion with respect to LDTs whereby the FDA does not generally actively enforce its regulatory requirements for such tests. However, in the past the FDA has stated its intention to modify its enforcement discretion policy with respect to LDTs. If there are changes in FDA regulations and legislative authorities such that the agency begins to exercise oversight over LDTs, or if the FDA disagrees that our marketed tests are within the scope of its criteria used for defining LDTs, we may become subject to extensive regulatory requirements and may be required to stop selling our existing test or launching any other tests we may develop and to conduct additional clinical trials or take other actions prior to continuing to market our tests. If the FDA allows our tests to remain on the market but there is uncertainty about our tests, if they are labeled investigational by the FDA or if labeling claims the FDA allows us to make are very limited, orders from health care providers or reimbursement for our tests may decline. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">While we believe that we are currently in material compliance with applicable laws and regulations as historically enforced by the FDA with respect to LDTs, we cannot assure you that the FDA will agree with our determination. A determination that we have violated these laws and regulations, or a public announcement that we are being investigated for possible violations, could adversely affect our business, prospects, results of operations and financial condition. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Moreover, if the FDA were to disagree with our conclusion that the PreTRM test falls within the scope of the agency&#8217;s LDT definition and that the PreTRM test is thus subject to FDA&#8217;s medical device authorities and implementing regulations, the agency could require that we obtain premarket approval or another type of device premarket authorization in order for us to commercialize the PreTRM test. As part of this process, we may also be required to conduct additional clinical testing before applying for commercial marketing authorization. Clinical trials must be conducted in compliance with FDA regulations in order to support a marketing submission to the agency for a regulated product, or the FDA may take certain enforcement actions or reject the data. Performing additional, new clinical studies and trials in order to obtain product approval from the FDA, if any were to become necessary, would take a significant amount of time and would substantially delay our ability to commercialize the PreTRM test, all of which would adversely impact our business. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">34</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, since 2017, Congress has been working on legislation to create an LDT and In Vitro Diagnostic, or IVD, regulatory framework that would be separate and distinct from the existing medical device regulatory framework. In March&#160;2020, a bipartisan group of members from both chambers of Congress formally introduced the Verifying Accurate, Leading-edge IVCT Development, or VALID Act, which would codify the term &#8220;in vitro clinical test&#8221;, or IVCT, and create new medical product category separate from medical devices that includes products currently regulated as IVDs as well as LDTs, among other provisions. The VALID Act would also create a new system for laboratories to use to submit their tests electronically to the FDA for approval, which is aimed at reducing the amount of time it would take for the agency to approve such tests, and establish a new program to expedite the development of diagnostic tests that can be used to address a current unmet need for patients. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Most recently, HHS published a policy announcement in August&#160;2020 stating that FDA must go through a notice-and-comment rulemaking process before requiring premarket review of LDTs as medical devices, rather than making such a change through guidance documents, compliance manuals, or other informal policy statements. Although the ultimate impact of HHS&#8217;s policy statement on the FDA&#8217;s plans for regulating LDTs and its current thinking relating to this category of diagnostic testing products is unclear, the August&#160;2020 announcement appears to confirm that laboratories may commercialize LDTs for clinical use without submitting such tests for FDA premarket review and marketing authorization under the medical device regulatory framework. HHS&#8217;s policy statement does not affect proposed legislation for the regulation of LDTs, such as the VALID Act described above. It is also unclear whether the Biden Administration, which assumed control of the executive branch on January&#160;20, 2021, will take the same position as the former administration or seek to revoke or revise the HHS policy announcement from August&#160;2020. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If Congress were to pass the VALID Act or any other legislation applicable to the FDA&#8217;s regulation of LDTs, we will likely be subject to increased regulatory burdens such as registration and listing requirements, adverse event reporting requirements, and quality control requirements. Any legislation or formal FDA regulatory framework affecting LDTs is also likely to have premarket application requirements prohibiting commercialization without FDA authorization and controls regarding modification to the tests that may require further FDA submissions. Any such process would likely be costly and time-consuming. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The outcome and ultimate impact on our business of any changes to the federal government&#8217;s regulation of LDTs is difficult to predict. Potential future increased regulation of our LDTs could result in increased costs and administrative and legal actions for noncompliance, including warning letters, fines, penalties, product suspensions, product recalls, injunctions and other civil and criminal sanctions, which could have a material and adverse effect upon our business, operating results, and financial condition. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Furthermore, should it be required in the future, we cannot be sure that the PreTRM test, or any new tests that we may develop will be reviewed and authorized for marketing by the FDA in a timely or cost-effective manner, if authorized at all. Even if such tests are authorized for marketing by the FDA, the agency could limit the test&#8217;s indications for use, which may significantly limit the market for that product and may adversely affect our business and financial condition. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The Federal Trade Commission and / or state enforcement or regulatory agencies may object to the methods and materials we use to promote our tests and initiate enforcement against us, which could adversely affect our business and financial condition.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Federal Trade Commission, or FTC, and/or state enforcement or regulatory agencies (including but not limited to the offices of state attorneys general) may object to the materials and methods we use to promote our current tests or other LDTs we may develop in the future, including with respect to the product claims in our promotional materials, and may initiate enforcement actions against us. Enforcement actions by the FTC may include, among others, injunctions, civil penalties, and equitable monetary relief. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The global data protection landscape is rapidly evolving, and we are or may become subject to numerous state and federal laws, requirements, and regulations governing the collection, use, disclosure, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">35</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">retention, and security of personal information. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations or standards or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions or to collect, store, transfer, use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal or state laws or regulations, our internal policies and procedures or our contracts governing our use and disclosures of personal information could result in negative publicity, government investigations and enforcement actions, claims by third parties and damage to our reputation, any of which could have a material adverse effect on our operations, financial performance and business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As our operations and business grow, we may become subject to or affected by new or additional privacy and security laws and regulations and face increased scrutiny or attention from regulatory authorities. In the United States, the federal Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH (collectively, HIPAA) requires organizations like ours to develop and maintain policies and procedures with respect to information that is protected under HIPAA, called protected health information, or PHI, that is used or disclosed in connection with our testing services, including the adoption of administrative, physical, and technical safeguards to protect such information. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">HIPAA further requires organizations subject to HIPAA, called &#8220;covered entities&#8221; to notify affected individuals &#8220;without unreasonable delay and in no case later than 60 calendar days following discovery, of certain unauthorized access, uses, or disclosures of PHI. If a breach affects 500 individuals or more, covered entities must report it to the HHS and local media contemporaneously with notice to affected individuals, and HHS will post information regarding the breach, including the name of the entity reporting the breach, on its public website. If a breach affects fewer than 500 individuals, the covered entity must notify HHS within the first 60&#160;days of the following calendar year. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Penalties for failure to comply with HIPAA and HITECH are substantial and could include corrective action plans, and/or the imposition of civil monetary or criminal penalties. HIPAA also authorizes state attorneys general to enforce HIPAA on behalf of state residents. Courts can award damages, costs and attorneys&#8217; fees related to violations of HIPAA in such cases. While HIPAA does not create a private right of action allowing individuals to sue us in civil court for HIPAA violations, its standards have been used as the basis for a duty of care claim in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Certain states have also adopted privacy and security laws and regulations, some of which may be more stringent than HIPAA and/or regulate information other than PHI. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. At the state level, for example, California recently enacted the California Consumer Privacy Act, or CCPA, an extremely comprehensive and stringent privacy law. The CCPA took effect on January&#160;1, 2020, and became enforceable by the Califronia Attorney General on July 1, 2020. It creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal data. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. CCPA does not apply to information that is protected by HIPAA, but CCPA still applies to other types of personal information held by HIPAA covered entities, such as personnel or marketing information. The regulations issued under the CCPA have been modified several times, and there is still some uncertainty about how the law will be interpreted and enforced. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, California voters also approved a new privacy law, the California Privacy Rights Act, or CPRA, on November&#160;3, 2020. The CPRA will modify the CCPA significantly, potentially resulting in further uncertainty, additional costs and expenses stemming from efforts to comply, and additional potential for harm and liability for failure to comply. The CPRA imposes additional obligations on companies covered by the legislation and will expand consumers&#8217; rights with respect to certain sensitive personal information. The CPRA also creates a new state agency that will be vested with authority to implement and enforce the CCPA and the CPRA. In addition, in February&#160;2021, the Virginia legislature became the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">36</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">second to enact a state-specific law called the Consumer Data Protection Act, or CDPA, which includes key differences from California&#8217;s law, further complicating compliance by industry and other stakeholders. Many similar laws have also been proposed in other states and at the federal level. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The CCPA, the CDPA, and similar laws may increase our compliance costs and potential liability. Any liability from failure to comply with the requirements of these laws could adversely affect our financial condition. All U.S. states have implemented data breach notification laws that overlap and often conflict with HIPAA and apply simultaneously. We must comply with all of these laws simultaneously in the event of a data breach which is a complicated and expensive proposition. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The regulatory framework governing the collection, storage, use and sharing of certain information, particularly financial and other personal information, is rapidly evolving and is likely to continue to be subject to uncertainty and varying interpretations. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our existing practices. Any failure or perceived failure by us, or any third parties with which we do business, to comply with our privacy policies, changing expectations, evolving laws, rules and regulations, industry standards, or contractual obligations to which we or such third parties are or may become subject, may result in actions or other claims against us by governmental entities or private actors, the expenditure of substantial costs, time and other resources or the incurrence of significant fines, penalties or other liabilities. In addition, any such action, particularly to the extent we were found to be guilty of violations or otherwise liable for damages, would damage our reputation and adversely affect our business, financial condition and results of operations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Although we work to comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one another or other legal obligations with which we must comply. Any failure or perceived failure by us or our employees, representatives, contractors, consultants, Contract Research Organizations, or CROs, collaborators, or other third parties to comply with such requirements or adequately address privacy and security concerns, even if unfounded, could result in additional cost and liability to us, damage our reputation, and adversely affect our business and results of operations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Security breaches, losses of data, and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and reputation.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the ordinary course of our business, we collect and store sensitive data, including PHI (such as patient medical records, including test results), and personally identifiable information. We also store business and financial information, intellectual property, research and development information, trade secrets and other proprietary and business critical information, including that of our customers, payers and collaboration partners. We manage and maintain our data utilizing a combination of on-site systems, managed data center systems and cloud-based data center systems. We are highly dependent on information technology networks and systems, including the internet, to securely process, transmit and store critical information. Although we take measures to protect sensitive information from unauthorized access or disclosure, our information technology and infrastructure, and that of our third-party billing and collections provider and other service providers, may be vulnerable to attacks by hackers, viruses, disruptions and breaches due to employee error or malfeasance. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A security breach or privacy violation that leads to unauthorized access, disclosure or modification of, or prevents access to, patient information, including PHI, could implicate state and federal breach notification laws, subject us to fines and mandatory corrective action and require us to verify the correctness of, or to reconstruct, database contents. Such a breach or violation also could result in legal claims or proceedings brought by a private party or a governmental authority, liability under laws and regulations that protect the privacy of personal information, such as HIPAA, HITECH and laws and regulations of various U.S. states, as well as penalties imposed by the Payment Card Industry Security Standards Council for violations of the Payment Card Industry Data Security Standards. If we are unable to prevent such security breaches or privacy violations or implement satisfactory remedial measures, we may suffer loss of reputation, financial loss and civil or criminal fines or other penalties. In addition, these breaches and other forms of </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">37</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">inappropriate access can be difficult to detect, and any delay in identifying them may lead to increased harm of the type described above. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Unauthorized access, loss or dissemination of information could disrupt our operations, including our ability to perform tests, provide test results, bill payers or patients, process claims and appeals, provide customer assistance services, conduct research and development activities, develop and commercialize tests, collect, process and prepare company financial information, provide information about our tests, educate patients and health care providers about our service and manage the administrative aspects of our business, any of which could damage our reputation and adversely affect our business. Any breach could also result in the compromise of our trade secrets and other proprietary information, which could adversely affect our competitive position. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, health-related, privacy, and data protection laws and regulations in the U.S. are subject to interpretation and enforcement by various governmental authorities and courts, resulting in complex compliance issues and the potential for varying or even conflicting interpretations, particularly as laws and regulations in this area are in flux. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices. If so, this could result in government-imposed fines or orders requiring that we change our practices, which could adversely affect our business and our reputation. Complying with these laws could cause us to incur substantial costs or require us to change our business practices and compliance procedures in a manner adverse to our business, operating results, and financial condition. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any failure or perceived failure by us or any third-party collaborators, service providers, contractors or consultants to comply with privacy, confidentiality, data security or similar obligations, or any data security incidents or other security breaches that result in the accidental, unlawful or unauthorized access to, use of, release of, or transfer of sensitive information, including personally identifiable information, or PHI, may result in negative publicity, harm to our reputation, governmental investigations, enforcement actions, regulatory fines, litigation or public statements against us, could cause third parties to lose trust in us or could result in claims by third parties, including class action lawsuits, any of which could have a material adverse effect on our reputation, business, financial condition or results of operations. While we have implemented data security measures intended to protect our information, data, information technology systems, applications and infrastructure, there can be no assurance that such measures will successfully prevent service interruptions or data security incidents or that these measures will be satisfactory to regulatory authorities in the event of an audit, investigation or complaint. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we, or our employees or contractors on our behalf, engage in conduct that violates health care laws, are suspected or accused of engaging in such conduct or are subject to investigation for actual or alleged such conduct, we could face substantial penalties and damage to our reputation, and our business operations and financial condition could be adversely affected.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We operate in one of the most highly regulated industries in the United States. Our business activities are, or may in the future be, subject to comprehensive compliance obligations under state and federal law, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">CLIA&#8217;s and CAP&#8217;s regulation of our laboratory activities. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">The federal Anti-Kickback Statute, or the AKS, which generally prohibits, among other things knowingly and willfully offering, paying, soliciting, or receiving any remuneration, directly or indirectly, in return for or to induce a person to refer an individual for any good, facility, item, or service reimbursable by a covered payer. A person or entity does not need to have actual knowledge of the AKS or specific intent to violate it to have committed a violation. Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved, imprisonment, and exclusion from government healthcare programs. In addition, the government may assert that a claim including items or services resulting from a violation of the AKS constitutes a false or fraudulent claim for purposes of the FCA or federal civil money penalties. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">The Stark Law, also known as the physician self-referral law, generally prohibits physicians from making referrals for certain services if the physician or an immediate family member has a prohibited financial relationship with the entity providing the services at issue. State enforcement agencies </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">38</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:40pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">may assert that a claim including items or services resulting from a violation of the state physician self-referral law constitutes a false or fraudulent claim for purposes of any state false claims statute. If we submit claims to Medicare or Medicaid in the future, our business activities will also be subject to the federal Stark Law. </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">The federal civil and criminal false claims laws and civil monetary penalty laws, such as the FCA, which impose criminal and civil penalties and authorize civil whistleblower or </font><font style="font-style:italic;letter-spacing:0.2pt;">qui tam</font><font style="letter-spacing:0.2pt;"> actions, against individuals or entities for, among other things: knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent; knowingly making, using or causing to be made or used, a false statement of record material to a false or fraudulent claim or obligation to pay or transmit money or property to the federal government or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay money to the federal government (sometimes referred to as a &#8220;reverse&#8221; false claim). The FCA also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">HIPAA, which created new federal criminal statutes that prohibit a person from knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payer (</font><font style="font-style:italic;letter-spacing:0.2pt;">e.g.</font><font style="letter-spacing:0.2pt;">, public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false, fictitious, or fraudulent statements or representations in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters; similar to the AKS, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">HIPAA, as amended by HITECH and their respective implementing regulations, including the Final Omnibus Rule published in January&#160;2013, which impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates, independent contractors or agents of covered entities, that perform services for them that involve the creation, maintenance, receipt, use, or disclosure of, individually identifiable health information relating to the privacy, security and transmission of individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. In addition, there are additional federal, state and non-U.S. laws which govern the privacy and security of health and other personal information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">The Eliminating Kickbacks in Recovery Act of 2018, or EKRA, which is an all-payer anti-kickback law that criminalizes the offer, payment, solicitation or receipt of any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce referrals to, or in exchange for, patients using the services of a recovery home, a substance use clinical treatment facility, or laboratory, unless an exception applies. Most of the safe harbors applicable under the AKS are not reiterated under EKRA, thereby potentially expanding the universe of arrangements that could be subject to enforcement. A violation of EKRA is punishable by imprisonment and fines. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">The federal health care fraud statute, which imposes criminal liability for executing or attempting to execute a scheme to defraud any health care benefit program and willfully embezzling or stealing from a health care benefit program (which include private insurers). Violations of this statute are punishable by imprisonment and fines, among other penalties. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">State data privacy and security laws, which may be more stringent than HIPAA. For example, the CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal data. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches. The CCPA is expected to increase data breach litigation and may increase our compliance costs and potential liability. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">39</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:40pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Many similar laws have been proposed at the federal level and in other states; in the event that we are subject to or affected by any such privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition. </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">Federal, state and local regulations relating to the handling and disposal of regulated medical waste, hazardous waste and biohazardous waste and workplace safety for health care employees. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">Laws and regulations relating to health and safety, labor and employment, public reporting, taxation and other areas applicable to businesses generally, all of which are subject to change, including, for example, the significant changes to the taxation of business entities were enacted in December&#160;2017. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">Additionally, we are subject to state equivalents of each of the healthcare laws and regulations described above, among others, some of which may be broader in scope and may apply regardless of the payer. Many U.S. states have adopted laws similar to the AKS and FCA, which may apply to our business practices, including, but not limited to, research, distribution, sales or marketing arrangements and claims involving health care items or services reimbursed by non-governmental payers, including private insurers. In addition, some states have passed laws that prohibit fee-splitting state fraud and abuse laws, such as fee-splitting restrictions, insurance fraud laws, anti-markup laws, prohibitions on waiving coinsurance, copayments, deductibles and other amounts owed by patients, and prohibitions on the provision of tests at no or discounted cost to induce physician or patient adoption. Some states also prohibit certain health care practices, such as billing physicians for tests that they order and business corporations practicing medicine or employing or engaging physicians to practice medicine. There are ambiguities as to what is required to comply with these state requirements and if we fail to comply with an applicable state law requirement we could be subject to penalties. Finally, there are state and foreign laws governing the privacy and security of health information, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Because we develop our LDTs solely for use by or within our own laboratory, and because we do not currently submit claims to Medicare, Medicaid or the Children&#8217;s Health Insurance Program, or CHIP, we believe we are exempt from the reporting requirements imposed under the federal Physician Payments Sunshine Act, or the Sunshine Act. The Sunshine Act requires, among other things, certain manufacturers of drugs, devices, biologics, and medical supplies reimbursed under Medicare, Medicaid or CHIP to annually report to CMS information related to payments and other transfers of value provided to physicians, certain other health care professionals beginning in 2022, and teaching hospitals and physician ownership and investment interests, including such ownership and investment interests held by a physician&#8217;s immediate family members. While we believe that the Sunshine Act does not apply to our business, we cannot assure you that the federal government or other regulators will agree with our determination. Moreover, we could become subject to Sunshine Act reporting requirements if (i)&#160;we begin submitting claims for reimbursement for our tests to an applicable government health care program; and (ii)&#160;the FDA requires us to obtain premarket authorization for our tests as medical devices or Congress enacts legislative reforms to the federal oversight of LDTs to subject them to FDA regulation and/or the reporting requirements of the Sunshine Act. A determination that we have violated these laws and related CMS regulations, or a public announcement that we are being investigated for possible violations, could adversely affect our business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, the rapid growth and expansion of our business may increase the risk of violating these laws or related internal compliance policies and procedures, as well as the possibility that we may be accused of and/or investigated for violating these laws, regulations, and related internal policies and procedures. We likewise may be accused of, and subject to investigation and/or enforcement for, violating these laws on the basis of conduct engaged in by our employees, contractors and/or other related third parties. Such accusations and investigations may stem from allegations made by whistleblowers under the </font><font style="font-style:italic;letter-spacing:0.2pt;">qui tam</font><font style="letter-spacing:0.2pt;"> provisions of the FCA or state law equivalents, as well as investigative efforts undertaken by state and federal regulatory and enforcement agencies. The evolving interpretations of these laws and regulations by courts and regulators increase the risk that we may be alleged to be, or in fact found to be, in violation of these or other laws and regulations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge and may not comply </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">40</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">under one or more of such laws, regulations, and guidance. Law enforcement authorities are increasingly focused on enforcing fraud and abuse laws, and it is possible that some of our practices may be challenged under these laws. Efforts to ensure that our current and future business arrangements with third parties, and our business generally, will comply with applicable healthcare laws and regulations will involve substantial costs. If our operations, including our arrangements with physicians and other healthcare providers are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, the curtailment or restructuring of our operations, exclusion fromparticipation in federal and state healthcare programs (such as Medicare and Medicaid), and imprisonment, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, any of which could adversely affect our ability to operate our business and our financial results.</font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Companies in our industry occasionally receive investigative demands, subpoenas, or other requests for information from state and federal governmental agencies. We cannot predict the occurrence, timing, outcome or impact of any such investigations. Any adverse outcome in one or more of these investigations could include the commencement of civil and/or criminal proceedings, substantial fines, penalties, administrative remedies and/or entry into corporate integrity agreements with governmental agencies, among other penalties. In addition, resolution of any of these matters could involve the imposition of additional costly compliance obligations. These potential consequences, as well as any adverse outcome from government investigations, could have a material and adverse effect on our business, operating results and financial condition. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Intellectual Property</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:7pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Any failure to obtain, maintain, and enforce our intellectual property rights could impair our ability to protect our proprietary technology and our brand.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our success and ability to compete depend, in part, on our ability to obtain, maintain and enforce patents, trade secrets, trademarks and other intellectual property rights and to operate without having third parties infringe, misappropriate or circumvent the rights that we own or license. If we are unable to obtain, maintain and enforce intellectual property protection covering our current and future tests or technology, others may be able to make, use or sell tests or technology that are substantially the same as ours without incurring the sizeable development costs that we have incurred, which would adversely affect our ability to compete in the market. Our ability to stop third parties from making, using, selling, offering to sell or importing our tests or technology is dependent upon the extent to which we have rights under valid and enforceable patents that cover these activities. However, the patent positions of diagnostic companies, including ours, can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. The U.S. Supreme Court and U.S. Court of Appeals for the Federal Circuit have in recent&#160;years issued a number of decisions relating to the patent-eligibility of diagnostic method claims. We cannot predict what impact these decisions may have on our ability to obtain or enforce patents relating to diagnostic methods in the future. We believe that no consistent policy regarding the scope of valid patent claims in these fields has emerged to date in the United States. The patent situation in the diagnostics industry outside the United States also is uncertain at least in a number of countries. Moreover, U.S. patent laws frequently change, including changes regarding how patent laws are interpreted, and the U.S. Patent and Trademark Office, or USPTO, frequently issues new procedures to the patent system. We cannot accurately predict future changes in the interpretation of patent laws or changes to patent laws that might be enacted into law. Those changes may materially affect our patents, our ability to obtain patents. Therefore, there can be no assurance that any current or future patent applications will result in the issuance of patents or that we will develop additional proprietary tests or technology which are patentable. Moreover, patents or pending applications that may issue in the future may not provide us with any competitive advantage. Our patent position is subject to numerous additional risks, including the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.61pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.61pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">we may fail to seek patent protection for inventions that are important to our success; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">any current or future patent applications may not result in issued patents; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">we cannot be certain that we were the first to file patent applications for the inventions covered by pending patent applications and, if we are not, we may be subject to priority or derivation disputes; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">41</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">we may be required to disclaim part or all of the term of certain patents or part or all of the term of certain patent applications; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">we may file patent applications but have claims restricted or we may not be able to supply sufficient data to support our claims and, as a result, may not obtain the original claims desired or we may receive restricted claims. Alternatively, it is possible that we may not receive any patent protection from an application; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">we could inadvertently abandon a patent or patent application, resulting in the loss of protection of certain intellectual property rights in a particular country. We or our patent counsel may take action resulting in a patent or patent application becoming abandoned which may not be able to be reinstated or if reinstated, may suffer patent term adjustments; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the claims of our issued patents or patent applications when issued may not cover our tests or technology; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">no assurance can be given that our patents would be declared by a court to be valid and enforceable or that a competitor&#8217;s test or technology would be found by a court to infringe our patents. Our patents or patent applications may be challenged by third parties in patent litigation or in proceedings before the USPTO or its foreign counterparts, and may ultimately be declared invalid or unenforceable, or narrowed in scope; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">there may be prior art of which we are not aware that may affect the validity of a patent claim. There also may be prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim, which may, nonetheless, ultimately be found to do so; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">third parties may develop tests or technology that have the same or similar effect as our tests and technology without infringing our patents. Such third parties may also intentionally circumvent our patents by means of alternate designs or processes or file applications or be granted patents that would block or hurt our efforts; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">there may be patents relevant to our tests or technology of which we are not aware; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">certain of our intellectual property was partly supported by a U.S. government grant awarded by the National Institutes of Health, and the government accordingly has certain rights in this intellectual property, including a non-exclusive, non-transferable, irrevocable worldwide license to use applicable inventions for any governmental purpose. Such rights also include &#8220;march-in&#8221; rights, which refer to the right of the U.S. government to require us to grant a license to the technology to a responsible applicant if we fail to achieve practical application of the technology or if action is necessary to alleviate health or safety needs, to meet requirements of federal regulations or to give preference to U.S. industry; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">our patent counsel, lawyers or advisors may have given us, or may in the future give us incorrect advice or counsel; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the patent and patent enforcement laws of some foreign jurisdictions may not protect intellectual property rights to the same extent as laws in the United States, and many companies have encountered significant difficulties in protecting and defending such rights in foreign jurisdictions. If we encounter such difficulties or we are otherwise precluded from effectively protecting our intellectual property rights in foreign jurisdictions, our business prospects could be substantially harmed, and we may not pursue or obtain patent protection in all major markets; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">we may not develop additional tests or technology that are patentable. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any of these factors could hurt our ability to gain patent protection for our tests and technology. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Issued patents covering our tests and technology could be found invalid or unenforceable if challenged.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our patents and patent applications may be subject to validity, enforceability and priority disputes. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability. Some of our patents or patent applications may be challenged at a future point in time in opposition, derivation, reexamination, </font><font style="font-style:italic;letter-spacing:0.2pt;">inter partes</font><font style="letter-spacing:0.2pt;"> review, post-grant review or interference or other similar proceedings. Any </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">42</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">successful third-party challenge to our patents in this or any other proceeding could result in the unenforceability or invalidity of such patents, which may lead to increased competition to our business, which could have a material adverse effect on our business, financial condition, results of operations and prospects. In addition, if we initiate legal proceedings against a third party to enforce a patent covering our tests or technology, the defendant could counterclaim that such patent covering our tests or technology, as applicable, is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. There are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the relevant patent office, or made a misleading statement, during prosecution. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include </font><font style="font-style:italic;letter-spacing:0.2pt;">ex parte</font><font style="letter-spacing:0.2pt;"> re-examination</font><font style="font-style:italic;letter-spacing:0.2pt;">, inter partes</font><font style="letter-spacing:0.2pt;"> review, post-grant review, derivation and equivalent proceedings in non-U.S. jurisdictions, such as opposition proceedings. Such proceedings could result in revocation of or amendment to our patents in such a way that they no longer cover and protect our tests or technology. With respect to the validity of our patents, for example, we cannot be certain that there is no invalidating prior art of which we, our licensor, our or its patent counsel and the patent examiner were unaware during prosecution. The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. If a defendant or other third party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on certain aspects of our tests and technology, which could have a material adverse effect on our business, financial condition, results of operations and prospects. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license intellectual property or develop or commercialize current or future tests and technology. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may not be aware of all third-party intellectual property rights potentially relating to our tests or technology. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until approximately 18&#160;months after filing or, in some cases, not until such patent applications issue as patents. We might not have been the first to make the inventions covered by each of our pending patent applications and we might not have been the first to file patent applications for these inventions. To determine the priority of these inventions, we may have to participate in interference proceedings, derivation proceedings or other post-grant proceedings declared by the USPTO, or other similar proceedings in non-U.S. jurisdictions, that could result in substantial cost to us and the loss of valuable patent protection. The outcome of such proceedings is uncertain. No assurance can be given that other patent applications will not have priority over our patent applications. In addition, changes to the patent laws of the United States allow for various post-grant opposition proceedings that have not been extensively tested, and their outcome is therefore uncertain. Furthermore, if third parties bring these proceedings against our patents, regardless of the merit of such proceedings and regardless of whether we are successful, we could experience significant costs and our management may be distracted. Any of the foregoing events could have a material adverse effect on our business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our intellectual property may be infringed upon by a third party.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Third parties may infringe one or more of our patents, trademarks or other intellectual property rights. We cannot predict if, when or where a third party may infringe our intellectual property rights. To counter infringement, we may be required to file infringement lawsuits, which can be expensive and time consuming. There is no assurance that we would be successful in a court of law in proving that a third party is infringing one or more of our issued patents or trademarks. Any claims we assert against perceived infringers could also provoke these parties to assert counterclaims against us, alleging that we infringe their intellectual property. In addition, in a patent infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly and/or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question, any of which may adversely affect our business. Even if we are successful in proving in a court of law that a third party is infringing our intellectual property rights, there can be no assurance that we would be </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">43</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">successful in halting their infringing activities, for example, through a permanent injunction, or that we would be fully or even partially financially compensated for any harm to our business. We may be forced to enter into a license or other agreement with the infringing third party at terms less profitable or otherwise commercially acceptable to us than if the license or agreement were negotiated under conditions between those of a willing licensee and a willing licensor. We may not become aware of a third-party infringer within legal timeframes for compensation or at all, thereby possibly losing the ability to be compensated for any harm to our business. Such a third party may be operating in a foreign country where the infringer is difficult to locate and/or the intellectual property laws may be more difficult to enforce. Some third-party infringers may be able to sustain the costs of complex infringement litigation more effectively than we can because they have substantially greater resources. Any inability to stop third-party infringement could result in loss in market share of some of our tests and technology or even lead to a delay, reduction and/or inhibition of the development, manufacture or sale of certain tests and technology by us. There is no assurance that a test or technology produced and sold by a third-party infringer would meet our or other regulatory standards or would be safe for use. Such third-party infringer tests or technology could irreparably harm the reputation of our tests or technology thereby resulting in substantial loss in our market share and profits. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Developments or uncertainty in the patent statute, patent case law or USPTO rules and regulations may impact the validity of our patent rights.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our patent rights may be affected by developments or uncertainty in the patent statute, patent case law or USPTO rules and regulations. For example, the patent position of companies engaged in the development and commercialization of diagnostic tests are particularly uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States or in other jurisdictions could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. For instance, under the Leahy-Smith America Invents Act, or the America Invents Act, enacted in September&#160;2011, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application is entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. These changes include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to challenge the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, </font><font style="font-style:italic;letter-spacing:0.2pt;">inter partes</font><font style="letter-spacing:0.2pt;"> review and derivation proceedings. The America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Various courts, including the U.S. Supreme Court, have rendered decisions that impact the scope of patentability of certain inventions or discoveries relating to the life sciences technology. Specifically, these decisions stand for the proposition that patent claims that recite laws of nature are not themselves patentable unless those patent claims have sufficient additional features that provide practical assurance that the processes are genuine inventive applications of those laws rather than patent drafting efforts designed to monopolize the law of nature itself. What constitutes a &#8220;sufficient&#8221; additional feature is uncertain. Furthermore, in view of these decisions, since December&#160;2014, the USPTO has published and continues to publish revised guidelines for patent examiners to apply when examining process claims for patent eligibility. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that may have a material adverse effect on our ability to obtain new patents and to defend and enforce our existing patents and patents that we might obtain in the future. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We cannot assure you that our patent portfolio will not be negatively impacted by the current uncertain state of the law, new court rulings or changes in guidance or procedures issued by the USPTO or other similar patent offices around the world. From time to time, the U.S. Supreme Court, other federal courts, the U.S. Congress or the USPTO may change the standards of patentability, scope and validity of patents within the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">44</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">life sciences technology and any such changes, or any similar adverse changes in the patent laws of other jurisdictions, could have a negative impact on our business, financial condition, prospects and results of operations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may be subject to claims challenging the inventorship of our patents and other intellectual property.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may be subject to claims that former employees, collaborators or other third parties have an interest in our patents, trade secrets or other intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our tests and technology. In addition, counterparties to our consulting, sponsored research, software development and other agreements may assert that they have an ownership interest in intellectual property developed under such arrangements. In particular, certain software development agreements pursuant to which certain third parties have developed parts of our proprietary software may not include provisions that expressly assign to us ownership of all intellectual property developed for us by such third parties. As such, we may not have the right to use all such developed intellectual property under such agreements, we may be required to obtain licenses from third parties and such licenses may not be available on commercially reasonable terms or at all, or may be non-exclusive. If we are unable to obtain such licenses and such licenses are necessary for the development, manufacture and commercialization of our tests and technology, we may need to cease the development, manufacture and commercialization of our tests and technology. Litigation may be necessary to defend against these and other claims challenging inventorship of our patents, trade secrets or other intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our business, including our software, workflows, consumables and reagent kits. In such an event, we may be required to obtain licenses from third parties and such licenses may not be available on commercially reasonable terms or at all, or may be non-exclusive. If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture and commercialization of our tests and technology. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees, and certain customers or partners may defer engaging with us until the particular dispute is resolved. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We employ individuals who were previously employed at other biotechnology or diagnostic companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees&#8217; former employers or other third parties. We may also be subject to claims that former employers or other third parties have an ownership interest in our patents. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and if we do not prevail, we could be required to pay substantial damages and could lose rights to important intellectual property. Even if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we are not able to prevent disclosure of our trade secrets and other proprietary information, the value of our tests and technology could be significantly diminished.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We rely on trade secret protection to protect our interests in proprietary know-how and in processes for which patents are difficult to obtain or enforce, including the proprietary algorithm that we use for our tests and technology, including the PreTRM test. We may not be able to protect our trade secrets adequately. We have a policy of requiring our consultants, advisors and collaborators to enter into confidentiality agreements and our employees to enter into invention, non-disclosure and non-compete agreements. However, no assurance can be given that we have entered into appropriate agreements with all parties that have had access to our trade secrets, know-how or other proprietary information. There is also no assurance that such agreements will provide for a meaningful protection of our trade secrets, know-how or other proprietary information in the event of any unauthorized use or disclosure of information. Furthermore, we cannot provide assurance that any of our employees, consultants, contract personnel or collaborators, either </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">45</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">accidentally or through willful misconduct, will not cause serious damage to our programs and our strategy, for example by disclosing important trade secrets, know-how or proprietary information to our competitors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">It is also possible that our trade secrets, know-how or other proprietary information could be obtained by third parties as a result of breaches of our physical or electronic security systems. Any disclosure of confidential data into the public domain or to third parties could allow our competitors to learn our trade secrets and use the information in competition against us. In addition, others may independently discover our trade secrets and proprietary information. Any action to enforce our rights is likely to be time consuming and expensive, and may ultimately be unsuccessful, or may result in a remedy that is not commercially valuable. These risks are accentuated in foreign countries where laws or law enforcement practices may not protect proprietary rights as fully as in the United States or Europe. Any unauthorized disclosure of our trade secrets or proprietary information could harm our competitive position. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Our Class&#160;A Common Stock and This Offering</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:7pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">There has been no prior public market for our Class&#160;A common stock, an active trading market for our Class&#160;A common stock may not develop and you may not be able to resell your shares at or above the initial public offering price.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Prior to this offering there has been no public market for shares of our Class&#160;A common stock. You may not be able to sell your shares quickly or at the market price if trading in shares of our Class&#160;A common stock is not active. The initial public offering price for our Class&#160;A common stock will be determined through negotiations with the underwriters, and the negotiated price may not be indicative of the market price of the Class&#160;A common stock after the offering. Although we intend to apply for our Class&#160;A common stock to be approved for listing on The Nasdaq Global Market, an active or liquid market in our Class&#160;A common stock may not develop upon the completion of this offering or, if it does develop, it may not be sustainable. As a result of these and other factors, you may be unable to resell your shares of our Class&#160;A common stock at or above the initial public offering price. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Further, an inactive market may also impair our ability to raise capital by selling shares of our Class&#160;A common stock and may impair our ability to enter into strategic collaborations or acquire companies or products by using our shares of Class&#160;A common stock as consideration. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The price of our Class&#160;A common stock may be volatile, and you could lose all or part of your investment.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The trading price of our Class&#160;A common stock following this offering is likely to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section and elsewhere in this prospectus, these factors include: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">our ability to successfully meet our obligations under our commercial agreement with Anthem and obtain broader market adoption of our PreTRM test; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">actual or anticipated variations in our and our competitors&#8217; results of operations, as well as how those results compare to analyst and investor expectations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">our failure to successfully commercialize our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">announcements by us or our competitors of new products, significant acquisitions, other strategic transactions, including strategic and commercial partnerships and relationships, joint ventures, divestitures, collaborations or capital commitments; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">changes in reimbursement practices by current or potential payers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">failure of analysts to initiate or maintain coverage of our company, issuance of new securities analysts&#8217; reports or changed recommendations for our Class&#160;A common stock; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">forward-looking statements related to our financial guidance or projections, our failure to meet or exceed our financial guidance or projections or changes in our financial guidance or projections; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">actual or anticipated changes in regulatory oversight of our products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">development of disputes concerning our intellectual property or other proprietary rights; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">46</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">commencement of, or our involvement in, litigation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">announcement or expectation of additional debt or equity financing efforts; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">any major change in our management; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">our inability to establish collaborations, if needed; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">additions or departures of key scientific or management personnel; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">our ability to effectively manage our growth; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">overall performance of the equity markets; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">sales of our common stock by us or our stockholders in the future; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">trading volume of our Class&#160;A common stock; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.09pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.09pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">changes in accounting practices; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">ineffectiveness of our internal controls; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">general political and economic conditions; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">other events or factors, many of which are beyond our control. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, the stock market in general, and the market for diagnostics companies in particular, has experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of the companies, including as a result of the COVID-19 pandemic. Broad market and industry factors may negatively affect the market price of our Class&#160;A common stock, regardless of our actual operating performance. If the market price of our Class&#160;A common stock after this offering does not exceed the initial public offering price, you may not realize any return on your investment in us and may lose some or all of your investment. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#8217;s attention and resources. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We do not intend to pay dividends on our Class&#160;A common stock, so any returns will be limited to the value of our Class&#160;A common stock.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Furthermore, future debt or other financing arrangements may contain terms prohibiting or limiting the amount of dividends that may be declared or paid on our Class&#160;A common stock. Any return to stockholders will therefore be limited to the appreciation of their stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our executive officers, directors and their affiliates and our principal stockholders own a significant&#160;percentage of our Class&#160;A common stock and will be able to exert significant control over matters subject to stockholder approval.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Based on shares outstanding as of &#8199;&#8199;&#8199;&#8199;&#8199;, 2021, and immediately following the completion of this offering, our executive officers, directors and our principal stockholders and their affiliates will beneficially hold, in the aggregate, approximately &#8199;&#8199;&#8199;&#8199;&#8199;% of our outstanding Class A common stock, excluding any shares purchased in this offering. These stockholders, acting together, would be able to significantly influence all matters requiring stockholder approval. These stockholders acquired their shares of Class&#160;A common stock (including shares of Class&#160;A common stock issuable upon the conversion of preferred stock) for less than the price of the shares of Class&#160;A common stock being acquired in this offering, and these stockholders may have interests, with respect to their Class&#160;A common stock, that are different from those of investors in this offering and the concentration of voting power among these stockholders may have an adverse effect on the price of our Class&#160;A common stock. This concentration of ownership control may adversely affect the market price of our Class&#160;A common stock by: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">delaying, deferring or preventing a change in control; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">47</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">entrenching our management and the board of directors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">impeding a merger, consolidation, takeover or other business combination involving us that other stockholders may desire; and/or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of us. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">See &#8220;Principal Stockholders&#8221; for more information regarding the ownership of our outstanding common stock by our executive officers, directors, principal stockholders and their affiliates. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If you purchase our Class&#160;A common stock in this offering, you will incur immediate and substantial dilution in the book value of your shares.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The initial public offering price was substantially higher than the pro&#160;forma as adjusted net tangible book value per share of our Class&#160;A common stock after this offering. Investors purchasing Class&#160;A common stock in this offering will pay a price per share that substantially exceeds the pro&#160;forma as adjusted net tangible book value per share after this offering. As a result, investors purchasing Class&#160;A common stock in this offering will incur immediate dilution of &#8199;&#8199;&#8199;&#8199;&#8199;$ per share, representing the difference between our pro&#160;forma as adjusted net tangible book value per share after giving effect to this offering and the initial public offering price. Further, investors purchasing Class&#160;A common stock in this offering will have contributed approximately &#8199;&#8199;&#8199;&#8199;&#8199;% of the total amount invested by stockholders since our inception, but will own only approximately &#8199;&#8199;&#8199;&#8199;&#8199;% of the shares of Class&#160;A common stock outstanding after this offering. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This dilution is due to our investors who purchased shares prior to this offering having paid substantially less when they purchased their shares than the price offered to the public in this offering. To the extent outstanding options are exercised, there will be further dilution to new investors. As a result of the dilution to investors purchasing shares in this offering, investors may receive significantly less than the purchase price paid in this offering, if anything, in the event of our liquidation. For a further description of the dilution that you will experience immediately after this offering, see &#8220;Dilution.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The dual class structure of our common stock may limit your ability to influence corporate matters and may limit your visibility with respect to certain transactions.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The dual class structure of our common stock may limit your ability to influence corporate matters. Holders of our Class&#160;A common stock are entitled to one vote per share, while holders of our Class&#160;B common stock are not entitled to any votes per share. Nonetheless, each share of our Class&#160;B common stock may be converted at any time into one share of our Class&#160;A common stock at the option of its holder by providing written notice to us, subject to the limitations provided for in our amended and restated certificate of incorporation to become effective upon the closing of this offering. Consequently, if holders of our Class&#160;B common stock following this offering exercise their option to make this conversion, this will have the effect of increasing the relative voting power of those prior holders of our Class&#160;B common stock, and correspondingly decreasing the voting power of the holders of our Class A common stock, which may limit your ability to influence corporate matters. Additionally, stockholders who hold, in the aggregate, more than 10% of our Class&#160;A common stock and Class&#160;B common stock, but 10% or less of our Class&#160;A common stock, and are not otherwise an insider, may not be required to report changes in their ownership due to transactions in our Class&#160;B common stock pursuant to Section 16(a) of the Exchange Act, and may not be subject to the short-swing profit provisions of Section 16(b) of the Exchange Act. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We are an emerging growth company and a smaller reporting company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our Class&#160;A common stock less attractive to investors.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are an emerging growth company, or EGC, as defined in the JOBS Act. For as long as we continue to be an EGC, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not EGCs, including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports and proxy statements and exemptions from the requirements of holding nonbinding advisory votes on executive compensation and stockholder </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">48</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">approval of any golden parachute payments not previously approved. We may remain an EGC or until the earlier of (a)&#160;the last day of the fiscal year (i)&#160;following the fifth anniversary of the completion of this offering, (ii)&#160;in which we have total annual gross revenue of at least $1.07&#160;billion or (iii)&#160;in which we are deemed to be a large accelerated filer, which requires the market value of our Class&#160;A common stock that is held by non-affiliates to exceed $700.0&#160;million as of the prior June&#160;30th, and (b)&#160;the date on which we have issued more than $1.0&#160;billion in non-convertible debt during the prior three-year period. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are also a smaller reporting company, meaning that the market value of our Class&#160;A common stock held by non-affiliates plus the proposed aggregate amount of gross proceeds to us as a result of this offering is less than $700.0&#160;million and our annual revenue is less than $100.0&#160;million during the most recently completed fiscal year. We may continue to be a smaller reporting company after this offering if either (1)&#160;the market value of our Class&#160;A common stock held by non-affiliates is less than $250.0&#160;million or (2)&#160;our annual revenue is less than $100.0&#160;million during the most recently completed fiscal year and the market value of our Class&#160;A common stock held by non-affiliates is less than $700.0&#160;million. If we are a smaller reporting company at the time we cease to be an EGC we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, we may choose to present only the two most recent fiscal&#160;years of audited financial statements in our Annual Report on Form 10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may choose to take advantage of some, but not all, of the available exemptions. We have taken advantage of reduced reporting burdens in this prospectus. In particular, we have not included all of the executive compensation information that would be required if we were not an EGC. We cannot predict whether investors will find our Class&#160;A common stock less attractive if we rely on certain or all of these exemptions. If some investors find our Class&#160;A common stock less attractive as a result, there may be a less active trading market for our Class&#160;A common stock and our stock price may be more volatile. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the JOBS Act, EGCs can also delay adopting new or revised accounting standards until such time as those standards apply to private companies, which may make our financial statements less comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Substantial amounts of our outstanding shares of Class&#160;A common stock may be sold into the market when lock-up or market standoff periods end, which could cause the price of our Class&#160;A common stock to decline.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our Class&#160;A common stock in the public market after the lock-up and other legal restrictions on resale discussed in this prospectus lapse, the trading price of our Class&#160;A common stock could decline. Based on shares of Class&#160;A common stock and Class&#160;B common stock outstanding as of &#8199;&#8199;&#8199;&#8199;&#8199;, 2021, upon the completion of this offering we will have outstanding a total of &#8199;&#8199;&#8199;&#8199;&#8199; shares of Class&#160;A common stock and &#8199;&#8199;&#8199;&#8199;&#8199; shares of Class&#160;B common stock. Of these shares, only the shares of Class&#160;A common stock sold in this offering by us, plus any shares sold upon exercise of the underwriters&#8217; option to purchase additional shares, will be freely tradable without restriction in the public market immediately following this offering. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The lock-up agreements pertaining to this offering will expire 180&#160;days from the date of this prospectus, subject to earlier release of all or a portion of the shares subject to such agreements by the representatives of the underwriters in this offering in their sole discretion. After the lock-up agreements expire, based upon the number of shares of Class&#160;A common stock and Class&#160;B common stock, on an as-converted basis, outstanding as of &#8199;&#8199;&#8199;&#8199;&#8199;, 2021, up to an additional &#8199;&#8199;&#8199;&#8199;&#8199; shares of Class&#160;A common stock, and &#8199;&#8199;&#8199;&#8199;&#8199; shares of Class&#160;B common stock upon conversion to &#8199;&#8199;&#8199;&#8199;&#8199;Class&#160;A common stock will be eligible for sale in the public market. Approximately &#8199;&#8199;&#8199;&#8199;&#8199;% of these additional shares are beneficially held by directors, executive officers and their affiliates and will be subject to certain limitations of Rule&#160;144 under the Securities Act of 1933, as amended, or the Securities Act. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, shares of Class A common stock that are either subject to outstanding options or reserved for future issuance under our existing equity compensation plans will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules, the lock-up agreements and Rule&#160;144 and Rule&#160;701 under the Securities Act. If these additional shares of Class A common stock are </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">49</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">sold, or if it is perceived that they will be sold, in the public market, the trading price of our Class A common stock could decline. Additionally, the number of shares of our Class A common stock reserved for issuance under our 2021 Equity Plan will automatically increase on January 1 of each year, beginning on January 1, 2022, by &#8199;&#8199;&#8199;&#8199;&#8199;% of the total number of shares of our capital stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by our board of directors or compensation committee. Unless our board of directors elects not to increase the number of shares available for future grant each year, our stockholders may experience additional dilution. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">After this offering, the holders of shares of our common stock will be entitled to rights with respect to the registration of their shares under the Securities Act as provided under the terms of an investors&#8217; rights agreement between us and the holders of our redeemable convertible preferred stock, subject to the 180-day lock-up agreements described above. See &#8220;Description of Capital Stock&#8201;&#8212;&#8201;Registration Rights.&#8221; Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by affiliates, as defined in Rule&#160;144 under the Securities Act. Any sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our management team has broad discretion to use the net proceeds from this offering and its investment of these proceeds may not yield a favorable return. They may invest the proceeds of this offering in ways with which investors disagree.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We expect to use the net proceeds from the transaction for the following purposes: (i)&#160;commercialization activities of PreTRM testing; (ii)&#160;clinical studies supporting commercialization of the PreTRM test, including the Anthem/PRIME study, and for product discovery and development studies; (iii)&#160;increase capacity and efficiency of our clinical laboratory and enhance our information technology infrastructure; (iv)&#160;further development of our proprietary proteomics and bioinformatics platform; and (v)&#160;for working capital and other general corporate purposes. We may also use a portion of the net proceeds to acquire, license and invest in complementary products, technologies or businesses, though we currently have no agreements or commitments to complete any such transaction. However, within the scope of our plan, and in light of the various risks to our business that are set forth in this section, our management will have broad discretion over the use of proceeds from this offering, and we could spend the proceeds from this offering in ways our stockholders may not agree with or that do not yield a favorable return, if any. If we do not invest or apply the proceeds of this offering in ways that improve our operating results, we may fail to achieve expected financial results, which could cause our stock price to decline. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We cannot specify with certainty all of the particular uses for the net proceeds to be received upon the completion of this offering. In addition, the amount, allocation and timing of our actual expenditures will depend upon numerous factors, many of which are beyond our control. Accordingly, we will have broad discretion in using these proceeds. In addition, until the net proceeds are used, they may be placed in investments that do not produce significant income or that may lose value. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change in control which could limit the market price of our Class&#160;A common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our amended and restated certificate of incorporation and amended and restated bylaws, which are to become effective upon the completion of this offering, contain provisions that could delay or prevent a change in control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">a requirement that special meetings of stockholders be called only by the board of directors acting pursuant to a resolution approved by the affirmative vote of a majority of the directors then in office; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">50</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">advance notice requirements for stockholder proposals and nominations for election to our board of directors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two-thirds of all outstanding shares of our voting stock then entitled to vote in the election of directors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">a requirement of approval of not less than two-thirds of all outstanding shares of our voting stock to amend any bylaws by stockholder action or to amend specific provisions of our certificate of incorporation; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.09pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.09pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the authority of the board of directors to issue convertible preferred stock on terms determined by the board of directors without stockholder approval and which convertible preferred stock may include rights superior to the rights of the holders of common stock. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the General Corporation Law of the State of Delaware, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These anti-takeover provisions and other provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change in control transaction or changes in our board of directors could cause the market price of our Class&#160;A common stock to decline. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The trading market for our Class&#160;A common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. Securities and industry analysts do not currently, and may never, publish research on our company. If no securities or industry analysts commence coverage of our company, the trading price for our stock would likely be negatively impacted. In the event securities or industry analysts initiate coverage, if one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price may decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our amended and restated certificate of incorporation to be effective upon the consummation of this offering designates certain courts as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our amended and restated certificate of incorporation that will become effective upon the completion of this offering provides that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any state law claims for (i)&#160;any derivative action or proceeding brought on our behalf, (ii)&#160;any action or proceeding asserting a claim of breach of fiduciary duty owed by any of our current or former directors, officers and employees, to us or our stockholders, (iii)&#160;any action or proceeding asserting a claim arising pursuant to any provision of the General Corporation Law of the State of Delaware, our amended and restated certificate of incorporation or our bylaws (in each case, as they may be amended from time to time), (iv) any action or proceeding to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or bylaws, (v) any action or proceeding as to which the Delaware General Corporation Law confers jurisdiction to the Court of Chancery of the State of Delaware, or (vi)&#160;any action asserting a claim against us or any of our directors, officers or employees that is governed by the internal affairs doctrine; provided, however, that this exclusive forum provision will not apply to any causes of action arising under the Exchange Act. Our </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">51</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">amended and restated certificate of incorporation will further provide that, unless we consent in writing to an alternative forum, the United States District Court for the District of Utah will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. We have chosen the United States District Court for the District of Utah as the exclusive forum for such Securities Act causes of action because our principal executive offices are located in Salt Lake City, Utah. In addition, our amended and restated certificate of incorporation will provide that any person or entity purchasing or otherwise acquiring any interest in shares of our Class&#160;A common stock is deemed to have notice of and consented to the foregoing provisions. We recognize that the forum selection clause in our amended and restated certificate of incorporation may impose additional litigation costs on stockholders in pursuing any such claims, particularly if the stockholders do not reside in or near the State of Delaware or the State of Utah, as applicable. Additionally, the forum selection clause in our amended and restated certificate of incorporation may limit our stockholders&#8217; ability to bring a claim in a forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders. The Court of Chancery of the State of Delaware or the United States District Court for the District of Utah may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders. Alternatively, if a court were to find the choice of forum provisions contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, results of operations and financial condition. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Because the applicability of the exclusive forum provision is limited to the extent permitted by applicable law, we do not intend that the exclusive forum provision would apply to suits brought to enforce any duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. We also acknowledge that Section&#160;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder and that there is uncertainty as to whether a court would enforce an exclusive forum provision for actions arising under the Securities Act. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Upon completion of this offering, we will become subject to certain reporting requirements of the Exchange Act. Our disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized and reported within the time periods specified in the rules and even if we are successful in remediating our material weakness, any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements or insufficient disclosures due to error or fraud may occur and not be detected. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We will incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As a public company, we will incur significant legal, accounting and other expenses that we did not incur as a private company. We will be subject to the reporting requirements of the Exchange Act, which will require, among other things that we file with the SEC annual, quarterly and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and The Nasdaq Global Market to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial reporting controls and changes in corporate governance practices. Further, in July&#160;2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, was enacted. There are significant corporate governance and executive compensation related provisions in the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">52</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:140pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Dodd-Frank Act concerning areas such as &#8220;say on pay&#8221; and proxy access. EGCs are permitted to implement many of these requirements over a longer period, which may be up to five&#160;years from the pricing of this offering. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We expect the rules and regulations applicable to public companies to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have an adverse effect on our business. The increased costs will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our Class&#160;A common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section&#160;404, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We will be required to disclose changes made in our internal controls and procedures on a quarterly basis and our management will be required to assess the effectiveness of these controls annually. However, for as long as we are an EGC, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal controls over financial reporting pursuant to Section&#160;404. We could be an EGC for up to five&#160;years. An independent assessment of the effectiveness of our internal controls over financial reporting could detect problems that our management&#8217;s assessment might not. Undetected material weaknesses in our internal controls over financial reporting could lead to restatements of our financial statements and require us to incur the expense of remediation. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">53</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSNRF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus contains forward-looking statements that involve risks and uncertainties. All statements other than statements of historical facts contained in this prospectus are forward-looking statements. In some cases, you can identify forward-looking statements by words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; or the negative of these words or other comparable terminology. These forward-looking statements include, but are not limited to, statements about: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">estimates of our addressable market, market growth, future revenue, key performance indicators, expenses, capital requirements and our needs for additional financing; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">our use of the net proceeds from this offering; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">our expectations regarding the rate and degree of market acceptance of our PreTRM test; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the impact of our PreTRM test on the field of bioinformatics and proteomics and the size and growth of the addressable bioinformatics and proteomics market; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">our ability to obtain funding for our operations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">our ability to manage and grow our business and commercialize our PreTRM test; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">our ability to develop and commercialize new products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">our ability to retain the continued service of our key professionals and to identify, hire and retain additional qualified professionals; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the pricing and reimbursement of our products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the implementation of our business model, strategic plans for our business, products and technology; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">developments relating to our competitors and our industry; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the accuracy of our estimates regarding expenses, capital requirements and needs for additional financing; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the impact of COVID-19 on our business; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">our financial performance. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in the &#8220;Risk Factors&#8221; section and elsewhere in this prospectus. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this prospectus may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable as of the date of this prospectus, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this prospectus to conform these statements to new information, actual results or to changes in our expectations, except as required by law. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">54</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:580pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">You should read this prospectus and the documents that we reference in this prospectus and have filed with the Securities and Exchange Commission, or SEC, as exhibits to the registration statement of which this prospectus is a part with the understanding that our actual future results, levels of activity, performance, and events and circumstances may be materially different from what we expect. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">55</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMAID">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:490pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">MARKET AND INDUSTRY DATA</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless otherwise indicated, information contained in this prospectus concerning our industry and the markets in which we operate, including our general expectations, market position and market opportunity, is based on our management&#8217;s estimates and research, as well as industry and general publications and research, surveys and studies conducted by third parties. We believe that the information from these third-party publications, research, surveys and studies included in this prospectus is reliable. Management&#8217;s estimates are derived from publicly available information, their knowledge of our industry and their assumptions based on such information and knowledge, which we believe to be reasonable. This data involves a number of assumptions and limitations which are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in &#8220;Risk Factors.&#8221; These and other factors could cause our future performance to differ materially from our assumptions and estimates. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">56</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tUOP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">USE OF PROCEEDS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We estimate that we will receive net proceeds of approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million from the sale of the shares of our Class&#160;A common stock in this offering, or approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million, if the underwriters exercise their option to purchase additional shares in full, based on an assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, the midpoint of the estimated price range set forth on the cover page of this prospectus, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Each $1.00 increase (decrease) in the assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, the midpoint of the estimated price range set forth on the cover page of this prospectus, would increase (decrease) the net proceeds to us from this offering, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us, by approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same. We may also increase or decrease the number of shares of Class&#160;A common stock we are offering. An increase (decrease) of 1,000,000 shares in the number of shares we are offering would increase (decrease) the net proceeds to us from this offering, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us, by approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million, assuming the initial public offering price stays the same. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The principal purposes of this offering are to increase our financial flexibility, create a public market for our Class&#160;A common stock and to facilitate our access to the public equity markets. We intend to use the net proceeds from this offering as follows: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million to $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million for commercialization activities relating to the PreTRM test; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million to $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million for clinical studies supporting commercialization of the PreTRM test, including the Anthem/PRIME study, and for product discovery and development studies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million to $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million to increase capacity and efficiency of our clinical laboratory and enhance our information technology infrastructure; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million to $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million for further development of our proprietary proteomics and bioinformatics platform including development of other product candidates in our pipeline; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the balance for working capital and other general corporate purposes. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We believe opportunities may exist from time to time to expand our current business through acquisitions or in-licenses of complementary companies, products or technologies. While we have no current agreements, commitments or understandings for any specific acquisitions or in-licenses at this time, we may use a portion of the net proceeds for these purposes. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We believe that the net proceeds from this offering, together with our existing cash and cash equivalents, will enable us to fund our operating expenses and capital expenditure requirements through &#8199;&#8199;&#8199;&#8199;&#8199;. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Although we currently anticipate that we will use the net proceeds from this offering as described above, there may be circumstances where a reallocation of funds is necessary. It is difficult to estimate with certainty the exact amounts of the net proceeds from this offering that may be used for the above purposes. The amounts and timing of our actual expenditures will depend upon numerous factors, including our sales and marketing and commercialization efforts, demand for our products, our operating costs and the other factors described under the &#8220;Risk Factors&#8221; section of this prospectus. Accordingly, our management will have flexibility in applying the net proceeds from this offering. An investor will not have the opportunity to evaluate the economic, financial or other information on which we base our decisions on how to use the proceeds. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Pending their use as described above, we plan to invest the net proceeds in short-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or guaranteed obligations of the U.S. government. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">57</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDIPO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:502pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DIVIDEND POLICY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all available funds and future earnings, if any, for use in the operation of our business and do not anticipate paying any cash dividends on our capital stock in the foreseeable future. Any future determination to declare and pay dividends will be made at the discretion of our board of directors and will depend on various factors, including applicable laws, our results of operations, our financial condition, our capital requirements, general business conditions, our future prospects and other factors that our board of directors may deem relevant. Our ability to pay cash dividends on our capital stock in the future may also be limited by the terms of any preferred securities we may issue or agreements governing any additional indebtedness we may incur. Investors should not purchase our common stock with the expectation of receiving cash dividends. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">58</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tCAP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CAPITALIZATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth our cash and cash equivalents and capitalization as of March&#160;31, 2021: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">on an actual basis; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">on a pro&#160;forma basis to reflect (i)&#160;the sale and issuance of 6,477,458 shares of our Series&#160;E convertible preferred stock in April 2021 for gross cash proceeds of $38.8&#160;million; (ii)&#160;the filing and effectiveness of our amended and restated certificate of incorporation immediately prior to the completion of this offering; and (iii)&#160;the conversion of all outstanding shares of our convertible preferred stock, including the 6,477,458 shares of Series&#160;E convertible preferred stock issued in April 2021, into an aggregate of 49,562,136 shares of our Class&#160;A&#160;&#160;common stock and Class&#160;B common stock upon the completion of this offering; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">on a pro&#160;forma as adjusted basis to additionally reflect the issuance and sale by us of &#8199;&#8199;&#8199;&#8199;&#8199; shares of our&#160;Class&#160;A common stock in this offering, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us, at an assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, the midpoint of the estimated price range set forth on the cover page of this prospectus. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our capitalization following the completion of this offering will be adjusted based on the actual initial public offering price and other terms of the offering determined at pricing. You should read this information together with our unaudited condensed financial statements and related notes appearing elsewhere in this prospectus and the information set forth under the &#8220;Summary Financial Data&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; sections. </font>
        </div>
        <table style="width:456pt;margin-bottom:6.9899999999999pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8.98pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:306.81pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 0.673pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of March&#160;31, 2021</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(unaudited) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.98pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:306.81pt;text-align:left;">
              <div style="white-space:nowrap; line-height:9pt; margin-bottom:-0.506666666666666pt;">
                <font style="letter-spacing:-0.16pt;">(in thousands, except share and per share data) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 0.673pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Actual </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 0.673pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Pro&#160;forma </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 0.673pt 0pt;" colspan="4">
              <div style="text-align:center; line-height:8.99pt;">
                <font style="letter-spacing:-0.16pt;">Pro&#160;forma as</font>
                <br >
                <font style="letter-spacing:-0.16pt;">adjusted</font><font style=" position:relative; bottom:3.25pt;font-size:6pt;letter-spacing:-0.12pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:0pt 0pt 0.5pt 0pt; width:306.81pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">60,016</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">98,816</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.06pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:4.06pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:306.81pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Loans payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,050</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,050</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:306.81pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Preferred stock warrant liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">494</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:306.81pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Capital lease obligation </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">179</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">179</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:306.81pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Convertible Preferred Stock: </font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:306.81pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Junior convertible preferred stock, par value of $0.0001; 22,047,294 shares authorized, actual, 20,414,766 shares issued and outstanding, actual; no shares authorized, issued or outstanding, pro&#160;forma and pro&#160;forma as adjusted. </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">77,844</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:306.81pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Senior convertible preferred stock, par value of $0.0001; 24,496,040 shares authorized, actual, 22,195,278 shares issued and outstanding, actual; no shares authorized, issued or outstanding, pro&#160;forma and pro&#160;forma as adjusted. </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">110,499</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:306.81pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Stockholders&#8217; (deficit) equity: </font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:306.81pt;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Class&#160;A common stock, $0.0001 par value: 75,000,000 shares </font>
                <br >
                <font style="letter-spacing:0.2pt;">authorized, actual, 4,120,842 shares issued and outstanding, actual; </font>
                <br >
                <font style="letter-spacing:0.2pt;">80,000,000 shares authorized, pro&#160;forma; 53,682,978 shares issued </font>
                <br >
                <font style="letter-spacing:0.2pt;">and outstanding, pro&#160;forma; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, pro&#160;forma as </font>
                <br >
                <font style="letter-spacing:0.2pt;">adjusted; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding, pro&#160;forma as </font>
                <br >
                <font style="letter-spacing:0.2pt;">adjusted. </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">5</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:306.81pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Class&#160;B common stock, $0.0001 par value: 3,000,000 shares authorized, actual, no shares issued and outstanding, actual; 3,000,000 shares authorized, pro&#160;forma; no shares issued and outstanding, pro&#160;forma; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, pro&#160;forma as adjusted; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding, pro&#160;forma as adjusted </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:306.81pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Additional paid-in capital </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">7,428</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">235,060</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:306.81pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accumulated deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(137,818<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(137,818<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.06pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.06pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:0pt 0pt 0.5pt 0pt; width:306.81pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total stockholders&#8217; (deficit) equity </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(130,390<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">97,247</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.06pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.06pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.75pt 0pt; width:306.81pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total capitalization </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">57,953</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">97,247</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.06pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">59</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:172pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt;">
          <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">The pro&#160;forma as adjusted information discussed above is illustrative only and will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. A $1.00 increase (decrease) in the assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, the midpoint of the estimated price range set forth on the cover page of this prospectus, would increase (decrease) the amount of cash and cash equivalents, additional paid-in capital, total stockholders&#8217; (deficit) equity and total capitalization on a pro&#160;forma as adjusted basis by approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of shares we are offering. Each increase (decrease) of 1,000,000 shares offered by us would increase (decrease) cash and cash equivalents, total stockholders&#8217; equity (deficit) and total capitalization on a pro&#160;forma as adjusted basis by approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million, assuming the assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, the midpoint of the estimated price range set forth on the cover page of this prospectus, remains the same, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The number of shares of our Class A common stock and Class B common stock outstanding as of March&#160;31, 2020 excludes the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">10,308,231 shares of our Class A common stock issuable upon the exercise of outstanding stock options as of March&#160;31, 2021, having a weighted-average exercise price of $1.22 per share; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">5,700,270 shares of Class A common stock issuable upon the exercise of warrants outstanding as of March&#160;31, 2021, having a weighted-average exercise price of $6.15 per share; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">169,533 shares of common stock (on an as converted basis) issuable upon exercise of warrants to purchase convertible preferred stock as of March&#160;31, 2021, having a weighted average exercise price of $3.46 per share; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">2,933,549 shares of common stock reserved for issuance pursuant to future awards under our 2011 Equity Incentive Plan, of which options to purchase 1,543,237 shares of Class A common stock having an exercise price of $4.27 per share were granted since March 31, 2021; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of Class A common stock reserved for issuance pursuant to future awards under our 2021 Equity Incentive Plan, which will become effective upon the completion of this offering; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of Class A common stock reserved for issuance pursuant to future awards under our 2021 Employee Stock Purchase Plan, which will become effective upon the completion of this offering. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">60</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDIL">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DILUTION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If you invest in our Class&#160;A common stock in this offering, your interest will immediately be diluted to the extent of the difference between the initial public offering price per share of our Class&#160;A common stock in this offering and the pro&#160;forma as adjusted net tangible book value per share of our Class&#160;A common stock immediately after this offering. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of March&#160;31, 2021, our historical net tangible book value (deficit) was $(131.8) million, or $(31.98) per share. Our historical net tangible book value (deficit) per share is equal to our total tangible assets, excluding deferred offering costs, less our total liabilities and the carrying value of our convertible preferred stock, divided by the number of outstanding shares of our Class&#160;A common stock and Class&#160;B common stock as of March&#160;31, 2021. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of March&#160;31, 2021, our pro&#160;forma net tangible book value as of March&#160;31, 2021 was $95.8&#160;million, or $1.79 per share. Pro&#160;forma net tangible book value is the amount of our total tangible assets, excluding deferred offering costs, less our total liabilities, after giving effect to: (i)&#160;the sale and issuance of 6,477,458 shares of our Series&#160;E convertible preferred stock in April 2021 for gross cash proceeds of $38.8&#160;million; and (ii)&#160;the automatic conversion of all outstanding shares of our convertible preferred stock, including the 6,477,458 shares of Series&#160;E convertible preferred stock issued in April 2021, into an aggregate of 49,562,136 shares of Class&#160;A common stock and Class&#160;B common stock upon the consummation of this offering. Pro&#160;forma net tangible book value per share represents pro&#160;forma net tangible book value divided by the total number of issued shares of our Class&#160;A common stock and Class&#160;B common stock as of March&#160;31, 2021, after giving effect to the pro&#160;forma adjustments described above. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">After giving further effect to the issuance and sale of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares of Class A common stock in this offering, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, at an assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, the midpoint of the price range set forth on the cover of this prospectus, our pro&#160;forma as adjusted net tangible book value as of March&#160;31, 2021, would have been approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million, or approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share . This represents an immediate increase in pro&#160;forma as adjusted net tangible book value per share of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;to existing stockholders and immediate dilution of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;in pro&#160;forma as adjusted net tangible book value per share to new investors participating in this offering. Dilution per share to new investors is determined by subtracting pro&#160;forma as adjusted net tangible book value per share after this offering from the assumed initial public offering price per share paid by new investors. The pro&#160;forma as adjusted information below is illustrative only and will depend on the actual initial public offering price and other terms of this offering determined at pricing. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table illustrates this per share dilution to new investors: </font>
        </div>
        <table style="width:456pt;height:136pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:370.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Assumed initial public offering price per share of our common stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; width:370.96pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Historical net tangible book value (deficit) per share as of March&#160;31, 2021, before giving effect to this offering </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(31.98<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; width:370.96pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Increase in historical net tangible book value per share attributable to the pro forma transactions described in the preceding paragraphs </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">33.77</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:370.96pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Pro&#160;forma net tangible book value per share as of March&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">1.79</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; width:370.96pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Increase in net tangible book value per share attributable to new investors participating in this offering </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; width:370.96pt;white-space:normal;text-align:left;">
              <font style="letter-spacing:0.2pt;">Pro&#160;forma as adjusted net tangible book value per share after giving effect to this offering </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:370.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Dilution per share to new investors participating in this offering </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:7.8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The information discussed above is illustrative only, and the dilution information following this offering will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. A $1.00 increase (decrease) in the assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, the midpoint of the estimated price range set forth on the cover page of this prospectus, would increase (decrease) the pro&#160;forma as adjusted net tangible book value by $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share and the dilution to new investors by $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting the estimated underwriting discounts and </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">61</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">commissions and estimated expenses payable by us. We may also increase or decrease the number of shares we are offering. An increase of 1,000,000 shares of Class A common stock offered by us would increase the pro&#160;forma as adjusted net tangible book value by $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share and decrease the dilution to new investors by $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, assuming the assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, the midpoint of the estimated price range set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and estimated expenses payable by us. Similarly, a decrease of 1,000,000 shares offered by us would decrease the pro&#160;forma as adjusted net tangible book value by $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share and increase the dilution to new investors by $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, assuming the assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, the midpoint of the estimated price range set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and estimated expenses payable by us. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If the underwriters exercise their option to purchase additional shares of Class&#160;A common stock in full, the pro&#160;forma as adjusted net tangible book value as of March&#160;31, 2021, will increase to $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million, or $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, representing an increase to existing stockholders of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, and there will be an immediate dilution of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share to new investors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes as of March&#160;31, 2021, on the pro&#160;forma as adjusted basis as described above, the differences between the number of shares of Class&#160;A common stock purchased from us, the total consideration and the average price per share paid by existing stockholders (giving effect to the conversion of all of our convertible preferred stock, including the 6,477,458 shares of Series&#160;E convertible preferred stock issued in April 2021, into 49,562,136 shares of our Class&#160;A common stock and Class&#160;B common stock upon the completion of this offering) and by investors participating in this offering, before deducting the estimated underwriting discounts and commissions and estimated offering expenses, at an assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, the midpoint of the estimated price range set forth on the cover page of this prospectus. </font>
        </div>
        <table style="width:456pt;height:80.44pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8.98pt;height:22.7pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:258.94pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:0pt;" colspan="7">
              <div style="text-align:center; line-height:8.99pt;">
                <font style="letter-spacing:-0.16pt;">Shares</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Purchased </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total Consideration </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:8.98000000000002pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Weighted</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Average</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Price/</font>&#8203;<br ><font style="letter-spacing:-0.16pt;">Share </font></div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:14.09pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:258.94pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.24pt 0pt 2.805pt 0pt; width:26.92pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.24pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Percent </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.24pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.24pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Percent </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.24pt 0pt 1.51pt 0pt; width:258.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Existing stockholders </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:26.92pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.035pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8203;</font><font style="position:absolute;">%</font>
            </td>
            <td style="padding:0pt;padding-left:5.035pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.32pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:1.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.565pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8203;</font><font style="position:absolute;">%</font>
            </td>
            <td style="padding:0pt;padding-left:5.565pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.15pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:3.15pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.49pt 0pt 1.51pt 0pt; width:258.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Investors participating in this offering </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:26.92pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.035pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8203;</font><font style="position:absolute;">%</font>
            </td>
            <td style="padding:0pt;padding-left:5.035pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.32pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.565pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8203;</font><font style="position:absolute;">%</font>
            </td>
            <td style="padding:0pt;padding-left:5.565pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.15pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:3.15pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.49pt 0pt 1.51pt 0pt; width:258.94pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:26.92pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.035pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">100<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:5.035pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.32pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.565pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">100<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:5.565pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.15pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.15pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:7.8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Each $1.00 increase (decrease) in the assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, the midpoint of the estimated price range set forth on the cover page of this prospectus, would increase (decrease) the total consideration paid by new investors by $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;, and increase (decrease) the&#160;percentage of total consideration paid by new investors by approximately&#8199;&#8199;&#8199;&#8199;%, assuming that the number of shares offered by us, as listed on the cover page of this prospectus, remains the same. Similarly, each increase (decrease) of 1,000,000 shares in the number of shares of Class&#160;A common stock offered by us would increase (decrease) the total consideration paid by new investors by $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million and increase (decrease) the&#160;percentage of total consideration paid by new investors by approximately&#8199;&#8199;&#8199;&#8199;% assuming that the assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, the midpoint of the estimated price range set forth on the cover page of this prospectus, price remains the same. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The table above assumes no exercise of the underwriters&#8217; option to purchase additional shares in this offering. If the underwriters&#8217; option to purchase additional shares is exercised in full, the number of shares of our Class&#160;A common stock and Class&#160;B common stock held by existing stockholders would be reduced to&#8199;&#8199;&#8199;&#8199;% of the total number of shares of our Class&#160;A common stock and Class&#160;B common stock outstanding after this offering, and the number of shares of our Class&#160;A common stock held by new investors participating in the offering would be increased to&#8199;&#8199;&#8199;&#8199;% of the total number of shares of our Class&#160;A common stock and Class&#160;B common stock outstanding after this offering. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The number of shares of our Class A common stock and Class&#160;B common stock to be outstanding after this offering is based on 53,682,978 shares of our Class&#160;A common stock and Class&#160;B common stock outstanding as of March&#160;31, 2021, after giving effect to the conversion of all of our outstanding shares of preferred stock, including the 6,477,458 shares of Series&#160;E convertible preferred stock issued in April&#160;2021, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">62</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:284pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">into an aggregate of 49,562,136 shares of our Class&#160;A common stock and Class&#160;B common stock upon the completion of this offering, and excludes the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">10,308,231 shares of our Class A common stock issuable upon the exercise of outstanding stock options as of March 31, 2021, having a weighted-average exercise price of $1.22 per share;</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">5,700,270 shares of Class A common stock issuable upon the exercise of warrants outstanding as of March 31, 2021, having a weighted-average exercise price of $6.15 per share; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">169,533 shares of common stock (on an as-converted basis) issuable upon exercise of warrants to purchase convertible preferred stock as of March 31, 2021, having a weighted average exercise price of $3.46 per share; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">2,933,549 shares of common stock reserved for issuance pursuant to future awards under our 2011 Equity Incentive Plan, of which options to purchase 1,543,237 shares of Class A common stock having an exercise price of $4.27 per share were granted since March 31, 2021;</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199; shares of Class A common stock reserved for issuance pursuant to future awards under our 2021 Equity Incentive Plan, which will become effective upon the completion of this offering; and</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;shares of Class A common stock reserved for issuance pursuant to future awards under our 2021 Employee Stock Purchase Plan, which will become effective upon the completion of this offering. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To the extent that any options or warrants are exercised, new options or other securities are issued under our equity incentive plans, or we issue additional shares of common stock in the future, there will be further dilution to investors participating in this offering. In addition, we may choose to raise additional capital because of market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. If we raise additional capital through the sale of equity or convertible debt securities, the issuance of such securities could result in further dilution to our stockholders. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">63</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMDAA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:13pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes appearing elsewhere in this prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere in this prospectus, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#8220;Risk Factors&#8221; section of this prospectus, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. You should carefully read the &#8220;Risk Factors&#8221; section of this prospectus to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements. Please also see the section entitled &#8220;Special Note Regarding Forward-Looking Statements.&#8221;</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:6pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Overview</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are a women&#8217;s health diagnostic company utilizing our proprietary proteomics and bioinformatics platform to discover, develop and commercialize clinically meaningful and economically impactful biomarker tests, with an initial focus on improving pregnancy outcomes. We believe that our method of combining the disciplines of proteomics and bioinformatics with rigorous clinical testing and economic analysis enables us to provide physicians and patients with actionable data and information designed to result in better maternal and neonatal health at lower cost. Our vision is to deliver pivotal and actionable information to pregnant women, their physicians and healthcare payers to significantly improve maternal and neonatal health and to dramatically reduce healthcare costs. We have built an advanced, proprietary and scalable proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are highly accurate predictors of dynamic changes that occur during pregnancy. By incorporating our proprietary technology platform into our rigorous data-driven development process, we have created a differentiated approach for effectively addressing major conditions of pregnancy. We envision that our comprehensive approach will enable us to fully characterize one of the most important periods in the lives of women and children, and will help to improve their well-being. Our goal is to develop and commercialize tests that inform important decisions during all pregnancies. We also believe that the work we perform in pregnancy can ultimately be leveraged more broadly to address other areas in medicine and healthcare. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our first commercial product, the PreTRM test, is the only broadly validated, commercially available blood-based biomarker test to accurately predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during week 19 or 20 of gestation that provides an accurate prediction of the expectant mother&#8217;s risk of delivering spontaneously before 37 weeks&#8217; gestation. Our commercialization strategy includes conducting clinical trials to demonstrate the health and economic benefits of early and accurate detection of preterm birth risk coupled with well-recognized interventions in higher risk patients. Anthem, whose health plans cover more than 10% of U.S. pregnancies annually, will make our PreTRM test available to eligible pregnant members as part of this multi-year contract. Anthem is the nation&#8217;s second largest health insurer with greater than 43 million members nationwide. Through this collaboration, a significant number of physicians and patients in the U.S. gain access to early and accurate predictions of preterm birth to enable more informed decision-making during pregnancy. Sera believes that its commercial collaboration with Anthem further validates the clinical and economic value of its PreTRM test and significantly de-risks initial commercialization. Sera further expects this provides a pathway for broader market adoption through subsequent coverage decisions by other major payers. We are actively discovering and developing several additional biomarker tests to predict other major conditions of pregnancy, such as preeclampsia, and gestational diabetes, among others, that have the potential to offer significant health benefits to women and their babies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our operations are located in Salt Lake City, Utah, including a CLIA-certified laboratory. Since our inception, we have devoted the majority of our efforts and resources to performing research and development, acquiring product rights, raising capital, establishing facilities, conducting clinical trials, and establishing commercial operations to market the PreTRM test. During this period, we have incurred annual net losses. We have largely funded our operations with proceeds from the sale of convertible preferred stock, debt </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">64</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">financings, and bank loans. Since inception through March 31, 2021, we have raised an aggregate of $207.1&#160;million of gross proceeds from private placements of our equity and debt securities and bank loans. In April 2021, we received $38.8 million in gross proceeds from the sale and issuance of shares of Series E convertible preferred stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have incurred significant operating losses over the last several&#160;years. Our net losses were $6.4 million and $4.7 million for the three months ended March 31, 2021 and 2020, respectively, and $19.8&#160;million and $16.5&#160;million for the&#160;years ended December&#160;31, 2020 and 2019, respectively. We expect to incur significant additional operating losses over at least the next year, principally as a result of our commercialization activities for the PreTRM test, and to support additional clinical studies, publications, and anticipated research and development activities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We had no significant commercial revenue for the three months ended March 31, 2021, and year ended December&#160;31, 2020, and we have no recurring sources of licensing or other revenue. We have signed an agreement with Anthem, pursuant to which Anthem will purchase our PreTRM test, and we continue to negotiate private payer insurance contracts that could eventually result in revenues. If we are unable to secure payer contracts that result in significant revenues or access additional funds, we may be required to delay, scale back or abandon some, or all, of our development programs and other operations. Until such time as we can generate significant revenue from the sales of our products, if ever, we may need to continue to finance our cash needs through equity offerings, debt financings or other capital sources, potentially including collaborations or other similar arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends and may require the issuance of warrants, which could potentially dilute your ownership interests. If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may have to significantly delay, reduce or eliminate some or all of our product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our ability to access capital when needed is not assured and, if not achieved on a timely basis, will materially harm our business, financial condition and results of operations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Without giving effect to the anticipated net proceeds from this offering, based on our current operating plan, we believe we have sufficient cash and cash equivalents on hand to support current operations for twelve months from the date of issuance of the financial statements. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Impact of COVID-19</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The pandemic caused by an outbreak of a novel strain of coronavirus, SARS-CoV-2, which causes a disease known as COVID-19, has resulted, and is likely to continue to result, in significant national and global economic disruption and has adversely impacted the manner in which we conduct our operations. The degree to which COVID-19 impacts our future business operations, research and development programs and financial condition will depend on future developments, including the ultimate duration and/or severity of the outbreak and any resurgences, actions by government authorities to contain the spread of the virus, the effectiveness of vaccines against the virus, and when and to what extent normal economic and operating conditions can resume. The ability of our employees and other business partners to travel and conduct other routine business activity has been and is likely to continue to be disrupted or adversely affected. The primary impact to our business has been the early cessation of enrollment in our AVERT study in March&#160;2020, and the delayed commencement of enrollment in our PRIME study until November&#160;2020. However, our laboratory has remained operational and, to the extent possible, we are conducting our other business operations with necessary or advisable modifications to employee travel and many of our employees working remotely. We will continue to actively monitor the rapidly evolving situation related to COVID-19 and may take further actions that alter our operations, including those that may be required by federal, state or local </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">65</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">authorities, or that we determine are in the best interests of our employees and other third parties with whom we do business. At this point, the extent to which the COVID-19 pandemic may affect our business, operations and development timelines and plans, including the resulting impact on our expenditures and capital needs, remains uncertain and is subject to change. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Collaboration Agreement with Anthem</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On February&#160;17, 2021, we entered into a Commercial Collaboration Agreement with Anthem relating to the commercialization of the PreTRM test. Under the agreement, we will provide PreTRM tests to eligible individuals enrolled in, or serviced or covered by, the health insurance products of Anthem. Pursuant to the agreement, Anthem will purchase a certain minimum number of tests from us for each of the first three&#160;years of the term of the agreement. Additionally, Anthem has agreed to pay us a certain minimum amount per year for the first three&#160;years of the term of the agreement. Anthem has been participating in our PRIME study, and at the conclusion of the PRIME study, we agreed to enter into Anthem&#8217;s standard lab provider agreement with longer term commercial pricing. See the &#8220;Business&#8201;&#8212;&#8201;Anthem Commercial Collaboration Agreement&#8221; section of this prospectus for a further description of this agreement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Factors Affecting Our Performance</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe there are several important factors that have impacted, and that we expect will continue to impact, our operating performance and results of operations, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">our ability to further increase the use and adoption of the PreTRM test or to develop new products and services in the future, and to successfully commercialize the PreTRM test and other products in the future; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the continued development of the market for proteomics and bioinformatics; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">our ability to secure payer contracts that result in significant revenues or to access additional funds, including our ability to perform our obligations under our agreement with Anthem; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">raising substantial additional capital to continue operations and execute on our business plan, until such time as we can generate significant revenue from the sales of our products, if ever; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">obtaining and maintaining intellectual property protection for our technology and products; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">other factors described in the &#8220;Risk Factors&#8221; section and elsewhere in this prospectus. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Key Components of Our Results of Operations</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:7pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Revenues</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We expect to derive substantially all our revenue in the near term from sales of the PreTRM test. To date, we have not generated material revenues from the commercial sale of the PreTRM test. We have signed an agreement with Anthem for the sale of the PreTRM test, and we continue to negotiate private payer insurance contracts that could eventually result in revenues. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Operating Expenses</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:9.5pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Cost of Revenue</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Cost of revenue reflects the aggregate costs incurred in delivering the proteomic testing results to clinicians and includes expenses for third-party sample collection and shipping costs, as well as our lab personnel, materials and supplies, equipment and infrastructure expenses associated with clinical testing, and allocated overhead including rent and equipment depreciation. We expect costs of revenue will generally move in line with the sales of the PreTRM test. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Research and Development Expenses</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Research and development expenses consist of costs incurred for our research activities and development of our product candidates. These expenses include: </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">66</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">clinical studies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.01pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">laboratory processes; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">research and bioinformatic activities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.01pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">biobanking and publication efforts; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">personnel-related expenses, including salaries, payroll taxes, employee benefits and stock-based compensation charges for employees, engaged in these research and development activities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.01pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">direct clinical study expenses incurred under agreements with clinical study sites or contract research organizations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.01pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">consultants engaged in our research and development efforts; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">laboratory materials and supplies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.01pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">facilities costs; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">depreciation, amortization and other direct and allocated expenses, including rent, insurance and other operating costs, incurred as a result of our research and development activities. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We expense all research and development costs, both internal and external, in the period in which they are incurred. We expect that our research and development expenses will continue to increase for the foreseeable future as we support additional clinical studies, publications and other product development activities. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Selling and Marketing Expenses</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Selling and marketing expenses consist primarily of salaries, payroll taxes, employee benefits and stock-based compensation charges for sales, marketing, and payer access personnel. Other significant costs include travel, consulting, public relations, and legal costs related to commercial efforts. We expect selling and marketing expenses to increase in the future as we incur additional expenses associated with the commercialization activities for the PreTRM test and related initiatives. Based on our commercial collaboration with Anthem, we are initially building our specialty OB-GYN commercial sales force to sell and support the PreTRM test in key territories in the United States where Anthem has a significant number of covered members. Upon further market adoption of the PreTRM test by other payers and the expansion of our pipeline, we expect to expand our dedicated sales force into additional territories in the United States to cover the entire U.S. OB-GYN sales channel. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">General and Administrative Expenses</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">General and administrative expenses consist primarily of salaries, payroll taxes, employee benefits and stock-based compensation charges for personnel in executive, finance, information technology, human resources, and other administrative functions. Other significant costs include facilities, corporate and intellectual property legal fees, accounting, insurance, consulting, and other professional fees. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We anticipate that our general and administrative expenses will increase in the future as we construct the appropriate infrastructure to support expanded commercialization efforts and ongoing research and development activities. We anticipate increased expenses related to audit, tax, and legal services associated with maintaining compliance with SEC requirements, as well as increased director and officer insurance premiums, board of director fees, and investor relations costs associated with operating as a public company. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Interest Expense</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Interest expense represents interest expense incurred on our loans payable and convertible promissory note, and amortization of a discount feature on a convertible promissory note. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Other Income (Expense), Net</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Other income (expense), net consists of interest earned on our cash, grant income, periodic mark-to-market changes on liabilities carried at fair value, and other gains and losses. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">67</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Results of Operations</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:7pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Comparison of the Three Months Ended March&#160;31, 2021 and 2020</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes our results of operations for the three&#160;months ended March&#160;31, 2021 and 2020: </font>
        </div>
        <table style="width:456pt;height:212.75pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:9.84pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:326.89pt;" rowspan="3">&#8203;</td>
            <td style="padding:0pt; width:6pt;" rowspan="3">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Three Months Ended March&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:14.09pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.24pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.24pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.24pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.98pt;height:23.07pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.587pt 0pt 2.478pt 0pt; width:0pt;" colspan="16">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">(in thousands)</font>
                <br >
                <font style="letter-spacing:0.16pt;">(unaudited) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.24pt 0pt 1.51pt 0pt; width:326.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Revenue </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">13</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">8</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">5</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.49pt 0pt 1.51pt 0pt; width:326.89pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Operating expenses: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.49pt 0pt 1.51pt 0pt; width:326.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Cost of revenue </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">5</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">3</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.49pt 0pt 1.51pt 0pt; width:326.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">2,396</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">2,050</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">346</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.49pt 0pt 1.51pt 0pt; width:326.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Selling and marketing </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">1,350</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">868</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">482</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.49pt 0pt 2.5pt 0pt; width:326.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">2,287</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">1,379</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">908</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.24pt 0pt 2.5pt 0pt; width:326.89pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total operating expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">6,038</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">4,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">1,738</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.24pt 0pt 1.51pt 0pt; width:326.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Loss from operations </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(6,025<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(4,292<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,733<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.49pt 0pt 1.51pt 0pt; width:326.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Interest expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(307<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(437<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">130</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.49pt 0pt 2.5pt 0pt; width:326.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other income (expense), net </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(27<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">33</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(60<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.24pt 0pt 3.25pt 0pt; width:326.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss and comprehensive loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(6,359<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(4,696<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,663<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:18.19pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Research and Development Expenses</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes our research and development expenses for the three&#160;months ended March&#160;31, 2021 and 2020: </font>
        </div>
        <table style="width:456pt;height:136.75pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:9.84pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:300.5pt;text-align:left;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Three Months Ended March&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt;" colspan="4" rowspan="2">
              <div style="white-space:nowrap; text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:14.09pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.98pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:300.5pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.597pt 0pt 2.478pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">(in thousands)</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(unaudited) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:300.5pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Research and Development </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:300.5pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Expenses: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:300.5pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Clinical studies </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">693</td>
            <td style="padding:0pt;padding-left:9.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">640</td>
            <td style="padding:0pt;padding-left:9.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.625pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">53</td>
            <td style="padding:0pt;padding-left:2.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:300.5pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Research and bioinformatics </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">732</td>
            <td style="padding:0pt;padding-left:9.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">655</td>
            <td style="padding:0pt;padding-left:9.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.625pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">77</td>
            <td style="padding:0pt;padding-left:2.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:300.5pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Laboratory operations </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.71pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">971</td>
            <td style="padding:0pt;padding-left:9.71pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.71pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">755</td>
            <td style="padding:0pt;padding-left:9.71pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.625pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">216</td>
            <td style="padding:0pt;padding-left:2.625pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:300.5pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total research and development expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,396</td>
            <td style="padding:0pt;padding-left:9.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,050</td>
            <td style="padding:0pt;padding-left:9.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.625pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">346</td>
            <td style="padding:0pt;padding-left:2.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:14.2pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Total research and development expenses increased by $0.3&#160;million to $2.4&#160;million for the three&#160;months ended March&#160;31, 2021 compared to $2.1&#160;million for the three&#160;months ended March&#160;31, 2020. The increase was due primarily to a $0.2&#160;million increase in laboratory operations costs. Clinical study and administrative costs associated with the PRIME study resulted in an increase of $53&#160;thousand, in addition to a $77&#160;thousand increase in research and bioinformatics expenses. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Selling and Marketing Expenses</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Selling and marketing expenses increased by $0.5&#160;million to $1.4&#160;million for the three&#160;months ended March&#160;31, 2021 compared to $0.9&#160;million for the three&#160;months ended March&#160;31, 2020. The increase was due primarily to an increase of $0.3&#160;million of personnel-related costs, $0.1&#160;million of consulting and outside services related to enhancing our reimbursement strategy, and $0.1&#160;million of marketing programs and materials development. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">68</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">General and Administrative Expenses</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">General and administrative expenses increased by $0.9&#160;million to $2.3&#160;million for the three&#160;months ended March&#160;31, 2021 compared to $1.4&#160;million for the three&#160;months ended March&#160;31, 2020. The increase was due primarily to an increase of $0.6&#160;million of personnel expenses, $0.2&#160;million of increased consulting and outside services, and $0.1&#160;million of increased stock-based compensation expense. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Interest Expense</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Interest expense was $0.3&#160;million for the three&#160;months ended March&#160;31, 2021 compared to $0.4&#160;million for the three&#160;months ended March&#160;31, 2020. This decrease in interest expense between periods primarily relates to a lower average loan payable principal balance outstanding. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Comparison of the Years Ended December&#160;31, 2020 and 2019</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes our results of operations for the&#160;years ended December&#160;31, 2020 and 2019: </font>
        </div>
        <table style="width:456pt;height:203.76pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:316.89pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:316.89pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.97999999999999pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:316.89pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.263pt 0pt 2.812pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:316.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Revenue </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">25</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">36</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(11<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.89pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Operating expenses: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Cost of revenue </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">11</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">18</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(7<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Research and product development </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">7,782</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">9,353</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,571<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Selling and marketing </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">3,645</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">2,963</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">682</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:316.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">6,558</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">4,278</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">2,280</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:316.89pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total operating expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">17,996</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">16,612</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">1,384</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:316.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Loss from operations </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(17,971<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(16,576<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,395<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Interest expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(1,839<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(1,972<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">133</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:316.89pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other income (expense), net </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(38<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">2,027</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(2,065<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:316.89pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss and comprehensive, loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(19,848<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(16,521<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(3,327<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17.51pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Research and Development Expenses</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes our research and development expenses for the&#160;years ended December&#160;31, 2020 and 2019: </font>
        </div>
        <table style="width:456pt;height:127.76pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:333.55pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:333.55pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.97999999999996pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:333.55pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.263pt 0pt 2.812pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:333.55pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Research and Development </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:333.55pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Expenses</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:333.55pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Clinical studies </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,557</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">4,537</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,980<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:333.55pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Research and bioinformatics </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,473</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,157</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">316</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:333.55pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Laboratory operations </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,752</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,659</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">93</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:333.55pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total research and development expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">7,782</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">9,353</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,571<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.5pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Total research and development expenses decreased by $1.6&#160;million to $7.8&#160;million for the year ended December&#160;31, 2020 compared to $9.4&#160;million for the year ended December&#160;31, 2019. The decrease was due primarily to the conclusion of the PREVENT study in October&#160;2019 and cessation of enrollment in the AVERT study in March&#160;2020, resulting in a decrease of $1.6&#160;million of clinical study costs related to the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">69</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">PreTRM test, and a decrease of $0.4&#160;million of administration costs related to these clinical studies. These changes were offset by a $0.3&#160;million increase in research and bioinformatics, and a $0.1&#160;million increase in laboratory operations costs. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Selling and Marketing Expenses</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Selling and marketing expenses increased by $0.6&#160;million to $3.6&#160;million for the year ended December&#160;31, 2020 compared to $3.0&#160;million for the year ended December&#160;31, 2019. The increase was due primarily to an increase of $0.3&#160;million of consulting and outside services related to enhancing our reimbursement strategy and $0.2&#160;million of personnel related expenses. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General and Administrative Expenses</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">General and administrative expenses increased by $2.3&#160;million to $6.6&#160;million for the year ended December&#160;31, 2020 compared to $4.3&#160;million for the year ended December&#160;31, 2019. The increase was due primarily to an increase of $1.3&#160;million of personnel expenses, $0.5&#160;million for severance and recruiting expenses, $0.2&#160;million of increased stock-based compensation expense, and $0.2&#160;million of increased consulting and outside services. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Interest Expense</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Interest expense was $1.8&#160;million for the year ended December&#160;31, 2020 compared to $2.0&#160;million for the year ended December&#160;31, 2019. This decrease in interest expense between periods primarily relates to a lower average loan payable principal balance outstanding. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Other Income (Expense), Net</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Total other income (expense), net decreased from income of $2.0&#160;million for the year ended December&#160;31, 2019 to an expense of $38&#160;thousand for the year ended December&#160;31, 2020. The change primarily relates to a $2.2&#160;million gain recognized on termination of a convertible note conversion liability, offset by a $0.1&#160;million loss on extinguishment of debt in 2019. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes the components of Other income (expense), net for the&#160;years ended December&#160;31, 2020 and 2019: </font>
        </div>
        <table style="width:456pt;height:112.76pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:385.96pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:385.96pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.24pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.24pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.97999999999996pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:385.96pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.253pt 0pt 2.812pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.24pt 0pt 1.51pt 0pt; width:385.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Interest income </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">42</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">64</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.49pt 0pt 1.51pt 0pt; width:385.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Fair value remeasurements </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">(80<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(129<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.49pt 0pt 1.51pt 0pt; width:385.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant income </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">17</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.49pt 0pt 2.5pt 0pt; width:385.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other gains (losses), net </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,075</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.24pt 0pt 3.25pt 0pt; width:385.96pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other income (expense), net </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">(38<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,027</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17.4pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Liquidity and Capital Resources</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:7pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Sources of Liquidity</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Since inception, we have not generated a significant amount of commercial revenue from product sales or any other sources and have incurred significant operating losses and negative cash flows from operations. We anticipate that we will continue to incur net losses for the foreseeable future. We have financed our operations primarily through private placements of preferred stock, debt financings, and bank loans, receiving in the aggregate gross proceeds of $207.1&#160;million through March&#160;31, 2021. As of March&#160;31, 2021, we had cash and cash equivalents of $60.0&#160;million and an accumulated deficit of $137.8&#160;million. In April 2021, we received an aggregate of $38.8&#160;million in net proceeds from the sale and issuance of shares of Series&#160;E convertible preferred stock. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">70</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Cash Flows</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes our cash flows for the&#160;periods indicated: </font>
        </div>
        <table style="width:456pt;height:121.75pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:9.84pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:239.72pt;text-align:left;" rowspan="3">&#8203;</td>
            <td style="padding:0pt; width:6pt;" rowspan="3">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Three Months Ended March&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:14.09pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.98pt;height:23.07pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.587pt 0pt 2.478pt 0pt; width:106.26pt;" colspan="10">
              <div style="text-align:center; line-height:8.99pt;">
                <font style="letter-spacing:0.16pt;">(in thousands)</font>
                <br >
                <font style="letter-spacing:0.16pt;">(unaudited) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.587pt 0pt 2.478pt 0pt; width:86.02pt;" colspan="10">
              <div style="text-align:center; line-height:8.99pt;">
                <font style="letter-spacing:0.16pt;">(in thousands)</font>
                <br >
                <font style="letter-spacing:0.16pt;">&#8199; </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:239.72pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Net cash provided by (used in): </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.21pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.21pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.21pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.21pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:239.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Operating activities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.21pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(6,950<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.21pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.21pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(4,615<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.21pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(16,868<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(19,324<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:239.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Investing activities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.21pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(41<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.21pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.21pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(8<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.21pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(149<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(6<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:239.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Financing activities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.21pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">53,474</td>
            <td style="padding:0pt;padding-left:7.21pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.21pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">10,667</td>
            <td style="padding:0pt;padding-left:7.21pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">9,160</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">33,049</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:239.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net increase (decrease) in cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.21pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">46,483</td>
            <td style="padding:0pt;padding-left:7.21pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.21pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">6,044</td>
            <td style="padding:0pt;padding-left:7.21pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(7,857<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">13,719</td>
            <td style="padding:0pt;padding-left:0.484999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17.1pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Comparison of the Three Months Ended March&#160;31, 2021 and 2020</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:9.5pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Operating Activities</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Net cash used in operating activities was $7.0&#160;million for the three&#160;months ended March&#160;31, 2021 compared to $4.6&#160;million for the three&#160;months ended March&#160;31, 2020. The net cash used in operating activities during the three&#160;months ended March&#160;31, 2021 was primarily due to a net loss of $6.4&#160;million offset by non-cash charges of $0.6&#160;million and a decrease in operating assets and liabilities of $1.2&#160;million. Non-cash charges during the three&#160;months ended March&#160;31, 2021 primarily consisted of $0.2&#160;million of interest expense, $0.2&#160;million of depreciation expense and $0.2&#160;million of stock-based compensation expense. The net cash used in operating activities during the three&#160;months ended March&#160;31, 2020 was primarily due to a net loss of $4.7&#160;million offset by non-cash charges of $0.7&#160;million and a decrease in operating assets and liabilities of $0.6&#160;million. Non-cash charges during the three&#160;months ended March&#160;31, 2020 primarily consisted of $0.4&#160;million of interest expense, $0.2&#160;million of depreciation expense and $0.1&#160;million of stock-based compensation expense. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Investing Activities</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Net cash used in investing activities was $41&#160;thousand for the three&#160;months ended March&#160;31, 2021 compared to $8&#160;thousand for the three&#160;months ended March&#160;31, 2020, representing purchases of property and equipment in both periods. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Financing Activities</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Net cash provided by financing activities was $53.5&#160;million for the three&#160;months ended March&#160;31, 2021 compared to $10.7&#160;million for the three&#160;months ended March&#160;31, 2020. Net cash provided by financing activities for the three&#160;months ended March&#160;31, 2021 was primarily due to net proceeds of $60.4&#160;million from the sale of Series&#160;E convertible preferred stock, proceeds of $1.1&#160;million from issuance of common stock warrants, $0.2&#160;million proceeds from options exercised, offset by $3.1&#160;million and $4.5&#160;million of loan and notes repayments, respectively, and $0.6&#160;million of deferred offering costs payments. Net cash provided by financing activities for the three&#160;months ended March&#160;31, 2020 was primarily due to $10.7&#160;million of net proceeds from the sale of Series&#160;D convertible preferred stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Comparison of the Years Ended December 31, 2020 and 2019</font>
        </div>
        <div style="margin-top:7.5pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Operating Activities</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Net cash used in operating activities decreased to $16.9&#160;million for the year ended December&#160;31, 2020 from $19.3&#160;million for the year ended December&#160;31, 2019. The net cash used in operating activities during the year ended December&#160;31, 2020 was primarily due to a net loss of $19.8&#160;million, offset by non-cash charges of $3.3&#160;million and a decrease of $0.3&#160;million in operating assets and liabilities. Non-cash charges during the year ended December&#160;31, 2020 primarily consisted of $1.6&#160;million of interest expense, $0.9&#160;million of depreciation expense and $0.7&#160;million of stock-based compensation expense. The net cash used in operating </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">71</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">activities during the year ended December&#160;31, 2019 was primarily due to a net loss of $16.5&#160;million, partially offset by non-cash charges of $0.8&#160;million and a decrease of $3.7&#160;million in operating assets and liabilities. Non-cash charges during the year ended December&#160;31, 2019 primarily consisted of $1.5&#160;million of interest expense, $0.9&#160;million of depreciation and amortization expense and $0.4&#160;million of stock-based compensation expense, offset with $1.3&#160;million of other gains and $0.6&#160;million of fair value adjustments. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Investing Activities</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Net cash used in investing activities of $0.1&#160;million for the year ended December&#160;31, 2020 compared to $6&#160;thousand for the year ended December&#160;31, 2019. The change in cash used in investing activities was due primarily to $0.1&#160;million of proceeds from the disposal of property and equipment in the year ended December&#160;31, 2019 and no similar proceeds in the year ended December&#160;31, 2020. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Financing Activities</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Net cash provided by financing activities decreased to $9.2&#160;million for the year ended December&#160;31, 2020 from $33.0&#160;million for the year ended December&#160;31, 2019. Net cash provided by financing activities for the year ended December&#160;31, 2020 was primarily due to net proceeds of $10.7&#160;million from the sale of Series&#160;D convertible preferred stock, proceeds of $1.1&#160;million from a Paycheck Protection Program, or PPP loan payable, offset with $2.7&#160;million of loan repayments. Net cash provided by financing activities for the year ended December&#160;31, 2019 was primarily due to $29.1&#160;million of net proceeds from the sale of Series&#160;D preferred stock and $6.6&#160;million of proceeds from convertible notes payable, offset with $3.3&#160;million of loan repayments. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Future Funding Requirements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We expect to incur significant additional operating losses and negative cash flows for the foreseeable future. We expect our losses in the future to be principally as a result of our commercialization activities for the PreTRM test, and to support additional clinical studies and anticipated research and development activities. We had no significant commercial revenue for the three months ended March 31, 2021 and year ended December&#160;31, 2020, and we have no recurring sources of licensing or other revenue. There can be no assurance that we will eventually achieve significant revenues or profitability, or if achieved, can sustain either on a continuing basis. If we are unable to achieve significant revenues or raise additional funding, when needed, we may not be able to continue the development or commercialization of our diagnostic products and could be required to delay, scale back or abandon some or all of our development programs and other operations. Management believes that its existing financial resources are sufficient to continue operating activities at least one year past the issuance date of these condensed financial statements. No assurance can be given that we will be successful in raising the required capital at reasonable cost and at the required times, or at all. Any additional equity financing may not be available on favorable terms, most likely will be dilutive to our current stockholders, and debt financing, if available, may involve restrictive covenants and dilutive financing instruments. Further, our operating plan may change, and we may need additional funds to meet operational needs and capital requirements for product development and commercialization sooner than planned. We currently have no credit facility or committed sources of capital. Our future funding requirements will depend on many factors, including the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the timing, receipt and amount of sales, if any, from the PreTRM test; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the cost and timing of establishing sales, marketing and other commercialization capabilities in the United States and abroad; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.09pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.09pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">our ability to develop and commercialize other products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the terms and timing of any collaborative, licensing and other arrangements that we may establish; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the cost, timing and outcomes of regulatory approvals; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the scope, rate of progress, results and cost of our clinical studies, and other related activities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the cost of preparing, filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">72</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the extent to which we acquire or invest in businesses, products or technologies, although we currently have no commitments or agreements relating to any of these types of transactions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.49pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.49pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">partnerships and other strategic options for our product and other product candidates; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">other factors described in the &#8220;Risk Factors&#8221; section and elsewhere in this prospectus. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We believe that our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements through &#8199;&#8199;&#8199;&#8199;.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Contractual Obligations and Commitments</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes our contractual obligations and commitments as of December&#160;31, 2020: </font>
        </div>
        <table style="width:456pt;height:136.75pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:231.29pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt; width:0pt;text-align:center;" colspan="28">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Payments Due by Period </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.98pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:231.29pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.597pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.597pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Less Than </font>
                <br >
                <font style="letter-spacing:-0.16pt;">1 Year </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.597pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">1-3 Years </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.597pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">3-5 Years </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.597pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">More than </font>
                <br >
                <font style="letter-spacing:-0.16pt;">5 Years </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.97999999999999pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:231.29pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.263pt 0pt 2.812pt 0pt; width:0pt;text-align:center;" colspan="28">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:231.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Bank Loan (including interest and fees)</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">3,159</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">3,159</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.815pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.815pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.495pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.495pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:231.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Convertible Note (including interest)</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(2)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">5,490</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5,490</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.815pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.815pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.495pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.495pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:231.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">PPP loan payable (including interest)</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(3)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,065</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">709</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.815pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">356</td>
            <td style="padding:0pt;padding-left:1.815pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.495pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.495pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:231.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Operating leases</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(4)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,099</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">545</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.815pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">554</td>
            <td style="padding:0pt;padding-left:1.815pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.495pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.495pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:231.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Capital leases</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(5)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">215</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">80</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.815pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">135</td>
            <td style="padding:0pt;padding-left:1.815pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.67pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.67pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.495pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.495pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:231.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">11,028</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">9,983</td>
            <td style="padding:0pt;padding-left:3.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.815pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,045</td>
            <td style="padding:0pt;padding-left:1.815pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.495pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.495pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:5.99pt; width:456pt;">
          <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:9.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:9.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Our bank loan, which consists of the amounts borrowed under our loan agreement with Pacific Western Bank, bears interest at a floating annual rate equal to the greater of (i)&#160;the prime rate plus 1.0% (4.75% at December&#160;31, 2020), and (ii)&#160;4.75%. The amounts in the table above assume payment at our current interest rate of 4.75%, which is subject to change, and also reflect the final payment fee on the loan. On March&#160;24, 2021, we repaid this bank loan, including principal and all accrued interest. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:5.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:5.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Our Convertible Note, which matured on March&#160;28, 2021, was repaid, including principal, accrued interest and final fee on March&#160;24, 2021. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:5.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:5.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">In April&#160;2020, we obtained a $1.1&#160;million loan through a bank under the Paycheck Protection Program, or PPP, under the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, as amended, which may be forgiven. To the extent all or part of the PPP loan is not forgiven, we will be required to pay interest on the PPP loan at a rate of 1% per annum and principal and interest payments will be required through the maturity date in April&#160;2022. This amount includes principal and all accrued interest. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:5.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:5.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Our operating lease obligations relate to our current corporate headquarters and laboratory space in Salt Lake City, Utah. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:5.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(5)</font>
          <br >
        </div>
        <div style=" margin-top:5.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Some of our fixed assets have been acquired by capital lease, and the amounts above represent the contractual monthly payments of principal and interest. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We enter into contracts in the normal course of business with third-party contract research organizations and clinical trial sites for our clinical trials, and with supply vendors for other services and products for operating purposes. These contracts generally provide for termination after a notice period, and, therefore, are cancelable contracts that are not included in the table above. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Off-Balance Sheet Arrangements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Since our inception, we have not engaged in any off-balance sheet arrangements, as defined in the rules and regulations of the Securities and Exchange Commission, or the SEC. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">73</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Critical Accounting Policies, Significant Judgments and Use of Estimates</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenue and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Determination of Fair Value of Common Stock</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are required to estimate the fair value of the common stock underlying our stock-based awards. Since there has been no public market of our common stock to date, the fair value of the shares of common stock underlying our share-based awards was estimated on each stock-based award grant date by our board of directors. To determine the fair value of our common stock, our board of directors considered input from management, relied in part upon the valuations of our common stock, which we determined with the assistance of independent valuation specialists using approaches and assumptions consistent with the American Institute of Certified Public Accountants Statement on Standards for Valuation Services, and assessed additional factors that we believed were relevant or that may have changed from the date of the most recent valuation through the date of the grant. These factors include, but are not limited to: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">our results of operations, financial position, and capital resources; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">our stage of development and progress of our research and development activities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">our business conditions and projections; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the external market conditions affecting the life sciences and biotechnology industry sectors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the trends and developments in our industry; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the valuation of publicly traded companies in our industry sectors, as well as recently completed mergers and acquisitions of peer companies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the lack of marketability of our common stock as a private company; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the prices at which we sold shares of our convertible preferred stock to outside investors in arms-length transactions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the rights, preferences, and privileges of our convertible preferred stock relative to those of our common stock; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the likelihood of achieving a liquidity event for our security holders, such as an initial public offering or a sale of our company, given prevailing market conditions. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For our valuations performed as of dates prior to December&#160;31, 2019, we used the option pricing method, or OPM, back-solve method. In an OPM framework, the back-solve method for inferring the equity value implied by a recent financing transaction involves making assumptions for the expected time to liquidity, volatility and risk-free rate and then solving for the value of equity such that value for the most recent financing equals the amount paid. This method was selected as management concluded that the contemporaneous financing transaction was an arms-length transaction. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For our valuations performed as of dates subsequent to December&#160;31, 2019, we used a hybrid method of OPM and the Probability-weighted Expected Return Method, or PWERM. PWERM considers various potential liquidity outcomes. Our approach included the use of an initial public offering scenario and a scenario assuming continued operation as a private entity. Under the hybrid OPM and PWERM approach, the per share value calculated under OPM and PWERM are weighted based on expected exit outcomes and </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">74</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">the quality of the information specific to each allocation methodology to arrive at a final estimated fair value per share of the common stock before a discount for lack of marketability is applied. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Following the completion of this offering, it will no longer be necessary for our board of directors to estimate the fair value of our common stock in connection with our accounting for stock-based awards we may grant, as the fair value of our common stock will be based on the closing price as reported on the date of grant on the primary stock exchange on which our common stock is traded. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Convertible Preferred Stock Warrant Liability</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Freestanding warrants to purchase shares of our convertible preferred stock are accounted for as liabilities at fair value, because the shares underlying the warrants contain contingent redemption features outside our control. Warrants classified as liabilities are recorded on the balance sheets at their fair value on the date of issuance and re-measured to fair value on each subsequent reporting period, with the changes in fair value recognized as interest expense and other income (expense) in the statements of operations. The fair value of the warrant liability is calculated using a Black-Scholes option pricing model, which requires the use of subjective assumptions. These assumptions include fair value of preferred stock, expected term, expected volatility, risk free interest rate, and expected dividend yield. The fair value of our preferred stock was determined by the same process to determine valuations of our common stock, which valuations we determined with the assistance of a third-party valuation specialist using approaches and assumptions consistent with the American Institute of Certified Public Accountants Statement on Standards for Valuation Services. See the subsection titled &#8220;Determination of Fair Value of Common Stock&#8221; above. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Stock-based Compensation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We maintain a stock-based compensation plan as a long-term incentive for employees and non-employee consultants. The plan allows for the issuance of incentive stock options and non-qualified stock options. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We recognize stock-based compensation expense for stock options on a straight-line basis over the requisite service period and estimate forfeitures based on historical evidence. Our stock-based compensation costs are based upon the grant date fair value of options estimated using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires the use of highly subjective assumptions to determine the fair value of stock-based awards. These assumptions include: the fair value of common stock, expected term, expected volatility, risk-free interest rate, and expected dividend yield. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Estimating the fair value of share-based awards as of the grant date using the Black-Scholes option pricing model is affected by assumptions regarding a number of variables. Changes in the assumptions can materially affect the fair value and ultimately how much stock-based compensation expense is recognized. These inputs, which are subjective and generally require significant analysis and judgment to develop, include fair value of common stock, expected term, expected volatility, risk free interest rate, and expected dividend yield. We will continue to use judgment in evaluating the expected volatility, expected terms, and interest rates utilized for our stock-based compensation expense calculations on a prospective basis. As of March&#160;31, 2021, there was $4.2&#160;million of unamortized stock-based compensation cost related to unvested stock options which is expected to be recognized over a weighted average period of 3.5&#160;years. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">JOBS Act and Emerging Growth Company Status</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are an EGC, as defined in the JOBS Act. We elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that we (1)&#160;are no longer an EGC or (2)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies, reduce disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and are exempt from the requirements of holding a nonbinding advisory vote on executive compensation and any golden parachute payments not previously approved. In particular, in this prospectus, we have provided only two&#160;years of audited financial statements and have not included all of the executive compensation-related information that would be required if we were not an EGC. As an EGC, we are also not required to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">75</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:169pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">have our internal control over financial reporting audited by our independent registered public accounting firm pursuant to Section&#160;404 of the Sarbanes-Oxley Act. As a result, our financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates and we are not required to provide auditor attestation regarding requirements of Section&#160;404(b) of Sarbanes-Oxley. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We will remain an EGC until the earliest to occur of: (1)&#160;the last day of the fiscal year in which we have at least $1.07&#160;billion in annual revenue; (2)&#160;the last day of the fiscal year in which we are deemed to be a &#8220;large accelerated filer,&#8221; as defined in Rule&#160;12b-2 under the Securities Exchange Act of 1934, as amended, or the Exchange Act, which would occur if the market value of our common stock held by non-affiliates exceeded $700.0&#160;million as of the last business day of the second fiscal quarter of such year; (3)&#160;the date on which we have issued more than $1.0&#160;billion in non-convertible debt securities during the prior three-year period; and (4)&#160;the last day of the fiscal year ending after the fifth anniversary of this offering. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Recent Accounting Pronouncements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A description of recent accounting pronouncements that may potentially impact our financial position, results of operations or cash flows is disclosed in the notes to the accompanying financial statements also included in this registration statement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Quantitative and Qualitative Disclosures About Market Risk</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:7pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Interest Rate Risk</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our cash and cash equivalents consist of cash held in an interest-bearing savings account. We do not hold any short-term investments. As a result, we believe that our exposure to interest rate risk is not significant, and a hypothetical 1.0% change in market interest rates during any of the periods presented would not have had a significant impact on the total value of our portfolio. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Foreign Currency</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We do not regularly incur expenses with vendors outside the United States or that are denominated in currencies other than the U.S. dollar. We may incur such expenses in the future at which point exchange rate fluctuations might adversely affect our expenses, results of operations, financial position and cash flows. To date, exchange rate fluctuations have not had a material effect on our results of operations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Effects of Inflation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Inflation generally affects us by increasing our cost of labor and clinical trial costs. We do not believe inflation has had a material effect on our results of operations during the periods presented and do not anticipate a material impact going forward. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">76</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tBUS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">BUSINESS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img src="lg_seraprognostics-4clr.jpg" alt="[MISSING IMAGE: lg_seraprognostics-4clr.jpg]" height="45" width="230" >
        </div>
        <div style="margin-top:13.2pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Seeking to improve the lives of mothers and babies</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Overview</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are a women&#8217;s health diagnostic company utilizing our proprietary proteomics and bioinformatics platform to discover, develop and commercialize clinically meaningful and economically impactful biomarker tests, with an initial focus on improving pregnancy outcomes. We believe that our method of combining the disciplines of proteomics and bioinformatics with rigorous clinical testing and economic analysis enables us to provide physicians and patients with actionable data and information designed to result in better maternal and neonatal health at lower cost. Our vision is to deliver pivotal and actionable information to pregnant women, their physicians and healthcare payers to significantly improve maternal and neonatal health and to dramatically reduce healthcare costs. We have built an advanced, proprietary and scalable proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are highly accurate predictors of dynamic changes that occur during pregnancy. By incorporating our proprietary technology platform into our rigorous data-driven development process, we have created a differentiated approach for effectively addressing major conditions of pregnancy. We envision that our comprehensive approach will enable us to fully characterize one of the most important periods in the lives of women and children, and will help to improve their well-being. Our goal is to develop and commercialize tests that inform important decisions during all pregnancies. We also believe that the work we perform in pregnancy can ultimately be leveraged more broadly to address other areas in medicine and healthcare. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our first commercial product, the PreTRM test, is the only broadly validated, commercially available blood-based biomarker test to accurately predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 19 or 20 of gestation that provides an accurate prediction of the expectant mother&#8217;s risk of delivering spontaneously before 37 weeks&#8217; gestation. Our commercialization strategy includes conducting clinical trials to demonstrate the health and economic benefits of early and accurate detection of preterm birth risk coupled with well-recognized interventions in higher risk patients. Anthem, whose health plans cover more than 10% of U.S. pregnancies annually, will make our PreTRM test available to eligible pregnant members as part of this multi-year contract. Anthem is the nation&#8217;s second largest health insurer with greater than 43 million members nationwide. Through this collaboration, a significant number of physicians and patients in the U.S. gain access to early and accurate predictions of preterm birth to enable more informed decision-making during pregnancy. Sera believes that its commercial collaboration with Anthem further validates the clinical and economic value of its PreTRM test and significantly de-risks initial commercialization. Sera further expects this provides a pathway for broader market adoption through subsequent coverage decisions by other major payers. We are actively discovering and developing several additional biomarker tests to predict other major conditions of pregnancy, such as preeclampsia, and gestational diabetes, among others, that have the potential to offer significant health benefits to women and their babies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There are approximately 140&#160;million births globally each year. Of these, it is estimated that as many as 25% are affected by various complications, including: preterm birth, preeclampsia, fetal growth restriction, stillbirth, hypertension of pregnancy, gestational diabetes, and others. In the United States, there are approximately 3.8&#160;million births annually, and over 10% of those pregnancies result in preterm births with profound short- and long-term health consequences to the mother and baby. These health consequences are estimated to lead to associated costs of approximately $25&#160;billion annually in the United States. Traditional methods to detect prematurity risk in time for proactive management have been limited and fail to identify the vast majority of women who will deliver prematurely. We believe our actionable blood-based biomarker test for prematurity risk can enable patients, physicians and payers to more proactively manage and mitigate the complications and associated costs of prematurity. Given that pregnancy is the launch point for the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">77</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">future health of babies and a key determinant in the future health of mothers and babies, we believe this area is ripe for innovation and better tools to improve patient outcomes. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Proprietary Technology Platform</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The complexities of the biological processes occurring during pregnancy have been a major obstacle in developing effective tests for pregnancy-related conditions. We are working to overcome this obstacle through our development of a proprietary technology platform consisting of biobanks, advanced mass spectrometry and other proteomic analytic methods and bioinformatics, which enables superior characterization of the biology of pregnancy and more accurate prediction of pregnancy outcomes. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">An analysis of protein pathways and expression at various points during pregnancy reveals the constantly evolving and dynamic changes affecting both the mother and the fetus. Earlier detection of changes in protein expression indicating the emergence of adverse pregnancy outcomes can enable proactive management of those conditions. A fundamental component of our platform is our proprietary and continually growing biobank consisting of comprehensive, clinically and demographically annotated blood samples collected from more than 10,500 pregnant U.S. women, representing broad demographic and geographic diversity inherent in the U.S. population. This differentiated resource enables us to develop and broadly validate our predictors. Further biobank diversity is also provided through our scientific collaborations with leading maternal fetal medicine experts around the globe, enabling us to analyze specimens collected from patients in the United States, Europe, Asia and Africa. In strict adherence to the authoritative National Academy of Medicine, or NAM, guidelines, we apply our innovative mass-spectrometry and other proteomic analytical methods and our protein information network knowledge to probe biobank samples for meaningful protein expression changes. We then subject the data to detailed bioinformatics analysis and use advanced tools, such as machine learning and artificial intelligence, to find relationships between various proteins and to discover important predictors. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Discovery, Development, and Commercialization Approach</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our product discovery and development approach is based on rigorous science- and health-based economic analyses as we discover, develop and commercialize biomarker tests designed to transform pregnancy-related care for patients, doctors and payers. We have initially applied our platform and capabilities to address the problem of preterm birth, given its profound health and economic impacts worldwide. In the future, we may use this technology to develop products for a number of health conditions other than premature births. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We use the following multifaceted approach in our research, development and commercialization efforts: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Significant Unmet Need:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We select specific conditions of pregnancy that are clinically meaningful and economically important and with significant unmet needs that lack effective solutions. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Proteomic and Bioinformatics Platform:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We utilize our platform to understand the biology underlying selected pregnancy-related conditions in order to discover, verify and broadly validate high-performing predictive biomarker tests. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Demonstrate Health and Economic Impact of Our Test and Treat Strategy:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We believe a critical element of our success will be to demonstrate the beneficial health and economic impacts of using the information provided by our biomarker tests. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Payer-Centric Reimbursement Coverage:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We have adopted what we believe is an innovative payer-centric approach for early commercialization of our biomarker tests, by seeking to leverage the health and economic benefits conferred by our biomarker approach to gain early reimbursement coverage from major health insurance payers. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Broader Market Adoption:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We are capitalizing on our innovative payer-centric reimbursement strategy to facilitate obtaining widespread commercial coverage of our biomarker tests from other healthcare payers. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">78</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Pipeline</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are developing a robust pipeline of novel blood-based biomarker tests for a number of major pregnancy related conditions beyond preterm birth by leveraging the biological insights provided by our proprietary technology platform. Our product candidates are designed to accurately predict and enable better management of a range of serious pregnancy-related conditions. We believe these product candidates, if successfully developed, have the potential to address significant unmet needs by providing more accurate detection of these pregnancy-related conditions and providing patients and physicians with earlier opportunities for interventional treatment. We retain worldwide development and commercialization rights to all of our product candidates. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our biomarker pregnancy pipeline consists of the following: </font>
        </div>
        <div style="position:relative;margin-top:10.2pt; text-align:center; width:456pt;">
          <img src="tm2110724d7-tbl_predictor4c.jpg" alt="[MISSING IMAGE: tm2110724d7-tbl_predictor4c.jpg]" height="301" width="603" >
        </div>
        <div style="margin-top:17.39pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The PreTRM Test&#8201;&#8212;&#8201;Our Solution for Preterm Birth</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our first product, the PreTRM test, is the only broadly validated, commercially available blood-based biomarker test to accurately predict the risk of spontaneous preterm birth. Preterm birth, which occurs in approximately 15&#160;million deliveries annually around the world, is defined as any birth before 37 weeks&#8217; gestation and is a leading cause of illness and death in newborns. The 2020 March of Dimes Report Card shows that of the approximately 3.8&#160;million babies born annually in the United States, more than one in&#160;10&#160;is born prematurely. Preterm births result in approximately $25&#160;billion in economic costs in the United States per year, largely as a result of profound short- and long-term health consequences to the mother and baby. Major long-term medical complications associated with preterm birth include learning disabilities, cerebral palsy, chronic respiratory illness, intellectual disability, seizures, vision and hearing loss. These complications can generate significant costs throughout the lives of affected children. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The PreTRM test is a non-invasive blood test given to a pregnant woman during week 19 or 20 of gestation. The PreTRM test provides an accurate prediction of the expectant mother&#8217;s individualized risk, expressed as a&#160;percentage, of delivering spontaneously before 37 weeks&#8217; gestation, as well as her relative risk compared to the average population risk. The great majority of single fetus, or singleton, preterm births are spontaneous, where the mother goes into labor and delivers without any apparent known pathology. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The protein biomarkers of preterm birth utilized in our PreTRM test have been extensively validated in multiple maternal fetal medicine centers located in the United States, Europe, Asia and Africa. In addition, we continue to build on our existing data to further demonstrate the clinical and economic benefits of intervening based on PreTRM test results. We believe our comprehensive approach to build evidence for our PreTRM test addresses key elements payers require in order to reimburse testing, including: </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">79</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">analytical validation of the testing platform, or measurement validity; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">clinical validation, or test validity; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">clinical utility of using validated predictions, or positive health benefit; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">economic utility, or cost effectiveness and healthcare savings. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Underscoring the benefits of the PreTRM test and treat strategy, the clinical and economic utility of the PreTRM test administered mid-pregnancy has been published by respected independent health economists in a leading maternal fetal medicine journal. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The strength of the data from our studies of the PreTRM test has enabled us to pursue an innovative and accelerated approach to commercialization. We have secured PreTRM test reimbursement through a major strategic payer, Anthem, representing an important step in achieving initial payer acceptance of our rigorous approach to prematurity, which we believe will help the PreTRM test obtain broader insurance coverage adoption. We believe that this collaboration significantly de-risks initial commercialization of the PreTRM test, as it provides reimbursement from a major payer covering more than 10% of U.S. pregnancies annually and provides a pathway for broader market adoption through subsequent coverage decisions by other major payers. The collaboration also enables us to generate more data to demonstrate the value of the PreTRM test and treat approach across diverse patient populations within Anthem&#8217;s insurance plans. In November&#160;2020, we were awarded a unique CPT</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> PLA code by the AMA Editorial Board, specifically for the PreTRM test, which we believe will also help drive payment and coverage decisions for PreTRM testing. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Team</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our team brings extensive experience and expertise in building and running highly profitable molecular diagnostics companies. We are led by Gregory C. Critchfield, M.D., M.S., our Chairman, President and Chief Executive Officer, who previously served as President of Myriad Genetic Laboratories; Douglas Fisher, M.D., our Chief Business Officer; Thomas Garite, M.D., our Vice President, Clinical Sciences, a past president of the Society for Maternal Fetal Medicine; Jay Boniface, Ph.D., our Chief Scientific Officer; and Nadia Altomare, our Chief Commercial Officer, all of whom have extensive leadership experience in the pharmaceutical, device and diagnostic companies. Jay Moyes, our Chief Financial Officer, or CFO, served as CFO with Myriad Genetics and has extensive experience in public and private financings, licensing transactions and acquisitions. We are supported by an experienced board of directors and clinical and scientific advisors that are leaders in the fields of maternal fetal medicine, bioinformatics, clinical trials and science based businesses. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Strengths</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We attribute our success and future growth prospects to the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Our differentiated approach to understanding and addressing major conditions of pregnancy.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We take a focused and data-driven approach based on rigorous science to understand the biology of pregnancy and the health and economic impacts of major pregnancy conditions. Our approach involves conducting controlled trials and health economic analyses to demonstrate the beneficial health and economic impacts of using the information provided by our biomarker tests. We also work with leading health economists and organizations to build rigorous models that describe how the application of our tests impacts both health and economic outcomes. Leveraging the demonstrated short- and long-term health and economic benefits of our biomarker approach, we aim to gain early reimbursement coverage from major health insurance payers by working with them to demonstrate the benefits of using our biomarker tests based upon analysis of claims data in their own plans. We intend to capitalize on our innovative payer-centric reimbursement strategy to facilitate obtaining widespread commercial coverage of our biomarker tests from other healthcare payers. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Our proprietary and scalable proteomics and bioinformatics platform technology creates clinically meaningful and economically impactful predictions for pregnancy.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We believe our proprietary proteomic and bioinformatics technology platform has the potential to enable critical advances in </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">80</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:40pt; width:416pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">the management of pregnancy and its outcomes. Our platform consists of biobanks, advanced mass spectrometry and other proteomic analytic methods and bioinformatics, which enables superior characterization of the biology of pregnancy and accurate prediction of pregnancy outcomes. We believe this platform has the potential to address significant unmet medical needs in the large, underserved market for the prediction of outcomes associated with pregnancy. </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">The PreTRM Test is the only broadly validated, commercially available blood test proven to predict the risk of an individual woman to deliver prematurely.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The predictive performance of the PreTRM biomarkers has been extensively validated in diverse populations and geographies and enables earlier proactive care addressing higher preterm birth risk that occurs among the 3.8&#160;million annual singleton pregnancies in the United States. We believe that based on our growing body of evidence regarding the clinical and economic benefits of the PreTRM test and our innovative collaboration with Anthem, as greater payer and physician adoption occurs throughout the United States, the PreTRM test has the potential to become an important standard of care for preterm birth. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Innovative and strategic partnership with Anthem.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We have secured early PreTRM test reimbursement through our strategic collaboration with Anthem, which represents an important step in achieving initial payer acceptance of our rigorous approach to prematurity and which we believe will help foster broader insurance coverage adoption. We launched this commercialization process in the first half of 2021, and from which we envision substantial penetration of Anthem&#8217;s network over the next few&#160;years. We believe this collaboration significantly de-risks initial commercialization of our PreTRM test, as it demonstrates reimbursement from a major payer covering more than 10% of U.S. pregnancies annually and provides a pathway for broader market adoption through subsequent coverage decisions by other major payers. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Broad pipeline covering additional significant conditions of pregnancy.&nbsp;&nbsp;&nbsp;</font><font style="letter-spacing:0.2pt;"> We are also developing a novel pipeline of blood-based biomarker tests for a number of major pregnancy-related conditions beyond preterm birth by leveraging the biological insights provided by our proprietary technology platform. We believe these product candidates, if successfully developed, have the potential to address significant unmet needs by providing more accurate detection of these pregnancy-related conditions and affording patients and physicians earlier opportunities for interventional treatment. We retain worldwide development and commercialization rights to all of our product candidates. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Deeply experienced team in biotechnology and molecular diagnostics test development and commercialization.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Our executive team has decades of experience in building and commercializing molecular diagnostics tests. We have worked to build a first-class scientific organization capable of harnessing and translating our platform technologies into innovative predictive solutions as we strive to deliver pivotal and actionable information to pregnant women, their physicians and payers to improve the health of patients as well as the economics of healthcare delivery. Our experienced discovery and development team performs rigorous bioinformatics analyses and strictly adheres to the authoritative guidelines published by the NAM on how to reliably develop and validate omics predictions made on complex biological data sets. Adhering to these guidelines, in the case of predicting preterm birth, we have been able to document generalizable biomarker predictive performance across independent cohorts of patients from the United States, Europe, Asia and Africa. Reflective of the scientific rigor of our efforts, our scientists have published best practice recommendations for the analysis of preterm delivery data. We believe this will improve the quality of statistical analysis of research data related to proteomic test development, enabling the broad community of statisticians, researchers, clinicians and regulators to better validate predictions prior to their clinical use. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Strategy</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our vision is to deliver pivotal and actionable information to pregnant women, their physicians and healthcare payers to significantly improve maternal and neonatal health and to dramatically reduce healthcare costs. Our goal as The Pregnancy Company is to discover, develop and commercialize clinically meaningful and economically impactful biomarker tests designed to improve pregnancy outcomes. We believe it is critical to innovate products that will be viewed as cost-effective by payers in order to receive reimbursement for our tests. We aim to accomplish our vision by implementing the following strategies: </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">81</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Accelerate the commercialization of the PreTRM test through our innovative strategic partnership with Anthem.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Through our collaboration with Anthem, the second largest health benefits company in the United States with plans covering more than 10% of U.S. pregnancies annually, we intend to accelerate commercialization of the PreTRM test and generate revenue for our test in Anthem&#8217;s network. We believe that sizable early penetration of the market will lay a foundation for future expansion of our PreTRM test to other insurance plans. We believe that through this partnership, a significant number of physicians and patients in the U.S. will have access to early and accurate predictions of preterm birth to enable more informed decision-making during pregnancy. We launched this commercialization process in the first half of 2021, and we envision substantial penetration of our testing into Anthem&#8217;s network over the next few&#160;years. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Expand coverage of the PreTRM test to additional payers to maximize the commercial opportunity.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp; We believe that the Anthem collaboration significantly de-risks early PreTRM test commercialization by demonstrating the clinical and economic benefits of the PreTRM test and will help incentivize broader market adoption the PreTRM test as we approach other payers. We believe that growing coverage of the PreTRM test will drive physicians to more broadly offer the testing to their patients, thereby significantly expanding the number of U.S. pregnancies benefiting from our technology. We also believe that, based on our growing body of evidence regarding the clinical and economic benefits of the PreTRM test, our innovative collaboration with Anthem and the resulting anticipated greater payer and physician adoption throughout the United States, the PreTRM test has the potential to create a new standard of care in pregnancies. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Apply our platform capabilities to broaden our pipeline and develop novel and high-performing biomarker tests for pregnancy-related conditions and potentially other health conditions.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Our proprietary technology platform is designed to provide deep characterization of the biology of pregnancy, which we are using to develop additional accurate predictors of pregnancy outcomes, such as preeclampsia, gestational diabetes, and other conditions. We plan to leverage the strength of our technology platform and expertise to discover and develop novel and high-performing protein biomarker tests that will provide women and their physicians more timely and actionable information for pivotal decisions, which will lead to improved maternal and newborn health. In the future, we aspire to expand our product offerings by deeply characterizing the biology of the pregnancy journey. Longer-term, we intend to explore the use of our platform to develop tests for medical conditions outside of pregnancy. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Continually enhance the value and capabilities of our proprietary technology platform through ongoing expansion and integration of our biobank and our proteomics and bioinformatics databases.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We believe that the breadth and depth of our databases, our unique proteomic analytical techniques and our bioinformatics approaches all position us to be the leader in providing important pregnancy information to patients and doctors. The continued expansion of our proprietary biobank, together with our innovative mass spectrometry, proteomic analytical methods and bioinformatics analyses, is designed to enable us to discover and broadly validate meaningful protein expression changes during pregnancy. We intend to further expand our product engine capabilities to enhance the reach and productivity of our approach to developing biomarker tests and services for pregnancy-related conditions. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Rapidly build a dedicated women&#8217;s health commercial infrastructure.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Based on our commercial collaboration with Anthem, we are initially building our dedicated specialty OB-GYN commercial sales force to sell and support the PreTRM test in key regions in the United States where Anthem has a significant number of covered members. Upon further market adoption of the PreTRM test by other payers and the expansion of our pipeline, we expect to expand our dedicated sales force into additional regions in the United States to cover the entire U.S. OB-GYN sales channel. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Evaluate strategic partnerships to maximize the value of our product offerings.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We may strategically enter into collaborations or other partnerships to maximize the commercial potential of the PreTRM test and our product candidates within or outside of the United States. We may explore strategic alliances or collaboration to accelerate the discovery, development, validation and commercialization of our product candidates. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">82</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:86.42pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The Biology of Pregnancy</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Pregnancy is a highly complex, dynamic process that leads to the formation of a human being. From its beginning, genes, proteins and metabolites are expressed in a coordinated fashion to enable the placenta, the uterus and the mother to support the development of a child during pregnancy. This duration of a full-term pregnancy is usually between 37 and 40 weeks. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">At the inception of pregnancy, the placenta begins its development as a critical organ necessary for a healthy pregnancy for both the baby and the mother. The placenta initially forms and evolves during pregnancy to become a large, highly active metabolic organ conducting numerous vital biological functions through the time of delivery. The placenta is the means of communication between the mother and the fetus. Life-enabling exchanges of oxygen, nutrients and protective antibodies as well as elimination of wastes are effected by the placenta. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Proteins and protein expression are critical molecular elements in driving and carrying out key processes that take place during pregnancy in both the mother and the fetus. Protein expression can, in some cases, become disordered, leading to adverse pregnancy outcomes, such as preterm birth, preeclampsia, gestational diabetes, stillbirth and other conditions. There are approximately 140&#160;million births globally each year. It is estimated that as many as 25% of pregnancies may have complications affecting the mother and/or the baby. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Maternal blood is a window through which maternal, fetal and placental communication can be deciphered. Subtle abnormalities in protein expression in the mother&#8217;s blood may provide insights into complications earlier in pregnancy that can be utilized to benefit the mother and the baby. These changes, if appropriately detected and understood, have the potential to predict that the mother and/or baby are trending toward adverse conditions in pregnancy, which can be serious and costly. Timely detection of these subtle changes can enable the application of specific interventions to address the emergence of such complications and thereby improve the health of mothers and babies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">To date, a deeper understanding of the abnormalities of protein expression has been limited by the lack of understanding of the molecular events of the biology of pregnancy. The development of meaningful predictions in pregnancy requires improved methods to better understand such biology. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Building clinically meaningful and economically impactful predictions for pregnancy requires a significant commitment of resources, the proper selection and application of state-of-the-art laboratory technologies, access to well-annotated biologic specimens and advanced bioinformatics capabilities. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Proprietary Technology Platform</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We believe our proprietary proteomic and bioinformatics technology platform has the potential to enable critical advances in the management of pregnancy and its outcomes. Our platform consists of biobanks, advanced mass spectrometry and other proteomic analytic methods and bioinformatics, which enables superior characterization of the biology of pregnancy and accurate prediction of pregnancy outcomes. Our platform, built on differentiated tools and capabilities, provides pregnant mothers and their doctors more clinically meaningful and economically impactful predictions of adverse pregnancy outcomes to enable more timely intervention and improve the well-being of both mother and baby. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">83</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Proprietary Technology Platform</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img src="tm2110724d3-fc_biobank4c.jpg" alt="[MISSING IMAGE: tm2110724d3-fc_biobank4c.jpg]" height="279" width="605" >
        </div>
        <div style="margin-top:17.99pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Proprietary Biobanks</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We have built proprietary biobanks of blood samples and related data over a number of&#160;years, which are key resources required to develop a deeper understanding of the biology of normal and adverse pregnancy outcomes. By continuing to aggregate proprietary bioinformatics insights gained from analyses of comprehensively annotated biobank specimens, we are working to develop and commercialize a variety of clinically meaningful and economically impactful biomarker tests for pregnant women and their healthcare providers. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Our large proprietary U.S. biobank resource was built by collecting blood from more than 10,500 comprehensively annotated blood samples from patients, which cover a broad range of gestational ages and represent the broad demographic diversity and geographic distribution of pregnant women across the United States. We collected the samples in two large multi-center trials: our PAPR study, beginning in 2011, and our TREETOP study, beginning in 2016. These two studies prospectively collected samples, together encompassing weeks 17 through 28 of pregnancy, from women carrying a single baby, and, as &#8220;all comers&#8221; studies, collected information on a variety of important pregnancy outcomes, including preterm birth, preeclampsia, gestational diabetes and other conditions. These samples and their associated data are carefully analyzed to discover and develop informative biomarker signatures for intended use pregnancy populations. We continuously work to add new samples to our biobanks in additional studies, generating greater opportunities for ongoing development of clinically meaningful and economically impactful biomarker predictions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe our work on proprietary biobanks has established us as a leader in proteomic approaches to characterize pregnancy. We also conduct our bioinformatics analyses on additional specimens from other institutions in the United States and abroad. We analyze each specimen by conducting proteomic and other measurements in our laboratory, which generates large sets of biomarker data for each specimen. Through the analysis and evaluation of biomarkers with advanced bioinformatics approaches, we discover novel predictions for various adverse pregnancy outcomes. We then are able to apply these predictions to non-overlapping independent samples from different biobanks available to us to confirm and validate the accuracy and performance of the predictions. We add to our biobanks on an ongoing basis by continuously analyzing larger numbers of samples from our own sponsored studies as well as those from collaborations with maternal fetal medicine leaders around the world. We have validated proprietary biomarker signatures consisting of proteins and clinical variables in samples collected from the United States, Europe, Asia and Africa. We believe that as our database and sets of predictions grow, verifying and validating the predictions can lead to more rapid and efficient development required to commercialize such predictions in the future. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">84</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Advanced Mass Spectrometry Approaches</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Mass spectrometry is a highly developed analytical technology capable of precise identification, quantification and characterization of proteins. We have developed and applied innovative state-of-the-art mass spectrometry techniques to screen and detect in our bio-specimens the dynamic changes in protein expression occurring in normal and abnormal pregnancy development. Our proprietary proteomics workflows enable detailed and efficient measurements of hundreds of proteins simultaneously from complex matrices, such as blood. We also utilize a variety of other screening techniques to explore and understand the pregnancy proteome, including large- and small-scale immunoassay screens, other ligand-binding assays and RNA analyses, among others. To ultimately validate biomarker performance, we translate and confirm, on our mass spectrometry platform, the findings that we have generated with these other analytical measurement technologies. Our rich and extensive database of omics data, combined with highly annotated clinical information, is analyzed by state-of-the-art bioinformatics capabilities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Through our innovative approaches and advances in proteomics, we have discovered and validated meaningful predictions for adverse pregnancy outcomes. Importantly, our mass spectrometry process is well-suited not only for discovery and development activities, but also for high volume commercial production through the use of robotics and automation. Mass spectrometry measurements can be performed on very small blood volumes, which is appealing for patient sample collection and can lower cost of goods in laboratory analyses. We believe that our specific applications of mass spectrometry-based proteomics can be scaled to efficiently and cost-effectively accommodate the growth that we anticipate in addressing the large pregnancy testing market. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Advanced Bioinformatics</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have assembled a powerful collection of advanced bioinformatics capabilities as a critical component of our platform. Bioinformatics is an essential field of science in which biology, statistics, advanced computational science and information technology are combined to systematically and comprehensively analyze complex biological information. The advanced bioinformatics tools that we apply at great scale to measurements conducted on our biobank samples to develop high-performing, important predictive algorithms include, but are not limited to: machine learning, artificial intelligence, causal inference, supervised learning methods, dimensionality reduction methods and advanced statistics. As a result of rigorously applying our core expertise and proprietary approaches in bioinformatics, we have discovered high-performing algorithms that reliably distinguish pregnancies with normal protein expression compared to those showing disordered protein expression. Deep bioinformatics insights into the biology of pregnancy have enabled us to discover, verify and validate important predictions of adverse pregnancy outcomes. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have built an experienced discovery and development team with the deep expertise in science and mathematics necessary to perform rigorous bioinformatics analyses. We strictly adhere to the authoritative guidelines published by NAM on how to reliably develop and validate omics predictions made on complex biological data sets. These guidelines require disciplined validation of predictions to ensure validity and reliability of such predictions before they can be used clinically or commercially. The NAM guidance calls for pre-specifying how the predictions are to be made and then applying testing in completely independent sample cohorts, in order to be certain that the predictions are valid. Adhering to these guidelines, we have been able to validate that a number of our adverse pregnancy predictors are replicable in independent cohorts of patients residing in United States, Europe, Asia and Africa. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Product Discovery, Development and Commercialization Approach</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We leverage our proprietary technology platform to develop and commercialize novel, high-performing biomarker tests that are designed to make a significant difference to patients, doctors and payers. In our product development efforts, we take a focused and data-driven approach based on rigorous science and economics. Our multi-faceted approach involves the following elements that we apply in the discovery, development and commercialization of our biomarker tests: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Significant Unmet Need.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We select specific conditions of pregnancy that are clinically meaningful and economically important and with significant unmet needs that lack effective solutions. We have initially applied our platform and capabilities to address the problem of preterm birth, given </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">85</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:40pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">its profound health and economic impacts worldwide. We intend to explore other areas of significant unmet need in pregnancy, including preeclampsia, gestational diabetes and others. </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Proteomic and Bioinformatics Platform</font><font style="font-weight:bold;letter-spacing:-0.2pt;">.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We utilize our platform to understand the biology underlying such conditions in order to discover, verify and broadly validate high-performing predictive biomarker tests. We pursued a multi-year effort to build an extensive biobank resource that we used to discover, verify and validate our first product, the PreTRM test. More than 10,500 patients were enrolled in two large U.S. multi-center clinical validation studies. Beyond their validation of the PreTRM test, these studies provide a deep view into the care and outcomes of diverse singleton pregnancies across the United States, enabling prediction of various other outcomes. We are continuing to conduct analyses by combining growing biobank data from multiple studies to provide new insights that will be the basis of discovering and developing biomarker predictions for a variety of important conditions of pregnancy. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Demonstrate Health and Economic Impact of Our Test and Treat Strategy</font><font style="font-weight:bold;letter-spacing:-0.2pt;">.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We believe a critical element of our success will be to demonstrate the beneficial health and economic impacts of using the information provided by our biomarker tests. Our approach involves conducting controlled trials and health economic analyses. In the case of our the PreTRM test, an important part of our commercialization strategy involves amassing clinical and economic data to definitively demonstrate that detecting the risk of preterm birth can enable proactive interventions which improve the health of mothers and their babies while at the same time saving substantial healthcare system costs. Our rigorous, controlled intervention trials, PREVENT-PTB, AVERT PRETERM TRIAL and PRIME, have been designed to evaluate our test and treat strategy in more than 10,000 patients. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We also work with leading health economists and organizations to build rigorous models that describe how application of the PreTRM test and treat strategy impacts both health and economic outcomes. We work to publish models that provide peer reviewed evidence of the value of our strategy, in the form of meeting presentations and articles. </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Payer-Centric Early Reimbursement Strategy.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We have adopted what we believe is an innovative payer-centric approach for early commercialization and reimbursement of our biomarker testing. Leveraging the demonstrated short- and long-term health and economic benefits of our biomarker approach, our plan is to gain early reimbursement coverage from major health insurance payers by working with them to demonstrate the economic benefits of using our biomarker tests based upon analysis of claims data from their own plans. With respect to the PreTRM test, we recently signed a major multi-year contract with Anthem, the second largest U.S. health benefits company, pursuant to which Anthem has agreed to purchase a substantial number of PreTRM tests for pregnant women in their network, and will facilitate commercializing PreTRM testing among its members. We believe that this innovative approach serves as a validation of the commercial value of the PreTRM test and treat strategy, and significantly de-risks our initial commercialization activities by providing a pathway for broader market adoption through subsequent coverage decisions by other major payers. In November&#160;2020, we were awarded a unique CPT</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> PLA code by the AMA Editorial Board, specifically for the PreTRM test, which we believe will also help drive payment and coverage decisions for PreTRM testing. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.09pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.09pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Broader Market Adoption.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We intend to capitalize on our innovative payer-centric reimbursement strategy to facilitate obtaining widespread commercial coverage of our biomarker tests from other healthcare payers. We plan to leverage publications of clinical and economic studies that further demonstrate benefits of the PreTRM test and treat strategy as we expand coverage across numerous U.S. payer networks. With respect to the PreTRM test, we believe that early coverage decisions by respected third-party payers, such as Anthem, will incentivize other payers to more rapidly cover our test. We also anticipate that payer decisions to cover the test will pave the way for physicians to order testing for their patients. Additionally, we believe that insurance coverage in the United States will help to facilitate coverage of our tests in other countries as we expand internationally in the longer-term. In parallel with our pursuit of broader insurance coverage, we intend to deploy our specialty OB-GYN sales force to help drive adoption among physician practices. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">86</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We envision that our comprehensive approach will enable us to fully characterize one of the most important periods of time in the lives of both women and children. We believe that the data and predictions that we develop will ultimately create important information tools and services for a variety of customers, including women, healthcare workers, insurers, pharmaceutical companies, researchers and related companies. Several future opportunities may be created by comprehensively profiling pregnancy, including, but not limited to: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">additional diagnostic predictors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">epidemiologic, efficacy and best practice assessment tools to better understand and address critical patient outcomes and disparities across the United States; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">pregnancy educational content development, based on our actual data, for physicians, PAs, nurse practitioners, midwives, regulators, insurers, researchers and healthcare students; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">pharmaceutical drug development tools. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We also believe that the work we perform in pregnancy could be leveraged more broadly to address other areas in medicine and healthcare. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The PreTRM Test</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Utilizing our product discovery, development and commercialization approach, we focused our first development and commercialization efforts on preterm birth. Prematurity is the leading cause of illness and death in newborns and accounts for approximately $25&#160;billion in annual expense in the United States. Unfortunately, current detection methods fail to identify the great majority of singleton pregnancies that end in preterm births. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our first product, the PreTRM test, is the only broadly validated, commercially available blood-based biomarker test for prematurity. The PreTRM test accurately predicts the risk that a pregnant woman carrying a single fetus, known as singleton pregnancy, will have a spontaneous preterm birth. The great majority of singleton preterm births are spontaneous, where the mother goes into labor and delivers without any apparent known pathology. The predictive performance of the PreTRM test biomarkers has been extensively validated in diverse populations and geographies, including in the United States, Europe, Asia and Africa. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The strength of the data from our numerous studies of the PreTRM test has enabled us to pursue an innovative approach to commercialization. We have secured early PreTRM test reimbursement through our strategic collaboration with Anthem, which represents an important step in achieving initial payer acceptance of our rigorous approach to preterm birth and which we believe will help foster broader insurance coverage adoption. We believe this collaboration significantly de-risks initial commercialization of the PreTRM test, as Anthem is a major payer with plans that include 400,000 U.S. deliveries, representing more than 10% of U.S. annual births and this will provide a pathway for broader market adoption through subsequent coverage decisions by other major payers. The clinical and economic utility of a biomarker test administered mid-pregnancy has been published by leading independent health economists, underscoring the benefits of the PreTRM test and treat strategy. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Preterm Birth</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Full-term pregnancy usually lasts between 37 and 40 weeks. Preterm birth is defined as any pregnancy delivering before 37 weeks&#8217; gestation. Preterm delivery includes two major categories: medically indicated preterm birth, where the doctor intervenes because of concerns for the health of the mother and/or the baby, and spontaneous preterm birth where the mother goes into labor spontaneously with no apparent or known pathology. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Of the estimated 140&#160;million annual births globally, approximately 15&#160;million births are preterm. In the United States, there are approximately 3.8&#160;million annual births, and the 2020 March of Dimes Report Card shows that the preterm birth rate has increased for the last five&#160;years, now exceeding 10% of U.S. births. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Preterm birth remains a leading cause of neonatal morbidity and mortality throughout the world, with approximately 22,000 annual deaths from prematurity occurring in the United States. Across the globe, approximately 15&#160;million preterm babies are born every year, of which about one million die. As a </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">87</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">consequence of their preterm birth, many infants require significant medical support in intensive care settings to survive and continue to develop. Preterm birth is also associated with significant long-term disability for many individuals, including learning disabilities, cerebral palsy, chronic respiratory illness, intellectual disability, seizures and impairment of vision and hearing, which can generate significant costs throughout the lives of affected children. The annual U.S. health care costs to manage short- and long-term complications of preterm birth have been estimated to be approximately $25&#160;billion, consisting of direct medical costs incurred during pregnancy, lost productivity due to preterm birth in the perinatal period as well as additional associated longer term medical costs for the mother and child. The estimated average expense per preterm delivery in the United States is approximately $65,000. Earlier preterm births are associated with higher costs due to the greater severity of complications occurring in babies born at earlier gestational ages. Given this, the ability to prolong the gestation period by even one week has the potential for significant savings as shown in the figure below. As a result, the economic benefit of a test that can enable effective interventions to prolong the length of time for a baby to continue developing </font><font style="font-style:italic;letter-spacing:0.2pt;">in utero</font><font style="letter-spacing:0.2pt;">, even for a short period of time, and to improve neonatal health before delivery is substantial. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Distribution of U.S. Preterm Births and Estimated Average First Year of Life Cost per PTB by Gestational Age at Birth</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img src="tm2110724d1-bc_birthweek4c.jpg" alt="[MISSING IMAGE: tm2110724d1-bc_birthweek4c.jpg]" height="335" width="570" >
        </div>
        <div style="text-indent:20pt; margin-top:13.99pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Unfortunately, traditional methods to predict preterm birth risk fail to identify the great majority of pregnancies that will result in preterm births. Currently, the two most commonly used predictors of preterm birth risk are a woman&#8217;s history of prior preterm delivery or a short cervical length measurement found early in pregnancy. It is estimated that only about 1 out of 6 singleton spontaneous preterm births can be detected proactively with these clinical methods. The great majority of singleton preterm births only become apparent when the woman goes into labor and delivers, at which point proactive management options are no longer possible. Therefore, the ability to identify the great majority of women who will, in fact, deliver prematurely, and thus be able to more proactively manage their risk, represents a significant unmet medical need and offers a pivotal opportunity to make a positive difference for the mother and the baby. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Proactive interventions to address higher preterm birth risk may include more frequent contact with the patient, additional clinical visits, more intensive education and monitoring of the patient during pregnancy, prophylactic administration of progesterone or anti-inflammatory medications, heightened awareness of impending delivery and reacting more promptly to changes indicative of preterm birth as the pregnancy progresses. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">88</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The PreTRM Test&#8201;&#8212;&#8201;Our Solution to Preterm Birth</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our first product, the PreTRM test, is the only broadly validated, commercially available blood-based biomarker test to accurately predict the risk of spontaneous preterm birth. The PreTRM test provides an early and individualized spontaneous risk prediction of preterm birth in asymptomatic singleton pregnancies, expressed as a&#160;percentage, of delivering before 37 weeks&#8217; gestation, as well as her relative risk compared to the average population. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The PreTRM test is a serum-based proteomic test that combines the ratio of insulin-like growth factor-binding protein 4, or IBP4, to sex hormone-binding globulin, or SHBG, with a woman&#8217;s height and weight to predict the risk of spontaneous preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman carrying a single fetus during weeks 19 or 20 of her pregnancy. The PreTRM test is drawn once in singleton pregnancies where there is no evidence of significant fetal anomalies by non-invasive pre-natal genetic screening, or NIPS, or ultrasound, and the women tested are not taking progesterone. The blood sample is analyzed in our CLIA-approved clinical laboratory using our high through-put mass spectrometry technology. Once the laboratory analysis is completed, a risk report is generated from our validated algorithm and the results are transmitted to the ordering clinician. The PreTRM test provides an early, accurate and individualized prediction of spontaneous preterm delivery risk based on the underlying biology taking place in her pregnancy. An example of a PreTRM test report is illustrated below. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Illustrative Example of PreTRM Test Report</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img src="tm2110724d1-tbl_pretrm4clr.jpg" alt="[MISSING IMAGE: tm2110724d1-tbl_pretrm4clr.jpg]" height="430" width="518" >
        </div>
        <div style="text-indent:20pt; margin-top:12.8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The protein biomarkers of preterm birth utilized in the PreTRM test have been extensively validated in multiple diverse populations in the United States, Europe, Asia and Africa. The PreTRM test accuracy has been rigorously assessed and validated in our PAPR study involving over 5,501 women in 11 obstetric centers across the United States. Our completed PAPR study validated the biomarker signature which is highly predictive of spontaneous preterm birth risk. The performance of the PreTRM test biomarkers was replicated in a second independent large prospective U.S. study, TREETOP, supporting that the IBP4 to SHBG predictor can be used to accurately risk-stratify patients for implementation of preterm birth preventive </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">89</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">strategies and direct patients to appropriate levels of care. The ability to accurately risk-stratify is critical for enabling precision care management. We and our collaborators are also conducting three prospective controlled intervention studies&#8201;&#8212;&#8201;The </font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Pre</font><font style="letter-spacing:0.2pt;">diction and Pre</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">vent</font><font style="letter-spacing:0.2pt;">ion of </font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">P</font><font style="letter-spacing:0.2pt;">re</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">t</font><font style="letter-spacing:0.2pt;">erm </font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">B</font><font style="letter-spacing:0.2pt;">irth, or PREVENT-PTB, study, or PREVENT-PTB, the Serum Assessment of Preterm Birth Outcomes Compared to Historical Controls, or AVERT PRETERM TRIAL and </font><font style="font-weight:bold;letter-spacing:-0.2pt;">P</font><font style="letter-spacing:0.2pt;">rematurity </font><font style="font-weight:bold;letter-spacing:-0.2pt;">R</font><font style="letter-spacing:0.2pt;">isk Assessment Combined With Clinical </font><font style="font-weight:bold;letter-spacing:-0.2pt;">I</font><font style="letter-spacing:0.2pt;">nterventions for Improving Neonatal outco</font><font style="font-weight:bold;letter-spacing:-0.2pt;">ME</font><font style="letter-spacing:0.2pt;">s, or PRIME&#8201;&#8212;&#8201;to demonstrate the value of identifying higher risk pregnancies coupled with proactive interventions to improve the well-being of mothers and newborns. Further underscoring the benefits of the PreTRM test and treat strategy, the clinical and economic utility of a biomarker test administered mid-pregnancy has been published by leading independent health economists. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The strength of the data from our clinical trials of the PreTRM test has enabled us to pursue an innovative and accelerated approach to commercialization. We have secured PreTRM test reimbursement through a major strategic payer, Anthem, representing an important step in achieving initial payer acceptance of our rigorous methods to address preterm birth. We believe this collaboration significantly de-risks initial commercialization of the PreTRM test, as it provides reimbursement from a major payer covering more than 10% of U.S. pregnancies annually and provides a pathway for broader market adoption through subsequent coverage decisions by other major payers. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Biomarker Discovery and Clinical Validation of the PreTRM Test</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:9.5pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Adherence to National Academy of Medicine Guidelines</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We rigorously adhere to authoritative NAM guidelines published in 2012 for developing and validating multi-omics predictions and applying important principles to address adverse conditions that arise in pregnancy. The guidelines specify three phases of work to be performed in non-overlapping sets of samples: </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Discovery Phase</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;A set of samples from patients whose outcomes are known are analyzed in the lab to find biomarker differences between individuals with an adverse outcome versus individuals without that particular outcome (</font><font style="font-style:italic;letter-spacing:0.2pt;">e.g.</font><font style="letter-spacing:0.2pt;">, pregnancies that deliver preterm versus term pregnancies). Algorithms are built on high performing predictions that can be tested in the next phase. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Verification Phase</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;High-performing predictive algorithms selected from discovery work are pre-specified and applied to a completely independent set of non-overlapping samples, with the laboratory being blinded to the outcomes. The performance of the algorithms is either independently verified, or confirmed, by an external statistician, who ranks the algorithms according to predictive accuracy. Once verified, highest performing algorithms are locked down in the form of optimized tests that can be validated in final validation phases before commercialization. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Validation Phase</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;In a third, entirely independent set of non-overlapping samples, the laboratory measurements are performed, and the laboratory is blinded to patient outcomes. The laboratory data are time-stamped and are transferred to an external statistician, who applies the pre-specified algorithm to the laboratory measurements and independently validates the performance of the test by breaking the blind. At this point, a prediction that has been independently and rigorously validated can be used for clinical decision-making in trials and/or commercialization. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">PAPR Study</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The biomarkers used in the PreTRM test have demonstrated strong clinical performance in accurately predicting women at risk of preterm birth across diverse patient populations in the United States, Europe, Asia and Africa. The initial discovery, verification and validation of our spontaneous preterm birth biomarker risk predictor was performed in the 5,501 patient </font><font style="font-weight:bold;letter-spacing:-0.2pt;">P</font><font style="letter-spacing:0.2pt;">roteomic </font><font style="font-weight:bold;letter-spacing:-0.2pt;">A</font><font style="letter-spacing:0.2pt;">ssessment of </font><font style="font-weight:bold;letter-spacing:-0.2pt;">P</font><font style="letter-spacing:0.2pt;">reterm </font><font style="font-weight:bold;letter-spacing:-0.2pt;">R</font><font style="letter-spacing:0.2pt;">isk, or PAPR, study. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The PAPR study was initiated in April&#160;2011 and the last observed birth occurred in February&#160;2014. The study was designed to discover, verify and validate biomarkers and clinical variables that accurately predict the risk of spontaneous preterm birth. We measured and evaluated protein expression of thousands of distinct proteins by their expression in maternal serum to assess their effectiveness as predictors of spontaneous preterm birth early in pregnancy before symptoms occur. The PAPR study analyzed blood samples collected from 5,501 pregnant women performed at 11 maternal fetal medicine sites, across gestation </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">90</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">from 17 weeks and zero days to 28 weeks and six days, and consisting of a diverse demographic ethnic and geographic groups of women broadly representative of the U.S. pregnant population. Samples were collected and processed in a standardized manner for frozen storage and subsequent laboratory analyses. Maternal serum was processed by our proprietary proteomic workflow, using liquid chromatography and mass spectrometry, and proteins were identified and quantified by multiple reaction monitoring mass spectrometry. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">From our analysis of thousands of proteins from these samples, we discovered and verified a specific combination of two proteins, IBP4 and SHBG, coupled with clinical variables consisting of a woman&#8217;s height and weight, which we developed into a proprietary predictive algorithm. That algorithm demonstrated highly accurate prediction of spontaneous preterm birth risk at mid-pregnancy. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We executed a multi-step process, strictly following NAM Guidelines, for discovery, verification and validation of the PreTRM test predictor. These steps involved pre-specification of study plans and analyses, site document verification of clinical data, blinding protocols for three independent sample sets and the use of outside statisticians for the un-blinding of data and read-outs of the results of both verification and validation. The collected samples were separated into three independent non-overlapping sets of patients, each set comprised of spontaneous preterm deliveries occurring before 37 weeks&#8217; gestation and term deliveries occurring during or after week 37 of gestation. From the first set of samples of 86 preterm deliveries and 172 term deliveries used in the discovery phase, we identified biomarkers and algorithms that could predict preterm births on samples drawn between 17 and 28 weeks. This led to our identification of the best performing predictor, found in samples drawn during weeks 19 and 20 of pregnancy. In the verification phase of the test development, the second set of completely independent samples of 50 preterm deliveries and 100 term deliveries was analyzed in a blinded fashion using the predictive algorithm discovered in the first phase and demonstrated consistent predictive performance. In the validation phase, the third completely independent set of samples of 81 preterm deliveries and 162 term deliveries was analyzed using the same algorithm, which again demonstrated consistent predictive performance. Following the readout of the pre-specified validation of test performance, the consistency across the three phases was examined. More than 500,000 data points were generated across the 217 preterm delivery cases and 434 matching term delivery controls examined across the three phases, in a 1:2 nested case:control design. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We utilized area under the receiver operating characteristic curve value, or AUROC, as a measure of the predictive performance of the PreTRM test. AUROC is an effective way to measure the diagnostic testing separation of measured biomarker scores found preterm cases versus those found in term control deliveries. External statisticians validated that a combination of biomarkers and clinical variables had an AUROC value of 0.75 for a prediction of spontaneous preterm birth before 37 weeks&#8217; gestation versus at or after 37 weeks&#8217; gestation. At a threshold where the sensitivity, or the fraction of preterm deliveries correctly classified as &#8220;higher risk&#8221;, and specificity, or the fraction of term deliveries correctly classified as &#8220;lower risk&#8221;, were maximized, the sensitivity was 0.75 and specificity was 0.74. In a Kaplan Meier analysis, performed to examine times to delivery across patients stratified at that same threshold, those at higher risk delivered earlier than those at lower risk, demonstrating highly statistically significant separation between the groups, </font><font style="font-style:italic;letter-spacing:0.2pt;">p</font><font style="letter-spacing:0.2pt;"> = 0.004. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">TREETOP Study</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our second large clinical validation study, A Mul</font><font style="font-weight:bold;letter-spacing:-0.2pt;">T</font><font style="letter-spacing:0.2pt;">icente</font><font style="font-weight:bold;letter-spacing:-0.2pt;">R</font><font style="letter-spacing:0.2pt;"> Ass</font><font style="font-weight:bold;letter-spacing:-0.2pt;">E</font><font style="letter-spacing:0.2pt;">ssm</font><font style="font-weight:bold;letter-spacing:-0.2pt;">E</font><font style="letter-spacing:0.2pt;">nt of a Spon</font><font style="font-weight:bold;letter-spacing:-0.2pt;">T</font><font style="letter-spacing:0.2pt;">ane</font><font style="font-weight:bold;letter-spacing:-0.2pt;">O</font><font style="letter-spacing:0.2pt;">us </font><font style="font-weight:bold;letter-spacing:-0.2pt;">P</font><font style="letter-spacing:0.2pt;">reterm Birth Predictor, or TREETOP, enrolled patients in October&#160;2016 through January&#160;2019, with the last delivery occurring in May&#160;2019. The TREETOP study enrolled 5,011 pregnant women from 18 sites across the United States, with blood drawn in a window of 18 weeks and zero days to 21 weeks and six days. The TREETOP trial was designed to assess and validate: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">accurate risk prediction for all preterm birth, including both spontaneous and medically indicated preterm births, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">possible expansion of a validated blood draw window for PreTRM testing, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the threshold for risk stratification of the PreTRM test, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">discover biomarkers predictive of time-to-birth remaining in a pregnancy, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">discovery of biomarkers that date the pregnancy, which we refer to as a pregnancy clock, and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">91</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the performance of additional biomarkers for prediction of spontaneous preterm birth and other pregnancy complications. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Given the large body of evidence generated from PAPR and our other collaborative biomarker studies, the TREETOP samples from the 5,011 enrolled subjects were randomized into two cohorts: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">a first patient cohort of 847 samples to validate certain pre-specified predictions originating from our earlier PAPR study work, and to verify new potentially enhanced predictions that could be validated later on the samples of the remaining unanalyzed cohort of patients, and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">a second cohort of remaining samples has been held in reserve to validate, in the future, a number of potentially enhanced predictions that may eventually be incorporated into our commercially available testing as we build our pipeline of adverse pregnancy outcome predictions. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Previous work performed on our proprietary PAPR study biobank samples demonstrated that our validated spontaneous preterm birth biomarkers accurately predicted risk not only for spontaneous preterm delivery, but also for medically indicated preterm delivery in which the majority are preeclamptic preterm deliveries. From our studies and publications in the literature, the biological function of the PreTRM test proteins suggested an ability to predict preeclampsia and other conditions of placental dysfunction. These conditions appear to underlie a number of adverse pregnancy outcomes that could be explored going forward in TREETOP. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In an analysis of the first cohort, the study demonstrated: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">accurate prediction by IBP4 and SHBG biomarkers of early preterm delivery, which refers to deliveries of less than 32 weeks&#8217; gestation due to any cause, with an AUROC of 0.76 (</font><font style="font-style:italic;letter-spacing:0.2pt;">p</font><font style="letter-spacing:0.2pt;"> = 0.023); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">accurate prediction of severe neonatal morbidity and mortality based on a standard published composite index with an AUROC of 0.67 (</font><font style="font-style:italic;letter-spacing:0.2pt;">p</font><font style="letter-spacing:0.2pt;"> = 0.005); and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">accurate prediction of increased neonatal hospital length of stay (</font><font style="font-style:italic;letter-spacing:0.2pt;">p</font><font style="letter-spacing:0.2pt;"> = 0.024). </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the first cohort, we also validated a PreTRM test risk threshold to statistically stratify higher versus lower risk patients based on a pre-specification of the threshold from PAPR data and by applying it to samples in this cohort. The validated threshold of 15%, twice the average population risk of spontaneous preterm birth, was demonstrated to statistically separate patients at higher versus lower risk of preterm delivery based on the PreTRM test results. This is the risk threshold for interventional actions to be taken in the PRIME prospective intervention trial that was initiated in 2020. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">PAPR and TREETOP together encompass a powerful resource of samples and clinical data from more than 10,500 pregnant women collected over an eight-year period to characterize what takes place biologically in pregnancy. Both PAPR and TREETOP enrolled a large number of women who were not known to be at risk of preterm birth based on other identified clinical factors, and as such, were not already covered by professional society guidelines addressing the need for risk stratification and guidance of treatment. We believe the results from these studies provides a deep view into the outcomes of diverse singleton pregnancies across the United States and prediction of these outcomes. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Prospective Intervention Studies&#8201;&#8212;&#8201;Demonstrating the Benefits of the PreTRM Test and Treat Strategy</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Following the validation of predictors for spontaneous preterm birth, we set out to demonstrate the value of identifying higher-risk pregnancies coupled with proactive interventions to improve the well-being of mothers and newborns. We have worked with respected collaborators to conduct three prospective intervention studies in order to demonstrate the clinical utility and economic value of the PreTRM test and treat approach. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">PREVENT-PTB Study</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The </font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">Pre</font><font style="letter-spacing:0.2pt;">diction and Pre</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">vent</font><font style="letter-spacing:0.2pt;">ion of </font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">P</font><font style="letter-spacing:0.2pt;">re</font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">t</font><font style="letter-spacing:0.2pt;">erm </font><font style=" text-decoration:underline #000000 solid;font-weight:bold;letter-spacing:-0.2pt;">B</font><font style="letter-spacing:0.2pt;">irth, or PREVENT-PTB, study was a prospective randomized controlled intervention study conducted at Intermountain Healthcare in Salt Lake City, Utah. We enrolled a total of 1,208 patients beginning in May&#160;2018 with the last patient enrolled in February&#160;2019. The study enrolled women who were 18&#160;years or older, with a singleton pregnancy between 19 weeks and </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">92</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">five days and 20 weeks and six days gestational age and with no history of prior preterm birth and normal cervical length at or before the time of enrollment. The purpose of the study was to evaluate the impact on the health and economics of applying the PreTRM test to screen pregnant women for risk of spontaneous preterm delivery and treating women identified at higher risk with proactive interventions. The clinical impact and outcomes evaluated included: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">length of stay in neonatal intensive care unit, or NICU </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.51pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">overall hospital length of stay </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.51pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">neonatal health improvement, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.51pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">NICU preterm cost reduction, and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.51pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">reduction in the rate of preterm delivery. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The PREVENT-PTB trial, using a pre-test randomization, strictly followed a NAM recommendation to assess the clinical impact of identifying higher risk patients coupled with simultaneous proactive interventions. Women who enrolled were randomized 1:1 into two groups&#8201;&#8212;&#8201;screened and control groups. The screened group was assessed by the PreTRM test, and those who were identified by the test as being at higher risk of preterm birth were offered a bundle of proactive interventions. These included weekly contact with a care management nurse, two preterm prevention clinic visits, cervical length monitoring, weekly injection of 17-hydroxy-alpha progesterone, daily administration of low-dose aspirin and the administration of corticosteroid treatment at a lower threshold if patients indicated clinical signs or symptoms of imminent delivery. Patients in the screened group that were found not to be at higher risk by the PreTRM test received standard obstetrical care. The control group did not receive the PreTRM test and received standard pregnancy care only. The diagram below illustrates the study design for PREVENT-PTB: </font>
        </div>
        <div style="margin-left:180pt; margin-top:8pt; width:276pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Study Design of PREVENT-PTB</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:9.5pt; text-align:center; width:456pt;">
          <img src="tm2110724d1-fc_prevent4c.jpg" alt="[MISSING IMAGE: tm2110724d1-fc_prevent4c.jpg]" height="316" width="556" >
        </div>
        <div style="text-indent:20pt; margin-top:12.01pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The PREVENT-PTB topline results were reported in a late-breaking poster session at the 2020 annual meeting of the Society for Reproductive Investigation. The outcomes between the screened group and the control group demonstrated the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.51pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">A statistically significant 83% decrease in median length of stay for spontaneous preterm neonates admitted to the NICU from 39.0&#160;days in the control group to 6.8&#160;days in the screened group (p=0.008); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.51pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">A statistically significant 79% decrease in median length of stay for any preterm neonates admitted to the NICU from 35.6&#160;days in the control group to 7.6&#160;days in the screened group (p=0.038); and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">93</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">Across all preterm birth categories, reductions in the rate of preterm births were observed, however the trial was not powered to definitively evaluate this outcome. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">AVERT PRETERM TRIAL</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Serum Assessment of Preterm Birth Outcomes Compared to Historical Controls, or AVERT PRETERM TRIAL, is a prospective, historically-controlled intervention trial conducted at Christiana Care Health System in Newark, Delaware. The purpose of the study is to evaluate the impact on health and economics by applying the PreTRM test to screen pregnant women for risk of spontaneous preterm delivery and to proactively intervene in individuals who are shown by the PreTRM test to be at higher risk of sPTB. The two co-primary endpoints are total neonatal hospital length of stay and composite neonatal morbidity and mortality in the PreTRM-screened group versus the historical control group, which did not have a PreTRM test. A number of secondary clinical impact and outcomes observations include reduction in total preterm births, a reduction in total hospital stay for sPTB and reduction in total hospital stay for any preterm birth, measures of neonatal health assessed as a composite neonatal morbidity/mortality index and NICU preterm costs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In this trial, we are comparing a screened group that is assessed with a PreTRM test and where higher risk patients receive intensive interventions, to a historical control group where patients do not receive PreTRM testing and receive usual standard of care treatment. Eligible women were screened using the PreTRM test taken during week 19 or 20 of pregnancy, and those identified as having a higher risk were offered a bundle of interventions, including daily vaginal progesterone, daily low-dose aspirin, closer monitoring by their clinicians and case management nurses. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Design of the AVERT PRETERM TRIAL</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img src="tm2110724d1-fc_preterm4c.jpg" alt="[MISSING IMAGE: tm2110724d1-fc_preterm4c.jpg]" height="309" width="519" >
        </div>
        <div style="text-indent:20pt; margin-top:12.9pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Health and economic outcomes of the screened group are being compared with those of the historical control arm. Due to the COVID-19 pandemic, trial enrollment of the prospective arm was stopped in March&#160;2020. We expect topline results of the study to be available around year end 2021. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">PRIME Study</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In collaboration with Anthem, we are conducting </font><font style="font-weight:bold;letter-spacing:-0.2pt;">P</font><font style="letter-spacing:0.2pt;">rematurity </font><font style="font-weight:bold;letter-spacing:-0.2pt;">R</font><font style="letter-spacing:0.2pt;">isk Assessment Combined With Clinical </font><font style="font-weight:bold;letter-spacing:-0.2pt;">I</font><font style="letter-spacing:0.2pt;">nterventions for Improving Neonatal outco</font><font style="font-weight:bold;letter-spacing:-0.2pt;">ME</font><font style="letter-spacing:0.2pt;">s, or PRIME, study, which is a prospective randomized controlled study of up to 6,500 enrolled pregnancies in approximately 10 respected maternal fetal medicine centers located within Anthem&#8217;s insurance network. We began enrollment in November&#160;2020, and enrollment is ongoing. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">94</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">After enrollment, all subjects will have a blood sample collected once during either week 19 and 20 of pregnancy. Prospectively enrolled pregnant women will be randomized 1:1 to either a screened arm, called the PTB Prevention arm, or a control arm that receives standard obstetrical care. Only subjects randomized to the PTB Prevention arm will receive the results of the PreTRM test. Those women randomized to the PTB Prevention arm will receive either routine standard care pregnancy management or a multimodal intervention protocol reserved for higher risk pregnancies based on the results of the PreTRM test. The design of the PRIME study is illustrated below. </font>
        </div>
        <div style="margin-left:180pt; margin-top:7.81pt; width:276pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Design of the PRIME Study</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:7.71pt; text-align:center; width:456pt;">
          <img src="tm2110724d1-fc_prime4c.jpg" alt="[MISSING IMAGE: tm2110724d1-fc_prime4c.jpg]" height="314" width="561" >
        </div>
        <div style="text-indent:20pt; margin-top:10.22pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the PTB Prevention arm, PreTRM test results will be reported to the subject, the study investigator and the subject&#8217;s primary pregnancy care provider. A woman with a reported &#8220;Higher Risk&#8221; test result, at or above the 15% threshold (which is equivalent to more than a doubling of average population risk of spontaneous preterm delivery less than 37 weeks&#8217; gestation), will receive multiple interventions, including weekly nurse case management contact, daily vaginal progesterone, daily low dose aspirin and additional vaginal ultrasound cervical length determinations, with cerclage considered for cervical lengths less than 10 millimeters. Subjects in the &#8220;Not Higher Risk&#8221; group will receive standard obstetrical care for the duration of pregnancy through hospital discharge. </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.71pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Major perinatal outcomes to be evaluated in each group include length of NICU and total hospital stay, measures of neonatal health, NICU preterm costs and preterm delivery rates. All subjects will be followed through the duration of the pregnancy and delivery, and neonates will be followed until initial hospital discharge to assess the course of pregnancy, labor and any related maternal or fetal complications. Readmission of infants will also be assessed at 180&#160;days, 1 year and 3&#160;years of life using the Anthem/</font>&#8203;<font style="letter-spacing:0.2pt;">HealthCore Integrated Research Database to evaluate longer-term outcomes and costs associated with preterm delivery. </font></div>
        <div style="text-indent:20pt; margin-top:7.71pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The study has a pre-specified interim look to evaluate the two co-primary endpoints, total neonatal hospital length of stay and composite neonatal morbidity and mortality, with a stopping criterion of statistical significance being reached by either one or the other of these outcomes, which is envisioned to take place at 2,800 deliveries completed. Interim results from the PRIME Study are expected in the second half of 2022. </font>
        </div>
        <div style="margin-top:10.82pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Other Relevant Studies and Publications</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:9.5pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Healthcore/Anthem Health and Economic Study</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">HealthCore, Inc., a subsidiary of Anthem, conducted an insurance claims data analysis on the cost-effectiveness of screening more than 40,000 mothers and babies within Anthem&#8217;s commercially insured </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">95</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">membership. The model evaluated the cost impact to be expected from screening with the PreTRM test, and from then providing a bundle of interventions to PreTRM-higher risk patients as compared to the effect of standard care without a PreTRM test. The model predicted that these interventions would result in: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">a 20% reduction in preterm birth before 37 weeks&#8217; gestation, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">$1,608 in gross savings per pregnant woman tested (accounting for all costs except that of a $745 list price cost modeled for the PreTRM test), </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">a 10% reduction in neonatal intensive care admissions, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">a 7% reduction in overall hospital length-of-stay, and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">a 33% reduction in births at less than 32 weeks&#8217; gestation. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The authors concluded that the PreTRM test and treat strategy demonstrated cost savings across a variety of reasonable assumptions and scenarios examined. An abstract reporting these results has been accepted for presentation at the 2021 International Society for Pharmacoeconomics and Outcomes health economic conference on May 18, 2021. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Clinical and cost impact analysis of a novel prognostic test for early detection of preterm birth</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In 2015, health economic and maternal fetal medicine experts built and published an independent model to analyze health and economic benefits of a novel mid-pregnancy preterm delivery risk biomarker test and treat strategy for the United States, where women at higher risk of preterm delivery would receive daily vaginal progesterone as a sole intervention. At a biomarker test sensitivity and specificity of 80%, the model predicted that identifying and intervening on higher risk pregnancies resulted in a 7% decrease in preterm birth rate, a 23.5% decrease in infant mortality, a 27% decrease in acute complications at birth and a 13% decrease in the rate of developmental disabilities, accompanied by a gross health economics savings, exclusive of the cost of testing, of $1,395 per pregnancy screened. These experts concluded that this approach could be a dominant strategy to improve health and decrease healthcare costs. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Product Pipeline</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">While we have leveraged our technology platform to currently pursue the development and commercialization of the PreTRM test, we believe our technology platform has broad applicability across a wide array of pregnancy-related conditions. We and our clinical trial collaborators are also continuing to conduct analyses by combining biobank data from the PAPR and TREETOP studies, to provide new insights into the predictive capabilities of the PreTRM test and other predictive biomarker algorithms. We are discovering, developing and validating a broad portfolio of product candidates including those focused on the conditions listed below: </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">When we refer to &#8220;discovering, developing and validating&#8221; our product candidates, we are referring to the three phases of work for development of predictive tests as published in the NAM guidelines, as summarized below. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the &#8220;discovery&#8221; phase, we analyze a set of biologic samples from patients whose pregnancy outcomes are already known to find biomarker differences between individuals who had an adverse pregnancy outcome versus individuals who did not have an adverse pregnancy outcome (</font><font style="font-style:italic;letter-spacing:0.2pt;">e.g.</font><font style="letter-spacing:0.2pt;">, pregnancies that delivered preterm versus pregnancies that lasted to term). We then build predictive algorithms, based on high performing predictions, to be tested in the next phase. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the &#8220;verification&#8221; phase, we apply the high performing predictive algorithms selected during the discovery phase to a completely independent set of new biologic samples that were not tested during the discovery phase. An independent, external statistician then verifies, or confirms, the performance of the algorithms, and ranks them according to predictive accuracy. Once they are verified through this process, the highest performing algorithms are &#8220;locked down&#8221; in the form of optimized tests that can be validated in a final phase, prior to commercialization. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the &#8220;validation&#8221; phase, a third, entirely independent set of biologic samples that were not tested during either the discovery phase or the verification phase are tested in a laboratory, with the laboratory </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">96</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">blinded to patient outcomes. The laboratory data are time-stamped and are transferred to an external statistician, who applies the pre-specified algorithms to the laboratory measurements and independently validates the performance of the test by breaking the blind. At this point, a prediction that has been independently and rigorously validated can be used for clinical decision-making in trials and/or commercialization. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Preeclampsia</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Condition.</font><font style="letter-spacing:0.2pt;"> Preeclampsia, estimated to affect 5% - 8% of pregnancies in the United States, is a complication characterized by high blood pressure and signs of damage to one or more organs, including liver, brain and kidneys, and may also have adverse effects on blood coagulation. Preeclampsia usually begins after 20 weeks of pregnancy in women whose blood pressure had been normal, but it can also arise earlier in pregnancies. Left untreated, preeclampsia can lead to serious, even fatal, complications for both the mother and baby. Once a pregnant woman is diagnosed with preeclampsia, a common treatment is to deliver the baby; however, if the delivery occurs before the infant reaches term, complications of preterm birth can ensue. We believe that a biomarker test to better identify women who are at higher risk of preeclampsia earlier in pregnancy could lead to better management of this serious condition. It is estimated that the U.S. annual cost of preeclampsia is approximately $5 billion. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Objective for a Biomarker Test</font><font style="letter-spacing:0.2pt;">. We are working to develop a protein biomarker test that can identify women at higher risk of developing preeclampsia as a means to enable earlier proactive interventions to mitigate the complications that occur as a result of this condition. We believe that such interventions could also prevent preeclampsia in certain patients, which has the potential of lowering the long-term risk of cardiovascular disease and stroke that occur later in life in women who suffer preeclampsia. There is also potential for a predictive biomarker test to inform therapeutic development to address this condition. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Development Status.</font><font style="letter-spacing:0.2pt;"> We have conducted discovery, verification and validation activities for a variety of preeclampsia biomarker predictions, some of which have been published. Some of these predictions include the use of our PreTRM test biomarkers as well as others. We are in the process of selecting which predictions will be validated in samples of our second TREETOP cohort prior to commercialization, based on the NAM guidelines described above. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Molecular Time-to-Birth</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Problem and Need</font><font style="letter-spacing:0.2pt;">. We have already developed high performing biomarker signature in our PreTRM test for spontaneous preterm birth risk. For a pregnant woman who is not at higher risk of preterm birth by our PreTRM test, she would typically like to know how much time is remaining in her pregnancy until delivery. Unfortunately, current methods for predicting the length of gestation, including due date prediction from last menstrual period and ultrasound dating based on fetal measurements early in pregnancy, lack precision and provide inaccurate dating as to when delivery will occur. We have identified biomarker signatures that predict the time remaining in a pregnancy with greater accuracy than is available from current methods. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Objective for a Biomarker Test</font><font style="letter-spacing:0.2pt;">. Our objective is to develop a more accurate time-to-birth prediction for women not at higher risk of PTB. We believe this will be of great interest to pregnant women as a consumer test that may serve as an aid to decision-making for travel, work, vacation planning and other life-scheduling decisions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Development Status</font><font style="letter-spacing:0.2pt;">. Using our proprietary biobanks and proteomics platform, we have discovered and verified biomarkers with superior time-to-birth predictive performance, as compared to current dating methods. We have developed the ability to determine more precisely how much time is remaining in a woman&#8217;s pregnancy based on her individual biology at the time of her blood draw, for example, during weeks 23 through 25 of pregnancy. We plan to validate a molecular time-to-birth predictor and publishing its performance data prior to making it available commercially, based on the NAM guidelines described above. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Gestational Diabetes Mellitus</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Condition</font><font style="letter-spacing:0.2pt;">. Gestational diabetes mellitus, or GDM, is characterized by high blood sugar levels, or hyperglycemia, during pregnancy in a woman who was not diabetic before her pregnancy. GDM is estimated to affect approximately 10% of pregnancies and cost $1.6 billion annually in the United States as a result </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">97</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">of short- and long-term maternal and child complications. GDM increases the risk of preeclampsia, depression, and the need for Caesarean sections. Babies born to mothers with poorly treated GDM are at increased risk of being too large, having low blood sugar after birth, and jaundice. If untreated, GDM can also result in stillbirth. Children born from mothers with GDM are also at risk of being overweight and developing type 2 diabetes. We believe that knowing who is at high risk of GDM earlier in pregnancy would be of great benefit given that interventions could significantly reduce the adverse effects of this condition. Current methods for identifying GDM in most patients typically take place between 24-26 weeks&#8217; gestation, missing opportunities to allow such women to receive proactive interventions earlier in pregnancy that may be effective in preventing or mitigating GDM. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Objective for a Biomarker Test</font><font style="letter-spacing:0.2pt;">. Our goal is to develop a blood-based biomarker test that can identify earlier in pregnancy which women are likely to develop GDM. We believe that such information will enable earlier interventions to mitigate risks and help focus resources on higher risk pregnancies as a means to improve the health of mothers and babies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Development Status</font><font style="letter-spacing:0.2pt;">. We have discovered and verified high performing biomarker prediction of GDM by applying our proteomics platform technologies to samples from our PAPR and TREETOP biobanks. We plan on further verifying and ultimately validating a GDM predictor and publishing its performance data prior to making it available commercially, based on the NAM guidelines described above. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Growth Restriction</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Condition.</font><font style="letter-spacing:0.2pt;"> Fetal growth restriction, or FGR, is estimated to affect as many as approximately 3%&#8201;&#8211;&#8201;7% of pregnancies worldwide. There are immediate consequences of FGR, including fetal challenges in withstanding the stresses of vaginal delivery, decreased oxygen levels and brain injury, hypoglycemia (low blood sugar), lower resistance to infection, difficulty in maintaining body temperature and abnormally high red blood cell counts. Longer-term, infants can have neurodevelopment issues, metabolic and cardiovascular complications. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Objective for a Biomarker Test for FGR</font><font style="letter-spacing:0.2pt;">. By identifying molecular events that precede measurable changes in fetal size, we aim to address the placental dysfunction and other growth restriction etiologies that lead to fetal growth restriction and thereby enable earlier proactive interventions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Development Status</font><font style="letter-spacing:0.2pt;">. We have discovered placental dysfunction biomarkers as a first step to predicting fetal growth restriction. We are working to discover additional biomarkers that illustrate expression differences in normal and growth-restricted pregnancies. We believe that this work could lead to improved detection of FGR pregnancies earlier and may lead to proactive interventions to better address this problem. Verification and validation phases and publication of our findings, based on the NAM guidelines described above, will be required before such testing can be commercialized. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Stillbirth</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Condition</font><font style="letter-spacing:0.2pt;">. Stillbirth is a heartbreaking and tragic outcome, with a reported incidence of 5.7 per 1,000 pregnancies in the United States. Stillbirth is typically defined as fetal loss occurring after 20&#160;weeks&#8217; gestation. Causes of stillbirth include placental or umbilical cord problems, preeclampsia, lupus, clotting disorders, lifestyle choices, and infection, among others. Approximately one-third of U.S. stillbirth cases occur without any known cause. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Objective for a Biomarker Test for Stillbirth.</font><font style="letter-spacing:0.2pt;"> Our goal is to discover biomarker expression changes that occur early during pregnancy that are highly predictive of changes taking place in the mother and/or the fetus that increase the risks of stillbirth, so that appropriate interventional strategies can be developed to address this condition. Given that our vision is to comprehensively profile the biology of pregnancy by leveraging our platform technologies to characterize disruption of normal developmental biology in both the mother and the fetus, we believe that there is a significant opportunity to improve earlier detection and the potential to develop targeted interventions to better address this serious problem. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Development Status</font><font style="letter-spacing:0.2pt;">. We have developed the ability to measure the expression of hundreds of proteins by our advanced mass spectrometry proteomic technology. These proteins are members of key biochemical proteomic pregnancy signaling pathways, including pathways that are operative in stillbirth. As we increase </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">98</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">the density of proteins characterized in future discovery work, we believe that further characterization of pregnancy and key proteomic expression factors in stillbirths vs. normal pregnancies is a promising area for further discovery, verification and validation of high performing biomarkers predictors with potential to improve detection and enable new interventions for stillbirth. Finally, we note that development for prediction of other adverse outcomes (</font><font style="font-style:italic;letter-spacing:0.2pt;">e.g.</font><font style="letter-spacing:0.2pt;">, growth restriction) has the potential to reduce stillbirth. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Postpartum Depression</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Condition</font><font style="letter-spacing:0.2pt;">. There are hormonal, physiological and psychological changes that occur in women both during and after pregnancy. Postpartum depression is a severe form of clinical depression related to pregnancy and childbirth, affecting approximately 15% of women during the year following delivery of a child. By contrast, the &#8220;baby blues&#8221; is a transient, well-known phenomenon that typically resolves on its own. The annual U.S. economic burden of postpartum depression is estimated to be approximately $2.4 billion. We believe that a biomarker test for postpartum depression is another area are where our platform can be beneficially applied. We believe that early identification of such pregnancies will enable a number of approaches that may prevent or mitigate the severity of this common condition, and that this information may also facilitate drug discovery. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Objective for a Biomarker Test for Postpartum Depression.</font><font style="letter-spacing:0.2pt;"> Our objective is to leverage our understanding of key pregnancy, pathways gained through the application of our advanced proteomic technologies and bioinformatics, to develop further insights for early identification of pregnancies that are destined to develop postpartum depression. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Development Status</font><font style="letter-spacing:0.2pt;">. In our discovery efforts, we have discovered protein expression patterns in hormone signaling pathways and other pathways of pregnancy that we believe may be operative in the development of postpartum depression. We are working to increase the coverage of biochemical signaling pathways and expression patterns related to postpartum depression in our protein expression database, which we believe will enable the development of a high performing predictor to address this area. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Timing of Pipeline Developments</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the development of high-performing biomarker signatures, the timing of when to move from the discovery phase to the verification phase to the validation phase, based on the NAM guidelines described above, is entirely dependent on the performance data. There are also the additional requirements to analytically validate the particular components measured in biomarker tests by our laboratory and to build the informatics and automation for integrating all components into new testing processes. Given the uncertainties in reliably predicting timing for these phases and additional requirements, we estimate that the timing for our next new commercially available product is a matter of&#160;years, not&#160;months. We will only advance our programs from one stage to the next if we believe that they qualify for advancement pursuant to the NAM guidelines described above. We believe that additional capital required to do this work could help to accelerate the progress on our comprehensive pregnancy pipeline. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Other Scientific Publications</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are including summaries of the following three publications because we believe that they provide evidence of, and support for, our leadership in the area of combining the disciplines of proteomics and bioinformatics with rigorous clinical testing and economic analysis to provide physicians and patients with actionable data and information designed to result in better maternal and neonatal health at lower cost. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Effects of Selective Exclusion of Patients on Preterm Birth Test Performance</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In December 2019, two of our employees, Dr. Boniface and Julja Burchard, together with Dr.&#160;George&#160;R. Saade of the Department of Obstetrics &amp; Gynecology, University of Texas Medical Branch, Galveston, Texas, published an article entitled &#8220;Effects of Selective Exclusion of Patients on Preterm Birth Test Performance&#8221; in the </font><font style="font-style:italic;letter-spacing:0.2pt;">Journal of Obstetrics and Gynecology</font><font style="letter-spacing:0.2pt;">. This publication highlighted an erroneous practice in preterm birth research that has led to artificial increases and incorrect claims of reported biomarker test performance. Some investigators have conducted analyses of biomarker differences in preterm deliveries vs. term deliveries by examining only those subjects remaining after exclusion of some preterm and/or term births near the 37&#160;week boundary between preterm and term deliveries. For example, an investigator may </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">99</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">analyze those preterm deliveries occurring before 34 weeks&#8217; gestation vs. term deliveries that occurred after 37 weeks&#8217; gestation, which selectively excludes all preterm subjects from analysis who delivered in weeks&#160;34 through the end of week&#160;36. Such an incomplete analysis fails to cover the high percentage of preterm deliveries that actually occur in this interval, and does not permit an accurate assessment of the performance of a predictor that would be applied to an entire intended use pregnancy population in actual clinical practice. This approach has been termed &#8220;gapping&#8221; because the resulting distribution of births in the analysis has a gap in it after exclusion of subjects. The publication examined the impact of gapping, utilizing biomarker data from our PAPR study. The omission of later preterm births from the analysis transformed moderate biomarker performance in classification of preterm birth risk to artificially high performance, a result significantly different from measuring a biomarker classifier&#8217;s performance on an entire intended use population, which has deliveries occurring at all possible gestational ages. Further, &#8220;performance&#8221; assessment in this incomplete population generated predictions that substantially under-estimated risk of preterm birth at fewer than 37 weeks while over-estimating risk of very early preterm birth. Incorrect risk prediction could lead to both under- and over-treatment, and has potentially serious clinical implications. The authors demonstrated that performance of a test cannot be derived from a population that does not account for all gestational ages that will be found in the population who will exist in the population to be tested and offered guidance to test developers to improve the design and analyses in preterm birth biomarker studies by including representative sets of preterm subjects and term control subjects at all gestational ages in order to report unbiased and accurate test performance measures. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This publication contains principles and guidance we have given for improving the analysis and design of biomarker prediction work. The publication has generated interest in the clinical and scientific community, with letters to the editor on the article appearing in the </font><font style="font-style:italic;letter-spacing:0.2pt;">Journal of Obstetrics and Gynecology</font><font style="letter-spacing:0.2pt;">. We believe that this work demonstrates the leadership position we have in pregnancy biomarker test development and validation. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Analytical Validation of Protein Biomarkers for Risk of Spontaneous Preterm Birth</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In June 2017, several of our employees, including Dr. Boniface, published an article entitled &#8220;Clinical Validation of Protein Biomarkers for Risk of Spontaneous Preterm Birth&#8221; in the </font><font style="font-style:italic;letter-spacing:0.2pt;">Journal of Clinical Mass Spectrometry</font><font style="letter-spacing:0.2pt;">, a leading mass spectrometry journal. Analytical validation is the process by which a laboratory establishes the measurement accuracy, in our case, at the biochemical level, of its laboratory processes. Analytical validation is a requirement of the authoritative NAM guidelines for multi-omics predictor development. Furthermore, analytical validity is one of the key elements that payers examine in their evaluative process for considering reimbursement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The article referenced above described a rigorous analytical validation of our commercial mass spectrometry proteomic workflow. This work demonstrated the accuracy (when compared to a reference model), linearity, limits of quantitation, analytical specificity and resilience to differences in patient serum and common endogenous interferents for commercial processes used to report our test results. In particular, this work comprehensively examined individual proteomic analyte performance which, when combined into a proteomic score consisting of a ratio of mass spectrometric measurements, fundamentally enables the computation of risk of preterm delivery of a patient. The authors illustrated how the methodology may be used by others performing similar work in the proteomic biomarker discovery, development and clinical test production community. We believe that this work illustrates our leadership in clinical proteomics. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The Building Blocks of Successful Translation of Proteomics to the Clinic</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In June 2018, Dr. Boniface and three other experts in the field of proteomic test development published an article entitled &#8220;The Building Blocks of Successful Translation of Proteonimics to the Clinic&#8221; in the journal </font><font style="font-style:italic;letter-spacing:0.2pt;">Current Opinion in Biotechnology</font><font style="letter-spacing:0.2pt;">. To date, very few mass spectrometry-based proteomic tests have been commercialized. The common elements in the development of two commercially available proteomic clinical tests were examined in this paper, which described the experience of two organizations in bringing products from discovery to commercial availability. The authors demonstrated that the tests, the PreTRM test and a blood test used to assess the cancer risk of lung nodules discovered by radiology, covering completely different medical conditions, shared elements that elucidate their successful clinical development. The paper concludes that development of both the PreTRM test and the lung nodules test benefited from the use of an unbiased systems-biology strategy, adherence to NAM best practices, careful attention to analytic </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">100</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">performance of biomarkers and the use of data normalization techniques. The purpose of this work was to demonstrate, both to the community and to regulators, principles that can be followed to successfully translate &#8216;omics research into actual clinical tests, and to offer insights to others on successful proteomic test development methods. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Commercialization</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The beginning of life and end of life are widely recognized to be costly periods for healthcare services in the human life cycle. Healthcare insurers characterize preterm birth as an exceptionally costly condition, and a number of them develop data and models that underscore the economic impact of preterm births. Given the substantial economic benefits that arise from the use of the PreTRM test, we are pursuing an innovative commercialization strategy focused on accelerating broad use of the PreTRM test by collaborating with a major health benefits provider. We are collaborating with Anthem in the PRIME study to generate rigorous data across approximately 10 centers in their network. Anthem is reimbursing us for PreTRM testing done as a part of that study at a specified rate per test, pursuant to a Laboratory Services Agreement described under &quot;&#8212; Material Agreements&quot; below. Furthermore, we have entered into an active commercial collaboration with Anthem to introduce PreTRM testing into its various health plans, supporting bundled payment mechanisms, including value-based contracting. We believe that entering the market with coverage provided by a well-respected, data-driven company such as Anthem will significantly de-risk reimbursement for us during early commercialization and also strongly influence other payers in their decisions to cover PreTRM testing for patients in their networks. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Generating publications and scientific presentations is a core pillar of our market awareness strategy and is important for establishing validity and utility of new products in the life sciences community. We plan to work closely with maternal fetal medicine experts, payers and key opinion leaders to generate clear use-cases, as well as peer-reviewed publications that illustrate our product performance claims and value proposition. We are working with more than 60 investigators world-wide. In addition, we plan to increase awareness by developing and deploying online and in-person training and educational tools that explain the PreTRM test and our proteomics and bioinformatics platform in easy-to-access, easy-to-understand and credible, scientifically rigorous ways. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We plan to build the full commercial team, composed of sales, marketing, customer service, and managed care personnel, required to effectively address this large market opportunity. We anticipate that our sales force will promote our products across the United States with a targeted focus on OB/GYNs and maternal-fetal medicine providers in the women&#8217;s health market, and we are building a sales team to call on physician offices to address the large OB/GYN sales channel opportunity. We are also recruiting an experienced market access team to secure contracts with commercial and governmental payers and self-insured employer groups, and plan to construct a multi-faceted digital marketing platform to scale consumer awareness and engagement. We are also evaluating the expansion of our business internationally, with the PreTRM test representing one potential avenue for expansion. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Clinical Laboratory Characteristics</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our PreTRM testing laboratory is based in Salt Lake City, UT. We operate under federal regulations as a CLIA laboratory and are approved to provide our clinical testing across all 50 states. We undergo regular inspections from federal and state regulatory authorities, and our laboratory is certified by the College of American Pathologists, or CAP. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have optimized our mass spectrometry-based proteomics workflow to be analytically validated to produce accurate and precise patient results. To meet the demands of the large intended use population of the PreTRM test, we have developed a new state-the-art affinity-capture mass spectrometry, or AC-MS, process. This higher through-put and lower-cost improvement to our current workflow utilizes custom monoclonal antibodies and magnetic beads. Affinity capture of our PreTRM test analytes using magnetic beads coated with antibodies is amenable to automated liquid handling robots using 96 or 384 well plates. Moreover, the AC-MS process results in a large decrease in the complexity of patient serum samples in a single highly parallel and multiplexed step, which translates to shorter mass spectrometry processing times. We believe the AC-MS process can be leveraged to enable a many-fold increase in capacity and significantly decrease turn-around time and cost of goods sold. We also believe that custom antibodies developed for the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">101</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">AC-MS process facilitate the development of immunoassay kits that address the world-wide market. AC-MS and immunoassay versions of the PreTRM test may be suitable for paper-based dried sample collection, or other low-cost sample collection devices in the future. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Material Agreements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:7pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Anthem Commercial Collaboration Agreement</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On February&#160;17, 2021, we entered into a commercial collaboration agreement with Anthem, the Commercial Collaboration Agreement, relating to the commercialization of the PreTRM test. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under this agreement, we will provide PreTRM tests to eligible individuals enrolled in, or serviced or covered by, the health insurance products of Anthem. We have also agreed to develop a sales, marketing, and customer service program, and to provide training and marketing to duly licensed physicians specializing in obstetrics and gynecology or family medicine, or licensed nurse midwives, at the reasonable request of Anthem. Pursuant to the agreement, Anthem will purchase a specified minimum number of tests from us for each of the first three&#160;years of the term of the agreement. Additionally, Anthem has agreed to pay us a specified minimum amount per year for the first three&#160;years of the term of the agreement. Anthem has further agreed to develop appropriate care management programs which incorporate the use of the PreTRM test. We will submit monthly invoices to Anthem for the sale of the PreTRM test at the negotiated rates. As of April 30, 2021, we had not provided any PreTRM tests to Anthem under the Commercial Collaboration Agreement and Anthem had not paid us any fees under the Commercial Collaboration Agreement. We and Anthem have also agreed to form a Joint Operating Committee to oversee the relationship, comprised of two voting members each from Anthem and us. Anthem has been participating in our PRIME study, and at the conclusion of the PRIME study, under the Commercial Collaboration Agreement, we have agreed to enter into Anthem&#8217;s standard lab provider agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Unless earlier terminated due to breach, the Commercial Collaboration Agreement will remain in effect until the later of (a)&#160;the third anniversary of the effective date or (b)&#160;the date on which Anthem has purchased a fixed number of PreTRM tests as agreed by the parties. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Anthem Laboratory Services Agreement</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Effective on November 10, 2020, we entered into a laboratory services agreement with Anthem, called the Laboratory Services Agreement, relating to our provision of PreTRM tests and related services during the course of the PRIME study. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under this agreement, we have agreed to provide clinical laboratory services as requested by participating physicians and other health care professionals, and will provide written reports to those physicians and professionals of the results of the services performed in accordance with the PRIME study. Anthem and we will collaborate on the conduct of the PRIME study, and Anthem will pay us a specified amount per test up to a specified maximum number of tests. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Unless earlier terminated due to breach, the Laboratory Services Agreement will remain in effect until the conclusion of the PRIME study, and it may thereafter be extended for additional terms of one year upon mutual agreement of the parties. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Labcorp Agreement</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On January&#160;9, 2017, we entered into a commercialization agreement, or the Commercialization Agreement, or the Agreement, with Laboratory Corporation of America Holdings, or Labcorp, whereby we appointed Labcorp as our exclusive distributor of the PreTRM test in the field of prediction of a patient&#8217;s likelihood to deliver a baby at less than 37 weeks&#8217; gestation in the United States. On June&#160;25, 2018, we amended the Agreement to (i)&#160;convert Labcorp&#39;s exclusive appointment to an appointment that is only exclusive with respect to certain types of laboratories and is otherwise non-exclusive, and (ii)&#160;to enable us to engage Labcorp to perform certain sample collection, processing, and shipment services. This Agreement is automatically renewed annually unless Labcorp terminates with one year of notice or either party chooses to terminate it due to a material breach of the Agreement, an assignment, or a change in control involving us. The Agreement does not otherwise have a defined expiration date. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">102</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the Agreement, Labcorp shall perform sample collection, processing, and shipment services in support of PreTRM tests as may be requested by us and our other distributors from time to time in accordance with the established Labcorp terms and conditions. We will perform the PreTRM test on each received sample and thereafter provide the result. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Competition</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The life science industry, including companies engaged in molecular diagnostics and proteomics, is characterized by rapidly advancing technologies, intense competition, substantial resources devoted to securing strong intellectual property protection and a focus on developing innovative, proprietary products. To our knowledge, however, there have been few successful efforts by others to date to discover, verify and validate prognostic biomarker tests to predict conditions of pregnancy, and we are aware of no competitors that have discovered, verified and broadly validated a blood-based biomarker test to predict a pregnant woman&#8217;s risk of a spontaneous preterm birth. We therefore believe that our PreTRM test has the benefit of strong first-to-market positioning and validated performance as we pursue our commercialization efforts. We consider our commercial collaboration with Anthem to be another advantageous competitive factor that we believe significantly de-risks our initial commercialization of the PreTRM test and can help encourage coverage decisions by other third-party payers. In addition, we believe that our proprietary technology platform, including our extensive biobanks, advanced mass spectrometry approaches and bioinformatics capabilities, provides us with valuable competitive assets to utilize in discovering and developing other proteomics tests for pregnancy conditions, several of which are already in our pipeline. Coupled with the experience and expertise of our management and scientific teams, we believe we possess meaningful potential to compete in developing and commercializing important products to improve the health of mothers and babies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Notwithstanding the foregoing advantages, given the potential market opportunity represented by the PreTRM test and other pregnancy-related proteomic tests that we may develop, we expect competition to emerge and intensify in the coming&#160;years, with one or more competitive prognostic tests resulting from competitors&#8217; efforts. Competing products may arise from various sources, including molecular diagnostic companies, clinical laboratory companies, life sciences tool companies, third-party service providers, academic research institutions, governmental agencies and public and private research institutions. From time to time, results of early biomarker discovery work are published in scientific literature. These publications are demonstrative of interest in the field, but they characteristically lack evidence of strict adherence to the NAM guidelines for multi-omics prediction development and have not achieved rigorous validation of predictions of interest. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Many of the potential competitors that may emerge, either alone or with their collaborators, have significantly greater resources, established presence in the market, expertise in research and development and greater experience in laboratory operations, obtaining regulatory approvals, gaining reimbursement and commercializing approved products than we do. These competitors also compete with us in recruiting and retaining qualified scientific, sales, marketing and management personnel, conducting clinical studies, publishing scientific research and acquiring technologies that may be complementary to, or necessary for, the ongoing robustness of our discovery, development and commercialization efforts. Other smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Additional mergers and acquisitions may result in even more resources being concentrated in our competitors. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Intellectual Property</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We rely on a combination of patents, trade secrets, copyrights and trademarks, as well as contractual protections, to establish and protect our intellectual property rights. Our success depends in part on our ability to obtain and maintain intellectual property protection for our tests and technology. In particular, we seek to protect the PreTRM test and any potential future tests and technology related to biomarkers relevant to pregnancy and neonatal heath through a variety of methods, including seeking and maintaining patents intended to cover current and future tests and technology, their methods of use and processes for their manufacture, and any other inventions that are commercially important to the development of our business. We seek to obtain domestic and international patent protection which includes, in addition to filing </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">103</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">and prosecuting patent applications in the United States, typically filing counterpart patent applications in additional countries where we believe such foreign filing is likely to be beneficial, including Europe, Japan, Canada, Australia and China. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of April 30, 2021, our intellectual property portfolio encompasses two issued U.S. patents, five pending U.S. non-provisional patent applications, one international patent application under the Patent Cooperation Treaty (PCT), nine granted foreign patents in China, France, Germany, Italy, Ireland, Japan, Spain, Russia, and the United Kingdom, thirty pending foreign patent applications, and one U.S. provisional application. Our owned patents and patent applications, if issued, are expected to expire between 2034 and 2039, in each case without taking into account any possible patent term adjustments or extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees.</font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Within our intellectual property portfolio, we own two patent families that relate to our PreTRM</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> test&#8201;&#8212;&#8201;a first patent family and a second patent family. The patent applications of the first patent family include composition claims directed to panels of biomarkers and corresponding method claims for determining probability for preterm birth, gestational age at birth or time to birth in a pregnant female. The first patent family includes a pending U.S. patent application, seven foreign patents granted in China, France, Germany, Italy, Ireland, Spain, and the United Kingdom, and 5 pending foreign patent applications in the EPO, China, Australia, Japan, and Canada. The granted patents and pending patent applications, if issued, are expected to expire in 2034, without taking into account maintenance, renewal, annuity, or other governmental fees. The patent applications of the second patent family include composition claims directed to compositions of biomarkers, panels of biomarkers, and corresponding method claims for determining probability for preterm birth in a pregnant female, and discloses methods for determining probability of gestational diabetes. The second patent family includes two issued U.S. patents, two foreign patents granted in Japan and Russia, one pending U.S. patent application and 10 pending foreign patent applications in the EPO, Canada, Australia, Japan, Hong Kong, Brazil, India, China, Israel and South Korea. The granted patents and pending patent applications, if issued, are expected to expire in 2036, without taking into account any possible patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We also own pending patent applications directed to other indications. One patent family relates to determining probability for preeclampsia in a pregnant female, and includes patent applications pending in the U.S., the EPO, Australia and Canada. The pending patent applications, if issued, are expected to expire in 2034, without taking into account any possible patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees. A second patent family relates to determining probability for preterm birth associated with preterm premature rupture of membranes in a pregnant female. It includes patent applications pending in the U.S., the EPO, Canada, Australia, Japan, Russia, China and Israel. The pending patent applications, if issued, are expected to expire in 2037, without taking into account any possible patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees. A third patent family relates to determining the estimated due date for a pregnant female, and includes patent applications pending in the U.S., the EPO, Canada and Australia. The pending patent applications, if issued, are expected to expire in 2038, without taking into account any possible patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees. A fourth patent family relates to determining a pregnant female&#8217;s risk of developing placental dysfunction. It includes one international patent application under the PCT and one U.S. provisional application. The pending patent applications, if issued, are expected to expire in 2039 and 2041, without taking into account any possible patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications we may own or license in the future, nor can we be sure that any of our existing patents or any patents we may own or license in the future will be useful in protecting our technology. Please see &#8220;</font><font style="font-style:italic;letter-spacing:0.2pt;">Risk Factors&#8201;&#8212;&#8201;Risks Related to Our Intellectual Property</font><font style="letter-spacing:0.2pt;">&#8221; for additional information on the risks associated with our intellectual property strategy and portfolio. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We continually assess and refine our intellectual property strategy in order to fortify our position, and file additional patent applications when our intellectual property strategy warrants such filings. We intend </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">104</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">to pursue additional intellectual property protection to the extent we believe it would be beneficial and cost-effective. Our ability to stop third parties from making, using, selling, offering to sell, importing or otherwise commercializing any of our patented inventions, either directly or indirectly, will depend in part on our success in obtaining, defending and enforcing patent claims that cover our technology, inventions, and improvements. With respect to our intellectual property, we cannot provide any assurance that any of our current or future patent applications will result in the issuance of patents in any particular jurisdiction, or that any of our current or future issued patents will effectively protect any of our tests or technology from infringement or prevent others from commercializing infringing tests or technology. Even if our pending patent applications are granted as issued patents, those patents may be challenged, circumvented or invalidated by third parties. Consequently, we may not obtain or maintain adequate patent protection for any of our tests or technology. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition to our reliance on patent protection for our inventions, tests and technology, we also rely on trade secrets, know-how, confidentiality agreements and continuing technological innovation to develop and maintain our competitive position. For example, some elements of manufacturing processes, analytics techniques and processes, as well as computational-biological algorithms, and related processes and software, are based on unpatented trade secrets and know-how that are not publicly disclosed. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees, advisors and consultants, these agreements may be breached and we may not have adequate remedies for any breach. In addition, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. As a result, we may not be able to meaningfully protect our trade secrets. For further discussion of the risks relating to intellectual property, see the section titled </font><font style="font-style:italic;letter-spacing:0.2pt;">&#8220;Risk factors&#8201;&#8212;&#8201;Risks Related to our Intellectual Property.&#8221;</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Government Regulation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:7pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Federal and State Regulations&#160;Related to Clinical Laboratories</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:9.5pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Clinical Laboratory Improvement Amendments of 1988</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As a clinical laboratory, we are required to hold certain federal certifications under CLIA to conduct our business. Our clinical laboratory facility located in Salt Lake City, Utah holds a CLIA Certificate of Accreditation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are also accredited by the CLIA to CAP. The Centers for Medicare &amp; Medicaid Services, or CMS, has deemed CAP standards to be equally or more stringent than CLIA regulations, and CAP is authorized to inspect the laboratories that it accredits on CMS&#8217; behalf. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under CLIA, a laboratory is any facility that performs laboratory testing on specimens derived from human beings for the purpose of providing information for the diagnosis, prevention, or treatment of disease or the impairment or assessment of health. CLIA requires that such laboratories obtain certification from the federal government and maintain compliance with various operational, personnel qualification, facilities administration, quality control and assurance, and proficiency testing requirements intended to ensure the accuracy, reliability, and timeliness of patient test results. CMS, part of the U.S. Department of Health and Human Services, or HHS, administers the CLIA certification program. CLIA certification is also necessary to bill state and federal health care programs, as well as many private insurers, for laboratory testing services. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">CLIA requires that we hold a certificate that specifies the categories of testing we perform and that we comply with certain standards applicable to such tests. In addition, CLIA specifies certain testing categories requiring periodic proficiency testing, and certified laboratories performing these tests must enroll in an approved proficiency testing program.</font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, as a condition of CLIA certification, our laboratory is subject to survey and inspection every other year, as well as random inspections. These biannual surveys are typically conducted by CAP because we hold a CLIA Certificate of Accreditation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Laboratories like ours that perform high-complexity testing are required to meet more stringent requirements than laboratories performing less complex tests. A high-complexity CLIA-certified laboratory </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">105</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">may develop, validate, and use proprietary tests referred to as laboratory developed tests, or LDTs. All of our current products are LDTs (as discussed further below under &#8220;Federal Oversight of Laboratory Developed Tests&#8221;). CLIA requires laboratories to demonstrate the analytical validity of any LDT used in clinical testing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If our laboratory is determined to be out of compliance with CLIA requirements at any inspection or otherwise, we may be subject to sanctions such as suspension, limitation or revocation of our CLIA certificate, a directed plan of correction, on-site monitoring, civil monetary penalties, civil injunctive suits, criminal penalties, among other potential penalties, as well as significant adverse publicity, all of which may have a materially adverse impact on our business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">State Regulation of Clinical Laboratories</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">CLIA provides that a state may adopt laboratory regulations that are more stringent than those under federal law, and a number of states have implemented their own more stringent laboratory regulatory requirements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our laboratory is located in Salt Lake City, Utah. Utah requires that laboratories located in this state hold a CLIA certificate (which we do), as well as approval by the Utah Department of Health, or UT DOH, to operate a laboratory. In addition to meeting CLIA requirements and holding a valid CLIA certificate, Utah requires that our laboratory timely notify the UT DOH of certain changes and demonstrate successful performance of proficiency testing in an approved proficiency testing program or approved alternative testing program. If our clinical laboratory is out of compliance with these standards, the UT DOH may revoke our approval to perform testing or potentially impose other remedial measures, any of which could materially affect our business. We maintain an approval in good standing with the UT DOH. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Additionally, several states require the licensure of out-of-state laboratories that accept specimens from those states and/or receive specimens from laboratories in those states. For example, in New York, our PreTRM test must be approved by the New York State Department of Health before it is offered in New York. As part of this process, the State of New York requires validation of our tests. New York State requires additional regulatory approvals for laboratories producing clinical results through the oversight of the NYS-CLEP program. Our laboratory is licensed by the appropriate state agencies in the states in which it operates, if such licensure is required. In particular, our laboratory holds state licenses or permits from and is subject to inspection by California, New York, Maryland, Pennsylvania and Rhode Island. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If a laboratory is out of compliance with state laws or regulations governing licensed laboratories, penalties may include suspension, limitation or revocation of the license, assessment of financial penalties or fines, or imprisonment. Loss of a laboratory&#8217;s state license may also result in the inability to receive payments from state and federal health care programs as well as private insurers, all of which may have a materially adverse impact on our business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Other states beyond those from which our laboratory currently holds licenses may adopt licensure requirements in the future, which could require us to modify, delay or discontinue our operations in such jurisdictions. If we identify any other state with such requirements or if we are contacted by any other state advising us of such requirements, we intend to follow instructions from the state regulators as to how to comply with such requirements. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Regulation of Clinical Trials</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have conducted and are currently conducting a variety of studies for the PreTRM test and our other tests in development that involve clinical investigators at multiple sites in the U.S. We may need to conduct additional studies for the PreTRM test, as well as other tests we may offer in the future, to drive test adoption in the marketplace and reimbursement. Should we not be able to perform these studies, or should their results not provide clinically meaningful data and value for clinicians, adoption of our tests could be impaired and we may not be able to obtain reimbursement for them. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The conduct of clinical trials is also subject to extensive federal and institutional regulations, which regulations are intended to assure that the data and reported results are credible and accurate, and that the rights, safety, and welfare of study participants are protected. Most studies involving human participants </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">106</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">must be reviewed and approved by, and conducted under the auspices of, a duly-constituted institutional review board, or IRB, which is a multi-disciplinary committee responsible for reviewing and evaluating the risks and benefits of a clinical trial for participating subjects and monitoring the trial on an ongoing basis. Companies sponsoring the clinical trials and investigators also must comply with, as applicable, regulations, guidelines and IRB requirements for obtaining informed consent from the study subjects, following the protocol and investigational plan, adequately monitoring the clinical trial, and timely reporting of adverse events. We believe our clinical trials conducted to date have met applicable regulatory requirements. The sponsoring company or the IRB may suspend or terminate a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk. In addition, studies involving human participants often require significant time and cash resources to complete and are subject to a high degree of risk, including risks of experiencing delays, failing to complete the trial or obtaining unexpected or negative results. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The International Committee of Medical Journal Editors, or ICMJE, requires trial registration as a condition of the publication of research results generated by a clinical trial. To fulfill this obligation organizations and individuals can provide the information required by ICMJE either to ClinicalTrials.gov, which is maintained by the U.S. National Institutes of Health, or to a World Health Organization registry. In accordance with this publication policy to ensure that our investigators can publish their findings, and to further our participant enrollment activities for various studies, we register all of the clinical trials that we sponsor with ClinicalTrials.gov. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Federal Oversight of Laboratory Developed Tests</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our first commercial product, the PreTRM test, is an LDT that we process in our single CLIA-certified central laboratory. Although the Food and Drug Administration, or FDA, has asserted that it has authority to regulate LDTs, it has historically exercised enforcement discretion and is not otherwise regulating most tests developed, manufactured and performed within a single high-complexity CLIA-certified laboratory. Any changes in FDA&#8217;s approach to regulation of LDTs generally, or its approach to regulating the PreTRM test specifically, could adversely impact our business. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">FDA Oversight of LDTs</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">While clinical laboratory tests are regulated under CLIA, which is administered by CMS, as well as by applicable state laws, the FDA separately has jurisdiction over medical devices pursuant to its authority under the Food, Drug, and Cosmetic Act, or FD&amp;C Act. In vitro diagnostic devices, or IVDs, intended for clinical purposes are a type of medical device under the FD&amp;C Act and thus fall within the FDA&#8217;s jurisdiction, and the agency applies its authority under the FD&amp;C Act to those IVDs and test kits that are manufactured, packaged, and distributed in interstate commerce. LDTs are considered to be a subset of IVDs that are designed, manufactured, and used within a single laboratory. The FDA regulates, among other matters, the research, testing, manufacturing, safety, labeling, storage, recordkeeping, premarket clearance or approval, marketing and promotion and sales and distribution of medical devices, including IVDs, in the U.S. to ensure that such products on the domestic market are safe and effective for their intended uses. In addition, the FDA regulates the import and export of medical devices. Many of the instruments, reagents, kits or other consumable products used within our laboratory are regulated as medical devices and therefore must comply with FDA quality system regulations and certain other device requirements. We have policies and procedures in place to ensure that we source such materials from suppliers that are in compliance with any applicable medical device regulatory requirements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Although the FDA has statutory authority to ensure that medical devices, including IVDs, are safe and effective for their intended uses, the FDA has historically exercised its enforcement discretion and not enforced applicable provisions of the FD&amp;C Act and regulations with respect to LDTs. Despite its exercise of enforcement discretion, for the last decade there have been proposals to modify how LDTs may be brought into a harmonized paradigm for oversight by the FDA and CMS. For example, in July&#160;2010, the FDA held a two-day public meeting to obtain input on how to apply its authority to implement a reasonable, risk-based, and effective regulatory framework for LDTs. The agency later issued draft guidance and a 2017 Discussion Paper to allow for further public discussion about an appropriate LDT oversight approach and to give congressional committees the opportunity to develop a legislative solution. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">107</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Since 2017, Congress has been working on legislation to create an LDT and IVD regulatory framework that would be separate and distinct from the existing medical device regulatory framework. In August&#160;2018, the FDA recommended changes to draft legislation that had been released by Congress in 2017, which, if made law, would give the agency the authority to revoke approval, request raw data, and take corrective action against test developers. Legislators subsequently provided opportunities for additional stakeholders to provide input on the proposed reform legislation. In March&#160;2020, a bipartisan group of members from both chambers of Congress formally introduced the Verifying Accurate, Leading-edge IVCT Development, or VALID Act, which would codify the term &#8220;in vitro clinical test&#8221;, or IVCT, and create a new medical product category for IVCTs separate from medical devices that includes products currently regulated as IVDs as well as LDTs, among other provisions. The VALID Act would also create a new system for laboratories to use to submit their tests electronically to the FDA for approval, which is aimed at reducing the amount of time it takes for the agency to approve such tests, and establish a new program to expedite the development of diagnostic tests that can be used to address a current unmet need for patients. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The future of the VALID Act is unclear. If the FDA decides to enforce regulation of all LDTs and undertakes notice-and-comment rulemaking to do so, or if the VALID Act or other legislation is passed, in either case reforming the federal government&#8217;s current oversight and regulation of LDTs, we may likely become subject to increased regulatory burdens such as registration and listing requirements, adverse event reporting requirements, and quality control requirements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Most recently, HHS published a policy announcement in August&#160;2020 stating that FDA must go through a notice-and-comment rulemaking process before requiring premarket review of LDTs as medical devices, rather than making such a change through guidance documents, compliance manuals, or other informal policy statements. Although the ultimate impact of HHS&#8217;s policy statement on the FDA&#8217;s plans for regulating LDTs and its current thinking relating to this category of diagnostic testing products is unclear, the August&#160;2020 announcement appears to confirm that laboratories may commercialize LDTs for clinical use without submitting such tests for FDA premarket review and marketing authorization under the medical device regulatory framework. HHS&#8217;s policy statement does not affect proposed legislation for the regulation of LDTs, such as the VALID Act described above. It is also unclear whether the Biden Administration, which assumed control of the executive branch on January&#160;20, 2021, will take the same position as the former administration or seek to revoke or revise the HHS policy announcement from August&#160;2020. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Future legislation or formal FDA regulatory framework affecting LDTs may have premarket application requirements prohibiting commercialization without FDA authorization and controls regarding modification to the tests that may require further FDA submissions. The process would likely be costly and time-consuming. We cannot be sure that the PreTRM test, or any new tests that we may develop or new uses for our products that we develop will be cleared or approved by the FDA in a timely or cost-effective manner, if cleared or approved at all. Even if such tests are cleared or approved, the products may not be cleared or approved for all indications. This could significantly limit the market for that product and may adversely affect our business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If the FDA were to disagree with our conclusion that the PreTRM test falls within the scope of the agency&#8217;s LDT definition and that the PreTRM test is thus subject to FDA&#8217;s medical device authorities and implementing regulations, the agency could require that we obtain premarket approval or another type of device premarket authorization in order for us to commercialize the PreTRM test. As part of this process, we may also be required to conduct additional clinical testing before applying for commercial marketing authorization. Clinical trials must be conducted in compliance with FDA regulations in order to support a marketing submission to the agency for a regulated product, or the FDA may take certain enforcement actions or reject the data. Performing additional, new clinical studies and trials in order to obtain product approval from the FDA, if necessary, would take a significant amount of time and would substantially delay our ability to commercialize the PreTRM test, all of which would adversely impact our business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Advertising of Laboratory Services and LDTs</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our advertising for laboratory services and tests is subject to federal truth-in-advertising laws enforced by the Federal Trade Commission, or FTC, as well as certain state laws. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the Federal Trade Commission Act, or FTC Act, the FTC is empowered, among other things, to (i)&#160;prevent unfair methods of competition and unfair or deceptive acts or practices in or affecting </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">108</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">commerce; (ii)&#160;seek monetary penalties and other relief for conduct injurious to consumers; and (iii)&#160;gather and compile information and conduct investigations relating to the organization, business, practices, and management of entities engaged in commerce. The FTC has very broad enforcement authority, and failure to abide by the substantive requirements of the FTC Act and other consumer protection laws can result in administrative or judicial penalties, including civil penalties, injunctions affecting the manner in which we would be able to market services or products in the future, or criminal prosecution. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Data Privacy and Security Laws</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We believe that we have taken the steps required of us to comply with both federal and state health information privacy and security statutes and regulations, including genetic testing and genetic information privacy laws. However, existing laws regulating such matters continue to evolve, including through amendments, new interpretations and guidance, and, around the world, lawmakers continue to propose new laws regulating privacy and data security, and we may not be able to maintain compliance in all jurisdictions where we do business. Failure to maintain compliance, or changes in laws regarding privacy or security could result in civil and/or criminal penalties, significant reputational damage and could have a material adverse effect on our business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Federal Privacy and Security Laws</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Health Insurance Portability and Accountability Act of 1996, or HIPAA, established comprehensive federal standards for the privacy and security of health information. The HIPAA standards apply to health plans, health care clearing houses, and health care providers that conduct certain health care transactions electronically (Covered Entities), as well as their respective business associates that perform services for them that involve the use, or disclosure of, individually identifiable health information. Title II of HIPAA, the Administrative Simplification Act, contains provisions that address the privacy of health data, the security of health data, the standardization of identifying numbers used in the health care system and the standardization of certain health care transactions. The privacy regulations protect medical records and other protected health information by limiting their use and release, giving patients the right to access their medical records and limiting most disclosures of health information to the minimum amount necessary to accomplish an intended purpose. The HIPAA security standards require the adoption of administrative, physical, and technical safeguards and the adoption of written security policies and procedures. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In 2009, Congress enacted Subtitle D of the Health Information Technology for Economic and Clinical Health Act. or HITECH provisions of the American Recovery and Reinvestment Act of 2009. HITECH amended HIPAA and, among other things, expanded and strengthened HIPAA, created new targets for enforcement, imposed new penalties for noncompliance and established new breach notification requirements for Covered Entities and Business Associates. Regulations implementing major provisions of HITECH were finalized on January&#160;25, 2013 through publication of the HIPAA Omnibus Rule. The Omnibus Rule contained significant changes for Covered Entities and Business Associates with respect to permitted uses and disclosures of Protected Health Information. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under HITECH&#8217;s breach notification requirements, Covered Entities must report breaches of protected health information that has not been encrypted or otherwise secured in accordance with guidance from the Secretary of HHS, or the Secretary. Required breach notices must be made as soon as is reasonably practicable, but no later than 60&#160;days following discovery of the breach. Reports must be made to affected individuals and to the Secretary and, in some cases depending on the size of the breach, they must be reported through local and national media. Breach reports can lead to investigation, enforcement and civil litigation, including class action lawsuits. We are currently subject to the HIPAA regulations as a Covered Entity and maintain an active compliance program. We are subject to audit under the HHS&#8217; HITECH-mandated audit program. We may also be investigated in connection with a privacy or data security complaint. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">There are significant civil and criminal fines and other penalties that may be imposed for violating HIPAA. These fines are adjusted for inflation each year. A Covered Entity or business associate is liable for civil monetary penalties for a violation that is based on an act or omission of any of its agents, including a downstream business associate, as determined according to the federal common law of agency. Penalties for failure to comply with a requirement of HIPAA and HITECH vary significantly depending on the failure and include civil monetary penalties. A single breach incident can violate multiple requirements. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">109</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Additionally, a person who knowingly obtains or discloses individually identifiable health information in violation of HIPAA may face a criminal penalties, which increase if the wrongful conduct involves false pretenses or the intent to sell, transfer or use identifiable health information for commercial advantage, personal gain or malicious harm. Proposed Modifications to the HIPAA Privacy Rule are currently out for public comment for until May&#160;6, 2021, and that there may be legislative changes in the regulatory requirements that result. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Further, submission of electronic health care claims and payment transactions that do not comply with the electronic data transmission standards established under HIPAA and HITECH could result in delayed or denied payments. Any non-compliance with HIPAA and HITECH, and related penalties, could adversely impact our business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">State Privacy and Security Laws</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition to federal enforcement, Covered Entities are also subject to enforcement by state attorneys general who were given authority to enforce HIPAA under HITECH. Moreover, the HIPAA privacy, security, and breach notification regulations do not supersede state laws that are more stringent or provide individuals with greater privacy and security rights or greater access to their records. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The compliance requirements of these laws, including additional breach reporting requirements, and the penalties for violation vary widely and new privacy and security laws in this area are evolving. For example, several states, such as California, have implemented comprehensive privacy laws and regulations. The California Confidentiality of Medical Information Act imposes restrictive requirements regulating the use and disclosure of health information and other personally identifiable information. In addition to fines and penalties imposed upon violators, some of these state laws also afford private rights of action to individuals who believe their personal information has been misused. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">California also recently adopted the California Consumer Privacy Act of 2018, or CCPA, which took effect on January&#160;1, 2020 and became enforceable by the state attorney general on July&#160;1, 2020. The CCPA establishes a new privacy framework for covered businesses by creating an expanded definition of personal information, establishing new data privacy rights for consumers in the State of California, imposing special rules on the collection of consumer data from minors, and creating a new and potentially severe statutory damages framework for violations of the CCPA and for businesses that fail to implement reasonable security procedures and practices to prevent data breaches. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The regulations issued under the CCPA have been modified several times. Additionally, a new privacy law, the California Privacy Rights Act, or CPRA, was approved by California voters in the election on November&#160;3, 2020. The CPRA will modify the CCPA significantly, potentially resulting in further uncertainty, additional costs and expenses stemming from efforts to comply, and additional potential for harm and liability for failure to comply. Other states in the U.S. are considering privacy laws similar to the CCPA. In February&#160;2021, the Virginia legislature became the second to enact a state-specific law called the Consumer Data Protection Act, or CDPA, which includes key differences from California&#8217;s law, further complicating compliance by industry and other stakeholders. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Other Federal and State Health Care Laws</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A variety of state and federal laws prohibit fraud and abuse involving private insurers (as well as state and federal health care programs). These laws are interpreted broadly and enforced aggressively by various state and federal agencies, including CMS, the Department of Justice, or DOJ, the Office of Inspector General for the Department of Health and Human Services, or OIG, and various state agencies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Although the Company does not currently submit claims to federal or state health care programs or other third-party payers, it may do so in the future and thus seeks to conduct its business in compliance with all federal and state fraud and abuse laws, regardless of the payer(s) covered by those laws. The Company is unable, however, to predict how these laws will be applied in the future or whether its arrangements will be subject to scrutiny under them by federal or state enforcement agencies. Sanctions for violations of these laws may result in a range of penalties, including but not limited to significant criminal and civil fines and penalties, and loss of licensure. Any such penalties would adversely affect the Company&#8217;s business. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">110</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Anti-Kickback Statute</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Anti-Kickback Statute, or AKS, prohibits, among other things, knowingly and willfully offering, paying, soliciting, receiving or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing, arranging for or recommending of an item or service that is reimbursable, in whole or in part, by a federal health care program. &#8220;Remuneration&#8221; is broadly defined to include anything of value, which can include (but is not limited to) cash payments, gifts or gift certificates, discounts, or the furnishing of services, supplies or equipment. A person or entity does not need to have actual knowledge of the federal AKS or specific intent to violate it or to have committed a violation. Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved, imprisonment, and exclusion from government healthcare programs. In addition, the government may assert that a claim including items or services resulting from a violation of the AKS constitutes a false or fraudulent claim for purposes of the federal False Claims Act, or FCA. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Some states have their own AKS provisions that apply to claims submitted to private insurers. These statutes also typically have their own safe harbor provisions or they may cross-reference the AKS safe harbors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">From time to time, the OIG has issued Special Fraud Alerts describing the agency&#8217;s view of how certain arrangements between laboratories and referring physicians implicate and potentially violate the AKS. For example, the OIG issued such Alerts in December&#160;1994 and June&#160;2014, and an Alert related to speaker programs issued in November&#160;2020 also applies to the business of laboratories. These Special Fraud Alerts do not have the force of law, but do provide insight into the agency&#8217;s potential enforcement priorities and its interpretation of the AKS as it relates to laboratories&#8217; business practices. Similarly, state enforcement agencies may issue opinion letters that describe their interpretation of how the state AKS applies to certain arrangements, and also provide insight into that agency&#8217;s enforcement priorities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The penalties for violating federal or state AKS provisions can be severe. Possible sanctions include criminal and civil penalties (including penalties under the FCA or a state law equivalent), imprisonment and possible exclusion from state or federal health care programs. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Physician Self-Referral Prohibitions</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Subject to certain exceptions, the federal ban on physician self-referrals (referred to as the Stark Law) is a civil statute that prohibits physicians from referring Medicare and Medicaid patients to an entity providing certain designated health services, which include laboratory services, if the physician or his/her immediate family member has any financial relationship with the entity. Many states also have their own self-referral bans, which may extend to all self-referrals regardless of the payer, unless an exception applies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Potential penalties for Stark Law violations include the return of funds received for all prohibited referrals, fines, civil monetary penalties (including penalties under the FCA or state law equivalents), and possible exclusion from state or federal health care programs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On December&#160;2, 2020, CMS published further modifications to the federal Stark Law. Among other things, CMS added exceptions for certain coordinated care and value-based arrangements among clinicians, providers, and others, which have varying degrees of applicability to laboratories. This final rule (with exceptions) became effective January&#160;19, 2021. We continue to evaluate what effect, if any, the rule will have on our business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Eliminating Kickbacks in Recovery Act</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In October&#160;2018, Congress enacted the Eliminating Kickbacks in Recovery Act of 2018, or EKRA, as part of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act, or SUPPORT Act. EKRA is an all-payer anti-kickback law that criminalizes paying any remuneration to induce referrals to, or in exchange for, patients using the services of a recovery home, a substance use clinical treatment facility, or laboratory. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Although it appears that EKRA was intended to reach patient brokering and similar arrangements in the context of substance use recovery and treatment, the language in EKRA is broad. For example, as written, EKRA prohibits the payment of incentive compensation to sales employees, whereas such payments are </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">111</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">expressly protected under the AKS and its safe harbors (and this practice is common in the industry). And most of the safe harbors available under the AKS are not reiterated under the EKRA&#8217;s exceptions. Therefore, compliance with an AKS safe harbor does not guarantee protection under the EKRA. EKRA thus potentially expands the universe of arrangements that could be subject to enforcement under federal fraud and abuse laws, as well as substantial penalties. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">EKRA does permit the DOJ to issue regulations clarifying or expanding the statute&#8217;s exceptions, but such regulations have not yet been issued. Because, moreover, EKRA is a new law, there is little guidance to indicate how and to what extent it will be applied and enforced by government agencies. The relationships between laboratories and physicians, sales representatives, hospitals, and customers may be subject to scrutiny under this statute. If imposed for any reason, sanctions under the EKRA could have a negative effect on our business. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">False Claims Act</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The FCA imposes civil liability on any person or entity that, among other things, knowingly presents, or causes to be presented, to the federal government, claims for payment that are false or fraudulent; knowingly making, using or causing to be made or used, a false statement of record material to a false or fraudulent claim or obligation to pay or transmit money or property to the federal government or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay money to the federal government. The FCA also prohibits the knowing retention of overpayments (sometimes referred to as &#8220;reverse false claims&#8221;). Under the reverse false claims provision, improperly retained overpayments must be repaid within 60&#160;days of identification unless a favorable decision is obtained on appeal. The FCA also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Penalties for violating the FCA include payment of up to three times the actual damages sustained by the government, plus substantial per-claim civil penalties, as well as possible exclusion from federal health care programs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Various states have enacted similar laws modeled after the FCA that apply to items and services reimbursed under Medicaid and other state health care programs, and, in several states, such laws apply to claims submitted to any payer, including private insurers. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There is also a federal criminal false claims statute that prohibits, in pertinent part, the making or presentation of a false claim, knowing such claim to be false, to any person or officer in the civil, military, or naval service or any department or agency thereof. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Health Care Fraud and False Statements</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The federal health care fraud statute criminalizes knowingly and willfully defrauding a health care benefit program, including private insurers. A violation of this statute may result in fines, imprisonment, or exclusion from government health care programs. The false statements statute prohibits knowingly and willfully falsifying, concealing, or covering up a material fact or making a materially false, fictitious, or fraudulent statement in connection with the delivery of or payment for health care benefits, items, or services. A violation of this statute may result in fines or imprisonment. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Civil Monetary Penalties Law</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The federal Civil Monetary Penalties Law, or CMP Law, prohibits, among other things, (1)&#160;the offering or transfer of remuneration to a Medicare or Medicaid beneficiary if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state health care program, unless an exception applies; (2)&#160;employing or contracting with an individual or entity that the provider knows or should know is excluded from participation in a federal health care program; (3)&#160;billing for services requested by an unlicensed physician or an excluded provider; and (4)&#160;billing for medically unnecessary services. The penalties for violating the CMP Law include exclusion, substantial fines, and payment of up to three times the amount billed, depending on the nature of the offense. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">112</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Physician Payments Sunshine Act</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The federal Physician Payments Sunshine Act imposes reporting requirements on manufacturers of certain devices, drugs and biologics reimbursed under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, or CHIP, for certain payments and transfers of value by them (and in some cases their distributors) to physicians, teaching hospitals and certain advanced non-physician health care practitioners, as well as ownership and investment interests held by physicians and their immediate family members. The reporting program (known as the Open Payments program) is administered by CMS. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Because we develop our LDTs solely for use by or within our own laboratory and we do not currently receive reimbursement from Medicare, Medicaid, or CHIP, we believe we are exempt from these reporting requirements. We could, however, become subject to such reporting requirements under the terms of current CMS regulations, if (i)&#160;we begin submitting claims for reimbursement for our tests to Medicare, Medicaid, or CHIP; and (ii)&#160;the FDA requires us to obtain premarket clearance or approval for our tests as medical devices or Congress enacts legislative reforms to the federal oversight of LDTs to subject them to FDA regulation and/or the reporting requirements of the Sunshine Act. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Other Potentially Applicable State Laws</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are subject to state and foreign equivalents of each of the healthcare laws and regulations described above, among others, some of which may be broader in scope and may apply regardless of the payer. Many U.S. states have adopted laws similar to the AKS and FCA, and may apply to our business practices, including, but not limited to, research, distribution, sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental payers, including private insurers. Such laws include fee-splitting restrictions, insurance fraud laws, anti-markup laws, prohibitions on waiving coinsurance, copayments, deductibles and other amounts owed by patients, and prohibitions on the provision of tests at no or discounted cost to induce physician adoption. Other potentially applicable state laws include direct billing requirements and prohibitions on the corporate practice of medicine. Many of our agreements may be subject to such laws. There are ambiguities as to what is required to comply with these state requirements, and if we fail to comply with an applicable state law requirement we could be subject to penalties. Finally, there are state laws governing the privacy and security of health information, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Reimbursement and Billing</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:9.5pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Coverage and Reimbursement</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the United States and markets in other countries, patients generally rely on third-party payers to reimburse all or part of the costs associated with their treatment. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payers is critical to new product acceptance. Our ability to successfully commercialize our products will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and third-party payers, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. The availability of coverage and extent of reimbursement by governmental and private payers is essential for most patients to be able to afford treatments. Sales of these or other diagnostic testing that we may develop will depend substantially, both domestically and abroad, on the extent to which the costs of our tests will be paid by health maintenance, managed care, and similar healthcare management organizations, or reimbursed by government healthcare programs, private health coverage insurers and other third-party payers. If coverage and adequate reimbursement is not available, or is available only to limited levels, we may not be able to successfully continue to commercialize our tests. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Factors payers consider in determining reimbursement are based on whether the product is: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">a covered benefit under its health plan; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">113</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">safe, effective and medically necessary; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">appropriate for the specific patient; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">cost-effective; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">neither experimental nor investigational. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, market-based changes have affected and will continue to affect the clinical laboratory business. Reimbursement from private insurers for diagnostic testing may shift away from traditional, fee-for-service models to alternatives, including value-based, bundled, and other risk-sharing payment models. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The growth of the managed care sector and consolidation of managed care organizations, or MCOs may also present various challenges and opportunities to us and other clinical laboratories. For example, MCOs have different contracting philosophies. Some MCOs contract with a limited number of clinical laboratories and engage in direct negotiation of rates, while others adopt broader networks with more uniform fee structures for participating clinical laboratories, and still others use capitation rates to fix the cost of laboratory testing services for enrollees. Our revenues may vary depending on the MCOs with which we enter contracts, if we decide to enter such contracts. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition to the potential reductions in test reimbursement, the Company may also see a decline or change in test volumes as a result of increased controls over the utilization of laboratory services by third-party payers, particularly MCOs. For example, MCOs have implemented, either directly or through third parties, various types of laboratory benefit management programs, which may include lab networks, utilization management tools (such as prior authorization and/or prior notification), and claims edits, which impact coverage and reimbursement of clinical laboratory tests. Some of these programs address clinical laboratory testing broadly, while others are focused on certain types of testing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Despite the potentially negative market changes related to reimbursement, several factors may positively impact test volume, including the expansion of managed care and private insurance exchanges. In addition, continued innovation in laboratory medicine will continue to foster greater appreciation of the value of women&#8217;s health diagnostics. Additional factors that may lead to future volume growth include an increase in the number and types of tests that are readily available (due to advances in technology and increased cost efficiencies). </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The Protecting Access to Medicare Act of 2014</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Reimbursement and billing for diagnostic services is highly complex. Laboratories must bill various payers, including private insurers and MCOs. While we do not currently bill state or federal health care programs for our testing, we expect to do so in the future. Submitting claims to various payers is complicated because each payer may have different billing requirements. Additionally, the audit requirements laboratories must meet to ensure compliance with applicable laws and regulations, as well as internal compliance policies and procedures, add further complexity to the billing process. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In April&#160;2014, Congress passed the Protecting Access to Medicare Act of 2014, or PAMA, which substantially changed the way in which clinical laboratory services are paid under Medicare&#8217;s Clinical Laboratory Fee Schedule, or CLFS. While PAMA directly affects Medicare reimbursement for laboratory testing, and we do not currently bill Medicare for our tests, PAMA has an indirect effect on rates paid by private insurers, which we currently only bill for performance of the ongoing PRIME study. Although we do not believe we are currently subject to PAMA&#8217;s requirements, we may be in the future. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">PAMA took effect on January&#160;1, 2018 and requires certain clinical laboratories to report to CMS private insurer payment rates and volumes for their tests. CMS then takes the weighted-median of payments made by private insurers for these tests to set reimbursement under the CLFS for qualifying tests, subject to certain phase-in limits. Laboratories that fail to report the required payment information may be subject to substantial civil monetary penalties. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">CMS&#8217;s methodology under PAMA (as well as the willingness of private insurers to recognize the value of diagnostic testing and pay for that testing accordingly) renders private insurer payment levels even more significant. This calculation methodology has resulted in significant reductions in reimbursement, even though </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">114</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">CMS imposed caps on those reductions. The reduction of reimbursement under the CLFS also affects rates paid by private insurers because those insurers often set their pricing for laboratory testing as a&#160;percentage of the amount set on the CLFS. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Given the many uncertainties built into PAMA&#8217;s price-setting process, we cannot predict how payments we receive from private insurers (or possibly from Medicare in the future), and thus our revenue, may change from year to year. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Health Care Reform and Legislation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">We likewise cannot predict whether or when Congress or state legislatures may take steps to regulate or change pricing of laboratory testing, and thus affect the reimbursement we receive as well as the Company&#8217;s revenue. Examples of such initiatives might include changes to the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, steps to address surprise billing, and increased price transparency, as well as administrative requirements that may continue to affect coverage, reimbursement, and utilization of laboratory services in ways that are currently unpredictable. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Since its enactment, there have been numerous judicial, administrative, executive, and legislative challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. Some of the provisions of the ACA have yet to be fully implemented, while certain provisions have been subject to judicial and Congressional challenges. Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, two bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017, or Tax Act, includes a provision that decreased the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year, commonly referred to as the &#8220;individual mandate,&#8221; to $0, effective January&#160;1, 2019. On December&#160;14, 2018, a federal district court in Texas ruled the individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the Tax Act, the remaining provisions of the ACA are invalid as well. On December&#160;18, 2019, the Fifth Circuit U.S. Court of Appeals held that the individual mandate is unconstitutional, and remanded the case to the lower court to reconsider its earlier invalidation of the full ACA. On March&#160;2, 2020, the United States Supreme Court granted the petitions for writs of certiorari to review this case, and held oral arguments on November&#160;10, 2020. Pending a decision, the ACA remains in effect, but it is unclear at this time what effect these developments will have on the status of the ACA. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August&#160;2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the&#160;years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers up to 2% per fiscal year, and, due to subsequent legislative amendments, will remain in effect through 2030 unless additional Congressional action is taken. Pursuant to the Coronavirus Aid, Relief, and Economic Security Act, also known as the CARES Act, as well as subsequent legislation, these reductions have been suspended from May&#160;1, 2020 through March&#160;31, 2021 due to the COVID-19 pandemic. Proposed legislation, if passed, would extend this suspension until the end of the pandemic. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Other Applicable Environmental, Health, And Safety Regulations</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are subject to numerous federal, state and local environmental, health and safety, or EHS, laws and regulations relating to, among other matters, safe working conditions, environmental protection, and handling or disposition of products, including those governing the generation, storage, handling, use, transportation, release, and disposal of hazardous or potentially hazardous materials, medical waste, and infectious materials. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Some of these laws and regulations also require us to obtain licenses or permits to conduct our operations. If we fail to comply with such laws or obtain and comply with the applicable permits, we could face substantial fines or possible revocation of our permits or limitations on our ability to conduct our operations. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">115</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Certain of our development activities involve use of hazardous materials, and we believe we are in compliance with the applicable environmental laws, regulations, permits, and licenses. However, we cannot ensure that EHS liabilities will not develop in the future. EHS laws and regulations are complex, change frequently and have tended to become more stringent over time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Although the costs to comply with applicable laws and regulations, we cannot predict the impact on our business of new or amended laws or regulations or any changes in the way existing and future laws and regulations are interpreted or enforced, nor can we ensure we will be able to obtain or maintain any required licenses or permits. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Human Capital</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of June 1, 2021, we had 71 full-time and three part-time employees. Among our staff, three persons hold M.D.s, five hold Ph.D.s and 56 hold a master&#8217;s or a bachelor&#8217;s degree in their respective disciplines. Our headquarters are located in Salt Lake City, Utah. None of our employees are subject to a collective bargaining agreement. We consider our relationship with our employees to be good. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Talent Acquisition and Retention</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We recognize that our employees largely contribute to our success. To this end, we support business growth by seeking to attract and retain best-in-class talent. We use internal and external resources to recruit highly skilled candidates for open positions. We believe that we are able to attract and retain superior talent as measured by our minimal turnover rate and high employee service tenure of 3.7&#160;years per employee. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Total Rewards</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our total rewards philosophy has been to create investment in our workforce by offering a competitive compensation and benefits package. We provide employees with compensation packages that include base salary, annual incentive bonuses and long-term equity incentive awards. We also offer comprehensive employee benefits, such as life, disability and health insurance, health savings and flexible spending accounts, paid time off, and a 401(k) plan. It is our express intent to be an employer of choice in our industry by providing a market-competitive compensation and benefits package. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Health, Safety and Wellness</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have always invested, and will continue to invest, in the health, safety, and wellness of our employees. We provide our employees with access to a variety of innovative, flexible, and convenient health and wellness programs. Program benefits are intended to provide protection and security, so employees can have peace of mind concerning events that may require time away from work or that may impact their financial well-being. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our investments and the prioritization of employee health, safety, and wellness took on particular significance in 2020 in light of the COVID-19 pandemic. To protect and support our team members, we implemented health and safety measures that included maximizing personal workspaces, altering work schedules and performing asymptomatic COVID-19 testing regularly for employees who work on site. To aid in containing the spread of COVID-19, we have implemented remote-work options and have limited employee travel. We continue to monitor this rapidly evolving situation and will continue to seek programs to educate and assist employees whenever possible. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Diversity, Equity, and Inclusion</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe a diverse workforce is critical to our success. Our mission is to value differences in races, ethnicities, religions, nationalities, genders, ages and sexual orientations, as well as education, skill sets and experience. We are focused on inclusive hiring practices, fair and equitable treatment, organizational flexibility and training and resources. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Training and Development</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe in encouraging employees in becoming lifelong learners by providing ongoing learning and leadership training opportunities. While we strive to provide real-time recognition of employee performance, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">116</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:444pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">we have a formal annual review process not only to determine pay and equity adjustments tied to individual contributions, but to identify areas where training and development may be needed. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Facilities</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our corporate headquarters and facilities are located in Salt Lake City, Utah. We currently lease a total of approximately 21,800 square feet of building space in Salt Lake City dedicated to research and development, administration and our CLIA-certified laboratory. The lease on our existing Salt Lake City facility expires on December&#160;31, 2022 and we have an option to renew the lease for one additional five-year rental period. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Legal Proceedings</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">From time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">117</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMAN">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">MANAGEMENT</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Executive Officers and Directors</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table provides information regarding our executive officers and directors as of June 1, 2021: </font>
        </div>
        <table style="width:481.72pt;height:323.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt; width:168pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Name </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Age </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt; width:276.46pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Position </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:168pt;">
              <font style="letter-spacing:-0.2pt;">Executive Officers:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:10.5pt; white-space:nowrap;text-align:center;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:276.46pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:168pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Gregory C. Critchfield, M.D., M.S. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; white-space:nowrap;text-align:center;">69</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:276.46pt;">
              <font style="letter-spacing:0.2pt;">Chairman, President and Chief Executive Officer </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:168pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Jay Moyes </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; white-space:nowrap;text-align:center;">67</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:276.46pt;">
              <font style="letter-spacing:0.2pt;">Chief Financial Officer </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.99999999999999pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:168pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">John J. Boniface, Ph.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; white-space:nowrap;text-align:center;">59</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:276.46pt;">
              <font style="letter-spacing:0.2pt;">Chief Scientific Officer </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:168pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Douglas Fisher, M.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; white-space:nowrap;text-align:center;">45</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:276.46pt;">
              <font style="letter-spacing:0.2pt;">Chief Business Officer </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:168pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">John Peltier, Ph.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; white-space:nowrap;text-align:center;">58</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:276.46pt;">
              <font style="letter-spacing:0.2pt;">Senior Vice President of Lab Operations </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:168pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Thomas Garite </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; white-space:nowrap;text-align:center;">77 </td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:276.46pt;">
              <font style="letter-spacing:0.2pt;">Vice President, Clinical Sciences </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:168pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Nadia Altomare </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; white-space:nowrap;text-align:center;">51</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:276.46pt;">
              <font style="letter-spacing:0.2pt;">Chief Commercial Officer </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:168pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Nichole L. Martin </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; white-space:nowrap;text-align:center;">43</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:276.46pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Vice President of Quality/Regulatory and HIPAA Privacy Officer </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:168pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Benjamin G. Jackson </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; white-space:nowrap;text-align:center;">42</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:276.46pt;">
              <font style="letter-spacing:0.2pt;">General Counsel </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:168pt;">
              <font style="letter-spacing:-0.2pt;">Non-Employee Directors:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:168pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Dennis Farrar </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; white-space:nowrap;text-align:center;">83</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:276.46pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:168pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Joshua Phillips </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; white-space:nowrap;text-align:center;">54</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:276.46pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:168pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Mansoor Raza Mirza, M.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; white-space:nowrap;text-align:center;">59</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:276.46pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:168pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Ryan Trimble </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; white-space:nowrap;text-align:center;">69</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:276.46pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:168pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Kim Kamdar, Ph.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; white-space:nowrap;text-align:center;">54 </td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:276.46pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:168pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Michael F. Minahan </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; white-space:nowrap;text-align:center;">61</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:276.46pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:168pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Elizabeth Canis </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; white-space:nowrap;text-align:center;">50</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:276.46pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:168pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Marcus Wilson, Pharm.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; white-space:nowrap;text-align:center;">58</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:276.46pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:168pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Charles D. Kennedy, M.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; white-space:nowrap;text-align:center;">58</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:276.46pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:168pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Joseph Siletto </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:center;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; white-space:nowrap;text-align:center;">52</td>
            <td style="padding:0pt;padding-left:1.625pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:276.46pt;">
              <font style="letter-spacing:0.2pt;">Director</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:11.8pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Executive Officers</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Gregory C. Critchfield, M.D., M.S.</font><font style="letter-spacing:0.2pt;"> has served as our Chairman, President and Chief Executive Officer since November&#160;2011. Dr.&#160;Critchfield brings decades of experience in the diagnostics industry, including a proven track record of successfully launching diagnostics products and significantly growing revenues for leading diagnostics companies. Previously, Dr.&#160;Critchfield was President of Myriad Genetic Laboratories, a wholly-owned subsidiary of Myriad Genetics, Inc., a molecular diagnostics company, from 1998-2010. Under his leadership, Myriad launched seven novel molecular diagnostic products across a variety of technology platforms and increased annual revenues from $2.2&#160;million to $326.5&#160;million. Prior to Dr.&#160;Critchfield&#8217;s role at Myriad, he served as Senior Vice President, Chief Medical and Science Officer of Quest Diagnostics (formerly Corning Clinical Laboratories). Prior to Quest Diagnostics, Dr.&#160;Critchfield was the Director of Clinical Pathology at Intermountain Health Care. Dr.&#160;Critchfield has served on the boards of Saladax Biomedical Inc., BioTrove Inc., Biocius Life Sciences, Inc., Integrated Diagnostics, Inc., Nodality,&#160;Inc., Metamark Genetics, Inc., Lantos Technologies and Condor Therapeutics, Inc., and currently serves as a director of Epic Sciences. He also served as both a reviewer and an NIH Study Section&#160;Chair for biomedical computing grants over a period of time encompassing fifteen&#160;years. He holds a B.S. in Microbiology from Brigham Young University, an M.S. in Biophysical Sciences from the University of Minnesota and an M.D. from the University of Utah College of Medicine. We believe that Dr.&#160;Critchfield&#8217;s perspective and experience as our President and Chief Executive Officer, as well as his depth of experience in the diagnostics industry, provide him with the qualifications and skills to serve on our board of directors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Jay Moyes</font><font style="letter-spacing:0.2pt;"> has served as our Chief Financial Officer since March&#160;2020. Mr.&#160;Moyes has been a member of the board of directors of Achieve Life Sciences, Inc., a public specialty pharmaceutical company, since </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">118</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">August&#160;2017. He has been a member of the board of directors of Puma Biotechnology, Inc., a public biotherapeutics company focused on oncology, since April 2012. He has been a member of the board of directors of Biocardia, Inc., a publicly held cardiovascular regenerative medicine company, since January&#160;2011. Mr.&#160;Moyes served as a member of the board of directors of Predictive Technology Group, Inc., a public molecular diagnostics and regenerative medicine company, from February&#160;2019 to December&#160;2019. Mr.&#160;Moyes was a director of Integrated Diagnostics, Inc., a privately held molecular diagnostics company from March&#160;2011 to November&#160;2016. Mr.&#160;Moyes was a member of the board of directors of Osiris Therapeutics, Inc., a public bio-surgery company, from May&#160;2006 until December&#160;2017 and Amedica Corporation, a public orthopedic implant company, from November&#160;2012 to August&#160;2014. He served as Chief Financial Officer of Amedica from October&#160;2013 to August&#160;2014, where he was responsible for developing and executing the company&#8217;s financial strategy. From May&#160;2008 through July&#160;2009, Mr.&#160;Moyes served as the Chief Financial Officer of XDx, Inc. (now CareDx, Inc.), a privately held molecular diagnostics company. In that role, he orchestrated the company&#8217;s right-sizing strategy. Prior to that, Mr.&#160;Moyes served as the Chief Financial Officer of Myriad Genetics, Inc., a public healthcare diagnostics company, from June&#160;1996 until November&#160;2007, and as its Vice President of Finance from July&#160;1993 until May 1996, where he led the financial team as it transitioned from a small private company to a publicly held enterprise. From 1991 to 1993, Mr.&#160;Moyes served as Vice President of Finance and Chief Financial Officer of Genmark, Inc., a privately held genetics company. In that role he established the company&#8217;s financial infrastructure. Mr.&#160;Moyes held various positions with the accounting firm of KPMG LLP from 1979 through 1991, most recently as a Senior Manager. At KPMG LLP, he was primarily responsible for conducting financial audits of high-tech and biotech clients. Mr.&#160;Moyes also served as a member of the Board of Trustees of the Utah Life Science Association from 1999 through 2006. He holds an M.B.A. from the University of Utah, a B.A. in economics from Weber State University, and is formerly a Certified Public Accountant. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">John J. Boniface, Ph.D.</font><font style="letter-spacing:0.2pt;"> has served as our Chief Scientific Officer since November&#160;2011. Prior to that, Dr.&#160;Boniface briefly served as our Vice President of Research from September&#160;2011 to November&#160;2011. In his role as Chief Scientific Officer, Dr.&#160;Boniface is involved with our product development. Dr.&#160;Boniface previously served as scientist and program director for multiple biotechnology companies focused on protein discovery and small molecule and immunotherapeutic drug development, including Myrexis, Myriad Genetics, Prolexys Pharmaceuticals and Eos Biotechnology. Dr.&#160;Boniface holds a Ph.D. in Biochemistry from Albany Medical College and a B.S. in Biochemistry from the University of Massachusetts, Amherst. Dr.&#160;Boniface was a post-doctoral scholar in the laboratory of Dr.&#160;Mark Davis, Department of Microbiology and Immunology, Stanford University School of Medicine. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Douglas Fisher, M.D.</font><font style="letter-spacing:0.2pt;"> has served as our Chief Business Officer since January&#160;2015. In his role as Chief Business Officer, Dr.&#160;Fisher manages our business and strategy development. Dr.&#160;Fisher served as a member of our board of directors from November&#160;2011 to January of 2015. In addition to his employment with our company, Dr.&#160;Fisher is also an Executive in Residence at InterWest Partners LLC, a venture capital firm and our affiliate. Prior to joining InterWest, Dr.&#160;Fisher served as Vice President of New Leaf Venture Partners LLC, a private equity and venture capital firm. Prior to joining New Leaf, Dr.&#160;Fisher was a project leader with The Boston Consulting Group, Inc., a global management consulting firm. Dr.&#160;Fisher currently serves on the board of private companies Boston Microfluidics, Inc., Gynesonics, Inc., Indi Molecular, Inc, Imagine Scientific, Inc. and Lycera, Inc. and public companies Precipio Diagnostics and Obalon Therapeutics, Inc. Dr.&#160;Fisher holds an A.B. and a B.S. from Stanford University, an M.D. from the University of Pennsylvania School of Medicine and an M.B.A. from The Wharton School of the University of Pennsylvania. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">John M. Peltier, Ph.D.</font><font style="letter-spacing:0.2pt;"> has served as our Senior Vice President of Laboratory Operations since August&#160;2016. In his role as Senior Vice President of Laboratory Operations, Dr.&#160;Peltier manages the Sera Clinical Laboratory. Dr.&#160;Peltier previously served as Laboratory Head and Senior Investigator at Novartis Institutes for Biomedical Research from August&#160;2009 to August&#160;2016. Prior to that, Dr.&#160;Peltier served as Senior Director, Spectrometry at Correlogic Systems, Inc. from April&#160;2007 to July&#160;2009, and as Director of Drug metabolism and Pharmacokinetics (DMPK) and Discovery Analytical Sciences at Prolexys Pharmaceuticals, from December&#160;2001 to March&#160;2007. Dr.&#160;Peltier holds a Ph.D. in Chemistry from McMaster University and a B.Sc. in Chemistry from McMaster University. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Thomas Garite</font><font style="letter-spacing:0.2pt;"> has served as our Vice President of Clinical Science since June&#160;2020. In his role as Vice President of Clinical Science, Dr.&#160;Garite directs all clinical research and related activities. Since February, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">119</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">2013, Dr.&#160;Garite also has served as the Chief Clinical Officer, a consulting role, at Perigen, Inc., a national patient safety company. From January 2001 to June 2020, Dr.&#160;Garite served as Director of Research and Education for Obstetrix at MedNax Medical Group, where he directed a collaborative research group composed of a consortium of private practices and university maternal-fetal medicine group. Under his leadership, his team published 25 collaborative studies including 10 multicenter collaborative research trials all in high-impact obstetric journals during his 18-year tenure with the company. Dr.&#160;Garite recently retired from his position as Edward H. Quilligan Professor of Obstetrics and Gynecology at the University of California at Irvine. Dr.&#160;Garite served 18&#160;years as this Department&#8217;s Chairman, and now holds the title of Professor Emeritus. He is also the past Editor in Chief of the American Journal of Obstetricians and Gynecology and remains Editor Emeritus. Dr.&#160;Garite has published more than 200 articles and chapters, including over 150 original peer-reviewed journal articles and is the author or co-author of five textbooks. His research has focused on intrapartum and antepartum fetal assessment through fetal heart rate monitoring, prematurity in general, premature rupture of membranes, the infectious etiology of prematurity, and the management of labor. Dr.&#160;Garite holds an M.D. from the University of California Irvine College of Medicine and attended California State University, Northridge for undergraduate studies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Nadia Altomare</font><font style="letter-spacing:0.2pt;"> has more than 20&#160;years of women&#8217;s healthcare diagnostics experience. Mrs.&#160;Altomare has served as our Chief Commercial Officer since May&#160;2017 and leads the company&#8217;s commercialization strategy and execution, accountable for the company&#8217;s marketing, public relations, sales, market access, customer service and billing functions. From May&#160;2015 to May&#160;2017, Mrs.&#160;Altomare served as President and then CEO and member of the Board of Directors at Abcodia Ltd, an early detection cancer diagnostics company, where she set up the U.S. subsidiary and held full P&amp;L accountability over the global business. Prior to Abcodia, Mrs.&#160;Altomare was the Vice President &amp; General Manager of a global DNA analysis business at ThermoFisher Scientific with full P&amp;L accountability. Previously, Mrs.&#160;Altomare was the Vice President &amp; General Manager of a cytogenetic DNA business at PerkinElmer. Earlier in her career, Mrs.&#160;Altomare held a number of leadership positions through a series of mergers and acquisitions and an IPO, resulting in a company ultimately acquired by PerkinElmer. Among her accomplishments was the startup, build and scale of the ViaCord division. Mrs.&#160;Altomare is currently on the Board of Savran Technologies, a private healthcare company focused on enabling the next generation of non-invasive diagnostics. She received an M.B.A from Northeastern University and a B.S. in Business Administration from the State University of New York at Stony Brook. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Nichole L. Martin</font><font style="letter-spacing:0.2pt;"> has served as our Vice President of Quality/Regulatory and HIPAA Privacy Officer, since May 2020. In her role as Vice President of Quality/Regulatory and HIPAA Privacy Officer, Ms.&#160;Martin oversees all quality assurance and regulatory activities within Sera, including the CAP/CLIA laboratory and regulated activities throughout the company. She works very closely with the heads of all departments to ensure the highest quality results delivery and compliance with applicable regulations. She is also responsible for development and monitoring of quality improvement initiatives, quality metrics, quality systems, regulatory reporting and communication as well as all regulatory aspects of study design. Ms. Martin holds a number of certifications from the American Society for Quality and the Regulatory Affairs Professionals Society. Previously, Ms.&#160;Martin served as Senior Director, Quality Management at Progenity, Inc., from June 2018 to May 2020, and as Quality Director, U.S. Head of Quality at Oxford Immunotec from December 2015 to May 2018 (Oxford Immunotec has since been acquired by Quest Diagnostics and PerkinElmer, Inc.). From 2008 to 2015, Ms.&#160;Martin served as Quality Director, Americas at Q</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">2</font><font style="letter-spacing:0.2pt;"> Solutions. Ms. Martin occasionally serves as a part-time consultant at Client Confidential in an ad-hoc capacity. Ms.&#160;Martin holds an M.S. in Quality Assurance, Manufacturing from California State University and a B.S. in Biochemistry and a minor in Genetics from North Carolina State University. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Benjamin G. Jackson</font><font style="letter-spacing:0.2pt;"> has served as our General Counsel since April 2021. From February 2006 to March 2021, Mr.&#160;Jackson was employed by Myriad Genetics, most recently serving as Executive Vice President, General Counsel and Secretary. Mr. Jackson held various positions in Myriad&#8217;s Legal Department, including serving as associate general counsel prior to assuming the role of general counsel. Mr. Jackson received his J.D. from the J. Reuben Clark Law School at Brigham Young University and a B.S. in microbiology, immunology and molecular genetics from the University of California, Los Angeles.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Non-Employee Directors</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Dennis Farrar</font><font style="letter-spacing:0.2pt;"> has served as a member of our Board since January&#160;2008. Mr.&#160;Farrar previously served as our Chairman and Chief Executive Officer from 2008 to 2011. Since 2009, Mr. Farrar has served as </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">120</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">cofounder and a Managing Partner of UpStart Ventures, a Salt Lake City life sciences venture capital seed fund, where he assists in managing UpStart&#8217;s investment portfolio and serves as Executive Chairman and a board member of portfolio company Elute, Inc. From March&#160;2016 to March&#160;2021, Mr.&#160;Farrar assisted in managing UpStart&#8217;s investment portfolio and serves as Executive Chairman and a board member of portfolio company Elute, Inc. Mr.&#160;Farrar has 30&#160;years of seed stage venture investing experience. Starting in the early 1990&#8217;s, Mr.&#160;Farrar was cofounder of the Founders Fund, which invested in and launched five university life sciences technologies, successfully exiting three companies. Mr.&#160;Farrar has cofounded 13 Salt Lake City-based life sciences companies, including Myriad Genetics. He also cofounded Utah Ventures, Utah&#8217;s first institutionally financed venture fund. Mr.&#160;Farrar has held numerous executive positions, including cofounder and CEO of Arcaris, Inc. and Q&#160;Therapeutics, Inc. Previously, he practiced corporate law for more than 20&#160;years with large firms in New York City, San Francisco and Salt Lake City. Mr.&#160;Farrar holds both a B.A. and J.D. from Stanford University. We believe Mr.&#160;Farrar&#8217;s qualifications to serve on our board include his management expertise of life sciences companies, his corporate and legal backgrounds, and his knowledge of our company through service on our board since 2008. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Joshua Phillips</font><font style="letter-spacing:0.2pt;"> has served as a member of our Board since January&#160;2011. Since 2008, Mr.&#160;Phillips has been a Managing Partner of Catalyst Health Ventures (CHV), a venture capital fund investing in medical technology and life science companies. Mr.&#160;Phillips led Catalyst&#8217;s investments in Novazyme Pharmaceuticals, Inc. (acquired by Genzyme Corp.), BioTrove, Inc. (acquired by Life Technologies Corp.), Biocius Life Sciences, Inc. (acquired by Agilent Technologies, Inc.), Vortex Medical, Inc. (acquired by AngioDynamics), Allegro&#160;Diagnostics, Inc. (acquired by Veracyte, Inc.), SevenOaksBiosciences (acquired by Medline Industries, Inc.), Pavilion Medical Innovations and Cruzar Medsystems, in addition to our company. Prior to joining Catalyst, Mr. Phillips was the Managing Partner of Catalyst Health and Technology Partners prior to CHV, where he led investments in Novazyme Pharmaceuticals, Inc. (NASDAQ:SNY), BioTrove, Inc. (NYSE:TMO) and Biocius Life Sciences, Inc. (NYSE:A). Mr.&#160;Phillips is a director at several privately held companies, including Conformal Medical, Inc., Brixton Biosciences, Inc., Saphena Medical, Inc., and Cruzar Medsystems, Inc. Mr.&#160;Phillips holds an M.B.A. from the Harvard Business School and a B.E. in Electrical Engineering and Mathematics from Vanderbilt University. We believe that Mr.&#160;Phillips&#8217; qualifications to serve on our board include his extensive experience in the life science, diagnostics and medical device markets, his extensive experience serving on boards as Chairman, Lead Director, Audit &amp; Compensation Committee Chair and Member and his knowledge of our company and its business through service on our board since January&#160;2011. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Mansoor Raza Mirza, M.D.</font><font style="letter-spacing:0.2pt;"> has served as a member of our Board since December 2014. Dr.&#160;Mirza is Chief Oncologist at the Department of Oncology, Rigshopitalet&#8201;&#8212;&#8201;the Copenhagen University Hospital, Denmark and Medical Director of the Nordic Society of Gynaecological Oncology, or NSGO. Dr.&#160;Mirza is Chairman of the European Network of Gynaecological Oncological Trial groups, or ENGOT. Dr.&#160;Mirza is both a medical and radiation oncologist, with a primary focus in non-surgical treatment of gynecologic cancers. His key academic goals are to promote clinical research, international trial collaboration and education, and he has broad experience in clinical protocol development, trial conduct and clinical trial regulations. Dr.&#160;Mirza is the author of several phase 1, 2 and 3 studies. Several of those studies led to FDA and European Medicines Agency registrations. He serves on several Independent Data Safety Monitoring Committees of international studies. He is an invited speaker at several international conferences, such as &#8220;Meet the Professor&#8221; at American Society of Clinical Oncology and &#8220;Presidential Symposium&#8221; at European Society for Medical Oncology. He is the author of global consensus guidelines for the management of ovarian cancer and of European guidelines for the management of several gynecological malignancies. His other current appointments include service as ESGO Council Member (European Society of Gynaecological Oncology), Executive Director of GCIG (Gynecologic Cancer InterGroup), Vice-Chairman of the Danish Gynecological Cancer Society, faculty member of the European Society of Medical Oncology and of ESGO. He also serves on the board of directors of Karyopharm Therapeutics Inc., a public pharmaceutical company and has served as a clinical consultant to Karyopharm Therapeutics Inc. since 2010. He has multiple publications in high-impact journals, including several publications in the New England Journal of Medicine and the Lancet. He holds an M.D., Diploma in Surgery and Diploma in Clinical Oncology from the Pirogov Moscow State Medical Institute as well as post-graduate education and certification in radiation and medical oncology from the University of Southern Denmark. We believe Dr.&#160;Mirza&#8217;s qualifications to serve on our board include his expertise in gynecologic cancers, and his knowledge of our company and its business through service on our board since December 2014. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">121</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Ryan Trimble</font><font style="letter-spacing:0.2pt;"> has served as a member of our Board since March&#160;2011. Dr.&#160;Trimble was appointed to Sera&#8217;s Board in March&#160;2011. He brings over 30&#160;years of experience in the healthcare services industry. He is a former senior executive with FHP International, Wellpoint Health Networks, P5 eHealth Systems, and SCAN Health Plan. He recently completed service on the boards of SCAN Health Plan and The Scan Foundation. Dr.&#160;Trimble has a B.S. in Microbiology from Brigham Young University, a D.D.S. from Loyola University in Chicago, and an M.B.A. from the University of Utah. We believe Mr.&#160;Trimble&#8217;s qualifications to serve on our board include his leadership experience with public companies and other board member experience, and his knowledge of our company and its business through service on our board since March&#160;2011. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Kim Kamdar, Ph.D.</font><font style="letter-spacing:0.2pt;"> has served as a member of our Board since November&#160;2011. Dr.&#160;Kamdar is currently a Partner at Domain Associates, LLC, a venture capital firm, where she has worked since 2005. Prior to Domain, Dr.&#160;Kamdar was a Kauffman Fellow with MPM Capital, as well as a research director at Novartis International AG. Dr.&#160;Kamdar is currently Chair of the Board of Directors of Seraphina Therapeutics and Truvian Sciences, Inc. and serves on the board of directors of EvoFem Biosciences, Inc. (Nasdaq: EVFM), Obalon Therapeutics, Inc. (Nasdaq: OBLN) and Singular Genomics Systems (Nasdaq:&#160;OMIC). Dr.&#160;Kamdar currently serves on the board of several private companies including: Epic Sciences, Inc., Alume Biosciences and Pleno, Inc. Dr.&#160;Kamdar serves as an advisory board member of Dr.&#160;Eric Topol&#8217;s NIH supported Clinical and Translational Science Award for Scripps Medicine and is also on the non-profit board for Access Youth Academy, an organization that is transforming the lives of underserved youth through academic enrichment, health and wellness, social responsibility and leadership through squash. Dr.&#160;Kamdar received her B.A. from Northwestern University and her Ph.D. in biochemistry and genetics from Emory University. We believe Dr.&#160;Kamdar is qualified to serve on our Board of Directors based on her extensive experience working and serving on the boards of directors of life sciences companies and her experience working in the venture capital industry and her knowledge of our company and its business through service on our board since November 2011. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Michael F. Minahan</font><font style="letter-spacing:0.2pt;"> has served as a member of our Board since January&#160;2017. He currently serves as the Senior VP and General Manager for Integrated Genetics, a division of Labcorp, a leader in Woman&#8217;s Health and Genetic testing. Mr.&#160;Minahan has over 25&#160;years of experience in genetics sales, marketing, managed care and operations. Prior to joining Lab Corp., Mr.&#160;Minahan worked for Genzyme Genetics, a division of the former Genzyme Corporation. During his time at Genzyme, he was responsible for building the commercial organization in both Genetics and Oncology, assisting in the completion of several successful acquisitions, and leading highly successful commercial launches of many innovative tests. We believe Mr.&#160;Minahan&#8217;s qualifications to serve on our board include his background and experience in the commercialization of genetics and oncology, and his knowledge of our company and its business through service on our board since January&#160;2017. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Elizabeth Canis</font><font style="letter-spacing:0.2pt;"> has served as a member of our Board since March&#160;2021. Since June 2020, Ms.&#160;Canis has served as the Vice President, Emerging Businesses &amp; Partnerships at Anthem. Between January 2018 and May 2020 she organized the enterprise strategy and key business priorities at Anthem, and also facilitated the planning and direction of all operational, financial and administrative activities of the Office of the Chief Executive Officer. Prior to joining Anthem, from May&#160;2017 to December&#160;2017, Ms.&#160;Canis served as Venture Lead at SavvySherpa, a health care venture capital and innovation firm. She also founded and served as CEO of The Pivot Group from October&#160;2014 to May&#160;2017, where she oversaw a team of industry experts, innovators and executives offering strategic consulting services to launch and expand a broad range of businesses. Additionally, Ms.&#160;Canis has served as the Vice President of Exchange Strategy at UnitedHealth Group, after holding several other positions at the company over her eleven-year tenure. She also served as Vice President of Strategy and member of the leadership team at Zest Health, where she identified and cultivated segment and distribution channel relationships, defined the pricing methodology, and constructed the operating model for the organization. Ms.&#160;Canis began her career at Deloitte. She holds an M.B.A. with distinction, with a concentration in strategy and finance, from the University of Michigan Ross School of Business and a B.A., with a focus in Mathematics, Economics and Political Science, from Northwestern University. We believe that Ms.&#160;Canis&#8217; background and experience within the healthcare industry, including her operating as liaison to Anthem&#8217;s board of directors while serving in the Office of Chief Executive Officer from January&#160;2018 to May&#160;2020, qualifies her to serve on our board. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">122</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Marcus Wilson, Pharm.D.,</font><font style="letter-spacing:0.2pt;"> has served as a member of our Board since March&#160;2021. He has served as the Chief Analytics Officer, or CAO, at Anthem since November&#160;2020. Previously, from October&#160;2003 to November&#160;2020, Dr.&#160;Wilson was President of HealthCore, Inc., or HealthCore, a subsidiary of Anthem. In his role as CAO at Anthem, Dr.&#160;Wilson has accountability for efforts to derive critical clinical and business insight from Anthem&#8217;s healthcare ecosystem to drive decisions for a broad range of healthcare stakeholders to improve healthcare quality, safety, access, and affordability. He is charged with defining and implementing Anthem&#8217;s enterprise analytics strategy. Efforts include setting analytic priorities, building new analytic capabilities, and driving value creation through the coordination of business and technical resources. He also has administrative oversight accountability for HealthCore, Anthem&#8217;s subsidiary that collaborates with various external stakeholders within the FDA, NIH, and life sciences industry, among others. Dr.&#160;Wilson currently has approximately five hundred employees under management. Additionally, Dr.&#160;Wilson founded, managed and grew a healthcare research organization for twenty-four years, seven&#160;years as an independent company and seventeen years as a subsidiary post-acquisition by WellPoint Health Network Inc. (now Anthem, Inc.). Prior to co-founding HealthCore in 1996, Dr.&#160;Wilson spent seven&#160;years on faculty at the Philadelphia College of Pharmacy and established and managed a clinical practice within an integrated delivery system owned by Blue Cross Blue Shield of Delaware where he oversaw the physician and patient clinical decision support, pharmacy policy, and clinical trials programs. He holds a PharmD from the Medical College of Virginia, a B.S. in Biochemistry from Virginia Tech and attended the Medical University of South Carolina for his residency in Family Medicine. We believe that Dr.&#160;Wilson&#8217;s background and experience within the healthcare industry, including acting as President of HealthCore, qualifies him to serve on our board. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Charles D. Kennedy, M.D.</font><font style="letter-spacing:0.2pt;"> has served as a member of our Board since July 2019. Since July&#160;2017, Dr.&#160;Kennedy has served as the Chief Executive Officer and Managing Partner of Blue Ox Healthcare Partners, LLC, or Blue Ox, where he leads the firm&#8217;s overall strategic focus and is a member of the Investment Committee. Prior to Blue Ox, Dr.&#160;Kennedy was Chief Population Health Officer for Healthagen, Aetna&#8217;s healthcare IT subsidiary, from 1/2015 to 1/2017. He also served as CEO of Aetna&#8217;s Accountable Care Solutions division, growing revenues from single digit million to a multi-billion-dollar subsidiary. Before Aetna, Dr.&#160;Kennedy was CEO of Anthem&#8217;s HealthCore subsidiary, Vice President of Health Information Technology for WellPoint, Co-Founder and CEO of CareAssured, and Director of Strategic Informatics at Blue Shield of California. Previously, Dr.&#160;Kennedy was a practicing physician on the medical staff at Kaiser Permanente and other Northern California medical facilities for seven&#160;years. He currently serves on the board of Blue Ox portfolio company Epic Sciences. Dr.&#160;Kennedy has served on the AHIP Foundation Board, and the advisory board for the Center for Healthcare Innovation, Healthcare and Life Science Innovation Lab. He was also a founding commissioner of the Certification Commission for Health Information Technology and served a five-year appointment as the health insurance industry representative to the U.S.&#160;Government on the HIT Policy Committee advising the management and distribution of a $30&#160;billion budget. He holds an M.D. in Internal Medicine from the University of California at Los Angeles, an M.B.A. in Corporate Strategy and Health Care Economics from Stanford University, and a B.S. in Genetics from the University of California at Berkeley. We believe that Mr.&#160;Kennedy&#8217;s background and experience in finance and information technology, including his over twenty-five (25) years of experience as a C-level executive and board advisor at several leading companies, qualifies him to serve on our board. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Joseph Siletto</font><font style="letter-spacing:0.2pt;"> has served as a member of our Board since March 2021. Since January 2017, Mr. Siletto has served as a Managing Director of Vivo Capital LLC, a healthcare-focused investment firm where he focuses primarily on growth equity and private equity transactions. During his time at Vivo Capital, Mr.&#160;Siletto has served on boards of directors and took an active operating role in the office of the CEO and later Chief Business Officer of Surgical Specialties Corporation. Mr. Siletto currently serves as a board member of Ser&#225;n Bioscience, LLC, Aerobiotix, Inc. and Swift Health Systems Inc. d/b/a Inbrace as well as board observer for Minerva Surgical Inc. and Neocis Inc. Until March 2021, Mr. Siletto was a director of Preventice Solutions, a leading commercial player in the cardiac imaging space that was acquired by Boston Scientific in March 2021. Prior to joining Vivo Capital, Mr. Siletto was the CEO of Scion Medical Technologies (acquired by Varian Medical) and before then he spent over a decade as a healthcare-focused investment banker at Banc of America Securities, SVB Alliant and Cowen and Company. Mr. Siletto has 20&#160;years of experience in life sciences transactions and investments as CEO, director, investment banker and investor in healthcare companies. He holds an M.B.A. from The Haas School of Business of the University of California, Berkeley, a B.A. from Duke University and also studied at the Beijing Language </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">123</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Institute. We believe that Mr. Siletto&#8217;s extensive experience in the life sciences industry, including his current and previous positions as a board member of other life sciences companies, qualifies him to serve on our board. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Board Composition</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our board of directors currently consists of eleven members, all of whom are expected to initially remain members of our board of directors upon the consummation of the offering. All eleven of our directors are members pursuant to the board composition provisions of our existing amended and restated certificate of incorporation and by-laws. Our board of directors may consider a broad range of factors relating to the qualifications and background of nominees, including diversity, which is not limited only to race, gender or national origin. We have no formal policy regarding board diversity. Our board of directors&#8217; priority in selecting board members is identification of persons who will further the interests of our stockholders through their established records of professional accomplishment, the ability to contribute positively to the collaborative culture among board members, knowledge of our business, understanding of the competitive landscape, professional and personal experiences, and expertise relevant to our growth strategy. Our directors hold office until their successors have been elected and qualified or until the earlier of their death, resignation or removal. Our amended and restated certificate of incorporation and amended and restated by-laws, both of which will become effective upon the completion of this offering will provide that our directors may be removed only for cause by the affirmative vote of the holders of at least &#8199;&#8199;&#8199;% of the votes that all our stockholders would be entitled to cast in an annual election of directors, and that any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, may be filled only by vote of a majority of our directors then in office. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to a letter agreement with Baker Bros. Advisors LP, or Baker Bros., from and after the closing of this offering, at any time that Baker Bros. beneficially owns shares or other equity securities representing at least 4% of our then-outstanding total voting power, it is entitled to nominate one individual, or an Investor Designee, to serve as a director on our board of directors. We are required to include the Investor Designee in the slate of nominees recommended to our stockholders for election as our directors at each annual or special meeting of our stockholders at which directors are to be elected. Baker Bros. is restricted from exercising this right during certain periods of time. As of June&#160;1, 2021, Baker Bros. had not exercised its rights to nominate an Investor Designee to serve as a director on our board of directors. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Director Independence</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Rule&#160;5605 of the Nasdaq Listing Rules requires a majority of a listed company&#8217;s board of directors to be comprised of independent directors within one year of listing. In addition, the Nasdaq Listing Rules require that, subject to specified exceptions, each member of a listed company&#8217;s audit, compensation and nominating and corporate governance committees be independent and that audit committee members also satisfy independence criteria set forth in Rule&#160;10A-3 under the Exchange Act. Under Rule&#160;5605(a)(2), a director will only qualify as an &#8220;independent director&#8221; if, in the opinion of our board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In order to be considered independent for purposes of Rule&#160;10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors, or any other board committee, accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its subsidiaries or otherwise be an affiliated person of the listed company or any of its subsidiaries. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our board of directors has determined that all members of our board of directors, except Gregory C. Critchfield, M.D., M.S. and Charles D. Kennedy, M.D., are independent directors, including for purposes of the rules of The Nasdaq Stock Market and relevant federal securities laws and regulations. There are no family relationships among any of our directors or executive officers. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Staggered Board</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In accordance with the terms of our amended and restated certificate of incorporation and amended and restated by-laws that will become effective upon the completion of this offering, our board of directors will be divided into three staggered classes of directors of the same or nearly the same number and each </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">124</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">will be assigned to one of the three classes. At each annual meeting of the stockholders, a class of directors will be elected for a three-year term to succeed the directors of the same class whose terms are then expiring. The terms of the directors will expire upon the election and qualification of successor directors at the annual meeting of stockholders to be held during the&#160;years 2022 for Class&#160;I directors, 2023 for Class&#160;II directors and 2024 for Class&#160;III directors: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">our Class I directors initially will be Dennis Farrar, Marcus Wilson, Pharm.D., Mansoor Raza Mirza, M.D. and Charles D. Kennedy, M.D.;</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">our Class II directors initially will be Elizabeth Canis, Joshua Phillips, Joseph Siletto and Michael F. Minahan; and</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">our Class III directors initially will be Kim Kamdar, Ph.D., Ryan Trimble and Gregory C. Critchfield, M.D., M.S.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our amended and restated certificate of incorporation and amended and restated by-laws will provide that the number of our directors shall be fixed from time to time by a resolution of the majority of our board of directors. Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class shall consist of one third of the board of directors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The division of our board of directors into three classes with staggered three-year terms may delay or prevent stockholder efforts to effect a change of our management or a change in control. See the &#8220;Description of Capital Stock&#8201;&#8212;&#8201;Anti-Takeover Effects of Delaware Law, Our Amended and Restated Certificate of Incorporation and Our Amended and Restated By-Laws&#8221; section of this prospectus for a discussion of these and other anti-takeover provisions found in our amended and restated certificate of incorporation and amended and restated by-laws, which will become effective immediately prior to the completion of this offering. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Committees of the Board of Directors</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our board of directors has an audit committee and a compensation committee and intends to establish a nominating and corporate governance committee, each of which will have the composition and responsibilities described below upon completion of this offering. Each of the below committees will have a written charter approved by our board of directors, effective upon completion of this offering. Each of the committees will report to our board of directors as such committee deems appropriate and as our board of directors may request. Upon completion of this offering, copies of each charter will be posted on the investor relations section of our website. Members will serve on these committees until their resignation or until otherwise determined by our board of directors. In addition, from time to time, special committees may be established under the direction of our board of directors when necessary to address specific issues. </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Audit Committee</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Effective upon completion of this offering, our audit committee will be comprised of Joshua Phillips, Ryan Trimble and Charles D. Kennedy, M.D. with Joshua Phillips serving as chair of the committee. Our board of directors has determined that each member of the audit committee has sufficient knowledge in financial and auditing matters to serve on the audit committee and except with respect to Dr. Kennedy, meets the independence requirements of Rule&#160;10A-3 under the Exchange Act and the applicable Nasdaq Stock Market rules. Our board of directors has determined that Joshua Phillips is an &#8220;audit committee financial expert&#8221; within the meaning of the SEC regulations and the applicable rules of The Nasdaq Stock Market. The audit committee&#8217;s responsibilities upon completion of this offering will include: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">selecting a firm to serve as the independent registered public accounting firm to audit our financial statements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">ensuring the independence of the independent registered public accounting firm; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">discussing the scope and results of the audit with the independent registered public accounting firm, and reviewing, with management and that firm, our interim and year-end operating results; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">establishing procedures for employees to anonymously submit concerns about questionable accounting or audit matters; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">125</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">considering the effectiveness of our internal controls and internal audit function; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">reviewing material related-party transactions or those that require disclosure; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">approving or, as permitted, pre-approving all audit and non-audit services to be performed by the independent registered public accounting firm. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Compensation Committee</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Effective upon completion of this offering, our compensation committee will be comprised of Kim Kamdar, Ph.D. and Dennis Farrar, with Kim Kamdar, Ph.D. serving as chair of the committee. Each member of this committee is a non-employee director, as defined by Rule&#160;16b-3 promulgated under the Exchange Act, and an outside director, as defined pursuant to Section&#160;162(m) of the Internal Revenue Code of 1986, as amended. Our board of directors has determined that each member of the compensation committee is &#8220;independent&#8221; as defined in the rules of The Nasdaq Stock Market. The composition of our compensation committee meets the requirements for independence under the listing standards of The Nasdaq Stock Market, including the applicable transition rules. Our board of directors intends to cause our compensation committee to be comprised of only directors that are independent under the rules of The Nasdaq Stock Market within one year of the date of this prospectus. The compensation committee&#8217;s responsibilities upon completion of this offering will include: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">reviewing and approving, or recommending that our board of directors approve, the compensation of our executive officers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">reviewing and recommending to our board of directors the compensation of our directors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">reviewing and recommending to our board of directors the terms of any compensatory agreements with our executive officers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">administering our stock and equity incentive plans; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">reviewing and approving, or making recommendations to our board of directors with respect to, incentive compensation and equity plans; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">reviewing all overall compensation policies and practices. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Nominating and Corporate Governance Committee</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Effective upon completion of this offering, our nominating and governance committee will be comprised of Kim Kamdar, Ph.D. and Joseph Siletto, with Kim Kamdar, Ph.D. as the chair of the committee. Our board of directors has determined that each member of the nominating and corporate governance committee is &#8220;independent&#8221; as defined in the applicable rules of The Nasdaq Stock Market. The nominating and corporate governance committee&#8217;s responsibilities upon completion of this offering will include: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">identifying and recommending candidates for membership on our board of directors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">recommending directors to serve on board committees; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">reviewing and recommending our corporate governance guidelines and policies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">reviewing proposed waivers of the code of conduct for directors and executive officers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">evaluating, and overseeing the process of evaluating, the performance of our board of directors and individual directors; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">assisting our board of directors on corporate governance matters. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Leadership Structure and Risk Oversight</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our board of directors is currently chaired by Gregory C. Critchfield, M.D., M.S., who also serves as our President and Chief Executive Officer. Our board of directors does not have a policy regarding the separation of the roles of Chief Executive Officer and Chairman of the board of directors, as our board of directors believes it is in our best interest to make that determination based on our position and direction and the membership of the board of directors. Our board of directors has determined that having an employee director serve as Chairman is in the best interest of our stockholders at this time because of the efficiencies achieved in having the role of Chief Executive Officer and Chairman combined, and because the detailed </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">126</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:208pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">knowledge of our day-to-day operations and business that the Chief Executive Officer possesses greatly enhances the decision-making processes of our board of directors as a whole. We have a governance structure in place, including independent directors, designed to ensure the powers and duties of the dual role are handled responsibly. We do not have a lead independent director. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our board of directors oversees the management of risks inherent in the operation of our business and the implementation of our business strategies. Our board of directors performs this oversight role by using several different levels of review. In connection with its reviews of our operations and corporate functions, our board of directors addresses the primary risks associated with those operations and corporate functions. In addition, our board of directors reviews the risks associated with our business strategies periodically throughout the year as part of its consideration of undertaking any such business strategies. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Each of our board committees also oversees the management of our risks that fall within the committee&#8217;s areas of responsibility. In performing this function, each committee has full access to management, as well as the ability to engage advisors. Our Chief Executive Officer reports to the audit committee and is responsible for identifying, evaluating and implementing risk management controls and methodologies to address any identified risks. In connection with its risk management role, our audit committee meets privately with representatives from our independent registered public accounting firm and our Chief Executive Officer. The audit committee oversees the operation of our risk management program, including the identification of the primary risks associated with our business and periodic updates to such risks, and reports to our board of directors regarding these activities. </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Compensation Committee Interlocks and Insider Participation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">None of the members of our compensation committee has at any time during the prior three&#160;years been one of our officers or employees. None of our executive officers currently serves, or in the past fiscal year has served, as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving on our board of directors or compensation committee. For a description of transactions between us and members of our compensation committee and affiliates of such members, please see the &#8220;Certain Relationships and Related Party Transactions&#8221; section of this prospectus. </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Corporate Code of Conduct and Ethics</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We plan to adopt a corporate code of conduct and ethics that applies to all of our employees, officers and directors, including those officers responsible for financial reporting, which will be effective upon completion of this offering. Upon the completion of this offering, our code of business conduct and ethics will be available on our website at </font><font style="font-style:italic;letter-spacing:0.2pt;">https://www.seraprognostics.com/</font>&#8203;<font style="letter-spacing:0.2pt;">. We intend to disclose any amendments to the code, or any waivers of its requirements, on our website or in a Current Report on Form 8-K. </font></div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">127</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tEXCO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EXECUTIVE COMPENSATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Summary Compensation Table</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth information regarding compensation earned with respect to the fiscal year ended December&#160;31, 2020 by our principal executive officer and the two next most highly compensated executive officers who earned more than $100,000 during the fiscal year ended December&#160;31, 2020, and were serving as executive officers as of such date, who are referred to as our named executive officers for 2020. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">To date, the compensation of our named executive officers has consisted of a combination of base salary, bonuses and long-term incentive compensation in the form of stock options. Our named executive officers, like all full-time employees, are eligible to participate in our health and welfare benefit plans. As we transition from a private company to a publicly traded company, we intend to evaluate our compensation values and philosophy and compensation plans and arrangements as circumstances require. </font>
        </div>
        <table style="width:456pt;height:143.45pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8.98pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:171.22pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Name and Principal Position </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center; line-height:8.99pt;">
                <font style="letter-spacing:-0.16pt;">Salary</font>
                <br >
                <font style="letter-spacing:-0.16pt;">($) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center; line-height:8.99pt;">
                <font style="letter-spacing:-0.16pt;">Option </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Awards</font>
                <br >
                <font style="letter-spacing:-0.16pt;">($)(1) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center; line-height:8.99pt;">
                <font style="letter-spacing:-0.16pt;">Non-Equity </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Incentive Plan </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Compensation</font>
                <br >
                <font style="letter-spacing:-0.16pt;">($) (2) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center; line-height:8.99pt;">
                <font style="letter-spacing:-0.16pt;">All Other </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Compensation </font>
                <br >
                <font style="letter-spacing:-0.16pt;">($) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center; line-height:8.99pt;">
                <font style="letter-spacing:-0.16pt;">Total </font>
                <br >
                <font style="letter-spacing:-0.16pt;">($) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:171.22pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt; text-align:justify;">
                <font style="letter-spacing:0.2pt;">Gregory C. Critchfield, M.D., M.S.</font>
                <br >
                <font style="font-style:italic;letter-spacing:0.2pt;">President and Chief Executive Officer</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2020</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">400,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">410,727</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.31pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">113,831</td>
            <td style="padding:0pt;padding-left:7.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.31pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">924,558</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:171.22pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt; text-align:justify;">
                <font style="letter-spacing:0.2pt;">Nadia Altomare</font>
                <br >
                <font style="font-style:italic;letter-spacing:0.2pt;">Chief Commercial Officer</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2020</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">340,616</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">78,901</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.31pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">70,000</td>
            <td style="padding:0pt;padding-left:7.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.31pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">489,517</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:171.22pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt; text-align:justify;">
                <font style="letter-spacing:0.2pt;">John J. Boniface, Ph.D. </font>
                <br >
                <font style="font-style:italic;letter-spacing:0.2pt;">Chief Scientific Officer</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2020</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">316,685</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">136,729</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.31pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">70,000</td>
            <td style="padding:0pt;padding-left:7.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.31pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">523,414</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:171.22pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt; text-align:justify;">
                <font style="letter-spacing:0.2pt;">Garrett K. Lam, M.D. </font>
                <br >
                <font style="font-style:italic;letter-spacing:0.2pt;">Former Chief Medical Officer</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2020</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">364,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">49,060</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.31pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">70,000</td>
            <td style="padding:0pt;padding-left:7.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.31pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">182,000<font style="position:absolute;">(3)</font></td>
            <td style="padding:0pt;padding-left:7.31pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">665,060</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">These amounts represent the aggregate grant date fair value for option awards granted during our fiscal year ended December&#160;31, 2020, computed in accordance with FASB ASC Topic 718. A discussion of the assumptions used in determining grant date fair value may be found in Note 8 to our financial statements. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Amounts represent cash paid for bonuses pursuant to each executive&#8217;s employment agreement during the 12-month period from January&#160;1, 2020 to December&#160;31, 2020. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Dr.&#160;Lam left employment with us on June&#160;19, 2020. This amount represents a separation payment. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Narrative Disclosure to Summary Compensation Table</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:7pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Base Salaries</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Each named executive officer&#8217;s base salary is a fixed component of annual compensation for performing specific duties and functions, and has been established by our board of directors taking into account each individual&#8217;s role, responsibilities, skills and expertise. Base salaries are reviewed annually, typically in connection with our annual performance review process, approved by our board of directors and adjusted from time to time to realign salaries with market levels after taking into account individual responsibilities, performance and experience. During 2020, the annual base salaries for Dr.&#160;Critchfield, Ms.&#160;Altomare, Dr.&#160;Boniface and Dr.&#160;Lam were $400,000, $340,000, $316,000 and $364,000, respectively. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Annual Bonus</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our Annual Incentive Plan is designed to reward the achievement of corporate objectives and individual performances. The eligibility to participate in the Annual Incentive Plan will be granted by the Board to director-level employees and above, with annual awards granted based on assessments of both individual and company performance measure against prospectively determined objectives. The annual target cash incentives based upon an employee&#8217;s annual cash compensation will be determined by position level as follows: 40% for CEO; 30% for other C-level employees (with the exception of Ms.&#160;Altomare, whose annual award level equals 40%); 20-25% for VP-level employees; and 15% for Department director-level employees. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">128</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For the fiscal year ended December&#160;31, 2020, each of our named executive officers was eligible to earn an annual bonus based on the achievement of certain pre-determined corporate performance objectives. During 2020, the target annual bonuses for Dr.&#160;Critchfield, Ms.&#160;Altomare, Dr.&#160;Boniface and Dr.&#160;Lam, were 40%, 40%, 30% and 30% of their base salary, respectively. The annual bonus earned by each named executive officer with respect to the fiscal year ended December&#160;31, 2020 is reported under the &#8220;Non-Equity Incentive Plan&#160;Compensation&#8221; column in the &#8220;2020 Summary Compensation Table&#8221; above. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Equity Compensation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Although we do not have a formal policy with respect to the grant of equity incentive awards to our executive officers, we believe that equity grants provide our executives with a strong link to our long-term performance, create an ownership culture and help to align the interests of our executives and our stockholders. In addition, we believe that equity grants promote executive retention because they incentivize our executive officers to remain in our employment during the vesting period. Accordingly, our board of directors periodically reviews the equity incentive compensation of our named executive officers and may grant equity incentive awards to them from time to time. Our named executive officers have been granted certain options to purchase shares of our Class A common stock, as described in more detail in the &#8220;Outstanding Equity Awards at 2020 Fiscal Year-end&#8221; table below. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Employment Agreements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have entered into executive employment agreements with each of our named executive officers in connection with their employment with us, the material terms of which are described below. These executive employment agreements provide for &#8220;at will&#8221; employment, subject to certain notice and severance requirements. Each of the named executive officers was also required to enter into restrictive covenant agreements which obligate each named executive officer to refrain from disclosing any of our proprietary information received during the course of employment and to assign to us any inventions conceived or developed during the course of employment. Such restrictive covenant agreements also contain non-competition and non-solicitation protections in our favor. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Gregory C. Critchfield, M.D., M.S.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We entered into an employment agreement dated as of November&#160;8, 2011 with Dr.&#160;Critchfield with respect to his service as our Chairman and Chief Executive Officer. Under the terms of the agreement, Dr.&#160;Critchfield was entitled to an initial annual base salary of $300,000, subject to increase by our board of directors or the Compensation Committee. Dr.&#160;Critchfield&#8217;s base salary for the fiscal year ended December&#160;31, 2020 was $400,000. In connection with the employment, Dr.&#160;Critchfield was granted a stock option to purchase 734,900 shares of our Class A common stock. Dr.&#160;Critchfield is also eligible to participate in our equity incentive plans and is entitled to participate in our health insurance and other employee benefit plans. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Dr.&#160;Critchfield&#8217;s employment agreement provides that in the event that (1)&#160;Dr.&#160;Critchfield&#8217;s employment is terminated other than for cause, death or disability or (2)&#160;Dr.&#160;Critchfield terminates his own employment for Good Reason, as defined in the agreement, he is entitled to receive the following severance benefits: (i)&#160;on the 60th day following the termination, the Company shall pay a lump sum amount equal to 12&#160;months of his base salary at the rate in effect at the time of the termination; (ii)&#160;a pro-rata bonus for the year in which Dr.&#160;Critchfield&#8217;s employment is terminated, provided that the Company then has a bonus plan in place; and (iii)&#160;any unvested equity will immediately be forfeited and any vested stock options will be exercisable for the balance of the remaining term of the original option grant. If the Company terminates Dr.&#160;Critchfield&#8217;s employment due to death or disability, the Company will provide health insurance reimbursement until the earliest of (x)&#160;the close of the 12 month period following Dr.&#160;Critchfield&#8217;s termination date, and (y)&#160;the date when Dr.&#160;Critchfield becomes eligible to receive health insurance coverage in connection with new employment or self-employment. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Nadia F. Altomare</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We entered into an employment agreement dated as of May&#160;15, 2017 with Ms.&#160;Altomare with respect to her service as our Chief Commercial Officer. Under the terms of the agreement, Ms.&#160;Altomare was entitled to an initial annual base salary of $320,000, subject to increase by our board of directors or the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">129</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Compensation Committee. Ms.&#160;Altomare&#8217;s base salary for the fiscal year ended December&#160;31, 2020 was $340,000. In connection with the employment, Ms.&#160;Altomare was granted a stock option to purchase 450,000 shares of the our Class A common stock. Ms.&#160;Altomare is also eligible to participate in our equity incentive plans and is entitled to participate in our health insurance and other employee benefit plans. Ms.&#160;Altamore is entitled to a bonus target of 40% of her base salary, prorated for time of service. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Ms.&#160;Altomare&#8217;s employment agreement provides that in the event that (1)&#160;Ms.&#160;Altomare&#8217;s employment is terminated other than for cause, death or disability or (2)&#160;Ms.&#160;Altomare terminates her own employment for Good Reason, as defined in the agreement, on the 60th day following the termination, (i)&#160;she is entitled to receive a lump sum amount equal to 6&#160;months of her base salary at the rate in effect at the time of the termination, and (ii)&#160;the Company will provide health insurance reimbursement until the earliest of (x)&#160;the close of the 12 month period following Ms.&#160;Altomare&#8217;s termination date, and (y)&#160;the date when Ms.&#160;Altomare becomes eligible to receive health insurance coverage in connection with new employment or self-employment. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the event that Ms.&#160;Altomare&#8217;s employment is terminated due to her death or disability and if the Company does not provide any insurance benefits payable to Ms.&#160;Altomare or her beneficiaries upon her death or disability and the Company has previously, but not necessarily in the then applicable calendar year, achieved $10,000,000 in annual gross revenue in a calendar year, then the Company shall pay Ms.&#160;Altomare a lump sum amount equal to 6&#160;months of the base salary at the rate in effect at the time of the termination of employment. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">John J. Boniface, Ph.D.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We entered into an employment agreement dated as of March&#160;14, 2012 with Dr.&#160;Boniface with respect to his service as our Chief Scientific Officer. Under the terms of the agreement, Dr.&#160;Boniface was entitled to an initial annual base salary of $225,000, subject to increase by our board of directors or the Compensation Committee. Dr.&#160;Boniface&#8217;s base salary for the fiscal year ended December&#160;31, 2020 was $316,000. Under the terms of the agreement, in connection with the second tranche milestone as determined by the purchasers of the Series&#160;A-2 convertible preferred stock, Dr.&#160;Boniface was entitled to receive a bonus of $50,000, or such greater amount as determined by the Board. In connection with the employment, Dr.&#160;Boniface was granted a stock option to purchase 158,000 shares of our Class A common stock. Dr.&#160;Boniface is also eligible to participate in our equity incentive plans and is entitled to participate in our health insurance and other employee benefit plans. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Dr.&#160;Boniface&#8217;s employment agreement provides that in the event that (1)&#160;Dr.&#160;Boniface&#8217;s employment is terminated other than for cause, death or disability or (2)&#160;Dr.&#160;Boniface terminates his own employment for Good Reason, on the 60th day following the termination, (i)&#160;he is entitled to receive a lump sum amount equal to 6&#160;months of the base salary at the rate in effect at the time of the termination, and (ii)&#160;the Company will provide health insurance reimbursement until the earliest of (x)&#160;the close of the 12 month period following Dr.&#160;Boniface&#8217;s termination date, and (y)&#160;the date when Dr.&#160;Boniface becomes eligible to receive health insurance coverage in connection with new employment or self-employment. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the event that Dr.&#160;Boniface&#8217;s employment is terminated due to his death or disability and if the Company does not provide any insurance benefits payable to Dr.&#160;Boniface or his beneficiaries upon his death or disability and the Company has previously, but not necessarily in the then applicable calendar year, achieved $10,000,000.00 in annual gross revenue in a calendar year, then the Company shall pay Dr.&#160;Boniface&#8217;s a lump sum amount equal to 6&#160;months of the base salary at the rate in effect at the time of the termination of employment. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Garrett K. Lam, M.D.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We entered into an employment agreement dated as of June&#160;13, 2018 with Dr.&#160;Lam with respect to his service as our Chief Medical Officer. Dr.&#160;Lam&#8217;s employment by the Company ended on June&#160;19, 2020. Under the terms of the agreement, Dr.&#160;Lam was entitled to an initial annual base salary of $350,000, subject to increase by our board of directors and the Compensation Committee. Dr.&#160;Lam&#8217;s base salary for the fiscal year ended December&#160;31, 2020 was $364,000. In connection with the employment, Dr.&#160;Lam was granted a stock option to purchase 375,000 shares of our Class A common stock. Dr.&#160;Lam was also eligible to participate </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">130</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:159.31pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">in our equity incentive plans and was entitled to participate in our health insurance and other employee benefit plans. Our Annual Incentive Plan provided for a bonus target of 30% of Dr.&#160;Lam&#8217;s base salary, prorated for time of service. Dr.&#160;Lam&#8217;s employment agreement provided that in the event that (1)&#160;Dr.&#160;Lam&#8217;s employment was terminated other than for cause, death or disability or (2)&#160;Dr.&#160;Lam terminated his own employment for Good Reason, on the 60th day following the termination, (i)&#160;he was entitled to receive a lump sum amount equal to 6&#160;months of the base salary at the rate in effect at the time of the termination of employment, and (ii)&#160;the Company would provide health insurance reimbursement until the earliest of (x)&#160;the close of the 12 month period following Dr.&#160;Lam&#8217;s termination date, and (y)&#160;the date when Dr.&#160;Lam became eligible to receive health insurance coverage in connection with new employment or self-employment. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">In the event that Dr.&#160;Lam&#8217;s employment was terminated due to his death or disability and if the Company did not provide any insurance benefits payable to Dr.&#160;Lam or his beneficiaries upon his death or disability and the Company had previously, but not necessarily in the then applicable calendar year, achieved $10,000,000 in annual gross revenue in a calendar year, then the Company would have been required to pay Dr.&#160;Lam a lump sum amount equal to 6&#160;months of the base salary at the rate in effect at the time of the termination of employment. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">On June&#160;19, 2019, the Company entered into a separation agreement with Dr.&#160;Lam. Under the separation agreement, following the separation date, the Company agreed to pay Dr.&#160;Lam for accrued but unused vacation and final wages through the separation date. In addition, in lieu of any severance payments or benefits described in his employment agreement, the Company agreed to pay severance compensation of $182,000 in a lump sum, and reimbursement for monthly COBRA premiums for up to 12&#160;months or until the date Dr.&#160;Lam becomes eligible to receive health insurance coverage in connection with new employment or self-employment. At the time of the separation, Dr.&#160;Lam owned no shares of Class A common stock or Class B common stock and had options to acquire 490,000 shares of Class A common stock, of which options to acquire 318,750 shares of Class A common stock remained unvested and whose vesting partially accelerated pursuant to Dr.&#160;Lam&#8217;s employment agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">&#8220;Good Reason&#8221; means (A)&#160;a material breach by the Company of any of the provisions; (B)&#160;assignment of Employee to a role, duties or responsibilities materially inconsistent with that of a Chief Executive Officer; (C)&#160;any circumstances caused by the Company that would require Employee to move his principal location of employment in excess of 45 miles from Company&#8217;s current offices in Salt Lake City, Utah; or (D)&#160;an involuntary material reduction of Employee&#8217;s then current Base Salary other than a reduction proportionately affecting all of the Company&#8217;s other senior-level executive employees. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Outstanding Equity Awards at December&#160;31, 2020</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table shows grants of stock options outstanding on the last day of the fiscal year ended December&#160;31, 2020, to each of the executive officers named in the Summary Compensation Table. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">131</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:352.5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:243.15pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Option Awards(1)(2) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.98pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:2.597pt 0pt 2.478pt 0pt; width:243.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Name </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.597pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center; line-height:8.99pt;">
                <font style="letter-spacing:-0.16pt;">Number of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Securities</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Underlying</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Unexercised</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Options (#)</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Exercisable </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.597pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center; line-height:8.99pt;">
                <font style="letter-spacing:-0.16pt;">Number of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Securities</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Underlying</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Unexercised</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Options (#)</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Unexercisable </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.597pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Option</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Exercise</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Price ($) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.597pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Option</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Expiration</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Date </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:243.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Gregory C. Critchfield, M.D., M.S. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">20</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">100.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">3/7/2021</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:243.15pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">40</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">100.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">4/29/2021</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:243.15pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">421,052</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">26,040</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">0.95</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5/28/2027</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:243.15pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">177,876</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">0.95</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5/28/2027</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:243.15pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">363,887</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">0.85</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2/27/2030</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:243.15pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">200,250</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">397,063</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">0.85</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2/27/2030</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:243.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Nadia Altomare </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">315,789</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">46,875</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">0.95</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5/18/2027</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:243.15pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">87,336</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">0.95</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5/18/2027</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:243.15pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">146,548</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">0.85</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2/27/2030</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:243.15pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">38,542</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">0.85</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2/27/2030</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:243.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">John J. Boniface, Ph.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">52,000</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">0.35</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12/14/2021</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:243.15pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">158,000</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">0.35</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">3/12/2022</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:243.15pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">12,150</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">0.35</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">9/10/2022</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:243.15pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">152,564</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">0.44</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12/28/2024</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:243.15pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">225,030</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">9,784</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">0.95</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5/18/2027</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:243.15pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">43,917</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">1,909</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">0.95</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">6/26/2027</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:243.15pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">39,232</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">253,571</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">0.85</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2/27/2030</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:243.15pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">27,497</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">0.85</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2/27/2030</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:243.15pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Garrett K. Lam, M.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">N/A</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.4pt; width:456pt;">
          <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Each of the outstanding equity awards in the table above was granted pursuant to our 2011 Equity Incentive Plan. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">For all options granted at hire, the vesting is as follows: 25% of the Shares subject to the Option shall vest on the first anniversary of the Vesting Start Date and 1/36 of the remaining Shares subject to the Option shall vest at the end of each one (1)&#160;month period thereafter, provided that the number of Shares vesting on each date shall be rounded down to the nearest whole number, whilst the number of Shares vesting on the final date shall be the remaining unvested balance of the Shares. For subsequent options granted, the shares shall vest on a monthly basis for four (4)&#160;years. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Compensation Risk Assessment</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe that although a portion of the compensation provided to our executive officers and other employees is performance-based, our executive compensation program does not encourage excessive or unnecessary risk taking. This is primarily due to the fact that our compensation programs are designed to encourage our executive officers and other employees to remain focused on both short-term and long-term strategic goals. As a result, we do not believe that our compensation programs are reasonably likely to have a material adverse effect on us. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Equity Compensation Plans</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our equity compensation plans were established to attract, retain and motivate our employees, officers, directors, consultants, agents, advisors and independent contractors by providing them with the opportunity to acquire a proprietary interest in us and to align their interests and efforts with the long-term interests of our stockholders. On November&#160;8, 2011, the board of directors adopted our 2011 Employee, Director and Consultant Equity Incentive Plan (the &#8220;2011 Plan&#8221;) and on &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2021, the board of directors </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">132</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">adopted the 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221; and collectively, the &#8220;Plans&#8221;). The Plans provide for, among other things, grants of restricted stock&#160;units, stock options, restricted stock and other stock-based awards to employees, directors, consultants and other individuals who provide services to us and our affiliates. As of &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2021, we have &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares of our Class A common stock reserved for issuance under the 2021 Plan. Since our 2021 Plan has been approved by our stockholders, we do not intend to make any additional grants under the 2011 Plan. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Eligibility</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Plans allow for grants, under the direction of the board of directors or compensation committee, as the plan administrator, of stock options, stock appreciation rights, restricted and unrestricted stock awards, restricted stock&#160;units and other stock or equity-related cash-based awards to employees, consultants and directors who, in the opinion of the plan administrator, are in a position to make a significant contribution to our long-term success. All employees, directors and consultants of the Company and its affiliates are eligible to participate in the Plans. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Shares Available for Issuance</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Subject to the provisions of our 2021 Plan, the number of shares available for issuance under the 2021 Plan will be increased on January&#160;1 of each year, beginning on January&#160;1, 2022, and ending on January&#160;2, 2031, in an amount equal to the lesser of (i)&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;% of the outstanding shares of our Class A common stock on such date or (ii)&#160;such number of shares determined by the plan administrator. Generally, shares of our Class A common stock reserved for awards under the Plans that lapse or are forfeited will be added back to the share reserve available for future awards under the 2021 Plan. However, shares delivered to or withheld to pay withholding taxes or any applicable exercise price will not be available for issuance. In addition, any shares repurchased on the open market using exercise price proceeds will not be available for issuance. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Stock Options</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Stock options granted under the 2021 Plan may either be incentive stock options, which are intended to satisfy the requirements of Section&#160;422 of the Code, or non-qualified stock options, which are not intended to meet those requirements. Incentive stock options may be granted to employees of the Company and its affiliates, and the aggregate fair market value of a share of our Class A common stock determined at the time of grant with respect to incentive stock options that are exercisable for the first time by a participant during any calendar year may not exceed $100,000. Non-qualified options may be granted to employees, directors and consultants of the Company and its affiliates. The exercise price of a stock option may not be less than 100% of the fair market value of our Class A common stock on the date of grant, and the term of the option may not be longer than ten&#160;years. If an incentive stock option is granted to an individual who owns more than 10% of the combined voting power of all classes of our capital stock, the exercise price may not be less than 110% of the fair market value of our Class A common stock on the date of grant and the term of the option may not be longer than five&#160;years. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Award agreements for stock options include rules for exercise of the stock options after termination of service. Options may not be exercised unless they are vested, and no option may be exercised after the end of the term set forth in the award agreement. Generally, stock options will be exercisable for three&#160;months after termination of service for any reason other than death or total and permanent disability, and for one year after termination of service on account of death or total and permanent disability, but will not be exercisable if the termination of service was due to cause. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Restricted Stock</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Restricted stock is Class A common stock that is subject to restrictions, including a prohibition against transfer and a substantial risk of forfeiture, until the end of a &#8220;restricted period&#8221; during which the grantee must satisfy certain time or performance-based vesting conditions. If the grantee does not satisfy the vesting conditions by the end of the restricted period, the restricted stock is forfeited. During the restricted period, the holder of restricted stock has the rights and privileges of a regular stockholder, except that generally dividend equivalents may accrue but will not be paid during the restricted period, and the restrictions set forth in the applicable award agreement apply. For example, the holder of restricted stock may vote the restricted shares, but may not sell the shares until the restrictions are lifted. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Restricted Stock Units</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Restricted stock&#160;units are phantom shares that vest in accordance with terms and conditions established by the plan administrator and when the applicable restrictions lapse, the grantee will be entitled to receive a payout in cash, shares or a combination thereof based on the number of restricted stock&#160;units as specified in the award agreement. Dividend equivalents may accrue but will not be </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">133</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">paid prior to and only to the extent that, the restricted stock unit award vests. The holder of restricted stock&#160;units does not have the rights and privileges of a regular stockholder, including the ability to vote the restricted stock&#160;units. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Other Stock-Based Awards and Performance-Based Awards</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The 2021 Plan also authorizes the grant of other types of stock-based compensation including, but not limited to stock appreciation rights and unrestricted stock awards. The plan administrator may award such stock-based awards subject to such conditions and restrictions as it may determine. We may grant an award conditioned on satisfaction of certain performance criteria. Such performance-based awards also include performance-based restricted shares and restricted stock&#160;units. Any dividends or dividend equivalents payable or credited to a participant with respect to any unvested performance-based award will be subject to the same performance goals as the shares or&#160;units underlying the performance-based award. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Plan&#160;Administration</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;In accordance with the terms of the Plans, the board of directors may authorize the compensation committee to administer the Plans. The compensation committee may delegate part of its authority and powers under the Plans to one or more directors and/or officers, but only the compensation committee can make awards to participants who are subject to the reporting and other requirements of Section&#160;16 of the Exchange Act. In accordance with the provisions of the Plans, the plan administrator determines the terms of awards, including which employees, directors and consultants will be granted awards, the number of shares subject to each award, the vesting provisions of each award, the termination or cancellation provisions applicable to awards, and all other terms and conditions upon which each award may be granted in accordance with the Plans. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, the plan administrator may, in its discretion, amend any term or condition of an outstanding award provided (i)&#160;such term or condition as amended is permitted by the applicable Plan and does not require stockholder approval under the rules of the Nasdaq Stock Market, and (ii)&#160;any such amendment will be made only with the consent of the participant to whom such award was made, if the amendment is adverse to the participant unless such amendment is required by applicable law or necessary to preserve the economic value of such award. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Stock Dividends and Stock Splits</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;If our Class A common stock is subdivided or combined into a greater or smaller number of shares or if we issue any shares of Class A common stock as a stock dividend, the number of shares of Class A common stock deliverable upon exercise of an option issued or upon issuance of an award will be appropriately increased or decreased proportionately, and appropriate adjustments will be made in the exercise price per share of stock options or purchase price, if any, and performance goals applicable to performance-based awards, if any, to reflect such subdivision, combination or stock dividend. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Corporate Transactions</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Upon a merger or other reorganization event, the board of directors, may, in its sole discretion, take any one or more of the following actions pursuant to the Plans, as to some or all outstanding awards: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">provide that all outstanding options will be assumed or substituted by the successor corporation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">upon written notice to a participant provide that the participant&#8217;s unexercised options will terminate immediately prior to the consummation of such transaction unless exercised by the participant within a specified number of days of such notice; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">in the event of a merger pursuant to which holders of our Class A common stock will receive a cash payment for each share surrendered in the merger, make or provide for a cash payment to option holder participants equal to the difference between the merger price times the number of shares of our Class A common stock subject to such outstanding options, and the aggregate exercise price of all such outstanding options, in exchange for the termination of such options; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">with respect to other stock awards, provide that outstanding awards will be assumed or substituted by the successor corporation, become realizable or deliverable, or restrictions applicable to an award will lapse, in whole or in part, prior to or upon the merger or reorganization event; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">with respect to stock awards, and in lieu of any of the foregoing, provide that, upon consummation of the transaction, each outstanding stock award will be terminated in exchange for payment of </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">134</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:40pt; width:416pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">an amount equal to the consideration payable upon consummation of such transaction to a holder of the number of shares of our Class A common stock comprising such award (to the extent such stock grant is no longer subject to any forfeiture or repurchase rights then in effect or, at the discretion of the board of directors or an authorized committee, all forfeiture and repurchase rights being waived upon such transaction); and </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.41pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">pursuant to the 2021 Plan, upon consummation of a Corporate Transaction, to the extent not assumed or substituted by the successor or cashed out, the outstanding awards will terminate. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Amendment and Termination</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The Plans may be amended by our stockholders. The Plans may also be amended by the board of directors or the compensation committee, provided that any amendment which is of a scope that requires stockholder approval as required by (i)&#160;the rules of the Nasdaq Stock Market or (ii)&#160;for any other reason, is subject to obtaining such stockholder approval. However, no such action may adversely affect any rights under any outstanding award without the holder&#8217;s consent unless such amendment is required by applicable law or necessary to preserve the economic value of such award. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Duration of Plans</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The 2011 Plan will expire by its terms on November&#160;8, 2021 and the 2021 Plan will expire by its terms on&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;, 2031. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">2021 Employee Stock Purchase Plan</font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Our 2021 Employee Stock Purchase Plan, or our ESPP, was adopted by our board of directors in &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;, approved by our stockholders in &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; and became effective on the date immediately prior to the date on which the registration statement of which this prospectus is part was declared effective by the SEC. The ESPP is intended to qualify as an &#8220;employee stock purchase plan&#8221; within the meaning of Section 423 of the Code. Our ESPP initially reserves and authorizes the issuance of up to a total of &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of Class A common stock to participating employees. Our ESPP provides that the number of shares reserved and available for issuance will automatically increase on each January 1, beginning on January 1, 2022 and ending on January 1, 2031, by the lesser of (i) &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of Class A common stock, (ii)&#160;0.5% of the outstanding shares of Class A common stock on the immediately preceding December 31 or (iii) such lesser number of shares as determined by the administrator of our ESPP. This number is subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization.</font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">All employees whose customary employment is for more than 20 hours per week are eligible to participate in our ESPP. Any employee who owns five percent or more of the voting power or value of our shares of Class A common stock is not eligible to purchase shares under our ESPP. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may make one or more offerings each year to our employees to purchase shares under our ESPP. Except as the administrator otherwise determines, offerings will usually begin on each January 1 and July 1 and will continue for six-month periods, referred to as offering periods. Each eligible employee may elect to participate in any offering by submitting an enrollment form at least 15 days before the relevant offering date. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Each employee who is a participant in our ESPP may purchase shares by authorizing payroll deductions of up to 15% of his or her eligible compensation during an offering period. Unless the participating employee has previously withdrawn from the offering, his or her accumulated payroll deductions will be used to purchase shares of Class A common stock on the last business day of the offering period at a price equal to 85% of the fair market value of the shares on the first business day or the last business day of the offering period, whichever is lower, provided that the administrator may, at the start of each offering, set a lesser maximum number of shares of Class A common stock that may be purchased by any one employee during each offering period. In addition, under applicable tax rules, an employee may purchase no more than $25,000 worth of shares of Class A common stock, valued at the start of the purchase period, under our ESPP in any calendar year. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The accumulated payroll deductions of any employee who is not a participant on the last day of an offering period will be refunded. An employee&#8217;s rights under our ESPP terminate upon voluntary withdrawal from the plan or when the employee ceases employment with us for any reason. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our ESPP may be terminated or amended by our board of directors at any time. An amendment that increases the number of shares of Class A common stock authorized under our ESPP and certain other amendments require the approval of our stockholders.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">135</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:346pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Other Compensation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">All of our current named executive officers are eligible to participate in our employee benefit plans, including our medical, dental, vision, life and disability insurance plans, in each case on the same basis as all of our other employees. We generally do not provide perquisites or personal benefits to our named executive officers, except in limited circumstances. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">401(k) Plan</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We maintain a 401(k) plan for employees. The 401(k) plan is intended to qualify under Section&#160;401(k) of the Internal Revenue Service Code of 1986, as amended, so that contributions to the 401(k) plan by employees or by us, and the investment earnings thereon, are not taxable to the employees until withdrawn from the 401(k) plan, and so that contributions by us, if any, will be deductible by us when made. Under the 401(k) plan, employees may elect to reduce their current compensation by up to the statutorily prescribed annual limit and to have the amount of such reduction contributed to the 401(k) plan. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Rule&#160;10b5-1 Sales Plans</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our directors and executive officers may adopt written plans, known as Rule&#160;10b5-1 plans, in which they will contract with a broker to buy or sell shares of our Class A common stock on a periodic basis. Under a Rule&#160;10b5-1 plan, a broker executes trades pursuant to parameters established by the director or officer when entering into the plan, without further direction from the director or officer. The director or officer may amend or terminate the plan in limited circumstances. Our directors and executive officers may also buy or sell additional shares of our Class A common stock outside of a Rule&#160;10b5-1 plan when they are not in possession of material, nonpublic information. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">136</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDICO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:193.91pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DIRECTOR COMPENSATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We did not pay any compensation, make any equity awards or non-equity awards to or pay any other compensation to any of the non-employee members of our board of directors in 2020 for their services as members of the board of directors. We have historically reimbursed our non-employee directors for reasonable travel and out-of-pocket expenses incurred in connection with attending board of director and committee meetings. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Non-Employee Director Compensation Policy</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We plan to adopt a policy with respect to the compensation payable to our non-employee directors, which will become effective upon the completion of this offering. Under this policy, each non-employee director will be eligible to receive compensation for his or her service consisting of annual cash retainers and equity awards. Dr.&#160;Critchfield will not receive separate compensation from us for serving as a member of our board. Our non-employee directors will receive the following annual retainers for their service: </font>
        </div>
        <table style="width:456pt;height:128.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt; width:264pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Position </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt; width:180pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Retainer </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:264pt;">
              <font style="letter-spacing:0.2pt;">Board Member </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:180pt;">
              <font style="letter-spacing:0.2pt;">$ </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:264pt;">
              <font style="letter-spacing:0.2pt;">Board Chairperson </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:180pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:264pt;">
              <font style="letter-spacing:0.2pt;">Audit Committee Chair </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:180pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:264pt;">
              <font style="letter-spacing:0.2pt;">Compensation Committee Chair </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:180pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:264pt;">
              <font style="letter-spacing:0.2pt;">Nominating and Corporate Governance Committee Chair </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:180pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:264pt;">
              <font style="letter-spacing:0.2pt;">Audit Committee Member </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:180pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:264pt;">
              <font style="letter-spacing:0.2pt;">Compensation Committee Member </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:180pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:264pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Nominating and Corporate Governance Committee Member </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:180pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Equity awards for non-employee directors will consist of (i)&#160;an initial equity award consisting of options to purchase&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of the combined organization&#8217;s Class A common stock, upon first appointment to the board of directors, and (ii)&#160;annual equity awards consisting of options to purchase&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of Class A common stock, vesting 12&#160;months after the grant date. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Directors may be reimbursed for travel, food, lodging and other expenses directly related to their service as directors. Directors are also entitled to the protection provided by their indemnification agreements and the indemnification provisions in the current certificate of incorporation and by-laws, as well as the amended and restated certificate of incorporation and amended and restated by-laws that will become effective upon the completion of this offering. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">137</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tCRAR">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Other than the compensation agreements and other arrangements described under &#8220;Executive Compensation&#8221; and &#8220;Director Compensation&#8221; in this prospectus and the transactions described below, since January&#160;1, 2018, there has not been, and there is not currently proposed, any transaction or series of similar transactions to which we were, or will be, a party in which the amount involved exceeded, or will exceed, $120,000 and in which any director, executive officer, holder of five&#160;percent or more of any class of our capital stock or any member of the immediate family of, or entities affiliated with, any of the foregoing persons, had, or will have, a direct or indirect material interest. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Sales and Purchases of Securities</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:7pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Series&#160;D Financing</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">From July&#160;2019 to February&#160;2020, we issued an aggregate of 8,348,707 shares of Series&#160;D convertible preferred stock to the below related persons at a purchase price of $4.34 per share for aggregate gross cash consideration of $36.2&#160;million and upon the conversion of certain convertible promissory notes held by the below related persons. Concurrently, we issued warrants to purchase an aggregate of 2,099,384 shares of Class A common stock initially exercisable at a price of $4.34 per share and warrants to purchase an aggregate of 2,099,384 shares of Class A common stock initially exercisable at a price of $5.21 per share. During the same period, we issued an aggregate of 3,579,460 shares of Series&#160;D convertible preferred stock upon the conversion of a series of convertible promissory notes previously issued to certain investors. We refer to these transactions collectively as our Series&#160;D Preferred Stock Financing. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The table below sets for the aggregate number and purchase price of shares of Series&#160;D convertible preferred stock issued to our directors, executive officers or holders of more than 5% of our capital stock, or an affiliate or immediate family member thereof: </font>
        </div>
        <table style="width:456pt;height:164.48pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8.98pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:250.06pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Name </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Warrants at </font>
                <br >
                <font style="letter-spacing:-0.16pt;">$4.34 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Warrants at </font>
                <br >
                <font style="letter-spacing:-0.16pt;">$5.21 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Aggregate</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Purchase Price*</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:250.06pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">ATH Holding Company, LLC</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,073,733</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">288,019</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">288,019</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">9,000,000 </td>
            <td style="padding:0pt;padding-left:1.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:250.06pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Entities affiliated with Blue Ox Healthcare Partners SP,&#160;LLC</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#65279;(2)</font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">5,385,946</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">787,731</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">787,731</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.755pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">23,375,000 </td>
            <td style="padding:0pt;padding-left:1.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:250.06pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Chione Ltd.</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(3)</font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">867,634</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">216,909</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">216,909</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">3,264,746 </td>
            <td style="padding:0pt;padding-left:1.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:250.06pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Entities affiliated with Domain Associates</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(4)</font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">524,981</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">131,246</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">131,246</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">2,278,412 </td>
            <td style="padding:0pt;padding-left:1.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:250.06pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">InterWest Partners X, L.P.</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(5)</font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">524,982</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">131,246</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">131,246</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">2,278,419 </td>
            <td style="padding:0pt;padding-left:1.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:250.06pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Laboratory Corporation of America Holdings</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(6)</font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">343,248</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">85,812</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">85,812</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">1,489,696 </td>
            <td style="padding:0pt;padding-left:1.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:250.06pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Entities affiliated with Catalyst Health Ventures, L.P.</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(7)</font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">140,899</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">35,225</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">35,225</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">611,487 </td>
            <td style="padding:0pt;padding-left:1.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:250.06pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Gregory C. Critchfield, M.D., M.S.</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(8)</font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">59,731</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">9,173</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">9,173</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">259,227 </td>
            <td style="padding:0pt;padding-left:1.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:250.06pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">The Trimble Trust</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(9)</font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">73,545</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">13,387</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">13,387</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.755pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">319,185</td>
            <td style="padding:0pt;padding-left:1.755pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.7pt; width:456pt;">
          <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">*</font>
          <br >
        </div>
        <div style=" margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Includes conversion of convertible promissory notes principal and interest into shares of Series&#160;D convertible preferred stock.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:4.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">ATH Holding Company, LLC, or Anthem Holding Company, beneficially owned more than 5% of our outstanding capital stock as a result of the Series&#160;D financing. Elizabeth Canis and Marcus Wilson, Pharm.D., members of our board of directors, are the Vice President, Emerging Businesses &amp; Partnerships, and the CAO of Anthem, an affiliate of Anthem Holding Company, respectively. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:4.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Blue Ox beneficially owned more than 5% of our outstanding capital stock as a result of the Series&#160;D financing. Charles D. Kennedy, M.D., a member of our board of directors, is the Chief Executive Officer and a Managing Partner of Blue Ox. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Chione Ltd., or Chione, beneficially owned more than 5% of our outstanding capital stock as a result of the Series&#160;D financing. Mansoor Raza Mirza, M.D., a member of our board of directors, is the appointed board member of Chione. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">138</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(4)</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Includes holdings of Domain Partners VIII, L.P., or Domain Partners, and DP VIII Associates, L.P., or DP VIII, which beneficially owned more than 5% of our outstanding capital stock as a result of the Series D financing. Kim Kamdar, a member of our board of directors, is Partner at Domain Associates, LLC, the Manager of Domain Partners and DP VIII, and a Member of One Palmer Square Associates VIII, L.L.C., the General Partner of Domain Partners and DP VIII.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(5)</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">InterWest Partners X, L.P., or InterWest Partners, beneficially owned more than 5% of our outstanding capital stock at the time of the Series&#160;D Preferred Stock Financing. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(6)</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Labcorp beneficially holds more than 5% of our outstanding capital stock. Michael F. Minahan, a member of our board of directors, is the Senior VP and General Manager for Integrated Genetics, a division of Labcorp. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(7)</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Joshua Phillips, a member of our board of directors, is the Managing Partner of Catalyst Health Ventures. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(8)</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Gregory C. Critchfield, M.D., M.S. is our Chairman, President and Chief Executive Officer. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(9)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Ryan Trimble, a member of our board of directors, is Trustee of The Trimble Trust</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Series&#160;E Financing</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">From February&#160;to April 2021, we issued an aggregate of 16,744,569 shares of our Series&#160;E convertible preferred stock at a purchase price of $5.99 per share for aggregate gross consideration of $100.3&#160;million, together with warrants to purchase an aggregate of 1,501,502 shares of our Class A common stock, initially exercisable at $9.99 per share. We refer to these transactions collectively as our Series&#160;E Preferred Stock Financing. </font>
        </div>
        <table style="width:456pt;height:107.48pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8.98pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:288.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Name </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Warrants at </font>
                <br >
                <font style="letter-spacing:-0.16pt;">$5.21 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Aggregate</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Purchase Price </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:288.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">ATH Holding Company, LLC</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,504,174</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,501,502</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">15,000,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:288.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Entities affiliated with Blue Ox Healthcare Partners SP, LLC</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(2)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,504,173</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">15,000,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:288.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Entities affiliated with Baker Bros. Advisors LP</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(3)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,921,536</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">17,500,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:288.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Vivo Capital Fund IX, L.P.</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(4)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">3,338,898</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">20,000,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:288.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">aMoon Growth Fund Limited Partnership</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(5)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">3,338,898</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">20,000,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:288.76pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">CHV Investments, LLC</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(6)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">333,890</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2,000,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.4pt; width:456pt;">
          <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Anthem Holding Company beneficially owned more than 5% of our outstanding capital stock as a result of the Series&#160;D financing. Elizabeth Canis and Marcus Wilson, Pharm.D., members of our board of directors, are the Vice President, Emerging Businesses &amp; Partnerships, and the CAO of Anthem, respectively. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Blue Ox beneficially owned more than 5% of our outstanding capital stock as a result of the Series D financing. Charles D. Kennedy, M.D., a member of our board of directors, is the Chief Executive Officer and a Managing Partner of Blue Ox. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Baker Brothers Life Sciences, L.P. and 667, L.P., which are affiliated with Baker Bros. Advisors LP, beneficially owned more than 5% of our outstanding capital stock as a result of the Series E Preferred Stock Financing. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Vivo Capital Fund IX, L.P., or Vivo Capital, beneficially owned more than 5% of our outstanding capital stock as a result of the Series E Preferred Stock Financing. Joseph Siletto, a member of our board of directors, is a Managing Director of Vivo Capital LLC, which is affiliated with Vivo Capital Fund&#160;IX, L.P. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(5)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">aMoon Growth Fund Limited Partnership beneficially owned more than 5% of our outstanding capital stock as a result of the Series E Preferred Stock Financing. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(6)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Joshua Phillips, a member of our board of directors, is the Managing Partner of Catalyst Health Ventures, which is affiliated with CHV Investments, LLC. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">139</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Agreements with Stockholders</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:7pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Anthem Commercialization Agreement</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In February&#160;2021, we entered into the Commercial Collaboration Agreement with Anthem, pursuant to which we will provide PreTRM tests to eligible individuals enrolled in, or serviced or covered by, the health insurance products of Anthem. Anthem agreed to purchase tests from us and will develop appropriate care management programs that incorporate the use of the PreTRM test. The Commercial Collaboration Agreement contains terms, conditions and pricing that are consistent with the terms, conditions and pricing customarily used by Anthem in similar agreements they have with third parties. See the &#8220;Business&#8201;&#8212;&#8201;Anthem Commercial Collaboration Agreement&#8221; section of this prospectus for a further description of this agreement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Anthem Laboratory Services Agreement</font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Effective on November 10, 2020, we entered into a laboratory services agreement with Anthem, called the Laboratory Services Agreement, relating to our provision of PreTRM tests and related services during the course of the PRIME study. The Laboratory Services Agreement contains terms, conditions and pricing that are consistent with the terms, conditions and pricing customarily used by Anthem in similar agreements they have with third parties. See the &#8220;Business&#8201;&#8212;&#8201;Anthem Laboratory Services Agreement&#8221; section of this prospectus for a further description of this agreement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Blue Ox Agreement</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In February&#160;2021, we entered into a consulting agreement with Blue Ox, pursuant to which Blue Ox will provide consulting services to effect the strategic rollout of the PreTRM test on Anthem&#8217;s network, as specified in the Commercial Collaboration Agreement with Anthem, to help establish widespread insurance coverage for the PreTRM test. The consulting agreement with Blue Ox contains terms, conditions and pricing that are consistent with the terms, conditions and pricing customarily used by Blue Ox in similar agreements they have with third parties. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Labcorp Agreement</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In January&#160;2021, we entered into a commercialization agreement with Labcorp, pursuant to which we appointed Labcorp as a distributor of the PreTRM test in the field of prediction of a patient&#8217;s likelihood to deliver a baby at less than 37 weeks&#8217; gestation in the United States. Under the agreement, we may also engage Labcorp to perform certain sample collection, processing, and shipment services. The commercialization agreement with Labcorp contains terms, conditions and pricing that are consistent with the terms, conditions and pricing customarily used by Labcorp in similar agreements they have with third parties. See the &#8220;Business&#8201;&#8212;&#8201;Labcorp Agreement&#8221; section of this prospectus for a further description of this agreement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Investors&#8217; Rights, Voting and Restricted Stock Agreements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In connection with our Series&#160;E Preferred Stock Financing, we entered into investors&#8217; rights, voting and right of first refusal and co-sale agreements containing registration rights, information rights, voting rights and rights of first refusal, among other things, with certain holders of our convertible preferred stock and certain holders of our Class A common stock and Class B common stock. These stockholder agreements will terminate upon the closing of this offering, except for the registration rights granted under our investors&#8217; rights agreement, as more fully described in &#8220;Description of Capital Stock&#8201;&#8212;&#8201;Registration Rights.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Baker Brothers Letter Agreement</font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to a letter agreement with Baker Bros., from and after the closing of this offering, at any time that Baker Bros. beneficially owns shares or other equity securities representing at least 4% of our then-outstanding total voting power, it is entitled to nominate an Investor Designee to serve as a director on our board of directors. We are required to include the Investor Designee in the slate of nominees recommended to our stockholders for election as our directors at each annual or special meeting of our stockholders at which directors are to be elected. Baker Bros. is restricted from exercising this right during certain periods of </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">140</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:340pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">time. As of June&#160;1, 2021, Baker Bros. had not exercised its rights to nominate an Investor Designee to serve as a director on our board of directors. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Indemnification Agreements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Prior to the closing of this offering, we intend to enter agreements to indemnify our directors and certain executive officers. These agreements will, among other things, require us to indemnify these individuals for certain expenses (including attorneys&#8217; fees), judgments, fines and settlement amounts reasonably incurred by such person in any action or proceeding, including any action by or in our right, on account of any services undertaken by such person on behalf of our company or that person&#8217;s status as a member of our board of directors to the maximum extent allowed under Delaware law. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Policies and Procedures for Related Party Transactions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In connection with this offering, we plan to adopt a written policy, effective upon completion of this offering, that requires all future transactions between us and any director, executive officer, holder of 5% or more of any class of our capital stock or any member of the immediate family of, or entities affiliated with, any of them, or any other related persons, as defined in Item&#160;404 of Regulation&#160;S-K, or their affiliates, in which the amount involved is equal to or greater than $120,000, be approved in advance by our audit committee. Any request for such a transaction must first be presented to our audit committee for review, consideration and approval. In approving or rejecting any such proposal, our audit committee will consider the relevant facts and circumstances available and deemed relevant to the audit committee, including, but not limited to, the extent of the related party&#8217;s interest in the transaction, and whether the transaction is on terms no less favorable to us than terms we could have generally obtained from an unaffiliated third party under the same or similar circumstances. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">141</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPRST">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:195.21pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PRINCIPAL STOCKHOLDERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth certain information with respect to the beneficial ownership of our Class&#160;A common stock and Class B common stock as of April 30, 2021 for: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">each person or group of affiliated persons known by us to be the beneficial owner of more than five&#160;percent of our capital stock; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">each of our directors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">each of our named executive officers; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">all of our current directors and executive officers as a group. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">To the extent that the underwriters sell more than&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;shares in this offering, the underwriters have the option to purchase up to an additional&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;shares at the initial public offering price less the underwriting discount. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities. Under those rules, beneficial ownership includes any shares as to which the individual or entity has sole or shared voting power or investment power. Except as noted by footnote, and subject to community property laws where applicable, we believe, based on the information provided to us, that the persons and entities named in the table below have sole voting and investment power with respect to all common stock shown as beneficially owned by them. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The&#160;percentage of beneficial ownership prior to this offering in the table below is based on 53,685,476 shares of Class A common stock and no shares of Class B common stock deemed to be outstanding as of April 30, 2021, assuming the conversion of all outstanding shares of our convertible preferred stock upon the closing of this offering into shares of Class A common stock, and the&#160;percentage of beneficial ownership after this offering in the table below is based on&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;shares of Class A common stock and no shares of Class B common stock assumed to be outstanding after the closing of the offering. The information in the table below assumes conversion of all warrants to purchase shares of preferred stock into warrants to purchase shares of Class A common stock upon the closing of the offering. The information in the table below assumes no exercise of the underwriters&#8217; option to purchase additional shares. Warrants or Options to purchase shares of Class A common stock that are exercisable within 60&#160;days of April 30, 2021 are deemed to be beneficially owned by the persons holding these options for the purpose of computing&#160;percentage ownership of that person, but are not treated as outstanding for the purpose of computing any other person&#8217;s ownership&#160;percentage. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">142</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:430.55pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8.98pt;height:18.82pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:316.46pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:8.98pt; padding-bottom:0.326666666666667pt;">
                <font style="letter-spacing:-0.16pt;">Shares</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Beneficially</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Owned </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Percentage of Shares</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Beneficially Owned </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.98pt;height:23.07pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:2.597pt 0pt 2.478pt 0pt; width:316.46pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Name and Address of Beneficial Owner</font><font style=" position:relative; bottom:3.25pt;font-size:6pt;letter-spacing:-0.12pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.597pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Before</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Offering </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.597pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">After</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Offering </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:316.46pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">5% Stockholders:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.46pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Entities affiliated with Blue Ox Healthcare Partners, LLC</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(2)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">9,465,582</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">17.1<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8199;&#8199;&#8199;&#8199;</font><font style="position:absolute;">%</font>
            </td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.46pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">ATH Holding Company, LLC</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(3)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">6,655,446</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">11.9<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8199;&#8199;&#8199;</font><font style="position:absolute;">%</font>
            </td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.46pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Entities affiliated with Domain Associates, LLC</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(4)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5,350,138</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">9.9<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8199;&#8199;&#8199;</font><font style="position:absolute;">%</font>
            </td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.46pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">InterWest Partners X, LP</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(5)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5,285,858</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">9.8<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8199;&#8199;&#8199;</font><font style="position:absolute;">%</font>
            </td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.46pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Chione, Ltd.</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(6)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">3,792,309</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">7.0<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8199;&#8199;&#8199;</font><font style="position:absolute;">%</font>
            </td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.46pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Laboratory Corporation of America Holdings</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(7)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">3,456,048</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">6.4<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8199;&#8199;&#8199;</font><font style="position:absolute;">%</font>
            </td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.46pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Vivo Capital Fund&#160;IX, L.P.</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(8)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">3,338,898</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">6.2<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8199;&#8199;&#8199;</font><font style="position:absolute;">%</font>
            </td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.46pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">aMoon Growth Fund&#160;Limited Partnership</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(9)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">3,338,898</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">6.2<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8199;&#8199;&#8199;</font><font style="position:absolute;">%</font>
            </td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.46pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Entities affiliated with Baker Bros. Advisors LP</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(10)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2,921,536</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">5.4<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8199;&#8199;&#8199;</font><font style="position:absolute;">%</font>
            </td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.46pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Named Executive Officers and Directors:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.46pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Dennis Farrar</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(11)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">731,433</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.4<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8199;&#8199;&#8199;</font><font style="position:absolute;">%</font>
            </td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.46pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Joshua Phillips</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(12)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2,076,921</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">3.9<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8199;&#8199;&#8199;</font><font style="position:absolute;">%</font>
            </td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.46pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Mansoor Raza Mirza, M.D.</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(13)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">78,065</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8199;&#8199;&#8199;</font><font style="position:absolute;">%</font>
            </td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.46pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Ryan Trimble</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(14)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">235,827</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8199;&#8199;&#8199;</font><font style="position:absolute;">%</font>
            </td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.46pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Kim Kamdar, Ph.D.</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(15)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5,363,920</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">9.9<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8199;&#8199;&#8199;</font><font style="position:absolute;">%</font>
            </td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.46pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Michael F. Minahan</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(16)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8199;&#8199;&#8199;</font><font style="position:absolute;">%</font>
            </td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.46pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Elizabeth Canis</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(17)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8199;&#8199;&#8199;</font><font style="position:absolute;">%</font>
            </td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.46pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Marcus Wilson, Pharm.D.</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(18)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8199;&#8199;&#8199;</font><font style="position:absolute;">%</font>
            </td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.46pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Joseph Siletto</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(19)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8199;&#8199;&#8199;</font><font style="position:absolute;">%</font>
            </td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.46pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Charles D. Kennedy, M.D.</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(20)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">9,465,582</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">17.1<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8199;&#8199;&#8199;</font><font style="position:absolute;">%</font>
            </td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.46pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Gregory C. Critchfield, M.D., M.S.</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(21)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2,629,184</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.8<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8199;&#8199;&#8199;</font><font style="position:absolute;">%</font>
            </td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.46pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Nadia Altomare</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(22)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">522,545</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.0<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8199;&#8199;&#8199;</font><font style="position:absolute;">%</font>
            </td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.46pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">John J. Boniface, Ph.D.</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(23)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">772,235</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.4<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8199;&#8199;&#8199;</font><font style="position:absolute;">%</font>
            </td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.46pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Garrett K. Lam, M.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">80,593</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8199;&#8199;&#8199;</font><font style="position:absolute;">%</font>
            </td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.46pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="font-weight:bold;letter-spacing:-0.2pt;">All current executive officers and directors as a group (21 persons)</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(24)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">23,358,616</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">39.6<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8199;&#8199;&#8199;</font><font style="position:absolute;">%</font>
            </td>
            <td style="padding:0pt;padding-left:4.53pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">*</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Indicates beneficial ownership of less than 1%. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:3.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Unless otherwise indicated, the address of all listed stockholders is c/o&#160;Sera Prognostics, Inc., 2749 East Parleys Way, Suite 200, Salt Lake City, UT 84109. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;7,890,120 shares of Class A common stock issuable upon the conversion of preferred stock and (ii)&#160;1,575,462 shares of Class A common stock underlying warrants that are exercisable as of April&#160;30, 2021 or will become exercisable within 60&#160;days of such date. Blue Ox Healthcare Partners, LLC is the manager of each of Blue Ox Healthcare Partners SP, LLC, BXHCP SP II, LLC, and BXHCP SP III, LLC, and may be deemed to have voting, investment and dispositive power with respect to the shares held by Blue Ox Healthcare Partners SP, LLC, BXHCP SP II, LLC, and BXHCP SP III, LLC. Charles D. Kennedy MD, Oded Levy, and John A. Neczesny, managing partners of Blue Ox Healthcare Partners, LLC, each may be deemed to share voting, investment and dispositive power with respect to these shares. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;4,577,906 shares of Class A common stock issuable upon the conversion of preferred stock and (ii)&#160;2,077,540 shares of Class A common stock underlying warrants that are exercisable as of April&#160;30, 2021 or will become exercisable within 60&#160;days of such date held by ATH Holding Company,&#160;LLC. Anthem,&#160;Inc., an Indiana corporation, holds one hundred percent (100%) of the beneficial ownership of ATH Holding Company,&#160;LLC. Anthem,&#160;Inc. is a publicly traded corporation </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">143</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">whose beneficial ownership is held by numerous individuals and entities. The address of ATH Holding Company,&#160;LLC is c/o&#160;Anthem,&#160;Inc., 220&#160;Virginia Avenue, Indianapolis, IN&#160;46205. </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;4,986,364 shares of Class A common stock issuable upon the conversion of preferred stock held by Domain Partners VIII, L.P. (Domain VIII), (ii)&#160;36,999 shares of Class A common stock issuable upon the conversion of preferred stock held by DP VIII Associates, L.P. (DP VIII), (iii)&#160;64,283 shares of Class A common stock held by Domain Associates, LLC (Domain Associates) and (iv)&#160;260,558 shares of common stock underlying warrants held by Domain VIII and 1,934 shares of Class A common stock underlying warrants held by DP VIII, that are exercisable as of April&#160;30, 2021 or will become exercisable within 60&#160;days of such date. The Managing Members of One Palmer Square Associates VIII, LLC (One Palmer), the general partner of Domain VIII and DPVIII, share voting and investment control with respect to the holdings of Domain VIII and DPVIII. The Managing Members of Domain Associates share voting and investment control with respect to its holdings. The Managing Members of One Palmer are James C. Blair, Brian H. Dovey, Brian K. Halak, Jesse I. Treu, and Nicole Vitullo. The Managing Members of Domain Associates are James C. Blair, Brian H. Dovey, Brian K. Halak, Kim P. Kamdar and Nicole Vitullo. The address of Domain VIII, DP VIII and Domain Associates is 202 Carnegie Center, Suite&#160;104, Princeton, NJ 08540. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(5)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;5,023,366 shares of Class A common stock issuable upon the conversion of preferred stock and (ii)&#160;262,492 shares of Class A common stock underlying warrants that are exercisable as of April&#160;30, 2021 or will become exercisable within 60&#160;days of such date. InterWest Management Partners X, LLC, or IMP10, is the general partner of InterWest Partners X, L.P. and may be deemed to have voting, investment and dispositive power with respect to the shares held by InterWest Partners X, L.P. Gilbert H. Kliman, managing director of IMP10, and Khaled A. Nasr and Keval Desai, venture members of IMP10, each may be deemed to share voting, investment and dispositive power with respect to these shares. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(6)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;3,358,491 shares of Class A common stock issuable upon the conversion of preferred stock and (ii)&#160;433,818 shares of Class A common stock underlying warrants that are exercisable as of April&#160;30, 2021 or will become exercisable within 60&#160;days of such date. Chione&#8217;s directors, Marcin Czernik, Andreas Hadjimichael and Anastasios Nikolaou, and its sole stockholder, Wiaczeslaw Smolokowski, may be deemed to share voting and investment power and beneficial ownership with respect to such shares. Each of such directors and stockholder disclaims such voting and investment power and beneficial ownership. Chione&#8217;s address is Simou Menardou 5, Kifisia Court. Office 225, Larnaca, Cyprus. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(7)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;3,284,424 shares of Class A common stock issuable upon the conversion of preferred stock and (ii)&#160;171,624 shares of Class A common stock underlying warrants that are exercisable as of April&#160;30, 2021 or will become exercisable within 60&#160;days of such date held by Laboratory Corporation of America Holdings. Laboratory Corporation of America Holdings is a publicly traded corporation whose beneficial ownership is held by numerous individuals and entities. The address of Laboratory Corporation of America Holdings is 531 South Spring Street, Burlington, North Carolina 27215. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(8)</font>
          <br >
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of 3,338,898 shares of Class A common stock issuable upon the conversion of preferred stock, which are held of record by Vivo Capital Fund&#160;IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund&#160;IX, L.P. The voting members of Vivo Capital IX, LLC, Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Mahendra Shah, Jack Nielsen and Michael Chang, may be deemed to share voting and investment power with respect to such shares. None of such voting members have individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares. The principal business address of Vivo Capital IX, LLC is 192 Lytton Avenue, Palo Alto, CA 94301. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.91pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(9)</font>
          <br >
        </div>
        <div style=" margin-top:3.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of 3,338,898 shares of Class A common stock issuable upon the conversion of preferred stock held by aMoon Growth Fund&#160;Limited Partnership, or aMoon Growth. aMoon Growth Fund&#160;G.P. Limited Partnership, or aMoon GP, is the sole general partner of aMoon Growth. aMoon General Partner Ltd., or aMoon Ltd., is the sole general partner of aMoon GP. Dr.&#160;Yair Schindel is the sole shareholder of aMoon Ltd. By virtue of such relationships, aMoon GP, aMoon Ltd. and Dr.&#160;Schindel may be deemed to have shared voting and investment power with respect to the shares of Class A common stock held by aMoon Growth. Dr.&#160;Schindel disclaims beneficial ownership of the shares of Class A common stock held by aMoon, aMoon G.P. and aMoon Ltd., except to the extent of his pecuniary interest therein, if any. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">144</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(10)</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of (i) 214,005 shares of Class A common stock issuable upon the conversion of preferred stock directly held by 667, L.P. (&#8220;667&#8221;) and (ii) 2,707,531 shares of Class A common stock issuable upon the conversion of preferred stock directly held by Baker Brothers Life Sciences, L.P. (&#8220;Life Sciences&#8221;, and together with 667, the &#8220;BBA Funds&#8221;). Baker Bros. Advisors LP (&#8220;BBA&#8221;) is the management company and investment adviser to the BBA Funds and has the sole voting and investment power with respect to the shares held by the BBA Funds. Baker Bros. Advisors (GP) LLC (BBA-GP) is the sole general partner of BBA. The managing members of BBA-GP are Julian C. Baker and Felix J. Baker. BBA-GP, Felix J. Baker and Julian C. Baker as managing members of BBA-GP, and BBA may be deemed to be beneficial owners of the shares directly held by the BBA Funds. Julian C. Baker and Felix J. Baker disclaim beneficial ownership of such shares, except to the extent of their pecuniary interest therein. The business address of the entities listed herein is 860 Washington Street, 3rd Floor, New York, NY 10014. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(11)</font>
          <br >
        </div>
        <div style=" margin-top:3.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Includes (i) 975 shares of Class A common stock held by UpStart Life Sciences Capital, LP and (ii)&#160;652,393 shares of Class A common stock issuable upon conversion of preferred stock held by UpStart Life Sciences Capital, LP. Mr.&#160;Farrar is the co-founder and Managing Partner of UpStart Life Sciences Capital, LP and may be deemed to beneficially own the shares held by UpStart Life Sciences Capital, LP. Mr.&#160;Farrar disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(12)</font>
          <br >
        </div>
        <div style=" margin-top:3.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of (i) 78,065 shares of Class A common stock held by Catalyst Health Ventures, L.P. (CHV LP), (ii)&#160;729,964 shares of Class A common stock issuable upon the conversion of preferred stock held by CHV LP, (iii) 25,928 shares of Class A common stock underlying warrants that are exercisable as of April 30, 2021 or will become exercisable within 60 days of such date held by CHV LP, (iv) 345,235 shares of Class A common stock issuable upon the conversion of preferred stock held by Catalyst Health Ventures (PF), L.P. (CHV PF), (v) 778,262 shares of Class A common stock issuable upon the conversion of preferred stock held by CHV Investments, LLC (CHV Investments), (vi) 40,662 shares of Class A common stock underlying warrants that are exercisable as of April 30, 2021 or will become exercisable within 60 days of such date held by CHV Investments, (vii) 74,945 shares of Class A common stock issuable upon the conversion of preferred stock held by Catalyst Health Ventures Follow-on Fund, L.P. (CHV FO) (together with CHV LP, CHV PF and CHV Investments, the CHV Funds), (viii) 3,860 shares of Class A common stock underlying warrants that are exercisable as of April 30, 2021 or will become exercisable within 60 days of such date held by CHV FO. CHV GP LLC is the general partner of CHV LP and CHV PF. CHV III GP LLC is the general partner of CHV Investments and CHV FO. Joshua Phillips, a member of our board of directors, is a managing member of CHV GP LLC and CHV III GP LLC, and a limited partner of CHV PF, CHV Investments, CHV GP LLC and CHV III GP LLC. The securities held by the CHV Funds may be deemed to be beneficially owned by Joshua Phillips. Joshua Phillips disclaims beneficial ownership of these securities except to the extent of his pecuniary benefit therein. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(13)</font>
          <br >
        </div>
        <div style=" margin-top:3.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of 78,065 shares of Class A common stock underlying options that are exercisable as of April&#160;30, 2021 or will become exercisable within 60&#160;days of such date held by Dr.&#160;Mirza. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.61pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(14)</font>
          <br >
        </div>
        <div style=" margin-top:3.61pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;78,065 shares of Class A common stock held by the Trimble Trust, (ii) 130,988 shares of Class A common stock issuable upon the conversion of preferred stock held by the Trimble Trust and (iii)&#160;26,774 shares of Class A common stock underlying warrants that are exercisable as of April&#160;30, 2021 or will become exercisable within 60&#160;days of such date held by the Trimble Trust. Mr.&#160;Trimble is the Trustee for the Trimble Trust and may be deemed to beneficially own the shares held by the Trimble Trust. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(15)</font>
          <br >
        </div>
        <div style=" margin-top:3.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;4,986,364 shares of Class A common stock issuable upon the conversion of preferred stock held by Domain VIII (ii)&#160;36,999 shares of Class A common stock issuable upon the conversion of preferred stock held by DP VIII (iii)&#160;64,283 shares of Class A common stock held by Domain Associates, (iv)&#160;13,782 shares of Class A common stock held by Dr.&#160;Kamdar, and (v)&#160;260,558 shares of Class A common stock underlying warrants held by Domain VIII and 1,934 shares of Class A common stock underlying warrants held by DP VIII, that are exercisable as of April&#160;30, 2021 or will become exercisable within 60&#160;days of such date. Dr.&#160;Kamdar, member of our Board, is a Member of One Palmer Square Associates VIII, LLC, the General Partner of Domain VIII and DP VIII Associates, and a Managing Member of Domain Associates and may be deemed to beneficially own the shares held by Domain VIII, DPVIII and Domain Associates. Dr.&#160;Kamdar disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">145</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:248pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(16)</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Mr.&#160;Minahan, a member of our board of directors, is Senior VP and General Manager for Integrated Genetics, a division of Laboratory Corporation of America Holdings, but has no voting or investment power with respect to the securities described in footnote 7. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(17)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Ms.&#160;Canis, a member of our board of directors, is Vice President, Emerging Businesses &amp; Partnerships at Anthem, which is affiliated with ATH Holding Company, LLC. Ms.&#160;Canis has no voting or investment power with respect to the securities described in footnote 3. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(18)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Dr.&#160;Wilson, a member of our board of directors, is the CAO at Anthem, which is affiliated with ATH Holding Company, LLC. Mr.&#160;Wilson has no voting or investment power with respect to the securities described in footnote 3. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(19)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Mr.&#160;Siletto, a member of our board of directors, is a Managing Director of Vivo Capital LLC. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(20)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;7,890,120 shares of Class A common stock issuable upon the conversion of preferred stock and (ii)&#160;1,575,462 shares of Class A common stock underlying warrants that are exercisable as of April&#160;30, 2021 or will become exercisable within 60&#160;days of such date held by Blue Ox Healthcare Partners SP, LLC as set forth in footnote 2. Dr.&#160;Kennedy, a member of our board of directors, is a managing partner of Blue Ox Healthcare Partners, LLC, and may be deemed to share voting, investment and dispositive power with respect to these shares. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(21)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consists of (i)&#160;1,476,033 shares of Class A common stock, (ii) 176,660 shares of Class A common stock issuable upon the conversion of preferred stock and (iii)&#160;18,346 shares of Class A common stock underlying warrants that are exercisable as of April&#160;30, 2021 or will become exercisable within 60&#160;days of such date, each held by the Gregory C. Critchfield &amp; Trust, of which Dr.&#160;Critchfield is a Trustee, and (iv)&#160;958,145 shares of Class A common stock underlying options that are exercisable as of April&#160;30, 2021 or will become exercisable within 60 days of such date held by Dr.&#160;Critchfield. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(22)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consist 522,545 shares of Class A common stock underlying options that are exercisable as of April&#160;30, 2021 or will become exercisable within 60&#160;days of such date held by Ms.&#160;Altomare. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(23)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Consist of 772,235 shares of Class A common stock underlying options that are exercisable as of April&#160;30, 2021 or will become exercisable within 60&#160;days of such date held by Mr.&#160;Boniface. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(24)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">See footnotes 11 to 23. Also includes shares beneficially owned by Jay Moyes, Douglas Fisher, M.D., John Peltier, Ph.D., Thomas Garite, Nichole L. Martin and Benjamin Jackson, each of whom are executive officers but not named executive officers. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">146</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDOCS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DESCRIPTION OF CAPITAL STOCK</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Upon the completion of this offering, our authorized capital stock will consist of &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of Class A common stock, par value $0.0001 per share, &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of Class B common stock, par value $0.0001 per share and&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;shares of preferred stock, par value $0.0001 per share, all of which will be undesignated. As of March&#160;31, 2021, there were 4,120,842 shares of our Class A common stock issued and outstanding and no shares of our Class B common stock issued and outstanding. This amount excludes our outstanding shares of convertible preferred stock, including 6,477,458 shares of our Series E convertible preferred stock issued in April 2021, which will automatically convert into an aggregate of 49,562,136 shares of our Class A common stock and Class B common stock upon completion of this offering. Based on the number of shares of our Class A common stock and Class B common stock outstanding as of March&#160;31, 2021 and assuming (i)&#160;the conversion of all outstanding shares of our preferred stock and (ii)&#160;the issuance by us of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;shares of our Class A common stock in this offering, there will be &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;shares of Class A common stock and Class B common stock outstanding and no shares of preferred stock outstanding upon the completion of this offering. As of March&#160;31, 2021, we had approximately 92 record holders of our capital stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following description of our capital stock and provisions of our amended and restated certificate of incorporation and amended and restated by-laws are summaries of material terms and provisions and are qualified by reference to our amended and restated certificate of incorporation and amended and restated by-laws, copies of which have been filed with the SEC as exhibits to the registration statement of which this prospectus is a part. The descriptions of our Class A common stock, Class B common stock and preferred stock reflect the content of the amended and restated certificate of incorporation and amended and restated by-laws that will become effective immediately prior to the completion of this offering. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Class A Common Stock and Class B Common Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Upon the completion of this offering, we will be authorized to issue two classes of common stock: Class A common stock and Class B common stock. Holders of our Class A common stock and our Class B common stock have identical rights, provided that, (i) except as otherwise expressly provided in our amended and restated certificate of incorporation or as required by applicable law, on any matter that is submitted to a vote by our stockholders, holders of our Class A common stock are entitled to one vote per share of Class A common stock, and holders of our Class B common stock are not entitled to any votes per share of Class B common stock, including for the election of directors, and (ii) holders of our Class A common stock have no conversion rights, while holders of our Class B common stock have the right to convert each share of our Class B common stock into one share of Class A common stock at such holder&#8217;s election, provided that as a result of such conversion, such holder would not beneficially own in excess of 4.99% of any class of our securities registered under the Exchange Act, except as expressly provided for in our amended and restated certificate of incorporation. However, this ownership limitation may be increased or decreased to any other percentage designated by such holder of Class B common stock upon 61 days&#8217; notice to us. Our Class A common stock and Class B common stock do not have cumulative voting rights. Accordingly, the holders of a majority of the outstanding shares of Class A common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they so choose, other than any directors that holders of any preferred stock we may issue may be entitled to elect. Subject to preferences that may be applicable to any then outstanding preferred stock, holders of our Class A common stock and Class B common stock are entitled to receive ratably those dividends, if any, as may be declared by the board of directors out of legally available funds. In the event of our liquidation, dissolution or winding up, the holders of our Class A common stock and Class B common stock will be entitled to share ratably in the assets legally available for distribution to stockholders after the payment of or provision for all of our debts and other liabilities, subject to the prior rights of any preferred stock then outstanding. Holders of our Class A common stock and Class B common stock have no preemptive rights or other subscription rights and there are no redemption or sinking funds provisions applicable to our Class A common stock and Class B common stock. All outstanding shares of our Class A common stock and Class B common stock are, and the Class A common stock and Class B common stock to be outstanding immediately prior to the closing of this offering will be, duly authorized, validly issued, fully paid and nonassessable. The rights, preferences and privileges of holders of our Class A common stock and Class B common stock are subject to and may </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">147</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future. The rights, preferences and privileges of our holders of Class A common stock and Class B common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future. Except as described under the &#8220;&#8212; Anti-Takeover Effects of Delaware Law, Our Amended and Restated Certificate of Incorporation and Our Amended and Restated By-Laws&#8221; section of this prospectus, the affirmative vote of a majority of the shares of Class A common stock present in person or by proxy, is generally required to take action under our amended and restated certificate of incorporation and amended and restated by-laws. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Preferred Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Upon the completion of this offering, our board of directors will be authorized, without action by our stockholders, to designate and issue up to an aggregate of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;shares of preferred stock in one or more series. Our board of directors can designate the rights, preferences and privileges of the shares of each series and any of its qualifications, limitations or restrictions. Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of Class A common stock and Class B common stock. The issuance of preferred stock, while providing flexibility in connection with possible future financings and acquisitions and other corporate purposes could, under certain circumstances, have the effect of restricting dividends on our Class&#160;A common stock and Class B common stock, diluting the voting power of our Class A common stock, impairing the liquidation rights of our Class A common stock and Class B common stock, or delaying, deferring or preventing a change in control of our company, which might harm the market price of our Class&#160;A common stock. See also the &#8220;&#8212; Anti-Takeover Effects of Delaware Law, Our Amended and Restated Certificate of Incorporation and Our Amended and Restated By-Laws&#8221; section of this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our board of directors will make any determination to issue such shares based on its judgment as to our best interests and the best interests of our stockholders. Upon the completion of this offering, we will have no shares of preferred stock outstanding and we have no current plans to issue any shares of preferred stock following completion of this offering. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Stock Options</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of March&#160;31, 2021, options to purchase an aggregate of 10,308,231 shares of our Class A common stock at a weighted-average exercise price of $1.22 were outstanding. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Warrants</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In connection with the Series E Preferred Stock Financing, we issued a warrant to purchase an aggregate of 1,501,502 shares of Class A common stock, initially exercisable at a price of $9.99 per share, or the Series E Warrant. The Series&#160;E Warrant may be exercised until the date that is five years after the issuance date of the Series E Warrant. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In connection with the Series D Preferred Stock Financing, we issued warrants to purchase an aggregate of 2,099,384 shares of Class A common stock, initially exercisable at a price of $4.34 per share, or the $4.34 Warrants, and warrants to purchase an aggregate of 2,099,384 shares of Class A common stock, initially exercisable at a price of $5.21 per share, or the $5.21 Warrants, and together with the $4.34 Warrants, the Series D Warrants. Each of the Series D Warrants may be exercised until the date that is ten years after the issuance date of the Series D Warrants. The $4.34 Warrants are subject to an anti-dilution provision, pursuant to which, with certain exceptions, if we issue shares of Class A common stock for no consideration or at a price that is less than the warrant exercise price then in effect, the warrant exercise price shall thereafter be adjusted to be a price that is 120% of the lower price at which such shares were issued, subject to a floor price of $3.47 per share, and subject to adjustment for stock splits, stock dividends, combinations or similar events. The $5.21 Warrants are subject to an anti-dilution provision, pursuant to which, with certain exceptions, if we issue shares of Class A common stock for no consideration or at a price that is less than 83.3% of the warrant exercise price then in effect, the warrant exercise price shall thereafter be adjusted to be a price that is 120% of the lower price at which such shares were issued, subject to a floor price of $4.17 per share, and subject to adjustment for stock splits, stock dividends, combinations or similar events. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">148</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition to the Series E Warrant and the Series D Warrants, as of March&#160;31, 2021, the following warrants were outstanding: (i)&#160;warrants to purchase 33,222 shares of our series A-2 preferred stock, which have an exercise price of $2.50 per share, and will be converted into warrants to purchase shares of Class A common stock upon completion of this offering, (ii)&#160;warrants to purchase 60,000 shares of our series B-1 preferred stock, which have an exercise price of $2.50 per share, and will be converted into warrants to purchase shares of Class A common stock upon completion of this offering, (iii)&#160;warrants to purchase 12,500 shares of our series B-2 preferred stock, which have an exercise price of $4.00 per share, and will be converted into warrants to purchase shares of Class A common stock upon completion of this offering, (iv)&#160;warrants to purchase 16,806 shares of our series C-1 preferred stock, which have an exercise price of $5.95 per share, and will be converted into warrants to purchase shares of Class A common stock upon completion of this offering and (v)&#160;a warrant to purchase 47,005 shares of our series D preferred stock, which has an exercise price of $4.34 per share, and will be converted into warrants to purchase shares of Class A common stock upon completion of this offering. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Registration Rights</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We entered into a Fourth Amended and Restated Investors&#8217; Rights Agreement, dated as of February&#160;23, 2021, or the Investors&#8217; Rights Agreement, with certain holders of our capital stock. These shares will represent approximately&#8199;&#8199;&#8199;&#8199;% of our outstanding Class A common stock and Class B common stock after this offering, or&#8199;&#8199;&#8199;&#8199;% if the underwriters exercise their option to purchase additional shares in full, and excluding shares of Class A common stock, if any, purchased by any holders of registration rights in this offering. These shares also may be sold under Rule&#160;144 under the Securities Act, depending on their holding period and subject to restrictions in the case of shares held by persons deemed to be our affiliates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the Investors&#8217; Rights Agreement, holders of registrable shares can demand that we file a registration statement or request that their shares be included on a registration statement that we are otherwise filing, in either case, registering the resale of their shares of common stock. These registration rights are subject to conditions and limitations, including the right, in certain circumstances, of the underwriters of an offering to limit the number of shares included in such registration and our right, in certain circumstances, not to effect a registration upon demand of the holders of registrable shares within 90&#160;days following the effective date of any registration statement that we file covering a firm commitment underwritten public offering in which the holders of registrable shares were entitled to join and in which we effectively registered all registrable shares that were requested to be registered. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Demand Registration Rights</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Following the date that is 180&#160;days after the date of this prospectus, the holders of at least a majority of registrable securities then outstanding under the Investors&#8217; Rights Agreement may require us to file a registration statement under the Securities Act on a Form S-1 at our expense, subject to certain exceptions, with respect to the then outstanding registrable securities of such holders having an anticipated aggregate offering price of at least $5.0&#160;million, and we are required to effect the registration as soon as practicable, and in any event within 120&#160;days. Any time after we are eligible to use a registration statement on Form S-3, the holders of at least 25% of our registrable securities under the Investors&#8217; Rights Agreement may require us to file a registration statement on Form S-3 at our expense, subject to certain exceptions, with respect to the then outstanding registrable securities of such holders having an anticipated aggregate offering price of at least $3.0&#160;million, and we are required to effect the registration as soon as practicable, and in any event within 90&#160;days. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Piggyback Registration Rights</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If we propose to file a registration statement under the Securities Act for the purposes of a public offering of our securities (including, but not limited to, registration statements relating to a secondary offering of our securities but excluding (i)&#160;a registration statement relating to the sale of securities to employees pursuant to a stock option, stock purchase, or similar plan; (ii)&#160;with respect to any corporate reorganization or transaction under Rule&#160;145 of the Securities Act; (iii)&#160;a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the registrable securities; or (iv)&#160;a registration in which the only Class A common stock being registered is Class A common stock issuable upon conversion of debt securities that </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">149</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">are also being registered), the holders of registrable securities are entitled to receive notice of such registration and to request that we include their registrable securities for resale in the registration statement. The underwriters of the offering will have the right to limit the number of shares to be included in such registration. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Expenses of Registration</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We will pay all registration expenses, other than underwriting discounts and commissions, related to any demand or piggyback registration. The Investors&#8217; Rights Agreement contains customary cross-indemnification provisions, pursuant to which we are obligated to indemnify the selling stockholders, in the event of misstatements or omissions in the registration statement attributable to us except in the event of fraud, and they are obligated to indemnify us for misstatements or omissions attributable to them. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Expiration of Registration Rights</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The registration rights will terminate upon the earliest to occur of the closing of certain liquidation events, such time when all of the holder&#8217;s registrable securities may be sold without limitation (and without the requirement for us to be in compliance with the current public information requirement) under Rule&#160;144 of the Securities Act and the fifth anniversary of the closing date of this offering. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Anti-Takeover Effects of Delaware Law, Our Amended and Restated Certificate of Incorporation and Our Amended and Restated By-Laws</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our amended and restated certificate of incorporation and amended and restated by-laws that will take effect in connection with the completion of this offering will include a number of provisions that may have the effect of encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board of directors rather than pursue non-negotiated takeover attempts. These provisions include the items described below. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Board Composition and Filling Vacancies</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In accordance with our amended and restated certificate of incorporation, our board of directors will be divided into three classes serving three-year terms, with one class being elected each year. Our amended and restated certificate of incorporation will also provide that directors may be removed only for cause and then only by the affirmative vote of the holders of majority of the shares then entitled to vote at an election of directors. Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the size of our board of directors, will only be able to be filled by the affirmative vote of a majority of our directors then in office, even if less than a quorum. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">No Written Consent of Stockholders</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our amended and restated certificate of incorporation will provide that all stockholder actions are required to be taken by a vote of the stockholders at an annual or special meeting, and that stockholders may not take any action by written consent in lieu of a meeting. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Meetings of Stockholders</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our amended and restated by-laws will provide that only a majority of the members of our board of directors then in office may call special meetings of stockholders and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders. Our amended and restated by-laws will limit the business that may be conducted at an annual meeting of stockholders to those matters properly brought before the meeting. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Advance Notice Requirements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our amended and restated by-laws will establish advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for election as directors or new business to be brought before meetings of our stockholders. These procedures will provide that notice of stockholder proposals must be timely given in writing to our corporate secretary prior to the meeting at which the action is to be taken. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">150</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Generally, to be timely, notice must be received at our principal executive offices not less than 90&#160;days or more than 120&#160;days prior to the first anniversary date of the annual meeting for the preceding year. The notice must contain certain information specified in our amended and restated by-laws. These provisions may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed. These provisions may also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to obtain control of our company. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Amendment to By-Laws and Certificate of Incorporation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As required by the Delaware General Corporation Law, any amendment of our amended and restated certificate of incorporation must first be approved by a majority of our board of directors and, if required by law or our amended and restated certificate of incorporation, thereafter be approved by a majority of the outstanding shares entitled to vote on the amendment, and a majority of the outstanding shares of each class entitled to vote thereon as a class, except that the amendment of the provisions relating to stockholder action, directors, limitation of liability, exclusive jurisdiction of Delaware Courts and the amendment of our amended and restated by-laws and amended and restated certificate of incorporation must be approved by not less than 75% of the outstanding shares entitled to vote on the amendment, and not less than 75% of the outstanding shares of each class entitled to vote thereon as a class. Our amended and restated by-laws may be amended by the affirmative vote of a majority of the directors then in office, subject to any limitations set forth in the amended and restated by-laws; and may also be amended by the affirmative vote of at least 75% of the outstanding shares entitled to vote on the amendment, or, if the board of directors recommends that the stockholders approve the amendment, by the affirmative vote of the majority of the outstanding shares entitled to vote on the amendment. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Blank Check Preferred Stock</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our amended and restated certificate of incorporation will provide for&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;authorized shares of preferred stock. The existence of authorized but unissued shares of preferred stock may enable our board of directors to render more difficult or to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of directors were to determine that a takeover proposal is not in the best interests of us or our stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer or insurgent stockholder or stockholder group. In this regard, our amended and restated certificate of incorporation grants our board of directors broad power to establish the rights and preferences of authorized and unissued shares of preferred stock. The issuance of shares of preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of Class A common stock and Class B common stock. The issuance may also adversely affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring or preventing a change in control of&#160;us. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Section&#160;203 of the Delaware General Corporation Law</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:10.5pt;">
          <font style="letter-spacing:0.2pt;">Upon completion of this offering, we will be subject to the provisions of Section&#160;203 of the Delaware General Corporation Law. In general, Section&#160;203 prohibits a publicly-held Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. A &#8220;business combination&#8221; includes, among other things, a merger, asset or stock sale or other transaction resulting in a financial benefit to the interested stockholder. An &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or did own within three&#160;years prior to the determination of interested stockholder status, 15% or more of the corporation&#8217;s voting stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:10.5pt;">
          <font style="letter-spacing:0.2pt;">Under Section&#160;203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:10.6pt; margin-top:7.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.6pt; margin-bottom:0pt; line-height:10.6pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">before the stockholder became interested, the board of directors approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">151</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:10.6pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:10.6pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:10.6pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:10.6pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">at or after the time the stockholder became interested, the business combination was approved by the board of directors of the corporation and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock that is not owned by the interested stockholder. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:10.5pt;">
          <font style="letter-spacing:0.2pt;">A Delaware corporation may &#8220;opt out&#8221; of these provisions with an express provision in its original certificate of incorporation or an express provision in its amended and restated certificate of incorporation or amended and restated by-laws resulting from a stockholders&#8217; amendment approved by at least a majority of the outstanding voting shares. We have not opted out of these provisions. As a result, mergers or other takeover or change in control attempts of us may be discouraged or prevented. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Exclusive Jurisdiction of Certain Actions</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:10.5pt;">
          <font style="letter-spacing:0.2pt;">Our amended and restated certificate of incorporation that will become effective upon the closing of this offering will provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of Delaware) will be the sole and exclusive forum for any state law claim for: (1)&#160;any derivative action or proceeding brought on our behalf; (2)&#160;any action or proceeding asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our directors, officers, employees or agents to us or our stockholders; (3)&#160;any action or proceeding asserting a claim against us arising pursuant to any provision of the Delaware General Corporation Law or our certificate of incorporation or bylaws (in each case, as they may be amended from time to time); (4)&#160;any action or proceeding to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or bylaws; (5) any action or proceeding as to which the Delaware General Corporation Law confers jurisdiction to the Court of Chancery of the State of Delaware; or (6)&#160;any action asserting a claim against us or any of our directors, officers or employees that is governed by the internal affairs doctrine. The choice of forum provision does not apply to any actions arising under the Exchange Act. Our amended and restated certificate of incorporation will further provide that, unless we consent in writing to an alternative forum, the United States District Court for the District of Utah will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. We have chosen the United States District Court for the District of Utah as the exclusive forum for such Securities Act causes of action because our principal executive offices are located in Salt Lake City, Utah. In addition, our amended and restated certificate of incorporation will provide that any person or entity purchasing or otherwise acquiring any interest in shares of our common stock is deemed to have notice of and consented to the foregoing provisions.</font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our current or former director, officer, other employee, agent, or stockholder to the company, which may discourage such claims against us or any of our current or former director, officer, other employee, agent, or stockholder to the company and result in increased costs for investors to bring a claim. Alternatively, if a court were to find the choice of forum provisions contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, results of operations and financial condition. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Nasdaq Global Market Listing</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:10.5pt;">
          <font style="letter-spacing:0.2pt;">We have submitted an application to list our Class A common stock on The Nasdaq Global Market under the trading symbol &#8220;SERA.&#8221; Our Class B common stock is not listed for trading on any securities exchange, and we do not plan to list the Class B common stock on any securities exchange. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Transfer Agent and Registrar</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The transfer agent and registrar for our Class A common stock will be American Stock Transfer &amp; Trust Company, LLC. The transfer agent and registrar&#8217;s address is 6201 15th Avenue, Brooklyn, New York&#160;11219. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">152</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSEFF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SHARES ELIGIBLE FOR FUTURE SALE</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Prior to this offering, there has been no public market for our Class&#160;A common stock, and we cannot assure investors that an active trading market for our Class&#160;A common stock will develop or be sustained after this offering. Future sales of our Class&#160;A common stock, including shares issued upon the exercise of outstanding options, in the public market after this offering, or the perception that those sales may occur, could cause the prevailing market price for our Class&#160;A common stock to fall or impair our ability to raise equity capital in the future. As described below, only a limited number of shares of our Class&#160;A common stock will be available for sale in the public market for a period of several&#160;months after completion of this offering due to contractual and legal restrictions on resale described below. Future sales of our Class&#160;A common stock in the public market either before (to the extent permitted) or after restrictions lapse, or the perception that those sales may occur, could adversely affect the prevailing market price of our Class&#160;A common stock at such time and our ability to raise equity capital at a time and price we deem appropriate. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Sale of Restricted Shares</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Upon the completion of this offering, based on the number of shares of our Class&#160;A common stock and Class&#160;B common stock outstanding as of March&#160;31, 2021, and assuming (1)&#160;the conversion of our outstanding convertible preferred stock, including the 6,477,458 shares of our Series&#160;E convertible preferred stock issued in April 2021, into an aggregate of 49,562,136 shares of our Class&#160;A common stock and Class&#160;B common stock, (2)&#160;no exercise of the underwriters&#8217; option to purchase additional shares of Class&#160;A common stock and (3)&#160;no exercise of outstanding options, we will have outstanding an aggregate of approximately&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;shares of Class&#160;A common stock and &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of Class&#160;B common stock. Of these shares, all of the&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares of Class&#160;A common stock to be sold in this offering, and any shares sold upon exercise of the underwriters&#8217; option to purchase additional shares will be freely tradable in the public market without restriction or further registration under the Securities Act unless the shares are held by any of our &#8220;affiliates&#8221; as such term is defined in Rule&#160;144 of the Securities Act. All remaining shares of Class&#160;A common stock and shares of Class&#160;A common stock subject to stock options and warrants or issuable upon conversion of Class&#160;B common stock held by existing stockholders immediately prior to the completion of this offering will be &#8220;restricted securities&#8221; as such term is defined in Rule&#160;144. These restricted securities were issued and sold by us, or will be issued and sold by us, in private transactions and are eligible for public sale only if registered under the Securities Act or if they qualify for an exemption from registration under the Securities Act, including the exemptions provided by Rule&#160;144 or Rule&#160;701, which rules are summarized below. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As a result of the lock-up agreements referred to below and the provisions of Rule&#160;144 and Rule&#160;701 under the Securities Act, the shares of our Class&#160;A common stock, including Class&#160;A common stock issuable upon conversion of Class&#160;B common stock (excluding the shares sold in this offering) that will be available for sale in the public market are as follows: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">beginning on the date of this prospectus, the&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares of Class&#160;A common stock sold in this offering will be immediately available for sale in the public market; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">beginning 181&#160;days after the date of this prospectus,&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;additional shares of Class&#160;A common stock will become eligible for sale in the public market, of which&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares will be held by affiliates and subject to the volume and other restrictions of Rule&#160;144, as described below; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the remainder of the shares of Class&#160;A common stock will be eligible for sale in the public market from time to time thereafter, subject in some cases to the volume and other restrictions of Rule&#160;144, as described below. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Lock-Up Agreements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In connection with this offering, we, our directors, our executive officers and stockholders holding substantially all of our shares of Class&#160;A common stock outstanding as of&#8199;&#8199;&#8199;&#8199;&#8199; , 2021 (assuming conversion of all of our outstanding shares of convertible preferred stock), and substantially all of our option holders who are not also stockholders have agreed, subject to certain exceptions, with the underwriters not to dispose of or hedge any shares of our Class&#160;A common stock or securities convertible into or exchangeable for </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">153</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">shares of Class&#160;A common stock during the period from the date of the lock-up agreement continuing through the date 180&#160;days after the date of this prospectus, except with the prior written consent of each of Citigroup Global Markets Inc., Cowen and Company, LLC and William Blair &amp; Company, L.L.C. as the representatives of the underwriters and certain other exceptions. The representatives of the underwriters have advised us that they have no current intent or arrangement to release any of the shares subject to the lock-up agreements prior to the expiration of the lock-up period. See the &#8220;Underwriting&#8221; section of this prospectus for additional information. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Following the lock-up periods set forth in the agreements described above, and assuming that the representatives of the underwriters do not release any parties from these agreements, all of the shares of our Class&#160;A common stock that are restricted securities or are held by our affiliates as of the date of this prospectus will be eligible for sale in the public market in compliance with Rule&#160;144 under the Securities Act. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Rule&#160;144</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In general, under Rule&#160;144, as currently in effect, once we have been subject to the public company reporting requirements of the Exchange Act for at least 90&#160;days, a person (or persons whose shares are required to be aggregated) who is not deemed to have been one of our &#8220;affiliates&#8221; for purposes of Rule&#160;144 at any time during the three&#160;months preceding a sale, and who has beneficially owned restricted securities within the meaning of Rule&#160;144 for at least six&#160;months, including the holding period of any prior owner other than one of our &#8220;affiliates,&#8221; is entitled to sell those shares in the public market (subject to the lock-up agreement referred to above, if applicable) without complying with the manner of sale, volume limitations or notice provisions of Rule&#160;144, but subject to compliance with the public information requirements of Rule&#160;144. If such a person has beneficially owned the sales proposed to be sold for at least one year, including the holding period of any prior owner other than &#8220;affiliates,&#8221; then such person is entitled to sell such shares in the public market without complying with any of the requirements of Rule&#160;144 (subject to the lock-up agreement referred to above, if applicable). In general, under Rule&#160;144, as currently in effect, once we have been subject to the public company reporting requirements of the Exchange Act for at least 90&#160;days, our &#8220;affiliates,&#8221; as defined in Rule&#160;144, who have beneficially owned the shares proposed to be sold for at least six&#160;months are entitled to sell in the public market, upon expiration of any applicable lock-up agreements and within any three-month period, a number of those shares of our Class&#160;A common stock that does not exceed the greater of: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">1% of the number of shares of Class&#160;A common stock then outstanding, which will equal approximately&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares of Class&#160;A common stock immediately after this offering (calculated on the basis of the number of shares of our Class&#160;A common stock outstanding as of &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;, 2021, the assumptions described above and assuming no exercise of the underwriters&#8217; option to purchase additional shares and no exercise of outstanding options or warrants); or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the average weekly trading volume of our Class&#160;A common stock on The Nasdaq Global Market during the four calendar weeks preceding the filing of a notice on Form 144 with respect to such sale. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Such sales under Rule&#160;144 by our &#8220;affiliates&#8221; or persons selling shares on behalf of our &#8220;affiliates&#8221; are also subject to certain manner of sale provisions, notice requirements and to the availability of current public information about us. Notwithstanding the availability of Rule&#160;144, the holders of substantially all of our restricted securities have entered into lock-up agreements as referenced above and their restricted securities will become eligible for sale (subject to the above limitations under Rule&#160;144) upon the expiration of the restrictions set forth in those agreements. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Rule&#160;701</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In general, under Rule&#160;701 as currently in effect, any of our employees, directors, officers, consultants or advisors who acquired Class&#160;A common stock from us in connection with a written compensatory stock or option plan or other written agreement in compliance with Rule&#160;701 under the Securities Act before the effective date of the registration statement of which this prospectus is a part (to the extent such Class&#160;A common stock is not subject to a lock-up agreement) is entitled to rely on Rule&#160;701 to resell such shares beginning 90&#160;days after we become subject to the public company reporting requirements of the Exchange Act in reliance on Rule&#160;144, but without compliance with the holding period requirements contained in </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">154</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:340pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Rule&#160;144. Accordingly, subject to any applicable lock-up agreements, beginning 90&#160;days after we become subject to the public company reporting requirements of the Exchange Act, under Rule&#160;701 persons who are not our &#8220;affiliates,&#8221; as defined in Rule&#160;144, may resell those shares without complying with the minimum holding period or public information requirements of Rule&#160;144, and persons who are our &#8220;affiliates&#8221; may resell those shares without compliance with Rule&#160;144&#8217;s minimum holding period requirements (subject to the terms of the lock-up agreement referred to below, if applicable). </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Registration Rights</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Based on the number of shares outstanding as of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; , 2021, after the completion of this offering, the holders of approximately&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; million shares of our Class&#160;A common stock, or their transferees, will, subject to any lock-up agreements they have entered into, be entitled to certain rights with respect to the registration of the offer and sale of those shares under the Securities Act. For a description of these registration rights, please see the &#8220;Description of Capital Stock&#8201;&#8212;&#8201;Registration Rights&#8221; section of this prospectus. If the offer and sale of these shares are registered, they will be freely tradable without restriction under the Securities&#160;Act. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Equity Incentive Plans</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We intend to file with the SEC a registration statement on Form S-8 under the Securities Act covering the shares of Class&#160;A common stock that we may issue upon exercise of outstanding options reserved for issuance under equity incentive plans. Such registration statement is expected to be filed and become effective as soon as practicable after the completion of this offering. Accordingly, shares registered under such registration statement will be available for sale in the open market following its effective date, subject to Rule&#160;144 volume limitations and the lock-up agreements described above, if applicable. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">155</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMUFI">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following is a summary of the material U.S. federal income tax consequences of the ownership and disposition of our Class&#160;A common stock to Non-U.S. Holders (defined below), but does not purport to be a complete analysis of all the potential tax considerations relating thereto. This summary is based upon the provisions of the Internal Revenue Code of 1986, as amended, or the Code, Treasury regulations promulgated thereunder, administrative rulings and judicial decisions, all as of the date hereof. These authorities may be changed or subject to differing interpretations, possibly with retroactive effect, so as to result in U.S. federal income tax consequences different from those set forth below. We have not sought and will not seek any ruling from the Internal Revenue Service, or the IRS, with respect to the statements made and the conclusions reached in the following summary, and there can be no assurance that the IRS or a court will agree with such statements and conclusions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This summary also does not address the tax considerations arising under the laws of any U.S. state or local or any non-U.S. jurisdiction, the 3.8% Medicare tax on net investment income or any alternative minimum tax consequences, or under U.S. federal gift and estate tax laws, except to the limited extent provided below. In addition, this discussion does not address tax considerations applicable to a Non-U.S. Holder&#8217;s particular circumstances or to a Non-U.S. Holder that may be subject to special tax rules, including, without limitation: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">banks, insurance companies or other financial institutions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">tax-exempt organizations, tax-qualified retirement plans, or government organizations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">brokers of or dealers in securities or currencies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.51pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">traders in securities that elect to use a mark-to-market method of accounting for their securities holdings; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">persons that own, or are deemed to constructively own, more than five&#160;percent of our capital stock (except to the extent specifically set forth below); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">certain U.S. expatriates, former citizens, or former long-term residents of the United States; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.51pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">persons who hold our Class&#160;A common stock as a position in a hedging transaction, &#8220;straddle,&#8221; &#8220;conversion transaction,&#8221; synthetic security, other integrated investment, or other risk reduction transaction; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">persons who do not hold our Class&#160;A common stock as a capital asset within the meaning of Section&#160;1221 of the Code (generally, for investment purposes); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.51pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">persons deemed to sell our Class&#160;A common stock under the constructive sale provisions of the Code; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">persons whose functional currency is not the U.S. dollar; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">real estate investment trusts or regulated investment companies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.41pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">pension plans; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">pass-through entities such as partnerships, S corporations, disregarded entities for federal income tax purposes and limited liability companies (and investors therein); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">persons for whom our stock constitutes &#8220;qualified small business stock&#8221; within the meaning of Section&#160;1202 of the Code or as &#8220;Section&#160;1244 stock&#8221; for purposes of Section&#160;1244 of the Code; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">persons required for U.S. federal income tax purposes to conform the timing of income accruals to their financial statements under Section&#160;451(b) of the Code; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">integral parts or controlled entities of foreign sovereigns; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.41pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">tax-qualified retirement plans; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">&#8220;controlled foreign corporations&#8221; &#8203;(including &#8220;specified foreign corporations&#8221;); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">&#8220;passive foreign investment companies&#8221; and corporations that accumulate earnings to avoid U.S.&#160;federal income tax; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">156</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">persons that acquire our Class&#160;A common stock as compensation for services. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, if a partnership, including any entity or arrangement classified as a partnership for U.S.&#160;federal income tax purposes, holds our Class&#160;A common stock, the tax treatment of a partner generally will depend on the status of the partner, the activities of the partnership, and certain determinations made at the partner level. Accordingly, partnerships that hold our Class&#160;A common stock, and partners in such partnerships, should consult their tax advisors regarding the U.S. federal income tax consequences to them of the purchase, ownership, and disposition of our Class&#160;A common stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">You are urged to consult your tax advisor with respect to the application of the U.S. federal income tax laws to your particular situation, as well as any tax consequences of the purchase, ownership and disposition of our Class&#160;A common stock arising under the U.S. federal estate or gift tax rules or under the laws of any U.S. state or local or any non-U.S. or other taxing jurisdiction or under any applicable tax treaty.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Definition of a Non-U.S. Holder</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For purposes of this summary, a &#8220;Non-U.S. Holder&#8221; is any beneficial owner of our Class&#160;A common stock that is not a &#8220;U.S. person,&#8221; and is not a partnership, or an entity disregarded from its owner, each for U.S. federal income tax purposes. A U.S. person is any person that, for U.S. federal income tax purposes, is or is treated as any of the following: (i)&#160;an individual who is a citizen or resident of the United States; (ii)&#160;a corporation (or other entity taxable as a corporation for U.S. federal income tax purposes) created or organized under the laws of the United States, any state thereof, or the District of Columbia; (iii)&#160;an estate, the income of which is subject to U.S. federal income tax regardless of its source; or (iv)&#160;a trust that (1)&#160;is subject to the primary supervision of a U.S. court and the control of one or more U.S. persons (within the meaning of Section&#160;7701(a)(30) of the Code), or (2)&#160;has a valid election in effect to be treated as a U.S. person for U.S.&#160;federal income tax purposes. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Distributions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As discussed under the &#8220;Dividend Policy&#8221; section of this prospectus, we do not anticipate paying any dividends on our capital stock in the foreseeable future. If we make distributions on our Class&#160;A common stock, those payments will constitute dividends for U.S. income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. To the extent those distributions exceed both our current and our accumulated earnings and profits, they will constitute a return of capital and will first reduce a Non-U.S. Holder&#8217;s basis in our Class&#160;A common stock, but not below zero. Any excess will be treated as capital gain and will be treated as described in the &#8220;&#8212; Gain on Sale or Other Disposition of Class&#160;A Common Stock&#8221; section of this prospectus. Any such distributions would be subject to the discussions below regarding back-up withholding and FATCA. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Subject to the discussion below on effectively connected income, any dividend paid to a Non-U.S. Holder generally will be subject to U.S. withholding tax either at a rate of 30% of the gross amount of the dividend or such lower rate as may be specified by an applicable income tax treaty. In order to receive a reduced treaty rate, a Non-U.S. Holder must provide us or our agent with an IRS Form W-8BEN (generally including a U.S. taxpayer identification number), IRS Form W-8-BEN-E or another appropriate version of IRS Form W-8 (or a successor form), which must be updated periodically, and which, in each case, must certify qualification for the reduced rate. Non-U.S. Holders should consult their tax advisors regarding their entitlement to benefits under any applicable income tax treaty. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Dividends paid to a Non-U.S. Holder that are effectively connected with the Non-U.S. Holder&#8217;s conduct of a U.S. trade or business within the United States (and, if required by an applicable income tax treaty, are attributable to a permanent establishment maintained by the Non-U.S. Holder in the United States) generally are exempt from the withholding tax described above. In order to obtain this exemption, the Non-U.S. Holder must provide the applicable withholding agent with an IRS Form W-8ECI or successor form or other applicable IRS Form W-8 certifying that the dividends are effectively connected with the Non-U.S. Holder&#8217;s conduct of a trade or business within the United States. Such effectively connected dividends, although not subject to withholding tax, are taxed at the same graduated rates applicable to U.S.&#160;persons, net of certain deductions and credits, subject to an applicable income tax treaty providing otherwise. In addition, if you are Non-U.S. Holder that is a corporation, dividends you receive that are </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">157</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">effectively connected with your conduct of a U.S. trade or business (and, if an income tax treaty applies, are attributable to a permanent establishment maintained by the you in the United States) may also be subject to a branch profits tax at a rate of 30% (or such lower rate as may be specified by an applicable income tax treaty) on such effectively connected dividends, as adjusted for certain items. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If you are eligible for a reduced rate of withholding tax pursuant to a tax treaty, you may be able to obtain a refund of any excess amounts currently withheld if you timely file an appropriate claim for refund with the IRS. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Gain on Sale or Other Disposition of Class&#160;A Common Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Subject to the discussion below regarding backup withholding and FATCA, a Non-U.S. Holder generally will not be required to pay U.S. federal income tax on any gain realized upon the sale or other disposition of our Class&#160;A common stock unless: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the gain is effectively connected with the Non-U.S. Holder&#8217;s conduct of a trade or business within the United States (and, if an income tax treaty applies, the gain is attributable to a permanent establishment maintained by the Non-U.S. Holder in the United States), in which case the Non-U.S. Holder will be required to pay tax on the net gain derived from the sale under regular graduated U.S. federal income tax rates, and for a Non-U.S. Holder that is a corporation, such Non-U.S. Holder may be subject to the branch profits tax at a 30% rate (or such lower rate as may be specified by an applicable income tax treaty) on such effectively connected dividends, as adjusted for certain items; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the Non-U.S. Holder is an individual who is present in the United States for a period or periods aggregating 183&#160;days or more during the calendar year in which the sale or disposition occurs and certain other conditions are met, in which case the Non-U.S. Holder will be required to pay a flat 30% tax on the gain derived from the sale, which tax may be offset by U.S. source capital losses (even though the Non-U.S. Holder is not considered a resident of the United States) (subject to applicable income tax or other treaties) provided that the Non-U.S. holder has timely filed U.S.&#160;federal income tax returns with respect to such losses; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.61pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.61pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">our Class&#160;A common stock constitutes a U.S. real property interest by reason of our status as a U.S. real property holding corporation, or USRPHC, for U.S. federal income tax purposes at any time within the shorter of the five-year period preceding the disposition or the Non-U.S. Holder&#8217;s holding period for our Class&#160;A common stock. Generally, a corporation is a USRPHC only if the fair market value of its U.S. real property interests equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests plus its other assets used or held for use in a trade or business. We believe we are not currently and do not anticipate becoming a USRPHC. However, because the determination of whether we are a USRPHC depends on the fair market value of our U.S. real property interests relative to the fair market value of our other business assets, there can be no assurance that we will not become a USRPHC in the future. Even if we become a USRPHC, however, gain arising from the sale or other taxable disposition by a Non-U.S. Holder of our Class&#160;A common stock will not be subject to U.S. federal income tax as long as our Class&#160;A common stock is regularly traded on an established securities market, as defined by applicable Treasury Regulations, and such Non-U.S. Holder does not, actually or constructively, hold more than five&#160;percent of our Class&#160;A common stock at any time during the applicable period that is specified in the Code. If the foregoing exception does not apply, then if we are or were to become a USRPHC a purchaser may be required to withhold 15% of the proceeds payable to a Non-U.S. Holder from a sale of our Class&#160;A common stock and such Non-U.S. Holder generally will be taxed on its net gain derived from the disposition at the graduated U.S. federal income tax rates applicable to U.S. persons. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Backup Withholding and Information Reporting</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Generally, we must file information returns annually to the IRS in connection with any dividends on our Class&#160;A common stock paid to a Non-U.S. Holder, regardless of whether any tax was actually withheld. A similar report will be sent to the Non-U.S. Holder. Pursuant to applicable income tax treaties or other agreements, the IRS may make these reports available to tax authorities in the Non-U.S. Holder&#8217;s country of residence. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">158</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Payments of dividends or of proceeds on the disposition of stock made to a Non-U.S. Holder may be subject to additional information reporting and backup withholding at a current rate of 24% unless such Non-U.S. Holder establishes an exemption, for example by properly certifying its non-U.S. status on an IRS Form W-8BEN, IRS Form W-8BEN-E, IRS Form W-8ECI, or another appropriate version of IRS Form W-8 (or a successor form). Notwithstanding the foregoing, backup withholding and information reporting may apply if either we or our paying agent has actual knowledge, or reason to know, that a holder is a U.S.&#160;person. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Backup withholding is not an additional tax; rather, the U.S. income tax liability of persons subject to backup withholding will be reduced by the amount of tax withheld. If withholding results in an overpayment of taxes, a refund or credit may generally be obtained from the IRS, provided that the required information is furnished to the IRS in a timely manner. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Foreign Account Tax Compliance Act</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Foreign Account Tax Compliance Act, or FATCA, imposes withholding tax on certain types of payments made to foreign financial institutions and certain other non-U.S. entities. FATCA imposes a 30% withholding tax on certain payments made to a &#8220;foreign financial institution&#8221; or to certain &#8220;non-financial foreign entities&#8221; &#8203;(each as defined in the Code), unless (i)&#160;the foreign financial institution undertakes certain diligence and reporting obligations, (ii)&#160;the non-financial foreign entity either certifies it does not have any &#8220;substantial United States owners&#8221; &#8203;(as defined in the Code) or furnishes identifying information regarding each substantial United States owner, or (iii)&#160;the foreign financial institution or non-financial foreign entity otherwise qualifies for an exemption from these rules. If the payee is a foreign financial institution and is subject to the diligence and reporting requirements in (i)&#160;above, it must enter into an agreement with the U.S.&#160;Treasury requiring, among other things, that it undertake to identify accounts held by &#8220;specified United States persons&#8221; or &#8220;United States-owned foreign entities&#8221; &#8203;(each as defined in the Code), annually report certain information about such accounts, and withhold 30% on payments to account holders whose actions prevent it from complying with these reporting and other requirements. If the country in which a payee is resident has entered into an &#8220;intergovernmental agreement&#8221; with the United States regarding FATCA, that agreement may permit the payee to report to that country rather than to the U.S. Department of the Treasury. FATCA currently applies to dividends paid on our Class&#160;A common stock. On December&#160;13, 2018, the U.S.&#160;Treasury Department released proposed Treasury Regulations under FATCA providing for the elimination of the federal withholding tax of 30% applicable to gross proceeds of a sale or other disposition of our Class&#160;A common stock. Under these proposed Treasury Regulations (which may be relied upon by taxpayers prior to finalization), FATCA will not apply to gross proceeds from sales or other dispositions of our Class&#160;A common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Prospective investors should consult their own tax advisors regarding the possible impact of these rules on their investment in our Class&#160;A common stock, and the possible impact of these rules on the entities through which they hold our Class&#160;A common stock, including, without limitation, the process and deadlines for meeting the applicable requirements to prevent the imposition of this 30% withholding tax under FATCA. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Federal Estate Tax</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Class&#160;A Common stock owned (or treated as owned) by an individual who is not a citizen or a resident of the United States (as defined for U.S. federal estate tax purposes) at the time of death will be included in the individual&#8217;s gross estate for U.S. federal estate tax purposes unless an applicable estate or other tax treaty provides otherwise, and therefore may be subject to U.S. federal estate tax. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">THE PRECEDING DISCUSSION OF U.S. FEDERAL TAX CONSIDERATIONS IS FOR GENERAL INFORMATION ONLY. IT IS NOT TAX ADVICE. EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS TAX ADVISOR REGARDING THE PARTICULAR U.S. FEDERAL, STATE AND LOCAL AND NON-U.S. TAX CONSEQUENCES OF PURCHASING, HOLDING AND DISPOSING OF OUR CLASS&#160;A COMMON STOCK, INCLUDING THE CONSEQUENCES OF ANY PROPOSED CHANGE IN APPLICABLE LAWS. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">159</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tUND">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">UNDERWRITING</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Citigroup Global Markets Inc., Cowen and Company, LLC and William Blair &amp; Company, L.L.C., the Representatives, are acting as joint book-running managers of this offering and as representatives of the underwriters named below. Subject to the terms and conditions stated in the underwriting agreement, which will be filed as an exhibit to the registration statement of which this prospectus is a part, with respect to the shares being offered, the underwriters named below have severally agreed to purchase, and we have agreed to sell to them, the number of shares of our Class&#160;A common stock indicated below: </font>
        </div>
        <table style="width:456pt;height:77.48pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8.98pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:412.45pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Underwriter </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:31.55pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number</font>
                <br >
                <font style="letter-spacing:-0.16pt;">of Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:412.45pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Citigroup Global Markets Inc. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:31.55pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:412.45pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cowen and Company, LLC </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:31.55pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:412.45pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">William Blair &amp; Company, L.L.C. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:31.55pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:412.45pt;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:31.55pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The underwriting agreement provides that the obligations of the underwriters to purchase the shares of our Class&#160;A common stock included in this offering are subject to approval of legal matters by counsel and to other conditions. The underwriters are obligated to purchase all of the shares of our Class&#160;A common stock (other than those covered by the over-allotment option described below) if they purchase any of the shares. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Shares of our Class&#160;A common stock sold by the underwriters to the public will initially be offered at the initial public offering price set forth on the cover of this prospectus. Any shares of our Class&#160;A common stock sold by the underwriters to securities dealers may be sold at a discount from the initial public offering price not to exceed $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share. After the initial public offering of the shares of our Class&#160;A common stock, if all the shares of our Class&#160;A common stock are not sold at the initial public offering price, the underwriters may change the offering price and the other selling terms. Any shares sold by the underwriters to securities dealers may be sold at a discount of up to $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share from the initial public offering price. The representatives have advised us that the underwriters do not intend to make sales to discretionary accounts. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If the underwriters sell more shares of our Class&#160;A common stock than the total number set forth in the table above, we have granted to the underwriters an option, exercisable for 30&#160;days from the date of this prospectus, to purchase up to additional shares of our Class&#160;A common stock at the initial public offering price less the underwriting discount. The underwriters may exercise the option solely for the purpose of covering over-allotments, if any, in connection with this offering. To the extent the option is exercised, each underwriter must purchase a number of additional shares of our Class&#160;A common stock approximately proportionate to that underwriter&#8217;s initial purchase commitment set forth in the table above. Any shares of our Class&#160;A common stock issued or sold under the option will be issued and sold on the same terms and conditions as the other shares of our Class&#160;A common stock that are the subject of this offering. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We, our officers and directors and substantially all of our stockholders have agreed that, subject to specified limited exceptions, for a period of 180&#160;days from the date of this prospectus, we and they will not, without the prior written consent of the Representatives, offer, sell, contract to sell, pledge or otherwise dispose of, including the filing of a registration statement in respect of, or hedge any shares of our Class&#160;A common stock or any securities convertible into, or exercisable or exchangeable for, our Class&#160;A common stock. The Representatives in their sole discretion may release any of the securities subject to these lock-up agreements at any time, which, in the case of officers and directors, shall be with notice. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Prior to this offering, there has been no public market for our Class&#160;A common stock. Consequently, the initial public offering price for the shares of our Class&#160;A common stock will be determined by negotiations between us and the representatives. Among the factors considered in determining the initial public offering price will be our results of operations, our current financial condition, our future prospects, our markets, the economic conditions in and future prospects for the industry in which we compete, our management, and currently prevailing general conditions in the equity securities markets, including current market valuations of publicly traded companies considered comparable to our company. We cannot assure you, however, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">160</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">that the price at which the shares of our Class&#160;A common stock will sell in the public market after this offering will not be lower than the initial public offering price or that an active trading market in our shares of Class&#160;A common stock will develop and continue after this offering. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have applied to list our Class&#160;A common stock on The Nasdaq Global Market under the symbol &#8220;SERA&#8221;. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table shows the per share and total public offering price, underwriting discounts and commissions that we are to pay to the underwriters and proceeds to us, before expenses, in connection with this offering. These amounts are shown assuming both no exercise and full exercise of the underwriters&#8217; over-allotment option: </font>
        </div>
        <table style="width:456pt;height:76.57pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:315pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.98pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:315pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.597pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Per</font>
                <br >
                <font style="letter-spacing:-0.16pt;">share </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.597pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">No</font>
                <br >
                <font style="letter-spacing:-0.16pt;">exercise </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.597pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Full</font>
                <br >
                <font style="letter-spacing:-0.16pt;">exercise </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:315pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Public offering price </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:315pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Underwriting discounts and commissions paid by us </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:315pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Proceeds to us, before expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:7.7pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We estimate that expenses payable by us in connection with this offering, exclusive of underwriting discounts and commissions, will be approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; million. We have also agreed to reimburse the underwriters for expenses in an amount up to $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; relating to the clearance of this offering with the Financial Industry Regulatory Authority, Inc. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with this offering, the underwriters may purchase and sell shares of our Class&#160;A common stock in the open market. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Purchases and sales in the open market may include short sales, purchases to cover short positions, which may include purchases pursuant to the underwriters&#8217; over-allotment option, and other transactions that would stabilize, maintain or otherwise affect the price of our Class&#160;A common stock. </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">Short sales involve secondary market sales by the underwriters of a greater number of shares of our Class&#160;A common stock than they are required to purchase in this offering: </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <font style="letter-spacing:0.2pt;">&#8220;Covered&#8221; short sales are sales of shares of our Class&#160;A common stock in an amount up to the number of shares of our Class&#160;A common stock represented by the underwriters&#8217; over-allotment option. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <font style="letter-spacing:0.2pt;">&#8220;Naked&#8221; short sales are sales of shares of our Class&#160;A common stock in an amount in excess of the number of shares of our Class&#160;A common stock represented by the underwriters&#8217; over-allotment option. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">The underwriters can close out a short position by purchasing additional shares of our Class&#160;A common stock, either pursuant to the underwriters&#8217; over-allotment option or in the open market. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <font style="letter-spacing:0.2pt;">To close a naked short position, the underwriters must purchase shares of our Class&#160;A common stock in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the shares of our Class&#160;A common stock in the open market after pricing that could adversely affect investors who purchase in this offering. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <font style="letter-spacing:0.2pt;">To close a covered short position, the underwriters must purchase shares of our Class&#160;A common stock in the open market or exercise their over-allotment option. In determining the source of shares of our Class&#160;A common stock to close the covered short position, the underwriters will consider, among other things, the price of shares of our Class&#160;A common stock available for purchase in the open market as compared to the price at which they may purchase shares of our Class&#160;A common stock through their over- allotment option. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">As an additional means of facilitating this offering, the underwriters may bid for, and purchase, shares of our Class&#160;A common stock on the Nasdaq Global Market, as long as such bids do not exceed a specified maximum, to stabilize the price of the shares of our Class&#160;A common stock. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">161</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Purchases to cover short positions and stabilizing purchases, as well as other purchases by the underwriters for their own accounts, may have the effect of preventing or retarding a decline in the market price of the shares. They may also cause the price of the shares of our Class&#160;A common stock to be higher than the price that would otherwise prevail in the open market in the absence of these transactions. The underwriters may conduct these transactions on the Nasdaq Global Market, in the over-the-counter market or otherwise. The underwriters are not required to engage in any of these transactions and may discontinue them at any time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act, or to contribute to payments the underwriters may be required to make because of any of those liabilities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A prospectus in electronic format may be made available on websites maintained by one or more of the underwriters or their respective affiliates. The representatives may agree with us to allocate a number of shares of our Class&#160;A common stock to underwriters for sale to their online brokerage account holders. Any such allocation for online distributions will be made by the underwriters on the same basis as other allocations. Other than the prospectus in electronic format, the information on the underwriters&#8217; or their respective affiliates&#8217; websites and any information contained in any other website maintained by any of the underwriters or their respective affiliates is not part of this prospectus, has not been approved and/or endorsed by us or the underwriters and should not be relied upon by investors in this offering. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Other Relationships</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The underwriters are full-service financial institutions engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, investment management, principal investment, hedging, financing and brokerage activities. The underwriters and their respective affiliates may, from time to time, engage in transactions with and perform services for us in the ordinary course of their business for which they may receive customary fees and reimbursement of expenses. In the ordinary course of their various business activities, the underwriters and their respective affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (which may include bank loans or credit default swaps) for their own account and for the accounts of their customers and may at any time hold long and short positions in such securities and instruments. Such investments and securities activities may involve securities and/or instruments of ours or our affiliates. If the underwriters or their affiliates have a lending relationship with us, certain of those underwriters or their affiliates routinely hedge, and certain other of those underwriters or their affiliates may hedge, their credit exposure to us consistent with their customary risk management policies. Typically, the underwriters and their affiliates would hedge such exposure by entering into transactions which consist of either the purchase of credit default swaps or the creation of short positions in our securities or the securities of our affiliates, including potentially the shares of Class&#160;A common stock offered hereby. Any such credit default swaps or short positions could adversely affect future trading prices of the shares of Class&#160;A common stock offered hereby. The underwriters and their affiliates may also make independent investment recommendations and/or publish or express independent research views in respect of such securities or financial instruments and may hold, or recommend to clients that they acquire, long or short positions in such securities and instruments. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Notice to Prospective Investors in the European Economic Area</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In relation to each member state of the European Economic Area (each, a Relevant Member State), an offer of shares of our Class&#160;A common stock described in this prospectus may not be made to the public in that Relevant Member State other than under the following exemptions under the EU Prospectus Regulation: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">to any legal entity which is a qualified investor as defined under the EU Prospectus Regulation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">to fewer than 150 natural or legal persons (other than qualified investors as defined under the EU&#160;Prospectus Regulation), subject to obtaining the prior consent of the relevant Dealer or Dealers nominated by us for any such offer; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">in any other circumstances falling within Article&#160;1(4) of the EU Prospectus Regulation, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">162</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">provided that no such offer of shares of our Class&#160;A common stock shall require us or any underwriter to publish a prospectus pursuant to Article&#160;3 of the EU Prospectus Regulation or supplement a prospectus pursuant to Article&#160;23 of the EU Prospectus Regulation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For purposes of this provision, the expression an &#8220;offer to the public&#8221; in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and the shares of our Class&#160;A common stock to be offered so as to enable an investor to decide to purchase or subscribe for any shares of our Class&#160;A common stock, the expression &#8220;EU Prospectus Regulation&#8221; means Regulation (EU) 2017/1129. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The sellers of the shares of our Class&#160;A common stock have not authorized and do not authorize the making of any offer of shares of our Class&#160;A common stock through any financial intermediary on their behalf, other than offers made by the underwriters with a view to the final placement of the shares of our Class&#160;A common stock as contemplated in this prospectus. Accordingly, no purchaser of the shares of our Class&#160;A common stock, other than the underwriters, is authorized to make any further offer of the shares of our Class&#160;A common stock on behalf of the sellers or the underwriters. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Notice to Prospective Investors in the United Kingdom</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus is only being distributed to, and is only directed at, persons in the United Kingdom that are qualified investors within the meaning of the UK version of the EU Prospectus Regulation which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, that are also (1)&#160;investment professionals falling within Article&#160;19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the Order), or (2)&#160;high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article&#160;49(2)(a) to (d)&#160;of the Order; or (3)&#160;any other person to whom this prospectus may otherwise lawfully be communicated or caused to be communicated to under the Order (each such person being referred to as a relevant person). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any person in the United Kingdom that is not a relevant person should not act or rely on this document or any of its contents. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Notice to Prospective Investors in Switzerland</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">An offer of shares of our Class&#160;A common stock described in this prospectus may not be made to the public in Switzerland (within the meaning of Sections&#160;3 and 35 the Swiss Financial Services Act (the FinSA) and of its implementing ordinance) other than under any of the statutory exemptions from the requirement to prepare and publish a prospectus, in particular Sections&#160;36 to 38 FinSA, including (without limitations): </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the offering in Switzerland is limited to professional clients (as defined in the FinSA) only; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the offering in Switzerland is addressed at fewer than 500 investors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the offering in Switzerland is limited to shares of our Class&#160;A common stock allocated to current or former members of the board of directors or management board or employees of our company or affiliated entities; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">the shares of our Class&#160;A common stock are admitted to trading on a foreign trading venue whose regulation, supervision and transparency are acknowledged as being appropriate by the domestic trading venue or whose transparency for investors is ensured in another manner. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Moreover, the shares of our Class&#160;A common stock described in the prospectus are not admitted to trading on any trading venue (exchange or multilateral trading facility) in Switzerland. This prospectus and its contents do not constitute a prospectus pursuant to the FinSA, and no such prospectus within the meaning of the FinSA has been or will be prepared for or in connection with the offering of the shares of our Class&#160;A common stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Notice to Prospective Investors in Australia</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">No prospectus or other disclosure document (as defined in the Corporations Act 2001 (Cth) of Australia, or Corporations Act) in relation to our Class&#160;A common stock has been or will be lodged with </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">163</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">the Australian Securities &amp; Investments Commission, or ASIC. This document has not been lodged with ASIC&#160;and is only directed to certain categories of exempt persons. Accordingly, if you receive this document in Australia: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">you confirm and warrant that you are either: </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <font style="letter-spacing:0.2pt;">a &#8220;sophisticated investor&#8221; under Section&#160;708(8)(a) or (b)&#160;of the Corporations Act; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <font style="letter-spacing:0.2pt;">a &#8220;sophisticated investor&#8221; under Section&#160;708(8)(c) or (d)&#160;of the Corporations Act and that you have provided an accountant&#8217;s certificate to us which complies with the requirements of Section&#160;708(8)(c)(i) or (ii)&#160;of the Corporations Act and related regulations before the offer has been made; a person associated with the company under Section&#160;708(12) of the Corporations Act; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <font style="letter-spacing:0.2pt;">a &#8220;professional investor&#8221; within the meaning of Section&#160;708(11)(a) or (b)&#160;of the Corporations Act, and to the extent that you are unable to confirm or warrant that you are an exempt sophisticated investor, associated person or professional investor under the Corporations Act any offer made to you under this document is void and incapable of acceptance; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <font style="letter-spacing:0.2pt;">you warrant and agree that you will not offer any of our Class&#160;A common stock for resale in Australia within 12&#160;months of that Class&#160;A common stock being issued unless any such resale offer is exempt from the requirement to issue a disclosure document under Section&#160;708 of the Corporations Act. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Notice to Prospective Investors in Canada</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The securities may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the securities must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#8217;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#8217;s province or territory for particulars of these rights or consult with a legal advisor. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to Section&#160;3A.3 of National Instrument 33-105 Underwriting Conflicts (NI 33-105), the underwriters are not required to comply with the disclosure requirements of NI 33-105 regarding underwriter conflicts of interest in connection with this offering. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Notice to Prospective Investors in Chile</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The shares of our Class&#160;A common stock are not registered in the Securities Registry (Registro de Valores) or subject to the control of the Chilean Securities and Exchange Commission (Superintendencia de Valores y Seguros de Chile). This prospectus and other offering materials relating to the offer of the shares do not constitute a public offer of, or an invitation to subscribe for or purchase, the shares in the Republic of Chile, other than to individually identified purchasers pursuant to a private offering within the meaning of Article&#160;4 of the Chilean Securities Market Act (Ley de Mercado de Valores) (an offer that is not &#8220;addressed to the public at large or to a certain sector or specific group of the public&#8221;). </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Notice to Prospective Investors in France</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="font-style:normal;letter-spacing:0.2pt;">Neither this prospectus nor any other offering material relating to the shares of our Class&#160;A common stock described in this prospectus has been submitted to the clearance procedures of the </font><font style="letter-spacing:0.2pt;">Autorit&#233; des March&#233;s Financiers</font><font style="font-style:normal;letter-spacing:0.2pt;"> or of the competent authority of another member state of the European Economic Area and notified to the </font><font style="letter-spacing:0.2pt;">Autorit&#233; des March&#233;s Financiers</font><font style="font-style:normal;letter-spacing:0.2pt;">. The shares of our Class&#160;A common stock have not been </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">164</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">offered or sold and will not be offered or sold, directly or indirectly, to the public in France. Neither this prospectus nor any other offering material relating to the shares of our Class&#160;A common stock has been or will be: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">released, issued, distributed or caused to be released, issued or distributed to the public in France; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">used in connection with any offer for subscription or sale of the shares of our Class&#160;A common stock to the public in France. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Such offers, sales and distributions will be made in France only: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">to qualified investors (</font><font style="font-style:italic;letter-spacing:0.2pt;">investisseurs qualifi&#233;s</font><font style="letter-spacing:0.2pt;">) and/or to a restricted circle of investors (</font><font style="font-style:italic;letter-spacing:0.2pt;">cercle restreint d&#8217;investisseurs</font><font style="letter-spacing:0.2pt;">), in each case investing for their own account, all as defined in and in accordance with articles L.411-2, D.411-1, D.411-2, D.734-1, D.744-1, D.754-1and D.764-1 of the French Code mon&#233;taire et financier; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">to investment services providers authorized to engage in portfolio management on behalf of third parties; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;">
          <font style="font-style:normal;letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;font-style:italic;">
          <font style="font-style:normal;letter-spacing:0.2pt;">in a transaction that, in accordance with article L.411-2-II-1&#176; -or-2&#176; -or 3&#176; of the French Code </font><font style="letter-spacing:0.2pt;">mon&#233;taire et financier</font><font style="font-style:normal;letter-spacing:0.2pt;"> and article 211-2 of the General Regulations (</font><font style="letter-spacing:0.2pt;">R&#232;glement G&#233;n&#233;ral</font><font style="font-style:normal;letter-spacing:0.2pt;">) of the </font><font style="letter-spacing:0.2pt;">Autorit&#233; des March&#233;s Financiers</font><font style="font-style:normal;letter-spacing:0.2pt;">, does not constitute a public offer (</font><font style="letter-spacing:0.2pt;">appel public &#224; l&#8217;&#233;pargne</font><font style="font-style:normal;letter-spacing:0.2pt;">). </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The shares of our Class&#160;A common stock may be resold directly or indirectly, only in compliance with articles L.411-1, L.411-2, L.412-1 and L.621-8 through L.621-8-3 of the French Code </font><font style="font-style:italic;letter-spacing:0.2pt;">mon&#233;taire et financier</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Notice to Prospective Investors in Germany</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Neither this prospectus nor any other offering material relating to shares of our Class&#160;A common stock described in this prospectus has been filed with or approved by the German Financial Services Supervisory Authority (</font><font style="font-style:italic;letter-spacing:0.2pt;">undesanstalt f&#252;r Finanzdienstleistungsaufsicht</font><font style="letter-spacing:0.2pt;">, or BaFin) according to the German Securities Prospectus Act (</font><font style="font-style:italic;letter-spacing:0.2pt;">Wertpapierprospektgesetz</font><font style="letter-spacing:0.2pt;">, or WpPG), the German Investment Code (</font><font style="font-style:italic;letter-spacing:0.2pt;">Kapitalanlagegesetzbuch</font><font style="letter-spacing:0.2pt;">) or the German Capital Investment Act (</font><font style="font-style:italic;letter-spacing:0.2pt;">Verm&#246;gensanlagengesetz</font><font style="letter-spacing:0.2pt;">) or with any other governmental or regulatory authority in Germany. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The offering is not being made, and may not be made to the public in Germany as a Relevant Member State, except pursuant to one of the exemptions under the EU Prospectus Regulation set out in the Notice to Prospective Investors in the European Economic Area above. For Germany as on Relevant Member State, the EU Prospectus Regulation was supplemented by the WpPG. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Notice to Prospective Investors in Hong Kong</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The shares of our Class&#160;A common stock may not be offered or sold in Hong Kong by means of any document other than (1)&#160;in circumstances which do not constitute an offer to the public within the meaning of the Companies Ordinance (Cap. 32, Laws of Hong Kong), or (2)&#160;to &#8220;professional investors&#8221; within the meaning of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong) and any rules made thereunder, or (3)&#160;in other circumstances which do not result in the document being a &#8220;prospectus&#8221; within the meaning of the Companies Ordinance (Cap. 32, Laws of Hong Kong) and no advertisement, invitation or document relating to the shares of our Class&#160;A common stock may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under the laws of Hong Kong) other than with respect to shares of our Class&#160;A common stock which are or are intended to be disposed of only to persons outside Hong Kong or only to &#8220;professional investors&#8221; within the meaning of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong) and any rules made thereunder. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Notice to Prospective Investors in the State of Israel</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the State of Israel this prospectus shall not be regarded as an offer to the public to purchase shares of Class&#160;A common stock under the Israeli Securities Law, 5728&#8201;&#8212;&#8201;1968, which requires a prospectus to be </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">165</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">published and authorized by the Israel Securities Authority, if it complies with certain provisions of Section&#160;15 of the Israeli Securities Law, 5728&#8201;&#8212;&#8201;1968, including, inter alia, if: (1)&#160;the offer is made, distributed or directed to not more than 35 investors, subject to certain conditions, or the Addressed Investors; or (2)&#160;the offer is made, distributed or directed to certain qualified investors defined in the First Addendum of the Israeli Securities Law, 5728&#8201;&#8212;&#8201;1968, subject to certain conditions, or Qualified Investors. The Qualified Investors shall not be taken into account in the count of the Addressed Investors and may be offered to purchase securities in addition to the 35 Addressed Investors. We have not and will not take any action that would require us to publish a prospectus in accordance with and subject to the Israeli Securities Law, 5728&#8201;&#8212;&#8201;1968. We have not and will not distribute this prospectus or make, distribute or direct an offer to subscribe for our Class&#160;A common stock to any person within the State of Israel, other than to Qualified Investors and up to 35 Addressed Investors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Qualified Investors may have to submit written evidence that they meet the definitions set out in of the First Addendum to the Israeli Securities Law, 5728&#8201;&#8212;&#8201;1968. In particular, we may request that Qualified Investors will each represent, warrant and certify to us and/or to anyone acting on our behalf: (1)&#160;that it is an investor falling within one of the categories listed in the First Addendum to the Israeli Securities Law, 5728&#8201;&#8212;&#8201;1968; (2)&#160;which of the categories listed in the First Addendum to the Israeli Securities Law, 5728&#8201;&#8212;&#8201;1968 regarding Qualified Investors is applicable to it; (3)&#160;that it will abide by all provisions set forth in the Israeli Securities Law, 5728&#8201;&#8212;&#8201;1968 and the regulations promulgated thereunder in connection with this offering; (4)&#160;that the shares of Class&#160;A common stock that it will be issued are, subject to exemptions available under the Israeli Securities Law, 5728&#8201;&#8212;&#8201;1968: (a)&#160;for its own account; (b)&#160;for investment purposes only; and (c)&#160;not issued with a view to resale within the State of Israel, other than in accordance with the provisions of the Israeli Securities Law, 5728 <font style="white-space:nowrap;">-1968;</font> and (5)&#160;that it is willing to provide further evidence of its Qualified Investor status. Addressed Investors may have to submit written evidence in respect of their identity and may have to sign and submit a declaration containing, inter alia, the Addressed Investor&#8217;s name, address and passport number or Israeli identification number. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Notice to Prospective Investors in Japan</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The shares of our Class&#160;A common stock offered in this prospectus have not been and will not be registered under the Financial Instruments and Exchange Law of Japan. The shares of our Class&#160;A common stock have not been offered or sold and will not be offered or sold, directly or indirectly, in Japan or to or for the account of any resident of Japan (including any corporation or other entity organized under the laws of Japan), except (1)&#160;pursuant to an exemption from the registration requirements of the Financial Instruments and Exchange Law and (2)&#160;in compliance with any other applicable requirements of Japanese law. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Notice to Prospective Investors in Singapore</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares of our Class&#160;A common stock may not be circulated or distributed, nor may the shares of our Class&#160;A common stock be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (1)&#160;to an institutional investor under Section&#160;274 of the Securities and Futures Act, Chapter 289 of Singapore, or the SFA, (2)&#160;to a relevant person pursuant to Section&#160;275(1), or any person pursuant to Section&#160;275(1A), and in accordance with the conditions specified in Section&#160;275 of the SFA or (3)&#160;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA, in each case subject to compliance with conditions set forth in the SFA. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Where the shares of our Class&#160;A common stock are subscribed or purchased under Section&#160;275 of the SFA by a relevant party which is: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">a corporation (which is not an accredited investor (as defined in Section&#160;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, shares, debentures </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">166</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:442pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:40pt; width:416pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">and&#160;units of shares of our Class&#160;A common stock and debentures of that corporation or the beneficiaries&#8217; rights and interest (howsoever described) in that trust shall not be transferred within six&#160;months after that corporation or that trust has acquired the shares of our Class&#160;A common stock pursuant to an offer made under Section&#160;275 of the SFA except: </font>
        </div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <font style="letter-spacing:0.2pt;">to an institutional investor (for corporations, under Section&#160;274 of the SFA) or to a relevant person defined in Section&#160;275(2) of the SFA, or to any person pursuant to an offer that is made on terms that such shares, debentures and&#160;units of shares of our Class&#160;A common stock and debentures of that corporation or such rights and interest in that trust are acquired at a consideration of not less than $200,000 (or its equivalent in a foreign currency) for each transaction, whether such amount is to be paid for in cash or by exchange of securities or other assets, and further for corporations, in accordance with the conditions specified in Section&#160;275 of the SFA; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <font style="letter-spacing:0.2pt;">where no consideration is or will be given for the transfer; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">
          <font style="letter-spacing:0.2pt;">where the transfer is by operation of law. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">167</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tLEMA">&#8203;</a><a name="tEXP">&#8203;</a><a name="tWYCF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:234pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">LEGAL MATTERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The validity of the shares of Class&#160;A common stock offered by this prospectus will be passed upon for us by Mintz, Levin, Cohn, Ferris, Glovsky &amp; Popeo, P.C., Boston, Massachusetts. Certain legal matters in connection with this offering will be passed upon for the underwriters by Goodwin Procter LLP, New York, New York. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EXPERTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The financial statements of Sera Prognostics, Inc. at December&#160;31, 2020 and 2019, and for each of the two&#160;years in the period ended December&#160;31, 2020, appearing in this Prospectus and Registration Statement have been audited by Ernst &amp; Young LLP, independent registered public accounting firm, as set forth in their report thereon appearing elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">WHERE YOU CAN FIND MORE INFORMATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have filed with the SEC a registration statement on Form S-1, including exhibits and schedules, under the Securities Act that registers the shares of our Class&#160;A common stock to be sold in this offering. This prospectus does not contain all the information contained in the registration statement and the exhibits and schedules filed as part of the registration statement. For further information with respect to us and our Class&#160;A common stock, we refer you to the registration statement and the exhibits and schedules filed as part of the registration statement. Statements contained in this prospectus as to the contents of any contract or other document are not necessarily complete. If a contract or document has been filed as an exhibit to the registration statement, we refer you to the copies of the contract or document that has been filed. Each statement in this prospectus relating to a contract or document filed as an exhibit is qualified in all respects by the filed exhibit. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Upon the completion of this offering, we will file annual, quarterly and current reports, proxy statements and other information with the SEC under the Exchange Act. You can read our SEC filings, including the registration statement, at the SEC&#8217;s website at www.sec.gov. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our website address is </font><font style="font-style:italic;letter-spacing:0.2pt;">https://www.seraprognostics.com/</font>&#8203;<font style="letter-spacing:0.2pt;">. The information contained in, and that can be accessed through, our website is not incorporated into and shall not be deemed to be part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference.</font></div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">168</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC2">&#8203;</a><a name="TOC3">&#8203;</a><a name="tITFS">&#8203;</a><a name="tITUI">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:373pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">INDEX TO FINANCIAL STATEMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:100pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:429pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tROIR"><font style="letter-spacing:0.2pt;">Report of Independent Registered Public Accounting Firm </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tROIR">F-2</a></font> <a href="#tROIR"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:429pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Financial Statements: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:429pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tBASH"><font style="letter-spacing:0.2pt;">Balance Sheets </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tBASH">F-3</a></font> <a href="#tBASH"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:429pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSOOA"><font style="letter-spacing:0.2pt;">Statements of Operations and Comprehensive Loss </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSOOA">F-4</a></font> <a href="#tSOOA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:429pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSOCP"><font style="letter-spacing:0.2pt;">Statements of Convertible Preferred Stock and Stockholders&#8217; Deficit </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSOCP">F-5</a></font> <a href="#tSOCP"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:429pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSOCF"><font style="letter-spacing:0.2pt;">Statements of Cash Flows </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSOCF">F-6</a></font> <a href="#tSOCF"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:429pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tNTFS"><font style="letter-spacing:0.2pt;">Notes to Financial Statements </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tNTFS">F-7</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">INDEX TO UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:85pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:424pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Unaudited Interim Condensed Financial Statements: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:424pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCBS"><font style="letter-spacing:0.2pt;">Condensed Balance Sheets</font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCBS">F-30</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:424pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCSOO"><font style="letter-spacing:0.2pt;">Condensed Statements of Operations and Comprehensive Loss </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCSOO">F-31</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:424pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCSOC"><font style="letter-spacing:0.2pt;">Condensed Statements of Convertible Preferred Stock and Stockholders&#8217; Deficit </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCSOC">F-32</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:424pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tCSOC1"><font style="letter-spacing:0.2pt;">Condensed Statements of Cash Flows </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tCSOC1">F-33</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:424pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tNTUI"><font style="letter-spacing:0.2pt;">Notes to Unaudited Interim Condensed Financial Statements </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tNTUI">F-34</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tROIR">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:126pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Report of Independent Registered Public Accounting Firm</font>
        </div>
        <div style="margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To the Stockholders and the Board of Directors of Sera Prognostics, Inc.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Opinion on the Financial Statements</font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have audited the accompanying balance sheets of Sera Prognostics, Inc. (the Company) as of December 31, 2020 and 2019, the related statements of operations and comprehensive loss, convertible preferred stock and stockholders&#8217; deficit and cash flows for the years then ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2020 and 2019, and the results of its operations and its cash flows for the years then ended in conformity with U.S. generally accepted accounting principles.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Basis for Opinion</font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">/s/ Ernst &amp; Young LLP</font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have served as the Company&#8217;s auditor since 2012.</font>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Salt Lake City, Utah</font> <br ><font style="letter-spacing:0.2pt;">March 26, 2021</font> <br ><font style="letter-spacing:0.2pt;">except for Note 1 and paragraph 5 of Note 16, as to which the date is </font> <br ><font style="letter-spacing:0.2pt;">May 5, 2021</font></div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tBASH">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SERA PROGNOSTICS, INC.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Balance Sheets </font>
          <br >
          <font style="letter-spacing:0.2pt;">(in thousands, except share and per share data) </font>
        </div>
        <table style="width:456pt;height:590.18pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:349.93pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.805pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.24pt 0pt 1.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.24pt 0pt 1.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.24pt 0pt 0.51pt 0pt; width:349.93pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Assets</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.49pt 0pt 0.51pt 0pt; width:349.93pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Current assets: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.49pt 0pt 0.51pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">13,533</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">21,390</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.49pt 0pt 0.51pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Accounts receivable </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.49pt 0pt 1.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Prepaid expenses and other current assets </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.49pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">198</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.49pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">161</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.24pt 0pt 0.51pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total current assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.24pt 0pt 0.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.24pt 0pt 0.51pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">13,733</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.24pt 0pt 0.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.24pt 0pt 0.51pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">21,552</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.49pt 0pt 0.51pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Property and equipment, net </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">965</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,635</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.49pt 0pt 1.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other assets </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.49pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">98</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.49pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">72</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.24pt 0pt 2.25pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.24pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">14,796</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.24pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">23,259</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.74pt 0pt 0.51pt 0pt; width:349.93pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Liabilities, Convertible Preferred Stock, and Stockholders&#8217; Deficit</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.49pt 0pt 0.51pt 0pt; width:349.93pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Current liabilities: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.49pt 0pt 0.51pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Accounts payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">441</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">748</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.49pt 0pt 0.51pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Accrued and other current liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,577</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,303</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.49pt 0pt 0.51pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Accrued interest on convertible note </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">996</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.49pt 0pt 0.51pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Deferred rent, current portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">130</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">114</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.49pt 0pt 0.51pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Capital lease obligation, current portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">69</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">72</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.49pt 0pt 0.51pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Convertible promissory note, current portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">4,353</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.49pt 0pt 1.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Loans payable, current portion </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.49pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">3,676</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.49pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">3,667</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.24pt 0pt 0.51pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total current liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.24pt 0pt 0.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.24pt 0pt 0.51pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">11,242</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.24pt 0pt 0.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.24pt 0pt 0.51pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">5,904</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.49pt 0pt 0.51pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Deferred rent </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">139</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">268</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.49pt 0pt 0.51pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Loans payable, net of current portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">348</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,935</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.49pt 0pt 0.51pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Convertible promissory note, net of current portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">3,507</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.49pt 0pt 0.51pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Preferred stock warrant liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">474</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">230</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.49pt 0pt 0.51pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Capital lease obligation, net of current portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">127</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">134</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.49pt 0pt 1.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other liabilities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.49pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.49pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">555</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.24pt 0pt 0.51pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.24pt 0pt 0.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.24pt 0pt 0.51pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">12,330</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.24pt 0pt 0.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.24pt 0pt 0.51pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">12,533</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.49pt 0pt 0.51pt 0pt; width:349.93pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Commitments and contingencies </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.49pt 0pt 0.51pt 0pt; width:349.93pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Convertible preferred stock: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0.5pt 0pt 0.5pt 0pt; width:349.93pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Junior convertible preferred stock, par value of $0.0001; 20,537,294 shares authorized, 20,414,766 shares issued and outstanding as of December&#160;31, 2020 and 2019; aggregate liquidation preference of $78,916 as of December&#160;31, 2020 and 2019; </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">77,844</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">77,844</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0.5pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Senior convertible preferred stock, par value of $0.0001; 12,320,844 shares </font>
                <br >
                <font style="letter-spacing:0.2pt;">authorized, 11,928,167 and 9,451,206 shares issued and outstanding as of </font>
                <br >
                <font style="letter-spacing:0.2pt;">December&#160;31, 2020 and 2019, respectively; aggregate liquidation preference of </font>
                <br >
                <font style="letter-spacing:0.2pt;">$102,535 and $81,035 as of December&#160;31, 2020 and 2019, respectively; </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">50,192</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">39,506</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.49pt 0pt 0.51pt 0pt; width:349.93pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Stockholders&#8217; deficit: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0.5pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Common stock, $0.0001 par value; 55,000,000 shares authorized,3,535,688 and </font>
                <br >
                <font style="letter-spacing:0.2pt;">3,170,805 shares issued and outstanding as of December&#160;31, 2020 and 2019, </font>
                <br >
                <font style="letter-spacing:0.2pt;">respectively </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.49pt 0pt 0.51pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Additional paid-in capital </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">5,889</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.51pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">4,987</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.49pt 0pt 1.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accumulated deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.49pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(131,459<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.49pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.49pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(111,611<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.24pt 0pt 1.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total stockholders&#8217; deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(125,570<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(106,624<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.24pt 0pt 2.25pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total liabilities, convertible preferred stock, and stockholders&#8217; deficit </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.24pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">14,796</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.24pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.24pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">23,259</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The accompanying notes are an integral part of these financial statements</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tSOOA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:328.34pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SERA PROGNOSTICS, INC.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Statements of Operations and Comprehensive Loss </font>
          <br >
          <font style="letter-spacing:0.2pt;">(in thousands, except share and per share data) </font>
        </div>
        <table style="width:456pt;height:232.66pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8.98pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:341.17pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended</font>
                <br >
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:341.17pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Revenue </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">25</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">36</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Operating expenses: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Cost of revenue </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">11</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">18</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">7,782</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">9,353</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Selling and marketing </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">3,645</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,963</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">6,558</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">4,278</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total operating expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">17,996</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">16,612</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Loss from operations </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(17,971<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(16,576<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Interest expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(1,839<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(1,972<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other income (expense), net </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(38<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">2,027</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss and comprehensive loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(19,848<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(16,521<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss per share, basic and diluted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(6.14<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(5.24<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Weighted-average shares of common stock outstanding, basic and diluted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">3,234,476</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">3,153,654</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:10pt; margin-top:5pt; text-align:center; width:446pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The accompanying notes are an integral part of these financial statements</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tSOCP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:12pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SERA PROGNOSTICS, INC.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Statements Of Convertible Preferred Stock And Stockholders&#8217; Deficit </font>
          <br >
          <font style="letter-spacing:0.2pt;">(in thousands, except share and per share data) </font>
        </div>
      </div>
      <div style="margin-top:12pt;margin-bottom:12pt;margin-left:27.16pt;width:541pt;">
        <table style="width:541pt;margin-bottom:7pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8.98pt;height:18.82pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:122.18pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Senior Convertible</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Junior Convertible</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Common Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:8.99pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Additional </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Paid-In </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Capital </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:8.98pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Accumulated </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:8.99pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Total </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Stockholders&#8217; </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:14.09pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:122.18pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.5pt 0pt; width:122.18pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Balance as of December&#160;31, 2018</font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">20,414,766</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">77,844</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">3,126,748</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.6pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">3,617</td>
            <td style="padding:0pt;padding-left:3.6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(95,090<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.185pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(91,473<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:122.18pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Issuance of Series&#160;D senior convertible preferred stock at $4.34 per share, net of issuance costs and commissions of $0.4&#160;million </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">9,451,206</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">39,681</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.6pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.185pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:122.18pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Fair value of warrants to purchase common stock issued to investors </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">&#8212;</div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.6pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">902</td>
            <td style="padding:0pt;padding-left:3.6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.185pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">902</td>
            <td style="padding:0pt;padding-left:2.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:122.18pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Fair value of warrants to purchase Series&#160;D Senior convertible preferred stock issued as commissions </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">&#8212;</div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(175<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.6pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.185pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:122.18pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Issuance of common stock upon exercise of stock options, and vesting of early exercised options </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">&#8212;</div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">&#8212;</div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">44,057</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.6pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">30</td>
            <td style="padding:0pt;padding-left:3.6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.185pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">30</td>
            <td style="padding:0pt;padding-left:2.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:122.18pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Stock-based compensation expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">&#8212;</div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">&#8212;</div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.6pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">438</td>
            <td style="padding:0pt;padding-left:3.6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.185pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">438</td>
            <td style="padding:0pt;padding-left:2.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:122.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">&#8212;</div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">&#8212;</div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.6pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.6pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(16,521<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.185pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(16,521<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.185pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.5pt 0pt; width:122.18pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Balance as of December&#160;31, 2019</font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">9,451,206</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">39,506</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">20,414,766</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">77,844</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">3,170,805</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.6pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">4,987</td>
            <td style="padding:0pt;padding-left:3.6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(111,611<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.185pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(106,624<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:122.18pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Issuance of Series&#160;D senior convertible preferred stock at $4.34 per share, net of issuance costs of $0.1&#160;million </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2,476,961</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">10,686</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.6pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.185pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:122.18pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Issuance of common stock upon exercise of stock options </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">364,883</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.6pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">176</td>
            <td style="padding:0pt;padding-left:3.6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.185pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">176</td>
            <td style="padding:0pt;padding-left:2.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:122.18pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Stock-based compensation expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.6pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">726</td>
            <td style="padding:0pt;padding-left:3.6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.185pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">726</td>
            <td style="padding:0pt;padding-left:2.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:122.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.6pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.6pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(19,848<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.185pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(19,848<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.185pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 2.583pt 0pt; width:122.18pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Balance as of December&#160;31, 2020</font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">11,928,167</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">50,192</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">20,414,766</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">77,844</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">3,535,688</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.6pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">5,889</td>
            <td style="padding:0pt;padding-left:3.6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">(131,459<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.11pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.185pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">(125,570<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.185pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:12pt;margin-bottom:19.84pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:10pt; text-align:center; width:446pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The accompanying notes are an integral part of these financial statements</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tSOCF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SERA PROGNOSTICS, INC.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Statements of Cash Flows </font>
          <br >
          <font style="letter-spacing:0.2pt;">(in thousands) </font>
        </div>
        <table style="width:456pt;height:589.07pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8.98pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:359.93pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.478pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended</font>
                <br >
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.25pt 0pt 1.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.25pt 0pt 1.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Cash flows from operating activities</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(19,848<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(16,521<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Adjustments to reconcile net loss to net cash used in operating activities: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Depreciation and amortization </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">895</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">946</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Stock-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">726</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">438</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Gain on disposal of fixed assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(103<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Non-cash interest expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1,589</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1,509</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Fair value adjustment to tranche forward liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(619<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other non-cash gain (loss) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">81</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(1,328<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Changes in operating assets and liabilities: </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Accounts receivable </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(2<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">6</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Prepaid expenses and other assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(62<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">23</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Accounts payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(307<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(534<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Deferred rent </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(114<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(98<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.5pt 0pt 1.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Accrued and other current liabilities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">174</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(3,043<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:0.2pt;">Net cash used in operating activities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(16,868<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(19,324<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:8.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Cash flows from investing activities</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Purchases of property and equipment </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(149<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(109<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.5pt 0pt 1.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Proceeds from disposal of property and equipment </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">103</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:0.2pt;">Net cash used in investing activities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(149<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(6<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:8.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Cash flows from financing activities</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Proceeds from issuance of Series&#160;D convertible preferred stock, net of</font>
                <br >
                <font style="letter-spacing:0.2pt;">issuance costs </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">10,686</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">29,147</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Proceeds allocated to issuance of common stock warrants </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">902</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Proceeds from exercise of stock options </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">176</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">28</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Proceeds from convertible notes payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">6,600</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Proceeds from loan payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1,050</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Payment of loan payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(2,667<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(3,333<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Capital lease principal payments </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(85<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(282<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.5pt 0pt 1.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Payment of deferred finance fees </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(13<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.25pt 0pt 1.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:0.2pt;">Net cash provided by financing activities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">9,160</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">33,049</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net (decrease) increase in cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(7,857<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">13,719</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.5pt 0pt 1.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cash and cash equivalents at beginning of year </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">21,390</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">7,671</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 2.25pt 0pt; width:359.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cash and cash equivalents at end of year </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">13,533</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">21,390</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:7.75pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Supplemental disclosure of cash flow information</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cash paid for interest expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">250</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">463</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:8.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Supplemental disclosure of non-cash investing and financing information</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Purchases of property and equipment in accounts payable and accruals </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">33</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">30</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Warrants to purchase convertible preferred stock issued as commissions </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">175</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.167pt 0pt 0.5pt 0pt; width:359.93pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Conversion of convertible notes and accrued interest to Series&#160;D convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.167pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">10,033</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The accompanying notes are an integral part of these financial statements</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tNTFS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SERA PROGNOSTICS, INC.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:2pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Notes to Financial Statements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">1. Description of Business and Financial Condition</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sera Prognostics, Inc. (the &#8220;Company&#8221;) is a women&#8217;s health company leveraging its proprietary proteomics and bioinformatics platform to discover, develop and commercialize clinically meaningful and economically impactful biomarker tests with an initial focus on improving pregnancy outcomes. The Company was incorporated in the State of Delaware on January&#160;17, 2008 and its operations are located in Salt Lake City, Utah, including a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Since its inception, the Company&#8217;s activities have consisted of performing research and development, conducting clinical studies, acquiring product rights, raising capital, establishing facilities, and establishing commercial operations to market the PreTRM test. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company is subject to risks and uncertainties common to companies in the diagnostics industry, including but not limited to, risks associated with commercializing products, completing preclinical and clinical studies, receiving regulatory approvals for product candidates, if required, development by competitors of new diagnostic products, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Products currently under development will require significant additional research and development efforts, including preclinical and clinical testing, prior to commercialization. These efforts require significant amounts of additional capital and adequate personnel and infrastructure. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Liquidity and Capital Resources</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company has incurred net losses and negative cash flows from operations since inception and had an accumulated deficit of $131.5&#160;million as of December&#160;31, 2020. The principal sources of the Company&#8217;s working capital to date has been the proceeds from the issuance of convertible preferred stock, convertible notes, and bank loans. As of December&#160;31, 2020, the Company had approximately $13.5&#160;million in cash and cash equivalents. From February through April 2021, the Company received an aggregate of $100.1&#160;million in net proceeds from the issuance of Series&#160;E convertible preferred stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Management expects the Company to incur significant additional operating losses and negative cash flows for the foreseeable future, principally as a result of the Company&#8217;s commercialization activities for the PreTRM test, and to support additional clinical studies and anticipated research and development activities. The Company had no material commercial product revenue for the year ended December&#160;31, 2020 and has no recurring sources of licensing or other revenue. There can be no assurance that the Company will eventually achieve significant revenues or profitability to sustain operations, or if achieved, can sustain either on a continuing basis. If the Company is unable to achieve significant revenues or raise additional funding, when needed, it may not be able to continue the development or commercialization of its diagnostic products and could be required to delay, scale back or abandon some or all of its development programs and other operations. Any additional equity financing, if available to the Company, may not be available on favorable terms, may be dilutive to current stockholders, and debt financing, if available, may involve restrictive covenants and dilutive financing instruments. Due to the proceeds from the issuance of Series E convertible preferred stock, management believes that its existing financial resources are sufficient to continue operating activities at least one year past the issuance date of these financial statements. The Company&#8217;s future operations are highly dependent on a combination of factors, including (i)&#160;the successful commercial launch and market acceptance of the PreTRM test; (ii)&#160;the success of other research and development programs; (iii)&#160;the development of competitive diagnostic tests by other biotechnology companies; (iv)&#160;the Company&#8217;s ability to manage growth of the organization; (v)&#160;the Company&#8217;s ability to protect its technology and products; and, ultimately (vi)&#160;the timely and successful completion of any additional financing. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">2. Significant Accounting Policies</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:7pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Basis of Presentation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America in the United States of America (U.S. GAAP). </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Use of Estimates</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period and accompanying notes. On an on-going basis, the Company evaluates its estimates, including those related to the determination of fair value of its shares of common stock and stock options, common and preferred stock warrants, valuation of deferred tax assets resulting from net operating losses, and useful lives of property and equipment. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. Actual results could differ materially from those estimates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In December&#160;2019, a novel strain of coronavirus, which causes COVID-19, was identified. Due to the rapid and global spread of the virus, on March&#160;11, 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. To slow the proliferation of COVID-19, governments have implemented extraordinary measures, which include the mandatory closure of businesses, restrictions on travel and gatherings, and quarantine and physical distancing requirements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There were no significant estimates contained in the preparation of the Company&#8217;s financial statements or impacts to the Company&#8217;s financial statements for the year ended December&#160;31, 2020 that were directly a result of the COVID-19 pandemic. The Company is not aware of any specific event or circumstance that would require an update to its estimates, judgments and assumptions or a revision of the carrying value of the Company&#8217;s assets or liabilities as of the date of the financial statements. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Cash and cash equivalents</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company considers all highly liquid financial instruments with original maturities of 90&#160;days or less at the date of purchase to be cash equivalents. As of December&#160;31, 2020 and 2019, cash and cash equivalents consist of cash and money market accounts and are stated at fair value. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Concentration of credit risk</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains bank deposits in accounts at a single federally insured financial institution and these deposits may exceed federally insured limits. The Company is exposed to credit risk in the event of default by the financial institution holding its cash to the extent recorded in the balance sheet. The Company has not experienced any losses on its deposits of cash. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Property and Equipment</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Property and equipment are recorded at cost less accumulated depreciation. Depreciation and amortization are computed using the straight-line method over the shorter of estimated useful lives of the assets or the respective lease term. The estimated useful life of each asset category is as follows: </font>
        </div>
        <table style="width:456pt;height:70pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:222pt;">
              <font style="letter-spacing:0.2pt;">Computer equipment </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:222pt;">
              <font style="letter-spacing:0.2pt;">3&#160;years </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:222pt;">
              <font style="letter-spacing:0.2pt;">Software </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:222pt;">
              <font style="letter-spacing:0.2pt;">3&#160;years </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:222pt;">
              <font style="letter-spacing:0.2pt;">Machinery and equipment </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:222pt;">
              <font style="letter-spacing:0.2pt;">5&#160;years </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:222pt;">
              <font style="letter-spacing:0.2pt;">Furniture and fixtures </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:222pt;">
              <font style="letter-spacing:0.2pt;">5&#160;years </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:222pt;">
              <font style="letter-spacing:0.2pt;">Leasehold improvements </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:222pt;">
              <font style="letter-spacing:0.2pt;">Shorter of useful life or remaining lease term</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Amortization expense of assets acquired through capital leases is included in depreciation and amortization expense in the statements of operations and comprehensive loss. Costs of repairs and maintenance that do not extend the useful life or improve the related assets are expensed as incurred. Costs of major replacement or improvement are capitalized. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in operating expense. During the&#160;years ended December&#160;31, 2020 and 2019, the Company recorded net gains on the disposal of property and equipment of $0.0&#160;million and $0.1&#160;million, respectively. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Leases</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company rents its facilities under an operating lease agreement and recognizes related rent expense on a straight-line basis over the term of the lease. The lease agreement contains an incentive allowance, rent holidays, scheduled rent increases, and renewal options. Rent holidays and scheduled rent increases are included in the determination of rent expense to be recorded over the lease term. Renewals are not assumed in the determination of the lease term unless they are deemed to be reasonably assured at the inception of the lease. The Company recognizes rent expense beginning on the date it obtains the legal right to use and control the leased space. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Deferred Offering Costs</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company defers offering costs consisting of legal, accounting and other fees and costs directly associated with in-process equity financings until such financings are consummated. After consummation of the equity financing, these costs are classified in stockholders&#8217; deficit as a reduction of additional paid-in capital recorded as a result of the financing. In the case of preferred stock financing, the costs incurred are recorded against the net proceeds recorded as preferred stock issued by the Company. If the in-process financing is abandoned, the deferred offering costs are expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss. As of December&#160;31, 2020, approximately $25.9&#160;thousand of deferred offering costs were recorded within other assets in the accompanying balance sheets. As of December&#160;31, 2019, no such costs were deferred. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Convertible Preferred Stock</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company records convertible preferred stock based on issuance price on the dates of issuance, net of issuance costs. The convertible preferred stock has been classified outside of stockholders&#8217; deficit as temporary equity on the accompanying balance sheet because the shares contain certain redemption features that are not solely within the control of the Company. The convertible preferred stock is not generally redeemable; however, upon certain change in control events that are outside of the Company&#8217;s control, including liquidation, sale or transfer of control of the Company, holders of the convertible preferred stock may have the right to receive its liquidation preference under the terms of the Company&#8217;s certificate of incorporation. The carrying values of the convertible preferred stock are adjusted to their liquidation preferences if and when it becomes probable that such a liquidation event will occur. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Revenue Recognition</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Revenue is generated from the sale of PreTRM tests. The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) 606. The standard contains principles applied to determine the measurement of revenue and timing of when it is recognized. The Company applies a five-step approach in accordance with the standard: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. The Company applies the five-step model when it is probable that the entity will collect the consideration it is entitled to in exchange for fulfilling its performance obligation. The Company recognizes revenue upon delivery of test results, which it considers to be the only performance obligation, and allocates 100% of the transaction price to this performance obligation. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Cost of Revenue</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Cost of revenue reflects the aggregate costs incurred in delivering the proteomic testing results to clinicians and includes expenses for third-party sample collection and shipping costs, as well as the Company&#8217;s </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">lab personnel, materials and supplies, equipment and infrastructure expenses associated with clinical testing, and allocated overhead including rent and equipment depreciation. Costs associated with performing the Company&#8217;s tests are recorded as the tests are processed regardless of whether and when revenue is recognized with respect to such tests. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Research and Development Expenses</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The Company expenses all research and development costs as they are incurred. Research and development expenses consist primarily of personnel costs, stock-based compensation charges, clinical trial costs, and third-party contracted services associated with research and development. The Company recognizes expense associated with third-party contracted services based on the completion of activities as specified in the applicable contracts. Costs incurred under contracts with clinical sites are generally accrued as patient encounters occur, consistent with the terms outlined in the associated contract. Upon termination of contracts with third parties, the Company&#8217;s obligations are limited to costs incurred or committed to date. As a result, accrued research and development expenses represent the estimated contractual liability to third parties at the reported period. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Stock-based Compensation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The Company recognizes stock-based compensation for all stock-based awards in accordance with ASC 718, </font><font style="font-style:italic;letter-spacing:0.2pt;">Compensation-Stock Compensation</font><font style="letter-spacing:0.2pt;">, which requires an entity to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The Company estimates the fair value of share-based awards issued under its employee compensation plans using the Black-Scholes option pricing model. Input assumptions used in calculating the fair value of stock-based awards represent management&#8217;s estimates and involve inherent uncertainties and the application of management&#8217;s judgment. These input assumptions include the estimated fair value of the Company&#8217;s common stock, the expected term of the awards, the expected common stock price volatility over the term of the awards, risk-free interest rates, and the expected dividend yield. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The Company uses the simplified calculation of expected life, volatility is based on an average of the historical volatilities of the common stock of select comparable publicly-traded entities with characteristics similar to those of the Company. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. Expected forfeitures are an estimate based on the Company&#8217;s historical experience and are re-evaluated annually and adjusted as necessary. The fair value of equity awards is recognized as compensation cost on a straight-line basis by the Company over the employee&#8217;s requisite service period (vesting period). Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if the actual forfeitures differ from those estimates. All stock-based compensation costs are recorded in the statements of operations and comprehensive loss based upon the underlying employee&#8217;s role within the Company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Prior to January&#160;1, 2020, equity instruments issued to non-employees were recognized in accordance with ASC 505-50 </font><font style="font-style:italic;letter-spacing:0.2pt;">Equity Based Payments to Non-Employees</font><font style="letter-spacing:0.2pt;">. Based on this guidance, awards were recorded at their fair value on the measurement date subject to periodic remeasurement and share based compensation expense was recognized over the vesting terms. On January&#160;1, 2020, the Company adopted ASU No. 2018-07 (Topic 718), </font><font style="font-style:italic;letter-spacing:0.2pt;">Compensation&#8201;&#8212;&#8201;Stock Compensation</font><font style="letter-spacing:0.2pt;">, which expanded the scope of Topic 718 to include share-based payment transactions with non-employees. The fair value of all outstanding and unvested previously granted non-employee awards was established on January&#160;1, 2020, the effective date of adoption, and share-based compensation expense will continue to be recorded on a straight-line basis over their remaining vesting period, consistent with share-based payment awards granted to employees. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company issued a convertible preferred stock warrant (see Note 9&#8201;&#8212;&#8201;Capital Structure) in conjunction with the issuance of Series&#160;D Convertible Preferred Stock. The award is recorded as a preferred stock warrant liability on the balance sheet and the resulting value is recognized as other income (expense) during each reporting period until the warrant is exercised or expires. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Income Taxes</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company recognizes deferred tax assets to the extent that it believes these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process whereby (1)&#160;it determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2)&#160;for those tax positions that meet the more-likely-than-not recognition threshold, it recognizes the largest amount of tax benefit that is more than 50&#160;percent likely to be realized upon ultimate settlement with the related tax authority. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company recognizes interest and penalties related to unrecognized tax benefits within the income tax expense line in the accompanying Statement of Operations and Comprehensive Loss. Any accrued interest and penalties related to uncertain tax positions will be reflected as a liability in the Balance Sheet. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Segments</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products. The Company&#8217;s chief operating decision maker, its chief executive officer, reviews financial information on an aggregate basis for making decisions regarding resource allocation and assessing performance. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Comprehensive Loss</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Comprehensive loss consists of net loss and other gains and losses affecting stockholders&#8217; deficit that, under U.S. GAAP, are excluded from net loss. For the&#160;years ended December&#160;31, 2020 and 2019, the Company has no transactions that would be reported to derive comprehensive loss. As such, net loss equals comprehensive loss for the periods presented. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Net Loss per Share Attributable to Common Stockholders</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration of potentially dilutive securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, convertible preferred stock, stock options, warrants to purchase common stock, warrants to purchase convertible preferred stock and convertible notes are considered to be potentially dilutive securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company applies the two-class method to calculate its basic and diluted net loss per share as the Company has issued shares that meet the definition of participating securities. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. The Company&#8217;s participating securities contractually entitle the holders of such shares to participate in dividends, but do not contractually require the holders of </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:56pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">such shares to participate in losses of the Company. In periods in which the Company reports a net loss, losses are not allocated to such participating securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Accordingly, in periods in which the Company reports a net loss, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Emerging Growth Company Status</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (a)&#160;no longer an emerging growth company or (b)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Recently Issued Accounting Pronouncements Not Yet Adopted</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In February&#160;2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2016-02, </font><font style="font-style:italic;letter-spacing:0.2pt;">Leases (Topic 842).</font><font style="letter-spacing:0.2pt;"> Under the new guidance, lessees will be required to recognize a lease liability and a right-of-use asset for all leases (with the exception of short-term leases) at the commencement date. The standard was effective for public entities for fiscal&#160;years beginning after December&#160;15, 2018 and for private companies for fiscal&#160;years beginning after December&#160;15, 2021. The Company is evaluating the effect that ASU 2016-02 will have on its financial statements and related disclosures. The Company expects to adopt this new standard on January&#160;1, 2022 and has not yet determined the effect of the standard on its ongoing financial reporting. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In December&#160;2019, the FASB issued ASU 2019-12, </font><font style="font-style:italic;letter-spacing:0.2pt;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</font><font style="letter-spacing:0.2pt;">. This standard removes certain exceptions for investments, intra-period allocations and interim calculations, and adds guidance to reduce complexity in accounting for income taxes. This standard will be effective for the Company on January&#160;1, 2022, with early adoption permitted. We are currently evaluating the potential impact this standard may have on our financial statements and disclosures. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In August&#160;2020, the FASB issued ASU No. 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40) (&#8220;ASU&#160;2020-06&#8221;), which simplifies the accounting for convertible instruments. The guidance removes certain accounting models that separate the embedded conversion features from the host contract for convertible instruments. ASU 2020-06 allows for a modified or full retrospective method of transition. This update is effective for fiscal&#160;years beginning after December&#160;15, 2021, and interim periods within those fiscal&#160;years. Early adoption is permitted. The Company is currently evaluating the impact this change will have on its financial statements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission (&#8220;SEC&#8221;) did not, or are not believed by management to, have a material impact on the Company&#8217;s financial position, results of operations or cash flows. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">3. Property and Equipment</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table presents the components of property and equipment, net, as of December&#160;31, 2020 and 2019 (in thousands): </font>
        </div>
        <table style="width:416pt;height:144.18pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:7.98pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:329.93pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.812pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:329.93pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:329.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Computer equipment </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">767</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">601</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:329.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Software </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">373</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">373</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:329.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Laboratory equipment </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">4,194</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">4,149</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:329.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Furniture and fixtures </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">292</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">292</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:329.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Leasehold improvements </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">701</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">689</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:329.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total property and equipment </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">6,327</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">6,104</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:329.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Less accumulated depreciation and amortization </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(5,362<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(4,469<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:329.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Property and equipment, net </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">965</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">1,635</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.99pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2020 and 2019, $3.0&#160;million and $2.9&#160;million of the Company&#8217;s laboratory equipment was subject to capital leases, which assets had recorded accumulated amortization of $2.6&#160;million and $2.0&#160;million, respectively. Associated amortization expense, included with depreciation expense, for the&#160;years ended December&#160;31, 2020 and 2019 totaled $0.6&#160;million. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Depreciation and amortization expense was $0.9&#160;million for the&#160;years ended December&#160;31, 2020 and 2019. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">4. Accrued and Other Current Liabilities</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table presents the components of accrued and other current liabilities as of December&#160;31, 2020 and 2019 (in thousands): </font>
        </div>
        <table style="width:456pt;height:128.68pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:7.97999999999996pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:376.59pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.812pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:376.59pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:376.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accrued paid time off </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">290</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">158</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:376.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accrued compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">996</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">782</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:376.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accrued clinical studies </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">183</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:376.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Unrecognized grant income </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">43</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:376.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Bank loan final payment fee </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:376.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other current liabilities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">191</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">137</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:376.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total accrued and other current liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,577</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,303</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17.99pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">5. Other Income (Expense), net</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table presents the components of other income (expense), net, for the&#160;years ended December&#160;31, 2020 and 2019 (in thousands): </font>
        </div>
        <table style="width:456pt;height:98.68pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:7.98000000000002pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:385.96pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.812pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:385.96pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:385.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Interest income </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">42</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">64</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:385.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Fair value remeasurements </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">(80<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(129<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:385.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Grant income </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">17</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:385.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other gains (losses), net </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,075</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:385.96pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other income (expense), net </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">(38<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,027</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">6. Loans and Convertible Promissory Notes</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Bank Loan</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In 2014, through a Loan and Security Agreement (the &#8220;Loan Agreement&#8221;) with Pacific Western Bank (the &#8220;Bank&#8221;) the Company obtained a term loan for $10.0&#160;million. The Loan Agreement, as amended, has a final repayment date of September&#160;1, 2021. Repayment of amounts borrowed are paid in equal monthly installments of principal, plus all accrued interest. The loan bears interest, on the outstanding daily balance, equal to the greater of 1.0% above the Prime Rate then in effect, or 4.75%. As of December&#160;31, 2020, the Company had total outstanding borrowings of $3.0&#160;million under the Loan Agreement, subject to an interest rate of 4.75% per annum. All of the Company&#8217;s scheduled principal payments are due within twelve&#160;months of the date of the financial statements and are therefore classified as a current liability. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, the Loan Agreement requires a Final Payment Fee (as defined in the Loan Agreement) equal to one-percent of the aggregate principal amount borrowed, or $0.1&#160;million. This fee, as well as deferred finance fees from the initiation of the bank loan in previous&#160;years, are recorded as a deduction from the carrying value of the loan payable and are amortized to interest expense over the remaining term of the Loan Agreement, or earlier termination date. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with Amendment No. 4 to the Loan Agreement, dated March&#160;1, 2017, the Company issued the Bank a fully-vested warrant (the &#8220;2017 Warrant&#8221;) to purchase 16,806 shares of series C-1 convertible preferred stock, par value $0.0001 per share (the &#8220;Series&#160;C-1 Convertible Preferred Stock&#8221;) at a purchase price of $5.95 per share with a ten-year term. Accounting for the 2017 Warrants is described in Note&#160;11&#8201;&#8212;&#8201;Warrants. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Loan Agreement, as amended, also contains a number of affirmative and restrictive covenants including limitations on mergers, consolidations and dissolutions, sales of assets, investments and acquisitions, indebtedness, liens, affiliate transactions, dividends and restricted payments, deposit accounts held at other institutions, and issuance of audited financial statements. The Loan Agreement contains events of default for non-payment of principal and interest when due, a cross-default provision with respect to other indebtedness having an aggregate principal amount of at least $0.1&#160;million and an event of default that would be triggered by a change in control, as defined in the agreement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2020, the Company was in compliance with its financial covenants under the Loan Agreement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Convertible Promissory Notes</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In November&#160;2018, the Company authorized the issuance of $7.6&#160;million of subordinated convertible promissory notes (the &#8220;2018 Notes&#8221;) to existing investors, bearing 5% interest and a maturity date of December&#160;31, 2019. In April&#160;2019, the Company received an additional $0.2&#160;million from an existing investor in conjunction with the 2018 Notes. The 2018 Notes were mandatorily convertible into shares of the Company&#8217;s Series&#160;D Convertible Preferred Stock and represented an advance of the aggregate purchase price of the closing of the anticipated Series&#160;D Convertible Preferred Stock Financing (as defined herein). In July&#160;2019, all $7.8&#160;million of the 2018 Notes&#8217; principal and $0.2&#160;million of accrued interest converted into 1,850,191 shares of Series&#160;D Convertible Preferred Stock at the transaction price of $4.34 per share (the &#8220;Series&#160;D Original Issue Price&#8221;). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In February&#160;2019, the Company authorized the issuance of a $6.4&#160;million subordinated convertible promissory note (the &#8220;February&#160;2019 Convertible Note&#8221;) to a current stockholder, bearing 12% interest and a maturity date of February&#160;26, 2021, to provide liquidity and additional working capital. On February&#160;15, 2021, the maturity date was extended to March&#160;28, 2021. The February&#160;2019 Convertible Note was optionally convertible into shares of Series&#160;D Convertible Preferred Stock at a conversion price equal to 80% of the issuance price of Series&#160;D. In July&#160;2019, $1.9&#160;million of the $6.4&#160;million February&#160;2019 Convertible Note&#8217;s principal and $0.1&#160;million of accrued interest was converted into 576,938 shares of the Company&#8217;s Series&#160;D Preferred Stock, at the option of the holder of the February&#160;2019 Convertible Note, at a conversion price equal to 80% of the issuance price of Series&#160;D of $4.34 per share. If not repaid or converted prior to the maturity date, the February&#160;2019 Convertible Note&#8217;s remaining principal and accrued interest shall convert, at the option of the Holder, into shares of Series&#160;C-1 Convertible Preferred Stock and the holder will receive a number of common stock warrants based on the amount of unpaid principal outstanding. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The conversion feature of the February&#160;2019 Convertible Note met the requirements for separate accounting and was recognized as a liability at the measurement date fair value of $2.4&#160;million, subject to remeasurement to fair value, with any changes in estimated fair value recognized as a component of other income (expense), net. A corresponding discount which reduces the carrying value of the February&#160;2019 Convertible Note was also recorded. The unamortized discount was written off in proportion to the partial conversion, with the remaining discount being accreted to interest expense until maturity. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company recognized additional interest expense of $0.8&#160;million from accretion of the discount in 2019. On the conversion date, the fair value of the conversion feature increased, resulting in a loss of $0.7&#160;million, which is shown, net of other fair value adjustments, as a component of other income (expense), net (see Note 5&#8201;&#8212;&#8201;Other income (expense), net). The proportional fair value of the liability at conversion resulted in a loss on extinguishment of $0.1&#160;million. Pursuant to the terms of the February&#160;2019 Convertible Note, the noteholder could no longer exercise the conversion feature, and therefore the conversion feature had no value, resulting in a gain of $2.2&#160;million. This gain is shown, net of the $0.1&#160;million loss on extinguishment, as other gains (losses), a component of other income (expense), net (see Note 5&#8201;&#8212;&#8201;Other income (expense)). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In August&#160;2019, the Company authorized the issuance of a $5.0&#160;million subordinated convertible promissory note (the &#8220;August&#160;2019 Note&#8221;) to a new investor and non-U.S. commercial partner. The August&#160;2019 Note bore 5% interest and had a maturity date of December&#160;31, 2019. The August&#160;2019 Note was mandatorily convertible into shares of Series&#160;D Convertible Preferred Stock with principal and all interest accrued thereon converting at a per share price equal to the price per share at which Series&#160;D Convertible Preferred Stock was sold to investors. In August&#160;2019, the August&#160;2019 Note legally converted. Pursuant to the terms of a letter agreement, dated May&#160;10, 2019, by and between the Company and the holder of the August&#160;2019 Note, the holder is entitled to purchase additional shares of Series&#160;D Convertible Preferred Stock, in the event that certain milestones, within the Company&#8217;s control, are met. As of December&#160;31, 2020 this milestone had not been achieved. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2020, the Company recorded an outstanding convertible note payable balance of $4.4&#160;million, and accrued interest of $1.0&#160;million, related to the February&#160;2019 Convertible Note. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Paycheck Protection Loan</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In April&#160;2020, the Company obtained a $1.1&#160;million loan through Pacific Western Bank under the Paycheck Protection Program (&#8220;PPP&#8221;) under the Coronavirus Aid, Relief, and Economic Security Act, as amended (&#8216;&#8216;CARES Act&#8217;&#8217;). The loan&#8217;s purpose is to maintain payroll and make rent and utilities payments as specified under the terms of the PPP. Under the PPP, borrowers may apply for loan forgiveness if the funds are used for payroll costs, mortgage interest, rent, and utilities payments over a specified term following receipt of the loan funds. During the term of the agreement, the Company utilized the loan funds for forgivable and applied for forgiveness. To the extent all or part of the PPP loan is not forgiven, the Company will be required to pay interest on the PPP loan at a rate of 1% per annum and principal and interest payments will be required through the maturity date in April&#160;2022. The loan proceeds are recorded as a loan payable, with the amount due within one year, $0.7&#160;million, recorded as a current liability and $0.4&#160;million recorded as a noncurrent liability, on the Company&#8217;s balance sheet as of December&#160;31, 2020. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table presents the maturity information regarding the Company&#8217;s loans and convertible promissory note (in thousands) as of December&#160;31, 2020: </font>
        </div>
        <table style="width:456pt;height:62.48pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8.98pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:269.43pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 and </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Thereafter </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:269.43pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Loan payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">3,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.08pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.08pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">3,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:269.43pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">February&#160;2019 Convertible Note </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">4,494</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.08pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.08pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">4,494</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:269.43pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Paycheck Protection Loan payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">702</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">348</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.08pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.08pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,050</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">7. Fair Value Measurements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2020 and 2019, the carrying amounts of the Company&#8217;s receivables, prepaid and other current assets, accounts payable, and accrued and other current liabilities approximate their fair values, principally due to the short-term maturities of the assets and liabilities. The recorded value of the loan payable and capital leases approximates the fair value as the interest rates approximate market interest rates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The fair value of the preferred stock warrant liability was estimated based upon a Black-Scholes option pricing model. The Company measures certain financial assets and liabilities (cash equivalents and the warrant liability) at fair value on a recurring basis. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The Company follows a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (Level&#160;1) and the lowest priority to measurements involving significant unobservable inputs (Level&#160;3). The three levels of the fair value hierarchy are as follows: </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Level&#160;1 measurements are observable, quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Level&#160;2 measurements are observable inputs other than quoted prices included in Level&#160;1 that are observable either directly or indirectly or quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Level&#160;3 measurements are unobservable inputs in which there is little or no market data, which require the Company to develop its own assumptions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2020, the Company&#8217;s cash equivalents have been classified as Level&#160;1 assets. The Company&#8217;s convertible preferred stock warrant liability has been valued using Level&#160;3 inputs (see Note&#160;11&#8201;&#8212;&#8201;Warrants). The Company, utilizing a third-party valuation firm to assist with the estimation of the fair value of common stock, employed a hybrid method of option-pricing model (OPM) and Probability-Weighted Expected Return Method (PWERM). Under the hybrid OPM and PWERM approach, the per share value calculated under OPM and PWERM are weighted based on expected exit outcomes and the quality of the information specific to each allocation methodology to arrive at a final estimated fair value per share of the common stock before a discount for lack of marketability is applied. This model also calculates the fair value of the other classes of equity, including preferred stock. This estimated preferred stock value, along with other significant unobservable inputs, was an input into a Black-Scholes option pricing model, which calculated the fair value of the preferred stock warrant liability. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The other significant unobservable inputs in this calculation are the remaining expected term, which considers the timing of a liquidation event that would net settle the awards before their contractual term expires, and the expected equity volatility, which is a statistical measure of the dispersion of returns for a given security. Volatility is determined based on select comparable public guideline companies in the same business sector. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Significant increases (decreases) in the term would result in significantly higher (lower) fair value measurements. Significant increases (decreases) in the volatility would result in significantly higher (lower) fair value measurements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The following table shows the Company&#8217;s assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands) as of December&#160;31, 2020: </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:1.82000000000005pt;margin-left:69.66pt;width:456pt;">
        <table style="width:416pt;height:78.59pt;margin-left:20pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:299.84pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Level&#160;1 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Level&#160;2 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Level&#160;3 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:299.84pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Assets:</font>
                <br >
                <font style="letter-spacing:0.2pt;">Cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">13,533</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.865pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.167pt 0pt 1.833pt 0pt; width:299.84pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Liabilities:</font>
                <br >
                <font style="letter-spacing:0.2pt;">Warrant liability </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.865pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.865pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">474</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:299.84pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">13,533</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.865pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">474</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table shows the Company&#8217;s assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands) as of December&#160;31, 2019: </font>
        </div>
        <table style="width:416pt;height:78.59pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:299.84pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Level&#160;1 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Level&#160;2 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Level&#160;3 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:299.84pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Assets:</font>
                <br >
                <font style="letter-spacing:0.2pt;">Cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">21,390</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.865pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.167pt 0pt 1.833pt 0pt; width:299.84pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Liabilities:</font>
                <br >
                <font style="letter-spacing:0.2pt;">Warrant liability </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.865pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.865pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">230</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:299.84pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">21,390</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.865pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">230</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Tables providing a roll forward of the fair value, as determined by Level&#160;3 inputs, of the Company&#8217;s convertible preferred stock warrant liability for the&#160;years ended December&#160;31, 2020 and 2019 are included in Note 11&#8201;&#8212;&#8201;Warrants. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">8. Related Party Transactions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In July&#160;2019, the Company entered into a consulting agreement with Blue Ox Healthcare Partners, LLC &#8220;Blue Ox&#8221;) to advise the Company on development of strategies with the goal to obtain widespread insurance coverage for the PreTRM test. Contemporaneously with the consulting agreement, Blue Ox participated in the initial closing of the Series&#160;D Convertible Preferred Stock financing in July&#160;2019 and appointed its designee to the Company&#8217;s board of directors (the &#8220;Board of Directors&#8221;). The Company paid consulting fees related to the consulting agreement of $0.4&#160;million and $0.1&#160;million for the&#160;years ended December&#160;31, 2020 and 2019, respectively. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In January&#160;2017, Laboratory Corporation of America, or Labcorp, and the Company entered into a strategic commercialization agreement contemporaneously with Labcorp&#8217;s participation in the Company&#8217;s sale of Series&#160;C Convertible Preferred Stock, par value $0.0001 per share. Under the agreement with Labcorp, amended in 2018, Labcorp is a non-exclusive distributor of the PreTRM test and performs certain sample collection, processing, and shipping services, for a fee. The Company paid fees related to this agreement of less than $0.1&#160;million for the&#160;years ended December&#160;31, 2020 and 2019. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On June&#160;25, 2019, the Company entered into a master services agreement with a Healthcore Inc., a wholly-owned subsidiary of Anthem Inc. This agreement covers a range of research projects, including their role as a contract research organization for the </font><font style="font-weight:bold;letter-spacing:-0.2pt;">P</font><font style="letter-spacing:0.2pt;">rematurity </font><font style="font-weight:bold;letter-spacing:-0.2pt;">R</font><font style="letter-spacing:0.2pt;">isk Assessment Combined With Clinical </font><font style="font-weight:bold;letter-spacing:-0.2pt;">I</font><font style="letter-spacing:0.2pt;">nterventions for Improving Neonatal outco</font><font style="font-weight:bold;letter-spacing:-0.2pt;">ME</font><font style="letter-spacing:0.2pt;">s (PRIME) study. The Company paid fees related to this agreement of $1.1&#160;million and $0.4&#160;million for the&#160;years ended December&#160;31, 2020 and 2019. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">9. Capital Structure</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:7pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Common Stock</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2020, the Company was authorized to issue 55,000,000 shares of $0.0001 par value common stock. Common stockholders are entitled to dividends if and when declared by the Board of Directors, subject to the prior rights of holders of all classes of stock outstanding having priority rights to dividends. The holder of each share of common stock is entitled to one vote. As of December&#160;31, 2020 and 2019, no dividends were declared. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following shares of common stock were reserved for future issuance: </font>
        </div>
        <table style="width:416pt;height:155.68pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:301.17pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:301.17pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:301.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Senior convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">11,928,167</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">9,451,206</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:301.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Junior convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">20,889,401</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">20,889,401</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:301.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Shares issuable under convertible note </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,383,989</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,247,663</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:301.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Warrants to purchase convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">169,533</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">167,460</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:301.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Warrants to purchase common stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">4,198,770</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">4,198,770</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:301.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Options to purchase common stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">8,517,220</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5,677,248</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.167pt 0pt 1.833pt 0pt; width:301.17pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Common stock available for future issuance under the 2011 Equity Incentive Plan </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">807,702</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">93,857</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:301.17pt;text-align:left;">
              <div style="font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Total</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">47,894,782</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">41,725,605</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17.79pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Convertible Preferred Stock</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Issued and outstanding convertible preferred stock and its principal terms as of December&#160;31, 2020 were as follows (in thousands, except share and per share amounts): </font>
        </div>
        <table style="width:416pt;height:118.55pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8.98pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 1.478pt 0pt; width:164.11pt;text-align:left;">
              <div style="white-space:nowrap; line-height:9pt; margin-bottom:-0.506666666666666pt;">
                <font style="letter-spacing:-0.16pt;">Series </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.478pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Authorized </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.478pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares Issued </font>
                <br >
                <font style="letter-spacing:-0.16pt;">and </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Outstanding </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.478pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Original Issue </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Price </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.478pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Aggregate </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Liquidation </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Preference </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.478pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Proceeds,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">net of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">issuance costs </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:164.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;A-1 Junior Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,390</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,390</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.25pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,000.00</td>
            <td style="padding:0pt;padding-left:3.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; ">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">1,390</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">1,390</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:164.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;A-2 Junior Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">7,941,499</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">7,908,277</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.25pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">2.50</td>
            <td style="padding:0pt;padding-left:3.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">19,771</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">19,595</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:164.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;B-1 Junior Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2,060,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2,000,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.25pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">2.50</td>
            <td style="padding:0pt;padding-left:3.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">5,000</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">4,914</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:164.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;B-2 Junior Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5,012,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5,000,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.25pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">4.00</td>
            <td style="padding:0pt;padding-left:3.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">20,000</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">19,984</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:164.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;C-1 Junior Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5,521,905</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5,505,099</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.25pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">5.95</td>
            <td style="padding:0pt;padding-left:3.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">32,755</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">32,653</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.5pt 0pt 1.5pt 0pt; width:164.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;D Senior Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">12,320,844</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">11,928,167</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.25pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">4.34</td>
            <td style="padding:0pt;padding-left:3.25pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">102,535</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">50,415</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 2.25pt 0pt; width:164.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total Convertible Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">32,858,138</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">32,342,933</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:26.25pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">181,451</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">128,951</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Issued and outstanding convertible preferred stock and its principal terms as of December&#160;31, 2019 were as follows (in thousands, except share and per share amounts): </font>
        </div>
        <table style="width:416pt;height:118.55pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8.98pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 1.478pt 0pt; width:164.11pt;text-align:left;">
              <div style="white-space:nowrap; line-height:9pt; margin-bottom:-0.506666666666666pt;">
                <font style="letter-spacing:-0.16pt;">Series </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.478pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Authorized </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.478pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares Issued </font>
                <br >
                <font style="letter-spacing:-0.16pt;">and </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Outstanding </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.478pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Original Issue </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Price </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.478pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Aggregate </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Liquidation </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Preference </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.478pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Proceeds,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">net of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">issuance costs </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:164.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;A-1 Junior Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,390</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,390</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.25pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,000.00</td>
            <td style="padding:0pt;padding-left:3.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">1,390</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">1,390</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:164.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;A-2 Junior Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">7,941,499</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">7,908,277</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.25pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">2.50</td>
            <td style="padding:0pt;padding-left:3.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">19,771</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">19,595</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:164.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;B-1 Junior Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2,060,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2,000,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.25pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">2.50</td>
            <td style="padding:0pt;padding-left:3.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">5,000</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">4,914</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:164.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;B-2 Junior Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5,012,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5,000,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.25pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">4.00</td>
            <td style="padding:0pt;padding-left:3.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">20,000</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">19,984</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:164.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;C-1 Junior Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5,521,905</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5,505,099</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.25pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">5.95</td>
            <td style="padding:0pt;padding-left:3.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">32,755</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">32,652</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.5pt 0pt 1.5pt 0pt; width:164.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;D Senior Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">12,320,844</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">9,451,206</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.25pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">4.34</td>
            <td style="padding:0pt;padding-left:3.25pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">81,035</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">39,729</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 2.25pt 0pt; width:164.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total Convertible Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">32,858,138</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">29,865,972</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">159,951</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 1.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">118,264</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.9pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The 2019 issuance of Series&#160;D Convertible Preferred Stock created a senior and junior preferred stock ranking, whereby Series&#160;D Convertible Preferred Stock, which we refer to as the &#8220;Senior Preferred Stock&#8221; is senior to all other classes of Preferred Stock, which we collectively refer to as &#8220;Junior Preferred Stock&#8221; (both Junior Preferred Stock and Senior Preferred Stock together, the &#8220;convertible preferred stock&#8221;). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In July&#160;2019, the Company authorized 12,320,844 shares of Series&#160;D Convertible Preferred Stock. Between July and December&#160;2019, the Company issued an aggregate of 9,451,206 shares for $4.34 per share to new and existing investors in exchange for $30.0&#160;million of proceeds, net of issuance costs, including conversion of $5.0&#160;million of principal associated with the August&#160;2019 Notes, and conversion of $7.8&#160;million and $0.2&#160;million of principal and accrued interest, respectively, associated with the November&#160;2018 Notes, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-18</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">and $1.9&#160;million and $0.1&#160;million of principal and accrued interest, respectively, associated with the February&#160;2019 Notes (see Note 6&#8201;&#8212;&#8201;Loan and Convertible Promissory Notes). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The terms of the sale of the Series&#160;D Convertible Preferred Stock include rights and preferences that differ from the terms of the sale of the Company&#8217;s Series&#160;C-1 Convertible Preferred Stock and previous preferred stock financings. Series&#160;D Convertible Preferred Stock is senior to all other classes or series of preferred stock and includes a liquidation preference equal to two times the original issue price of $4.34. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Purchasers of Series&#160;D Convertible Preferred Stock also received 2,099,385 warrants to purchase shares of common stock of the Company at a price of $4.34 per share, and 2,099,385 warrants to purchase shares of common stock of the Company at a price of $5.21 per share. The Company allocated a portion of the proceeds of the Series&#160;D Convertible Preferred Stock Financing to the warrants based on the estimated fair value of these warrants and recorded those amounts on the accompanying Statements of Cash Flows and Statements of Convertible Preferred Stock and Stockholders&#8217; Deficit. We refer to the foregoing transactions collectively as the &#8220;Series&#160;D Preferred Stock Financing.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Prior to the Series&#160;D Preferred Stock Financing, the Company entered into a consulting agreement with an agency to facilitate investment from certain non-US investors. This agreement specified that the Company would pay both a fee and warrants to purchase shares of Series&#160;D Convertible Preferred Stock based on a&#160;percentage of the amount received from certain non-US investors. The Company paid fees of $0.4&#160;million and issued 44,931 fully vested warrants to purchase shares of Series&#160;D Convertible Preferred Stock to this consultant, which the Company estimated to have a fair value of $0.2&#160;million. The Company recognized the fees and the fair value of the warrants issued as a reduction to additional paid-in capital and recorded a corresponding preferred stock warrant liability on the accompanying Balance Sheets. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the terms of the Series&#160;C-1 Preferred Stock Purchase Agreement dated January&#160;9, 2017, by and among the Company and the purchasers identified therein, as amended on February&#160;9, 2017, Labcorp committed to purchase, and the Company authorized, 1,509,661 shares of series C-2 convertible preferred stock, par value $0.0001 per share (the &#8220;Series&#160;C-2 Convertible Preferred Stock&#8221;), for $8.28 per share, in exchange for $12.5&#160;million in cash, subject to adjustment, and conditional upon the Company&#8217;s achievement of a milestone, as defined in the stock purchase agreement, which included achieving positive results in one of two clinical outcome studies. The Company recorded this preferred stock tranche forward obligation to issue contingently redeemable shares of Series&#160;C-2 Convertible Preferred Stock as a forward contract liability in the Company&#8217;s balance sheets at its estimated fair market value and remeasured the liability at each annual reporting period. As the milestones related to this commitment are not expected to be achieved, the Company has determined the fair value of this forward tranche liability was $0 as of December&#160;31, 2020 and 2019. The Company reported $0 and $0.6&#160;million of other income related to the change in fair value for the&#160;years ended December&#160;31, 2020 and 2019, respectively. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The holders of convertible preferred stock have various rights and preferences including the following: </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Dividends</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The holders of convertible preferred stock are entitled to receive dividends out of any assets legally available only when, as, and if declared by the Company&#8217;s board of directors, prior to and in preference to any declaration or payment of any dividend on the common stock. Such dividends are noncumulative. As of December&#160;31, 2020, and 2019, there were no cumulative dividends owed or in arrears. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Liquidation Preference</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the event of any liquidation, dissolution or winding up of the Company, the holders of Series&#160;D Convertible Preferred Stock then outstanding will be entitled to an amount per share equal to two times the Series&#160;D Original Issue Price, plus all declared and unpaid dividends on such share of Series&#160;D Convertible Preferred Stock, before any payment are made to the holders of common stock, the Junior Preferred Stock or any other class or series of stock junior to the Series&#160;D Convertible Preferred Stock. If available funds and assets are not sufficient to pay the holders of Series&#160;D Convertible Preferred Stock the full amount to which they are be entitled, payments will be made on a pro&#160;rata, equal priority, pari&#160;passu basis. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-19</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">After the payment of the Series&#160;D Convertible Preferred Stock preferential liquidation amount, the holders of shares of Junior Preferred Stock then outstanding, on a pari&#160;passu basis, will be entitled to an amount per share equal to the series C-1 convertible preferred stock original issue price of $5.95, series B-2 convertible preferred stock original issue price of $4.00, series B-1 convertible preferred stock and series A-2 convertible preferred stock original issue price of $2.50 or series A-1 convertible preferred stock original issue price of $1,000, as applicable, plus any dividends declared but unpaid thereon, before any payment shall be made to the holders of common stock. If available funds and assets are not sufficient to pay the holders of Junior Preferred Stock the full amount to which they are entitled, payments will be made on a pro&#160;rata, equal priority, pari&#160;passu basis. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Conversion Rights</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Each outstanding share of convertible preferred stock is convertible, at the option of the holder at any time and from time to time, into such number of fully paid and non-assessable shares of common stock as is determined by dividing the respective original issue price of the convertible preferred stock, as applicable, by the respective conversion price of the convertible preferred stock, as applicable, in effect at the time of the conversion. Conversion of all shares of convertible preferred stock is automatic upon (i)&#160;the closing of a public offering of common stock at a price per share of at least 1.2 times the original issue price of the Series&#160;D Convertible Preferred Stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the common stock) resulting in at least $40.0&#160;million of gross cash proceeds; or (ii)&#160;affirmative election of at least a majority of the shares of preferred stock outstanding. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2020, the Series&#160;D Convertible Preferred Stock conversion price is equal to $4.34. As of December&#160;31, 2020 and 2019, the series C-1 convertible preferred stock conversion price was equal to $5.95, the series B-2 convertible preferred stock conversion price was equal to $4.00, the series B-1 convertible preferred stock and series A-2 convertible preferred stock conversion prices were equal to $2.50 and the series A-1 convertible preferred stock conversion price was equal to $3.00. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The conversion price of convertible preferred stock is subject to adjustment as a result of stock dividends, splits and other equity structuring transactions, and due to subsequent sales of common stock at a lower effective price. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Redemption Rights</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Each outstanding share of convertible preferred stock is redeemable by the Company at a price equal to the applicable liquidation preference per share, plus any dividends per share declared but unpaid thereon (the &#8220;Redemption Price&#8221;), in three annual installments commencing not more than 60&#160;days after receipt by the Company at any time on or after the 5th anniversary of the Series&#160;D Convertible Preferred Stock original issue date, July&#160;31, 2019, from the holders of at least a majority of the Series&#160;D Convertible Preferred Stock then outstanding of written notice requesting redemption of all shares of convertible preferred stock (the Redemption Request). Upon receipt of a Redemption Request, the Company will apply all of its assets to any such redemption, and to no other corporate purpose, except to the extent prohibited by Delaware law governing distributions to stockholders. Changes in the fair value of the Company&#8217;s convertible preferred stock or common stock would not affect settlement amounts. The carrying value of the convertible preferred stock has not been accreted up to its redemption value as no redemption events are considered probable as of December&#160;31, 2020 and 2019. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Upon the occurrence of certain change in control events that are outside the Company&#8217;s control, including liquidation, sale, or transfer of the Company, holders of the convertible preferred stock can effectively cause redemption for cash. As a result, the Company has classified the convertible preferred stock as mezzanine equity on the accompanying balance sheets as the stock is contingently redeemable. The Company has elected not to adjust the carrying values of the convertible preferred stock to the liquidation preferences of such shares because it is uncertain whether or when an event would occur that would obligate the Company to pay the liquidation preferences to holders of shares of convertible preferred stock. Subsequent adjustments to the carrying values to the liquidation preferences will be made only when it becomes probable that such a liquidation event will occur. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-20</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:233.97pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Voting Rights</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The holders of each share of convertible preferred stock are entitled to the number of votes equal to the number of shares of common stock into which such share is convertible. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">10. Stock-based Compensation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:7pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Equity Incentive Plans</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">In February&#160;2008, the Company established the 2008 Stock Incentive Plan (the &#8220;2008 Plan&#8221;) and reserved shares of the Company&#8217;s common stock for sale and issuance under the 2008 Plan. In November&#160;2011, the 2008 Plan was terminated and the remaining authorized shares were no longer available for future grants. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">In November&#160;2011, the Company established the 2011 Employee, Director and Consultant Equity Incentive Plan (the &#8220;2011 Plan&#8221;) and reserved shares of the Company&#8217;s common stock for sale and issuance under the 2011 Plan. The 2011 Plan provides for the grant of incentive and non-statutory stock options as well as restricted stock to employees, nonemployee directors and consultants of the Company, which are to be granted at a price that is not less than 100% of the fair value of the stock at the date of grant. Options and restricted stock generally vest over a four-year period and options generally expire ten&#160;years from the date of grant. Options are exercisable only to the extent vested. In February&#160;2020, the Board of Directors approved an increase to the number of shares of common stock options available for grant under the 2011 Plan by 3,918,700 and reserved the same number of shares of the Company&#8217;s common stock for issuance under the 2011 Plan. As of December&#160;31, 2020, the 2011 Plan, as amended, permits the Company to grant up to 12,709,379 shares of the Company&#8217;s common stock, plus any additional awards granted under the 2008 Plan that are forfeited, expire or are cancelled without exercise after November&#160;8, 2011. In August&#160;2020, the Board of Directors approved an amendment to the Plan that will automatically increase the number of shares authorized for issuance under the Plan on the first day of each fiscal year beginning in fiscal year 2021, which was 2,001,859 for 2021. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Stock Options</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Unless otherwise noted, references to &#8220;options&#8221; in the subsequent disclosures, refers to the combined incentive and non-statutory stock options issued as employee and non-employee stock-based compensation, </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-21</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">and authorized under the 2008 Plan and 2011 Plan. The following table summarizes information about these options granted and outstanding: </font>
        </div>
        <table style="width:456pt;height:269.02pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8.98pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:222.27pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center; line-height:8.99pt;">
                <font style="letter-spacing:-0.16pt;">Number of </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Shares</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Subject to </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Options </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Outstanding </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center; line-height:8.99pt;">
                <font style="letter-spacing:-0.16pt;">Weighted-</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Average Grant </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Date</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Fair Value </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center; line-height:8.99pt;">
                <font style="letter-spacing:-0.16pt;">Weighted-</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Average </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Exercise Price </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Per Share </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center; line-height:8.99pt;">
                <font style="letter-spacing:-0.16pt;">Weighted-</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Average </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Remaining </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Contractual</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Life (In Years) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:222.27pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Outstanding&#8201;&#8211;&#8201;December&#160;31, 2018 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.370000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">5,673,947</td>
            <td style="padding:0pt;padding-left:0.370000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.7pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.43</td>
            <td style="padding:0pt;padding-left:12.7pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.73</td>
            <td style="padding:0pt;padding-left:12.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">6.86</td>
            <td style="padding:0pt;padding-left:15.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:222.27pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Granted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.370000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">234,000</td>
            <td style="padding:0pt;padding-left:0.370000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.7pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.45</td>
            <td style="padding:0pt;padding-left:12.7pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.87</td>
            <td style="padding:0pt;padding-left:12.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:222.27pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Cancelled </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.370000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(186,642<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.370000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.7pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.44</td>
            <td style="padding:0pt;padding-left:12.7pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.82</td>
            <td style="padding:0pt;padding-left:12.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:222.27pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Exercised </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.370000000000001pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(44,057<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.370000000000001pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.7pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">0.42</td>
            <td style="padding:0pt;padding-left:12.7pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.505pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">0.75</td>
            <td style="padding:0pt;padding-left:12.505pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.52pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.52pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:222.27pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Outstanding&#8201;&#8211;&#8201;December&#160;31, 2019 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.370000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">5,677,248</td>
            <td style="padding:0pt;padding-left:0.370000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.7pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.42</td>
            <td style="padding:0pt;padding-left:12.7pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.73</td>
            <td style="padding:0pt;padding-left:12.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">6.04</td>
            <td style="padding:0pt;padding-left:15.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:222.27pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Granted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.370000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">4,036,933</td>
            <td style="padding:0pt;padding-left:0.370000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.7pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.45</td>
            <td style="padding:0pt;padding-left:12.7pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.85</td>
            <td style="padding:0pt;padding-left:12.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:222.27pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Cancelled </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.370000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(750,522<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.370000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.7pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.43</td>
            <td style="padding:0pt;padding-left:12.7pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.80</td>
            <td style="padding:0pt;padding-left:12.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:222.27pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Expired </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.370000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(81,556<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.370000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.7pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.62</td>
            <td style="padding:0pt;padding-left:12.7pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.16</td>
            <td style="padding:0pt;padding-left:12.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:222.27pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Exercised </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.370000000000001pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(364,833<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0.370000000000001pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.7pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">0.28</td>
            <td style="padding:0pt;padding-left:12.7pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.505pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">0.48</td>
            <td style="padding:0pt;padding-left:12.505pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.52pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.52pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:222.27pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Outstanding&#8201;&#8211;&#8201;December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.370000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">8,517,220</td>
            <td style="padding:0pt;padding-left:0.370000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.7pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.44</td>
            <td style="padding:0pt;padding-left:12.7pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.79</td>
            <td style="padding:0pt;padding-left:12.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">6.99</td>
            <td style="padding:0pt;padding-left:15.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 3.25pt 0pt; width:222.27pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Vested and expected to vest at December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.370000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">8,218,460</td>
            <td style="padding:0pt;padding-left:0.370000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.7pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">0.44</td>
            <td style="padding:0pt;padding-left:12.7pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">0.79</td>
            <td style="padding:0pt;padding-left:12.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">6.91</td>
            <td style="padding:0pt;padding-left:15.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.417pt 0pt 2.583pt 0pt; width:222.27pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Vested and exercisable at</font>
                <br >
                <font style="letter-spacing:0.2pt;">December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.370000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">4,937,617</td>
            <td style="padding:0pt;padding-left:0.370000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.7pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">0.43</td>
            <td style="padding:0pt;padding-left:12.7pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.505pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">0.74</td>
            <td style="padding:0pt;padding-left:12.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.52pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">5.44</td>
            <td style="padding:0pt;padding-left:15.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.417pt 0pt 2.583pt 0pt; width:222.27pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Non-vested options at</font>
                <br >
                <font style="letter-spacing:0.2pt;">December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.370000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">3,579,603</td>
            <td style="padding:0pt;padding-left:0.370000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.7pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">0.45</td>
            <td style="padding:0pt;padding-left:12.7pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.505pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">0.85</td>
            <td style="padding:0pt;padding-left:12.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Total aggregate intrinsic value of options exercised during the&#160;years ended December&#160;31, 2020 and 2019 was $0.1&#160;million and $8.5&#160;thousand, respectively. The total fair value of options vested for the&#160;years ended December&#160;31, 2020 and 2019 was $0.6&#160;million and $0.5&#160;million, respectively. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The assumptions used to value employee stock options are as follows: </font>
        </div>
        <table style="width:416pt;height:91.57pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8.98pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:290.34pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended</font>
                <br >
                <font style="letter-spacing:-0.16pt;">December 31,</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended</font>
                <br >
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290.34pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:290.34pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected volatility </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">52.8&#8201;&#8211;&#8201;62.1<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">53.2&#8201;&#8211;&#8201;54.4<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:290.34pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Risk-free interest rate </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">0.4&#8201;&#8211;&#8201;1.2<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">1.7&#8201;&#8211;&#8201;2.6<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:290.34pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected term (in&#160;years) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">5.2&#8201;&#8211;&#8201;6.2</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">5.5&#8201;&#8211;&#8201;6.0</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:290.34pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected dividends </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8.5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table presents the impact of employee stock-based compensation expense in the statements of operations for the periods indicated (in thousands): </font>
        </div>
        <table style="width:416pt;height:83.68pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:317.97pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:317.97pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.24pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.24pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.24pt 0pt 1.51pt 0pt; width:317.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Research and development expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">208</td>
            <td style="padding:0pt;padding-left:8.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">155</td>
            <td style="padding:0pt;padding-left:8.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.49pt 0pt 1.51pt 0pt; width:317.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Sales and marketing expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">131</td>
            <td style="padding:0pt;padding-left:8.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">74</td>
            <td style="padding:0pt;padding-left:8.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.49pt 0pt 2.5pt 0pt; width:317.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">General and administrative expense </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.505pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">320</td>
            <td style="padding:0pt;padding-left:8.505pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.505pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">153</td>
            <td style="padding:0pt;padding-left:8.505pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.24pt 0pt 3.25pt 0pt; width:317.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total employee stock-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">659</td>
            <td style="padding:0pt;padding-left:8.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">382</td>
            <td style="padding:0pt;padding-left:8.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17.59pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Nonemployee Stock-based Compensation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">During the&#160;years ended December&#160;31, 2020 and 2019, the Company granted options to purchase 65,000 and 40,000 shares, respectively, of common stock to non-employee consultants. These options were </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-22</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">granted in exchange for consulting services rendered and vested over the service term, which approximates the options&#8217; vesting period. The fair value of each option on the date of grant is estimated using the Black-Scholes option model. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The fair value of each award grant had estimated assumptions as follows: </font>
        </div>
        <table style="width:416pt;height:82.59pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290.34pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290.34pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:290.34pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected volatility </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">54.5&#8201;&#8211;&#8201;59.5<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">52.5&#8201;&#8211;&#8201;53.7<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:290.34pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Risk-free interest rate </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">0.6&#8201;&#8211;&#8201;0.9<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">1.7&#8201;&#8211;&#8201;2.7<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:290.34pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected term (in&#160;years) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">9.4&#8201;&#8211;&#8201;10.0</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">9.2&#8201;&#8211;&#8201;10.0</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:290.34pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected dividends </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8.3pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table presents nonemployee stock-based compensation expense in the statements of operations for the periods indicated (in thousands): </font>
        </div>
        <table style="width:416pt;height:83.68pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:317.97pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:317.97pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.24pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.24pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.24pt 0pt 1.51pt 0pt; width:317.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Research and development expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">28</td>
            <td style="padding:0pt;padding-left:11.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">27</td>
            <td style="padding:0pt;padding-left:11.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.49pt 0pt 1.51pt 0pt; width:317.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Sales and marketing expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">9</td>
            <td style="padding:0pt;padding-left:11.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">25</td>
            <td style="padding:0pt;padding-left:11.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.49pt 0pt 2.5pt 0pt; width:317.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">General and administrative expense </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.005pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">31</td>
            <td style="padding:0pt;padding-left:11.005pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.005pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">4</td>
            <td style="padding:0pt;padding-left:11.005pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.24pt 0pt 3.25pt 0pt; width:317.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total nonemployee stock-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">68</td>
            <td style="padding:0pt;padding-left:11.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.005pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">56</td>
            <td style="padding:0pt;padding-left:11.005pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.29pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Total stock-based compensation expense during the&#160;years ended December&#160;31, 2020 and 2019 was $0.7&#160;million and $0.4&#160;million, respectively. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">At December&#160;31, 2020, there was $1.4&#160;million of unamortized stock-based compensation cost related to unvested stock options which is expected to be recognized over a weighted average period of 2.93&#160;years. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">11. Warrants</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:11pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Warrants to purchase common stock</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In conjunction with the issuance of Series&#160;D Convertible Preferred Stock, the Company issued 2,099,385 warrants to purchase common stock shares of the Company at a price of $4.34 per share, and 2,099,385 warrants to purchase shares of common stock of the Company at a price of $5.21 per share. These warrants were measured at fair value on the date of the transaction and allocated a portion of the Series&#160;D Preferred Stock Financing proceeds. The initial fair value of the common stock warrants, calculated using the Black-Scholes option pricing model, was $0.9&#160;million. The fair value of the warrants were recognized as a component of additional paid-in capital in the accompanying financial statements. As an equity instrument these warrants are not required to be remeasured to their fair value each reporting period. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Warrants to purchase preferred stock</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In conjunction with the issuance of Series&#160;D Convertible Preferred Stock, the Company issued a third-party consultant a fully-vested warrant to purchase 44,931 shares (the &#8220;2019 Warrant&#8221;) of Series&#160;D Convertible Preferred Stock at a price of $4.34 per share. The initial fair value of the 2019 Warrant was calculated using the Black-Scholes option pricing model and recorded as a reduction in additional paid-in capital associated with Series&#160;D Preferred Stock Financing. The 2019 Warrant, which increased to 47,005 shares in conjunction with the issuance of additional shares of Series&#160;D Convertible Preferred Stock in 2020, remains outstanding at December&#160;31, 2020, and is immediately exercisable for cash, with 47,005 shares to be issued upon settlement of the 2019 Warrant. During the fiscal year, any changes in the fair value of these warrant liabilities are recorded as a component of other income (expense). Total adjustments to the fair value of this warrant liability during the years ended December&#160;31, 2020 and 2019 resulted in other income (expense) of $(0.1) million and $1.5 thousand, respectively. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-23</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:68.12pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with various debt financings, refinancing, and amendments to the Loan Agreement with the Bank, the Company has, from time to time, issued warrants to purchase shares of Series A-2, B-1, B-2, and C-1 Convertible Preferred Stock. Each of these warrants are exercisable for cash, fully-vested at the grant date, and have a ten-year expiration. The initial fair values of each these warrants was calculated using the Black-Scholes option pricing model and recorded as a reduction to the carrying value of the bank loan payable in the year of issuance. During the fiscal year, any changes in the fair value of these warrant liabilities are recorded in interest expense. Total adjustments to the fair value of these warrant liabilities during the&#160;years ended December&#160;31, 2020 and 2019 resulted in $0.2&#160;million of interest expense and a $0.2&#160;million reduction of interest expense, respectively. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes the warrants to purchase convertible preferred stock and the fair value as of December&#160;31, 2020 and 2019 (in thousands, except share and per share amounts): </font>
        </div>
        <table style="width:416pt;height:137.07pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8.98pt;height:18.82pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 2.805pt 0pt; width:187.76pt;text-align:left;" rowspan="2">
              <div style="line-height:8.99000000000001pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Related </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Series </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:41.25pt;" rowspan="2">
              <div style="text-align:center; line-height:8.99000000000001pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Grant </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Date </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:8.99000000000001pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Number of </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Warrants </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:8.99000000000001pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Exercise </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Price </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Fair Value Year-Ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:14.09pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:187.76pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Series&#160;A-2 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:41.25pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">Sep 2012 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">26,000</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.50</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;41</td>
            <td style="padding:0pt;padding-left:0.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;7</td>
            <td style="padding:0pt;padding-left:0.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:187.76pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Series&#160;A-2 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:41.25pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">Sep 2014 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">7,222</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.50</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">13</td>
            <td style="padding:0pt;padding-left:0.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">4</td>
            <td style="padding:0pt;padding-left:0.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:187.76pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Series&#160;B-1 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:41.25pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">Dec 2014 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">60,000</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.50</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">113</td>
            <td style="padding:0pt;padding-left:0.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">30</td>
            <td style="padding:0pt;padding-left:0.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:187.76pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Series&#160;B-2 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:41.25pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">Dec 2015 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">12,500</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.00</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">22</td>
            <td style="padding:0pt;padding-left:0.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">6</td>
            <td style="padding:0pt;padding-left:0.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:187.76pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Series&#160;C-1 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:41.25pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">Mar 2017 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">16,806</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">5.95</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">31</td>
            <td style="padding:0pt;padding-left:0.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">10</td>
            <td style="padding:0pt;padding-left:0.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:187.76pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Series&#160;D </font>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:41.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Jul 2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">47,005</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:13.5pt; text-align:right; white-space:nowrap;">4.34</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.82pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">254</td>
            <td style="padding:0pt;padding-left:0.82pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.82pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">173</td>
            <td style="padding:0pt;padding-left:0.82pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:187.76pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Total </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:41.25pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">169,533</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">474</td>
            <td style="padding:0pt;padding-left:0.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.82pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">230</td>
            <td style="padding:0pt;padding-left:0.82pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:9.19pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">All warrants outstanding to purchase convertible preferred stock were remeasured as of December&#160;31, 2020 and 2019, using the Black-Scholes option-pricing model with the following assumptions: </font>
        </div>
        <table style="width:416pt;height:157.58pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:7.97999999999996pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:290.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.812pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290.34pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.24pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.24pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.24pt 0pt 1.51pt 0pt; width:290.34pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;A-2 stock price fair value </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">3.41</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">1.53</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.49pt 0pt 1.51pt 0pt; width:290.34pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;B-1 stock price fair value </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">3.41</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">1.53</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.49pt 0pt 1.51pt 0pt; width:290.34pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;B-2 stock price fair value </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">3.58</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">1.71</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.49pt 0pt 1.51pt 0pt; width:290.34pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;C-1 stock price fair value </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">3.89</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">2.02</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.49pt 0pt 1.51pt 0pt; width:290.34pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;D stock price fair value </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">7.35</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">5.70</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.49pt 0pt 1.51pt 0pt; width:290.34pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected volatility </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">59.5&#8201;&#8211;&#8201;72.5<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">49.8&#8201;&#8211;&#8201;53.2<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.49pt 0pt 1.51pt 0pt; width:290.34pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Risk-free interest rate </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">0.1&#8201;&#8211;&#8201;0.9<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">1.6&#8201;&#8211;&#8201;1.9<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.49pt 0pt 1.51pt 0pt; width:290.34pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected term (in&#160;years) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">1.7&#8201;&#8211;&#8201;9.1</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">2.7&#8201;&#8211;&#8201;9.8</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.49pt 0pt 1.51pt 0pt; width:290.34pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected dividends </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.49pt 0pt 1.51pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:9.19pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Liability classification requires the warrants to be remeasured to their fair value at each reporting period. As of December&#160;31, 2020 and 2019, the fair value of preferred stock warrants outstanding was $0.5&#160;million and $0.2&#160;million, respectively, and was recorded in warrant liability as a long-term liability in the accompanying balance sheets. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-24</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following is a summary of the Company&#8217;s preferred stock warrant liability activity for the&#160;years ended December&#160;31, 2020 and 2019 (in thousands): </font>
        </div>
        <table style="width:456pt;height:118.05pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8.98pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:402.85pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;text-align:center;" colspan="4">
              <div style="text-align:center; line-height:8.99pt;">
                <font style="letter-spacing:-0.16pt;">Warrant </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Liability </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Outstanding </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.26pt 0pt 1.49pt 0pt; width:402.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Outstanding&#8201;&#8211;&#8201;December&#160;31, 2018 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.91pt;width:0pt;">&#8203;</td>
            <td style="padding:3.26pt 0pt 1.49pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.26pt 0pt 1.49pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">240</td>
            <td style="padding:0pt;padding-left:8.91pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.51pt 0pt 1.49pt 0pt; width:402.85pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Valuation of warrants to purchase preferred stock at issuance of Series&#160;D warrants </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.91pt;width:0pt;">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">175</td>
            <td style="padding:0pt;padding-left:8.91pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.51pt 0pt 2.5pt 0pt; width:402.85pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Net decrease in fair value of preferred stock warrants </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.91pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.51pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.51pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(185<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.91pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.26pt 0pt 1.49pt 0pt; width:402.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Outstanding&#8201;&#8211;&#8201;December&#160;31, 2019 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.91pt;width:0pt;">&#8203;</td>
            <td style="padding:3.26pt 0pt 1.49pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.26pt 0pt 1.49pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">230</td>
            <td style="padding:0pt;padding-left:8.91pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.51pt 0pt 2.5pt 0pt; width:402.85pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Net increase in fair value of preferred stock warrants </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.91pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.51pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.51pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">244</td>
            <td style="padding:0pt;padding-left:8.91pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.26pt 0pt 3.25pt 0pt; width:402.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Outstanding&#8201;&#8211;&#8201;December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.91pt;width:0pt;">&#8203;</td>
            <td style="padding:3.26pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.26pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">474</td>
            <td style="padding:0pt;padding-left:8.91pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:16.71pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">12. Commitments and Contingences</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:7pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Operating Leases</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company leases a total of approximately 21,800 square feet of office and laboratory space under a single non-cancelable operating lease with a termination date of December&#160;31, 2022. Under the terms of the lease agreement, the Company has an option to renew the lease for one additional five-year rental period. The lease included a tenant improvement allowance from the landlord for structural and cosmetic changes to the new space. The tenant improvements were completed and delivery of possession occurred on September&#160;1, 2018. The tenant improvement allowance has been accounted for as a liability of the Company within deferred rent and is amortized monthly as a reduction to rent expense. A corresponding leasehold improvement asset has been recorded with monthly depreciation being recorded as depreciation expense. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Scheduled base rent increases of 3% occur annually each August. The Company recognized rent expense on a straight-line basis over the term of the operating lease. The difference in actual amounts paid and amounts recorded as rent expense during the period was recorded as deferred rent on the accompanying balance sheets. For the&#160;years ended December&#160;31, 2020 and 2019, the Company recognized rent expense of $0.4&#160;million. Amounts classified as deferred rent at December&#160;31, 2020 and 2019 totaled $0.3&#160;million and $0.4&#160;million, respectively. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Capital Leases</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The full value of all leased equipment, including advance payments, are classified as assets on the Company&#8217;s balance sheets. The portion of the future payments designated as principal repayment are classified as a capital lease obligation. As of December&#160;31, 2020 and 2019, the Company classified the aggregate amount of scheduled capital lease obligation payments due within twelve&#160;months of the date of the financial statements, $0.1&#160;million, as a current liability, and the remaining $0.1&#160;million due thereafter, in other liabilities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table presents the Company&#8217;s future minimum lease payments as of December&#160;31, 2020 (in thousands): </font>
        </div>
        <table style="width:456pt;height:63.57pt;margin-top:9.99999999999994pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8.98pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:277.13pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 and </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Thereafter </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:277.13pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Operating leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">545</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">554</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.08pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&nbsp;&nbsp;&nbsp;&#8212;</td>
            <td style="padding:0pt;padding-left:5.08pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,099</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:277.13pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Capital leases </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">80</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">80</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">55</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.08pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.08pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">215</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:277.13pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">625</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">634</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">55</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.08pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.08pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,314</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:16.8pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Indemnification</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company has agreed to indemnify its officers and directors for certain events or occurrences, while the officer or director is or was serving at the Company&#8217;s request in such capacity. The maximum amount of potential future indemnification is unlimited; however, the Company purchases director and officer insurance coverage that provides for corporate reimbursements of covered obligations that limits the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-25</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:68.49pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Company&#8217;s exposure and enables it to recover a portion of potential future amounts paid. The Company is unable to reasonably estimate the maximum amount that could be payable under these arrangements since these obligations are not capped but are conditional to the unique facts and circumstances involved. Accordingly, the Company has no liabilities recorded for these agreements as of December&#160;31, 2020 and 2019. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Employee Agreements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The Company has signed various employment agreements with key executives pursuant to which if their employment is terminated by the Company without cause or by the employees for good reason, or following a change in control of the Company, the employees are entitled to receive certain benefits, including severance payments, accelerated vesting of stock and stock options, and certain insurance benefits. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Legal Matters</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The Company is not currently a party to any material litigation or other material legal proceedings. The Company may, from time to time, be involved in various legal proceedings arising from the normal course of business activities, and an unfavorable resolution of any of these matters could materially affect the Company&#8217;s future results of operations, cash flows, or financial position. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">13. Retirement Savings Plan</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">In 2012, the Company established a savings plan available to all eligible employees, which qualifies under Section&#160;401(k) of the Internal Revenue Code. Employees may contribute to the plan amounts of their pre-tax salary subject to statutory limitations. Annually, the Company&#8217;s board of directors determines the amount, if any, of a Company match. The Company has not provided a match for the&#160;years ended December&#160;31, 2020 or 2019. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">14. Income Taxes</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The Company has not recorded any income tax expense for the&#160;years ended December&#160;31, 2020 and 2019, due to its history of operating losses. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The provision for income taxes includes the following components for the&#160;years ended December&#160;31, 2020 and December&#160;31, 2019 (in thousands): </font>
        </div>
        <table style="width:416pt;height:131.09pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:168pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9.45pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9.45pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:129.23pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9.45pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9.45pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9.45pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9.45pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:168pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Current: </font>
              </div>
            </td>
            <td style="padding:0pt; width:9.45pt;">&#8203;</td>
            <td style="padding:0pt; width:9.45pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:129.23pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Federal </font>
            </td>
            <td style="padding:0pt; width:9.45pt;">&#8203;</td>
            <td style="padding:0pt; width:9.45pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:9.45pt;">&#8203;</td>
            <td style="padding:0pt; width:9.45pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:168pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9.45pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9.45pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:129.23pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">State </font>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9.45pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9.45pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9.45pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9.45pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:0pt 0pt 0.5pt 0pt; width:168pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:9.45pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:9.45pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:129.23pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Total current provision </font>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:9.45pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:9.45pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:9.45pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:9.45pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:168pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Deferred </font>
              </div>
            </td>
            <td style="padding:0pt; width:9.45pt;">&#8203;</td>
            <td style="padding:0pt; width:9.45pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:129.23pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Federal </font>
            </td>
            <td style="padding:0pt; width:9.45pt;">&#8203;</td>
            <td style="padding:0pt; width:9.45pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">3,658</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:9.45pt;">&#8203;</td>
            <td style="padding:0pt; width:9.45pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">3,535</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:168pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:9.45pt;">&#8203;</td>
            <td style="padding:0pt; width:9.45pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:129.23pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">State </font>
            </td>
            <td style="padding:0pt; width:9.45pt;">&#8203;</td>
            <td style="padding:0pt; width:9.45pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">1,498</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:9.45pt;">&#8203;</td>
            <td style="padding:0pt; width:9.45pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">1,142</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:168pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9.45pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9.45pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:129.23pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Change in valuation allowance </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9.45pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9.45pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(5,156<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9.45pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:9.45pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(4,676<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:0pt 0pt 0.5pt 0pt; width:168pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:9.45pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:9.45pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:129.23pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Total deferred provision </font>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:9.45pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:9.45pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:9.45pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:9.45pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:168pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total Income tax benefit (provision) </font>
              </div>
            </td>
            <td style="padding:0pt; width:9.45pt;">&#8203;</td>
            <td style="padding:0pt; width:9.45pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.75pt 0pt; width:129.23pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:9.45pt;">&#8203;</td>
            <td style="padding:0pt; width:9.45pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:9.45pt;">&#8203;</td>
            <td style="padding:0pt; width:9.45pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-26</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The benefit (provision) for income taxes differs from the amount computed at federal statutory rates as follows (in thousands): </font>
        </div>
        <table style="width:456pt;height:141.59pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:281.85pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:281.85pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Computed Federal income tax benefit (expense) at the statutory rate </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">4,167</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">21.00<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">3,469</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">21.00<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:281.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">R&amp;D credits </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">304</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">1.53<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">351</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">2.15<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:281.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Equity-based expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(136<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">-0.68<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(34<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">-0.21<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:281.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">State income taxes, net of federal benefit </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">1,065</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">5.36<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">958</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">5.79<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:281.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">State net operating loss carryforward true up </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">49</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">0.25<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(127<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">-0.77<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:281.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(294<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">-1.48<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">58</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">0.35<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:281.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Valuation allowance </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:0pt 0pt 0.5pt 0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(5,156<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">-25.98<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(4,676<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">-28.31<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:281.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Income tax benefit (provision) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.75pt 0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.21pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Significant components of the Company&#8217;s net deferred income tax assets (liabilities) are as follows (in thousands): </font>
        </div>
        <table style="width:456pt;height:205.59pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:359.93pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:359.93pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Deferred tax assets: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Net operating loss carryforwards </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">31,234</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">26,607</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">R&amp;D </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">2,033</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1,729</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Accruals and reserves </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">419</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">338</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Deferred revenue </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">11</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Equity-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">220</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">169</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total deferred tax asset before allowance </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">33,908</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">28,856</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Less: valuation allowance </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(33,864<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(28,708<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total deferred tax asset </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">44</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">148</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:359.93pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Deferred tax liabilities: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:359.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Depreciation and amortization </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(44<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(148<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:359.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net deferred tax assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.2pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets. A significant piece of objective negative evidence evaluated is the cumulative loss incurred since inception. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Such objective evidence limits the ability to consider other subjective evidence such as the Company&#8217;s projections for future growth. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On the basis of this evaluation, a full valuation allowance of $33.9&#160;million and $28.7&#160;million has been recorded as of December&#160;31, 2020 and 2019, as it is more likely than not that the deferred tax assets will not be realized. The valuation allowance increased by $5.2&#160;million and $4.7&#160;million for the&#160;years ended December&#160;31, 2020 and 2019, respectively. Accordingly, there is no tax benefit presented in the accompanying financial statements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2020, the Company had U.S. federal and state net operating loss carryforwards of approximately $125.1&#160;million and $79.0&#160;million, respectively. Of the federal net operating loss carryforward amount, $54.9&#160;million can be carried forward indefinitely, while the remainder begins to expire after 2028, if not utilized. The state net operating loss carryforward amounts begin to expire at various dates after 2023.</font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have not completed a Section 382 analysis under the Internal Revenue Code regarding the limitation of NOL and credit carryforwards. If a change in ownership were to occur, the annual limitation may result in the expiration of NOL carryforwards and credits before utilization. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-27</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:15.97pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Because of the change of ownership provisions of the Tax Reform Act of 1986, use of a portion of the Company&#8217;s NOL and tax credit carryforwards may be limited in future periods. Further, a portion of the carryforwards may expire before being applied to reduce future income tax liabilities. There are currently no federal or state tax audits in progress. All prior tax&#160;years remain subject to examination by Federal and State of Utah authorities due to the existence of net operating loss carryforwards. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company recognizes the tax benefit of an uncertain tax position only if it is more likely than not that a tax position will be sustained upon examination by the appropriate taxing authorities, based on technical merits. The reversal of the uncertain tax positions would not affect the Company&#8217;s effective tax rate to the extent that it continues to maintain a full valuation allowance against its deferred tax assets. As of December&#160;31, 2020 and 2019, the Company did not record any material interest expense or penalties related to uncertain tax positions or the settlement of audits for prior periods. The Company does not expect a significant increase or decrease in its uncertain tax positions within the next 12&#160;months. A reconciliation of the beginning and ending amount of uncertain tax positions (in thousands): </font>
        </div>
        <table style="width:416pt;height:83.68pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:317.97pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:317.97pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:317.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Balance at the beginning of the year </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,152</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">918</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:317.97pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Gross increases&#8201;&#8211;&#8201;prior period </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:317.97pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Gross increases&#8201;&#8211;&#8201;current period </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">202</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">234</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:317.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Balance at the end of the year </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,354</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,152</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">15. Net loss per share</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth the computation of the basic and diluted net loss per share (in thousands, except share and per share amounts): </font>
        </div>
        <table style="width:416pt;height:68.68pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:301.17pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:301.17pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.24pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.24pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.24pt 0pt 1.51pt 0pt; width:301.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(19,848<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 1.51pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(16,521<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.49pt 0pt 2.5pt 0pt; width:301.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Weighted average common stock outstanding, basic and diluted </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">3,234,476</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.49pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">3,153,654</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.24pt 0pt 3.25pt 0pt; width:301.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss per share&#8201;&#8211;&#8201;basic and diluted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(6.14<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.24pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.24pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(5.24<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.99pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company excluded the following potentially dilutive securities, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because their impact under the &#8220;treasury stock method&#8221; and &#8220;if-converted method&#8221; would have been an anti-dilutive</font><font style="font-weight:bold;letter-spacing:-0.2pt;">:</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:416pt;height:128.68pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:301.17pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:301.17pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:301.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Senior convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">11,928,167</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">9,451,206</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:301.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Junior convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">20,889,401</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">20,889,401</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:301.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Shares issuable under convertible note </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,383,989</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,247,663</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:301.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Warrants to purchase convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">169,533</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">167,460</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:301.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Warrants to purchase common stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">4,198,770</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">4,198,770</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:301.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Options to purchase common stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">8,517,220</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">5,677,248</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:301.17pt;text-align:left;">
              <div style="font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Total</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">47,087,080</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">41,631,748</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-28</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:350pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">16. Subsequent Events</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company has performed an evaluation of its subsequent events through March&#160;26, 2021, which is the date the financial statements were available to be issued. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In February&#160;2021, the Company entered into a Commercial Collaboration Agreement with Anthem, Inc. and its Affiliates (Anthem). This agreement provides defined reimbursement within a defined period for use of the PreTRM test within Anthem&#8217;s network of covered members. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In February&#160;2021, the Company extended the maturity date of its February&#160;2019 Convertible Note to March&#160;28, 2021. On March&#160;24, 2021 the Company repaid the outstanding principal balance of $4.5&#160;million and accrued interest of $1.1&#160;million related to this Note. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On March&#160;24, 2021, the Company repaid the outstanding principal of $2.0&#160;million, accrued interest of $6&#160;thousand, and Final Payment Fee of $0.1&#160;million related to its Bank Loan with Pacific Western Bank. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Between February and April&#160;2021, the Board of Directors increased the number of authorized common shares to 83,000,000 and authorized the issuance of up to 17,529,215 shares of Series E Convertible Preferred Stock. During this period the Company issued an aggregate of 16,744,569 shares of Series&#160;E Convertible Preferred Stock for $5.99 per share to new and existing investors in exchange for $100.1&#160;million, net of issuance costs. In conjunction with this financing, the Company also issued a warrant to purchase 1,501,502 shares of Common Stock of the Company at a price of $9.99. The issuance of Series E Convertible Preferred Stock changed the date on which the Company can redeem the Preferred Stock from at any time on or after the 5th anniversary of the Series D Original Issue Date of July&#160;31, 2019 to the 5th anniversary of the Series E Original Issue Date of February&#160;23, 2021.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-29</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="tCBS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SERA PROGNOSTICS, INC.</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Condensed Balance Sheets</font><font style="letter-spacing:0.2pt;"> </font>
          <br >
          <font style="letter-spacing:0.2pt;">(in thousands, except share and per share data) </font>
        </div>
        <table style="width:456pt;margin-bottom:7pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8.98pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:345.37pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.728pt 0pt;" colspan="4">
              <div style="text-align:center; line-height:8.99pt;">
                <font style="letter-spacing:-0.16pt;">March&#160;31,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.728pt 0pt;" colspan="4">
              <div style="text-align:center; line-height:8.99pt;">
                <font style="letter-spacing:-0.16pt;">December&#160;31,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.98pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:345.37pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.513pt 0pt 2.062pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.16pt;">(unaudited) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:345.37pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Assets</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:345.37pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Current assets: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:345.37pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">60,016</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">13,533</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:345.37pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Accounts receivable </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">8</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.75pt 0pt 0.5pt 0pt; width:345.37pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Prepaid expenses and other current assets </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">421</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">198</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:345.37pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total current assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">60,445</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">13,733</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:345.37pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Property and equipment, net </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">826</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">965</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.75pt 0pt 0.5pt 0pt; width:345.37pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other assets </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">1,473</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">98</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 2.5pt 0pt; width:345.37pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.75pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 1.75pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">62,744</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.75pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 1.75pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">14,796</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:345.37pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Liabilities, Convertible Preferred Stock, and Stockholders&#8217; Deficit</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:345.37pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Current liabilities: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:345.37pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Accounts payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">829</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">441</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.99999999999997pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:345.37pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Accrued and other current liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">2,001</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,577</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:345.37pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Accrued interest on convertible note </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">996</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:345.37pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Deferred rent, current portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">134</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">130</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:345.37pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Capital lease obligation, current portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">70</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">69</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:345.37pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Convertible promissory note, current portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">4,353</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.75pt 0pt 0.5pt 0pt; width:345.37pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Loans payable, current portion </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">702</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">3,676</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:345.37pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total current liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">3,736</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">11,242</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:345.37pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Deferred rent </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">104</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">139</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:345.37pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Loans payable, net of current portion </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">348</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">348</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:345.37pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Preferred stock warrant liability </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">494</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">474</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.75pt 0pt 0.5pt 0pt; width:345.37pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Capital lease obligation, net of current portion </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">109</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">127</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:345.37pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">4,791</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">12,330</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:345.37pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Commitments and contingencies </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:345.37pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Convertible preferred stock: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1pt 0pt 0.5pt 0pt; width:345.37pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Junior convertible preferred stock, par value of $0.0001; 22,047,294 shares authorized, 20,414,766 shares issued and outstanding as of March&#160;31, 2021 and December&#160;31, 2020; aggregate liquidation preference of $78,916 as of March&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">77,844</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">77,844</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1pt 0pt 0.5pt 0pt; width:345.37pt;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Senior convertible preferred stock, par value of $0.0001; 24,496,040 and </font>
                <br >
                <font style="letter-spacing:0.2pt;">12,320,844 shares authorized as of March&#160;31, 2021 and December&#160;31, 2020, </font>
                <br >
                <font style="letter-spacing:0.2pt;">respectively; 22,195,278 and 11,928,167 shares issued and outstanding as of </font>
                <br >
                <font style="letter-spacing:0.2pt;">March&#160;31, 2021 and December&#160;31, 2020, respectively; aggregate liquidation </font>
                <br >
                <font style="letter-spacing:0.2pt;">preference of $164,035 as of March&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">110,499</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">50,192</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1pt 0pt 0.5pt 0pt; width:345.37pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Stockholders&#8217; deficit: Common stock, $0.0001 par value; 78,000,000 and 55,000,000 shares authorized as of March&#160;31, 2021 and December&#160;31, 2020, respectively; 4,120,842 and 3,535,688 shares issued and outstanding as of March&#160;31, 2021 and December&#160;31, 2020, respectively </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:345.37pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Additional paid-in capital </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">7,428</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">5,889</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.75pt 0pt 0.5pt 0pt; width:345.37pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accumulated deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(137,818<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(131,459<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.5pt 0pt 0.5pt 0pt; width:345.37pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total stockholders&#8217; deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(130,390<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(125,570<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 2.5pt 0pt; width:345.37pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total liabilities, convertible preferred stock, and stockholders&#8217; deficit </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.75pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 1.75pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">62,744</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.75pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 1.75pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">14,796</td>
            <td style="padding:0pt;padding-left:2.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The accompanying notes are an integral part of the condensed financial statements</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-30</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="tCSOO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:316.34pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SERA PROGNOSTICS, INC.</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Condensed Statements of Operations and Comprehensive Loss</font><font style="letter-spacing:0.2pt;"> </font>
          <br >
          <font style="letter-spacing:0.2pt;">(unaudited) </font>
          <br >
          <font style="letter-spacing:0.2pt;">(in thousands, except share and per share data) </font>
        </div>
        <table style="width:456pt;height:232.66pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8.98pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:341.17pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Three Months Ended</font>
                <br >
                <font style="letter-spacing:-0.16pt;">March&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:341.17pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Revenue </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">13</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">8</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Operating expenses: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Cost of revenue </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">5</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">3</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,396</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,050</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Selling and marketing </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,350</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">868</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">2,287</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">1,379</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total operating expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">6,038</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">4,300</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Loss from operations </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(6,025<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(4,292<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Interest expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(307<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(437<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other income (expense), net </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(27<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">33</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss and comprehensive loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(6,359<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(4,696<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss per share, basic and diluted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(1.71<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(1.48<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Weighted-average shares of common stock outstanding, basic and diluted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">3,725,328</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">3,171,251</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The accompanying notes are an integral part of the condensed financial statements</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-31</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="tCSOC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:162.18pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">SERA PROGNOSTICS, INC.</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Condensed Statements of Convertible Preferred Stock and Stockholders&#8217; Deficit</font><font style="letter-spacing:0.2pt;"> </font>
          <br >
          <font style="letter-spacing:0.2pt;">(unaudited) </font>
          <br >
          <font style="letter-spacing:0.2pt;">(in thousands, except share and per share data) </font>
        </div>
        <table style="width:456pt;height:204.16pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
          <tr style="line-height:8.98pt;height:18.82pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:118.59pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.312pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.15pt;">Senior Convertible</font>
                <br >
                <font style="letter-spacing:-0.15pt;">Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.312pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.15pt;">Junior Convertible</font>
                <br >
                <font style="letter-spacing:-0.15pt;">Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.25pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.312pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.15pt;">Common Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.312pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:8.99000000000001pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.15pt;">Additional</font>
                <br >
                <font style="letter-spacing:-0.15pt;">Paid-In</font>
                <br >
                <font style="letter-spacing:-0.15pt;">Capital </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.312pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:8.97999999999999pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.15pt;">Accumulated</font>
                <br >
                <font style="letter-spacing:-0.15pt;">Deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.312pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:8.99000000000001pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.15pt;">Total</font>
                <br >
                <font style="letter-spacing:-0.15pt;">Stockholders&#8217;</font>
                <br >
                <font style="letter-spacing:-0.15pt;">Deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
          </tr>
          <tr style="line-height:7.5pt;height:12.84pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:118.59pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 1.555pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.15pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 1.555pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.15pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 1.555pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.15pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 1.555pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.15pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.25pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 1.555pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.15pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 1.555pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.15pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
            <td style="padding:2pt 0pt 2pt 0pt; width:118.59pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.15pt;">Balance as of December&#160;31, 2020</font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 2pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">11,928,167</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 2pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:2pt 0pt 2pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">50,192</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 2pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">20,414,766</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.195pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 2pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:2pt 0pt 2pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">77,844</td>
            <td style="padding:0pt;padding-left:0.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 2pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">3,535,688</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.835pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 2pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:2pt 0pt 2pt 0pt; min-width:6pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.975pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 2pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:2pt 0pt 2pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">5,889</td>
            <td style="padding:0pt;padding-left:5.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.885pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 2pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:2pt 0pt 2pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">(131,459<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.895pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 2pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:2pt 0pt 2pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">(125,570<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.895pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:118.59pt;white-space:normal;text-align:left;">
              <div style="margin-left:7.5pt; text-indent:-7.5pt;">
                <font style="letter-spacing:0.15pt;">Issuance of Series&#160;E senior convertible preferred stock at $5.99 per share, net of issuance costs of $0.1&#160;million </font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">10,267,111</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">60,307</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.895pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.895pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:118.59pt;white-space:normal;text-align:left;">
              <div style="margin-left:7.5pt; text-indent:-7.5pt;">
                <font style="letter-spacing:0.15pt;">Fair value of warrants to purchase common stock issued to </font>
                <br >
                <font style="letter-spacing:0.15pt;">investor </font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1,071</td>
            <td style="padding:0pt;padding-left:5.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.895pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">1,071</td>
            <td style="padding:0pt;padding-left:5.895pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:118.59pt;white-space:normal;text-align:left;">
              <div style="margin-left:7.5pt; text-indent:-7.5pt;">
                <font style="letter-spacing:0.15pt;">Issuance of common stock upon exercise of stock options </font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">585,154</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">229</td>
            <td style="padding:0pt;padding-left:5.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.895pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">229</td>
            <td style="padding:0pt;padding-left:5.895pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:118.59pt;text-align:left;">
              <div style="margin-left:7.5pt; text-indent:-7.5pt;">
                <font style="letter-spacing:0.15pt;">Stock-based compensation </font>
                <br >
                <font style="letter-spacing:0.15pt;">expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">239</td>
            <td style="padding:0pt;padding-left:5.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.895pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">239</td>
            <td style="padding:0pt;padding-left:5.895pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.25pt 0pt 1.25pt 0pt; width:118.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.15pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.195pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.195pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.835pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.835pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.975pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.975pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.885pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">(6,359<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.885pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.895pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">(6,359<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.895pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
            <td style="padding:2pt 0pt 2pt 0pt; width:118.59pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.15pt;">Balance as of March&#160;31, 2021</font>
              </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">22,195,278</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">110,499</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">20,414,766</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.195pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:3pt double #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">77,844</td>
            <td style="padding:0pt;padding-left:0.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.25pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">4,120,842</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.835pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.975pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:3pt double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">7,428</td>
            <td style="padding:0pt;padding-left:5.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.885pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:3pt double #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">(137,818<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.895pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:3pt double #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">(130,390<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.895pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <table style="width:456pt;height:167.66pt;margin-top:15pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
          <tr style="line-height:8.98pt;height:18.82pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:117.45pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.312pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.15pt;">Senior Convertible</font>
                <br >
                <font style="letter-spacing:-0.15pt;">Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.312pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.15pt;">Junior Convertible</font>
                <br >
                <font style="letter-spacing:-0.15pt;">Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.312pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.15pt;">Common Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.312pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:8.98999999999995pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.15pt;">Additional</font>
                <br >
                <font style="letter-spacing:-0.15pt;">Paid-In</font>
                <br >
                <font style="letter-spacing:-0.15pt;">Capital </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.312pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:8.98000000000002pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.15pt;">Accumulated</font>
                <br >
                <font style="letter-spacing:-0.15pt;">Deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.312pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:8.98999999999995pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.15pt;">Total</font>
                <br >
                <font style="letter-spacing:-0.15pt;">Stockholders&#8217;</font>
                <br >
                <font style="letter-spacing:-0.15pt;">Deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
          </tr>
          <tr style="line-height:7.5pt;height:12.84pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:117.45pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 1.555pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.15pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 1.555pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.15pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 1.555pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.15pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 1.555pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.15pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 1.555pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.15pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 1.555pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.15pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
            <td style="padding:2pt 0pt 2pt 0pt; width:117.45pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.15pt;">Balance as of December&#160;31, 2019</font>
              </div>
            </td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 2pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">9,451,206</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.195pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 2pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:2pt 0pt 2pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">39,506</td>
            <td style="padding:0pt;padding-left:0.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 2pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">20,414,766</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.195pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 2pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:2pt 0pt 2pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">77,844</td>
            <td style="padding:0pt;padding-left:0.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 2pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 2pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">3,170,805</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.835pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 2pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:2pt 0pt 2pt 0pt; min-width:6pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.975pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 2pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:2pt 0pt 2pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4,987</td>
            <td style="padding:0pt;padding-left:5.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.885pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 2pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:2pt 0pt 2pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">(111,611<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.895pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 2pt 0pt; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:2pt 0pt 2pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">(106,624<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.895pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:117.45pt;white-space:normal;text-align:left;">
              <div style="margin-left:7.5pt; text-indent:-7.5pt;">
                <font style="letter-spacing:0.15pt;">Issuance of Series&#160;D senior convertible preferred stock at $4.34 per share, net of issuance costs of $0.5&#160;million </font>
              </div>
            </td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">2,476,961</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">10,704</td>
            <td style="padding:0pt;padding-left:0.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.895pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.895pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:117.45pt;white-space:normal;text-align:left;">
              <div style="margin-left:7.5pt; text-indent:-7.5pt;">
                <font style="letter-spacing:0.15pt;">Issuance of common stock upon exercise of stock options </font>
              </div>
            </td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">1,100</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:5.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.895pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:5.895pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:117.45pt;text-align:left;">
              <div style="margin-left:7.5pt; text-indent:-7.5pt;">
                <font style="letter-spacing:0.15pt;">Stock based compensation </font>
                <br >
                <font style="letter-spacing:0.15pt;">expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">135</td>
            <td style="padding:0pt;padding-left:5.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.895pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">135</td>
            <td style="padding:0pt;padding-left:5.895pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.25pt 0pt 1.25pt 0pt; width:117.45pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.15pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.195pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.195pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.195pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.195pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.835pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.835pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.975pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.975pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.885pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">(4,696<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.885pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.895pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 1.25pt 0pt;border-bottom:1px solid #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">(4,696<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.895pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
            <td style="padding:2pt 0pt 2pt 0pt; width:117.45pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.15pt;">Balance as of March&#160;31, 2020</font>
              </div>
            </td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">11,928,167</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.195pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:3pt double #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">50,210</td>
            <td style="padding:0pt;padding-left:0.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">20,414,766</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.195pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:3pt double #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">77,844</td>
            <td style="padding:0pt;padding-left:0.195pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:3pt double #000000; min-width:24pt; text-align:right; white-space:nowrap;">3,171,905</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.835pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:3pt double #000000; min-width:6pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.975pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:3pt double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">5,123</td>
            <td style="padding:0pt;padding-left:5.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.885pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:3pt double #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">(116,307<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.895pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:3pt double #000000; min-width:3pt; text-align:right; ">$</td>
            <td style="padding:2pt 0pt 1.25pt 0pt;border-bottom:3pt double #000000; min-width:21.75pt; text-align:right; white-space:nowrap;">(111,184<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.895pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">The accompanying notes are an integral part of the condensed financial statements</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">F-32</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="tCSOC1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SERA PROGNOSTICS, INC.</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Condensed Statements of Cash Flows</font><font style="letter-spacing:0.2pt;"> </font>
          <br >
          <font style="letter-spacing:0.2pt;">(unaudited) </font>
          <br >
          <font style="letter-spacing:0.2pt;">(in thousands) </font>
        </div>
        <table style="width:456pt;height:582.07pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8.98pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:366.59pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.728pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Three Months Ended</font>
                <br >
                <font style="letter-spacing:-0.16pt;">March&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:366.59pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 2.055pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.5pt 0pt 2.055pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:366.59pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Cash flows from operating activities</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(6,359<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(4,696<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:366.59pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Adjustments to reconcile net loss to net cash used in operating activities: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Depreciation and amortization </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">201</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">227</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Stock-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">239</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">135</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Non-cash interest expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">168</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">355</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other non-cash gain (loss) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">19</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(5<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Changes in operating assets and liabilities: </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Accounts receivable </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(6<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Prepaid expenses and other assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(223<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(118<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Accounts payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">339</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">94</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Deferred rent </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(31<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(27<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.75pt 0pt 0.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Accrued and other current liabilities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(1,297<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(580<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:0.2pt;">Net cash used in operating activities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(6,950<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(4,615<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:366.59pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Cash flows from investing activities</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.75pt 0pt 0.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Purchases of property and equipment </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(41<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(8<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:0.2pt;">Net cash used in investing activities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(41<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(8<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:366.59pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Cash flows from financing activities</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1pt 0pt 0.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Proceeds from issuance of Series&#160;D senior convertible preferred stock, net of issuance </font>
                <br >
                <font style="letter-spacing:0.2pt;">costs </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">10,704</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1pt 0pt 0.5pt 0pt; width:366.59pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Proceeds from issuance of Series&#160;E senior convertible preferred stock, net of issuance costs </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">60,415</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Proceeds allocated to issuance of common stock warrants </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,071</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Proceeds from exercise of stock options </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">229</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Payment of convertible notes payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(4,494<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Payment of loan payable </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(3,100<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Capital lease principal payments </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(17<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(38<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.75pt 0pt 0.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Payment of deferred offering costs </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(630<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.5pt 0pt 0.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:0.2pt;">Net cash provided by financing activities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">53,474</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">10,667</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net increase in cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">46,483</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">6,044</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.75pt 0pt 0.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cash and cash equivalents at beginning of year </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">13,533</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.75pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">21,390</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 2.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cash and cash equivalents at end of period </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.75pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 1.75pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">60,016</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.75pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 1.75pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">27,434</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:366.59pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Supplemental disclosure of cash flow information</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cash paid for interest </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,277</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">82</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:366.59pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Supplemental disclosure of non-cash investing and financing information</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Purchases of property and equipment in accounts payable and accruals </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">21</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">6</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1pt 0pt 0.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Series&#160;E senior convertible preferred stock offering costs included in accounts payable </font>
                <br >
                <font style="letter-spacing:0.2pt;">and accrued liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">82</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1pt 0pt 0.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Series&#160;E senior convertible preferred stock offering costs prepaid and deferred in prior </font>
                <br >
                <font style="letter-spacing:0.2pt;">period and reclassified to Series&#160;E senior convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">26</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.5pt 0pt; width:366.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Deferred offering costs included in accounts payable and accrued liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">771</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The accompanying notes are an integral part of the condensed financial statements</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-33</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="tNTUI">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SERA PROGNOSTICS, INC.</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Notes to Unaudited Interim Condensed Financial Statements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:6pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">1. Description of Business and Financial Condition</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sera Prognostics, Inc. (the &#8220;Company&#8221;) is a women&#8217;s health diagnostic company utilizing its proprietary proteomics and bioinformatics platform to discover, develop and commercialize clinically meaningful and economically impactful biomarker tests with an initial focus on improving pregnancy outcomes. The Company was incorporated in the State of Delaware on January&#160;17, 2008 and its operations are located in Salt Lake City, Utah, including a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Since its inception, the Company&#8217;s activities have consisted of performing research and development, conducting clinical studies, acquiring product rights, raising capital, establishing facilities, and establishing commercial operations to market the PreTRM test. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company is subject to risks and uncertainties common to companies in the diagnostics industry, including but not limited to, risks associated with commercializing products, completing preclinical and clinical studies, receiving regulatory approvals for product candidates, if required, development by competitors of new diagnostic products, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Products currently under development will require significant additional research and development efforts, including preclinical and clinical testing, prior to commercialization. These efforts require significant amounts of additional capital and adequate personnel and infrastructure. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Liquidity and Capital Resources</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The accompanying condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company has incurred net losses and negative cash flows from operations since inception and had an accumulated deficit of $137.8&#160;million as of March&#160;31, 2021. The principal sources of the Company&#8217;s working capital to date has been the proceeds from the issuance of convertible preferred stock, convertible notes, and bank loans. As of March&#160;31, 2021, the Company had approximately $60.0&#160;million in cash and cash equivalents. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s management expects the Company to incur significant additional operating losses and negative cash flows for the foreseeable future, principally as a result of the Company&#8217;s commercialization activities for the PreTRM test, and to support additional clinical and preclinical trials and anticipated research and development activities. The Company had no significant commercial product revenue for the three&#160;months ended March&#160;31, 2021 and has no recurring sources of licensing or other revenue. There can be no assurance that the Company will eventually achieve significant revenues or profitability to sustain operations, or if achieved, can sustain either on a continuing basis. If the Company is unable to achieve significant revenues or raise additional funds, when needed, it may not be able to continue the development or commercialization of its diagnostic products and could be required to delay, scale back or abandon some or all of its development programs and other operations. No assurance can be given that the Company will be successful in raising the required capital on reasonable terms and at the required times, or at all. Any additional equity financing, if available to the Company, may not be available on favorable terms and may be dilutive to current stockholders, and any debt financing, if available, may involve restrictive covenants and dilutive financing instruments. The Company&#8217;s management believes that its existing financial resources are sufficient to continue operating activities at least one year past the issuance date of these condensed financial statements. The Company&#8217;s future operations are highly dependent on a combination of factors, including (i)&#160;the successful commercial launch and market acceptance of the PreTRM test; (ii)&#160;the success of other research and development programs; (iii)&#160;the development of competitive therapies by other biotechnology and pharmaceutical companies; (iv)&#160;the Company&#8217;s ability to manage growth of the organization; (v)&#160;the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-34</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Company&#8217;s ability to protect its intellectual property, technology and products; and, ultimately (vi)&#160;the timely and successful completion of any additional financing. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">2. Significant Accounting Policies</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">There have been no significant changes to the accounting policies during the three&#160;months ended March&#160;31, 2021 as compared to the significant accounting policies described in Note 2 of the &#8220;Notes to Financial Statements&#8221; in the Company&#8217;s audited financial statements included in the audited financial statements included elsewhere in this prospectus. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Basis of Presentation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The accompanying condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America in the United States of America (U.S. GAAP) and applicable rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) regarding interim financial reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative U.S. GAAP included in the Accounting Standards Codification (&#8220;ASC&#8221;), and Accounting Standards Update (&#8220;ASU&#8221;) issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;). </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Unaudited Interim Condensed Financial Statements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The accompanying condensed balance sheet as of March&#160;31, 2021, and condensed statements of operations and comprehensive loss, condensed statements of cash flows, and condensed statements of convertible preferred stock and stockholders&#8217; deficit for the three&#160;months ended March&#160;31, 2021 and 2020, are unaudited. The balance sheet as of December&#160;31, 2020 was derived from the audited financial statements as of and for the year ended December&#160;31, 2020. The unaudited interim condensed financial statements have been prepared on a basis consistent with the audited annual financial statements as of and for the year ended December&#160;31, 2020, and, in the opinion of the Company&#8217;s management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the Company&#8217;s financial position as of March&#160;31, 2021, and the condensed results of its operations and its cash flows for the three&#160;months ended March&#160;31, 2021 and 2020. The financial data and other information disclosed in these notes related to the three&#160;months ended March&#160;31, 2021 and 2020 are also unaudited. The condensed results of operations for the three&#160;months ended March&#160;31, 2021 are not necessarily indicative of the results to be expected for the full year ending December&#160;31, 2021 or any other period. These interim condensed financial statements should be read in conjunction with the Company&#8217;s audited financial statements included elsewhere in this prospectus. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Use of Estimates</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The preparation of the condensed financial statements in conformity with U.S. GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenue and expenses during the reporting period and accompanying notes. On an on-going basis, the Company evaluates its estimates, including those related to the determination of fair value of its shares of common stock and stock options, common and preferred stock warrants, valuation of deferred tax assets resulting from net operating losses, and useful lives of property and equipment. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. Actual results could differ materially from those estimates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In December&#160;2019, a novel strain of coronavirus, which causes COVID-19, was identified. Due to the rapid and global spread of the virus, on March&#160;11, 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. The COVID-19 pandemic and the rapidly evolving reactions of governments, private sector participants and the public in an effort to contain the spread of the COVID-19 virus and address its impacts have intensified and have had significant direct and indirect effects on businesses and commerce. The extent to which the COVID-19 pandemic may impact the Company&#8217;s business, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-35</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:75.63pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">financial condition, cash flows and results of operations, in particular, will depend on future developments that are highly uncertain, and many of which are outside the Company&#8217;s control. Such developments include the availability and effectiveness of actions taken to contain or treat COVID-19, the ultimate geographic spread and duration of the pandemic, the extent and duration of a resurgence of the COVID-19 virus and variant strains thereof, new information concerning the severity of the COVID-19 virus, the effectiveness and intensity of measures to contain the COVID-19 virus and the economic impact of the pandemic and the reactions to it. Such developments, among others, depending on their nature, duration and intensity, could have a significant adverse effect on the Company&#8217;s business, financial condition, cash flows and results of operations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">There were no significant estimates contained in the preparation of the Company&#8217;s condensed financial statements or impacts to the Company&#8217;s condensed financial statements for the three&#160;months ended March&#160;31, 2021 that were directly a result of the COVID-19 pandemic. The Company is not aware of any specific event or circumstance that would require an update to its estimates, judgments and assumptions or a revision of the carrying value of the Company&#8217;s assets or liabilities as of the date of the condensed financial statements. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Recently Issued Accounting Pronouncements Not Yet Adopted</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">In February&#160;2016, the FASB issued ASU 2016-02, </font><font style="font-style:italic;letter-spacing:0.2pt;">Leases (Topic 842).</font><font style="letter-spacing:0.2pt;"> Under the new guidance, lessees will be required to recognize a lease liability and a right-of-use asset for all leases (with the exception of short-term leases) at the commencement date. The standard was effective for public entities for fiscal&#160;years beginning after December&#160;15, 2018 and for private companies for fiscal&#160;years beginning after December&#160;15, 2021. The Company is evaluating the effect that ASU 2016-02 will have on its interim financial statements and related disclosures. The Company expects to adopt this new standard on January&#160;1, 2022 and has not yet determined the effect of the standard on its ongoing financial reporting. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">In December&#160;2019, the FASB issued ASU 2019-12, </font><font style="font-style:italic;letter-spacing:0.2pt;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</font><font style="letter-spacing:0.2pt;">. This standard removes certain exceptions for investments, intra-period allocations and interim calculations, and adds guidance to reduce complexity in accounting for income taxes. This standard will be effective for the Company on January&#160;1, 2022, with early adoption permitted. The Company is currently evaluating the potential impact this standard may have on its financial statements and disclosures. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">In August&#160;2020, the FASB issued ASU No. 2020-06, </font><font style="font-style:italic;letter-spacing:0.2pt;">Debt with Conversion and Other Options (Subtopic&#160;470-20) and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</font><font style="letter-spacing:0.2pt;">, which simplifies the accounting for convertible instruments. The guidance removes certain accounting models that separate the embedded conversion features from the host contract for convertible instruments. ASU&#160;2020-06 allows for a modified or full retrospective method of transition. This update is effective for fiscal&#160;years beginning after December&#160;15, 2021, and interim periods within those fiscal&#160;years. Early adoption is permitted. The Company is currently evaluating the impact this change will have on its financial statements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the SEC did not, or are not believed by the Company&#8217;s management to, have a material impact on the Company&#8217;s financial position, results of operations or cash flows. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-36</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">3. Property and Equipment</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table presents the components of property and equipment, net, as of March&#160;31, 2021 and December&#160;31, 2020 (in thousands): </font>
        </div>
        <table style="width:416pt;height:139.07pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8.98pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:311.91pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">March&#160;31,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:311.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Computer equipment </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.73pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">823</td>
            <td style="padding:0pt;padding-left:1.73pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">767</td>
            <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:311.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Software </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.73pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">373</td>
            <td style="padding:0pt;padding-left:1.73pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">373</td>
            <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:311.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Laboratory equipment </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.73pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">4,200</td>
            <td style="padding:0pt;padding-left:1.73pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">4,194</td>
            <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:311.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Furniture and fixtures </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.73pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">292</td>
            <td style="padding:0pt;padding-left:1.73pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">292</td>
            <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:311.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Leasehold improvements </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.73pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">701</td>
            <td style="padding:0pt;padding-left:1.73pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">701</td>
            <td style="padding:0pt;padding-left:7.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:311.91pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total property and equipment </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.73pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">6,389</td>
            <td style="padding:0pt;padding-left:1.73pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">6,327</td>
            <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:311.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Less accumulated depreciation and amortization </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.73pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(5,563<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.73pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(5,362<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:311.91pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Property and equipment, net </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.73pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">826</td>
            <td style="padding:0pt;padding-left:1.73pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">965</td>
            <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:10.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of March&#160;31, 2021 and December&#160;31, 2020, $3.0&#160;million of the Company&#8217;s laboratory equipment was subject to capital leases, which assets had recorded accumulated amortization of $2.8&#160;million and $2.6&#160;million, respectively. Associated amortization expense, included with depreciation expense, for the three&#160;months ended March&#160;31, 2021 and year ended December&#160;31, 2020 totaled $0.1&#160;million and $0.6&#160;million, respectively. </font>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Depreciation and amortization expense was $0.2&#160;million for the three&#160;months ended March&#160;31, 2021 and 2020, respectively. </font>
        </div>
        <div style="margin-top:9.63pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">4. Accrued and Other Current Liabilities</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table presents the components of accrued and other current liabilities as of March&#160;31, 2021 and December&#160;31, 2020 (in thousands): </font>
        </div>
        <table style="width:416pt;height:108.57pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8.98pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:311.91pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">March&#160;31,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:311.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accrued paid time off </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.395pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">394</td>
            <td style="padding:0pt;padding-left:3.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">290</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:311.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accrued compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.395pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">605</td>
            <td style="padding:0pt;padding-left:3.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">996</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:311.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accrued invoices related to proposed equity offering </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.395pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">743</td>
            <td style="padding:0pt;padding-left:3.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:311.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Bank loan final payment fee </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.395pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">100</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:311.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other current liabilities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.395pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">259</td>
            <td style="padding:0pt;padding-left:3.395pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">191</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:311.91pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total accrued and other current liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.395pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,001</td>
            <td style="padding:0pt;padding-left:3.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,577</td>
            <td style="padding:0pt;padding-left:8.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.62pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">5. Other Income (Expense), net</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table presents the components of other income (expense), net, for the three&#160;months ended March&#160;31, 2021 and 2020 (in thousands): </font>
        </div>
        <table style="width:416pt;height:78.57pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8.98pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:323pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">March&#160;31,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">March&#160;31,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:323pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Interest income </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.085pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:8.085pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.75pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">28</td>
            <td style="padding:0pt;padding-left:9.75pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:323pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Fair value remeasurements </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.085pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">(10<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.085pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.75pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">5</td>
            <td style="padding:0pt;padding-left:9.75pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:323pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other gains (losses), net </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.085pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">(19<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.085pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.75pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.75pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:323pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Other income (expense), net </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.085pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">(27<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.085pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.75pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">33</td>
            <td style="padding:0pt;padding-left:9.75pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.62pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">6. Loans and Convertible Promissory Notes</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:2pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Bank Loan</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In 2014, through a Loan and Security Agreement (the &#8220;Loan Agreement&#8221;) with Pacific Western Bank (the &#8220;Bank&#8221;) the Company obtained a term loan for $10.0&#160;million. The Loan Agreement, as amended, had </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-37</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">a final repayment date of September&#160;1, 2021. Repayment of amounts borrowed are paid in equal monthly installments of principal, plus all accrued interest. The loan bears interest, on the outstanding daily balance, equal to the greater of 1.0% above the Prime Rate then in effect, or 4.75%. In addition, the Loan Agreement requires a Final Payment Fee (as defined in the Loan Agreement) equal to one-percent of the aggregate principal amount borrowed, or $0.1&#160;million. On March&#160;24, 2021, the Company repaid the outstanding principal of $2.0&#160;million, accrued interest of $6&#160;thousand, and the Final Payment Fee of $0.1&#160;million related to this loan. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Convertible Promissory Notes</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In February&#160;2019, the Company authorized the issuance of a $6.4&#160;million subordinated convertible promissory note (the &#8220;February&#160;2019 Convertible Note&#8221;) to a current stockholder, bearing 12% interest and a maturity date of February&#160;26, 2021, to provide liquidity and additional working capital. On February&#160;15, 2021, the maturity date was extended to March&#160;28, 2021. The February&#160;2019 Convertible Note was optionally convertible into shares of Series&#160;D Convertible Preferred Stock at a conversion price equal to 80% of the issuance price of the Series&#160;D Convertible Preferred Stock. In July&#160;2019, $1.9&#160;million of the $6.4&#160;million February&#160;2019 Convertible Note&#8217;s principal and $0.1&#160;million of accrued interest was converted into 576,938 shares of the Company&#8217;s Series&#160;D Preferred Stock, at the option of the holder of the February&#160;2019 Convertible Note, at a conversion price equal to 80% of the issuance price of the Series&#160;D Convertible Preferred Stock of $4.34 per share. If not repaid or converted prior to the maturity date, the February&#160;2019 Convertible Note&#8217;s remaining principal and accrued interest shall convert, at the option of the Holder, into shares of Series&#160;C-1 Convertible Preferred Stock and the holder will receive a number of common stock warrants based on the amount of unpaid principal outstanding. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The conversion feature of the February&#160;2019 Convertible Note met the requirements for separate accounting and was recognized as a liability at the measurement date fair value of $2.4&#160;million, subject to remeasurement to fair value, with any changes in estimated fair value recognized as a component of other income (expense), net. A corresponding discount, which reduces the carrying value of the February&#160;2019 Convertible Note, was also recorded. The unamortized discount was written off in proportion to the partial conversion, with the remaining discount being accreted to interest expense until maturity. The Company recognized additional interest expense of $0.1&#160;million and $0.2&#160;million from accretion of the discount during the three&#160;months ended March&#160;31, 2021 and 2020, respectively. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On March&#160;24, 2021, the Company repaid the outstanding principal of $4.5&#160;million and accrued interest of $1.1&#160;million related to the February&#160;2019 Convertible Note. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In August&#160;2019, the Company authorized the issuance of a $5.0&#160;million subordinated convertible promissory note (the &#8220;August&#160;2019 Note&#8221;) to a new investor and non-U.S. commercial partner. The August&#160;2019 Note bore 5% interest and had a maturity date of December&#160;31, 2019. The August&#160;2019 Note was mandatorily convertible into shares of Series&#160;D Convertible Preferred Stock with principal and all interest accrued thereon converting at a per share price equal to the price per share at which Series&#160;D Convertible Preferred Stock was sold to investors. In August&#160;2019, the August&#160;2019 Note legally converted. Pursuant to the terms of a letter agreement, dated May&#160;10, 2019, by and between the Company and the holder of the August&#160;2019 Note, the holder is entitled to purchase additional shares of Series&#160;D Convertible Preferred Stock, in the event that a milestone, as defined in the agreement and within the Company&#8217;s control, is achieved. As of March&#160;31, 2021 this milestone has not been achieved. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Paycheck Protection Loan</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In April&#160;2020, the Company obtained a $1.1&#160;million loan through Pacific Western Bank under the Paycheck Protection Program (&#8220;PPP&#8221;) under the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), as amended. The loan&#8217;s purpose is to maintain payroll and make rent and utilities payments as specified under the terms of the PPP. Under the PPP, borrowers may apply for loan forgiveness if the funds are used for payroll costs, mortgage interest, rent, and utilities payments over a specified term following receipt of the loan funds. During the term of the agreement, the Company utilized the loan funds for forgivable purposes and applied for forgiveness. To the extent all or part of the PPP loan is not forgiven, the Company will be required to pay interest on the PPP loan at a rate of 1% per annum and principal and interest payments will be required through the maturity date in April&#160;2022. The loan proceeds are recorded </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-38</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">as a loan payable, with the amount due within one year, $0.7&#160;million, recorded as a current liability and $0.3&#160;million recorded as a noncurrent liability, on the Company&#8217;s balance sheet as of March&#160;31, 2021. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">7. Fair Value Measurements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of March&#160;31, 2021 and December&#160;31, 2020, the carrying amounts of the Company&#8217;s receivables, prepaid and other current assets, accounts payable, and accrued and other current liabilities approximate their fair values, principally due to the short-term maturities of the assets and liabilities. The recorded value of the loan payable and capital leases approximates the fair value as the interest rates approximate market interest rates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The fair value of the preferred stock warrant liability was estimated based upon a Black-Scholes option pricing model. The Company measures certain financial assets and liabilities (cash equivalents and the warrant liability) at fair value on a recurring basis. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company follows a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (Level&#160;1) and the lowest priority to measurements involving significant unobservable inputs (Level&#160;3). The three levels of the fair value hierarchy are as follows: </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Level&#160;1 measurements are observable, quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Level&#160;2 measurements are observable inputs other than quoted prices included in Level&#160;1 that are observable either directly or indirectly or quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Level&#160;3 measurements are unobservable inputs in which there is little or no market data, which require the Company to develop its own assumptions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of March&#160;31, 2021, the Company&#8217;s cash equivalents have been classified as Level&#160;1 assets. The Company&#8217;s convertible preferred stock warrant liability has been valued using Level&#160;3 inputs in a Black-Scholes option pricing model (see Note 11&#8201;&#8212;&#8201;Warrants). The Company, utilizing a third-party valuation firm to assist with the estimation of the fair value of common stock, employed a hybrid method of option-pricing model (OPM) and Probability-Weighted Expected Return Method (PWERM). Under the hybrid OPM and PWERM approach, the per share value calculated under OPM and PWERM are weighted based on expected exit outcomes and the quality of the information specific to each allocation methodology to arrive at a final estimated fair value per share of the common stock before a discount for lack of marketability is applied. This model also calculates the fair value of the other classes of equity, including preferred shares. This estimated preferred stock value, along with other significant unobservable inputs, was an input into a Black-Scholes option pricing model, which calculated the fair value of the preferred stock warrant liability. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The other significant unobservable inputs in this calculation are the remaining expected term, which considers the timing of a liquidation event that would net settle the awards before their contractual term expires, and the expected equity volatility, which is a statistical measure of the dispersion of returns for a given security. Volatility is determined based on select comparable public guideline companies in the same business sector. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Significant increases (decreases) in the term would result in significantly higher (lower) fair value measurements. Significant increases (decreases) in the volatility would result in significantly higher (lower) fair value measurements. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-39</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table shows the Company&#8217;s assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands) as of March&#160;31, 2021: </font>
        </div>
        <table style="width:416pt;height:84.59pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:299.84pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Level&#160;1 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Level&#160;2 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Level&#160;3 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:299.84pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Assets: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:299.84pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">60,016</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.865pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:299.84pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Liabilities:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:299.84pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Warrant liability </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.865pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.865pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">494</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:299.84pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">60,016</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.865pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">494</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table shows the Company&#8217;s assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands) as of December&#160;31, 2020: </font>
        </div>
        <table style="width:416pt;height:84.59pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:299.84pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Level&#160;1 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Level&#160;2 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Level&#160;3 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:299.84pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Assets: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:299.84pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">13,533</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.865pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:299.84pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Liabilities: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:299.84pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Warrant liability </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.865pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.865pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">474</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:299.84pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">13,533</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.865pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">474</td>
            <td style="padding:0pt;padding-left:1.865pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Tables providing a roll forward of the fair value, as determined by Level&#160;3 inputs, of the Company&#8217;s convertible preferred stock warrant liability for the three&#160;months ended March&#160;31, 2021 and 2020 are included in Note 11&#8201;&#8212;&#8201;Warrants. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">8. Related Party Transactions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In January&#160;2017, Laboratory Corporation of America (&#8220;LabCorp&#8221;) and the Company entered into a strategic commercialization agreement contemporaneously with LabCorp&#8217;s participation in the Company&#8217;s sale of Series&#160;C Convertible Preferred Stock, par value $0.0001 per share. Under the agreement with LabCorp, amended in 2018, LabCorp is a non-exclusive distributor of the PreTRM test and performs certain sample collection, processing, and shipping services, for a fee. The Company paid fees related to this agreement of less than $0.1&#160;million for the three&#160;months ended March&#160;31, 2021 and 2020. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In July&#160;2019, the Company entered into a consulting agreement with Blue Ox Healthcare Partners, LLC (&#8220;Blue Ox&#8221;) to advise the Company on development of strategies with the goal to obtain widespread insurance coverage for the PreTRM test. Contemporaneously with the consulting agreement, Blue Ox participated in the initial closing of the Series&#160;D Convertible Preferred Stock financing in July&#160;2019 and appointed its designee to the Company&#8217;s board of directors (the &#8220;Board of Directors&#8221;). The Company paid consulting fees related to the consulting agreement of $0.1&#160;million and $0.1&#160;million for the three&#160;months ended March&#160;31, 2021 and 2020, respectively. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In June&#160;2019, the Company entered into a master services agreement with Healthcore Inc., a wholly-owned subsidiary of Anthem Inc. (&#8220;Anthem&#8221;). This agreement covers a range of research projects, including Healthcore&#8217;s role as a contract research organization for the </font><font style="font-weight:bold;letter-spacing:-0.2pt;">P</font><font style="letter-spacing:0.2pt;">rematurity </font><font style="font-weight:bold;letter-spacing:-0.2pt;">R</font><font style="letter-spacing:0.2pt;">isk Assessment Combined With Clinical </font><font style="font-weight:bold;letter-spacing:-0.2pt;">I</font><font style="letter-spacing:0.2pt;">nterventions for Improving Neonatal outco</font><font style="font-weight:bold;letter-spacing:-0.2pt;">ME</font><font style="letter-spacing:0.2pt;">s (PRIME) study. The Company paid fees related to this agreement of $0.2&#160;million and $0.1&#160;million for the three&#160;months ended March&#160;31, 2021 and 2020. In November&#160;2020, the Company entered into a Laboratory Services Agreement with Anthem related to the PRIME study. This agreement provides a contracted rate for tests performed pursuant to the study. The Company recognized revenues related to this agreement of $9&#160;thousand for the three&#160;months ended March&#160;31, 2021. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In February&#160;2021, the Company entered into a Commercial Collaboration Agreement with Anthem and its affiliates (the &#8220;Commercial Collaboration Agreement&#8221;). The Commercial Collaboration Agreement provides defined reimbursement within a defined period for use of the PreTRM test within Anthem&#8217;s network of covered members. Pursuant to the Commercial Collaboration Agreement, Anthem will purchase </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-40</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:23pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">a certain number of tests for each of the first three&#160;years of the term of the agreement. Additionally, Anthem has agreed to pay a certain minimum amount per year for the first three&#160;years of the term of the Commercial Collaboration Agreement. The Company has also agreed to develop a sales, marketing, and customer service program, and to provide training and marketing to duly licensed physicians specializing in obstetrics and gynecology or family medicine, or licensed nurse midwives, at the reasonable request of Anthem. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Anthem has further agreed to develop appropriate care management programs which incorporate the use of the PreTRM test. The Company and Anthem have also agreed to form a Joint Operating Committee to oversee the relationship, comprised of two voting members each from Anthem and the Company. The Company will submit monthly invoices to Anthem for the sale of the PreTRM test at the negotiated rates. Anthem has been participating in the Company&#8217;s PRIME study and at the conclusion of the PRIME study, under the Commercial Collaboration Agreement, the Company has agreed to enter into Anthem&#8217;s standard lab provider agreement. Unless earlier terminated due to breach, the Commercial Collaboration Agreement will remain in effect until the later of (a)&#160;the third anniversary of the effective date or (b)&#160;the date on which Anthem has purchased a fixed number of PreTRM tests as agreed by the parties. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Commercial Collaboration Agreement with Anthem is considered to be within the scope of ASC&#160;Topic 808, Collaborative Arrangements (&#8220;ASC 808&#8221;), as the parties are active participants and exposed to the risks and rewards of the collaborative activity. The Company determined the PreTRM tests to be a performance obligation for which Anthem is a customer and a unit of account within the scope of ASC 606. The associated transaction price is based on the contractual minimum number of tests and the agreed upon defined reimbursement amount per test. The transaction price was allocated to this single performance obligation, which will be recognized upon delivery of test results expected to occur over the term of the agreement. All other items promised to Anthem are immaterial in the context of the Commercial Collaboration Agreement. There were no revenues or cash receipts related to the Commercial Collaboration Agreement for the three&#160;months ended March&#160;31, 2021. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">9. Capital Structure</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:7pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Common Stock</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of March&#160;31, 2021, the Company was authorized to issue 78,000,000 shares of common stock, consisting of 75,000,000 shares of $0.0001 par value Class&#160;A common stock and 3,000,000 shares of $0.0001 par value Class&#160;B common stock (together, the &#8220;common stock&#8221;). As of March&#160;31, 2021, 4,120,842 shares of Class&#160;A common stock and no shares of Class&#160;B common stock were issued and outstanding. Holders of our Class&#160;A common stock and our Class&#160;B common stock have identical rights, provided that, (i)&#160;except as otherwise expressly provided in our amended and restated certificate of incorporation or as required by applicable law, on any matter that is submitted to a vote by our stockholders, holders of our Class&#160;A common stock are entitled to one vote per share of Class&#160;A common stock, and holders of our Class&#160;B common stock are not entitled to any votes per share of Class&#160;B common stock, including for the election of directors, and (ii)&#160;holders of our Class&#160;A common stock have no conversion rights, while holders of our Class&#160;B common stock have the right to convert each share of our Class&#160;B common stock into one share of Class&#160;A common stock at such holder&#8217;s election, provided that as a result of such conversion, such holder would not beneficially own in excess of 4.99% of any class of our securities registered under the Exchange Act, except as expressly provided for in our amended and restated certificate of incorporation. However, this ownership limitation may be increased or decreased to any other&#160;percentage designated by such holder of Class&#160;B common stock upon 61&#160;days&#8217; notice to us. Our Class&#160;A common stock and Class&#160;B common stock do not have cumulative voting rights. Holders of Class&#160;A common stock and Class&#160;B common stock are entitled to ratably receive dividends, if any, as may be declared by the Board of Directors, subject to the prior rights of holders of all classes of stock outstanding having priority rights to dividends. As of March&#160;31, 2021 and December&#160;31, 2020, no dividends were declared. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-41</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following shares of common stock were reserved for future issuance: </font>
        </div>
        <table style="width:416pt;height:141.59pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:275.91pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">March&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:275.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Senior convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">22,195,277</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.09pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">11,928,167</td>
            <td style="padding:0pt;padding-left:9.09pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:275.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Junior convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">20,889,401</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.09pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">20,889,401</td>
            <td style="padding:0pt;padding-left:9.09pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:275.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Shares issuable under convertible note </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.09pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,383,989</td>
            <td style="padding:0pt;padding-left:9.09pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:275.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Warrants to purchase convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">169,533</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.09pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">169,533</td>
            <td style="padding:0pt;padding-left:9.09pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:275.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Warrants to purchase Class&#160;A common stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5,700,270</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.09pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">4,198,770</td>
            <td style="padding:0pt;padding-left:9.09pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:275.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Options to purchase Class&#160;A common stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">10,308,231</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.09pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">8,517,220</td>
            <td style="padding:0pt;padding-left:9.09pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.167pt 0pt 1.833pt 0pt; width:275.91pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Class&#160;A common stock available for future issuance under the 2011 Equity Incentive Plan </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">2,933,549</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.09pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">807,702</td>
            <td style="padding:0pt;padding-left:9.09pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:275.91pt;text-align:left;">
              <div style="font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Total</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">62,196,261</td>
            <td style="padding:0pt;padding-left:3.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.09pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">47,894,782</td>
            <td style="padding:0pt;padding-left:9.09pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of March&#160;31, 2021 and December&#160;31, 2020, approximately $1.4&#160;million and $26&#160;thousand of deferred offering costs related to an equity offering, respectively, were recorded within other assets in the accompanying condensed balance sheets. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Convertible Preferred Stock</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Authorized, issued and outstanding convertible preferred stock and its principal terms as of March&#160;31, 2021 were as follows (in thousands, except share and per share amounts): </font>
        </div>
        <table style="width:456pt;height:162.55pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8.98pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:180.6pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Series </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Authorized </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares Issued </font>
                <br >
                <font style="letter-spacing:-0.16pt;">and </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Outstanding </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Original </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Issue </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Price </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Aggregate </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Liquidation </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Preference </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Proceeds,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">net of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">issuance costs </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:180.6pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;A-1 Junior Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,390</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,390</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,000.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">1,390</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">1,390</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:180.6pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;A-2 Junior Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">7,941,499</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">7,908,277</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">2.50</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">19,771</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">19,595</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:180.6pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;B-1 Junior Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2,060,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2,000,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">2.50</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">5,000</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">4,914</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:180.6pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;B-2 Junior Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5,012,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5,000,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">4.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">20,000</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">19,984</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:180.6pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;C-1 Junior Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5,521,905</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5,505,099</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">5.95</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">32,755</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">32,653</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:180.6pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;C-2 Junior Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,510,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">8.28</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:180.6pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;D Senior Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">11,975,172</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">11,928,167</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">4.34</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">102,535</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">50,415</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:180.6pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;E Senior Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">12,520,868</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">10,267,111</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">5.99</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">61,500</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">61,378</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:180.6pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total Convertible Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">46,543,334</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">42,610,044</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">242,951</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">190,329</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Authorized, issued and outstanding convertible preferred stock and its principal terms as of December&#160;31, 2020 were as follows (in thousands, except share and per share amounts): </font>
        </div>
        <table style="width:456pt;height:147.55pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8.98pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:180.6pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Series </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center; line-height:8.99pt;">
                <font style="letter-spacing:-0.16pt;">Shares </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Authorized </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center; line-height:8.99pt;">
                <font style="letter-spacing:-0.16pt;">Shares Issued </font>
                <br >
                <font style="letter-spacing:-0.16pt;">and </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Outstanding </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center; line-height:8.99pt;">
                <font style="letter-spacing:-0.16pt;">Original </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Issue </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Price </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center; line-height:8.99pt;">
                <font style="letter-spacing:-0.16pt;">Aggregate </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Liquidation </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Preference </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center; line-height:8.99pt;">
                <font style="letter-spacing:-0.16pt;">Proceeds,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">net of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">issuance costs </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.26pt 0pt 1.49pt 0pt; width:180.6pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;A-1 Junior Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.26pt 0pt 1.49pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.26pt 0pt 1.49pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,390</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.26pt 0pt 1.49pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.26pt 0pt 1.49pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,390</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.26pt 0pt 1.49pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.26pt 0pt 1.49pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,000.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:3.26pt 0pt 1.49pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.26pt 0pt 1.49pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">1,390</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.26pt 0pt 1.49pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.26pt 0pt 1.49pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">1,390</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.51pt 0pt 1.49pt 0pt; width:180.6pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;A-2 Junior Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">7,941,499</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">7,908,277</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">2.50</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">19,771</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">19,595</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.51pt 0pt 1.49pt 0pt; width:180.6pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;B-1 Junior Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2,060,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2,000,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">2.50</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">5,000</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">4,914</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.51pt 0pt 1.49pt 0pt; width:180.6pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;B-2 Junior Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5,012,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5,000,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">4.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">20,000</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">19,984</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.51pt 0pt 1.49pt 0pt; width:180.6pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;C-1 Junior Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5,521,905</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5,505,099</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">5.95</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">32,755</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">32,653</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.51pt 0pt 1.49pt 0pt; width:180.6pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;C-2 Junior Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,510,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">8.28</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.51pt 0pt 1.49pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.51pt 0pt 2.5pt 0pt; width:180.6pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;D Senior Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.51pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.51pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">12,320,844</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.51pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.51pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">11,928,167</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.51pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.51pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">4.34</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.51pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.51pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">102,535</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.51pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.51pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">50,415</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.26pt 0pt 3.25pt 0pt; width:180.6pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total Convertible Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.26pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.26pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">34,368,138</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.26pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.26pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">32,342,933</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:3.26pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.26pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">181,451</td>
            <td style="padding:0pt;padding-left:0.395pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.26pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.26pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">128,951</td>
            <td style="padding:0pt;padding-left:3.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-42</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The 2019 issuance of Series&#160;D Convertible Preferred Stock created a senior and junior preferred stock ranking, whereby Series&#160;D Convertible Preferred Stock, and the subsequently issued Series&#160;E Convertible Preferred Stock (together the &#8220;Senior Preferred Stock)&#8221; are senior to all other classes of Preferred Stock (collectively the &#8220;Junior Preferred Stock&#8221;) (both Junior Preferred Stock and Senior Preferred Stock together, the &#8220;convertible preferred stock&#8221;). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Senior Preferred Stock include rights and preferences that differ from the Junior Preferred Stock rights and preferences. The Series&#160;D Convertible Preferred Stock includes a liquidation preference equal to the greater of two times the original issue price of $4.34 per share of Series&#160;D Convertible Preferred Stock plus all declared and unpaid dividends on such shares of Series&#160;D Convertible Preferred Stock and such amount per share as would have been payable had all shares of Series&#160;D Convertible Preferred Stock been converted into common stock immediately prior to such liquidation event. The Series&#160;E Convertible Preferred Stock includes a liquidation preference equal to the greater of the original issue price of $5.99 per share of Series&#160;E Convertible Preferred Stock plus all declared and unpaid dividends on such shares of Series&#160;E Convertible Preferred Stock and such amount per share as would have been payable had all shares of Series&#160;E Convertible Preferred Stock been converted into common stock immediately prior to such liquidation event. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with various preferred stock financings, the Company issued warrants to purchase common stock and warrants to purchase preferred stock and are described in Note 11&#8201;&#8212;&#8201;Warrants. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the terms of the Series&#160;C-1 Preferred Stock Purchase Agreement dated January&#160;9, 2017, by and among the Company and the purchasers identified therein, as amended on February&#160;9, 2017, LabCorp committed to purchase, and the Company authorized, 1,509,661 shares of series C-2 convertible preferred stock, par value $0.0001 per share (the &#8220;Series&#160;C-2 Convertible Preferred Stock&#8221;), for $8.28 per share, in exchange for $12.5&#160;million in cash, subject to adjustment, and conditional upon the Company&#8217;s achievement of a milestone, as defined in the stock purchase agreement related to the issuance of the Series&#160;C-2 Convertible Preferred Stock, which included achieving positive results in one of two clinical outcome studies. The Company recorded this preferred stock tranche forward obligation to issue contingently redeemable shares of Series&#160;C-2 Convertible Preferred Stock as a forward contract liability in the Company&#8217;s balance sheets at its estimated fair market value and remeasured the liability at each annual reporting period. As the Company does not expect that the milestones related to this commitment will be achieved, the Company has determined the fair value of this forward tranche liability was $0 as of March&#160;31, 2021 and December&#160;31, 2020. The Company reported $0 of other income related to the change in fair value for the three&#160;months ended March&#160;31, 2021 and 2020. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The holders of convertible preferred stock have various rights and preferences including the following: </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Dividends</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The holders of convertible preferred stock are entitled to receive dividends out of any assets legally available only when, as, and if declared by the Board of Directors, prior to and in preference to any declaration or payment of any dividend on the common stock. Such dividends are noncumulative. As of March&#160;31, 2021 and December&#160;31, 2020 there were no cumulative dividends owed or in arrears. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Liquidation Preference</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the event of any liquidation, dissolution or winding up of the Company, the holders of Series&#160;D Convertible Preferred Stock then outstanding will be entitled to an amount per share equal to the greater of two times the original issue price of $4.34 per share of Series&#160;D Convertible Preferred Stock plus all declared and unpaid dividends on such shares of Series&#160;D Convertible Preferred Stock and such amount per share as would have been payable had all shares of Series&#160;D Convertible Preferred Stock been converted into common stock immediately prior to such liquidation event. Holders of Series&#160;E Convertible Preferred Stock will be entitled to the greater of the original issue price of $5.99 per share of Series&#160;E Convertible Preferred Stock plus all declared and unpaid dividends on such shares of Series&#160;E Convertible Preferred Stock and such amount per share as would have been payable had all shares of Series&#160;E Convertible Preferred Stock been converted into common stock immediately prior to such liquidation event. Such payment is to be made before any payment is made to the holders of common stock, the Junior Preferred Stock or any other </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-43</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">class or series of stock junior to the Series&#160;D Convertible Preferred Stock and Series&#160;E Convertible Preferred Stock. If available funds and assets are not sufficient to pay the holders of Series&#160;D Convertible Preferred Stock and Series&#160;E Convertible Preferred Stock the full amount to which they are be entitled, payments will be made on a pro&#160;rata, equal priority, pari&#160;passu basis. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">After the payment of the Senior Preferred Stock preferential liquidation amount, the holders of shares of Junior Preferred Stock then outstanding, on a pari&#160;passu basis, will be entitled to an amount per share equal to the series C-1 convertible preferred stock original issue price of $5.95 per share, series B-2 convertible preferred stock original issue price of $4.00 per share, series B-1 convertible preferred stock and series A-2 convertible preferred stock original issue price of $2.50 per share or series A-1 convertible preferred stock original issue price of $1,000 per share, as applicable, plus any dividends declared but unpaid thereon, before any payment shall be made to the holders of common stock. If available funds and assets are not sufficient to pay the holders of Junior Preferred Stock the full amount to which they are entitled, payments will be made on a pro&#160;rata, equal priority, pari&#160;passu basis. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Conversion Rights</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Each outstanding share of convertible preferred stock is convertible, at the option of the holder at any time and from time to time, into such number of fully paid and non-assessable shares of common stock as is determined by dividing the respective original issue price of the convertible preferred stock, as applicable, by the respective conversion price of the convertible preferred stock, as applicable, in effect at the time of the conversion. Conversion of all shares of convertible preferred stock is automatic upon (i)&#160;the closing of a public offering of common stock at a price per share of at least 1.2 times the original issue price of the Series&#160;E Convertible Preferred Stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the common stock) resulting in at least $40.0&#160;million of gross cash proceeds; or (ii)&#160;affirmative election of at least a majority of the shares of preferred stock outstanding. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of March&#160;31, 2021 and December&#160;31, 2020, the conversion price of the Convertible Preferred Stock issued by the Company was as follows: </font>
        </div>
        <table style="width:416pt;height:137.48pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8.98pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:311.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Series </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">March&#160;31, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
                <br >
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:311.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;A-1 Junior Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.895pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.92</td>
            <td style="padding:0pt;padding-left:5.895pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.44pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.92</td>
            <td style="padding:0pt;padding-left:11.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:311.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;A-2 Junior Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.895pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.50</td>
            <td style="padding:0pt;padding-left:5.895pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.44pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.50</td>
            <td style="padding:0pt;padding-left:11.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:311.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;B-1 Junior Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.895pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.50</td>
            <td style="padding:0pt;padding-left:5.895pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.44pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.50</td>
            <td style="padding:0pt;padding-left:11.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:311.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;B-2 Junior Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.895pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.00</td>
            <td style="padding:0pt;padding-left:5.895pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.44pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.00</td>
            <td style="padding:0pt;padding-left:11.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:311.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;C-1 Junior Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.895pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">5.95</td>
            <td style="padding:0pt;padding-left:5.895pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.44pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">5.95</td>
            <td style="padding:0pt;padding-left:11.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:311.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;C-2 Junior Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.895pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">8.28</td>
            <td style="padding:0pt;padding-left:5.895pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.44pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">8.28</td>
            <td style="padding:0pt;padding-left:11.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:311.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;D Senior Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.895pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.34</td>
            <td style="padding:0pt;padding-left:5.895pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.44pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.34</td>
            <td style="padding:0pt;padding-left:11.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:311.91pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;E Senior Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.895pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">5.99</td>
            <td style="padding:0pt;padding-left:5.895pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.44pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">
              <div style="font-weight:bold;">&#8203;</div>
            </td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:bold;">&#8212;</div>
            </td>
            <td style="padding:0pt;padding-left:11.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The conversion price of convertible preferred stock is subject to adjustment as a result of stock dividends, splits and other equity structuring transactions, and due to subsequent sales of common stock at a lower effective price. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Redemption Rights</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Each outstanding share of convertible preferred stock is redeemable by the Company at a price equal to the applicable liquidation preference per share, plus any dividends per share declared but unpaid thereon (the &#8220;Redemption Price&#8221;), in three annual installments commencing not more than 60&#160;days after receipt by the Company at any time on or after the 5th anniversary of the Series&#160;E Convertible Preferred Stock original issue date, February&#160;23, 2021, from the holders of at least a majority of the Senior Preferred Stock then outstanding of written notice requesting redemption of all shares of convertible preferred stock (the &#8220;Redemption Request&#8221;). Upon receipt of a Redemption Request, the Company will apply all of its assets to any such redemption, and to no other corporate purpose, except to the extent prohibited by Delaware law </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-44</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:23pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">governing distributions to stockholders. Changes in the fair value of the Company&#8217;s convertible preferred stock or common stock would not affect settlement amounts. The carrying value of the convertible preferred stock has not been accreted up to its redemption value as no redemption events are considered probable as of March&#160;31, 2021 and December&#160;31, 2020. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Upon the occurrence of certain change in control events that are outside the Company&#8217;s control, including liquidation, sale, or transfer of the Company, holders of the convertible preferred stock can effectively cause redemption for cash. As a result, the Company has classified the convertible preferred stock as mezzanine equity on the accompanying balance sheets as the stock is contingently redeemable. The Company has elected not to adjust the carrying values of the convertible preferred stock to the liquidation preferences of such shares because it is uncertain whether or when an event would occur that would obligate the Company to pay the liquidation preferences to holders of shares of convertible preferred stock. Subsequent adjustments to the carrying values to the liquidation preferences will be made only when it becomes probable that such a liquidation event will occur. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Voting Rights</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The holders of each share of convertible preferred stock are entitled to the number of votes equal to the number of shares of common stock into which such share is convertible. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">10. Stock-based Compensation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:7pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Equity Incentive Plans</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In February&#160;2008, the Company established the 2008 Stock Incentive Plan (the &#8220;2008 Plan&#8221;) and reserved shares of the Company&#8217;s common stock for sale and issuance under the 2008 Plan. In November&#160;2011, the 2008 Plan was terminated and the remaining authorized shares were no longer available for future grants. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In November&#160;2011, the Company established the 2011 Employee, Director and Consultant Equity Incentive Plan (the &#8220;2011 Plan&#8221;) and reserved shares of the Company&#8217;s common stock for sale and issuance under the 2011 Plan. The 2011 Plan provides for the grant of incentive and non-statutory stock options as well as restricted stock to employees, nonemployee directors and consultants of the Company, which are to be granted at a price that is not less than 100% of the fair value of the stock at the date of grant. Options and restricted stock generally vest over a four-year period and options generally expire ten&#160;years from the date of grant. Options are exercisable only to the extent vested. In February&#160;2020, the Board of Directors approved an increase to the number of shares of common stock options available for grant under the 2011 Plan by 3,918,700 shares and reserved the same number of shares of the Company&#8217;s common stock for issuance under the 2011 Plan. As of December&#160;31, 2020, the 2011 Plan, as amended, permits the Company to grant up to 12,709,379 shares of the Company&#8217;s common stock, plus any additional awards granted under the 2008 Plan that are forfeited, expire or are cancelled without exercise after November&#160;8, 2011. In August&#160;2020, the Board of Directors approved an amendment to the 2011 Plan that will automatically increase the number of shares authorized for issuance under the Plan on the first day of each fiscal year beginning in fiscal year 2021, which amount was 2,001,859 shares for 2021. In March&#160;2021, the Board of Directors approved an increase to the number of shares of common stock available for grant under the 2011 Plan by 2,500,000 and reserved the same number of shares of the Company&#8217;s common stock for issuance under the 2011 Plan. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Stock Options</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless otherwise noted, references to &#8220;options&#8221; in the subsequent disclosures, refers to the combined incentive and non-statutory stock options issued as employee and non-employee stock-based compensation, and authorized under the 2008 Plan and 2011 Plan. The following table summarizes information about these options granted and outstanding: </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-45</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:184.52pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8.98pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:228.05pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center; line-height:8.99pt;">
                <font style="letter-spacing:-0.16pt;">Number of </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Shares</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Subject to </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Options </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Outstanding </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center; line-height:8.99pt;">
                <font style="letter-spacing:-0.16pt;">Weighted-</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Average </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Grant Date</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Fair Value </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center; line-height:8.99pt;">
                <font style="letter-spacing:-0.16pt;">Weighted-</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Average </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Exercise Price </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Per Share </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center; line-height:8.99pt;">
                <font style="letter-spacing:-0.16pt;">Weighted-</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Average </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Remaining </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Contractual</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Life (In Years) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:228.05pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Outstanding&#8201;&#8211;&#8201;December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">8,517,220</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.18pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">0.44</td>
            <td style="padding:0pt;padding-left:5.18pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">0.79</td>
            <td style="padding:0pt;padding-left:7.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">6.99</td>
            <td style="padding:0pt;padding-left:15.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:228.05pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Granted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2,376,652</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.18pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1.47</td>
            <td style="padding:0pt;padding-left:5.18pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">2.56</td>
            <td style="padding:0pt;padding-left:7.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:228.05pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Expired </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(70<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.18pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">61.52</td>
            <td style="padding:0pt;padding-left:5.18pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">100.00</td>
            <td style="padding:0pt;padding-left:7.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:228.05pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Cancelled </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(417<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.18pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">0.49</td>
            <td style="padding:0pt;padding-left:5.18pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">0.95</td>
            <td style="padding:0pt;padding-left:7.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:228.05pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Exercised </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">(585,154<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.18pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">0.25</td>
            <td style="padding:0pt;padding-left:5.18pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.505pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">0.39</td>
            <td style="padding:0pt;padding-left:7.505pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.52pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.52pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:228.05pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Outstanding&#8201;&#8211;&#8201;March&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">10,308,231</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.18pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">0.69</td>
            <td style="padding:0pt;padding-left:5.18pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1.22</td>
            <td style="padding:0pt;padding-left:7.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">7.75</td>
            <td style="padding:0pt;padding-left:15.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 3.25pt 0pt; width:228.05pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Vested and expected to vest at March&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">9,739,423</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.18pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">0.67</td>
            <td style="padding:0pt;padding-left:5.18pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">1.18</td>
            <td style="padding:0pt;padding-left:7.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.52pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">7.64</td>
            <td style="padding:0pt;padding-left:15.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:228.05pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Vested and exercisable at March&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">4,812,806</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.18pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">0.46</td>
            <td style="padding:0pt;padding-left:5.18pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.505pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">0.80</td>
            <td style="padding:0pt;padding-left:7.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.52pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">5.88</td>
            <td style="padding:0pt;padding-left:15.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:228.05pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Non-vested options at March&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">5,495,425</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.18pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">0.89</td>
            <td style="padding:0pt;padding-left:5.18pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.505pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">1.59</td>
            <td style="padding:0pt;padding-left:7.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.52pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.7pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table presents the impact of stock-based compensation expense in the statements of operations for the periods indicated (in thousands): </font>
        </div>
        <table style="width:416pt;height:93.57pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8.98pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:337.84pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Three&#160;months ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">March&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:337.84pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">2021</td>
            <td style="padding:0pt;padding-left:1.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">2020</td>
            <td style="padding:0pt;padding-left:1.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:337.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Research and development expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">64</td>
            <td style="padding:0pt;padding-left:1.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">54</td>
            <td style="padding:0pt;padding-left:1.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:337.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Sales and marketing expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">62</td>
            <td style="padding:0pt;padding-left:1.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18pt; text-align:right; white-space:nowrap;">29</td>
            <td style="padding:0pt;padding-left:1.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:337.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">General and administrative expense </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.04pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:18pt; text-align:right; white-space:nowrap;">113</td>
            <td style="padding:0pt;padding-left:1.04pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.04pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:18pt; text-align:right; white-space:nowrap;">52</td>
            <td style="padding:0pt;padding-left:1.04pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:337.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total employee stock-based compensation </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:18pt; text-align:right; white-space:nowrap;">239</td>
            <td style="padding:0pt;padding-left:1.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.04pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:18pt; text-align:right; white-space:nowrap;">135</td>
            <td style="padding:0pt;padding-left:1.04pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.71pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">At March&#160;31, 2021, there was $4.2&#160;million of unamortized stock-based compensation cost related to unvested stock options which is expected to be recognized over a weighted average period of 3.5&#160;years. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">11. Warrants</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:11pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Warrants to purchase common stock</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In conjunction with the issuance of Series&#160;D Convertible Preferred Stock, the Company issued 2,099,385 warrants to purchase shares of common stock at a price of $4.34 per share, and 2,099,385 warrants to purchase shares of common stock at a price of $5.21 per share. Because these warrants are equity classified, the Company allocated the relative fair value of the cash proceeds between the Series&#160;D Convertible Preferred Stock and the warrants. Proceeds allocated to these common stock warrants on a relative fair value basis, calculated using the Black-Scholes option pricing model, were $0.9&#160;million and were recognized as a component of additional paid-in capital in the accompanying condensed financial statements. As an equity instrument, these warrants are not required to be remeasured to their fair value each reporting period. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A certain investor of Series&#160;E Convertible Preferred Stock also received 1,501,502 warrants to purchase shares of common stock of the Company at a price of $9.99 per share. Because these warrants are equity classified, the Company allocated the relative fair value of the cash proceeds between the Series&#160;E Convertible Preferred Stock and the warrants. Proceeds allocated to these common stock warrants on a relative fair value basis, calculated using the Black-Scholes option pricing model, were $1.1&#160;million and were recognized as a component of additional paid-in capital in the accompanying condensed financial statements. As an equity instrument, these warrants are not required to be remeasured to their fair value each reporting period. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Warrants to purchase preferred stock</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In conjunction with the issuance of Series&#160;D Convertible Preferred Stock, the Company issued a third-party consultant a fully-vested warrant to purchase 44,931 shares (the &#8220;2019 Warrant&#8221;) of Series&#160;D </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-46</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Convertible Preferred Stock at a price of $4.34 per share. The initial fair value of the 2019 Warrant was calculated using the Black-Scholes option pricing model and recorded as a reduction in additional paid-in capital associated with Series&#160;D Preferred Stock Financing. The 2019 Warrant, which increased to 47,005 shares in conjunction with the issuance of additional shares of Series&#160;D Convertible Preferred Stock in 2020, remains outstanding at March&#160;31, 2021, and is immediately exercisable for cash, with 47,005 shares to be issued upon settlement of the 2019 Warrant. The Company paid fees of $0.4&#160;million to this consultant and the estimated fair value of the warrants was $0.2&#160;million. The Company recognized the fees and the fair value of the warrants issued as a reduction to additional paid-in capital and recorded a corresponding preferred stock warrant liability. Total adjustments to the fair value of this warrant liability during the three&#160;months ended March&#160;31, 2021 and 2020 resulted in other expense of $10&#160;thousand and other income of $4&#160;thousand, respectively. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with various debt financings, refinancing, and amendments to the Loan Agreement with the Bank, the Company has, from time to time, issued warrants to purchase shares of convertible preferred stock. Each of these warrants are exercisable for cash, fully-vested at the grant date, and have a ten-year expiration. The initial fair value of each these warrants was calculated using the Black-Scholes option pricing model and recorded as a reduction to the carrying value of the bank loan payable in the year of issuance. During the fiscal year, any changes in the fair value of these warrant liabilities are recorded in interest expense. Total adjustments to the fair value of these warrant liabilities during the three&#160;months ended March&#160;31, 2021 and 2020 resulted in $10&#160;thousand of interest expense and a $1&#160;thousand reduction of interest expense, respectively. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes the warrants to purchase convertible preferred stock and the fair value as of March&#160;31, 2021 and December&#160;31, 2020 (in thousands, except share and per share amounts): </font>
        </div>
        <table style="width:456pt;height:137.07pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:9.84pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt; width:210.95pt;text-align:left;" rowspan="2">
              <div style="white-space:nowrap; line-height:9pt; padding-bottom:0.326666666666667pt;">
                <font style="letter-spacing:-0.16pt;">Related Series </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt; width:41.25pt;" rowspan="2">
              <div style="text-align:center; line-height:8.98000000000002pt; padding-bottom:0.326666666666667pt;">
                <font style="letter-spacing:-0.16pt;">Grant</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Date </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:8.98000000000002pt; padding-bottom:0.326666666666667pt;">
                <font style="letter-spacing:-0.16pt;">Number of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Warrants </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:8.98000000000002pt; padding-bottom:0.326666666666667pt;">
                <font style="letter-spacing:-0.16pt;">Exercise</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Price </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Fair Value as of </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.98pt;height:23.07pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.597pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">March&#160;31,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.597pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">December&#160;31,</font>
                <br >
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:210.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;A-2 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:41.25pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">Sep 2012 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">26,000</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.50</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.25pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">42</td>
            <td style="padding:0pt;padding-left:7.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">41</td>
            <td style="padding:0pt;padding-left:12.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:210.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;A-2 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:41.25pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">Sep 2014 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">7,222</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.50</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.25pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">14</td>
            <td style="padding:0pt;padding-left:7.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">13</td>
            <td style="padding:0pt;padding-left:12.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:210.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;B-1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:41.25pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">Dec 2014 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">60,000</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2.50</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.25pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">119</td>
            <td style="padding:0pt;padding-left:7.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">113</td>
            <td style="padding:0pt;padding-left:12.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:210.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;B-2 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:41.25pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">Dec 2015 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">12,500</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.00</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.25pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">23</td>
            <td style="padding:0pt;padding-left:7.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">22</td>
            <td style="padding:0pt;padding-left:12.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:210.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;C-1 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:41.25pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">Mar 2017 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">16,806</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">5.95</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.25pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">32</td>
            <td style="padding:0pt;padding-left:7.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">31</td>
            <td style="padding:0pt;padding-left:12.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:210.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;D </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:41.25pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">Feb 2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">47,005</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:13.5pt; text-align:right; white-space:nowrap;">4.34</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.25pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">264</td>
            <td style="padding:0pt;padding-left:7.25pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.795pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">254</td>
            <td style="padding:0pt;padding-left:12.795pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:210.95pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:41.25pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">169,533</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.25pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">494</td>
            <td style="padding:0pt;padding-left:7.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">474</td>
            <td style="padding:0pt;padding-left:12.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:7.5pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Liability classification requires the warrants to be remeasured to their fair value at each reporting period. As of March&#160;31, 2021 and December&#160;31, 2020, the fair value of preferred stock warrants outstanding was $0.5&#160;million and was recorded in warrant liability as a long-term liability in the accompanying condensed balance sheets. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following is a summary of the Company&#8217;s preferred stock warrant liability activity for the three&#160;months ended March&#160;31, 2021 (in thousands): </font>
        </div>
        <table style="width:416pt;height:72.55pt;margin-left:20pt;margin-top:10.0000000000001pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8.98pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:362.85pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;text-align:center;" colspan="4">
              <div style="text-align:center; line-height:8.99pt;">
                <font style="letter-spacing:-0.16pt;">Warrant </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Liability </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Outstanding </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:362.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Outstanding&#8201;&#8211;&#8201;December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.575pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">474</td>
            <td style="padding:0pt;padding-left:10.575pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:362.85pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Net increase in fair value of preferred stock warrants </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.575pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">20</td>
            <td style="padding:0pt;padding-left:10.575pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:362.85pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Outstanding&#8201;&#8211;&#8201;March&#160;31, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.575pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">494</td>
            <td style="padding:0pt;padding-left:10.575pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:16.6pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">12. Commitments and Contingences</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:7pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Operating Leases</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company leases a total of approximately 21,800 square feet of office and laboratory space under a single non-cancelable operating lease with a termination date of December&#160;31, 2022. Under the terms of the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-47</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">lease agreement, the Company has an option to renew the lease for one additional five-year rental period. The lease included a tenant improvement allowance from the landlord for structural and cosmetic changes to the new space. The tenant improvements were completed and delivery of possession occurred on September&#160;1, 2018. The tenant improvement allowance has been accounted for as a liability of the Company within deferred rent and is amortized monthly as a reduction to rent expense. A corresponding leasehold improvement asset has been recorded with monthly depreciation being recorded as depreciation expense. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Scheduled base rent increases of 3% occur annually each August. The Company recognized rent expense on a straight-line basis over the term of the operating lease. The difference in actual amounts paid and amounts recorded as rent expense during the period was recorded as deferred rent on the accompanying balance sheets. For the three&#160;months ended March&#160;31, 2021 and 2020, the Company recognized rent expense of $0.1&#160;million. Amounts classified as deferred rent at March&#160;31, 2021 and December&#160;31, 2020 totaled $0.2&#160;million and $0.3&#160;million, respectively. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Capital Leases</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The full value of all leased equipment, including advance payments, are classified as assets on the Company&#8217;s balance sheets. The portion of the future payments designated as principal repayment are classified as a capital lease obligation. As of March&#160;31, 2021, the Company classified the aggregate amount of scheduled capital lease obligation payments due within twelve&#160;months of the date of the condensed financial statements, $0.1&#160;million, as a current liability, and the remaining $0.1&#160;million due thereafter, in other liabilities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table presents the Company&#8217;s future minimum lease payments as of March&#160;31, 2021 (in thousands): </font>
        </div>
        <table style="width:456pt;height:63.57pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8.98pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:277.13pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2022 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2023 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">2024 and </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Thereafter </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:277.13pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Operating leases </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">410</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">554</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.08pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.08pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">964</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:277.13pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Capital leases </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">61</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">80</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">55</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.08pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.08pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">196</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:277.13pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">471</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">634</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">55</td>
            <td style="padding:0pt;padding-left:0.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.08pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.08pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,160</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:16.9pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Indemnification</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company has agreed to indemnify its officers and directors for certain events or occurrences, while the officer or director is or was serving at the Company&#8217;s request in such capacity. The maximum amount of potential future indemnification is unlimited; however, the Company purchases director and officer insurance coverage that provides for corporate reimbursements of covered obligations that limits the Company&#8217;s exposure and enables it to recover a portion of potential future amounts paid. The Company is unable to reasonably estimate the maximum amount that could be payable under these arrangements since these obligations are not capped but are conditional to the unique facts and circumstances involved. Accordingly, the Company has no liabilities recorded for these agreements as of March&#160;31, 2021 and December&#160;31, 2020. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Employee Agreements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company has signed various employment agreements with key executives pursuant to which if their employment is terminated by the Company without cause or by the employees for good reason, or following a change of control of the Company, the employees are entitled to receive certain benefits, including severance payments, accelerated vesting of stock and stock options, and certain insurance benefits. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Legal Matters</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company is not currently a party to any material litigation or other material legal proceedings. The Company may, from time to time, be involved in various legal proceedings arising from the normal course of business activities, and an unfavorable resolution of any of these matters could materially affect the Company&#8217;s future results of operations, cash flows, or financial position. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-48</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:147.66pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">13. Net loss per share</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth the computation of the basic and diluted net loss per share (in thousands, except share and per share amounts): </font>
        </div>
        <table style="width:416pt;height:77.66pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8.98pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:301.17pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Three Months Ended </font>
                <br >
                <font style="letter-spacing:-0.16pt;">March&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:301.17pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:301.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(6,359<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(4,696<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:301.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Weighted average common stock outstanding, basic and diluted </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">3,725,328</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">3,171,251</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:301.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss per share&#8201;&#8211;&#8201;basic and diluted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(1.71<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(1.48<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company excluded the following potentially dilutive securities, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because their impact under the &#8220;treasury stock method&#8221; and &#8220;if-converted method&#8221; would have been an anti-dilutive: </font>
        </div>
        <table style="width:416pt;height:128.68pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:301.17pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">March&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:301.17pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2021 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.805pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:301.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Junior convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">20,889,401</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">20,889,401</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:301.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Senior convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">22,195,278</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">11,928,165</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:301.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Shares issuable under convertible note </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,247,663</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:301.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Warrants to purchase convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">169,533</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">169,533</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:301.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Warrants to purchase Class&#160;A common stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5,700,270</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">4,198,770</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:301.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Options to purchase Class&#160;A common stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">10,308,231</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">8,591,168</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:301.17pt;text-align:left;">
              <div style="font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Total</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">59,262,713</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">47,024,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">14. Subsequent Events</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company has performed an evaluation of its subsequent events through May&#160;27, 2021, which is the date the interim financial statements were available to be issued. The Company concluded that no events or transactions have occurred that require disclosure in the accompanying condensed financial statements, other than the following: </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In April&#160;2021, the Board of Directors increased the number of authorized shares of common stock to 80,000,000 shares of Class&#160;A common stock and 3,000,000 shares of Class&#160;B common stock, and authorized the issuance of an additional 5,008,347 shares of Series&#160;E Convertible Preferred Stock. In April&#160;2021, the Company issued an aggregate of 6,477,458 additional shares of Series&#160;E Convertible Preferred Stock for $5.99 per share to new and existing investors in exchange for $38.7&#160;million, net of issuance costs.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-49</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 0pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:2.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 2.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:74.57pt; text-align:center; width:456pt; line-height:20pt;font-weight:bold;font-family:Times New Roman, Times, serif;font-size:18pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; Shares<font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.36pt;"> </font></div>
        <div style="position:relative;margin-top:74pt; text-align:center; width:456pt;">
          <img src="lg_seraprognostics-4clr.jpg" alt="[MISSING IMAGE: lg_seraprognostics-4clr.jpg]" height="60" width="307" >
        </div>
        <div style="margin-top:77.06pt; text-align:center; width:456pt; line-height:20pt;font-weight:bold;font-family:Times New Roman, Times, serif;font-size:18pt;">Class A Common Stock<font style="font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.36pt;"> </font></div>
        <table style="width:456pt;margin-top:86pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:20pt;">
          <tr style="line-height:20pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:20pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:144pt;">Citigroup </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:144pt;text-align:center;">
              <div style="text-align:center;">Cowen </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0.5pt 1pt 0pt; width:144pt;text-align:right;">
              <div style="text-align:right;">William Blair</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:72.57pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2021 </font>
        </div>
        <div style="margin-top:74.57pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Through and including&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;, 2021 (the 25th day after the date of this prospectus), all dealers that effect transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers&#8217; obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions. </font>
        </div>
        <div style="margin-top:74.97pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 74.9699999999999pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:2.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 2.5pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PART II</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">INFORMATION NOT REQUIRED IN PROSPECTUS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:6pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ITEM 13.&nbsp;&nbsp;&nbsp;OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth all costs and expenses, other than underwriting discounts and commissions, paid or payable by the Registrant in connection with the sale of the Class A common stock being registered. All amounts shown are estimates except for the SEC registration fee and the FINRA filing fee: </font>
        </div>
        <table style="width:416pt;height:158.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:366.29pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.805pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:366.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">SEC registration fee </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">&#8199;10,910 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:366.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">FINRA filing fee </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">15,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:366.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Nasdaq Global Market initial listing fee </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:366.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Blue sky qualification fees and expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:366.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Printing and engraving expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:366.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Legal fees and expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:366.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accounting fees and expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:366.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Transfer agent and registrar fees and expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:366.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Miscellaneous expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.99999999999997pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:366.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.6pt; width:456pt;">
          <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:12.1pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">* To be provided by amendment</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ITEM 14.&nbsp;&nbsp;&nbsp;INDEMNIFICATION OF DIRECTORS AND OFFICERS.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;145(a) of the Delaware General Corporation Law provides, in general, that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation), because he or she is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding, if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;145(b) of the Delaware General Corporation Law provides, in general, that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor because the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#8217; fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, except that no indemnification shall be made with respect to any claim, issue or matter as to which he or she shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, he or she is fairly and reasonably entitled to indemnity for such expenses that the Court of Chancery or other adjudicating court shall deem proper. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;145(g) of the Delaware General Corporation Law provides, in general, that a corporation may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of his or her status as such, whether or not the corporation would have the power to indemnify the person against such liability under Section&#160;145 of the Delaware General Corporation Law. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our Amended and Restated Certificate of Incorporation, or the Charter, which will become effective upon completion of the offering, provides that no director of our company shall be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duty as a director, except for liability (1)&#160;for any breach of the director&#8217;s duty of loyalty to us or our stockholders, (2)&#160;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (3)&#160;in respect of unlawful dividend payments or stock redemptions or repurchases, or (4)&#160;for any transaction from which the director derived an improper personal benefit. In addition, our Charter provides that if the Delaware General Corporation Law is amended to authorize the further elimination or limitation of the liability of directors, then the liability of a director of our company shall be eliminated or limited to the fullest extent permitted by the Delaware General Corporation Law, as so amended. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Charter further provides that any repeal or modification of such article by our stockholders or amendment to the Delaware General Corporation Law will not adversely affect any right or protection existing at the time of such repeal or modification with respect to any acts or omissions occurring before such repeal or modification of a director serving at the time of such repeal or modification. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our Amended and Restated By-Laws, or the By-Laws, which will become effective upon completion of the offering, provide that we will indemnify each of our directors and officers and, in the discretion of our board of directors, certain employees, to the fullest extent permitted by the Delaware General Corporation Law as the same may be amended (except that in the case of amendment, only to the extent that the amendment permits us to provide broader indemnification rights than the Delaware General Corporation Law permitted us to provide prior to such the amendment) against any and all expenses, judgments, penalties, fines and amounts reasonably paid in settlement that are incurred by the director, officer or such employee or on the director&#8217;s, officer&#8217;s or employee&#8217;s behalf in connection with any threatened, pending or completed proceeding or any claim, issue or matter therein, to which he or she is or is threatened to be made a party because he or she is or was serving as a director, officer or employee of our company, or at our request as a director, partner, trustee, officer, employee or agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise, if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of our company and, with respect to any criminal proceeding, had no reasonable cause to believe his or her conduct was unlawful. Article VII, </font>
          <br >
          <font style="letter-spacing:0.2pt;">Section 2 of the By-Laws further provides for the advancement of expenses to each of our directors and, in the discretion of the board of directors, to certain officers and employees. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, the By-Laws provide that the right of each of our directors and officers to indemnification and advancement of expenses shall be a contract right and shall not be exclusive of any other right now possessed or hereafter acquired under any statute, provision of the Charter or By-Laws, agreement, vote of stockholders or otherwise. Furthermore, Article VII, Section 5 of the By-Laws authorizes us to provide insurance for our directors, officers and employees, against any liability, whether or not we would have the power to indemnify such person against such liability under the Delaware General Corporation Law or the provisions of Article VII, Section 1 of the By-Laws. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with the sale of Class A common stock being registered hereby, we have entered into indemnification agreements with each of our directors and our executive officers. These agreements will provide that we will indemnify each of our directors and such officers to the fullest extent permitted by law and the Charter and By-Laws. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We also maintain a general liability insurance policy, which covers certain liabilities of directors and officers of our company arising out of claims based on acts or omissions in their capacities as directors or officers. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In any underwriting agreement we enter into in connection with the sale of Class A common stock being registered hereby, the underwriters will agree to indemnify, under certain conditions, us, our directors, our officers and persons who control us within the meaning of the Securities Act of 1933, as amended, against certain liabilities. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ITEM 15.&nbsp;&nbsp;&nbsp;RECENT SALES OF UNREGISTERED SECURITIES.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the three&#160;years preceding the filing of this registration statement, we have issued the following securities that were not registered under the Securities Act. Also included is the consideration, if any, received by us for such shares, warrants and options, and information relating to the section of the Securities Act, or rule of the Securities and Exchange Commission, under which exemption from registration was claimed. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">(a) Preferred Stock Issuances</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">From July&#160;2019 to February&#160;2020, we issued an aggregate of 8,348,707 shares of Series&#160;D convertible preferred stock at a purchase price of $4.34 per share for aggregate gross consideration of $36.2&#160;million. During the same period, we issued an aggregate of 3,579,460 shares of Series&#160;D convertible preferred stock upon the conversion of a series of convertible promissory notes previously issued to certain noteholders. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">From February to April&#160;2021, we issued an aggregate of 16,744,569 shares of our Series&#160;E convertible preferred stock at a purchase price of $5.99 per share for aggregate consideration of $100.3&#160;million. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">(b) Option Issuances</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Since January&#160;1, 2018, we have granted to employees, officers, directors, consultants and other service providers options to purchase an aggregate of 8,803,822 shares of our Class A common stock, with exercise prices ranging from $0.81 to $4.27 per share, pursuant to the 2011 Employee, Director and Consultant Equity Incentive Plan, or the 2011 Plan. Since January&#160;1, 2018, 1,051,417 shares of Class A common stock have been issued upon the exercise of stock options pursuant to the 2011 Plan. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">No underwriters were used in the foregoing transactions, and no discounts or commissions were paid. All sales of securities described above were exempt from the registration requirements of the Securities Act in reliance on Section&#160;4(a)(2) of the Securities Act, Rule&#160;701 promulgated under the Securities Act or Regulation&#160;D promulgated under the Securities Act, relating to transactions by an issuer not involving a public offering. All of the foregoing securities are deemed restricted securities for purposes of the Securities Act. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">(c) Warrant Issuances</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In connection with our Series&#160;D Preferred Stock Financing, we issued warrants to purchase an aggregate of 2,099,384 shares of Class A common stock initially exercisable at a price of $4.34 per share and warrants to purchase an aggregate of 2,099,384 shares of Class A common stock initially exercisable at a price of $5.21 per share. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In connection with our Series&#160;E Preferred Stock Financing, we issued warrants to purchase an aggregate of 1,501,502 shares of Class A common stock initially exercisable at a price of $9.99 per share. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ITEM 16.&nbsp;&nbsp;&nbsp;EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a) Exhibits. </font>
        </div>
        <table style="width:456pt;height:134.48pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8.98pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:37.08pt;">
              <font style="letter-spacing:-0.16pt;">Exhibit&#160;</font>
              <br >
              <font style="letter-spacing:-0.16pt;">Number </font>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:406.92pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Description of Exhibit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:37.08pt;">
              <font style="letter-spacing:0.2pt;">1.1*</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:406.92pt;">
              <font style="letter-spacing:0.2pt;">Form of Underwriting Agreement. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:37.08pt;">
              <font style="letter-spacing:0.2pt;">3.1 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:406.92pt;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2110724d11_ex3-1.htm">Amended and Restated Certificate of Incorporation, as amended. </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:37.08pt;">
              <font style="letter-spacing:0.2pt;">3.2* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:406.92pt;white-space:normal;">
              <font style="letter-spacing:0.2pt;">Form of Amended and Restated Certificate of Incorporation (to be effective upon completion of the offering). </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:37.08pt;">
              <font style="letter-spacing:0.2pt;">3.3 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:406.92pt;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2110724d11_ex3-3.htm">By-Laws of the Registrant. </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:37.08pt;">
              <font style="letter-spacing:0.2pt;">3.4* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:406.92pt;">
              <font style="letter-spacing:0.2pt;">Form of Amended and Restated By-Laws (to be effective upon completion of this offering). </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:37.08pt;">
              <font style="letter-spacing:0.2pt;">4.1* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:406.92pt;">
              <font style="letter-spacing:0.2pt;">Specimen Common Stock Certificate. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:37.08pt;">
              <font style="letter-spacing:0.2pt;">4.2</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:406.92pt;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2110724d11_ex4-2.htm">Form of Common Stock Purchase Warrant&#8201;&#8211;&#8201;I. </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:644.48pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8.98pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:37.08pt;">
              <font style="letter-spacing:-0.16pt;">Exhibit&#160;</font>
              <br >
              <font style="letter-spacing:-0.16pt;">Number </font>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:406.92pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Description of Exhibit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:37.08pt;">
              <font style="letter-spacing:0.2pt;">4.3</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:406.92pt;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2110724d11_ex4-3.htm">Form of Common Stock Purchase Warrant&#8201;&#8211;&#8201;II. </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:37.08pt;">
              <font style="letter-spacing:0.2pt;">4.4 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:406.92pt;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2110724d11_ex4-4.htm">Form of Series&#160;E Warrant. </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:37.08pt;">
              <font style="letter-spacing:0.2pt;">4.5 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:406.92pt;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2110724d11_ex4-5.htm">Fourth Amended and Restated Investors&#39; Rights Agreement, dated as of February 23, 2021. </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:37.08pt;">
              <font style="letter-spacing:0.2pt;">5.1* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:406.92pt;">
              <font style="letter-spacing:0.2pt;">Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:37.08pt;">
              <font style="letter-spacing:0.2pt;">10.1*</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:406.92pt;">
              <font style="letter-spacing:0.2pt;">Form of Indemnification Agreement. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:37.08pt;">
              <font style="letter-spacing:0.2pt;">10.2+</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:406.92pt;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2110724d11_ex10-2.htm">2011 Employee, Director and Consultant Equity Incentive Plan. </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:37.08pt;">
              <font style="letter-spacing:0.2pt;">10.2.1</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:406.92pt;white-space:normal;">
              <font style="letter-spacing:0.2pt;">Form of Stock Option Agreement under the Registrant&#39;s 2011 Employee, Director and Consultant Equity Incentive Plan</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:37.08pt;">
              <font style="letter-spacing:0.2pt;">10.3*+</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:406.92pt;">
              <font style="letter-spacing:0.2pt;">2021 Employee, Director and Consultant Equity Incentive Plan. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:37.08pt;">
              <font style="letter-spacing:0.2pt;">10.4*+</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:406.92pt;">
              <font style="letter-spacing:0.2pt;">Form of 2021 Employee Stock Purchase Plan. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:37.08pt;">
              <font style="letter-spacing:0.2pt;">10.5&#8224;</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:406.92pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2110724d11_ex10-5.htm">Commercial Collaboration Agreement, dated as of February&#160;17, 2021, by and between Anthem, Inc. and the Registrant. </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:37.08pt;">
              <font style="letter-spacing:0.2pt;">10.6&#8224;</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:406.92pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2110724d11_ex10-6.htm">Laboratory Services Agreement, effective as of November&#160;10, 2020, by and among Anthem Health Insurance and Amerigroup Corporation and the Registrant. </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:37.08pt;">
              <font style="letter-spacing:0.2pt;">10.7.1&#8224;</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:406.92pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2110724d11_ex10d7-1.htm">Commercialization Agreement, dated as of January&#160;9, 2017, by and between Laboratory Corporation of America Holdings and the Registrant. </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:37.08pt;">
              <font style="letter-spacing:0.2pt;">10.7.2&#8224;</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:406.92pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2110724d11_ex10d7-2.htm">First Amendment to the Commercialization Agreement, dated as of June&#160;25, 2018, by and between Laboratory Corporation of America Holdings and the Registrant. </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:37.08pt;">
              <font style="letter-spacing:0.2pt;">10.7.3</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:406.92pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2110724d11_ex10d7-3.htm">Second Amendment to the Commercialization Agreement, dated as of January&#160;25, 2021, by and between Laboratory Corporation of America Holdings and the Registrant. </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:37.08pt;">
              <font style="letter-spacing:0.2pt;">10.8&#8224; </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:406.92pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2110724d11_ex10-8.htm">Side Letter with Baker Bros. Advisors LP, dated as of April&#160;29, 2021, by and between Baker Bros. Advisors LP and the Registrant. </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:37.08pt;">
              <font style="letter-spacing:0.2pt;">10.9+</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:406.92pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2110724d11_ex10-9.htm">Employment Agreement by and between the Registrant and Gregory C. Critchfield, M.D., dated November&#160;8, 2011. </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:37.08pt;">
              <font style="letter-spacing:0.2pt;">10.10+</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:406.92pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2110724d11_ex10-10.htm">Employment Agreement by and between the Registrant and Jay M. Moyes, dated March&#160;24, 2020. </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:37.08pt;">
              <font style="letter-spacing:0.2pt;">10.11+</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:406.92pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2110724d11_ex10-11.htm">Employment Agreement by and between the Registrant and Douglas C. Fisher, dated January&#160;27, 2015. </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:37.08pt;">
              <font style="letter-spacing:0.2pt;">10.12+</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:406.92pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2110724d11_ex10-12.htm">Employment Agreement by and between the Registrant and Nadia Altomare, dated May&#160;15, 2017. </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:37.08pt;">
              <font style="letter-spacing:0.2pt;">10.13+</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:406.92pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2110724d11_ex10-13.htm">Employment Agreement by and between the Registrant and John J. Boniface, dated March&#160;14, 2012. </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:37.08pt;">
              <font style="letter-spacing:0.2pt;">10.14+</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:406.92pt;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2110724d11_ex10-14.htm">Employment Agreement by and between the Registrant and Garrett Lam, dated June&#160;13, 2018. </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:37.08pt;">
              <font style="letter-spacing:0.2pt;">10.15+</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:406.92pt;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2110724d11_ex10-15.htm">Separation Agreement by and between the Registrant and Garrett Lam, dated June&#160;19, 2020. </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:37.08pt;">
              <font style="letter-spacing:0.2pt;">10.16+</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:406.92pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2110724d11_ex10-16.htm">Employment Agreement by and between the Registrant and Benjamin Jackson, dated April&#160;13, 2021. </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:37.08pt;">
              <font style="letter-spacing:0.2pt;">10.17+</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:406.92pt;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2110724d11_ex10-17.htm">Offer Letter by and between the Registrant and John Peltier, dated July&#160;8, 2016. </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:37.08pt;">
              <font style="letter-spacing:0.2pt;">10.18+</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:406.92pt;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2110724d11_ex10-18.htm">Offer Letter by and between the Registrant and Thomas Garite, dated June&#160;17, 2020. </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:37.08pt;">
              <div style="text-align:justify;">
                <font style="letter-spacing:0.2pt;">10.18.1+</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:406.92pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2110724d11_ex10d18-1.htm">Amendment to Offer Letter by and between the Registrant and Thomas Garite, dated July&#160;1, 2020. </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:37.08pt;">
              <div style="text-align:justify;">
                <font style="letter-spacing:0.2pt;">10.18.2+</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:406.92pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2110724d11_ex10d18-2.htm">Second Amendment to Offer Letter by and between the Registrant and Thomas Garite, dated July&#160;30, 2020. </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:37.08pt;">
              <div style="text-align:justify;">
                <font style="letter-spacing:0.2pt;">10.18.3+</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:406.92pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2110724d11_ex10d18-3.htm">Third Amendment to Offer Letter by and between the Registrant and Thomas Garite, dated April&#160;28, 2021. </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:37.08pt;">
              <font style="letter-spacing:0.2pt;">10.19+</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:406.92pt;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2110724d11_ex10-19.htm">Offer Letter by and between the Registrant and Nichole Martin, dated March&#160;30, 2020. </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:71.93pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:104.48pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8.98pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:37.08pt;">
              <font style="letter-spacing:-0.16pt;">Exhibit&#160;</font>
              <br >
              <font style="letter-spacing:-0.16pt;">Number </font>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.478pt 0pt; width:406.92pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Description of Exhibit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:37.08pt;">
              <font style="letter-spacing:0.2pt;">10.20</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:406.92pt;white-space:normal;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2110724d11_ex10-20.htm">Lease Agreement, effective as of August&#160;1, 2017, by and between Eastland Regency, L.C. and the Registrant. </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:37.08pt;">
              <font style="letter-spacing:0.2pt;">21.1</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:406.92pt;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2110724d11_ex21-1.htm">Subsidiaries of Registrant. </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:37.08pt;">
              <font style="letter-spacing:0.2pt;">23.1</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:406.92pt;">
              <div style="letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2110724d11_ex23-1.htm">Consent of Independent Registered Public Accounting Firm. </a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:37.08pt;">
              <font style="letter-spacing:0.2pt;">23.3* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:406.92pt;">
              <font style="letter-spacing:0.2pt;">Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in Exhibit&#160;5.1). </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:37.08pt;">
              <font style="letter-spacing:0.2pt;">24.1</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:406.92pt;">
              <div style="letter-spacing:0.2pt;">
                <a href="#POA">Power of Attorney (included on signature page).</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">*</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">To be filed by amendment. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8224;</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Portions of this exhibit (indicated by asterisks) have been omitted in accordance with the rules of the Securities and Exchange Commission. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">+</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Indicates a management contract or any compensatory plan, contract or arrangement.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(b)</font>
          <br >
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.2pt;">Financial Statement Schedules. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">No financial statement schedules are provided because the information called for is not required or is shown either in the financial statements or notes.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ITEM 17.&nbsp;&nbsp;&nbsp;UNDERTAKINGS.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The undersigned Registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The undersigned Registrant hereby undertakes that: </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a) For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule&#160;430A and contained in a form of prospectus filed by the registrant pursuant to Rule&#160;424(b)(1) or (4)&#160;or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b) For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial </font><font style="font-style:italic;letter-spacing:0.2pt;">bona fide</font><font style="letter-spacing:0.2pt;"> offering thereof.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="POA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SIGNATURES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant has duly caused this registration statement on Form S-1 to be signed on its behalf by the undersigned, thereunto duly authorized, in Salt Lake City, Utah, on the 11th day of June, 2021. </font>
        </div>
        <div style="margin-left:220pt; margin-top:24pt; width:236pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SERA PROGNOSTICS, INC.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:220pt; margin-top:24pt; width:236pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">/s/ Gregory C. Critchfield, M.D., M.S.</font>
        </div>
        <div style="margin-left:220pt; margin-top:3pt; width:236pt;">
          <div style="margin-left: 0pt; width: 236pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-left:220pt; margin-top:2.49pt; width:236pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Gregory C. Critchfield, M.D., M.S.</font>
          <br >
          <font style="letter-spacing:0.2pt;">Chairman, President and Chief Executive Officer </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SIGNATURES AND POWER OF ATTORNEY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We, the undersigned directors and officers of Sera Prognostics, Inc. (the &#8220;Company&#8221;), hereby severally constitute and appoint Gregory C. Critchfield, M.D., M.S. and Jay Moyes, and each of them singly, our true and lawful attorneys, with full power to them, and to each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-1 filed herewith, and any and all pre-effective and post-effective amendments to said registration statement, and any registration statement filed pursuant to Rule&#160;462(b) under the Securities Act of 1933, as amended, in connection with the registration under the Securities Act of 1933, as amended, of equity securities of the Company, and to file or cause to be filed the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as each of us might or could do in person, and hereby ratifying and confirming all that said attorneys, and each of them, or their substitute or substitutes, shall do or cause to be done by virtue of this Power of Attorney. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement on Form S-1 has been signed by the following persons in the capacities and on the dates indicated. </font>
        </div>
        <table style="width:456pt;height:265.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:7.97999999999996pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.812pt 0pt; width:168pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Signature </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.812pt 0pt; width:168pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Title </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.812pt 0pt; width:96pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Date </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:17.917pt 0pt 0.5pt 0pt; width:168pt;text-align:left;">
              <div>
                <font style="letter-spacing:0.2pt;">/s/ Gregory C. Critchfield, M.D., M.S.</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 168pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">
                <font style="letter-spacing:0.2pt;">Gregory C. Critchfield, M.D., M.S. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:17.917pt 0pt 0.5pt 0pt; width:168pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Chairman,</font>
                <br >
                <font style="letter-spacing:0.2pt;">Chief Executive Officer, President and Director</font>
                <br >
                <font style="font-style:italic;letter-spacing:0.2pt;">(Principal Executive Officer)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:17.917pt 0pt 0.5pt 0pt; width:96pt;white-space:nowrap;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">June 11, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:18.167pt 0pt 0.5pt 0pt; width:168pt;text-align:left;">
              <div>
                <font style="letter-spacing:0.2pt;">/s/ Jay Moyes</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 168pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">
                <font style="letter-spacing:0.2pt;">Jay Moyes </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:18.167pt 0pt 0.5pt 0pt; width:168pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Chief Financial Officer</font>
                <br >
                <font style="font-style:italic;letter-spacing:0.2pt;">(Principal Accounting Officer and Principal Financial Officer</font><font style="letter-spacing:0.2pt;">) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:18.167pt 0pt 0.5pt 0pt; width:96pt;white-space:nowrap;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">June 11, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:18.167pt 0pt 0.5pt 0pt; width:168pt;white-space:normal;text-align:left;">
              <div>
                <font style="letter-spacing:0.2pt;">/s/ Dennis Farrar</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 168pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">
                <font style="letter-spacing:0.2pt;">Dennis Farrar </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:18.167pt 0pt 0.5pt 0pt; width:168pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Director </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:18.167pt 0pt 0.5pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">June 11, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:18.167pt 0pt 0.5pt 0pt; width:168pt;white-space:normal;text-align:left;">
              <div>
                <font style="letter-spacing:0.2pt;">/s/ Joshua Phillips</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 168pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">
                <font style="letter-spacing:0.2pt;">Joshua Phillips </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:18.167pt 0pt 0.5pt 0pt; width:168pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Director </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:18.167pt 0pt 0.5pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">June 11, 2021</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:18.167pt 0pt 0.5pt 0pt; width:168pt;white-space:normal;text-align:left;">
              <div>
                <font style="letter-spacing:0.2pt;">/s/ Mansoor Raza Mirza, M.D.</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 168pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">
                <font style="letter-spacing:0.2pt;">Mansoor Raza Mirza, M.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:18.167pt 0pt 0.5pt 0pt; width:168pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Director </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:18.167pt 0pt 0.5pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">June 11, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style=" width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:14.5pt;font-weight:bold;font-size:12.5pt;">
          <font style="letter-spacing:-0.25pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:423.91pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:188.5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:7.98pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.812pt 0pt; width:168pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Signature </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.812pt 0pt; width:168pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Title </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.812pt 0pt; width:96pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Date </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:17.917pt 0pt 0.5pt 0pt; width:168pt;white-space:normal;text-align:left;">
              <div>
                <font style="letter-spacing:0.2pt;">/s/ Ryan Trimble</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 168pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">
                <font style="letter-spacing:0.2pt;">Ryan Trimble</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:17.917pt 0pt 0.5pt 0pt; width:168pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Director </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:17.917pt 0pt 0.5pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">June 11, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:18.167pt 0pt 0.5pt 0pt; width:168pt;white-space:normal;text-align:left;">
              <div>
                <font style="letter-spacing:0.2pt;">/s/ Kim Kamdar, Ph.D.</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 168pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">
                <font style="letter-spacing:0.2pt;">Kim Kamdar, Ph.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:18.167pt 0pt 0.5pt 0pt; width:168pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Director </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:18.167pt 0pt 0.5pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">June 11, 2021 </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:18.167pt 0pt 0.5pt 0pt; width:168pt;white-space:normal;text-align:left;">
              <div>
                <font style="letter-spacing:0.2pt;">/s/ Michael F. Minahan</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 168pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">
                <font style="letter-spacing:0.2pt;">Michael F. Minahan </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:18.167pt 0pt 0.5pt 0pt; width:168pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Director </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:18.167pt 0pt 0.5pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">June 11, 2021</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:18.167pt 0pt 0.5pt 0pt; width:168pt;white-space:normal;text-align:left;">
              <div>
                <font style="letter-spacing:0.2pt;">/s/ Charles D. Kennedy, M.D.</font>
              </div>
              <div style="margin-top:2.5pt; text-align:justify;">
                <div style="margin-left: 0pt; width: 168pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">
                <font style="letter-spacing:0.2pt;">Charles D. Kennedy, M.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:18.167pt 0pt 0.5pt 0pt; width:168pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">Director </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:18.167pt 0pt 0.5pt 0pt; width:96pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">June 11, 2021</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>lg_seraprognostics-4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lg_seraprognostics-4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ < )" P$1  (1 0,1 ?_$ .4  0 " @(# 0$
M       ("0<* 08"!0L#! $!  (#  ,! 0            8'! 4( 0,) @H0
M   & 0,"! (%! H," \   $" P0%!@< $0@2"2$Q$Q1!"E%A(A46<9$R(_"!
MH;87MQAX.3JQT4(S0R1UUG>76!G!X;0U)M<X&I.D5665-D969I8G-U=G*!$
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ML54#!A&3:5R'>;*RM44 $;JO8&#A70LA>$,=-1= )^05%HGT&)ZHHG#[0$$
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ME%3 00*4P[ /NMK>M=W"6MNI:O4<*H\V8R UTU)\8]=6K3H4FK5C*DBDD^0
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M7@H/I2.]!$&QSJ.F;9MZ@EL7CO/L3RN6'R]%*=U4$MK2:G4(UD)RU)$PI\9
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M).'_ &$ISAASDMUCK^0)+)?$S+/'+,N*I"2DE8V!RG2W5T_"C1&#G19(EAK
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M;  >'U:Y>_'%_P ?T:0C^=9N5<#D4!,Z*A#)J)*$ Y5"F#I,4X&W*8AB"("
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MB3[29D_@D(DEK61GPTA$8N9O'9KRQXLYRX[.I,D*?*F/YNMQDPJ50S>*GCI
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ME[K<W3KI7H>UU.R1SF'L%<L,<SEX69BGA>AU'R4:_17:/&BY/ Q#D$/(0V$
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M)3EFCY:YP7;ZCD[0(U>E;4I!P2OQ,JZ@%3T/GUB*C%V^8YU6L+DNM%ZC$E2
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MAZZA@64I*2Z2;U3D)96*L5$ST!%B^]_]Q2\(B[M:&RHG:L63I(3**-3",4/
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M/\;15/=/_D[7^E/Z)C8M[7W]'%P5_FF8"_BRK>JSY5_W)?\ ]KJ_I&+!P?\
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MZ]^=  ,HW(8# &JSG N0XBY9:-"I<V<_A>FI<D>$U434RZZ2GXQFXGF&&R5
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M4!BB#3>\MSDG5BQ)+$DZF.0L]R+,\ER%;*9FXJ5[NO5:HTR=H9NNU9R4#H
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MS1-!J:8M%AD7+UP"1"(IG7%-(A$B$*6MLQE+G-Y*KD[R7KU6G(=    H]B@
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M*QC$3LT1FE+S$=2:_'UYG)22<>D@R(^>-X\IU02(4@&,.P:C^2O7R60K9"H
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M7:WD8SK7;%#VR!AK/7GR<G V&)CIV%DD2JD1?Q,LT2?QSU(BZ:2Y$W31<AP
MY2G #>( .HY=6M>RN:EG=*4N:3LCKIHRDJPTF-""-"1$SL+^TREE1R5@XJ6-
MQ22I3< @,CJ&1@" 1-2#(@'S CW6L>,R&D(X$=OSZ0B/EDY9\8*=8Y*H6WD'
MAJKVF&>?=\Q7[#D>I0TM%/0 @BVD6,C*MUV:Q2' 1!0I? =]2>TX5S"_M$OK
M+&7]:RJ+N5TH5&5AYJ0I!'NB"Y#N?VYQ.0J8G*9W$VV3HMMJ4JMU1INC>3JS
M@J?>!&:X*PP-IB6,_69J)L4%)H$=1LU!2+.7B9!LI_>W+&1CUG#-V@I\#IG,
M4?IU'[FVN;.LUM=TWI7*&3(ZE64^15@"#[")Q,+&^LLG:I?XZM2N+&JH*5*;
MK4INIZ%74E6'M!(CW.O1&3#2/,-(0TA.&D(:0AI"&D(:0AI"&D(:0AI".##T
MAO\ L_X@TA'2+YDO'V+H%>T9(NM7HM>;"!59FV3D; QX*&$"IH$<R3ANFLY6
M.8"II$ZE%#F I0$1 !V&-Q63S-R+/$V]:YNC^131G;WR4&0\23H!J=(U&;Y!
M@N-6)R7(;RVLL>O6I7J+36?0 %B)L3H%$R3H 3&&<?<T>*>5)Q*LT//>-IVQ
M.5S-6,'^(6\7*RBY2'4,G#,)H(YS-#Z:9C +0JP"4-P';QUOLIP'FF&MS=Y+
M&7=.U F7V%E4?QRFX)U_*EKI$0P/=[MCR:\&.PF<Q]:_9MJT_5".Y\J:U-AJ
M>?P;M->D2< Y1VV'??XAXA]7CJ(Q8T>6D(:0AI'B&D>8:0AI"&D(:0AI"&D(
M:0CQ P#Y?G_9YZ0CRTA#7@](1&CDKR'BL#U1)=%-G*76=!8E9@G)E?14!N9$
MKJ4D2H'(NG'-/7+L'40RRGV"F#8QB\[?>)[^8SLAQA:U%:5SS&]#"SMG)VG:
M5#UJP4AA2I[AH"IJ-\"D?$RW)V=[2WW<_.-3J-4H<<MB#<5E F-T]M.G,%34
M:1UD0B_$0?A#5H<3<%.<YY!E+G=$7"U2@)$LU,**MU4$+/8))T[>DC45P2*W
M523<I&7>$(;<I#)D$ !4-?.;[K796Y[U\\N>7\P2H_%K&N+BNS*RB[NJKO46
MDK2"L%8&I7"GX5*(0!4$=D]]>YM'MGQ2CQ[CK(N>NJ7HT@&!:VH4U5#4*S+
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MK*?_ %   ZJ=M0EP%F<%NN>/*7CE=<?M^8U.P#(8NR++H5XE[P+-3JRE'EG
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M;K*++/#@X24.43%#TRRBKVM[86?)_P!D+K)9!LS6_FE4T@$FLU2HWI&;M(D
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M69ZE3:ID VU=Y685U,B+CTDDT4TT42$222(1))-,H$(FFF4"D(0I0 I2$*
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;&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2110724d3-fc_biobank4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2110724d3-fc_biobank4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X )D%D
M;V)E &3      0, %00#!@H-  !?X  !3NH  <&N  )*B?_; (0  0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0(" @(" @("
M @(" P,# P,# P,# P$! 0$! 0$" 0$" @(! @(# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#_\( $0@!I .. P$1
M  (1 0,1 ?_$ 50  0 " P # 0$            %!@0'" (#"0$* 0$  04!
M 0$              0($!08' P@)$   !P   @<%!P0" P$      0(#! 4&
M%0<0(#! $10U$A,T%A=08"$Q,C,V(B-$-T$D)0@8<!$  00 ! ,"!@D+#@L%
M! <) @$#! 4 $1(&(1,4,2)!43(C%0<0(#!A0M0UE19QD5)R,],DM'4VED"!
MH<%B@J*RTE-SLW244&"QDD-C);75=C>#DS1$)M%4A!=P\/%D186VPJ.DQ%7%
M5F=W$@ ! @(#!@\-!P,% 0$! 0$! @, $2$2!#%!49'1,A P0&%Q@:&QP2*2
MTA,SDR#PX4)2<H+"(T-S%#108&*BLL,%\70UXE.#LR058W"C1!,!  (" 0(#
M" ,! 0$      0 1(3%!46$0\'$@,(&1H;'1\4!@P>%0</_:  P# 0 "$0,1
M   !^_@(VOSYSS6']ZGSB        /$CZJ]Y8G)W2WN0
M              (RPNZ5JFQ>5=/[,        ?D3ZJ:K[N.L9UQX@#3>3QFN
M;VTZCP&=]\3KHV">P$:9I[05XS"5 ! $^ #G+-8B$4]387,^0
M                  *'IVS>-%5^W35P        !XTSK'1-OS\SB]@[)@Q
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M;_H!7;'(;DZ1HV!975=P>6N.TZ_\\TSB=I(I)8")*-+IN&LRMGO.DD7\
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MP&Q=ATVVW%M7ZJJ[7-=KF!KJ@ZX@JY@ZHA*D-5,-5,-33\\MPYG'U^(
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M8P #YR;'@+UL.G2-W;UZN:[75!5S!U1!5H*M#5(69]'GZ_,[=.6QM?B
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M-$[IZ1HX CR0  !6R6,X   & 9X!RSI>T]*[IJW.&<PO4&#S0  &MR-+F6<
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M4^<LWJ]CMKS^A#A_?.B<!GY B"5/(JLQ_.9WOY]VEK6V?>SE/6-K3
M$?#YU?!WU[2M/V;>W8N95K 9CK?Z:X1Z/+TF,IC\JX\?G-\*?6^+;>XF.W\K
MWO?VDE[^.9<V^7<V^9<^&9=6^7=6^;=>.9=6V->6N[^G:#@65U7<'EKCM.O\
M,S.ODULK*,Y-U,,VK#4AKN9OZ/="F2[&B.K$   <LZ7M/2NZ:MSAG,+U!@\T
M -<$J>XCR7-'IVDCVGZ>LL1Z 8!B%[/:  ?._8<%&;1J/MO;6"KF#J05<0=:
M&F8:J829X]SNDZ;RF ZLUG:OZ5^']]  '.-5'\_/>/G_ +DY?UO[2ZKM&D,Q
MKM6NK+J/7=O      _#C/Y>[]SE\_=EZC^B.*_LNA^X\FJNNYN7REAEW'A\Y
MOA3ZWQ;;W&5USG.\=CPUAJHS+FWR[FWS+GPS+KPR[JWS;JWS[RV]F7QFY.BZ
M0 *&?I1S8QB'K+J5\LX (XQB:   .6=+VGI7=-6YPSF%Z@P>: '#*K5LKR:\
M1TO#0$ST)$:.F:\29:85$F4;!3V@I   X.SF$Z7LKSEW>]'UKD+&"JF#KB$J
M0U4PU4Q<5\4;'SS6=_B^K-9VK^E?A_?0 !S971_/)WWYX^P'%.[_ $MQ63XG
MV#5.I-=VOFG(VW(63LMM6WOM_P :N2KZVW):77O,TPJ*[=$4;W\J_,=!6=QG
MT5S'S[V+D#Y4^ANX/KOYMN.TZ_:MCP=<P>7E\G8>WT\_G;\-?6E=P66'OZKS
M[;^V8&X^<Y=S;YES;Y=S;YMSX9=U;S.6QVV.F:'1]>S.T-VU4 ?+B:KY"JRR
MH>^8DCLB(V4      #E?2=JZ9W;5>9,]@NI,%G/=$@5@BC61,FVR%**;/-?E
M(-N'O(\CC9X  !\U\]@OHE@<[[_3SXUW;3>:MDP$'4A:IAJIA:F!3Z<3;+SK
M7=[C-NXK,_3SG_2@ !QOL>K\7;EHGWX^>_I3MG6-BY:R6)Z"RF.CK3*TOV\]
MA>/IDHSZ9Y+O[.64^JNB;HK@$SE%?NK\M>UM_P!G=8_ ^P\:_)_T5=MMUS*N
M/  "NX/+0.&R@]O5>?;9VG!W3RJR[FWS+FWR[FWS+GPMFRX+</5>=YMW;ZAT
M/;]O;YJ   $*30       /&F>/=(VOK[>=3C:Z.6<]@^OM>SX'S85>DUS*ZG
M@8! GUBBG,     !S7E\5K.UN.WK*]\@<V;)KW!N\Z=5O6F&K0LS"S/*V<T;
M4&3P8    ^VO"_HCZ(Z-N-]R^-   K=5/K13_;QF*:L:)G")F/$L%%?-OS-W
MGESYS[<    /#K7.]Q9[%VZB<NYM\RYM\NYM]D[]INWNH<_]GI2*5B,E@8?)
M[$V_6@          .?=!W&5WC4MV^WF-(WMEHS+8OKO!YNS>'L        !@
MU1QMG<'I^UN/HYBLK-@ UOD;#YJ]"TC4&2LH6I$51SME-2T/F=9    'T;Y?
MV#[M\YZ/F@      'X?/GXC^K-6<YW<    8W;>6[SJ3U5.7<^&?=VN[.N<T
MV9T'3 !^&B]8S^1B,EN;>-2]_MY@        8%G<\Z:3M=-V; =BYS%>\ @#
MD#+XBG>GCC        'Z8BKIO#9C?%->>  "+]//YS;YI_'&T8")KIU/=8'E
M[8=+  \U6V<3G8_T\M9Y+"C<6'V'^E+@/T/L]       'HHJ^:OP)]BU;6\X
M    /1]!\>WSA,K(^WE-Y7&]%=TY#<MKUT  >)2**M#:ALL2>H        0>
M_EO';-<VLGW   \3\        !^GD    #C_ &?7_F%T#3:9Z67%FU\W '06
MK;I]"N6=;]^:TO;&,SW"V[:GP'OW->P-"Z7]M^3];Z&4@     #US'/VRZ/A
M:1T7GCYS[?2N"]?P[2Y   ]E='[])\3W9I>T73:==Z9^@.,3F7Q@   'X?A^
M         \C]                   -29*P^5?0-.^8>_\ ((?UMQM#%9WZ
MO\7[9S#WGX_U[E]9W5H_6N]^0_3/.-S;_F?T&C[[R#Z!<J^A.E=<W+S
M/P^;/5_GWYY=2^?;]B]@[[X]]+[;Y;V;G[Y-^BJ-RWH   DMZU+!W_5.M=DP
M'2W?.-9=SX                                   0OIY_ /L/&N$MQT
M$=+:GN_U&TS8.,^O?-5 R>!Z+Y?] =MZ[N7SYZGP#3NP:6)^UR/U*XG]4=AZ
M9TO(    ,*OR^:'6_GC@?I?!Q.VN1[+^6_N[I?YZ[CIWD?1Z7BLCF[WJ4/R#
MI/KHK KG>^1=R=)T7ICKO-/V8
M X^V# ?S?=V^>/Q'NBO[?<2^@.F=6V;Y]=W^2^=MSY:  /V)ZMT?K7T)Y?WO
M>VO[;[T@ 85?GRANG,?G+U7Y\U#G=0 O&)V7Z-_&GZ&Z,^&OK'T^7I8>L\Z[
M*^R/F/6FF;/H_P":.[4_E'0Y3+XW>/W3\E]J;%@_T
M                 &&?S^]CXSSEEL+VUS/JO15IY:=ZO\\<R;AS(    ;4P
MNU[]UC?-E8K8)#RNH*YQVILWJW.NU<_JE[B  !W)RCZ+Z-^;?JW2OSUV?"F+
MY]T?&/&_8?FGLKE'T/:.(=W\?>WZKWK4K6D
M            4]''65P?)77_ )MYXW3E?A,     2OC=7*PRP _#7F4P/A-(
M  &]-8W_ *"T3K4!YW'//2N&:NSFHCZ$<?\ I;Z0<V[=F
M                        XLWOD_R>[=\I@     =G:#V+46<U43%O>[?P
M6Y4K(8/7&6UK2>PZ2     )NUR'TH^>/M'NG#['D
M                   C4?)SM'S)R!T'BX     [%T3KO'6]\BGK7(?5?B_U
M;\TNN?-&9Y^T[;WFCMBT<    #(H].XN&?6OT8TSI5R2
M                       *O7Y_'CN?RESUN?+     .Q=$Z[QUO?(NXN==
MTYDV_F&N,MK6U,+MD[;WFCMBT<    >ZFOJWC_TQ]+N<=HVFD
M                             <N[#I_S+ZW\[ZAVWF8   %GL\I] N8]
M\MMCEP![Z:]&;'I/"W1N&?DP   )/QNK]S+OOUBYAW+H#PN_T
M                             'XCY3]5X1IC*8#4>\<@A[BQ %OL<M:;
M+*4S(8CPFB!N+*^8[-T')8+QF /9%5GL\I5+W$@  6W#[/[>==P^@F"VKOW4
M.A_H                                         -997 _+CK7",/&Y
M?7FQ\^U?M/.OP'4.G=2V?A]CM5CG/&JUJ]W9VNRR4KXW6B]CTCHG5N@ZHS6K
M[4PNTZJS6JYU%<KX7GSOZG\\ 27C=731.P9>"W3>F4PWUAY)WK.\_4
M                                    <3;]RWFO:](@+*_C/-K[:.<Z
MPV?GTEY7$GXW/HJI_48U5'NBKSBJ.];:5\;OT54>ZFO\1X33[8KJ]YBYBWOK
MEIG4I;5.CVO*8F]9'%=\<YZWO?7=M
M            A?>U^='4^+17M;^*:[:W=?LKW6V<TV$V+1Z'G]-Q:_$   "=
MMLA9M:WK,UG?;7AMMNV4PUYO\?[9IVIAM@[QYQUO]
M                        !H/9=/Y=W+GX'XG H]*A:WGKM+ZG7F(J5[B(
M>ZQD=[VOKJI]OEZY7A?2UCE;/C\Y,6^0FKW&W>\LI?U\?) ]L5=S<XZU<[#*
M                                            >N:>.>@<MJ][C@ !
MXIQXJPJ*\2FKT15[$955&=73DU4>:/T  W+KVU]&ZEO0
M                     H=_AJ3?8G\      *5DL3I#9=1         'NIJ
MZ0T_?,[R]@     !LG$[':?"\_0                            #3>;U
M:Q6U_L+&YH                        >*-#Y_4YG&YC<-EE0
M                   -'9[4]XX';-,YS5=S8/:N#%5;E=XC"3GHQS**VF01
M,F3+2R;RBYPU=+=T13)F)B4TT=5M:(DYCL:&FLYJVY<'M.C$\J3.QD1<)64+
M$^U$=+9,1HV:K5$91F3,$C<L-=2\(:LF9DV+#72.UT;) .)<YJW;&#VGR
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MSTGD29\3-AKN6ZH:RF-FF$G3Z:P;V1I=.]%/8<1MX    '#F<U?N#![1Y@
M                          T%GM2VSB\]9+6_
M     TYE]=T[X7'8F/S7Z                            #U'.>6US7WM
MX?@                        +#99/J&PR\B
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M.>L]3/[+9VY)YC;"9F[/9ZZLT%??[2SM**[TU#0O[W60D82SO+"/VU]_-O\
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MLZU*Y64NV1+IV4*D19$1SJLR'XRTV$]L-3YS#;=I9M*8G3HJUK6ZL5DE#$B
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M2']5282CO'6N6!9.E7RRI[*P<Y3W%G55G*Y(A0\A7P9<KE@MWAO*UM&*E8R
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M\U [=S]NYA2(%CV5D1KF-?@DA%C/RW:NG9KT];\Q8T4.P2_BYD5:J77D.#[
M<'V X/L!P?8#@^P'!]@.#[ <'V X/L!P?8#@^P'!]@.#[ <'V X/L!P?8#@^
MP'!=>81B)\IRIRD*O2A"4%UO AX$/ AX$/ AX$/ AX$/ AX$/ AX$/ AX$/
MAX$/ AX$/ AX%V>WY6Q+H6,*96RKJ/Q#)=3*89RY:SV5.#'588"N7G?E"\=Y
MT8!NC)MM;J\OR^D5L[ 0Y3-?VRE$@I/-+#1I5K$XJW*JF?:?COQG.NA*G%,F
MF;J2%75R;-R#7QZ]KLO AX$/ AX$/ AX$/ AX$/ AX$/ AX$/ AX$/ AX$/
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M[8.@>UZ4X[VW(:\5VR"@WQH4QQW6QMB*%%6P#PRCV;:CLR&6/9H0,9R1GRV
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M_P#,Z:/PKO'85<5M&]%55W3+9\-C]W079USJ+24F6 B4?)L%2D3)XVOJ>T_
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M[BRRCV0X^$W>X<:3G%,.69KK[HV1>V[D%MP$+%T'0+3W5/R3/ ;VU3**(_\
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M'\C:%)*ATR!(:Y7#BFT*345?UVW(=[[Z(:_Y?^QF$>A^JTP=BS_],)V-%ES
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M/-65LH;JBJ29S-47;@C^.<?L[;3[R7.D:J\6A)D:IN;&2+(LV9AQ;MJ4@E2
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MV=Y\9S_;.\^,Y_MG>?&<_P!L[SXSG^V=Y\9S_;.\^,Y_MG>?&<_VSO/@_+H
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MUMDV1NC<5Y2#L^HEWUDMG87<JHF'N"H8ERF)$ER2Y56KFWGICKT=M0Y'+U:
MT8]8YT5Q(O*U8NRN3.D6DFZ75T]_S6&[28])D2FF3\;AZ%S'X.22TE[BNMR<
MX-[*\>WKRQ6V@LPHTJ6/IG8.XH#C-'*@\G1#<C*PTIHFM'!7C?I4W=U#87U?
MMRVB7?<[=$A;=G<>WFEG#/31&K;0H4USG1XAZ1%>\#?DX]9XP]R[K0=GP]H6
M%'S=QVKZM3;-H2L'91O23*>S)Z+_ ,.[JC!S#T-CFF5TD/=%Y+W@UZVGJRLV
MVY=6+L$]N#;Z)3"TRN%$]$! )]3D*"].K(H)AEDM7#E6PTU'Z W7)K7G]W76
MS8[MRN\]PA+>:F4U39%<V4".#*MP7."H>: >I4Q7S;3=$BXF_P#HQ"HZ:\OM
MN7*/R(<,'CK]K750S4[GK+8C5V0G3@^V1Z=36A?:>KR4F2'_ .IHQ+I340$W
M3/!F?;I;5M<D_=887]P/^3W/4VX;9?9 2B7C[15%[<>8NK1M$^"DZ3H\7D*X
MH=F.[<&XGB?C0W\^WX3D<C\/CQYQNJE)X>=$=%?!X8\IE$7AXL?A5!%>\?(G
M.QO!_K(\O+CC\+I;-G^SNQ97]8</"<U^QA_VF 99=G;T9RO'^QA.7N2"&?\
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M!@4C,5TAQ'&RX+Q+6,M;IGQQEN[9W+1P=PQ?H\_,"1Z)N;"'.'IA5UDFR5P
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MP7+<'ZAAI),+S)#-VWXK1CF2OUK%DV;'/ZKJC[V-.;M6^O!&; D.&9>)JR
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M<&?$,@ZAB.#Y)V")XWI66D8VW-RW--6;9](,;?#<UA*FR(,?J+V1MA7JV=*
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M8%,U5 ](1/3YADODJCUR6I/L\_8B5-8RLB=-<Y;#2*B=@DX9F2\ ;::!2)?
M**N//R*^?>S6Q])37'&"1.PNECH:KHCME_G+Q7$29#"&Z@L2HCH17Z]EP>J=
MA. \7.?C@3#72+JR53[R9"O')3FO5C\ITS==)7&'!#67<8;)S)5;CMY BZ1U
MZ=2HBJN(D%]8C,6!H!WFR8+@3NE;0(_(;:==4(W-R<S/EN(K:#HR)<@D16X3
MSK#FI&HSE>T^:$!M%RS?>CM)DCF:YF/!/'PP](G/5[CCIIRFC>8>&-' =+;2
M*2Z5<,M1FJ)VGIS(0%<<B''AD9)WWP995 1? V2#DI^_X/J]FY_RH[_%#%U=
M9>=-&=O5Z]Y#%RR0WK1]K),O-5L?D'Q\F9]:,(CD1--J7CS44_4"^ DR(53@
MJ$*YBJ>^BXF,"FEHCY[*)V(T^G-0$]YE24/WOL;,_L$G^)7XY,Z.DICD_<R,
MP[[DJ*P)Y@J+W.=B*-?&&,CW%U!)PM2A&G(/W0S[-6+'ZM-_NZ^Q*_\ COQ/
M:V&_Z7<G^^QP]_2N?QE]FO>SX0KPFOG:%J^KQ]#8%?&B>X[B^UJ/XL_V)$?F
M&SSV'6>:W]T;YH*&L/W0YYI@(*RW)NEQP^:X.C+6OD &MS0 Y>->/L+ W%8[
MFB5SU_=29.UG&:ROA26 W#,E, ^9T@7Y0YR(+BIU:(:%W>[EB=9R=LRI++_K
M=OYFY66:EYZWMMIG:33A(+0-]=:T"3>1(6,V+C;V7,05R7.JMX>V9D+;P;KW
M&FVV9>W99OTO5;= *N>[7K!>FTU,NZ6^?'YH-MQ"\YI:[<,-U,>TK-UM[<W+
M'N'6-EV=,_8RY$9Q'(]YO.?N-R#?2)$]4<@O16750D'[@/D.-[0VAN"IH'*;
M:\6[KW:.SK7)MLWNBG> ^E=8:?L)M;6MR.IG-B8]JJX6>>-^/U>VY;#M9O#9
M4O9W15\H$A,%*H2NI&W@9;06V"%7NJ)A-/<[_D)D\_NG;-W<;2+<GK2<]&QJ
M:QL#Z^QM.95V:U\5@I+C4Z#K&)*%-#3BZT,/*QMMI:FV9@^G=H,^A))&_=I#
M22VVE>X0S)CSE@3'<^[FYK[2U8L_1>Q)#FS)NY(+]37W-%N?T36R(-*\%C9N
M[(JF"LWX5G,4!:1V)R4,5-1151<0)4W:=FFECUHUL-OZ+V7,KTEM,2ML,MQ5
M&T>K8/-F/])F^ZVRX3B<U2U$NU6:2CE5<M[U9K*L9+4!]I5W=5.TUW4C:ODV
MG+M$M8Y".M4>$-0#W4TX:DSJ*W2%N*8_ZR[2(8R(*P;:JD[A&KVWU+R-=++?
MYM629Y.IR%++),TKH;>U3VRS.VS?Q)LB#M_=-:W'M#:C6%.E_=7J\V[L(-K'
MYB/JWR]2)I>>4M+5IOBVC=-/NNBJ8[!9%TT';S*Q)2,E\!N5N YCF29(J:?<
M(OY/8_K7<?O/VL>K;\E;]_%:#VKLVQVMMR?-?45?ES:2LE2GE$!;%77WXQNN
M*("B)FO8F),,**F"'-:C1YD4:R$,:6Q#:%B&S)81CE/M1&00&Q)%0!3).&$N
MBIJHKE$1$MEKHBV:(+?)1$GJSU2(C7=\KR>&)W3[<H6/2;1L67)J*]KT@PZN
M;K,[1'3JVG%7O">I%P_JJJTNIKTJ9.J#%7J*H4,4K'\VO.UZ"X7F2S;[R\,7
M6Y;L]N!UEZEG L[6#65_H!'(L2&Q7Q+&6X7+02CY@H*UQ+)!PEPSM_;SDR0\
MU8I:-U5:<E^3S$E,STFBPKKCW-R<%W5GJ[R+B9TNVZ"-Z0:)F?T]/7L]<R9:
MS:F<N./4M&?%1/-%7#U6UMRA;K)#B.R*YNGKP@/NCEI=>B#'2.XX.7!5'/$:
MN?VSM]ZOA$X<."[35SD.(;W%XHT8XRLL$ZOE**)GCT7,K8$NMT--^CY,.._!
MY;.GDM](ZV3&AK2FE-.0Y<,.)45-95(\C2/)70(L%'48%181Q(S36M&1)4'/
MR47A@B6IK=16(7!%T,7,K=L1%NU)>5FMB @B(_\ =$1.W!L3:"EELN3';$V9
M-7!?:.P>^[3S;=8(2F._"=\LO"N(D*3MJ@D0X'-Z"(]35SL:%SCYCW2,'')J
M-S7.\6A$U+VX%ML1  %   1!$!%,A$13@(BGMO5]'8T\TGMRJ*$N2+HB5I:<
M_ JHF 9> FW 1$(#322</%[CN1LO*B6;M<J<.[Z,0:[1PX=SI<O>]C:/]JG?
M[HL/;ROZ1<;H_*CO\4,;3B)QZKTC>2 R7N/SIY5X9\.\I5].P7U"PV"?! 4^
MLF&8G3O6MQ*1%C5D540E120160[I=)E'..E$ R)?!EQQ35M[M:/4Q;AB;):=
M28)R6V8<<725R/S2-LQ<>:$@,0/O]G!?=X4G[,'XR_495M\%7QZEE%];V-EP
MFWFXZK53G>8ZBJ"(TU7*N>6(@NR6I/5,"8JT)(@HW9UB<=7;GKQ _?\ XO-Q
M8_5IO]W7V)/_ ,=^)[6PW_2[D_WV.'OZ5S^,OLV''+D2ZF7_ )LAR'__ #^&
ME_<#_D]P0112)>Q$[<;A \M7*IR7+P9C/X>UD5X[CHBGQ!D'*A);UZRXP1 )
MR44B,DCG,C& 55Q21-")QQ)Z'<5%-Z*/U<SI+>OD=)%RU=3)Y,@^1'TKY99#
MAFPIIM5N-L[RCI9'HRXB/!$*ZG-0Q>>=B]8@JTCBF@+IUZ>U.W$6<[=5+4*<
M!N09;EC#"+,;;8.4XY%D$\C4@ C-DXJBJH@"I=F'+AO<-&=2T[R';0+: 5<V
M_P!WS+DU'^F!WOIW5+/CB+92-QT,>NG*:0K!ZWKVH4Q6U47$BRCD(Q(4%3CI
M5<L-O,N ZTZ N-.MDAMN-FB$#C9BJB8&*YHJ<%3$=BSC]2U$GP[../.?9Y<Z
MO>1^(]G'=:(N4ZF>E<P7PHOM7HKQ2 ;?!0,HDN5 D(B_S,R"]'EQS_=-F)8B
M5E='"+!@L-QHL<-2BVTVF0IJ-2<<)>TB)5(EXJJK[A%_)[']:[C]Y^UCU9DO
M8=?OMD5\;I0*9Y ^JK<<U_6]KOZ=)W?.JXE/N:%MVBA0Z&EM%YLR+5.HTW'<
MAMS)TY]R8HL:I"-MJJDXABF2?1YB_MHC/TVV_4=7:U.UDOV:ZTH[:;,B2V(,
M-^J:DMOP44,VA>;7@Z*+J#$;:;VY'J_E;CWY6N;E&OHNOL&=M-UQU\3DR(+E
M4U(T6*N/J,8=;;7=T]Y4@Q$M9[CK6VK^Y<M::+L:.M@_&W7?5,67,#<\F# ;
MHZZ'6-\Q(N3RZLS-.!8VK8\^#46FX9^V:VQM&#@6E?4#;N $RTBNH](K)#'\
MT2FXUYQ,U5..(^W)6Y9D]G;OK+V<S#MV8E W+([>OL92L3!;J3KCL*%V)D"B
MRV*\[SK9*@Z=G[>@;D/;D"XK]Q29SS42GD/O.5@0G8XLG;PYC31()GGP5-&?
M#/)4=G.6SO*I?5[-W&L&% J48W'9U>X]RUC+[SCL&7+9@V\.H;UMQS97,LVB
M!/*CV:S7)26NV@G./W);";"ODRIU=&&YV_ V]:NV<ZGA!-<Y@S&RY?*%3+B0
M)/H(6]3LA1_83<>:_4[=)^&NXK-^-,!\8=:Q'>YK" X'=%4:,<N/?*ZVI)W/
M=RI4+<M>Q6/U6VJ2QW1:UTK;3%U*@M-]+%H(W1$YF4@HADH_!\4*D^E<B PD
M7=ZG/CU>UWITOT/<1H=:^]HBV=1SD"4B.],I,. BZ%S5'<4X/[KB[00/5]&W
M/+M"KJAZ-.G>F9%=)DS0LQ1IJN88AYN"P<94<>SUB*(F&-EI9MO6Q[H"T])Q
MXD/I9'J_*O\ 30FRB-O-ISG?]GB>1%\+FJ??]P]7<45S-F/NF:X*(NH1(::*
MR2KV:#4S_7'#(/CH?%M.5)!/.M\.Q?YQO/X*_K98T20S:)5Y,D.++J>\OP33
MPBO'];C[=L2["< 5^HI(BXW8^?EO;FO73R3)-3EI*,LD\'%?8VC_ &J=_NBP
M]O-==,&VVU-QQQPD!MML!U&9F60B BF:JO9C<%A =1^'*LGG([R(J(ZWP%'!
M0D0M):>'O8V^(IW&]J;3=3L\J9MRML'NQ$3B_++_ .WV+:ZWIKA;NG6DALY-
MC FMQ(43[A$9@V)L'7A'<8;72:.\6DR[$XJ[ EU<ZP:B*'/B.QI,@81NMF0"
M^TIETZO(*JB+EJRQ!*PM;VEVH;56%+-IXL&12NW)2W!GUV\#>B2)D9+,2:9B
MFA-LBIYZM>>-N6KNX?6P5A;2]OQ[1[T)$6I=CS[6*S-3:SR;>SFVAM<(X:WM
M2:^ZN'W#OQ8M;O>4O:.U[RZ]&0["!5=0V!6VY(T;EL09]5"!\G$5L"SY2J/?
M3.]W)&F UN"HVW>QI\B(;+J1]P4T%X79+) *L*$@P"2UEF/+='%"U(N?60WM
M6SD15ZXZ*&WNV5+';MM/M6*B,M+KGU#,AF.X+AQ^ *7%4123T=*W5+H8E%35
M,JPET;=0W=[@E713I$&2X^L:=#K68D&.V+[3+>?4J8EEEI$/54_>!Z32^DPY
M&^8D6(U,=HH]"S?].S#5ERM8W(0O].9H"@VB*?+4N.&Z;9.];#=MQ W3%8ET
MVZ(3,9\6(^WMYV,VI<M1J*SJF[IRDTL.Y$C+K(KKT+BC3:\H8;U[7^A'(MLR
M*?1?<<S<E'6.R+V(:(ZW)IV)#J(!JC9J0EW@7C2O5^[9VZW-S3_HV=?N-JM'
MEWMC"F'5VU4<"'#Z*%%G,)SXY<P.2O;FFK&Z+-W?6_:[<^U*6?86U%.;H(4B
M%=A4.S5YJ!2N=7MZ:]$U0N42#RM>1Y^16N-;@L[X[7U?-W0CN$H3L6)=7%]M
M2F8DF<&! 4*ZM2Q,])9KQ5%+CPL9U'OK<5];]"2R*Z=#H#;E/D3?4.T0A71U
MJI+3"NE':4WFU<T"6?;BLMZ[>]O<4,$[.%8U6X*^/%O8\WEY>C+?DQ8:];7O
MN"2J;:$@BFG4)ZL1WOL9K(?]['EE^SR?8VEI ^3Z"LV'GT'4#*RHT(&M?8F9
M:5R\>6*DD%SIX\!\3?0<P1QN77/-@2]B$[R%PP]Q06&E)%RX$2H\UHS^U=SQ
M:23 P:T5),N*/<>)N-:,.B)>'E]2F>)LLM0Y/.@VBCP=!^#29N(7B!R"H_5^
MICF'J @D7*("IEF$JT-\#^HH-HJ>-%PO617XW.-TFN<V3?,%#XJ.KM1,_9W%
M[U?7K^O]):%,_JY$N&/M!_R>WT-#FOA7X(IXR7'#O.+Y3B]OU$^Q'%\"]KL2
MI=#[1OK6R_A%[6L1^A;89@2MR'Z/K0V?5TL-;>OMHPN511IY6TUN4X\VKIR5
M8/->+1KF8[3]#[=K)3]9ZM#V_8PYZU+T%;1QRF==B2(STD8\\T<8?>;4M48I
M HIEDN>)UE/K9;W5S]AOC)F.[4@OJQM^_P"?+YL&DGNQF.E@<03F2"($\M2\
MV.\MO.UX7E)LU)D3;%<S9I5NE(W9+@[A?9;M#CO@Q-HH2<IM'D(<G!%<A+4C
M-ATUJL6KW-56D0)'T#:WQ8M-5,J"_8SYK03MKVEA5OFVL8IBJZ8(??;+2J1Y
M@4.ZAL3NMTV22H^X=C/7$);B-71]-A3N5M7M&767*P-4B*VZYR\R[Q\PD&DA
MW3$"-:1X+;4N-6,1XT)@A5=#3+$1!B-*VUI0D:\UKST=W+W=I!_T4*,!?552
M<_BGC]YC;N\6A-?H=N*%9SN5FKJTDP':FZ$$1%5<H4Y37W@P#K1BXVX(FVX!
M(8&!IJ$P(<Q(2%<T5/:3HTBIK'X]HZDBS8>@17&;%\4:07IS1M*$MT48#(G$
M)>XGB3#9PMN4,0V767V3BU%?')I^,+X1GFR:CBH.QPE.(!)Q%'"R\I<0Y.WY
M&U?1CD^SGS&9VU*O<U-=SW_P,[%P>HKWNOC/,%E(;?\ ._#UCEBHH;&MK-P!
M4)*-J1;5,"1E)GRW9TYZ.PZRZW#!Z4\N0!Y(Y)FN6>#KY4.+)@.-HRY"D1VG
MHALCEI:.,X!,DVFE.&66(\2)25$6)$F)818L>MAL1XT\<T&='9;9%MF8*+P<
M%$/W\4=S:A"G0Z>%;1#I["M8GQIA62PU!\ED&3391"B9IYH\U7M3+ /QX$*.
M^W"9K0>9BL-.A71B(X\ ' !#&$P9JH->0*JN28MF-OP*;;5A;1CC/6D';].Z
M9BX>IP9D5V+R+&.]Q0VW>!(2]B\<6=C.CT$U^P6JY,2LVU%I*6M]#JZ[&>A5
MBRK/3..4\KI/JXIZ\M.G+$A;&@I9ZRWF9$I9M7!E+)D1V.ECOR.>P?.>8C)R
MP(LU$."<,)(KJ2H@2$%X$?A5L.*\@2%;*0*.L,@>E\F04T^$HIGV)B%&D;;H
M7XU:BC71WJ>O=8@(1:R2$T<=0BH1)GW$3CBQW1.EL2I4BM8I:UMB"L/T?4M2
MWYQLO.E,EG.DR)+HJ3GFA\VFD$XY^WM9#.1P]MQ(NUHYCY)S!>*QN5X_#9DO
M-LK_ $7UVQ\0I@X\IH'V7$R-LTS1??\ &))X%3BF')E=KEP$S(V_*D14\.I$
M^ZLC]DG%$[?'[9G^E;_CIC<XJF2CN*Z147@J*EE)145/![%/N1Z,<QNK<DN+
M&;,6S=5Z%)BBB&6:)D3^:^\F/S4F?WYG^1C\U)G]^9_D8_-29_?F?Y&/S4F?
MWYG^1C\U)G]^9_D8_-29_?F?Y&%A5\5RFJWO.3F><CC\US/,6G' 042(WEGH
M^$7%? GL4BHJ*B[0V6B*BHJ9AM*E;-/J@X"HOB5,+)< I#[A(S#AM?=IDD^
M- B"99>$E1"5$[$(LA5Q@*QZ;=2S>B3)MNVY!H]LQWWG&32FART'KY*,-IG)
M820HY(HN$N6;5;',GGB7GSI)*7X1+(40S "54::%$TB*>!..:YK@;:8Y;(2E
M".9 CV\YBGM3K'$>KBLZL7>DE+#>%"'NIGDFK4F*QIFQW2_"II4"96UDW<=A
M*JXDBLEM3(9LU[IK&#E.L^!/)54\.)6[V(IA<3&#:>7FETG-=".R].;B+YIJ
MP?CQ&VS='(B!,E[5SW4VXT\(;RB!$O1:?,$>$(!UG.93L8D%") (D[= ^+&V
MY#C;O,VJXXY49/$B-DY7.U1<Y/\ 3ITCR]OPN.$ZAG=-38S79%KZ?V];2(+L
M%BVG+Z1B 4.6,M:XYVJ03')<$7'3)O)2+#M?519TV#5WD5Y':4K$=Q,[AFND
M#%S&M)+T>PD63IBOGT=-31-'$>[@;!JZW!97:.1K@Y]P6Y;2RD-1J:V@Q%-)
M$0LX<:HOI#HH #W#YBYH/"TM)[/52KBF2EMR6INTCSJSTG'98D2-$$0U1[.*
M#+<M%0@<$10\Q')Z8Y97]XVU <K&Y>X9>Z+&/M^MN5*J.-%E3&Q:I!G 6CFD
M0.\I/+0<\;DKFQW):UEY21UW-N2SLG)C[%/.JI?HZ,3MG*"V5MBM<<5L&F#(
M%<RXFN2 =BLIT(&W96S7F)M5>%$&JYU84J%- Z[2DMA\8XDJJAMFX*<%5,($
MG<F])C;2=+6M2[C>KPT+XN*#+-:  *PK",<3S8N:G40$\';Z&VU/F6#L^3*M
M9LJ4MI.F2YS^L7YEK82VNY*?&%P0U#,!%1320YQ@\)V#!?\ =QIR+_6^PVPQ
M9R6V6@0&VQ)-( /!!3AV)CY6E_YR?R<?*TO_ #D_DX^5I?\ G)_)Q\K2_P#.
M3^3CY6E_YR?R<-K/E.RE:0D;5U470A9:LN"=N7L[C_)U?_\ J?;^&/M$_P G
MML_(93RG%_BA]D7^3"-M#DGA\9+XR7PK[%;,+@S8LN5+Q+V"X1=1#_7-T5']
M?W H]9 A5S!NN2#8@Q6(C)/N\77B;C@V"NN9=XNU?U"JJN2)Q55[$3QKBPLA
MS5HG]#*^-EE$::7WNX*8R][$J#+:%^-+8=C2&33,'67@5MULD\(F!*BX+U9W
M[Q+*K6G'=H6,A?EW;C:^:B\Q>X5G2 O*<!,E5D4)!R15]INXUW#=Q=]0MW08
MNSMLQ[&<W%GTZ]#T*-;>;R@VT.Q8-\I+QMN*!#Y8?"VCMB5N&R7<)>M"V@7L
M,+6R9MAI4>W"V#$Q]I]J:Q"-N3&Y&9"BZ45OBWW=J5USNJXVYMP-N[J<D2J[
M<%C"-O>,:U /1KLAI]XFI4.G7J&*_+ENN%JY1J>1[H?^E&Y&]UQ)>WQ]7]2<
MR? *ZJW8-<<&4NW@;@Q[I^ZD./\ 7H[&7D$.G)GR<4\I[<>YQ=N/6SN/;$YD
M-PVJ14HP])$E?%C]5R8G+6/DV\T@/M(O<,<ATPZNPO) ;:K]P^L.J"QN=Y7.
MU^J?J;98]7"M=W5T*QL%>C0B(V0=5M)!#DI%I1M:NQL=[.3S9V['>9K8=]N7
M:=K. +J:,.PV\=G01*O>,Z3!%D'PEQ'%<TED*:P-6'^4\QSF6W>1(% ?9Y@(
M?*?!") >;SR),UR7W4(E:K<C=5UKC4,%=)\L\E1VUE@N>F!7IWESX&60^/)A
M7-3SB:G7I+OW63)?-7I,EQ5S53?>-2QE[+DVG1N).XF<;R8LI?#EX([Q>/R%
M7MR\K#L:6RY'D-%I<:='28K]1>U%\"]BI[1<;L>_][O[.=XTRL)3DU-/[G)_
MAX<O<]J2->I7*?HWDRR5MZLL)U>+2^->C89/ZAIB+;2M+S4"&(0HY]X6YJOF
MX<S0HZ4-L$#1Q7O<<D4!7W!')];"F."WRD.3&9>-&M6OEH3@DNC7QR\>""-6
M06 .6$\A:BL@*S6U0FY.0BB<YLDS%?!A69%1%:S;BL\V&"1'^1#T"PQSF4$N
M4+;:#E]B*?8CDPA456?2HB,*Y#9<)M$=>?X&8J7W=\S]\R5>W#K2TT!GGL+&
M<<BL!%>6.1"1L\YA =$'-&2Y+Y*JGAP,N;4U\N2#!11>D1&'CZ<T(29S,%S;
MTF29>!"7QKAVO]#0&XKS3C) S&;:5$=2*AD!@*$#J]"RNI.]J:%>U,,::"IS
MB@ ,%T,=2! -7![RAFI<PE+/M55SQ("OCC'&4_U#HBJY:T89C-B"+P:99CQP
M  '(1$>&*Z,B][S[SB>]YH&O_P!OW.W_ /O!U43ZNJQ9F:<__@<\O>][#'V@
M_P"3VHOR44&>T0[#=_D@OUUP@ *"(ID@HF2(GO)[+K/DGEJ:<'RFG074VX/O
MB28*-+R;MH/FIK*\%/3P&6TGPF7TX^\O#Q9_J?T)"/583TY;NGMC1G,M6>7^
MD?!<O>'C]C@3(?.$F:JO;[(M'S6)L1]N96V,0^3/K9K*YM2X4A.\T\"_K+X<
M!5^LJ$^49KS;&]JV(X] ?:'2('>P6$=?K)*_"<%"9)5\&2KA)E-9P;2*N7GX
M$IF4VBDFI!-63+EGE\%<E3]2')ER&(L=M,W'Y+H,,MIXS==(0%/JKARNV)&^
ME=KFK2SPY@;;KS[-<FR0<IRAY2-QM>M/AIA^\O7W[.XL%%9ME(! 1&A^YPX3
M"=R' 9^"V/U5PVR"9:11/V/:\N6'+D@*I'G-(G/97Q+_ #K.?:!</%DO''*F
MMZH[A+TTUK-8TA.W)"_T;J)V@O%/?3C[3JA14"PIMORN/PG4IH428?C[T^*Z
MO_US]SEUZEYVEM&K9I$!=2P+46($XB<3L:C38L5$1?A2%R[<-&GP@%?KI^H9
M>2YA$TP@_P"PU*ZGZT@S]SBL_"FW\8D7]Q6P9?,'QY*5F"_K)AM/W*?Y/901
M12(ER043-55>Q$1,"_-1"=[09[0;]\_ 9_L)[9FVJ"5F?'SR,,N^/A;<%>!M
MEGV+@8MVTM5-3NJ9HO1/*GP@=7/E9^(^"?981QHP< O)-LD,"^H0JJ+^I%=E
M/LQVD[7'G!;'ZYJB9X*)MYHY<E>YUBMKR6_!FT!)FX?ODFGWBPEE9\PW"/FD
M3JZB(EXYJJYKA!'@B>T476Q+/QIA9T*&D"7GJZFL>D5<C7GGJ5VO=C$19^//
M""UO'?0@*:1 =X7R"(IP013K. BF/SRWY^F-]\<Q^>6_/TQOOCF/SRWY^F-]
M\<Q^>6_/TQOOCF/SRWY^F-]\<Q^>6_/TQOOCF/SRWY^F-]\<Q^>6_/TQOOCF
M/SRWY^F-]\<Q^>6_/TQOOCF/SRWY^F-]\<Q^>6_/TQOOCF/SRWY^F-]\<Q^>
M6_/TQOOCF/SRWY^F-]\<Q^>6_/TQOOCF/SRWY^F-]\<Q^>6_/TQOOCF!?M.L
MN'M6KFW5A.ME4O"2A/D/M:ES^Q\.!S:!$#+2 B@B*>)!1,D3""V*(B>+V[L.
M=';DQGATN,NCJ$D_RB0KQ14XHO9AVQI$=GU:9FXQY<R"/:N:)QDQQ^R3O"GE
M)PU>SM6RX9-LVU :IY6JOG);MJY]LWN'2*KVHWE\'VP@ J1$J"(BF9$2\$$4
M3BJJN =3;5LTVX*&T4N(<)'0+/(V>LY'-!=*\1S3AAR9,V_:MPVONTP8CC\-
MGM^[2F$=8:[/A$G9[-7)<7\#DN^C+),L_P#9]C^#2',LQS<BZT>;X_=&QP#1
M+F[&_!W/MV?-E^RGZ@/[5<2F9*+FKSCK;J^3(:<,B!\%^$AI]9>"\?<]M0$R
MR:BR[0T\(N6,OI40O?6/4ME]0DP*>][ LQP5PU\78B?9$O8(IA#+)V4J=YW+
M@'C%K/L3W^U?<%1QH5S][!%6S),;-<_,/.-_Q5QPO;;^_P G[YCY<MO[_)^^
M8^7+;^_R?OF/ERV_O\G[YCY<MO[_ "?OF/ERV_O\G[YCY<MO[_)^^8^7+;^_
MR?OF/ERV_O\ )^^8^7+;^_R?OF/ERV_O\G[YCY<MO[_)^^8^7+;^_P G[YCY
M<MO[_)^^8^7+;^_R?OF/ERV_O\G[YCY<MO[_ "?OF/ERV_O\G[YC);NVR7M_
M#I/WS&N;)>>7PDZ9&J_5S7C@>XBDGA5,9"F2>W[,=F.S'9CLQV8[,=F.S'9C
MLQV8[,=F.S'9CLQV8[/=';*B1J#:KF;L;@$*<7:O9PC22^R3N$O;]EAZ%/CN
MQ)3!:76'ATF*_P"0A5.Q4X*G9B]81!YU5(K;]E57(^0VZ=1/9:15[W,2U9=)
M.W3'S[$7VK=K;ON5M(9F$=6@%RRMW6ETN,U;!J@HT)=TY+GFFUS1-9IHP3M-
M#A[6KVF_PBT)T0L%;\DCF[@EJ,D>9K[P-$RRN?!O"I)GV%R\OW5VN@\X=?#_
M $UC(K^;E]DF:>+/!I06$J#9, KR-.B4*5RA5-3K1-F3;J!VD@FJHG'++#&Y
M8;+4=)4Q(5LPP#;,8I3S;KT2PC,!DC75C'<1\1%&Q<$53+F98!IH#<<<) !M
ML5,S(ER$0$<R(E7$2TW2 ,G$>;DL;774=G,?:/4RW; VJ)40N:'G1<))1#P1
MM-6M.?*SYLA><:K\(G.^2_KJONZD2H@IQ55[$PL([MHG$,FR<9CRY$821<O_
M !3##D<D)?A"2BGA5,).J'X=C#D#S.F<4)D!_M17&'&CU-&667,9,#]_"HBK
M62>/X)8&G3&OBBV60M<?L7T;R[-9+A6I#3C+B<=#@J*Y+V$F?:)>!>Q?<! $
MU&9((BG:I$N2(GU5Q:O-Y$Q"<;JHY#Q FZEENNYH+X4D'&5SW]7L:6DT-#]U
M?).X'O)]F?O8Y3 ^+F.+]T<7QDO[78GN?9CLQV8[,=F.S'9CLQV8[,=F.S'9
MCLQV8[,=F.S'9_@GDSVN5+;%4B6+(BDJ,OBS_P!,QGVMEP\62\<-Q+P$*EM!
ME5#EJVUS8;D"UCNP)#N1?<Y<5F0KJ-ED2&"*G@+$VMF!RI=?+D0I3:Y^;D17
M38>#BB+W7 7V8D&21! ;%^?9N 6DQKH#129(M%D63\@0Y3?!?..#A[=EXP@Q
M(B,Q*NKC>::51;4*ZHA(NKE,---\57-4 5)=1=NN:]HC-DJQ*V/FU AIV(C#
M&:IKT\%<+4X7A7V)%\6H6*R/(C,JF:=19VD.5"A16U1.*HCAO'_JVE\:82#:
M]7WN0]S(3C;4E#8,7!T\UI]I4+3DN8KP7QX=8H:XJ<!%SGW,A[JKUQC(D<%R
MUY,9N&PK?E#&:CB2>5JPK5<'TDMAS[[;RI5,.)FF;LI$SE\<ER9S$OLTP)A,
MAI&$LTKTKHJ1<D7/E\P02?H_[;/+ GD+4EH4&?$SS<BN]B/#V*[!?7R3^"7=
M+CI4LT]U?VO1/ZF\R:MYS:\"\!0(YHO9VH\J?:?9>QS:F<['$BU.QER=B/KE
MI\]&<U-$6GAJRUIX%3#\&VK$CRV(Z/2#;13A&TK[;*FTZOG(I:WQ1&W->?V:
MKPQI@EUL#+,:^8JNMM9^&$[P?A%Q_P!&2(J^4BXY[7-%OFHRY&DCY^,Z0F8C
MS1%&931HV6DQTKP[PCPS]M,MC\FHAO3PS3-%ECI9K 5%X*CMF^R*^\N&W2S4
MW4UD1+FJJJ\555XJJK@9$G4S"[47L<?]YO/L#]U]; LL-BVT"9" ]B?MJJ^/
MM7_$A^!8QF9D20&AUA\=8$G^42%>Q4XHO9ABQB@:0+J**:RX_A]<VS&D(JZE
M(C>C*RZ1KEK=,_%[+\ U07+>GFP(NKX<H'(UDTPGC=E>CU:;3X3AHF*GT4H.
M.P7R>.&I@WU NM:%5HC(060TH\ 7B2$N7'@I&[MJ_; /*,J>P0!XY<36/I[<
M*BIDJ<%1>"HJ>!<,5LB3%B/PK@[(4E/-1@FQY<>*P\(O/F#7.@K!11#@I"\6
M6>66.BK<[R4V&E A$*01-,TR.>J$V0\.UI'<$$R3T\%2S&MAIR(B<<QYJ(NN
M4:>-Q2R\&7LLV%=(.-*87NF'80KP-IT%[CK+H\# LQ)."X:@RU;@VRY#T9%D
MS)7[*N<<7,L_YDEYB?!UIFJ(0$BHOB]R<D2GFH[#0J;KSQBVTV \2,S-4$!%
M.U5[,/4VUW#:AEJ;E6R9MNR![%:A(J(;+2^%S@:_!R3B7L0JYHA YDEJ/S#\
MAI'#1#><_P!6R&9%[R8)8Y+5;4J31Y$1O2Y+Y:\IJ7.T=^;93#7@A$J-ZM(:
M03",LUSQM!W0)UX!,D3L4A$21%_77 JK0Q8S2JK<<"U]\N"N/.:0YKF7!."(
MB=G:N;[SSHQXD1KGRI!)J1MO4("( F2NOO.&@-A\(E\"9JF=7*60XODP9;!0
M+$_%RF3-V-),OL&7G'/>PH&) 8KD0DBB0JG:BHO%%3VE72M(74W,H;.2*(6K
MT?#)V+7A[Z29BO$J?ZD%Q%>M&\E%L5;A$G9^ZD_R/K^+&2<$3L3_ !*G,,,\
MRRB(EA5Z4S<6;%$\HXH($9]:P9LH/!-;@DOD^R#S)FTZT8N-.MDH.-N J$!@
M8JA 8$F:*G%%PPWNJ 49V6\U%BRW4Y7TACDV_P VS;AJ(DVL9QH =='S3YN=
MWO">.H9,FB[0(545'Q:23BF Z*:U.F],@7+K*\P"FM&0"XXZG<.8<?2CV6??
M',EUJ67MLTX*F&X]IJMX8]WFD>FR:')43*26H90CGV.HI+EDABF&VXM@T,D^
M'1RLHDU"7L!&7"TOEE_,DZ*>/' D]L;K[S;+;8ZS-PQ 0%%1-1$2HB)FN'&:
MLO3DU,T1(A(D(2\9SLB;,?Z)'/UL?[1DZ(B%J:KHNIJ$VJ9Z2(%(B?<'4O>-
M25,^&2</:5C\L^5&ZD6I#O\ ,LR$*.X^OO,@[J_6Q-JBR8FM.H.1J@CU,=SN
MMF2\-+O$4+@.:HO9@FW )MP"43 T42$DX*A(O%%3V'*J0:M=8]%<CNY^;&;&
M(^G!]/YA_FD"K\!20O!@!5D$TAD2Y(B@0^5FO@5%3":VDMXJ=U#U\NR8%$[O
M)G:7%<$/L'D='+@FGMP2UYK*TZE*&0<JS9$<U77$S+G" IFILDX*)VY>PTQJ
M1L252==7-198;%7)#Y9<=++($2^\F)6Y)36IQP@;KVC05&! C@,>$P.2()/A
M&;'6YX3S7PKG_B639=A(J8F7=57/R*2U,ICQ0V%<;K9[IKU;3S; ?@T=]U>8
MTND6^_RT\C"229"HJ]6DK6X5R)%51RUC%:Y9S+)T4+B$=IU4\.28;6IK5M['
MAG=7C .-,GX3K:1%=A,9> Y!27/A#RUPEEN6X<LKK/F>CV"698F?@ZDC<T1
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MO/ZV2G_X1M]UF4[KS^YS+C)ZKAI_1=8:+P4$P4"&TQ15#O!Z%7H:.3 S1?\
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MBN3L9-!,2)&<HMO5<GT@K,DS%'%<D$K9*FE#4D'#%_+89CR;#U:5JOM1^:C
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ML-.0B;.00/YA&#SCFIU-.:%GB;%*H*0,]J&S(>FV=O/G(S7*)0&HME-GR+&
MW#(45M&'6T!4X8<>;KYH2W9OI$K(=P;C2WZWIRBD^-QZ6]*-D['+2YI=1'/A
M9Y88JZJ,D6#'YJM,\QUY=3[IR'G''I#CK[SKS[I$1F1$1+FJ^TW-_P PV?\
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M[4+.=ZZ=!F*K-I))PY*VDCF%+R<D:U-"-.]GEA9KM;RT$X#[[7I2U9K)+E4
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MAL;\G/5>Z=D=C;3+=V+8E=4*R&B.8](.#(,N\[&%1%HNP!SP\R[N*?;!+W9
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M\4B\20R7\0>.^4L\*04L(]S( E)[/.8UM3X),[\+]AI80T2,@L.Q4:F;OU)
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M6>6$KU91&SO6Q%<U;<#>H4"E-;*OIBH"E$!*"8)=C+E;>Y\9      H P &
M#^$&TL%^E5Q;C163IB5E =X%LD\11]M#;V^U.XP<(C[%P"<7YP#Y+X<"=QD.
M":Z5+:R/N"'GGB;9M\';-LVS?X=S#,K;_75G9-X8V\4HIF<$Z:P$( \F5>5A
M$&7(NQDL:+P8AI#:X0&J;D2<B<BNUYNO'*GN5M=F><L4;S7+@6A:@!S:$""
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MG)8J5(UZP !QF7Z1*1U YC#B.!ZR KB&TMJB0P!2WWI-BO U13)YHC=J*_,
MJLB(JM:NKQ  :"O%!!T6[I*Z<Z(EANXDFX+T-L+18HS?X6^?*67H*H0=@;"U
M<^"\^['!PN)3=U8YQ.*+L:^7]B 9>X4OCO<^J"6=#:5Z=G(UH2'+U4NJ$5:6
M"[SV42K(H5 P*1GM2UL-JX1D!F]9YTP70*S>SC#UPM"L!*+FTHP?_K5NV.EE
MC&Q'>PTC#5I-L 05PNER%"& ,Q6-#IM5F.7SS[O;DT.+6CD(^IE I2*...7Q
M>L\&Q>>NT:ZPU'!0F@,!XO5:VNHZ4ASA+U,8RUV"QC"6#.Z6_D%@![]@4<5
M-JX*FM:(C)2]N?%9<>+TV1/<<!(XJ->H[$S.U5!B-Q,G)2L]5 _Q/]73NUQP
M1(1,CF40&J$%!C(,;^#7-[&J$C;Z.@/\]G"'Q#.1FAEW!5@8ZX"(6$%BW7JL
MP+?X>)])3#3]#LW8S3.:SM[JNFL,W+T5\1:R4-E8>]:7_?X-P<R7BWP-._NR
MK..5XVZCC(NBL]FYG'#?P58X 56:]4FF;Y0=/G.O802G4*3M(LBX1B$$SZDX
M82&U?=E9PV8*EK%CJ0O1_B:0JE^UR[-L:N%5Y[#C.@##1#D0KK0E45>8/0
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MFB+^VZK",3)TB2NQS@Y2^] ?JE%C72(R@&7H77$H2[K+LP#> ^1_3VBPT%I
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MJ"*..*..**/^;!>\@Z_ROG.Z:80\#V>AQ?KGZ#['ZK&_S8\&_KIM_%[BP_\
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MZ;K8@Q?\>[@O<[WG5=[U*@%P%1(- 4!Z'CCDHI,JV')Y)A(NUJW<H/0Q'9/
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MV4^Q_6X5_P ?SOK_ .]"OB4<&"WC?1NZ;]QS_!?\IZY9Z[K&#+>\?R_.^O\
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M&N0IIU31^DK/ N51RRPNIR;_  6.ES(O&04JEP +T?H\ O!N5@IL>?Z/]0$
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M_9^C_P"S]'_V4@Y[E:\?HLCCZ000002YLNO]/0^\MK?T'8\!1:BZ@^C_ "8
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M,IEI: BM,]8OU/QH_K2+(B>JSZ/^:]O^TPTP+F=R=Z=R*\Q7S+/M_P"#^/\
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M.HKZ@_%*O_B7_]H # ,!  (1 Q$  ! #J        #[
M              "O-MMMMMMMM+  24* 2      "8
M           -@         &D"@<60C1NH_\   #G.          $]:#=0
M      #DHL           " ( $.IMQ8-H!  Y0W5ZL     F[S9  @[X
M!EJA;;X            \0 !I)Q($H;%@ W272\WW QZ03;;;H  %MXB3[?=$
M#K; V'SVTWZH    LX  !DD@ /+8  I2>^P')T4<S;;;;3H   )3\%;ZG #;
MX D72SNWH    $X !<(M9EX2F  A2@6UO@!=#;;;;?BH    B*$SY!$/;X
M2+CK208SX $X    !   H   A0DI:OY;^;;;;;;KC    $P KS9<P;X %W\%
MN_?XBH $X  !/#_KX    A3) _-4E;;;;;;:K      V!RRD\\;X !$IO
M    $X #$( % %    A#V83_ $T&VVVVVVO$0     78NG[9>^  <"8
M  !.!@)0[O-N0   (;O]8_5TVVVVVVV]$      #*&A"UP^'!/#U2C*P:  !
M.  L8!;Z!2 )0(9<L"X'VVVVVVVVZ     N  1%GS H.-AX'014G.^  !.
M6BL"XA!4K (8#?+ZFVVVVVVWMR%0   )&(+;_%7BN !F:;[<QR:6 !.   +0
M!  !*  )J9&Z>2VVVVVW?-HT*  !Y%.+PGW1$V !56M-R(OS\ !. !;H<YZ5
MT\  .UK-VM3S==:VW<   +R !'2* G6^IP. !   !      !.   #2  "
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M0    ,I BP"0          !J C0         M0  <FTVVVVW@       (@
M  #_ !<  #<         6<  6222222220&@  !XCMMNKM]
M"$E   3%))))))))+FP   2222222220    #I-M[K9@       3C@   9<P
M    0222222222                    -)L@2$9       *-I   9W
M                               !UN^OO2#     (25YTD =@
M                             )O!*223&,  =V2& (=_X
M                          ([.R2222%&LB222!%\)D
M                       #_&22222$DDR2229R2<
M                     *2222224E+6222223Z
M                  /222222"9AF22222<T
M               "J22222"11F22221$@
M             9R2220+_P#LTDDDEE@
M           #;$DAQB/DEDDDD_4
M         YA,DN[>^?5LDQ,@
M      #G>55?J8 SL$V-
M   "J IHDDDDEZK"4
M _\ ])--8@T>9^^                                            "
MVVVP(3O+VVV@                                     .__ /\ _P#_
M /PDDDDDDDDDDK__ /\ _P#_ /T                             &@
M                      ''                             !#"BS;W
M5A]]9G(80J*Y\?E1]B9 '                             # %K++'=R_
MY_KX /SI_P T*F>K60 (                             P@^T\V[UP
M  (/9U>);/EV0   (                             P!VDGX]'P
M+Y)O-,;E\    (                             P0S\R1:YN0    $NA
M&         (                             P!Z:=7;K(     "?2@!2
M*      (                             Q0M$,/:C@    *,;J_1*#6
M    8                             "
M"P                            !'DDDDDDDDDDDDDDDDDDDDDDDDDH
M                                                      (
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MG;@K"8F5<#0HQ=6W-M]9OO\ <7/T^0PAP#'(TNB.EGRWJT3U&FE[K)%U ;(
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M@(G:4LQ4AX(F0 *"@"U5<$8OU#D(J(P!TS;\)\8>/%9AL,88(L4L0NT#H,T
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MBK-@26&,P%:TP@"BCBZB@"Z*      \07L:#/&]=9XG+YT"J,4(/EH8P^AX
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M/-U"B"S$I[* 03UM3@XO=K#KW0U%$^)%0V6E30!"]7N=QEIS$V0 ^I6^Q#^
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M06VB"L^8EVF6GT&(.H%Z($27-YK.E<=J72 X!@X "V!RJ%%$D%E%MBL[( L
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M !UT*U. TCCR.)'GA !)<X^"S&1SJ65-M2C#[3'2I%S%G91E!F&2]]&!QNQ
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MN_&S8   &#WPB.;OPI^[$C46(TB:1,B<(V<04(#<#&1;Y0);JD!.]T;K1X-
M.Z*0.GK ZH .N4M;G(ROO$H-:: E/[( H1(5JIO*-I=R5=:5%$'OX7!X.:62
MTF3V)U9?AY)T]H-2W?/C;OG^*8F68E:?D0+4L51;\/65Q**^$ NH9#O*-SK\
M)S\YQY[2IB<=XUKO->ON/K(_I(00000> A"!+PC,(W*X%2"9/"MS&D H H -
M ?P*!;?3'Q8E>2R\U!*LAH=<EK$P_$4JP GU?+ -!Z (J!97OB,R%(L-?6!6
M4D+10#AM3D@!:.Q; -AXW8O!I?9A[2O#R3IX$2 "U=!U9:'&FK*-(C2(T[$\
M&4SOQX5BY4J4RI3XTZYE<>_,3,\2VJG;B7X6^+?,X[3<OCCP?<?61_2000>
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M#5-*)6;WO%_@#*V6UD*:(I4\'D7$&!6]);="6$S3: L(9$:*\3S$6V3=)4Z
MS7'HDH?"YI\[P:7V)7?G<>RK^48F+2U3\.:FV[@SGP:Q?2%8[SB +4*:[S@E
M8F)6>TQ.8_Y*\]IQ*+COVOJ8S\B#Q!!X!X$@/J6 ]\&GL\.K5(;0 #: .4$M
M$M<F!KI@VZ'!:V-5.^KEK#52SDJY:RU<%T!W?B8^@^[&8!]%=(/95QSDG)_
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M8(GY*<08HB[:I:@DX!90[2/+4\%:3KU$G-:@*8 6C;+L8)@F*FU+4%#]!%8
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M&;(2@6\0#/6N$6J:B+0S[8,R*IL%5[%;G$RTMD,0<4#3 HQ Z4\H6_!<'0K
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M"4"G(+I+%+#7A@%7G6?PJ $%%B:27XFD3*J%K.<A6ZLNCI7*59C00/%+3'$
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MJCR2CH#(@3#9'&F"@2C(D$))N@Z*<*\A9%"%F2:=5/+$8B1&Q<H^>Q. 64
MJ<8(U!E7:7$,RY V1^Q'6EC!ZK1G0;7!F.@6QR/47R(R:DBZY1U?5&WH<
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M_P#(!BPW'CT_UE9UGST^7?'6 NC(WY\O^0!KO;\K^DHQZ3M<DH:.?/\ W/\
MI[%M[(TK=+KOL56<K*S6N+]@AUG5#P-3F7 Z@4?I,.0Z8?E=34,>26WUFF%W
M9Y':?4*?N@WZP^XS]<)?OC7?R="99)5K;T&Z>Q:Z"*(Y#M*D:'+LA# 9?A6Z
MK-##8"APEI+]OR;K&_MA!*=2U33BL=@"S1= ,)+MK.%LO(4P+MFB+) F0;%
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M (=> *YL+*NPEQ"D!#>@TJU[' : !0 ![RG5\X" 0<*YH*P.8TL/(!I6"NS
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MEH!:Y6K6W;'MBGP B%F&'&C7\S<^N9PD+)=K.C>5(HI1*X)I7*06;HR.A"8
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MBZ_YU[_N:>C_ %]N$?.AUG5#P.LV^!.\;%R-.Q:W>R$K,+Q&)O;(I**G1+?
MRG&)57 TO?3Z)TU@D*;7!TU$VF=XJD"(TM"*E0*+; M4 R[U 460.$CGKB$!
MMB1X5*97;-MP5$R5*HPFDPZ30LZ!H-L7U(FDP2A:+6WQ$0"IH#F/;@X:G"S)
M>[A,"@4K@8#    :  BGW IJ%4:C<)NYRFK+LK0 O;8"6LUH5--LY['(SYU
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MBWW1(207ITG*EX*L9M8[_@H/80YV/B]Z.-'NP29-ERY-8KT2]KQ7>WC0<E5
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M:NUK:"[FF<0T5JMYS80M;D;?Z,TFRTT-)2L(/N#.,HT"T]@%87H6&R] 5!-
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M8L. JT9#9*QFIJ,&5MJM1SU8?NG*O$'+0  JD %6B62T/8\EH%<XKB \9U:
M180$++HH;4K,-HQ3@L"V4!:T%-$$L 4(<A G14[2N^M!?1N+@Q)0@DQ82!XH
M%P *QHP+-5O/)6-X2=*M*"6<T:,2@ Y$+$>$:?8(T:3O%-CB@ WDP4V6$E#^
MOV'EG2")U;:N57:O7^E5BCQW6H%U51=#>(B00-(\> "2(*"Q"D1!$;')*RU
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MGA@&Q_J!>WE6)$.'%)A+]\=!S2@AXHF*I$46->*]>YTW5!22E@AJX,LS4@#
MS[YLA=#CM<(UV*)\$8M8T@HM1CE%/*JY?>I5!U@Y730-1M/$(P#CT(&U5T6G
M,T#_ %!!*9>UK!OY$Y&0PM%>_!(?;#XI73"K%<Q@YADA5.!JPM4%4-:!^1%!
M$FC;"-K?G71]ZO3^1)=0%J$ "UE>4=*(@;H(L %*4/ZB,4[  @!$11$1,(D$
MK#D-[<M9@')>A[XD5PB$4!L\BTU,+%"PL85!6N*Y;M5GG71]XO1-MY<  J$
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MLCK^8%1O-0#7=_S_ +[CSWI_0&NVJXEIKF7%TSJY@[:EKJ-N66-\RTO+X?\
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CDR9,F3)DR;WR9,F3)DR9,F3)DR9-SOO-;DQ#MH)P#_XE_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tm2110724d7-tbl_predictor4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2110724d7-tbl_predictor4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!R .4 P$1  (1 0,1 ?_$ 0$  0 " @,! 0$!
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MM.S_ '1\T^UG>4'O'?//> S9'QZN+#]:S\!FMON=IV?[H^:?:SO*#WCOGGO
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M/>.^>>\!FR/CU<6'ZUGX#-;?<[3L_P!T?-/M9WE![QWSSW@,V1\>KBP_6L_
M9K;[G:=G^Z/FGVL[R@]X[YY[P&;(^/5Q8?K6?@,UM]SM.S_='S3[6=Y0>\=\
M\]X#-D?'JXL/UK/P&:V^YVG9_NCYI]K.\H/>.^>>\!FR6/TXXUO$UE7;O5:+
MW[LMV\Q9(V/@YA/1#[FM?TOMEIO"3FNWG&E=IHT5)RPG=HHZB,#TY0P 9!Y_
M/"$PSMCE;6WUN/NO9+GM=JL]EHVB59IKVK63E@YK'*U8+,5%@J(L%14RH<JP
MW]>TZVR9,R;&6^:Q%2BS"BN1%3 V.+(-Q^-;Q-8JV[VIB]A;+=@L6-]CYQ83
M+0^YK7]4[&:;/DYT-YN)7::S%2BL*/9R.G @].;,#F1N9SQ1,\[Y977+N/NO
M:[GLEJM%EI6B;9I3W+63DBYS&JY8),1$BJJL$1$R(+=?U[2;;.DRYL);)KT1
M*+,"(Y41,+8XLI7#X]7%A^M9^ S6WW.ULNS_ '1\T^UG>4.+[QWSSW@,V1\>
MKBP_6L_ 9K;[G:=G^Z/FGVL[R@]X[YY[P&;(^/5Q8?K6?@,UM]SM.S_='S3[
M6=Y0>\=\\]X#-D?'JXL/UK/P&:V^YVG9_NCYI]K.\H/>.^>>\!FR/CU<6'ZU
MGX#-;?<[3L_W1\T^UG>4'O'?//> S9'QZN+#]:S\!FMON=IV?[H^:?:SO*#W
MCOGGO 9LCX]7%A^M9^ S6WW.T[/]T?-/M9WE![QWSSW@,V1\>KBP_6L_ 9K;
M[G:=G^Z/FGVL[R@]X[YY[P&;(^/5Q8?K6?@,UM]SM.S_ '1\T^UG>4'O'?//
M> S9'QZN+#]:S\!FMON=IV?[H^:?:SO*#WCOGGO 9LCX]7%A^M9^ S6WW.T[
M/]T?-/M9WE![QWSSW@,V1\>KBP_6L_ 9K;[G:=G^Z/FGVL[R@]X[YY[P&;(^
M/5Q8?K6?@,UM]SM.S_='S3[6=Y0>\=\\]X#-D?'JXL/UK/P&:V^YVG9_NCYI
M]K.\H/>.^>>\!FR;'N(SQ;^(3 _XB/=1L#Z*]\W#@U@GJ2?^RF$5STDEB1/3
MCTQ=?_Q)&RQV/VQV.6_6)#JJ:7Z/\X+A<[+G=:W:W/W=O#UATNSTZB\Y\IGY
M2:E&6RC1;W+TC"*X5BY>%5-I>E]7G9^CU,V%999;W=RQ8N=&*X6K",,28/D-
M</QZN+#]:S\!FMON=KLO9_NCYI]K.\H:OWCOGGO 9LCX]7%A^M9^ S6WW.T[
M/]T?-/M9WE![QWSSW@,V1\>KBP_6L_ 9K;[G:=G^Z/FGVL[R@]X[YY[P&;(^
M/5Q8?K6?@,UM]SM.S_='S3[6=Y0>\=\\]X#-D?'JXL/UK/P&:V^YVG9_NCYI
M]K.\H/>.^>>\!FR/CU<6'ZUGX#-;?<[3L_W1\T^UG>4'O'?//> S9'QZN+#]
M:S\!FMON=IV?[H^:?:SO*#WCOGGO 9LCX]7%A^M9^ S6WW.T[/\ ='S3[6=Y
M0>\=\\]X#-D?'JXL/UK/P&:V^YVG9_NCYI]K.\H/>.^>>\!FR/CU<6'ZUGX#
M-;?<[3L_W1\T^UG>4'O'?//> S9'QZN+#]:S\!FMON=IV?[H^:?:SO*#WCOG
MGO 9LCX]7%A^M9^ S6WW.T[/]T?-/M9WE![QWSSW@,V1\>KBP_6L_ 9K;[G:
M=G^Z/FGVL[R@]X[YY[P&;(^/5Q8?K6?@,UM]SM.S_='S3[6=Y0>\=\\]X#-D
M?'JXL/UK/P&:V^YVG9_NCYI]K.\H/>.^>>\!FR/CU<6'ZUGX#-;?<[3L_P!T
M?-/M9WE![QWSSW@,V1\>KBP_6L_ 9K;[G:=G^Z/FGVL[R@]X[YY[P&;(^/5Q
M8?K6?@,UM]SM.S_='S3[6=Y0>\=\\]X#-D?'JXL/UK/P&:V^YVG9_NCYI]K.
M\H/>.^>>\!FR/CU<6'ZUGX#-;?<[3L_W1\T^UG>4'O'?//> S9'QZN+#]:S\
M!FMON=IV?[H^:?:SO*#WCOGGO 9LCX]7%A^M9^ S6WW.T[/]T?-/M9WE![QW
MSSW@,V1\>KBP_6L_ 9K;[G:=G^Z/FGVL[R@]X[YY[P&;(^/5Q8?K6?@,UM]S
MM.S_ '1\T^UG>4'O'?//> S9'QZN+#]:S\!FMON=IV?[H^:?:SO*#WCOGGO
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MXZO^*:_^ONJ_]4#R_P#G0&O,_51_5UK_ #S?Y)T?>_\ \S)_ 7_">6*O*YU
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M2O\ TE5TW<[^U?[YM/XAN[Z_1/U*5^,:@*[D:04 H!0"@% * 4 H!0"@% *
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M_P"S!_W0.E?^DJNF[G?VK_?-I_$-W?7Z)^I2OQC4!7<C2"@% * 4 H!0"@%
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M:YO]1;DJM6;)>2]59!TDV/VW;2RX&*TS4SM14UA<OHG)3 <C9(+Y1N.8,FH
M"#DSY0PFA*6&=@@^CL'<QGSIN]%Y6=KK).D25O:7;I-G<B/=5N2>VDQ[7*D6
MQ3 J*CJ.-<A@9=-EF*DYDQZ6-UG?,151*25:P<BI&"_(J0C_ !F6(/"F@5XN
M9O28U92ET75Y6TT;^UXR4O6AUJSMFHN*2S\2D(V#7'8ZV[#25@*X2.1W-9.'
M<  2N/5[ "#B!9Y89F]MX2)3K+.E2?6J6U;/%*QTJ",28KX-:Z8N!8442,<,
M42)=MS6>8])K'OZ(LA)F&BC\+J-&*JC4PX8JOR0.3''">UW>TVRY'Z'L0<E+
M%$8T+O\ AV'8^D?7)!G-])<IE581XH:BXW$^U:'!GM!ZDCY$%9+2U U91%,%
MQL!R0(X%Q8M.]UY2+#)M#[,DJE,F,F3'LG+*8LN%%4:C$F49J+%KG(D(*D'*
MBP2KFLTRT/EMFTX-:K6M<Q'K2QI%7*V+(05$58X,*10UG":O9EMW;ZGGTR:2
M!7":[1N*4SBTN>F[!NY+-@@U'"+D=SJ2:;<@[>RQ-A@ *XI',/*PV)BY>_/K
MM"7K&XO6[5D*M13_ )R$J,,58K46C'!%6QX(1-5T3_\ H=#5)B)64>][N$=%
M%QPPXX?+ VM'^#K"BS,>GK6;LFS PV+LBL;3-9XD) 'A!^2''2SKE$RC)9<_
MUN%'@[&6-@X\BE@#B.:& 5DJV%\1,<LQ,>9U)N^=N98K;-FRI,R?9FR'-5E:
MQCTG3$9"$UK7=SC1R1:[@Q&X6X[.Z?(8U[VRYJS$6E05S58VE]153#PIC0B!
MK<-#7.6!M1Y*B^9)C3-=ILC?;21)54I"9;."E9HI.F19-,2&<::"V%U2;9ST
M]S62P:04&.&!4['/+,P*:OAT>7,F[SWE9$MEEM4B2MY2)MG9+1CG5;EM,:".
M5R(Y*$%I*B)'@1,9A9=5EG5,V3,>EEF,F.=21*257?01%AAC@PX.&)'V^K*U
MU0-$.&LZ]<R#B$;3V<N\>9UR2*T&>VY<5,$*1(E)IR)(*JS3*@FNG)JYFC(2
M::Q'Z*Q,>U\ 2V68H./(W?GWE,O^\Y-Y*VMEMLO<L<YTM(LF*JL1T%;2P*J0
MQIC7 IBO&796W=97V5%H.6;A<B(Y8.;@=#'#@^3(:@J[D:04!^LU_0'_ /:#
M^1E>HGZ?_P!M^,>9?T;_ "/\1Y O^*:_^ONJ_P#5 \O_ )T!KS)U4?U=:_SS
M?Y)TG>__ ,S)_ 7_  GEBKRN=0% * 4!Z\I!'@2*R\8IL]+/#U0M3E7A\QRK
M/*&#T9L$7<1SR0Y]=\3#?<##,-Z.O3HFYE:21$\\65#"QB &$&.+>X8W1B8^
M';.EX6M9KKO;>+KW2\7HV:CW]&:QL["CXOHT49%%:C8XDQ10[K-Z-)1B6A;,
MEC6S-56T4K5<K,"I!L8JZ"QB:RD;AD:^NB1=%=>$";)7M/VW4,PSLDZ#*FRF
M:5B6,H=>$*O*4Y!3B2T*YB[C<\D)9AD&,4DOD5)I8I0T#8<W8?$3&W:'[TWC
M*LUOO*9(D^K['/F26P<ZL?,;-;+8JI1@UBTDI+%7118)"!JFW39GS;/96S']
M)GRVO7 E%K58KEPQBKL&# B8<*F3&>%QK,H.0B_D&=WT2@)GZ^[!3[.;&,.#
M7N1-DV2DP <9::$E)5H?D-XQJ->7SLA)]D,P9%P#(=7-V.<O1X998DWKO1LI
M;/,L\M;P?:9,J4Z$YDERSJ2Q6L8U_P"31BTD3'%M'&66Z+(KZQLQW1FRGO>D
M6.>E"&*BY6]U22$<6&)8[*"(*7FWJ'C P) NSE;AD;UR3Z3R9#,<*#[<X[77
M'P="+OA,"%5449[('19I11P@&!#!?$K@:*6 MEB"'K>GV^7,MGK"*SDO2RLH
MLF/1C:2,3N5P+17OE8J06,%CC7E=&L[F2.C0H+9)SHN:V*P5<?!%,2+_  H:
MYI7U T]@B*FTWY:G69D#:IPZVQELR53TN.$AP0B=+R?@FK2+!Y0\E'#+M)2%
MBUE3 3)>.9@-JQO#(+(2W.#MEV2R7S?-X6MTRQV>0ZZ6VE\B*O5)O<119L%[
ME64D[Q(OAA-7.L5AL\E&SIDQ+8LILSO45G=849EI0X5[F)=K:?0?1PE,$Q/-
M$5YFBW6S5'4_6R19<;[/9[/4'TZ';-J<QD"*4AB&59WK(0RJ]C3@$4'.KK5Q
M DP_;,$' <KE@9#T=U;P7\ZQR9#TD3;TM=KG,EJYSD8ULI7+,5\&I@;"#&M[
MY,*P7 ;"V7==Z3WS&K,99),ECG(B)%5?!&HF%<*QBY5Q+E3"0X'PRM7TTD_9
MN<TYS9AJNFZGQ#M^R#Z''S-,S6=:L@RL:C%;C%P-M1<R>UPWLEJZ6,5+J@1L
M)'%$,!&;=( &*'?FKO1>KG2[#*D2/6RVN99W(KW52.9+IH]'(U7451456PI8
M%3'!3!ZILB(ZT.F3.AI);-2#4IP<ZBK52,(Q3'&'":2'#B@X+ZY@U1E4PV,%
MA3Q;@ZZ"5+K8Z#B='LCC+(!$08D JB)]@\C& .>86(U\K87OC:UZ[S+K*MM;
M!)M%*4,48881PPCBB:!U&DM"-"."..'!'Y3IZN5% * V_P#"(_VGW^Z!W4_T
M:UTW?'^RO[YLWXYN[E_2_P!2F_BFH"NY&D-O'!I;20Y)UV0$42$2#JC7T7V4
M>+,6IS0&TXHN9+Z;J<VC;6?;O*.U%<"(40VJHWL9.F12@^()+$;EPSPOEAET
M[?6:^58+,C5G4'V^2UR2E<DQS%5U)C:*HJJY,")%,,#=W$QK[1-BC(I9WJBO
M1%:BI""K%%2"<.#$7/?<(:X[KOG4F!GA,&LY;8E+CW;%\;%S/HS&[?QC@!CL
MQJ8OZ($]>(-UNL%H/1X)Q=!40C%DPN7'!*97!%SOG< 7+26>WWE<<BV7A)DV
MI;M699VR95J>M.DYU"8J*Y7N:U8MA2545<*<*'.F6>RV^9)LSWR>E(V8KW2F
MI1@B1;&"(BK@7%P?P$*P?PV-/IF8A.:>^N;6;#$P3(J1#!JV]3>M#+7V$1:;
M9:.3QD^?"3REA (K"&0>SF%!P1V>*>40T@IUK,6X@P0%^=;]Y[YL5H6PU$A]
MMDR4F34;7N1ZN<ZBR4K9:JBJUL:4R"4EA""*I@L]U6&?+Z163&R'S*+%6K14
M@B1<^+DBD5Q-BL$C\A@T?\+=@/!N1M+(TS*8\$M]G;<*&W#Z:Y9 <%HD>&IP
MW0&49G'BP^2$XR4N8N)N&6STPV(IPJJWRQYXEL \L]HWKM$F9-LB2$Z>Y]G2
MSL=%*QMHX7)C:LN#T?@P*TQRKHE/:R=6+T=&S*Q4@M%9? G M*+:.5%.UC#A
M?QC(NG3GF<TM3^R951-4Y2VK3#KV3(<;$6NA(C8HIKMV:SF*IOC&>WFF++?3
MK9 O(BE^CW2CX7RMC>]@LJ6K>JU6:^F6%&V>99'6N7(5&K,=,:KX)2<]&U35
M15PRU=3P?PDR;HDS;"L]5FMG))=,PT4:J-PP1(TUBGUD2B6HECA\0Q,+L$EI
MYB*; B>(=,]  %%G0GG!L?N]]23-<8FC(R]DMS"ZF!&R<$1";9H\J#'#&2@K
M#C!X <X2PN>&JLF\5ML4GH<B$RUSK;:X.FUKVM9*?BA+:]ZQI(C41(-1,."!
MS)UV2)[ZZ9%LEDB3@9015<]N.+E:W@BL<*E5_APZI1N!L&\)AV+D![QE#FT<
M1P.TEO71*C=VC24A3.P\WPWE?!:4'0;:J LM\@9P[6L&84@03)$R2QPN-EB(
M%MO>6]K2MGDV*S2Y=JG669-<DY7MH+*?15((VDJ*O>X&JJ*CL6!>'ZKL<JM?
M/FN=)9.:Q%8C5I(Y(HL8P14X<>)4/Z<G#7UIUW5)Z7]KYLF M%+%W.OIA'"U
M#3';BNYS:_BR24DJDE/])7#IC(%L-5G+Z;<RG) )M2/FQ1<"G+S+<Z)6\]Z7
MBRSR[HD25M<RQ=)>DQRHV%)6(QBHG?.<CH.=!J)"(?=5DLJS'6R8^I;/JFJU
M$58PI4G1X$14P)%5X#L->^%UKM(T4-B2Y!V0<"6V9REN:HX@B3$D:&V Q6^T
M8E5B3=)2[,#:FV1F2_3J8Z%E4 S$0FZ :44HEC<0P-T@H 6=;QWKO*S6MUEL
M]F:LV1)E/FL6L>Y73$55ERW2F.8BM1%[MZHURX$3 JDV6Z++-DI-FS51DQ[V
ML<E%$1&X*3D>Y%PKP-PHF/@*GZ*1,*XG?NZW#BBT<S,9Z';@NL<V;:K8DE)4
M#+!;1;I+-8XLX#%410."87NGN)/O8Z1M>PQ;*U\N6MO?]L25)L$UJ/A-O"SM
MP.<Q4IN^LB8T3A8N!<2G#NZ33?:&JK8LLTU<2.3 G!'%\CDPIP%J7KPS];$5
MAR>@MR9IF4=A(]T!9&_PQ-59K.)Q"&T55+9!ERQR,J%U@9WJ+JR,/((4B;#+
M%R01?+' 7I1<<ZU,C>B\WVB5,FR)"7=,O!UDBCG+,I(KJ+X0HHWN<*158XH(
M<R9=5E;+>ULR8MJ;9DG8DHPP1;&,8X<' :.Z[V=?-O\ PB/]I]_N@=U/]&M=
M-WQ_LK^^;-^.;NY?TO\ 4IOXIJ KN1I"UVAZ,D.+>+3-ON!*35U!7=K==T9;
M1%DB54TA92%.7F>24DI533H0Y)035 D/F". -AF$,%GEAGC?&][5J+_>^7<5
MMF2U5LQMDG*BHL%14EN5%14PHJ+B4YEW-:Z\)#7(BM6<Q%1<2I20VY.EZ(FU
M1_BQ0;*4*:^(B!JM'4ZRS!$HQY!\>Q6]H[<,.SBWF>VV/FZF"AMJR^E2(WE?
M,D:+*F1H0SF3Q$"QR%PYV/3Y,B9=+;HM]DGVETRUS)4N;+?-?,:])DI7.=1>
MKH*Q4BBMA",%P&[?,;;%MMGG2Y2-DM>YCFL:U6JUZ(B11$C2188<AG"SPT8I
MGW8F2&ZXY&%69":45:BF&G <($X"@R0WNA2%"*"ON)[MQ)D)7;['<^3,SQ!+
MFRA._:2N=,6&-&"N8P>0V!F\]KN^[94R5+HV9\ZT4ILVMFL:K)JHC55B*YM+
M"J*O<M1((BPP7==4FTVI[7.C-:R7!C*#'*CF(JJB.5$6'"B857&J%*6SH9K5
M&3/>,B;E2-L9%[4/[<O74F,DQK1:V,G\W33(24];699F=I&U]QYED%,*+Y'
M5 0!U!5,"XCW*#& K@9B;R;O!>=JG,LURRK--FI8VVAZNF.H+25427+=!N%8
M+W;T1J8(HBQ0X#+NLDICIMO=-8Q9RRVP:D4@D5<Y(K@PI@;%<D3FQ#H1J:.Q
MM:%J<YZF0-6W@F238MUF6X?C9#/--);C!DTI#B=*4JI;T5DUSY$7.^#N.>*$
MG6#4BB?C<003I,L<*K;-X+W2T6IE@L\BA8)+)D])CU1RJ]BS%ERU:BMBUJ=\
M[N57$D"9%VV-9<IUHF3*5HF.;+5K4@B(ZC2=%47"O F&!ES/X2;<7!V8K+,M
MK!!@QL_]R8TWG=J<EI2@3@)PZA@J*V:--X?$7JRPFR4U0R@Z3UNX=^LCW#RR
MOC:V=\,[>^;+1[&26K:)LNS/LK5546:EH@F'(K'11T.!(EY=RM=1<YZU;'36
MS5P=PLO#@RTDQ1/HC\+B&,M:F:^W?-ZPRYCEK7!Q[.1P,X'; 2%#J<B@CNDP
MP(J=1!S2*A3(K/9_);4S"[72D;-'3U,X&7YIBX)B^$/WKMOK1]GDR&OL4FTI
M(?!LU9BKW-.8U6L66C6*[O7.I*U(X(H2VZ)'1&S)DQ6SWREF-BK$;##!JQ<C
ME588T2"*L,.$[,+AIZDFI3@[5LI/,VVV<V#U];$R,P109;!2X71W*^X+49$9
M$;*B^9<=W.JK*V\TCJ=A@BA8OU52* X"9F\1:JN\]\)9)]ZK9Y'JNSVATMT'
M/68K6348YZ)1HHB-6,%55BU5Q0)]56)9TNQI,F=+FRD<F!$:BJRDC56,5552
M&+A3A->6UFLB/K&U=8TY4<"X;F:7(/(3=*C+44\N1(1LG/M<4\HO;8>-\<%4
M-Q'64GX'U4N<QP$+"&@K8XVQR^SV.Z;T?>DVU.8UJ6*3/65+<BQ5ZL1*QV2"
M.6#53'!366RR-LC)*.5:]\NFY-&*]RF6,,*QRE.*W1P3;_\ [ S_ /;]_P#A
MA73?_P!!_P#AO_<F[_\ KG_K?^Z-1)(V.GG"A\KEA@9)&0#9?(0$$P'B.6%Q
M&!R$+F0Q2X^%A,+7O@)AEAE;[&5KVO>U=Q<U'-5JXE2!I46"Q3&>HUSP_"R*
M\GQQ<TZ+(YPUX6.'H@2\S8\#8[?-Q.D;KR(6RUH+Q=9G"D/1HR W) (GU@W;
M OGT!W]<886RPZ3#Q5*MMN?)E[GNFS?6+;Q66Y]):Q;,S\O3I1I=TQ4:F'"F
M#Y#MSY$AKW7TC&=&6S(Y&P2BDUWY.C#%@=%5^7"4D?/"YB1BZQW>CEG%21-A
M/Q54+;0()Q.R!TJ(G$2<**1>@,'MUOFY(PG<_*.;,/9BE5'%&$2%10+YE@/L
MYA99[R1O5;)]Z5$J0CKNZ6MGP-FK,1456UJK0JD923"VE2:BQ7A-?,NB1+LE
M8^8J6FI29A5E%8I&@B4J=*'#""KB)A(:.ZYP+L]+>ND<R>_7W,#$T_GJ2I.-
MRC#<9K,9I**JZV-Z4V6B,8,^L*RH;>ER3CO<=:N5)72Q,P[D[9#!9B9<-U^W
ME>%U2;RM,J7+L4RV2F,27,>CU5)RRW*Z"(B-BF!L5I8:6!3.EWV6S6M]EE/<
MZ>V0]SJ36JU$5B.1$PX\.."0X"RD@QOKM:%8TA^ T%';9,EP5YYW"7%9^:SP
M,J.UY9J""YB9)PJDFV.+T@)DG.!02C^!FQ<UF00 RA PG#"#7R#*ZNS6F\NG
M3;;>#G.<M^2K,B,GS4:V"M541D$8K$14A%(OBY'(B85Y<V59:ADBS(B)T!\U
M566R*X%PTL*TE@OR)@5/DU0;":?ZEZ\QV98#PG&7B6Y:7!\1S0,@YQTFJL#N
M14E5,0'+C$""MM\PHN])<2"UW,7$[>4K!(YPR%F%; '(0.UNW7=?-\7C:4M$
MF1)6Y5GS)4::I-:DM5;6*BP:J*YJ]PWND3#A@::TV&Q6655OF/Z<DMKH4>X6
ME!:**F%%1%QK@7Y"Y"EPH->&@P4637$L[+H8492WJ<UYK9LH)$+H#H?+7V#=
M*>WE =JQ4TY--RQ#0J:;$SL!@\KD1%(MEE<D-F*7,7 TK=[KRG6AUEEMLKEF
MR;0Z4YBS5:UTEJN2E,<Q)<R/#5QHKWR05(\Y;FLK):37+-2@^6CT<C454>L,
M#4=2;_E0CP8EADT[Z9Q<[W+OI#NL.!!IHY7?O4W7%NMYYQHR2XS8>TEO1\LC
M-.9;Z(J2VZ$*-$)3Q!MCR"@FEDO:PAX'$4/&L5WWU:I,J[[;>L7O6[[1.56O
M=W36-:Z+FJB-5ZI_ U<#5@I:T6&2]]ID62#6])EL1%:F!7*J8%PJC4_CX2 E
MGAN:KOE3E1M:\S9."LX=6]G8,UZV)&E)BLY!1W,DS'-&,#B2)#N2(LFSY#%!
M?8>6-DA:P$-#DQ<1^DQL$+A6P9O->UG9*FWC(D)+M=EFSI-6]RJU9<JMH3(I
M!8M^LW BX(84..ZZK',<]EFF3%=)G,8^DB(BTG4*38+P+P+AAA(PW T.UXAR
M%YSD"#I6EUXN;6/<A3U*E<C)C1:;>0%]0N6>IDDX6!FW%A54@P44XSA"!KM#
MF]?RY306!;"^)>N7<U_WE;;=(L]ODR62K58DM$M6.<JHG<Q1])$3#2BD,6)8
MXS#;;NLTB1,FV=[W/E3ZMU)$1%QX4@JXH0PX\>#$:C*[@:4V_P#%W_V8/^Z!
MTK_TE5TW<[^U?[YM/XAN[Z_1/U*5^,:@*[D:0WPZEZMH'$6TL@R-68UD%-F;
M6G<YK1]*KE;;>2R;H4=6=F#H1KT\>"NGDRZHXQH^=Z">+$K'<C%B1##+$,0.
MV?1Y= OB]9F[=]S[5/>Y;%:K$Y\MKE56I/D)WC458-IM5%6$(KC13L5BL;;T
ML$N5+:B3Y4]&N5$PU<SA5>&BJ+".)#.$/636_B(;2[+R@7;<JQY!X6PK1U_A
M,6 VU!<80JV6H3)@M%"=B^]99=C1:JFN*:8DE%45JHH)AR*0RGD.%TV8UL;8
M)EZ7GNW=-ELJNDS+?T9TZ;6NFOFN=WRM1LMKG(B*JM28Y48VC!80,C;)9;SM
MDV<B/99ZU&,H(QK$3$BJKE1(X$6BG=+$GO6G3UK-=0U<@3$./U!XM+BM[Q0$
MJRJX(D9SS%=")$<.B)Q&RZV'2"=*+:&.=1A399-.F!RY(P8Z4/E$PME?7WI?
M,V:VUWA^422^Z;+-26DQS:*S)D5@YL%18+!7(B*J)!<!R;)86,639NY5[;9-
M925J+%&MX47&F",%Q$4<,G335AESQPXE6=5]Z/.;-IT:0Y@:\9"QZQW=K\3C
MM,3)*;;=;\AYN(_VZHN-S6;)E1!,%BHY9.-! @#%LK?KNW+WIOJ]I]WWDRP-
M8RPV1S);GTW-G*]58Y5912"-;21JHJHJI%47@,%TV&QR[195M"N=:)R.<C:*
M*RCW2(CHX8K".+ O!PE>M?N%_&<SZI&I255N?F5*IS7^9IX;:PY4J'6M#JQC
M%9-Q*A-IMIJN%] 3M(R:NIZ%A<9S(J3FDD<C/+EAG8'+G[*\=ZK58KW2R,;9
MWV1+1+E.1JS'3$K%1*3G(VJ8J*N!CG4EA\IQK-=$J?8ZY5F-G53GHJHU&K1C
M@1%6FZ,.^1((6A<>K^K:-*\%-O70@L-HXXN#>]=@GUA)47,)VI+C[:A@^]VX
M\K8*KE= Y:77@=,*UU@QA; NV;@)^",,*#AS"^JE7K>K[':)MY*UR-OILEM"
M8]JMA,1JMP-;^3:E&BF-\74T1<?+?9+&V=+9945%6PJ]:346,6Q1<*KW2X8Z
M."C\E7QN&;K\&+GKC:9);MO&'J;^-3D4R9C5_%SN/A&/? )"O;>:P"\L7%DR
M[7M9QY7LC8F;\VX7/MT-;1-Z+Q_K*HD^H>F5'?.KN_JZV$*-&E]3OH</"<3U
M39O_ "M-_K"IK,24.]I48QC&'UL1RCG#/UMPC P2)3+,PVPICAA('$E()PS-
M9P40IB( Q0'DZHU4U>RS=WJ:VI\HH2:. 4 +$PL,,QQ#&>>0(4)O1>?2D<Z1
M(]7)>JV)5I.K%6E1:]$A11$^LBJJKP(F-96Z;+4P29,Z5T1)^)*,(15L8QCD
MP8/E-'E=[.OEO^'M_P"?K1[^U_K3_P!\[*K3;Q_\/V_]3G_YMQSKL_K*S_GY
M?\I!Q"?_ #];P_VO]EO^^=ZTW<_X?L'ZG(_S;1>?]96C\_,_E*6-TF2VC&FI
MNZVX0L9QO+DIPLL:\1S&:1*C13I&9$=Y3&YG8$X9-6V"M!&F\L*H)9I@IZ&,
MH@B%2Q\?//F"Y6L'EK;\?.M5[V&YDFS9-DGMG/>LMRL<^K:V#$>F%$[I5=16
M*HG!C.58$9*L5HMU!CYTM6-:CDI(VDJQ<K5P+B@D>$D!MQ:W-^91)2/*,#DM
M+(TBO3M_[&3>[H0C<9"3YY:<1J@"6IOZ'8V/D6XP4YQ.I><B>DB]FBYHX(V
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M-5JX7*BJUJJU7=\K55.YCPP.GQXA^RF$2&(DP4(Z#".0^-KR;DH*)X_"F@U
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MP)_AQJI5FML<,4!^LU_0'_\ :#^1E>HGZ?\ ]M^,>9?T;_(_Q'D"_P"*:_\
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M2GK&*RE18L18JJHF!56*Q5$A9+WME8DQ:"K5HQ45C51[4Q4TAW6),*XN#A,
MD+?[9N319?LYW<AV2IIC-CPPYFRBLEJ(+508GC9P%7.QH^CUO)24536 VFXL
M$\1004S "^=\Q+B99Y"B99<BS[O7794DU3'4Y$UTQKE<Y7+,>E%SWJJQ>Y47
M"KH\$,2&.;>5KFTZ;DHS&(U41$1$:U8HUJ(F!$7(4OK=G % * 4!M_X1'^T^
M_P!T#NI_HUKIN^/]E?WS9OQS=W+^E_J4W\4U 5W(TA+\03I)$%#R.9C=7*)
MLKQ"_P""WMD;24U6LHQO)R<$E/!(+XJ18S9.-GR0..(9L#F&0+VY0\\;_9KA
MVRP6:WI*2TM5R29S)K<*I![%BU<&."\"X%X3/(M$VSJY92PIL5BX(]R[ J?2
M(0G22-=WSE(T5*Y1$=>37>3-R/'$E-6@;H#];*FT',5ZDK%C93I3B$KCA8"\
MSI <LK9X7QRM:]ENL%FO*1T:UHKI--KH(JIA8Y'-PID5$^<6>T3;+,K9*P?!
M4Q1P*D%Q_(I.NNV_FQ&L3(,Q['1N.E9L O/*3&@4DR*6!* T82CDD!(5Y+C
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MXTBW)@553 N3@.7$NDNAD?/.:UYQ)TYOV(GYP?Q-WXQ(.L.-%>2XL3'6\,V
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MO)C&A&2X@1&:H+T0JD&GCC\0U] *N-0>)ME [ %FDD67+*0;+P5A6^ IE !
M+!W#P$PZM;]T+1;KU?:56S-LLR>R8KD28DU*"HM%&TJFDL*-91IJU513;6>^
MI5GLB2D2:LYLMS42+:&%%2,84X)&-"-&.(T-UW\ZZ* 4 H!0"@% * 4!^LU_
M0'_]H/Y&5ZB?I_\ VWXQYE_1O\C_ !'D"_XIK_Z^ZK_U0/+_ .= :\R=5']7
M6O\ /-_DG2=[_P#S,G\!?\)Y8J\KG4!0"@% * 4 H!0"@% * 4 H!0"@-O\
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M?2/4%VZ+LX_)\^'%ZHR=XE'_ ""GOA?O.IF^D>H+MT79Q^3Y\.+U1D[Q*/\
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M :$#(NP4O.W..(?*.MF/ELL^,#QUV8J;(-,AW1\D**0NE![.8L;( "YJ0F8
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MP0\LL[6O.$$]FFDU3KC3'@<;+?-NU%)&TU&=)I&3AW&DIRAR]?3TQ;%+9J9
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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MFZ.FM8RI>B@^!\@($GC&;D[V $SQ S86&]6Y_BUV"A,F(Y8A_: 1ER^Y5=%
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MR%N!U>'#ZTE#E4:<@]7X<#F Q(EI;'D;!G)V+L'DS%="<]GP,K8X6,".2S@
MP-V,Y7N)TV&-^7[%J LV49+1(/1?D8DW$<J_'4UV@R7([@"( :^N-%@*SW76
M2W%-2QQL9-H[669*<!HB!GE? N,L&\\+6N-GR@4XVAUXX<[XD>/7EM^PM9#\
MIR2<;\&14N3<:9:6\'^J6/+*TV(EC\5T*!!1=BP(HK)\T214ZQ@SF*9&$#!O
M?/.]P)06=*]3W ^([DE:@&-%%[Q0CLE 82\8;I:XZ(D1D;$48Q(BEL;XD%D.
M,5480XVKGPC6;?/"YF4^Y8?/,2X$7F=%^'=$KGQF-0U\UXCETJL@%+!R(IHS
M>:QY0E":GJ"U4P$->/#DL33XE.1GX$G% \<\CRPMJX8 5A31G#',#!UC2'1C
M7%N+84'-;7C2F5WM&\C1Q&<N(;>:+:<30*>@"TIN=49"6>6FT IF&*R$4XM9
M@!B]7)%$S(T8PN5+BVH"VT?*D PY%L5QZR7G'K9C)I-6'HPBPG=ZH=TR[?6T
M],9<)-U#43:IGVN,\2Y,L20<<!!1E@7FXENFSRY+@3C0"@,?7'8U6P9;A-RN
M5OMXV\7 $TVB57%E.23+J=0R4K+H+:;@!\R7%7' *B()XYB2*V%,Y%20XML.
MC!$RQ R"@(_398BQ9<F#.1Y+C]5=PJ@\$D)JIKR;IYR"*L>Y(.#_ $S!#*J0
MJGFH,?-TI=E@&P72)EU(K8S8/K 7/ R!RNQJLM.++#Q<K?::0<<#3:914<JR
MG(2<:=3]=2,Q6*VBQY4,E2P[@>CV<:>CI)+'*YE153Y<H7P$,#A!Y 9!0&/N
M)V-5GEDTX[7*WVN467 @--(-.)93D0LJNIUJI9":[:31U,R6"/.!R+9T$F0)
M!7R,G#0V 0.&8F6.-P,@H!0&/N)V-5GEDTX[7*WVN467 @--(-.)93D0LJNI
MUJI9":[:31U,R6"/.!R+9T$F0)!7R,G#0V 0.&8F6.-P,@H!0"@% * 4 H#!
M'=^R"?Z")^;M5'8P>?'CP)3Q7&]PL$>/3;&(/E3XPVK1)IG9,:RH]X^*KP\3
M[(AIP[R:"(Y6<L.1NAF;XW-$RRJGC#A<N.(X=[\ZQ :6[/\ DJ(WCN(>EI88
M\5\0MW<5_A9,/8B(HECE-9D#9:_([I*,R&Y1@5$="V_5YS-F8VBX#PZRNGS(
M2V44>A)C@DL@"V0]D!:K63=B;R7&*$AY_P"QKUV$0))VBVMC1':,-S^6*E8Q
M;#03WBH,YA[#\/>7H7;TG10V8K1D('&TAMA1*)JL=*AF.TULL<$N9A80!$W_
M  STWSB33]:(-V4=KA8L:N?3UUNWA[QZV%4N3BB8D%J3Y)Q'9)Q2 +U*Z@X]
MAF0L*":.32+'[DB#//X'.H=8PS-V*";.)IN9.4;;/<0-#/;?2OK#).N\0ZNN
M3A;0"Q\4 !#W(?D@D\CD@#FX_6&@O*&RI]3EO$-D&4,N(."@)@0IWJX>>0IH
M,@+.\,.*5<KQ@.-%)KW=C^./DF9TI*K#/77$AN)LHJI,>L;.E)72"IL)KIRJ
M9+1*=#&;#3$#, X%6SGF 9P-CY]:L7$"DR)H].^_TE\;77)I.G61@0A)/$,N
MA28_Y&B!TR;/[4$38SA%Q&%*&3)=X-IF(Y_ DGE\28Q_ 04H;S&&PRMET5\$
M80!(3UEO>%*9?'0V*BG8G8I^OK1Z49)A75V""J@C+L=MA"4HEAY6=$CK37]$
M5)P22\(^1U8TMHX:D:,$D\R1,"6+YW/&N>P8 :VYMF60YSU8>8SKW>7)*U?A
M;??A<N!&EE V*'FM9B8X]UKFS IR%LLM:SP_'RTEI.:@BNE/)A#'KL%PV%(J
M(9:V 9'&070A_>#;5Q\3$JP<]I!B:L#Q%@(%:FO[YF!152<IZ D(XP4FM(J!
MK0T=9U]3-*LCQ]EA(1>7S3K2V^84K]E"CE010\,XA@!BT1RMN6\-)>&ML2L[
M];67D/?OBLM;4V2;E7(Q0T&/X(:\@;RQDH-^*T(PPC1!)=#N(,5//J"VI8JA
MNY\B1R"L&&3P#S8 9GI=L!MTC[$:(G7;N1L1+3>?'$CXBFCKF8,FN!IK#.7X
M/@-IR.>C8TXRJ4S415<,GI+@0@SV;F-&\U$7[4KE?J0>!>Q4!["ZJ2* 4!D[
M3_?$;]Q"?IY:I;C()"JX% * 4!%LRPTP)^CY8BN44]66V"XQDV[G;J6ZG2T@
M'0FIR@741&RXS;064)26F:NY%K%EA&'&S3%M.$%(GP#!,<< 0#0SJB_HWB"&
M/^'QE.?W@S8[@Q,X2RPSR+\DQ;1VI'C=V+=FO^B"E&=E!V.4PG-Q#<RO!K2E
M4FG]8-!B&B@QX$+ 3G9WP FJ(9HU)ACA.%,]NU%ODH-:,5OF>"T5. ;%+5C.
MJAC8YR'=6D8HTSZ@@"BH:PV#C.;J2FG!@B)P88NG&<\P11+9 =#K6D1-Q"QI
MVV?9FRFK)6?E-[:B2*6CW7V6HIVD:>L2%K$O2<XM>TG9:T02(10I%?TAXNAU
M^DIHNII(.!$(NCHBL9Q:Y)<% @+4Z>">KSMB9;3F@7D-MS6Q]?8W@%Q2-(Q=
ME2$Z-47)LL'"C"<$ QN59JPE/9V2B_)"5IJ=1$$\A )#"76@CYX<I ,4D!Z:
M: 4 H!0$42K_ $;_ -:[/_A&L\CZ_P";4Q3?J_A(?GWU]2S\_@H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0&
MS[A/)^SAG9Q(-:^BW*MLK=/[[#2WB;S8-V#F;RN,4<08.6%C#@,6P&[#P!O8
MY8Y;+/&^);$WE;P_UU3=T&;H/9O.E*UNI=$1D*ZNA@5D<3$P5RKW-&"+%ZL0
M]D_W7)'61,ZR)4W<-:-W-H^L73*71>BTL+9J)CFKW71D;^4K(JBI+2:J>RFO
M0T^NIYR=E]H===2_^(3CF1MFIJC>"6&M<&E_,E)=TH.I+:" HNY1W<8*Z0;A
M-25QRY8=8-HS;/F@P,<KYY DQ<[6Y,,N0#6'QL>+DO(CNE=Z:/[BNYOGX8UY
MUOFB)AR6QS%CN&)6S?TE+UE5>@.%D.&7\Z]Y\1VL4R+N\-8<"0UFF3)YCVSL
M,#G@.!+.SW$WF6,L.)A$&.U*PV-@6AQ5]2$77J/<5E/Q?Z1IW)#@UB#5U5IH
M&)$8_P!RCG+.U1+9+8@>2;F85P2]C5ASA0,4#K$_9#<8A(P6Q&>Y>P9ZY7_B
MD7#PVR4+G5MJ"P8%J(YIV-,D^P#;,LT<5%66"20:L&G*IM1&,I88 6)2P.5A
M!! ,7;&USQF**-EU"=N(3,:7N8]8OXP+*V+X7YME /YB1DS(O9,RI,+M\ZAM
MQND3.LB&PF(CHZV1?:A>Q9^G%7L\4Z:,9884!',>2?L3J_JA%#";.S4S/M@S
M)_PJ$V[1^@4FG&:XV5%TI11KM'646&8D;I1FI)-KI+-;;@NCY%C'7L%<J7#'
M4NMGLA30@'7OS97=!<@3B42XV-UMB8L,Z'\-[@^SM"#)C979*(P1)-F_6WTL
MD%7>"$<9"F(NHJTH-<;ID;$8!',74A<QRPN0!.Y<#+^(#Q!=GV$;W_>#CW+G
MW7G9&-92TH0]0]:F$F)Z?#SXU3E4W )&098$)'8V6;KN*ZY) <.)UT9K01E$
M62:>A6-!X&@R!P#V]T!JD?R-N.X-8=UDG01W1.QMK#6TCY[LW--A ZHQZGX@
MNQA#NW%3 )(CEO@H&V8&H D,QDXZ7Q/9A=*'CA>XH=G<'S$)P_.6PG,%ZEM(
M)B+R2=;ZE(H&JD@@OY1:98Z3:Q]ZA1&KX.DZVBBC?)0*M\TN8CB$PQ[W&P+9
M88Y_;6O5236<Q]>]PWOKAK#.4E2]"H_XJ^L3KE'7EHP!!C\;,G+,E/33)]0P
MU 77(;RFA_ &$5";DD&S.:,EH(%EIQ!)IS(8O@F!EC(%"MRMZV3L# <>-YE[
MAH:^SRNBFNDMSP[HL=[0?!J-)1 WQX>1$*27!@1)NA+2Y,9J6M+YK!./E110
M,L\NLD<L!,,,P+.M^0"+IV%A%J19L YMHM8V'Q(8 "BB8'))!::0B[^<^CVW
M"Y,D9-J92X9K.0FZTN>WU7GC*BN*E*+C-IMA@ 2@)(J!"$.[2GG3!6L+EV9W
MKE+6A^(O#?X8$OZYH+'5"0:OL5*$M,4%4EUWEX5)$2>6W#F?K^ 3V:88P 2F
M$C@W!'*$R1Q:!-" 944VJ?3GW[A6[9FY\(C<D_>_8O6I\LEZ[G)YM[K4>-)L
M;&LK!#2]"6;'IYJ06S&0_&(@V1GLH.)%>Y@U@DYGP#)EQ&0, (8@2?7W#FF\
M+H<2S6Y"+7:6@,#XRL\2*ZCOEP0"GK^]T>15M-)=AELFOXHSHUO@IP.56LF'
M0A,$C)%QP$*\X/FT!8S.1UYW3,A:\ZV[Q35*^HCNVIU29N,\LZ= 9/>)5TOV
M!=XWOL;KPV-D,0W$K+2"21HJC9>$$!5#2HW33I&!)&2&8);$N!%4P3Y)[,8S
M):#KW$6$5M19,G$NCDF0D_<97TUE:1&["6S*>THD>:1M:YV$M11.,D0(Q,!$
MOT >2VAW=*>H8K*L9/W3C(]P-G.R^P![\4K0Q\K,NRC L*;"OZ"$O9:?W<*W
M88EF+XC?>OLAOY(4)"5P"A1%A1U2-.*,S66X#J?8A=OC.@QU0<G<(,8("D^L
M>0LJ<037A:(S_*4[0Q%+BX@C+U<F ])ZBYRDJ0^U63H*OJ8JF[2%\",N)K2G
M&0GPS+KXXI\9>3VJ1R,FS0A>PMP.@XSFU\BQ<O[/"Q++[RB^0]:-2D&6&%BN
M[?INM#)[R%+&5W(UC<=P0WXZD9Z[JN9XG&@42CJ(XRQ5F9#$04HJ>(F#"X=+
M </<"36V[Y?5DZ4MOG<UIL0>+YPNFE#.H6$I(*6R'YKK^-OI"ZVBNH$-C)X9
MM^H+DS-*CT'>I:Q@X67D@PCAJ@9(B:2\@(969>+N!]:H/]8W#?#SW(+A\21Q
M3]K0NR8@. O <B-34C:(D6)I\-=E%C\+I\1*9&S>0^853@7*ECV/GK*QGHSV
M($LL&0%=I30YG,4EAP!2M+TB<"T\XFNIN\(V,N1](9V-6B_W EL4[GF&5;ZL
MH&C*6,HE"N ( XXH& F F5\; 95$.S3K7G)KR[6WM^_'OM[)L@;4(NZ6H)Z2
MDEQH<!,=BQ/L0O*! :$")46T!$]<Y;:K*;Z(Y[%" KMP/E<#QI4%72YNP&%)
MLX2UKO!T0/1U;+;4R.)L_P +J*IMDM46Y09YA:2IW><TZAQ2GO*/7-(J:5C7
M69HGL=E5$!RK8()1!:Z&7LO"@]82LC @'3ZZR^^GI/S BYS2>1D1L1-Q0=?#
M3&($MJU[=4-D /K1#;(1UMT'8EV1]'SE=8(;M:YKK*>)@IE$)7Q/D #PEP!0
M@0+U\0294)O; R"RIIW6?VCT>L739NS'K8Y&$ZB;:4I3V$/R%,J)) Q)ICE\
M!MCUZ%45HL#$C&5\U LYA'WD%FF&1\B@H %,UF;Y0CHWM2J1^[G T#)A"XXD
MJX9X)F"(K%7Y&48ZIKD?.(=.42PQ]$7&FIKIH4,MEE;H1A<L!<<[X6Y )2>#
MMF;7MX6CM)V'F^2$IZ? NE!8/S"\@W^JDGE/O%::\(3H.U1U!,!+LYMRE'%@
MB!Q"30RZ(G]!B(EE" @AC,8#HDW;Y$:*/*DSO#>*>L]K$QL\10W-VGD=>C$H
MBQ*W(4M))UCW(0>Z"P30UZQ@=(:[=P0GLNE2".^C*D6S63B@"N F,0*RLJ:W
M\X)S$AY6E@-[,$A.G"&E)$9PN[9W?0\SWVN[P+C?>AM1EL]'C.*,QR+S<3VZ
M,I,]'45]$3"W9J@7%*Y*V8.0&P_BRSBN-^0D"*&Q)[TC)92]=)&EH!1'W* T
M<CC%5,N$BT&DX$QX-B/Y,EN?Y+;RV3R+ LE/1CS?!Q5BF:H"(:44C#("J#@F
M_8658+F7:8;9^:T-TP+PP>'+M?'3?CAY$VC%JS,TJ,R7W[(KK>S004L-)D1O
MOX5G$"AI&4+CH=B%Q.@+!#9X#A@=YL-(B&[-@&N0E;;=Z(6R"!QBM9V2V=-3
M<G(A!LCZ^-^;HU-Q4HI$#F$T!0/-]Q,@8@^Q7L"#F>%6S(R;=6R(AW3+ >FV
M@% * 4 H!0"@,$=W[()_H(GYNU4=C!5+8O:;7S4EGH+_ -CY3;<2L]TO--CM
MNKCFN?N667NL)"\O);93PDTD?-&%4\CM@^8##L']M@5S^SR\EKQC)(J:'$9T
M:?[%[R69L]%#C9V$GLV%CBDF+]QC21*LAJ>*.Q6*OH=R^+@;J\[E#.V">&?*
ME[&L;\\.^0?VU3!06?=R_'<:(SGE)]K#.8: @(HA]XR$Z3R,VDM(;R7C<80V
MXW2J"$RQ)((8WYW.,CXA!\O]ZH!TK2FB+'W(LM1(T'NB+\DP2;99"7F>0%&S
M5V"<D5K O9D%UX/,' ($1R-0Q@>+<S//G 96O?DO]B@)&&)$S(Y,R8*%C!E.
M&$,)Y@8 (4<B.,6&)C#DQ1,,A"PPI,R(%EEA?'+(,3+&]^;E>UP.30"@% ==
M9'2<2 R5BEIV*68R-YF$VQ(M8@/D?,#&SV0Q.P75Q<CILP(*+?+&]Q!,\LLN
M6][WN!][DB5SME&Y0K=0Q*Y$L3]RX77<268N ^92QKF=/8KF.'CG</G<R^>-
MK\G+:@.50"@% * 4!D[3_?$;]Q"?IY:I;C()"JX% * 4 H#@J28FK),5.5T\
MBJIX^0.8Q%2*%SQ,;,L.$:+Y"E308H F1<R#@)A>^-[X"88Y6Y+VM>@.=0'S
M&!",!"@#A!C@#AY@C C88B!#!"8WP$"%#SME@(&)AE>V6-[7M>U^2] <?LY/
MY2%^HD^5+Y>S+]6!Y4[E+9D[]0^T_6G*3$R"_.^;^=Y7Q_Y-[VH#F4 H!0"@
M(HE7^C?^M=G_ ,(UGD?7_-J8IOU?PD/S[Z^I9^?P4 H!0"@% * 4 H!0"@%
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MB"KYIY'-6+E12)=4S*%\E$ D.)@*.3!.W#N9"*C"AXY9AXY6PRRQM>]N6UJ
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MI: 7NE]C)Z;9+32AD;H !;@;OJ 4 H!0"@,$=W[()_H(GYNU4=C!B-02* 4
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M** 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M0=<%Q X91)#VW3)->T+L*'=6&IK2[C4OAS.2<9A<3=DD%>5&T*Z&8 TTX!D
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M+6#KMXO4,[59*;CPBI56S4&,C7Z(&6*[3YP5:/CY>CCF;*@3#2>ER4;W"S$
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M6U^!:\;OZ=F<MBDMNVRXMBR:-"LKOF&"\A+VK)"-B[D;#)D%Z,C,1*.FURP
MJ4=+&P\QK"X!Y 9QNCNXMZN.9E,IH1S'+V<;CBF;9U6CLQSZ2UN8R;&.OXD?
M!OPHVGHHQU))=VRD<[QR0B:B"%DU,Q+ #F%172B]@A1@, /\3MGI,MQ^V%^.
M#S+B!W,J,G,X9,D!QG6D]F*<E'738':)/,+$0&&6;Z2/6A&>NZN XE[-P%AT
ME:Z8ODG"%R!XX"!>2 9)<DQPU'LK.J/5"*5.0V^"[RL?K*GDJN%N-M=''4&<
M ZLLTA$NE/ ZT1B)I72NA$LC*8XY"Q@W8M8T,!,% * 4 H"*)5_HW_K79_\
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M9\0F?93<F<6OQVN\VXA9L:3V<$9[ +JTL+B0IV1%07'%*7TE)1R(:,?#P$-
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M>S^Q ZDZ'7%$^MF6U]Z-N?HYB"%GOKPZLB3?P'8SE1P5M2;J\5*FC988,44
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MK9VP?^R,P3K(85Q"=\GNF.C2O5-L1TPVHD"Y%FR@MX05";Y&_4R*:6PR%'&
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M9)A ZJH4C14QF1*[2=3"*)A5+5"B@KK_ '@ =&"=L"2S!"%L(+C?FVR(L"3
M]@.%O&"HW]'F1J1'$#:Y,+6+B*0INN^FFUV239:2\$V-&?)+;60DXFSF_F$J
MR(HC.U.ZL;4KX8V+D;89&<+! XTCE(*=2GP;)?=F[DHRVF.V,WEKI/.TT*;5
M/I*D6=]XVBZ&"X(I26H4.MELP'!<O1U ,JK1A98Z<I-MV.4T7/-83"Q?(@IE
M@  \9B#9@5U*>@'%)7-[<G(U[QVJ:!M74H%H8Y*WIH&]$'8AY3$9<@N-TZR'
MZ+C(;D"*X7L;N;ZWAGR@V#Y,[QP0)-4!#@1.-CMX*<XG5=>6GQ#8YX@4O[?1
M1.1EJ*@[7>\7RA*I]R#P)/IXNV,'4XT.S'51 P!PBYPT@+!<(5*,@8B#B9S'
M,08=L-P")/V&G5>EM;EB-4)+>O$EOLP^$%/,N\8VO:F/1FP0FR]"9H[9LDPS
M;O<+G@))S+X9XXI0I;[<87'*V0&:(-J&B?#Q;^ONL1*"]C&Q"\Y+*3.&Q\IH
MJ@>9Q)Y(20FS=,CKD8B43<'TW,#1!5 1UHJ74+A XAYCE^3',3#'#*H50;.L
M,,0\<<,,<<,,,;88886MCCACC:UL<<<;6M;''&UN2UK?8M:H)/ZH!0"@% *
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M]NG',\:14HP@"H*^5@!G7MDVX4<9,JU?2R[E#7$Z.50RH@\]1$P#/A8C9AB
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M8C4$B@% * 4 H!0"@% * 4 H!0"@% 9.T_WQ&_<0GZ>6J6XR"0JN!0"@% *
M4 H!0"@% * 4 H"*)5_HW_K79_\ "-9Y'U_S:F*;]7\)"5ZP&44 H!0"@% *
M 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4!0^-H=B>?8]VMB:;XV8\N1@[-I)0"<T?R,V$=XL]=
MQ2U-I+27=4;Z\4/)AP1,64XN;+9YAWS+F@ Q0[XB88Y6L[@^8A.'YRT,A1>E
M/&%WQ"Z%DGLE$=48.6+T?))12UTIHI2XU#K43\DQNDQTDI=/0"AK#H200I8/
MHPK!8Y!X\E[5),!:FM3*;&N%M=BX::4('X2(PLYW6VFXF-A2<!0LQ,V,8<.9
M,"YW$(\*"8',@A##&K "#7QY^?VV60&L1>X6FT,EM%OI,H;DQ*3<\::[1_KO
M$*]&NJ"\ED$,*,]A=;IZ19.>2.[]E'7Z6.9;,:XDB!Q++C)B8#U[I0KY6!S#
M- 63;^ATCN"5&SL+.4WLUSS80V%BJ8E_.-8@5&-'.;%AB#9HAYCQ&UD!Q2H^
MG0EY66)V7G(=7E!8511S9O,H$2 +V!N$!%T5<-W8+7-AQI&.NNWS;82"'JQJ
M3K)-[Q4X R7I%5C&J+!PC0K,,$FQ)9!;D8/2161C9/&(N(D]DI&% *'00S.8
M!H!1 V#O."_2_8Z"-@?2GL_N3C^>6+Z)=B=;])N^XU$!GM3M[M<MV-Z,=U/-
MZ#J1OKO7^7I .@Y!@-1$4\#9C14W'Q'#5"TP8K/OKQ.VOL9RC%V@,5L_:T\F
MS.P%R,D=?GF?LW2I+\@*$<L];$"-B-W!H'WL<RN85C>&&0Y8R!(#KX.#'5MB
ME.8D]&TP7T]_/B$Y#D%X3-H=%<T[.M1=AUE1FQ5-+@F;WVNJB,RVO)2-%9'/
M,NKMM=,MA1/JI]-,9&#I;LT SN$6O(&PL73^?F2*\GO$TX;#RX!,H&O!IR;6
MR05G:*IZBA/;SVG629>>J0E)<>(DZ]*71DYL>BA\XV$K/)(+DP $XJ!'Z1P4
M!UF.9?C^1GYK&G(SZ2XGS28^AK4,9EZU.V3H<F9N38DS?/VK#FG!YQ$^G ^5
MIM627"B-LJSRIQ"5U@MF>&S.$!D@#8?HOIT0U":<B$,&QJXS%>2WH5=!]J:A
M:M,75>'VV02&\F-U)2B+<;IEP/%YK UR1@^=5W$N*0]S)[, F$1)!!%[ 4^P
MX6,M+\+L35I_[,,52UTUOAV8(CU-3VY RRER:U@I!UFE#4:.G#,KM5YK74>1
M!H0@>8%M%+EDA-;>3D'%P/G#!<7'H: V&SMK2F3GJJ[-9U)SF$ PLQVD-MKR
M.12 CBHPY"9F"4L1C+:(B#GP@!G!'$BMQ+<:>7S-8X==3PL<A.3ERH"ASRX4
MN*M&NI\9%G[%TG-O7Z.9.;+\:.SL,N&6(AF67);6&J]'?LZ[(<:TPQFVG!)R
M@_TM>.#IZZ,L)XA=X*.!<4F)<44X!\X3X2V</LJ/&=GL "XL8^!X=10N? B
MNW,%(GP_I4?4C$0\DPG(ITDG#2D2>(:>)T'( B"%,C 8)K 7$J"!Q3G#)GTX
MF1W%R;N$AQ_!VO3?V5;NM@L>0:JH^P3' GN$Y=A=DJBY+1B:!VL:<&NR5*6
MJ";36LG75KI061S$,?*XV $=(7!G-HB=-AIO/;6V*5R6-;FU"0"3"VLCI;:1
MZ7LB3FY*K=E.3WF[M@GQ)DRJRBN(8I-0Q4U  [V6, $"<P,%C!M1 L0:T'FQ
MN/X38J+)XC-%V2&G"1I;,BO&&G4XX8/-J:H'@B'Y4BDZU$B96V\+DQG) 2,Y
MD5=!603A 8L&1&+&2^1K,R!V,:<-PVQP9&45N;PW4]9AU\V(BN2G(7C )ND%
M:3-EYN?DZOJ3T5 "?:I=$:Z.X7\,G([8$-G3!9()E@AU@R-B(8$ L0Y-4O2&
M+-2XT]/>I_BN/^!WUVUZ+=8].>Y)NCH'9?9OI$!Z,^DW3]+T_3J'4N3F]&/R
M\Z@*2_"+9"?MTK;"(;>TRS0W'LJ1VJ47J\=%(HD#=!NOHNH([L4F<Q=I'<JJ
MQ-$:*O(Z1VL55!&J.Z6Z3-F224H%A[)RDF 1NB<'A_X$9L**<\PRS#LDP\Z(
M][;@/60W"Y.6Y-/O>/'\T=D]KHK;,RXP=(TLMM:CG"YL1I-IC9*(BZMW",DB
MIX$B3 L4AZ!S8[)?/S[/^Q$;N.05>4]2)%'08G@5PL-CHR7JGWU=3:"7Z5SE
M(;B/"/<:8Q1AE0T8YQ$4KE; J*&+@&7 @-^<)N6WA%$9Q,9EG5MW),3')K1(
M]5)9U0<#I<\;(DG/$PZFO+$52(QYXC"98XGMI%%(TFJPB4Z2S><97$GF&32A
MRN8ID"[NS$//--A;6E:;)AY3(]M0)B@B4S!A3YZW(DH-QFIAZ)YF7!2J> 'D
MYY*4H:?SE6"9($+')5< 0!<.V&0V.6($71EI9M<P=OY,VC7-GM;Y*PDYX"D1
M2[VT]F _+\>:W@+!8^B:W0_*%M]+QQ&K?3RY,,R=42$>VQ7W!?)652)P:P 0
M $D Z,=%I8T=0.]'G>BL@1T^N\/T)Y.O^@&SC=V-[+]$O2Z_5>UNP.QNG[3$
MZ#I>M]&)S>K9 ?QOYJ-,6X;:C%BL.<XUC.-FZ[E%SS'%LL0;(,UQ]L0GA)5B
M338<AIL;;.ZPKAB-D=4,CJ*J@&%$^DN8P$3 40!"(!@H= P]VZF;?&EMK2RP
M]FX!9NQ!Z#G'KC+SM2]6'RGQ$M,/)^*KQBEXQ?$V>TRP[&'(4+EUP^ 6#4WH
MXDA8%4C0F0!##,$( "'&[PT]@HLFN+G_  YLUKSG&6NL+17K[JQ%^P&H,MS(
MH:ZQNP8[18^=1M@K[*WN@R/PY.E4FF"8J[KR9F*SBEW 20Q.S@1 # $G1EI9
MM<P=OY,VC7-GM;Y*PDYX"D12[VT]F _+\>:W@+!8^B:W0_*%M]+QQ&K?3RY,
M,R=42$>VQ7W!?)652)P:P 0 $_Z6,5SMYG3!)3T;J@T'1LCL7*T[CM57+FB"
MVA-)5'1X]B(LXTDY>PZ$[#D)QPVS:RG98X9IRL9,EL^<(%F)F!<>@,2<8Q$,
M8M8V4$,Y7"SOAE@8R!MC;GVY;7M;&_.Y;U58 QSK2+YJ'^[L_P# J(ID ZTB
M^:A_N[/_  *13(!UI%\U#_=V?^!2*9 .M(OFH?[NS_P*13(!UI%\U#_=V?\
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M)9CR+#\4)C!PMFWLC/=V=1E#(R/:XEU+K6-N89QPY<*F)!QV+PBH.8KCA1Q
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MX]@]<9 =VMNI*GH(HN=IH;QU_)'-2&W/T!,57D-+*+238HY=A',>DMV9GLP
MC)TL7* "6+G2P>1<J+,$!=KC4;5;8ZRQ'K&BZCI:B2?.RFX\%:VGY&118C,N
M-G@24Z"Y FWF>BS2GKK"S><B6#'(D%173#Z*C]"(*=PPZ0$3&$^4'6-3B_HX
M+T;Z2OP-**AKD6VS2>'HL[EGW1%I=&/[9%S@;*5A#D8(Y\HK Q,8DP/)%N[B
M?,2[J.=\@2F).V UT 60T&WX<^^0<@O%$UD>\3PDS70_(\099>C]8BG:0Y%C
M627(PG>CMAD-XR:<I5MIQ=%!,XJZAB4P&-BF"> &75>L#%2!)CW#0V(F+8%8
MXD)677AZ6@0'Q/MB]=XF#]'VL@^BD.L1B0JLM1G\YL(B+FN]E*3M4!.T%*YQ
M4'ZQS1C(F(86.!00BT.,NA/-S1^M)>KTH8:S; 3K+.KFJ^S!A[1SBA3=L!%8
M$@%B;9,,/%5R=;#9TM.N+%]%:"T8N<&/'B/*>()H0F.=($$(_E&NJ'9G:7=S
M(G-^']^.MS.NHO-[PO2'T7_%!Z;DY.^GM;['/YO5>C^SS.?^=U-$$E3-QTX7
M@W8Q6@E[1>:))<8+FN3%V*>!J9X=2G%%4D[+%&L<;B THC5W"3?DUMN. WHF
MW>BRA!V#0;#"<T SD7,8A1 %L]0-^'/N%-NR;#:NLCW9D-:RS1/>N+HV%=3]
M8F2,ZIQ@B1TYG*#09T>)QHP^3B.O-E2Q6\5DP$6(E<@Q"&5Q#&-KW0)-CM0!
M0"@,G:?[XC?N(3]/+5+<9!(57 H!0"@% :4]T=AMHHUV<?BEVWM;#&D4,0M"
M3G?4UPQ!VLC[8",Y'&\9C-S0^9-6I_#'D%2CF,V"D-#(]:.DMQGTH(THG% L
M5 +V'R P&)-W9?D[;$RO*<PS.R8<!WKGO3 E'Y[6QA&]23(L+NN1H>(-%3FC
M-OE=@"VQ$AO2.LE]*<A=>$C+"RH4;0I/)=OF!8#'2FW.[+($6H]G)_&HG<\G
M%8PQ,R9*K'C2/FEK4JMZ3I3,[F.J)#2VS$9#E.!HPA<./D]H.%P8.0N;?S\0
MB1E04LSQ].20-\C+>S.D=K(CXC]TM][,UR$[*" Z6LKD5U 6"=Q! ;F$Y531
MS)(V'@.#F'GS,[\P3#+#+DRQO:P&44 H!0"@(HE7^C?^M=G_ ,(UGD?7_-J8
MIOU?PD/S[Z^I9^?P4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M+97P F^_% F!-FLY%[+A:2)(8\,/#7B&I"";NI>]$OO225J2(TA&0Y!D=O;
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M9%\\>43GH@V(5 % * 4!D[3_ 'Q&_<0GZ>6J6XR"0JN!0"@% * 4 H!0"@%
M* 4 H"*)5_HW_K79_P#"-9Y'U_S:F*;]7\)"5ZP&44 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4!5?5K_ %C/[5$N_P GJL[@^8A.'YRQ#L:R$^&LY64Z2/:C9>#?
M66LXDSK1PEVBA.!.,I*N1ZXG&"B@4ZVGFQ ^E %"&#YW.PSQRM:]JDG6ID?,
MU(CY/BHF@E;Q\F,TI'Q5L'A#2J2NS22(&W $$X*J#G#JD5NB!6+B9&1111L.
M6XF665[WN!0DEPDM'\&LL,YPLJ6I!1%B-DB&<,9*VCV@?9] B)N/YB2<UXW9
MJJX9@.J+*;+:>L9H9PG9*%*&L.H]'F-F&,8P& G%@Z.ZYQYV(<(-IX.ASH<O
MID]82#)4M2Q)TEK,KH<;*L/H#G=,@/MZKSK=9=OQFM&4=/2U$T91B183G E,
M!K8B6 C=6X86F*LD1FV+1R[$AE1A$$2Z_$V"W9HFMOL=_P )0/@+C#T83@V4
MJ02R;/+38>1@;JX+PP6<S0)HT7.9F2ITX .!;]:BUB.&1V'+:PA=<D*,F^_6
MLR'!VFL%^Q$*3A6@,^"/9150 1%+ML5A)-^E-EC Q;JGZWS"L*-T@%3DCAK:
MB)!MY<C)>RLVW>R93CLK'3BFR:7!%T<-"<"AXA+R5"L=*S_--2%<GXGJ0Y8<
MPURJ69(DQ1"J>(3+"B@Y@9 Z.']K"[I')R8IM=[%C]U*-EMTLQ%F*74*(I/7
MX;*H)*)G'+L-I+V*1E*#B8!5JI09,\M)9PT.$D)P1O,R$G$,"P'4IW#AU+(N
M5IN0RRGHO@QZ[),>4;LIT35-+ABB/528VT^6?)9-IQ J/\Q&!-ONIL2<X4\1
M.%21R19.6!R98,$I8( ,#J6UPRM1F\UG8S3S:E)^(;H9K?C@E>4MBM@Y*6X[
MCQGNE&?#+:$-.EXR:K.B&BK/>C;2E=./MDXF+0*FC)AK([F.EIV94"PT#:XQ
MIKFD.A/8-GHK*S[<F+N?S[DZ17S+<EOEP (R6VTXZZI"D=?<KK5"Z&VD0FG)
MQ2YG$DG$BV 18$+'G<X"OJ+PS-/T4P[,/0E]+3<<[1E=AIT?.B<YP<T9QHTI
MT33Z1+Z/"L?+4AG&M#.+Z354T7&';19--$2AD4J0%*%,\@+@6S>D2QW(D2NF
M"WJV"KABA[1ZLQ4ZF<=-*-B:RP'"W3#366Z9/ ' 5C $\WS8A?(<,Q@:QMES
M\1<1+6SL! RKHKKB=1(7;J"WWQ&B9 $5G8+C+*')BEV'U=)A=1(M$B=C)0<L
M</=M.9=;>>3!13(>9PX,?+'$_$P 9"%%,Y#@<-C</O4.-4-O-IDQ)V(AM3\7
MFS=3[/V3E )*#U2=R^^M?BQ815>AX?J<<N9SG1@ ,LL@3H(N)8[B9+! @A@8
M.H<+W2];<:VNN..W@YTM7)S4G$XV<4W3@JPJTD[8]KO)FSRG,2%#$B7BUFI\
MJ($@+ 2D 0200@\CN>97$OGCA?$#MC7#AU<5@) $=2;+S]<4GQ,#"#Q?$A['
M[!/IZ&HW(+Z<ZT1%2%MT26IW:IIN.E*!4T\\E!DCQ92R,&\1>LG3HID#N'/P
M_M;70B!IXR=)R"Y0).[Z"TJLR<YE9DS%94'BY A9:>964VV^$UX%C3LC!M%4
ME9)8&<4I6"MF*:*BF!,Q<@,L9FD^LD?HF;>:<:9)J8/#SM@<]<=ZR$KJ2Q&K
M^=BV_'V27UQ:=BBMN%U/5[N106%9RGC!AS*2F>',F% 087//("2E*!8G5VM$
MK*46IUALP8X&&Z8L3.W7(%Z++L9)PB2QSW7 %@)06^Q$\7(/HE$4X"9Y><8P
M%R^S0$-JVB&MRU,XLY'FX]+N$[("'+JRQR\N2L4@QQS"V$I)1FS+CDU_+/(*
M&5R2$$J@$!BZJ81,S':*>34<[YJ)(H:  C="X6^FR$W'*S+LR1' R5N*W/![
M=93PGR=G:TX>B%WFFZ=68_U^0E^13Y"!4/$RSD;J633Q23:6"C)Y<D,7+$2@
M((&:1_P^-88\5S#I+H$D/5\J#SB>0UB098GN=99?"X\H."=Q>*EE4<,@R*X#
M0P;/*OI4"!)8=&G#!&,<!RXN((%@P,)/\+[5$T13T]. G)H!IHTC$0#4=;/;
M#QNKB,&5G$&[7K#AM=8DE-Y:-P\9<V&9Y.0,S&15 ,F#.:5<C<T9Z4":)VUS
M+O6&F&P8DP;K 7X*>4.R)!(&988BT&\KP@OHRB@,DZ$EE31Q*8KN9Z:;:2GD
M3 $,E4-7,9%L+C8!VH# V7P[M:([E->F)CC[+-AW.J65N<72E).\V\!>+G/)
MKD4PU9>7G'!WXQ.4*+I%5, !!#)1IOBH^1,$(IU7JH08.('0VX8NG>961D@V
MRI /M22&'*47BL8S/<\8,J.X[G%1*JTQLZ#FX3D@J1@I#D<\2"LH!-*R1?$E
MA8@6N GVL4L!VB-PW]5TF.7K$1TE/[ZC5^-]LMM69LO[H[H3>C(A)E+J4YV6
MHQT#,6P#Y$B1V,UR(1 ^D+C5R1EI,.$2PI8T%F7!RP X*SHHT$QC-N+8Z5G$
M$UG3LK$\^;(/.3Y&D66)@E<.%SK9>342CK_D%8=C@6LE-V1*S$$T5.G DTHR
MBQTB4"#YP(= 7YH!0"@% 8FXE$<D,6Q"P RL(%G>_3 X"WM?'/DMR7R^S:WV
M:JJ@K!LKM[#NH<5J,S3^[TYDL8DKH;;*# -Q9<[@<CL<Y[!+;#.9K/:B8M.M
MX.UPJ E@BB>FDS)D2ULQ+XV"#$SP@DB75#B.07N$NR"QH\+R,PI;BDHWE61H
M/GZ%7[!,Q-1 =_7[M-SFV-(Z$B'U%LN(-.$R /$,C9?#EPQ&R"$%#PR$%PLW
MX0#2<E[-4;N"'@#<QFLYC)^*3@!CG</(?)1N-8GB#B);FWROGS;7^QR\M,))
M&COV<BQB2%!T4NEYMU.D#9)5>2/"3:P(F3YM_&H^8*O)[R%2QDXJ;)%TY!9*
M*,<&-F10"U[Y@A8B9##@AB,(,U<\LMIF-]Y.ET.%LHK?CQOJ+K?*F<S*X@-1
MN)*2:75!87,<,LQB!(LC$AC-\L\;<H(>66/+:U,((@BO;QD36ML,I&J!(#B9
MLG:ZL39YA3)>)G<EPJY(\DDWT3312DC*Z401@)--I0@*J,V!^A62J29"-# 8
M89VH"P)-V=H =9(#)!XMTQDOU@G@6,@=.2,BDS@'2@Y9A],4.%Q A<>7G!B8
M98Y6ME:]K(@_HNZ<S>(F901*-8 F!R@N1<(N-B$:*BY &BPF0>65L#!8?#+
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MBHF45PS9"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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MTYCAPR*AO1U3,AI<0NY18TIRB)J'N <U\CMQHUR.*V7>>S*= YS7EN)J%DI
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M2&?--F0@L@-)NK;2V-CF+)?6"J-,,@R$0T"E5*V1B)F:7;IZCO1X;$./*+"
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M=>'(V8[=<HQ^J3.[),USCE*@=(D1AX32*%LEL!&6O;9>^$;*3B).L=EMQ?E
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M3D_Z;^_SN3^[]FL,<,3*84[OV03_ $$3\W:L;L8,1J"10"@% * 4 H!0"@%
M* 4 H!0"@,G:?[XC?N(3]/+5+<9!(57 H!0"@% * 4 H!0"@% * 4!%$J_T;
M_P!:[/\ X1K/(^O^;4Q3?J_A(0'\1;2'ZR4<?=I_^+Z[QV6=8?LFUYF[1XB^
M('J8^\5WZS]@?$6TA^LE''W:?_B^G99UA^R;7F;M#X@>IC[Q7?K/V!\1;2'Z
MR4<?=I_^+Z=EG6'[)M>9NT/B!ZF/O%=^L_8'Q%M(?K)1Q]VG_P"+Z=EG6'[)
MM>9NT/B!ZF/O%=^L_8'Q%M(?K)1Q]VG_ .+Z=EG6'[)M>9NT/B!ZF/O%=^L_
M8'Q%M(?K)1Q]VG_XOIV6=8?LFUYF[0^('J8^\5WZS]@?$6TA^LE''W:?_B^G
M99UA^R;7F;M#X@>IC[Q7?K/V!\1;2'ZR4<?=I_\ B^G99UA^R;7F;M#X@>IC
M[Q7?K/V!\1;2'ZR4<?=I_P#B^G99UA^R;7F;M#X@>IC[Q7?K/V!\1;2'ZR4<
M?=I_^+Z=EG6'[)M>9NT/B!ZF/O%=^L_8'Q%M(?K)1Q]VG_XOIV6=8?LFUYF[
M0^('J8^\5WZS]@?$6TA^LE''W:?_ (OIV6=8?LFUYF[0^('J8^\5WZS]@S%@
M[K:I2BZTIC,&=F Y7<N9C!(R"35! CZH.  (:$+$<#I<M@9-=7!SSL%AE<3*
MV-^;:_)7 O/J_P!]+GL3[QO.[;3)L,N"N>K8HU%6$5@JP2*HD5P&WN+KCZK]
MYKTE7+<5]V&TWK/54ERFO5'/5$551M)$17015HHL5@L$+15T\\EB@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0&J1
M_;DQ?H#K#NMMC,J!)#GCJ+-I'R(OHL3M4%X/<WZ4NQA,Y.NFI1Y6;Z,"7 4U
M\$0P9/J!$H !CE>XO/O@'G9W!\Q"</SFQ%,>JA($/)\C1@GY8JCVC4H]8\2I
M 3%9MY8J#D:X:ZTD][(PN)9<0,K&#I<-2*Y8AFRM^DPO;$3'[%232!J[MW)<
M8/)K8[=SWN''\@I<(2I(.QT"[I:YQBVF.[EB,([L]WVY]*YR@*+&K$SA+QR:
M;JB.(A8.YPF#K0,=<%)A&2PAV@.G/\8P_.L&RZ6CL.+XYE,"(&7.L<*<,3P0
MV'4&XR!9LAQA.ILS44/1"P4:+);3RTJIH(J24$=2,;L8.=GK)NZ>/EB!8M+X
MQT4*6TRG!F1*)"["2]AW?JV;<5I_Q,3\2E%BK2^RG&XU76X&+KIJ?#962F\,
MA66O3<18PRMD?'104W&YNX&)RSQ#-S%'4UV3]'>I[;C)K/\ AN/IPUEEI>G
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M/!Q";81L0>\#,%G1U=CKJ .J*JRM)J6O*"NZ45/1@U$$T!FH6Q' ! X\9\7
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MJB!YMU2)I[D)EC[)48Z>+*73HZ8="66#(S.4KE5U,N&'@:$+E30>0)LD4'
MKKLGIA(&P&UL;RPBSK*D#,1LZP39"SH7H1<;*29"<)N3Y+A1QY-8<I(<8R6W
MRS756VP3]A5E/#3G.CG,2XB4?)BYB#6 DC'0374!A3)&*<CN1%8TT1O$D6JJ
M&AN0RCW93:@IE%V-%)F-E8@$ N-1P,Q/(%#1(_UD<<!1) &,+XY8<EP,5&T#
M3E=MJ.#TVGVQ?\NX/UFR0Q=C70Z(<!E&(7''J"Z6LS[1BSVO"#:UQ2$TDW'Z
MX"2B >82CBYBRX<#7;JF.8=@P,<3N%UKT(S#S,?[JF:8 G"I;,K+Y<$C/-&N
MY7XJ[;LDNPIF/+AYD--E$T?(\C@<]*"0BZ.70QLK6(A@@A%P00.2/PY&XJE#
MJD[MH=KWY*N+XA5YM6<7BY(54W_'Q?7]:=2U'#0:#9+P41A+T?!R?:V"K&U-
MHJ3@7\5*XRDI&CA5/,DP.#CPPXA$4SR>HR]L,L0N ZIC?[ UG/NF/,(4B20)
MU2)&1WT[&'V=%Q"5CN)8*6G",A(CB=*^UVT84,<TI+)]4(V*@9Q+^AC8E)GL
M)CH,^;$PPWF?#UX <*9&:S$RRCRQ$&2<EIMVE([5FN'I@9=SV("9ET2\@IJ$
MYBW6A\ %$(+/$/ "2I!U+8#SCW7Z.F\Y'Y$Y#6!Z1N]897(_/MA1<#:'C-HK
M,>):&;RE-IR4AN!#6H[<BBBJ'7R)@]D6.YF"QDLH!@' 0(Q6>'7 *[%+&ATZ
M=D*S2CV/=C8T01 '$F!J^;=VB;:^UI*S4#F3>S ,*0"8Y#%TP7$$/ J+;#(3
M :UKXW YTNZ*-62W0B/9GSGL/KP[2\0).O[V<$$.2.DI1EF%V\=6E1N,5]"2
M)%TDX)XC75'2LF4E>;6+>=*0*M'NI*8&)G/&@(J>/"LA5QC+Z(UY;V%B*''B
MW8*;[YUZBURQHEQ2\<M;DEIMR)%A0/N6)W5+B(>16FPT5(.ED5TI:4LIJ6 "
MH$S7)GEF!7%OZ&SXH;JQL\5A&.,37^%=NYRVR1BZ1LPO.^)5]0DYMSNE)V$?
MZ\GH^2U]E2@]E^;\5IYCK+A4FRE*!58NVRH?;V8A8#8O%NFT1Q%^+-Z*&7@)
M^*?%#^AN+^UEDB<ZPT9'[O?2$1U="CE.UEC#NS3NKC ]5P#YPW.#SY^/, M?
M0"@% * P1W?L@G^@B?F[51V,%=)8@>))S'BLS*S,)/$>$I=:\\18(=.JY*[0
MEMEIR^DM=YD[)*BGXG#J0G.@^%@ ;L8)YV,WOF#EECA?&"3"=E=0M==O$)K-
M_8*.@WJ"Q5XPYV.MICH>L?/=EKAU*-H:D=:,BQJY&>_FSVPC'1"IX(DI  G@
M+VP'P$QQQM9& (>5>&%H8L$882C&M[0)(^O\:O&'(N0T!6>3704N*I"+7+O>
M/G(A-MRI*1(S4= F69DZ3<@*N",?$$.96ZV)F-E,5!&C:X,O#7:C>76LF:W8
MG$9S,%HQ8NA.B7IX>QU1CF/Y)9<NL)EBK+SE%>6<&^R'_'B,<1R^!C'!,!)6
M)ENC)"#%Q$5!?*988BK8:,GA#,W,)MR;%K^2LD9W,EV)X:BBK)&XP1D'I LK
MXBE3I Z7",E#0&81HF;!#' $#&#PSQ@%(V/P?^'#'C6F%HMS6)OCD9]9G=Q+
MBT[7M*DA/YX1YU])4_0,:3W^^W-)*2S+*" GBV2T]6*$;9D"O(%^MP>9,5!+
M^Q'#[U VKS81B=(=*NM2C)OJC/9:\CO*18\<Z8RUT D57V,<=,:N]H.-P,1P
M%$\,)01%$T;2CP5\\!RXF(HMLT5!E*GI5JBKN/7!U'8&CVZOJ&WW0T];,2B/
MV:CQ&UGFSBC <3<;3:31BC;S0SK0( $PRAHH8 *X@X9@8A"XVSLBH(W-<-+1
M\SK&Q-.,(%1TS7.+WF0D:.F"WG7(38-LE_ICJ5WL0>C9?;==R7(R0Z"KG7SI
MK$\"KXF>4R('S^BRYE(J#)B6@>H*<B%&Z4A5&#1B.V!?>0J3S<#T'OAM:57<
M',#,F1D=RBFQES%=PL9N4S$R2LL_L7*WQ^UI%07#J * 4 H!0&3M/]\1OW$)
M^GEJEN,@D*K@4 H!0"@-'81Y2U5W/AA^8OO8V4(5G5)V])R3-64I/O9A"G"8
M$-MNC89FPI'>K,>+;Q#8*]$L;PZ^"[>$9#0+F30+;]' BQD\J!8B@9)ON?9N
MS$$1,[8A7MR8XFO8*4D'537<3"4>(;H,?:;J>BJN*3XE5^Z\I[]U@<CPQAF*
MV2Z'H4LX&^9NKE$#  $2Z>9R%L!@L^Q_M-J=*\>R6Q7^^)09S76(;BB$2TF;
M&R<XUF3,S6M[TUY:NO$E1X/@=*2,\Y3VC<3;D-T2,H=.>)HA!35SQP.Z$7*G
M +N\/6;XJD&&&E'#(DQ_2NZV7%47RDXY$DM%749P36U)]&>RXU-FT"RQD,$9
MC6?'>T74=0;%LP@"@1 4J"6+%@"X=P+^T H!0"@(HE7^C?\ K79_\(UGD?7_
M #:F*;]7\)#\^^OJ6?G\% * 4 H!0"@% * 4 H!0"@.60/GDH\25$LZ;35--
M-ECZ<HD#(Q,\0/$QL#!0Z2-E\PS!4V5,!XYAB898YX9XVRQO:]K7JDV5+G2W
M29S6ODO:K7-<B*CD5(*BHN!45,"HN!4,LB?/LL]EILSWR[3+>CF/:JM<US5B
MUS7)!6N:J(J*BHJ*D4/:#PQ=B)LV-UW*N::F@>(J*">P;R!)1C N3*2VFDPQ
M 1U\%+M<,R$HI1D#JIXT&%8@<,\N0&728& 0?07K>W6W?W5WI=9-WY[72IC:
M;Y"15;,Y<*,5V)6N1:3&JM-K<#D@K7.^P/[MV_\ OEU@[@-O+?&R/9:)#ZJ5
M:U@UMN8U%19J,P*CF*E"8]$JICXJQ:23&,V-UXJ/8(4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@*KZM?ZQG]JB7?Y/5
M9W!\Q"</SD@[(3(GZZ:\3UL&KI!QP)4$PQ*,R*:"G7RQ4%M/C!CKKV.I!&^
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M?TS_ $4? G_S3_LW_> ^ !_ZL_P#_P#C-3XF?]2?TS_11\"?_-/^S?\ > ^
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M@DMS=3%&&%38DCL?#!F#$18LW%F5 Y#;/H6DN7,X03@6NI+62A8L2=!D^JE
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MI]&)DA:/X1AAU*&'XV6S^.GSL>C6%4DQ7:S)9*U)RAN 415<+--4F\["$4P
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M\J,BBS-S->!#V]% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M'CKS\C&076-&;!1G[NQ(K8V<=R7(47MI]'&D]&UKX#G9S*:&5-.5F)A:QZX
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M'[F98K%,;W_"RT6AB_4Q.DR7)W>"9,2A1:_TBUZHGT,% * 4 H!0"@% * 4
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M[WY@MA0@P)"H#!'=^R"?Z")^;M5'8P8C4$B@% * 4 H!0"@% * 4 H!0"@%
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0%5]6O\ 6,_M42[_ ">JSN#YB$X?G,KVN9LF2-JWLI'L++V35F-]P#,;
M-B9SX&[I^;<DQT1VXT1AKV)^PQ>Y+)'=)XJ8L-TF'1W#YW.MR<MJDGGK_%42
M7!,J*Z-2.'A)FJS 1R_"J0'NAJ<2)42$3[I@#BO:OS%)H>*245.@?:A$D*M
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M>K]&\K^Q_P HTJ.7+SBMY+LQCK2=#78390V6RH8D%JM%L)I9&;;906" F(2
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M H!0"@% * 4 H!0%5]6O]8S^U1+O\GJL[@^8A.'YRU%5)% * 4 H!0"@% *
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M4!-81I_,$PP-9TR>&B3;<\B0 M-*-6ZX3"NM$RV*>24G$?<615)#P(XVR)8
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M;TZ_>#NS=*R7M*M=WO1F],Y8VB4Q$5BL5.YFS,/<37+!$1$59C>[<B*B.?\
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M5;02QW# W@;.*HV=\KF.C+@;#Z 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% 8([OV03_01/S=JH[&"B&Y6E<<;MM2)&Q(3TE>/#D'3JT-C(U><,
MN=':3S;TGL9N/1L-Q3!5%QLNPEF4)DGV=%Z+JMLKF, LN?:V&6.<(L"2NIGA
M":K*D<RHT7&X9[=LD3%*,23<\=GW3+ZNL;+XRY .1>\&OMO2 8)61VR=B4(#
M(%#(DD@%'*%QQ@KD\PQ<\;S$%<=@>$K(#Q=^A1:/-EMB%Y*@C:.9-@YJGB4)
MT&5MBPE&18J6FXG*46#",4Y&*  7=PI2]VRFM]':81',SCV?GB8,!C3$@M9"
M'"EU@@-XZR2&SS\JJS]U?7-J'BB/)XO,BX''*TA;E M\*=9'FU2R;I49YO->
MR;)3(L8*]F %.9;#$'(+$,/"(DGT:_"ZA9D3:[)<9<Q[8,MJ/23I-FQ:UR94
M]KK)@ 289B1#2/(\A!HK13T21<CKD,'AU*Z6*YA6Z551<C)9.!SYMK(@C6/N
M#3KTR''(CV69NVYDQ_OG7Y5UA19*>\QI"9*$70ZK+:2X1D9AR;&#$CE^J#B!
M4T C?!?<ZBXU[, K8 4X( *.$*BI!US<X)^K2=D\UEXR'L'+$C2',^MLWO*6
MWZYHR)OQ><.J"\><</()P..HD8#*]&R"DJ&<E+/!&Q5U>XU\S9X07' 3!%09
M^4X2&LY&=<9C+.Z>0VB'LT)N@#K'WD%<M: -K,Q<%'&;P&7DV;O )Q .7&ZT
M$G6<'HZ$LY=;Q3K"8A\Q$DR)E\+'69B-G7-IHA^3\TO5[::0]OXUR/.I('-#
MRO)JA(*DXRSF&#; &"HT@S$EJ/5B86)8<+'$&V1C/F97S14@V1U!(H!0"@%
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M@@D>G.=&09)8UD/?,]D" !<.@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0&+KZ2;41B^9:P=\0@\\<N?G;#[.67+;DMR7Y?L6JJHJ@Q_P!&%3_F
M@?XZW^#404#T85/^:!_CK?X-(*!Z,*G_ #0/\=;_  :04#T85/\ F@?XZW^#
M2"@>C"I_S0/\=;_!I!0/1A4_YH'^.M_@T@H'HPJ?\T#_ !UO\&D% ]&%3_F@
M?XZW^#2"@>C"I_S0/\=;_!I!0/1A4_YH'^.M_@T@H'HPJ?\ - _QUO\ !I!0
M/1A4_P":!_CK?X-(*!Z,*G_- _QUO\&D% ]&%3_F@?XZW^#2"@>C"I_S0/\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>tm2110724d1-bc_birthweek4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2110724d1-bc_birthweek4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@#" 4F P$1  (1 0,1 ?_$ 0X  0 # 0$! 0$! 0$
M       ("0H'!@4$ @,!"P$!  ,!  ,! 0            8("0<!! 4" Q
M  4$ 0 %!@8. PL&" 45  ,$!08! @<("1$2$Q06TQ65U587(=15EC@*,2*2
M5)2DY&97=[<8>!DCM;9!,B2TUH>7Q]=(6%$E=C>G.7$SDS0F-N<:88%"4D,U
M:(B8N'ER*%DZ@K-$Y88GR&FI2EH1 0 ! @0"! <)" T'!@T% 0 ! @,1! 4&
M$@<A41,(,4$BM%5U-W&RTQ24%C9V%V$RTK-T%1@)0E(C,Y-4A*3$U(7%1I%B
M0W,D15:!T5,T-96A<H)C1&3D)66EY689P:*#H[4G_]H # ,!  (1 Q$ /P#?
MP
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M8H(I:FLOZW4.*K<$UP
M
M                           !4'SXR#.<8X?-[WC7,B1'90LQ"B0671,E
M6=($>/'J=Q!ES8ZMU4%.^I[F?"KA(59B@GH,3%$WFVUI6RE:!5IQ&X"X'9EP
MW8/?YO -&I.UF8%8C-O9OF5LQ1=DF/YDN923LOESN;2GL\A0Y4QS:Y76.F6K
M$9B1MM0GM=;"[D]]0XG]5AGTUQYI5R<2F#$3:4:9XHV)RI*-+4TR\YF*W9AC
M\8DLBDS,T=],[<M*N:D48-5DIJ6)[7M:NO\ _.C5-0'S?JP6D6N>WVM.;^27
M<3&>/-K=K=E-D\JDR>;YQB$:R:1%6IEN93ST$;CLM;7=CC+P]OCRN4J524@D
MZYM.2(BZEI2*%WA[B30C$'$_]92T^@^JS,V8:P1R78(F$5SUK_ D_F?&J3([
M IGAV.L@1O'[1<5'XR8LEC(V(T]J9&0G;B37>J>I9:U270/%\??\N+]^GF?_
M )O7[LG[\O[Z>1^Y?ON^[/P]^Y+X?8/<'[F??3_S%X;\)=IV_F[_  WP[YD[
MQ_1]F Z1PK[(X:T[UFYGMG(6L?V_BBP_MYD28Z7V+?.%J!^0D(;VZ913"EC_
M $\ZK(?-9RJC;-$R;NFBAR6]D9_SC<O 7><6>M>2,38?FVPNRJ"TG=#>.;4V
M/V=L,MOJ=!%SPVE-^)]>&Z\WK'%1G6[%I;?%TY5;K[;EZ=<II=6JFZH"ST!\
ME^?F2*L3U)Y,[ML?CD<:7%^D#\\K4[:T,C(SHSG!U=W5Q5F%)$#:VH$YAQYQ
MM]I915EUUU:4I6H#+&Q\\O(1NQ)LC2+B$XH7C:C5_%LL<(D?L7F',D7P@WY0
M7M%EACG7'D8G"R&4^U*OL.*3%.#P[V)E*:]<WH#S:):!/+CYYI&/?7%&TC2@
MUMGV)-]-/X[+E.6=#IT^50SAPE3&VO58VTPZ7+HNVJ'!EE<H:;60]4>QDK&-
MR4%VJD=Q)Z$]<&6'BHW,W#;>>;?[++=Q;3:4Y5V"F4!A6?<;69<:$\ETCADK
MR!$2)1+)#*S,4JS9TTH2$)*M6B3I6*BON1=+C*5LLNM#_P!%X!2QR@<QD?T,
MR/AO57". YIN=OCL0G,<<4ZR8\=BV$Y'&*FNB(B=Y D]S2_W1V-G+V9=4BVQ
M&9VJ=K7'J#D*5->JH$$L>\\FX^N>TV$-:^8WCIMTC8]FWXF)8<SY!<O1K*F,
MD\N/5MK8F9)>NC;E+(S:A,<GI)8N6)I!16R6J2#53?5*;>J("?G*ES#P[CJ?
ML-8$QMA29;=[O[)JK2<&:LXY<:M+RZM%S@H:KYK,GXIEDJF-16KBB5$HZEMZ
MHYP/1*J4[!,D6K$H5X'\]&]FE\^Q:3S(\73EI]KWF65(H@Q;,8IS#&,UP['K
MXYVWWMZ/)#1"5LS2I+;DI"E8>7<[H7JU B4')&I=V1EM@6L<I'*SB'C)U]@N
M77.'2#8#(.<)@S8[UMPKC-R3T>LT3-^2%N" MND*=!("FZ+V(CR*F.*9"YF7
MFK$A*=,H-4EVU"GS(G.]RJ:3MT;SAR5\-#IAC4"1R1D9'C*.(L^PG)<RQ@ED
MJOL6=;+XJS.4B+[X:8>2DL3/5T0M4K3*%6'6J+RTMP1V^MN[6Y&FF@6.X!BW
M71ZR-J/F]#@O/)6[S5-*(83''1T?7Q=",>W8_5PZKDYJII&;T;D0NN=4=22E
MEMER6MUM:U"QO$W,FZ:E<.S=N9OII[D+5E5B]=CK7_"F%#)ZV3V8;+DUQ+CU
MPQW/HF\G1*#M<6:9QWIZ./3J2U?FQNCBQ1:<K,J6FN",LYYR^9+7G'16VVTG
M!LZ032RU.VODD>8SL=%GS,F/H<]*T25/(Y9$"D:V4MOFJU5UU!;U%HV16MUE
MIZA#96IM TWZW[!8RVMP-B;9##3NH?,89G@['/H:O6I+F]RHTOB6T_N#PW77
MFW-KXT*NT2+DU;[^[JR#"^M=U>FH>WR/D6#XAQ]-\JY,DS7#,=8VB<@G,ZES
MV=5.T1F)15J5/<@?'(VRPPRU&V-:(TZ_JVW7UMLZ+;;KJTI4,N,2YVN4+<M+
M)LT\8O#A(,[:=Q60/[0TYCR_F^(XLE.8$49<3T;LZ8]A;XMCQUQA9J!2CJE:
M+Y<:2ML[(VMBJPQ%:%M?%3RPX@Y2<:Y"<H]!Y9@G8# \LK -D]9<BG5.G>'9
MA52[(DQ)ZR]K8CWJ/N"]@<4A*HYN;5EBYM5IU*-,:3U;@KFR?SK[3[ ;$9HU
MVX:N/5=OJFUN>CXQFC86798BV(L(I9<B5J$*^+0-VE"^.LTONL5HU!:=75\2
MGN/=#CT*%6@[)<:$IN*'F8_?ZR=G/4C8C7>2:;[Y:T)['/*. ),^>(D3Q$[5
M;2UJIO"W<YL95][>B<WYN[TE-(.)+2N[<I2+G!.J[4L(WYLYSME,O;09DU(X
M>=!'#?J5ZX.E6#.V;9+E2,8BP3%)8D5K$#E#F"12E:P,<C<"'!N5I"U![XW7
M+%*!5<@3+TI7>K@[UQ8<T3GNUG',ND.UNM$BTIWXP"RIY+,<*2&04D3',HE6
MUDHLE,'=SVYJ5%W)+9(W*[D%U%Q1[4XIER%>O3W'WI@[%Q?<K?\ ,CRGOSC3
MW"^YG]QW8 S!?GKWH^\3WG]G(LE,'BGS;[NH+X*Z?=YVO<>W=_\ SSJ]X_HN
ML8#9/E;_ '>N5?2SC(]POB_][_'[Y.O?;[T?,'N\\REY0,\U^[;W=/7BWO/N
MVZ.W\_MG4[[_ .+N['^E",^_7/["]!-]KM()AK/,,EK';7!DR]CJ1XZFREVR
M'E/+<WE+S",::\P?"Z3'#@I=9!-)2WD$VN=C[=5*0<:?5$9:GK:8%B?&]L)N
M7LOA"6Y'W<U!_<GR-;EA[9X%B$Z:))TYK\0VPZ"/D:F#Z[I>QJG?%DA?G=M4
MIC4C><7<U=:]*36_JU#C?-QM#B'3KCNRQGK.>I^-]U\<1B48J;7?7G+!L8)A
M$K52;(T=8&ET<C)AC?+##11%7)>6XI^U9%-U3T]O4O)OZ#;0X%O9S"Q+C5XU
M-']SV?5UE?H)L(]:U8V:L*L.2DV,X[A&)98P'+\K(?,KTT8EE"-Y9<;,\$M:
M4S<E8VDI01?:875+:5:GO"&^7N='DU78^D>XFI'#;,LK<=4697>9-F<LF9C8
M,>Y1RQBYF)/7&9?BF$BDRW)D5QZY-!%SBB57,+_:>STM7F7$V7WE$!>;QU[Y
MXAY*-2\:;:872O#-')R6Z-;]#Y'W>LB@4ZC*XQIEL.>34=UR188UN)/:)597
M5L7-YZ=32POMNSL#T'(3] 7>'^$#9;]C$U 8N^!WDKW>B/&=B;5#C1XZ9%NM
ME/#[]E229YR--,EQ7"&$L9*I]EJ;R>*0!L?YRXQI'D.?.D0,)<U*9$Z)J-R9
M8FZ+51AAQ:<-'_%5S+I]]<H9MU&V&UYE6F>^FMZ6UURCKU+WFQ^2NT6JL;T)
MDR@CV:W,K@O;4ACXUFJB34E2K4KP@4(U;@E4=XM#XO&INM@+8;D:Y7, XQT5
MP_K;DK6/)[9&\M[%0,Z%F3C:IU43C)#,5)\C%Q_$$#?RG!,OCZE=;1S?)&9V
MSD;T&TNZYAH0R>/K*$XEF<]R-.M<./*=9XW'U^VER1KEA[$T'RJ;($>4XCBF
M6SV)3S8K)3O7%C @PECV,K8PUV7HU"IT[TN?B4EJ\JTDU70**.5+>GD.GG)K
MPY9"SUQ:2[$F=L SU*^XQPX@S2V/*?:R<N4AP_(9'$X&^)X.XIX&2QR="4T6
MG7FR2TR]5:;2ZM+>K<$U_K#>S:R.9Z^K&[@;.8O?M<C8CGF4; 9TQ*M<;IW)
M,/H8AE'0^=SZ*'.2%FC]\J=HJW-:DOK$H4MRHPKHM*LK=2@"<&;^=WE=P'"5
MFX.2.#^;0GC^1*F16KE<KS[$$NP3)!WQT1(&^;S7&32E=I% SE:9:6:8WN3"
M4B0*3K$Q[MU?\)N"X+/G+OJ9@?C7:.4)>Y2*3X(FL%ATIQE'VI"E23R=23(-
M"TT6QT2VJU=4+3*BG:IR=V[4^\EKL0K#KKC+$]>L%-4IYS.9?$^+*;EYGX,W
M",Z/VL[?.'=X9]DHPZYGAV,G,M(J\8R.(D-RB9(D[0TGW+55SG#F1*432E5)
MZ(JEZBT-+.I^SN*MS]<</[282<5SEC'-4-0S",WNR.C>]-W:FJ&]ZCC^AL.4
MD))%%)"@5MC@62<>GL6I#:%'&E=0RX)"@/-R^91#'L9>9I/I5&X/#HZCN<)!
M+)>^-D:C+$WV7V%WKGE^>E2)K;$=IAEMM33S;+*5NI3I^&@"JO O-MI#MGN&
MT:;ZEO&0MDI%:VRAXR#FK&$$=5^N>+$,:CCD]IRY1E1Q\W(W)5*%Z0EO:C6E
M.O:U2L_J=]M-MM*," .-.&G(NPO-#N#O]R5XVQAFW!*)G:H/HWCB9O[7E&(,
M4=9U"5G:WM\Q<YMMS UJ&Q@:3W E M)4);'N1+%U2S%]A:NP*VN;O">K^N7*
M=P].?&U#<:XCY '_ &986N;XXUM9F2(V/.**RF&H"GC+\%Q\F;V=H;5B-6]-
MRM8M)1W.T:N=2UUZA$@I5($O/K!+CKKE'DNX5-;-L'J M&L2!ZVQV!V(NRM(
MRHKC8V'0G'D><8Q9*GA>\,+60E7*X:ZH2[+SZGJE"TM,3;?>?0A0'I=?,2_5
M(MI\EH<.X)A^C$TR<\.%&F/0Q45-H:\2UVOO,+*:859.S8P1-7114JZI2=IO
M6'&V4ZUEMUOP@-44>C[-$V!CBT<;D[1'HTSMD?86E)2ZU*ULS,B(;FMN36W7
M7W6IT2%-8792M:UI;;3X0%6',/R>._$WKI =F*Z[J-A(*]YLB>)\AIV_)M^.
M7+'#-+6>1N2.>%T]W&0")*C)6QWN%4=]S;6Y6M36T/Z#+JV!]KE@Y0H9Q?Z2
M&[C4@!.=Z/,RQM"<;8^0SNS'Z?(+ID0\UP)O1S2D1G=4!*&$-;D[E]1I5U56
MHJ%?T=#*G%A]#%W)YCK)'$Z5RKUA]S/#"-7IQL*]XR+EA;J>W2''+'([Y5BM
M)-:1U!8Y+B)S%E3"0XU:2*G'4M-JD+K6I- Y'A/F0QP\<2S+RT;7XR.U9QN^
M,,FDC=BY%.:Y;EKNA23UY@&/FF..1\*QA8^2K*[BUDGM:2B(E,2E7$GJ%1:>
MQ0<2%9B?F]YFYEC4O<'%_!/)GG2.K2?-$"Y]V"CJ#/LJQFE).<;)JR8W*;J3
MVU*\,-2EZ2J.'O*0Y/TWIU*HF^P^@7RZ.<AFN>^^G\8W3Q-)/,&*W%GD"N<D
M3D] QNF)'V$DF&S^-9!-N57MC4HB-A-R@U70ZJ-0W7DK2C+DQY9E0H[:N>'D
M%W6?<A2/A_XHG[:;6?&DF<8L=L=FC+T6P:S9,<6:\^US]V\5FKC#;UQ-"J$G
ME%$N3B[E$*2J+FY">9:0 LOXIN6V'\DS=F/'TMPY,M6-O=99$FBNQ6L.1%1J
MV00U8K-5I$,A8'=0SQU2^QE:XMJE,9VR!(L0*BJ6'%5).1J584Y?5U7%O:.3
MWZS\[.RY&UM;7OF0XN3DXJ243>W-Z+83D"4K%RY8IO*3I$:1.5<8::9=;879
M;6ZZM*4K4!:IIGS".7(=N#EG$FG.L*K)&E6"EU\8R'R"R7+"B%01_P @$)KS
M%$,PGC0O%$D4Y7.[4P@PM760-*?S==<M.[ D]K\YA"J6\Z>[VSV=L[8EX=>-
M(S<W'^L\X78[R?L3DC-,/Q#CU]F37>K2.C'C]%*W2'MSHG3*T5QJ93:^J5JY
M'<6?YN().(..":W%/S%6<@.1,^:MYVUOF6FV\.KUJ)7EW $N>J2E&KC:Q:0V
M6S&'26C,P*%3:G6+V^Y20H26EVD/" Y$K<4Q]5%@7:
M
M                                                "BWZQ7OQE[CN
MXRL@Y?P(I3LV7Y_/(5@Z$S)2A1.ML 43LE]<GR8I6MQL-0K7A!%8NO(;NV+.
M)3N2D@\PHXLJXJ\*YM:_JD_&M)=9(8Z;'..:LN[$Y3@K/-LB9P8LLN,:JWSN
M<,Z9^?5F.H\@;S(C>RM[JXF50WOC>]'*:4[516_K]G:'VOJ[&9,S82SMR,\.
MF9IZ7F'%''7*$J3 N47A C0K&K%+M(9,@6PB6*.FB:]OL150+T2<WM/-AESF
MEH>8C+1EIPY?@7C=Y']()CFF:?5_]XM(,X:-YJR@_P Q5Z_9O>SIM$\3Y"6$
M)+%35$)MBY%+D[D9&X_1 BJ;1[9EA[=8A+<$2XQ,4LJ$.$>F>W!'UD/C#7;M
M[*1_9#<Y\A^3=E,XWXE9SF;!F L"XUC4Z18/QUCE"YL+$^T8UL]8'TI2K5-R
M$Q8K>R+[RN\7J5ZH-C>S?';HSN:]1Z2[2ZK86S?)XH38D8)3.(4V+I2A;2S#
MS[&2LE3EI7Q7';5"DPWS:>H-0=K?4SLNO7K *TL@1+&^U6\F.=,\<Q2)P+C\
MXCRX9L-L/&H1'6V/8VDVT9K4IDFLNOC9'HZB3,)D3PC&3%D_DK<02831V/8R
M#R;3*5 0BU_SISS<M&-Y+OQI=M'KCI;K [S;([5J9KE.\&QC)[[G6'8VF+S#
M*OF=,BOS'*W['JI]D4:6(#+H^:7V9Q)_53%E6)U:@+G.(C?M\Y&],(UG.>P9
M'C/-$4G$[PCG^!-%YIT=C>9<6NMC9*28NI/7NIYL?=$2M$O(LO4J;TE5=R6I
MZBI'>#0YUS].LV9^&SD(5X_[UY].P"ZM2_N=U;#?!+X_Q]DR7UZVG$5JE]W#
M@Z]O3K5I<1UZ5MOI7J7!^;ZOZS8[8^&SC^3XQM;?,"W!3>\O)C90OLCLB/3^
M_.>5KE-Y91/:.163%+L4IK=2MUIQ=UM;KNKTU"G].4AC/UR<^S#MJ>RZ=:&&
M&[2%M%;"^HNL@-JAFND1954U+E!Y44QX;2E]#ZW=HGOK\-:5+#]?#[_^<<\]
M/_\ "O\ :EH :_@&0#3 U/,/K>'*(MR6229,L>:?0AOPZ@<;3KK&.)WQ74=(
MM<HV6JO46)E3BT2*\XV\HRVZZCPMK;9;8:;;8%[7)O!.,J>8DQPAY1%>&6[%
M#=EIK<,7+\PY <L:)R\NVQF3DMI$7D;%)8J^'/1L;,<;^YE*;BC;2J&WEW&$
MDWV!0WB$I#)/KE>TU^8;4]5&/]#(\;JK5VK9>9:N6XVUS(D5T9H9534I1YMF
MV2*&4L[O7LJJ_LTK=V@6@_6267';SPJ;RUR3:VVMS3"8.]1A8X4+M-0Y$1Y8
M@5F/[FI1<4:<F<G&5'ID-*E=6XXE683==0HTSI"HB;:'6\DG#-PFL+[N! =3
M]]L28FQ/D73IQR;,6AM.R,H+CD0;(JUI6$QWK,W5R6LK!$7!&[-"1U6(591=
MMR([O=;+ ^%L%NK]8#X],/2%9RJZ*Z@<DNE$?,C)>7LFX_NC=;U#6CDC-1O>
MY3&#VPIKHC3OY:)80I7XP2HDJXHHPQ0GK2RZP.D?6*<VX?V0^K@XOSEK^QVQ
M7"V2I/JK(L:1"UB;8O2%Q0RY6D;836.,MU[(Q70VQ+5LJD0W7H4]4E;$]UQ-
M++JA.CDPT>P/R(\16J&L^8=E\>ZO2]3'-=LBZ^S7(TGCK(QO&8XSAA1%&^,*
MF9\?6!7+$+Y&L@N*,U,WFWK4QJDE464=<30@T*YLEYU^LR<=&&9A?N=K5J)R
ML:AP.#N5<Q2V/+4=TT78M8FV\R0+9:B4-D.=7UK+C"4XQY6+\=2+JEEWJEIM
M]MIQIH:1N+O:G7W='1G!>PVL.-4>&<03)KD:-IQ$AC\?BZ7&S_&I@_QV:14A
MGBB9%'2TZ:6MJPXE0D))+7$'6*JEEW'766A7]]:&=9NT\(>Y!T)[U957=@YJ
MEBE#=6U8FA#KL%BY#(.SZAQ9MR5=8>6D64MM-IW%0?U[:%]>^P)[\2[-CI@X
MP./QNQ3:V^!OW/M?7!L-:Z%VE+7!YQE''F3.2ZTLHBMK\Z2E>M4N=#"RSJ.)
MI]#;+#.O;0,O#6]R#%WUD'G65:NTZO8<6F2,BS5!';C+&A!G1MP]KG)&9S([
MB>W6&3!1D%RH:=V!IJJU:YN734LRBCL L8^J)LD):^&N N,6(0EO\CSMG9UR
M4<EMI12HF*64)V%NN<KNI;6Y47CUG8K;.FMW010OX?[E L%RQ'./"+[EY_RY
MB\W#E_+FW:L391<U-$\=KLU.,):L;IC8QXAQJWRI.WJV>]&WLUA:I0WVGU(L
M2]4ZG03=0*P?J=C;$2^)I^D3+W=3,)1M?F1;DYTK?<H=EDI2,6/4K:4[+#J5
M4&F%1"C<=996^ZVG>;C*=%YIG2%QCC!.,JO)BPSQ:KPT1R@VXE.;VA$GR"Y(
M\T+<1>8GI.8>NQTADI+4[,MD>JJI18L:S3;2"BZVF4H216P*)_JOOTIN?/\
MC_4?M%V4 ?CY(7!"=]:\X9&PI6G,<$.O$M5K45AMERE*F<2MK"T)YY5*UO*+
M5WH#J%UK2G6[*[H^P _'GN/LC_\ 7)M.;GIK1NGF+1AYD#1:M)M4%H7M# =G
MB4+H249TE56(:*K[R+[J5J2;U3+.J999=:&Q4!G!^M@?]R5L;^L#7?\ ;?"
M%0/UDW_\VXXHOU@:+?\ W!V=0&UJ=1*,Q?7^901@8VUKAL=P[(8DRQI.F+\T
M-T9:(4L9FUC(1F4O*\VI&I/8GM*NI6WLK:6UZ: ,TGU-O_NCY'_%_F7^Q.(0
M%_W(3] 7>'^$#9;]C$U 4R?5*8_%&;A:PRY1TAK*=Y;ES8"03PQOLK8K52M-
MDMVBJ,]\NZ?Z5TM@\99BK+OO(M/3^X BYGTLLKZY)I%=C/LR+E.@$L,V&\TV
MW67+3+8-MV2R>)JFV5H:984G@W9U+K2E+"4E*UZ;;J '!#_WX?UBS]?[#^UG
M.8#X_P!7+C[(IY;/K+TJ/;$9LC9MYUD?:GF\FVYP0,DEV7W=<7]L3'U^V+1N
MZZ)MII]E/@OO1%5K_>4 ?8YWO^_#^KI_K_?OVLX, ?%^LO1UCE_)7]6MB4F;
M$KU&Y1O+)8[(69=94Q$[,;WGS0AL=FQ872MM;TJ] I,*,ITTZ;+ZT 7K<U]E
ME_$=R-6WVVWTIJ%FV^E+K:74I>7"W(PNZE*TK3K67VTNI7[-*TI6@#/Y@+3G
M7_?/ZK/H]K9G;9*!ZLK9#YWE&&,G9#DT988]9F"+9FS15D8UK9)7^-V2Q&^,
M#FY)#T215:L*+.[V5;?<GH7>'_)/D7ZSGQL83D+%L=@'43E6U'Q]C=V9LBN;
M K*-GBK#C+'E"-Z12)M5(,>2&7([H:0:G=>]0>5FJ">O<IO44J::8&B#B4V^
MUUWAT3Q#GO5_$C;@+&+L=+6(_"#.PQN.M>+YLRR=SI.8ZWHH@W-$:5H5DB5'
M.1"Y*E2U<25]JDX@A2:<26';M\)?M9 M0\ZR_1_'T;RGM4Q0^Q7AV!2VJ2K&
M_/MSTU)W2AY*Z4PM(L6-L8.7+$:<QR(M4K$Y175.Z_8&!AAU+?\ 5C>[8*R+
M?62]RMN8[ME'I-WB.:/;4QISTUT_9+C7(E.RJ8V?%U35&G6YU;RDG54J3(.:
MX]M?94MW+MHMO#?C@7#&!L$8QC4"UMQOC/%^)4S>D71F/XFCT?CT05(UB0@Q
M.]IK(XG(1/"AV3=0XQPON./6UN[4PTRZZMU0A1&=DM'.7"(;Z:0Q:6RR6I<2
MK)%K!MO$KH_+L:R>(N,K5SV#NC2VN$B9V\\TPY? 7I.4N26G$VFHKNBZM: ,
MF'*9QJ1[ZMQ?@SE*XOLQY"B"Q/F&/X,RE@_+[A'\B1F=Q::L4DE*AN:W=;'D
M;H0TNR. *$3FF/HK<"[5EJYN6H#4E:&AH^V6T%XF.2#?3#>1-FII#<L[485P
M:P6-NE#]FR!T.10)2M=,B-LIRCKPV'VY+=B4ZS)!!QURT^C$J)M1V'ICB+[[
M5 10Y_.)GC[=>,S97-T,URP=KWF/6K&*K*>*<J8;@,-P\_('.$+4KFEACBJA
M34PII$RRHJIS8F0K;#Z$+%Q9J/LE-++P%GW"]GS*.SW%EI)F_-*I4YY0F6%6
MQ/+7Y?6^YQE:R(O#S"4DT=#+["^V=ILUQLAV5&6VVEF*%M]UE*65M ?US.:O
MW;B<76ZN"$;;YVDKSA203.!H;"S+U*K(V)34>5X"B1W$VW'E*'65PM(CK6RE
M:W%J+K+J76776W!EJPIGALY5FSZK;J&YWIY@T0ICG>RNSK4[T*<2J4T/97O#
M./%,M0W6F7*$^0Y+C=[2FT.LZJBCN3=7I+.OOM"%4GS-.->^$G?CAH:EBY9G
M2%\N#;H-BEAH8;<\NV,LPY'6Y=BBM&GI2Y51IR ZXCE!5RFA5Q!R9Y*MI_2*
M+>D++OK1N*737/C8XG=1\;)XS?BW'NPN%\4WTF-JLB N;IBK"[C#( GG]Y*F
MRXV,NZ4]T5N=#:&'&EEF&]>AEM:W!/4DGZVTG**((*X?2"""["222;,UEE$E
M%VTL+**+LI;86679;2EMM*4I2E.B@"JJ$:C[A<?_  ;\\S;DF?ZQ2EQS*[7Y
M!;XUJ=DEPGL7@%V3G)#!]A8^YH.ZM!D.0EP XA.D0F7'FT0I+[5%QMA=+*AU
MCBL;/K(+3QW:CI=,DG%.BUC-Q"SN>)29O;E:R<WLKTL<'AT5SNC#_P T5G*^
M2KUI[U4C[6YS,/K7[:M0$H^-[2?DUAO-MDO>7>"?:#(YSE769QQ3F3&FLN2)
M#=,W) V),:F0.4JL6R!OM=BKBK8*SEJ'%0IJ5W:TOJ%])E+@&<B*:C\F&]>[
MOUCK6/1*6QN#XCE&X^;YGM,M=)"5&WO)"N"9TV\48(UZ9%Z<Z]WJCS(]NS]8
MOLJ40SUL:R_.:TE/U4C@&POZM[N#@;8#C6@N,8!CJ*Z^9&TW)LPALAA5I0FQ
M\J'SYD+6FJ\BKTKM?YW['+%Z!8\+%C@8<JH^6.B8\\\Y(:=>%2N&N.?E=T$G
M6P&8>!+<?3K;_3?,66GV>KL!Y!E48E)R2;F]DI,C-\M:3:Q16]1YD6)D![DD
MFT95N"2B6]8BI=85?8$^^*CE,=<]<A&8M1=[>.J!:4<H+9BVLBD>2(8R1ISO
MS% &=%"35#"LG-A#K,+D)+&D:%C99;(I*R+T#52EBHDU"028&G<
M
M                                                         0LY
M"-%\0\CVIN4M2<U&.C=%<AHVY4U2M@HF\202:QMR3OD0FC!579>08L97A'9V
MZ>_JEKT)AZ0RZA1]]0% ^,]./K16I^.6'5/ 6XG'MF+"D%94<(Q+G/.,5R"V
MY@A<!92+6N,M[NQ)('*VHU5'VI*66F)672ZI1-"RKE9UEE*6!:#Q$\3Z+C=@
M6;)-E'*ZS9/;O;J<>]':_.SNVU0(YE*35#^Y$QR/-2J\]12+LSI+W8^JE3U%
M+HK<#U!A*4JJ=$E"IB \0',%Q7Y5S:W\-&Q6K#YI[G:>*LC6Z][>(9?1;B26
MN*%.W&J(^OBL8<J/"=N:D"=OL<"G)"H6-Z-"2M0*C4EJNH6;\7'%CEG5W,&=
M]Z-Y\[,>TG(ALVUMD5G>2(JR',6.,78Q9[VDU%B7$J%2VL*F^-GJ8ZVFJ5-[
M6U4-L;4A5J0NXH\]6%O&6EN2VW%^0EV&&*,R?+J6&R(W&,?FKTJCD.=I[1J5
M4BB.6OR%O=E[3&3'NI/?STZ52H+2TOJ4489U;:A%CCVTYLTWU;8<23)^2Y,S
M#.GJ6YBVFRFJ34,-S7L=E]==(LPSQSM4DEWK$+B[J*-K?8<7;<4QMZ-/=;3L
MN@!2C$>*?F4T60Y"UKXMMX=6HEHO.IM-);CQ@V7@<V?<W:EH\@O*AX?HWA9:
MR1>8QB=(4"UP/4I:OZE*1<JK4ZJ8M0>J4G!=-QLZ%0'C<U*@6L$'DSUD!>SK
MG^99+RG)2[B)'E?+$V<;WB<3YX2W+7*J&YS6W6)TB:Y2I,3-R5.4:H4G6&*#
M0F'D"!P_*D#FV,,A,"&5P'(\1DD#G$7<Z&W-LDA\O9EL>DK X6D&$G7(7AE<
M3TYM++[+JEF5Z*TK\(#*1B/BUYU.+DN;X%XL=K-2,K:62&8/LHQ=!=S&>7D9
M&P6=*E1B]V3-ZZ&1%>@=T]JDZEQYUBZ]"O5EWK;&1$>K56FA8KQ'<1$STAR!
ML!N3M]G%+M-R([9G6E9ES$U-=[/"XI$RUZ!QKCS'",QM8U)[*X.+(W'*U%[<
MU)K4[4VHD3<B(0UJJ#].C7%QE[5KE2Y(M\Y?D'&\AQSNCYF\!PZ-WR>LUBOF
MUY0N1OBZUT84#%;VA26MMO<U:K[:M.GHI\("\<!GUY-.(7/69-L<7<F7&QG^
M)ZS;^XQB]8 _WY,:USOA?.>/Z)E3>F8Y^2V,LH6-;@C:' ]%>?YH="UJ2U);
MU$AZ%,LL"(#'P_\ *7R%[:Z\Y_YJ\_:V*\%ZH2@B>XMU1U4;I0;%IE/$BMI<
M*KYRME#"S7)&=S7,B&JXQ0OD"E0B3'MZ4EK*6'J+PG+RO<0N2MM\V8$WVT;S
MNTZL<B^L*6YB@&2),U'.^-\C00XUZNK \EI$C3(E2)*AME+K84LL:G<E4WN:
MUO6H5)1Z<Y"$ LF\4G-=RG.^-,5\N6S^JF/-+8!-&:;3?#>F+;,J3/.CQ'+[
MKF\J0/DJC3;;'D9J56H)*56.9Q"(PRJBUG,4EIE!(6'\N_#?=OKBW5=QU>RD
MWZK;.:#RANEFH4X*:C#X/%RVSP7>BA[PE;DBYU:&ML6XY8538N3$+JMQK;U:
MHE)9YEM KDS/H!]94WZQ>LT\W+VST$Q-K-+S&IBS=DG 45F[WEO*$/:WEO7J
M4Z!D<H/%&?\ YV/:BU!J9.?#RE!=U2#_ /![S4M0LIY".&J-;+<0S+Q>ZZS)
M#BI-B>.X?0X7DTZ*4NS4H<L0+$-Y=^1CX^@L7GG3A%1=<XN"))<84YK>]VI3
M;;*IC B!DSA3W3WIXIXKI]R%[*85(VYU_P M,,ZU2SMKDR22^%PJ+8^QI'X#
M"HQ/J.T/QC)) N>:W/9SJM0(T)J=0<W*BJJ+D-2#@Y+.-.OK3^?<1/\ I_F;
M;_CPCV(IW$W'&>4=C85'YTKS3*\<R%NN8978A:2<6QABMDC['EYY!M4J".&5
MNJ94M>GOK8?4-"G'[I1C3COU"PQJ#B=>Y/D6Q(PKTRJ5/9"5,^32621]=);-
M9@ZD).L2E.D$J?%9Y*:AAUJ%)<2EL,OL(LNJ'<<[82QOLGAG*& <OL!<HQAF
M&#R+'TX8KS3$QBZ/29M/;%U42TFM%+:Z);#^V2*R:VGI%199Q5UIEEMU RW8
M>XV_K#W'%#5VI_'ON!I9E[4)(\2+W)O.UL<E[=EW!3))7E:[J$!B6-061,C@
MG0.#T:KI7MGU&<I+.,):T)1MJ*X+0N(;B.+XZV/.V5,X9:,V<W9V^EALXV>S
MLO;+D+0[K#W!X>"X9#&E9;VR:+IW:0+%*M084F,=E)MEUR9*G3HT:4*U6'B'
MY:.+_)N;J<*.Q.LBC4G/$T5Y'-U=V[;):9[F9LZ)+4"H['C]'6%[H]-:%O1)
MTI*D]>VJ#4"=$F7)7$U%1>8$T^(KB"S'J+G38O?[?//,?V;Y#=JD9#!.9K#6
MY6BQYCF#$J&50=#80<X,L76.I;EX492*F>9VA&VMK*B;T*0LDHXU4$/J\0?*
M5QLYWSU.^$C8+6I'K5LC+C\BRO4G;5JE5S#C">K^V*/6XR>XNQ/)JUI;R#.Q
M27F+6=1:VV)42TMUN0$*ZA*OB?X@,]ZX;-9VY(N17/D5V4Y M@V&R&*W+'[<
MK2XNQ) J7LQ9S!#CW-CBI[DN5M47:$!=Y+,U)VEN0WI"+5-%!Z@T(:/7$'RT
MZ&[Y[7;3\0&==4C<1;MS(Z?Y:PEM6GFY*>-3-Q?Y-*[U"/PG&'FYW98U(IH]
M&M*M(Y-RQ.C=*HCD:NTFBB\/18=X&]U$7)QIYRA[-;>8WSMG*$N$ZDFU!A+9
M(8RRU-=('(,?XUQAK?%&R(HF-NQOC=C<R[:J72K<X.BHY4K/+H8;2R@3WG?%
MQEZ5\[N%N5A'D'&Z;#N--:'7"3MCI3?)_>6O?U\=RRSENS?84PF1:K/8?D!-
M==VCA8=U"3>BSIZE+@O& 55<T6A61N2WC\RIJ+BF8PF!S6>2;%SVW27(5S[9
M%D:>"Y"CTP<2EMT;:'QVH<L0M%Y1/9IK[>UNMZU;;>FM @[RO<,^==_.*73#
M0;&^4L30W(^M4FUU>Y7,IN9,+80_)\-ZX9%PP^%1ZYAC+N_5.='Z9$*DG>49
M%O="C.TK89U;+@T(S5D42:&RV-I#24ZJ01E^9$QZCK]W)4.K4J0$FG]E889V
M)9BBE;NK;6[JTKT4K4!4+P1<:F5N*C25UUBS%/,>Y%EJ_.,\RD6_XTODE\=L
M:)7'X.T(V^^LI8X^Y^<DQ\7.N-Z"*E=0RSJWUKUJ4"R_9W%KOG'6O87"D?<&
MUH?\P8.RSBUD=7FJJC0V.^0($_Q-M<'6J).J6T;42UVL,/[$HPWLK;NI9==T
M4J&3_3KAMYSN)7"S!$./O;K43(]N0//T@V'P?L"W3]3BAERM23O;;',DX'>T
M,-22%+YZQ*GCZ)^1KJMM+G1JO,K5P)N2V(@L[XE^(O-.JF=]A.0+?S/4?V>Y
M#-GF]-&I9,8>WK4N.,68^2GM)UT&QZ:Z,\:7+TZ^V--!%3*-+0E;FUH2($:6
MPNP\Y6'L../BXR]IGR&<I6X,ZR#C>4PC>[);;-L=QB)7R>Z50]O137(DF,23
M2UX86QHM67I)B073N*E79VA1G3=U>K6X'%9Q<9>T+W&Y<]CLC9!QO,8MR%[+
MI<VXS8X5?)[G^%,!&4MEYW<TSJCZPM#=:\5;LVMY-/-YZPGMDBC[?J]G=>',
M^;+B?VIWLRWHMM7I#FS$>(ME=')Y()9$D^<TDA,QX_U=Y!CZ3M*\]=&8?/UJ
M=9'G6"W6F(SF=4F<TZZMEQJ:I5+C ^?NOQ3;C;N9<X.\]9'S'@2S*''+F!HS
M%M4K;T<S:6+*<@KD+6*<22W"S:CBAUJ5.JNPBYV)BW:C;;;<L34K6VG:U+"V
M7?\ UWD^V^DNU&L4+>V&-2W/.#LA8MCC_**N%L=9W>81]8T(7!ZJTHG%SHVI
M3U-+C>P(.-ZE*]6RM?@ 4SRS@$,S;P<8"XL<SY:C[+F;7=8LG>/<V0!N='N'
M,^54DNR<ZLRLUJ?$D<D#K$W.*9*5M;@53N:@LPWO!5;[DY=I@1X?M1_K6.1L
M0N^H\^W$X\DN-Y-%5N.)?LZT-N0EF<7K'[RSF,;W4DOW3-#;=+E["N,3F*[&
MMM7=ZMN.L<[#:VK+@OSXW-"\:<:>GF)]0\7/+E*VK'R5W<)).WI"E;'G($\E
M;NKD$OEZ]M1G*B&HE>ZKKBD**AZJYO;$Z9+<H47$U/,"=("-NS>GNKFYL%,Q
MOM-@C&N<8AU3^XHIY&T;FXL!RGL>\+XC)"[4\FACL;0BRVJQI6(E74IU>TZM
M:T 5FZ6\,:CCJV4C\VU&W0V)8]-5*68$3S0K*KW?E/%I:]\CSB1'GS%4H>5I
M#MC\Z/RJJ5:?9>E7+W.RE]ASCV=M"# B7M#P_;[X.WWRSR/<-FQ>%<33O8]*
MG.V9ULV*9GTW#N2WY'1.J62)N<(Y'I6JH[25Z),<3K;R6M8D<UBTU.ZE)UQZ
M6@<R*X;N3_D?V PEE/F[V:P \Z[Z^RQ)D&$Z8:E-LI)@TSF3<?V=I^2'B31Z
M.G$HW,E/:6J-JKD2VYH4*$2(YHN6*C $L^4_A[S]L/M-AKDBXY-D(_JSO[AF
M+V8]-<\@-ZUPQ#EF 6&O%$S1-RVN.S%2A6(T$C7HU%YS&]IW- 801>21>C3J
M+ A)F'C Y[^4=CBVOW)IMOJ9@O3M))(V_98A>G+/,5N2,V%QIP2NR)L>C)/'
MF]C3I[5B6AR>XYQN:D+G:0OO95QB--;8&JG$6*H)@K%>.,+8O84\7QQB>#Q?
M'4%CR6Z^\EFBD.94; Q-]#C:W'*3$[:@+MO.,K<:=?TWWW77W5K4.B ,Q7$'
MP#2OC1Y!-J]KI#D_'\VQ9-XODG&.K,"CU94>_P"*<79 S81E*C._)Y SI&1G
M<&IM9DB2GFE0H*-.5K[^FVA]_:!_GE?@!E&2.=^&\I!>3<?H==$DTQ9FN<X3
MONEA<U><Z88Q:JAT DS>WIFCP5>G;I>V-3Q54>LHJMN-7TM+ZY]:F!;QR;\=
MN(.434:<ZI9@<'*,IGI<UR['V0V1*2X/>,,H1JQ;9%YNW-2I0D1O9*=.Y*T#
M@@--([^TKU2<L]*<86J)"BM#J/\ 6N([BXO5!DWCT,6X]3,Y$(:]MG)!D$G8
M]KQ^G3$-)1MAEF*52.^>)X^GJ58X&I%;M569V]7NBKH<"PMHX^.'[7C1CCZE
M6@KB<=FN-9G;<B5V:FDA07,*_-3]EB/TB4U5*$*%Q6*H\TEQ$E.TMI!2TU0D
M2)"S;CS%=YR@P*@\0<9?/]QDM$BUOXUMN-0,SZ8&2"1.6&F'<%CE:/)^#T<H
M<E#PO1$FQ&&.+>X%IW!QO-ON+<%C8L66'+"F5ON5G)[PL/XC.(K(^E&3-A=T
MMS<^H]JN0O;,M ARWE=G:S6R&P^)(CVU;?C['O>VUB7+&-8N8FOM#:MC,C)1
M,K8B1-J,A%_3A]3BLXN,O:%[C<N>QV1L@XWF,6Y"]ETN;<9L<*OD]S_"F C*
M6R\[N:9U1]86ANM>*MV;6\FGF\]83VR11]OU>SNO#G*GB&S7@[F4.Y*=*\CX
MI@V%=AH[>P[VZWSLR6(4F4W)Z6'VRJ<0DB.1I[8+9,N-*0R OOU4IE\D(75-
M452O"RRT((8LXA^9[BEGN9HWQ ;*:G373C+F1G/)+5@';MLER=_QO)7M C0&
MJ$#A$XHK+=;FUD8T+7>X$/C?YQ(2);CVNIA=3K0G3QD\2FS>)=Q<N<GG)=L#
M ]@MY<IP,C%4:9L/L:EIPSAC'5A;&6>CC!SK'XJX.;X>WL*=O*J4U("D::Y;
M>::Y*7$U24&A(
M                            'PY+)XW#&%UE4PD+'%(NQ(S7!\DDE=D#
M$PLS>3T=LN=7AT4)6]N1E=-.L:<999;_ ':@.":Q[B:U;CQ!TF^M^7X7E)D8
MY1,XB]V1Q[;U;NS.\'FTC@3I>[,A:BYU;FMT>8NI/:5AQ5B9X:[R%R.\Y(H)
M-O#KJC*&,T:@](KR)!4JI*<:G4IE$N8"%"=01?<4<0>2:X6F$G$F6UMNMNI2
MZVZE:5IT@/K,<RB$G-/(C<JC<A/2EVG*26-\;'8U.5?=U+#3RT"I1>27=?\
M!2ZZE*5K\ #YY^2,=I9DFQRIGL+3Y"6(Z.*."'REC)F2ION+--HN31<Q=:]G
MHZE)S+J&VD5LZMEU>GHI7H#V!QQ2<HT\\TL@@@N\XXXZ^TLHDHNVMYAIIE];
M;"RR[+:UNNK6E*4ITU >3AN0X!D9"K=,>SB'SMM0++VY<XPV3,LH0HW NRTR
M]"K5LBU<G3K+"[Z75*ONI?2E:5Z.BH#V
M
M
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M2PHL!JO
M
M
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MT["H3LT\R!B#AFXU^,76[;Z1.4%GN0[L9Z],[4TQJ2S"EVQF9%#O.W&#K5#
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MVEU:4K\-0'4
M
M
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M@.N
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M0
M
M
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MQA,3XX??'W'RP
M
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MTU5=@'6'/P
M
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M.LQGJ/$$I]@G'T]'/6 81UF,]1X@E/L$X^GHYZP#".LQGJ/$$I]@G'T]'/6
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MO';7:QX_Q+ 8=C."LEE]3+&>'0./-T6C#7:96E*F6M[(U$$TNK2G32SI >^
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MKP545Q'1/AB<::HBNFJF/>B<(N
M
M                                                    #!+N']+C
M:;^(W-_[3).-*-B?0C1O564\WML..;7M5W-]8-1\\O(Y"5.?    .U:V?2*P
M'^NK%G]N6(1_=GT5U/U?F/Q-:8\N_:!H7KC)><VV_P!&9K=<
M                 9*-C]+GSE]YH=T=9]L=E-BL/ZRZ281U<D>NN!L)35+C
M?WRI\\0U:^9!S&L6KVA\2O3;"LBLBR/K5): Y351W%/:L36)C"%(=:_]TTXX
M_P!-^_\ _P#;+M?^S(!I5A$2;8#"XA!&8]P5-$*B[!$FI2[*:+750VQQI2,Z
M$]S66E$6JW U*CMN.-I990PRM;NK3IZ 'J
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M-9V?KE_;VO6ILZEEZ\*H\--4>&FNBKHXJ*XPJIJ\<3TQ$XQ'KQ*WP
M
M
M                  !@EW#^EQM-_$;F_P#:9)QI1L3Z$:-ZJRGF]MAQS:]J
MNYOK!J/GEY'(2ISX   !VK6SZ16 _P!=6+/[<L0C^[/HKJ?J_,?B:TQY=^T#
M0O7&2\YMM_HS-;K@                            #-[RI<23KL_MK!-R
M57+;.- W>(0])CW%),6:XI#7B/V$VT7RQ"PY7NRECB6.C7*5EEBQ8S7F'(;#
M.M?V5>T,K<$!LIZ09#PQCF:97R'];1V1;(/CZ.N4JE*]FD"::.R5E:4]RE::
MVQ*$Y]D4ODBZA5E>R1-J!8M47]%A15]]:6U#7/@MZ9Y+A+#LCCTZ6908'_%>
M/7ICR6XI%R!PR(SNL2:%S9.ER%TMM<T2R6HC[' TI12AY=ZBMIE.O2H#J@
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M
M
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M3%5,S$Q+ZX^L^>
M
M                                    #!+N']+C:;^(W-_[3).-*-B?
M0C1O564\WML..;7M5W-]8-1\\O(Y"5.?    .U:V?2*P'^NK%G]N6(1_=GT5
MU/U?F/Q-:8\N_:!H7KC)><VV_P!&9K=<
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M335$Q,3#//.Y+-Z=F[N0S]NNSG;-=5%RBN)IJHKIG"JFJ)Z8F)C"8?N'NO6
M
M
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MB7ZA[+^
M
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M)B8PF)CHF)B>F)B>B8GP/]!_1^
M
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M4.F)B<)\+_H\@
M
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MO4K:-=$G O!V:5*QLO;EGF2,/;]2].H8%:>^J7PE([U5+#DZ4HZWLTIQM?\
M!J_T-]:%=G4JN_=9[RV=VKGJ>2_."Y=RU67N_%\GF,SC15EJZ9X/B.;FO"JF
MB*HX;-RO]ZG]RKF+7!-OL7/CDGEM>RL\R^75%N]3=M]MF;-C"JF_35'%\:R\
M4XQ55,>5=HI_?(_=*8FOBBNU0:<*/
M
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MBF)[2CR.**;-QHZIB
M
M                                 P2[A_2XVF_B-S?^TR3C2C8GT(T;
MU5E/-[;#CFU[5=S?6#4?/+R.0E3GP   #M6MGTBL!_KJQ9_;EB$?W9]%=3]7
MYC\36F/+OV@:%ZXR7G-MO]&9K=<                       !BLY,]/_JZ
M\4W6GINU?(5D[7IUR%DYKSOLWH_C#)TE<L)9'RDH[E(#95DZ!PS'$\7P653N
MBJQ8Z4JN0.:I,MO/050W'6J '5';8#@ZWKY/-5LSOO*1)<M)\>SK"L:TVT!:
MHQF.+Z\QK8Q,Y(8ACJ9)695!R&0Z1+)2N;;DEEMC,D)/3$V+#E"*AA%P:_P
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M+K3O.!-A=:EVEJ*4M^#H =(   !P;8W5W7?;S&ZG$.S>'(#F['"ER1O5L6R
MP)'M&@?&^T\I"_,J@VVUP8'Y(G5'$EK4)R=5:0>:50SLS3+;@@=QQ<,>E'&V
MD52+%F(L;N^<E<HR\M]_5\,5I)T@@F0<G3250_'+"JDLKGCA&FO'V-W]KB1R
MAO6IJOZ=EM6*RK3%%Y-@=7VKXEN.'=R=)<G[1:CXKRKD=,C0MQD\5IWR,2]T
M;VPBB5L0R*10AZC+M*$;8EI0I,4XFJK$Y5*6%TMLI2E EWA+!.&=;,;L&(,
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M/SD7&TZZMY[.MS7M6[5Q7K5'3&4JJ\%5.&/^SUS/1XK4X4X\%5.%@(O6JJ
M
M
M           ,$NX?TN-IOXC<W_M,DXTHV)]"-&]593S>VPXYM>U7<WU@U'SR
M\CD)4Y\    [5K9](K ?ZZL6?VY8A']V?174_5^8_$UICR[]H&A>N,EYS;;_
M $9FMUP                      4U\P.)>'-?",49VY>8Q!3H5%)4MQ+BJ
M93=5F6U.VRG(#0X3%;&$2+#ZRU<:<]M.-%"JIJM/>47:WUMH99=?2V\,R^ L
MI?4[LH>^KWKZ^X?U_P#=WL!D?%N-O/\ --NIG[[,3Q'S-X.V"9/#99?A2/Y(
M\X*>[,J_K.2'N5W;UKU[0':F_+GU53$&=]-W31/7B [&[-RG<W7&$XU9,9R#
M:B/R;&K^^9!;[V#-!%,AEWQ>26X\E:-N.L9C:VWN9QUA=*T+H;6@;D@$+]]4
MVO,QU\=\!;([!N&L\1VF>$V (ODB/9%8,4S6^>O[.^3)ICF/IW*6UWC[--W9
MG@KA<@M4IS>]7$W$%6&'FE%WAFRBOU2V*H]LLKS&0[V;OI=<WC%\%:<=RF*[
M/-Q&V3I/V]:H,EK9E=\7:X6P5=B]"EOLN8B4)MRTHZM]3J4IT )'NGU3W3&2
M(C&69[R\K4[BRTQ-Y[ATPVEQR[QB1HDZHE5>U/C=^[Z1>I;U-Y%*7TL,*-MI
M]L7?9?2V^@: 6O)FLNOD@U_T\1Y$Q[!IQ(XK9!]?\%J96C,GS_#\4P!T=#+8
M]&%"U5)E[#%(+!U-Y[B=95/91+U##JGF66WA(T
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MF[FZMM6YKV=>N8U41C,Y.NN>BBKQS8JJG"U7^QF8MU]/!5<G0+JJR@
M
M
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MM;SKBK##B3#J5-J%DX
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M5KJGHLW*NF9HG_17*O#]Y5,UQ%5<S1;Q7<
M
M                                            &"7</Z7&TW\1N;_V
MF2<:4;$^A&C>JLIYO;8<<VO:KN;ZP:CYY>1R$J<^    =JUL^D5@/]=6+/[<
ML0C^[/HKJ?J_,?B:TQY=^T#0O7&2\YMM_HS-;K@
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MD&+"DL'B62H^X/#^8WT.O7VP[_"BTDX[F2G,--JS&KJ6$65-KT%TZP">8
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M7R7S_++4OSAI_'?V?F;DQ9N3TU6JIQJ["]_G1$3P5^"Y3$ST515$2T%I7"
M
M
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M:.I"2VMJ4ERE$4:7Q<4FMNZ;K4Y:I==2RE?AI;2@#J
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M[4S-<_%K\QC,3AC-F],1A3=IZ<)Z(NT1QTQ$Q711)P60<7
M
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MB*XZHHHDMG4T8HI84@BD?-4WV4+[XK*5&6&%FVDU),L,N"1&H^[>M>\&$J[
M:[Y#3R;'R!X?XQ+Z/C:Y0Z3XWF42M*OED*R7%).F;'N$RB-E'EFJ4ZXHNVY*
M<4J)O-2GDGF!7!_[P[QX^>_.G4V7_=K]X'NM_?R_=HR;^XOX\\[^'?,?[P?F
MSS3W?Q#_ ()YQ[IYJZ?\([SW/_"0%XR16E7I4RY"I3K4*U.2K1K$AQ:E*K2J
M2[3DZE,H)NO)/3GDWTOLOLK6VZVM*TK6E0$&-U^1G6W0ZS&K-EM1D2:Y8S8\
M.##A'7K!&.I%F//V8'1F(*5O9<$QK%"#G%:C94AUMZE8J,2(B[K["J&U/,+*
MO!I1R,ZV[XV9*9L2*,B0K+&$WAO8<W:]9WQU(L.9^P^Z/)!JMD+G>-9602XH
MD;TD)NO3+$IBM$9=9>54VAY9A5@1DV!YQ--,"9<RKAU%%-H]AG?7GLZ;.2_5
MG6^?9RQEK+?5.H6JR<VSZ-IRV*,J&=N1*#EY::]<8@JE4$J*%JDYQ!83S:]R
M-7GG5DO=EMS;!U&JIN.U.5:9KJO.3Q,N$(BCKEK@IM4IB7=(Z(E:<Q$<U&IK
M'8ET+N07IK5MM2*!7Y@WG9TFS;E'$N-%4;VCP6@V,=$S)J_EW936O(N%\';-
M.[A9:<RMN%\FR9'1F?5DB3&DW-MBZC;<O,4ITY'75'DD7A<T  ,O?*ME#$F%
M^>W@BR;G3(F.<3XNBL%Y"U$CR#EF6QF"0&-J%^OZYHC9[W+)@X-4=9SELJ<$
M*5#<>H+N,<#R"RJU.O+MJ'/M[M_N/N8<T? ]EN*;KZ<2G'>)2^3HG,&38]LA
MA-[A>,BIGJU%V7&Q629HVS-4QPPN5RCO*1CM=%*:BY?VA27KF]:T!\_F9W2T
MYV7SGP=Q37';+6C8"4L/--IA(7R-82SOBW*S^RL%)AYMJ^.S-!)4_.+<ST<5
MQ"?O)Q=A/;'66=;K7VTJ&M4!2;SS:;9^W<U Q=CC6A_P_'<L8^VSPIF]C5YP
ME2R(P=57'*.:&IVXU>WM3NK7."MW=4O41V%EW'DVF]!EE:4Z0J$W&TV^M![Q
MXNCV(LT*>+%+%(SEC&F9&TR$O.8&)VNEV*9"5)HP6I6+VAZ)-9S'$FE%1-"K
M;S2NFVTRROVP#ZVX^I_UH_>36G*NJ>:%'%6EQAF%I:6:6J(2[9A8I26C9I,R
M2Q'5H=E[4]HT9U71@(I?=>E.I<56ZVE*5K2Z@:P\%0UWQSA'#F/9!<CO?H)B
MO'L->[VXZ]2WWN\7B30R.5R%0:2G,/1W+$-]2K[B[+KK.BM;;:UZ*!U0
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M
M
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M0)W1I<"BE11"DHM8@5%F6VF66&6TNZ+K:5Z: /N
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ME7:JJLKF(CR;UN)\?BINT1,1=M^&F<)C&BJFJKN8[2YF
M
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MC0H4::PI.D1I$Y5I911=MMA=EM+;:4I2E '[
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M,UX6\W:B9M3$SA3%SQV;DQAY%?1,XQ;KN1$RD*.].3@
M
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MMOZC<TG6\O=RNI6IPKMW*9IJCJG"?#$QTTU1C35&$TS,3B^Z/M/F
M
M                                                     #!+N']+
MC:;^(W-_[3).-*-B?0C1O564\WML..;7M5W-]8-1\\O(Y"5.?    .U:V?2*
MP'^NK%G]N6(1_=GT5U/U?F/Q-:8\N_:!H7KC)><VV_T9FMUP
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M'%SH5:X&KUYA1SEVQI)-G3=UTX:0
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M-S96YELUT\,S&-N[3$X<=JY'DW*?NTS.$^35%-43$>]$X1<
M
M                                            8)=P_I<;3?Q&YO\
MVF2<:4;$^A&C>JLIYO;8<<VO:KN;ZP:CYY>1R$J<^    =JUL^D5@/\ 75BS
M^W+$(_NSZ*ZGZOS'XFM,>7?M T+UQDO.;;?Z,S6ZX
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MK>GE=W1$20G[X[/#@>K5&]7KGJ3S#;ZW7WW75#Z@
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M>F)B8Z)B8Z8F%5*J:J*IHKB8KB<)B>B8F/#$QXIA_8_3\@
M
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MYVIU)92DBU>T.))M+#+;;[:7]%U*5I6@#V0
M                                 A]GC3?'F7^^/K)83!IV;0PZYZ;$
MEE6IZ45K<9_Z0M!5Q)9YQYEU>LK)J6IZ;NL94ZEM+!4[G=W2-@\U^UUO1HHT
M7>U6-4YBS1'8YBOIG_:K%/#%554XXW[?#>QGBKF]%,4+ <L.\)NS8'9Z9J4U
M:GMBG".QN53VMFGP?N%V<9IBF,,+5?%;PC"GLYF:D&(]DO8O3!]31.;M)[_
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M&/#-.$SVD=@<Z
M
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M*W]'6KT=-0[F
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MB)B8GHF)C&'ZQ[3^
M
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MIEEM]O3T74I7IH ^@
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M]>6U*S/335X)CQ5T51C3715AC373,TU>*7K!*'P@
M
M                            !@EW#^EQM-_$;F_]IDG&E&Q/H1HWJK*>
M;VV''-KVJ[F^L&H^>7D<A*G/@   ':M;/I%8#_75BS^W+$(_NSZ*ZGZOS'XF
MM,>7?M T+UQDO.;;?Z,S6ZX     S-_66.AEQOH9D7.#:]2GCGQIN;"Y+O\
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MIQ%V"7L)BLBY*J,9I*TI'IKO4I;JW7)E%Z%;96\NM:ULNZ:?W 'J
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MCCMU>51,QX:9IJJ[$.M.?
M                                                        YM)\
MRX@A+K>Q3/*N-HB]ED$J3&:3SF,,#K8F44K<G47M[JZ)%=I!]M*ULOK9U;J4
M^"M1];)Z#KNH6?C.0R6;OY>9F.*W9N5TXQX8XJ:9C&/'&*/:EN[:>C9J<EK&
MJ:=E,[%,3-N]F;-JO"?!/!7735A/BG#"?$\]^\GKK^GS"O\ I3@WKT>U\T]U
M>C-0^3WOP'S_ +1.7_IW1_EN6^$/WD]=?T^85_TIP;UZ'S3W5Z,U#Y/>_ /M
M$Y?^G='^6Y;X0_>3UU_3YA7_ $IP;UZ'S3W5Z,U#Y/>_ /M$Y?\ IW1_EN6^
M$/WD]=?T^85_TIP;UZ'S3W5Z,U#Y/>_ /M$Y?^G='^6Y;X0_>3UU_3YA7_2G
M!O7H?-/=7HS4/D][\ ^T3E_Z=T?Y;EOA'76UR;GEN;WAG<$3LT.R)*Y-;HVJ
MB%S<Y-RX@M4A<&]<E,-3+$2Q,;:84:7=<687=2ZVM:5I4?#O6;N7NU6+]-5%
M^BJ::J:HF*J:HG"::HG"8F)C"8GIB>B4KR^8R^<R]O-Y2Y1=RMVBFNBNBJ*J
M*Z*HBJFJFJF9BJFJ)B::HF8F)B8G!^T?S?V  !@EW#^EQM-_$;F_]IDG&E&Q
M/H1HWJK*>;VV''-KVJ[F^L&H^>7D<A*G/@   ':M;/I%8#_75BS^W+$(_NSZ
M*ZGZOS'XFM,>7?M T+UQDO.;;?Z,S6ZX     S"\\:=HQ[NGP\[5;00UXGG&
MQKYF/-=^SMEL9<IK ,7Y,G4*8F#7O+V6(HTMKF:LB\6G-+%!*Y0F5$([DAZ6
MRVA[D60L#AG(=L'J+R/;I\1D2XS9Y \[[?X=W7Q?FN>YKP*AI(4V#M+(6E<?
M?2BR;/VE"6Q((W(SSV@DA@<%=:K#$UR*I-ERZPM2'1]4-B<,<0G)-RJZ^;MS
MR/Z\8NW%V#4;_P"J^9LA&K&7%N4"\LI5)N<HBFGCFGM:4$T@LMN1)ZM)RBAI
MO0=>07:35/50'KN,K(C+E7:_F3YP7=KDS5J).&& X[UOE2V-/32\Y(P=I]BQ
M;7+N68Q&G,AN7O,1F#W'$YS$I-+H>>>4K25H08G-*H'U.6F45Y-N('!F^>C4
M9E65::^[&X=WZQ+"5L?<VB<39NUVFDUA4T;445*L<5![LB8W1Y6V([[#[E2=
M%=0DLQ1>07<'!N6?DUU?Y2="V#0OCKRJS[!;0<ATLPQ HSC:,-KFND^&80DR
M%#<C9+G6>VBU"<9BMC@T?C!B1VN<>H>EJ>8H*M,(3'*"@]_/W/'_  _<UC%L
M)G%Q]WFCVZNCF,=8$V?7PAV/A&-MC-;C(^T0N,Y.DEQ+DEA;7+,51DNB%6J.
M)(5JS3+[Z]1&L46!][#<O@/*USH$;4X$5VY.TGT*TVG&OIV<VHAW20+)^RF>
MW5Z33"(8SE!5B B:LL9Q2_5M<%J4XPE&LLLO+Z2U:)48'&N(CD!UDXC-1LJ<
M;G(GF&/ZXYIT RQG1O8V:?(75L6YTP;-\@2W,$!RQA5.6U=XR:WSA3*W*Q$C
M;;5#G3LR:&$%T.*M 3Y^KUX9R?%-5MAMHLS0EZQS/N1?=W8G>=/!I.B4-$JB
MF/LPO+7; 6N1L=_0D:ESF@9CWHFPJE;KD+PGZ]W32A907V     ,5NJO%9"N
M9+*V].?>0[;3;:[8C%.Z.<,$UUOQ9F1LQ[&M;<90Z1WEXPCZ2(KXS*'-.RR>
M/4JK:G BY*W.R2RY1;WM5WI7>%DN$?JQV@V \T8ASK#LP[ON<NPME" 99BK;
M+-A&YZBKA),<RMIF#&ADK-9CQ%>[1]6YLQ1:U-0XFIZ:Z^RE]G6ZU T6@
M
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MCSFT+E>%%^(\JUCX+>8B(PIJ\5-R/W.YT8<%<]G$L!:)PH
M
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M18F<TA2M*8I1&F%VG%W74OM#1< X/L[EJ:X)P#E/+V.<+S#8J<0&+GOT:PC
M#C")EDAR*4I2+(Y'CBFE],+<#BS[C*5HD/KU2Z_:_P!V@9*H1]86Y0E^\^<8
M JX@=KY=%&#"^-'QJT\:DB))EG$#FZN"HM=E>5RY-ALR2N\7G]EE"$*52G+3
MD7EUJ7?=6M0$A,R\V?+W.L6SF&8!X%=V\39IE4?6,&,\G3"^V2QB!2YUZJ-I
ME;XP/V%V]B=V]D/.[>\A:H3HS.IT'&EE]:^T-/N%O>=[G,3>^SS7[Y?=G _>
MWYD[IYE]YWA9J\>^:.X?X#YK\5=[[OV/]%V75ZGVO0 Z8
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M\3T\=J>FJ[8CQQTW+<=,S71Q546(B_2I0
M
M    #'QS0?3>?OU<X^_J]6+T\@O9Y;_*K_OH9-=\#VS7_5^5][4J?':57
M  !O:T\^B/JS_#EA#]F<8&:^^_IOK/K7-^<7&X_*7V5;9^K^G>9V4C1%700
M 8)=P_I<;3?Q&YO_ &F2<:4;$^A&C>JLIYO;8<<VO:KN;ZP:CYY>1R$J<^
M  =JUL^D5@/]=6+/[<L0C^[/HKJ?J_,?B:TQY=^T#0O7&2\YMM_HS-;K@
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M^H
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MSA,51,3$Q,8Q/1+]0]E_
M                                                  8^.:#Z;S]^
MKG'W]7JQ>GD%[/+?Y5?]]#)KO@>V:_ZOROO:E3X[2JX     -[6GGT1]6?X<
ML(?LSC S7WW]-]9]:YOSBXW'Y2^RK;/U?T[S.RD:(JZ"  #!+N']+C:;^(W-
M_P"TR3C2C8GT(T;U5E/-[;#CFU[5=S?6#4?/+R.0E3GP   #M6MGTBL!_KJQ
M9_;EB$?W9]%=3]7YC\36F/+OV@:%ZXR7G-MO]&9K=<
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M=X3D%XIYN6LSA;>6UIDYZ@CMSK[>H&E
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M6V];VGJ]W0]P9>O+:G9GRJ*O'$^"JFJ,::Z*O#373,TSXI>J$F?#
M
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MVET2W0GI+;D?),@0P>)'M5N;WV8PV+.QCR_E%%/%22#F_K]K:>5U>O0-N8
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MM+A:J-+--3I>_=W//(M46D*5)1H6B@
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M*L6=<.
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MFN&#LU.K4DMK8E;'+*>,8O.5S>FLN-/NM3HE3[<792IE]:6VT^VK]D!(\
M
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M6=N:=J=F[E\_9JFFNW<IFBNBJ/%535$3$^['@Z7TA]!Z8
M
M       ,?'-!]-Y^_5SC[^KU8O3R"]GEO\JO^^ADUWP/;-?]7Y7WM2I\=I5<
M     &]K3SZ(^K/\.6$/V9Q@9K[[^F^L^M<WYQ<;C\I?95MGZOZ=YG92-$5=
M!  !@EW#^EQM-_$;F_\ :9)QI1L3Z$:-ZJRGF]MAQS:]JNYOK!J/GEY'(2IS
MX   !VK6SZ16 _UU8L_MRQ"/[L^BNI^K\Q^)K3'EW[0-"]<9+SFVW^C,UNN
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M(6U)V&'0.+L$,B;&DZ_=6:,Q=I2,;"U)NTNO,[NW-:$HFSK5K7JV4Z:U >H
M
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MLW)_:U^3,XQ;KN83*1 [ZY*
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M+;)FQ(2_T1*U#D8F4VE)DIYAE*4#?$
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M*Z*H\55-41,3]R8?0'O/5
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M\U8:75*J8ADV,%DE:$#9+6=WMNM(=VU=(2W-OH8470NTYK,Z+[JUK86&C@
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MQ3>T(<J0)@G21KN4FITAJBY 0^VE5ON**NOK9TULMK7HH'<0
M
M        $?,WZUXYSDAOO?47F>5$DU+;9DT$E6.Z?JV=4DAQLKU"GIN+K2G]
M"?7K66]-"C"JW5N'!^<O=WY?\Z<E->MV?BFYZ*,+6?L4Q%^G"/)INQT4YBU'
M1^YW.FF,8M5VIF:G5^6W.+=W+/,Q3IESXQH=56-S*79F;573TS;GIFS<GI\N
MCHF<)KHKB(A6E6_8K1R2T+K7S_CUQ65K;2M%:R#OW7^ST5Z*'Q>1W%%_8_HS
M;JV?_M!-OPYUS7S^[EVXHHF?CVPLQ=Z/O[FG9G'_ /=D\W,1X/(KF:?]/9IZ
M;C\/*3O+Z-Q1_LN[+-O_ #:,Y8P__;F<OC/^=3'%_HKD]%E^#]D<=YT0=#"L
MJT2E,1::ZPYV.*L=TM*4IVJE!=3JEO+989\';DTZ;*5M[6PJZZVVNBW)CO"[
M!YU9'#0[OQ7<UNB*KV0OU4Q?H_;5VIZ(S%F)Z.TMQC3C3VM%J:J:9IMS*Y/[
MMY99K'5+?QC1*ZL+6;M1,VJNJFN.F;-R8_85]$]/9U7(IF4@1W9RH
M
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M;=?==?=2SIK6M>FH#V@
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MIIKMW*9HKHJCPTU4U1$TS'CB8B7[A[KU@
M                                               8^.:#Z;S]^KG'
MW]7JQ>GD%[/+?Y5?]]#)KO@>V:_ZOROO:E3X[2JX     -[6GGT1]6?X<L(?
MLSC S7WW]-]9]:YOSBXW'Y2^RK;/U?T[S.RD:(JZ"  #!+N']+C:;^(W-_[3
M).-*-B?0C1O564\WML..;7M5W-]8-1\\O(Y"5.?    .U:V?2*P'^NK%G]N6
M(1_=GT5U/U?F/Q-:8\N_:!H7KC)><VV_T9FMUP
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M?-,",.9(;/,;*SD+98UJH@XO21 [FW)KEM$Y%Y55)I*VTE(&T\
M
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M15/AMW,/]'7A,X3-$UTQQ3W@=N<O
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M+'\!4$=Z;GZ81928=0JVQL2HJ.%]#$9JHA,I("X0
M
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M>
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MJD)5YY5MYMM32Z7!8.
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M\,S%<1]]3#J8Z8A
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M>\&(?*_X@Y_$@,8/>#$/E?\ $'/XD!C![P8A\K_B#G\2 Q@]X,0^5_Q!S^)
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MNMC#_0N>Q,XPLHMUZQAM]I=EO<7*G6OONI;;3IN1TMITW5_NUZ P,8>O!Y
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MD2C,F4^2W9G8KD/X?>1W>2"8<RU),8\?6*X?@Y#)=5,<X>A;PJ9T^93H+,I
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M#V/(5-+D[K.G0IX<%E'Y267>B0MSA?TWUKU2U(:A@
M
M 'GI/$HQ-6H]CEK TR)I44KVB!W1$+2*7UMK;0XFAUEUR=272OVAI=;3+*_#
M;=2OPCX&Y-K;;WAIE>B[IR.5U#2Z_#;OVZ;E..&'%3Q1,TUQ^QKIF*J9Z:9B
M7UM%U[6MN9ZG4]!S5_*9^CP5VJZJ*L.J<)\JF?'35C3/@F)A7SE;CRCCE<>[
M8?D!L67]:IQ4:D1ZMP8NO3X;"T#S9:H>VVVVM*5I4ZBZM:__ "K:?8H?S.[A
M.W]1JKU7E/GZM,SV/%&4S55=W+8^*+>8B*\Q9C_61F9Q\=,>"UVQN]EJ^3BC
M(;_RE.>RN&$YBQ%-N]AXYKLSPV;G_D39C#Q3+AC=FW:[5M:F8\E,[C)(O:9>
M2E+EEYCJB4EVUZ*489TBO5&VF4LMMZA)QJBTDNO15/96M.CBV0YR=Z#NTYRW
MHO,3*9C4-MQ5--$9V9O6ZX_]6U*W-<Q.$1PV[E=V+=,X38IF8PZ7F^6_(SG;
MEJ]3V=F+.3UJ8B:IRL1:KIG_ ,_DJXIC#&9QKHIMS75&,7:HCIG/B?<S#>3^
M[-ZIUN@DE.J67YEEAI"1,I47TI2MC6_6W^:UEM3*TL+M-N3*3+J_ 2+J<KN]
MWRCYD]GD,SF9T3<5>$?%\[--%%=4^*SF8GL;D8^33%<VKM<^"TK/OKN\<PME
M\>;L6(U31J<9[;*Q55533'CNV,.THZ.FJ:8N6Z8\-Q+*E:5I2M*TK2M*5I6E
M>FE:5^Q6E?[M*BT<3$QC'3$N$3$Q.$^%_P!'D
M                         9[^=^8RZ)_NK^%93(XUW_WX=_\ #[XYLW?>
MZ^Z#NO>_-RI-WGNW>3.SZ_6ZG:7='1UJ]-G^[?D,CG?SS\<LVKW#\4PXZ*:L
M,?C6.'%$X8X1CAX<(4+[[NKZKI7S8_-F:S&6[3\X\797*[?%P_$.'BX*HQPQ
MG#'P8SAX99[O?#ES]*61OGO)O68L]^8M$_B>5_@K?X*AGSMW7Z3U#Y3>_#/?
M#ES]*61OGO)O68?F+1/XGE?X*W^"?.W=?I/4/E-[\,]\.7/TI9&^>\F]9A^8
MM$_B>5_@K?X)\[=U^D]0^4WOPSWPY<_2ED;Y[R;UF'YBT3^)Y7^"M_@GSMW7
MZ3U#Y3>_#/?#ES]*61OGO)O68?F+1/XGE?X*W^"?.W=?I/4/E-[\-K7X>'Y]
MDFE[(YR)Z=G]RNR%/2;G!Z<5CHNN))7):%%7*UQQY]2RJ5Z+;>MT6_W!27GK
MELME-_7+.5MT6K7Q6S/#13%,8S$XSA$1#4_NEY[.ZCR?LYG4+UV_F)S^9CCN
M5U5U8153A'%5,SA'BC%:4..+,   Q\<T'TWG[]7./OZO5B]/(+V>6_RJ_P"^
MADUWP/;-?]7Y7WM2I\=I5<     &]K3SZ(^K/\.6$/V9Q@9K[[^F^L^M<WYQ
M<;C\I?95MGZOZ=YG92-$5=!  !@EW#^EQM-_$;F_]IDG&E&Q/H1HWJK*>;VV
M''-KVJ[F^L&H^>7D<A*G/@   ':M;/I%8#_75BS^W+$(_NSZ*ZGZOS'XFM,>
M7?M T+UQDO.;;?Z,S6ZX                      *\M^N4W2GC188HY[89
M3515_P ADO-^,<=Q>)2><Y"R0H83FM,Y(XNP1ML6$EW$*7I*550XJ&]#0T^V
MRI]+J] "D/.',1S%[!XERSE'C[XMI!K?@;&^-\@Y)==H>0M07"I"MAL,B[K*
M%#K L $.3.XJWP]H:[C6Y06KEC.>HOML/MM*MK?>'^?%MQS92Y$L;Z8<J'(C
MR";5[*SQ;(()M%B77AG=6'$.M&,)C")PEDL-M78QB:-2R2=8SR&(HU=RE 3'
MRU-"["5!!UEG6O#6:  ,N$2QOKGFCZR7O/'-ZX[!<A3R):Q:D+.-O'V<&IID
MD24XF6Q!U7;#R/&$7FA"R.N4R9LTD*>Q-1$WKR"C'4PJG02KO+"K['F--0)/
M]5'RQ)]G4D#9GK%LLWK?]7YD[T9VN;Q/8LC/&25.)67%+T:7:]MSI,9FT-K<
MX(VRZVJUIJ=:=;V)=;RPV5Z-.F3WS2?3UZS;8Y%YG=]6M?73+I;S:HM=[,GN
M&)8BKGUCK:L,.5VN5LK-5T/H;?<90WK=:M;NFH"4H    #P>-L80##\5I",9
M19KAL3I))S+Z,3.6:6AI)LESB19*GCSU#C3K^^2>=RUR<U->MT7*5AE:4MI6
ME*![P
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MJ:HB8F.J8Q?J'LOX@
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MF.MN.K:9<GZ]++J!J[
M                                                           ?
MS?9899<69;;?9?;=9?9?;2ZR^RZE:76W6UI6EUMU*]%:5^"M!^:J::Z9HKB)
MHF,)B>F)B?#$QXXEYIJJIJBJF9BJ)QB8\,3UPB'EC2K#F2JJ7%K;[\?24^IA
MM76+$DEMJA1?;7HO<HW?4MM/M[2M;[ZINYG&75K6XVO2*I\T.YWRDYB3<S^F
MV)T'<-<S5V^2IIBU75/CNY2<+-48^55V787*YQFJY.+ONQ>\;S!V=%&4SMV-
M6T>G".RS,S-RFF/%;S$8W(G#HCM.UHICHBB$%ET-VGTU7J7>-K3WZ EF7'JU
M3<4I?(4I(ZU+KKY P&UL61Q36E+:&*;>PK2M>H6JOI6O32G.[1[S/=&SUS5M
MO7J\]L:FKBKKM17F=/KIQQF<UE:L+F4K\$57J>SZ9X+>9JB9QLUEMP\D>\-E
M:-/UBW3E=TS'#13<FFSG*9ZK%^,:,Q3X9IMSQ_MJ[%,X83$PUO3C/('=6><=
MGC>3F4++H8YJJ&Q1P/KT6UJE?;[2J-E;ZTK=V:ZTHNRE:6T.,N%M.47?5Y=;
M[[/2=Y\.WMR51$8WJ\<E=J\'D9F8CL<>F>',1133&%,7KE2OO,/NR[RVIQZA
MMK'6-%C&<+=.&:MT_P"=9C'M,/!Q69JJGIF;=$)P%F6&V6&E7V&%F66F%F%W
M4OL,LOI2ZR^R^VM;;K+K:]-*T^"M!<ZBNB[1%RW,56ZHB8F)QB8GIB8F.B8F
M.F)A6NJFJBJ:*XF*XG"8GHF)CPQ,>*8?V/T_(
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MJ&VNLL<V5G1MJ^2N=IZQP.M<'U4FO5'4O4'W4,-KTF7U^VJ'K
M
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M&SI-(5-RU_D1K&TI&PQ]?%E]UUZMX=[TM5"DVM:U,.,NNK7X0'J
M
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M[2,..S/@B>TIBB9G"BNM(L=_<C
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M6 _UU8L_MRQ"/[L^BNI^K\Q^)K3'EW[0-"]<9+SFVW^C,UNN
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MUM0O+*\-BHE<VNK2YI2EK<Y-ZU/>8G6(5R,^PTHTNZZPPN^EUM:TK2H#Z0
M
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M9FW^Z9>YU87(CR9GPQ1<BBYAT\&#LPZZYX
M          SF<_\ _NF?Y^/]3(M3W9O]]_R/^E,^^_9_A;^TO[O9RQ:EGV
M   -@_"]]"%B_6/D'_'T@HOS]]H=S\DL>]EK-W/_ &,6/6&:]_2M@'%5H@
M8^.:#Z;S]^KG'W]7JQ>GD%[/+?Y5?]]#)KO@>V:_ZOROO:E3X[2JX     -[
M6GGT1]6?X<L(?LSC S7WW]-]9]:YOSBXW'Y2^RK;/U?T[S.RD:(JZ"  #!+N
M']+C:;^(W-_[3).-*-B?0C1O564\WML..;7M5W-]8-1\\O(Y"5.?    .U:V
M?2*P'^NK%G]N6(1_=GT5U/U?F/Q-:8\N_:!H7KC)><VV_P!&9K=<
M                      '-<L8:Q%GF&...LW8NQ[E^ N]M;7.%Y-AT>G,7
M7?:764O4,<E;W)MO.+MOKU#.SZ]E:]-M:5^$![1@8F>+,3+&8\W)6>/QUI;F
M)C:4)="436SM",EO;&Y&33X"DJ)$GL*+M_\ DV6TH ^L
M
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MZ,E=RU=4SP5SA5:N1'CMW:<:*^N8BKBIQCBIIGH=&'0$1
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MZX
M
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M<UT1C;B?%%ZFW5/[5W(=I<T                              !G,Y_\
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M_NSZ*ZGZOS'XFM,>7?M T+UQDO.;;?Z,S6ZX
M
M
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MYS)9W3LS7DM0LW;&<MSA5;N4545TSU54U1%43]R8A^X>Z]4
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M Q."2I*VUP,-O5U+()ZMP:"@
M
M        '^9Q)2@HT@\HLX@XN\DXDZRTPHTHRVMAA1I=]+K#"S++JTNMK2M*
MTKT5'\[MJU?M56+]--=FNF::J:HB::J9C"8F)Z)B8Z)B>B8Z)?NW<KM5TW;5
M4TW:9B8F)PF)CIB8F.F)B>F)CP(CY/TGPGD3O"YM:#<?OQU+KJ.,0H2D;C#>
MBO4JLCAEES/>7UKJW7]VL2'&5^R8*K\R.YSR<W]VF=T_*U:%KE>,]KD>&BU-
M7B[3*3$V)C&<:NRILUU3X;CO.R^\?S'VEP9;.7Z=5TNG_1YK&JY$>/@S$3VL
M3AT1VDW:*?%0A4Y:X;5ZY+E#[B21.$D9K+Z'FW0XTR]0IL+K]I5Z@+G140XF
M]-OP6$V.-+;:_P!]3X:4IWJ/=\[SO=^SMS6^5FH7]1TB)XJOB$S-5<1X/C&F
M7N.F[/1][;IS41$_?1TQ%CLGS?Y'<W<M1IF_,I9R>HS'#'QN(BFF9\/8YZWP
MU6X^[7-B9GQ3T8]"QUR&.+8IHPYJA)Y2I(;W-8^1@BY&O3'E7]D9YUBSJ<72
MTZR[X3JDJ"JVUI6EI%:]%M)[L#O[:AIV8C0^<.C5TYFU5V=S,9.F;=VBJ)X9
M[;)WJHPJCPW)MW:)C"8IL3.%,1/=W=.RF<L_G3ESJ5-5BNGCHLYFKCHJIF,8
M[+,VHGHGP417;JQQCBN^&5@N/<P8TRHE[U Y@T/U]I=#3VXHZY*\H[.GHK<M
M95UB9U2V4N^"E]Y-++J_WM:T%[]A\V.77,W+?&=D:ME<]7%/%5:BJ:,Q;CKN
M9>Y%%ZB,>CBJHBF?%,PJENSE_O+9%_L=SZ?F,K3,X4W)CBLUS_F7J)JM53AT
MX15C'CB'2AT1#@          5/\ -#]"%]_6/C[_ !]6.U<@O:';_)+_ +V%
M7>^![&+_ *PROOZF/@7H9,@    #1IP ?[V?^8?_ %S"JW>9_P!R?RS^BM!.
MXG_BG^S?[P:,Q59H(  #.9S_ /\ NF?Y^/\ 4R+4]V;_ 'W_ "/^E,^^_9_A
M;^TO[O9RQ:EGV     -@_"]]"%B_6/D'_'T@HOS]]H=S\DL>]EK-W/\ V,6/
M6&:]_2M@'%5H@  8^.:#Z;S]^KG'W]7JQ>GD%[/+?Y5?]]#)KO@>V:_ZOROO
M:E3X[2JX     -[6GGT1]6?X<L(?LSC S7WW]-]9]:YOSBXW'Y2^RK;/U?T[
MS.RD:(JZ"  #!+N']+C:;^(W-_[3).-*-B?0C1O564\WML..;7M5W-]8-1\\
MO(Y"5.?    .U:V?2*P'^NK%G]N6(1_=GT5U/U?F/Q-:8\N_:!H7KC)><VV_
MT9FMUP                                    !3UR58!T,W5S#JQJCG
M;-60L';KIE4ZS9I-D#!DED6/]@(4MB+58OR+(,<3U/&GR)I4-S7%R375O<+N
MNI+;R32;;#R23BPS_P"G^QW(1Q5PC2652O/L3VTT$VRY/]F]))'CO(..V.)Y
M]PID>1[N[-0N_*48R9&%Q2G)9F1)) WZ:O-KPEN3I5:HUJ3E$6'IEQ(7C_60
MO^Y*WW_5_C[]M^+P'R.15ADDD^KO9[;(I155V+XVF=Y.M1F*2C[V"-XDCDCE
MA?2DMN.O),BK4MM-+Z.H:56ZR_HLNNJ D1J?D+&_\E?7O(_?FFN+F?C.QP^.
MJBA22K4W1F,:RM7B)$L1TKW-/:QIVQ2F5)KNBTB\B\J^E.K6E R><:C+(\:/
MWU/V598/4%P]P9^62.LIKP>K5H4$ERXIR8KQ&GH6Y66)42R2MLPCI396RO7,
MHCLM)Z;$Y50%ZWUB"MS\LX9<=QDWJ91DO-5IY(8=W:IA+HD9(>AR%9*WM.N2
MVW."!O85DC:E*LXJG05;;8;=\)=H#1T   #X#LGDAQQ5S*YM:$BA70:6O;#U
MQEYW7NKU[#"EZ2EEG4K2G5ZM:]-.GI'F,/&\=+Y7<9[[01WYOK/7(\^2=)W&
M>^T$=^;ZSUR'DG2=QGOM!'?F^L]<AY)TG<9[[01WYOK/7(>2=)W&>^T$=^;Z
MSUR'DG2=QGOM!'?F^L]<AY)TG<9[[01WYOK/7(>2=)W&>^T$=^;ZSUR'DG2=
MQGOM!'?F^L]<AY)TG<9[[01WYOK/7(>2=)W&>^T$=^;ZSUR'DG2=QGOM!'?F
M^L]<AY)TG<9[[01WYOK/7(>2=)W&>^T$=^;ZSUR'DG2=QGOM!'?F^L]<AY)T
MG<9[[01WYOK/7(>2=)W&>^T$=^;ZSUR'DG2=QGOM!'?F^L]<AY)TG<9[[01W
MYOK/7(>2=)W&>^T$=^;ZSUR'DG2=QGOM!'?F^L]<AY)TG<9[[01WYOK/7(>2
M=)W&>^T$=^;ZSUR'DG2=QGOM!'?F^L]<AY)TG<9[[01WYOK/7(>2=)W&>^T$
M=^;ZSUR'DG2=QGOM!'?F^L]<AY)TG<9[[01WYOK/7(>2=)W&>^T$=^;ZSUR'
MDG2=QGOM!'?F^L]<AY)TG<9[[01WYOK/7(>2=)W&>^T$=^;ZSUR'DG2=QGOM
M!'?F^L]<AY)TG<9[[01WYOK/7(>2=)W&>^T$=^;ZSUR'DG2=QGOM!'?F^L]<
MAY)TG<9[[01WYOK/7(>2=)W&>^T$=^;ZSUR'DG2=QGOM!'?F^L]<AY)TG<9[
M[01WYOK/7(>2=)W&>^T$=^;ZSUR'DG2=QGOM!'?F^L]<AY)TG<9[[01WYOK/
M7(>2=)W&>^T$=^;ZSUR'DG2=QGOM!'?F^L]<AY)TG<9[[01WYOK/7(>2=)W&
M>^T$=^;ZSUR'DG2=QGOM!'?F^L]<AY)TG<9[[01WYOK/7(>2=)W&>^T$=^;Z
MSUR'DG2=QGOM!'?F^L]<AY)TG<9[[01WYOK/7(>2=)W&>^T$=^;ZSUR'DG2=
MQGOM!'?F^L]<AY)TG<9[[01WYOK/7(>2=)W&>^T$=^;ZSUR'DG2=QGOM!'?F
M^L]<AY)TG<9[[01WYOK/7(>2=)W&>^T$=^;ZSUR'DG2=QGOM!'?F^L]<AY)T
MG<9[[01WYOK/7(>2=)W&>^T$=^;ZSUR'DG2=QGOM!'?F^L]<AY)TG<9[[01W
MYOK/7(>2=)W&>^T$=^;ZSUR'DG2=QGOM!'?F^L]<AY)TG<9[[01WYOK/7(>2
M=)W&>^T$=^;ZSUR'DG2=QGOM!'?F^L]<AY)TG<9[[01WYOK/7(>2=)W&>^T$
M=^;ZSUR'DG2=QGOM!'?F^L]<AY)TG<9[[01WYOK/7(>2=)W&>^T$=^;ZSUR'
MDG2=QGOM!'?F^L]<AY)TG<9[[01WYOK/7(>2=)W&>^T$=^;ZSUR'DG2=QGOM
M!'?F^L]<AY)TN7Y$P2VY63U)G3?!WI1:5<40Z^&ER)\26UMI2E$KT@>TSD59
M96E*]GVE2KJVTZUM:? .:[_Y0<M>9^7['>ND97.7XIFFF_A-O,T1_F9BW-%Z
M(CHGAXYHF8CBIF.A-=I<Q=Z[&O=IMC4+^6M3.-5K'CLU?^-9KXK<S/3'%P\4
M8SA5$H/S'CTF#%?1^Q1/25#DB-HI1MCI<I8G(@RSINI<V2%#<8713;=7H+H8
M6GI2GV3>D4/W[W#-9T?-?GWDWK-SXQ:JX[>7S=?8WZ*HZ?W'.68IIFK'[V*[
M5K"/#=F>E:[:?>OTW4;'YJYD:;3V-RGAKNY>GM+543_TF6NS,\/[;AKN8^*W
M$/%)]F-K]?U!4=RHQK'A):9V:<V:H+S59]EEOVUK5,FXRY(\TZ;:UJ888OK]
MFG6I_<A6E]Y#O*\A<_;T+FUIM_4=,BK"/CU,TW:HB/\ T?4K7';O],3,UU_&
MO'&,>*2Y_DOR3YL92O5>7V=M9/.S&,_%9B;=,S/^FR5SAKM>'HII^+^*<)\<
MLL8;A0_(_=D2J=L$%?SJ%VU:9C'SF]*:?=T6WV(7^Q],9C[.UK2TNAIJ<\WI
MIT%=/32ERN6W>_Y-<P>SR>:SDZ)KM<1'89_AM435/1,6\S$SEZHQZ*8KKM7*
M\8PM>&(K=O3NZ\R=H<>9L9:-3TJG&>URF-=44^*:[$Q%ZF<.FKAIN44X3C7X
M)F6!:6=&V6&E2.-&%F66F%F%L*J^PRR^E+K+[+[7FMMUEUM>FE:?!6@M%1<M
M7:(N6YBJW5$3$Q.,3$],3$QT3$QTQ,.%545T5317$Q7$X3$QA,3'AB8\4P_O
MN,]]H([\WUGKD?OR7YZ3N,]]H([\WUGKD/).D[C/?:"._-]9ZY#R3I.XSWV@
MCOS?6>N0\DZ3N,]]H([\WUGKD/).D[C/?:"._-]9ZY#R3I57\QJ65%:5OE[N
M[-"Q'[PX#2I*)I4(SZF57JNI=0XQQ4VTMMK]FG5^'_E':>0>'VA6\/XI>]["
MKO? Q^QF_P"L,K[^ID<%YV30     T-<#!#^=^]7YC<&Y!U?<;WKO[><O[7I
M]\/8]EV2Q)V74Z+^MT];K=-/L='PU7[S&'_N3'_US^BM!.XI_BG^S?[P:&>X
MSWV@COS?6>N15?R6@?2=QGOM!'?F^L]<AY)TG<9[[01WYOK/7(>2=+/-SSD/
MY/[JGGQP;E_6]^7=>X-YR#LNCW/=MVO:K%?:]?ILZO1U>KT5^ST_!:CNSX?^
M^\/_ %/^E,_._7_A;^TO[O9Y1:AGV     -<?#DEE1NE;'>T.S0C1^\.?4H2
MM:5"P^AE%Z7KW5.+<4UM;;J_8IU?@_Y11CGYA]H5S'^*6?>RUE[G^/V,V/6&
M:]_2M0[C/?:"._-]9ZY'%O)6BZ3N,]]H([\WUGKD/).D[C/?:"._-]9ZY#R3
MI9'.8TMS*W4?+'94D6+/=Y :W'(DIB,BI=4"KL[:$F*%-U+K:?9KUOA_Y!>?
MD'[/;>'\:O\ OH9-=\#VS7_5^5][4JO':570    !NMU%1S6[4_6&Y(^,)*6
M[7G"MR8HYC5''%)ZXVC522S3;78NTTRPOHI==2VVEU:=/13[ S9WUP_/?6?6
MN;\XN-QN4N/V5;9^K^G>9V4ANXSWV@COS?6>N1%?)=!Z3N,]]H([\WUGKD/)
M.D[C/?:"._-]9ZY#R3I84MNK5%NV&SUJLPLY5;L-FJU2:274DDU13),EH<84
M5=>9<47>9TUMMK==6VE>CIK]D:3;%^A&C>JLIYO;8<\VO:KN;ZP:CYY>1Y$J
M<^    =EUSH==L)@BU/?86HNS+C"A!AEE3"RSJS=CH5>87;=94RRV_HK6VE:
M5K3X.F@C^[/HKJ?J_,?B:TQY>>T#0O7&2\YMMYW<9[[01WYOK/7(S/\ );K=
M+^RD4YH874U^C]Y5+[*FV6,*NR^XNEU.O;;?5WNI;==;TTI7HKT5'CR3I>Q'
MAY  !$#=?>?7;0#$1&8MBI.Z-C4]RAF@4!AD08ETQR;E;(LC,O*8,?8Q@S32
MYUEDL=JEWW6$E]0DDHN\T\THJVZ^@1%UWYFM?\V;!0S5O)N =T=(LW94;7=T
MPM$-X<!4PH5FPI@16N+TBQH_M4OG$==7IL0UNO,0*U2);UK*E6E7'5M+N#V&
MV?+1@?5G.*36!@P]M3N!LM2$E9+D^"=+,-EYHGV.L>*C[$K=,,C5<I3"HQ$V
MUV4&EVIB#W*J\VAZ>^B?J*DUQP20TLW?U^WZP^=F;7I_>ES.RRY_QU/8?,XZ
MXPO)>*LF12]/9*,;Y.A#Q;8Z129,7>R;SDQG7+O).+-),-*,LOJ'9\VYJQ;K
MEB7(&=,US)IQ]BG%T9<9=.9@]WG40,K&VETN--[%*4H7."Y4=?80D1IBCE:U
M6:60068<999<%4.&N=W5?*.2<*P2;8+W9U>B^S;\V1;6+.VT^NQ^*\"[!R60
MDU5Q%BQU/2)9)#B7*;H;BCV4M[1,_G,M03V%;[S;+:A*_=WDDP%HHX8IA4XC
MV8LS9TSLY.S=A76?6K'AV6<^Y-LCJ:Q9)G>/PZQS8FQ#'8VD,H:L<'1Q;TEE
ME+ZVF7]D;V8-(N23 6];AE:%0>/9BPSG3!+DTMV:M9]E<>'8FS[C*R1)KUD9
M=Y!#KW-];%T=DB0NIJ-P:W%P27V5LK<99VI7:!&+.G./K+B'+F9L1P3 ^Z^V
MINLZPQKV?R+J)KU?EW%&NCTC3J%KTPY/FBN714JQ\C+<B4GNB5G(=S6^B126
M=2P],H)*"SK7S8#$&U&%\=["X#F[7D7$.5(^5)83,&BU24F<V^JE2@5D*$2X
MA*Y-+PS.R)0A<$*LDE8@7ICDR@LLXJ^RT.R                  "MCD(XT
ML?;Z*,&Y"3Y6RAK;LSJ]+'>8:[[+X85M1,YQ\JE"-&VS*/.#2_(ES'+(7+FY
MO(L7-ZBPNZ^I%MMIUI!JLA4%8W'=PDY885>"<M\C>R.6LZ235K8W9[,FNNM:
M]IQ!"\,P/(<SV=R]/([LC(4^(+G.N0<A9%LD!,\;25SE9X14O]6GL+"T-J4H
M+J]Z]0(1OOJ=F347(\FE4.A6:F5E9'Z2PFYHME+4G8Y;'Y@G-:+GUM=VFAQR
MZ.E%7]LF-M[*^[HI2[HK0.WQ#&$9BN)(OA=21;*(=',<LF,#TLD3(EUDBC+/
M&4T4-(?T=$]C>LM=VM/6U45V5"3*&76]2EM>@!0R;P"/C=CA_P!/X/R6;:P7
MC*E#T[+772)L8<6.3J@BLBD"B22#$D5V=>(^KS#'L.NBU28G,8^LHH>A./+4
MG*35)Y]X6-[<<96N>V&K^+]7[[)5@YHUW=L;2O5;(F$W?POD/6N<X<;;&C&,
MGQJ\*RG&PJZ.-!?<C$ZFTZU0DNK6EY:JQ.J(#@FO?%%+H]M#CS<C=[=K+W(!
MG7!$9E$3UMOG6.L6X6Q?A!+-T7FN82MCQ;B9I0L3WDY_9J40G/RLRIIB7J]H
M48<G1')0N,
M
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MTJY[HY-<RMH15<U;2LQ5DZ9_?K$1?M8?MIJM35-%,_\ G(HGKB)=X';G,
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MMJ],>LM++^P>XFUZ*4K;0!HZ
M
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M,C@A52--&S%2=*J4-,?865K:Z*#++:K#4)BBVTNPVTJP+30
M
M
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M3)DY19)!-EMEEMMM*4H'W
M
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M]N6(1_=GT5U/U?F/Q-:8\N_:!H7KC)><VV_T9FMUP
M
M
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M;N?^QBQZPS7OZ5L XJM$  #'QS0?3>?OU<X^_J]6+T\@O9Y;_*K_ +Z&37?
M]LU_U?E?>U*GQVE5P     ;VM//HCZL_PY80_9G&!FOOOZ;ZSZUS?G%QN/RE
M]E6V?J_IWF=E(T15T$  &"7</Z7&TW\1N;_VF2<:4;$^A&C>JLIYO;8<<VO:
MKN;ZP:CYY>1R$J<^    =JUL^D5@/]=6+/[<L0C^[/HKJ?J_,?B:TQY=^T#0
MO7&2\YMM_HS-;K@
M
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M,S6ZX
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M'XFM,>7?M T+UQDO.;;?Z,S6ZX
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M#IH*X7K<V;U=F9QFBJ8Q]R<%W,K?C-9:WF:8F*;ENFJ(ZN*(G#_POWC^3^X
M ,=TCY>=ZFZ0OS>ER9';$J%Y=$::RN-H'?6Q.F7'D$V5OO8:WWUM+LI3IK6M
M:_W1>S*\CN7-W*V[M>3NS75;IF?W>]X9B)G]FR5U#O7<[,OG[]BUJ.7BU1>K
MIC_9,M/1%4Q'^BZH?&_G"[X_I.CG^C2 ^H!_?["^6W\3N_*+WX;T_P!+/G?Z
M2R_R/+?!'\X7?'])T<_T:0'U 'V%\MOXG=^47OPS]+/G?Z2R_P CRWP1_.%W
MQ_2='/\ 1I ?4 ?87RV_B=WY1>_#/TL^=_I++_(\M\$?SA=\?TG1S_1I ?4
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M]9PH6S[M/_4M7_UN7][=9U]^?_M7;GY/G/?Y=GO%GU"P    !M-XEO\ N^\
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M_#EF_P#9G)Q*MB?3?1O6N4\XMN?<VO95N;ZOZCYG>8)1I0PX     %L'"_\
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M1,QTQ,3X?!,2I#J&EZEI-[XMJF7OY;,8?>W;==NKHF8GR:XB>B8F/!X8F'^
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M/Y0/IX[$?](XW_8&)C0CD_[-M+_U5S\==8T]Y/VWZ_\ E%KS:P@0.E.&@
M #_T1(=_ZHQ;_HXQ_P!6)1EOGO\ KM[_ %M?OI;\:1_V5E?R>W[R'HQZKZ
M /\ SNYC_P"MTI_Z1OG]9JAJ1D?^I6?]51[V& ^K_P#:N:_*+GOY><'M/G@
M  )8:)?3+UC_ %U0'^OD@A?,?Z!:OZOO>\EU'DE[7MM^N,M^-I;MQG"VW  !
M$_>WZ&FSGZE9]_4*L33EQ]/=(]86??PY=SM]D.Y/4^9_%5,) T>8D     "X
M3A#^F6Z?J5G']?0L<+[POT"H]86?>75L^YE[7KOJ?,_C<NUQBD+54  %/G-Y
M]#1K_75!_P"H9H.Z]WKZ>U^K[WO[2IG?-]D-KUQEOQ689&Q=UE4     -*_
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M+-90  5/\T/T(7W]8^/O\?5CM7(+VAV_R2_[V%7>^![&+_K#*^_J8^!>ADR
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M27ZX/0>&K3M7W!G)X>#"=R:;>PIC#RI^.YZ(F9PCR^FYX<9Z9Q5<[OU/&O\
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M"/[L^BNI^K\Q^)K3'EW[0-"]<9+SFVW^C,UNN
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M5IUR%3989>5?<G5I3#2#K;3;+K:UMNK2EU*T^S0!^X
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M/#D>^06;T6A\@!A!X<CWR"S>BT/D ,(/#D>^06;T6A\@!A!X<CWR"S>BT/D
M,(/#D>^06;T6A\@!A!X<CWR"S>BT/D ,(/#D>^06;T6A\@!A!X<CWR"S>BT/
MD ,(/#D>^06;T6A\@!A!X<CWR"S>BT/D ,(/#D>^06;T6A\@!A!X<CWR"S>B
MT/D ,(/#D>^06;T6A\@!A!X<CWR"S>BT/D ,(/#D>^06;T6A\@!A!X<CWR"S
M>BT/D ,(/#D>^06;T6A\@!A!X<CWR"S>BT/D ,(/#D>^06;T6A\@!A!X<CWR
M"S>BT/D ,(/#D>^06;T6A\@!A!X<CWR"S>BT/D ,(/#D>^06;T6A\@!A!X<C
MWR"S>BT/D ,(/#D>^06;T6A\@!A!X<CWR"S>BT/D ,(/#D>^06;T6A\@!A!X
M<CWR"S>BT/D ,(/#D>^06;T6A\@!A!X<CWR"S>BT/D ,(/#D>^06;T6A\@!A
M!X<CWR"S>BT/D ,(/#D>^06;T6A\@!A!X<CWR"S>BT/D ,(/#D>^06;T6A\@
M!A!X<CWR"S>BT/D ,(/#D>^06;T6A\@!A!X<CWR"S>BT/D ,(/#D>^06;T6A
M\@!A!X<CWR"S>BT/D ,(/#D>^06;T6A\@!A!X<CWR"S>BT/D ,(/#D>^06;T
M6A\@!A!X<CWR"S>BT/D ,(/#D>^06;T6A\@!A!X<CWR"S>BT/D ,(/#D>^06
M;T6A\@!A!X<CWR"S>BT/D ,(/#D>^06;T6A\@!A!X<CWR"S>BT/D ,(/#D>^
M06;T6A\@!A!X<CWR"S>BT/D ,(/#D>^06;T6A\@!A!X<CWR"S>BT/D ,(/#D
M>^06;T6A\@!A!X<CWR"S>BT/D ,(/#D>^06;T6A\@!A!X<CWR"S>BT/D ,(/
M#D>^06;T6A\@!A!X<CWR"S>BT/D ,(/#D>^06;T6A\@!A!X<CWR"S>BT/D ,
M(/#D>^06;T6A\@!A#_ML>8++K;[&-GLOLNI=;=:V(K;K;K:]-MUMU"*5I=2M
M/@J#SA#[    *\-X^*307DB=<=/>Z.!??,YXG;Y&U0!3[T<T8[\P():I9U<A
M(['%&18*G=?."A@27=9;8IO*[+H*K92Z^EP2@UNUPPQJ-A* ZYZ\PWW?8:Q@
MWN#5!H=XBE<K\QH'5\=)(O(\0S=\DLJ<^W>GI2=UEBY1?;VG4MK0NVRVT.W@
M                                   Y+A+"..]>8#3&>+&E4R1"V;95
MR%1 L=7%Z/\ %.:<J3/,^05O?W52J6=BZY G[HJ*)Z_9)2CK2";;"B[++0ZT
M
M
M
M                                                 \#DO*N,,+Q!
MRR#F#(T%Q5!&:WK.TSR-+&&%15MIV9IU*+7^2+VUJ377%$7W4I>;2MU+:]%*
M]%0%;&YO+K@/6W2"%;EX92W;8H\]9*C^"]4(=C5VL;$V?<V3!^DT:CD6:I0Y
M-YY32PU<X:ZWJ7.B15;W=#=5,6HO-(M,"'$]Y+N3C0V38%G7*!J[J,T:G9[R
MS#<+O.4]2,P9'D\PUBF&23%1<-4YICF3HVU-LMCI*I->G='".GU1);2C#BSC
M3KD:%8%T^UFS^)=--?\ )>R6;GDYGQ]C)AN=5Q+>26MD,E>%:@AKB\'A[5><
MGJ^3:<R1:E:6A%2^SO3@K*LK=9;6Z^T(#<*/(ME?DZU1GNP69,41O"DNB^R>
M5L,68\CMTAO,8FF!H8@L2)),9)5!J\V8(CY$<E<+K2D9-QR?IM3$_#90+?@
M    ! #DPW_A7&SJM(=C)5"Y!E&0JI1%\88AQ'%E!:%_RQF.?JCT,(@R)T-2
MKRV=.M,2'JEBNB96:G0)#[R$RH^A28T*P,J\FW*3H"CQ7GGDVU-U#9-.,BY
MA&/<B3#5C-60I/E35%5D1=YN8G_,#5D*.((?/&-I=#2DCD;&5ER<N[K&DJ#*
MW$$'A)'?7?[=;%VZV%M&M#=<L*Y\RO/]<9[LM,ZYHR2_8U:8S!XGD!AQX@O;
MW1J0JTAQR]Y=#;;K#J]:M;;:6]'_ ,H)/:.9(Y+YXZY%)W]ULUWP(T-K?&S,
M9*\'9B=<I*I*Y*5+Q;*$TB3N2%):S)VQ*2BN37V5NJ=<<92O1U* +#P
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M+-)GCG$&8LZY$8-T,TXD@J]Z2*)G'2HU#G3#\)<I2G83U"!M<3U9_12E$_G
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M/RQ"<A--7F*Y+P[+WEH:W&]G4)+R*JVU;UUJ#OJ>TV_MZJ4Z4+8P
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MLZEO4BL9"L>P7%SU,':-XWQ7 :R)T?)&['H2CSE2$M,5VA-]+@V@@
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MC-EAUQ#/SF=J><?Y>NCR=(UR201>22 @I"Z=E:K56$*C3KNQ.1I$0:!@
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MN 5P<8O'W_+CPUES$GO;]\GO4V?S)LAX@\!>[SS%[VSV$[P9YJ\:3GSIX?\
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M7T@4Z:^Y#P%VO?N\9@DV5_>/[R_&A7=NIXB[AYG\/F=/8]OWVG7[&T+'P
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M7*;E+K5.G-/L+[$HNP+50
M
M
M
M
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M;V2)$H.KUNFEG12M:!Z#$^4H)G'%F-,UXM??%&,LP8_AN4L=27S8\,GB*"9
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M6^ZRP)E@
M
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MG&7WU)OZ@:5
M
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M->&IO2.-RMLK:H*/0F*D]Y5]M>TZ:] #3GMA_P!P7LK_ />@,R?_ '&$C .
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MQMF&8)OD2.L<66&W=J5>H71?)[8YIBK:%&W%V'WUK=85T5#32
M
M
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M4+:?)(WB#'1-A-%EY!=QZU:HMZ3"BB;ZA:N
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M?UZCN/8>C7XIS*4^*Z+#,7.$VFBPIO*N4F45K[D5$=3+BW!+86&N4
M
M
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M*WMA:3,:LIZ]S87$U.CK<H+4JK:*#$%+R V*@   X'L7A"N>X*FB%DG418]
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MB"EY ;%0
M
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MDDI;X^L4H"#3T"964C..(+OO+NOLMK0)[@
F                                               #_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tm2110724d1-tbl_pretrm4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2110724d1-tbl_pretrm4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@"]@.2 P$1  (1 0,1 ?_$ 2P  0  !04!
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M2))[WD?94TZWDO+KWR5EL=+V=F- 3A#=RCH*EK=QHR46+AVP#QQQ"!QMP[%
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M%[6N[<NGQ^EPX?/J5_6RO]Q5?C&LIV9^7_\ IT#>IUC8WHL>5>[_ -Q2G_\
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M7*YSG.?5>RKN3VJ*=VS&HJ/ET(+-00K&' Z7&C-A% OT^JS45Q1*I92YBX>
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MV*4_+4V7S"OV<;7O:W;OV;=G]:]3.FW*(_8Y>8F9 U47>]US=C\-=HQRPO\
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M5%IR*J+5$[%3HSK-X7&WV@77D[6^71.16*B)O57>V(O+1>?LT,62,M99_FT
M\I1=%KJ<J,G%3IX^X B5R+>*%DX//,W?-<4<BB9D-:X=\,0\!,A<L^Q;'C:]
M[=Z9;B'I;!7WF_*WUM#>5:FXYW?]]2G>)5VW>1>2E%JNP^>&%X>ZNSV/7(XK
M'7<UDB.7I&L7<[VN]WRT;LHJ4K6J=DC0OK-/>QQP^FPY&:Z]3*9QLI'2@!8@
MB)^6-[AV",JRF<)IH(MKX=@/(U?/*_GN%K7M5#4W$;1NE+=;K+WUM')N(Y&J
M]-]6K6BHB5<J+1=J)S%;3'#C6FIY]S!8^YG5'JU51B[B.;2J*JT:BI7G<G+[
M)X&28R?$-O==C61D'!%=S<' ++2:&=3C]R!HP#@9! $-I*DH%1+Y Y6RO;IX
MY8<>S\RO:T]J+&ZEQ$.;L=ME,U71OYG-VI5M41>SS'CY[3N5P.8EQ&5CW,C
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M>;D*<LK8H73N5$B;M55Y$3LJI1*8YDNDA<80 78N/K"!## "6L?.\,12XV0
MV'2[AQPRZ N/#I8\<;]CA>M@P\*N(<\?2QX?(;B\B] _:G9Y.0UA<<:N&5G(
ML4V:QV^WE_:M6GL+3G]@X_YR[1[CT;;'1WTK<;]E1.7M:V/1Z5[\"678QZ5O
MU:J1\)N(DB][A\@J5\"_N%)O'#A?(M&YK'[4\*WMDXDO;7719BU5FM-EQH&H
ML0C@J:KO7!0%Q1D]0"S*AB%#.8A?$; Q80Z#CT;X\;W$QX6\]:O!DT9J>',-
MP$EC<MS#_<PJQ4D7E38WEYE[1E,6N](SX5^H(LA:.PT>QTR2-6-%V<KN1.5.
MV2<_.9:+\+WOLI'-N'&][]VJ%K6MPOEYJ=;^]MQKVW<)^(:/1OF?(;RKL_8N
MVF/NXS<,XT:K\UCJ.153]JW:B+39^0G/#>UNOT_J2NE0[*38?Y] *%CRR60C
M8HHI H<&N7*F1@QP ,NI%'QOA;+'C;I=BL=SVE<_IA&KGK2>T<]U&I*Q6*J^
MQ4R?36M=-:P61--W=O>-A1%>L3D<C:UHBJG)7==3VEH=+-FYVM.OAH)/E>7&
MHUE08&PX2*(.<5EW(#CE;NBR$@DU18ZCSM_/W Z/8[=>E@N'VK=20+=8C'W5
MQ;(M-YD;E;7VZ4/+S_$O16FKE++,9*RM[Q4KN/E:CJ>U6O,=5"N\FK6P"QBV
MHLF5KN=R"A"& &]EBK(2Z8 "Z5Q12J4XTQ'/F0PK8WZ5PP\^C:U_F52U#H+5
M>G+=+K,X^ZM;:M-][%:WMKL(Z<XDZ*U-=>187)V=S>;>\9(USMGL(=<\M^M2
M(^=*VS7E.K&07(WCF:<L(QP^:L<3CX.-LQBIBP9/+"PH>.=KWX7OPXU>X[AM
MK;+V++_%XR\GLW\CV1.<U?PI4L<IQ9T#@KY]AE<K90W;%HYCY$1S53E14/-7
MYENC]KWM\(V/>E;L='TP.7O:]^U:^-B=[U=IPFXBN6B8?(*OP+^X>?\ ;GPN
M]-8_QK2=T,;/P9L 972D122V7V9;6*?FO H!L4;-,Q5;G,4W(R&.7 RQQ-W(
M#6PO:W"]PLOF5C><TIJ#3E$S=G<6BNK3I8W,K3:M-Y$,JTWKK3&K7.;@+ZVN
MUCIO=$]'4JJHE?PH5 VOQK'$5%VIR&7\AIE>V.-[WOPM:W&]^/#A]/S*C5$V
MKR"M-I1B[^81IPQ7"L-1T;!QZC.%!.#)ZNF&U U<P1.E\^J'+#W")" XBA"W
MMCE:V5^&78K.\=PUUSE+5M]88J^FM'I5'LB<YJU["H:YO^+'#W'W<EA=9C'Q
MWD2JUS%F:CFJFQ45.5%0[V/MY]29.4RB&R]@HQ6ULZ+< HEA.,L4.FQ[WOT
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MSE2-51$3;M,0LN-W#6[G;;-R]CTCW42LB)^7_@]DKY17&@.1+)K;?64U:1U
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MPQOT;\+]GC>ME\=.(VO-+ZM7':=N$ALT8Q41&5VK&Q5JOMJO)1/8K4U5U?\
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M_-285K8Y6OECPO?S;5T?QXUGJ/1V$QC]/U29R-WE1J.KWJILJE$I2J^V<O<
M]$Z5UWG\E;ZGHL,:/W45V[^>FU>SRT3VC(7@7EP:A:]R4BRI%;<5RCU;Q50
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M]KD6O.59@8X]&][6[-\KWOV;]OA;Y]8LE=M>R; <M'*B=DY%1)10"@% * 4
MH!0&V^.-^/&W;X<?I<>'[-*\W,$V+5.4H^WY #QTPV:RMTNE>'GQGQOGE?SW
MI$9MYM^'#AC;L=JLPT$Y7:VQ2+R+?0)^!9&]TP3B7$S[/\RNVOD$R\O/N*A9
MH\7V#PR.;-VRMQM@!%]\?G7RP==[_1[-ZZ*ZU[&ODPMNY*Q-;,J>VG1HFWVC
MF'J=JNYFYOSU?&B^TCY>;\!<-YP]O_H'2AV^RI,+*_9OQXY/9!X]GM^96J>
M*[W%BR:O(B._NO-O]8_O>$=^Y.559_?86(M!N644W'BM>D/.75E@9ISK.MS)
M,(H94Z5'[B(DA<CHAC,R$-F(/BHAAW[5N =K<.QQKH7C)Q2BTCGTQRXZTN9$
MW7+)*UKE6K&JB=\U>1%HFWF.6^#G!RYXAZ=9DH,M>64D>\U&1.>C4[]]5HUZ
M(M>5:IRJ9'.CVG)33J.%Z/L7XLR &MN41PY'%8MB1"3ND1)D>XB10(84(,+(
M4K?/++CTKWX<>/"N2==ZM];LU%DFV=O;(C5_=M:W:BHM>]1.6OXCM+A=P_\
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M4=?+XWZTDG!3D+4U,57<UKG#8B&JM<TF*Z@,V1CG7@MQ[M57,!Y*>14.V6/
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MR_9,V6Q&A%*1&E%#]7CL/N%?<<5OG-/R2CCM/$2>)]-(%CYE9Z9FYPP!F74
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MV#SQOQXXB!VZ F-^/9Z5L\;VO\^OL/$K'1HL?N.8^)DJ.214?[OG.44-#DC
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M"6RQ^JZ0M^EYM83!P@X8VLO3PXN%)/\ /G^,,ZGXT<4+J+H+C+W*Q_YD"?\
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MX@+Z&H%%9%6T56*!'TM72%0@*8(J26I$3 8Q<P")F$,%GCGAE?&]KW [2@%
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MD=PA["-.3E+5'<Y$V!<\N@)X63S3&W(>T3H9@J6950K%EM=46R>(8B88$S
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M-ZUY=7EQ=23O?[M9$5/:V5_I-OX^SCL(88K=*1-CIV.9>5"8M4CT!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M 4 H!0"@% * 4 H#Y@?] .@,[WDV_)X0[^'^TGY6DYT!<_H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * ^8'_0#H#.]Y-OR>$._A_M)^5I.= 7/Z 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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MF.YW6VE-,7]IB\_?06N0OW[EO&]51TKMYK*,HB[=Y[4VTVN0G16.&4B@% *
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M2*YS:(Z^U7+YUR* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M1S55$F'JGS(P9OT1EC;%](C8;SJA8&2 GBU4$R?"1AU1K(H3E:A4@$I'#ZJ
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MO^;3\<;FJRX1?R^ZP_[1\TC/0XV?S+:'_P"S?/93(LKD0[9% * 4 H!0"@%
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MN\N[V?<UIR[>0):VR3K<I&SRE4VOW4WEV4]U2O(B)R\AV-42N* 4 H!0"@%
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MR0C3HL84<3>:5<OB'_!]=?L4!,GE;\HW937C8#3]W[":[P U"VBT1OZ/$:?
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M3DETP:4E% (8M+%O)H>?565L2>1T7"^!>PF7; KQH!0"@% * 4 H!0"@% *
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M">)$C:*XWVTQ,O*8'$E-&,P7A!6RT6MUX.A?$Q 0$!*?4I0VS&+=67S0F !
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M *^(HH2<5,IPIHR6+!Y9 9T= * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% 4@<PG^8+O#_ *H&RWXF'K0&%@8CK<AO<L7D9/#9_8>*9?Y?[IV=
MY="84UU9L/DXGE)GI"Y8R+'QE;G=04GO@ND6=<#@K]4GHHRL!ED%@:*=;<3
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M/K9L!$\7 3O)7I"LRM'&UBFJLMQ2@(*O"GI(!2E8QD;&**0HI<^.&#<UB-@
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M<=C2.F9#\<L")8X0BK6CR+F2U8Z8;9(Y#9DFZS&2A$&TUT(GF8$&,9%4A#3
M"X=Q,\\[X!VZ5[WXWH#VU 4Q3]J=&NPSZUNE)RJ3N:4FZIRU[+,1OUA'D1-<
M1$550#[0D"/U@1?;SE(*4:RNS5,5*<)"P 1D<O8(4J9*'"Y<R$!4[0'#4$Y/
M5B1A-52)-33S@=P39!0+ G"1H*][7N$8*F<! !P[WM:_1RQO;L4!&+ERY,N
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M=V9$;&,,1.JOGU?3M;+AQMQH#F&"Y<X7'*&P 314T"*7,EC 6 Y<P7'PR"&
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@/F!_T Z SO>3;\GA#OX?[2?E:3G0%S^@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H#Y@?] .@,[WDV_)X0[^'^TGY6DYT!<_H"@SFB[
M21JOR[MRMAX?+];*$30!(+L8IJZ:&L!(;C+(PI=.=AE*'+&RB@39HIGTV'",
M!YELP265AK=5TZ Q2-G8BUNY;&G>FV_I^1^;"N[7R*S8?V'DKF8P.ZU/8]A*
MK@>-V"KJT>;!1U+^SD3Q(IQ=+IE\Y)R$C%2^)HT1 P[J.FL APSH%6,O<^[<
MLGLEMD-!4/M^1H4T\W/.ZE*.MK7U W1ER=9T1HX<Z,TYZDEO[,Q<B*FM,8N1
MK&5$500VZMWQ.&4LMGD9"N(,GV/@=WM[SH.8O#!'FF3A'[8U RU]Y6>VD*1*
MMLMQ,F6S<LSLP9:=$=,\RD8.HK*0;49#D;YE]8FK*X:88 -6$QP[@"[DR[O
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M;UTW9LWB[ ,ETK:5.+;6W0B(H8<2DV:EK*K'ZX9;0F!E8&44X<@.$:PQ)F<
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M=P.YYI2V9%($"9L.Y8L.$H"9YA Y@Y 2HYEG/>B[4ED;J-37YER%+<]:B,Y
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M@% * 4 H!0"@% * 4 H!0"@)$;31>OS?K'L9"[4.(Z>Z9>@B7HO;1]PF#I1
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M0\EWPL'; UU0Q8"C38;Q?_9([%NK#,BN)M!GHHPKK,\XP2#[3D3:K3]Y:X[
MOV6)#EXS)\*RVRU*5GS)L*H:S(AW#)IN\03(90%,J!7 G=0S+$0.ZW"Y'&^D
MOH6N1D5<UDVHFV+]+&?KV7VID*9=C-6]FHDGA S5!L9;(2O#J*ZC^P47IHZL
M(*&D.TO94$,W%,6OB,;,9W RB=88XD2'M<8(BB7)/4)JE&-HCCYCR%+BJ$.$
MI20\&NUTQ&<#R.V-C&3XAA?4R8AC(4T*,<&OGTS H@V0F>0$]* 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% ?,#_H!T!G>\FWY/"'?P_P!I/RM)
MSH"Y_0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4!\P/^@'0&=[R;?D\(=_#_ &D_*TG.
M@+G] * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0'S _Z = 9WO)M^3PAW\/\ :3\K2<Z
MN?T H"Q?#'/(B^3=G>9-KFZH97HU+\NEHSX_%>03SZ2EI.EMJ:V*:61E=214
M6S?1Q6KDW@'2A#B8F#1S#'%8"M?.W1O>X'>:7<\C6C8;2ER[L[+X-G1%D-?8
M%YZZ'4.9)115D<R^6:E("H8():D70FX*L+1O!7'M9-)DC!D,(@,->^0>.5\
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M.>6=NL#MF!0H:YWVF#OVNU,U7UID>--IE?9.5)7BIUNJ)Y60%,K":E&<=BR
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MS0F<LJH(Z8DDEF3&B*]FM@WE047,)>+BH0.60P@>.%@1?.7XWH"J"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@/F!_T Z SO>3;\GA
M#OX?[2?E:3G0%S^@% 8,<^<I_F&.2:ML7C'$$K@"?M-S/MN8D>ZJ$\F:CYJW
M+PW<9\&I4B2V,("[2YP5MH:A"Y?*Q(2UE4,03+H%;6%SOD!UZQRM-]H\QA>=
M2L/;&)*%KQS?N99/:W&VK"QK<:V/,0IL\C1NDPI/T(-^< 'K"2TJ,P\R![!)
MBH2]-@2JGG<MBGC8]WE )IQWR[MHM:?S>.ZC>TMV@DUI0-S!]W]G)@T[D"9=
M:IBV>S;>VT6QXP6-.2,TX\CO6. &.[&0\(\S=($=HPJIFW%-:MEBKXAY&L$H
M#JV%RZM['&,W7L;TK=$(!N'QIG73F+&HL-N^'E$['NIJ0VG$*[)#5#3)>JBT
MQ0VRH*N 1XBEF#1GNK/.Q4,R%C8;("HG1/53:B$E.!M))>Y89&57-"?,IEK;
M5U\P&3W$Q2L.$X_77DN/-M3W$[D:S[,2NZ=B5U.52*4$W5),Z@IB4+^F?68!
M"V3P*.X_T7YF#PVIU =\JZF3(T!8!YNXL\S"68";II$^C;3B=7=2R*E29K]&
M4/E&U+<G.A8:Y0H,[G6XKJ"P+W.5"%N<.F![@ 9#7(>UNFW5'EULR&]A&"H1
MI)B9,FR+D/-134$-3-ET1ZSD^72UU#(VW5183,@U= 52YG#'$>XF&(EL<\<<
M[7QL!C5-7D![--7D1,@\G-':%0YD##=2:\2.DSKV$1';J\MFD7=DPK I+GU^
M=;E5->5M!-0@)WT&">1C&QQ5QZT2^9D44L*!-3:[E?[;.G9/F31:X($WMG6-
M^8+LK&DV1<NZ]RYI9#FN*RS,1FXKA$=FI;GB!9XV @YS:W&4\?%'LA)9^RAB
M3L 1(A7,V,&@*F5K4C:Z*)CYC.NCIY9H>^Q7?7=.'M@(JV,E!VL3'79NQ8E%
M&L$<]G=]!/%O3,UW1KW9!.^DI!+2+&5<<<;(I@$ .$6/ 2PV3T9W928\YRVA
MR+HB[-AW1S0MVUG8V =QB+BB4.#63&K_ '(Q%I*1IR<KH>Z?)+ 4-8 6\?\
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M <0*Y8AT5FJ;.8E+#[V"8CR<6X4 \F_2%VQ ]E]>>J,QT[F)M:(1TBS]-*Y
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M%(5#EBX>6&(@]RQ$X.-8$/(3&V671Z-KY6XW[-J ]50"@(8PP1<(4<<4,
M/,888;/$,($(/&^8@HHF=\< PP\,;WRRO>UK6MQO0$MT^:8<5B1=22I9C-33
MS@=ABA]/?C6.$C05[WM84N:+*H@ X=[VO;I8Y7MV* ](CO=EN%644! =[77%
MU(3T=65D5'7TE35DM*<);NU 4U%.)&QSA)/7"?\ "DQA<,0S(7G@[Y8]F@/4
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * IDW7:#FD'33;=@LM&..)XO?62>F
M@TV^G8X9J"ZYG+%;K1D%&(X"9AX9G%-4.A !6RRQM?/.W&]J L><K[D?H+3@
M[EVR[M]-6\\C2;K<RXQE)JZ@3W-* LZW:ZSVAM3 FEGF7%3?8:&H)BI%1PT+
M@A8FUM0Q(98]FXUKY=("W4PN7ALCK[R,CR&S= VRK;>OW<Y6<^P:>JZ\1'-.
MP@L#%-C7,M)C^9;$D8LJ-.4GLT&>11S+:1ENQ],!"$S'L5Q&QZS$"GHKRZMZ
M#";MM)9[5/:.18^*<T?EC;P+T-3DWH*39KW!UAAEE2<'-+7&9,/X(,#GGP?4
MW4F'SC/+! #E+%\21D$52 SQ$ K9W U*E#:S3?9.7H/Y1CJ@!7=/,5UMGI(B
MI4-( >R.P4=Q<X2($HS"OP*Y'$58T/.)S$A\R>"(04 CZ\5 S,J&%PK C" 2
MOW T'W%F2:>;#.,?:@249AR2)UY#VQ;7UY6$UG-];V&@_5B %PML!K^@MH)P
M'68HNJ-EE3)%%!#N:%)B'TNY8ED;$[GQ% [;=+4?8#;5@/+9S6WEES!J*T$'
MF1ZC[!/2/"!&/3&UVT\7P;'4@-!WS/EIY*_?9KVWWA&:^\ ,V\UCY,[@^P[#
MF54"]P0,AP+OO)!UU?D2%=TI?=[!VECDALQ/2.^DA/VP1]?(R?[U4&TULFRX
M)6#USUOCE@,:",7IF&6 &)CV'45:Z9@=&#!Z>.9@"R=,G*9W2<.K'-TF"&XB
M<C2W!5.:?S6'!"S>4 "(!S9W0K>F.F%#\FMA/+Y*&">MI;G0K]]#6R.Y=:47
MFQA<MB$,8RRR ESLSICS!7#%L)09\#F<LP;\@> ]96HY->(,U9<3W<NP;<AT
MFE/2!MJM@IW(+;MA^-F"\<<C>2(U#*4?6>JRQ3C-U(7$3 ">3>Y<.SS@;\NC
MO#59T+"MEXJ%&VFK(&=+323BB!N4UHQ&1S\1-_-8R$,DI$3W2G@]6,#? +,4
M,(8(QECU8E 2XFOE'[H/J/X!8D%:_*$7.X]XM*RM79'6D\@V&,15-H4EZ1@_
M'E 3Z705!'(W?$B8H2NG&3*D/W#W2HBCFC%L+BYT!7[R9=6I=3-SR>Q[SA;>
M6*2L=Z+-K5]R+>TD:Z=ZTL\XL%W<VG"2B./X=UFAQD+,PH,>71!!DZ054X'Q
M+Y9$NKRM<*U@,JN@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * ^8'_ $ Z SO>3;\GA#OX?[2?E:3G0%S^@% 83$.C<K,N)XQ6-S P]2A5
MP/?C;C)#"F(*+QIO$:7L=(=B&$0!KMKRADK9.FXMD;O>X&K+G"Y6]C5K7H#M
MN71MML] SDY9T+[(SFN1G&QWD*RQ,QYIR(XB3>01W<SI87LX?<YXRY^YC63L
M:VO11+_@<ANF6(%\KYAVQ#RRL!1]&F__ #$=FF7RP867]AMC4I(DCEU3OM0]
MI-B38G7_ %=DV9)I;^T,O1:7#<4RSRFEVLIMV$8[:J>LF6X0%Q%42YJXIL',
MH7S&" R.(8F*=)\\7N?\J;+.R/W]."_HAMNG/U^Q>[&6^&2^CC/;$QLE)>B6
MYXZSS8RB<=;>;I-04,4OHE"RD8, 88X=7?#$#'9>@.B!OD[\GI/U>"UDSYK)
MV3.7]C"PL&X1U;9\I, #A:YB0#<C&HYM[(I-#+MP,]DN"."]B6)^Q7(Q_G6)
M:]@/=3]S&=I -X$^:X/VPV55(X*\ZAEZ-&&R^)6A*/8),Q\1=Y5LO^"VEI(D
M@O24GN"EIQG(0:3EM0;I@P$('G@1+G<L.I I='E;8;3=P\PII0'M=L)@XISY
M^R;J/+2R8E6"VN]2,4N%%,+RI*1!WNY@HC<BR9Y76$@!M=_Y\4HVTHL5MC8E
MB-?,2X&4AR196VA=!7<Z'MB).&E=OP1.J(C0VKO?8B"]E)_9#7=+6S45^))X
MD"!LK("FYF2X4W,<F:4L,58<JJ7"%X!E@@@@+[% * 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% 8\//KUP<&T:UR^X^93QU<>S[;\\/^26[H9MI
M(CBC^.MWP6>P <5A&2KMG+,TXG9$A55Q/EB9H.R;<)4%N:SR"XE#8%I*']MT
MK1.)N9U#$/0X\N4WN>6GK3-(6=>TE1:6^T"-V0=AB9]-:AW2*.&,BMMO823-
MS.;8IHTWG"9]*"8MB7$;&Q,4J$!R .;SS/61K_NZSEZ55X*;-<>8+HQ!#"D/
M8S7K7EL3"3C?:G%0,K[3FB*8%75F$L5)#!3P;@W13@"I@"8$P,&2YNW5%0.3
MLSS$.;=J\S^;2]<-Z6S)*=RD-BM3"R<F+^J$((*ELXR=KG''::>CB3E1OD02
M3+;,;DG+T4LVV":<X#H@AG,XHB6R+!E0*G]D]T^9>O2QSU5V&=X&+ D>\IU.
MC:4(OBQ4UYAY\^RLE'(".2VY8X?;R=I$1PIR"Z3+5-IZ8,G8AK(BNJA8X'@@
M2]BPP%NV?N9].,)[';>[[P\STMLSKL9RN>44=;Q180[N1!B!Q[1+;?/K"N?;
MBL?) K(C+*N0T53BR@:#+9JMRG==Q0;"A"@9!O*8V4WS>L\[1:[[B9RT_P!G
M,!JQ=(4*S-L!"<&:VSJ<R<P2@0?[$D&(X'=J\SKI*>I8$S;>5 29$48GD/B9
MR'SR"N&!C]S1!:;+'-'YZ#A5>3@C\TDDR7Q!QDTZSVR$:P.H0:4$UB*'C)!+
M)NQ;37DY3#N"3KF<1&^"9.ELTS'$/&XX@..0$'4W>_>EKZ]\J?0?5:=IM. *
M'+6?VW+PG.$=9HRV4EQS*9G8^3XP9<'EF7LJNM9N)T9:^"(8:.KJ!2]E4VGE
M"MBF0  F!@,"X!&',+YHF\+]U$U42YKCOESS.H<LR8]X-A)5O&L23 FO&0HY
MV3=^KK:9Z>6? KX8328:@:9F#T7LD^XRB425 4N$8+YE[7Q E),W--YH<F3(
MVM=8*FMH''5#_+\;VQS\E_ERP_"^Y<-;'S6KNQ?;@2^$[Y^5661:.J8&"$"5
M5SS? #64M=%.%[&LP@P;A@>)V(YENUS4FAZ;, L2(8;V<1?%D$78U56BL;1J
M\W6TYI WX1V(YT!*D Z6=*PI0Z9.=U*!)L#J9]*!'&#'$L*<PR'N!4,_-H.9
M T7M'^N,F[O-2;T#F*\JB?\ 9!NKZ!KE%3/5]4Y%CF*"DAG3C1)M,4 1W1(_
MF^HF4,B*Y#:BH64;]T &@[@=2(!<'Y&Y"1R_(L@)5DB3SDGFG3K^\W*UC"@W
M4]#.LQFG4E8*I;#,'R1HT9=XB.=(FC'IN=OB<,]V=7GC;$'#B!C*(>GNG\(^
M+0ZV\QZ.&:DPUS'4%293G@'8"/UI>1)E>DY8[7JK-1FFCIR<HB]_1I8C\(Z7
M'2\")BWI>5$,YXXX%A!,0+@',!YNO,'AN<I_DZ!YV=B[$NKVRFN4&R!$#3U-
MA<YJBU'(XA&<AR]$,S[+2>Z",_N67#*^Y>D7"CDL9(IN%NB(/8"]SH8$DI*V
MVW6Y?4_^,,SS'\[XR.YTS9+3.#6BA.6(VP:;+5=NPY-OBL66KE,5PL"5RA*+
M@5-LDDCK 4IR+"F44U6^68%RXH%3KPWWYCS<USY@VJDZGI@>S^EAOZ^:]:,R
M_.<)PCK;L4K2[N@Y<(+<3.=$1Z_N]<:N(;'P<V;F;BN5*$C.2>FF;C=U#=3C
MB!T^U7)GY;D)\U#D)ZR-G5F-S48S,V^8B@STFJ!)1SRFXW!FIK)<$?N%_7Q4
M[7-K"2[!1U;'("X./=IC/*]KXWMC8#H]XMMI,Y<+VY[!K31O0_"REI=J_P G
MEHP*LHD.1Z?745HNEWQQ$F;5="XL(1]5?S?;D>JPR:BEED8[@D WM<MU>6-L
MJ [K:W=3F[P"^N;PQDCF!-59"Y;<6ZX[1M56&T_A$D?D4M.24FJ:O!"L'GBH
MD46*6Z" H8DSN 1AX"B#%LAEG+$$7 P!Y67><!S5YAE_;EWZLX/AI-O3U/UE
M#;,$-#6Z%)(A"35F0XY;$@R"/M+.,IOIK2K%+?=0JN: :0[3$*6N1"#N-D*/
M@(**!FAL5R#O)D,YWFD@9OF74U6\Y#""8-EE PB#KB034Q4@<^2O<F=&31#5
MP<A@;W"$RPOECYV]J ]50"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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MP/@CE)R) JTEN*(T]4Q1G0FX)8;+648J.!DFV)"#Y!6L8R&QOEC<#O)"T"U
ME5:V5<,@PFAN59W!8['C?9$\97'B5$E)D1N5R),E 50TYQDP4HN@%<[X!B)F
M)(<2U_X7/._9H"2,L<G3EJSA(J%*LH:L-5SO)$;L>M(P)9W2<AMIZMR*"*>E
MQND2XPFX^$AA3859B4DE2A#OP3%S($H7#!M?JL,<+ 7+000BX00  08   >
M(((.&(80(0>-L P@@\+8X!AAX8VMCC:UK6M;A:@(E * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M 4 H!0"@% * 4 H!0"@% ?,#_H!T!G>\FWY/"'?P_P!I/RM)SH"Y_0"@% *
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M_>+W;:O#NYZFVHWW+D70=[2RU-?PW7&"+LTP!1"I)A@*B$]#KC<!R1#X.1=
M!2TL\=$SN'D>+D C!808#OAN?=IVD0D])D>D9[6L!4C7;EK:3R1!3GAQ+,3\
MR9N>J<<5FL44&*U7RYDU:05TB0%R*#(RFIFS.>-@PBV8F6.-P*9=W^?+@S]
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M>Y,:*PU&L:?+Y6%",&NS\3I1.0Q1."R.3Z&5@NL$ ]!RI9)THV?Y-',9Y?\
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M8Y$PRYRXY3'J* J+H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@/F!_P! .@,[WDV_)X0[^'^TGY6DYT!<_H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * ^8'_ $ Z SO>3;\GA#OX?[2?E:3G0%S^@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M0N6-L<KV F50"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M"S#5I%>S;B9;-1&=7W "RB(LBR>181T NM@877! TXF;N8"OE;CF):V.7G:
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M7,AT^B50V(D3ER369?[UU[;V1P=[R:P51UQHZ.@R4HB045!74$XXP1R9HN0
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M 4!B&<X?Y4V#/P7@+\9KEKO_ *O?\#\G\/??-HSYL=9C^8/$_ 8_YU*9>=<
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MLN/_ %9-S[I4!BF<X?Y4V#/P7@+\9KEKO_J]_P #\G\/??-HSYL=9C^8/$_
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M]ZZ@'D2^@OA7;?\ V1#'O74 \B7T%\*[;_[(ACWKJ >1+Z"^%=M_]D0Q[UU
M/(E]!?"NV_\ LB&/>NH!Y$OH+X5VW_V1#'O74 \B7T%\*[;_ .R(8]ZZ@'D2
M^@OA7;?_ &1#'O74 \B7T%\*[;_[(ACWKJ >1+Z"^%=M_P#9$,>]=0#R)?07
MPKMO_LB&/>NH!Y$OH+X5VW_V1#'O74 \B7T%\*[;_P"R(8]ZZ@'D2^@OA7;?
M_9$,>]=0#R)?07PKMO\ [(ACWKJ >1+Z"^%=M_\ 9$,>]=0&/;XPAR%=<^4'
M#FO4CPE,4V28J3!)CH9*V1E,1BYIZ8GH36"72YM*LTFBW#%C@QC/H9]=F)AT
M.UC:_9H#)<YP_P J;!GX+P%^,URUW_U>_P"!^3^'OOFT9\V.LQ_,'B?@,?\
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M*,);S1$M#6U)"/MR1VNSW04, I#E(&<,Q"6((P)K#(//.W'@!5O0"@% * 4
MH!0%N#=[FX<O;EQ.ICLG<W8'V&W/)#?472RTSV*9ND/TY04I1Q23Y[NV*HV?
M*>G=0H96#ZHV* -E]5CA?'LT!,+2GF/Z2<Q1M.IU::3^V9J36,>(I[R(DD9Y
M,UU-<95[N]*!UUCR,VV>]4Q-6;IAFQ(X,GXE#ERPM@1,[AY]$"MV@% * IPV
MPVXUZT>A)Q[&;1R#[&$--)0;J4X7CWJ/=Z^EY]UKA%MH '>]'C:=KJ-]WK2D
M"#T@"(F 73Z8E\ [996 G^DJI!<2DQ;2A^ZDQ83R2JG&>J& [H(*!8,V3'ZD
MP&"8!ZXN-CET1,,<\>/#*UK\;4!*N5-AH,@Y:BUN3#+##C5>FY^)47Q D/)Q
MIR$H23(JX;)D$=E,XL>&"$77(I'%  ($J!;,43,7&UK<;VH#PD+;F:V;#S)L
MGK]#TD=]\NZA.!GM;8AI=Y[];_L>KS^ <YEID?3YT-9$;+L]-@6:I9=:AG5,
M$#N;@-F'<0*V8%3] * Z]652"&E*:VJC]RIB.GG551,]4,/W.03RPALX/U)<
M,8P-U)<'++HAX99Y<.&-KWX6H"PR4\:$Y%ATT6)@[T%\!C9@$L%F;UQVY(%<
M!!Q,0L,C)X] 98B2+XY9VOF,,(&$'CQRSRQQM>]@+EZYS M/$"4=5(;-S<AG
MW]N^WUUUZK$VR@O-XMZ86TVV\4=BLNHC]:+;6V"DI>#=/ F@!E13(8' Q+6+
MW%R[% 5CT!3 U=S-;'MM9)^D;8DCTSV>AJ/V_*4DQEWGOTEWN,1TXMW-!7>_
M10:Q2/5CN[%UI_\ FI!6-' NZ/X0+#H"= "I^@% * P@O%??E3>?G_I_,?E%
M;*4!EW;8;<:]:/0DX]C-HY!]C"&FDH-U*<+Q[U'N]?2\^ZUPBVT #O>CQM.U
MU&^[UI2!!Z0!$3 +I],2^ =LLK 3_254@N)28MI0_=28L)Y)53C/5# =T$%
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MDV/C#4C,D$5 %1VVX5%HC.$\"+F-D(N+!T:V5L1,<,0,DZ@% * 4 H!0"@%
M* 4 H!0"@% 80?.[_P"DT\C;_F(_*>?M 98N_P 9D(EHANN<B2ZAC*Q34C9
MS&623?.RKC(0$./,5EW3+AY8"64+.3 MU/1O:_6<.%^- 6$^3*WN6R5\6W:2
MA.!&)?@P*L2S"<W<4G#CG<<9XA.EUI\A7>9QM]%_@R$1+#$P&Q8AEBY BV:/
M9#_A,TZ^0%.\D26D; [:\J+E)<N;:.?=).6A*^ESIV=:DK0<XI5CR?)6::>X
MY6*M:+(WDZ?R)V8&L"B$([S4P+&\1LLD=5Q%S+&"82?CB!;XV_WKWWTR@SG:
M:+MS=R?9LQT0D+2-9U]W&6W@8SV :[>F]Y,89W1%(<L(6!4^[EXJ37<TT<P;
M$P-"&TI6M;#  3 J3 JURA;=C'G#1=RY3W-\YC9B(MSN78A;=S,\B4H-5-DE
MLR$7<DDDC2%KJIXL\R@ZY,\RZ8_+&; MI/ .713 Z4.9,6RP.8 47*/,:Y@J
MCR(]6'EANE*S7G%O\[1*TX,[)B.$W9^+\.$XNE%PE@)763RC<20$TDMFP#)S
M!6,"XG2R:6#-""7"N+D!<Y79,V-Y2_-T8>L2ES'=A]D]=MF]%-G-@I97=V79
MA-IK5UZ09%TSR<%."4G-Q(;6#4BO$S%=BX3?30")0<L.<+Y9&!PR0H(%J&"-
MO-XHRV6Y0,[-O<#FMRPR]W]XVA#DI/S<1Q1VSM0MA8[D"9FJS%+#6748A)$C
M.9@HZ>SG&+:ZR>P+E0S>8 Z;@0OT * KZT(E+?Y]+?-WYA3QWJV ?\<<L+8/
MF27AG2P^LKJM'DL+C0A"3S#9;$D&@EH(\M1^SLS"$,V&_B7,%TY7("&@+!#"
MVSH"BC3;:?FGAIF@&];2E7FIS6[IVV#22.U"1LDZH*"Y9\C0J[G<NH:^C:P-
M<.7_ $Z9;\:J4DW""P#;Q/.YT(T8 #(XD>XSP$[CY_:SF5ZI\_+>>4>8ALS"
M(FKZUN]KO'^E#&>J*EZW 0M',)K%SK,F.&'"BFR#G6I5;+@,MHDNA^EBV67R
MAD^&,,8P!+@@9$?)?9!^3>0SJ#&Z4^7A&"G(.H"VR$Z2X]/@I3^CP^ZPG@@D
MWRQU,P7-ETUX-(P?Q/I@X@0F )TN'GEAE:U[7 P_])IYV4T!Y&T]2SKUL/(C
M:>>U?-;;>EX3O=@R:NLC5U#+(+I<#XV$:R::3;E$1Z204$+)3@4S6=\.)5.%
M+7+F@ A+@7Y28&T/*6YM'+0UC1.8'MGOI"O,,1YD;DRQCMO(8,RO2/W/'#:0
MU,C,,;KV2<$K,%CGU)9R' 2PK"%0B",J8&#!O+(,P4 G7XUAMB!"'+G2M<4I
M:/)#QWFEIJ0D.:0R!E:<B+#J ?(OB:72DMXC@(><((*2F)Z&:* VZP4%P\,<
ML<NC>@+8_(/V>U3:W-#WCT6U*,RLP-/MQ(5:,JZZ$GDV5J(7^S);B:/$QIR^
ME-$F?"P-X+SF2U96<(2D7M; L$WB]L,+9!Y99 =4Q]YM[)$B+7;DU*.S4R)?
M,13N;O)^K$U[!(SI6R$Q+.G,'"#S$_9D*.<(41:N34&<\BI=*%S'P[J247J\
MQ.J$L)D!)O8_:OF)[;[;<W18CB6.:^R5_1.:'A#.I3(T=<<5M74=A"10KO!(
M3'/NNER#*3#7G<VY8Q8V"GD?N15+%"QLX8QR.E2X27<"HE[2YS,^8%S&N7-J
M@-NQ-6B(^Q?)[:,P;0$H(7P[ !2<WY3V#2'^Z8[2VXY0FZV'L]SS)30 %@B>
M[I24J]PP1<\@L0\@*<.9YLCM*IR?S.Y1@/?+FHR#GH>M,M@-P[JVX&EK;HEK
M:X68HE&N]6;L@L.J5<W9LS(QM5)9 G0DA!!-Y+HAC'(0V2S +A@5LF]@MPN9
MGNERFM*7=NML1IQ'DK\GV#=^Y7?&JCN*0A+&PL[R$QL3SA((+K))(I$LVTP\
M2$.^E 1,\FXER2GCD6Z5P128%MIP<T+F)P1HQS.D=+W&EZ=)'(\XQL:*,W97
MNU.6G*Q8E.DIK4UQ\0ZF&CY)D,;)\WBTL43@BQA/3B'IWCW(.5$P+#A 7G.4
M>^M[8<YE+@UJ>2OS*WSI9)>MXCY(WYL#PB%T[.1W.K94[!F%%HJS'E60E90B
M-UI)0V& 'T2X6)L:P68/33[G3P$N.=PZ9V97/KY0+FUHUN;^W,VINO\ M9WE
M:\NE^LZ,4&0>[(^E-/<?=SY?X@+20^]-I&CZX%W7E;ND9-P+A?PPH=J DDY&
M;S)N7VP.<]SU)>UMBG36=90@V%8<A#5J+'6R)A3V8:/O^*(N79Z?!MAW7(^6
ME9J@]RKY;+(4:QP3TQNH%"X&.-C '-D=3W+Y7K-Y1F]+8YH.V>ZB[O3/>N<8
M;$ZW3E(Q23H;DUO;"L\P]%58UL8ET\0>+D]I6O8@5$3Q#@XAY131.L" MF0'
M \A&R1N+N\X_&"GJX^;1NOKRC<O;;_;D?7ECQ1- ;*9C2"8SAF19:A:4CHA0
MVZU:$$U*815,*-LF>2$\((L;$MF)GQPP ]_HGS--R]I=SO%P5*3Y;?"$B[/Z
MO[PB[#QZE*AMML29W9!B-M PV;(SP9A'$@@'UAP&8Q3' #<,M@6".#XY%<,
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M ^DXH#Y@?] .@,[WDV_)X0[^'^TGY6DYT!<_H#$,Y/'RILY_@O/OXS6U7?\
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MQJ:Y(UI"U&>BNHNUT'T!;@8(PUC.30&:1A5S;P0P^3.(8B'@R^)W/ /+&XO
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M>9YR*D=;T:UST]Y>T+%55CI/-%C?;^;F4^I0L8+&68<CR46C+2WZ<2:X[BJ
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M$""R!"#R  N$!R9R\7XY7^PTY2]/LAPR[@G-/X*@8FIJ,R7Y*8<9R6[3Y12
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MK7R .63JM-C*GF.(B>BZ[HG4#RK!J)*4P21*#"@E14#8QXP>BQF/!P*20D*
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M^U=V ]R3^7&@'D9O]J[L![DG\N- /(S?[5W8#W)/Y<: >1F_VKNP'N2?RXT
M\C-_M7=@/<D_EQH!Y&;_ &KNP'N2?RXT \C-_M7=@/<D_EQH!Y&;_:N[ >Y)
M_+C0#R,W^U=V ]R3^7&@'D9O]J[L![DG\N- /(S?[5W8#W)/Y<: >1F_VKNP
M'N2?RXT \C-_M7=@/<D_EQH!Y&;_ &KNP'N2?RXT \C-_M7=@/<D_EQH!Y&;
M_:N[ >Y)_+C0#R,W^U=V ]R3^7&@'D9O]J[L![DG\N- /(S?[5W8#W)/Y<:
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M H!0"@% * 4 H#"#YW?_ $FGD;?\Q'Y3S]H#-\H!0"@% * 4 H!0"@% * 4
MH!0"@% >;>2X*V&@ZG(  &:';S;7%P$L-EE@$8%24PT?# %SP\_B&-F7MCE>
MW9M:_8H"PCK=XPIJ\Y=7M7Y1VD+.R.9WV)U_>>Q@$.PI#LW3D"7CUFS*]8F5
M%5+-,1EN@YB72^\X=0/7.W L5)@#C9Y6#QPZ8%7<E<[#EKQ4GQ"M.+8,PK-^
M:8?0-@VVX&+%4PR"CMB"70L!MQ"ER63+-8:T)#C'/.3/).N9<^"7F =!'!&P
M#S+CV# [1P<Y7EVM.6IVAES3SZ3.K6EIFWW-2L,PI".,)DLTNR&Z_P BX#4A
MI384&<>+NA!=)/!! *G!CCA/YYE$T$T8"$#Q \Z0YW/+F.1D]Y,,RZ]D"\?O
MJ-8T78N=<"3LUI]-OJ:"2DJ0VWVQ R]'1"5G>-*J4C'#2$.EI1LH<+DS.?6X
M]RF>J +/.XY=2-$C F&\KOI73))?TJ1>W6"VX#G5Q3:6?<$IY96G%ON6$4B/
M#<GM0:'TL\7,.$913"Y9/!-%\\A+XF ;B =E*/.JY;L2H\6.%>GM0<B#+D.)
MFQ:"JQC$4S2L6;.ORL>NE%)HE(./(_<9N)8_LKAB$Q#3C#310S1<P%<+IE3-
M@0*9N9%S\M5M-HHV%RAISIL[;#0NP8T>I5JI[.E5:A+(>53K05&4WGC/K+:2
ME%[67GA'3DS6T8H86@1E / (,/I##@ B@7/=Q-VM<="XT;<P;0O<Y'\=NB3&
MC$J<XBC5=3PQ">+VP5!D, ZF,]'7%@!/R 13(@QBQ?(,+$/L^>RQM<"@F/.<
MA!>"3M;+,SOUHHL(19*.M#!AA(9,5[&F=@EP_LW#;(DJ/([?<3KT> KJW-+I
M.N_'N)&:A51[C)6OBH=SF2YK (#AO_G5:_8*.C+RB)RM%;U[V3G'8:'IQD>4
M0'?$:YKJ8USAQXR7(!9ZM-^)#866>YFFHM6Y95*K98M@"4S[H#OF%F"+F!<(
M9.Z&OKTU5ONQFZU)BZS78JI*0,E2FUW%&P \8)I88\%(.+>=R<F.H!LKR<#W
M4DB#$0AU8J* ,4"%",ELQ0+4FTOC#NGT7:?[#;!0 &^I>E2&FZQEI(A)^PW/
M,*+RND2FJCI,>R@K$I C%#7BD'*^1443OG"+9)?=%RQ 4P6.'RF&8%PO#>QA
MP]HK&.Y&X*@1BH!SLF-3SI1&FRID4C8TCR0(F)2''T?QLZH^;\ZK"\NN54#)
MD$L^VB2S:^5\C14OB&-<,"W7LSSM0U! TV,\O-/AV5UG:?:F0=3'"+M2+,>O
MR5",FQVSBSK<#<E9",,(2262O).!POW2 91!<KES0 P.(@(P8F0%.2[SK-_#
MNF>VNU#"UPTK.C<NN;)S@;<!.4)WF);;3Q=$5CL$=&<&K*\V(F%3G<AJJ<]<
MPSY9QG$4V2,%L,NSB/; ,"8\_<USF :QQ#I6Z)P9/+,C-X;MR6I)3.>3[V3F
MIE:VQE&.$'DI81UV8Y-=T4H2HT78?5.O2[@%2"FGW&%*X8&,LQ<KX 5_<JKF
M!OG?AE;"''ZT8: 5M>YU.0K:7=8)24IJU:F_J6<UWCFYX7DM7;;445PJBX.?
M BI!9%1, 1\0\\1KW&R!  NJT H!0"@% * 4 H#""\5]^5-Y^?\ I_,?E%;*
M4!F^T H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% 807
MCO/\UG1[_3_(GXNB] 5%<X?Y4V#/P7@+\9KEKO\ ZO?\#\G\/??-HSYL=9C^
M8/$_ 8_YU*9>=< 'TG% ?,#_ * = 9WO)M^3PAW\/]I/RM)SH"Y_0&(9R>/E
M39S_  7GW\9K:KO_ *PG\#\9\/8_-I#YL=6?^8/+? 9#YU$9.>V7\UC9?_5_
MF7\73CK@ ^DYBA>)+_S!=KO];\Q^)B+J S/: 4 H!0"@% * 4 H!0"@% * 4
M H!0%G+=[F$[0PKNWK[H]JGK;$,WR#.,$RC./IS,$Y+T,(*(FQ<L%D]32 CB
M)&,B]U&CI<S80+,7$ /I^=RRQQ\]0$MH,\8)T3=FH>NNS6Q[M.:W.2>D>53N
M,1DFQ)D^K2%>#7PO1Y*#I!/PE'+L-&(C2EYO"BEW6>(IB6(5%PL-D"8P' "
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MY:M<N:7YUY0CAY:.U<^);ND55A>\*8[&,U!5<1%4DR5<D=AQ[N=K+1\N>4G
MG$6XCAN0OZ97].ABQH6QL+(W>X0% >P_)HWEWJ;&U;TV^V"U:1=A9<TJ8FBT
M28:^1_*"5$+>C]"V+8VQ[TD:0PWLMJ+I57L[G2R0"I1/3@P4U')VOB'F-D*)
MG0%W;F:ZA.?>'4]S0(T?82,JZFZF4Z/2381D.9XQFZ"K27 58PW%,ZQ'*T9'
MCX\HV#MW,Y&V? 6TL3#B7OP$SH"S$QO%^Y==C&U,8NVTWQ?.,=0;N_).R[CU
M]<?LQR]$;:A1XQZE,E%UMC)RSVZGQ)CE0$E42Q%@4TY#?5W,'A, P,<L,AS
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MR%%S\_<"AS6+D[39!$*<E^,U"2XC'6^6I)<_/R5E5" =6:8^[2ZUI=1$G)A
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M'RILY_@O/OXS6U7?_6$_@?C/A['YM(?-CJS_ ,P>6^ R'SJ(R<]LOYK&R_\
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MTQF2N7& E+-'C()5^Q4Q7>CJ;3UI6M=N9'H&@;6J<+S;'VW\1O;3N:3S_79
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ME(^EM55:N<Q[)%1$=5R,D:BJKDWEOP<Q?F1S%H4]FF5MKN@R)&#]2\QFP_\
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M*JY6O78B-5U>%:N-O"@% =2OHQ-QH2TWE"XV)!>25%&/7+YXAF+$U0F,1,W
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MS3T,AJ@:TC=9%.V&1R@LGZS J;A5&?%;]5L(VNN9M..^^&Y-*3D@TDIHZ65
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MRSN_S>M'8X6$'9U'(F5&1"B87B&7C*7%CB[T'0F.%%5EY&4C+)+'6LM656<
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MHOC<K7-V;-CD5#O+'9"TRV/@RM@])+&YA9+&[]*.1J/8[;MVM5%VGH*M"]%
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M=;W4CF[L\\C$J^-B[R-1R;M$6BJBUC<N[Y%-Z?Z,-LO_ $V0ZUYQ<_F0MO\
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MYP_RIL&?@O 7XS7+7?\ U>_X'Y/X>^^;1GS8ZS'\P>)^ Q_SJ4R\ZX /I.*
M^8'_ $ Z SO>3;\GA#OX?[2?E:3G0%S^@,0SD\?*FSG^"\^_C-;5=_\ 6$_@
M?C/A['YM(?-CJS_S!Y;X#(?.HC)SVR_FL;+_ .K_ #+^+IQUP ?2<Q0O$E_Y
M@NUW^M^8_$Q%U 9GM * 4 H!0"@% * 4 H!0"@% * 4 H"U1S(.6BL[\JD8+
M*/L&CQ"8CA/<R:"E/75/6O:5O!&'&&'CB^&*7G!F*;ABR6$2X>-B:\CJ@=L
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M\%X"_&:Y:[_ZO?\  _)_#WWS:,^;'68_F#Q/P&/^=2F7G7 !])Q0'S _Z =
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M 4 H!0"@% 807BOORIO/S_T_F/RBME* S?: 4 H!0"@% * 4 H!0"@% * 4
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MX#T_^Z)'7H>@'EO.K/@/3_[HD=>AZ >6\ZL^ ]/_ +HD=>AZ >6\ZL^ ]/\
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MX#T_^Z)'7H>@'EO.K/@/3_[HD=>AZ >6\ZL^ ]/_ +HD=>AZ >6\ZL^ ]/\
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% 8AG.'^5-@S\%X"_&:Y:[_P"KW_ _)_#W
MWS:,^;'68_F#Q/P&/^=2F7G7 !])Q0'S _Z = 9WO)M^3PAW\/\ :3\K2<Z
MN?T!B&<GCY4V<_P7GW\9K:KO_K"?P/QGP]C\VD/FQU9_Y@\M\!D/G41EYUP
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MI]>*C'$TN+W#?#/$:P@F0 'T!* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * Q#.</\ *FP9^"\!?C-<M=_]7O\ @?D_A[[YM&?-CK,?
MS!XGX#'_ #J4R\ZX /I.* ^8'_0#H#.]Y-OR>$._A_M)^5I.= 7/Z Q#.3Q\
MJ;.?X+S[^,UM5W_UA/X'XSX>Q^;2'S8ZL_\ ,'EO@,A\ZB,O.N #Z3B@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0%"^R2AR[W--
M400MM.IZT+6P$@DC!2%(NE929AR3W.EG#QG :[+:*N8S<)M+.J26/A88$#J!
MARHN&.6686=L<EP6LM5Z8BD@T[D+NRAE<CGI#(YB.5$HBNW52JHFQ#%-1:%T
M;JZ:.XU/C+*_GA:K6.GB;(K&JM51JN1:(J[5H34RTYU6RC11ANVOT4AQ<J.2
M[R.,@!G)!="R=UT\FDW=)<L 7#R(N+TJ(!%N[0,@S/<^'5]/H7O:]ZG$/7*9
MEFHO.U\N;9#T*3+*]7]%O*[HE55[Z/><KMQU6[RUI7:6"\,>'OF)^F/,V.33
M\D_3N@2%B1]-NM9TJ(B=[)N-1N^VCMU-VM*H3+C6'8NAMF!QY%+$;<>LL,0V
M/Z0-)."1"HIL^'@"=43 A'JC1I5-!!88B&Q1,S.5@\..?G<>'C9G4.;U%D5R
M^=NIKO(JB)ORN5ZT;M1J;U41J*JT:B(W:NS:I[N"TSI_3&+3"Z=LX++%HJKT
M<+4C17.2CG*K:*KU1$J]55RT3;L0E*_X(U">B5&6OTD,*&UPJUTZQJ)8M<H:
M!FKIZ0W2.!0R,SD(T8P71DPH0)8XGKE\<P10PO\ ..GT:]+':YUAB,I<YK&9
M&[@REXKEGD9(J.E5RJY5?S*M556K2K57O:'EY3A[HC-XBTP.6Q=E<8BQ1J6\
M3XT<V%&HC41E=J(K41')6CT3OJG?QJ_]9=I(H>+>B=S17,\,$QW; ;W168;1
M'&Q28Z.E!MUY14L$$SK$HM9-1E/ F<3+XXXA%QK!WPMC>UJQB::6XE=<7#G/
MG>Y7.<Y5<YSG+57.5:JJJJU55VJNU3+(((;:%EM;,;';QM1K6M1&M:UJ4:UK
M4HB-1$1$1$1$1*(24;D7<NN8T53TD:[*UPD%!TH=$8+:MK>E)366D_7)W'"B
M\X8D4C;&!#%"8ZP8)X*)M'SR""SRPL-F'V.E>J95.+*_*QY<DZ3*'L)+^E>N
MTB3+W<04S[\<\:H"BIN!23+!8D%!WELRUDIZ'BH0 8>(RL7.B=4$&'>]\,,,
M<0)SKNG6JKH6)W<#DUZB%>6]H&RVV;L2IJ[%0% W-#59R$"V&F@R*(:)"]\Z
M:V4 L&4(!F>G8H$'A8+H]'&]@)K,^+HZ8$;H$/,QE-MNQ4UFF48;=CU/2BN#
M01V203;(Q%HD4+,,1/!;9-'QL4")6P[GP*XV"MA8.UL: IHUSY<FB&HKX<TE
MZRZF09"+_=Y,TF+;NCY@HJ$N9(QXV"?.H"6>  N(W6V;.%0114U.[E(B9@!7
MR"OU0?1 GS#L#0QKVWUUJP=&#)BAMN=Y+\AN%#8B 0;J8M/EU9%LW([%$HG
M@A&EY<S)A7,F<K7$%N'CTKWX6H"F2;.5ORZ=D);!G>=M,->I2EW')-S//IW1
MPA*2PX<T<( LEY/+&Y? D^,D\D4"+!76 CU\"H(8%OX'#'"P%2J)K]"#;EY=
MGYOQ2PT6:W,QTF-'!**8VTPD]5>/D$P4-HK,/+Q<# Z.VTHR0 S+E+Y=2%D%
MCT<;=&U >ND./&++3%=D92:TT%]QZ^T%1:[S9CH3BRNW7.W5<MF45$5:2S>
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M 4!B&<X?Y4V#/P7@+\9KEKO_ *O?\#\G\/??-HSYL=9C^8/$_ 8_YU*9>=<
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MYIMN?6O(Z4A(:H2)D#@XR':X6?69CB" 9E- * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@,0SG#_*FP9^"\!?C-<M=_P#5[_@?D_A[[YM&
M?-CK,?S!XGX#'_.I3+SK@ ^DXH#Y@?\ 0#H#.]Y-OR>$._A_M)^5I.= 7/Z
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M;O;*]NMH"FS7WDY<L_5>>1]F("U,8L>3-<9QF$ARDUU_K2.RC#N"&+.0>,F
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MSC<^:7BOG)+ASGSNO%5SG*JN<Y6,JJJNU55=JJO*7':]TU6* 4 H!0"@% *
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MJ/C^]C]6M^H^G9;]JNB-+[=/VGP*'Q#X^)N\9M2-[&5F3\:%S&O>-1"@% *
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M82.;90+L5WYKKB1$V=))MHFW<8J-1:[RK>-K,#F04 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * Q#.</\ *FP9^"\!?C-<
MM=_]7O\ @?D_A[[YM&?-CK,?S!XGX#'_ #J4R\ZX /I.* ^8'_0#H#.]Y-OR
M>$._A_M)^5I.= 7/Z Q#.3Q\J;.?X+S[^,UM5W_UA/X'XSX>Q^;2'S8ZL_\
M,'EO@,A\ZB,O.N #Z3F))NJG\SC;;G+S[J'IUS WCJ>RXDU6AF9<&T%QS;!T
M=R*)=NK(I;$JWU@T&?-J"F$*)TN&-^CV*@JJA,B5.7^:8Y_U_P#[^&OV[?\
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MT_ZZ^0/I)QGUH4=Q;Q#>5J?[3XL@O#F_[*_V/USS#TTXYYS,:#J=P_.ED0\
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MB63O)YD>YZ<Z<FW;SJ9:ETQR51BT]HTZK_99_J_]2I?/\7Z$GXNZ1\H;X/\
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M./ECG:][=;E^I:H;C_TE)M]GZ"$&^0G9MUF7ZU6BSO1:5)_V?Z*$MVW8?O\
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MB;3AR.W1)#L55?%$65HF7,)[73%.[<0A<$03 RLJ'<Z6G]/#(P-A;+&V4UM
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MX0XV?;^E^[5)W*5&\A#OVZ@5V^Y-<[\;?0M?]>U')4(FWM'"JB71B(^-3_\
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M1S'(_GYT6TRN:S2LRV>M;I\<6+NV11P(C.BD:U6))TE6JY5?O+14<F[S>Q/
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MN1R\ZR)CGF'=/M$T+Y%<+';""XG,GA/=CV>:=PXE0\P,"]L1N/\ G%\<L?\
ML/9/_=M]M?R(3,]TOM)_232JW=RE4@"=O^[YEJM9/=*$Y24$_MA<>\#36RVP
M1],W*[HBDAL-Y-[I)DO3!<7V:LI221[L4#!0@4[K/FPP^M'%"!#Z72SSQQM>
M]I8G(V5KG>Y1R+^,HO15143E5%,<,/E][F19R\.2JX$2$!GOLQRR95:,B2SK
M"1D*-2;@=[(4B#L;,D([&?6;H&C-3?[=3%4FH)P&2T&1/!X#A8CY&.I!$]5;
MNV?>7+5=2"=JHCJ+L78J52E:=G82-AE2&)42LD:U5*I^'V*E2.FNDSG%C3F*
M;'[O:7L]]NK;K9YW;2Q]I'(A"&YJ64- CYDE6_"R LFUH=P10G32\Q"(^>>>
M"CF01LCI>PIL#*QK$&UO+I$=##:RJUL;$:KTWF\J]\NS;NI^/L%Q;PKW\DS$
M57.5VZM%Y$V>Q4IBFK4_FYQ5-$.VUJ6Y ,AO!,C&2G<ZH:D6'F)KLB;4N*9>
M[]F#NV3"D,L'(TL0$V-:$Y%9,:IR#B*,DH#73R )8(V&&()-%<XV2)WE"-V5
M1$<CE=N(WO=Q4V(Y7U<Y5Y555Y ^*\8].CKMHNQ41-ZO?;R+M5*;&TYD,HT3
MS/I_M5CKCU3CYVX>>OVN';JB[E)VJG)SD._;J"%=FUJ&F5KVMV?F7_6M1=G*
M3(J5.'5$N3$1\:G_ /J(_P#VG_\ [GBK*\_-_#_0=6=6/_[W_P!C_P#FBN;Q
M;/Y/%;_UC))_Y+QW4L'N5,-ZPW_KYG_E\7]^4O\ %ZHS<II!#BB_5W^A:J:$
MZ<AMO:]N''S>'Z]N-JH.]TI63D-M^U4J\A$X0GGA.E;LV^;_ +6UO-JW*B<A
MKAV_I?MVJC,BJRB=DJ,Y2Q/$?)IDR#=GY4V>COF+3>DN&=9IM+<RHXT.04KG
MG^E=\917]BU1D!PMI9?Z?'99&)X)1,@3/@%T\KC;,L$&+;I5D5QJ**ZL8[&>
MRB5D46XQ=]Z;JTIO(U%1N]7:JJFU>4\>'#26]T^ZCN9$=(_>=WK5KMKNU5%6
MG-1%V<QVC7Y*K5;$NLD?+963%73V+=M5/>*+M+3+08H#5:&PYT\KKR:=SE8N
M5Q?ZU&S5=J^<4TQMC\"^ XF-C QGAGD)3FU-*^W<G0,3)26Z0.GWG56/8B]Y
M[E'*B(BNY>PB$[,*QLS5Z5RV3)NE;'1*(_E]URJU%551OY2LO:;1%B[?@3.C
MS"[W(*W)+UN<6N#,3&X&72#D0IK_ %/-:DY^-Q1%&/@K3S?*@B-C 6YTMD3+
M$6N 5P!N$>4^[/*L,M-C5B=;-;OLG21RKMWU:E&M7L-:BNY%JJN5:[&TOKNP
MCO$>DSEW71*Q*?FUVN5.RJT;R[*-ISK7KM%M'P]-$J9%!=EE2FR4I\D)(D"2
MWZ+'[&B) ,&&LPFO&;22&M%<9D4YDM,BE-1I%^Z10 \S2D>%&,#B9=(,,*AF
M,MYS?&UD:16\+%:UN\YZ[7*YRJ]W?+556G,B41/9GQUAY"UZN>LDLCD5RT1J
M;$1J(C6[$V)^%=I4S*P>8EHXZ!@ OT)6: F77A#B]?AC91Z1<'J+VZL<3CYW
M//SEN'9KS[?\_P"#=_07K_=,_P ]":6'U5OI_L7JV+\X8WF_X?[522\I<1_T
M''RRM8/+'CV;W[%NSYEOU*I$ZHI#M:_5W^C^Y4CI&-6CEVD:TV$ 2]LLKWMV
M;=C]BU6;W(O(01*(01NU;_:_LU3:7"<PJ+O<K[1%.4TR[5_[O-JV*R<IQQ+7
MO:W#YM4WJB)M*S%1%VD'H9?,_7M^[5*J$^^U!TK8\+7OPO\ 3_:JUEVO)VN1
M4V%%/,#8<SR9J^[6CKM+1.$9L/OJ#C$;2.JI5UM"1W,G3E')\D5<"7@04AS*
M*LW+W)CW#!SR"L-82^.>.&0>?L:<N+&URS)LE"L]@D<N^Q%HJM6)Z+1:IM3E
M3VJ>R>5F8;J>P='92)%=*^/=<J51%21J[4V[%Y"S,M\E;82:TC<V3)8=^KD!
M["; B:UKT6,K5=O/8UKPS)"U><-G>VI D#%W(+17'FOOM5%,D#HED?'-)3C@
MV0>1\7*^-\T9KK&V#[&ULV7=SC;;ITD=<*WIG,G3=<QFZKD:C$HJ=]WRHGN4
M,;=I*_NV75Q<NMX;V;HE8V)%Z-KHEJCG;R(KE<M47O>]15Y2XQI;J-L6R=DM
MF]U=OE^$S4]S\U8IC!#8>O9E[J,5QW&L3)AVP(8+ID% ;3M<2^]7$HY'3ES"
M;A@GV!Q"!$&PSX!XOGLQC;G%6N PC9_-]N^1ZOFW$D?)(J?FL<YK4:U*)1VV
MM51.?W,5BK^&_GRN36+RR9K&(V-55C6L3LN1%57*M5V;.:I1+NGRE-BMF6E'
MJ\1>$#N:77 KSP]Y^092=$U(T7),P30WV(V(]F&'UB,D])=:XZ]/V:PB#988
M:\2*AG$@H&8'S('Q3 V?M8+5^/P\\L;X[EEDQL+(71MA618HE>Y\4J2*K4;<
MN>Z2;<5:.6B;S41#S,KIF_OXF/:Z%URJR.D1ZO1B/>C4:]BLHJK"UJ-CWD2K
M4JNZY54ORQ\UU=EQTP&:NNA1?"XTF8UVRM/18QQP5W>K(*$02E%T*F&.>>.*
MBX#A3,V/:V65K"BY=F]:QOI67%U)/&Q(XWR.<C$Y&HJJJ-3V&IL3VC-;.-T,
M+8GN5[VL:BN7E<J)157V5Y3UF.5NCE;CV>S\WYE6?-0NUVD"X>?9RX=CLWX\
M;?-^C3V2/(FTAU $"_:O]"]67/\ A+HA6[=0E_=K_ESA.4X^?^5O]#]NK;\U
M"JAKAYOTOVZ(5&<Y*Z<@\Q86E\(,< KF)%S_  \#1D(8<L6SS:BOCB.8!+7L
M8& !O?I9XA^?RQM>V/9X5>XU:9*W5454Z>/8G^<A3O-MC,G)^R?_ '5)D9VO
MQO?S.Q^Q:O+>O?*7M:&RI0;!;V[%_,JQ5S2NU%HJ''OE:]NQ>J<JHK"=B+O%
MJ3;;DXZ3;8JB.ZE2(H[8,@^SFTYJD"0VW'+5-.R5\$-3.*;E8SX4SI? PI-R
M01#?15;Y99YBVPMV+UG&G.)FJ=.QNMX[F>:S\D?!'&Z1Z,BWD1&R1HBT1T=.
M\[!BV9T1@<P]LSX8H[GRALKWM8W>DHJJYCU7E:^O?$O)LY.S2E9_3."A[#2)
M&FK^T3ZC.2=GM5FVTV8<;DGNR,A6^*7S;\B'RW?I&J,\<FHG9+I5/N)F=S!R
MZ H(>6 85UC.)EQCK.U=+90SY^PAEBM;MSWHZ)DN]7>C1=R5S-]W1JZF[7D5
M:JMM?:)AO+B=([F6+$W<D;Y[=K6JV1T=.1Z]\Q';K=]&\M.5$V)<1E37Q F)
MVL!1>BJ:,,*/$&0 DJ."!?)-(FGP^&UDPB;_ #*V3.@G@U!E1\LKZ8D%00PP
M0!7 .<ROD9+$<RV$8_,S8RVF9:M1+R9\=956JI'&[I%C1JI2CY&QN>JK54C1
MON7/1V3WF-COIHW3JJV\37T8FQ-][=Q'U1:U:Q7M:B;$WU=RHVE).AW+80=(
M7&Y73E,;DF!8,1-&6OK%%56*P(Z+,R$(A/.519;=524=I205D%\9&G0-=2="
MKAFHGL00L;8@VZRPGN:SUW-JR%EMY+';1)<RW,E)))5?/,C$>Y%D55CCHQ-V
M)G>MJO+LIYFFM*QX"1T_3OGD6&.%E6,9NQ1*Y6M5&(F^^KEWI'=\M$Y-M;E^
M=KWX7MYEJP&J;M#+D.+?ZF_T+_L53>Y%385VHJ<I"XVJT5CJ\@HINQOV,OI?
MMT1CJ\A%"4\*X9!0U$@68X)K,.,6$'F9+!# ES&>#42<<ARX)B]S 0(U[=+#
M$3S^.-[6R[/&KK.?_P 7N5HJ(MQ)L6BJG?KRTV%GCTI80)6O[%G]U"9M>27A
M"OV[_1JV=[I2X;[E/:./?L]BIB*<IQ;VX7OC?MV[=O[NQ4I<44AB?4_3J1_N
M29K5<M$Y2%T;VX=CM]JJ7*'(K?=$++M_2JWE<B*E>P5(E1S5IV3;QJEOM*I8
M_P!U-#-V]FS>R<((TM:U9:E;3KL4JJ^LO"/1D78"%"3$6D)7<*.RPV$RR+=F
M,56,MT 1.4G8L GTP,3(OAG?'# :^Z=&:ZT5IAN-SLUGD_6S%LG:QL<R.M+E
M96N:QTG2R*^WW4>J/9!&K'JF\J;50USJ32VILXMYB8KFQ]7[]T*N5\:MN($C
M5JN:SHV(V:JM3==*]'-K1%V(I+.;N55LDYSFVD$Q+*,,HFG6\DLQU+<QJ;S"
M>IO86-U%$-,\Q):5'!4DB*#(>.+^$9)80$VK*"?DG6,"!XA99XV,9WV%XK::
MM(\3GLO:WK]98*TF@MVQ]&EI,CDD2%TRJY)8^BZ545L;'[]$551.]2VR>@,W
M<.R&*QT]LS3>5N(Y9E?OK<1JU6=*D:(U6/Z3<145[F[M52E>^6ZE,T%.*65>
M*VJ67B+2AV/ E5XF"Z88.&':?E9M$22;!8N! VGC(XK2C-6.&77CD*;[LS="
M&A9XX]0 9L+J+"YZVQ$-W=NC=-F;E6QHKD1(T@>JNNMJ+O=).U$@V-W>@EG1
M5WG-IL/)XJ;(26]NUZ1XV&KUI7?65J(D&Q4W=R)567:M>E9$O(CJV[^4AH7,
MFGYB6'%)3]CM63W,FI\;72HO5)05"TE/6+Y&E HY]AI4QD\<?-,EYXX*8"8:
M!1KW31":<&+EGGGEC;#8/&37^%UC'9VV,M[EDD3UFWIVP-6&*>&%66<'0(F]
M;Q[JO:LG?HYZI1$3;A?#S262TVMQ-?30N9(U(J1+*J2OBDE1UQ+TO),^J-5&
M=[1J+R\EZSY]:*-H(BN6B<I"SRMEC>UK\;_3^;\^I'<I<,:K42O9.'>U[7X7
MJD5#B9?59?1O^S4I73D0TOVK_0J5>0F;RI[9"OVJHKR%=>0V7JD_D_"2H0\_
M,^G^U5%2=ILH3$'/ZJ_TOV+4!Q<K7M>_'S;W_9KRG>Z7VRLG(2U;.&6,A2=G
M<8'/'.S,Z(. 8N(H'10S%LNN$SOU0O6W[./0^IMV+]FO5O%1<59I14ITNW91
M>_3DY^V65JG_ -0N%JG^K_!WJE.>X.J2WL0-"+_C612$23SK=(IF18D?JRS0
MI ;>&:TWSS6>+0=;2S6FX.HMMWH9W' 40L>*FRPY<$8//*V&08F4:#UM;Z5;
MD<7E[1U]IG+6B07,+)>@D[QZ212QR[DB-DB>E41S'-<USFJFU%3QM5Z8FSRV
M=]CKAMKF\?<++!*Z/I6=\U621O9O,56/:NU4<CD5$5%V46BE'Y3KH8S=C:0V
M#L65(;EL39V=-L%*<UZ*RZHPG:_=ET$BU9K:AF*B3N3#2,R'0VD5-*!XEUJY
MDOD2N+CEQ%Z 6P;KC?99&ZN\5E,2Y^@+G#V>-;9LN5;-%#CWK):2I<K$Y'S1
MR/D<N]%NNW]U?<U=B$/#"YLH+>_L<@C=6P9*YO5N70HZ)\EVU&7#%A1[5;&]
MC6-2DE4W:\]$JPUWT[=&M^MDI1@TYAS5)SFQ^2C+\E3\::!5.R.S+,1\(1TR
M"BL8!4-DD\9#3P"^*63&.&0;#$0<A[YAY9AU@FJM?66K=7V69OK#<TWCK6WM
M;>R2574M+5J]' ^96HKD>Y7=(]&M6CW;M%1%,HP.D[G3^GKG&VMWO9J\GFGE
MN5C1*W$Z]_*V-%5$W4IN-5RI5J;U4JA3"^.4FVUG8J.)48\C(;/C9FF]9#X[
M148Q).J5&[EJB<&-L9&B";CKD*K<;-U]]9AWU!8$39A1&P&'ZZXAL2X>58_C
MK=V^E+S"9*TEN,O<-R+4E;<+%;2><T1)GW5FD:LN)(=ODRJ]K8T5K=VD:5\.
MXX56\^=MLK97#(<?"ZS58UA1\S/(E58VV]RKT="R7_7INN5ZU=6KUI> R^JO
M]&]<_FW5Y39YE[5+SDS&JG*<4S:_0O?_  ?^OM5S;JB/1%Y:_P!!<QJE:<Y9
ML8?_ $J#E[?Z"YL_)FV;KZF]5+^&K_A4_NQGS_XW_P#J=WM?TJ9VE=+&DS$,
MYP_RIL&?@O 7XS7+7?\ U>_X'Y/X>^^;1GS8ZS'\P>)^ Q_SJ4R\ZX /I.*
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M3?\ N\VU>,G(>C%[LXMKVMQXWMV[^;4'<I<*0LOJK_2_8JFO*#AY?59?1O\
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M,^UC]##_ *V]4%Y5]M2NWW/^7L$/+ZF_T+_L5*O(H.!5L53=CVZE?R$\?+^
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MMACV>SV1NS_BU3FP.1<B5CD]X_N%S;Y6VF54>]*(G.K4_I(-\1+]O$//Y_\
M"WX?JX50]7LBO^JD]X_N%RMY9+_K&)_I)W2%GCEQ[. =OKUOV,*>KV1\&_WK
M^X/*[+PC%_TD[I*F7RMC+52L!>/0QE"$!\;!'A$_*PA6:& 9 O<?/&UA [#
MXWS [9K'B#;LB6J[M,!D62JO1O\ W4B>X>O+&].Q[/X.4M[FZLU8B=(S]XS\
M].9[5[),WH#_ +[#Z' ;_>5YRZ=R%?W<GO7?JE^E]94]VSWR=TA9=T98WQZN
MW9M_YO\ [RI7:>R*M5.B?[Q_ZH2_LF+O*]FS^LWND#$$2U_/886M_P"?=O\
MW-6_JYDO!2>\?^J3^=['FE9[]O=&>'#AYSYOU%AK_J\,:>KF37_52>\?W!YW
MLO"Q^^;W2%? ._U6&?SN.(W[>-J@NG,FG^JD]X_]4AYWL>>6/WS>Z0[X7M>_
M0O>V/F6X#6^CVL?FU;OTYD][]W)[Q_ZI79E[#=_>,7_2;W3CWMGQOYZ_;O\
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M_P =5#U/XE\UC>_]SF^*)O7/#^&C\9'^L0.I+?-"^R"_\;4_JUQ*39Y#>_\
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MC+SK@ ^DXH!0"@% * 4 H!0"@% * 4!*-&"RM/$D#7N'T!(CA,+&UA@LA;9
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M[&Z3P]FV.[@1&*MWDI6KOMJN\]EM!17,1'-<KMU'[Z.<C+RU<['3XH!0"@%
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M[!S;'VDRRK]X$F:U.IT+&Y4P(P+7%]DQBL%6((K03&03%*F2Z:+*0JR6NKC
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M::AXQRP)'I>SL7LO,<UTO?Y*-611L8]55S8)W2,D7O\ O.\155'2(RKE-?\
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MB.$R^2I8(6PIS$L\M@!,"&8]\K@"!IMS>0F.&.-L\+FLKY7O;+'@!-R@% *
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M]+3<*[_K<X-^9FC,2=WQ"L2/R#-.W(M.*4$H=*YJV3&(-?+HBW$)Y"#&@BV
MV P)>W65<?QPPV+NK?3-K83.X4Q8R2TEM'=&D\[IDWI;IZHNYTSI>2CZ(U7J
MU6N?LHY/J^YS+V=UJR\R4#>,<N6CO8;UO2+;V[8';L-I&CDW^@;%RU8JN>C$
M<CFLVWG&[=P9(")=VAHP3INDIUW(&W1CIA P7>Y ?3;%$&4@"RB*DV/]9W/<
M</ :X/1Z=K9<:YTN_)$NY?(%D6QZ1W1](C4DW*KN[Z-56H_=IO;JJE:TV'4-
MDMZMG$N12),AT;>E2-7+'TE$W^C5R(Y6;U=W>1'4I7:=S5N70H!0"@% * 4
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MBT5%I13NJMBZ% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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MPD@,0E,J6SYB;3.;#[YAK AQU;5EVC%.6:%&Z[!C97!9)5%4BWB+&5W ^#Y
M $)QK 1LF6P/6Z.6.'<M@\(?I+$Y27'3Y#'37%[:Z2GNXL8LMUW]PR]D8ENU
MKI'3,CA:YRK;Q*Q[E9M15WZ[ 9K/,XB/*6^,R<%K87FM+>RERR0VG[.VDL(I
M%N7O;&V!\D[FM:ES,CV-238J)T>[RD78_9F0I'C>!F=M.HJ[1'V_?\)IFSS3
M9\8*:A)4?(\#%)!-)UP0F^;C]4=#,6112/IP2*X@"#9A#B C9!YXBR7.C]%X
MG#WFJ<C@V1Y!-/P7CL;++<M;;SOOE@1U5D2=L<S$1_1/=5$1S4<U%16U+77&
MO,UF['2&,U"^7&KJ:XL696&&U<ZZMV8]+A6T2-UN^6!ZK'TS&(U7*U[FN5JH
MZY'H/),EO^/9F0I5>8\B.&%=I)U@8@^%!(14-:<[;C-Q@)J&JKY%NDDU%LLB
MEC%\1<RY<+'.V.-\K99]+/+3O%3#8;%9;'76"MDM+3)8.ROG0M>][(Y+F-7/
M:QTBN?N(J;$<Y:56E$HB;RX/9S/9C"Y2TU#=+>WN*U!?X]L[F,C?+%:RHV-\
MC8VM9OJB[5:U*T2M5JJUSUK$VT* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H#$,YP_P J;!GX+P%^
M,URUW_U>_P"!^3^'OOFT9\V.LQ_,'B?@,?\ .I3+SK@ ^DXH#Y@?] .@,[WD
MV_)X0[^'^TGY6DYT!<_H#$,Y/'RILY_@O/OXS6U7?_6$_@?C/A['YM(?-CJS
M_P P>6^ R'SJ(R\ZX /I.* 4 H!0"@% * 4 H!0"@)+MN!(^:[PE=V$20YHO
M,C@:[S=[,50TI29 ;\;"671;OM%13"5<=.=#@34Q-Q4A;F! 1Q4HL/@$$8Z\
M4?([S5.6O<?86$KD:_'120Q3-WFS=!(Y7] ]Z.HZ.-SI%C3=1425[5<YFZUN
M+6.C\-89/(Y&)JN9E)HIYH'HQT'E$3$9Y0QBLJV61K(DE7>5KEBC>C6OWW/F
M6KI[<L.4="TF)0QUJ%E4VFKAQ.+&E% +&R?5K0J6=S %.I]CI 'H&+ 98W&#
MQMCE;*W"U>-;S7FZZQMGR)'.K4<Q'*C9%1:L1R51'4<M6[W(NU*'O7,-EOMR
M%U'&LMNUZMD<U%=&BMH]6.HKF[S4H[=IO)L6I+J$Q(0<;/)RC!*,RB[3E $-
MS!N=G-,FU[/#',4P&&KJ>(:2D*1XS<7K+=,V'UO&]_F]GU]2)J6SR#L)JB2Y
M6_LEZ/HY95EZ+8G>-[Y[6I2FQJT/$TJ[2E]C&Z@TC%:ICL@G2I+#"V+IJJO?
MN[QCG+6NUZ5Y2';V!W>XC\*YI,>.!>BP)L/8U'IMMI!X-DV6Q5,5IN0HE&DW
M-.2C1H8J;R*CE[8C896SO:^-[WXQ_P#]HQ]FS4B27<5K?+)"DZ2/;TVXC4EC
M5R.WG(B*W>:[8NSE)4]4,E>OTLL=E->8](IUMEB8[H.D5RPRHQ6[K%54?NN;
MM1:\A+XX8U_T\!?LCR+(Q5L&IXERRTX'G(JJG>FCC>"JDET=J,I'R34M/N(C
M-)HMP(@DD0P!,RY GF*,(*-D8,">M&S5?$)UKA\19NG9B\?N1PV[7;L<37*^
M69^\YW?RRR*^5ZN1'/>C6HUJ,8GC2OT;PS;>9S-WS;>3,9+?DGN7MWY9GL1D
M,#-UC:LAAB2.&-&JK8V*YRN<KWNJ(+M1K%$8XW"C:0"S>4;'L5!!+HZ<"C'L
M5.XEU+$XEAEL2)FRC<7*X]L\,NNZ5^GQXWK$GW]])<MO))I77;-W=>KW*]N[
M[FCJ[R;M$W:+LYC-68['QVKK&."%MD_>WHT8U&.W_=;S$3=7>JN]5-M=H!:C
M6+G4E2+MI  44%,LBH:@"CIP1U%1[!]39)236!;$=.3+!>=Z@'+ +H]CH\*.
MO[Y\<D+YI5AE?OO:KW*CW\N\Y*T<ZNW>6J^R&X['LECG9!"D\,>Y&Y&-1S&4
MIN,6E6MILW6T2G,>946/%#?4W))ZBR6&F+N2(HY.I]9M5##<!EOER5Q%0-87
M\$^ZL=3L2!;^%#$%SPR#PX7QO:UK5>0Y/.W<,.%AN;I]KTK>B@Z5_1I(J][N
M1[VZCMY=BHB+5>4L)\3IVSGGS\]I9QW?1.Z6XZ&/I%C1O?H^3=WW-W4VHJJB
MHG(4FI&WO+JDTH&03I4U_=A2)$4](":FG$](,8LE(:96Q@^XVPFJB1CF0$0"
M&'6YYIP?7EP,+Y\+88WO;/+CA_Q>PLBRS6.5@DOY&P.<CGITSY5HV.1S7]]O
MNV(DB[KG+3E4UU;<2N">>C2&'(X:YCQL3KAK7-8O0,A2KI8FO9WO1MVJL:;S
M6I7D12F.5)0T%V8/M)L1OO"+$QAM)+Q'!:D-'&P6;Q](#25=S.A<P:KLCYQH
M:,ZD9**GC8*XGA%%(L'<:]A,[]7T,UP>$XJ:,BN+W,:92_9-)"BRW:2+(U^^
MR.-G2Q3QO?$]RL:L,BNC<N[L3;7 M0Y_@]KN:VL,'JQ<<^".94ALG1)&YB,?
M++)T4UO+&R5C$>]L\:,E:F]M5:4GQKA(/+>>R=$VOD,O:%)55HF;0)",45?"
M270]B91O%N[CRHAG',E8'AEFW<N9\WF0MAEA?',6V 8>'G,6UAB>,.-FO]6:
MBMLE8V]_,KKE[%?%"JR+NM:](W;J,VHQB/JB[&U55VY=H?,\#LK!CM&:7N\5
MD;G'0(VU9(C)9T;&F\Y\;I6;ROV+(]8Z*E%=1&ILGULE'4+2PLZ[LZ6W HD5
M1)G5)DN,6JEX$C=WX\&"S'H(<07"E'&ZX['V,$UEH\,JWZ)+##'$+',V%T[8
M"XMH[+ZCP-OE\A@(F.@DQ;K>YE=5.@BGFAH^-R21[LRRL8D7NU7OE2-U*MS#
M7.$TMJ*ZPF,U',]EQ'EV75K$S=7RB:W@GWHY&+'+O0)$^1TON$2C461M:.]3
M)X>NT,PDXC$FMN.VG C3+%C;A1C;'3C;%3"QM9* EA16>EHAXF+85;/!7M8,
MGG>PV=L[VMPOE:RPBZNU%J6%F%FO)]4SJJ1O29R3N5&*JHDKGM5*,:O*]-B4
M]@]#/IHK2^E9WYZ"RMM'VS461BP-6W:BO1$5861N:M9')R,7OEK[)T;[U.AF
M1'S"3S<#=+7(0,AR8W&A')5(:OL8*2/*B2W4=<(N1H'6X>!.%DL%L%A4X(J*
M3" &Z60F(UNCCA<XO7FHL1C,ECK29>ERDMM)+<*^7REK[9TCV.CE;(U45RR.
M217(]7)1$5NU5M,OPZTOFLMBLI>0-Z'#PW44-LC(?)7,NV1LD;+"Z)R.1B1-
M6-&*Q&NJKD=L1)NJ$9QPK$&TE*L?LA32V6.5-,Y-4&H@G2#3-$0\021EM$S)
M 0NA#E <+8!9E<0L@\;6MC>UK5C\6:S%O+-/!=W+)[E%25S97HZ5';5214<B
MO15VJCJUYS)9L#@[F&"WN+*TDM[546%KH8W-A5J4:L35:J1JU-B*Q$5$Y#QS
M,#@21TUUD62C1RYDAH*SNA%W$4]LHXA!(4$!5QS><<*!05,# [B*+(ELS9*V
M.17,>_3O;++LUZ.1756'F@ER4EY#<7$<5Y$YTC]Y[7M_8W#51U:JQ*,?[I&[
M-B'EXMNC\Y!<0XJ*QGMK:2:QF:V)BM8Z-_[>V<BMINH]:O916*[;15.64;T"
MIBV)$Q%#B)/<:@RBRL+&A1,9A1;.QRAJY=*)J8C-! #/&64CKI@(L&-<MD1+
MF\\ \;XB96M>G)=ZIFMDSTLN0?9LN58EPKIE8VX>Q7*WIE7=29[$5RIO;[F(
MJJBHA5CLM(072Z<BBQK+Y]JCUM4; CW6T;T8C^@1-Y8&2*C4=N]&UZHU%1RH
MAZX6/6".B+#9&8[0&;;AQPP7V^*VD41$7, BY<J'@L)69*Y!3Q#*E @\;#!Y
MVL&%AC;L8VM:P;ELJVYCO6W-PEY#^[D21^^RJJJ[CJ[S=JJNQ4VJJ\YZ3L+A
MW6DM@ZTMEL9OWD:Q,Z.2B(B;[-W==1$1.^1=B(G(B'DG/E"T)LE.<3A2&6P6
M%'YP@&DG2[8)$D)CCN14+-T$X0!24O,%L$S)Y9P#-',, "Y<$7,0P(&#B)G:
M_LDU'J3)/M+22YNLK=M=O(LBJ^9(VK(J.5[JR*C6*K6*KG.5$:Q%<J(>;?KI
M;2N*9>WL=K9X>S<U&.2)K8X%E>D:.:C&4B:KGHCWHC6M:JN>Y&HY4F6FHZ0C
MV.XI"4G)6*DHG%A1Q32)8C8^KJ&=A#ZJ=L5""L:43PEK9##B=(47*W'+*]Z\
M::XN+C=6X>]ZL8C&[SE=NL;L:U*JM&MYFIL3F0]V"VMK7?2VC9&DCW/=NM1N
M\]VUSW41*N<ONG+M7G4[&J)7% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4!B&<X?Y4V#/P7@+\9KE
MKO\ ZO?\#\G\/??-HSYL=9C^8/$_ 8_YU*9>=< 'TG% ?,#_ * = 9WO)M^3
MPAW\/]I/RM)SH"Y_0&(9R>/E39S_  7GW\9K:KO_ *PG\#\9\/8_-I#YL=6?
M^8/+? 9#YU$9>=< 'TG% * 4 H!0"@% * 4 H!0"@+6$P,A[OSF*C8"/6:&[
M'# TG0)'2D)D.QR-M@N:4DB9Y *DR3H+)_\ Q6OBV21PA!R'2Q%,X!%\A>D&
M$':MXZ?R6,Q?")%2VQLV8N]226[GS11R3QVS[.!56-7=\Q-]%1K]J-57HVBN
M4Y\U-B<ME^-BHMUE(,)9Z5CN61P32Q6\MVR]N$:V5&]Y(NXJ*Z/8KD1BNJC6
MH6K9=>4Z).NNERLX97G!#42VLR\HJ+1,+>Q\>+KLDX9V'[)BFUY9C%NO7!7G
M<H43P@2"*\$\5) *B6'ROEW3ET-Y8#':8GU?J.WM+#&2PNS3&ME1F/N&16R1
M-WFRVMS)#N62JY5?-:2)*YR;J4W$KSWJ3)ZMM]$Z6N;W(Y:*=N!D<Z%7Y.VD
MFNEF=NNBO+6.??R"(U&QP7L:PM8N^M=]:3&F,_L5CL>LRO@UYE08/48LT$6]
ML$I)'64:?C;,'#6?3AM$%QFMY*R/GFXX%>^3T+((26?&"!N$!<F7$'N'X^GH
MM(KH^/!+/CI=3,OLXS%N<C'V*3)N;DCF32.W6R1L_P"ANG61B*N\_I'HVON:
MGFULFN)=1);Y2'2C\?IY^78Q7LR"P+O[\39((V;SHI'UOFVZ12.1-UG1,<^E
MPC?R'$B4I,Y?APH&^!T@KL421SAABN9W(A!*:"@PW&JV6,Q6N?* I8P9M'*!
M *=[AC! #" 8"V#,"89ZFX5:AN,'A=61R+;)<.Q"O1)XXGN=*V>-NY21JJY*
M/<JQ[45R(Y6U8BIN;C%IBVU!GM&2QI=K;-S;6.6WEF8UD+K>5^_6)R(Q=YC$
M;+L<C55B.H]R+1DAOJ7,YM;0%Y!V7%W>$W;,HCTB$P8E#*#2>J&#^4P#I@)N
M#)GL1AQ,4B_, Z55@!,E/(^)8<,3,:_3K8MSB\ FFIG>285.&B::1\-VB6WE
MJY3H&JB+(CO*O*EN=YCHG)T:,3=5$;L-86F7U(NJX&>6YY>*ZZK6.>S5;KR!
M,1Y0]'*D2L\C2S2UW7LF:JRK(N^URNVE>7*S8[O3-<BTFR,\YB<T@28OODLM
M)$JNMPK11I)+$F&6$5L$&BA."UC#<**:6=[L,YWOF(=R%"OT^I"+X!ZNXX9/
M'S:P=A</;8Z'%644*L?:Q1L65T]I:OD=*^/9(K7)N-38C*.2F\YZKM[J_8G)
M6^B&Y[-W63GS-_-<(]EW-(](66][>,B;#')MC:YCM]R[5?5JUW&L1+9, OB8
M!I^E!HK3TG:7S+RCK:_%ZBCJ<X-P!H!AH2^KLH&>X+E)CJ4?-!0 '"#26M=B
MKQ?#&QD(,7$8(03#/=&JL9I]NE+&_MK;%X]EO>8OH41ME(LO?QLF6QO;:9L\
MK515EN?+8'*NZY6JUR(J:&T=EM2NUED,;=767R3[JRR_3JKK^)(:1R/@3(6%
MW ZWA<BHD-IY!<-1-YK7(YJJBU0<OK467'2R=$IMF.1$8FV==&"]346Q0BQB
MH-%Y$E&04LTUS8$CO%7<RB<50$DA804,L53T_$883'K+7PMECGA/%C7^ L<E
MJC36GK21U[E[J%+FZ?<MEA5L#DD1;>)D;4:KG417.DD5$1:;:*F?<&>&VI,A
MBM(ZKU/>Q-L,)9SK:6C+5T,[77#%B<ES,^5SGHQM51K(XT<Y4WMB*B^JCALN
M0 OSH;#-];!NYG*_LVW85*/A]\. T%*10+-#Z9>WIMB*:RL%C<OUELA+]&W9
M[%6.8O;-S^'.[+$O0PP=)1S?V=+UJKO[>]HFWOJ;-IZ.#L+YC.*.]#*G3SW"
MQ58[]I6P<B='L[^J[$W:[=G*4=ZJ'7X[);Y9B4FOV6=@,8:9IE/?,=OC7!5B
M5I:NDQX136D<%3Y."8;"#>QIMFP+I)3)0-+X:CU&.>(EC(H0PFPM=1XNPP&M
M)YK6PQ*Y&X1T-Q#D&W4N25+QTJ(ZV6>?H4D1>E=T;8%CWE14W&N:FLN'DN7R
M.I-!V\%YDLSYKM5;/;3XQ]G#BFK8MA<K;I+>W2=8E3H6+(^X23=147I'-<MQ
MZ9S3A W_ %(<0^MIH:7RW9?4(;/(R%DZE=/D;*4TO&0%%E-<04$)R/0H@EVW
MD$0"SP'.!6ZJ]^KRO?'3^G&6C^%+&HV)ZOUC:-NVO?T3'6_DSN@;-+15CA5Z
MW%7JBM8O?<J;=X:HDO6<8WN5\K$CT->.LG,CZ5[;GRMGE#H(E5$EG2-+94C1
M4<].]Y%6EG5G2'/P>N6XK6;+WV"D-PD=?X]7;24V'YL(JM\I))686DEJ:>=;
M,PL9(D"/Y]7D%1,#*Q5N+AE!R(DQL; ?P8>>'0N1Q.E5UAIZ^O;;$VEH[*SL
M\GD@L&R+;K:2N:Y)+29\$]BQ[6I$ZXA;.CWM7>VJB\RXS-:Q31&I\?87>9O;
MUN&MI/*HKC(OC2Z2]A8YKHKV!EQ;Y"2-SG3,MIWVZQL<FYWK52K39IJ3.*+S
M+IK;3_V52'S"4GPP>UY1&B_9#3&:#8RW8VNXQTEB)9C%">!,_<T8!-@C &RF
M&.(EL0P\\Q\A,"T7?:<:W1FF[VTPTF,R5E>-OWRP6[IEI)<=&CIW)OQ*VC58
MJ.8Y=E55$:B;&UYCM4.=KO55C>9V/+8K(63L='#<7+84K';=(K+=B]',UU7-
M>U6O8B(ZB-57JZ5VS#WD!NO6<#LA/[;9J3Z!NVS4>-4="/RZBP(-J2?D1F$F
M,:#,I80<3V15,H-F$9SN:P5C"^+<&X>0>9FU_;T9C,3=XW&1XFTP$^E5TU,^
MX>]MJ^^3*-MYEF2CE\JWVJB*U-U8FP)O5148>!KO*YFRRN6ES5YJ2WUBFJX&
M6K(W7C,>N'=<P-MU16(EGN.151R[Z3.N%W5:J*\\U)!J;V:H/,D:5G=&>O3F
MYB>^ZM([A"49M8B,H+9A8;(L2]^+IA)#5I'+M%8N(?'2;DPO2TZH@8Y&L[X!
M!7QO<.S361AMI61V][JV'2.#;;QJVSG>UB,D2ZZ&*\>VW65G>-EWUZ1D;E1B
M5<ZMCG)-5XR>ZADDN;#1<^M=0/N9$=?6['2*^);/II;&-]RD+ZR.AW$Z)\C4
M61:-:J=S%+8FM(FN+)9<R[,[UG%UZ!SR2@A]K!&:0TU[34VWLN%H7;CW*+J,
MG%2Q8Y&Z6 <,A.,H03U@X&65#6&:B: $%ML[>Z;N--WV!LHL=;:9@U78K>P,
M=9[T-G)"Q;R2%6/<JJEPYS&K;N?)$Q7P,5(6.1MSI['ZIMM58_4=_-E+O5EQ
MH[(-Q]P]M\C9[Z*>1+&*=)&-1$=;,:]Z7+(XYGI'<2(L\C'.XMGU(YJ.%4/7
M64-N7TYC6D<UJFY922U&:#>;!G<LTF]WC]ZF3T3R6#5E$60/3<E8DW!+6R2R
MF&0>.0>'6Y5/->'9F(UU?8X"ULFZELVXA;=MFG3V2RR=-TO0N7I;9(.B?OW"
M?O7*BJBKNI3\[9R3!R)HG(:DN[]VE+Y^:2Z=>KY/?I#'T'0].UO0W2W'3,W+
M9?W3$5$5J;RU, ,=<BQRRBS76^)M=<)R/RF7[*4N>S"^7>_&_C*Y512TA35"
MYIU"FDYJ+>;553ULT\C8H#B#C:^)?'$+#HX8[)VV<L['(V-MC8-26>O(+:U\
MDAB@D\E5KGM:J1(CI6=*UE)'[RUY7JKEKGC,3=:?OLAB\C=Y6XTK?<.;B[O/
M+9YKB/RM',8YZ+*JMADZ%\E8X]QM$V,1&I2ZKIT,[S&INM([_N:N\Q8*BL1Q
M9'[B74A%')E(UQ1%6XU[B^FPN-[9&^EY[NB^?&UNU6C.(3<>S7F9;BMWS<F4
MN>CW?<[O3/HC:;-U/S?ZM#H7AD[)OX<X)^9WO.BXBTZ3>KO;W0,JKZ[=]?SZ
M_G5*D*PXS@4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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MDV_)X0[^'^TGY6DYT!<_H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M#OUYT/@T\L#X\.UOZ/:@'?KSH?!IY8'QX=K?T>U ._7G0^#3RP/CP[6_H]J
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C?Y/KTM_]K]YO_&/_ -V?YD7_ ,V__P"=?^W_ /\ LB@/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm2110724d1-fc_prevent4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2110724d1-fc_prevent4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@"+@/8 P$1  (1 0,1 ?_$ -P  0 " @(# 0$
M       '" 8)!0H#! L" 0$!   ' 0$!              $" P0&!P@%"0H0
M   & @$ ! D(! T"!@(!!0 " P0%!@$'"!$2$PD4E=56%U>7&%@ATM-4U!46
MUB*4EC@Q(U6U=K9WMWB8&3D*039183(D)3<S=7$T0B:&N!$  0,# @$&"P()
M"0@" @(#  $" Q$$!1(&(3'2$Y,5!T%1T2*24Q14E%4683)Q@:&R(W-U-PB1
ML4*STS0U-A?PP5)R,R1TM.%B\4."HB4F&/_:  P# 0 "$0,1 #\ [_
M
M                 #KN\A^1=TW3<)HQYN0:41K(.VU9K#1TJWBR1B)S(-GS
M]LCE,DA)OT2=JHHMVF4\J&(GDJ>,%'PU[\>_3=?>QNB[<Z[GBV;'.]MI:,>K
M84B:JM;)(UM$DED:FMSGZE:KE8RC$1#ZS=TW=)MWNZV_;HVVBDW.^)KKBY<U
M'2+(J:G,8Y:JR-BKI:UFG5I1SJNJI6T:%-P
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MC:C8DE<QTD<K&)1&:FQO21&HC%<C7(B.<Y7;+1WZ<=
M
M
M            '5+'YNS[C
M           %[N[N_P#OUY_9]8OYSKX['_@;_?3+^Q+K^MMCF+^+/]UL?[5@
M_JYS>,/KZ?-8
M
M                                          ZI8_-V?<8
M F;CS6H.X;KUS6++'IRL%,V)%G)QRJBZ2;ML9NX.9(ZC95!<F,F)C/24Y<_)
M_"-J]Q^ Q&Z>]G!;?S\#;G#7=\UDL2JYJ/8K7+158K7)Q1.1R*:\[U\QDMO]
MW.7S.'E6#)V]HKXY$1JJUR.:E41R*U>7PHJ%^;SKZK5*<L[..X$/+%6Z^\DB
M-K6ELV>8-)6*C\J&Q,$:9C7AVJ"S=/*G4[13)<?]<CM#=^R-N;:S&1M;'N8E
MOL#8RRHV\3+7$;)H8JKTZ,Z)ZL:YJ:M.IU$\*G+FVMU9O.XRRN+OO1CM,O=Q
MQJZV7'0/?%+)3]$KND9J5'+IKI;5? A 5=U93'VD^--F1J47)VR\;\:5&</(
MRTM%M;'$*V&59(P4F]:$DLQ4>Z(W325<MF:KA)/I.4BAL=4VE\%W=;5O.Z78
M&X(L9;W&Y<OO1EE<++--$RZA6YF8VWED8DO0Q/1K6/EB@?(QM7-:]R:5VCEM
M[;AMN\?>.&DOYX<%C=K.NH4CBBD=;RI!$]9HV/6/I9&JYSFQR2M8YWFJYJ+5
M,9E..$]=-M;@BX9"CZPJ.MWQ5;)(REIDW5+JB#E/'@<>UL$A#,9:4.Y[%4Q#
M*LT,=!,X/DO23KX_D>X?-;K[R]T8[%,Q&WMLX&9%NI9KN5]A9M<GF1LN98(Y
MIE=I>K5?!'R+J5M6:O:LN][%[=V)@+W(.R6:SV8BI;QQ6T;;NY5J^?(Z".9\
M4:-JU%1LK^5-.JCM/G:<7+32;1IF4L+C6]_K6R+TU@H6.A[=,?=-A:E=_P 4
ML]GHZN.? (2::%*HFNV*Z<IIJ8ZZ)5,&3+6MOX=]Q;1W#M3(YR3 YK 9[,,M
MX(H+V?H;EB/X.DN(K5_1V\[*.;)$DTK6N35$V1',2E/WU83<F%W#98EF7Q68
MP^,=--)+:Q=+ Y6\49!)<-US0NJUS)%CC<YJZ9',5'+*L;Q]J=GIO*5#,%2J
M9:Z9LV)AJ],25ME?PI0X=.?C#SJ7X@DFT8=_%MH<K@N%G##PE;&<8(EVIBE&
MQ[#N2VUN':O>+"MGB<5N3$[@A@MIY;V;V/'0)<Q+<)[3*V)9(60)*B/DM^E?
MP1D?2.:TP>\[U<[A=P[)E2ZR.1P>1PTLL\4=K%[3>RK!(D*]!&Z1&2.E6-5:
MR?HV<5<_0CE,+H7%Y:M;JTO'79>I['UELIS-9C9ZIR[M_79HL;!23I9BJ[1+
M'/&SILX334Q@N>H?!<X*<V2*D)BFS/X>)<!WL[3L=VOQN>[OL_)/T5Q9SODM
MITBMY7NC5[4B>U[7(UW!=+J*C7*K9&MR+='?5'F.[G<5WMQM]B-YX=D/2074
M3&3P])-&U'HU5D8YKFJYO%*I5%5J(YCG80TXV2EQG]I3[6?I.M-9U'8MCJ3:
MQ7J;6BHGPQO,.$64'&J90>KNEVK11'K&5,0N"FQ^F8V#8QB-MW"9'=.9W%FK
M:]Q&W]@8S.W5FVZR$[H8=;9W-CMXETR.>YC%957JB47[SG(J&23]\-EM_%X3
M%SVN2S.\K_$6]TZ"RA2670Z)JOFD2K$:CG(^B-15JGW4144AG:>K+7I^V*U"
MW)L<OO 6DJPD(IUE]#S,0_[3#25B7ATFZCABNH@H3&3IIGP=,Q<EQG U3WB]
MW6Y.Z[<KMK[G;#[9T+)HY(7])!/#)71-"]6M5T;E:YM5:U4<UR*U%0V'LG>V
M#W_@FY_ K)[-TCHGLE;HEBE935%*RKD:]$5JT1SD5'(J*J*6BA].TK8NF^.5
MFK$ VC[!*;>;:KV8Z:.GQ_#LR4ADS61>)JNUB(91@VB2Q\HD2S@SK.,%S^CD
M=$8ONLVEOKNLV)N#;UE'!F[G<[</E7L?(O2=+)5DKT<]R-TV[&/<K&LHLRHB
M+YJFE<AW@[CVCW@[NPV9NGRXJ# .R6.:YK$T=&RCHV*C45U9G.8FM7<(D553
MB3:_X\:=?<D:>O$5QDGI4^L[I;I^/(]ES1RSFDRTW5Y5R=XH^^\4&[>0=1R^
M>A4N.MCJYQT9ST[;O>X[NLO._K%S8NPB;W3+M^_O;F)))UB<^PFN+29RO63I
M6M;(^UD6CT2J::45:ZWM>]CO!MNZ#(1W]W(O>,F9M+6"161=(C;R*&YB:C$9
MT:N<QL[$JU5HM>5$I4*L\?I78T1*[05G]?:?UO+V:48U=Y?K M$-'JQGCLZ<
M1!$[&1<.D(HB>43JJGQ_^$_093*:F2\P[?[D\EOK&7/>')>X3:^PKK(2QVC\
MC<NA9(Y7O5(+=-,KGMA1%C<][D^XZBO5DBMWYF>]6QVC?P;+9:Y7/[OM[.-]
MRRR@25[$1C4669:QM:LJJCT:U%^\VJ,ULK[+#B)M=]LB9UAE:J,IN*I+C8+.
M5>3+G%:L=81?L(Q)[ 2S:,<]KX6[?X*3PE-J0O9G[0R?1CIN++^&/O)O-^7?
M=ZKL;#EK;$.R3)GSO]ENK1LD<226TS(GUUOD1&]*V)J:7](YE$K1NN_K8UMM
M"WWHC;Z3&SY)MB^-D3?:+>X5CY%9/$Z1M-+6*J]&Z15U-T(ZJTR#/#FR%BJ_
M:,[8TIFCSBBK%2[ENAL5Z/G$UL-TH+PA:.04D7[M?!RI^#%4P7L%3*]D4I<G
M]I?X6<\F-LMPKN7:7TA>.=&M^E^OLT=PCM*6^IT35ED>[4C>B1R)T<BR=&UK
M5?Y?_P#T%AUOKK"I@MQ_4MLB/2S]D3IWPJFI9M*2*D;&MHKND5JKK8C-:JJ-
MQE#B;M VR[7K9^M6(8](AR62SW&5EU&E+C*VJEA=O-*2IV?A.&[E'!\D(9 B
MI>R4RH4A4U#%\"'^&KO#=O\ R6PKQ^/M78BU2ZN[Z:966$5JJ:FSK,K-6E[:
MJUJQM>FB36UC8WN;[$O?ILM-G6.\+5M[<-R5PMO;6D42.NY+A%TNA2-'Z=35
MHBN1ZM74S0KE>Q'?B7XL7F/M.N8",L-(LL-M5VX94N]P,R[D*>\=-,&\,;/'
MK>,5?-'#4Q<X.3#=3]+!L%R;)%,$DR?\.>\++<6"PMA?8B_Q>Y)'1V.0MYWR
M63WL^^U\C8ED8YE%1R)&[BCD155CT;-C^^W;-UA,OE+RTR5GD,'&U]W93Q-9
M=L:[[KF,=(C'-=RHJO;P5%6B.:KN2M'$>\UFKWNP%M^N+$_UHNKBZ5:LV)Q)
MS\+'D7623DW+<\:V2127;H&<X25,DOAN7/6+A4ITBW^X?X9=X;?V[F<VW*8&
M^O< ]?;[2TNG2W,$:.<B2N:L3$:CFM65&/5DB1HNIJ2-?$VSPO?SMK,YK&8I
M;#+VEKF6I[)<W$#8X)GJU%6-KDD<JJURI&KFHYBO5*.5CFR+50<X&\0
M    "]W=W?\ WZ\_L^L7\YU\=C_P-_OIE_8EU_6VQS%_%G^ZV/\ :L']7.;Q
MA]?3YK
M
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M:5CIWN>GP-ZT)#2.X:]<(2HW5>UV=S4==1=-HM7,HSD6R7W;B'B&\E*.719
MV5NS*9+!L9,;'7-U28)<]ZVU\-O'9F*OMTV.4Q&+RSKR[?98R&QQ]I5DK$Z+
MH(&RS/>DJJ_2BLK5RIK6C,N@[O,_D]L[HR%IM^[Q^2O\<EM;MNK^2[O;FCXW
M+TG2RNCC:U8T1FI4=3@BZ4JZ/Z]M;7S-[SC5<V5JD3:7XM_ )LM9'.+']X3]
MR=L_!NJS-EMV[>20-CPCL>C"F.GHSC/1A6$[R-DVMWWOR3W\;6;C]M[.71+_
M -UTMS?/9HHSS-398U3I-%-25HJ+3*<ML?==Q;]VC(;-[G83V7V[SH_^WZ."
MT:_55_G:71O3S-7W>'@K1(<<G3@         !>[N[O\ []>?V?6+^<Z^.Q_X
M&_WTR_L2Z_K;8YB_BS_=;'^U8/ZN<WC#Z^GS6
M
M
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M7.>]6U1NN21SY'Z:KIU.5&U6E*K6/!@YE@
M   !>[N[O_OUY_9]8OYSKX['_@;_ 'TR_L2Z_K;8YB_BS_=;'^U8/ZN<WC#Z
M^GS6
M
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M-C(G)P>C&OD5SVJK%5S4:JZ54V/#O Y#
M
M
M                           (\V;_ -O,/Z6TS^L\8(IR_B7^8@I(8@1
M
M
M
M                     CS9O_;S#^EM,_K/&"*<OXE_F(*2&($0
M
M
M
M             (\V;_V\P_I;3/ZSQ@BG+^)?YB"DAB!$
M
M
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M4.5%T6P
M
M                                      '4#Y<<KK[R8V18)!_/R:&M
MF$N[;4&E(N5FT'&P31=1&.D7<:F?"#VQ2:!<.'3I;"BN%%,I)F(@FDD3Y1=Z
MG>?G.\7<,]Q//*FWF2N2VMT54C9&U51CW,3@Z5Z><][JNJNEJHQK6I]2.[#N
MTPO=]@(((8(US[XFK<W"HBR/D<B*YC7KQ;$Q?-8QM&T34Y%>YSEJ2-6&SP
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M61S'21RM:E$8JHQ[9*(B.<K'41RN5VZP=B'(X
M
M
M      !T31\3S[+@
M     &T7NBOWJY'^R:W_ ,\U,=*_PJ?O.D_9<_\ 60'.?\4'[MH_VG!_5S'9
MM'T;/GH
M
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M.D_9<_\ 60'.?\4'[MH_VG!_5S'9M'T;/GH
M
M
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M:Q7.2E&_<U*J576N.>#H    -HO=%?O5R/\ 9-;_ .>:F.E?X5/WG2?LN?\
MK(#G/^*#]VT?[3@_JYCLVCZ-GST
M
M                                                         .B:
M/B>?9<                                                  VB]T
M5^]7(_V36_\ GFICI7^%3]YTG[+G_K(#G/\ B@_=M'^TX/ZN8[-H^C9\]
M
M
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MZN32JHVJ[?!U<<N
M
M
M          $>;-_[>8?TMIG]9XP13E_$O\Q!20Q B
M
M
M
M  !'FS?^WF']+:9_6>,$4Y?Q+_,04D,0(@
M
M
M                                                       1YLW_
M +>8?TMIG]9XP13E_$O\Q!20Q B
M
M
M                       !Z[IVU8MU7;URW9M4"=HNY=+)MVZ),9QC)U5E
M3$33)C.?X<YQ@2N<UC5<]41J>%>"$S6N>Y&L15<O@3BICWXYI7GA5OV@B?M8
MH^UVOK8_23RE;V.[]5)Z+O(/QS2O/"K?M!$_:P]KM?6Q^DGE'L=WZJ3T7>0?
MCFE>>%6_:")^UA[7:^MC])/*/8[OU4GHN\@_'-*\\*M^T$3]K#VNU];'Z2>4
M>QW?JI/1=Y!^.:5YX5;]H(G[6'M=KZV/TD\H]CN_52>B[R#\<TKSPJW[01/V
ML/:[7UL?I)Y1['=^JD]%WD'XYI7GA5OV@B?M8>UVOK8_23RCV.[]5)Z+O(/Q
MS2O/"K?M!$_:P]KM?6Q^DGE'L=WZJ3T7>0?CFE>>%6_:")^UA[7:^MC])/*/
M8[OU4GHN\@_'-*\\*M^T$3]K#VNU];'Z2>4>QW?JI/1=Y!^.:5YX5;]H(G[6
M'M=KZV/TD\H]CN_52>B[R#\<TKSPJW[01/VL/:[7UL?I)Y1['=^JD]%WD'XY
MI7GA5OV@B?M8>UVOK8_23RCV.[]5)Z+O(/QS2O/"K?M!$_:P]KM?6Q^DGE'L
M=WZJ3T7>0C[95VIIZ^QP2VU@^<6RG&S@L]%&S@I;+&&,;HP[SGH*7'3G/_3
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M(.M;EC5<^-Z-3PJU43^8R$5R@
M
M                                                        !\]7
MGISBVES.W-;+%.VB83U5&V"3::LUVB^<HUFNU5H[60AWRL23*+5[9Y5D0J[Y
M^LF9PHLIE,N2()HHI\2;RW=D=U966>:1W9S7JD,55T-8B^:M.17JG%SEXJJT
MX(B(G;6S=HX[:N*B@AC;VBYB+-+1-;GJE7)7E1B+P:U%HB)7BJJJT3&'&8@
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M:%
M
M                                /ETCYYGT+
M                               -X'_'^_?KE_[!=@?UCH8V[W*_YP?_
M .%)^?&:C[Z?\GM_\R/\V0[JPZO.4
M
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ML7\**B7VV]VV6Y)+FUBAN+:_M'(DD4S4:]NJNE:(J\%HOVI^!45:7#%#*P
M       #>!_Q_OWZY?\ L%V!_6.AC;O<K_G!_P#X4GY\9J/OI_R>W_S(_P V
M0[JPZO.4
M
M                                      #Y=(^>9]"P           -
M\7*3O+;54./G=_TGB!R/FX"9U_QJI]2W?"5-J[9%BKK7*3K>(:1<S^(($K.2
M6CW4?(HX,V,NAGJGZ39*8N<[DW%OZXM<)A;3;%^]DL%@QEPUB*E)&QQ-1':F
MT6BHY.%4Y33FW=@VUUF\U=[GL&/BFOWOMW/5%K&Z25RJW2ZJ516KQHI8&W<D
MN[JW/SET=NW;%BUG:6$]Q 2K]OLUEUY*R=/A>4C!^S4@YO;M,/#1D?864?77
MCMDFKV:[3"J35,RJ2+5)1'VKK/;&RN[[/+9)]O(Q^+TO>^)58V[14TNFCTHC
MD1JJVM%2J-2J(U%3Q;7 [YQ6T+S$XUEQ&]F3U,8R1$>ZT5%U-A?J56JKD1U*
MHZBN6BJY47Q[/Y@\?5N.6F-7RG*;6FU+]J_G7IC95C<:_P!*N--T2-UO69!D
MI)GH-?K]0B8R8KM6;/\ ^,=J)D?/%TW79D612045AD-T81<%:8^3(V]S>V^8
M@E<L<"P1I$Q4KT;6L1'-8B\7*FIRZJ(J(BJQ^U\VF=NLA'CKBVLKC#SQ-22=
M)Y%E>BTZ1SGJK7/5.#472U%;6BJJ)'M.YB<:XWO+>\$W:^VI$M]6[>XP7NBZ
MXMYHFS&9VBURL5I1O'PS5F2$-*M%G*U8?EP=RW01QX/GI/CI+UK*UW1@6;^S
M>6?<M3'76.DCB?1]'O5L"(U$TU2NAW*B)PY>0OKK:^>DV#A,2RV<N1M<A')*
MRK*L8BSJKE751::V\BJO'DY2)K#<N(G,CAYQ @]G<GV/'+87$&M6"@W:E2-)
MLMH?W*G+*P.&T]KE.,*1I)6J0C*LW[-'*V"F>K*%<8;I))**^9/=[9W3M?%P
MY#()87V,C=')&L;WJ]GFT=%3@KU1B<*_>5=6E$15]*"UW-M;=&4FQ^/6^L<G
M(V2.1)&,1C_.JV6O%&(KUJM/NHFG4JJB7!W!SPX>[2Y*<T]9R.Y,0NE^7G'+
M4VO8??D/5+1+1U*O>NVMS3:M)JOGCXV?6@GI[FIX4<B&"&RW(F91)-0ZZ>49
M3>.U\CG\MCY+K1BLG8PQMN6L>Y(Y(D?1'-HCM*ZUKP\")5$553&,7L[=&.P.
M)R#+77E<9?32NMW/8U9(Y5CJK755NI-"4X^%5HJHB+6B!W3Q9X><>M<\6J9R
M%@^0EDO7,O3N]=J7VIUBS16NM7T6BV>A22_@+V3;Y<3TXX2I:!E,-"+F[%1P
M10B1D6^''@09;;NU\)!MVTOF7L\V5@N)I&,>D44<;XUX*J5<[]&G(B\%=5$5
M&ZO?FQ6XMT9N?<5U8OLH(<5/;PQO>Q999)&2)Q1.#6^>OWJ<4:J*M7:<O8\Q
M.-:7-KO0MGJ;4B2T/>O&"W4;4]BS$V;+:Y6N1H])BV4,R;8A,OV2R[^+73P=
MVDW1QE/.<GQC.,YNF;HP";MW#D%N6^QWF/?'"ZCZ/>L<:(U$TU3BBIYR(G#E
M+5^U\\NTMO8]+9WMEGD&23-JRK&))(JN5=5%X*B^:JKQY"O].Y+:.C>$O=Y:
MP>[ CF]\T[S>:;1V5731TZ9S5:$G>+5*'L3MR2*,P=MBL'Z*G9ME5W'0?&.S
MZ<9QCQ;7/XB/:6#Q[YVI>6N72:5M'59'TCUU*M**E%1:(JK]A[5U@,O)NW.9
M!D#EL[K$+%$ZK:/DZ-B:42M46J*E51$^TO11MW]W>YYB\NN9,]R*UVCMB3N3
M"&XPJ7S7^QK%2JPFRU31&:FX5X:(B6CR;?9L+EY'M6JQV"[3,6LHFH4SE%=#
M+[3+['=NG)[IFOH$R3I4;:=)'*Z-E(8TZ=6M1%<NI7-1%TJFA51?.1R8A>8C
M?#=KXS:T-C.N-;$KKOHY(FR/K-(O0(YRJC4THURJFI%UHBIYJHL :0D^%56W
M-R1L^V^86G>1&\ML:W:6?4O(C<6CK1.ZRHNRG$M;$+;'6"D7!O*,G,[B-1A5
MHE7+?#-HS(HV;E_1*U6\7$R;3MLK?W&2REK?9>Y@1\-S/;O=%'+J?K1T;ZHK
MJ=&K%II:U%:W_A7VLO'NRXQ5A;XS%W5CB+:=636T%PQLLD6EFA6R,5%1M>D1
MZ5U*ZCG?\22+O/F]QQE9+NOY[/(>'VT\XW[YFYG=MF@-3R>M_!(92T01L6B$
MUO#UF,8-:JFS@U3,6[!(SY5@5 ZC8KE8Z6+[,;NP4DFWIO;FW+K"\<Z=[85B
MHW6WSVQ-8B(RC5THU-2MHJMU*J%AB-HYV./<,/L+K9E_9M; QTR2U=H=YCI7
M/55?5R:E<NE'51':413!O>,XKTK=7>VV&(W_  %NK_*KC9M/&JY9M5K?%)3-
M_P!B1-P61UV@@ZBEG&'\6]DD6^7KDK1JMD^#_H8Z<8L^W=NVF6W-/%>LE@R-
MA-T+D8]-4DK7_HDJE:HJHFI:(O+P+SL+<5WB=M02V3XIL=?P],BO8NF.)S/T
MO!:45$5=*55/M.)V)<N&'.=3B/O6^<N(?C=:=$ZEUQK#<6JK+1[A*2RJ6MIM
M[-FE]8/H1%VRE%+"O)NBM^SRX6;M_!C*I]LF=#-.^NMJ;O7&9B\R;;"XL[:*
M*>%T;U=^B<KM42MJBZE5:<JHFFJ516E6QM=U;03)X>SQC[^WO+F66"9LC$;^
ME:C:2HZBII1$K6B*NJBT5%.<V!W@F@=RM.]^L1K%BH'Y#TCC]3="0,U%2Y)R
M_MM6P]VKDE(JX9,W[**<O.W;NRIO%6N4F[M)+/2HFID5;W>N%RK=SS])T2WT
M-LRW:Y':I$A;(U5X(J(J\'4<J41R)RHI1LME9K%.VQ D?2I8S7+[AS5;IC69
MT;D3BJ*J)Q2K46JHJ\BH4EY2;SU1>^[\[OO4-2N+*9V/J'TS^D>KH,I9!U5_
MQ+9F[Z#\*=NX]O&N_O!J3)R^#++]7&.@W5S\@Q/<68QMYLK"8RVE1]_:]/TK
M*.JS6]%;551$6J>)5,LV[A\E9[US>3N8E98770=$^J4?H8J.HB*JI1?&B&L$
M:]-A          &\#_C_ '[]<O\ V"[ _K'0QMWN5_S@_P#\*3\^,U'WT_Y/
M;_YD?YLAW5AU><H
M
M                                             'RZ1\\SZ%@
M                                            &\#_ (_W[]<O_8+L
M#^L=#&W>Y7_.#_\ PI/SXS4??3_D]O\ YD?YLAW5AU><H
M
M
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MGW72(U6M1GC:U'.J[D<J^;5$JO8 &Z32P
M
M
M                           !&.W/^T"_TBJO]8(\3-^\0=R$G"4B
M
M
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M'"V$4S$*=7*:9C&ZA3*%QG/_ )X"BIRD:H9*(
M
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M?Z/X_*0\)) @1
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MSNE5+66.16\NES74KXZ*M#DA1+D
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MR;..C&38Q_#G A12-3F@
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M4S%Q-=9&9RN?+*]TCWN7BJN<Y555_&< +HL
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M-6CJ7K%ECUG9$2E0\-,ME,J:>2IDL)6(Q]$Y"[C<KFU7E-E(IDX
M                              !J+[ZO]SR,_MEI7\Q7(;__ (;OWA/_
M &=-^?"<D_QH?N@B_;-M_57!U.!W@?*0
M                      [A7=$_N+ZT_I%LC^O<Z/GQW_\ [S[W]3;_ -0P
M^OG\)/[CL;_Y%Y_[4ILQ&ESI4
M                #4)WZ/\ MO[=_I5J7^\JMBM!_P!1"G+]PZ&POBT
M                                             .Z7_P <O]R/:7^*
MB[_W2:/%G<??3\'E+J'[OXS?R+<J@
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MDT>+.X^^GX/*74/W?QF_D6Y5
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M>[-8WCAAPOU/5[-]Z; U-Z4O2! ?<U@9?<'XCGT7L-_\K(Q+2%E?#&Q,F_\
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MV-_\B\_]J4V8C2YTJ
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MJWO92\F;W=/N+2.-O\EK1F[?ARV2?_P6P*EMN,J+[\-PT#(6[_Y=]9V).R\
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M8I          '=+_ ..7^Y'M+_%1=_[I-'BSN/OI^#REU#]W\9OY%N50
M                                   #47WU?[GD9_;+2OYBN0W_ /PW
M?O"?^SIOSX3DG^-#]T$7[9MOZJX.IP.\#Y2
M                         '<*[HG]Q?6G](MD?U[G1\^._P#_ 'GWOZFW
M_J&'U\_A)_<=C?\ R+S_ -J4V8C2YTJ
M                      !J$[]'_;?V[_2K4O\ >56Q6@_ZB%.7[AT-A?%H
M                                                  =TO_CE_N1[
M2_Q47?\ NDT>+.X^^GX/*74/W?QF_D6Y5
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MC*\48C47BA848D;!
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MN5XZ#AHQC&I+JE(=T5EV^2)=IV2=C(_6[5X"Z8W2VGA+UB0G
M                                                       CQ'_[
M8DO[/(3^LE@$W]'\9#^E^(D,2D0
M
M           "/)+_ .SZK_1*U_SA71'^C^/RD/"2&($0
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MH8O7*10R9C8*8Q?EQC/_ $!45.4B<R(
M                                               CR2_^SZK_ $2M
M?\X5T1_H_C\I#PDAB!$
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M32N>STTB$3(67K/5(F7!"8Z:C$YST%+C&,=.<]/_ /(F7[J$$Y5)&$I$
M
M           CR2_^SZK_ $2M?\X5T1_H_C\I#PDAB!$
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MA/?+7K8^</>%T#Z\=/\ M,I?EL.Q<Q[I<]4_FCMS">^6O6Q\X>\+H'UXZ?\
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M[:YM7]'=1OCD\3FJU?Y%1%+ZWNK6[9TEK)'+'XV.1R?RHJH9&*!7
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MBPOK1J.NH98FKR*]CFHOX*HA<VV1Q]XY66D\,KDY48]KE3\*-53.!:%X
M         '4D_P"1WSTVQ0K;1.&6J+7.4BOS^O6^R=PR]==NHB4M;6PS<W!5
MJBYEVJC=^C -6U;<O))!$W82'AK=)0QBHJI9S#;6/AD8Z]F1'.1VEJ+QI1$5
M5IX^-$\5%.P/X:>[_$9"SN-[9>&.>XCN5AMVO1'-C5C6O?+I6J:U5[6L5>+-
M+E1/.13J"#,CL@
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M=(Y:JJK555>555>*JOC/3$Q(
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M41J<$1$2A'PO"Q
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MHV#MG_#5_6._F0^@/\,G[N'_ +2F_JX3K_#(3H<
M                             ^NL-.GQW   #J6?\JW_ + X8?TPW7_,
MNMQT;_#S_?,I^J@_.E.8_P")3^XXG];<?FQ'3,'4!R<
M                                 ?45[KO_ &Z>%7^&[57]5F X![P/
M\[97_P Z7\]3Z,]W/^0\1^SX?S$+XC$#-                      -)O\
MR%/]K7=?],-,?WJ54;5[E_W@6OZJ?^J>:A[\_P!W%W^M@_KF'SJQVP<(
M                                              '?$_XO7[@>WO\
M&#?_ .Y?C^.0^_[_ #C;?LR/^ON#M#^'3_)-U^U9?_7MCLA#1QOT
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M!P#W@?YVRO\ YTOYZGT9[N?\AXC]GP_F(7Q&(&:
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M1LKBO0'6S-^:;U]/V56QU"I1L4XG)AY%2TE!-8V=6BX=FLX434*RST)92_\
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M^X;"_P"'/6O]:-BC8.V?\-7]8[^9#Z _PR?NX?\ M*;^KA.O\,A.AP
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MUUE[S"6UQG[;V3-.B3IHM3'HV1.#M+HWR-5CE34SSU5&JB.HY%1(@%8]D
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MU!S$X6<D>-.^.[^YA[+LVFJ2YY0W?D#QAY(P=&GKK"U=]9;'87A&%II[!O\
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M_/4^C/=S_D/$?L^'\Q"^(Q S0                     #2;_R%/]K7=?\
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M[GQVX)(8Y(4Z.SCQUO[4V70B*QUS+;R(K%5JJKG*J)6B.5&HCNG$.FSE,
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M-I8HY7:(VHB*Y>5SEY7.5$1%<Y56B(E:(A$HK'K@
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M=7=U?7+[R]D?+=R.5SWO<KG.<O*KG+557[54QL5RW
M    #ZBO==_[=/"K_#=JK^JS < ]X'^=LK_YTOYZGT9[N?\ (>(_9\/YB%\1
MB!F@                     &DW_D*?[6NZ_P"F&F/[U*J-J]R_[P+7]5/_
M %3S4/?G^[B[_6P?US#YU8[8.$
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M;V!N+# W<%]N*XB='&V!Z2,BU(K5DDD8JL16<J1ZM;G:45J-JY._R->'ST
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M=G_1&UX<-(YK[U7.EF<W[JROI5&U1%5K6M:Q%7BNFM$K1-A@PLSH
M                              (\U7_V4Q__ &]M_K?.B9WWB#>0D,2D
M0                                                      "/*K_
M -Z[0_\ V]8_JA$B9?NH03E4D,2D0
M
M                                                    CS5?_93'
M_P#;VW^M\Z)G?>(-Y"0Q*1
M                 ([J_P"C>-G)Y^0QI"JN"_\ AE)2K,D"Y_\ +/:-#XZ/
M_+_S$R_=0@G*I(@E(@
M
M                                        !'FJ_P#LIC_^WMO];YT3
M.^\0;R$AB4B
M      1W6_\ O[9/_P#IW\RKB9?NH"1!*
M
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MQA:B\8RODD.QLGZE_P"3RC_1[O-^37GHMYP_U<>[9^,+47C&5\DAV-D_4O\
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M2M:M%5CFN1%^W2JT,J%N7(
M                                                       :0>3W
M>+[KVMNBP\,N[-K]?NFVJDY-&[UY)V]HHZT[QV5RZ<L%XU+#EDYC[;=VJ[57
M.282D&J:J)T$VC]4CLK+W;3&P0P)>Y15;"OW&)]Y_D3^3\*<*[VVKW:X/$X2
M/>W>A))!AYDU6ME&M+B\X(J.X*BQQ*BIX6.5%1ROC16+)@.O^Z TK+S2.S>9
M=_V9S=W:Z;ES*6K<-ML&*=&N,J]MX%4:/'RQ"L(!J7^*29/W<@T(3Y4D42]1
M-.K)F9T;T5DUD$'B:B5_&OC^U$0]/(=\>;A@7%[*M[7!8-%\V.WC9TCDY*R2
MJWB]>57-:QWC<[BJW?AN&7$&O,4XV$XL<=8QDGU<]BUTMKA/M5"HI(>$.5/P
MYE5V[.D@3!UE3'54ZN,F-G(L'7UZY:NFE5?^9WE,%FWKO&YDZ6?+9)S_ !K<
MS?AHGG\$X\$3@G@.5]T[BS\-.@/8WKK\N"'MEWZV3TG>4H_5VZ_F>1^)FYX]
MT[BS\-.@/8WKK\N![9=^MD])WE'U=NOYGD?B9N>/=.XL_#3H#V-ZZ_+@>V7?
MK9/2=Y1]7;K^9Y'XF;GCW3N+/PTZ ]C>NORX'MEWZV3TG>4?5VZ_F>1^)FYX
M]T[BS\-.@/8WKK\N![9=^MD])WE'U=NOYGD?B9N>/=.XL_#3H#V-ZZ_+@>V7
M?K9/2=Y1]7;K^9Y'XF;GCW3N+/PTZ ]C>NORX'MEWZV3TG>4?5VZ_F>1^)FY
MX]T[BS\-.@/8WKK\N![9=^MD])WE'U=NOYGD?B9N>/=.XL_#3H#V-ZZ_+@>V
M7?K9/2=Y1]7;K^9Y'XF;GCW3N+/PTZ ]C>NORX'MEWZV3TG>4?5VZ_F>1^)F
MYX]T[BS\-.@/8WKK\N![9=^MD])WE'U=NOYGD?B9N>/=.XL_#3H#V-ZZ_+@>
MV7?K9/2=Y1]7;K^9Y'XF;GCW3N+/PTZ ]C>NORX'MEWZV3TG>4?5VZ_F>1^)
MFYX]T[BS\-.@/8WKK\N![9=^MD])WE'U=NOYGD?B9N>/=.XL_#3H#V-ZZ_+@
M>V7?K9/2=Y1]7;K^9Y'XF;GCW3N+/PTZ ]C>NORX'MEWZV3TG>4?5VZ_F>1^
M)FYX]T[BS\-.@/8WKK\N![9=^MD])WE'U=NOYGD?B9N>/=.XL_#3H#V-ZZ_+
M@>V7?K9/2=Y1]7;K^9Y'XF;GCW3N+/PTZ ]C>NORX'MEWZV3TG>4?5VZ_F>1
M^)FYX]T[BS\-.@/8WKK\N![9=^MD])WE'U=NOYGD?B9N>/=.XL_#3H#V-ZZ_
M+@>V7?K9/2=Y1]7;K^9Y'XF;GCW3N+/PTZ ]C>NORX'MEWZV3TG>4?5VZ_F>
M1^)FYX]T[BS\-.@/8WKK\N![9=^MD])WE'U=NOYGD?B9N>/=.XL_#3H#V-ZZ
M_+@>V7?K9/2=Y1]7;K^9Y'XF;GG\-Q,XKG*8IN-''XQ38R4Q3::USDIBYQT9
M*;&:YG&<9QGY<![9=^MD])WE(_5V[$XIE,C7_P F;GE7MO=TIP(VZB1?T#U_
M5%D:&(O"W'1.<ZCG(!^B8JC63C6-3(TJ:[]FL0JB1WL8[*10N#8+TBZAS&0A
M_P#V*]OA1_G(O\O'^13*</WO=X&'73[?)=VSN#H[K_N&O1>5KEDK(B*G!=+V
MU0KCZ5N>_=2N&TMM*U6?GKP,8J(MIVVOV>#\EM!PN#=4LO*O3NESW:L1;<V>
MV7>KN$#E1+CM88F2D6N>AQ^7X1(EOD/ G]!Z_P"Y?P?_ -C)%P_=_P![35BQ
M,46W]_N15;&B_P#97;O^%J43HGN7D1J(J57A.O%N_;5.UM>;PUY4]KZHMD3=
M]?7>)1FJU985;*S)^R6R9-0ATU"IN6,@Q<IG;NVC@B3IFZ24073353.0N/30
MR02+#,BMD:M%1?\ ;_\ )SSE\1DL%DIL1EX7P9&!ZM>QR<47^945**UR*K7-
M5'-545%)"%,\X   -%/?[\X]D<.>*%9@=,SCFI[0W]<'E)872.<>"SE0IL%$
MYE[E,5I<INV:6%T=RPCT7)2]9HB^562.FX(@?&W.YW:=CN?<4DV48DF/LXDD
M5BI5KWN6C&N\;4HYRIX5:B*BM54--=]F\;_:FV8X,2]8LC?2K&DB+1S(VMU2
M.8O@<M6M1?Z*.545'(U3Y[<A(R$N_>2DJ^>2<G(N5GLA(R#E=Z_?/'*AE7#M
MX[<G5<.7*ZILF.H<QC&-G.<YSD=GL8R-B1QHC8VI1$1*(B)R(B)P1#AJ21\K
MUDE<KI'+555:JJKRJJKQ55\9Z8F)
M               )>T9OG;O&S95=VYI&]SVOK[6'B+J/F8)XH@5TB15-5Q#S
M;'.3,)^O294^R>1[Q-9F[1SE-5,Q<YP/-RV'QN=L7XW+0LFLY$HK7)R>)S5Y
M6N3E:YJHY%XHJ'JX;-93;^0CRF'F?!>QK5'-6E?&UR<CFKR.:Y%:Y."HI]1_
MB/O=+D]QCT5R )&IPSC;&LJK<)6&0POX+#V&0C$<66)8G<F.X7CHRP).4&ZI
M\Y,L@F0^?_4/G_N3$+@,]=X97:FVT[V([PN:B^:JTX55M%5/ M4/HWM?-)N+
M;MEG$;H==6['N:G(URIY[4KQHCJHB^%$12Q(\0]T
M
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ME$G4ZF6<=*6>/04SDV,X.Z)T8STYZ'VD-3=6BOG*E?Q)_P#DR0"(
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MGP3!DBX-^#[2^18O.G..JNIC!>MCY1&BDJ2,<J(B\5K^1:+_ "*2.($X
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M\RZW'1O\//\ ?,I^J@_.E.8_XE/[CB?UMQ^;$=,P=0')P
M                                  !].7N@_P#;/X;_ -CT;_.LN."N
M\K_/>4_\E?YD/H?W6_N^Q/\ XB?SN-D(P<SX
M
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M_P E?YD/H?W6_N^Q/_B)_.XV0C!S/@
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M<,/Z8;K_ )EUN.C?X>?[YE/U4'YTIS'_ !*?W'$_K;C\V(Z9@Z@.3@
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MVTQ^?O\ (SWKJ,@;:Q6T4<:K56W#WP:Y5:G!%B<RKO$BJIULAO,T
M    !].7N@_]L_AO_8]&_P ZRXX*[RO\]Y3_ ,E?YD/H?W6_N^Q/_B)_.XV0
MC!S/@
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M*<Q_Q*?W'$_K;C\V(Z9@Z@.3@
M              #Z<O=!_P"V?PW_ +'HW^=9<<%=Y7^>\I_Y*_S(?0_NM_=]
MB?\ Q$_G<;(1@YGP
M                                             !H6X?\ ^Z!WQO\
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M61MKRJC&HE5^U:57[5)6'G'I@
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M=BS,.
M
M                                 #0MP_\ ]T#OC?Z7\0/[KM@#(;W_
M  JR_P"63\Y#H+>'[J]E_J<C_7Q&V$>.:E  @;;/(*M:JG:]2V]4V!M#9-JC
MI&;A-::K@F$[:U*Y$.&C*3M$JO.35:JM8K;1^^1;8>2LFR17<J811RJI@Q<1
M1*\? 4I)FQJC:*YZ^!.6GC\"(GX5/>U#O6L;?7M4*U@+I0[U1%XI"[:VV1!H
M0%TK1)YNX=0,@NE'R,W 3,'.),G'@DE%2#^/<';+)D6RHDH4I4H(Y6R52BH]
M.5%Y4_V\:<"8&3]C)-R.XYZT?M%,G*1TR<(NFYS)FR0^"+('43-DA\9QGHS\
MF<= @545%Y#S(KHN"940627(55= QT5"*$*LV64;.4<F)DV,*MW"1DSE_A(<
MN2YZ,XS@ 8]'68DA-VR&4A+#%)U-6*34G9B-PQKT^24B4I8SFLR9G!RRC6**
MKX.\/DB>$')#$^7HZ0)4=552B\/]N!S1)!@HQS)IOF9XW"!W69 CE$S'#9,I
MCJ.,N\'RAA!,A,Y,?K=7&,9SG($U4I7P&"7#:=5I3[5S"34>/#;>OR.N:@YB
M$F[YD:=7I=SOB3A^X\*2*A%&@Z*]QA9/MC96,D7J=!\F+&A(Z1K5:B_TEHG\
MBK_N/-9ME5VJ7?6E E"21IW:KVTL*P=JV258)KU"M.K5+9E'!W*2C1,T8T/A
M')$U<G5Z"YP7'Z04\(<]K7-8O*ZM/Q)4SIRZ;,D%73QP@T:H%ZZSERLF@@B3
M'1C)U5E3$33+C.?X<YQ@0)^3E'A3;P;PWPA#P/L/"O"^V3\&\&[/M?".WZW9
M=AV7Z77Z>KU?EZ>@ >(\@P38XDU'S,D;E CK$@=RB5CELH4ITW&'>3X0R@H0
M^,E/UNKG&<9QD!5*5\!BELV'5:3(4",L+Y5L[V==$]?TXJ#-T\)(V=6JVFZ)
MLUE6J2J;% U>ID@KVZV2(]9(I.MUSDQF-*DKGM:J(O*Y:)^&BK_,AQFL=K5+
M;-<3LU86=(M%K#L&M),9<C5E+*/=:7^QZVLKDC%)VZ,>.Q8ZNY[!7!L]= R9
MC8(8V28*E"#)&R-U-\:I_(JHOY4,9W3O>"TF:A-)&G[!O<YLJSR%2J-8UM!Q
ML]/R$I%52?NLB;+64FX%NFT9UVLO%SG[;)L82Z.KGI!$J2RRI%2J*JN6B(GX
M%7^9#S:MW(\V:_E6#G3>ZM8EBV:+LK_:56@Z^PE,K+91RTBEHFU6!1P\1QCK
MG*<B9<$^7!LY^0%2@CE61532YOX4_P#E29SG(D0ZBARIIIE,=10YL$(0A,9,
M8YS&S@I2E+CISG/R8P(%4CB^[6J6O(*M6.76<R$3;-@:\UM$.($C63*I8=FW
M6'H5=54/X6@CB,2G9M'PI4ASF21*<Q2',7JYBB5)'R-8B.7D543^5:(24($Y
MZAG[$CQ...]:$D%D3.$F)G")7BK<F<E.NFUR?"YT2F+G&38+DN,X_A 53D\)
M&,=N2KSCJ1:5F.M-H4@MLKZ;LQH.ONETJO:&<.A-R$C.*.C-,(5:/:/&Y5I!
M+MDL+.$R8P;.<]6-"FDK5X-JM':5^Q?(2<5^Q.\4CB/6AY!%$KA5B5PB9XDW
M/G!2+J-<'RN1$QC8Q@V2X+G.?X1 J53D\)^O#&GA>&'A3?P[+?+S#+MT_"\M
M"J%1,ZPVZW;9;E6-@F3]'5P;.,=/2 ^SPGL@         I7WCO[A7+S^P#9?
M]6GPOL9_B$/ZQO\ .9OW:_Y_P_[1@_/0M#W?G[A?"/\ PB<;/[FJ8+3(_P"(
M3_KG_G*8CWB?O SO[9O?_9E+=BS,.
M
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MS*6[%F8<
M
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MXA/^N?\ G*8CWB?O SO[9O?_ &92W8LS#@
M
M
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MHU[2D5J/<ZG<D8=[F-EE:I8H>PI1<B4O7,PD5(AX\*Q>E+\N4E<E4QC_ *"
M:]C_ +BHM/$M3+ )@             I7WCO[A7+S^P#9?]6GPOL9_B$/ZQO\
MYF_=K_G_  _[1@_/0M#W?G[A?"/_  B<;/[FJ8+3(_XA/^N?^<IB/>)^\#._
MMF]_]F4MV+,PX
M
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M>$670\,226@Y>''^<C;(BS:FK5J-HOF:4Y4HB^-4_)Q-LPD/0
M  "E?>._N%<O/[ -E_U:?"^QG^(0_K&_SF;]VO\ G_#_ +1@_/0M#W?G[A?"
M/_")QL_N:I@M,C_B$_ZY_P"<IB/>)^\#._MF]_\ 9E+=BS,.
M
M
M                #0MP_P#]T#OC?Z7\0/[KM@#(;W_"K+_ED_.0Z"WA^ZO9
M?ZG(_P!?$;81XYJ4                  ,*V+KZL;4I<]0+BV>NJ[8FZ"#X
ML9+2D#*-U6;UM)QTA%3<([82T3*1<HR1<MG#=9-5%=(IL9^011:<25[&R-5C
MONJ8/J;0=*T_(6:?AY*\VVXW%"&8V2];+N]@OUOD(BN9DC5Z 3E9]XX+&0$,
MK,O%46;--NAV[I58Y3JJ&/DJU)(X6QJJI57+RJJJJ\.3E)M$"J
M               4K[QW]PKEY_8!LO\ JT^%]C/\0A_6-_G,W[M?\_X?]HP?
MGH6A[OS]POA'_A$XV?W-4P6F1_Q"?]<_\Y3$>\3]X&=_;-[_ .S*6[%F8<
M
M
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M,I;L69AP
M
M                                    :%N'_P#N@=\;_2_B!_==L 9#
M>_X59?\ +)^<AT%O#]U>R_U.1_KXB]/)O0E?Y/Z*V'HFT3,M7H>_QL<U5G(/
ML<R46]A9V*LT.\31<8[%VW1F85OEPW-DF'+?KI=<G7ZY?(1:+4U!/"D\3HG*
MJ(O_ .3"N&?%&M<--)1^F:U:)JY))3\U9Y6Q3;=NQ5?S$V9L1?+**:J.$8F.
M1:,4"$0PLMGKE.H8^3'ST1<[4M22VMVVT71-55XUJ8!MJSS6K^7-5V6OJ[;U
M[J#KCC9:*I):MU[,WO[OLCK9M:GV[*3)$E_]EVT9&*J%R?/R]&/D^4$XMI]I
M)(Y8[E)-+E;H5."5XU0PV7V&XC-_0G)2?T7OV<UY:=$J:JKK)GI>UV38.L[E
M [$LLS:"36MX=E*VV)A]M0<I&%3DDVN6>2U],CE1,JR/3&G"G"I*KZ3).K'J
MQ643@JJBU6O#EX\./V%=WO'3<C#66G2UZ@6" ],]@WMHS8=!:E;.5],\9N3&
M\<[1AF]BRR=+MF^-/Z]C'483#<V,,7<X=F3.$RE.6-4K^#^="BL,B1MTM5-2
MN:J?\+7.K^1.'XR:>/&A-OI3.X(>2E[?I8NI(I#CCQYV%%Q%3F9-35D;M6R;
M0S9:Y%WJ!M-6?1\Y0)&IUA;*[!9-%6!<]CU%B$,C!53\)5AADJY%JW3YK5X<
ME56J514Y*)^(Y^Q,K'HO>5BMNT*)M_E' [&X[4+54-=*OJJ$N\T6P5&V[0D+
MM3+?5:/#Q5>JT5L]C?(E;+]1C&U]7,8=-XHGA$A\N5.'#B1<BQ2JZ1'2(YB)
M5$KR*M45$X)6J>).'$KWQ@@K7QDC=:6W;F@=OST3/<5Z5JR BZ3K2?V?8]2V
M&I[$VM.W77<]5JVSEIJ-8[!C+C"N"RJJ*<>Y-$=BY6)A-#)HKQX(OA*,".@1
MKI&.5%C1."55%15JE$\=4X\G Q@^LMCZFJ&KG3RF\A]>V]SIG8]=C7&JM2U_
MD[3FU4O&X+W?8+C'M#51*W85H(E"J,]$,$)EK+0L:\(5=H=X5)L3.(U1?%2O
MX"7HWQM;5'M=I7D34E%<JZ52B\B4XU1/!4\3RB;XI=E7L6P(;>FM_27QOT73
MF5,XN<>-3[ZIT6K4J2>#N.AI<USUQLY_KV%B[.\6=,4G3UM5ED)%3)WAU4%5
M,PJGY0K)6NU/1[=3&I1C4<G!.+>*+3CR>#[385]U;2U'PEK%.HD#9I#;\#IR
MB:TJ44_D&ELG:]<)2+@Z-$25GG8&-CXV59Z^=R!'TQ(-VZ2!FD<NN7]'HSF7
M@KJKR%Y22.U1K$7I$:B)X:+R<?P>%?L()U[QMW+QHVKQ[L["[-MQTV)HKGB]
M-PT!JQ"DOZQKW$*[M=&MT_)1UELAYEO"WZIMF3MZY3[5N6Q.W)LJ944Z(JJ*
MB_RE)D$L$C'5U-IIY*43E1>5?"GY5*TZ]K^PZVT@J3":\W.WUYKO3>_V-CK7
M(72\*P4XV-7^MK(1.%T]R5B8*GMMP-)VWE;1_0D6P*OX94SQP[2.@7!HKX_"
M4&(]M&HUVAK751S?N\%Y'<*U7\-4XF<:;S);=UQP<J= T5LW7#O0NOEK-=KE
M8M>N:Q4OP](<;[=0UJ?1;6J1"*V3C;%RN<;*=>(6=I]@Q,Z>X3=$(D"\%6OA
M)XJR,B:QCFJQ*JJI1*:52B+X:JJ+P_&35Q+U):ZS>..D_<*#*0[JF=VWH'6+
MF6FH11NO6[Q'2!CVVF&=N4<*1T\U2;I>&M<9*I@I"]?'1@0<O+^$J6\;FO8Y
MR4I U/P+X4,8X6:2M59LW'Z9V!K63B7=0[O;6>LW,A9*^=%6OVPUXFG5JIIU
MGJ'2QF#1I&YGC;Y%,H]7KXZN>C)R\M/&0MHG-<Q7MI2%$X^.O%"V?"RJ3]&X
MMZ:J-G@G]8G*_6%HUY7Y-FI'/8@J,S*>!L5&*I$SM"(L<I833ZN,%2ZN,8QC
MH$KN4N+5KF6[6N2BHA:(0*X                   !2OO'?W"N7G]@&R_ZM
M/A?8S_$(?UC?YS-^[7_/^'_:,'YZ%H>[\_<+X1_X1.-G]S5,%ID?\0G_ %S_
M ,Y3$>\3]X&=_;-[_P"S*6[%F8<
M
M                                                       &A;A_
M_N@=\;_2_B!_==L 9#>_X59?\LGYR'06\/W5[+_4Y'^OB-L(\<U*
M          ''2\5'ST3)P<LV*]BIF/>Q4FS.90A'<?(ME6;UL<Z)TU2%7;+&
M+G)3%-C&?DSC/R@05$5*+R*>O7*_#U*O055KK%.,K]9AHNOP4:DHLJE'P\,R
M0CHQBFJY46<*)M&38B>#*'.?."])LYSTY -:C6HUO(B4.9 B
M             4K[QW]PKEY_8!LO^K3X7V,_Q"']8W^<S?NU_P _X?\ :,'Y
MZ%H>[\_<+X1_X1.-G]S5,%ID?\0G_7/_ #E,1[Q/W@9W]LWO_LRENQ9F'
M
M
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M5RF ;YN&7>]LQ=Q_].7*W;T\/!T\BIQ\/*6>%J8L
M
M
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M>4YP>]TCU>]55[E555?"J\JGG E
M
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MHB.:QFW<>,:<
M
M                                            HMWA:7!5;C[+(]X
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MD?@W<T>GCOC_ ($N/?\ F&B/+0>SX7WB3T!V!W,?/\C\&[FCT\=\?\"7'O\
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MW WUC'SGX
M
A                                        #__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tm2110724d1-fc_preterm4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2110724d1-fc_preterm4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@"(@.4 P$1  (1 0,1 ?_$ /\  0 !!0$! 0$!
M       '! 4&" D* P(!"P$!   ' 0$               $" P0%!@<("1
M  8" 0$""0,,"PL)!04)  (#! 4& 0<($1()(1,4%9;6&%@95Y?7,4$BU)75
M%E:V%Z<:42/3539VMSAXF#EQ)#24-76U=\C8"F&!D3)",X=)2J'!)3>)4D2T
MA2;&1XAB0V.X*7D1  $# @,"!P@," P% @4$ P ! @,1!!(%!B$',5'2$Y-5
M%T'1(A14E!8887&!D3*24]/4%38(H;(C<[.D=3?PL4)2<J(S0S1T-5;!8H)$
MM"2&PL3%1TCA8X,EPX1V_]H # ,!  (1 Q$ /P#W\
M
M                                       *),V?.+HO:SG&&3 V"=K/
M9+DR\EC)L%Z=,9-V<8SGKUSTQ^Q@!W2M
M
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M.:Y:NB<J*K:.X7,=14V[6JB(JNQ)3N6.O'(0
M         H4^OG-WX/!Y#'=,]/JY\HE.N.O3P],=/!];K_R@0[I7 1
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M'D??']M7_P"7B_B4];[G?L5'_F)?XT.- Y6=4
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M%Z9$EKIC4%]-/;VEG.^XMG-;*U&KB8YRJC4<WAJJM6FSN$]UJ?3]C#!<7=Y
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M>&F)JJVM-M*UIW#8<FU/D&H%>W)[J.=[$JYJ51R(NRN%R(ZE=E:4-;A@3/
M   '6_N/O[1?4O\ %;:_\G%C'3-T?VYMOS<WZ)QS/>Y]AKG\Y#^E:>Z<>P#R
M                                  % G_E-YCI_]PCO#X>N?[XE?!]7
MIX.@$.Z5X$0                /$!W\/]H#8O\ 5=K3_1CP>1]\?VU?_EXO
MXE/6^YW[%1_YB7^-#C0.5G5       -\N#/%&F\I?:7_  OL=FKWYDN-U\W1
M ?@V:*+YVGJIY)Y'%3'G2/?]8ASY1GQOB?%+>#'9/@;EI#3=KJ+ZP\:DD9XI
M823MP4VN92B.JB^"M=M*+[)INK]276G?$/%8XW^-W\<#L5=C7UJK:*GA)396
MJ>P.)7%&F\@M)\T]FV6QV:%EN,^GFFQJI'P1HK$=/2CAO;%3,;#A_'O'.6!3
M5]/&/)E$%.AS?9?4Z-,Z;M<[RG-LPN))&2Y?:I*Q&THY51^QU45:>"G J*-2
MZDNLDS;*<OMXXWQ9A=+$]75JU$5FUM%1*^$O#5#\;1XA+-JSP]0TG3MZW#97
M)'7KJROZ[8*JRQ'3$VV9P+TYM5&AVQ7DO5FK>0<+.'3O.?$($(H<Y28.;#,=
M,*VWRMN4Q7DM_?P*]6N8E'.1&K^1PI5S$15557@2BJM*D<OU.CKC-'9M+9Q6
M%A.C$<UZU:U5<GY;$M&O541$1.%:HB5H8Y:^[\Y?Z]O>M]?;#T7>*I,;5LB%
M7IJIFL;,L)B6.3REPP8RL-*O(164;1Q5'/DAW:2QTDCFQCH4V<6]SHK4]C>0
M65]9S1RW,B,9L1R.7A5$5JJVJ)5<.)%HBE>VUKIB^LY[VQO(9(K:/&_:K5:G
M BJCD1U%6B5HJ55"1^6?=O[FXX\FHGC;28^W;SDK?$,)?74[7Z$O"O+RAYK;
M/+&I&UEE8+<JU951Z=9!VY5=^*(5N=8^4T\9[-_J70F:Y%J!N0VC9;R25J.B
M<V/"LFQ%=1B.?1&+5'*KJ;%5:(6&FM=Y5GNGW9]=NBLXXG*V5KI$<D>U4;5Z
MM957I16HC:[41*J05N/AAREX_255BMPZ3N=)7N\HV@JFZ>MV4A#3LZ\4PFV@
MV-@A7LG GF5LYZX:&<E<=C[/).SC.1A\UTIJ+))(X\TM)85F<C6*M%:YR\#4
M<U5;B]BM>[0S&5ZJT[G4<DF5W<4S86JYZ(JHYK4X7*UR([#[-*=RI,=![OG?
M$7M+74%R(TON:A:YM&V834LS)5Z&B5[@O9IZGR5XCX6G1<BNX1G)1>NQJCGQ
MA$EFB92&34.5;H092RT3G,>8P0YY:74-C)<MA<K6MQJ]S%D1K$6N)5:BK6BH
MG JUV&+O=;9-)ET\V1W=K-?1VSIFHYSD9@:](U<]41,*8EI2J*O"B4VF#,N%
M>[MK[XWAJ?C7J;9NQ8[4NQKI55E)>,CHF7@8F$M$[#0*&P9)TO%U> MCYG"G
M\:T,NEE1TBN5 AL)YQBS9I/-\RSF[RW(;:XG9;3R,\)$:YK6O<UO.JM&->J-
MVI5*JBT387C]5Y3EN36>99]<V\#[F"-_@JJM<YS&N=S:)5[F(KMBT6B*E5VF
M$17#[D_-;F=\>8[1VPE-SQ[4\B_H*\&LQEF$.3+<OX0/5WQFT8TK*F7B/BY-
M1<L>KXY/L+&\83M6D>E]0RYJN1LLY_K5J56/#14;L\)56B(S:E'JN%:I1=J%
MW)J?3T65)G;[R#ZJ<M$DQ517;?!2E55^Q:L1,246J;%)WUOW?>W8WEGH3CCR
M?HE\TVRW/9<1;:633AUEWL8DU.M(.:Q-I9G:Q).XU51 KA,IUS-O'$PJ0N3E
MZYBPT5F<>I;+(M0PS6K+N2B+X.U*;58[PF*J;*\-*I5-IA[_ %KEDFFKW/=/
M30W3[2.JM\*B+78CV^"]$7;3@K1:+L-6.0VN8O3^_MY:D@WS^3A=6[AV9KF(
MDI7+?,I(1=(NDW68]])9:(MFF7[MI&$46\4FFGXPV>R4N.F,:[GEC'E>=7F6
M0JYT5O=2Q-5:55(Y',15I1*JB56B(E38LDOI,TR6SS.9&MEN+6*5R)6B+)&U
MZHE:K1%6B555H=PMG]VKW;&K^1M;XE6;DMR3@-TWEQ4HFIY<U"J3=2/.; <%
MCZ<U?2$95FIL^<919)$Q<J($*8^.VJF7J<O7<PT%H++\]CTU<7]^S-IE8C*L
M8YF*1:,151B<*T3A3V53A.1Y?KW7F89%)J6WL+!^4PH]SZ/>U^&-*O5$5Z\"
M57@7V$7@.8SCNZ.4\UO3=NC-3ZUG-O2>C;@^JMGLU:28QE<,0JZYH-\K)SLF
MRBXYU8(M+#I)B=T=T0N3%S@WBS9'/W:&U%+G%WD^6V[[J2SE5CWMHC>%<*U<
MJ(BN3:C:U]XZ W7.G8LGM,XS*X9:QWD2/8Q]5=_S)1J*JHU=BNI3WR2>)O=?
M;OY#\D+;QWV(SM6@G^OJ_B;OM@FZ+BT&JZDDV4<5)LYALVFJIO&EO*W5\C>-
MWJB!RIY,7MES@7VFMWN;YYGTN1WR263X&8I'.CQX*I5B*W&RJ/HN%R.5-E4J
M6&I=X649'D46>6*QWK)WX8VMDP8Z+1ZH[ ^BLJF)JM1=O<(SE.)[>H\4=J[3
MOE<W/7]U:RY%&TK*0^8&(/JF'3;0U4>/XFQ394UI5O?F\A-KEPV25RAE'Q&>
MF<F-UL)--MMM-W.8WD=VS-K>^YA6X6\RVC6*K7.^$DB*Y=B+2E"_CU(ZYU);
M9=9R6C\IN+'GT=B=SSJN>B*UO L:HU-JI6M3#;WP0Y@ZQU<ENB_<?-BU;6IF
MK)\YL4G%HD/#LI Z:3-Y9(1)TK8JNU666(3QDBT:D*HH0ILX,<N,VMYH[5&7
MY<F;7ME/'8415<J?!1>!7-KB8GLN:G"G&A=V>L=+YAF/U597L$E_541J+\)4
MX4:ZF%Z^PUR\"\1?*3W=O-K8T;"3-+XX["G(:R4J&V) S"3:,:1,M3[$V*]@
M99E)R$DT8K'F6AO&MFV%/*UT\&,1+."FZ5;30VK;^-DMI83OBDB;*UU$1JL<
ME6N155$\)-J)7$J<"%&[UQI*QD?%=W\#)8Y71.;55<CVK1S51$5?!78J_!3N
MJ2]Q9[L/=G)K7?)>Y-FEKIT[H#SG78>DN:&:2E-A[9@6KAW8=3F4?6>MNJ?8
MX0BK##@RS1YDF7Y,93QDF<9RFG=WV;:@L<PNFI)%-95:V-8ZK+,U%5T.U[58
MYO@UJCOA)LV&,U%O!RG3]]86KECEAO:.=(DE$BA<M&S;&.1[7>%2BM^#P[2"
MM7\"N8FZ->_G5U=Q]V!<* IY5EE8(YDS1)-%8K*-W:E<CW[YI+69)!TB=')X
M]NY+XY,Z?7ME,7&'R[1NJ,VL?K++K*:6RVT<B)X5-BX454<_;L\%%VHJ<*&8
MS#66E\JOOJ[,;V"*]V5:JKX-=J8E1%:S9M\)4V*B\"FIKMHZ8.G+%\V<,GK)
MPLT>,W:*C=TT=-U#(N&SENL4BJ#A!4F2G(;&#%-C.,XQG UIS7,<K'HJ/1:*
MB[%14X45.,V1KFO:CV*BL5*HJ;45%X%1>(IQ*3       =1O_)6_^J+_ +)X
MZ'_]J/\ W#_\F<\_^Z__ +>_^</>@/9)XW
M  #B!_Q /\Q2(_U]:_\ R<O@Y'OI^Q[?\Y'^+(=;W+?;!W^3D_&C/%0/)YZP
M     .GG<UOF4;WD?'%[(O&K!FC^=_QSMZX1:MDO&:&V@DGXU=<Z:2?C%5"E
M+USCJ8V,8\.1T'=8]D>O+![U1K4Y_:JT3_#S'/MZ;'R:#OV1HKGKS.Q$JO\
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M_<??VB^I?XK;7_DXL8Z9NC^W-M^;F_1..9[W/L-<_G(?TK3W3CV >0
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M?\0#_,4B/]?6O_R<O@Y'OI^Q[?\ .1_BR'6]RWVP=_DY/QHSQ4#R>>L
M         VFTERNN6C-+\F=(UZN5F7@.4->IM<MTM,EE<S%?:TI>T.&"]<RQ
MD&C+#AV:U+86\J27+T3)V<%^RZ[%E.I+K*,IS#*((XW0YBQC7N=7$U(U>J8:
M*B57&M:HO AKN;:;M<XS7+\VGDD;-E[WN8UM,+EDP5Q515HF!*45.%35D:Z;
M$                               !UO[C[^T7U+_ !6VO_)Q8QTS=']N
M;;\W-^B<<SWN?8:Y_.0_I6GNG'L \@
M   !0IYQYS=XZ>'R&.SG/7ZN,N)3ICI];IG&?^D"'=*X"(
M  'B [^'^T!L7^J[6G^C'@\C[X_MJ_\ R\7\2GK?<[]BH_\ ,2_QH<:!RLZH
M                                                '4;_ ,E;_P"J
M+_LGCH?_ -J/_</_ ,F<\_\ NO\ ^WO_ )P]Z ]DGC<
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MBHJ+P*BIL5%[BH6T4RH
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MY:_35P]L>8-E<^-%6G.-<B51M>%[5155O"K5141:.IYN1P<[P
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MI$*FDDDF7!$TDDR8P1--,F,8*7&,8QC'3 RZ(C4HFQ$,0JJJU7:JGT$2
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MUUFV:WK.:O;FXFBXGR/>GO.54).&0,>
M                           !'>L?X//_ .-MS_*:3$SN'W"5O 2()28
M                                                         *%/
MKYR=^#P>0Q_0W3PYSX^3ZXZ_7[/_ +.H$.Z5P$0
M                    ([VK_ E]_G:I?E=!"9O"04D02D0
M
M        ([UC_!Y__&VY_E-)B9W#[A*W@)$$I,
M                                    %"G_ )2=^'/^ Q_@\'3'[?)^
M'IUZ]<_W/K?] AW2N B
M!'>U?X$OO\[5+\KH(3-X2"DB"4B
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MBJY68)<*)PJK8G/<B(FU55*(FU5-J1TTYL
M    :#=Y3M6TZHXLV1]3W[B(FK?/0=$Q,LEE&\A%1TT5^\EEV#A(Y%&[IU&Q
M*K7"A<]M,KC)B9*?!3%X=]X?4^9Z7W9W$^4O=%>7<\=MSC55',9)B<]6JE%1
MSF,5E4VHCE5**B*G:_N_Z:RW4V\>WAS5C9;2U@DN.;<B*U[H\+6(Y%V*B/>C
MZ+L7"B+5%5%\HP^8!]+
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MVL1<UO+I\;GJFU(HL*-C1>XBNQ/=3X2JE?@I3DF/+)Z=
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M^[5^]RP_,77_ (\APS[QG[J+[\];?IXSU4#Z;'S;
M             "A3Z><W?[/D,=U_N>42G3P=/V>OU\_\WUQ#NE<!$
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MS^.V?_CE_P"]O_IAQG_\A?\ V9_]2/6,/J(?,X
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MK][EA^8NO_'D.&?>,_=1??GK;]/&>J@?38^;8
M          4*?^4G?@S_ (#'^'P=,_M\GX.O3KUQ_=^O_P!(AW2N B
M          !Y=.]=_G=S/\1*1_\ @G(^:WWH/WJS?Y&W_%4^B_W:?W7Q?YVX
M_&0YL#SP>@         OM6_A/7/\_1'^D&XOLL_U*W_/Q_C(669?Z?/^9?\
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M_P#X[?\ 9_';/_QR_P#>W_TPXS_^0O\ [,_^I'K&'U$/F<
M              '+KO=?YJD?_K9J'^AK8/-?WJOW8Q_M2#]'.>C/NO\ [R9/
MV9/^DA/,D/G&?0L          WXU/S"UG4= 0W'_ &KQM:;HKT)=Y.^,W;S:
M$G34B3+Y!ZS;JE81-2D'&%&3&2<)8R9V8BF%<YR3&<8Z=QTOO9TYE6A8=":G
MT\S.+"&]?<M<Z\?;ISCD<U%PL@<M6M>]/AJBXJX45$.*:FW6:AS36\NM]-Y^
M[*;Z:S9;.:VS9.O-M5KE3$^9J4<YC5^ BIAX:*I^X#EWIK7V[=/[CU'Q58:W
M_-K^<#\(*XRVU-3?X=_AC4EJM$^-EY>HJ_@_^"_EKE<OBVKGROQ^2&\7V2G$
MUCO6TCD6LLIU;I73#,O^KO&N=B;?22>,^,0+"RLDD"\US.)[MC'X\5%PT12%
M[NOU9GFD,UTIJ?4K[_ZP\6YJ5UE''XOS$R3/HQDZ<[SV%C=KVX,-4Q55##7/
M*][(Z9<::C:T2KR+_D:KOJ/V(I9EG*==>NCFPUC3P;>K*+N"1"YRKY>$6,<^
M$^F&N<YQ@8>3>A-<:0=I&WMTMKA^H%S)MTLRJD3E7P6<VD*JN!51W.(Y56FR
M(RT>[2&#5C=5W%PMS;LR%,N=:I$B<ZU/A/YQ9D1,:5;S:M1$KMD.T]%M454-
MBO>2NVZ5QLKICZV.6[\D=>;K=6EEL@R$1'XB86C4"59P2\/,O<,4TE#J).';
MHK4K9-53&28S["R7-+7*<_?O%U39Z=MU7+O_ %&;6N8+,V[I&W!';6KVQK'(
M["B*JM<]Z,2-KG)0\D9SEMSFF0LW?Z8N]03HF8?^GRJZL$A=:U>[')<7+'2(
M^-N)51$<UC%>LCFM6IQMH7,G\"-:\=->?FX\Y_F!W.IM[SQ^%_D7X6=M_-O?
MP>\W_@N[\Q=//'9\K\>]_P"[Z^)^RZ%\D9'O<^IM.Z?R#ZOYSZBSA;[G.?P\
M_5TCN:P\R[F_[2F/%)P? V[/5N=;J?K?4&?9[X_S?UWE/B6#F,7,^#&WG<7/
M-YS^SK@PQ\/P]FV6)7G]1&KO<>P=<\;8R@;UW)&3E;E]AXV%+V&/BX2=4P=Y
M(Q]=<P[!HC9%R(H&741\G0</D"NCDZ&.V-L]UOTR2*7-\^T_IZ.PUMF\<D3[
MKQJ25K(Y5\)S8EC:U)E1&JY6X6ND:DJI15C76K;<EG,D659'GV?R7VC<JDCE
M9:^+,B<^2-/!:Z5'N<L2*KD:CL3FQN6-%JB2)@M>YZV6G(\4#56C,V3_ (R0
MEZKKM:1L2TBPV+$7U"":2;9RP0A8U6MY;-H?.4C%</NC@Z:GU$NPIA;#?AF.
M4LTNN663&3Z<AN8G*^57MNV7*1M>BM2-BQ42/P5Q2>$K7?R:.S%]N6R_-7:F
M3,KQ[X=0S6\K4;$C76K[99',5'+(]):J_P +P8_!1S?Y56Q[N7>^BK;3'U2T
M]QAK>J7=AGT[%8K?+6=W?K.W-A0JYZ_4'TG&,E*Q!Y<(IY-A$W11+)T\))E.
M?MX'5VMM%9ID[\JTEINWRN6>=)99WS.N9DVUYJ!SV-6&.J)7"NU*MPM15KG=
M*:,UEEF;,S356HKC,XH(%BB@9"VVA793G9VL>Y)I**M,2;%H[$Y42FNNO;I)
MZYOE,O\ #8[4K2K3 VE@GE4R)%W,%)MI)-LJH0ILX0=9;>+4QT-C)#9QG&<9
MSC.@9#G%SI_.[//;/_%6=S%,U*TJL;T>B*O$ZE%X=BKL4WO/,IM\^R6[R2[_
M ,-=VTD+EI6B2,5BJB<:5JGLHAT$-WD,R;E@;DN;5Y#1A]:'U>?6YKMC)#P2
MB^953M6G-.[)L'LILOLDS&>'KXOM?]L=V7[PEVN]!=XJY:GBRY=XGXIXQ_=*
MN-?RW,?+?E*<S_RU[IP]-P=HF[1-WR9BOC"9AXYXUXO_ 'B)@_L>?^2_)UYW
M_FIW"#=6<O[%0MN;>V%8ZG&[ JN^RVMEM?7DM).F+*>A[7)/)%=HQF4$%UXU
MW&E?*MVRWB%2$;JJ$PGC.2&3TO3.]?,,CU5FN?9A:QW^69YS[;VU>]S6RQSO
M<]6MD1%5CF8G-8["J(QSDP[45NXZDW6V&=:8RO(["YDL<RR3F76=TQB.=&^%
MC6HYT:JB/:_"USFXD57-:N+8J.RN\<P*BG1ZIJ/1>F$=2ZKA]D0VT;5%NKI)
MVVR7JQ0KEDX:MY"?DF)31T8F5@@7!/%N3=MLB?&2E(9,^4SK>OE3<EM=*Z*R
M=,KTS%F$=Y,QUP^>:YEC5JM1TKV^ Q,+4I1ZU8Q45$16KC<GW6YHN<7.J-99
MLN9ZDEL)+.%Z6[((K>*1'(Y6QL=X3UQ.VU8E'O14551R7UWSQ\JW;R2W'^:K
ML>T)J;.K_P '/PY[7X(]:E6JMY\\[_@>7S__  >\?Y-Y*R_[[L>-^P[9KZ7?
M=SFLM0ZM^K*?7V5^)\UXS_8?D(8><YSF/RO]EBP8(_A4Q;*K91;E^;TAD&E/
MK*OU'F?CG.^+_P!O^6EFYO!S_P"3_M<./')\&N';1,6J/-NQT+77&2G5.FM6
M<[QMN=SM;6ROIY5ZRN+>[2=E<RD$\KZ,0P7AVJD59UV2BI)!P=0G4Y<)YSC!
M<7E6^3,,CR#3F4Y7:-9>Z>O+B=)G2JYLZ7#YE?&Z)&-6-JLF=&JI*Y53:F%5
MHF2S3=#89UGNH<US.[<^RS^T@A6)L:-= MNR)&2-E5[D>J/A;(B+&U$78N)$
MJM)N7DCHV\UFXL]<\6:SKZZ;(F2SUMO4W:WE]D8EXJ\S(R;>A-9.)9(55*4=
MJ*>,.AV"X25,0B1>RD9.EJ[>%HO.LMNX=/Z9MK#.,PFYV>YDG=<O8Y78WI;-
M>QJ0H]RK56T3"JHC4HU6U=*:!UCD^86DN?:DN+[*+"+FX;>.%MLU[4;A8MRK
M'N696-1*(ZJU1%5RU<CLEL'.3S[RGU9R8_-?Y+^;2IQ=7_ K\-?'^>O-L59(
MSR[\)/P21\V^._"'M^*\@7[/B>SV\]OJ7)7^^CQW>;EF\7ZMP_5UJR'Q?QBO
M.8&3,Q<[S"8*\[6G-.IAI5:U3'6.YWQ/=OF6[[ZQQ?6%T^;QCQ>G-XWQ/P\U
MSZXZ<U2O.-KBK1*473"_6C\.+U=+IY#YK_"^V6.T>;?*?+?-WX03#R6\A\L\
MG:>5^2>5^+\;XI+QG9[78+UZ8Y!GF9?76=WF<8.:\;NI9L%<6#G9'/PXJ-Q8
M<5*X4K2M$X#K629=]3Y-:91CYSQ6UBAQTPXN:8UF+#5V'%AK3$M*TJO"8F,6
M9,        .A7=<_SRM??YAO_P"1<R.]?=J_>Y8?F+K_ ,>0X9]XS]U%]^>M
MOT\9ZJ!]-CYM@                                !0)_P"4WF>O_P!P
MCO!X>N/[XE?#]3IX>H$.Z5X$0                /+IWKO\[N9_B)2/_P $
MY'S6^]!^]6;_ "-O^*I]%_NT_NOB_P [<?C(<V!YX/0         5\4]\V2<
M=)>*\?YO?LWOB>WXOQWDCA-?Q7C.PIXOQGB^G:[)NG7KTR*]K-XM<QW%,7-O
M:ZG!7"J+2NVE:<10N8?&+>2"M,;'-KPTJBI6FRM*G378_.SC=MVV/KSL;@M%
M6BUR2#%N^F76^K*U6<(QK1%@R3,C&T1DT+ANT0(3'93QG."]<]<^$>C=0[[-
MWNJLT?G6H-%17.:2(U'2.S.9JJC&HUJ49;-;L:B)L3VSSUD&YK7^E\L9DV0Z
MREM\LC5RMC3+8G(BO<KG+5]PYVURJNU37B1Y/U_&D-W:,JFIDJI6]L;48;%@
MSHW1Q)I4.,C7,$LTJ:;5W72.;$1)*$PGAXHZ:F_;.N4L]GH;0KC>38)HS.=%
M97E:6N79IF;;J.EPKTMF,6)6P(UT59:)'3G%>Q=M<.S;O4&[J^76&3ZRS+,U
MN<PRS+76LE8$8MR]Z2(Z95;+2*JR5YM&/393%MV;HZJY46CD=RBV1;82K:F@
M8/8FGT:-;]);;V8_C8[9D-$I*-S1%7NK:C$9-K<N5XIA!-VU(CANNOUR;&,J
M)=>TQO-S+>#O*S#-+.VRN"RS#*4MI\NOKQS&7D;$5.;AN$MD:DZXEPH]B-P.
M?P[7-Y-J7=OEV@MW.7Y9>7.9S7EAFJW$&865HU[K21ZHN.:W6XQ+ F%,2L>K
ML36<&QKK[RYN-/U+QJT3K!"GT+7EOJ_(-AM%II.D;$_.$XKM.@(^U]E6TW11
M1^]=3%@D)Y(Y7:J>2JD4-A,N<-S%Q?;U<WRG2V[O)--LM+&PS:VSYMXW+K>Z
M\:6*WB9-MFN%5SEDE?*U4>Y**BJC47FU1++=?E6:ZFW@9SJ)]U>W^5W&1NLW
M9A<6OBR2SR.AV0P(C6HR)L;D5C5V*B*Y4QHJP1CO#85[>^45JLF@&-GK_)Z.
MU=#S5-D=C/&[6!C->51U5'J/G>/J#5]*.)YN[,N@NB6/4CEBD,7*V2XR-([>
M[.;.]2YGF&1,N;'4D=G');ONW(D3+6!8')SC8&N>LJ.5S7-YI8G(BIC5*FY]
MA=W%DVG,ML,[?;WVG9+Q\<[;5JK(^ZF29JX'3JUB1JW"YKEE25JJBX$6AB\[
MSBKS%YQ[KVJ]+HT+4.@K^SV8A15;J\F9BX6M%RNNLZE;8\AE56O1)\Z22/EL
MY.7RDYL]28323QM[OGL(9<AL-,Y.ECI3([YMXELMPZ22>9%55<^=T:JW8YZ-
M7 ]4QJJ[,+6Y&RW/7TT6>7VI,V6]U3G=DZT6X2W;&R"%41$1D+9$1VUK%5,;
M$7"B)1<3G?UAS@J]@SNRI[@TDE?]1;BVI([?;5!M>Y&"L-&MC[*6,J15L81*
M"DDW,@S02.7R=GC/[8;PE542/&#?-EM^N<Y7JS)DOM*YMF;K]($N7QRVT[J;
M63M8BO2C6M5,,?\ *7@<YJIMS^8V/U1F>ELX6QU1E66ML5G6W;)%<0MKL?"Y
MZHQ:N<Y%Q/\ Y*<+6N35'=NR:QM"Z>?:7JVJ:?JK*,9P\+3JJ7"Y4FK,RQ_+
MYV:.U9N;#/NSKY\<[423R8A"%[/V.3&Y?K+4.6ZDSCQW)\LM<IRQD;8X[>';
M1&U\*23"U997*OA/5$541$ILJO2](9!F.G<I\3S?,KG-<R?(Z22>;9574\&.
M.KDBC;3P6(JT556NVB31P_Y@SG$F4V&]C:HG<6=]KC*,-'*SWF%.-GH9TY7K
M]B.<T).I2)8LDD[)EJ9)+*GC^N%B=,X-N&Z?>Q>[K+F_FM[5+N*^MVLP++S2
M,EC55BE_LY$?@QO3!1M<7PTI1=2WI[K+/>=;6,-Q<K:2V5PY^)(^<5\<B(DL
M7]I&K<>!BXZK3#\%:U3ZU_F/8H'B1;^+):SER:TV)U)$V$>PG([BZ_)2\#.R
M]<) YAE3.LRLC$K^.<FD"8,D\,7*.<EP;,UCO;O['=7=[LTML2W-PKTNN=HY
MD3Y(I'Q<US:XL;V.Q/YU*I(J8*I59;[=387N\^UWCK<84MH$8MMS7@OE8R2-
MDJR<XE,#7MPLYI:+&BXJ+1+[K_EIKU74=*TWR(T2ANROZLDI*2UI+,KS+T:;
MA6\JZ*\?UV4<1K-V:6A7:V>SG[-/L(II$\6?*29R7N1;TLA=I6STCK[)&YS8
M99(]]H]MS);21H]<3HGJQKL<;E]E*-1J85PM5MGGF[+/&ZHN]5Z%SEV47V91
ML9=L=;LN(Y%8F%LK$>YN"1J>PM7*Y<28G(N1Y[P.QR&S-S[#L&O8YZAL[2$E
MHFL5>)L)X6-UU5G&/_AAVBRL%*J3GD"RBRZJ62,RKKN#Y(9$G93+D>W;,)]1
MYOG]_81O9F63/RV&%DJQLM85^!A58WK)A57.5M(\3G*J*Q*-3'IN0L(-/93D
M5C?2,?EV<,S&:9\7./NID^'B1)&)'B1&M1U7X6M2J/6KEC-#E=XG4O&+5OX!
M=KV<-E2&P_/OX4]/PR\ONLA</,_FS\',_@]XKR_R?RCRA]VNQXSQ>.O8QKC-
MZ&#2VF]->(U]'LQ==<YSW^(Q7#I^;P<U^2IBP8L4E:8L.VAL+]VF/4VHM1^.
M_P"OY>VUYOF?[##;M@QX^=_*UPXL.&.E<.+NDN*<]8:S6[D GLK2C>WZ=Y"2
MM8GIW7'X<OX^8K$[58N)CH^6@KG'PK%15956&;JJERS1[64$B8.4I5,+;4[?
MA:9CFV>IJ+)VW>DL^EAEDM/&7-DAD@8QC7QW#(VJJJL;7.3FVUPM2J(CD?K#
M=RUWE^5Y([3^;NM=59'%-''=>+M<R:.9[W.9) Z1R(B)(YK5QNIB<M%56X++
M3.:M)UIN(VP==<<JO3Z>SU3.:NBZ5!V;+&7=^>5XY52W6V[+UF2?6>;P2-(3
M)%&Q,=G_ /J94RJHK9Y/OAR;3FK?K[3^G[:TREF5R6;+>.;#([G%8JSSW"PO
M=-)X")16)L_E8L3G7>;;H\WU!I7ZCS[/KFZS5V9QWC[B2+$QO-H]$@AMTE8V
M&/PU6J.7;_)PX6MA&L<AOP<XP;)XW_@AY9^<*]P-V_#/S_Y/YH\R&KYO-GX.
M^9%_.'E/F+_OO+D.QXW_ +LW9^RTW+=>_5^[;,=WOBF/Q^^CN/&.=IS?-\UX
M'-<VN*O-_"YQM,7P5IMV_,="^/[Q<OU]XU@\1LI+?F.:KCYSG?#YWG$PTYSX
M/-NK3X25V:UCG9T           WL_P#+*_\ X[?]G\=L_P#QR_\ >W_TPXS_
M /D+_P"S/_J1ZQA]1#YG                            !R_[W!!9;BBV
M42244(UVG3UW)R%R8J")HVRM2JJYQCH1/+ARF3KGP=H^,?5R/-OWJ&/?NP:Y
MJ*K6YG J^PF"9*KQ)543VU0]$_=A>QF\MS7*B.=ELZ)[*XXEHGLT15]I%/,:
M/G"?0X                                                .B/=9M
M7#CF-2%445%4V-:OKIV<A<Y*W;GJLBR*LKG_ +*9G;Q)/&?_ +2F,?7'??NS
MQR/WMV;F(JM9;7*N]A.9>VJ^QB<B>VJ'"?O'R1LW57C7JB.?<6R-]E>>:ZB>
MSA:J^TBGJA'TS/F\                                 % G_E-YCI_]
MPCO#X>N?[XE?!]7IX.@$.Z5X$0                /+QWL"2J?+F4.HFH0B
M] I*J!CD,4JR6&SU#*B1C8QA1/"R)R9SCKCM$SCZN,CYL?>A:YN]217(J(ZQ
MMU3V4HY*IQI5%3VT5.X?1;[L[FNW81HU456WUPB^PM6K1>):*B^TJ*<U!YV/
M0(                                                = ?,DK\+_R
M_P B6\D]MCSWX_[#L>:OS-?@YY;_ -;KXGSY_>WU.OC/K=/".Z^)W7JV\_@7
MFO3'G*_\GB'-8O:YSP/;]@XAXW;>L5S.-.=]$>;I_P _C_.X?;YOPO:/5B/I
MV?-<                            ,!VCK.H;BH-FUK>X[,I5K7'^023<
MBGB'*1DET7C&08N,%/Y-)14BV2<ME.R;!%TBYR4V,9QG!ZET[E6K<CN=.YW'
MSF674>%Z(M%2BHYKFKW'L>C7L7;1S46B\!F].:AS32N=V^H,FDYO,K9^)BTJ
MBU16N:Y.ZQ[5<QR;*M<J53A."MO[FS<[><>DH.S]8R]:RNJ:.<V]>U5R<*VR
M?.4$GK*%JMI8'733SC!U"."E.;'7!"XSV<>'\V^Z/J^.]>F1YEELN757 LZS
M124KL1S8X9FU1.%4<B*NVB<![2RO[UNDWV;%SO+LQBS"B8D@2&6.O=5KI)H7
M45>!%;5."J\*XQ\'/DW^/6B?2;8'T8#&^J5O'\MR3IKKZ&9'UJMWOD><]#;?
M2Q\'/DW^/6B?2;8'T8!ZI6\?RW).FNOH8]:K=[Y'G/0VWTL?!SY-_CUHGTFV
M!]& >J5O'\MR3IKKZ&/6JW>^1YST-M]+'P<^3?X]:)])M@?1@'JE;Q_+<DZ:
MZ^ACUJMWOD><]#;?2Q\'/DW^/6B?2;8'T8!ZI6\?RW).FNOH8]:K=[Y'G/0V
MWTL?!SY-_CUHGTFV!]& >J5O'\MR3IKKZ&/6JW>^1YST-M]+'P<^3?X]:)])
MM@?1@'JE;Q_+<DZ:Z^ACUJMWOD><]#;?2Q\'/DW^/6B?2;8'T8!ZI6\?RW).
MFNOH8]:K=[Y'G/0VWTL?!SY-_CUHGTFV!]& >J5O'\MR3IKKZ&/6JW>^1YST
M-M]+'P<^3?X]:)])M@?1@'JE;Q_+<DZ:Z^ACUJMWOD><]#;?2Q\'/DW^/6B?
M2;8'T8!ZI6\?RW).FNOH8]:K=[Y'G/0VWTL?!SY-_CUHGTFV!]& >J5O'\MR
M3IKKZ&/6JW>^1YST-M]+'P<^3?X]:)])M@?1@'JE;Q_+<DZ:Z^ACUJMWOD><
M]#;?2Q\'/DW^/6B?2;8'T8!ZI6\?RW).FNOH8]:K=[Y'G/0VWTLLL%W1_(^P
M,UGS*ZZ1221D9.,,5U9+V13*\4^7CW!RX2ULL7*)UFYLDSG.#9+G&<XQGP8+
M]TG>.G_>Y)TUU]#"?>KW>+_V>==#;?2R]?!SY-_CUHGTFV!]& >J5O'\MR3I
MKKZ&/6JW>^1YST-M]+'P<^3?X]:)])M@?1@'JE;Q_+<DZ:Z^ACUJMWOD><]#
M;?2Q\'/DW^/6B?2;8'T8!ZI6\?RW).FNOH8]:K=[Y'G/0VWTL?!SY-_CUHGT
MFV!]& >J5O'\MR3IKKZ&/6JW>^1YST-M]+'P<^3?X]:)])M@?1@'JE;Q_+<D
MZ:Z^ACUJMWOD><]#;?2Q\'/DW^/6B?2;8'T8!ZI6\?RW).FNOH8]:K=[Y'G/
M0VWTL?!SY-_CUHGTFV!]& >J5O'\MR3IKKZ&/6JW>^1YST-M]+'P<^3?X]:)
M])M@?1@'JE;Q_+<DZ:Z^ACUJMWOD><]#;?2Q\'/DW^/6B?2;8'T8!ZI6\?RW
M).FNOH8]:K=[Y'G/0VWTL?!SY-_CUHGTFV!]& >J5O'\MR3IKKZ&/6JW>^1Y
MST-M]+'P<^3?X]:)])M@?1@'JE;Q_+<DZ:Z^ACUJMWOD><]#;?2Q\'/DW^/6
MB?2;8'T8!ZI6\?RW).FNOH8]:K=[Y'G/0VWTL?!SY-_CUHGTFV!]& >J5O'\
MMR3IKKZ&/6JW>^1YST-M]+/Z3N<N3&3%P>]Z+*3)L8.8EDOYS%+UQVLE)G6:
M>#FQCZF,F+C.?KX$4^Z5O%JF*]R2GYZZ^AI_&07[U6[ZFRRSFOYJV^EJ=6^%
M?!FK\36$M.OILETVA9F*<;,65)F>/BXF&PJ@\4KU>9JK+KY:JOVY%'#I;)57
M1D4LX31*7L9]/;GMRV6[KH);V:9+S4MRQ&23(U6L9'5'+%$U55<*N1%<]VUZ
MM;X+$2AYJWM[X\QWF316<,*VFG+=ZO9$KL3WR45J2RN1$2J-54:QNQF)WA/5
M:F^8[><7                                 "A3Z^<W?A\'D,=TQU^I
MGRB4ZYZ=?!UQT\/U^G_(!#NE<!$                #1/FGP?K'+2+AI9M.
M8IFS*HS7805F,RQ(1LE$++Y>9K]B:)G0=J,4G9U%&RZ*G;9J+JF\6K@YB9XG
MO@W,Y;O2MH;J.;Q/4=JQ6Q38<3'L5<7-2M2CE:CJJQS5K&KG+A<CE:=EW2;X
M,QW97,MM)#XWIZY>CI(L6%['HF'G8G+5J.5M$>UR4>C6IB:J(IR=/W.7)C!C
M8)>]%F)@V<$,>R7\AC%ZY[.3$QK-3!#9Q]7&#&QC/U\CR\OW2MXM5PWN24_/
M77T-?XSTPGWJMWU-MEG-?S5M]+0_GP<^3?X]:)])M@?1@(>J5O'\MR3IKKZ&
M1]:K=[Y'G/0VWTL?!SY-_CUHGTFV!]& >J5O'\MR3IKKZ&/6JW>^1YST-M]+
M'P<^3?X]:)])M@?1@'JE;Q_+<DZ:Z^ACUJMWOD><]#;?2Q\'/DW^/6B?2;8'
MT8!ZI6\?RW).FNOH8]:K=[Y'G/0VWTL?!SY-_CUHGTFV!]& >J5O'\MR3IKK
MZ&/6JW>^1YST-M]+'P<^3?X]:)])M@?1@'JE;Q_+<DZ:Z^ACUJMWOD><]#;?
M2Q\'/DW^/6B?2;8'T8!ZI6\?RW).FNOH8]:K=[Y'G/0VWTL?!SY-_CUHGTFV
M!]& >J5O'\MR3IKKZ&/6JW>^1YST-M]+'P<^3?X]:)])M@?1@'JE;Q_+<DZ:
MZ^ACUJMWOD><]#;?2Q\'/DW^/6B?2;8'T8!ZI6\?RW).FNOH8]:K=[Y'G/0V
MWTL?!SY-_CUHGTFV!]& >J5O'\MR3IKKZ&/6JW>^1YST-M]+'P<^3?X]:)])
MM@?1@'JE;Q_+<DZ:Z^ACUJMWOD><]#;?2Q\'/DW^/6B?2;8'T8!ZI6\?RW).
MFNOH8]:K=[Y'G/0VWTLLM@[H_D?7(M67?772*K9%Q'-C$:62]G7RI)R+2,0R
M4JVMD$\D(X>%R?[+&<$QG.,9STQF*?=)WCKL\=R3IKKZ&/6KW>>1YST-M]++
MU\'/DW^/6B?2;8'T8"'JE;Q_+<DZ:Z^ACUJMWOD><]#;?2Q\'/DW^/6B?2;8
M'T8!ZI6\?RW).FNOH8]:K=[Y'G/0VWTL?!SY-_CUHGTFV!]& >J5O'\MR3IK
MKZ&/6JW>^1YST-M]+'P<^3?X]:)])M@?1@'JE;Q_+<DZ:Z^ACUJMWOD><]#;
M?2Q\'/DW^/6B?2;8'T8!ZI6\?RW).FNOH8]:K=[Y'G/0VWTL?!SY-_CUHGTF
MV!]& >J5O'\MR3IKKZ&/6JW>^1YST-M]+'P<^3?X]:)])M@?1@'JE;Q_+<DZ
M:Z^ACUJMWOD><]#;?2Q\'/DW^/6B?2;8'T8!ZI6\?RW).FNOH8]:K=[Y'G/0
MVWTL?!SY-_CUHGTFV!]& >J5O'\MR3IKKZ&/6JW>^1YST-M]+'P<^3?X]:)]
M)M@?1@'JE;Q_+<DZ:Z^ACUJMWOD><]#;?2Q\'/DW^/6B?2;8'T8!ZI6\?RW)
M.FNOH8]:K=[Y'G/0VWTL?!SY-_CUHGTFV!]& >J5O'\MR3IKKZ&/6JW>^1YS
MT-M]+'P<^3?X]:)])M@?1@'JE;Q_+<DZ:Z^ACUJMWOD><]#;?2Q\'/DW^/6B
M?2;8'T8!ZI6\?RW).FNOH8]:K=[Y'G/0VWTLR2I]S9NMS.,D[SL_5L/6_&ES
M(/*FO;+).81P;&3ILHV8JU48&54+UQ@YW>,$SGKV3=.SG(97]T?6,EZQN=9E
MED.75\-T"SS24XFLDA@;5>-7[.&B\!89G]ZW2,=F]V39=F4N84\%LR0Q1UXW
M/9-,ZB<2,V\%4X3L[[*VH/9W]F/S,Y_-MYC\U?X23SYYQ\N\\_A3YP\3XO\
M"/\ "'^__&^*\3X_['Q7B?VH>O>S+2?H#V<<R[T=YG!P_E,>+G.>QTISO._E
M:X<.+9AP>">3>TG5/IWVA\ZWT@Y['P?D\.'F^9PUKS7-?DZ5Q8=N+'X1L<.@
MFA                                                       $=Z
MQ_@\_P#XVW/\II,3.X?<)6\!(@E)@
M                           H4^GG-W^SY#'=?[GE$IT\/7]GK];'_/\
M6$.Z5P$0                                         ([VK_ E]_G:
MI?E=!"9O"04D02D0
M                                     ([UC_!Y_P#QMN?Y328F=P^X
M2MX"1!*3
M      !1)]KSBZZ_]7R*/Z?4_P"MX^2[7_+]3H!#NE:!$
M                          ".]J_P)??YVJ7Y700F;PD%)$$I$
M
M              ".]8_P>?\ \;;G^4TF)G</N$K> D02DP
M                                            4*?3SF[_ &?(8[K_
M '/*)3IX.G[/7Z^?^;ZXAW2N B
M       !'>U?X$OO\[5+\KH(3-X2"DB"4B
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M  ^#IG]OD_!UZ=>N/[OU_P#I$.Z5P$0
M            ([VK_ E]_G:I?E=!"9O"04D02D0
M                                 #13O#SG+H%L4IC%PI?JX13!39Q@
MY,,)U3!3XQGH8N#D*;IGP=<8S]8>.?OQN<W<M&C55$=G5JB^RG-W"T7C2J(O
MMHB]P]-?=-:U=Z;U5$54RJX5/87'"E4]Q53VE4X;#Y GTL
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M2^_SM4ORN@A,WA(*2()2(
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M']S?]_F5_P"6O?\ Q)3S_P#>=_<]F'Y^U_\ (C.^(^T)\N0
M                    H4^GG-W^SY#'=?[GE$IT\/7]GK];'_/]80[I7 1
M                                         CO:O\"7W^=JE^5T$)F\
M)!21!*1
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MW^97_EKW_P 24\__ 'G?W/9A^?M?_(C.^(^T)\N0
M             HD^OG%UX/L?(H_IGKGZOCY+M8Z=>F.F.GU@(=TK0(@
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MU\/D,=C..GU,8<2G3/7Z_7.<_P#0!#NE<!$
M                ".]J_P "7W^=JE^5T$)F\)!21!*1
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MBH?51KFO:CFJBM5*HJ<"IQH?D0)@
M              .AG=YZSGYC:+C9AFB[>K5&)E6!)%1,Q4)&>F&N&!(QJ8W9
MPOEK'N55US%[7BLX3*;IXPH]P?<>W?YUFF\1^\!T3X].Y9;31I*J4;+<3LYM
M(F*OPL$;WR2*E<'Y-'4YQ#R?][#6656&BF:-;(U^=W\\3UC1=L<$3L:R.XL4
MC6L8BTQ>&J? 4[4#ZR'SI                                 "A3_RD
M[\&?\!C_  ^#IG]OD_!UZ=>N/[OU_P#I$.Z5P$0
M                    ([VK_ E]_G:I?E=!"9O"04D02D0
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MO!X>N/[XE?#]3IX>H$.Z5X$0
M     ([VK_ E]_G:I?E=!"9O"04D02D0
M                                                     ([UC_!Y
M_P#QMN?Y328F=P^X2MX"1!*3
M                      !0)]/.;SZO7R".ZYZ^#IY1*]/!T^J!#NE>!$
M                                       ".]J_P)??YVJ7Y700F;PD
M%)$$I$
M                           ".]8_P>?_ ,;;G^4TF)G</N$K> D02DP
M                                                         4*?
M7SF[\/@\ACNF.OU,^42G7/3KX.N.GA^OT_Y (=TK@(@
M                        1WM7^!+[_.U2_*Z"$S>$@I(@E(@
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M:YJ\3FN1%1?85#HUE?6696L=_ETT5Q8RMQ,DC>U['MXVO:JM<GLHJH704"Z
M                                "A3Z><W?[/D,=U_N>42G3P]?V>OU
ML?\ /]80[I7 1                                          CO:O\
M"7W^=JE^5T$)F\)!21!*1
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M'],]<_5\?)=K'3KTQTQT^L!#NE:!$
M          ".]J_P)??YVJ7Y700F;PD%)$$I$
M                                Y%]]7_,\C/\ 7+2O]!7(=_\ NW?O
M"?\ LZ;\>$\D_?0_=!%^V;;]%<'DX'O ^4@ 'U007=+)-VR*KAPL<J:*""9U
MEEE#YZ%3223P8ZAS9\&,8QG.1!SFL:KWJB,1-JKL1/;4G9&^5Z1QHKI'+1$1
M*JJ\2(FU5/ZX;.&:ZC9V@LU<HF["S=PD=!=(^.F>RHDJ4JA#=,_4SC&1!CV2
M-1\:HYB\"HM47W4(R1R0O6*5KFR)PHJ*BI[:+M0^(F*8
M                         '3'NB?Y]&M/XN[(_(2='&-__P"["]_/6_Z=
MAZ5^Z3^_'+?\O>?^+*>PH?/<^O@
M4*>,><W>>OA\ACL9QT^IC#B4Z9Z_7ZYSG_H AW2N B
M                       !'>U?X$OO\[5+\KH(3-X2"DB"4B
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MZZDQ7UVC7R.EK%&R.-,4M&O>Y51(VKM.;'-KC:QXI<@K-J.(L3NT0+2.A)^
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M .["]_/6_P"G8>E?ND_OQRW_ "]Y_P"+*>PH?/<^O@
M               4*?\ E)WX,_X#'^'P=,_M\GX.O3KUQ_=^O_TB'=*X"(
M                                       $=[5_@2^_SM4ORN@A,WA(
M*2()2(
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MG\7=D?D).CC&_P#_ '87OYZW_3L/2OW2?WXY;_E[S_Q93V%#Y[GU\
M                          "A3_RD[SU+_@,?X/!VL?M\GX<^#KV<]?!_
MS@0[I7 1                                          CO:O\  E]_
MG:I?E=!"9O"04D02D0
M            #D=WU":BG#IB8B9SE1W%25%C$(8Q4D\PUN1PHIG&,X3)E54I
M>N>F.T;&/JYP.^_=O<B;PWHJHBKETR)[/AQ+L]Q%7W#R7]\]KG;GXU:BJB9Q
M;*OL)S=PE5XDJJ)[:HAY-1[R/E$
M               '33NATU%.<VN3$3.<J-:V.HL8A#&*DGFD3*.%%,XQG"9,
MJJE+USTQVC8Q]7.!Q??^Y$W8WB*J(JS6Z)[/Y9B[/<15]P]+_=(:YV_#+E:B
MJB6UXJ^PGBTB57B2JHGMJB'L''SX/KT
M    %"GT\YN_J]KR&.Z_4Z=/*)3L]/K]>O7J!#NE<!$
M                        ".]J_P "7W^=JE^5T$)F\)!21!*1
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MS;Q*Y'.9&YR-<]\CFL5\BL;1&(QB45SG]31PX]1@
M            !0I]?.3O'UO(8_IX?#URO)]?L>O@^I]7IX?^;P"'=*X"(
M                                      $=[5_@2^_SM4ORN@A,WA(*
M2()2(
M                          $=ZQ_@\_\ XVW/\II,3.X?<)6\!(@E)@
M                                                        H4_\
MI._LL_X#'_8^'IC]OD_LOV.IO_<!#NE<!$
M               ".]J_P)??YVJ7Y700F;PD%)$$I$
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M>'IG]OD_L?V.I?\ W@0[I7 1
M      CO:O\  E]_G:I?E=!"9O"04D02D0
M                       ".]K_ , 9[_\ *_\ 34<)F?"!(@E
M                                                  1W_P#O8_\
M#O\ _:43?R/=!(@E                             4*?^4W?AQ_@,=X.
MGA_PB4\.<]/#C/UO"!#NE<!$
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MT"W+]/@>BV7_ ,^;WV\@>JWN_P#+,YZ6V^B#]9QYZ?))Q$] MR_3X'HME_\
M/F]]O('JM[O_ "S.>EMOH@_6<>>GR2<1/0+<OT^!Z+9?_/F]]O('JM[O_+,Y
MZ6V^B#]9QYZ?))Q$] MR_3X'HME_\^;WV\@>JWN_\LSGI;;Z(/UG'GI\DG$3
MT"W+]/@>BV7_ ,^;WV\@>JWN_P#+,YZ6V^B#]9QYZ?))Q$] MR_3X'HME_\
M/F]]O('JM[O_ "S.>EMOH@_6<>>GR2<1/0+<OT^!Z+9?_/F]]O('JM[O_+,Y
MZ6V^B#]9QYZ?))Q$] MR_3X'HME_\^;WV\@>JWN_\LSGI;;Z(/UG'GI\DG$3
MT"W+]/@>BV7_ ,^;WV\@>JWN_P#+,YZ6V^B#]9QYZ?))Q$] MR_3X'HME_\
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MGY\D/#[T W1_O !V Z.\IS/I(/HX]8O6WDN5=%<?21^M"\_/DAX?>@&Z/]X
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MDAX?>@&Z/]X .P'1WE.9])!]''K%ZV\ERKHKCZ2/UH7GY\D/#[T W1_O !V
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M]50\]'I,   *!/IYS>?5Z^01W7/7P=/*)7IX.GU0(=TKP(@
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M,;NZE<U$1SLSF55XUYN!-ON(B'GU&Q'HD
M                     /<)_P ,-(OE^'.](M9RHHPC^2<DY9-CYQDC9:1U
MEKDKTR6<X[9<./(4LY+U[.#%ZXQC)C9SHFJD3QV->ZL7_P 2GA/[TT<;=:6$
MJ(B2.RQJ*O&B3S4]ZJGI2&L'F,     QB[/'4=3+=(,ECMGC&L3[QHX3SC"B
M#IM%.UD%D\YQG&#I*DP;'_+@5[5K7W4;'I5JR-14]A50M[Q[H[25[%H]L;E1
M>)4:M#_(C444644554.JJJ<RBJJAC'444.;)CJ*'-G)CG.;.<YSG/7.1])D1
M$2B<!\NU556J[54_ $
M     /VFHHBHFJDH=)5(Y5$E4S&(HFH0V#$43.7.#$.0V,9QG&>N,@J(J47@
M(HJHM4V*A_KM49TY?4JGO7BZKEV\JU?=.G*Q\J+.'+B):++KJG-U,=554^3&
MSGPYSD?-J[:UEU*QJ4:DCD1/815/J'9N<^SB>]:N6-JJO&JM0RD6Y<@ 4*?7
MSF[^IT\ACOV.O7RB4Z]?^UT_8Z^#]CZX$.Z5P$0                /#/W^
M[EROW@TTDNX7629:DUFV9IJJJ*)M&QVLJ\,W;$.;)4$#.W:JN2%Z%RHJ<W3M
M&SG-]!_9^Z6LOPSBF*Q2
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M,]CI\'KWE1I;E.SLT(^EI&?TL_5?Q=5<M'Y6:4/-'5<N<IOWJ6?')XQG'5/
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M2J9TE4CF3524*8BB:A#9*=-0AL8,0Y#8SC.,XZXR-L145*IP&GJBHM%V*A^
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M=CJ=WHTFHJDWG(Q<C4BZ7B%$^BQ,E,G@ITU4E%4%D5E)F/1Z5382N:K5HIK
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M+2/7,:+GLF06;LH<JHL3;1L*)AB;1<,[HTQ/=6M4G397PO)(-P/8
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M^N-YYA#@WW SV U*TWG,1?*?E',L-6N;)1JDK9EH38>]I;MQ$WLJ:KE)2LT
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M%)UK?;DI S#M0TBD\+(MXM4JA"MDD>PU,FC4AV(J514J22<*<-:%1WW_ /\
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M_P!'/6OY4;%&Y:9_TU?SCOXD/H9]V3]W#_VE-^CA//\ #83T.
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M;/<+A^GM/O?:R/L;-9+%J-ME6&-5MVM1$:D"X:Q(B-:B)'A1$:E.!"(Q6,P
M            'MW_ .&!_FD\@/Z1BO\ )G1!HNJO\9'^;_\ B4\+?>H^V&7?
MLU/T\IZ7QJYY@     ,/V'_ "\_Q/LW^A7HN;+_&1?G6_C(6M_\ X&;\T_\
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M?BH9@+8N@ *%/_*3O[+/^ Q_V/AZ8_;Y/[+]CJ;_ -P$.Z5P$0
M      /#!W^7]H58_P#57K'_ $8]%]!_9^Z6LOPSBT*Q2        #*Z3>KO
MK2SQEVUQ<K50+G"^6^9K=2;#+U6SQ/G*/=Q,CYLGX)XPE6'E\4_7;+>*5)XU
MNLHF;J0YL9@J(J47@(HJIM3A+]2=R[?UI:92\ZXVKLC7]UG$'S::N%)O-GJE
MIF&TH]1DI-O*6""E&$M((2,BV3<+D56.599,ISXR8N,X*U%2BHE BJFU.$ON
MIN16^M#YEOS+[DV7JQ.>PGB;;T2YSU::2QD2Y*W6D6<4^;-'CEL3.<)*J$,J
ME@V<$-C&<]2M:[X2(H153@4C.PV.PVZ<E+-;)V9L]DG'BLA-6&PRCZ:G)=^O
MGM+OI26DEW+^0>+&\)U55#G-GZN1&E-B< +W)[)V+-TJM:VF;]=9?75+=R3^
MG4&3M,Z_I53?3+IT^F'E:JSM^K!03N5?/EUG*C5!(ZZJQSGR8QS9S"B5KW15
M:4[@HFR=BZMEW-AUE?KKKJ?>Q3R">3E$M,Y49=W!R)D32$,YDJ^_CWJ\4_,V
M3RLW,?**N4R]HN>SCH5$7AVA%5. N.L=O[5TK8<VW4.Q[MK.RF;'9*S=&LTO
M6)%RQ4,4ZC!XXB';4[QBH<N,F15[:1LXQG)>N, J([8J50(JIM0ME^V+?MJ6
M=_==F76U; M\IXO$A9KG/REDG79$2]ANBM)R[IV\,W;)_8))]OQ:1,8*3&"X
MQ@$1$2B< 557:O"?J\;)V+LY]$2>R;]==A24!7V%3@9"\6F=MCZ$JT4L[<1=
M:B'<\_?KQM?C5WZYV[-$Q&R)UU,D)C)S9R1$3@"JJ\)^[OLW9&S9MG9=D;!N
M^P;''1K"%C[!=[7/6R;8P\6=92,B6<K//W[]K&QRCA0R"!%"I(F.;)"XSG/4
MB(G!L"JJ\)F<GR4Y%S4G;IJ9W[NN6F-@50U#ODM)[4O3^3NU&,BZ;&IEN?NI
MU5U9*H9N]63S'/#K,\D6.7Q?0YL9AA;Q(1Q.XU/BTY%\@V#W7<FQWMN1E(ZA
MBG\%J>0:;/NS=[J^#E(A* DX;7;M&<(O2HJ1@42,EV\:9LBLT(5$Y<IXP41P
MMXDVC$O&NPB5^_?2CYY)R;QW(R4B[</Y"0?N%G;Y^^=K'<.WCQVX.HNZ=NEU
M#'44.8QSG-G.<YSG.1$@94XV3L5W0F&JW=^NKK6$78#VR,UPXM,ZO0HZTJ-G
MC)2RL*>H_-7FE@.SD7"67B;<KG*2ZA<G[)S8S"B5KW15:4[A(==Y2<DZAKQW
MJ6J[\W!7-8OD'+5S0X78EKC:J9F^R;+]DG#-)1)DW8R/;-Y2@F0B3C!LX4*;
MKGK!6M5:JB5(XEI2JT/GJSD]R-T?$R<!IW>NV=804RJJYDX6C7ZS5J)=/5DD
MT%)(\=%239F25R@B4F'92%<E(7&,'QC *UKOA(BA'*G IC-3W9N6AW"7V'1M
MM[.IE_L&9 T]>:G?;57;A-FEG6'TKF7LT/*LYJ2S)/<86<>.7/XY7';/U-X1
M%6M5**B4(55%JG"1NNNNZ76=.EE7+ERJHNX<+J'67776/E159953)E%555#9
M,8QLYR;.>N?"(D#X@         ZH_P#DC_\ U4?]DD4O[_\ Z/\ B5/[K_J_
MX&Q/_$TZ'OD-R6U1R,Q%.G>L+QJF'UKB?0;JG:0U]IL_;I=Q R:Y"G1:*2]>
MGF[IAXPQ#.O$.\$+G#8^1M>E[B-UJ^VK^5:]74XT5$V^XJ;?<XSWC]UW/\OG
MTO=Z:QHF:P7;IL"KM=%(R-J/:G"N%[%:^GP:LJOA(>9,;0>H@
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MD.:3Y/F3%9>V\BL<GM<"IQM<E'-5-BM5%38I$PR)BP
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MRF\G5SB\MW(K,/=0MID5'5[AY_!<%$
M                  /1I[!VZO@5]O\ !2P?AG[1WMB_@)Y"O^$WYO\ \!OS
M3>.\T>1^5?P/_P#U+XKKXWS?]GU[7[0+?G$Y_P!BE"M@7FO9K4];>P]<4#;5
M0F:!L^F5F_TFPMLM)JJVZ&83T'(H_5)Y1'R*#AOE9!3&#I*XQA1%0N#D,4^,
M9Q;1RR0O22)RMD3@5%HIE\MS/,<GO&9CE4\MO?1K5LD;E8Y/:5JHM%X%3@5-
MBU0YFR?<9=U=+/W,BZXIL$G#H^#JIQFW-^0K IBD*3&&T7#;481C,G9)CJ5%
M$A<YZYSCKG.<Y5,^S9J429:?T6+_ !M.H1;^=[,,:1,S=RM3^=;VCE]USH%<
MONJI0_ @[J;W5_TX<C_I?$?K_-_EOZK.25.W[>WUM^JV7T<? @[J;W5_TX<C
M_I?#Z_S?Y;^JSDCM^WM];?JME]''P(.ZF]U?].'(_P"E\/K_ #?Y;^JSDCM^
MWM];?JME]''P(.ZF]U?].'(_Z7P^O\W^6_JLY([?M[?6WZK9?1Q\"#NIO=7_
M $X<C_I?#Z_S?Y;^JSDCM^WM];?JME]''P(.ZF]U?].'(_Z7P^O\W^6_JLY(
M[?M[?6WZK9?1Q\"#NIO=7_3AR/\ I?#Z_P W^6_JLY([?M[?6WZK9?1Q\"#N
MIO=7_3AR/^E\/K_-_EOZK.2.W[>WUM^JV7T<? @[J;W5_P!.'(_Z7P^O\W^6
M_JLY([?M[?6WZK9?1Q\"#NIO=7_3AR/^E\/K_-_EOZK.2.W[>WUM^JV7T<?
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MU]-M:8J5VTJ:8_ 1[IOW4OTZ<D_IB&T=L.\;K']7M?F34^Q3=EU9^L7?SX^
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M=IMJ-<-G   "A3Z^<G>?K>0Q_3P>'KA>3Z_9=/#]7ZG7P?\ /X1#NE<!$
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MEY _2L'/2\?X$'-,XA\$_NR/=G_3+R!^E8.>EX_P(.:9Q#X)_=D>[/\ IEY
M_2L'/2\?X$'-,XA\$_NR/=G_ $R\@?I6#GI>/\"#FF<0^"?W9'NS_IEY _2L
M'/2\?X$'-,XB0M;]T_W>>J+%'VNG<8ZAF<BG:;Z.<6Z>OFR&K1ZCTRW=HQ6Q
MK9:XDKALH7"B1_$=I)4N%"9*?&#8@LLBI15(I&Q.!#H>*9.
M            1WM?^ ,]_P#E?^FHX3,^$"1!*
M                                    CO\ _>Q_X=__ +2B;^1[H)$$
MH                            "A3Z><W?U>UY#'=?J=.GE$IV>GU^O7K
MU AW2N B                                         !'>U?X$OO\
M.U2_*Z"$S>$@I(@E(@
M       $=[7_ ( SW_Y7_IJ.$S/A D02@
M                               ([_\ WL?^'?\ ^THF_D>Z"1!*
M                         H4_\I.\="_X#'^'P=K/[?)^#/AZ]G'3P?\
M.!#NE<!$                                         ".]J_P)??YV
MJ7Y700F;PD%)$$I$                            -8-P\UN(W']\M$[E
MY(Z:U[/-S%*O6)^^U].VI=K!<X,>I-GKFR83Q@Y<Y/Y+V<8-CKGPX%U#8WEP
ME8(GN;QHBT]_@-JR;0^L=0QI-DF67MS;KP/9$_F^D5$9_6(&^+CW;'OA:B^Z
M,K]Z1<?4^9_(O-@['MYO4UY[S>4/BX]VQ[X6HONC*_>D/J?,_D7CL>WF]37G
MO-Y0^+CW;'OA:B^Z,K]Z0^I\S^1>.Q[>;U->>\WE#XN/=L>^%J+[HROWI#ZG
MS/Y%X['MYO4UY[S>4/BX]VQ[X6HONC*_>D/J?,_D7CL>WF]37GO-Y0^+CW;'
MOA:B^Z,K]Z0^I\S^1>.Q[>;U->>\WE#XN/=L>^%J+[HROWI#ZGS/Y%X['MYO
M4UY[S>4/BX]VQ[X6HONC*_>D/J?,_D7CL>WF]37GO-Y0^+CW;'OA:B^Z,K]Z
M0^I\S^1>.Q[>;U->>\WE#XN/=L>^%J+[HROWI#ZGS/Y%X['MYO4UY[S>4/BX
M]VQ[X6HONC*_>D/J?,_D7CL>WF]37GO-Y0^+CW;'OA:B^Z,K]Z0^I\S^1>.Q
M[>;U->>\WE&$;&[V#NYI:F3,?'<N=3.WCCS?XENE(RF5%/%2K%93LXS%8Q]@
MDF8V?#]3 F;E&9HM5A?[Q#L>WF]37GQ6\HS?XN/=L>^%J+[HROWI$OU/F?R+
MR/8]O-ZFO/>;RA\7'NV/?"U%]T97[TA]3YG\B\=CV\WJ:\]YO*'Q<>[8]\+4
M7W1E?O2'U/F?R+QV/;S>IKSWF\H?%Q[MCWPM1?=&5^](?4^9_(O'8]O-ZFO/
M>;RA\7'NV/?"U%]T97[TA]3YG\B\=CV\WJ:\]YO*'Q<>[8]\+47W1E?O2'U/
MF?R+QV/;S>IKSWF\H?%Q[MCWPM1?=&5^](?4^9_(O'8]O-ZFO/>;RA\7'NV/
M?"U%]T97[TA]3YG\B\=CV\WJ:\]YO*'Q<>[8]\+47W1E?O2'U/F?R+QV/;S>
MIKSWF\H?%Q[MCWPM1?=&5^](?4^9_(O'8]O-ZFO/>;RA\7'NV/?"U%]T97[T
MA]3YG\B\=CV\WJ:\]YO*'Q<>[8]\+47W1E?O2'U/F?R+QV/;S>IKSWF\H_I>
M]O[MDQBEQS"U!C)LX+C)I.3(7KG/3':.>**4N/V<YSC& ^I\S^1?[Q!=S^\U
M$K]2WGQ6\HV]U1OS1V]XU:8TKN#6>V(UL1,[QSKR[URWEC\*YR4A)-."D7RT
M8MDY<ERFX*F?!L9QG&,XS@6<UO/;KAG8YB^RBI_&:=F^GL^R"5(<\LKJSE7@
M2:)\=?Z.-J8O;2J$M"B8<           "VS$S#UZ+?SD_*QL'"Q;91[)S$P^
M:QD7',T<=I9V_D'JJ#1FV2+X3**'*4N/JY$\44LTB10M<^5RT1K4555>)$3:
MJ^T4Y98H(W33N:R%J55SE1$1.-578B>RIHK:^]0[N>ERJL+.<S-!'D&YC$7)
M WR,MS9%0F"^,15D*F:;CTW"1C=DZ>5<'(?!BFQ@Q38QMUON]UO=1\[%E=Y@
M7^=&K%]Y^%?=H:;<[R=!VDJPS9M98T_FR(]/?9B2OL5,:^+[W9_OD:?^Z4M]
MZ!<=FNN^J[GWD[Y;=J6[WK:U]]W)'Q?>[/\ ?(T_]TI;[T!V:Z[ZKN?>3OCM
M2W>];6OONY(^+[W9_OD:?^Z4M]Z [-==]5W/O)WQVI;O>MK7WW<D?%][L_WR
M-/\ W2EOO0'9KKOJNY]Y.^.U+=[UM:^^[DCXOO=G^^1I_P"Z4M]Z [-==]5W
M/O)WQVI;O>MK7WW<D?%][L_WR-/_ '2EOO0'9KKOJNY]Y.^.U+=[UM:^^[DC
MXOO=G^^1I_[I2WWH#LUUWU7<^\G?':EN]ZVM??=R1\7WNS_?(T_]TI;[T!V:
MZ[ZKN?>3OCM2W>];6OONY(^+[W9_OD:?^Z4M]Z [-==]5W/O)WQVI;O>MK7W
MW<D?%][L_P!\C3_W2EOO0'9KKOJNY]Y.^.U+=[UM:^^[DCXOO=G^^1I_[I2W
MWH#LUUWU7<^\G?':EN]ZVM??=R1\7WNS_?(T_P#=*6^] =FNN^J[GWD[X[4M
MWO6UK[[N281\6SNW/SD>=O:_U'YN_ CS=Y7YQE?$^6^?O*?)NOFGKXSQ'V7U
M/J"/9KKO#3ZLN:UXD[X[4MWO6UK[[N29O\7WNS_?(T_]TI;[T"'9KKOJNY]Y
M.^.U+=[UM:^^[DCXOO=G^^1I_P"Z4M]Z [-==]5W/O)WQVI;O>MK7WW<D?%]
M[L_WR-/_ '2EOO0'9KKOJNY]Y.^.U+=[UM:^^[DCXOO=G^^1I_[I2WWH#LUU
MWU7<^\G?':EN]ZVM??=R1\7WNS_?(T_]TI;[T!V:Z[ZKN?>3OCM2W>];6OON
MY(^+[W9_OD:?^Z4M]Z [-==]5W/O)WQVI;O>MK7WW<D?%][L_P!\C3_W2EOO
M0'9KKOJNY]Y.^.U+=[UM:^^[DCXOO=G^^1I_[I2WWH#LUUWU7<^\G?':EN]Z
MVM??=R1\7WNS_?(T_P#=*6^] =FNN^J[GWD[X[4MWO6UK[[N2/B^]V?[Y&G_
M +I2WWH#LUUWU7<^\G?':EN]ZVM??=R1\7WNS_?(T_\ =*6^] =FNN^J[GWD
M[X[4MWO6UK[[N2/B^]V?[Y&G_NE+?>@.S77?5=S[R=\=J6[WK:U]]W),BJW>
MI]W+<99"$A.9>A2R#DQ2-RSEX851JLH<V")HIR5I\S1IG"IS8P1/QW;/G/3&
M,Y%"XW>ZWM8UEERN\P)_-C5Z^\S$ONT+BVWDZ"NY4AAS:RYQ>#%(C$]]^%*^
MQ4WMAYF'L,6PG("5C9R%E&R;V,F(=\UDXN19K8[2+MA(,E5VCQLJ7PE43.8I
ML?4R-0EBEAD6*9KF2M6BM<BHJ+Q*B[47VS<XI8IXVS0.:^%R51S5145.-%38
MJ>RA<A(5     "A3_P I._#G_ 8_P>#IC]OD_#TZ]>N?[GUO^@0[I7 1
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M7ZJ*Z*I,IJHK)*5XQ%$E"&R4Q38SC.,],AC?QK[XPMXD-0-G]U=QYF93\/\
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M>JJ]5JJKW3E=U=7-]<R7EX]TMW*]7O>Y55SG.6JN55VJJKM4OH@6X
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MM>%:$A76>H[W>3F**ZW21UOE[7<$<$:JCI$1>!SUKMX4<LJ<"I3MP.5'9@
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M&$>P9MB)MVC)DU1(FDDF4I$TRX*7&,8Q@4.$J\!7@
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MZ'U*OB.YS2>7Q?V=S)?W#UXWLF1K:I[#95:B\2<&TZV#$G(0
M                                    Y8]W2F:D]YAWNFKV&<9KSRQ\
M9]L(($P5%%G8]@:ZF;+:%R(E)G*B\P[LB>5E,G\)FA<X+U.893,_#RNSE7X5
M'M]Q%HGO4_"=5WE*E]NPT=FLG^);%>VZKW59#,UC$KQ-1BT3_F]@[DC '!@
M   #3WO";<^HG!'F-;(I5PWEH?C/NM2)=M3X378RSK7L^QBY!,^?J98/W2:W
M@\/1/P>$;-HNV9=ZNRRWD1%C=?P51>ZB2-54]U$5#5=<W3[+1F:W,:JDK,ON
M,*IPHY8G(B^XJHIJIW9U,84/N_N'\)&II)-WVA->W-0J/_4R_P!C0B&PI53/
M[6G^VK2EH6.IX,_MAL^$W_6SL6N[I]YK+,Y7U5R7DC/<B=S:?@8AAMW5FRQT
M+E,,:(C76,4FSCE;SJ_A>M?9-XQJ9N8
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M*3-KW*=011*H
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MG[1N?TSR31'V+RC]EVOZ",VO&NFS@
M               :H<\_YC7,[^B?R*_D@N V+2'VMRO]HVWZ9AK&M_L7F_[+
MNOT$A)'==_V=/"K^C?JO\EF L-?_ &VS7_/3?CJ3[N?L'E'[/A_$0WQ&H&Z
M 4*?7SF[\'@\ACNF>GU<^42G7'7IX>F.G@^MU_Y0(=TK@(@
M   </.&/\]CO4O\ 7UKK\F+**TGP&>T4F?#=[9T[%$J@
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M%BFBQAIES '5A%'\*PPDT4\E450QE'H113&,'-(O"7\+59$UKJU1.Z3H!5
M           #EOP>_M>N]C_BAPP_D5C1E+__ $:T_I2?C*=3UY^YW2/Y[,O_
M "5.X8P!P@     T.[T3^SIYJ_T;]J?DL_&WZ ^VV5?YZ'\=#2]XWV#S?]GS
M?B*1OP,_F-<,?Z)_'7^2"GB_U?\ :W-/VC<_IGDFB/L7E'[+M?T$9M>-=-G
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M]$ZR_=7HO\SF/Z>$ZSC$G(P
M           Y;\'O[7KO8_XH<,/Y%8T92_\ ]&M/Z4GXRG4]>?N=TC^>S+_R
M5.X8P!P@     T.[T3^SIYJ_T;]J?DL_&WZ ^VV5?YZ'\=#2]XWV#S?]GS?B
M*1OP,_F-<,?Z)_'7^2"GB_U?]K<T_:-S^F>2:(^Q>4?LNU_01FUXUTV<
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M3614*8ARE.7.,0*N-%9C;M2E31C2_.:P7SA!:N2-OIT)%[6J4/XAUKN$5?\
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M^(I&_ S^8UPQ_HG\=?Y(*>+_ %?]K<T_:-S^F>2:(^Q>4?LNU_01FUXUTV<
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M$9E*<M$C!J.7B&%D2(TIMC!L>-3-B*JFWC+=EO(U8T7X&%N+^DU-GX:>\6:
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M\D%P&Q:0^UN5_M&V_3,-8UO]B\W_ &7=?H)"2.Z[_LZ>%7]&_5?Y+,!8:_\
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MDT[@(N/<2I\.%CGZKF4SVS9-]7.<A55X21L<;%56-:BKQ(B$D@3@
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M>M=<J%RG"SJDF[:779W(NSW*M1,= 0[E=M&1<6K!OBLF+$O[>F=PGXUQ)MX
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M^##R;A]DZG816PK!.-F;^:PVPJFBW57PS/V5552GP="*514&P[^BH
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M2,ZP8/H]T^8/63.4<JII*H+K(J)EP8ASES@V;1R(CE1."I<)M1%7A)$$"(
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MY:Y*M:_#1:+38M/=_CH8[KCG'BV:FT79'&D-R6[:^U=30&T)C66L:I!.'<%
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M8K:$S+AKW(E'(UW JIL7VMM=J;4JB5-LA K@
M  <M^#W]KUWL?\4.&'\BL:,I?_Z-:?TI/QE.IZ\_<[I'\]F7_DJ=PQ@#A
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M[+M?T$9M>-=-G
MU0YY_P QKF=_1/Y%?R07 ;%I#[6Y7^T;;],PUC6_V+S?]EW7Z"0DCNN_[.GA
M5_1OU7^2S 6&O_MMFO\ GIOQU)]W/V#RC]GP_B(;XC4#=  *%/KYR=^#P>0Q
M_0W3PYSX^3ZXZ_7[/_LZ@0[I7 1                 X><,?Y['>I?Z^M=?
MDQ916D^ SVBDSX;O;.G8HE4
M           /*K_Z@;_Q,_V>Q>?]O[A;?WWNG5#AS_:@=\?_ !OX??R7;!&5
MO/\ 2K+^C)^,AZ)UE^ZO1?YG,?T\)UG&).1@
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MNOR8LHK2? 9[129\-WMG3L42J
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M<M&N%>A(*WAXT$=RY^!SF4C?P+6NVBKP4]@Z#"!=@
M  <M^#W]KUWL?\4.&'\BL:,I?_Z-:?TI/QE.IZ\_<[I'\]F7_DJ=PQ@#A
M  !H=WHG]G3S5_HW[4_)9^-OT!]MLJ_ST/XZ&E[QOL'F_P"SYOQ%(WX&?S&N
M&/\ 1/XZ_P D%/%_J_[6YI^T;G],\DT1]B\H_9=K^@C-KQKILX
M                                    &J'//^8US._HG\BOY(+@-BTA
M]K<K_:-M^F8:QK?[%YO^R[K]!(21W7?]G3PJ_HWZK_)9@+#7_P!MLU_STWXZ
MD^[G[!Y1^SX?Q$-\1J!N@ %"GT\YN_V?(8[K_<\HE.GAZ_L]?K8_Y_K"'=*X
M"(                '#SAC_ #V.]2_U]:Z_)BRBM)\!GM%)GPW>V=.Q1*H
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M[6YI^T;G],\DT1]B\H_9=K^@C-KQKILX
M                  &J'//^8US._HG\BOY(+@-BTA]K<K_:-M^F8:QK?[%Y
MO^R[K]!(21W7?]G3PJ_HWZK_ "68"PU_]MLU_P ]-^.I/NY^P>4?L^'\1#?$
M:@;H !0IYSYR=XZ_8X8Q^<8\'7KE>3ZYZ?5\.,8_Y (=TK@(@
M     </.&/\ /8[U+_7UKK\F+**TGP&>T4F?#=[9T[%$J@
M                                 !Y5?_4#?^)G^SV+S_M_<+;^^]TZ
MD<<EOP%[X7O1M>R9L>7;0J/%_<-8.JGANK(5NLT/%?FEVJ.5E,K-8RPWPK)1
M7'@,HCC.<$[79&5N/RF36DB<#%>U?;5:I^!*GHO4;?']S.E,QB_L[6:^MW]V
MCWRXVHO$KF18D3B7NTJ=;QB3D(
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ME''[L*<RY/<5BHOLF]PU$W8
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M38G"KFO7^4RO;\<H.T
M     <0^<TPKS\Y4:9[L#53DTS38&WU_=O..U1:SA2(INM*2\;R<5K&2>,NV
MB6PVUVND;")_LFLBK%FSUQAUXCJ^DHDT=IZZU]F"8;I\3H+!BTJ^61%1941?
MY+$1=O=:DG_+7C&MYUUOJ2TW<98N.T9*VXS%[:X8XHU16PJJ?RWJJ;/Y+EC_
M .;#Z04446R*3=NDD@W02310013*DBBBD7!$DDDB8*1-),A<8*7&,8QC'3 X
M:JJY5<Y:JIW9$1J(UJ4:A]1 B !0I]?.;OP>#R&.Z9Z?5SY1*=<=>GAZ8Z>#
MZW7_ )0(=TK@(@                </^\>AYSBIR8T9WC]9C)&1U\QBDN/7
M*^.AFJ[EPAK&Q2_E55O*K5J4QG6("=<EPID^2^,=-(QMC/95SDE>.CV+$O#P
MH4G^"Y']S@4Z/5RQP-P@(6U5:8CK!6[%&,IF"G(ETD^C):*D6Y'3%^Q=H&.B
MX:NFZI3D,7.<9QD45146B\)51:[4X"]"
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MI&X@  !0I]/.;O\ 9\ACNO\ <\HE.G@Z?L]?KY_YOKB'=*X"(
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M#X7?=T^Y5QO^:NK?: >G^MNM;[IG]\=G.@^J,OZ%G>'PN^[I]RKC?\U=6^T
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MQ@2JJKPDR(B<!DX@
M
M                "A3_ ,I._#G_  &/\'@Z8_;Y/P].O7KG^Y];_H$.Z5P$
M0
M
M
M         I2?X:X_[G_!6G_5_P"__P"]>_\ >?\ ]G_['_\ -VP!5
M
&    #__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>tm2110724d1-fc_prime4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2110724d1-fc_prime4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@"+ /> P$1  (1 0,1 ?_$ 04  0 " @,! 0$!
M       '"08(! 4* P(+ 0$!  $% 0$!              $" P0&!P4("1
M  8" 0$#! @.#P4$" (+  (#! 4& 0<("1$2$Q066!DAU!75UA=7ES$BE%65
MI;56EG>GUQB8TB.S-G:V-[?G.&AX.0H:08>H67E1,B0T,W2T)8;'2+AA0L9'
MB'%2=6)31#4G$0 " 0(# P0+" D.# ,'!0$  0(1 Q($!2$Q!D%1$P=A<=$B
M,M*3%%47&(&1H9)3TY05L4)2(U2D-E8(\,'A8G*B,W.SU.0U=3>RPC1TA+3$
M9:461F:#A7;Q@B1%M<4X0T1D=PEC_]H # ,!  (1 Q$ /P#W\
M
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M9:Y._H>:M]+EKDZ8\*>&=N;247.W*E7%)2C*$J1;<5LJ.^G'@
M
M
M                  #5/F[G..,&SNS.<>Q3,>Q['L9V#4\9Q_\ NSC(^;_T
MN6U^CSQ#3_\ @_\ U+)G<?T;DGUT:+7_ /E_ZCFCS[C\2S]50
M                                      "UKIC?_KN_W:__ *?#](O_
M //C_J[_ ,J_^XGPY^F;_P!-_P#F'^PEK0_2(^'
M
M
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M_I\/TB__ ,^/^KO_ "K_ .XGPY^F;_TW_P"8?["6M#](CX<
M
M
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MIT          M:Z8W_Z[O]VO_P"GP_2+_P#SX_ZN_P#*O_N)\.?IF_\ 3?\
MYA_L):T/TB/AP
M
M                                           U2YO?U7]G?_!?\X53
M'S=^EU_^//$/^@?_ %+)G<?T;O[Z=%_TO_4<T>?@?B8?JJ
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M_3X?I%__ )\?]7?^5?\ W$^'/TS?^F__ ##_ &$M:'Z1'PX
M
M
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MI1:335&?KSELSE\[E[>;RER%W*W8*<)P:E&<9*L91DJIQ::::=&MJ.*,<O@
M                                              !='T[M8V&H4.W7
M>>:.(Y+8KR S!,G:>45UX2NH2QFTUA,V,*$;2KB?5PCDW9XB:&%"X[AR&-^K
M_P"@UU?:WPOP;J?%VLVIV+>NW<MYO;FL,I9?+1O.-^CVJ%Z69FH5\*-M7$L$
MXRE^=GZ6?&>E:_Q/D.&]+N0O3TFW?Z:<75*]?E:Q6:[G*U&Q%SIX,IN#[Z,D
MK$1]RGR8
M
M                                       !&-PTOJ:_/#25QUY4Y^3.
M4A%)5[#M/=54B>$RID6DT4TGZR:1$\%*4RF<%+[&.S&<XSS[BCJHZM>-,T\_
MQ3H>FYW4&DG>N6(=,TJ)*5V*5R22223DTEL6QLW/0.L3CKA;+K*</ZMGLKDT
MVU:A=ET2;K5JVVX)MMMM13;VO:D87^BIQW^26J?4[GVT-3]G#J-_-G3?BS\<
MV+UX=;7IW/?&CXH_14X[_)+5/J=S[:#V<.HW\V=-^+/QQZ\.MKT[GOC1\4?H
MJ<=_DEJGU.Y]M![.'4;^;.F_%GXX]>'6UZ=SWQH^*/T5.._R2U3ZG<^V@]G#
MJ-_-G3?BS\<>O#K:].Y[XT?%'Z*G'?Y):I]3N?;0>SAU&_FSIOQ9^./7AUM>
MG<]\:/BC]%3CO\DM4^IW/MH/9PZC?S9TWXL_''KPZVO3N>^-'Q1^BIQW^26J
M?4[GVT'LX=1OYLZ;\6?CCUX=;7IW/?&CXH_14X[_ "2U3ZG<^V@]G#J-_-G3
M?BS\<>O#K:].Y[XT?%'Z*G'?Y):I]3N?;0>SAU&_FSIOQ9^./7AUM>G<]\:/
MBC]%3CO\DM4^IW/MH/9PZC?S9TWXL_''KPZVO3N>^-'Q1^BIQW^26J?4[GVT
M'LX=1OYLZ;\6?CCUX=;7IW/?&CXH_14X[_)+5/J=S[:#V<.HW\V=-^+/QQZ\
M.MKT[GOC1\4?HJ<=_DEJGU.Y]M![.'4;^;.F_%GXX]>'6UZ=SWQH^*/T5.._
MR2U3ZG<^V@]G#J-_-G3?BS\<>O#K:].Y[XT?%,)G>,NA&USH;!#5U829R7G1
MY<W*@Y\-UY'%(K-?%QY3VY\%4V3%_P#Q%2_1OZC*-_\ +.F_%GXX]>'6UZ=S
MWQH^*9M^BIQW^26J?4[GVT*?9PZC?S9TWXL_''KPZVO3N>^-'Q1^BIQW^26J
M?4[GVT'LX=1OYLZ;\6?CCUX=;7IW/?&CXH_14X[_ "2U3ZG<^V@]G#J-_-G3
M?BS\<>O#K:].Y[XT?%'Z*G'?Y):I]3N?;0>SAU&_FSIOQ9^./7AUM>G<]\:/
MBC]%3CO\DM4^IW/MH/9PZC?S9TWXL_''KPZVO3N>^-'Q1^BIQW^26J?4[GVT
M'LX=1OYLZ;\6?CCUX=;7IW/?&CXH_14X[_)+5/J=S[:#V<.HW\V=-^+/QQZ\
M.MKT[GOC1\4?HJ<=_DEJGU.Y]M![.'4;^;.F_%GXX]>'6UZ=SWQH^*/T5.._
MR2U3ZG<^V@]G#J-_-G3?BS\<>O#K:].Y[XT?%'Z*G'?Y):I]3N?;0>SAU&_F
MSIOQ9^./7AUM>G<]\:/BC]%3CO\ )+5/J=S[:#V<.HW\V=-^+/QQZ\.MKT[G
MOC1\4?HJ<=_DEJGU.Y]M![.'4;^;.F_%GXX]>'6UZ=SWQH^*/T5.._R2U3ZG
M<^V@]G#J-_-G3?BS\<>O#K:].Y[XT?%'Z*G'?Y):I]3N?;0>SAU&_FSIOQ9^
M./7AUM>G<]\:/BG:Q'&W0L&[3?QVIJ21VB<JB*KJ%;R7@J$[W<423DL.TDU"
M9-VX,4N,X-C&?HXQG'HZ9U"]3.CYJ.<R'#6D+,Q:<7.Q&[A:K1I7<:35:II5
M3H]Z5,+/]<'6AJ>7>5S>NZD[$E1J-Z5NJ>]-V\+:?*FZ4JMS9-F,8QC&,8QC
M&,=F,8]C&,8^AC&/]F,#K:22HMQS=MMU>\_T2
M
M
M                                  ([LG[_ +6W_P 8_<5 5+P6"1!2
M
M
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M]=+9_D @?G"D/@F'M@:CZ"L?2I?,#V2M/]-WOHT?GAZZ6S_(! _.%(?!,/;
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MTTXR491E%2V-J-8
M
M                                             -(NH[*/HCA;N]W'
MKG;KJQ].BU%"9R7)F,WL:GPLFAG)<XSW'4;(*I&Q]#)3YQGV!QK](+,WLIU/
MZS=L2<9NWEX-K[FYF[%N:]V$I)]AG7^H7+6<UUM:/:OQ4H*=^:7[:WE;]R#]
MR<8M=E'DJ'Y:'Z<
M     %\W16D7RL=R,B5'2QXUD]U5(M&1C=J#=]*(;#;2+I,G_P"59XWAVI#Y
M_P!N$"?]@^WOT/<Q>EE^(,K*3>7A/)3C'D4IK-*<EV9*W!/]RCXN_2WL68W]
M!S48I9B<,Y&4N5Q@\JXI]B+G-K]TR\P?:1\<@
M
M
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M[8/C0
M
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M]GHI?_4O_N:_^:H^V/T._P#J+_0/]M/C/]+C_I__ $[_ &,O9'VP?&@
M
M
M                        !HEU+_ZDFZO]W'\[5#'$_P!(K^YO6/\ 1/\
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MREK-7>DN1C.Y*+GNK&,YR4$DZ*,%&"6Q15$1"-4-I   "]GHI?\ U+_[FO\
MYJC[8_0[_P"HO] _VT^,_P!+C_I__3O]C+V1]L'QH
M
M
M           :9=0JLR]MX;[PB8-JH\?(0<!83H)$.<_N;4+K6;;-JE(3!C9\
MFA81PIGV/H$'(>OG3LWJO5)K65R47._&S:NT6_!8S%F_<?N6[<G[AUCJ-U#*
MZ9UK:/FLY)0LN]<M5?W=_+W;-M>[<N17NGD:'Y6GZ?@
M                                %^O1;KDNTKG("UN&BB<'.S&N8*+>
MF*;!'4E66=T?3*"><EP4WDC>TLLYSC.?95[,]G^W[E_0_P!/S=K3]=U2<&LE
M?NY2W"7)*=F.8E<2_<J];]\^)_TM<_E;N?T33(23SEFUFKDX\T+TK$;;?[IV
M;GO%WH^RSY
M
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MD
M
M                                                          1W
M9/W_ &MO_C'[BH"I>"P2(*0
M
M
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M>YIK8T^1HY]>LWLM>EE\Q"4+\)-2C)-2BUL::>U-<J9VXNEH
M
M
M                  T0ZFVW[9HG@GR)V717[B)MD;5H.O0LNS/E)]#N-@W:
ML:\5F(]<IBG;244UM2CANJ7/?273*<OLEP-.ZP-4S.C\'9[/Y.3CF8VXQC);
MXNY<A:Q+F:4VT^1I,W'J_P!,RVL<89'(9R*EEI7)2E%[I*W;G=POG3<$FN5.
MA_/:,8QC9,;.3&-G)C&-G.3&-G/;G.<Y]G.<Y'Q+O/MG=L1^1!(
M                                       >M[_+J;=MUIU+R#T]-2+E
M_6-3V>@6*FI.EC+>Y"6T&]XQ.Q#'OXR9M&8D:-AX5$N?#PY>+GQC!E#Y-]+]
M1NIYG,:9G=+NR<LOEKEN4*_:]*KF**YE6WBINK)OE9\T=>6F9;+ZEDM4M14<
MQF;=R,Z?;=$[>&3YW2YAKOI%+D1Z.!W4X6
M
M
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MTG_9SU%CZ&/GH
M
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M4-_\U_T;_:#YYZ^?_E7^D_[.>HL?0Q\]
M
M
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M/_RK_2?]G/46/H8^>@
M
M                                               "L'K,-7+SIK<E
M46B"KA4C?5#HR:)#*'*V8[SUD]>+Y*7&<X2:LVZBJAOH%(3.<^Q@<^ZU(REP
M%GU%-NEE^XLQ:;]Y*IT'JKE&''N0<FDJWE[KR]U+WVZ'@G'QH?90
M                                         !ZD/\MF@N5#F6Y,BJ5L
MLKQ[02<93/A!5=N3=RCA%-7./#.J@FZ2,<N,YR7"A<Y[.]CM^A^H9.FJRH\+
M>6V]KSBOV5[Y\\=?#5=*C58DLSL[?F]/L/WCU##Z%/GL
M
M
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MSG%^KO4<S%6[$8X+5M.JA!-O:]F*3;;E*BJ]B2226Z0VLU0
M
M
M                                           ".[)^_P"UM_\ &/W%
M0%2\%@D04@
M
M                                    "+;]&,IJR:YB9)(SB.>RU@PZ
M;87<-RK8;UB1=(X,=LJBKV)N$"FQV&Q[./\ L%471-HA[T<[XJ*#]8?MI->^
M(8Y$CXJ*#]8?MI->^(8Y ?%10?K#]M)KWQ#'(#XJ*#]8?MI->^(8Y ?%10?K
M#]M)KWQ#'(#XJ*#]8?MI->^(8Y ?%10?K#]M)KWQ#'(#XJ*#]8?MI->^(8Y
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M+IV&!3(IGRMPODIBIFSCV.SV,B6VX[><CE]PE\4$@
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MO9+B&U;QRRU["W*"HI3LW(O#<C%M*2:A<6]PP]\;\CFYW$
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M.5OW5"NS'*Y"+DUN;PP23>Y5IO90(/I(^&0
M                     -P. $S)P7-'C:\B7B[%RYVI7(9=5 ^2&5C+ N:"
MF&9\XSCO(/XJ1614+GV,D4S@:/UDV+68X#U6%Z*E%9.<E7[J"QQ?;4HIKLHZ
MOU%YO,Y+K?X>NY6;A<EJ=JVVN6%U]'<CVI0G*+[#/<B/SZ/V>
M                                               #Q#?Y@JVSLYSM
M:UN1>G5A:3INBQU>8%R8J#1.:=3MAE'&4^]E,[UZ_D,X45[,&,BBB3/;A,HS
M<NN\KV3%O>'[A1H+Y:
M     MTZ&EJFZ]U)=+Q$4[.V87JN[<JME1+D^,2$(SU7;KN@T4P4Y2F(2QTV
M/7[#8,7O(8SV=N,9Q:OK[VRY:??H]Z P#+
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M329SG7-"UGAK5+NBZ_EKV4U6RTIVKD7&4:JJ='O4DTXR58RBTXMIIF'C./)
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M1/=(/ST/VG
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MBW!XN506PB]3;+9P8V.YWDU,%I4XR;2>U%3BTJLUX%12
M!:CT3_\ $WXS_P"^7_[?MK"U>_@G[GV2Y:\-'OS& 98
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MV>ZJN +FO<6WN%NBTENWT=F_=EF:V\FY4E8NV^C=G#'"Y*=7=K%+"Z\5*_\
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M?&G63H60X8X_UGA_2U*.FY/4K]JTI-R<;<+DE"+D]LL,:*KVNE6VR"!L1I0
M  ;6\%OZX_&;\<]#^[K0:;UA_D-JW^87O\!G3NI7^]KAS^U\M_*1/=(/ST/V
MG                                           "&-2\A])[W=75CJ#
M8]=O[O74PE 7="!6<+'K<RNI((I1\EA=NA@CA12*<XQ@O>QVHF]D5.,H[UO(
M33W$SBDD           #PP]?+_$*L?XJ]8_<QZ,ZQ_!^Z8M[P_<*61>+0
M        %]-YD)BI] G1!M3NG,:RO?)JXLN1KJNJ+(.GRF)C:36 A[8JT\(Q
MH9_$P5:RH5;!R'.DR3R?&#X3/87^4.O-L+K_ ()4Y]I#VA*-S"Y0ZKX7: W8
MM*-."MTY)0]6UY=I5K3?=Y*9*XN9;! 4FP/CK7LR9XMK.LVA#)K1;=<A2]TQ
M4$T\3)PBY2CX="$I223\&IO%KZH\,>2?-+<_353X24'5U1J"FVZ!0=XU!]8_
MCJ@;3J/RYIF]V6POY!8MDB9UW"++MFSOOD-APW37RN50XH;G&"N8JOF*UAE)
MPH1)6(#C#QIX$<#]VVGB=J/?>U-I;DW!KJUSMW<S.8:5@H+<>P:\O(N(]FOY
M%-3"%?B&K2(5=HK-&1,&6.V64PGW)>*5R44VDE^L1WJ@G1-U-_>/=#TGQ8ZE
MG41TKK73582JS?B$\VS$G>/I95>$A/<;5[^W:KC,'<*>%2+I.VDCQ<AC&6;9
M8H)(Y*ECNXMR<I6HR;VU*XI1FTN8K]C'/#O3_3>U)R\N'#&@;,V7M;?FZ:C
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MV=+RJZREJDI-G$.E5\K9,W3.\3PV20RV*=2M.:G&KJI(I:BXNBI0\] R"R
M         !:CT3_\3?C/_OE_^W[:PM7OX)^Y]DN6O#1[\Q@&6
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M\59K4>'=4NQRGG/#&7L6<G2W+"X9?!T?3+I._?>+$XN%=M$C(J7SRW;1[GR
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M<.?VOEOY2)[I!^>A^TX
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MAG%KGVTW,H&'TB?#0
M   &WO .*D9GFAQK9Q;15ZY1VO6955%'&,G)'03@TY,.S8SG&/"CXF.774S]
M'":>>SM^@-(ZR+UJQP'JL[TE&#R=R-7]U-8(KMN4DEV6=5ZC<KF,WUO<.VLM
M!SN+5+,VE]Q;?27)=J,(2D^PF>Y0?GR?M
M                 'G<Z#O[]^HQ^/\ A/NOM89%_='M%FUOEVST1C'+P
M        'B"_S!%7FH7GDC//V:B43<M-4&3@7V"*Y;NT8IU8*](H86,F5'+Q
MF_BS942*8QB)*I&-V84*,W+O[W[IBWO#]PHX%\M
M                          6X]#:KS<_U)M)RL4Q5=L*17]NVBRKID.8D
M9".]47&EH/E\E*8J:2ECM\>VQDV2E[[@N.WMSC&;5]_>V7+7AH]Z8P#+
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M\A7],@>T?_N;\;_HH]AS_NC_ (;_ $\>H*_M8?D*_ID#VC_]S?C?]%'L.?\
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M&W*<W2F-1;B6##FAW<
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M;*P
M         (\M7[]=7_\ \WL_\4)85+P60]Z)#%)(
M                                                >=SH._OWZC'X
M_P"$^Z^UAD7]T>T6;6^7;/1&,<O
M    1XM_*Q&_B\F_XR5\5?:^Z1]M[A(8I)
M
M      CRU?OUU?\ _P WL_\ %"6%2\%D/>B0Q22
M                                               'G<Z#O[]^HQ^/
M^$^Z^UAD7]T>T6;6^7;/1&,<O
M  1XM_*Q&_B\F_XR5\5?:^Z1]M[A(8I)
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M#EB@LLIW$RD3)WU#YSV%Q@N.WV,8P(>\D[D0
M             /.YT'?W[]1C\?\ "?=?:PR+^Z/:+-K?+MGHC&.7@
M                             (\6_E8C?Q>3?\9*^*OM?=(^V]PD,4D@
M
M  !@^R_Y/KE_!V4_]E4$Q\)=LA[C+6'_ )%E_P"J-OW$@@DY8
M                                           ,=M_[T[1_!V;^YKD2
MMZ[8%0_>G5_X.PGW-; ][[8,B$
M   #SN=!W]^_48_'_"?=?:PR+^Z/:+-K?+MGHC&.7@
M                  (\6_E8C?Q>3?\ &2OBK[7W2/MO<)#%)(
M                                                     8/LO^3Z
MY?P=E/\ V503'PEVR'N,M8?^19?^J-OW$@@DY8
M                                ,=M_[T[1_!V;^YKD2MZ[8%0_>G5_
MX.PGW-; ][[8,B$                                     #SN=!W]^
M_48_'_"?=?:PR+^Z/:+-K?+MGHC&.7@
M       (\6_E8C?Q>3?\9*^*OM?=(^V]PD,4D@
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M#6*96V.;K&>HKL4&[1VR26P9%%5O@SK'O6E#OH^"7K=QR[V6\]!PQR\
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MN-4_BH?RUL_FE#[K/S[
M       #^G+T@_\ #/X;_B>C?NK+CX*ZROR[U3_.7]A'Z']5O]WVD_YHOLR+
M(1HYOP           'G<Z#O[]^HQ^/\ A/NOM89%_='M%FUOEVST1C'+P
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M4;^,FDY]RI*5+!6"/6(=%['++'5;J$P;!CI'34/7&6)5::93)4=*U(#%12
M %JG1-4.3J;<:RD.<I52;E35*4V2X4)C06TU<$4QC.,')A1,INS/;CO%QGZ.
M,"U>_@G[GV2Y:\-'OP& 98             4M_Y@/_"_W1_"[3?\Z56'N<._
MUK#M2_P6=N_1X_O4R/\ $YG^0N'\\T=&/T:       ]4&O>5EWX?]!#BMLN@
MTS4]YF)SEI>*,YB=Q4A.^UEO&R;KD%/K2+&'4D8TK:=1=5E%))SXF<D;K+$[
MN?$[<:G<RD,[Q#>M7)3C%64ZQ=']HM_-M/D_4>$LAQE^D%JVEZA?S=BS;T>U
M=4LM=Z*;E%92"3E2584FVXTVM1?(3SMC<E@Y!:3_ ,O[N*U0-,K$_>.>VOW\
ME!:]KY:K38Y5CNUA#))P< 1T\+&H*-XTBBA<*G[RQSG_ /S=F,>S9CE[^HV8
M.3C'+O:W5^"][-?TC1<OP[KG6'HN4N7[N7L</WE&=Z?27'7*N7?3HL3K*BV;
MJ+D.X3Q=+KLCKS:6XL3I*]SCNNR=:S.N2QEH9TN]636T ^B,W..I%A=2L6HT
M>,H9>5;JG25;81<RS/*BN.^F9.'T=NUI]_-JN0C"2ELJE)[JKMT]YEE^8Y'3
M.K_7.++?2<!V,K?C>Q0=VU"]-2Z.5V"C*J<E;:34JJW.BV-/)+E![\K.O.@K
M7.4$^YLN]X#F>M#; DG]I97:81=QEREV<-!V*TQ\A+-YBTUBM(LHR5/ETX6+
M(M%B*J'5*<V:(2R\KFH2RBIEW8JME%N56ER)NK789C9*_P /9K4NL#,\*VU:
MT"YHF*S%6W:BU*W%RE"VU%QMSFY3MK"E@E%I)-$9Q&YML;*W/_F*:%L#8EON
M-%I7&WD<A3:78IQ]*5.I$I]=O\'735BNNEE(> 6CXUHD7Q&B**BRA,*JF.MC
MOBZ[%FU8TVY;C&-R5V%6EM=6FZO>SU+VB:1I>B=6VH:=EK-G/W]3R;N7814;
MESI)V93QS7?33DWLDVDG146PV@UE*W:>T[TJ;QQ$U+R!VQKRDZ0HK-SC2/*"
MF:1TO7K] 1\*VVA6>2E)F*?8\6<ZTBQ=HR+I9P<ZJAGA&N,.U,++XEV,(WLW
M;SD[<+LKC\*#E)I^"X--4['N5V;M4U2UD<OK7%N0XQSFG934K^?NM>=9&YFL
MS.U-R=B>2NQN0P43BX1222P.?>+#'2V[<E[_ *JZ:74=W)QXE6>C[-9^JQ;8
M[RO5EKC[0VK7G)2-'+7-K2K[&Q48T<MG\PW<%)(QJ#<AT%CX;F\(^#&S[>5M
MWM4RUC,KI(K*+PE2M'*E5VN1^Z;QD>%]/U;K/X:T7B.#S^5M<)6W2_;<'/!=
MS71N[:E*3346JPFVTTL2JJ'GQX(2DC-]0?AK-2[US)2TOS)X\2DI(O%3KNW\
MB_W;4';UZZ7/G)UG+IRJ8YSYSG)C&SG(V+4$HZ=?BMB5B?\ @L^B>/[5NQU=
M:W8LQ4;,-%SD8I;$DLK<227(DMB/4S8.:&F(KK<?HZR_"#CO(7AUMFL55KR;
M5CFI=PM9^8UE"2,-:BOI&$D6IY:*4=HLT>X9-7*"9,)J$/V#4XY&_+0O.5?N
M*W@;P?:T4G5;_=/E'+\$:W=ZB_\ F2SKNI1R"R<[CR-7YLX1ORC*W123PRHY
M/>JMU31II+UB8IG&?_,8UF>M%CNLI%;]ULDM;+<5J6RSZ*VX9QTQDICR!I'Q
MIGCA@NEG)FC9JT-CLR@@BCDB1,U3C<S6FSBE%.V]BW+O>3]53=K.:LYWBCJU
MS67M6K%J>GWZ6[=<$&LM%.,:MRHFGX4I2^ZE)U;MMHT)M[<\CIUS<H7>_':2
M2XSM6$#RWX@<C:=L+@VM2HNJR;^.E;+K?9Z+&KLVTD5 AR(%J;UZGXK4ONAY
M,AA^V\>Y*S84U!V[JZ7;;N0:NUKN4H[?WR6_95T?'\_?T;1+6=CDIZ?J5IZH
MW/3]1R=RSJBNRN14HPO6&[C<:TKYQ&+I-]'BET<M.>G+MOC%QSZ>'&*T<A6C
M6[U-OU*[=2=3[!91T>VJU,V=.1FR(2J[GDXUZ_9Q\95XBKYE%R'RF[]S#ND7
M":.%&Y%DL[4[.:S.I789;O9^:IR7*XIIN/;;IS5W<IN?65H_%/$O6/JN5X<;
ML9Q\,6[N8LMMSN6(RLRN9:,DFY3E/HU2L<>&47*DFGYLNIEI?=FBN;>^:COR
MS3E]N\M<'UT9;*G4BI+[)J%J64?U2W-DVZ:4:U06BNZS49,L8913IFM'HX*1
MI@A=FTN_8S&1MSRZ4;:C3"OM6MZ_7J]KK7E/IOJOUO0]?X%T_.</VK>7R,+*
MM.S#=9N6]ERVZ]\VI=\I2[ZY&4;DJN=7?+RKY4ZTXR]/3I"9V+Q$T9RJ+=>.
MD][E8W0P4>FHI:W5]'^Z.*P8C-YA#-HQ/(^69SCV?<Y#V,]@U_*92[FM2SG1
MWKEG#=7@\M7+?VJ;.V< X2X3U3BCK&XR^K=9S^DNQJ4,7FSITN.>:PX]JKT>
M!X?W<C?V(L.OENI+PBVX^72K4?O?IA3C?BMJA5S68BB:HV8[S19IE3-4R[2M
ML(>*7E=;2TDQPLJQ<K9Q@B)"9:G:L4//E&Y]67[*VNWFETDMM91VJLE6OA4>
M_P"&K.>7LMJ,>K+7='MIW;FG\51>?S%)RNYBPNEB[F8BYN4E&]&$J*45O;>-
M3N2TOW;:=U:QXUZ<I^W-#7+7S[//72][T[;>HCS-J&VYQIL>KW>MRDNACW'U
M^E/M=,RT8V?I2ST[GR)BW?NW7LIKD\;-L0L7<U.=FY&2\WDI*S;<5A:=.6F+
M=1;W1+D-WT/*:'JG$^=SNCZA8S,/^7\S:S-O1]-N9>+LW+4XQ??7L#S,9.#M
MQ4<4G"$-\7AVHY=T38.Q]+<_;=LIMRHX7S3;1EAF+O(S>[J5OCA9N55E6EF\
M;4-?1E\,_L<2O:B$*T:*5^#JSQDNL0V,%=E1:+8F3N6[5_+PM=%?CTB2I%PN
MQV[W39L[+DGVMIJ?!VH:=IFN</9/3'I.MV'GX1M*.5NY74LM6:<KEZ5JD)*W
MX4E>NWXR2:VP<IK2%IQVVWR=XQ= 6_Z2K:%UHVAKA9<[FM;>=@6$/KA)MMG3
MSAVO9%).2:.$4VF-=2Z:F$DU3^.W(C@N55VY%<]YFSE<UJ-N^\-RY%851UEW
MLMWQE^I,WJ?$FC\+<4]86G:[==C/ZA9AYM;<)N5ZN7S"2AABTZ]-;:JTJ-RK
M2,FI.V5_+?\ YDW^[EKG^9V;%JU_ :9_&R_PD>7IG]1=67]I7O\ 6(FC_5PE
M]Z[&Z</2HVQ,W&\W?64MJ]DRV;9)B^O;#'S^^9&I,G-<DK<RD)QV_L%\3@H:
MTIDE'*"Z[4OEJ!ETS+G34S]'67M:GF[,8QC=4^]25*0KMILV*KCL[1O?4]9T
M#3>LOBW2+%FQ8U2&;;L0C:4'#**XU.-MJ*4+6.5ANW%I2^]R46HIKSB#93Z5
M       _IV],;_#RX8?W<M6?Q68#EFJ?UE?_ (V7V3\M.M+^\?6_[2O_ ,HS
M>D8!H0   57=;7_"UY=_P/IW\ZE#'0NJG^\'3?XV?\C<.;=;W]W&J?Q4/Y:V
M?S2A]UGY]@  !=K9.D0JOTK=?]0K6E]GK7<WT5*7;9&I747&)M8?6<%<;%3K
M+:ZNZ:*&EI'S47:QKV0PLGX2,>LY6,<O@D*IRJQUDI=85[@O/V86\JI*W:O)
MNLKLH1G&$T]BQUE&-'5R453:Z=?S'5<WU;6..=/OSNYMQ=R[9:5(V8W)6YS@
MUWSP-0E*JHHN3JJ)/67E%P<A]&<9.GMN^GV>U7>V\UJKLF9DJ6>&:G)7YBFR
M>NHV'AJJ6+*M)S2TVO=SD[BA,JY433*3&<FS@>]P_P 67=7U[6M)S-NW:RVE
M7+45/$^^C-7'*4Z[(X>C[5&ZFO<1\'6M&X>T+6,K<NWLUJ]J[)V\*[V5MVE&
M,*;98NDY=M4J$+;<X(\RM"T9MLO<G&?<>N:$X.U24M5HI$Q'Q,8L^4(BR;V!
M<R!LUER\74*FDG(X:J**YP0N,F]@>KIO%_#&L9MY#2\_E;^<5>\A<BVZ;W'[
MI+>W&M%M/(U3@SBS1<FM0U;3\WE\DZ=_.W)15=REL[QM[$I4;>PGOEQTQ-U\
M0^-?&?D?=2SSR,WTPG#6^MNZ'*UU;2,^U3A'-6J]PEW<D]1=RMX8/WKAB7*#
M,QDXM?)2GQVY+X_#?'NE<2Z[G]#RN!7,G*."2N*73Q>)3G!)*BMM14MLMLUN
M/:XHZN]7X6X?T_7\WC=O.QEC@[<H^;R6%PA.3;K*XG)QV1V0>_D_'"S@Q5.4
M?&/J!;YG[U8:M+\-]75*_P!:@(B.C7D=<GECB-KR2\?.N7IL.6#9L?7B)2F;
M]ILX<'[?^Z4.*>+<SP_K^C:/9LPN6]4S$[<I2;3@HNRJQ2V-OI'OYD.$N#<M
MQ'P[KFM7[URW=TG+0NPC%)JXYQO.DF]J2Z);N=G^\>^#%4W-T_N9',>3O5AA
M;+QDFZ/%05-81T:X@K.G:Y* 8N%99^X-A^S.T),&,3".,X-DF.WZ.0UKBW,:
M7QEI?#%NS"=C/PN.4VWBA@4FJ);'7#RC0^#<MJW ^K<5W+UR&8TZ=N,;:2<9
MXW%/$WM5,7(87R8X>--;VCB]2-'1N^-BW+D'I.A7_%5MVG[+5;!(W>X'<IJ0
M6L(@\0B_OU5,='&&4DS(NDZ^F[I\]W/9E:%Q-+/9?4,WJTLG8RN2S=RWCA>C
M.*MPIWUV5:6Y_=1E1KF,3B'A6.GYG3LGH\<[?S>>R=NY@G8G"3N3KWMF.&MR
M'W,XII\Y@&S>!/-#34/;K%M'C)N.D5RAQ4%.7"R3E*E4*Y7XBRO5(R#D'\^F
MBK$$;2$FB=L4Q5C=UR0R1NZH7)<9F0XPX6U2[;L:?G\K=OWI2C",9K%)Q59)
M1\*J6W=NV[C!U'@KBW2;5V_J6G9NSE[,8RG.5N6",9ND6Y>#1O9OW[-YO'RW
MZ..^-6VC6S'B]KO=W)&IV+B]J_?-XLL-0U'J=6L=_E;RT<TR/]P4E4Y=PQCZ
MHDX2;(X6D#$<=XR7<R3.=3X;ZSM'U#+WYZ_?RF1S$-0NY>W&5RF.-M6VIO%N
MJYM-ND=F_>;CQ1U4ZUIN9R\.'+&<U#+7-.LYFY.-NN"=V5Q.VL/A-*":2K+;
MNI0KIT3Q.Y*\G)2<A] Z1V+M5Y6")GLIZG7'KV/KQE\JE;(3LPH1"(B'CS+=
M3P$'"Z:R_A'\,INX?LW;5^(]"T"W"[K.;L9>-SP<<DG+GPQWM*JJTFE55WHT
M/1>&>(.(KD[6B9._F9V_#P0;4:[E*7@Q;HZ)M-T=%L9^(WB?R:E[ML/6L=H/
M;3G86IH%Y:=F4@M$L2=JHU;8$:J.IVRP*K!.2BXHB+U$^%U$\)G363.7.2G+
MG,W.(M!M92SGIYS++)9F:A:N=)'!<DZTC&5:-['L3KL?,1;X9XANYR_I]O)9
MIY[*P<[MOHY8[<%2LIQI51VK:U2C3Y3!MKZ?VCHJY.==[BHEDUO>V,;"R[^H
MVZ-6A[!',;%%-9N'4D8MS@KN/6=QCU)7P5BD63[W=4(4^,EQEZ=J>GZOE5G=
M,O6[^4<I)3@\46XMQE1K8Z--56Q\CH8>IZ5J.C9MY#5;-S+YU1C)PFL,DI14
MHU3VJJ:='M7*DR]C9'3'Z:7'+7G&RR<H^;6\-:VCD/I:E[>BX>"TNI=(MFUL
M4'#/Y5(KVN1,LJDVC)&4RD3"N/'43)WL%SD<CR/'O'>N9W/V.']*RE_+Y+-3
MLN4K^!MQE)+9)K:TJ[-B9V;4.KSJ^T#(Z?F.(]7SF7S.?REN^HQL=(DI1BY;
M81EL3=-NUHCVW='VG:NY[4OC%;]L[.V'I?:NC5]\:RV9HS4$O>]B2U;7.^:L
M&4EKB#3L;I([20C%?*':&5&QV:C=QVHF5.W1S<MUEYK4.#[NOY;+9>QJF7S?
MF]VUF+T;=I25&VKLL*VIJB='B4H[4E)X.:ZK,IIO&MGAW-9K,W])S.3\YLW<
MO8E<NR@ZI)VHXGL:=9*JPN,MC;BJS=)\&.8/(ZHR5^T9QSVMLVE13MU'N;16
M*L]=0BTBQ2PN]C(M^KA!";E&:9R^*V99<+IY4(4Q,&.3!M[U7BWAG0\S')ZM
MGLOE\U))J$YI2H]S:^U3Y'*B>W;L9SW2.#>*M?RLL[HV0S.8RD6TYP@W&JWI
M/=)KE4:M56S:B=^-/!!GN+C=U$=P; G+GKJ]\'JWKJ10U^YKZ3->6G[;*[&B
MIVOW)I-)MIFOO*^YHQ4S(X3*N1510JA<9+C \C7>+Y:9KFB:9DX6K^3U:Y<7
M2*5:1@K3C*#C6,E)7*UK2B5#VN'^"X:KH&O:KGIWK&=T>W::M.-'*4W=4HW%
M*DHN+MTI2M6T]QIML+0NZ-35NAV_9^K[MK^M;1BLSNN9>X5^0K[:[0>&[)WF
M9K6)-%NK+17DLDW4\H1*9')'"6>]V*$[=HR6L:7J-^]ELAF+5Z_EY8;L824G
M;E5K#*E:.J:H]NQ\S-3SVBZMIF7LYK4<M>L9?,QQ6I3BXJY&B>*%:8HT:=5L
MVKG1:OQ)Z=G$78G V:YQ<K.2.SM*U6&W9):?6:T?7S>]-_*2QU;=0SGR1HU>
MS1EG[B:5(IDJ64DRIESG..W(YYQ)QMQ)DN+X<)\.Y'+YK,3RBO5N7';V5DI*
MK:CL45RU=3I7#' G"^?X+GQCQ+J&9RF6AG'8I;M*XJT@XNB3EM<G7914,*YG
M].?2FJ^*FL>;O$#D;+\A>/\ >]CNM23*=NH3V@W6KW-%M..&Y_<]WALJ_CEU
M:XZ06(HT:JH'.V41,Z1<Y40RN%^-]5U#B',<*<2Y&.2UFS85Z."XKD)PK%/:
MJT??)JC:??)X7&CQ.+> ](TWAK+\8<+9^6>T.]F'8ECMNW<A<I)K8Z57>-.L
M4UWK6)2JM,MA<$N9>IM8M=S;+XR;HI&L'*35=2XV*ASL=&1;=\J1!@ZL)%FN
M'M8:/UU"$05D4FJ:QU4RDR;*A,&VC)<7<+ZCGWI>0S^5NZ@J]Y&Y%MM;U';2
M;7*HMM4==S-2SW!G%FF:<M6U#3LW9TYI/I)6Y))/8G+96">RCFDG54WH[&A]
M/WFUL_5Y-T:\XN;IN.L7#-U(Q]L@:/,/VDU',U#I.9"NLTD,RED8)*IG)E9@
M@Y2R9,^,&SDA\%HSG&7"FGZA]5YW4,K:SZ:3A*Y%.+>Y2>Z+[$FGM7.BYDN!
M^+]1T[ZVR.FYN[IS3:G&W)J26]Q6^:[,4UL?,R"VNF-LO=52^\FFN[>XT[ 6
M\E FMEI0;X]-BKLHSCI E5?3N$O(6TZ9C+M5<-S&PIW'!,]G8; ]:6J:=#48
MZ3*_:6ISM=)&UB6-VZM8U'>XUBU7=L9XT=)U.>FRUF-BZ]*A=Z*5W"^CC<HG
M@<MRE22=-^U&^?!OINW/D/RZTIQOW]&;(T+";NUO9]I5&R.JL5O*SU/BZA-V
M6!L=<:3Q$6DI SB\1X17)<Y(8F39+G.<#4.+..,KHG#>;US1I6,Y=RE^%J<5
M.JC-SC&49..U2CBK0W3@[@#-Z[Q1D] UN.8R5G.9>=Z$W"DI04)3C*"EL<9.
M-*G)3Z5VYWG!;9W.9@>PFK5!VO8J?&T(]!DU9"SZPK*<?B9W>TLZ4D1DE3(F
M15?,G)L,E$DW$6OC*V.S)2TOK!TN'%V7X2G@Z>]EXS=SI%2%V5<-API7&UAD
MN^3:FMA4NK;5I\&YCC*'2>;V,S*"M]&ZSLPIBS"G6G1Q>*+[UI.$MI5L.@'.
M    _IR](/\ PS^&_P")Z-^ZLN/@KK*_+O5/\Y?V$?H?U6_W?:3_ )HOLR+(
M1HYOP           'G<Z#O[]^HQ^/^$^Z^UAD7]T>T6;6^7;/1&,<O
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MA0   %J/1/\ \3?C/_OE_P#M^VL+5[^"?N?9+EKPT>_,8!E@
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M6G-7?3L'R8F>D>LSQAG1)$CIN:/,QRL5Z5Z58F6AF9F_8OAUA?!?#R3Z?O\
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M2>3><T^S?GT=[(9V5B_E9.XY/SFS/H82DG)M4G<3C1X5B4I\GC--:0T)L/\
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M<O            >&'KY?XA5C_%7K'[F/1G6/X/W3%O>'[A2R+Q:
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MO_QLOLGY:=:7]X^M_P!I7_Y1F](P#0@   JNZVO^%KR[_@?3OYU*&.A=5/\
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M            >&'KY?XA5C_%7K'[F/1G6/X/W3%O>'[A2R+Q:
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MR3C*,DZ--/:FGL:>U'3BX60
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M,VL&NFR@           >=SH._OWZC'X_X3[K[6&1?W1[19M;Y=L]$8QR\
M        !X]/\PYQIOD+O:G<H8Z'>R6L;M2(&B6"<:H+N&]8O=8=RQ6C"94(
M0R,<TL5?=MC,#G-C"Z[5T3LQDA>_F9>2PX>4Q[T77%R'G&&06
M    #9WB9RSVAPSV@[VWJ1I47UG?5&9I3AO=89W.PIX6==Q3Q_C+!G*PZN7.
M58=+!395R7!<FQDN>WV*9P4U1[BJ,G%U1MO?.L-RRN% N6NZY#:+TW%[ A75
M;MLQIG4\=3;/*P#YNX9O8OW:6D9=1D1=F[63*NW(D[0PL8R*J9^PV*%9@G5U
M94[DFJ;#7:$YT;J@-=<5-8,6M(S6^'>UU-R:E.O!2"DFYMRM\>;%,G;W19M-
M*9A_=]\<N$4$F9_)^PGB=['?S5@C5OE:(QNB7,=[:.H5OFW0G+* E6= *QYF
MSM5L.WLM*])(KMG]/=D>Q.*<H>?5+"MS+)X\8JY7F3X]C&2@K<53]J,;=>R=
M>;G_ ,B6\?Q&:04K7:N\X4$LJ>EIR AED9?PK:I >[R%O,_D9"/L320:5Y-J
MJCY.@BJU7724*<JG9AT<=O[;>,<MG8-A[IUA>2%MK>YJI&ZOXO:ZB>05%MM)
MW ;6FG3U:5OB]SAI&!EKO8IWSH?34O>DXR7=$;NW3A9LEE<YO)\Y-G(I5F*:
M=6Z$])+;NVG1ZOZMG)765 U_3#TOCUL>P:@@35C36X=JZE;7#<>I8(C7R)A'
M4:WFF6#9FA%,RD20\J9N\^"F1-3*B9<%!VHMUVJH5R25-FPP'2/4JY"Z<B-P
M5B;B=4<@J7O.Y/-C[$HW(^B8V94978LDNDYD[N6')+01,3LBNU;'6PH95J8[
M1 W@XRD7(F5N+H]J:YB%-JNYI\Y'O+#G#NSF8CJY'<:5()G4<+-0%5-2ZN6J
MIFCIQ6)5<I/F#9\O%E(U+"()MDVB#1%%(N2E)V=G9,(1A7#RD2DY;S3P5E(
M             !?+T!^--\OO+F/Y&EAWK/66BX6Y(KV=R@NC&2]XN=/E*6RJ
M<6XR3"3^2:P5K<R#HI,F*T132\7)3.$,*6+\DH8>5EVU%N5>1'M?&$90
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MZ=/H5<;OFJJWM >AZP.-O2N>\K/NGF^KG@/T1I_D8=P>J[Z=/H5<;OFJJWM
M/6!QMZ5SWE9]T>KG@/T1I_D8=P>J[Z=/H5<;OFJJWM /6!QMZ5SWE9]T>KG@
M/T1I_D8=P>J[Z=/H5<;OFJJWM /6!QMZ5SWE9]T>KG@/T1I_D8=P>J[Z=/H5
M<;OFJJWM /6!QMZ5SWE9]T>KG@/T1I_D8=P>J[Z=/H5<;OFJJWM /6!QMZ5S
MWE9]T>KG@/T1I_D8=P>J[Z=/H5<;OFJJWM /6!QMZ5SWE9]T>KG@/T1I_D8=
MP>J[Z=/H5<;OFJJWM /6!QMZ5SWE9]T>KG@/T1I_D8=P>J[Z=/H5<;OFJJWM
M /6!QMZ5SWE9]T>KG@/T1I_D8=P>J[Z=/H5<;OFJJWM /6!QMZ5SWE9]T>KG
M@/T1I_D8=P>J[Z=/H5<;OFJJWM /6!QMZ5SWE9]T>KG@/T1I_D8=P>J[Z=/H
M5<;OFJJWM /6!QMZ5SWE9]T>KG@/T1I_D8=P>J[Z=/H5<;OFJJWM /6!QMZ5
MSWE9]T>KG@/T1I_D8=PZ.T=,+IWM:U8G+?A=QR1<-X.67063U95R*)+(L'"B
M2J9L,.TITSEQG&<?0S@2N/\ C:O]:Y[RL^Z/5SP'Z(R'D8=P5?IA=.]U6JZY
M<<+N.2SAQ!Q*ZZRFK*N=1599@W4554-EAVF.H<V<YSGZ.<@^/^-J_P!:Y[RL
M^Z/5SP'Z(R'D8=P[SU7?3I]"KC=\U56]H"/6!QMZ5SWE9]T>KG@/T1I_D8=P
M>J[Z=/H5<;OFJJWM /6!QMZ5SWE9]T>KG@/T1I_D8=P>J[Z=/H5<;OFJJWM
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M03'PEVR'N,M8?^19?^J-OW$@@DY8
M                      ,=M_[T[1_!V;^YKD2MZ[8%0_>G5_X.PGW-; ][
M[8,B$                                     #SN=!W]^_48_'_  GW
M7VL,B_NCVBS:WR[9Z(QCEX                                    "/
M%OY6(W\7DW_&2OBK[7W2/MO<)#%)(
M                                8/LO^3ZY?P=E/_95!,?"7;(>XRUA
M_P"19?\ JC;]Q(().6
M            #';?^].T?P=F_N:Y$K>NV!4/WIU?^#L)]S6P/>^V#(A
M                                 \[G0=_?OU&/Q_PGW7VL,B_NCVBS
M:WR[9Z(QCEX                                    "/%OY6(W\7DW_
M !DKXJ^U]TC[;W"0Q22
M                      &#[+_D^N7\'93_ -E4$Q\)=LA[C+6'_D67_JC;
M]Q(().6
M #';?^].T?P=F_N:Y$K>NV!4/WIU?^#L)]S6P/>^V#(A
M                      \[G0=_?OU&/Q_PGW7VL,B_NCVBS:WR[9Z(QCEX
M                                    "/%OY6(W\7DW_&2OBK[7W2/M
MO<)#%)(
M          8/LO\ D^N7\'93_P!E4$Q\)=LA[C+6'_D67_JC;]Q(().6
M                                                  #';?\ O3M'
M\'9O[FN1*WKM@5#]Z=7_ (.PGW-; ][[8,B$
M             #SN=!W]^_48_'_"?=?:PR+^Z/:+-K?+MGHC&.7@
M                            (\6_E8C?Q>3?\9*^*OM?=(^V]PD,4D@
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M5O4-1-R             #SN=!W]^_48_'_"?=?:PR+^Z/:+-K?+MGHC&.7@
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M%RW>LGK=%VS>-%DW+5VU<IE6;N6SA$QT5VZZ)\'(<F<E,7.,XSG&18+AR
M            1UMW:51TCJW86X+\^S'4S6=/L%VLKM,N%'!8FNQKB3=(LT,F
M)Y5(.R-_";(XSWEESD(7Z8V!=LVIW[L;-O;.<DE[IZ6CZ5G-=U7+:-I\<6=S
M5Z%J"Y,4Y**;?(E6K?(DWR%&'34U+;MW6*X=3[DFS.\WER3,]5U! /CKN(W2
MG'SQ56E/KU0;.NTK'SEB4RKX<D[5%XQ1)7)L+OI#*WO:I>A8C'2LK_D]KPG]
MU/E;[7V>PD=\ZS=7R>A9:SU6<,RPZ#IE/.)JBEF<WON3N-;\$MF'<IIKP;=O
M#MQR(Y'7?4G)/A-IRMQ55>UGDC==K5R\OIMC+N9V*8T6A(VF(5JCIA.1L>Q=
MN)!3)')GC5\0Z/L$*F;Z<8>6RMN]E;]^3>.U&+5*4VNCKL^Q0U#ASAK(ZQPS
MKFM9F=V.:TRQ8G:47%0D[MUVY=(G&3:2VK#*.W>VMA&5(ZI7&_8*FNUZY6-_
MJUS;3*TXUI=W.D;@A3;S;*C&3$M):VJDUA%0M@V Z:P+I-HS9IK(N7B1FA%_
M*R*($NSTG,V\6)V\4&L2Q*J3HL37(MNU^[N/4SW53Q+IRS,<S=TY9G)RM]-:
M6:MNY:MW)1C&]<C7O+*<XN4I-.,6IN.!J3C;0O5:I6P="Z[V/L#4VX8[9NR[
MY>Z)2-3:\U7<;+-[+>TR=M.9%]JPD@BQ3ML14ZC!)N+*]PNFTA9'QVBQ\*IX
M)F[F-(N6\Q*U;G#HHQ3<I224:I>%S5;[U<JVGI\0=4N>T[B#,Z9IV<R4M+RN
M7M7;N8O7[<(V5<C;PJ_2O1RN7)M68T<KL,,TJ.I,6>IAQR=1VNE:W%[FNUHV
M@PV2>L:RIFHK7.[02L6HI%C%;$HE@I22"4G6[C6'K[L<H/?!;$12.OE?"'=5
M-9^J\RG+$X1A!QK)R2C26YI\J?8/&]6'$L+N969GDK&5RLK.._<S%N-C!F(N
M5F["[7#.W-+O7&LFVHX<54ON_P"I-Q\+KG3.P*U"[BV%(;Y>[ C=?:MH>L9>
M;VVY?ZE.HAM-G*TU9=A[DN* [(5%^51QVF.H3+?QR&P<0M+S/2SMR<(JW2LG
M*D>^\';V>3X2FWU9\1/4L[IV:GDLO;T^-F5Z_=OQCETLQML.-RCQ*ZML*+D>
M+"U0X$[SPK,?>Z7+L'::VEYOB?M/DM,0[K7%_:[H*PUM.P[*368L7[B+B8YM
M",7#M-[%NV1I)=RF4S=3*>,X/,=/D[<D_P"'5Z,%WRP]\G]GD:=.<N9?@'-7
M,A?LW$UK=O5[&2C)7K3RU;T9.*;2E*3DU%QN1E@46\2KNR*[=1_BO0F\ ZF+
M9//4+/H2J\CX,T#5):;5D==7VSQ%*H2+5JQ34=KVRZ6N;08L(LB9G)E/$.IA
M)%)10M-O3,W<;44MEQP=73ODFW[B2JV8V1ZM>+-0E<A9LVXRM:A<R<L=R,:7
MK4)7;M6]BMV[<7*=QO#2B56TG+?'SE-KWD6O>H2NP6QJ#?-9/(-ML#5VWZ3(
MZ_V+54+4R<R53EI& ?G<I*0UICV2RK%R@NL14J)\&[IB]T6<SE+F6PRDXRMS
MK2476+IOV\ZY3Q^(N%-1X;CE[^9N9;,:?FHR=F_E[JO6;CMM1N1C-4[ZVVE*
M+2:JMZ*G=T=2'EU2+IS2E*DZX3,=8\0KZE YI>T%MEP&Y=DPA8R,EEF]3>Q]
M]4KSVP.DW9V[<WN:1([O*9/!SV^SZ]C3,G<MV%/I^EO1K6.%QB^SLK3W3KFB
M=6G!^>R.B6LXM<EJFL9?'TMA69Y:S+%**=Q.UC4%1-]^WAJ\1O#&=3CCHM<O
MB\G&&S:_;H.A539&S\*T&:?U73U3M&E&6]<3>Q;>T2S&0<5&59^1HHH?'C+2
M?:@BB?N*&)@/2LS@Z2+@X.3C':JR:E@I%<NWX#1;O5=Q)')?6-B65N9.YF+E
MFQ]]BKF8N6\R\KALVWWTI2FG)+<H=\Y*JK&.Q.K)JJ%T]M*[T[6>[F]YK&H7
MFY-95'9VH;A4&FVJ)AZPC&FPJN\13=F>:Y9NIAFXDGQLH+L(Q?RM1$J!%#DN
MV](O2O0MSG;Z-SPR<9)X7S/]ML=%RO8>IIO5'JU_6<ID<[FLB\A=SBRU^Y8S
M%NX\O=HY.S-;*7FHR4([5.:P*6)I/+4>J7I-A4ZI,6#7?(8\ZKJZ.VSMB"KF
MC+O)KZ*I3M](1F+AM-JNW:OZU5I0T*\DHQ3";ET]@$R214?)5DE#T?5-]SE&
M,K>''ABW)=^^:/.]J3YGLWF'+JIURYF[UG+YG3>@6:EE\O*>:M16:NI*71V&
MFU.Y'%&$U6,8W6[3EB32D*9ZCG&^-VHXU!%*;#NMH9UFHWI[(46@3%EJC&@7
M6CN-@PM[?V=IDL6QJQH B&#N%3D-Y0]03(0_>/DEN.F9EV>FEAC"K6UT=4\+
M5.>OV#SK'5KQ+=TE:S=66L95W;EI*[=C"X[MJZK,K2@^^=S'6B5=D9-M458Q
M;=6GCA((I*Q6ON3DOF5UJGMZG(QNA+4NML'73?MS9+53L&43(\A:7A-3W3=N
MC-&N.Y_X=1QXB/B77H^96^5I4EA??K8^1/LOD6WLT/4EU0\2VY-7LQI<,&:\
MWN.6;MI6;S\"W<YI7=F",<4MO?*-'3:/9O(B/:<-ME<J].NHBTL(OC?>=[:V
M<3C&4Q"S>(?6TM>:N6=BDW,+-IL':K1$CQMA9H[(7)T^^DICM+BVLLWG8Y2]
M5-W5"5-ZK))TWKM&JZ7PY<GQIE>$]94[5R>IVLK>47'%'%>C:G@E24:JKPRI
M*.YT:*QM&]2CD86]\6&W(//$^YT+E/J:X;,:,N-"^P#;4TXC4=3([<=XV76;
M7;;2S.@6+5,Q63;G2,DY0<&\0V$,)J^I?TS+='=>6Z:-RU-1[^F&598>]:2[
M9U'7NK+AOZOU:?#OUO8U#2<Y;L-YU6>@S+N9AY==#.W;MNN+ODW6L7%4[ZJV
MN@>JIQHME/87*I5_>]H;V>Q5FHZS@X73=E<6;<-DL$+*3TA&ZMB%<H&LR5'8
MPKK$\\,=O'QJJ>"97/E1+OXDM)S4)X)NVFDW)N2I%)T[Y\E:[%O9J68ZI^)\
MIG)9+.7-/M2M6IW+\I9F"AEX0E&"=^6W!TKE'HHT<YIUPJCI*^M^?''O9]BU
M-4860N$-:-PS&V:G!0%OITI6)6N; T>Q:2FS=:WUG)8(M4;U7(UZFOEDXQW7
M".>^BHH7.,YLW=/S-J,YR47""BVTZU4O!DN=/G/)U/J_XBTK+9S.7XV9Y7)0
MR]R4[=R,XSLYIN-B]:<?X2U-IK$MSV22(BSU7.,+Z$AK!387>6S(Z2JL_L26
M/K?3]BM2M*U=7+=/4I[L^[I-3IY@*:XF:O(&;'SXCU=HURX*V\$Z9SWOJC-*
M3C-VX--1[Z259-)X5SNC78Y*GL>J7BFW?GE\[/(96[&["S'ILQ"WTM^=N%U6
M+5?#N*,X56R*E+#BJFEWUVZGG&JHN+BG$Q^XMGLJ#1==[4MT[J?5%DNM<@M5
M[-JAKM ;(E)YL5M&1E5;5KNNG9W*B+E-,QC$14*BXRC3#2LU-1Q8(.4I12E)
M)N471QISUW&/D>JWB?.1LN]+)96>8S%ZQ;AF,Q"U.=^Q<Z*=F,'64KCGWL5%
M.+>^2<HUB6]=30K';V_-84JASJM;U_Q#D^15 W+,ZTV1+:]<OD=<7'9$;8+L
M>(0C5$=1/HB!;(M'S==LO*RIUHQNH5YC&,7K>EULV[MR2Q2O8'%2BI>$HT5?
MMJO:N1;7L/7R'5?TFCZ?JF>S%M9G,:Q')W<M&]9C>2Z:W9E"UB;_ /B%*<G*
M+4E;MTNR3@2M-]1W4.OJ]04;A&;$V%<GVAJ)OC:RFBM4VZWU?5E&ML&UD?/J
MY>(LL\J56>*E=.&S199[+HL$,JK)9)W5%+4=,O7)2P.,8*XX1QR2<FGN7._>
M53R;'5KK.HYG,/)RRV6R4=0NY6QYU?MVYW[MN3716]B5RXN]4I)1MN;I%UJE
MD&Q.HUQ^H<LI!Q,5M[;DIC3U4WZ@VTMJZP;!3<:?M^7QH^]Y>,<-F$?!M&S'
M*SE1XJV\,BJ12X.JH5,46M,S-Q8FX06-P[Z27?+D[?:,?3>K;B'4+/3WIY/)
MVO/+F4;S-^%FF8MTK:HZMR;=(J*E6C;HE4E^^\I]:T_BE8.7T2LYMVLH[4AM
MO0&(]-:/?6B(>0B<O7HU%-^W*O$OIM9T@VSARD7+157/C%QW#8Q9MY2[/-K)
MR[VZYX7V-NWWCQM/X4U/.<6V^#KR5G5)9SS>=:-0DI89MT=)**3EWK[Y+8]J
M-3M([.ZG4M(Z/V-LO6''2Z:<W6O!OK?3-724U5=D\?:C:XXLG!6F3G-@VU*
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MWN,M8O\ 69KD&^DG*UI]J5&K&7A)QQI;:3D\2KLV]));)QI=>.6G9
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MG%[U*+<9)]E--';\IFK&>REK.Y62GE;UN,X26Z49I2BUV&FF9,+!D
M     >=SH._OWZC'X_X3[K[6&1?W1[19M;Y=L]$8QR\           !47U5]
MZ;";0FJ.%>AI,T5NSF'+RU8=61JJ;RO7FG81!)QL>UF(W53=-U'T2HJW34QD
MIS,D)#*!RN$DC%O6HK;.7@K[);FVZ0CO9*.B=(4#CKJZK:EUM$I1E;K#$B1E
MLII8D9V54(3,I8YURD1/RZ;F7)<JKJYQV8]@A,%2(0A:92<G5[R]&*BJ+<2\
M()                                           #!MEZVI>WZ':-:;
M#@VMCIMPBG$/.1+O&<%6;KXP9-PV6)V+,I%@X(1=JY2R59LX3(JF8IR%SB4V
MG5;R&DU1[C5;I9;/NFJKIN'IP[?G'<]8>/#9I;M"6F3\3+VY<=YIRV2BT,K'
M,9)4]'=2C-K@B><D;$=Y9)XPFP]BJZDTKBW/?VRS"L6[;Y/L%TXLEP
M       *6>NW.S#OAU1-&0+]=@_Y5\HM%\?EE69TL.R1L[-2-P76PF8V%SM/
M+Z4U15\/&>_XY4S_ +6H;&?<T",5G97Y;K-J<_>5/USM_4%E[,.-,QKV8BI6
M])TK-9M5K3%&,;:[%:79-5YJK:D6"UROP]2KT#5:ZP0BZ_68:+K\%&-B]QM'
M0\*Q0C8Q@W+_ /E09LFQ$R8_V%+@>=*4IR<Y;9-U?;9S_,YB]G,S<S>9DYYB
M[.4Y2>]RDW*3?9;;9JSOOC7.;?Y"</-SQMEBH>,XT7#9UEG(5\T=KO[,A?*0
MC5&C:)<(9PW:*L'"7BJ96[<&)GL+[(R\OFHV<M>L--N[&*3YJ.IM?#_$UC1N
M'=9T2[:G.[JEFQ",DTE!VKKN-R3VNJV*AKAK#I^7"A:5Z?VK'>P:U(/^'&WW
MNRK+*MHN429W)BZ;[(1+&0:*ILK,'9<WA+.3N.TG[0?_ +<#)NZC"Y?S%U1:
M5^&%=CP=_O&RZKUAY+4-<XAU6&7NQMZUDU9A%RC6VT[+Q2>YK[T]W.C7%STI
M-OIZVTC3W5ZX_;$<\7=A[TE=0PMZI.RHRI7?7O(2=D;3=H;;2E<NYIIG;(BR
M+-7,.]A<IMFZ;7"+A%SWSJFROK>STMR:C<BKL88FG&J<%1.-52C5:I_ ;+'K
M:T9ZGGLY&QJ.6CJN6RL<Q*U=LRN6KV4BH6I9?':PNW*"E&Y&Y63<L491HDMC
M^._3\L6F=J:"VF]FM31;C7$'R'\^:KJVG3U7K$C9-WO:>=B>K)34U/RJK.NQ
ME11;N'<FZ5>R!\85-@F<]S&+F=1C?LW+24WB<*.33=(UWT2WUY-B-9XCZP\M
MK6DZAI4(9R<<S<R?17+]R$YJ&55RO288PC6<KC:C"*C!;%7>0S=.F!L64T3K
M?5J,EQXVBI2=K[\O\E6MQ5.[LZZ_;[AN\E<(*1J^Q-=2<'MR@66H&<IIN21S
MTK*7[,>-@G@)&S?MZK:68E=:NPQ0@JQ:KWJHZJ58M/LJJ/;R/6GIMK7LSJLH
MZEE5?RF4M*>7N6G-/+VHVY*=F]&67NPN4;3G'%;^UKB9._'K@5>-47'CM9-C
M[;:;?3U#QEVOH6VJ6%C,NY&V*;*V.RNK)%LM.24RJI4JE7V^()LB]76<*L6R
M/>[/IBXQ\SJ%N]"[&U#!CNQFJ4V88TY*;6]O;/ XBX_R&K9+4LMIF3>3><U3
M+YNW@<4K?0V7:;:C&/WRY-]+)Q22DY4YS62O='!ZRTANS6UAVW#6.V3]IU47
M1=EF*_+2L31]5Z(M4K:-;:WMT<I*L9*6CI#%A?,Y?+)TADQ#(*D,H=N0N<J6
MM)WX78P:@E+$DU5RFJ.2YMR:J;1F>NB%S7<CJ>7R<[63MVK_ )U",XQE=OYJ
MW&%Z];>%QC)8(RMXHO;B324FS=CA)Q)L7'60V=;[O!<?ZW:-ADJL8C!\?ZS=
MXZ!C(6JIRV4\RUGV)89NTV=[)/)8RI4SIM4&&"F(GA3Q,FQ@Y_.1S*C"V[CA
M&NV;5:NG(DDOUS1^.>+\MQ);RN3R-S4;N4RW22Q9N=ISE*YA\&%F$8045&E:
MR<][I2ABFN^FUIMOOCDIN[>.O]0[HE-O[;C]B:^4M-%83\G08MG"M&*D,LM8
M&KQLLHK)-<./VHOA9SV=N.T5W-3O^;VK&7E."A"CHZ5V[]AEZEUF:U+0-,T+
M0LQG,E:R>3=F]T=UPC=DY-XJ0:?@NFW:93+<(<6RT=1)Q9K<T;U7G+5-<U*/
M3A(];$[0FM,TA\4[I^ZRY428RCC$EGW0:I$R5+N%\-3_ +QA0L_@AEE&/?Y=
MR>W<ZRQ?L&+9XZ\TRG#<<K9;S>@WKUQXFL%UW,UYPDJ;8JG>2>^NU&FM"Z4M
MY3I>RZ=>GG&*IN9KCE==#T^[ZCUYL1Q<I26M\2VA%MAWE[>;N[:Q9%&#/&7<
M)"I)(.7"YE,.4R)IHYS;FKV^DA.WTK2NJ;4FJ*CK147O-^\;IJ'6UD'GLKG<
MA'5+T8:E:S5RUF+UE6XQMR<NAM*U:3EM?>W;C;25,+;<CJK9TM=Y6*P8OTI+
M\2+]>;QJBCZMV4GL"A;@-4ZLOJY"7J-+N^K8Z'V 5Y(/7VMUF",Q%3:IF3F7
M9F<)J)MU?)4ZH:M8C'HTKT;<9N4:.-7BVM2JONJT:VT=-^TO9/K6T'+9?ZOM
M0UC+Y"QF[M^ST-W+])<5]QN7+5]RLT25Y3=NY:6*-N2BTY+&]U-3\(W^JK)R
MH>QUHK1X#>F@^/.DJ7&1L XAR5!'1^H+;J]1XZ8)KN6J$5*'GVZ[9HU4/Y,@
MAE/)C9P7(P;V?5Z%E-/%;N3D]M:XI*7ZQH^K\<V]6RVDPN6KOG&0U#.9FY*4
MU+I'FLQ;OT3HFY1P-2E)=\W6A'M!Z?MPI_Q#^4[!K3SXHN"-ZXC2/@1<HG[L
M6*V^;WD]O9>(;]HA6GN*;OH*?MYN_CLS[&1<N:C"?24B^_S"N=I*NSM[3T=0
MZP\EG?K##E[L?/-?M:A&LH]["WCK;?/)XMC6S83O!\69^)Z?*_#12U0ZMF5X
ML6'C[BYD9/2P6)B:UO)T=*PY8&S[H>YJ+I]A<R7;XN4RYQCV1CRS<9:CY[1X
M>E4Z<M%*M#P;_%>7O=8BXU5J:RJU:&;Z.JQX8WHW<%=V)I4KNJ8UHWI^Z3T9
MH>,I-4UIJ6%W6KQ]9ZBN&YJ_1XV/G;-8UJ"A6+-9EY?R3W?\EL<Z51\Y)E7"
MCCOX\7O&QCLKS&HW\QF'.<INQTF)1;V)5JES;%L,G7>L/7->U^>>S>:SD]#6
MHO,6\M.[)PA#I7.$%&N"L(TC%THN2B("V9TUK!:^./"S7<98=96'97#J'1B6
MS'8T+;'&H=F,96E)4VW1DZWJTO#W"$\JRV;OF#UNJJHW<-^PZ*A5,Y+D6M4C
M#,W[C4U:O.O>M8HT=52NQ\S1L.E]9N6RG$NMZC=MYJWIFM3Q-V96UF+#C=Z2
MW*+N1E;E2KC.+24D]C5#I;+TQ[E+\5(_6U4MFH-1[^B=[R>^X"XZMI5EA=?5
MB:L5?-K^Q5UFA*3LU<IQE(ZZ4\D7>O7&7#QPB@=5/'A$SB8ZI".;=V:G/+NW
M@:DTVTG5/<DN^VT6XOY7K1R5GBV6IYNSG,YP]/(1RD[=^["5Z<83Z:$VXQC;
MBU>[Y1BJ13DD]K,6VATFGC6RTZ:T@GH&>B6''[6^@YZM<@JQL*380IM;-'T=
M'[-IZ^O;1!JR$_+,7^?+XR3*9J[<$RL=QWE38Q7:U=.,HW^D3=R4TX-;<7VK
MJGLYFMW,96E=;L)Y6]8UUZA;O2U&]FX3RD[,7+IFF[%Q7H2I"+7>3AWT4\*C
M1(G"I]/*9IM3YMU"(NE/;Q_*+BKJ3CQ4DXNLO(*,ILIKC1NP=4/Y]Y"(.WJ+
M:"DY6Z$>MF+594[5LEE+*AS=ALV)ZE&<[$W&5;5V4WMK7%-2I7GV4J>%F^L:
MQG<WH><O6+SN:5JV8SES%-2E<C>S5F^H*32K.,;;C*<DL4G6BW&+V/I[;C.Z
ML#:I;3UHC7-D]/)MPAV0SL51M+F;;2=>UI>JU6+O2)>-L35@V8+VZS-'#]N_
M8N5/<ULLDEV+*D52KCJ5G8YPEBCF>EC1JFV2;3V<R=*/>9>6ZQ=%4+<LWE,T
M\SEN(WJ=EPN6U%QG>M3G:NQE!MM6X24'"26.2;[U-/Y/N"')77:]D6XZ[=U!
M$XW;QCTOQWWN39U/M4TI%RVF:'(ZYA=H:L5A)-N19Z:LSKLA8>4339Y<%(LJ
MJIWO#2+4,K=IYS";Z.[*<,+2\)XG&5>RMZVDPX^X8U*-J/$F3SD_,=4S.<RO
M07+<<4<S=5Z5B_BBZ+'"+Z2VW*E8I*E7)VKN *^H[);#UN\,GM3D.#>O>(=>
M0DF#LLXG)T8EI35NDR=)51GEI+9GRJ9;(YR9(Y3%+GN]T6KNH]-&../?J^[C
MYMM-B]X\K5>L*.L9:RLS8E'-QUV]J$W%K#AN]']ZCRUC@IB>_9RU)@I_$:)_
M06KW"S9<NG.QB6AF.F++8Z^DJS\55O720V+'!HO<'.W<L'R9'C4J^#EPJD3"
MA3%[2YL3SC\_>>M*CZ3$D^W6C/'SO&%[_GVYQOID';NO4'F80GMWSQ8)4WIJ
ML94IL;I0@K3O&;G=$3>CZ=N+E)05M%\>7,,K#ETU5[I3]K;V9U.*/#56&WC*
MS%BD:^C I-RHJR3*-(JE*F)DJ_>/DK@F1>S6GN-R=FU+SBY6N)IQA7:W#96O
M,WN/>UKBC@&]8S^=T72LPM>U%2Q><SMW+&5=R6*Y+*QC",W.M5"4VG;K6.RL
M7K!K[I8\@8W9^O-D[+V_J:Z6+7B?)*'?WWW.VA(;2VTQWOKB^T9A9=@6.UV6
M=B8E_5E;@B=&#AF+:-31;*8*X.94G@9=S5LN[4K5J$XQE@V=[AC@DG1));Z;
MVZFTZCUK\/7=+S.F:9D\W8RV9\RDK5;"L9=Y6]:NN%F%N$)25SHVG=N2E-N2
M[U)/%,VS.FM8+7QQX6:[C+#K*P[*X=0Z,2V8[&A;8XU#LQC*TI*FVZ,G6]6E
MX>X0GE66S=\P>MU55&[AOV'14*IG);%K5(PS-^XU-6KSKWK6*-'54KL?,T>+
MI?6;ELIQ+K>HW;>:MZ9K4\3=F5M9BPXW>DMRB[D96Y4JXSBTE)/8U0W%X9\=
M'W&G5$K49EIJ]A9+9?;%L.RL-/5B:K%#82DXUB(I!A%)V6:GK)-'8PT T1/(
MR"_E3K),=\I<%QVX6=S*S5Y3CC<5%)8FF]G:22VM[$:9QKQ);XGU>&<L/-2R
MUG+PLP>8G&=UQBY2;E@C"$:RG)J$%AC78S*N76JXS=W%[?VJI5NDX1NFJ+M&
M,O&*F8K.>3@W;ZLRI,*F(EY1#6-HU=I9-G!<*H%SGV!1D[SL9NW>7VLU[U=O
MOK88G!^K7="XJT_5K3:E8S=J3[,,24X]J4'*+[#.OZ0NU9+<O3<XG7&8=*O)
M5EKIQKYZX<*^,[6-J:T6#5K5=ZJ8ZBJCIVPIZ*QCJ9RHKXG?-[)NT3K-E6-3
MO06[%7XR4OUQUQZ3:T7K-U?)64HV99E7DEL2\XMPOM+L)W&J+8J4Y"R(>8<S
M   "H?KH[(G=>]-/>K"K^)BQ;4>4+3<<=-;"&/)M@76%C[&U5.8R:?ARM21D
M&6>^HFGC+G&39R7&2&Z5U29&SG>.\I/,?P.75R\^W;A)Q?N3PRY=QR[KDS]_
M(]7V=AEOX?,NW87:NW(J2_\ >ABCO2V^X;&Z<UI":9U+K/4E<222@]:42JT>
M,\%/"15FU8A&405VH7_O'</3-,K*G-G)U%5#&-G)LYSGR-3SUW4]1OZC?_A;
M]Z=Q]N4FZ=I5HN9&UZ1IUG2-+RVE9>BLY>Q"VNU"*C7MNE7SMU9)(P3T0
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M#F_\UF=SZE/\FXK_ /2^<^PBRT>6<T
M                  "N/_+^?X7^E_X7;D_G2M(]/B+^M9]J/^"CHWZ0_P#>
MIGOXG+?R%LND'AG$0   I#Z]F,*\4-%LE<859R/-WCDQD&BF.^V?LE'-L449
MO4#=J3IJHHD4V4SX,3.2XSG';C ZOU/;.(LW->%'2<RT^5/O-JYGV3D'73MX
M;R4'MA+6,JFN1JL]C7*NPRQH::=*
M                "N;H+_U6N0']^?DA^[4\;EUP?E#DO[(RW^.<UZE_R=SW
M]LYO[,"[L<H.O@           >=SH._OWZC'X_X3[K[6&1?W1[19M;Y=L]$8
MQR\           !0WQ-QC/-[JEJYQC*IMZZZ2,IG&,J&21K%DPBGD^?ILII8
M/GNX[>PO;GL^B+\_ CVBFWX4NV6/BV70
M                  *U.H%_*?TUO^HIQV_C#@7+>Z7[EEJ[]K^Z+\!8*@
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MZG_RASO]D9G_ !#D'71^3N1_MG*?9F6,C33I0
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MK>35&="  !0YQ,_KM=4G\?&O_P"+%B%^?@1[13;\*7;+'A;+H
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MNC\G<C_;.4^S,L9&FG2@
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M$5I'Y'-5_-[4?>@,4N=BB'Q%:1^1S5?S>U'WH#%+G8HA\16D?D<U7\WM1]Z
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M8L0OS\"/:*;?A2[98\+9=
M        K4Z@7\I_36_ZBG';^,.!<M[I?N66KOVO[HOP%@J
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M7ZG_ ,H<[_9&9_Q#D'71^3N1_MG*?9F6,C33I0
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M@OM&W(H*BASB9_7:ZI/X^-?_ ,6+$+\_ CVBFWX4NV6/"V70
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MHMHG%*GA#U-O*3<.HLM,X4PBB^P]K[G&$<ER;)<%SV_3",2Q8>6A--E2=!)
M    !7-T%_ZK7(#^_/R0_=J>-RZX/RAR7]D9;_'.:]2_Y.Y[^V<W]F!8GMG^
MLWQ(_P!_7\W\:.5+P7[AUY[T:G<L.&VQ^17-_C[?F<_MS6^I*9I/9=<M>UM)
M;78:OO4+:):8:/8&O-W;.0\[W,;-HD-Y3Y,Q6:Y*7!55"9[,"N$U&#6QNO*4
MRBW)/;2AT%JZ<%%KFT. %+HFIFNP..^F;[R2O.['.R9F!N#E_9;_ *S/FK6^
MZ,[>^+)WF:FME,V9^UHR=$:*()&.D@W2+DLJXVI-OOFE0C DTEN1%=LX4[PE
MK%=F[?4\:ZITUU:./?(AG&*3VO<0[OCE2:[58>V6,\,O82HDC8U&.7;YA5$2
MR;A(G=29J$,7ME3C3?MP->Z0XNO8Q(X>.#.X63Z;E(K3,"QDS]:FD\I8F192
MNMF;Y+C##J4U5];FSM&=2<-8YJJVDC8@N\28,8ZF2L<Y5^G8X\_VE/=&%\WV
MU?<(UJO%;E_,<JM57VTZ(D:[!:[YO7O:MJD*S)\9*MJ%.A6PUL;QMWI,3 M8
M[=E[L,HR79.;#(6*6<R1E5$TT8]4Y5/)9<X8&D]\>S_["%&6*M.7L'%F>)#/
MBSTA:M,W6FZYT?RBT'-USD(:?>R5$;S<WMK56T;#<JQ#25X@GTBWN4].T9X[
MBHAJD_=*%4?)MT2_2Y1#%CO;-L7L#CAM\TD6@].?6<_KWBW6K/>&"C3:F_K#
M;>3.V45"'0=YO>[94]O48NV[DJ*C5]!UQQ&QBJ:G9DBC+.,]GT,6KC3E1;EL
M]XK@J1J][VE4=BZ>G4#O-*V3R/7O];JN][)R:;\MJWQ<?TG7L].LKQK*Q/(+
M4-;QR-1VDO#1+:-ULEA%LV2RO')-W.6SA7OJ+'3O*Y;34?M:4K]G86W";6+[
M:M:?LDOW/A'NVX\7N?;+&B(MGO'?'.2$W5JQD_G]5KVIQK)O?M!6(KK%T0LZ
M\/"9A8R'M.,-%Y%NXSG+@J21O*T\+TJ<5*.WO5&GV2IQ;B]FULP7?W%;E_LS
MD?<Y5CHB1/6XWF=IS<E?G:9)\9*AK:SZGIDG3<9MMBD)EJUWU=]UM6#-\FNV
M>2[&)9M"*$;)*F.@DO,9P4=_VO9_]A$HR<MW+V#X\C]6W[C%QEWAR$MS6NTC
M:.JNJCLGEUQ^C[!;:T4NU*C=+Z@V;5)HO#R[YT8^Q]>R$DJ>%QE*8,5EV';I
M&)VE1:E)16YQHQ).,6^52J?[>N"6WJGH'AH2N:OVQ<-HTVB;2GMG7G4=RU&S
MOD/MK?IHNVW^&O6L=Z1:%"V/09F==*L')B.VKYJDP(0R64#=T%..*6U4[G:#
M@U%;-I(U;X><HYC$*YVCI373U9YTH=C\:+?5Z+9:)J>C.=KV7<D198_6\2UH
MJ;AI39"1H[4RJLG$PQJPVE,'PF<B!B)B,<.1OPZDX9<J^UH=5Q=X]<F:% \C
M4+GQ1>[9UE):)IE,IVIN1\GQ9C-T[+N5=F/#7UP]W5K2-783FHXF!*4S9S:D
M^[AT1/+1NEC+C)TY1;5'1UY*T][N$1C)5V;*=@LKY=(J-NGMR>;K5UO3UF_#
M3=2*M2:.VK]K5E$M(V5,]=;/F)$V3QO"&+EL15$I4E"I8,3&"YQ@6X?PB_=+
M[)<EX#[1N6*"HH<XF?UVNJ3^/C7_ /%BQ"_/P(]HIM^%+MECPMET   ,?MEK
MKM%J]ANENEFL#5JG"R5AL4T]R?#2+AHAHJ^D7R_A$45,1LU0,;ND*8YNSL*7
M)LXQDDVZ+>&TE5[BN*G]6GC%:K15(60KV[J%5[Y-YK]*VSL#7!(+55GDC./(
MT2QMD;STD^(V4>&*F=9=DBDU[W><F13*<Y;KLR2Y*EI7HMTVT?*;W_'-K+XV
M_B)\[&GQL^:'G[YF^22GEOFCY;[G>[7EOD/N1X'EO[7W/*/&[?9[G9[(MX73
M%R%S$JX>4DX02   $'R7(77$5R!@.,SMS+8VE9=>+;0BVB<4J>%-5$).:B%%
MEIC!\(HO?+(!QC".2Y-DN"Y[?IA.%X<7)4C$L6'EH3@()  CS;.T*KI;7%OV
MI>%GJ%2I$0I-SRT:S/(/DV*2J2)S-F29B'<J8.L7Z7&<9[!*3;HMY#:BJO<=
MM0;K![*HE*V+6%'*M:OU2KEUKRKQN9F\4@[5#LYV)4=M#Y,=JY.P?IY43SG.
M2&SDN?H"&J.CWDIU55N-#=H=4CCAKF]VO7\/ [CW'*:^541V-+:7H"=PK-!5
M;+JMW^+)./9R!;E3C%43E<*M,.D4U"'2[^54U$RW%:DU78BV[L4Z;7VB59CG
MMQIB^.[/E&WN+V?U(ZFV5:5D("$?/)R,L3Q7P#0<Q7ERM)*+DF:N<>*FJ4O[
M6=-4F3HJIJ'CHY8L'*3TD<./D-RA05@ 1C\<VLOC;^(GSL:?&SYH>?OF;Y)*
M>6^:/EON=[M>6^0^Y'@>6_M?<\H\;M]GN=GLB<+IBY",2KAY23A!)&,5N;64
MWM6SZ1B[8T=[3IL!'VFS5 C24(\B8"4Q'982*SQ5BG%+).<2S?L*DX.ICQ<=
MI<=F>R:.F+D(Q*N'E.\V)>X/6%%MNQ+,61/7Z7 R5CF2Q#!:4DS1T6V.Z=88
M1S?]O>NLI)Y[B9/ICY]C A*KHMY+=%5[AKN]P>SZ+4MB5DLB2OW2!C;'#%EV
M"T7)ECI1L1TUP_CG'[>R=824QWTS_3$S[&0:HZ/>$ZJJW&9 #'K?:(JD5.T7
M2=.NG!U"NS5HF5&R.7+DD5 1KF6D3MVY<X,NN5HT/DA,9QDQNS'^T$JN@;HJ
MF):9V[3=\:RJ>V]?KR#BG7-H[>P:THP4C'ZB#*4?1"^7+%4QU&YL/(Y3&,9S
MGM+C&?\ :)DG%T>\B+4E5;B3A!(   5J=0+^4_IK?]13CM_&' N6]TOW++5W
M[7]T7X"P5             !25UD_WS=+C_J;<<_N@]'NZ+X.;_S69W/J4_R;
MBO\ ]+YS["++1Y9S0     X*<7&(GPJC',4E2O'$@51-HW(?$@[3.B[?8.5/
M!L/'22IBJ*_]\Y39QG.<9R HC ]IZN@MOUQK4+3(S[:L^[\/,ST-"/FS!M<8
M^'7,Z\T;0HJQ=NG-2E76$CO6[91JLY*B5(RW@F534E.A1<MJY'#*N&OO]A]@
MDH05GR701<HK-G**3ANX2407073(JBNBJ3*:J*R2F#$424(;)3%-C.,XSV9
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MBP6^>=LH1JU/-6=[/3F6R9B9>?M[G*TMUV%F%E0EB<I2:5%6FSX%7MNK[)L
MW8,6A7)6K)HV*]<+/'A6[=%$KMVYP7#ATYPF0N%W"^"X[YS]IC=F.W.1!>HC
M_6;)G'-DV<>T;,6B/?\ !:LT$FK9+Q%#*J>&@@0B1.^J<QL]F,=ILYSGV<@*
M4W K)F1VJ_(T;$?+I$07>%02*[612SG*2*KC!,+*))YS]*7.<XQ_L 46_E/]
M=LVC]NJT?-6[UHMC!5FKM!-PW5*4Q3EPJBL4Z:F,'+C..W&?9QC(#?O.04I2
MEP4N,%*7&"E*7&,%*7&.S&,8Q[&,8P .,Y9,WOD_EC1L[\D<I/6OE*"2_DSQ
M#O> [;^*0_@N4>_GN*%[#E[<]F0%*G*             5Q_Y?S_"_P!+_P +
MMR?SI6D>GQ%_6L^U'_!1T;](?^]3/?Q.6_D+9=(/#.(@  !2)UZ/ZK7'_P#O
MS\;_ -VN ZOU/_E#G?[(S/\ B'(.NC\G<C_;.4^S,L9&FG2@    "DC?6KG=
MIZ@-PM/#GEA :DYELM5PT7L?5>R*!.O:G:J7AG5'C%Q%VJ5JLG7GC5U'%A\N
MFL:C*.4EF^5BG;JHKE+9DJW*P=)T*ENV[C4"R[ D]U\5^HQK#96N]7:UV[Q]
ME:[<[_L3B\V85*J[LLSF1MT<;XR',8BJK;55'WEKEQA=3'EBRIS&2;*H*%4H
M;K"2:2:YN4GE7,2%9HMJQXZ=,_CO6+]R5N5CVGJUCLOXD=8W2)JTMLHDK0H&
MWR439-PV6SUMC1]?TCO/T8>.(@^(DT2,F?!,H-UB2_!C%5K3<.5L@Z(VIN:K
M\'NI_4C7W9, MI/<&F(6@,WFVWU\M&LD)G<T-#3]6B=HQ1H]Q(M4FL85HL9I
ME)JKGQLE)^W*F4BLE"2V['^N3151MA6JQ<./O-3IZN8/=NZ;D?D[K:UN-TL=
M@WR0LL%9Y"+UZWF&SEI!+E(QAV[60DR&:-TL939$:($1[N/%\6I5C..U[40]
MJ?8-8:_59;DAP>YA<RMK\@MLQVYV\CM*O.:8CL->/H%2A6;=D5OJ"1H+O)(]
M5E9FTT9FBV4*GE/*S8[9(KE/)U::.4'-MU_5L&YT6XSC#E?:54X#:%KTKR!V
M'-,N'E5O4GQ\T]>8+2U5=,E6CAHG?;]MV=M,:D51LHT13;1R<:\51(W,8BA3
MN\)*SO48[7LW;ANJ^R0A'[EWW+]/:EMFVZ-B1-J@^J#'::KEO\^W]GGH>EGU
M0\EV5=>VELJPS=X"-GY=1P5-?'D;HI$\%2(B5),E-9='O^V)HL7N&ZFY=-S%
M8Y+\0>!DGR)W^32VPVFS]KWN\SFQSM-B;4OITIA\A4'US91T7XD>T>P"&6S(
MV%E,>ZANW*CGR55.MKOU"KHR$]E>4S/@A2F6N>I9SLHL;>K'L>/JU!U)$,;3
M;IXMGLIVC:OU/"%?F)[!C*R3REI9Q"Y46SY3C$?@JW[;@XF"I=DB'X*.SYMO
MHBK=3SIZ7':Z[=GIQ"+O$;$24WE,E=B]G'0G4XEXLZ<X39L72-EDJNMXQU,8
M2\!-3V,)YR$]EV+?@A>"^<^?4NE(*Q<KNG#4J"]9/]X1V_(FP$2A5$'4S":]
MS.TU_)/9[#7QUVT Z2CU'12KD,BLT:.S8QDF%<&7-LHI>%41W,U[TQQ[IN_^
M275';77=^R=5LJ5N.2L#)O0;\:C,8MR9WL!0^Q[4FAV*3S6JDCBE;E7,1HU(
MHXR;M.L0R=,8J4I5;6TENB1#[39_*?DEQ3X4I*725V*Z1L>W(^^:=@N04+I;
M?/(JN5"5(RJ,_#R,PL:?O#.JM(V0:/C,F\@Y47:9<+)K..\X;16<XQ[M&QL3
M,P4?P>Q^GYSEUHYNG*2#L7'JQQ%KDM5;HLB+RQZY4D23+"&HI[BU[[JZZYD4
MV+DRC!T@Q,F\9>+A+!52J*M]N2V[!RHZFQ'V<WK?3&XJ4J1W=;];[/XXQNY;
M54:7N.%UW=-CV.;J"MF7H,??[;)5^$C:?1#LBY91)G&<HQJG@)%,N1LH0ZTC
M!5HT-FU]DQK==-W@3@AS4I^Y;#>VE7T)M33UCTO7;!R#UOMN\QT7=-B-Z5.Z
MWW*IKJU6I5>+IZ&6[N-:R16&/=/]N;D[&QTDTE+HY*6Y/G^R2J55#8?8FN;E
M(;XZ:/&"F<@-YT"F; X\7M:SV.OWY^I:I&/5IEINDLEEVO@T4X?JQY5HR.=K
MM%SQC<Z1DL9,@02T\48IM*A'(V9=9+_L/C9R^Y,5.D72^VR$X^=+!:7H<-;Y
M]]8VJ]HU^GK6,A[Q888B;>!D;(9-MES)NTV2&7&#K_\ HR*&QB:N,VE79$;T
MNV?/CWI>/8:CXE\MY?GSL;7NVMJ6BNS-RDMC7AS=Z'N%[/.'RLAI1.EO[776
MQ'R)V/N>10B[I1LHV6[&WB^!ELBMBGBVLAO;2FPT^Y.VBVW6.Y><C=:77D_=
MF^M-P.ZU"[Q/N6)TIK+44M&V2$:?%]KS5;.T3MOO#(D?--VZ#DB,:HL14KA4
MJ2WB&6IE5UE&NQ[^8J7,;UT*P2]MZG?#2U6!X:0GK-TRZA8)N0.1),[Z7F9&
M_P E)/#IHD313,Y>N3GR4A2EQDW9C&,>P*TZW8O]J1]J^V7D"\4     %<W0
M7_JM<@/[\_)#]VIXW+K@_*')?V1EO\<YKU+_ ).Y[^V<W]F!8GMG^LWQ(_W]
M?S?QHY4O!?N'7GO1M0*22"]Z[:L6JF&O$:A1F6P;5LO94?K:!@Y.W^8\8B]>
MU6WVU62D)_%<M:B+=NPIRQ,$*S.8ZBI?9+C&<BJ*KOW)$-T(ZC=\[JD9BVZZ
MSH*N--S5.)I5S/5'&Z2GH\QKJ[OKG",K#&;#:ZU</DIR.L%&>-G,4[@VV<D.
MDLBX5+D^$YPQWUV=HC$ZTIM(VA^7VXGVF&VZ9'CI6(Z'L=JUI0Z)$H;V-(/I
MVX;-WU3]"Q;.<5SJ5DE68=A,6HSY9X3#\^4&W<PAWE.\2<"Q8:_!V*D8G2M"
M<=;[JO,ULY[J':VJ66M[@:BJ[&KSBM;#9[*K4U66,\QK4PF[D?-NF2\%-,)6
M5:^&@O'&;NT%3'1<',@NFG2XJE4ZHE-UH]Y'VRM@W38.P=AZ;@.,>M=VUS6/
MF%+3:^R]DQD"R<S=DBG%AALQ57E=67=BJ[B4V^>XY4<HF*KG&2]S':82DDJU
M:;#;>RE20Z5RMTK;X;6KMS;HZIV?:,'$34!KRQ/&9+PF24DI2#43<0\<N_\
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M6KO\(R[:_@T;]B@N   !6IU OY3^FM_U%..W\8<"Y;W2_<LM7?M?W1?@+!4
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M]S)E%HL9D[*3+5X5%3**A\$/V&FMY5"[;N5P-.A)@@K
MKC_R_G^%_I?^%VY/YTK2/3XB_K6?:C_@HZ-^D/\ WJ9[^)RW\A;+I!X9Q$
M *1.O1_5:X__ -^?C?\ NUP'5^I_\H<[_9&9_P 0Y!UT?D[D?[9RGV9EC(TT
MZ4     :E\B>#G&#E3(QDYNK6+*Q6:'9$C(^U1LO/5>R)Q::ZKA.+=2E;DXM
M:5CD5G"IDD'F'":!EE#)8(8YLYIE",_"1*;6X[B@\->,^LM1VK1E-U- 1FM+
MVT6:7>$67EI%[;B+M\-CJS]BD)!S8WSA)/'_ (<^7>,M#9[6_A9!0BEA2V"K
MK7E(RG.FQPQGJ)K[7#G4&6M6U;(STE1B1MZV*RG(0]HDO=>Q-"VQ.V9M+R.E
MI#.5#(+O%4T39[4,)9]D1T<*)4V(59WT?T^N($11=HZRB-.-8F@[H4IRNR*K
M%W+8D=$3ZM!E$)JJ+-T&5N0S7EHV4;$6.>,RR,[-C.'&52F-C,]'"C5-C%62
MY+<<=,3EST]L*4IOE5OT%&OX?4LOYPVM#S3CI2*0A'S?R!O.(Q<[X\6V(EWY
M-!XH7N]XIL'SDV9PQJGRHBK-?;;TS>$UXO=NV)9M*LWLY>S2;JV,VULO,/7)
M>9ERO"/K&>N0MECXAK8#^Z"RB;I!)(R#I3+I+!'?[>*7;@W5K:3B9VUWZ=7#
MS8:&LFUGU&FX2U%4F- I9F5PO<6[1HT9A;R&IS<G'V9O*6>';9<*9*616<JX
M\54O?[JRQ3G;@Z;-PJSM6G 'B-'TU/7L?J)&/I"&XF>_FM88778S.(8;9CXI
M:$9VB-:MK>D6,10B%\M\1K?PXG*1$\9;9\)/NNCA2E-E:BK) Y"\5M%<I86"
MA-UTA.TDJT@K*U>4:RTU7;!7GS@J)':D5.UZ0C)-!!Z5LEXR!E#MU3))G,3)
MTDS$JE&,O"(3:W'6:/X=\<>-]BL%LTMK9"DV&UP</7K'(H62XR_NM&P::!&.
M7+*P6&6CBR"JC?"SIXFB1V^<F.LX45544.:(PC%UBMI+;>\S_<^B=1<AJ<K0
M=ST2%OU54<D?)1\KAVW<Q\@FDJ@22A9F+<L)N"DRMUU$\.63E!?PU#$[_=,;
M&9E%25'N(3IN(6X^<">*?%^=<6O3VJF,-;W+99EYV3,Q/VRP-&3DIDW#6)?6
M:4E,0:3E$V4ULLBMSKIY[JN3E]@4QMPBZI;26V]YB.PNF?PLV=8;A;K7J!5:
MU7^RN[7<;#'W[9$7)3LI(KF<222YV5N20:Q$@N;OJ,6Z:+/Q"E.5,IR$,4[4
M'M:VC$S/-B\&.*^T=<Z_U5:M2Q&*?JA+PM:H0$E/5B7I9383RXS#6* E(^>_
M]X+)$7=X7<+%>NB%<+X47*53$N$6J-;$*O>=EKWA=QGU?JFZ:5J.KHMOK[9"
M;DNPHV3DIV<D[F=VB9%5>?L<O*/+"Y62*<V6^2.4\-#FR9OA(V<Y!0BEA2V,
M5=:F&S73PX?SNIZAI1WJ)!*A:^EYF>HB#:VWDMBJ4O89#W5FW<+<UK*O;D2R
M4A@JJJ!WJC8QDT^U/L33[L='"F&FP5=:F45CA#Q;J.E+5QZA]2PY=4WM9!W=
MX)Y)3[Z2MLDV=L7[:6G+2YEE+2YE&4A&H+MEBO"&9JI%RW\+!<8Q*A%1PTV"
MKWG/IO#7C=K^=TS9:CKCW)F^/D'::WJ%[YWWQ_YHPMU+.DLS/R:3M#UI/^Z9
M;,^_;)--ZJCX_P"U&3[B?<*$51I;A5F<%X^:=QM^R[X/2FSG:=PU\;5=FL3V
M5GGS.8H"CN,?*UMW57DJO4,MEG$.WRHJ5@5PH0F2&4R0YRFG"JXN4BKI0U_U
MUTW.&NJMDQFU:7J!NRM4!+.9ZK)2%GM\[7*E-.U"K*RE:JLU//Z_%O4ER%4;
MG*WSY$H0AFWA933R2E6X)U2VDXF<&?Z9'""T6N[W"?T>PD9+8+J0DK&R\[+T
MQ@,S$LHJK)3D/7XRSLHFOS;I18^<.F*3=9ODY_ ,EXBG>=%"M:;QB9.U?XO:
M-J^P:#M2%I2S:_:PU5'Z3H]A<6R[22T-K&*,_,PK1V4G8WD9+9;YDU__ !KU
M!S(FP?L,OG!2]E6&*=>5(59/PD@     KFZ"_P#5:Y ?WY^2'[M3QN77!^4.
M2_LC+?XYS7J7_)W/?VSF_LP+$]L_UF^)'^_K^;^-'*EX+]PZ\]Z-J!22:P\F
M],.=W$T;!'8/7U;K&](FZ7?W,M4M39-I5V&N=F0F7<?-U^8@K"DX+/6!@3)&
M+DBYTU#=N,I84P*HRPUYZ%,E6G;)*UCI36>GBSF:!758Q[9E6"MBG)>?LMPM
M$[B)2<(P[:6MESF+!9G\?#)O5\,VRKLS=IY0ME$A,JJ=Z')O>2DEN--[=Q]V
M ^X+UG2[_7K2]VJ&V?IVV636V)RLHM[54Z7RVI6VK; )S$U*,*P965U]".RD
M(X=I)**'PD8V#9[!6I+'6NRGZQ2T\-/U;SL^/FB'M3WOC9E/XZ->*5)^+.?I
M]YK25QJ4R^VW8'5AK4K1)!Y5M?3-EJ$>TUTR:S6$)59X265/-*-BHX;8,<R4
MJQHW5U"5)52HC,'?$ZM7_?F\MA[.AK(X@[6SU<PIZL#M38-0:2+2NU9['V%&
M7@*)<X!J[PG(+%)C,@W4,HGG."YRGVX$8VHI(G"FVV==L+C!*S\UO.NT"/@M
M>5&Z\&F/&?6LY%%:,&]*G#O]OMB-8Z+C2^Z,7#P#&TQ+@N44L)G\(I2=XZ78
M4I;F]KQ5(<=Z6ZE")=7<<;U?K0^8[FJ.^H>F-^/NRM(OC[<VAQVF&.6>T5:0
MTG:_J>"T!6DWRE1PSIB*Y9.=<P+QJJS980B<F.JHUJ<DO!I6M>7]<A1;WUW'
M6V+CGR+M] J^T;O[NDWY#[IHEVM\!JJS:Z9VN6HNKM27?3,+!:^L.Q&$AKA%
MP^M5TDMC,6<T9-)J[EUFF7;1T5-PB4HIT7@T_7K^P,,FJOPJ_J[ID.DN.^S&
M>W*'MVW52\L<8VGMB]39]Q7G5%QV8PS-Z*HNGZU8)Y+4\2PH,)895A5CQYFL
M(\G,)1B*)UW^3KJMT(<E1I<WZY*3K5G-+H7;]?G*I,1]*;3#=/?O-";EVC&R
M5QBZC*AR%F+2YJ-SR5^^:M7K9$KU%9^T25S(I^/]*@H<I\%8D_>7P"C^%F,4
M_5._=+T*PTAEH/.Y7>W^.>DM?.GR%XUM$P&O;E1M---46&D[-\Z[)%RKO5C=
MTW/+(/*TTLCI9:3DB>YY<^$HYEN,G6M*-D4:5*5JCOH3BCL.L<<.0^J$V;*R
M6JZ;*UU+UV==O8EN\O$72:!QZJIK5-.571L,Y-=YK9^IA-VIXY/"+W?8,GG+
M&G)/DIW25%I-%F(M%9JOSJ_J1\QO[J_(3^:2W"N'AKMHIGX+[1M0*"HH<XF?
MUVNJ3^/C7_\ %BQ"_/P(]HIM^%+MECPMET   .MF8:(L41*0$_%Q\W!S<>\B
M9B'EF;>0BY6+D&ZC5_'2+!TFJU>,GC54R:J2A3$4(;)38SC(;AOV,T(K_2OX
M)UFZHWJ.T7'K2+5[B290\O:+I.U-H_*JFMA8M7F+"^AW2!529R5LX269DP?.
M"I8*4F"7'=N-4J6U:MIUH;&7/BYH;8.WJ9OJW:]8RNVM?MD6=5N)9>R1KADU
M;*OE6R#Z,B9EC!SZ;<\FOX>)!JZ[A53%QV%]@4J4DL*>PJ<(N6)[T:[&Z6/!
M%7%D3<:)9N&=G>&?+QQKIL1NPAEU7K:17Q4FS*VM2U$CATU)@^([+?M;XRV[
M<-<^"*NEN<Y3T5OF-IX#0NJ:OMFS;SA:PLWVK<:K$4JRVYQ8[5)+RU;@TXI*
M,8+QDG-O(1-9 D*V[SE-L1VL9/)E%3Y.?)J,3:P\A7A2>+E(G/P4XJGT8;C?
MG4[,VGL3R]J:5EQ9+D_=Q=F<'.=2>B+/)6)[:XR1_;#EP9%Z4N4E#I9+E)10
MAIZ2>+%7:4]'##AIWIU6N>GUQ$U7,EL=0U"T2L!Z7/Z^DI69M%UL9[!5+21Z
MC88VS,)ZQR$/8C2K204;G6>-EER-,)MDSD;HI)DEW)O>PK<%N1B-<Z8/"&K'
MCEHK3)R/(2V1=SKLDML+9RDM6IB$=/'T2E 2Q;DG(QL4U>OCKG9D5\G=KE25
M<E6401.G+NS?*0K5M<AM#KS1FK-4VC9USH-7]P;+N6R)V[9$E[MV*4\X["D>
M043D/(YJ7D6$/W3RJ^?"8)-4,^)[)/I2]E#DVDGN16HI-M;V:S6'IE<)+5;K
M9<YW2C1U(W==^^L4<VMU[B:VXEI/Q_+9MG7(>S1\3$2Y_*E,IK-$D/)U#F41
MPFKG)Q5TLTJ5*7:@W5HW.IM1KVOZA5:'48_W)JE)K<'4:Q%>5OG_ +F5ZMQC
M6&A8_P NDW+V2>^11K))/Q7"RJZG=[RAS&SDV:&VW5[RM))46XU#W%TXN&V]
MKLYV)L33K)U;Y)R1U/2M?L5LIWG(M@V#*K3S2JSD0R?/779^W//#*]5[?IEL
MYQC.*U<G%43V%#MPDZM;24[3Q'XYW'3$=QYFM6PQ--13MC(,*-!2$_4V"#^.
M<K/6[W+^J2\+-+.U'CA19=11R8[I4YCK94-G.<QCDI8J]\2X1<<-.],/U/P/
MXK:1V6YVYK?5C2$O1T'S2+DG,]9IIG5V<F58C]G4(::F9"(K#9=)PHD4K-!+
MR=NH=!'PT#F2S+N3DJ-["%;A%XDMI@RO3'X2+7D]]/I1AA\K/&M*M<)9K@2@
M*6$RBBONEF@EG\5,I,94R7#0K4K#!/I,(=WMQETLZ4J.BA6M">[AQ@T3?-PT
MG?UJU^TD=O:[0;MJE=$IFRQ;N/0:+/EVB3R.B)IA"3I6JDDOX7N@V=>'A7."
M]F/8%*E)1PK<2X1<L3WHA+'37X6EV/\ &AC2L9[N^[QK5[BYG[4:B><QCY4S
M,_%^:;S3_&[V?80\C\CQGV<(][V15TDZ4J1T4*UH3)-\5- 6+=D?R,EM=M%]
MSQD,_@&UV;SEHCG!XN2K,K3GB+Z'C9QI791<]8FG#,B[IFLX22,7N'*9)+)(
MQR4<->])P1<L5.^/M6.+VBZ;HZ4XW5NC>YVEIJ-L<1)4SSFN#SRF.MKAVZL#
M?SB?V!U:T?=!=ZJ;OIOB'2[W8F8F,8Q@YR<L3\(*$5'"O!,&V)P7XO;1U]K?
M6ELUH1:MZ@CFL1K)>/LMKC+-3HMHBV;ECHZW-)LEF=,UD&:6%4W;IR54Z9%#
M8RJ0BA95R2;:>UD.W!I)K8C@.> ?$IUI%'CT;4,6GK)O8B7%)BA+V%&P%N9$
M3MO.X]Q)+8M:U@,T4,W,LH\-@S3/DV2^38PEATD\6*NT='##AIL/K0^!'$[6
M3^;E:1JDL%*V?6\_J:T2+>Z;"4=6:BVI;RBPQM@,XMBJ<O(2BY2&/(K%/)$\
M)+":Y"HI8(=R;WOE"MP6Y<AL%JW5U%TO0:YK#6D'YM4:I-G+.OP?NG,3/N>W
M>2#N4<)^Z<_(2LPZ\1^^54[5W"AL=_NXS@N,8Q2VY.KWE22BJ+<9^()   "M
M3J!?RG]-;_J*<=OXPX%RWNE^Y9:N_:_NB_ 6"H             *2NLG^^;I
M<?\ 4VXY_=!Z/=T7P<W_ )K,[GU*?Y-Q7_Z7SGV$66CRSFAIMJC@IHK37)#:
MW*6G)6WXRMO%GO.!M*SZ3VKQ2UKFV5DM3FO19(UN];+V";8)KK>5.G94<]XC
M<J"9LD%3DVJ<AC6\K:M7Y7XUQRW\VW:R5^3%.LFP>/\ MZDT^/++6FST2>B(
M&,.\9QQ7\HZ:&*T:9?2*[9@T\=3L+XBRA$R]O:8V,>R(6QER_&4[,HQ\)Q9$
M5M8;SWC*T=J_U WU-6J!8GFQ':VPK?4+.^MMIA:S/1U#K$?$:\E[*V:U\UFF
MD7\N]=NT5<-6'DJ+=;+HZS>=B+<E=NM5CABG7:TZNFQ;*\N\U(QHWDI8R13>
M6UQM7*J7&/D-I63=7O8V@B5R-O%]H5?2KCNB435LS'5JM:L=RE2S%M54VR4L
MAETR(O&-FB3ETG55?"8W17Y;XR_@Y1VN-*M*E$MB6RG/NV&=[OJESTO3]G[J
M(UA4+Y5MPZ"ONCHE_8&37XPK)$Z=HVF+1KAOENZPZS)WV(>6&#:-_P#OJ++I
M.,$.F3';"VNA7=C*U&5W9C4HN/9[U1:]W:C<*NZAE*;QC<ZA:.BS]N5UC:HR
M8EU%<(>=>R+C&3$E;[(X6=*=U!6VWN<>/U<G-@I#NL]N<8P*:[:F3&VXV.CW
MRPOW6][]UFJ"VH=W5K66ZM',M/FNWZ1-2@(UOLW%MH3:K:X?2&@]?:7G&.RX
MZ8LD==))M1G]-5D8S-<CI@K]JJDV[6:I#.3U554Z[C'Z.[&$K2C7&M]51=ZH
M[=M=E*JB?N'+VYQ@VW-[+OMBJ1(Z8K4#"U[?6J$92<;,I"7Y:U4VL8F+;OSJ
MD.E"0KFLZ301=NS)&;N3VV0R?'_I\*$U3]6XFY8N.;E';%)27[M4_6C\+)V?
M:'L[GARYT>5U%+[ D=:'2G7#Y4Y:_9]ERF?.FX$FUDDG*GF[>;LY>$D#>&N;
M+-\KG)%<]I317OJ\A==J7FW1?;X??>]^XWO-?-E:YWUN_:3/:'Q *:]0HE#I
MJ+*$N]]UN]FMGV&A\AM1[E7I3E6CS]PBXRK24;2GR4&_>N2Y)(K95>LFB>,$
M7E-)4J69PO7;G28,-$M[6UJ494V5V;-GPI'-V+K/;.U;+8=R/]%; J>3JZ;@
M8FA0.V-=U3?S1'7!MTOY#:-9LM8OLGJ1*S(.]J(1D?%2=A.U>0A9+#M1)1RW
M02)I;*B<+ER3NN#7@[*I2V8MJ:=*[:4;W5,.)I+DLU<T?9\NANAZ^@W.[H-"
MN:ZF^*M<Y"H5G8LMK*7K,WL"2EF$3H&Q695:AND9]:*DD71T%(\Q7#]5)WWU
M5NV%/17]EQXJK%L6#%1TI7[5O9MIV-^TV@J^K]BU?A_9]<PD,QSL^9J6X'L9
M7M@3-;OC'SFV3/W.U-H:V2"%5A*1+E\HL^$'39**]PTC=K8A5V1,**158J\A
M?C;G'+."7WQJ6^CVNKV[*<O-3W#51UIC>EGL-[F9O3^Y;/"6;3L#5VC?;^\M
M3Q][)8J;M6JW!VG%OM.6?%:UY+O(U%5]4WD4=PUS-1^#2V(Y'P4U9JBQT5V4
MFW&33C3;)5JFG]JZ+L4Y5MH=*>+WG1-KZ-M=AUCL:_M%-W2B] I>S)SCHIR-
M7CX[C=MB)M#R6NM'FV.KYW$65X0T"68LBLGEHDY3<ODO%12).QID4NPN0E*,
MFL>Q/#B\%UVK9VJNO9)*M/'G<ERKEFG<U%O!3NQ,\N[ O1E[)7G!J0XVUJ-I
MKR@5]U),I!6#=2\\ZA$I&7.Q6<,6LG).>QPNF7RI6*K[!7*S<E%NE'+'LKNJ
MJ+NOLLSG>_'F\WQM$1L#68E_$M^-;S5KR-</89NPS,N-GZ1L'N(9D[6(W5C3
MUVER/:;NY;]B6$\Y[5"%R32]\KO693HHI4P4^&+^PF;(1](G6_)&V[)49(%K
M,OI#7E(:R.'#7+E:=KE\V?//V2C0JGEI4&L?:6RA%#%PD8RQL%SDV#XQ3793
MLEY1?3.?VKBE[S?=)P$%T                "N/_+^?X7^E_P"%VY/YTK2/
M3XB_K6?:C_@HZ-^D/_>IGOXG+?R%LND'AG$0   I$Z]']5KC_P#WY^-_[M<!
MU?J?_*'._P!D9G_$.0=='Y.Y'^V<I]F98R--.E                  !J-S
MBY0M^(/'.X[D)%-)^Q-5XRN4F!D%5D8^5M]@<9;QI)$S=1%R>,C6R2[YRFDH
MFJLW:'3(HF<^#EIG+!&I*570T7=+]7K5-9I.[Y&WZ^Y$8FGT&[O?%N"UQ 5J
M3JT'.E27<M*S<HYA%3DC+P:2G@+G<.%TVB^?$[CY$ALYM_?5WV_L$]Z]AN#N
MOJ%<;M!6M&AWR5NBMX3J[&Z6&J5:AV*U2M*K4@VP[3DKD>':N(Z$P@WSWUD\
MKG623R4YB8343.>N5R,=CWD)-G)N/4.XCT.E:@V-9-J)-:-O2*N,QKJRH5RS
MO6,FTH.&!+6D^2:Q"KZ'DXMY(IM,LW**;M1[WFY$S+%R0'<@DFWL8HS&[9U+
MN*%.JVM;-(6FT22^V*H>]5"IURCV*P7)2F).)!JM9I>$BVCCW$BTE8IQ[+E5
M-0Y45#$*;":F2G<@DGSC"S;'46W]<[WU_ [1U19V=NI%D2<'BYAHB\:&RHS<
MJLWK-['R+=G)1D@Q=H'36;N$4E4S%]DO9G&<U)J2JMQ&XDH2
M       KFZ"_]5KD!_?GY(?NU/&Y=<'Y0Y+^R,M_CG->I?\ )W/?VSF_LP+$
M]L_UF^)'^_K^;^-'*EX+]PZ\]Z-J!22='9K'"4ZMV"W6600B:Y58.6L<_*N<
MYPVC(2#8.).5D'&<8SG"#-BU44/G&,Y[I<@MNQ!NBJ:X:8Y5UG8.B)+=FS8;
MXALU"8F8':-3N<XU>KZRE(Y^U\A;6.:;LV+/'NM6YF*E2GPF4B3:32P;/TIC
M"IQ:EA6TI4JJKV'+EN9_&6!+'FG-J1\,:2@FUL20E("WQ[MI3'=CM%30O<TR
M=5Y)W7J!F>IL@D:>?D;0Y$TDUC.<(.&RBK!+F&**)%U7O75&ZRSQM86]M:/-
MI2+Q,$)'344LBUG6R[ROS#5"=C8Q:4K=C9ME58V4:E6CI%)(YVRZI2FSB'%Q
MWDII[CO_ (T-?YB6D[BUQ68I_>E]9,W955#%<7YK<7FOW=432*GE?,PTN,<X
M8K)]W]J504,?."$,?"C%48?K[D7I;:EF>U"A7IE8)]I&OIMNV)&SL>TL$#&2
M#.*D[#3)B6BV$-?*[&R,DU1<2$*X?LT%':&#J%\=+ORXM;6%)/8CO=Q[0C]/
M:^E[T]AY6RN6SVNU^NU2"\EQ-V^Z76QQ-,H]1B5'Z[5@W>V6VSS-F5=PJFV:
MX6RLN<B*9SXB*Q.@;HJD<5+8/(QE;*U$[ATM18FL7)609MK/J+9MDV1FA2S6
M'DIYLTV0PLFK=<^25U\TBU&:4XP5<I>ZJB""K1%-P1?$M1IL>TBLN5"$YA\:
M+"UL[^+VY731M1JLG>Y66?-YJ(AW=$A72#*7O-7EY>+8QMWI48[>()KRT*J_
MCTC.4<&6QXR7?8)<PQ1YS#+ISMX\U;7EYV#&6Q2S(4+-3/*P:$+9828>1]TF
MS0M<L,.UG8%DXF:C,*MG1F<RS3<1+WR14J+@YB]@E0DW08XTJ2,ZY5\>V3ZQ
M1[S:$$U<T^%;6&XY7;S"36GQ#^J5N[13JVOSQN&-8/.UFW1[B.2?*-UI(R^4
M6I%5TEDTXP2YB<2,>=\L]:R5:A['KMUB[Y=;CU/J"P0CY*>HMDJ+W:EM@ZVR
ME9VLVNN-+,PPV8S99!JBY9-B2:!/VE<I#>*5@?+S$8ER<YM(*2HU7YU?U(^8
MW]U?D)_-);A7#PUVT4S\%]HVH%!44.<3/Z[75)_'QK_^+%B%^?@1[13;\*7;
M+'A;+H                  5*[-W[RFY!\M=@\5>)=YJ&F*[HZNQ$IM7<L_
M4HZ^2KFQS*;!RWK5=@IMJ_A>ZEE]Y,<BR":F5&;P_E!<)HIJW5&$8*<]K?(6
MG*<IX(;$N4EC0&YN3&L4=YP'.EA"-ZII>+3L\'R:@84L-3M@U1-#RF5,^AHL
MF2I6)@FX0RF@P8HY6/E5MA#*R&#N(DHNG1[WR$Q<E57-RY3+],=1'C%O38$'
MK*GV*UQMMMK%[)TAK<J)9JFRO$='MG3YP\J\E*,$V3Y/R!FJN3"AT3JD)GN%
M,;&2XAVY157N)C<A)T6\^= ZCW$;9EQ:46H[)5=6!5E>Y623D*].0C&N1&N8
MAW-V66LDC,,F+.*CTH^/<'2.8YLJ%0,;LP3NF,=N:56%<@W1/:-5=1OBCN38
M4-K6G7>;3G+8Y?-*'(62DVNL5O8+B-,J5ZC49V:BFC-XND9')2IK^3**J9*F
MF4ZF<$!VYQ56%=A)T3-YQ05@                 !6IU OY3^FM_P!13CM_
M&' N6]TOW++5W[7]T7X"P5             !25UD_P!\W2X_ZFW'/[H/1[NB
M^#F_\UF=SZE/\FXK_P#2^<^PBRT>6<T       Z]]%1<H9@>3C6$B:+?HRL8
M9\S;NS1THW2610DF&7":F6;]!%RH0BR?=4*50V,9Q@V>T0TGO.P D
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M449-2!,X+$*,CN6RBAU%%?V["25RW'#'E6WE*9.K+!160
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M .+%B%^?@1[13;\*7;+'A;+H
M          %:G4"_E/Z:W_44X[?QAP+EO=+]RRU=^U_=%^ L%0
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MI\1?UK/M1_P4=&_2'_O4SW\3EOY"V72#PSB(   4B=>C^JUQ_P#[\_&_]VN
MZOU/_E#G?[(S/^(<@ZZ/R=R/]LY3[,RQD::=*
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MY3^FM_U%..W\8<"Y;W2_<LM7?M?W1?@+!4             %)763_?-TN/\
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M]VN ZOU/_E#G?[(S/^(<@ZZ/R=R/]LY3[,RQD::=*
M                             "N;H+_U6N0']^?DA^[4\;EUP?E#DO[(
MRW^.<UZE_P G<]_;.;^S MXVMK&K[CU_8]<7!-YF%L39OC#V+=J1\W!3$8^:
MS%<M-=DT?VZ)LU4L,>UDHUV3Z=L^:I*8[<E[!RE-Q=4=>:JJ,UGK>\]J:/:H
M4SE93[784(=,S2-Y-:GH<W<M?7J.;=TK.6O](HK.?N6G;BJW,3W3(M'+5?+G
M!U6LD1,^&J%6%2VQ]YE*;CLE[YF!.<?$4Y<&-R"UJV/[.#MWTZ2/>H'+G)3H
MNF#Y)N]9N$S8S@Z:J9%"&QG!L8SCL#!/F9.*/.?O].'B'Z1.J_PI9?L@P3YF
M,4><?IP\0_2)U7^%++]D&"?,QBCSC].'B'Z1.J_PI9?L@P3YF,4><?IP\0_2
M)U7^%++]D&"?,QBCSC].'B'Z1.J_PI9?L@P3YF,4><ZUASXX6RIG)8OD[IJ2
M,S4PB[*PNT2\,U5SD^,).<-UE,H*9RF;Z4W9GZ7/_8'1SYF,<><[+].'B'Z1
M.J_PI9?L@P3YF,4><?IP\0_2)U7^%++]D&"?,QBCSC].'B'Z1.J_PI9?L@P3
MYF,4><?IP\0_2)U7^%++]D&"?,QBCSC].'B'Z1.J_P *67[(,$^9C%'G.,YY
MN\;UDSDI]TE-LR^<%*TK>F*1=]L3SYRIWL(M"M:-7IEO'Y4.7Z==\LT:-B9P
MHX622[5,,$N78,43IZ51]H;NV/6=U;UK2FMZ?KIX\E-'Z >2,1.SL=9'L<^A
MC[?W%)P3V4K:E[1@I-PT@X..<O65>2<KN%'CI\NGB/-J*PQW\K"3;J]QN2*"
MHH<XF?UVNJ3^/C7_ /%BQ"_/P(]HIM^%+MECPMET
M                          "M3J!?RG]-;_J*<=OXPX%RWNE^Y9:N_:_N
MB_ 6"H             *2NLG^^;I<?\ 4VXY_=!Z/=T7P<W_ )K,[GU*?Y-Q
M7_Z7SGV$66CRSF@ $<;#O%FI2,6K6].['VZ>05=INVVO)3448M!D;D0,BO*&
MVQM/6#=9)_E8Q4L,E'A\92-XI4\9)D\HHG.4?!C*7:I^NT?77MTLET9R+JR:
MCV%J1=DZ20;1VPI+5,D\ETE$O$.]CCZIV=LZ/2:H'_:S8=KM5LG_ .ZF8OTP
M,0E*2[Z+CVZ?K-D$;>@*]>N2>AJ/LF-8SFOO,+<-SKU8GR(/*K9=MUJ5U@S@
MU)2(=Y4CYN=JE)G)Q[%M7":F"E.[>ID,HQPJWE;$VMY:N*,[\(3VPI)TY&U3
M["K3W^0B+<EHIFC)RV5;C?"RD!M"_P!ITE6MAQ6JJM6'\;42VXVPWT9<8VIV
M)S!:O+MVQURINH_!WZY554CPR[]N\;I,&SB55[]Q;N2C:;C85+C<4Z);*UVT
M=%5T^Q6NPQZ(VER(E)2A:G=7"^4A[8^2GQ=XOVPJMHA?<#C6TAQ9W+MUPA-U
MBB8F]:1-NC+=1"9C)#W'9MEF7DIEX]R3#K#I1;^Q^N4JY>;5NK3<Z5:C6F"3
MW+96JV;.;82;J2R[3L3?7NVK'R&(VAKCM"X4/&GK/6-<L8!Y%0<Q>*K&5V,F
M(:J15]/NUFM4\/I0^9+,2=RV?-TXEHD4AD(=%LH7+<KCI<E/8Y-86EV53=7%
MLJ]M-^Q&F\#M_;-2XF:E?ZKMVTB)Z8X"Z&ODI":YINA%*?"3Q=/GGDWFZ;AO
M5^C)2E:D8N(:G]R:9AM.-&*:ZYE%5'+4B=5%BV\YC*Y<CEXNVY=[9B]BC3=]
MLY<G8CM^ G_9^W=W/Z+R2V]5-NYULIH9Q7X*!UL2I4.9JUA3?ZOUK?Y&>N3F
MRP$A=3S<ZXV$LW@<1LM',$"M6IW#=^8ZZ9XHJI<Y=N7+N&Y<C+#@W*BH]B>V
MNWEV4:]TX9=][_D[]-W&,8;82J$'R3>:=+45ZSH*,T4K0Z_N0NFIV:E+G8+$
MRW8>_2K=NXFHI1%PT8K/5V; D:Z14PY747P#I;SFY+%A4Z4I'#12P[ZXJ\J]
MQ49M9NY[+?&+QWKD.\8PSRWVW9\,A9S5VN3T]571-$[)?L)VKK6*+E$(N59/
MFJ>39*3N.D.^V7*HW553/2MS+]UO'"*V-M[:+9WKW5(JXA.'>I^G[H2QM8.T
M;+>,N/&NKLC5:57ZLWMDXM.TF$GO-^"C&F:Q$RLFB9_E(KEVMAZ^R3*SE99P
M<YSS+;)]LHRWWO)PDDY/ G14KN]PSKCUN:T;LE9B?D;/JN'BXR-.R<Z3K>+-
M*;3ILP[5BWC5_M*3N#6CS=9E$8_Q$LP9ZFT\([GQ/+W1<)@U0JLW976VW%+[
ME5JNW6E.U3W3I.1E1<K;EXE7C%UNS=JRWDRKF:"UE6+>@/E76K-S/SV.3B4X
MK$K(V%/"::*1U7QFJ*2>,D0*IDZAB>QKL$7H_?;<JNF.E.3=+;VS7B\UFMR-
M Y*<@I*+8K\BM<;VLT+KV[+%[USIZE2MU=AM3ZYK$QDWNC!52]P+R-R]AVRJ
M3&8\XG!G":F79\YE/<N2A9G%.$[S_AHS='RJCV)=A[-G+7LG:M;=R.MDOKM\
MVY!S%8C=M\Q.3W'A.%AM>:K=-J=KG4,QRCDX2<@7<]39>1<[,PQT&A&IO9%5
M_"X:/?$6B7#I,RZK9S<A.*])IXVE*Y*.Y;$L78W][3;L[!V]-O>^MG3^G]8(
M[KE*@LY8<\F%XO\ !TC6[NWVI;B[R@U_HVA3;9E8:E-TF!EIB-F%',L1")RR
M6\I<$00;G\F5;*);>U]@F,[MR4;>*G\)5T57ADHK>J=O8=UQ<V7NBQ3'&Z4V
M1LU:]-.2_$JQ\@).N&J-.KD%KRS0$CQX.PB:,M7X5E8UX1[#[O62>EFY"87.
MZCR+(*MTU#-RFEMIR,FQ.[)P<Y5QVW*E$J/O=W+]MRU,?O)M@Q&X.:=_I^YS
M:V;ZMU_J^]9@$JY2)B'LTC#:YLTOA'93FUPLQ,H49TWA?)\$@G,!(XSER?#_
M #DJ94BI1)HB6-7+LXRPX4G39MV/?7D[5'V3#9?DCR(G9N_7RNU_;\%"ZZM]
M7@&>O4*SH1OJ5TQ)7:3-VYKM:ZW^?BMJQ\_)^<S@T>XBE89I'H&9'.WD,&4\
M51%#O7FW.*DE%K92--RK5MUY>2G)O/I26NPH+<^XJC7]KRE9?[SY>6"O2^PD
MJ5K):QP$-K[CM7[TWK]47DZ>]AY"TSC-TW9M#3;68:,HJ%=+)-,N5EUC-E.T
MB8XU=E%2HYW*5HJJD4Z+9O[==BYS/8_8.\;%?X/0Z6XY"./"[AVQK>P[BAZ9
MKQ6WW*N5;4&N]J0<C'L)2L2NNXBX04E?C0,FX2A#QRKN*=&*P1,<J:*BI7L%
M2G=E-6L6Z35:*K22?-2NVCV<FXQO3^^^0%OMNKKU+L-L$INTM@3$!+U*U5C0
M=<U%5:F_3M!:XG1K"PL1-U2>P*Z[B&:;_$FJ]3DL%?\ <BV!L(X;&E3LD6[U
MZ4HS:EAD]S44DMN[;BKV^SL1+?)F$U/8=B5R(MVK7_)O8LA0Y1'7_'YTP@).
MG0+0DVGF;VS8WEI(2JT'"SH[*/+//U#/2%;90B45W)ET5(5:;-B+E]6W-*4>
MDG39'D[;KL7-5^X:;<I)N^4[CN?CML(^XL1FM-&,;%<K_3]7;UO59V9=RIN3
M5+7+?;$#3)U@SH] 48INIZ0G9!@\F#(QZ#COH+2J1JE2M48V8<XV>AGBI&%6
MTI--\BK3<N5O?L[)<U"RS6?AHF=8I2:#*:C&$LS0FH69K<RBUD6J3QNE+5VQ
M,(JP0$FFBMC"[)^U;/&JN#)+))J%,3%L]).J36Y^Y\#.S D   *X_P#+^?X7
M^E_X7;D_G2M(]/B+^M9]J/\ @HZ-^D/_ 'J9[^)RW\A;+I!X9Q$   *1.O1_
M5:X__P!^?C?^[7 =7ZG_ ,H<[_9&9_Q#D'71^3N1_MG*?9F6,C33I0
M                                          5S=!?^JUR _OS\D/W:
MGC<NN#\H<E_9&6_QSFO4O^3N>_MG-_9@7=CE!U\           #SN=!W]^_4
M8_'_  GW7VL,B_NCVBS:WR[9Z(QCEX           "ASB9_7:ZI/X^-?_P 6
M+$+\_ CVBFWX4NV6/"V70
M       *U.H%_*?TUO\ J*<=OXPX%RWNE^Y9:N_:_NB_ 6"H
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MRE(+S/\ ($30&8=7O>+&FCS%,@9FIW\]I,X[,]H5Y>4JP0P8*+!S<AF@@J
M #'K=8V5/JEGMTB9,L?5J]-6-^957*"164)&N9-T95?"2^44\(-3=X^"'[N/
M9[N?H"J$7.:@M[:7OF3D\M/.YNUD[5>DNW(P7+ME)16S97:^<TAZ"T"Z@^EO
MQW6=]\BD_([?GDD%$3(G0:N-RWUBT[>\;/BD=MH\K@A\8QC*:Q>S'L=N<_B"
M2EJUVG(HK]ZC=OT@<Q"_UK:E&&ZW'+PKSM9:TW[S='V47#CQ3C    4C]?U(
MS#@A#WS]M*EJGDKH+8;EP4GC-6B#&SN8'+F1;D(=TZ9%5L12^&AV*F5,3LSV
M=[&>K=3;4^+Y9/97,9',6Z<KK%2HGN3[WEV4J<AZ[5T?!D,[MIE=0RUUOD5)
MN-6M[7?;EMK0L2162<))+H*IKH+ID6161.51)9)0N#IJI*$R8BB:A#8R4V,Y
MQG&>W T]IQ='L:.D)J24HNL6?002
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MC+%BD[2IM6%KD;Q+8]M?M>2E$6E"@SP
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M[-RRZF4F[/,NR:,6B:IS9*DQC7ZANS!?9OP[ZTX\JVEMO#<4N1["Q86R^
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M;6;P&Q$.UT<BSM3L1<8)(X.5Q>E%26.WNYN8B$VG@GOY^<M.%HO
M                                  !6CRAY=VVP7']#[A2S3V=RHN97
M,1+3,,H5W4=!0_C-V<W;[U.H8681<K#(.3Y32/D_D+C!#."&6,W9N[L()+'/
M9'[):G<^TAX7V"SWA/Q)I_#'1$!J2N.C3]@7<N;3LR]N2*%D]@[%FB(YG[,^
M,NJLN5'L02:LTC',9)DV2*<QU?$5/:G-SE5B,5%4-MA05
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ME*0I2$*4I"EP4I2XP4I2EQV%*4N.S&"XQCV,#EV_:]YUG=L6X_0
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M4W615&*BJ(V6%)4
M
M                                   5#]+3]#KSFY@_HH_'-[J?&O&?
M'+\;7N%Y+YW>Z%[\E\R_<7Z?W'\H]T._X_T_=\+_ /$7KN/9BINV%N&&KPUW
MEO LEP
5                        /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>10
<FILENAME>tm2110724d11_ex3-1.htm
<DESCRIPTION>EXHIBIT 3.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit 3.1</B></P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SIXTH AMENDED AND RESTATED<BR>
CERTIFICATE OF INCORPORATION<BR>
OF<BR>
SERA PROGNOSTICS, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Pursuant to Sections 242 and 245 of the<BR>
General Corporation Law of the State of Delaware)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sera Prognostics, Inc., a
corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the
 &ldquo;<B>General Corporation Law</B>&rdquo;),</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>DOES HEREBY CERTIFY:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.3pt">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;That
the name of this corporation is Sera Prognostics, Inc., and that this corporation was originally incorporated pursuant to the General
Corporation Law on January 17, 2008. An Amended and&nbsp;Restated Certificate of Incorporation was filed with the Secretary of State of
the State of Delaware on&nbsp;February 23, 2021. Thereafter, a Certificate of Amendment to the Amended and&nbsp;Restated Certificate of
Incorporation was filed with the Secretary of State of the State of Delaware on&nbsp;March 18, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.3pt">2<B>.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;That
the Board of Directors (the &ldquo;<B>Board</B>&rdquo;) of this corporation duly adopted resolutions proposing to amend and restate the
Certificate of Incorporation of this corporation, declaring said amendment and restatement to be advisable and in the best interests of
this corporation and its stockholders, and authorizing the appropriate officers of this corporation to solicit the consent of the stockholders
therefor, which resolution setting forth the proposed amendment and restatement is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>RESOLVED</B>, that the
Certificate of Incorporation of this corporation be amended and restated in its entirety to read as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>First:
</B></FONT>The name of this corporation is Sera Prognostics, Inc. (the &ldquo;<B>Corporation</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>Second:
</B></FONT>The address of the registered office of the Corporation in the State of Delaware is Corporation Trust Center, 1209 Orange Street,
in the City of Wilmington, County of New Castle, Delaware 19801. The name of its registered agent at such address is The Corporation Trust
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>Third:
</B></FONT>The nature of the business or purposes to be conducted or promoted is to engage in any lawful act or activity for which corporations
may be organized under the General Corporation Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>Fourth:
</B></FONT>The total number of shares of all classes of stock which the Corporation shall have authority to issue is (i) 75,000,000 shares
of Class A Common Stock, $0.0001 par value per share (&ldquo;<B>Class A Common Stock</B>&rdquo;), (ii) 3,000,000 shares of Class B Common
Stock, $0.0001 par value per share (&ldquo;<B>Class B Common Stock</B>&rdquo;) and (iii) 46,543,334 shares of Preferred Stock, $0.0001
par value per share (&ldquo;<B>Preferred Stock</B>&rdquo;). The Class A Common Stock and the Class B Common Stock are referred to together
as the &ldquo;<B>Common Stock</B>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a statement
of the designations and the powers, privileges and rights, and the qualifications, limitations or restrictions thereof in respect of each
class of capital stock of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;COMMON
STOCK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Class A Common Stock. All Common Stock, whether outstanding on the date hereof or issued hereafter shall be Class A Common Stock
unless specifically designated Class B Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>General</U>. The voting, dividend and liquidation rights of the holders of the Class A Common Stock are subject to and qualified
by the rights, powers and preferences of the holders of the Preferred Stock set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">1.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Voting</U>. The holders of the Class A Common Stock are entitled to one vote for each share of Class A Common Stock held at
all meetings of stockholders (and written actions in lieu of meetings). There shall be no cumulative voting. The number of authorized
shares of Class A Common Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by (in addition
to any vote of the holders of one or more series of Preferred Stock that may be required by the terms of the Certificate of Incorporation
of the Corporation (the &ldquo;<B>Certificate of Incorporation</B>&rdquo;)) the affirmative vote of the holders of shares of capital stock
of the Corporation representing a majority of the votes represented by all outstanding shares of capital stock of the Corporation entitled
to vote, irrespective of the provisions of Section 242(b)(2) of the General Corporation Law, and without a separate class vote of the
holders of Class A Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Class B Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">2.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>General</U>. The voting, dividend and liquidation rights of the holders of the Class B Common Stock are subject to and qualified
by the rights, powers and preferences of the holders of the Preferred Stock set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">2.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Voting</U>. The Class B Common Stock shall be non-voting except as may be required by law; <U>provided</U>, the holders of the
Class B Common Stock shall be entitled to vote, as a separate class, on any amendment to the Certificate of Incorporation that (a) modifies
any powers, rights or privileges of the Class A Common Stock in a manner that differs from the powers, rights or privileges of the Class
B Common Stock (other than with respect to the status of the Class B Common Stock as non-voting) or (b) modifies the non-voting status
or conversion powers, rights or privileges applicable to the Class B Common Stock. The number of authorized shares of Class B Common Stock
may be increased or decreased (but not below the number of shares thereof then outstanding) by (in addition to any vote of the holders
of one or more series of Preferred Stock that may be required by the terms of the Certificate of Incorporation) the affirmative vote of
the holders of shares of capital stock of the Corporation representing a majority of the votes represented by all outstanding shares of
capital stock of the Corporation entitled to vote, irrespective of the provisions of Section 242(b)(2) of the General Corporation Law,
and without a separate class vote of the holders of Class B Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">2.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Conversion</U>. Each holder of shares of Class B Common Stock shall have the right to convert each share of Class B Common
Stock held by such holder into one share of Class A Common Stock at such holder&rsquo;s election, which shall be made upon written notice
to the Corporation delivered as provided in Section 4.3.1 of Subsection B of this Article Fourth, provided that, upon the closing of an
initial public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, the shares of Class
B Common Stock may only be converted into shares of Class A Common Stock during such time or times as immediately prior to or as a result
of such conversion would not result in the holder(s) thereof beneficially owning (for purposes of Section 13(d) of the Securities Exchange
Act of 1934, as amended, and the rules and regulations promulgated thereunder (collectively, the &ldquo;Exchange Act&rdquo;)), when aggregated
with affiliates with whom such holder is required to aggregate beneficial ownership for purposes of Section 13(d) of the Exchange Act,
in excess of the Beneficial Ownership Limitation. The &ldquo;<B>Beneficial Ownership Limitation</B>&rdquo; means initially 4.99% of any
class of securities of the Corporation registered under the Exchange Act, which percentage may be increased or decreased by a holder of
outstanding shares of Class B Common Stock to such other percentage as such holder may designate in writing upon 61 days&rsquo; notice
(delivered as provided in Section 4.3.1 of Subsection B of this Article Fourth) to the Corporation, <U>provided</U>, <U>however</U>, that
such increase or decrease shall only be applicable to such holder and <U>provided further</U>, <U>however</U>, that no holder may make
such an election to change the percentage unless all holders managed by the same investment advisor as such electing holder make the same
election.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Adjustments; Distributions</U>. The Corporation shall not give effect to any stock split, stock dividend, stock combination
or similar event affecting the Class A Common Stock or Class B Common Stock without effecting the same such stock split, stock dividend,
stock combination or similar event for the Class A Common Stock or Class B Common Stock, respectively. The Corporation shall not declare,
pay or set aside any dividends or distributions on shares of Class A Common Stock or Class B Common Stock unless the Corporation declares,
pays or sets aside the same dividend or distribution on each share of Class A Common Stock or Class B Common Stock, provided, that dividends
payable in Common Stock shall be paid in the same class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PREFERRED
STOCK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.3pt">1,390 shares of the
authorized Preferred Stock of the Corporation are hereby designated &ldquo;<B>Series A1 Preferred Stock</B>&rdquo;, 7,941,499 shares
of the authorized Preferred Stock of the Corporation are hereby designated &ldquo;<B>Series A2 Preferred Stock</B>&rdquo;, 2,060,000
shares of the authorized Preferred Stock of the Corporation are hereby designated &ldquo;<B>Series B-1 Preferred Stock</B>&rdquo;,
5,012,500 shares of the authorized Preferred Stock of the Corporation are hereby designated &ldquo;<B>Series B-2 Preferred
Stock</B>&rdquo;, 5,521,905 shares of the authorized Preferred Stock of the Corporation are hereby designated &ldquo;<B>Series C-1
Preferred Stock</B>&rdquo;, 1,510,000 shares of the authorized Preferred Stock of the Corporation are hereby designated
 &ldquo;<B>Series C-2 Preferred Stock</B>&rdquo;, 11,975,172 shares of the authorized Preferred Stock of the Corporation are hereby
designated &ldquo;<B>Series D Preferred Stock</B>&rdquo;, and 12,520,868 shares of the authorized Preferred Stock of the Corporation
are hereby designated &ldquo;<B>Series E Preferred Stock</B>&rdquo;, with the following rights, preferences, powers, privileges and
restrictions, qualifications and limitations. &ldquo;<B>Junior Preferred Stock</B>&rdquo; means the Series A1 Preferred Stock, the
Series A2 Preferred Stock, the Series B-1 Preferred Stock, the Series B-2 Preferred Stock, the Series C-1 Preferred Stock and the
Series C-2 Preferred Stock. &ldquo;<B>Senior Preferred Stock</B>&rdquo; means the Series D Preferred Stock and the Series E
Preferred Stock. Unless otherwise indicated, references to &ldquo;Sections&rdquo; or &ldquo;Subsections&rdquo; in this Part B of
this Article Fourth refer to sections and subsections of Part B of this Article Fourth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Dividends</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>As of the date of the effective date of the filing of the Second Amended and Restated Certificate of Incorporation of the Corporation
on November 7, 2014, any and all outstanding and unpaid dividends accrued with respect to the Series A2 Preferred Stock were forfeited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">1.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Corporation shall not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the
Corporation (other than dividends on shares of Common Stock payable in shares of Common Stock) unless (in addition to the obtaining of
any consents required elsewhere in the Certificate of Incorporation) the holders of the Preferred Stock then outstanding shall first receive,
or simultaneously receive, a dividend on each outstanding share of Preferred Stock in an amount at least equal to (i) in the case of a
dividend on Common Stock or any class or series that is convertible into Common Stock, that dividend per share of Preferred Stock as would
equal the product of (A) the dividend payable on each share of such class or series determined, if applicable, as if all shares of such
class or series had been converted into Common Stock and (B) the number of shares of Common Stock issuable upon conversion of a share
of Preferred Stock, in each case calculated on the record date for determination of holders entitled to receive such dividend or (ii)
in the case of a dividend on any class or series that is not convertible into Common Stock, at a rate per share of Preferred Stock determined
by (A) dividing the amount of the dividend payable on each share of such class or series of capital stock by the original issuance price
of such class or series of capital stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination
or other similar recapitalization with respect to such class or series) and (B) multiplying such fraction by an amount equal to the applicable
Original Issue Price (as defined below); <U>provided</U> that, if the Corporation declares, pays or sets aside, on the same date, a dividend
on shares of more than one class or series of capital stock of the Corporation, the dividend payable to the holders of Preferred Stock
pursuant to this <U>Section 1</U> shall be calculated based upon the dividend on the class or series of capital stock that would result
in the highest Preferred Stock dividend. The &ldquo;<B>Original Issue Price</B>&rdquo; for each series of Preferred Stock shall mean:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>with respect to the Series A1 Preferred Stock, $1,000.00 per share, subject to appropriate adjustment in the event of any stock
dividend, stock split, combination or other similar recapitalization with respect to the Series A1 Preferred Stock (the &ldquo;<B>Series
A1 Original Issue Price</B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>with respect to the Series A2 Preferred Stock, $2.50 per share, subject to appropriate adjustment in the event of any stock dividend,
stock split, combination or other similar recapitalization with respect to the Series A2 Preferred Stock (the &ldquo;<B>Series A2 Original
Issue Price</B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>with respect to the Series B-1 Preferred Stock, $2.50 per share, subject to appropriate adjustment in the event of any stock dividend,
stock split, combination or other similar recapitalization with respect to the Series B-1 Preferred Stock (the &ldquo;<B>Series B-1 Original
Issue Price</B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> with respect to the Series B-2 Preferred Stock, $4.00 per share, subject to appropriate adjustment in the event of any stock dividend,
stock split, combination or other similar recapitalization with respect to the Series B-2 Preferred Stock (the &ldquo;<B>Series B-2 Original
Issue Price</B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>with respect to the Series C-1 Preferred Stock, $5.95 per share, subject to appropriate adjustment in the event of any stock dividend,
stock split, combination or other similar recapitalization with respect to the Series C-1 Preferred Stock (the &ldquo;<B>Series C-1 Original
Issue Price</B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>with respect to the Series C-2 Preferred Stock, $8.28 per share, subject to appropriate adjustment in the event of any stock dividend,
stock split, combination or other similar recapitalization with respect to the Series C-2 Preferred Stock (the &ldquo;<B>Series C-2 Original
Issue Price</B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>with respect to the Series D Preferred Stock, $4.34 per share, subject to appropriate adjustment in the event of any stock dividend,
stock split, combination or other similar recapitalization with respect to the Series D Preferred Stock (the &ldquo;<B>Series D Original
Issue Price</B>&rdquo;); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>with respect to the Series E Preferred Stock, $5.99 per share, subject to appropriate adjustment in the event of any stock dividend,
stock split, combination or other similar recapitalization with respect to the Series E Preferred Stock (the &ldquo;<B>Series E Original
Issue Price</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Liquidation, Dissolution or Winding Up; Certain Mergers, Consolidations and Asset Sales</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">2.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Preferential
Payments to Holders of Senior Preferred Stock</U>. In the event of any voluntary or involuntary liquidation, dissolution or winding
up of the Corporation or a Deemed Liquidation Event (as defined below), before any distribution or payment shall be made to the
holders of any Common Stock or the holders of shares of any other series of Preferred Stock, the holders of shares of Senior
Preferred Stock shall be entitled to be paid out of the assets of the Corporation legally available for distribution to its
stockholders, and in the event of a Deemed Liquidation Event (as defined below), the holders of shares of Senior Preferred Stock
then outstanding shall be entitled to be paid out of the consideration payable to stockholders in such Deemed Liquidation Event or
out of the Available Proceeds (as defined below), as applicable, before any payment shall be made to the holders of Common Stock,
the Junior Preferred Stock or any other class or series of stock ranking on liquidation junior to the Senior Preferred Stock and
together with any shares of Preferred Stock ranking on liquidation <I>pari passu</I> with the Senior Preferred Stock by reason of
their ownership thereof, an amount per share equal to (i) with respect to each share of Series D Preferred Stock, the greater of (a)
two times the Series D Original Issue Price of such share of Series D Preferred Stock plus all declared and unpaid dividends on such
share of Series D Preferred Stock and (b) such amount per share as would have been payable had all shares of the Series D Preferred
Stock been converted into Common Stock pursuant to Section 4 immediately prior to such liquidation, dissolution, winding up or
Deemed Liquidation Event, and (ii) with respect to each share of Series E Preferred Stock, the greater of (a) the Original Issue
Price of such share of Series E Preferred Stock plus all declared and unpaid dividends on such share of Series E Preferred Stock and
(b) such amount per share as would have been payable had all shares of Series E Preferred Stock been converted into Common Stock
pursuant to Section 4 immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event (the amount payable
in respect of Senior Preferred Stock pursuant to this sentence is hereinafter referred to as the &ldquo;<B>Senior Preferential
Liquidation Amount</B>&rdquo;). If upon any such liquidation, dissolution or winding up of the Corporation or Deemed Liquidation
Event, the assets of the Corporation available for distribution to its stockholders shall be insufficient to pay the holders of
shares of Senior Preferred Stock or any shares of Preferred Stock ranking on liquidation <I>pari passu</I> with the Senior Preferred
Stock the full amount to which they shall be entitled under this <U>Subsection 2.1</U>, the holders of shares of Senior Preferred
Stock or any shares of Preferred Stock ranking on liquidation <I>pari passu</I> with the Senior Preferred Stock shall share ratably
in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be
payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were
paid in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">2.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>After the payment of the Senior Preferential Liquidation Amount as set forth in <U>Subsection 2.1</U> above upon any voluntary
or involuntary liquidation, dissolution or winding up of the Corporation or a Deemed Liquidation Event, the holders of shares of Junior
Preferred Stock then outstanding, on a <I>pari passu </I>basis, shall be entitled to be paid out of the assets of the Corporation available
for distribution to its stockholders, and in the event of a Deemed Liquidation Event (as defined below), the holders of shares of Junior
Preferred Stock then outstanding shall be entitled to be paid out of the consideration payable to stockholders in such Deemed Liquidation
Event or out of the Available Proceeds (as defined below), as applicable, before any payment shall be made to the holders of Common Stock
or any other class or series of stock ranking on liquidation junior to the Junior Preferred Stock by reason of their ownership thereof,
an amount per share equal to the greater of (i) the sum of applicable Original Issue Price for such series of Junior Preferred Stock,
plus any dividends declared but unpaid thereon and (ii) such amount per share as would have been payable had all shares of the applicable
series of Junior Preferred Stock been converted into Common Stock pursuant to Section 4 immediately prior to such liquidation, dissolution,
winding up or Deemed Liquidation Event, taking into account the simultaneous application of this <U>Subsection 2.2</U> to all series of
Junior Preferred Stock (the amount payable pursuant to this sentence is hereinafter referred to as the &ldquo;<B>Junior Preferential Liquidation
Amount</B>&rdquo; and, with the Senior Preferential Liquidation Amount, the &ldquo;<B>Preferential Liquidation Amounts</B>&rdquo;). If
upon any such liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event, the assets of the Corporation available
for distribution to its stockholders shall be insufficient to pay the holders of shares of Junior Preferred Stock the full amount to which
they shall be entitled under this <U>Subsection 2.2</U>, the holders of shares of Junior Preferred Stock shall share ratably on a <I>pari
passu </I>basis in any distribution of the assets available for distribution under this <U>Subsection 2.2</U> in proportion to the respective
amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with
respect to such shares were paid in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">2.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Distribution
of Remaining Assets</U>. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation,
after the payment in full of all applicable Preferential Liquidation Amounts required to be paid to the holders of shares of
Preferred Stock, the remaining assets of the Corporation available for distribution to its stockholders or, in the case of a Deemed
Liquidation Event, the consideration not payable to the holders of shares of Senior Preferred Stock pursuant to <U>Subsection
2.1</U>, the holders of shares of Junior Preferred Stock pursuant to <U>Subsection 2.2</U> or the remaining Available Proceeds, as
the case may be, shall be distributed among the holders of the shares of Common Stock, pro rata based on the number of shares held
by each such holder. The aggregate amount that a holder of a share of Preferred Stock is entitled to receive under <U>Subsections
2.1</U> and <U>2.2</U> is hereinafter referred to as the &ldquo;<B>Total Preferred Liquidation Amount</B>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">2.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Deemed Liquidation Events</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">2.4.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Definition</U>. Each of the following events shall be considered a &ldquo;<B>Deemed Liquidation Event</B>&rdquo; unless the
holders of at least a majority of the outstanding shares of Preferred Stock, voting together as a single class on an as-converted basis,
elect otherwise by written notice sent to the Corporation at least ten (10) days prior to the effective date of any such event:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>a merger, consolidation or reorganization in which the Corporation is a constituent party or a subsidiary of the Corporation is
a constituent party and the Corporation issues shares of its capital stock pursuant to such merger or consolidation, except any such merger
or consolidation involving the Corporation or a subsidiary in which the shares of capital stock of the Corporation outstanding immediately
prior to such merger or consolidation continue to represent, or are converted into or exchanged for shares of capital stock that represent,
immediately following such merger or consolidation, at least a majority, by voting power, of the capital stock of (i) the surviving or
resulting corporation or (ii) if the surviving or resulting corporation is a wholly owned subsidiary of another corporation immediately
following such merger or consolidation, the parent corporation of such surviving or resulting corporation; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the sale, lease, transfer, exclusive license or other disposition, in a single transaction or series of related transactions, by
the Corporation or any subsidiary of the Corporation of all or substantially all the assets of the Corporation and its subsidiaries taken
as a whole, or the sale or disposition (whether by merger, consolidation or otherwise, and whether in a single transaction or a series
of related transactions) of one or more subsidiaries of the Corporation if substantially all of the assets of the Corporation and its
subsidiaries taken as a whole are held by such subsidiary or subsidiaries, except where such sale, lease, transfer, exclusive license
or other disposition is to a wholly owned subsidiary of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">2.4.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Effecting a Deemed Liquidation Event</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Corporation shall not have the power to effect a Deemed Liquidation Event referred to in <U>Subsection 2.4.1(a)(i)</U> unless
the agreement or plan of merger, consolidation or reorganization for such transaction (the &ldquo;<B>Merger Agreement</B>&rdquo;) provides
that the consideration payable to the stockholders of the Corporation in such Deemed Liquidation Event shall be paid to the holders of
capital stock of the Corporation in accordance with <U>Subsections 2.1</U>, <U>2.2</U> and <U>2.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> In the event of a Deemed Liquidation Event referred to in <U>Subsection 2.4.1(a)(ii)</U> or <U>2.4.1(b)</U>, if the Corporation
does not effect a dissolution of the Corporation under the General Corporation Law within ninety (90) days after such Deemed Liquidation
Event, then (i) the Corporation shall send a written notice to each holder of Preferred Stock no later than the ninetieth (90th) day after
the Deemed Liquidation Event advising such holders of their right (and the requirements to be met to secure such right) pursuant to the
terms of the following <U>clause (ii)</U> to require the redemption of such shares of Preferred Stock, and (ii) if the holders of at least
a majority of the then outstanding shares of Preferred Stock, voting together as a single class on an as-converted basis, so request in
a written instrument delivered to the Corporation not later than one hundred twenty (120) days after such Deemed Liquidation Event, the
Corporation shall use the consideration received by the Corporation for such Deemed Liquidation Event (net of any retained liabilities
associated with the assets sold or technology licensed, as determined in good faith by the Board), together with any other assets of the
Corporation available for distribution to its stockholders, all to the extent permitted by Delaware law governing distributions to stockholders
(the <B>&ldquo;Available Proceeds</B>&rdquo;), on the one hundred fiftieth (150th) day after such Deemed Liquidation Event, to redeem
all outstanding shares of Preferred Stock at a price per share equal to the applicable Total Preferred Liquidation Amount. Notwithstanding
the foregoing, in the event of a redemption pursuant to the preceding sentence, if the Available Proceeds are not sufficient to redeem
all outstanding shares of Preferred Stock, the Corporation shall redeem a pro rata portion of each holder&rsquo;s shares of Preferred
Stock to the fullest extent of such Available Proceeds, based on the respective amounts which would otherwise be payable in respect of
the shares to be redeemed if the Available Proceeds were sufficient to redeem all such shares, and shall redeem the remaining shares as
soon as it may lawfully do so under Delaware law governing distributions to stockholders. The provisions of <U>Section 6</U> shall apply,
with such necessary changes in the details thereof as are necessitated by the context, to the redemption of the Preferred Stock pursuant
to this <U>Subsection 2.3.2(b)</U>. Prior to the distribution or redemption provided for in this <U>Subsection 2.3.2(b)</U>, the Corporation
shall not expend or dissipate the consideration received for such Deemed Liquidation Event, except to discharge expenses incurred in connection
with such Deemed Liquidation Event or in the ordinary course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">2.4.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Amount Deemed Paid or Distributed</U>. The amount deemed paid or distributed to the holders of capital stock of the Corporation
upon any such merger, consolidation, sale, transfer, exclusive license, other disposition or redemption shall be the cash or the value
of the property, rights or securities paid or distributed to such holders pursuant to such Deemed Liquidation Event by the Corporation
or the acquiring person, firm, or other entity. The value of such property, rights or securities shall be determined in good faith by
the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Voting</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">3.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>General</U>.
On any matter presented to the stockholders of the Corporation for their action or consideration at any meeting of stockholders of
the Corporation (or by written consent of stockholders in lieu of meeting), each holder of outstanding shares of Preferred Stock
shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Preferred
Stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. Except
as provided by law or by the other provisions of the Certificate of Incorporation, holders of Preferred Stock shall vote together
with the holders of Common Stock as a single class on an as-converted basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">3.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Election of Directors</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">3.2.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The holders of record of the shares of Preferred Stock exclusively and voting together as a single class on an as-converted basis,
shall be entitled to elect nine (9) directors of the Corporation (the &ldquo;<B>Preferred Directors</B>&rdquo;). The holders of record
of the shares of Common Stock and of any other class or series of voting stock (including the Preferred Stock), voting together as a single
class on an as-converted basis, shall be entitled to elect the balance of the total number of directors of the Corporation. Any director
elected as provided in the preceding sentence may be removed without cause by, and only by, the affirmative vote of the holders of the
shares of the class or series of capital stock entitled to elect such director or directors, given either at a special meeting of such
stockholders duly called for that purpose or pursuant to a written consent of stockholders. <FONT STYLE="color: black">If the holders
of shares of Preferred Stock or Common Stock, as the case may be, fail to elect a sufficient number of directors to fill all directorships
for which they are entitled to elect directors, voting exclusively and as a separate class, pursuant to the first sentence of this <U>Subsection
3.2</U>, then any directorship not so filled shall remain vacant until such time as the holders of the Preferred Stock, Common Stock,
or the appropriate combination thereof, as the case may be, elect a person to fill such directorship by vote or written consent in lieu
of a meeting; and no such directorship may be filled by stockholders of the Corporation other than by the stockholders of the Corporation
that are entitled to elect a person to fill such directorship, voting exclusively and as a separate class.</FONT> At any meeting held
for the purpose of electing a director, the presence in person or by proxy of the holders of a majority of the outstanding shares of the
class or series entitled to elect such director shall constitute a quorum for the purpose of electing such director. <FONT STYLE="color: black">Except
as otherwise provided in this <U>Subsection 3.2</U>, a</FONT> vacancy in any directorship filled by the holders of any class or series
shall be filled only by vote or written consent in lieu of a meeting of the holders of such class or series or by any remaining director
or directors elected by the holders of such class or series pursuant to this <U>Subsection <FONT STYLE="color: black">3.2</FONT></U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">3.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Preferred Stock Protective Provisions</U>. At any time when any shares of Preferred Stock are outstanding, the Corporation shall
not, either directly or indirectly by amendment, merger, consolidation or otherwise, do any of the following without (in addition to any
other vote required by law or the Certificate of Incorporation) the written consent or affirmative vote of the holders of at least a majority
of the then outstanding shares of Preferred Stock, voting together as a single class, given in writing or by vote at a meeting, consenting
or voting (as the case may be), and any such&nbsp;act or transaction entered into without such consent or vote shall be null and void
<I>ab initio</I>, and of no force or effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">3.3.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>liquidate, dissolve or wind-up the business and affairs of the Corporation, effect any merger or consolidation or any other Deemed
Liquidation Event, or consent to any of the foregoing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">3.3.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> amend, alter or repeal any provision of the Certificate of Incorporation (a) in a manner that adversely affects the rights, preferences
or privileges of any series of Preferred Stock or (b) to allow for the creation, authorization or issuance of additional shares of Other
Securities (as defined below);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">3.3.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="color: black">amend the Bylaws of the Corporation (the &ldquo;<B>Bylaws</B>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">3.3.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>create, or authorize the creation of, or issue or obligate itself to issue shares of, any additional class or series of capital
stock that is senior or <I>pari pasu</I> with any series of Preferred Stock (&ldquo;<B>Other Securities</B>&rdquo;), or increase the authorized
number of shares of any series of Preferred Stock or increase the authorized number of shares of any Other Securities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">3.3.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>(i) reclassify, alter or amend any existing security of the Corporation that is <I>pari passu</I> with any series of Preferred
Stock in respect of the distribution of assets on the liquidation, dissolution or winding up of the Corporation or Deemed Liquidation
Event, the payment of dividends or rights of redemption, if such reclassification, alteration or amendment would render such other security
senior to any series of Preferred Stock in respect of any such right, preference or privilege, or (ii) reclassify, alter or amend any
existing security of the Corporation that is junior to any series of Preferred Stock in respect of the distribution of assets on the liquidation,
dissolution or winding up of the Corporation or Deemed Liquidation Event, the payment of dividends or rights of redemption, if such reclassification,
alteration or amendment would render such other security senior to or <I>pari passu</I> with any series of Preferred Stock in respect
of any such right, preference or privilege;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">3.3.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>purchase or redeem (or permit any subsidiary to purchase or redeem) or pay or declare any dividend or make any distribution on,
any shares of capital stock of the Corporation other than (i) dividends or other distributions payable on the Common Stock solely in the
form of additional shares of Common Stock, if otherwise expressly provided herein, and (ii)&nbsp;repurchases of stock from former employees,
officers, directors, consultants or other persons who performed services for the Corporation or any subsidiary in connection with the
cessation of such employment or service at the lower of the original purchase price or the then-current fair market value thereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">3.3.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>create, or authorize the creation of, or issue, or authorize the issuance of any debt security or create any lien or security interest
(except for purchase money liens or statutory liens of landlords, mechanics, materialmen, workmen, warehousemen and other similar persons
arising or incurred in the ordinary course of business) or incur other indebtedness for borrowed money, including but not limited to obligations
and contingent obligations under guarantees, or permit any subsidiary to take any such action with respect to any debt security lien,
security interest or other indebtedness for borrowed money, if the aggregate indebtedness of the Corporation and its subsidiaries for
borrowed money following such action would exceed $250,000, unless already included on the budget approved by the Board, including at
least two (2) of the Preferred Directors, other than trade lines of credit in the ordinary course of business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">3.3.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>increase or decrease the size of the Board;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">3.3.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>change the principal business of the Company, enter new lines of business, or exit any then-current line of business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">3.3.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT> sell, assign, license, pledge or encumber material technology or intellectual property, other than licenses granted in the ordinary
course of business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">3.3.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>amend, modify or adopt any equity incentive plan or any transfer, vesting or repurchase provisions in any stock option, restricted
stock or similar agreement; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">3.3.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>change the rights, preferences or privileges of the Preferred Stock in any way; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">3.3.13<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>amend this <U>Subsection 3.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">3.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="color: black"><U>Series E Preferred Stock Protective </U></FONT><U>Provisions</U>. At any time when any shares of
<FONT STYLE="color: black">Series E Preferred Stock </FONT>are outstanding, the Corporation shall not, either directly or indirectly by
amendment, merger, consolidation or otherwise, do any of the following without (in addition to any other vote required by law or the Certificate
of Incorporation) the written consent or affirmative vote of the holders of at least a majority of the then outstanding shares of Series
E Preferred Stock, voting together as a single class on an as-converted basis, given in writing or by vote at a meeting, consenting or
voting (as the case may be), and any such&nbsp;act or transaction entered into without such consent or vote shall be null and void <I>ab
initio</I>, and of no force or effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">3.4.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>amend the Certificate of Incorporation in any way which alters or changes the powers, rights, preferences or privileges of the
Series E Preferred Stock so as to affect them adversely in a manner that shall not so affect the entire class; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: black">3.4.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>amend the Certificate of Incorporation to increase the authorized number of shares of <FONT STYLE="color: black">Series
E Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">3.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="color: black"><U>Series D Preferred Stock Protective </U></FONT><U>Provisions</U>. At any time when any shares of
<FONT STYLE="color: black">Series D Preferred Stock</FONT> are outstanding, the Corporation shall not, either directly or indirectly by
amendment, merger, consolidation or otherwise, do any of the following without (in addition to any other vote required by law or the Certificate
of Incorporation) the written consent or affirmative vote of the holders of at least a majority of the then outstanding shares of Series
D Preferred Stock given in writing or by vote at a meeting, consenting or voting (as the case may be), and any such&nbsp;act or transaction
entered into without such consent or vote shall be null and void <I>ab initio</I>, and of no force or effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">3.5.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>amend the Certificate of Incorporation in any way which alters or changes the powers, rights, preferences or privileges of the
Series D Preferred Stock so as to affect them adversely in a manner that shall not so affect the entire class; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: black">3.5.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>amend the Certificate of Incorporation to increase the authorized number of shares of <FONT STYLE="color: black">Series
D Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">3.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="color: black"><U>Series
D Special Voting Investor Preferred Stock Protective </U></FONT><U>Provisions</U>. So long as the Special Voting Investor (as such
term is defined in that certain Series D Purchase Agreement between the Corporation and the Purchasers listed therein, dated as of
July 31, 2019, as amended), holds at least 1,843,318 shares of Series D Preferred Stock, the Corporation shall not, either directly
or indirectly by amendment, merger, consolidation or otherwise, do any of the following without (in addition to any other vote
required by law or the Certificate of Incorporation) the written consent or affirmative vote of the Special Voting Investor, given
in writing or by vote at a meeting, consenting or voting (as the case may be), and any such&nbsp;act or transaction entered into
without such consent or vote shall be null and void <I>ab initio</I>, and of no force or effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">3.6.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>create, or authorize the creation of, or issue or obligate itself to issue shares of, any additional class or series of capital
stock that is senior to the Series D Preferred Stock (&ldquo;<B>Other Senior Securities</B>&rdquo;), or increase the authorized number
of shares of any series of Preferred Stock or increase the authorized number of shares of any Other Senior Securities; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">3.6.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>amend the Certificate of Incorporation in any way which alters or changes Subsection 1.2 (or any subsection thereof) of Article
FOURTH, Part B;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">3.6.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>amend the Certificate of Incorporation in any way which alters or changes Subsection 2.1 of Article FOURTH, Part B, including the
Senior Preferential Liquidation Amount described therein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">3.6.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>amend the Certificate of Incorporation in any way which alters or changes this Subsection 3.6 (or any subsection thereof) of Article
FOURTH, Part B.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">3.6.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>amend the Certificate of Incorporation in any way which alters or changes Subsection 4.4.4(a) of Article FOURTH, Part B; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">3.6.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>amend the Certificate of Incorporation in any way which alters or changes Subsection 6.1 of Article FOURTH, Part B.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">3.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="color: black"><U>Series C-1 Preferred Stock and Series C-2 Preferred Stock Protective </U></FONT><U>Provisions</U>.
At any time when any shares of <FONT STYLE="color: black">Series C-1 Preferred Stock or Series C-2 Preferred Stock</FONT> (together, the
 &ldquo;<B>Series C Preferred Stock</B>&rdquo;) are outstanding, the Corporation shall not, either directly or indirectly by amendment,
merger, consolidation or otherwise, do any of the following without (in addition to any other vote required by law or the Certificate
of Incorporation) the written consent or affirmative vote of the holders of at least a majority of the then outstanding shares of Series
C Preferred Stock, voting together as a single class on an as-converted basis, given in writing or by vote at a meeting, consenting or
voting (as the case may be), and any such&nbsp;act or transaction entered into without such consent or vote shall be null and void <I>ab
initio</I>, and of no force or effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">3.7.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>amend the Certificate of Incorporation in any way which alters or changes the powers, rights, preferences or privileges of the
Series C-1 Preferred Stock or the Series C-2 Preferred Stock so as to affect them adversely in a manner that shall not so affect the entire
class; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="color: black">3.7.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>amend the Certificate of Incorporation to increase the authorized number of shares of <FONT STYLE="color: black">Series
C-1 Preferred Stock and/or Series C-2 Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">3.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="color: black"><U>Series
B-1 Preferred Stock and Series B-2 Preferred Stock Protective </U></FONT><U>Provisions</U>. At any time when any shares of <FONT STYLE="color: black">Series
B-1 Preferred Stock or Series B-2 Preferred Stock</FONT> (together, the &ldquo;<B>Series B Preferred Stock</B>&rdquo;) are
outstanding, the Corporation shall not, either directly or indirectly by amendment, merger, consolidation or otherwise, do any of
the following without (in addition to any other vote required by law or the Certificate of Incorporation) the written consent or
affirmative vote of the holders of at least a majority of the then outstanding shares of Series B Preferred Stock, voting together
as a single class on an as-converted basis, given in writing or by vote at a meeting, consenting or voting (as the case may be), and
any such&nbsp;act or transaction entered into without such consent or vote shall be null and void <I>ab initio</I>, and of no force
or effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">3.8.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>amend the Certificate of Incorporation in any way which alters or changes the powers, rights, preferences or privileges of the
Series B-1 Preferred Stock or the Series B-2 Preferred Stock so as to affect them adversely in a manner that shall not so affect the entire
class; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">3.8.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>amend the Certificate of Incorporation of the Corporation to increase the authorized number of shares of <FONT STYLE="color: black">Series
B-1 Preferred Stock and/or Series B-2 Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">3.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="color: black"><U>Series A2 Preferred Stock Protective </U></FONT><U>Provisions</U>. At any time when any shares of
Series A2 Preferred Stock are outstanding, the Corporation shall not, either directly or indirectly by amendment, merger, consolidation
or otherwise, do any of the following without (in addition to any other vote required by law or the Certificate of Incorporation) the
written consent or affirmative vote of the holders of at least a majority of the then outstanding shares of Series A2 Preferred Stock
given in writing or by vote at a meeting, consenting or voting (as the case may be), and any such&nbsp;act or transaction entered into
without such consent or vote shall be null and void <I>ab initio</I>, and of no force or effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">3.9.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>amend the Certificate of Incorporation in any way which alters or changes the powers, rights, preferences or privileges of the
Series A2 Preferred Stock so as to affect them adversely in a manner that shall not so affect the entire class; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">3.9.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>amend the Certificate of Incorporation to increase the authorized number of shares of Series A2 Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">3.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Series A1 Preferred Stock Protective Provisions</U>. At any time when shares of Series A1 Preferred Stock are outstanding, the
Corporation shall not, either directly or indirectly by amendment, merger, consolidation or otherwise, do any of the following without
(in addition to any other vote required by law or the Certificate of Incorporation) the written consent or affirmative vote of the holders
of at least a majority of the then outstanding shares of Series A1 Preferred Stock given in writing or by vote at a meeting, consenting
or voting (as the case may be), and any such&nbsp;act or transaction entered into without such consent or vote shall be null and void
<I>ab initio</I>, and of no force or effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">3.10.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>amend the Certificate of Incorporation in any way which alters or changes the powers, rights, preferences or privileges of the
Series A1 Preferred Stock so as to affect them adversely in a manner that shall not so affect the entire class; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">3.10.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>amend the Certificate of Incorporation to increase the authorized number of shares of Series A1 Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> Optional Conversion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The holders of the Preferred
Stock shall have conversion rights as follows (the &ldquo;<B>Conversion Rights</B>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">4.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Right to Convert</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">4.1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Conversion Ratio</U>. Each share of Preferred Stock shall be convertible, at the option of the holder thereof, at any time and
from time to time, and without the payment of additional consideration by the holder thereof, into such number of fully paid and nonassessable
shares of Class A Common Stock as is determined by dividing the applicable Original Issue Price for each series of Preferred Stock by
the applicable Conversion Price (as defined below) for each series of Preferred Stock in effect at the time of conversion. Notwithstanding
the preceding sentence, each share of Preferred Stock may, at the option of the holder thereof in accordance with Subsection 4.3.1, convert,
without the payment of additional consideration by the holder thereof, into such number of fully paid and non-assessable shares of Class
B Common Stock as is determined by dividing such applicable Original Issue Price by such applicable Conversion Price in effect at the
time of conversion of each share of Preferred Stock. The &ldquo;<B>Conversion Price</B>&rdquo; for each series of Preferred Stock is as
follows: (i) for the Series A1 Preferred Stock, the Conversion Price is the &ldquo;<B>Series A1 Conversion Price</B>,&rdquo; which shall
initially be $3.00, (ii) for the Series A2 Preferred Stock, the Conversion Price is the &ldquo;<B>Series A2 Conversion Price</B>,&rdquo;
which shall initially be equal to the Series A2 Original Issue Price, (iii) for the Series B-1 Preferred Stock, the Conversion Price is
the &ldquo;<B>Series B-1 Conversion Price</B>,&rdquo; which shall initially be equal to the Series B-1 Original Issue Price, (iv) for
the Series B-2 Preferred Stock, the Conversion Price is the &ldquo;<B>Series B-2 Conversion Price</B>,&rdquo; which shall initially be
equal to the Series B-2 Original Issue Price, (v) for the Series C-1 Preferred Stock, the Conversion Price is the &ldquo;<B>Series C-1
Conversion Price</B>,&rdquo; which shall initially be equal to the Series C-1 Original Issue Price, (vi) for the Series C-2 Preferred
Stock, the Conversion Price is the &ldquo;<B>Series C-2 Conversion Price</B>,&rdquo; which shall initially be equal to the Series C-2
Original Issue Price, (vii) for the Series D Preferred Stock, the Conversion Price is the &ldquo;<B>Series D Conversion Price</B>,&rdquo;
which shall initially be equal to the Series D Original Issue Price, and (viii) for the Series E Preferred Stock, the Conversion Price
is the &ldquo;<B>Series E Conversion Price</B>,&rdquo; which shall initially be equal to the Series E Original Issue Price. Such initial
Conversion Price, and the rate at which shares of Preferred Stock may be converted into shares of Class A Common Stock or Class B Common
Stock, shall be subject to adjustment as provided below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">4.1.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination of Conversion Rights</U>. In the event of a notice of redemption of any shares of Preferred Stock pursuant to <U>Section
6</U>, the Conversion Rights of the shares designated for redemption shall terminate at the close of business on the last full day preceding
the date fixed for redemption, unless the redemption price is not fully paid on such redemption date, in which case the Conversion Rights
for such shares shall continue until such price is paid in full. In the event of a liquidation, dissolution or winding up of the Corporation
or a Deemed Liquidation Event, the Conversion Rights shall terminate at the close of business on the last full day preceding the date
fixed for the payment of any such amounts distributable on such event to the holders of Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 2; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">4.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Fractional Shares</U>. No fractional shares of Common Stock shall be issued upon conversion of the Preferred Stock. In lieu
of any fractional shares to which the holder would otherwise be entitled, the Corporation shall pay cash equal to such fraction multiplied
by the fair market value of a share of Common Stock as determined in good faith by the Board. Whether or not fractional shares would be
issuable upon such conversion shall be determined on the basis of the total number of shares of Preferred Stock the holder is at the time
converting into Common Stock and the aggregate number of shares of Common Stock issuable upon such conversion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">4.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Mechanics of Conversion</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">4.3.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notice of Conversion</U>. In order for a holder of Preferred Stock to voluntarily convert shares of Preferred Stock into shares
of Common Stock, such holder shall (a) provide written notice to the Corporation&rsquo;s transfer agent at the office of the transfer
agent for the Preferred Stock (or at the principal office of the Corporation if the Corporation serves as its own transfer agent) that
such holder elects to convert all or any number of such holder&rsquo;s shares of Preferred Stock and, if applicable, any event on which
such conversion is contingent, and the number of shares of Class A Common Stock and Class B Common Stock such series of Preferred Stock
shall be converted into (in the absence of which, such shares shall be converted into Class A Common Stock) and (b), if such holder&rsquo;s
shares are certificated, surrender the certificate or certificates for such shares of Preferred Stock (or, if such registered holder alleges
that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation
to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction
of such certificate), at the office of the transfer agent for the Preferred Stock (or at the principal office of the Corporation if the
Corporation serves as its own transfer agent). Such notice shall state such holder&rsquo;s name or the names of the nominees in which
such holder wishes the certificate or certificates for shares of Common Stock to be issued. If required by the Corporation, any certificates
surrendered for conversion shall be endorsed or accompanied by a written instrument or instruments of transfer, in form satisfactory to
the Corporation, duly executed by the registered holder or his, her or its attorney duly authorized in writing. The close of business
on the date of receipt by the transfer agent (or by the Corporation if the Corporation serves as its own transfer agent) of such certificates
(or lost certificate affidavit and agreement) and notice shall be the time of conversion (the &ldquo;<B>Conversion Time</B>&rdquo;), and
the shares of Common Stock issuable upon conversion of the shares represented by such certificate shall be deemed to be outstanding of
record as of such date. The Corporation shall, as soon as practicable after the Conversion Time, (i) issue and deliver to such holder
of Preferred Stock, or to his, her or its nominees, a certificate or certificates for the number of full shares of Common Stock issuable
upon such conversion in accordance with the provisions hereof and a certificate for the number (if any) of the shares of Preferred Stock
represented by the surrendered certificate that were not converted into Common Stock, (ii) pay in cash such amount as provided in <U>Subsection
4.2</U> in lieu of any fraction of a share of Common Stock otherwise issuable upon such conversion, and (iii) pay all declared but unpaid
dividends on the shares of Preferred Stock converted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">4.3.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Reservation
of Shares</U>. The Corporation shall at all times when any Preferred Stock shall be outstanding, reserve and keep available out of
its authorized but unissued capital stock, for the purpose of effecting the conversion of the Preferred Stock, such number of its
duly authorized shares of Common Stock as shall from time to time be sufficient to effect the conversion of all outstanding
Preferred Stock; and if at any time the number of authorized but unissued shares of Common Stock shall not be sufficient to effect
the conversion of all then outstanding shares of Preferred Stock, the Corporation shall take such corporate action as may be
necessary to increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such
purposes, including, without limitation, engaging in best efforts to obtain the requisite stockholder approval of any necessary
amendment to the Certificate of Incorporation. Before taking any action which would cause an adjustment reducing the applicable
Conversion Price of any series of Preferred Stock below the then par value of the shares of Common Stock issuable upon conversion of
such series of Preferred Stock, the Corporation will take any corporate action which may, in the opinion of its counsel, be
necessary in order that the Corporation may validly and legally issue fully paid and nonassessable shares of Common Stock at such
adjusted applicable Conversion Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">4.3.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Effect of Conversion</U>. All shares of Preferred Stock which shall have been surrendered for conversion as herein provided
shall no longer be deemed to be outstanding and all rights with respect to such shares, including the rights, if any, to receive notices
and to vote, shall immediately cease and terminate at the Conversion Time, except only the right of the holders thereof to receive shares
of Common Stock in exchange therefor, to receive payment in lieu of any fraction of a share otherwise issuable upon such conversion as
provided in <U>Subsection 4.2</U> and to receive payment of any dividends declared but unpaid thereon. Any shares of Preferred Stock so
converted shall be retired and cancelled and may not be reissued as shares of the applicable series, and the Corporation may thereafter
take such appropriate action (without the need for stockholder action) as may be necessary to reduce the authorized number of shares of
Preferred Stock accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">4.3.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Further Adjustment</U>. Upon any such conversion, no adjustment to the applicable Conversion Price shall be made for any
declared but unpaid dividends on the Preferred Stock surrendered for conversion or on the Common Stock delivered upon conversion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">4.3.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Taxes</U>. The Corporation shall pay any and all issue and other similar taxes that may be payable in respect of any issuance
or delivery of shares of Common Stock upon conversion of shares of Preferred Stock pursuant to this <U>Section 4</U>. The Corporation
shall not, however, be required to pay any tax which may be payable in respect of any transfer involved in the issuance and delivery of
shares of Common Stock in a name other than that in which the shares of Preferred Stock so converted were registered, and no such issuance
or delivery shall be made unless and until the person or entity requesting such issuance has paid to the Corporation the amount of any
such tax or has established, to the satisfaction of the Corporation, that such tax has been paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">4.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Adjustments to Conversion Price for Diluting Issues</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">4.4.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Special Definitions</U>. For purposes of this Article Fourth, the following definitions shall apply:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Option</B>&rdquo; shall mean rights, options or warrants to subscribe for, purchase or otherwise acquire Common Stock
or Convertible Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> &ldquo;<B>Series E Original Issue Date</B>&rdquo; shall mean the date on which the first share of Series E Preferred Stock was
issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Convertible Securities</B>&rdquo; shall mean any evidences of indebtedness, shares or other securities directly or indirectly
convertible into or exchangeable for Common Stock, but excluding Options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<B>Additional Shares of Common Stock</B>&rdquo; shall mean all shares of Common Stock issued (or, pursuant to <U>Subsection
4.4.3</U> below, deemed to be issued) by the Corporation after the Series E Original Issue Date, other than (1) the following shares of
Common Stock and (2) shares of Common Stock deemed issued pursuant to the following Options and Convertible Securities (<U>clauses (1)</U>
and <U>(2)</U>, collectively, &ldquo;<B>Exempted Securities</B>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>shares of Common Stock, Options or Convertible Securities issued as a dividend or distribution on any series of Preferred Stock;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: black">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>shares of Common Stock, Options or Convertible Securities issued by reason of a dividend, stock split, split-up or other
distribution on shares of Common Stock that is covered by <U>Subsection 4.5</U>, <U>4.6</U>, <U>4.7</U> or <U>4.8</U><FONT STYLE="color: black">;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 1in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>shares of Common Stock or Options issued to employees or directors of, or consultants or advisors to, the Corporation or any of
its subsidiaries pursuant to a plan, agreement or arrangement approved by the Board, including at least two (2) of the Preferred Directors;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 1in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>shares of Common Stock or Convertible Securities actually issued upon the exercise of Options or shares of Common Stock actually
issued upon the conversion or exchange of Convertible Securities, in each case provided such issuance is pursuant to the terms of such
Option or Convertible Security;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 1in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>shares of Common Stock, Options or Convertible Securities issued to banks, equipment lessors or other financial institutions, or
to real property lessors, pursuant to a debt financing, equipment leasing, real property leasing transaction or other similar transaction
that is primarily of a non-equity financing nature, approved by the Board, including at least two (2) of the Preferred Directors;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 1in"><FONT STYLE="color: black">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>shares of Common Stock, Options or Convertible Securities issued pursuant to the acquisition of another corporation by the
Corporation by merger, purchase of substantially all of the assets or other reorganization or to a joint venture agreement, provided,
that such issuances are approved by the Board, including at least two (2) of the Preferred Directors<FONT STYLE="color: black">;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 5; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 1in">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> shares of Common Stock, Options or Convertible Securities issued in connection with a license, collaboration or strategic partnership
arrangement and not principally for equity financing purposes, provided, that such issuances are approved by the Board, including at least
two (2) of the Preferred Directors;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 1in">(viii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>148,880 shares of Common Stock, Options or Convertible Securities issued pursuant to that certain License Agreement between Brigham
Young University and the Corporation, dated May 21, 2008, as amended;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 1in">(ix)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>shares of Common Stock, Options or Convertible Securities issued, or deemed issued, pursuant to (A) that certain Series C Preferred
Stock Purchase Agreement dated as of January 9, 2017, between the Corporation and the Purchasers named therein, as amended, or (B) that
certain Series E Preferred Stock Purchase Agreement dated as of February 23, 2021, between the Corporation and the Purchasers named therein
(the &ldquo;<B>Series E Purchase Agreement</B>&rdquo;); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 1in">(x)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>shares of Common Stock issued or issuable upon an IPO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">4.4.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Adjustment of Conversion Price</U>. Subject to Subsection 4.4.4, no adjustment in the applicable Conversion Price shall be
made as the result of the issuance or deemed issuance of Additional Shares of Common Stock if the Corporation receives written notice
from (i) the holders of at least a majority of the then outstanding shares of Preferred Stock, voting together as a single class, or (ii)
notwithstanding subpart (i), if such adjustment purports to affect the Series A1 Conversion Price, Series A2 Conversion Price, Series
B-1 Conversion Price, Series B-2 Conversion Price, Series C-1 Conversion Price, Series C-2 Conversion Price, Series D Conversion Price,
or Series E Conversion Price alone, then the holders of at least a majority of the then outstanding shares of Series A1 Preferred Stock,
Series A2 Preferred Stock, Series B-1 Preferred Stock, Series B-2 Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock,
Series D Preferred Stock, or Series E Preferred Stock, as applicable, acting together as a separate class, agreeing that no such adjustment
shall be made as a result of the issuance or deemed issuance of such Additional Shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">4.4.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Deemed Issue of Additional Shares of Common Stock</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8239;&nbsp;</FONT>If
the Corporation at any time or from time to time after the Series E Original Issue Date shall issue any Options or Convertible Securities
(excluding Options or Convertible Securities which are themselves Exempted Securities) or shall fix a record date for the determination
of holders of any class of securities entitled to receive any such Options or Convertible Securities, then the maximum number of shares
of Common Stock (as set forth in the instrument relating thereto, assuming the satisfaction of any conditions to exercisability, convertibility
or exchangeability but without regard to any provision contained therein for a subsequent adjustment of such number) issuable upon the
exercise of such Options or, in the case of Convertible Securities and Options therefor, the conversion or exchange of such Convertible
Securities, shall be deemed to be Additional Shares of Common Stock issued as of the time of such issue or, in case such a record date
shall have been fixed, as of the close of business on such record date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>If
the terms of any Option or Convertible Security, the issuance of which resulted in an adjustment to the Conversion Price of any series
of Preferred Stock pursuant to the terms of <U>Subsection 4.4.4</U>, are revised as a result of an amendment to such terms or any other
adjustment pursuant to the provisions of such Option or Convertible Security (but excluding automatic adjustments to such terms pursuant
to anti-dilution or similar provisions of such Option or Convertible Security) to provide for either (i) any increase or decrease in
the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any such Option or Convertible Security
or (ii) any increase or decrease in the consideration payable to the Corporation upon such exercise, conversion and/or exchange, then,
effective upon such increase or decrease becoming effective, the adjusted Conversion Price applicable to such series of Preferred Stock
computed upon the original issue of such Option or Convertible Security (or upon the occurrence of a record date with respect thereto)
shall be readjusted to such Conversion Price as would have obtained had such revised terms been in effect upon the original date of issuance
of such Option or Convertible Security. Notwithstanding the foregoing, no readjustment pursuant to this <U>clause&nbsp; (b)</U> shall
have the effect of increasing the applicable Conversion Price for such series of Preferred Stock to an amount which exceeds the lower
of (1) the Conversion Price in effect for such series of Preferred Stock immediately prior to the original adjustment made as a result
of the issuance of such Option or Convertible Security, or (2) the Conversion Price that would have resulted for such series of Preferred
Stock from any issuances of Additional Shares of Common Stock (other than deemed issuances of Additional Shares of Common Stock as a
result of the issuance of such Option or Convertible Security) between the original adjustment date and such readjustment date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>If
the terms of any Option or Convertible Security (excluding Options or Convertible Securities which are themselves Exempted Securities),
the issuance of which did not result in an adjustment to the Conversion Price for any series of Preferred Stock pursuant to the terms
of <U>Subsection 4.4.4</U> (either because the consideration per share (determined pursuant to <U>Subsection 4.4.5</U>) of the Additional
Shares of Common Stock subject thereto was equal to or greater than the Conversion Price then in effect for such series of Preferred
Stock, or because such Option or Convertible Security was issued before the Series E Original Issue Date), are revised after the Series
E Original Issue Date as a result of an amendment to such terms or any other adjustment pursuant to the provisions of such Option or
Convertible Security (but excluding automatic adjustments to such terms pursuant to anti-dilution or similar provisions of such Option
or Convertible Security) to provide for either (i) any increase in the number of shares of Common Stock issuable upon the exercise, conversion
or exchange of any such Option or Convertible Security or (ii) any decrease in the consideration payable to the Corporation upon such
exercise, conversion or exchange, then such Option or Convertible Security, as so amended or adjusted, and the Additional Shares of Common
Stock subject thereto (determined in the manner provided in <U>Subsection 4.4.3(a)</U>) shall be deemed to have been issued effective
upon such increase or decrease becoming effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Upon the expiration or termination of any unexercised Option or unconverted or unexchanged Convertible Security (or portion thereof)
which resulted (either upon its original issuance or upon a revision of its terms) in an adjustment to the applicable Conversion Price
for any series of Preferred Stock pursuant to the terms of <U>Subsection 4.4.4</U>, the applicable Conversion Price shall be readjusted
to such Conversion Price as would have obtained had such Option or Convertible Security (or portion thereof) never been issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any Option or Convertible Security,
or the consideration payable to the Corporation upon such exercise, conversion and/or exchange, is calculable at the time such Option
or Convertible Security is issued or amended but is subject to adjustment based upon subsequent events, any adjustment to the applicable
Conversion Price for any series of Preferred Stock provided for in this <U>Subsection 4.4.3</U> shall be effected at the time of such
issuance or amendment based on such number of shares or amount of consideration without regard to any provisions for subsequent adjustments
(and any subsequent adjustments shall be treated as provided in <U>clauses (b)</U> and <U>(c)</U> of this <U>Subsection 4.4.3</U><FONT STYLE="color: black">)</FONT>.
If the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any Option or Convertible Security,
or the consideration payable to the Corporation upon such exercise, conversion and/or exchange, cannot be calculated at all at the time
such Option or Convertible Security is issued or amended, any adjustment to the applicable Conversion Price for any series of Preferred
Stock that would result under the terms of this <U>Subsection 4.4.3</U> at the time of such issuance or amendment shall instead be effected
at the time such number of shares and/or amount of consideration is first calculable (even if subject to subsequent adjustments), assuming
for purposes of calculating such adjustment to the applicable Conversion Price that such issuance or amendment took place at the time
such calculation can first be made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">4.4.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Adjustment of Conversion Price Upon Issuance of Additional Shares of Common Stock</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>Notwithstanding
anything to the contrary (including Subsection 4.4.2), in the event the Corporation shall at any time after the Series E Original
Issue Date issues Additional Shares of Common Stock (including Additional Shares of Common Stock deemed to be issued pursuant to
Subsection 4.4.3), without consideration or for a consideration per share less than the Series D Conversion Price in effect
immediately prior to such issuance or deemed issuance, then the Series D Conversion Price shall be reduced, concurrently with such
issuance or deemed issuance, to the consideration per share received by the Corporation for such issue or deemed issue of the
Additional Shares of Common Stock; provided that if such issuance or deemed issuance was without consideration, then the Corporation
shall be deemed to have received an aggregate of $.001 of consideration for each such Additional Share of Common Stock issued or
deemed to be issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In the event the Corporation shall at any time after the Series E Original Issue Date issue Additional Shares of Common Stock (including
Additional Shares of Common Stock deemed to be issued pursuant to <U>Subsection 4.4.3</U>), without consideration or for a consideration
per share less than the applicable Conversion Price for any series of Junior Preferred Stock or Series E Preferred Stock in effect immediately
prior to such issue, then the applicable Conversion Price for such series of Preferred Stock shall be reduced, concurrently with such
issue, to a price (calculated to the nearest one-hundredth of a cent) determined in accordance with the following formula:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.2in; text-align: left">CP<SUB>2</SUB> = CP<SUB>1</SUB>* (A + B) &divide;
(A + C).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of the foregoing formula, the following
definitions shall apply:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;CP<SUB>2</SUB>&rdquo; shall mean the Conversion Price in effect for each applicable series of Junior Preferred Stock immediately
after such issuance or deemed issuance of Additional Shares of Common Stock;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 1in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;CP<SUB>1</SUB>&rdquo; shall mean the Conversion Price in effect for each applicable series of Junior Preferred Stock immediately
prior to such issuance or deemed issuance of Additional Shares of Common Stock;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 1in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;A&rdquo; shall mean the number of shares of Common Stock outstanding immediately prior to such issuance or deemed issuance
of Additional Shares of Common Stock (treating for this purpose as outstanding all shares of Common Stock issuable upon exercise of Options
outstanding immediately prior to such issuance or deemed issuance or upon conversion or exchange of Convertible Securities (including
the Preferred Stock) outstanding (assuming exercise of any outstanding Options therefor) immediately prior to such issue);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 1in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;B&rdquo; shall mean the number of shares of Common Stock that would have been issued if such Additional Shares of Common
Stock had been issued or deemed issued at a price per share equal to CP<SUB>1</SUB> (determined by dividing the aggregate consideration
received by the Corporation in respect of such issue by CP<SUB>1</SUB>); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 1in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;C&rdquo; shall mean the number of such Additional Shares of Common Stock issued in such transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 9; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">4.4.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Determination of Consideration</U>. For purposes of this <U>Subsection&nbsp;4.4</U>, the consideration received by the Corporation
for the issuance or deemed issuance of any Additional Shares of Common Stock shall be computed as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Cash and Property</U>: Such consideration shall:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>insofar as it consists of cash, be computed at the aggregate amount of cash received by the Corporation, excluding amounts paid
or payable for accrued interest;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 1in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>insofar as it consists of property other than cash, be computed at the fair market value thereof at the time of such issue, as
determined in good faith by the Board; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 1in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>in the event Additional Shares of Common Stock are issued together with other shares or securities or other assets of the Corporation
for consideration which covers both, be the proportion of such consideration so received, computed as provided in <U>clauses (i)</U> and
<U>(ii)</U> above, as determined in good faith by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Options and Convertible Securities</U>. The consideration per share received by the Corporation for Additional Shares of Common
Stock deemed to have been issued pursuant to <U>Subsection 4.4.3</U>, relating to Options and Convertible Securities, shall be determined
by dividing the total amount, if any, received or receivable by the Corporation as consideration for the issue of such Options or Convertible
Securities, plus the minimum aggregate amount of additional consideration (as set forth in the instruments relating thereto, without regard
to any provision contained therein for a subsequent adjustment of such consideration) payable to the Corporation upon the exercise of
such Options or the conversion or exchange of such Convertible Securities, or in the case of Options for Convertible Securities, the exercise
of such Options for Convertible Securities and the conversion or exchange of such Convertible Securities, by the maximum number of shares
of Common Stock (as set forth in the instruments relating thereto, without regard to any provision contained therein for a subsequent
adjustment of such number) issuable upon the exercise of such Options or the conversion or exchange of such Convertible Securities, or
in the case of Options for Convertible Securities, the exercise of such Options for Convertible Securities and the conversion or exchange
of such Convertible Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">4.4.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Multiple Closing Dates</U>. In the event the Corporation shall issue on more than one date Additional Shares of Common Stock
that are a part of one transaction or a series of related transactions and that would result in an adjustment to the applicable Conversion
Price for any series of Preferred Stock pursuant to the terms of <U>Subsection 4.4.4</U> then, upon the final such issuance, the applicable
Conversion Price for such series of Preferred Stock shall be readjusted to give effect to all such issuances as if they occurred on the
date of the first such issuance (and without giving effect to any additional adjustments as a result of any such subsequent issuances
within such period).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">4.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Adjustment for Stock Splits and Combinations</U>. If the Corporation shall at any time or from time to time after the Series
E Original Issue Date effect a subdivision of the outstanding Common Stock, the applicable Conversion Price in effect for each series
of Preferred Stock immediately before that subdivision shall be proportionately decreased so that the number of shares of Common Stock
issuable on conversion of each share of such series shall be increased in proportion to such increase in the aggregate number of shares
of Common Stock outstanding. If the Corporation shall at any time or from time to time after the Series E Original Issue Date combine
the outstanding shares of Common Stock, the applicable Conversion Price in effect for each series of Preferred Stock immediately before
the combination shall be proportionately increased so that the number of shares of Common Stock issuable on conversion of each share of
such series shall be decreased in proportion to such decrease in the aggregate number of shares of Common Stock outstanding. Any adjustment
under this subsection shall become effective at the close of business on the date the subdivision or combination becomes effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">4.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Adjustment for Certain Dividends and Distributions</U>. In the event the Corporation at any time or from time to time after
the Series E Original Issue Date shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to
receive, a dividend or other distribution payable on the Common Stock in additional shares of Common Stock, then and in each such event
the applicable Conversion Price in effect for each series of Preferred Stock immediately before such event shall be decreased as of the
time of such issuance or, in the event such a record date shall have been fixed, as of the close of business on such record date, by multiplying
the applicable Conversion Price then in effect for such series of Preferred Stock by a fraction:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
numerator of which shall be the total number of shares of Common Stock issued and outstanding immediately prior to the time of such issuance
or the close of business on such record date, and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
denominator of which shall be the total number of shares of Common Stock issued and outstanding immediately prior to the time of such
issuance or the close of business on such record date plus the number of shares of Common Stock issuable in payment of such dividend or
distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding the foregoing, (i) if such record
date shall have been fixed and such dividend is not fully paid or if such distribution is not fully made on the date fixed therefor, the
applicable Conversion Price for each series of Preferred Stock shall be recomputed accordingly as of the close of business on such record
date and thereafter the applicable Conversion Price for each series of Preferred Stock shall be adjusted pursuant to this subsection as
of the time of actual payment of such dividends or distributions; and (ii) that no such adjustment shall be made if the holders of Preferred
Stock simultaneously receive a dividend or other distribution of shares of Common Stock in a number equal to the number of shares of Common
Stock as they would have received if all outstanding shares of Preferred Stock had been converted into Common Stock on the date of such
event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">4.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Adjustments
for Other Dividends and Distributions</U>. In the event the Corporation at any time or from time to time after the Series E Original
Issue Date shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a
dividend or other distribution payable in securities of the Corporation (other than a distribution of shares of Common Stock in
respect of outstanding shares of Common Stock) or in other property and the provisions of <U>Section 1</U> do not apply to such
dividend or distribution, then and in each such event the holders of Preferred Stock shall receive, simultaneously with the
distribution to the holders of Common Stock, a dividend or other distribution of such securities or other property in an amount
equal to the amount of such securities or other property as they would have received if all outstanding shares of Preferred Stock
had been converted into Common Stock on the date of such event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">4.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Adjustment for Merger or Reorganization, etc</U>. Subject to the provisions of <U>Subsection 2.3</U>, if there shall occur any
reorganization, recapitalization, reclassification, consolidation or merger involving the Corporation in which the Common Stock (but not
the Preferred Stock) is converted into or exchanged for securities, cash or other property (other than a transaction covered by <U>Subsections
4.4</U>, <U>4.6</U> or <U>4.7</U>), then, following any such reorganization, recapitalization, reclassification, consolidation or merger,
each share of Preferred Stock shall thereafter be convertible in lieu of the Common Stock into which it was convertible prior to such
event into the kind and amount of securities, cash or other property which a holder of the number of shares of Common Stock of the Corporation
issuable upon conversion of one share of such series of Preferred Stock immediately prior to such reorganization, recapitalization, reclassification,
consolidation or merger would have been entitled to receive pursuant to such transaction; and, in such case, appropriate adjustment (as
determined in good faith by the Board) shall be made in the application of the provisions in this <U>Section 4</U> with respect to the
rights and interests thereafter of the holders of the Preferred Stock, to the end that the provisions set forth in this <U>Section 4</U>
(including provisions with respect to changes in and other adjustments to the applicable Conversion Price for such series of Preferred
Stock) shall thereafter be applicable, as nearly as reasonably may be, in relation to any securities or other property thereafter deliverable
upon the conversion of such series of Preferred Stock. For the avoidance of doubt, nothing in this <U>Subsection 4.8</U> shall be construed
as preventing the holders of Preferred Stock from seeking any appraisal rights to which they are otherwise entitled under the General
Corporation Law in connection with a merger triggering an adjustment hereunder, nor shall this <U>Subsection 4.8</U> be deemed conclusive
evidence of the fair value of the shares of Preferred Stock in any such appraisal proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">4.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Certificate as to Adjustments</U>. Upon the occurrence of each adjustment or readjustment of the Conversion Price for any series
of Preferred Stock pursuant to this <U>Section 4</U>, the Corporation at its expense shall, as promptly as reasonably practicable but
in any event not later than ten (10) days thereafter, compute such adjustment or readjustment in accordance with the terms hereof and
furnish to each holder of such series of Preferred Stock a certificate setting forth such adjustment or readjustment (including the kind
and amount of securities, cash or other property into which such series of Preferred Stock is convertible) and showing in detail the facts
upon which such adjustment or readjustment is based. The Corporation shall, as promptly as reasonably practicable after the written request
at any time of any holder of Preferred Stock (but in any event not later than ten (10) days thereafter), furnish or cause to be furnished
to such holder a certificate setting forth (i) the Conversion Price then in effect for each series of Preferred Stock that is so adjusted
or readjusted, and (ii) the number of shares of Common Stock and the amount, if any, of other securities, cash or property which then
would be received upon the conversion of such series of Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt"></P>

<!-- Field: Page; Sequence: 12; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">4.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Notice of Record Date</U>. In the event:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Corporation shall take a record of the holders of its Common Stock (or other capital stock or securities at the time issuable
upon conversion of the Preferred Stock) for the purpose of entitling or enabling them to receive any dividend or other distribution, or
to receive any right to subscribe for or purchase any shares of capital stock of any class or any other securities, or to receive any
other security; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>of any capital reorganization of the Corporation, any reclassification of the Common Stock of the Corporation, or any Deemed Liquidation
Event; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>of the voluntary or involuntary dissolution, liquidation or winding-up of the Corporation, <FONT STYLE="color: black">then, and
in each such case, the Corporation will send or cause to be sent to the holders of the </FONT>Preferred Stock <FONT STYLE="color: black">a
notice specifying, as the case may be, (i) the record date for such dividend, distribution or right, and the amount and character of such
dividend, distribution or right, or (ii) the effective date on which such reorganization, reclassification, consolidation, merger, transfer,
dissolution, liquidation or winding-up is proposed to take place, and the time, if any is to be fixed, as of which the holders of record
of Common Stock (or such other capital stock or securities at the time issuable upon the conversion of the </FONT>Preferred Stock<FONT STYLE="color: black">)
shall be entitled to exchange their shares of Common Stock (or such other capital stock or securities) for securities or other property
deliverable upon such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation or winding-up, and the
amount per share and character of such exchange applicable to the </FONT>Preferred Stock <FONT STYLE="color: black">and the Common Stock.
Such notice shall be sent at least 10 days prior to the record date or effective date for the event specified in such notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Mandatory Conversion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">5.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Trigger
Events</U>. Upon either (a) the closing of the sale of shares of Common Stock to the public at a price of at least 1.2 times (1.2X)
the Series D Original Issue Price (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or
other similar recapitalization <FONT STYLE="color: black">with respect to the Common Stock</FONT>), in a firm-commitment
underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, resulting
in at least $40,000,000 of proceeds, net of the underwriting discount and commissions, to the Corporation (a &ldquo;<B>Qualified
Public Offering</B>&rdquo;) or (b) the date and time, or the occurrence of an event, specified by vote or written consent of the
holders of at least a majority of the then outstanding shares of Preferred Stock, voting together as a single class on an
as-converted basis (the time of such closing or the date and time specified or the time of the event specified in such vote or
written consent is referred to herein as the &ldquo;<B>Mandatory Conversion Time</B>&rdquo;), (i) all outstanding shares of
Preferred Stock shall automatically be converted into shares of Class A Common Stock, at the then effective conversion rate as
calculated pursuant to <U>Subsection 4.1.1</U> and (ii) such shares may not be reissued by the Corporation; <I>provided</I> that, a
holder of shares of Preferred Stock may elect, upon written notice to the Corporation (delivered as provided in Section 4.3.1 of
Subsection B of this Article Fourth)) at least seven days prior to the closing of the Qualified Public Offering, to have all or a
portion of its shares of Preferred Stock automatically convert into shares of Class B Common Stock at the then effective conversion
rate as calculated pursuant to <U>Subsection 4.1.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">5.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Procedural Requirements</U>. All holders of record of shares of Preferred Stock shall be sent written notice of the Mandatory
Conversion Time and the place designated for mandatory conversion of all such shares of Preferred Stock pursuant to this <U>Section 5</U>.
Such notice need not be sent in advance of the occurrence of the Mandatory Conversion Time. Upon receipt of such notice, each holder of
shares of Preferred Stock in certified form shall surrender his, her or its certificate or certificates for all such shares (or, if such
holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable
to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss,
theft or destruction of such certificate) to the Corporation at the place designated in such notice. If so required by the Corporation,
any certificates surrendered for conversion shall be endorsed or accompanied by written instrument or instruments of transfer, in form
satisfactory to the Corporation, duly executed by the registered holder or by his, her or its attorney duly authorized in writing. All
rights with respect to the Preferred Stock converted pursuant to <U>Subsection 5.1</U>, including the rights, if any, to receive notices
and vote (other than as a holder of Common Stock), will terminate at the Mandatory Conversion Time (notwithstanding the failure of the
holder or holders thereof to surrender certificates at or prior to such time), except only the rights of the holders thereof, upon surrender
of any certificate or certificates of such holders (or lost certificate affidavit and agreement) therefor, to receive the items provided
for in the next sentence of this <U>Subsection 5.2</U>. As soon as practicable after the Mandatory Conversion Time and, if applicable,
the surrender of any certificate or certificates (or lost certificate affidavit and agreement) for Preferred Stock, the Corporation shall
(a) issue and deliver to such holder, or to his, her or its nominees, a certificate or certificates for the number of full shares of Common
Stock issuable on such conversion in accordance with the provisions hereof and (b) pay cash as provided in <U>Subsection 4.2</U> in lieu
of any fraction of a share of Common Stock otherwise issuable upon such conversion and the payment of any declared but unpaid dividends
on the shares of Preferred Stock converted. Such converted Preferred Stock shall be retired and cancelled and may not be reissued as shares
of such series, and the Corporation may thereafter take such appropriate action (without the need for stockholder action) as may be necessary
to reduce the authorized number of shares of Preferred Stock accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Redemption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">6.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>General</U>.
Unless prohibited by Delaware law governing distributions to stockholders, shares of the Preferred Stock shall be redeemed by the
Corporation at a price equal to the applicable Total Preferred Liquidation Amount (the &ldquo;<B>Redemption Price</B>&rdquo;), in
two (2) equal annual installments commencing not more than sixty (60) days after receipt by the Corporation at any time on or after
the fifth (5<SUP>th</SUP>) anniversary of the Series E Original Issue Date, from the holders of at least a majority of the shares of
the Senior Preferred Stock then outstanding of written notice requesting redemption of all shares of Preferred Stock (the
 &ldquo;<B>Redemption Request</B>&rdquo;). Upon receipt of a Redemption Request, the Corporation shall calculate the aggregate amount
due to holders of the Preferred Stock if the applicable Total Preferred Liquidation Amount were distributed in full to such holders
pursuant to <U>Subsections 2.1</U> and <U>2.2</U> (such amount, the <B>&ldquo;Aggregate Redemption </B>Amount&rdquo;) and shall
apply all of its assets to any such redemption, and to no other corporate purpose, except to the extent prohibited by Delaware law
governing distributions to stockholders. The date of each such installment shall be referred to as a &ldquo;<B>Redemption
Date</B>&rdquo; and the one-half of the Aggregate Redemption Amount due on each Redemption Date shall be referred to as the
 &ldquo;<B>Redemption Installment Amount</B>&rdquo;. On each Redemption Date, the Corporation shall use the Redemption Installment
Amount to redeem all outstanding shares of Senior Preferred Stock and Junior Preferred Stock at a price per share equal to the
amount that such holders would have received if the Redemption Installment Amount were distributed to such holders in connection
with a Deemed Liquidation Event pursuant to <U>Subsections 2.1</U> and <U>2.2</U>. If on any Redemption Date Delaware law governing
distributions to stockholders prevents the Corporation from redeeming all shares of Preferred Stock to be redeemed, subject to the
priority of payments set forth in <U>Subsections 2.1</U> and <U>2.2</U>, the Corporation shall ratably redeem the maximum number of
shares that it may redeem consistent with such law, and shall redeem the remaining shares as soon as it may lawfully do so under
such law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Value: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">6.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Redemption Notice</U>. The Corporation shall send written notice of the mandatory redemption (the &ldquo;<B>Redemption Notice</B>&rdquo;)
to each holder of record of Preferred Stock not less than ten (10) business days prior to each Redemption Date. Each Redemption Notice
shall state:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the number and series of shares of Preferred Stock held by the holder that the Corporation shall redeem on the Redemption Date
specified in the Redemption Notice;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the Redemption Date and the Redemption Price;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the
date upon which the holder&rsquo;s right to convert such shares terminates (as determined in accordance with <U>Subsection 4.1</U>);
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>for holders of shares in certificated form, that the holder is to surrender to the Corporation, in the manner and at the place
designated, his, her or its certificate or certificates representing the shares of Preferred Stock to be redeemed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">6.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Surrender of Certificates; Payment</U>. On or before the applicable Redemption Date, each holder of shares of Preferred Stock
to be redeemed on such Redemption Date, unless such holder has exercised his, her or its right to convert such shares as provided in <U>Section
4</U>, shall, if a holder of shares in certificated form, surrender the certificate or certificates representing such shares (or, if such
registered holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably
acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the
alleged loss, theft or destruction of such certificate) to the Corporation, in the manner and at the place designated in the Redemption
Notice, and thereupon the Redemption Price for such shares shall be payable to the order of the person whose name appears on such certificate
or certificates as the owner thereof. In the event less than all of the shares of Preferred Stock represented by a certificate are redeemed,
a new certificate representing the unredeemed shares of such series of Preferred Stock shall promptly be issued to such holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt"></P>

<!-- Field: Page; Sequence: 3; Value: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">6.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Rights Subsequent to Redemption</U>. If the Redemption Notice shall have been duly given, and if on the applicable Redemption
Date the Redemption Price payable upon redemption of the shares of Preferred Stock to be redeemed on such Redemption Date is paid or tendered
for payment or deposited with an independent payment agent so as to be available therefor in a timely manner, then notwithstanding that
any certificates evidencing any of the shares of Preferred Stock so called for redemption shall not have been surrendered, all rights
with respect to such shares shall forthwith after the Redemption Date terminate, except only the right of the holders to receive the Redemption
Price without interest upon surrender of any such certificate or certificates therefor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 76.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Redeemed
or Otherwise Acquired Shares</U>. Any shares of Preferred Stock <FONT STYLE="color: black">that</FONT> are redeemed or otherwise acquired
by the Corporation or any of its subsidiaries shall be automatically and immediately cancelled and retired and shall not be reissued,
sold or transferred. Neither the Corporation nor any of its subsidiaries may exercise any voting or other rights granted to the holders
of Preferred Stock following redemption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Waiver</U>. Except as otherwise set forth herein, any of the rights, powers, preferences and other terms of any series of Preferred
Stock set forth herein may be waived on behalf of all holders of such series of Preferred Stock by the affirmative written consent or
vote of the holders of at least a majority of the shares of such series of Preferred Stock then outstanding acting together as a separate
class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notices</U>. Any notice required or permitted by the provisions of this Article Fourth to be given to a holder of shares of
Preferred Stock shall be mailed, postage prepaid, to the post office address last shown on the records of the Corporation, or given by
electronic communication in compliance with the provisions of the General Corporation Law, and shall be deemed sent upon such mailing
or electronic transmission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-transform: uppercase"><B>Fifth:
</B></FONT>Subject to any additional vote required by this Sixth Amended and Restated Certificate of Incorporation or Bylaws, in furtherance
and not in limitation of the powers conferred by statute, the Board of Directors is expressly authorized to make, repeal, alter, amend
and rescind any or all of the Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-transform: uppercase"><B>Sixth:
</B></FONT>Subject to any additional vote required by this Sixth Amended and Restated Certificate of Incorporation, the number of directors
of the Corporation shall be determined in the manner set forth in the Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-transform: uppercase"><B>Seventh:
</B></FONT>Elections of directors need not be by written ballot unless the Bylaws shall so provide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-transform: uppercase"><B>Eighth:
</B></FONT>Meetings of stockholders may be held within or without the State of Delaware, as the Bylaws may provide. The books of the Corporation
may be kept outside the State of Delaware at such place or places as may be designated from time to time by the Board of Directors or
in the Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-transform: uppercase"><B>Ninth: </B></FONT>To
the fullest extent permitted by law, a director of the Corporation shall not be personally liable to the Corporation or its
stockholders for monetary damages for breach of fiduciary duty as a director. If the General Corporation Law or any other law of the
State of Delaware is amended after approval by the stockholders of this Article Ninth to authorize corporate action further
eliminating or limiting the personal liability of directors, then the liability of a director of the Corporation shall be eliminated
or limited to the fullest extent permitted by the General Corporation Law as so amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Any repeal or modification of
the foregoing provisions of this Article Ninth by the stockholders of the Corporation shall not adversely affect any right or protection
of a director of the Corporation existing at the time of, or increase the liability of any director of the Corporation with respect to
any acts or omissions of such director occurring prior to, such repeal or modification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-transform: uppercase"><B>Tenth:
</B></FONT>To the fullest extent permitted by applicable law, the Corporation is authorized to provide indemnification of (and advancement
of expenses to) directors, officers and agents of the Corporation (and any other persons to which General Corporation Law permits the
Corporation to provide indemnification) through Bylaw provisions, agreements with such agents or other persons, vote of stockholders or
disinterested directors or otherwise, in excess of the indemnification and advancement otherwise permitted by Section 145 of the General
Corporation Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Any amendment, repeal or modification
of the foregoing provisions of this Article Tenth shall not (a) adversely affect any right or protection of any director, officer or other
agent of the Corporation existing at the time of such amendment, repeal or modification or (b) increase the liability of any director
of the Corporation with respect to any acts or omissions of such director, officer or agent occurring prior to, such amendment, repeal
or modification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-transform: uppercase"><B>Eleventh:
</B></FONT>The Corporation renounces, to the fullest extent permitted by law, any interest or expectancy of the Corporation in, or in
being offered an opportunity to participate in, any Excluded Opportunity. An &ldquo;<B>Excluded Opportunity</B>&rdquo; is any matter,
transaction or interest that is presented to, or acquired, created or developed by, or which otherwise comes into the possession of, (i)
any director of the Corporation who is not an employee of the Corporation or any of its subsidiaries, or (ii) any holder of Preferred
Stock or any partner, member, director, stockholder, employee, affiliate or agent of any such holder, other than someone who is an employee
of the Corporation or any of its subsidiaries (collectively, the persons in <U>clauses (i)</U> and <U>(ii)</U> are &ldquo;<B>Covered Persons</B>&rdquo;),
unless such matter, transaction or interest is presented to, or acquired, created or developed by, or otherwise comes into the possession
of, a Covered Person expressly and solely in such Covered Person&rsquo;s capacity as a director of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-transform: uppercase"><B>Twelfth: </B></FONT>Unless
the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery in the State of Delaware shall
be the sole and exclusive forum for any stockholder (including a beneficial owner) to bring (i)&nbsp;any derivative action or
proceeding brought on behalf of the Corporation, (ii)&nbsp;any action asserting a claim of breach of fiduciary duty owed by any
director, officer or other employee of the Corporation to the Corporation or the Corporation&rsquo;s stockholders, (iii)&nbsp;any
action asserting a claim against the Corporation, its directors, officers or employees arising pursuant to any provision of the
Delaware General Corporation Law or the Corporation&rsquo;s certificate of incorporation or bylaws or (iv)&nbsp;any action asserting
a claim against the Corporation, its directors, officers or employees governed by the internal affairs doctrine, except for, as to
each of (i) through (iv) above, any claim as to which the Court of Chancery determines that there is an indispensable party not
subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of
the Court of Chancery within ten days following such determination), which is vested in the exclusive jurisdiction of a court or
forum other than the Court of Chancery, or for which the Court of Chancery does not have subject matter jurisdiction. If any
provision or provisions of this Article Twelfth shall be held to be invalid, illegal or unenforceable as applied to any person or
entity or circumstance for any reason whatsoever, then, to the fullest extent permitted by law, the validity, legality and
enforceability of such provisions in any other circumstance and of the remaining provisions of this Article Twelfth (including,
without limitation, each portion of any sentence of this Article Twelfth containing any such provision held to be invalid, illegal
or unenforceable that is not itself held to be invalid, illegal or unenforceable) and the application of such provision to other
persons or entities and circumstances shall not in any way be affected or impaired thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-transform: uppercase"><B>Thirteenth:
</B></FONT>In connection with repurchases by the Corporation of its Common Stock from employees, officers, directors, advisors, consultants
or other persons performing services for the Corporation or any subsidiary pursuant to agreements under which the Corporation has the
option to repurchase such shares at cost upon the occurrence of certain events, such as the termination of employment, Sections 502 and
503 of the California Corporations Code shall not apply in all or in part with respect to such repurchases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">*&nbsp;&nbsp;&nbsp; * &nbsp;&nbsp;&nbsp;*</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to Section 228(a) of the General Corporation Law, the holders of outstanding shares of the Corporation having no less than the minimum
number of votes that would be necessary to authorize or take such actions at a meeting at which all shares entitled to vote thereon were
present and voted, consented to the adoption of the aforesaid amendments without a meeting, without a vote and without prior notice and
that written notice of the taking of such actions has been given in accordance with Section 228(e) of the General Corporation Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;That
this Sixth Amended and Restated Certificate of Incorporation, which restates and integrates and further amends the provisions of this
corporation&rsquo;s Certificate of Incorporation, as amended, has been duly adopted in accordance with Sections 141, 228, 242 and 245
of the General Corporation Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>IN WITNESS WHEREOF</B>, this
Sixth Amended and Restated Certificate of Incorporation has been executed by a duly authorized officer of this corporation on this 29<SUP>th</SUP>
day of March 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-size: 10pt">/s/ Gregory C. Critchfield, M.D., M.S.</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Gregory C. Critchfield, M.D., M.S.</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">President and Chief Executive Officer</FONT></TD></TR>
  </TABLE>




<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="margin: 0pt"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATE OF AMENDMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RESTATED CERTIFICATE OF INCORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SERA PROGNOSTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is hereby certified that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
name of the corporation (hereinafter called the &ldquo;<B>Corporation</B>&rdquo;) is Sera Prognostics, Inc. The date of filing of the
Certificate of Incorporation of the Corporation with the Secretary of State of the State of Delaware was January 17, 2008. Thereafter
a Restated Certificate of Incorporation was filed on March 29, 2021 (the &ldquo;<B>Restated Certificate</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Restated Certificate of Incorporation is hereby amended to change the authorized capitalization of the Corporation by striking out the
first sentence of the first paragraph of Article FOURTH of the Restated Certificate in its entirety and by substituting in lieu of said
first sentence of the first paragraph of Article FOURTH, the following sentence:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;The total number of shares of
all classes of stock which the Corporation shall have authority to issue is (i) 80,000,000 shares of Class A Common Stock, $0.0001 par
value per share (&ldquo;<B>Class A Common Stock</B>&rdquo;), (ii) 3,000,000 shares of Class B Common Stock, $0.0001 par value per share
(&ldquo;<B>Class B Common Stock</B>&rdquo;) and (iii) 51,551,681 shares of Preferred Stock, $0.0001 par value per share (&ldquo;<B>Preferred
Stock</B>&rdquo;). &rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Restated Certificate of Incorporation is hereby further amended to change the preferred stock designations of the Corporation by striking
out the first paragraph of Part B of Article FOURTH of the Restated Certificate in its entirety and by substitution in lieu of said first
paragraph of Part B of Article FOURTH, the following paragraph:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;1,390 shares of the authorized
Preferred Stock of the Corporation are hereby designated &ldquo;<B>Series A1 Preferred Stock</B>&rdquo;, 7,941,499 shares of the authorized
Preferred Stock of the Corporation are hereby designated &ldquo;<B>Series A2 Preferred Stock</B>&rdquo;, 2,060,000 shares of the authorized
Preferred Stock of the Corporation are hereby designated &ldquo;<B>Series B-1 Preferred Stock</B>&rdquo;, 5,012,500 shares of the authorized
Preferred Stock of the Corporation are hereby designated &ldquo;<B>Series B-2 Preferred Stock</B>&rdquo;, 5,521,905 shares of the authorized
Preferred Stock of the Corporation are hereby designated &ldquo;<B>Series C-1 Preferred Stock</B>&rdquo;, 1,510,000 shares of the authorized
Preferred Stock of the Corporation are hereby designated &ldquo;<B>Series C-2 Preferred Stock</B>&rdquo;, 11,975,172 shares of the authorized
Preferred Stock of the Corporation are hereby designated &ldquo;<B>Series D Preferred Stock</B>&rdquo;, and 17,529,215 shares of the authorized
Preferred Stock of the Corporation are hereby designated &ldquo;<B>Series E Preferred Stock</B>&rdquo;, with the following rights, preferences,
powers, privileges and restrictions, qualifications and limitations. &ldquo;<B>Junior Preferred Stock</B>&rdquo; means the Series A1 Preferred
Stock, the Series A2 Preferred Stock, the Series B-1 Preferred Stock, the Series B-2 Preferred Stock, the Series C-1 Preferred Stock and
the Series C-2 Preferred Stock. &ldquo;<B>Senior Preferred Stock</B>&rdquo; means the Series D Preferred Stock and the Series E Preferred
Stock. Unless otherwise indicated, references to &ldquo;Sections&rdquo; or &ldquo;Subsections&rdquo; in this Part B of this Article Fourth
refer to sections and subsections of Part B of this Article Fourth.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Restated Certificate of Incorporation is hereby further amended to change the preferential payments to holders of Senior Preferred Stock
of the Corporation by striking out Section 2.1 of Article FOURTH of the Restated Certificate in its entirety and by substitution in lieu
of said Section 2.1 of Article FOURTH, the following Section 2.1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;2.1&nbsp;&nbsp;&nbsp;<U>Preferential Payments
to Holders of Senior Preferred Stock</U>. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation
or a Deemed Liquidation Event (as defined below), before any distribution or payment shall be made to the holders of any Common Stock
or the holders of shares of any other series of Preferred Stock, the holders of shares of Senior Preferred Stock shall be entitled to
be paid out of the assets of the Corporation legally available for distribution to its stockholders, and in the event of a Deemed Liquidation
Event (as defined below), the holders of shares of Senior Preferred Stock then outstanding shall be entitled to be paid out of the consideration
payable to stockholders in such Deemed Liquidation Event or out of the Available Proceeds (as defined below), as applicable, before any
payment shall be made to the holders of Common Stock, the Junior Preferred Stock or any other class or series of stock ranking on liquidation
junior to the Senior Preferred Stock and together with any shares of Preferred Stock ranking on liquidation pari passu with the Senior
Preferred Stock by reason of their ownership thereof, an amount per share equal to (i) with respect to each share of Series D Preferred
Stock, the greater of (a) one and one-half (1.5) times the Series D Original Issue Price of such share of Series D Preferred Stock plus
all declared and unpaid dividends on such share of Series D Preferred Stock and (b) such amount per share as would have been payable had
all shares of the Series D Preferred Stock been converted into Common Stock pursuant to Section 4 immediately prior to such liquidation,
dissolution, winding up or Deemed Liquidation Event, and (ii) with respect to each share of Series E Preferred Stock, the greater of (a)
one and one-half (1.5) times the Original Issue Price of such share of Series E Preferred Stock plus all declared and unpaid dividends
on such share of Series E Preferred Stock and (b) such amount per share as would have been payable had all shares of Series E Preferred
Stock been converted into Common Stock pursuant to Section 4 immediately prior to such liquidation, dissolution, winding up or Deemed
Liquidation Event (the amount payable in respect of Senior Preferred Stock pursuant to this sentence is hereinafter referred to as the
 &ldquo;Senior Preferential Liquidation Amount&rdquo;). If upon any such liquidation, dissolution or winding up of the Corporation or Deemed
Liquidation Event, the assets of the Corporation available for distribution to its stockholders shall be insufficient to pay the holders
of shares of Senior Preferred Stock or any shares of Preferred Stock ranking on liquidation pari passu with the Senior Preferred Stock
the full amount to which they shall be entitled under this Subsection 2.1, the holders of shares of Senior Preferred Stock or any shares
of Preferred Stock ranking on liquidation pari passu with the Senior Preferred Stock shall share ratably in any distribution of the assets
available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them
upon such distribution if all amounts payable on or with respect to such shares were paid in full.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Restated Certificate of Incorporation is hereby further amended to change the definition of &ldquo;Qualified Public Offering&rdquo; by
striking out Section 5.1 of Article FOURTH of the Restated Certificate in its entirety and by substitution in lieu of said Section 5.1
of Article FOURTH, the following Section 5.1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&ldquo;5.1&nbsp;&nbsp;&nbsp;<U>Trigger
Events</U>. Upon either (a) the closing of the sale of shares of Common Stock to the public at a price of at least 1.2 times (1.2X) the
Series E Original Issue Price (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other
similar recapitalization with respect to the Common Stock), in a firm-commitment underwritten public offering pursuant to an effective
registration statement under the Securities Act of 1933, as amended, resulting in at least $40,000,000 of proceeds, net of the underwriting
discount and commissions, to the Corporation (a &ldquo;<B>Qualified Public Offering</B>&rdquo;) or (b) the date and time, or the occurrence
of an event, specified by vote or written consent of the holders of at least a majority of the then outstanding shares of Preferred Stock,
voting together as a single class on an as-converted basis (the time of such closing or the date and time specified or the time of the
event specified in such vote or written consent is referred to herein as the &ldquo;<B>Mandatory Conversion Time</B>&rdquo;), (i) all
outstanding shares of Preferred Stock shall automatically be converted into shares of Class A Common Stock, at the then effective conversion
rate as calculated pursuant to <U>Subsection 4.1.1</U> and (ii) such shares may not be reissued by the Corporation; <I>provided</I> that,
a holder of shares of Preferred Stock may elect, upon written notice to the Corporation (delivered as provided in Section 4.3.1 of Subsection
B of this Article Fourth)) at least seven days prior to the closing of the Qualified Public Offering, to have all or a portion of its
shares of Preferred Stock automatically convert into shares of Class B Common Stock at the then effective conversion rate as calculated
pursuant to <U>Subsection 4.1.1</U>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Certificate of Amendment to the Restated Certificate has been duly adopted in accordance with the provisions of Sections 141, 228 and
242 of the Delaware General Corporation Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to Section 228(a) of the Delaware General Corporation Law, the holders of outstanding shares of the Corporation having no less than the
minimum number of votes that would be necessary to authorize or take such actions at a meeting at which all shares entitled to vote thereon
were present and voted, consented to the adoption of the aforesaid amendments without a meeting, without a vote and without prior notice
and that written notice of the taking of such actions has been given in accordance with Section 228(e) of the Delaware General Corporation
Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>, the Corporation has
caused this Certificate of Amendment to be signed this 26<SUP>th</SUP> day of April, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">SERA PROGNOSTICS, INC.</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-size: 10pt">/s/ Gregory C. Critchfield, M.D.</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Gregory C. Critchfield, M.D.</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">President</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.3
<SEQUENCE>11
<FILENAME>tm2110724d11_ex3-3.htm
<DESCRIPTION>EXHIBIT 3.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: right; margin: 0pt"><B>Exhibit 3.3</B></P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="margin: 0pt"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AMENDED AND RESTATED BYLAWS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">OF</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SERA PROGNOSTICS, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">(a Delaware corporation)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">ARTICLE I &#8212; MEETINGS
OF STOCKHOLDERS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Place of Meetings; Telephonic Meetings</I></B>.&nbsp; Meetings of stockholders of Sera Prognostics, Inc. (the &#8220;<B>Corporation</B>&#8221;)
shall be held at any place, within or outside the State of Delaware, designated by the Corporation&#8217;s board of directors (the &#8220;<B>Board</B>&#8221;).
The Board may, in its sole discretion, determine that a meeting of stockholders shall not be held at any place, but may instead be held
solely by means of remote communication as authorized by Section&nbsp;211(a)(2) of the Delaware General Corporation Law (the &#8220;<B>DGCL</B>&#8221;).
In the absence of any such designation or determination, stockholders&#8217; meetings shall be held at the Corporation&#8217;s principal
executive office. Unless otherwise restricted by the certificate of incorporation or these bylaws, the stockholders may participate in
a meeting by means of conference telephone or other communications equipment by means of which all persons participating in the meeting
can hear each other, and such participation in a meeting shall constitute presence in person at the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Annual Meeting</I></B>.&nbsp; An annual meeting of stockholders shall be held for the election of directors at such date
and time as may be designated by resolution of the Board from time to time. Any other proper business may be transacted at the annual
meeting. The Corporation shall not be required to hold an annual meeting of stockholders provided that (i) the stockholders are permitted
to act by written consent under the Corporation&#8217;s certificate of incorporation and these bylaws, (ii) the stockholders take action
by written consent to elect directors, and (iii) the stockholders unanimously consent to such action or, if such consent is less than
unanimous, all of the directorships to which directors could be elected at an annual meeting held at the effective time of such action
are vacant and are filled by such action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Special Meeting</I></B>.&nbsp; A special meeting of the stockholders may be called at any time by the Board, chairperson
of the Board, chief executive officer or president (in the absence of a chief executive officer) or by one or more stockholders holding
shares in the aggregate entitled to cast not less than ten percent (10%) of the votes at that meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">If any person(s) other than the
Board calls a special meeting, the request shall:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>be in writing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>specify the time of such meeting and the general nature of the business proposed to be transacted; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> be delivered personally or sent by registered mail or by facsimile transmission to the chairperson of the Board, the chief executive
officer, the president (in the absence of a chief executive officer) or the secretary of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The officer(s) receiving the
request shall cause notice to be promptly given to the stockholders entitled to vote at such meeting, in accordance with the provisions
of <B>Sections&nbsp;1.4</B> and <B>1.5</B> of these bylaws, that a meeting will be held at the time requested by the person or persons
calling the meeting. No business may be transacted at such special meeting other than the business specified in such notice to stockholders.
Nothing contained in this paragraph of this <B>Section&nbsp;1.3</B> shall be construed as limiting, fixing, or affecting the time when
a meeting of stockholders called by action of the Board may be held.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Notice of Stockholders&#8217; Meetings</I></B>. All notices of meetings of stockholders shall be sent or otherwise given
in accordance with either <B>Section&nbsp;1.5</B> or <B>Section&nbsp;7.1</B> of these bylaws not less than ten (10) or more than sixty
(60) days before the date of the meeting to each stockholder entitled to vote at such meeting. The notice shall specify the place, if
any, date and hour of the meeting, the means of remote communication, if any, by which stockholders and proxy holders may be deemed to
be present in person and vote at such meeting, and, in the case of a special meeting, the purpose or purposes for which the meeting is
called.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Manner of Giving Notice; Affidavit of Notice</I></B>. Notice of any meeting of stockholders shall be given:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>if mailed, when deposited in the United States mail, postage prepaid, directed to the stockholder at his or her address as it appears
on the Corporation&#8217;s records;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>if transmitted by private carrier, upon the day delivery is guaranteed by the carrier;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>if personally delivered, upon delivery; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>if electronically transmitted as provided in <B>Section&nbsp;7.1</B> of these bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An affidavit of the secretary
or an assistant secretary of the Corporation or of the transfer agent or any other agent of the Corporation that the notice has been given
by mail or by a form of electronic transmission, as applicable, shall, in the absence of fraud, be prima facie evidence of the facts stated
therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><B><I>Quorum</I></B>.
Except as otherwise provided by law, the certificate of incorporation or these bylaws, at each meeting of stockholders the presence
in person or by proxy of the holders of shares of stock having a majority of the votes which could be cast by the holders of all
outstanding shares of stock entitled to vote at the meeting shall be necessary and sufficient to constitute a quorum. If, however,
such quorum is not present or represented at any meeting of the stockholders, then either (i)&nbsp;the chairperson of the meeting,
or (ii)&nbsp;the stockholders entitled to vote at the meeting, present in person or represented by proxy, shall have power to
adjourn the meeting from time to time, without notice other than announcement at the meeting, until a quorum is present or
represented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Adjourned Meeting; Notice</I></B>.&nbsp; Any meeting of stockholders, annual or special, may adjourn from time to time to
reconvene at the same or some other place, and notice need not be given of the adjourned meeting if the time, place if any thereof, and
the means of remote communications if any by which stockholders and proxy holders may be deemed to be present in person and vote at such
adjourned meeting are announced at the meeting at which the adjournment is taken. At the continuation of the adjourned meeting, the Corporation
may transact any business which might have been transacted at the original meeting. If the adjournment is for more than 30 days, or if
after the adjournment a new record date is fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each stockholder
of record entitled to vote at the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Conduct of Business</I></B>. Meetings of stockholders shall be presided over by the Chairman of the Board, if any, or in
his or her absence by the Vice Chairman of the Board, if any, or in his or her absence by the President, or in his or her absence by a
Vice President, or in the absence of the foregoing persons by a chairperson designated by the Board, or in the absence of such designation
by a chairperson chosen at the meeting. The Secretary shall act as secretary of the meeting, but in his or her absence the chairperson
of the meeting may appoint any person to act as secretary of the meeting. The chairperson of any meeting of stockholders shall determine
the order of business and the procedure at the meeting, including such regulation of the manner of voting and the conduct of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Voting</I></B>. The stockholders entitled to vote at any meeting of stockholders shall be determined in accordance with the
provisions of <B>Section&nbsp;1.11</B> of these bylaws, subject to Section&nbsp;217 (relating to voting rights of fiduciaries, pledgors
and joint owners of stock) and Section&nbsp;218 (relating to voting trusts and other voting agreements) of the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as may be otherwise provided
in the certificate of incorporation or these bylaws, each stockholder shall be entitled to one vote for each share of capital stock held
by such stockholder. Voting at meetings of stockholders need not be by written ballot and need not be conducted by inspectors of election
unless so determined by the holders of shares of stock having a majority of the votes which could be cast by the holders of all outstanding
shares of stock entitled to vote thereon which are present in person or by proxy at such meeting. At all meetings of stockholders for
the election of directors a plurality of the votes cast shall be sufficient to elect. All other elections and questions shall, unless
otherwise provided by law, the certificate of incorporation or these bylaws, be decided by the vote of the holders of shares of stock
having a majority of the votes which could be cast by the holders of all shares of stock entitled to vote thereon which are present in
person or represented by proxy at the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><B><I>Stockholder
Action by Written Consent Without a Meeting</I></B>.&nbsp; Unless otherwise provided in the certificate of incorporation, any action
required by the DGCL to be taken at any annual or special meeting of stockholders of a corporation, or any action which may be taken
at any annual or special meeting of such stockholders, may be taken without a meeting, without prior notice, and without a vote, if
a consent or consents in writing, setting forth the action so taken, shall be signed by the holders of outstanding stock having not
less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares
entitled to vote thereon were present and voted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prompt notice of the taking of
the corporate action without a meeting by less than unanimous written consent shall be given to those stockholders who have not consented
in writing and who, if the action had been taken at a meeting, would have been entitled to notice of the meeting if the record date for
such meeting had been the date that written consents signed by a sufficient number of holders to take the action were delivered to the
Corporation as provided in Section&nbsp;228 of the DGCL. In the event that the action which is consented to is such as would have required
the filing of a certificate under any provision of the DGCL, if such action had been voted on by stockholders at a meeting thereof, the
certificate filed under such provision shall state, in lieu of any statement required by such provision concerning any vote of stockholders,
that written consent has been given in accordance with Section&nbsp;228 of the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Record Date for Stockholder Notice; Voting; Giving Consents</I></B>. In order that the Corporation may determine the stockholders
entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof, or entitled to express consent to corporate
action in writing without a meeting, or entitled to receive payment of any dividend or other distribution or allotment of any rights,
or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action,
the Board may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted
by the Board and which record date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(i) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in
the case of determination of stockholders entitled to notice of or to vote at any meeting of stockholders or adjournment thereof, shall,
unless otherwise required by law, not be more than sixty (60) nor less than ten (10) days before the date of such meeting;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(ii) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in
the case of determination of stockholders entitled to express consent to corporate action in writing without a meeting, shall not be more
than ten (10) days after the date upon which the resolution fixing the record date is adopted by the Board; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in
the case of determination of stockholders for any other action, shall not be more than sixty (60) days prior to such other action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If no record date is fixed by the Board:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(i) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business
on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding
the day on which the meeting is held;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(ii)
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the record date for determining stockholders entitled to express consent to corporate
action in writing without a meeting when no prior action of the Board is required by law, shall be the first date on which a signed
written consent setting forth the action taken or proposed to be taken is delivered to the Corporation in accordance with applicable
law, or, if prior action by the Board is required by law, shall be at the close of business on the day on which the Board adopts the
resolution taking such prior action; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(iii) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
record date for determining stockholders for any other purpose shall be at the close of business on the day on which the Board adopts
the resolution relating thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A determination of stockholders of record entitled
to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the Board
may fix a new record date for the adjourned meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Proxies</I></B>.&nbsp; Each stockholder entitled to vote at a meeting of stockholders or to express consent or dissent to
corporate action in writing without a meeting may authorize another person or persons to act for such stockholder by proxy authorized
by an instrument in writing or by a transmission permitted by law filed in accordance with the procedure established for the meeting,
but no such proxy shall be voted or acted upon after three years from its date, unless the proxy provides for a longer period. The revocability
of a proxy that states on its face that it is irrevocable shall be governed by the provisions of Section&nbsp;212 of the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.13<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>List of Stockholders Entitled to Vote</I></B>. The officer who has charge of the stock ledger of the Corporation shall prepare
and make, at least ten (10) days before every meeting of stockholders, a complete list of the stockholders entitled to vote at the meeting,
arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in the name of each stockholder.
The Corporation shall not be required to include electronic mail addresses or other electronic contact information on such list. Such
list shall be open to the examination of any stockholder, for any purpose germane to the meeting for a period of at least ten (10) days
prior to the meeting: (i)&nbsp;on a reasonably accessible electronic network, provided that the information required to gain access to
such list is provided with the notice of the meeting, or (ii)&nbsp;during ordinary business hours, at the Corporation&#8217;s principal
executive office. In the event that the Corporation determines to make the list available on an electronic network, the Corporation may
take reasonable steps to ensure that such information is available only to stockholders of the Corporation. If the meeting is to be held
at a place, then the list shall be produced and kept at the time and place of the meeting during the whole time thereof, and may be inspected
by any stockholder who is present. If the meeting is to be held solely by means of remote communication, then the list shall also be open
to the examination of any stockholder during the whole time of the meeting on a reasonably accessible electronic network, and the information
required to access such list shall be provided with the notice of the meeting. Such list shall presumptively determine the identity of
the stockholders entitled to vote at the meeting and the number of shares held by each of them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">ARTICLE II &#8212; DIRECTORS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><B><I>Powers</I></B>.
Subject to the provisions of the DGCL and any limitations in the certificate of incorporation or these bylaws relating to action
required to be approved by the stockholders or by the outstanding shares, the business and affairs of the Corporation shall be
managed and all corporate powers shall be exercised by or under the direction of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Number of Directors</I></B>. The number of directors shall be determined from time to time by resolution of the Board, provided
the Board shall consist of at least one&nbsp;member. No reduction of the authorized number of directors shall have the effect of removing
any director before that director&#8217;s term of office expires.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Election, Qualification and Term of Office of Directors</I></B>. Except as provided in <B>Section&nbsp;2.4 </B>of these bylaws,
directors shall be elected at each annual meeting of stockholders to hold office until the next annual meeting. Directors need not be
stockholders unless so required by the certificate of incorporation or these bylaws. The certificate of incorporation or these bylaws
may prescribe other qualifications for directors. Each director, including a director elected to fill a vacancy, shall hold office until
such director&#8217;s successor is elected and qualified or until such director&#8217;s earlier death, resignation or removal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Resignation and Vacancies</I></B>. Any director may resign at any time upon notice given in writing or by electronic transmission
to the Corporation. When one or more directors so resigns and the resignation is effective at a future date, a majority of the directors
then in office, including those who have so resigned, shall have power to fill such vacancy or vacancies, the vote thereon to take effect
when such resignation or resignations shall become effective, and each director so chosen shall hold office as provided in this Section
in the filling of other vacancies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise provided
in the certificate of incorporation or these bylaws:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Vacancies and newly created directorships resulting from any increase in the authorized number of directors elected by all of the
stockholders having the right to vote as a single class may be filled by a majority of the directors then in office, although less than
a quorum, or by a sole remaining director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Whenever the holders of any class or classes of stock or series thereof are entitled to elect one or more directors by the provisions
of the certificate of incorporation, vacancies and newly created directorships of such class or classes or series may be filled by a majority
of the directors elected by such class or classes or series thereof then in office, or by a sole remaining director so elected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If at any time, by reason of
death or resignation or other cause, the Corporation should have no directors in office, then any officer or any stockholder or an executor,
administrator, trustee or guardian of a stockholder, or other fiduciary entrusted with like responsibility for the person or estate of
a stockholder, may call a special meeting of stockholders in accordance with the provisions of the certificate of incorporation or these
bylaws, or may apply to the Court of Chancery for a decree summarily ordering an election as provided in Section&nbsp;211 of the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If, at the time of filling
any vacancy or any newly created directorship, the directors then in office constitute less than a majority of the whole Board (as
constituted immediately prior to any such increase), then the Court of Chancery may, upon application of any stockholder or
stockholders holding at least ten percent (10%) of the total number of the shares at the time outstanding having the right to vote
for such directors, summarily order an election to be held to fill any such vacancies or newly created directorships, or to replace
the directors chosen by the directors then in office as aforesaid, which election shall be governed by the provisions of
Section&nbsp;211 of the DGCL as far as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Place of Meetings; Meetings by Telephone</I></B>.&nbsp; The Board may hold meetings, both regular and special, either within
or outside the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise restricted by
the certificate of incorporation or these bylaws, members of the Board, or any committee designated by the Board, may participate in a
meeting of the Board, or any committee, by means of conference telephone or other communications equipment by means of which all persons
participating in the meeting can hear each other, and such participation in a meeting shall constitute presence in person at the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Regular Meetings</I></B>. Regular meetings of the Board may be held without notice at such time and at such place as shall
from time to time be determined by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Special Meetings; Notice</I></B>.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Special meetings of the Board
for any purpose or purposes may be called at any time by the chairperson of the Board, the chief executive officer, the president, the
secretary or any two directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notice of the time and place
of special meetings shall be:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>delivered personally by hand, by courier or by telephone;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>sent by United States first-class mail, postage prepaid;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>sent by facsimile; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>sent by electronic mail,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">directed to each director at that director&#8217;s
address, telephone number, facsimile number or electronic mail address, as the case may be, as shown on the Corporation&#8217;s records.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the notice is (i) delivered
personally by hand, by courier or by telephone, (ii) sent by facsimile or (iii)&nbsp;sent by electronic mail, it shall be delivered or
sent at least twenty-four (24) hours before the time of the holding of the meeting. If the notice is sent by United States mail, it shall
be deposited in the United States mail at least four (4) days before the time of the holding of the meeting. Any oral notice may be communicated
to the director. The notice need not specify the place of the meeting (if the meeting is to be held at the Corporation&#8217;s principal
executive office) nor the purpose of the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <B><I>Quorum</I></B>. At all meetings of the Board, a majority of the total number of directors shall constitute a quorum for
the transaction of business. The vote of a majority of the directors present at any meeting at which a quorum is present shall be the
act of the Board, except as may be otherwise specifically provided by statute, the certificate of incorporation or these bylaws. If a
quorum is not present at any meeting of the Board, then the directors present thereat may adjourn the meeting from time to time, without
notice other than announcement at the meeting, until a quorum is present.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A meeting at which a quorum is
initially present may continue to transact business notwithstanding the withdrawal of directors, if any action taken is approved by at
least a majority of the required quorum for that meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Board Action by Written Consent Without a Meeting</I></B>. Unless otherwise restricted by the certificate of incorporation
or these bylaws, any action required or permitted to be taken at any meeting of the Board, or of any committee thereof, may be taken without
a meeting if all members of the Board or committee, as the case may be, consent thereto in writing or by electronic transmission and the
writing or writings or electronic transmission or transmissions are filed with the minutes of proceedings of the Board or committee. Such
filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained
in electronic form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Fees and Compensation of Directors</I></B>. Unless otherwise restricted by the certificate of incorporation or these bylaws,
the Board shall have the authority to fix the compensation of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Approval of Loans to Officers</I></B>. The Corporation may lend money to, or guarantee any obligation of, or otherwise assist
any officer or other employee of the Corporation or of its subsidiary, including any officer or employee who is a director of the Corporation
or its subsidiary, whenever, in the judgment of the Board, such loan, guaranty or assistance may reasonably be expected to benefit the
Corporation. The loan, guaranty or other assistance may be with or without interest and may be unsecured, or secured in such manner as
the Board shall approve, including, without limitation, a pledge of shares of stock of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Removal of Directors</I></B>. Unless otherwise restricted by statute, the certificate of incorporation or these bylaws, any
director or the entire Board may be removed, with or without cause, by the holders of a majority of the shares then entitled to vote at
an election of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No reduction of the authorized
number of directors shall have the effect of removing any director prior to the expiration of such director&#8217;s term of office.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">ARTICLE III &#8212; COMMITTEES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><B><I>Committees
of Directors</I></B>. The Board may designate one or more committees, each committee to consist of one or more of the directors of
the Corporation. The Board may designate one or more directors as alternate members of any committee, who may replace any absent or
disqualified member at any meeting of the committee. In the absence or disqualification of a member of a committee, the member or
members thereof present at any meeting and not disqualified from voting, whether or not such member or members constitute a quorum,
may unanimously appoint another member of the Board to act at the meeting in the place of any such absent or disqualified member.
Any such committee, to the extent provided in the resolution of the Board or in these bylaws, shall have and may exercise all the
powers and authority of the Board in the management of the business and affairs of the Corporation, and may authorize the seal of
the Corporation to be affixed to all papers that may require it; but no such committee shall have the power or authority to
(i)&nbsp;approve or adopt, or recommend to the stockholders, any action or matter expressly required by the DGCL to be submitted to
stockholders for approval, or (ii) adopt, amend or repeal any bylaw of the Corporation,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Committee Minutes</I></B>. Each committee shall keep regular minutes of its meetings and report the same to the Board when
required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Meetings and Action of Committees</I></B>.&nbsp; Meetings and actions of committees shall be governed by, and held and taken
in accordance with, the provisions of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Section&nbsp;2.5</B> (place of meetings and meetings by telephone);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Section&nbsp;2.6 </B>(regular meetings);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Section&nbsp;2.7</B> (special meetings and notice);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Section&nbsp;2.8</B> (quorum);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Section&nbsp;2.9</B> (action without a meeting); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Section&nbsp;6.10</B> (waiver of notice)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">with such changes in the context
of those bylaws as are necessary to substitute the committee and its members for the Board and its members. <I>However</I>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the time of regular meetings of committees may be determined either by resolution of the Board or by resolution of the committee;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>special meetings of committees may also be called by resolution of the Board; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>notice of special meetings of committees shall also be given to all alternate members, who shall have the right to attend all meetings
of the committee. The Board may adopt rules for the government of any committee not inconsistent with the provisions of these bylaws.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>ARTICLE IV &#8212; OFFICERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <B><I>Officers</I></B>. The initial officers of the Corporation shall be a Chairman of the Board, Chief Executive Officer, Vice
President - Development, a Secretary and a Chief Financial Officer. The Corporation may also have, at the discretion of the Board, a chairperson,
one or more vice presidents, one or more assistant vice presidents, one or more assistant treasurers, one or more assistant secretaries,
and any such other officers as may be appointed in accordance with the provisions of these bylaws. Any number of offices may be held by
the same person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Appointment of Officers</I></B>. The Board shall appoint the officers of the Corporation, except such officers as may be
appointed in accordance with the provisions of <B>Section&nbsp;4.3</B> of these bylaws, subject to the rights, if any, of an officer under
any contract of employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Subordinate Officers</I></B>. The Board may appoint, or empower the chief executive officer or, in the absence of a chief
executive officer, the president, to appoint, such other officers and agents as the business of the Corporation may require. Each of such
officers and agents shall hold office for such period, have such authority, and perform such duties as are provided in these bylaws or
as the Board may from time to time determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Removal and Resignation of Officers</I></B>. Subject to the rights, if any, of an officer under any contract of employment,
any officer may be removed, either with or without cause, by an affirmative vote of the majority of the Board at any regular or special
meeting of the Board or, except in the case of an officer chosen by the Board, by any officer upon whom such power of removal may be conferred
by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any officer may resign at any
time by giving written notice to the Corporation. Any resignation shall take effect at the date of the receipt of that notice or at any
later time specified in that notice. Unless otherwise specified in the notice of resignation, the acceptance of the resignation shall
not be necessary to make it effective. Any resignation is without prejudice to the rights, if any, of the Corporation under any contract
to which the officer is a party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Vacancies in Offices</I></B>. Any vacancy occurring in any office of the Corporation shall be filled by the Board or as provided
in <B>Section&nbsp;4.2</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Representation of Shares of Other Corporations</I></B>. The chairperson of the Board, the president, any vice president,
the treasurer, the secretary or assistant secretary of the Corporation, or any other person authorized by the Board or the president or
a vice president, is authorized to vote, represent, and exercise on behalf of the Corporation all rights incident to any and all shares
of any other corporation or corporations standing in the name of the Corporation. The authority granted herein may be exercised either
by such person directly or by any other person authorized to do so by proxy or power of attorney duly executed by such person having the
authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Authority and Duties of Officers</I></B>. All officers of the Corporation shall respectively have such authority and perform
such duties in the management of the business of the Corporation as may be designated from time to time by the Board or the stockholders
and, to the extent not so provided, as generally pertain to their respective offices, subject to the control of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <B><I>Salaries</I></B>. The salaries of the officers shall be fixed from time to time by the Board, and no officer shall be prevented
from receiving such salary by reason of the fact that such officer is also a director of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">ARTICLE V &#8212; RECORDS
AND REPORTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Maintenance and Inspection of Records</I></B>. The Corporation shall, either at its principal executive office or at such
place or places as designated by the Board, keep a record of the minutes of all meetings of its stockholders and the Board, a record of
all actions taken by the stockholders and the Board without a meeting, a record of all actions taken by a committee of the Board exercising
authority of the Board on behalf of the Corporation, a record of its stockholders listing their names and addresses and the number and
class of shares held by each stockholder, a copy of these bylaws as amended to date, accounting books, and other records.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any stockholder of record, in
person or by attorney or other agent, shall, upon written demand under oath stating the purpose thereof, have the right during the usual
hours for business to inspect for any proper purpose the Corporation&#8217;s stock ledger, a list of its stockholders, and its other books
and records and to make copies or extracts therefrom. A proper purpose shall mean a purpose reasonably related to such person&#8217;s
interest as a stockholder. In every instance where an attorney or other agent is the person who seeks the right to inspection, the demand
under oath shall be accompanied by a power of attorney or such other writing that authorizes the attorney or other agent so to act on
behalf of the stockholder. The demand under oath shall be directed to the Corporation at its registered office in Delaware or at its principal
executive office.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Inspection by Directors</I></B>. Any director shall have the right to examine the Corporation&#8217;s stock ledger, a list
of its stockholders, and its other books and records for a purpose reasonably related to his or her position as a director. The Court
of Chancery is hereby vested with the exclusive jurisdiction to determine whether a director is entitled to the inspection sought. The
Court may summarily order the Corporation to permit the director to inspect any and all books and records, the stock ledger, and the stock
list and to make copies or extracts therefrom. The Court may, in its discretion, prescribe any limitations or conditions with reference
to the inspection, or award such other and further relief as the Court may deem just and proper.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Annual Report</I></B>. The Corporation shall cause an annual report to be sent to the stockholders of the Corporation to
the extent required by applicable law. If and so long as there are fewer than one hundred (100) holders of record of the Corporation&#8217;s
shares, the requirement of sending of an annual report to the stockholders of the Corporation is expressly waived (to the extent permitted
under applicable law).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">ARTICLE VI &#8212; GENERAL
MATTERS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">6.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><B><I>Stock
Certificates; Partly Paid Shares</I></B>. The shares of the Corporation shall be represented by certificates, provided that the
Board may provide by resolution or resolutions that some or all of any or all classes or series of its stock shall be uncertificated
shares. Any such resolution shall not apply to shares represented by a certificate until such certificate is surrendered to the
Corporation. Notwithstanding the adoption of such a resolution by the Board, every holder of stock represented by certificates and
upon request every holder of uncertificated shares shall be entitled to have a certificate signed by, or in the name of the
Corporation by the chairperson or vice-chairperson of the Board, or the president or vice-president, and by the treasurer or an
assistant treasurer, or the secretary or an assistant secretary of the Corporation representing the number of shares registered in
certificate form. Any or all of the signatures on the certificate may be a facsimile. In case any officer, transfer agent or
registrar who has signed or whose facsimile signature has been placed upon a certificate has ceased to be such officer, transfer
agent or registrar before such certificate is issued, it may be issued by the Corporation with the same effect as if he were such
officer, transfer agent or registrar at the date of issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Corporation may issue the
whole or any part of its shares as partly paid and subject to call for the remainder of the consideration to be paid therefor. Upon the
face or back of each stock certificate issued to represent any such partly paid shares, upon the books and records of the Corporation
in the case of uncertificated partly paid shares, the total amount of the consideration to be paid therefor and the amount paid thereon
shall be stated. Upon the declaration of any dividend on fully paid shares, the Corporation shall declare a dividend upon partly paid
shares of the same class, but only upon the basis of the percentage of the consideration actually paid thereon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">6.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Special Designation on Certificates</I></B>. If the Corporation is authorized to issue more than one class of stock or more
than one series of any class, then the powers, the designations, the preferences, and the relative, participating, optional or other special
rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights
shall be set forth in full or summarized on the face or back of the certificate that the Corporation shall issue to represent such class
or series of stock; <I>provided, however</I>, that, except as otherwise provided in Section&nbsp;202 of the DGCL, in lieu of the foregoing
requirements there may be set forth on the face or back of the certificate that the Corporation shall issue to represent such class or
series of stock a statement that the Corporation will furnish without charge to each stockholder who so requests the powers, the designations,
the preferences, and the relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications,
limitations or restrictions of such preferences and/or rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">6.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Lost Certificates</I></B>. Except as provided in this <B>Section&nbsp;6.3</B>, no new certificates for shares shall be issued
to replace a previously issued certificate unless the latter is surrendered to the Corporation and cancelled at the same time. The Corporation
may issue a new certificate of stock or uncertificated shares in the place of any certificate theretofore issued by it, alleged to have
been lost, stolen or destroyed, and the Corporation may require the owner of the lost, stolen or destroyed certificate, or such owner&#8217;s
legal representative, to give the Corporation a bond sufficient to indemnify it against any claim that may be made against it on account
of the alleged loss, theft or destruction of any such certificate or the issuance of such new certificate or uncertificated shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">6.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><B><I>Construction;
Definitions</I></B>. Unless the context requires otherwise, the general provisions, rules of construction, and definitions in the
DGCL shall govern the construction of these bylaws. Without limiting the generality of this provision, the singular number includes
the plural, the plural number includes the singular, and the term &#8220;person&#8221; includes both a corporation and a natural
person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">6.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Dividends</I></B>. The Board, subject to any restrictions contained in either (i)&nbsp;the DGCL, or (ii)&nbsp;the certificate
of incorporation, may declare and pay dividends upon the shares of its capital stock. Dividends may be paid in cash, in property, or in
shares of the Corporation&#8217;s capital stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board may set apart out of
any of the funds of the Corporation available for dividends a reserve or reserves for any proper purpose and may abolish any such reserve.
Such purposes shall include but not be limited to equalizing dividends, repairing or maintaining any property of the Corporation, and
meeting contingencies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">6.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Fiscal Year</I></B>. The fiscal year of the Corporation shall be the twelve (12)-month period ending December 31 in each
year and may be changed by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">6.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Seal</I></B>. The Corporation may adopt a corporate seal, which shall be adopted and which may be altered by the Board. The
Corporation may use the corporate seal by causing it or a facsimile thereof to be impressed or affixed or in any other manner reproduced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">6.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Stock Transfer Agreements</I></B>. The Corporation shall have power to enter into and perform any agreement with any number
of stockholders of any one or more classes of stock of the Corporation to restrict the transfer of shares of stock of the Corporation
of any one or more classes owned by such stockholders in any manner not prohibited by the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">6.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Registered Stockholders</I></B>. The Corporation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> shall be entitled to recognize the exclusive right of a person registered on its books as the owner of shares to receive dividends
and to vote as such owner;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>shall be entitled to hold liable for calls and assessments the person registered on its books as the owner of shares; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>shall not be bound to recognize any equitable or other claim to or interest in such share or shares on the part of another person,
whether or not it shall have express or other notice thereof, except as otherwise provided by the laws of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">6.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Waiver of Notice</I></B>. Whenever notice is required to be given under any provision of the DGCL, the certificate of incorporation
or these bylaws, a written waiver, signed by the person entitled to notice, or a waiver by electronic transmission by the person entitled
to notice, whether before or after the time of the event for which notice is to be given, shall be deemed equivalent to notice. Attendance
of a person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends a meeting for the express
purpose of objecting at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or
convened. Neither the business to be transacted at, nor the purpose of, any regular or special meeting of the stockholders need be specified
in any written waiver of notice or any waiver by electronic transmission unless so required by the certificate of incorporation or these
bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">ARTICLE VII &#8212;
NOTICE BY ELECTRONIC TRANSMISSION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">7.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Notice by Electronic Transmission</I></B>. Without limiting the manner by which notice otherwise may be given effectively
to stockholders pursuant to the DGCL, the certificate of incorporation or these bylaws, any notice to stockholders given by the Corporation
under any provision of the DGCL, the certificate of incorporation or these bylaws shall be effective if given by a form of electronic
transmission consented to by the stockholder to whom the notice is given. Any such consent shall be revocable by the stockholder by written
notice to the Corporation. Any such consent shall be deemed revoked if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Corporation is unable to deliver by electronic transmission two consecutive notices given by the Corporation in accordance
with such consent; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>such inability becomes known to the secretary or an assistant secretary of the Corporation or to the transfer agent, or other person
responsible for the giving of notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">However, the inadvertent failure to treat such inability
as a revocation shall not invalidate any meeting or other action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Any notice given pursuant to
the preceding paragraph shall be deemed given:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
if by facsimile telecommunication,
when directed to a number at which the stockholder has consented to receive notice;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
if by electronic
mail, when directed to an electronic mail address at which the stockholder has consented to receive notice;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>if by a posting on an electronic network together with separate notice to the stockholder of such specific posting, upon the later
of (A)&nbsp;such posting and (B)&nbsp;the giving of such separate notice; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>if by any other form of electronic transmission, when directed to the stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An affidavit of the secretary
or an assistant secretary or of the transfer agent or other agent of the Corporation that the notice has been given by a form of electronic
transmission shall, in the absence of fraud, be prima facie evidence of the facts stated therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">7.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Definition of Electronic Transmission</I></B>. An &#8220;electronic transmission&#8221; means any form of communication,
not directly involving the physical transmission of paper, that creates a record that may be retained, retrieved, and reviewed by a recipient
thereof, and that may be directly reproduced in paper form by such a recipient through an automated process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">7.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Inapplicability</I></B>. Notice by a form of electronic transmission shall not apply to Sections 164, 296, 311, 312 or 324
of the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE VIII &#8212;
INDEMNIFICATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">8.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Indemnification of Directors and Officers</I></B>. The Corporation shall indemnify and hold harmless, to the fullest extent
permitted by the DGCL as it presently exists or may hereafter be amended, any director or officer of the Corporation who was or is made
or is threatened to be made a party or is otherwise involved in any action, suit or proceeding, whether civil, criminal, administrative
or investigative (a &#8220;<B>Proceeding</B>&#8221;) by reason of the fact that he or she, or a person for whom he or she is the legal
representative, is or was a director, officer, employee or agent of the Corporation or is or was serving at the request of the Corporation
as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust, enterprise or non-profit entity,
including service with respect to employee benefit plans, against all liability and loss suffered and expenses reasonably incurred by
such person in connection with any such Proceeding. The Corporation shall be required to indemnify a person in connection with a Proceeding
initiated by such person only if the Proceeding was authorized by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">8.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Indemnification of Others</I></B>. The Corporation shall have the power to indemnify and hold harmless, to the extent permitted
by applicable law as it presently exists or may hereafter be amended, any employee or agent of the Corporation who was or is made or is
threatened to be made a party or is otherwise involved in any Proceeding by reason of the fact that he or she, or a person for whom he
or she is the legal representative, is or was an employee or agent of the Corporation or is or was serving at the request of the Corporation
as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust, enterprise or non-profit entity,
including service with respect to employee benefit plans, against all liability and loss suffered and expenses reasonably incurred by
such person in connection with any such Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">8.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Prepayment of Expenses</I></B>. The Corporation shall pay the expenses incurred by any officer or director of the Corporation,
and may pay the expenses incurred by any employee or agent of the Corporation, in defending any Proceeding in advance of its final disposition;
<I>provided, however</I>, that the payment of expenses incurred by a person in advance of the final disposition of the Proceeding shall
be made only upon receipt of an undertaking by the person to repay all amounts advanced if it should be ultimately determined that the
person is not entitled to be indemnified under this <B>Article VIII</B> or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">8.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Determination; Claim</I></B>. If a claim for indemnification or payment of expenses under this <B>Article VIII</B> is not
paid in full within sixty days after a written claim therefor has been received by the Corporation the claimant may file suit to recover
the unpaid amount of such claim and, if successful in whole or in part, shall be entitled to be paid the expense of prosecuting such claim.
In any such action the Corporation shall have the burden of proving that the claimant was not entitled to the requested indemnification
or payment of expenses under applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">8.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Non-Exclusivity of Rights</I></B>. The rights conferred on any person by this <B>Article VIII</B> shall not be exclusive
of any other rights which such person may have or hereafter acquire under any statute, provision of the certificate of incorporation,
these bylaws, agreement, vote of stockholders or disinterested directors or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">8.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <B><I>Insurance</I></B>. The Corporation may purchase and maintain insurance on behalf of any person who is or was a director,
officer, employee or agent of the Corporation, or is or was serving at the request of the Corporation as a director, officer, employee
or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against him or her
and incurred by him or her in any such capacity, or arising out of his or her status as such, whether or not the Corporation would have
the power to indemnify him or her against such liability under the provisions of the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">8.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Other Indemnification</I></B>. The Corporation&#8217;s obligation, if any, to indemnify any person who was or is serving
at its request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust, enterprise or non-profit
entity shall be reduced by any amount such person may collect as indemnification from such other corporation, partnership, joint venture,
trust, enterprise or non-profit enterprise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">8.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Amendment or Repeal</I></B>. Any repeal or modification of the foregoing provisions of this <B>Article VIII</B> shall not
adversely affect any right or protection hereunder of any person in respect of any act or omission occurring prior to the time of such
repeal or modification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">ARTICLE IX &#8212; AMENDMENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These bylaws may be adopted,
amended or repealed by the stockholders entitled to vote. However, the Corporation may, in its certificate of incorporation, confer the
power to adopt, amend or repeal bylaws upon the directors. The fact that such power has been so conferred upon the directors shall not
divest the stockholders of the power, nor limit their power to adopt, amend or repeal bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SERA PROGNOSTICS, INC.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CERTIFICATE OF ADOPTION OF AMENDED AND RESTATED
BYLAWS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned hereby certifies
that he is the duly elected, qualified and acting Secretary of Sera Prognostics, Inc., a Delaware corporation (the &#8220;<B>Corporation</B>&#8221;),
and that the foregoing Amended and Restated Bylaws, comprising 16 pages, were adopted as the Corporation&#8217;s Amended and Restated
Bylaws on November 8, 2011 by the Corporation&#8217;s Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The undersigned has executed
this Certificate effective as of November 8, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: left; padding-left: 10pt; text-indent: -10pt">/s/ Jonathan L. Kravetz, Secretary</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt; width: 50%">&nbsp;</TD>
  <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Jonathan L. Kravetz, Secretary</TD></TR>
</TABLE>




<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="margin: 0pt"></P>

<!-- Field: Page; Sequence: 8; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>12
<FILENAME>tm2110724d11_ex4-2.htm
<DESCRIPTION>EXHIBIT 4.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

                           <P STYLE="text-align: justify; margin: 0pt">&nbsp;</P>

<P STYLE="margin: 0pt; text-align: right"><B>Exhibit 4.2</B></P>

<P STYLE="margin: 0pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><I>Execution Version</I></B></P>

<P STYLE="margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;<B><U>ACT</U></B>&rdquo;), OR THE SECURITIES LAWS OF
ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND
UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER, SUCH OFFER,
SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>WARRANT TO PURCHASE COMMON STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: Black 1pt solid; text-align: justify; width: 43%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.75pt; text-align: justify">Corporation:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.75pt; text-align: justify">Number of Shares:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.75pt; text-align: justify">Class of Stock:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.75pt; text-align: justify">Initial Exercise Price:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.75pt; text-align: justify">Issue Date:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.75pt; text-align: justify">Expiration:</P></TD>
    <TD STYLE="border-top: Black 1pt solid; text-align: justify; width: 57%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sera Prognostics, Inc., a Delaware corporation</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[__]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Common Stock, $0.0001 par value per share</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">$4.34 per share</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">July 31, 2019</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">July 31, 2029</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS WARRANT CERTIFIES THAT,
for good and valuable consideration, the receipt of which is hereby acknowledged, [__] or its assignee or transferee (&ldquo;<B><I>Holder</I></B>&rdquo;)
is entitled to purchase the number of fully paid and nonassessable shares of Common Stock, $0.0001 par value per share (the &ldquo;<B><I>Shares</I></B>&rdquo;)
of Sera Prognostics, Inc. (the &ldquo;<B><I>Company</I></B>&rdquo;) at the initial exercise price per Share (the &ldquo;<B><I>Warrant
Price</I></B>&rdquo;) all as set forth above and as adjusted pursuant to Article 2 of this warrant, subject to the provisions and upon
the terms and conditions set forth in this warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="color: black">ARTICLE
1</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="color: black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="color: black"></FONT>EXERCISE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B>Method of Exercise</B>. Holder may exercise this warrant by delivering this warrant, a duly executed Notice of Exercise
in substantially the form attached as Appendix 1, and a duly executed Joinder to the Third Amended and Restated Investors&rsquo; Rights
Agreement, dated as of July 31, 2019, between the Company and certain stockholders of the Company (as amended from time to time, the &ldquo;<B>Investors&rsquo;
Rights Agreement</B>&rdquo;), and the Third Amended and Restated Voting Agreement, dated as of July 31, 2019, between the Company and
certain stockholders of the Company (as amended from time to time), in substantially the form attached as Appendix 2 to the principal
office of the Company. Unless Holder is exercising the conversion right set forth in Section 1.2, Holder shall also deliver to the Company
a check for the aggregate Warrant Price for the Shares being purchased.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>1.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B>Conversion Right</B>. In lieu of exercising this warrant as specified in Section 1.1, Holder may from time to time
convert this warrant, in whole or in part, into a number of Shares determined by dividing (a) the aggregate fair market value of the Shares
or other securities otherwise issuable upon exercise of this warrant minus the aggregate Warrant Price of such Shares by (b) the fair
market value of one Share. The fair market value of the Shares shall be determined pursuant to Section 1.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>1.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B> Fair Market Value</B>. If the Shares are traded regularly in a public market, the fair market value of the Shares
shall be the closing price of the Shares reported for the business day immediately before Holder delivers its Notice of Exercise to the
Company. If the Shares are not regularly traded in a public market, the Board of Directors of the Company and the Holder shall jointly
determine fair market value in their collective reasonable good faith judgment; <I>provided</I>, that if the Board of Directors of the
Company and the Holder are unable to agree on the fair market value per share of the Shares within a reasonable period of time (not to
exceed twenty days from the Company&rsquo;s receipt of the Notice of Exercise), such fair market value shall be determined by a nationally
recognized investment banking, accounting or valuation firm jointly selected by the Board of Directors of the Company and the Holder (the
 &ldquo;<B><I>FMV Dispute Proviso</I></B>&rdquo;). The determination of such firm shall be final and conclusive, and the fees and expenses
of such firm shall be borne equally by the Company and the Holder. In determining the Fair Market Value of the Shares, an orderly sale
transaction between a willing buyer and a willing seller shall be assumed, using valuation techniques then prevailing in the securities
industry without regard to the lack of liquidity of the Shares due to any restrictions (contractual or otherwise) applicable thereto or
any discount for minority interests and assuming full disclosure of all relevant information and a reasonable period of time for effectuating
such sale and assuming the sale of all of the issued and outstanding Common Stock (including fractional interests) calculated on a fully
diluted basis to include the conversion or exchange of all securities then outstanding that are convertible into or exchangeable for Common
Stock and the exercise of all rights and warrants then outstanding and exercisable to purchase shares of Common Stock or securities convertible
into or exchangeable for shares of Common Stock; <I>provided</I>, that such assumption shall not include those securities, rights and
warrants (a) owned or held by or for the account of the Company or any of its subsidiaries, or (b) convertible or exchangeable into Common
Stock where the conversion, exchange or exercise price per share is greater than the Fair Market Value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>1.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B>Delivery of Certificate and New Warrant</B>. Promptly after Holder exercises or converts this warrant, the Company
shall deliver to Holder certificates for the Shares acquired and, if this warrant has not been fully exercised or converted and has not
expired, a new warrant representing the Shares not so acquired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>1.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B>Replacement of Warrants</B>. On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction
or mutilation of this warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory
in form, substance and amount to the Company or, in the case of mutilation, on surrender and cancellation of this warrant, the Company
at its expense shall execute and deliver, in lieu of this warrant, a new warrant of like tenor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>1.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B>Treatment of Warrant Upon Acquisition of the Company</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.14in"><FONT STYLE="color: black"><B>1.6.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></B></FONT>&ldquo;<B><I>Acquisition</I></B>.&rdquo;
For the purpose of this warrant, &ldquo;Acquisition&rdquo; means (a) merger or consolidation of the Company into or with another
entity, or a plan of exchange between the Company and any other entity, or the merger or consolidation of any other entity into or
with the Company (except for a merger, consolidation or exchange in which the holders of the voting power of the capital stock of
the Company immediately prior to such merger, consolidation or exchange continue to hold at least 50% of the voting power of the
capital stock of the Company or the surviving or acquiring entity), (b) sale, lease, exclusive license or other disposition of all
or substantially all of the assets of the Company, or (c)&nbsp;the acquisition of ownership by any Person or group of more than 50%
of the Company&rsquo;s voting stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.14in"><FONT STYLE="color: black"><B>1.6.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B>Exercise Upon Acquisition</B>. Upon the closing of any Acquisition in which the consideration to be received by the
Company&rsquo;s stockholders consists of cash, marketable securities, or a combination of both cash and marketable securities, this warrant
shall be deemed to have been automatically converted pursuant to Section 1.2, and thereafter Holder shall participate in the Acquisition
on the same terms as other holders of the same class of securities of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.14in"><FONT STYLE="color: black"><B>1.6.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B>Assumption of Warrant</B>. The Company shall not effect any Acquisition not referred to in Section 1.6.2 unless,
prior to the consummation thereof, the successor person or entity (if other than the Company) resulting from such transaction, shall assume,
by written instrument satisfactory to the Holder, the obligations of this warrant, upon which this warrant shall thereafter be exercisable
for the same securities and/or other property as would have been paid for the Shares issuable upon exercise of the unexercised portion
of this warrant as if such Shares were outstanding on and as of the closing of such Acquisition, subject to further adjustment from time
to time in accordance with the provisions of this warrant. Alternatively (and notwithstanding anything to the contrary herein), with respect
to any Acquisition, Holder shall have the right to elect prior to the consummation thereof, to give effect to the exercise/ conversion
rights contained in Section 1.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="color: black">ARTICLE
2</FONT><BR>
<BR>
ADJUSTMENTS TO THE SHARES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>2.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></B></FONT><B>Stock
Dividends, Splits, Etc</B>. If the Company declares or pays a dividend or any other distribution on its Common Stock payable in Common
Stock, cash or other securities, or subdivides the outstanding Common Stock into a greater amount of Common Stock, then upon exercise
of this warrant, for each Share acquired, Holder shall receive, without cost to Holder, the total number and kind of securities, cash
or other property to which Holder would have been entitled had Holder owned the Shares of record as of the date the dividend, distribution
or subdivision occurred (subject to further adjustment in the event the rights of any such securities or property are subsequently amended
to <FONT STYLE="color: black">increase the number of shares of Common Stock issuable thereunder or to lower the exercise or conversion
price thereof</FONT>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>2.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></B></FONT><B>Reclassification,
Exchange or Substitution</B>. Upon any reclassification, exchange, consolidation, substitution, or other event that results in a
change of the number and/or class of the securities issuable upon exercise or conversion of this warrant, Holder shall be entitled
to receive, upon exercise or conversion of this warrant, the number and kind of securities and property that Holder would have
received for the Shares if this warrant had been exercised in full immediately before such reclassification, exchange,
consolidation, substitution, or other event (subject to further adjustment in the event the rights of any such securities or
property are subsequently amended to <FONT STYLE="color: black">increase the number of shares of Common Stock issuable thereunder or
to lower the exercise or conversion price thereof</FONT>). The Company or its successor shall promptly issue to Holder a new warrant
for such new securities or other property. The new warrant shall provide for adjustments which shall be as nearly equivalent as may
be practicable to the adjustments provided for in this Article 2 including, without limitation, adjustments to the Warrant Price and
to the number of securities or property issuable upon exercise of the new warrant. The provisions of this Section 2.2 shall
similarly apply to successive reclassifications, exchanges, substitutions, or other events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>2.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B>Adjustments for Combinations, Etc.</B> If the outstanding Shares are combined or consolidated, by reclassification
or otherwise, into a lesser number of shares, the Warrant Price shall be proportionately increased. If the outstanding Shares are combined
or consolidated, by reclassification or otherwise, into a greater number of shares, the Warrant Price shall be proportionately decreased.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>2.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B>Adjustment to Warrant Price Upon Issuance of Common Stock</B>. Except as provided in Section 2.5 and except in the
case of an event described in either Section 2.1 or Section 2.2, if the Company shall, at any time or from time to time after the Issue
Date, issues Additional Shares of Common Stock <FONT STYLE="color: black">(as defined in the Company&rsquo;s Certificate of Incorporation)
</FONT>(including Additional Shares of Common Stock deemed to be issued pursuant to Subsection 4.4.3 of Section B of Article Fourth of
the <FONT STYLE="color: black">Company&rsquo;s Certificate of Incorporation</FONT>) without consideration or for consideration per share
(determined in accordance with Section 4.4.5 of Section B of Article Fourth of the Company&rsquo;s Certificate of Incorporation) less
than the Warrant Price in effect immediately prior to such issuance or sale (or deemed issuance or sale), then immediately upon such issuance
or sale (or deemed issuance or sale), the Warrant Price in effect immediately prior to such issuance or sale (or deemed issuance or sale)
shall be reduced (and in no event increased) to a Warrant Price equal to 120% of the lowest price per share at which any such share of
Common Stock has been issued or sold (or is deemed to have been issued or sold); <I>provided</I>, that if the Warrant Price as so adjusted
would be less than the Adjustment Floor, then the Warrant Price shall instead be adjusted to be equal to the Adjustment Floor. The term
 &ldquo;<B><I>Adjustment Floor</I></B>&rdquo; shall mean $3.47, <FONT STYLE="color: black">subject to appropriate adjustment in the event
of any stock dividend, stock split, combination or other similar recapitalization with respect to the Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>2.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B>Exceptions to Adjustment Upon Issuance of Common Stock</B>. There shall be no adjustment pursuant to Section 2.4
to the Warrant Price with respect to any Excluded Issuance. &ldquo;<B><I>Excluded Issuances</I></B>&rdquo; means <FONT STYLE="color: black">any
issuance or sale by the Company after the Issue Date of: (a) Shares issued upon the exercise of warrants issued pursuant to the Purchase
Agreement (as defined below); and (b) &ldquo;Exempted Securities&rdquo; (as defined in the Company&rsquo;s Certificate of Incorporation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>2.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Effect of Certain Events on Adjustment to Warrant Price</B>. For purposes of determining the adjusted Warrant Price under Section
2.4, </FONT>the provisions of (a) clauses (b) through (e) of Subsection 4.4.3 of Section B of Article Fourth of the Company&rsquo;s Certificate
of Incorporation shall be incorporated herein by reference <I>mutatis mutandis</I>, and (b) Subsection 4.4.5 of Section B of Article Fourth
of the Company&rsquo;s Certificate of Incorporation shall be incorporated herein by reference <I>mutatis mutandis</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>2.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></B></FONT><B>Certificate
as to Adjustments</B>. Upon each adjustment of the Warrant Price, the Company at its expense shall promptly compute such adjustment,
and furnish Holder with a certificate of its Chief Financial Officer setting forth such adjustment and the facts upon which such
adjustment is based. The Company shall, upon written request, furnish Holder a certificate setting forth the Warrant Price in effect
upon the date thereof and the series of adjustments leading to such Warrant Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Fractional Shares</B>. No fractional Shares shall be issuable upon exercise or conversion of the warrant, and the Number of Shares
to be issued shall be rounded up to the nearest whole Share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="color: black">ARTICLE
3</FONT><BR>
<BR>
REPRESENTATIONS AND COVENANTS OF THE COMPANY AND HOLDER</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>3.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B>Representations and Warranties</B>. The Company hereby represents and warrants to the Holder that all Shares which
may be issued upon the exercise of the purchase right represented by this warrant shall, upon issuance, be duly authorized, validly issued,
fully paid and nonassessable, without violation of any preemptive right or similar rights, and free of any liens, taxes, and encumbrances
except for restrictions on transfer provided for herein or under applicable federal and state securities laws. The Company will pay all
expenses in connection with, and all taxes and other governmental charges that may be imposed with respect to, the issuance or delivery
of Shares upon exercise (or conversion) of this warrant; provided, that the Company shall not be required to pay any tax or governmental
charge that may be imposed with respect to any applicable withholding or the issuance or delivery of the Shares to any Person other than
the Holder, and no such issuance or delivery shall be made unless and until the Person requesting such issuance has paid to the Company
the amount of any such tax, or has established to the satisfaction of the Company that such tax has been paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>3.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B>Notice of Certain Events</B>. The Company shall provide Holder with not less than 10 days prior written notice of,
including a description of the material facts surrounding, any of the following events: (a) declaration of any dividend or distribution
upon its Common Stock, whether in cash, property, stock, or other securities and whether or not a regular cash dividend; (b) offering
for subscription pro rata to the holders of any class or series of its stock any additional shares of stock of any class or series or
other rights; (c) effecting any reclassification or recapitalization of Common Stock; or (d) the merger or consolidation with or into
any other corporation, or sale, lease, license, or conveyance of all or substantially all of its assets, or liquidation, dissolution or
winding up.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>3.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B>Registration Under Securities Act of 1933, as amended</B>. The Company agrees that the Shares shall be &ldquo;Registrable
Securities&rdquo; and Holder shall be an &ldquo;Investor&rdquo; and a &ldquo;Holder&rdquo; under the Investors&rsquo; Rights Agreement
upon Holder&rsquo;s due execution and delivery to the Company of a Joinder in substantially the form of <B><U>Appendix 2</U></B>, and
the Company will use its best efforts to cause the Shares into which this warrant is exercised (or converted), immediately upon such exercise
(or conversion), to be listed on any domestic securities exchange upon which shares of Common Stock or other securities constituting Shares
are listed at the time of such exercise (or conversion).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>3.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B> Holder Investment Representations</B>. Holder makes the following representations to the Company in connection with
the issuance of this warrant and the Shares (collectively, the &ldquo;<B><I>Securities</I></B>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.15in"><FONT STYLE="color: black"><B>(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT>The Holder is aware of the Company&rsquo;s business affairs and financial condition, and has acquired sufficient information
about the Company to reach an informed and knowledgeable decision to acquire the Securities. The undersigned is purchasing the Securities
for its own account for investment purposes only, not as a nominee or agent, and not with a view towards, or for resale in connection
with, any &ldquo;distribution&rdquo; thereof for purposes of the Securities Act of 1933, as amended (the &ldquo;<B><I>Securities Act</I></B>&rdquo;).
The undersigned has such knowledge and experience in financial business matters and the undersigned is capable of evaluating the merits
and risks of the purchase of the Securities and of protecting its interests in connection therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.15in"><FONT STYLE="color: black"><B>(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT>The Holder understands that the Securities have not been registered under the Securities Act in reliance upon a specific
exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the undersigned&rsquo;s investment intent
as expressed herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.15in"><FONT STYLE="color: black"><B>(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT>The Holder further understands that the Securities must be held indefinitely, and the undersigned must therefore bear
the economic risk therewith, unless the Securities are subsequently registered under the Securities Act or unless an exemption from registration
is otherwise available. In addition, the undersigned understands that the certificate evidencing the Securities will be imprinted with
a legend which prohibits the transfer of the Securities unless they are registered or such registration is not required. Holder is aware
of the provisions of Rule 144 promulgated under the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.15in"><FONT STYLE="color: black"><B>(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT>The Holder is familiar with the provisions of Rule 144, promulgated pursuant to the Securities Act, which, in substance,
permits limited public resale of &ldquo;restricted securities&rdquo; acquired, directly or indirectly, from the issuer thereof, in a non-public
offering subject to the satisfaction of certain conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.15in"><FONT STYLE="color: black"><B>(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT>The Holder further understands that in the event that all of the applicable requirements of Rule 144 are not satisfied,
registration under the Securities Act, compliance with Regulation A, or some other registration exemption will be required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.15in"><FONT STYLE="color: black"><B>(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT>The Holder is an &ldquo;accredited investor&rdquo; as defined in Rule 501(a) of Regulation D promulgated under the Securities
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>3.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT>&ldquo;<B>Market Stand Off</B>&rdquo; <B>Agreement</B>. The Holder agrees that the Shares shall be subject to the Market
Standoff provisions in Section 2.11 of Investors&rsquo; Rights Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>No <FONT STYLE="text-underline-style: double; color: windowtext">Voting</FONT> Rights</B>. Holder, as a Holder of this warrant,
will not have any voting rights until the exercise of this warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>Reservation
of Shares</B>. During the period between the Issue Date and the Expiration, the Company shall at all times reserve and keep
available out of its authorized but unissued Common Stock or other securities constituting Shares, solely for the purpose of
issuance upon the exercise of this warrant, the maximum number of Shares issuable upon the exercise of this warrant, and the par
value per Share shall at all times be less than or equal to the applicable Warrant Price. The Company shall not increase the par
value of any Shares receivable upon the exercise of this warrant above the Warrant Price then in effect, and shall take all such
actions as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable
shares of Common Stock upon the exercise of this warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="color: black">ARTICLE
4</FONT><BR>
<BR>
MISCELLANEOUS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>4.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B>Term: Exercise Upon Expiration</B>. This warrant is exercisable in whole or in part, at any time and from time to
time on or before the Expiration Date set forth above. If this warrant has not been exercised prior to the Expiration Date, this warrant
shall be deemed to have been automatically exercised on the Expiration Date by &ldquo;cashless&rdquo; conversion pursuant to Section 1.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>4.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B>Legends</B>. This warrant shall be imprinted with a legend in substantially the following form as well as any additional
legends that the Company and Holder mutually agree upon with respect to such Shares:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify; text-indent: 0.65in">THE SHARES EVIDENCED BY
THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;ACT&rdquo;), OR THE SECURITIES LAWS
OF ANY STATE AND, EXCEPT AS SET FORTH IN THAT CERTAIN WARRANT TO PURCHASE STOCK ISSUED BY THE ISSUER TO HOLDER DATED FEBRUARY __, 2019,
MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL
COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>4.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></B></FONT><B>Compliance
with Securities Laws on Transfer</B>. This warrant and the Shares issued upon exercise of this warrant may not be transferred or
assigned in whole or in part except in compliance with applicable federal and state securities laws by the transferor and the
transferee (including, without limitation, the delivery of investment representation letters and legal opinions reasonably
satisfactory to the Company, as reasonably requested by the Company). The Company shall not require Holder to provide an opinion of
counsel if the transfer is to any affiliate of Holder, provided that any such transferee is an &ldquo;accredited investor&rdquo; as
defined in Regulation D promulgated under the Act. Additionally, the Company shall also not require an opinion of counsel if there
is no material question as to the availability of Rule 144 promulgated under the Act. This warrant and the rights evidenced hereby
shall be binding upon and shall inure to the benefit of the parties hereto and the successors of the Company and the successors and
assigns of the Holder. Subject to the foregoing, such successors and/or assigns of the Holder shall be deemed to be a Holder for all
purposes hereunder. In the case of a transfer of the warrant, upon surrender and delivery by Holder, the Company shall execute and
deliver a new warrant or warrants in the name of the assignee or assignees and in the denominations specified in any instrument of
assignment provided to the Company by the assignor, and shall issue to the assignor a new warrant evidencing the portion of this
warrant, if any, not so assigned and this warrant shall promptly be cancelled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>4.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B>Notices</B>. All notices and other communications from the Company to the Holder, or vice versa, shall be deemed
delivered and effective when given personally or mailed by first-class registered or certified mail, postage prepaid, at such address
as may have been furnished to the Company or the Holder, as the case may be, in writing by the Company or such Holder from time to time.
All notices to the Holder shall be addressed as provided in the Investors&rsquo; Rights Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>4.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B>Amendments</B>. This warrant and any term hereof may be changed, waived, discharged or terminated only by an instrument
in writing signed by the party against which enforcement of such change, waiver, discharge or termination is sought.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>4.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B>Attorneys&rsquo; Fees</B>. In the event of any dispute between the parties concerning the terms and provisions of
this warrant, the party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such dispute,
including reasonable attorneys&rsquo; fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Governing Law</B>. This warrant shall be governed by and construed in accordance with the laws of the State of Delaware, without
giving effect to its principles regarding conflicts of law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Warrant Register</B>. The Company shall keep and properly maintain at its principal executive offices books for the registration
of the warrant and any transfers thereof. The Company may deem and treat the person or entity in whose name the warrant is registered
on such register as the Holder thereof for all purposes, and the Company shall not be affected by any notice to the contrary, except any
assignment, division, combination or other transfer of the warrant effected in accordance with the provisions of this warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Cumulative Remedies</B>. The rights and remedies provided in this warrant are cumulative and are not exclusive of, and are in addition
to and not in substitution for, any other rights or remedies available at law, in equity or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Equitable Relief</B>. Each of the Company and the Holder acknowledges that a breach or threatened breach by such party of any of
its obligations under this warrant would give rise to irreparable harm to the other party hereto for which monetary damages would not
be an adequate remedy and hereby agrees that in the event of a breach or a threatened breach by such party of any such obligations, the
other party hereto shall, in addition to any and all other rights and remedies that may be available to it in respect of such breach,
be entitled to equitable relief, including a restraining order, an injunction, specific performance and any other relief that may be available
from a court of competent jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>Entire
Agreement</B>. This warrant, together with the Investors&rsquo; Rights Agreement, and that certain Stock Purchase Agreement dated
July , 2019 (the &ldquo;<B><I>Purchase Agreement</I></B>&rdquo;) constitutes the sole and entire agreement of the parties to this
warrant with respect to the subject matter contained herein, and supersedes all prior and contemporaneous understandings and
agreements, both written and oral, with respect to such subject matter. In the event of any inconsistency between the statements in
the body of this warrant, the Investors&rsquo; Rights Agreement and the Purchase Agreement, the statements in the body of this
warrant shall control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[Signature Page Follows]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the undersigned
has executed this Warrant to Purchase Stock as of the date set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif">Sera Prognostics, Inc.</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 44%">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Gregory C. Critchfield, M.D., MS</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">President and Chief Executive Officer</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><U>APPENDIX 1</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">NOTICE OF EXERCISE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
undersigned hereby elects to purchase ______________ shares of Common Stock, $0.0001 par value per share of SERA PROGNOSTICS, INC. pursuant
to the terms of the attached warrant, and tenders herewith payment of the purchase price of such shares in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
undersigned hereby elects to convert the attached warrant into shares in the manner specified in the warrant. This conversion is exercised
with respect to _____________ of the shares covered by the warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>[Strike paragraph that does not apply.]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please
issue a certificate or certificates representing said shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">(Holder&rsquo;s Name)</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">(Address)</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
undersigned represents it is acquiring the shares solely for its own account and not as a nominee for any other party and not with a view
toward the resale or distribution thereof except in compliance with applicable securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">Holder or Registered Assignee</TD>
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">(Signature)</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">(Date)</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><U>APPENDIX 2</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">JOINDER</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">DATE: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned hereby agrees,
effective as of the date hereof, (i) to become a party to that certain Third Amended and Restated Investors&rsquo; Rights Agreement (the
 &ldquo;Investors&rsquo; Rights Agreement&rdquo;) dated as of July __, 2019, as amended from time to time, by and among Sera Prognostics,
Inc. and the other parties thereto and for all purposes of the Investors&rsquo; Rights Agreement, the undersigned shall be included within
the terms &ldquo;Investor&rdquo; and &ldquo;Holder&rdquo; as defined in the Investors&rsquo; Rights Agreement, and the undersigned agrees
to be bound by the terms and conditions of the Investors&rsquo; Rights Agreement as an Investor and Holder thereunder, and (ii) to become
a party to that certain Third Amended and Restated Voting Agreement (the &ldquo;Voting Agreement&rdquo;) dated as of July __, 2019, as
amended from time to time, by and among Sera Prognostics, Inc. and the other parties thereto and for all purposes of the Voting Agreement,
the undersigned shall be included within the terms &ldquo;Investor&rdquo; and &ldquo;Stockholder&rdquo; as defined in the Voting Agreement,
and the undersigned agrees to be bound by the terms and conditions of the Voting Agreement as an Investor and Stockholder thereunder.
The address and facsimile number to which notices may be sent to the undersigned is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 45%; font-size: 10pt">ADDRESS:</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 4%">Fax:</TD><TD STYLE="border-bottom: Black 1pt solid; width: 44%; text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
                               <TD STYLE="width: 5%; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 50%">&nbsp;</TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
  <TD STYLE="width: 3%">By:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 47%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD COLSPAN="2">Name:</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>13
<FILENAME>tm2110724d11_ex4-3.htm
<DESCRIPTION>EXHIBIT 4.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

                           <P STYLE="margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0; text-align: right"><B>Exhibit 4.3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><I>Execution Version</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;<B><U>ACT</U></B>&rdquo;), OR THE SECURITIES LAWS OF
ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND
UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER, SUCH OFFER,
SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WARRANT TO PURCHASE COMMON STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 43%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.75pt; text-align: justify">Corporation:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.75pt; text-align: justify">Number of Shares:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.75pt; text-align: justify">Class of Stock:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.75pt; text-align: justify">Initial Exercise Price:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.75pt; text-align: justify">Issue Date:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.75pt; text-align: justify">Expiration:</P></TD>
    <TD STYLE="width: 57%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sera Prognostics, Inc., a Delaware corporation</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[__]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Common Stock, $0.0001 par value per share</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">$5.21 per share</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">July 31, 2019</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">July 31, 2029</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS WARRANT CERTIFIES THAT,
for good and valuable consideration, the receipt of which is hereby acknowledged, [__] or its assignee or transferee (&ldquo;<B><I>Holder</I></B>&rdquo;)
is entitled to purchase the number of fully paid and nonassessable shares of Common Stock, $0.0001 par value per share (the &ldquo;<B><I>Shares</I></B>&rdquo;)
of Sera Prognostics, Inc. (the &ldquo;<B><I>Company</I></B>&rdquo;) at the initial exercise price per Share (the &ldquo;<B><I>Warrant
Price</I></B>&rdquo;) all as set forth above and as adjusted pursuant to Article 2 of this warrant, subject to the provisions and upon
the terms and conditions set forth in this warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="color: black">ARTICLE
1</FONT><BR>
<BR>
EXERCISE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B>Method of Exercise</B>. Holder may exercise this warrant by delivering this warrant, a duly executed Notice of Exercise
in substantially the form attached as Appendix 1, and a duly executed Joinder to the Third Amended and Restated Investors&rsquo; Rights
Agreement, dated as of July 31, 2019, between the Company and certain stockholders of the Company (as amended from time to time, the &ldquo;<B>Investors&rsquo;
Rights Agreement</B>&rdquo;), and the Third Amended and Restated Voting Agreement, dated as of July 31, 2019, between the Company and
certain stockholders of the Company (as amended from time to time), in substantially the form attached as Appendix 2 to the principal
office of the Company. Unless Holder is exercising the conversion right set forth in Section 1.2, Holder shall also deliver to the Company
a check for the aggregate Warrant Price for the Shares being purchased.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>1.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B>Conversion Right</B>. In lieu of exercising this warrant as specified in Section 1.1, Holder may from time to time
convert this warrant, in whole or in part, into a number of Shares determined by dividing (a) the aggregate fair market value of the Shares
or other securities otherwise issuable upon exercise of this warrant minus the aggregate Warrant Price of such Shares by (b) the fair
market value of one Share. The fair market value of the Shares shall be determined pursuant to Section 1.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font-size: 10pt; text-align: right; margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>1.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B> Fair Market Value</B>. If the Shares are traded regularly in a public market, the fair market value of the Shares
shall be the closing price of the Shares reported for the business day immediately before Holder delivers its Notice of Exercise to the
Company. If the Shares are not regularly traded in a public market, the Board of Directors of the Company and the Holder shall jointly
determine fair market value in their collective reasonable good faith judgment; <I>provided</I>, that if the Board of Directors of the
Company and the Holder are unable to agree on the fair market value per share of the Shares within a reasonable period of time (not to
exceed twenty days from the Company&rsquo;s receipt of the Notice of Exercise), such fair market value shall be determined by a nationally
recognized investment banking, accounting or valuation firm jointly selected by the Board of Directors of the Company and the Holder (the
 &ldquo;<B><I>FMV Dispute Proviso</I></B>&rdquo;). The determination of such firm shall be final and conclusive, and the fees and expenses
of such firm shall be borne equally by the Company and the Holder. In determining the Fair Market Value of the Shares, an orderly sale
transaction between a willing buyer and a willing seller shall be assumed, using valuation techniques then prevailing in the securities
industry without regard to the lack of liquidity of the Shares due to any restrictions (contractual or otherwise) applicable thereto or
any discount for minority interests and assuming full disclosure of all relevant information and a reasonable period of time for effectuating
such sale and assuming the sale of all of the issued and outstanding Common Stock (including fractional interests) calculated on a fully
diluted basis to include the conversion or exchange of all securities then outstanding that are convertible into or exchangeable for Common
Stock and the exercise of all rights and warrants then outstanding and exercisable to purchase shares of Common Stock or securities convertible
into or exchangeable for shares of Common Stock; <I>provided</I>, that such assumption shall not include those securities, rights and
warrants (a) owned or held by or for the account of the Company or any of its subsidiaries, or (b) convertible or exchangeable into Common
Stock where the conversion, exchange or exercise price per share is greater than the Fair Market Value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>1.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B>Delivery of Certificate and New Warrant</B>. Promptly after Holder exercises or converts this warrant, the Company
shall deliver to Holder certificates for the Shares acquired and, if this warrant has not been fully exercised or converted and has not
expired, a new warrant representing the Shares not so acquired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>1.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B>Replacement of Warrants</B>. On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction
or mutilation of this warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory
in form, substance and amount to the Company or, in the case of mutilation, on surrender and cancellation of this warrant, the Company
at its expense shall execute and deliver, in lieu of this warrant, a new warrant of like tenor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>1.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B>Treatment of Warrant Upon Acquisition of the Company</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: black"><B>1.6.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></B></FONT>&ldquo;<B><I>Acquisition</I></B>.&rdquo;
For the purpose of this warrant, &ldquo;Acquisition&rdquo; means (a) merger or consolidation of the Company into or with another
entity, or a plan of exchange between the Company and any other entity, or the merger or consolidation of any other entity into or
with the Company (except for a merger, consolidation or exchange in which the holders of the voting power of the capital stock of
the Company immediately prior to such merger, consolidation or exchange continue to hold at least 50% of the voting power of the
capital stock of the Company or the surviving or acquiring entity), (b) sale, lease, exclusive license or other disposition of all
or substantially all of the assets of the Company, or (c)&nbsp;the acquisition of ownership by any Person or group of more than 50%
of the Company&rsquo;s voting stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font-size: 10pt; text-align: right; margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: black"><B>1.6.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B>Exercise Upon Acquisition</B>. Upon the closing of any Acquisition in which the consideration to be received by the
Company&rsquo;s stockholders consists of cash, marketable securities, or a combination of both cash and marketable securities, this warrant
shall be deemed to have been automatically converted pursuant to Section 1.2, and thereafter Holder shall participate in the Acquisition
on the same terms as other holders of the same class of securities of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: black"><B>1.6.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B>Assumption of Warrant</B>. The Company shall not effect any Acquisition not referred to in Section 1.6.2 unless,
prior to the consummation thereof, the successor person or entity (if other than the Company) resulting from such transaction, shall assume,
by written instrument satisfactory to the Holder, the obligations of this warrant, upon which this warrant shall thereafter be exercisable
for the same securities and/or other property as would have been paid for the Shares issuable upon exercise of the unexercised portion
of this warrant as if such Shares were outstanding on and as of the closing of such Acquisition, subject to further adjustment from time
to time in accordance with the provisions of this warrant. Alternatively (and notwithstanding anything to the contrary herein), with respect
to any Acquisition, Holder shall have the right to elect prior to the consummation thereof, to give effect to the exercise/ conversion
rights contained in Section 1.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="color: black">ARTICLE
2</FONT><BR>
<BR>
ADJUSTMENTS TO THE SHARES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>2.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B>Stock Dividends, Splits, Etc</B>. If the Company declares or pays a dividend or any other distribution on its Common
Stock payable in Common Stock, cash or other securities, or subdivides the outstanding Common Stock into a greater amount of Common Stock,
then upon exercise of this warrant, for each Share acquired, Holder shall receive, without cost to Holder, the total number and kind of
securities, cash or other property to which Holder would have been entitled had Holder owned the Shares of record as of the date the dividend,
distribution or subdivision occurred (subject to further adjustment in the event the rights of any such securities or property are subsequently
amended to <FONT STYLE="color: black">increase the number of shares of Common Stock issuable thereunder or to lower the exercise or conversion
price thereof</FONT>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>2.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></B></FONT><B>Reclassification,
Exchange or Substitution</B>. Upon any reclassification, exchange, consolidation, substitution, or other event that results in a
change of the number and/or class of the securities issuable upon exercise or conversion of this warrant, Holder shall be entitled
to receive, upon exercise or conversion of this warrant, the number and kind of securities and property that Holder would have
received for the Shares if this warrant had been exercised in full immediately before such reclassification, exchange,
consolidation, substitution, or other event (subject to further adjustment in the event the rights of any such securities or
property are subsequently amended to <FONT STYLE="color: black">increase the number of shares of Common Stock issuable thereunder or
to lower the exercise or conversion price thereof</FONT>). The Company or its successor shall promptly issue to Holder a new warrant
for such new securities or other property. The new warrant shall provide for adjustments which shall be as nearly equivalent as may
be practicable to the adjustments provided for in this Article 2 including, without limitation, adjustments to the Warrant Price and
to the number of securities or property issuable upon exercise of the new warrant. The provisions of this Section 2.2 shall
similarly apply to successive reclassifications, exchanges, substitutions, or other events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font-size: 10pt; text-align: right; margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>2.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B>Adjustments for Combinations, Etc.</B> If the outstanding Shares are combined or consolidated, by reclassification
or otherwise, into a lesser number of shares, the Warrant Price shall be proportionately increased. If the outstanding Shares are combined
or consolidated, by reclassification or otherwise, into a greater number of shares, the Warrant Price shall be proportionately decreased.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>2.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B>Adjustment to Warrant Price Upon Issuance of Common Stock</B>. Except as provided in Section 2.5 and except in the
case of an event described in either Section 2.1 or Section 2.2, if the Company shall, at any time or from time to time after the Issue
Date, issues Additional Shares of Common Stock <FONT STYLE="color: black">(as defined in the Company&rsquo;s Certificate of Incorporation)
</FONT>(including Additional Shares of Common Stock deemed to be issued pursuant to Subsection 4.4.3 of Section B of Article Fourth of
the <FONT STYLE="color: black">Company&rsquo;s Certificate of Incorporation</FONT>) without consideration or for consideration per share
(determined in accordance with Section 4.4.5 of Section B of Article Fourth of the Company&rsquo;s Certificate of Incorporation) less
than 83.3% of the Warrant Price in effect immediately prior to such issuance or sale (or deemed issuance or sale), then immediately upon
such issuance or sale (or deemed issuance or sale), the Warrant Price in effect immediately prior to such issuance or sale (or deemed
issuance or sale) shall be reduced (and in no event increased) to a Warrant Price equal to 120% of the lowest price per share at which
any such share of Common Stock has been issued or sold (or is deemed to have been issued or sold); <I>provided</I>, that if the Warrant
Price as so adjusted would be less than the Adjustment Floor, then the Warrant Price shall instead be adjusted to be equal to the Adjustment
Floor. The term &ldquo;<B><I>Adjustment Floor</I></B>&rdquo; shall mean $4.17, <FONT STYLE="color: black">subject to appropriate adjustment
in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>2.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B>Exceptions to Adjustment Upon Issuance of Common Stock</B>. There shall be no adjustment pursuant to Section 2.4
to the Warrant Price with respect to any Excluded Issuance. &ldquo;<B><I>Excluded Issuances</I></B>&rdquo; means <FONT STYLE="color: black">any
issuance or sale by the Company after the Issue Date of: (a) Shares issued upon the exercise of warrants issued pursuant to the Purchase
Agreement (as defined below); and (b) &ldquo;Exempted Securities&rdquo; (as defined in the Company&rsquo;s Certificate of Incorporation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>2.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Effect of Certain Events on Adjustment to Warrant Price</B>. For purposes of determining the adjusted Warrant Price under Section
2.4, </FONT>the provisions of (a) clauses (b) through (e) of Subsection 4.4.3 of Section B of Article Fourth of the Company&rsquo;s Certificate
of Incorporation shall be incorporated herein by reference <I>mutatis mutandis</I>, and (b) Subsection 4.4.5 of Section B of Article Fourth
of the Company&rsquo;s Certificate of Incorporation shall be incorporated herein by reference <I>mutatis mutandis</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font-size: 10pt; text-align: right; margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>2.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></B></FONT><B>Certificate
as to Adjustments</B>. Upon each adjustment of the Warrant Price, the Company at its expense shall promptly compute such adjustment,
and furnish Holder with a certificate of its Chief Financial Officer setting forth such adjustment and the facts upon which such
adjustment is based. The Company shall, upon written request, furnish Holder a certificate setting forth the Warrant Price in effect
upon the date thereof and the series of adjustments leading to such Warrant Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Fractional Shares</B>. No fractional Shares shall be issuable upon exercise or conversion of the warrant, and the Number of Shares
to be issued shall be rounded up to the nearest whole Share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="color: black">ARTICLE
3</FONT><BR>
<BR>
REPRESENTATIONS AND COVENANTS OF THE COMPANY AND HOLDER</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>3.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B>Representations and Warranties</B>. The Company hereby represents and warrants to the Holder that all Shares which
may be issued upon the exercise of the purchase right represented by this warrant shall, upon issuance, be duly authorized, validly issued,
fully paid and nonassessable, without violation of any preemptive right or similar rights, and free of any liens, taxes, and encumbrances
except for restrictions on transfer provided for herein or under applicable federal and state securities laws. The Company will pay all
expenses in connection with, and all taxes and other governmental charges that may be imposed with respect to, the issuance or delivery
of Shares upon exercise (or conversion) of this warrant; provided, that the Company shall not be required to pay any tax or governmental
charge that may be imposed with respect to any applicable withholding or the issuance or delivery of the Shares to any Person other than
the Holder, and no such issuance or delivery shall be made unless and until the Person requesting such issuance has paid to the Company
the amount of any such tax, or has established to the satisfaction of the Company that such tax has been paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>3.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B>Notice of Certain Events</B>. The Company shall provide Holder with not less than 10 days prior written notice of,
including a description of the material facts surrounding, any of the following events: (a) declaration of any dividend or distribution
upon its Common Stock, whether in cash, property, stock, or other securities and whether or not a regular cash dividend; (b) offering
for subscription pro rata to the holders of any class or series of its stock any additional shares of stock of any class or series or
other rights; (c) effecting any reclassification or recapitalization of Common Stock; or (d) the merger or consolidation with or into
any other corporation, or sale, lease, license, or conveyance of all or substantially all of its assets, or liquidation, dissolution or
winding up.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>3.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B>Registration Under Securities Act of 1933, as amended</B>. The Company agrees that the Shares shall be &ldquo;Registrable
Securities&rdquo; and Holder shall be an &ldquo;Investor&rdquo; and a &ldquo;Holder&rdquo; under the Investors&rsquo; Rights Agreement
upon Holder&rsquo;s due execution and delivery to the Company of a Joinder in substantially the form of <B><U>Appendix 2</U></B>, and
the Company will use its best efforts to cause the Shares into which this warrant is exercised (or converted), immediately upon such exercise
(or conversion), to be listed on any domestic securities exchange upon which shares of Common Stock or other securities constituting Shares
are listed at the time of such exercise (or conversion).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font-size: 10pt; text-align: right; margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>3.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B> Holder Investment Representations</B>. Holder makes the following representations to the Company in connection with
the issuance of this warrant and the Shares (collectively, the &ldquo;<B><I>Securities</I></B>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: black"><B>(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT>The Holder is aware of the Company&rsquo;s business affairs and financial condition, and has acquired sufficient information
about the Company to reach an informed and knowledgeable decision to acquire the Securities. The undersigned is purchasing the Securities
for its own account for investment purposes only, not as a nominee or agent, and not with a view towards, or for resale in connection
with, any &ldquo;distribution&rdquo; thereof for purposes of the Securities Act of 1933, as amended (the &ldquo;<B><I>Securities Act</I></B>&rdquo;).
The undersigned has such knowledge and experience in financial business matters and the undersigned is capable of evaluating the merits
and risks of the purchase of the Securities and of protecting its interests in connection therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: black"><B>(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT>The Holder understands that the Securities have not been registered under the Securities Act in reliance upon a specific
exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the undersigned&rsquo;s investment intent
as expressed herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: black"><B>(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT>The Holder further understands that the Securities must be held indefinitely, and the undersigned must therefore bear
the economic risk therewith, unless the Securities are subsequently registered under the Securities Act or unless an exemption from registration
is otherwise available. In addition, the undersigned understands that the certificate evidencing the Securities will be imprinted with
a legend which prohibits the transfer of the Securities unless they are registered or such registration is not required. Holder is aware
of the provisions of Rule 144 promulgated under the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: black"><B>(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT>The Holder is familiar with the provisions of Rule 144, promulgated pursuant to the Securities Act, which, in substance,
permits limited public resale of &ldquo;restricted securities&rdquo; acquired, directly or indirectly, from the issuer thereof, in a non-public
offering subject to the satisfaction of certain conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: black"><B>(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT>The Holder further understands that in the event that all of the applicable requirements of Rule 144 are not satisfied,
registration under the Securities Act, compliance with Regulation A, or some other registration exemption will be required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: black"><B>(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT>The Holder is an &ldquo;accredited investor&rdquo; as defined in Rule 501(a) of Regulation D promulgated under the Securities
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>3.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT>&ldquo;<B>Market Stand Off</B>&rdquo; <B>Agreement</B>. The Holder agrees that the Shares shall be subject to the Market
Standoff provisions in Section 2.11 of Investors&rsquo; Rights Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>No <FONT STYLE="text-underline-style: double; color: windowtext">Voting</FONT> Rights</B>. Holder, as a Holder of this warrant,
will not have any voting rights until the exercise of this warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font-size: 10pt; text-align: right; margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>Reservation
of Shares</B>. During the period between the Issue Date and the Expiration, the Company shall at all times reserve and keep
available out of its authorized but unissued Common Stock or other securities constituting Shares, solely for the purpose of
issuance upon the exercise of this warrant, the maximum number of Shares issuable upon the exercise of this warrant, and the par
value per Share shall at all times be less than or equal to the applicable Warrant Price. The Company shall not increase the par
value of any Shares receivable upon the exercise of this warrant above the Warrant Price then in effect, and shall take all such
actions as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable
shares of Common Stock upon the exercise of this warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="color: black">ARTICLE
4</FONT><BR>
<BR>
MISCELLANEOUS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>4.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B>Term: Exercise Upon Expiration</B>. This warrant is exercisable in whole or in part, at any time and from time to
time on or before the Expiration Date set forth above. If this warrant has not been exercised prior to the Expiration Date, this warrant
shall be deemed to have been automatically exercised on the Expiration Date by &ldquo;cashless&rdquo; conversion pursuant to Section 1.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>4.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B>Legends</B>. This warrant shall be imprinted with a legend in substantially the following form as well as any additional
legends that the Company and Holder mutually agree upon with respect to such Shares:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify; text-indent: 0.5in">THE SHARES EVIDENCED BY
THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;ACT&rdquo;), OR THE SECURITIES LAWS
OF ANY STATE AND, EXCEPT AS SET FORTH IN THAT CERTAIN WARRANT TO PURCHASE STOCK ISSUED BY THE ISSUER TO HOLDER DATED FEBRUARY __, 2019,
MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL
COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>4.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></B></FONT><B>Compliance
with Securities Laws on Transfer</B>. This warrant and the Shares issued upon exercise of this warrant may not be transferred or
assigned in whole or in part except in compliance with applicable federal and state securities laws by the transferor and the
transferee (including, without limitation, the delivery of investment representation letters and legal opinions reasonably
satisfactory to the Company, as reasonably requested by the Company). The Company shall not require Holder to provide an opinion of
counsel if the transfer is to any affiliate of Holder, provided that any such transferee is an &ldquo;accredited investor&rdquo; as
defined in Regulation D promulgated under the Act. Additionally, the Company shall also not require an opinion of counsel if there
is no material question as to the availability of Rule 144 promulgated under the Act. This warrant and the rights evidenced hereby
shall be binding upon and shall inure to the benefit of the parties hereto and the successors of the Company and the successors and
assigns of the Holder. Subject to the foregoing, such successors and/or assigns of the Holder shall be deemed to be a Holder for all
purposes hereunder. In the case of a transfer of the warrant, upon surrender and delivery by Holder, the Company shall execute and
deliver a new warrant or warrants in the name of the assignee or assignees and in the denominations specified in any instrument of
assignment provided to the Company by the assignor, and shall issue to the assignor a new warrant evidencing the portion of this
warrant, if any, not so assigned and this warrant shall promptly be cancelled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font-size: 10pt; text-align: right; margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>4.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B>Notices</B>. All notices and other communications from the Company to the Holder, or vice versa, shall be deemed
delivered and effective when given personally or mailed by first-class registered or certified mail, postage prepaid, at such address
as may have been furnished to the Company or the Holder, as the case may be, in writing by the Company or such Holder from time to time.
All notices to the Holder shall be addressed as provided in the Investors&rsquo; Rights Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>4.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B>Amendments</B>. This warrant and any term hereof may be changed, waived, discharged or terminated only by an instrument
in writing signed by the party against which enforcement of such change, waiver, discharge or termination is sought.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"><B>4.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B>Attorneys&rsquo; Fees</B>. In the event of any dispute between the parties concerning the terms and provisions of
this warrant, the party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such dispute,
including reasonable attorneys&rsquo; fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Governing Law</B>. This warrant shall be governed by and construed in accordance with the laws of the State of Delaware, without
giving effect to its principles regarding conflicts of law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Warrant Register</B>. The Company shall keep and properly maintain at its principal executive offices books for the registration
of the warrant and any transfers thereof. The Company may deem and treat the person or entity in whose name the warrant is registered
on such register as the Holder thereof for all purposes, and the Company shall not be affected by any notice to the contrary, except any
assignment, division, combination or other transfer of the warrant effected in accordance with the provisions of this warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Cumulative Remedies</B>. The rights and remedies provided in this warrant are cumulative and are not exclusive of, and are in addition
to and not in substitution for, any other rights or remedies available at law, in equity or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Equitable Relief</B>. Each of the Company and the Holder acknowledges that a breach or threatened breach by such party of any of
its obligations under this warrant would give rise to irreparable harm to the other party hereto for which monetary damages would not
be an adequate remedy and hereby agrees that in the event of a breach or a threatened breach by such party of any such obligations, the
other party hereto shall, in addition to any and all other rights and remedies that may be available to it in respect of such breach,
be entitled to equitable relief, including a restraining order, an injunction, specific performance and any other relief that may be available
from a court of competent jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font-size: 10pt; text-align: right; margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>Entire
Agreement</B>. This warrant, together with the Investors&rsquo; Rights Agreement, and that certain Stock Purchase Agreement dated
July , 2019 (the &ldquo;<B><I>Purchase Agreement</I></B>&rdquo;) constitutes the sole and entire agreement of the parties to this
warrant with respect to the subject matter contained herein, and supersedes all prior and contemporaneous understandings and
agreements, both written and oral, with respect to such subject matter. In the event of any inconsistency between the statements in
the body of this warrant, the Investors&rsquo; Rights Agreement and the Purchase Agreement, the statements in the body of this
warrant shall control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Signature Page Follows]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font-size: 10pt; text-align: right; margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the undersigned
has executed this Warrant to Purchase Stock as of the date set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Sera Prognostics,
    Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Gregory C. Critchfield, M.D., MS</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">President and Chief Executive Officer</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font-size: 10pt; text-align: right; margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><U>APPENDIX 1</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTICE OF EXERCISE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
undersigned hereby elects to purchase ______________ shares of Common Stock, $0.0001 par value per share of SERA PROGNOSTICS, INC. pursuant
to the terms of the attached warrant, and tenders herewith payment of the purchase price of such shares in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
undersigned hereby elects to convert the attached warrant into shares in the manner specified in the warrant. This conversion is exercised
with respect to _____________ of the shares covered by the warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>[Strike paragraph that does not apply.]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please
issue a certificate or certificates representing said shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-top: Black 1pt solid; width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(Holder&rsquo;s Name)</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="border-top: Black 1pt solid; text-align: justify; width: 50%">(Address)</TD>
    <TD STYLE="width: 50%">&nbsp;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
undersigned represents it is acquiring the shares solely for its own account and not as a nominee for any other party and not with a view
toward the resale or distribution thereof except in compliance with applicable securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Holder or Registered Assignee</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="border-top: Black 1pt solid; text-align: justify; width: 50%">(Signature)</TD>
    <TD STYLE="width: 50%">&nbsp;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="border-top: Black 1pt solid; text-align: justify; width: 50%">(Date)</TD>
    <TD STYLE="width: 50%">&nbsp;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font-size: 10pt; text-align: right; margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><U>APPENDIX 2</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">JOINDER</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 5%">DATE:</TD>
<TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 25%">&nbsp;</TD>
<TD STYLE="text-align: justify; width: 70%">&nbsp;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned hereby agrees,
effective as of the date hereof, (i) to become a party to that certain Third Amended and Restated Investors&rsquo; Rights Agreement (the
 &ldquo;Investors&rsquo; Rights Agreement&rdquo;) dated as of July __, 2019, as amended from time to time, by and among Sera Prognostics,
Inc. and the other parties thereto and for all purposes of the Investors&rsquo; Rights Agreement, the undersigned shall be included within
the terms &ldquo;Investor&rdquo; and &ldquo;Holder&rdquo; as defined in the Investors&rsquo; Rights Agreement, and the undersigned agrees
to be bound by the terms and conditions of the Investors&rsquo; Rights Agreement as an Investor and Holder thereunder, and (ii) to become
a party to that certain Third Amended and Restated Voting Agreement (the &ldquo;Voting Agreement&rdquo;) dated as of July __, 2019, as
amended from time to time, by and among Sera Prognostics, Inc. and the other parties thereto and for all purposes of the Voting Agreement,
the undersigned shall be included within the terms &ldquo;Investor&rdquo; and &ldquo;Stockholder&rdquo; as defined in the Voting Agreement,
and the undersigned agrees to be bound by the terms and conditions of the Voting Agreement as an Investor and Stockholder thereunder.
The address and facsimile number to which notices may be sent to the undersigned is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 7%">ADDRESS:</TD>
<TD STYLE="text-align: justify; width: 43%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 3%">Fax:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 47%"><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD>
    <TD STYLE="width: 50%">&nbsp;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 50%">&nbsp;</TD>
<TD STYLE="text-align: justify; width: 3%">By:</TD>
<TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 47%">&nbsp;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify; width: 50%">Name:</TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0pt"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>14
<FILENAME>tm2110724d11_ex4-4.htm
<DESCRIPTION>EXHIBIT 4.4
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: right; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Exhibit 4.4</B></FONT></P>

<P STYLE="text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">THIS
WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;<B><U>ACT</U></B>&rdquo;),
OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE
TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY
TO THE ISSUER, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>WARRANT
TO PURCHASE COMMON STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 43%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Corporation:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number
    of Shares:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Class
    of Stock:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Initial
    Exercise Price:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Issue
    Date:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expiration:</FONT></P></TD>
    <TD STYLE="text-align: justify; width: 57%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Sera
    Prognostics, Inc., a Delaware corporation</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: yellow">[__]</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common
    Stock, $0.0001 par value per share</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">$9.99
    per share</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: yellow">[__]</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">,
    2021</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: yellow">[__]</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">,
    2026</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">THIS
WARRANT CERTIFIES THAT, for good and valuable consideration, the receipt of which is hereby acknowledged, <FONT STYLE="background-color: yellow">[__]
</FONT>or its assignee or transferee (&ldquo;<B><I>Holder</I></B>&rdquo;) is entitled to purchase the number of fully paid and nonassessable
shares of Common Stock, $0.0001 par value per share (the &ldquo;<B><I>Shares</I></B>&rdquo;) of Sera Prognostics, Inc. (the &ldquo;<B><I>Company</I></B>&rdquo;)
at the initial exercise price per Share (the &ldquo;<B><I>Warrant Price</I></B>&rdquo;) all as set forth above and as adjusted pursuant
to Article 2 of this warrant, subject to the provisions and upon the terms and conditions set forth in this warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">ARTICLE
1</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
<BR>
EXERCISE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><B>1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">Method
of Exercise</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">. Holder may exercise this warrant by delivering this
warrant, a duly executed Notice of Exercise in substantially the form attached as Appendix 1, and a duly executed Joinder to the Fourth
Amended and Restated Investors&rsquo; Rights Agreement, dated as of February 23, 2021, between the Company and certain stockholders of
the Company (as amended from time to time, the &ldquo;<B>Investors&rsquo; Rights Agreement</B>&rdquo;), and the Fourth Amended and Restated
Voting Agreement, dated as of February 23, 2021, between the Company and certain stockholders of the Company (as amended from time to
time, the &ldquo;<B>Voting Agreement</B>&rdquo;), in substantially the form attached as Appendix 2 to the principal office of the Company.
Unless Holder is exercising the conversion right set forth in Section 1.2, Holder shall also deliver to the Company a check for the aggregate
Warrant Price for the Shares being purchased.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><B>1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">Conversion
Right</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">. In lieu of exercising this warrant as specified in Section
1.1, Holder may from time to time convert this warrant, in whole or in part, into a number of Shares determined by dividing (a) the aggregate
fair market value of the Shares or other securities otherwise issuable upon exercise of this warrant minus the aggregate Warrant Price
of such Shares by (b) the fair market value of one Share. The fair market value of the Shares shall be determined pursuant to Section
1.3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><B>1.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">Fair
Market Value</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">. If the Shares are traded regularly in a public market,
the fair market value of the Shares shall be the closing price of the Shares reported for the business day immediately before Holder
delivers its Notice of Exercise to the Company. If the Shares are not regularly traded in a public market, the Board of Directors of
the Company and the Holder shall jointly determine fair market value in their collective reasonable good faith judgment; <I>provided</I>,
that if the Board of Directors of the Company and the Holder are unable to agree on the fair market value per share of the Shares within
a reasonable period of time (not to exceed twenty days from the Company&rsquo;s receipt of the Notice of Exercise), such fair market
value shall be determined by a nationally recognized investment banking, accounting or valuation firm jointly selected by the Board of
Directors of the Company and the Holder. The determination of such firm shall be final and conclusive, and the fees and expenses of such
firm shall be borne equally by the Company and the Holder. In determining the Fair Market Value of the Shares, an orderly sale transaction
between a willing buyer and a willing seller shall be assumed, using valuation techniques then prevailing in the securities industry
without regard to the lack of liquidity of the Shares due to any restrictions (contractual or otherwise) applicable thereto or any discount
for minority interests and assuming full disclosure of all relevant information and a reasonable period of time for effectuating such
sale and assuming the sale of all of the issued and outstanding Common Stock (including fractional interests) calculated on a fully diluted
basis to include the conversion or exchange of all securities then outstanding that are convertible into or exchangeable for Common Stock
and the exercise of all rights and warrants then outstanding and exercisable to purchase shares of Common Stock or securities convertible
into or exchangeable for shares of Common Stock; <I>provided</I>, that such assumption shall not include those securities, rights and
warrants (a) owned or held by or for the account of the Company or any of its subsidiaries, or (b) convertible or exchangeable into Common
Stock where the conversion, exchange or exercise price per share is greater than the Fair Market Value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><B>1.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">Delivery
of Certificate and New Warrant</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">. Promptly after Holder exercises or
converts this warrant, the Company shall deliver to Holder certificates for the Shares acquired and, if this warrant has not been fully
exercised or converted and has not expired, a new warrant representing the Shares not so acquired.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><B>1.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">Replacement
of Warrants</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">. On receipt of evidence reasonably satisfactory to the
Company of the loss, theft, destruction or mutilation of this warrant and, in the case of loss, theft or destruction, on delivery of
an indemnity agreement reasonably satisfactory in form, substance and amount to the Company or, in the case of mutilation, on surrender
and cancellation of this warrant, the Company at its expense shall execute and deliver, in lieu of this warrant, a new warrant of like
tenor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><B>1.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">Treatment
of Warrant Upon Acquisition of the Company</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><B>1.6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B><I>Acquisition</I></B>.&rdquo;
For the purpose of this warrant, &ldquo;Acquisition&rdquo; means (a) merger or consolidation of the Company into or with another entity,
or a plan of exchange between the Company and any other entity, or the merger or consolidation of any other entity into or with the Company
(except for a merger, consolidation or exchange in which the holders of the voting power of the capital stock of the Company immediately
prior to such merger, consolidation or exchange continue to hold at least 50% of the voting power of the capital stock of the Company
or the surviving or acquiring entity), (b) sale, lease, exclusive license or other disposition of all or substantially all of the assets
of the Company, or (c)&nbsp;the acquisition of ownership by any Person or group of more than 50% of the Company&rsquo;s voting stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><B>1.6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">Exercise
Upon Acquisition</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">. Upon the closing of any Acquisition in which the
consideration to be received by the Company&rsquo;s stockholders consists of cash, marketable securities, or a combination of both cash
and marketable securities, this warrant shall be deemed to have been automatically converted pursuant to Section 1.2, and thereafter
Holder shall participate in the Acquisition on the same terms as other holders of the same class of securities of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><B>1.6.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">Assumption
of Warrant</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">. The Company shall not effect any Acquisition not referred
to in Section 1.6.2 unless, prior to the consummation thereof, the successor person or entity (if other than the Company) resulting from
such transaction, shall assume, by written instrument satisfactory to the Holder, the obligations of this warrant, upon which this warrant
shall thereafter be exercisable for the same securities and/or other property as would have been paid for the Shares issuable upon exercise
of the unexercised portion of this warrant as if such Shares were outstanding on and as of the closing of such Acquisition, subject to
further adjustment from time to time in accordance with the provisions of this warrant. Alternatively (and notwithstanding anything to
the contrary herein), with respect to any Acquisition, Holder shall have the right to elect prior to the consummation thereof, to give
effect to the exercise rights contained in Section 1.1 or the conversion rights contained in Section 1.2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">ARTICLE
2</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
<BR>
ADJUSTMENTS TO THE SHARES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><B>2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">Stock
Dividends, Splits, Etc</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">. If the Company declares or pays a dividend
or any other distribution on its Common Stock payable in Common Stock, cash or other securities, or subdivides the outstanding Common
Stock into a greater amount of Common Stock, then upon exercise of this warrant, for each Share acquired, Holder shall receive, without
cost to Holder, the total number and kind of securities, cash or other property to which Holder would have been entitled had Holder owned
the Shares of record as of the date the dividend, distribution or subdivision occurred (subject to further adjustment in the event the
rights of any such securities or property are subsequently amended to <FONT STYLE="color: black">increase the number of shares of Common
Stock issuable thereunder or to lower the exercise or conversion price thereof</FONT>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><B>2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">Reclassification,
Exchange or Substitution</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">. Upon any reclassification, exchange, consolidation,
substitution, or other event that results in a change of the number and/or class of the securities issuable upon exercise or conversion
of this warrant, Holder shall be entitled to receive, upon exercise or conversion of this warrant, the number and kind of securities
and property that Holder would have received for the Shares if this warrant had been exercised in full immediately before such reclassification,
exchange, consolidation, substitution, or other event (subject to further adjustment in the event the rights of any such securities or
property are subsequently amended to <FONT STYLE="color: black">increase the number of shares of Common Stock issuable thereunder or
to lower the exercise or conversion price thereof</FONT>). The Company or its successor shall promptly issue to Holder a new warrant
for such new securities or other property. The new warrant shall provide for adjustments which shall be as nearly equivalent as may be
practicable to the adjustments provided for in this Article 2 including, without limitation, adjustments to the Warrant Price and to
the number of securities or property issuable upon exercise of the new warrant. The provisions of this Section 2.2 shall similarly apply
to successive reclassifications, exchanges, substitutions, or other events.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><B>2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">Adjustments
for Combinations, Etc.</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif"> If the outstanding Shares are combined or
consolidated, by reclassification or otherwise, into a lesser number of shares, the Warrant Price shall be proportionately increased.
If the outstanding Shares are combined or consolidated, by reclassification or otherwise, into a greater number of shares, the Warrant
Price shall be proportionately decreased.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><B>2.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">Certificate
as to Adjustments</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">. Upon each adjustment of the Warrant Price, the
Company at its expense shall promptly compute such adjustment, and furnish Holder with a certificate of its Chief Financial Officer setting
forth such adjustment and the facts upon which such adjustment is based. The Company shall, upon written request, furnish Holder a certificate
setting forth the Warrant Price in effect upon the date thereof and the series of adjustments leading to such Warrant Price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><B>2.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">Fractional
Shares</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">. No fractional Shares shall be issuable upon exercise or conversion
of the warrant, and the Number of Shares to be issued shall be rounded up to the nearest whole Share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">ARTICLE
3</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
<BR>
REPRESENTATIONS AND COVENANTS OF THE COMPANY AND HOLDER</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><B>3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">Representations
and Warranties</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">. The Company hereby represents and warrants to the
Holder that all Shares which may be issued upon the exercise of the purchase right represented by this warrant shall, upon issuance,
be duly authorized, validly issued, fully paid and nonassessable, without violation of any preemptive right or similar rights, and free
of any liens, taxes, and encumbrances except for restrictions on transfer provided for herein or under applicable federal and state securities
laws. The Company will pay all expenses in connection with, and all taxes and other governmental charges that may be imposed with respect
to, the issuance or delivery of Shares upon exercise (or conversion) of this warrant; provided, that the Company shall not be required
to pay any tax or governmental charge that may be imposed with respect to any applicable withholding or the issuance or delivery of the
Shares to any Person other than the Holder, and no such issuance or delivery shall be made unless and until the Person requesting such
issuance has paid to the Company the amount of any such tax, or has established to the satisfaction of the Company that such tax has
been paid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><B>3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">Notice
of Certain Events</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">. The Company shall provide Holder with not less
than 10 days prior written notice of, including a description of the material facts surrounding, any of the following events: (a) declaration
of any dividend or distribution upon its Common Stock, whether in cash, property, stock, or other securities and whether or not a regular
cash dividend; (b) offering for subscription pro rata to the holders of any class or series of its stock any additional shares of stock
of any class or series or other rights; (c) effecting any reclassification or recapitalization of Common Stock; or (d) the merger or
consolidation with or into any other corporation, or sale, lease, license, or conveyance of all or substantially all of its assets, or
liquidation, dissolution or winding up.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><B>3.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">Registration
Under Securities Act of 1933, as amended</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">. The Company agrees that
the Shares shall be &ldquo;Registrable Securities&rdquo; and Holder shall be an &ldquo;Investor&rdquo; and a &ldquo;Holder&rdquo; under
the Investors&rsquo; Rights Agreement upon Holder&rsquo;s due execution and delivery to the Company of a Joinder in substantially the
form of <B><U>Appendix 2</U></B>, and the Company will use its best efforts to cause the Shares into which this warrant is exercised
(or converted), immediately upon such exercise (or conversion), to be listed on any domestic securities exchange upon which shares of
Common Stock or other securities constituting Shares are listed at the time of such exercise (or conversion).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><B>3.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">Holder
Investment Representations</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">. Holder makes the following representations
to the Company in connection with the issuance of this warrant and the Shares (collectively, the &ldquo;<B><I>Securities</I></B>&rdquo;):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Holder is aware of the Company&rsquo;s business affairs and financial condition, and has acquired sufficient information about the Company
to reach an informed and knowledgeable decision to acquire the Securities. The undersigned is purchasing the Securities for its own account
for investment purposes only, not as a nominee or agent, and not with a view towards, or for resale in connection with, any &ldquo;distribution&rdquo;
thereof for purposes of the Securities Act of 1933, as amended (the &ldquo;<B><I>Securities Act</I></B>&rdquo;). The undersigned has
such knowledge and experience in financial business matters and the undersigned is capable of evaluating the merits and risks of the
purchase of the Securities and of protecting its interests in connection therewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Holder understands that the Securities have not been registered under the Securities Act in reliance upon a specific exemption therefrom,
which exemption depends upon, among other things, the bona fide nature of the undersigned&rsquo;s investment intent as expressed herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><B>(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Holder further understands that the Securities must be held indefinitely, and the undersigned must therefore bear the economic risk therewith,
unless the Securities are subsequently registered under the Securities Act or unless an exemption from registration is otherwise available.
In addition, the undersigned understands that the certificate evidencing the Securities will be imprinted with a legend which prohibits
the transfer of the Securities unless they are registered or such registration is not required. Holder is aware of the provisions of
Rule 144 promulgated under the Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><B>(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Holder is familiar with the provisions of Rule 144, promulgated pursuant to the Securities Act, which, in substance, permits limited
public resale of &ldquo;restricted securities&rdquo; acquired, directly or indirectly, from the issuer thereof, in a non-public offering
subject to the satisfaction of certain conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><B>(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Holder further understands that in the event that all of the applicable requirements of Rule 144 are not satisfied, registration under
the Securities Act, compliance with Regulation A, or some other registration exemption will be required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Holder is an &ldquo;accredited investor&rdquo; as defined in Rule 501(a) of Regulation D promulgated under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><B>3.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B>Market
Stand Off</B>&rdquo; <B>Agreement</B>. The Holder agrees that the Shares shall be subject to the Market Standoff provisions in Section
2.11 of Investors&rsquo; Rights Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><B>3.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">No
<FONT STYLE="color: windowtext">Voting</FONT> Rights</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">. Holder, as
a Holder of this warrant, will not have any voting rights until the exercise of this warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><B>3.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">Reservation
of Shares</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">. During the period between the Issue Date and the Expiration,
the Company shall at all times reserve and keep available out of its authorized but unissued Common Stock or other securities constituting
Shares, solely for the purpose of issuance upon the exercise of this warrant, the maximum number of Shares issuable upon the exercise
of this warrant, and the par value per Share shall at all times be less than or equal to the applicable Warrant Price. The Company shall
not increase the par value of any Shares receivable upon the exercise of this warrant above the Warrant Price then in effect, and shall
take all such actions as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable
shares of Common Stock upon the exercise of this warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">ARTICLE
4</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
<BR>
MISCELLANEOUS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><B>4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">Term:
Exercise Upon Expiration</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">. This warrant is exercisable in whole or
in part, at any time and from time to time on or before the Expiration Date set forth above. If this warrant has not been exercised prior
to the Expiration Date, this warrant shall be deemed to have been automatically exercised on the Expiration Date by &ldquo;cashless&rdquo;
conversion pursuant to Section 1.2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><B>4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">Legends</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">.
This warrant shall be imprinted with a legend in substantially the following form as well as any additional legends that the Company
and Holder mutually agree upon with respect to such Shares:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">THE
SHARES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;ACT&rdquo;), OR
THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN THAT CERTAIN WARRANT TO PURCHASE STOCK ISSUED BY THE ISSUER TO HOLDER DATED
FEBRUARY __, 2021, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR,
IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT
FROM SUCH REGISTRATION.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><B>4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">Compliance
with Securities Laws on Transfer</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">. This warrant and the Shares issued
upon exercise of this warrant may not be transferred or assigned in whole or in part except in compliance with applicable federal and
state securities laws by the transferor and the transferee (including, without limitation, the delivery of investment representation
letters and legal opinions reasonably satisfactory to the Company, as reasonably requested by the Company). The Company shall not require
Holder to provide an opinion of counsel if the transfer is to any affiliate of Holder, provided that any such transferee is an &ldquo;accredited
investor&rdquo; as defined in Regulation D promulgated under the Act. Additionally, the Company shall also not require an opinion of
counsel if there is no material question as to the availability of Rule 144 promulgated under the Act. This warrant and the rights evidenced
hereby shall be binding upon and shall inure to the benefit of the parties hereto and the successors of the Company and the successors
and assigns of the Holder. Subject to the foregoing, such successors and/or assigns of the Holder shall be deemed to be a Holder for
all purposes hereunder. In the case of a transfer of the warrant, upon surrender and delivery by Holder, the Company shall execute and
deliver a new warrant or warrants in the name of the assignee or assignees and in the denominations specified in any instrument of assignment
provided to the Company by the assignor, and shall issue to the assignor a new warrant evidencing the portion of this warrant, if any,
not so assigned and this warrant shall promptly be cancelled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><B>4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">Notices</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">.
All notices and other communications from the Company to the Holder, or vice versa, shall be deemed delivered and effective when given
personally or mailed by first-class registered or certified mail, postage prepaid, at such address as may have been furnished to the
Company or the Holder, as the case may be, in writing by the Company or such Holder from time to time. All notices to the Holder shall
be addressed as provided in the Investors&rsquo; Rights Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><B>4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">Amendments</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">.
This warrant and any term hereof may be changed, waived, discharged or terminated only by an instrument in writing signed by the party
against which enforcement of such change, waiver, discharge or termination is sought.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><B>4.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">Attorneys&rsquo;
Fees</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">. In the event of any dispute between the parties concerning
the terms and provisions of this warrant, the party prevailing in such dispute shall be entitled to collect from the other party all
costs incurred in such dispute, including reasonable attorneys&rsquo; fees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><B>4.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">Governing
Law</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">. This warrant shall be governed by and construed in accordance
with the laws of the State of Delaware, without giving effect to its principles regarding conflicts of law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><B>4.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrant
Register</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">. The Company shall keep and properly maintain at its principal
executive offices books for the registration of the warrant and any transfers thereof. The Company may deem and treat the person or entity
in whose name the warrant is registered on such register as the Holder thereof for all purposes, and the Company shall not be affected
by any notice to the contrary, except any assignment, division, combination or other transfer of the warrant effected in accordance with
the provisions of this warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><B>4.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">Cumulative
Remedies</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">. The rights and remedies provided in this warrant are cumulative
and are not exclusive of, and are in addition to and not in substitution for, any other rights or remedies available at law, in equity
or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><B>4.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">Equitable
Relief</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">. Each of the Company and the Holder acknowledges that a breach
or threatened breach by such party of any of its obligations under this warrant would give rise to irreparable harm to the other party
hereto for which monetary damages would not be an adequate remedy and hereby agrees that in the event of a breach or a threatened breach
by such party of any such obligations, the other party hereto shall, in addition to any and all other rights and remedies that may be
available to it in respect of such breach, be entitled to equitable relief, including a restraining order, an injunction, specific performance
and any other relief that may be available from a court of competent jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><B>4.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif">Entire
Agreement</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">. This warrant, together with the Investors&rsquo; Rights
Agreement, the Voting Agreement and that certain Stock Purchase Agreement dated February __, 2021 (the &ldquo;<B><I>Purchase Agreement</I></B>&rdquo;),
constitutes the sole and entire agreement of the parties to this warrant with respect to the subject matter contained herein, and supersedes
all prior and contemporaneous understandings and agreements, both written and oral, with respect to such subject matter. In the event
of any inconsistency between the statements in the body of this warrant, the Investors&rsquo; Rights Agreement, the Voting Agreement
and the Purchase Agreement, the statements in the body of this warrant shall control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">[Signature
Page Follows]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">IN
WITNESS WHEREOF, the undersigned has executed this Warrant to Purchase Common Stock as of the date set forth above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Sera
    Prognostics, Inc.</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gregory
    C. Critchfield, M.D., MS</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Chief Executive Officer</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><U>APPENDIX
1</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">NOTICE
OF EXERCISE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
undersigned hereby elects to purchase ______________ shares of Common Stock, $0.0001 par value per share of SERA PROGNOSTICS, INC. pursuant
to the terms of the attached warrant, and tenders herewith payment of the purchase price of such shares in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
undersigned hereby elects to convert the attached warrant into shares in the manner specified in the warrant. This conversion is exercised
with respect to _____________ of the shares covered by the warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>[Strike
paragraph that does not apply.]</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please
issue a certificate or certificates representing said shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Holder&rsquo;s
    Name)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
undersigned represents it is acquiring the shares solely for its own account and not as a nominee for any other party and not with a
view toward the resale or distribution thereof except in compliance with applicable securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Holder
or Registered Assignee</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Signature)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Date)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><U>APPENDIX
2</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">JOINDER</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">DATE:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
undersigned hereby agrees, effective as of the date hereof, (i) to become a party to that certain Fourth Amended and Restated Investors&rsquo;
Rights Agreement (the &ldquo;Investors&rsquo; Rights Agreement&rdquo;) dated as of February __, 2021, as amended from time to time, by
and among Sera Prognostics, Inc. and the other parties thereto and for all purposes of the Investors&rsquo; Rights Agreement, the undersigned
shall be included within the terms &ldquo;Investor&rdquo; and &ldquo;Holder&rdquo; as defined in the Investors&rsquo; Rights Agreement,
and the undersigned agrees to be bound by the terms and conditions of the Investors&rsquo; Rights Agreement as an Investor and Holder
thereunder, and (ii) to become a party to that certain Third Amended and Restated Voting Agreement (the &ldquo;Voting Agreement&rdquo;)
dated as of February __, 2021, as amended from time to time, by and among Sera Prognostics, Inc. and the other parties thereto and for
all purposes of the Voting Agreement, the undersigned shall be included within the terms &ldquo;Investor&rdquo; and &ldquo;Stockholder&rdquo;
as defined in the Voting Agreement, and the undersigned agrees to be bound by the terms and conditions of the Voting Agreement as an
Investor and Stockholder thereunder. The address and facsimile number to which notices may be sent to the undersigned is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADDRESS:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fax:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 52%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.5
<SEQUENCE>15
<FILENAME>tm2110724d11_ex4-5.htm
<DESCRIPTION>EXHIBIT 4.5
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 4.5</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FOURTH AMENDED AND RESTATED INVESTORS&rsquo;
RIGHTS AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">THIS FOURTH AMENDED AND RESTATED
INVESTORS&rsquo; RIGHTS AGREEMENT (this &ldquo;<B>Agreement</B>&rdquo;) is made as of the 23<SUP>rd</SUP> day of February, 2021, by and
among Sera Prognostics,&nbsp;Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), each of the investors listed on <U>Schedule
A</U> hereto, each of which is referred to in this Agreement as an &ldquo;<B>Investor</B>&rdquo;, each of the stockholders listed on
<U>Schedule B</U> hereto, each of whom is referred to herein as a &ldquo;<B>Key Holder</B>&rdquo;, and any Additional Purchaser (as defined
in the Purchase Agreement (as defined below)) that becomes a party to this Agreement in accordance with <U>Section&nbsp;6.9</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>RECITALS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>WHEREAS</B></FONT>,
the Company, the Key Holders and certain of the Investors previously entered into the Third Amended and Restated Investors&rsquo; Rights
Agreement, dated July&nbsp;31, 2019 (the &ldquo;<B>Prior Agreement</B>&rdquo;), in connection with the sale of shares of the Series&nbsp;D
Preferred Stock by certain of the Investors;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>WHEREAS</B></FONT>,
the Company and the Investors are holders of shares of the Company&rsquo;s Series&nbsp;A Preferred Stock, Series&nbsp;B Preferred Stock,
Series&nbsp;C Preferred Stock, Series&nbsp;D Preferred Stock or are parties to the Series&nbsp;E Preferred Stock Purchase Agreement of
even date herewith (the &ldquo;<B>Purchase Agreement</B>&rdquo;); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>WHEREAS</B></FONT>,
in order to induce the Company to enter into the Purchase Agreement and to induce the Investors to invest funds in the Company pursuant
to the Purchase Agreement, the Investors and the Company hereby agree to amend and restate the Prior Agreement as set forth herein, and
agree that this Agreement shall govern the rights of the Investors to cause the Company to register shares of Common Stock issuable to
the Investors, to receive certain information from the Company, and to participate in future equity offerings by the Company, and shall
govern certain other matters as set forth in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NOW,
THEREFORE</B></FONT>, the parties hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Definitions.
</U>For purposes of this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B>Affiliate</B>&rdquo;
means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is controlled by, or is under common
control with such Person, including without limitation any general partner, managing member, officer or director of such Person or any
venture capital fund now or hereafter existing that is controlled by one or more general partners or managing members of, or shares the
same management company with, such Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B>ATH
Holding</B>&rdquo; means ATH Holding Company, LLC, an Indiana limited liability company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B>Board</B>&rdquo;
means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B>Blue
Ox</B>&rdquo; means Blue Ox Healthcare Partners SP, LLC, a Delaware limited liability company, </FONT>BXHCP SP II, LLC, a Delaware limited
liability company, and BXHCP SP III, LLC, a Delaware limited liability company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B>Common
Stock</B>&rdquo; means shares of the Company&rsquo;s common stock, par value $0.0001 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B>Damages</B>&rdquo;
means any loss, damage, claim or liability (joint or several) to which a party hereto may become subject under the Securities Act, the
Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises
out of or is based upon (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in any registration statement
of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto;
(ii)&nbsp;an omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements
therein not misleading; or (iii)&nbsp;any violation or alleged violation by the indemnifying party (or any of its agents or Affiliates)
of the Securities Act, the Exchange Act, any state securities law, or any rule&nbsp;or regulation promulgated under the Securities Act,
the Exchange Act, or any state securities law.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B>Derivative
Securities</B>&rdquo; means any securities or rights convertible into, or exercisable or exchangeable for (in each case, directly or
indirectly), Common Stock, including options and warrants.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B>Exchange
Act</B>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B>Excluded
Registration</B>&rdquo; means (i)&nbsp;a registration relating to the sale of securities to employees of the Company or a subsidiary
pursuant to a stock option, stock purchase, or similar plan; (ii)&nbsp;a registration relating to an SEC Rule&nbsp;145 transaction; (iii)&nbsp;a
registration on any form that does not include substantially the same information as would be required to be included in a registration
statement covering the sale of the Registrable Securities; or (iv)&nbsp;a registration in which the only Common Stock being registered
is Common Stock issuable upon conversion of debt securities that are also being registered.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B>Form&nbsp;S-1</B>&rdquo;
means such form under the Securities Act as in effect on the date hereof or any successor registration form under the Securities Act
subsequently adopted by the SEC.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.11.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B>Form&nbsp;S-3</B>&rdquo;
means such form under the Securities Act as in effect on the date hereof or any registration form under the Securities Act subsequently
adopted by the SEC that permits incorporation of substantial information by reference to other documents filed by the Company with the
SEC.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.12.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B>FOSUN</B>&rdquo;
means Fosun Industrial Co., Limited, a corporation organized under the laws of the Hong Kong Special Administrative Region of China.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.13.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B>GAAP</B>&rdquo;
means generally accepted accounting principles in the United States.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.14.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B>Holder</B>&rdquo;
means any holder of Registrable Securities who is a party to this Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.15.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B>Immediate
Family Member</B>&rdquo; means a child, stepchild, grandchild, parent, stepparent, grandparent, spouse, sibling, mother-in-law, father-in-law,
son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, of a natural person referred to herein.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.16.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B>Initiating
Holders</B>&rdquo; means, collectively, Holders who properly initiate a registration request under this Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.17.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B>IPO</B>&rdquo;
means the Company&rsquo;s first underwritten public offering of its Common Stock under the Securities Act.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.18.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B>Key
Employee</B>&rdquo; means any executive-level employee (including division director and vice president-level positions) as well as any
employee who, either alone or in concert with others, develops, invents, programs, or designs any Company Intellectual Property (as defined
in the Purchase Agreement).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.19.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B>Key
Holder Registrable Securities</B>&rdquo; means (i)&nbsp;shares of Common Stock held by the Key Holders, and (ii)&nbsp;any Common Stock
issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other
distribution with respect to, or in exchange for or in replacement of such shares.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.20.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B>Major
Investor</B>&rdquo; means any Investor that, individually or together with such Investor&rsquo;s Affiliates, holds at least fifteen percent
(15%) of the shares of Registrable Securities (as adjusted for any stock split, stock dividend, combination, or other recapitalization
or reclassification effected after the date hereof) originally purchased thereby.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.21.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B>New
Securities</B>&rdquo; means, collectively, equity securities of the Company, whether or not currently authorized, as well as rights,
options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or
exchangeable into or exercisable for such equity securities.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.22.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B>Person</B>&rdquo;
means any individual, corporation, partnership, trust, limited liability company, association </FONT>or other entity.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.23.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B>Preferred
Director</B>&rdquo; means any director of the Company that the holders of record of the Preferred Stock, voting as a single class on
an as-converted basis, are entitled to elect pursuant to the Restated Certificate.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.24.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<B>Preferred
Stock</B>&rdquo; means, collectively, shares of the Company&rsquo;s Series&nbsp;A1 Preferred Stock, Series&nbsp;A2 Preferred Stock, Series&nbsp;B-1
Preferred Stock, Series&nbsp;B-2 Preferred Stock, Series&nbsp;C-1 Preferred Stock, Series&nbsp;C-2 Preferred Stock, Series&nbsp;D Preferred
Stock, and Series&nbsp;E Preferred Stock.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.25.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B>Registrable
Securities</B>&rdquo; means (i)&nbsp;the Common Stock issuable or issued upon conversion of the Preferred Stock; (ii)&nbsp;any Common
Stock, or any Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of the
Company, acquired by the Investors after the date hereof; (iii)&nbsp;the Key Holder Registrable Securities, <U>provided</U>, <U>however</U>,
that such Key Holder Registrable Securities shall not be deemed Registrable Securities and the Key Holders shall not be deemed Holders
for purposes of <U>Subsections 2.1</U>, <U>2.10</U>, <U>3.1</U>, <U>3.2</U>, <U>4.1</U> and <U>6.6</U>; (iv)&nbsp;any Common Stock issuable
or issued upon exercise of the Warrants (as defined in the Series&nbsp;D Preferred Stock Purchase Agreement between the Company and the
Investors party thereto, dated as of July&nbsp;31, 2019); and (v)&nbsp;any Common Stock issued as (or issuable upon the conversion or
exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange
for or in replacement of, the shares referenced in clauses <U>(i)</U>, <U>(ii)</U>, and <U>(iv)</U>&nbsp;above; excluding in all cases,
however, any Registrable Securities sold by a Person in a transaction in which the applicable rights under this Agreement are not assigned
pursuant to <U>Subsection 6.1</U>, and excluding for purposes of <U>Section&nbsp;1.44</U> any shares for which registration rights have
terminated pursuant to <U>Subsection 2.13</U> of this Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.26.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B>Registrable
Securities then outstanding</B>&rdquo; means the number of shares determined by adding the number of shares of outstanding Common Stock
that are Registrable Securities and the number of shares of Common Stock that are Registrable Securities issuable (directly or indirectly)
pursuant to then exercisable and/or convertible securities.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.27.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B>Restated
Certificate</B>&rdquo; means </FONT>the Company&rsquo;s Fifth Amended and Restated Certificate of Incorporation, as amended from time
to time.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.28.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B>Restricted
Securities</B>&rdquo; means the securities of the Company required to bear the legend set forth in <U>Subsection 2.12(b)</U>&nbsp;hereof.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.29.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B>SEC</B>&rdquo;
means the Securities and Exchange Commission.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.30.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B>SEC
Rule&nbsp;144</B>&rdquo; means Rule&nbsp;144 promulgated by the SEC under the Securities Act.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.31.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B>SEC
Rule&nbsp;145</B>&rdquo; means Rule&nbsp;145 promulgated by the SEC under the Securities Act.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.32.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B>Securities
Act</B>&rdquo; means the Securities Act of 1933, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.33.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B>Selling
Expenses</B>&rdquo; means all underwriting discounts, selling commissions, and stock transfer taxes applicable to the sale of Registrable
Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel
borne and paid by the Company as provided in <U>Subsection 2.6.</U></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.34.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B>Series&nbsp;A
Preferred Stock&rdquo;</B> means, collectively, shares of the Series&nbsp;A1 Preferred Stock and Series&nbsp;A2 Preferred Stock.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.35.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B>Series&nbsp;A1
Preferred Stock</B>&rdquo; means shares of the Company&rsquo;s Series&nbsp;A1 Preferred Stock, par value $0.0001 per share.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.36.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B>Series&nbsp;A2
Preferred Stock</B>&rdquo; means shares of the Company&rsquo;s Series&nbsp;A2 Preferred Stock, par value $0.0001 per share.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.37.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B>Series&nbsp;B
Preferred Stock&rdquo;</B> means, collectively, shares of the Series&nbsp;B-1 Preferred Stock and Series&nbsp;B-2 Preferred Stock.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.38.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B>Series&nbsp;B-1
Preferred Stock</B>&rdquo; means shares of the Company&rsquo;s Series&nbsp;B-1 Preferred Stock, par value $0.0001 per share.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.39.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B>Series&nbsp;B-2
Preferred Stock</B>&rdquo; means shares of the Company&rsquo;s Series&nbsp;B-2 Preferred Stock, par value $0.0001 per share.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.40.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B>Series&nbsp;C
Preferred Stock&rdquo;</B> means, collectively, shares of the Series&nbsp;C-1 Preferred Stock and Series&nbsp;C-2 Preferred Stock.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.41.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B>Series&nbsp;C-1
Preferred Stock</B>&rdquo; means shares of the Company&rsquo;s Series&nbsp;C-1 Preferred Stock, par value $0.0001 per share.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.42.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B>Series&nbsp;C-2
Preferred Stock</B>&rdquo; means shares of the Company&rsquo;s Series&nbsp;C-2 Preferred Stock, par value $0.0001 per share.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.43.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B>Series&nbsp;D
Preferred Stock</B>&rdquo; means shares of the Company&rsquo;s Series&nbsp;D Preferred Stock, par value $0.0001 per share.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.44.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<B>Series&nbsp;E
Preferred Stock</B>&rdquo; means shares of the Company&rsquo;s Series&nbsp;E Preferred Stock, par value $0.0001 per share.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Registration
Rights.</U> The Company covenants and agrees as follows:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Demand
Registration.</U></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#8239;&#8239;(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Form&nbsp;S-1
Demand</U>. If at any time after the earlier to occur of (i)&nbsp;three (3)&nbsp;years after the date of this Agreement; or (ii)&nbsp;one
hundred eighty (180) days after the effective date of the registration statement for the IPO, the Company receives a request from the
Holders of at least a majority of the Registrable Securities then outstanding that the Company file a Form&nbsp;S-1 registration statement
with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price of at least $5 million,
then the Company shall (A)&nbsp;within ten (10)&nbsp;days after the date such request is given, give notice thereof (the &ldquo;<B>Demand
Notice</B>&rdquo;) to all Holders other than the Initiating Holders; and (B)&nbsp;as soon as practicable, and in any event within one
hundred twenty (120) days after the date such request is given by the Initiating Holders, file a Form&nbsp;S-1 registration statement
under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional
Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such
Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of
<U>Subsections 2.1(c)</U>&nbsp;and <U>2.3</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#8239;&#8239;(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Form&nbsp;S-3
Demand</U>. If at any time when it is eligible to use a Form&nbsp;S-3 registration statement, the Company receives a request from Holders
of at least twenty-five percent (25%) of the Registrable Securities then outstanding that the Company file a Form&nbsp;S-3 registration
statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price of at least
$3 million, then the Company shall (i)&nbsp;within twenty (20) days after the date such request is given, give a Demand Notice to all
Holders other than the Initiating Holders; and (ii)&nbsp;as soon as practicable, and in any event within ninety (90) days after the date
such request is given by the Initiating Holders, file a Form&nbsp;S-3 registration statement under the Securities Act covering all Registrable
Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the
Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of <U>Subsections
2.1(c)</U>&nbsp;and <U>2.3</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Notwithstanding
the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this <U>Subsection 2.1</U> a certificate
signed by the Company&rsquo;s chief executive officer stating that in the good faith judgment of the Board it would be materially detrimental
to the Company and its stockholders for such registration statement to either become effective or remain effective for as long as such
registration statement otherwise would be required to remain effective, because such action would (i)&nbsp;materially interfere with
a significant acquisition, corporate reorganization, or other similar transaction involving the Company; (ii)&nbsp;require premature
disclosure of material information that the Company has a bona fide business purpose for preserving as confidential; or (iii)&nbsp;render
the Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer
taking action with respect to such filing, and any time periods with respect to filing or effectiveness thereof shall be tolled correspondingly,
for a period of not more than one hundred twenty (120) days after the request of the Initiating Holders is given; <U>provided</U>, <U>however</U>,
that the Company may not invoke this right more than once in any twelve (12) month period; and <U>provided further</U> that the Company
shall not register any securities for its own account or that of any other stockholder during such one hundred twenty (120) day period
other than an Excluded Registration.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#8239;&#8239;(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to <U>Subsection 2.1(a)</U>&nbsp;(i)&nbsp;during
the period that is sixty (60) days before the Company&rsquo;s good faith estimate of the date of filing of, and ending on a date that
is one hundred eighty (180) days after the effective date of, a Company-initiated registration, <U>provided</U>, that the Company is
actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; (ii)&nbsp;after
the Company has effected two (2)&nbsp;registrations pursuant to <U>Subsection 2.1(a)</U>; or (iii)&nbsp;if the Initiating Holders propose
to dispose of shares of Registrable Securities that may be immediately registered on Form&nbsp;S-3 pursuant to a request made pursuant
to <U>Subsection 2.1(b)</U>. The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant
to <U>Subsection 2.1(b)</U>&nbsp;(A)&nbsp;during the period that is thirty (30) days before the Company&rsquo;s good faith estimate of
the date of filing of, and ending on a date that is ninety (90) days after the effective date of, a Company-initiated registration, <U>provided</U>,
that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective;
or (B)&nbsp;if the Company has effected two (2)&nbsp;registrations pursuant to <U>Subsection 2.1(b)</U>&nbsp;within the twelve (12) month
period immediately preceding the date of such request. A registration shall not be counted as &ldquo;effected&rdquo; for purposes of
this <U>Subsection 2.1(d)</U>&nbsp;until such time as the applicable registration statement has been declared effective by the SEC, unless
the Initiating Holders withdraw their request for such registration, elect not to pay the registration expenses therefor, and forfeit
their right to one (1)&nbsp;demand registration statement pursuant to <U>Subsection 2.6</U>, in which case such withdrawn registration
statement shall be counted as &ldquo;effected&rdquo; for purposes of this <U>Subsection 2.1(d).</U></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Company
Registration</U>. If the Company proposes to register (including, for this purpose, a registration effected by the Company for stockholders
other than the Holders) any of its Common Stock under the Securities Act in connection with the public offering of such securities solely
for cash (other than in an Excluded Registration), the Company shall, at such time, promptly give each Holder notice of such registration.
Upon the request of each Holder given within ten (10)&nbsp;days after such notice is given by the Company, the Company shall, subject
to the provisions of <U>Subsection 2.3</U>, cause to be registered all of the Registrable Securities that each such Holder has requested
to be included in such registration. The Company shall have the right to terminate or withdraw any registration initiated by it under
this <U>Subsection 2.2</U> before the effective date of such registration, whether or not any Holder has elected to include Registrable
Securities in such registration. The expenses (other than Selling Expenses) of such withdrawn registration shall be borne by the Company
in accordance with <U>Subsection 2.6</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Underwriting
Requirements.</U></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#8239;&#8239;(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If,
pursuant to <U>Subsection 2.1</U>, the Initiating Holders intend to distribute the Registrable Securities covered by their request by
means of an underwriting, they shall so advise the Company as a part of their request made pursuant to <U>Subsection 2.1</U>, and the
Company shall include such information in the Demand Notice. The underwriter(s)&nbsp;will be selected by the Company and shall be reasonably
acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder&rsquo;s
Registrable Securities in such registration shall be conditioned upon such Holder&rsquo;s participation in such underwriting and the
inclusion of such Holder&rsquo;s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute
their securities through such underwriting shall (together with the Company as provided in <U>Subsection 2.4(e)</U>) enter into an underwriting
agreement in customary form with the underwriter(s)&nbsp;selected for such underwriting. Notwithstanding any other provision of this
<U>Subsection 2.3,</U> if the managing underwriter(s)&nbsp;advise(s)&nbsp;the Initiating Holders in writing that marketing factors require
a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities
that otherwise would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting
shall be allocated among such Holders of Registrable Securities, including the Initiating Holders, in proportion (as nearly as practicable)
to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling
Holders; <U>provided</U>, <U>however</U>, that the number of Registrable Securities held by the Holders to be included in such underwriting
shall not be reduced unless all other securities are first entirely excluded from the underwriting.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#8239;&#8239;(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In
connection with any offering involving an underwriting of shares of the Company&rsquo;s capital stock pursuant to <U>Subsection 2.2</U>,
the Company shall not be required to include any of the Holders&rsquo; Registrable Securities in such underwriting unless the Holders
accept the terms of the underwriting as agreed upon between the Company and its underwriters, and then only in such quantity as the underwriters
in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities,
including Registrable Securities, requested by stockholders to be included in such offering exceeds the number of securities to be sold
(other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the offering,
then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities,
which the underwriters and the Company in their sole discretion determine will not jeopardize the success of the offering. If the underwriters
determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable
Securities that are included in such offering shall be allocated among the selling Holders in proportion (as nearly as practicable to)
the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all
such selling Holders. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters
may round the number of shares allocated to any Holder to the nearest one hundred (100) shares. Notwithstanding the foregoing, in no
event shall (i)&nbsp;the number of Registrable Securities included in the offering be reduced unless all other securities (other than
securities to be sold by the Company) are first entirely excluded from the offering, (ii)&nbsp;the number of Registrable Securities included
in the offering be reduced below twenty percent (20%) of the total number of securities included in such offering, unless such offering
is the IPO, in which case the selling Holders may be excluded further if the underwriters make the determination described above and
no other stockholder&rsquo;s securities are included in such offering, or (iii)&nbsp;notwithstanding <U>(ii)</U>&nbsp;above, any Registrable
Securities which are not Key Holder Registrable Securities be excluded from such underwriting unless all Key Holder Registrable Securities
are first excluded from such offering. For purposes of the provision in this <U>Subsection 2.3(b)</U>&nbsp;concerning apportionment,
for any selling Holder that is a partnership, limited liability company, or corporation, the partners, members, retired partners, retired
members, stockholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners,
members, and retired members and any trusts for the benefit of any of the foregoing Persons, shall be deemed to be a single &ldquo;selling
Holder,&rdquo; and any pro rata reduction with respect to such &ldquo;selling Holder&rdquo; shall be based upon the aggregate number
of Registrable Securities owned by all Persons included in such &ldquo;selling Holder,&rdquo; as defined in this sentence.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#8239;&#8239;(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;For
purposes of <U>Subsection 2.1</U>, a registration shall not be counted as &ldquo;effected&rdquo; if, as a result of an exercise of the
underwriter&rsquo;s cutback provisions in <U>Subsection 2.3(a)</U>, fewer than fifty percent (50%) of the total number of Registrable
Securities that Holders have requested to be included in such registration statement are actually included.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Obligations
of the Company.</U> Whenever required under this <U>Section&nbsp;1.44</U> to effect the registration of any Registrable Securities, the
Company shall, as expeditiously as reasonably possible:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#8239;&#8239;(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;prepare
and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable efforts
to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities
registered thereunder, keep such registration statement effective for a period of up to one hundred twenty (120) days or, if earlier,
until the distribution contemplated in the registration statement has been completed; <U>provided</U>, <U>however</U>, that (i)&nbsp;such
one hundred twenty (120) day period shall be extended for a period of time equal to the period the Holder refrains, at the request of
an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration, and (ii)&nbsp;in
the case of any registration of Registrable Securities on Form&nbsp;S-3 that are intended to be offered on a continuous or delayed basis,
subject to compliance with applicable SEC rules, such one hundred twenty (120) day period shall be extended for up to sixty (60) days,
if necessary, to keep the registration statement effective until all such Registrable Securities are sold;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#8239;&#8239;(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;prepare
and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in connection with such
registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered
by such registration statement;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#8239;&#8239;(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;furnish
to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities Act,
and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#8239;&#8239;(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;use
its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other securities
or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; <U>provided that</U> the Company shall
not be required to qualify to do business or to file a general consent to service of process in any such states or jurisdictions, unless
the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#8239;&#8239;(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;in
the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary
form, with the underwriter(s)&nbsp;of such offering;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#8239;&#8239;(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;use
its commercially reasonable efforts to cause all such Registrable Securities covered by such registration statement to be listed on a
national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued
by the Company are then listed;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#8239;&#8239;(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;provide
a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number for all
such Registrable Securities, in each case not later than the effective date of such registration;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#8239;&#8239;(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;promptly
make available for inspection by the selling Holders, any managing underwriter(s)&nbsp;participating in any disposition pursuant to such
registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders,
all financial and other records, pertinent corporate documents, and properties of the Company, and cause the Company&rsquo;s officers,
directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney,
accountant, or agent, in each case, as necessary or advisable to verify the accuracy of the information in such registration statement
and to conduct appropriate due diligence in connection therewith;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#8239;&#8239;(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;notify
each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been declared
effective or a supplement to any prospectus forming a part of such registration statement has been filed; and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#8239;&#8239;(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;after
such registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or supplement
such registration statement or prospectus.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the Company
shall ensure that, at all times after any registration statement covering a public offering of securities of the Company under the Securities
Act shall have become effective, its insider trading policy shall provide that the Company&rsquo;s directors may implement a trading
program under Rule&nbsp;10b5-1 of the Exchange Act.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Furnish
Information</U>. It shall be a condition precedent to the obligations of the Company to take any action pursuant to this <U>Section&nbsp;1.44
</U>with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding
itself, the Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required to
effect the registration of such Holder&rsquo;s Registrable Securities.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Expenses
of Registration</U>. All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or qualifications
pursuant to <U>Section&nbsp;1.44</U>, including all registration, filing, and qualification fees; printers&rsquo; and accounting fees;
fees and disbursements of counsel for the Company; and the reasonable fees and disbursements of one (1)&nbsp;counsel for the selling
Holders (&ldquo;<B>Selling Holder Counsel</B>&rdquo;), shall be borne and paid by the Company; <U>provided</U>, <U>however</U>, that
the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to <U>Subsection 2.1</U> if the
registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered
(in which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be
included in the withdrawn registration), unless the Holders of a majority of the Registrable Securities agree to forfeit their right
to one (1)&nbsp;registration pursuant to <U>Subsection 2.1(a)</U>&nbsp;or <U>Subsection 2.1(b)</U>, as the case may be; <U>provided further
</U>that if, at the time of such withdrawal, the Holders shall have learned of a material adverse change in the condition, business,
or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable
promptness after learning of such information, then the Holders shall not be required to pay any of such expenses and shall not forfeit
their right to one (1)&nbsp;registration pursuant to <U>Subsection 2.1(a)</U>&nbsp;or <U>Subsection 2.1(b)</U>. All Selling Expenses
relating to Registrable Securities registered pursuant to this <U>Section&nbsp;1.44</U> shall be borne and paid by the Holders pro rata
on the basis of the number of Registrable Securities registered on their behalf.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Delay
of Registration</U>. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any registration
pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of
this <U>Section&nbsp;2</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Split-Segment; Name: 1 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Indemnification</U>.
If any Registrable Securities are included in a registration statement under this <U>Section&nbsp;1.44</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To
the extent permitted by law, the Company will indemnify and hold harmless each selling Holder, and the partners, members, officers, directors,
and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities
Act) for each such Holder; and each Person, if any, who controls such Holder or underwriter within the meaning of the Securities Act
or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned
Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding
from which Damages may result, as such expenses are incurred; <U>provided, however</U>, that the indemnity agreement contained in this
<U>Subsection 2.8(a)</U>&nbsp;shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected
without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the Company be liable for any Damages
to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information
furnished by or on behalf of any such Holder, underwriter, controlling Person, or other aforementioned Person expressly for use in connection
with such registration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To
the extent permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of
its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within
the meaning of the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act),
any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other Holder,
against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance
upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with
such registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses
reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such
expenses are incurred; <U>provided, however</U>, that the indemnity agreement contained in this <U>Subsection 2.8(b)</U>&nbsp;shall not
apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Holder,
which consent shall not be unreasonably withheld; and <U>provided further</U> that in no event shall the aggregate amounts payable by
any Holder by way of indemnity or contribution under <U>Subsections 2.8(b)</U>&nbsp;and 2.8(d)&nbsp;exceed the proceeds from the offering
received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such
Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Promptly
after receipt by an indemnified party under this <U>Subsection 2.8</U> of notice of the commencement of any action (including any governmental
action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is
to be made against any indemnifying party under this <U>Subsection 2.8</U>, give the indemnifying party notice of the commencement thereof.
The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate
jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory
to the parties; <U>provided, however</U>, that an indemnified party (together with all other indemnified parties that may be represented
without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying
party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual
or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure
to give notice to the indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying
party of any liability to the indemnified party under this <U>Subsection 2.8</U>, to the extent that such failure materially prejudices
the indemnifying party&rsquo;s ability to defend such action. The failure to give notice to the indemnifying party will not relieve it
of any liability that it may have to any indemnified party otherwise than under this <U>Subsection 2.8</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To
provide for just and equitable contribution to joint liability under the Securities Act in any case in which either (i)&nbsp;any party
otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this <U>Subsection 2.8</U> but it is judicially
determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the
denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this <U>Subsection
2.8</U> provides for indemnification in such case, or (ii)&nbsp;contribution under the Securities Act may be required on the part of
any party hereto for which indemnification is provided under this <U>Subsection 2.8</U>, then, and in each such case, such parties will
contribute to the aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others)
in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in connection
with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect
any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined
by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged
omission of a material fact, relates to information supplied by the indemnifying party or by the indemnified party and the parties&rsquo;
relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; <U>provided, however</U>,
that, in any such case, (x)&nbsp;no Holder will be required to contribute any amount in excess of the public offering price of all such
Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y)&nbsp;no Person guilty of fraudulent
misrepresentation (within the meaning of Section&nbsp;11(f)&nbsp;of the Securities Act) will be entitled to contribution from any Person
who was not guilty of such fraudulent misrepresentation; and <U>provided further</U> that in no event shall a Holder&rsquo;s liability
pursuant to this <U>Subsection 2.8(d)</U>, when combined with the amounts paid or payable by such Holder pursuant to <U>Subsection 2.8(b)</U>,
exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder<B>)</B>, except in the
case of willful misconduct or fraud by such Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Notwithstanding
the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered into
in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting
agreement shall control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Unless
otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the obligations of
the Company and Holders under this <U>Subsection 2.8</U> shall survive the completion of any offering of Registrable Securities in a registration
under this <U>Section&nbsp;1.44</U>, and otherwise shall survive the termination of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Reports
Under Exchange Act</U>. With a view to making available to the Holders the benefits of SEC Rule&nbsp;144 and any other rule&nbsp;or regulation
of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a
registration on Form&nbsp;S-3, the Company shall:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;make
and keep available adequate current public information, as those terms are understood and defined in SEC Rule&nbsp;144, at all times
after the effective date of the registration statement filed by the Company for the IPO;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;use
commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company under
the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;furnish
to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i)&nbsp;to the extent accurate, a written
statement by the Company that it has complied with the reporting requirements of SEC Rule&nbsp;144 (at any time after ninety (90) days
after the effective date of the registration statement filed by the Company for the IPO), the Securities Act, and the Exchange Act (at
any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities
may be resold pursuant to Form&nbsp;S-3 (at any time after the Company so qualifies); (ii)&nbsp;a copy of the most recent annual or quarterly
report of the Company and such other reports and documents so filed by the Company; and (iii)&nbsp;such other information as may be reasonably
requested in availing any Holder of any rule&nbsp;or regulation of the SEC that permits the selling of any such securities without registration
(at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form&nbsp;S-3
(at any time after the Company so qualifies to use such form).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Limitations
on Subsequent Registration Rights</U>. From and after the date of this Agreement, the Company shall not, without the prior written consent
of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective
holder of any securities of the Company that would allow such holder or prospective holder (i)&nbsp;to include such securities in any
registration unless, under the terms of such agreement, such securities are included in such registration only to the extent that the
inclusion of such securities will not reduce the number of the Registrable Securities of the Holders that are included, except for shares
that are Exempted Securities (as defined in the Company&rsquo;s Certificate of Incorporation), or (ii)&nbsp;to initiate a demand for
registration of any securities held by such holder or prospective holder; <U>provided that</U> this limitation shall not apply (a)&nbsp;to
any additional Investor who becomes a party to this Agreement in accordance with <U>Subsection 6.9</U>, or (b)&nbsp;to the issuance of
a warrant to purchase securities of the Company to a bank, equipment lessor or other financial institution, or to a real property lessor,
in connection with a third party bona fide loan, lease or other similar financing arrangement for the benefit of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.11.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>&ldquo;Market
Stand-off&rdquo; Agreement.</U> Each Holder hereby agrees that it will not, without the prior written consent of the managing underwriter,
during the period commencing on the date of the final prospectus relating to the registration by the Company of shares of its Common
Stock or any other equity securities under the Securities Act on a registration statement on Form&nbsp;S-1 or Form&nbsp;S-3 and ending
on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180) days in the case
of the IPO, or such other period not to exceed an additional thirty-five (35) days as may be requested by the Company or an underwriter
to accommodate regulatory restrictions on (1)&nbsp;the publication or other distribution of research reports and (2)&nbsp;analyst recommendations
and opinions, including, but not limited to, the restrictions contained in applicable FINRA rules, or any successor provisions or amendments
thereto), (i)&nbsp;lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract
to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of
Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock held immediately
before the effective date of the registration statement for such offering or (ii)&nbsp;enter into any swap or other arrangement that
transfers to another, in whole or in part, any of the economic consequences of ownership of such securities, whether any such transaction
described in clause (i)&nbsp;or (ii)&nbsp;above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise.
The foregoing provisions of this <U>Subsection 2.11</U> shall apply only to the IPO, shall not apply to the sale of any shares to an
underwriter pursuant to an underwriting agreement, or the transfer of any shares to any trust for the direct or indirect benefit of the
Holder or the immediate family of the Holder, <U>provided</U> that the trustee of the trust agrees to be bound in writing by the restrictions
set forth herein, and <U>provided further</U> that any such transfer shall not involve a disposition for value, and shall be applicable
to the Holders only if all officers and directors are subject to the same restrictions and the Company uses commercially reasonable efforts
to obtain a similar agreement from all stockholders individually owning more than one percent (1%) of the Company&rsquo;s outstanding
Common Stock (after giving effect to conversion into Common Stock of all outstanding Preferred Stock). The underwriters in connection
with such registration are intended third-party beneficiaries of this <U>Subsection 2.11</U> and shall have the right, power, and authority
to enforce the provisions hereof as though they were a party hereto. Each Holder further agrees to execute such agreements as may be
reasonably requested by the underwriters in connection with such registration that are consistent with this <U>Subsection 2.11</U> or
that are necessary to give further effect thereto. Any discretionary waiver or termination of the restrictions of any or all of such
agreements by the Company or the underwriters shall apply pro rata to all Holders subject to such agreements, based on the number of
shares subject to such agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.12.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Restrictions
on Transfer</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not recognize
and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions
specified in this Agreement, which conditions are intended to ensure compliance with the provisions of the Securities Act. A transferring
Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder
to agree to take and hold such securities subject to the provisions and upon the conditions specified in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Each
certificate or instrument representing (i)&nbsp;the Preferred Stock, (ii)&nbsp;the Registrable Securities, and (iii)&nbsp;any other securities
issued in respect of the securities referenced in clauses (i)&nbsp;and (ii), upon any stock split, stock dividend, recapitalization,
merger, consolidation, or similar event, shall (unless otherwise permitted by the provisions of <U>Subsection 2.12(c)</U>) be stamped
or otherwise imprinted with a legend substantially in the following form:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">THE SECURITIES REPRESENTED
HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES MAY&nbsp;NOT BE SOLD,
PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS
OF SAID ACT.THE SECURITIES REPRESENTED HEREBY MAY&nbsp;BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY
AND THE STOCKHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Holders consent to the
Company making a notation in its records and giving instructions to any transfer agent of the Restricted Securities in order to implement
the restrictions on transfer set forth in this <U>Subsection 2.12.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
holder of each certificate representing Restricted Securities, by acceptance of ownership thereof, agrees to comply in all respects with
the provisions of this <U>Section&nbsp;1.44</U>. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there
is in effect a registration statement under the Securities Act covering the proposed transaction, the Holder thereof shall give notice
to the Company of such Holder&rsquo;s intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner
and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably requested by the Company, shall be
accompanied at such Holder&rsquo;s expense by either (i)&nbsp;a written opinion of legal counsel who shall, and whose legal opinion shall,
be reasonably satisfactory to the Company, addressed to the Company, to the effect that the proposed transaction may be effected without
registration under the Securities Act; (ii)&nbsp;a &ldquo;no action&rdquo; letter from the SEC to the effect that the proposed sale,
pledge, or transfer of such Restricted Securities without registration will not result in a recommendation by the staff of the SEC that
action be taken with respect thereto; or (iii)&nbsp;any other evidence reasonably satisfactory to counsel to the Company to the effect
that the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration under the Securities Act,
whereupon the Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such Restricted Securities in accordance
with the terms of the notice given by the Holder to the Company. The Company will not require such a legal opinion or &ldquo;no action&rdquo;
letter (x)&nbsp;in any transaction in compliance with SEC Rule&nbsp;144 or (y)&nbsp;in any transaction in which such Holder distributes
Restricted Securities to an Affiliate of such Holder for no consideration; provided that each transferee agrees in writing to be subject
to the terms of this <U>Subsection 2.12</U>. Each certificate, instrument or book entry evidencing the Restricted Securities transferred
as above provided shall bear, except if such transfer is made pursuant to SEC Rule&nbsp;144, the appropriate restrictive legend set forth
in <U>Subsection 2.12(b)</U>, except that such certificate, instrument or book entry shall not bear such restrictive legend if, in the
opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance with any provisions
of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.13.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Termination
of Registration Rights</U>. The right of any Holder to request registration or inclusion of Registrable Securities in any registration
pursuant to <U>Subsection 2.1</U> or <U>Subsection 2.2</U> shall terminate upon the earlier to occur of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
closing of a Deemed Liquidation Event, as such term is defined in the Restated Certificate;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>such
time as such Holder holds less than 1% of the Company&rsquo;s outstanding Common Stock, the Company has completed an IPO and all Registrable
Securities of the Company issuable or issued upon conversion of the shares held by and issuable to such Holder (and its Affiliates) may
be sold pursuant to Rule&nbsp;144 during any ninety (90) day period; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
five (5)&nbsp;year anniversary of the IPO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Information.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Delivery
of Financial Statements</U>. The Company shall deliver to each Major Investor:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;as
soon as practicable, but in any event within one hundred twenty (120) days after the end of each fiscal year of the Company, (i)&nbsp;a
balance sheet as of the end of such year, (ii)&nbsp;statements of income and of cash flows for such year, and (iii)&nbsp;a statement
of stockholders&rsquo; equity as of the end of such year, all such financial statements audited and certified by independent public accountants
of regionally recognized standing selected by the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>as
soon as practicable, but in any event within forty-five (45) days after the end of each of the first three (3)&nbsp;quarters of each
fiscal year of the Company, unaudited statements of income and of cash flows for such fiscal quarter, and an unaudited balance sheet
and a statement of stockholders&rsquo; equity as of the end of such fiscal quarter, all prepared in accordance with GAAP (except that
such financial statements may (i)&nbsp;be subject to normal year-end audit adjustments and (ii)&nbsp;not contain all notes thereto that
may be required in accordance with GAAP);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;as
soon as practicable, but in any event within thirty (30) days after the end of each quarter, executive summaries of the Company&rsquo;s
financial operations and activities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;as
soon as practicable, but in any event thirty (30) days before the end of each fiscal year, a budget and business plan for the next fiscal
year (collectively, the &ldquo;<B>Budget</B>&rdquo;), approved by the Board and prepared on a monthly basis, including balance sheets,
income statements, and statements of cash flow for such months and, promptly after prepared, any other budgets or revised budgets prepared
by the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;such
other information relating to the financial condition, business, prospects, or corporate affairs of the Company as any Major Investor
may from time to time reasonably request; <U>provided</U>, <U>however</U>, that the Company shall not be obligated under this <U>Subsection
3.1</U> to provide information (i)&nbsp;that the Company reasonably determines in good faith to be a trade secret or confidential information
(unless covered by an enforceable confidentiality agreement, in form acceptable to the Company); or (ii)&nbsp;the disclosure of which
would adversely affect the attorney-client privilege between the Company and its counsel; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;upon
the request of any Major Investor, unaudited statements of income and of cash flows for such month, and an unaudited balance sheet and
a statement of stockholders&rsquo; equity as of the end of such month, all prepared in accordance with GAAP (except that such financial
statements may (i)&nbsp;be subject to normal year-end audit adjustments and (ii)&nbsp;not contain all notes thereto that may be required
in accordance with GAAP).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">If, for any period, the Company
has any subsidiary whose accounts are consolidated with those of the Company, then in respect of such period the financial statements
delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such
consolidated subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Notwithstanding anything else
in this <U>Subsection 3.1</U> to the contrary, the Company may cease providing the information set forth in this <U>Subsection 3.1</U>
during the period starting with the date sixty (60) days before the Company&rsquo;s good-faith estimate of the date of filing of a registration
statement if it reasonably concludes it must do so to comply with the SEC rules&nbsp;applicable to such registration statement and related
offering; provided that the Company&rsquo;s covenants under this <U>Subsection 3.1</U> shall be reinstated at such time as the Company
is no longer actively employing its commercially reasonable efforts to cause such registration statement to become effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Inspection</U>.
The Company shall permit each Major Investor, at such Major Investor&rsquo;s expense, to visit and inspect the Company&rsquo;s properties;
examine its books of account and records; and discuss the Company&rsquo;s affairs, finances, and accounts with its officers, during normal
business hours of the Company as may be reasonably requested by the Major Investor; <U>provided</U>, <U>however</U>, that the Company
shall not be obligated pursuant to this <U>Subsection 3.2</U> to provide access to any information that it reasonably and in good faith
considers to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in form acceptable
to the Company) or the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Observer
Rights</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;So
long as (i)&nbsp;Blue Ox owns more than zero percent (0%) and less than ten percent (10%) of the shares of the Common Stock (including
shares of Common Stock issued or issuable upon conversion of Preferred Stock) it has originally purchased, which number is subject to
appropriate adjustment for all stock splits, dividends, combinations, recapitalizations and the like, and (ii)&nbsp;ATH Holding does not
have the right to appoint an observer pursuant to clause (b)&nbsp;below, the Company shall invite a representative of Blue Ox to attend
all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of
all notices, minutes, consents, and other materials that it provides to its directors; <U>provided</U>, <U>however</U>, that such representative
shall agree to hold in confidence and trust all information so provided (provided, that, notwithstanding the foregoing and for the avoidance
of doubt, nothing herein shall restrict such representative from disclosing such information to Blue Ox, subject to Section&nbsp;3.5 below);
and <U>provided further</U>, that the Company reserves the right to withhold any information and to exclude such representative from any
meeting or portion thereof if access to such information or attendance at such meeting would adversely affect the attorney-client privilege
between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest, or if such Investor or its representative
is a competitor of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 7; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;So
long as ATH Holding owns Preferred Stock, the Company shall invite a representative of ATH Holding to attend all meetings of the Board
of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents,
and other materials that it provides to its directors; <U>provided</U>, <U>however</U>, that such representative shall agree to hold in
confidence and trust all information so provided (provided, that, notwithstanding the foregoing and for the avoidance of doubt, nothing
herein shall restrict such representative from disclosing such information to ATH Holding, subject to Section&nbsp;3.5 below); <U>provided
further</U>, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion
thereof if access to such information or attendance at such meeting would adversely affect the attorney-client privilege between the Company
and its counsel or result in disclosure of trade secrets or a conflict of interest, or if ATH Holding or its representative is a competitor
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Termination
of Information and Observer Rights.</U> The covenants set forth in <U>Subsections 3.1</U>, <U>3.2</U> and <U>3.3</U> shall terminate and
be of no further force or effect (i)&nbsp;immediately before the consummation of the IPO, (ii)&nbsp;when the Company first becomes subject
to the periodic reporting requirements of Section&nbsp;12(g)&nbsp;or 15(d)&nbsp;of the Exchange Act, or (iii)&nbsp;upon a Deemed Liquidation
Event, as such term is defined in the Restated Certificate, whichever event occurs first.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Confidentiality</U>.
Each Investor agrees that such Investor will keep confidential and will not disclose, divulge, or use for any purpose (other than to
monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement
(including notice of the Company&rsquo;s intention to file a registration statement), unless such confidential information (a)&nbsp;is
known or becomes known to the public in general (other than as a result of a breach of this <U>Subsection 3.5</U> by such Investor),
(b)&nbsp;is or has been independently developed or conceived by the Investor without use of the Company&rsquo;s confidential information,
or (c)&nbsp;is or has been made known or disclosed to the Investor by a third party without a breach of any obligation of confidentiality
such third party may have to the Company; <U>provided</U>, <U>however</U>, that an Investor may disclose confidential information (i)&nbsp;to
its attorneys, accountants, consultants, and other professionals to the extent necessary to obtain their services in connection with
monitoring its investment in the Company; (ii)&nbsp;to any prospective purchaser of any Registrable Securities from such Investor, if
such prospective purchaser agrees to be bound by the provisions of this <U>Subsection 3.5</U>; (iii)&nbsp;to any existing or prospective
Affiliate, partner, member, stockholder, or wholly owned subsidiary of such Investor in the ordinary course of business, <U>provided
that</U> such Investor informs such Person that such information is confidential and directs such Person to maintain the confidentiality
of such information; or (iv)&nbsp;as may otherwise be required by law, <U>provided that</U> the Investor promptly notifies the Company
of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Rights
to Future Stock Issuances</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Right
of First Offer</U>. Subject to the terms and conditions of this <U>Subsection 4.1</U> and applicable securities laws, if the Company proposes
to offer or sell any New Securities, the Company shall first offer such New Securities to each Investor. An Investor shall be entitled
to apportion the right of first offer hereby granted to it in such proportions as it deems appropriate, among (i)&nbsp;itself, and (ii)&nbsp;its
Affiliates, <U>provided that</U>, each such Affiliate&nbsp;agrees (a)&nbsp;to enter into this Agreement and each of the Fourth Amended
and Restated Voting Agreement and Fifth Amended and Restated Right of First Refusal and Co-Sale Agreement of even date herewith among
the Company, the Investors and the other parties named therein, as an &ldquo;<B>Investor</B>&rdquo; under each such agreement, and (b)&nbsp;agrees
to purchase at least such number of New Securities as are allocable hereunder to the Investor holding the fewest number of Preferred Stock
and any other Derivative Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Company shall give notice (the &ldquo;<B>Offer Notice</B>&rdquo;) to each Investor, stating (i)&nbsp;its bona fide intention to offer
such New Securities, (ii)&nbsp;the number of such New Securities to be offered, and (iii)&nbsp;the price and terms, if any, upon which
it proposes to offer such New Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;By
notification to the Company within twenty (20) days after the Offer Notice is given, each Investor may elect to purchase or otherwise
acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals (i)&nbsp;the
proportion that the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable,
of the Preferred Stock and any other Derivative Securities then held, by such Investor bears to the total Common Stock of the Company
then outstanding (assuming full conversion and/or exercise, as applicable, of all Preferred Stock and other Derivative Securities) (the
 &ldquo;<B>Pro Rata Share</B>&rdquo;) <B><U>plus</U></B> (ii)&nbsp;to the extent any New Securities are not included in any Investor&rsquo;s
Pro Rata Share, each Investor that is a Holder of Series&nbsp;D Preferred Stock, an additional number of New Securities equal as nearly
as possible to such Investor&rsquo;s Pro Rata Share (it being the intention that Investors holding shares of Series&nbsp;D Preferred
Stock be entitled, as nearly as possible, to 200% of their Pro Rata Share). At the expiration of such twenty (20) day period, the Company
shall promptly notify each Investor that elects to purchase or acquire all the shares available to it (each, a &ldquo;<B>Fully Exercising
Investor</B>&rdquo;) of any other Investor&rsquo;s failure to do likewise. During the ten (10)&nbsp;day period commencing after the Company
has given such notice, each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition
to the number of shares specified above, up to that portion of the New Securities for which Investors were entitled to subscribe but
that were not subscribed for by the Investors (&ldquo;<B>Over Allotment Securities</B>&rdquo;) which is equal to the proportion that
the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of Preferred Stock
and any other Derivative Securities then held, by such Fully Exercising Investor bears to the Common Stock issued and held, or issuable
(directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then
held, by all Fully Exercising Investors who wish to purchase such unsubscribed shares; <U>provided</U>, <U>however</U>, that such Over
Allotment Securities shall first be allocated to Investors holding shares of Series&nbsp;D Preferred Stock until such Investors shall
have been given the opportunity to purchase 200% of their Pro Rata Share and thereafter to all Fully Exercising Investors. </FONT>The
closing of any sale pursuant to this <U>Subsection 4.1(b)</U>&nbsp;shall occur within the later of ninety (90) days of the date that
the Offer Notice is given and the date of initial sale of New Securities pursuant to <U>Subsection 4.1(c)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 9; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
all New Securities referred to in the Offer Notice are not elected to be purchased or acquired as provided in <U>Subsection 4.1(b)</U>,
the Company may, during the ninety (90) day period following the expiration of the periods provided in <U>Subsection 4.1(b)</U>, offer
and sell the remaining unsubscribed portion of such New Securities to any Person or Persons at a price not less than, and upon terms
no more favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale
of the New Securities within such period, or if such agreement is not consummated within thirty (30) days of the execution thereof, the
right provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless first reoffered to the Investors
in accordance with this <U>Subsection 4.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
right of first offer in this <U>Subsection 4.1</U> shall not be applicable to (i)&nbsp;Exempted Securities (as defined in the Restated
Certificate); (ii)&nbsp;shares of Common Stock issued in the IPO; and (iii)&nbsp;the issuance of additional shares of Preferred Stock
pursuant to the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Notwithstanding
any provision hereof to the contrary, in lieu of complying with the provisions of this <U>Subsection 4.1</U>, the Company may elect to
give notice to the Investors within thirty (30) days after the issuance of New Securities. Such notice shall describe the type, price,
and terms of the New Securities. Each Investor shall have twenty (20) days from the date notice is given to elect to purchase up to the
number of New Securities that would, if purchased by such Investor, maintain such Investor&rsquo;s percentage-ownership position, calculated
as set forth in <U>Subsection 4.1(b)</U>&nbsp;before giving effect to the issuance of such New Securities. The closing of such sale shall
occur within sixty (60) days of the date notice is given to the Investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Termination</U>.
The covenants set forth in <U>Subsection 4.1</U> shall terminate and be of no further force or effect (i)&nbsp;immediately before the
consummation of the IPO, (ii)&nbsp;when the Company first becomes subject to the periodic reporting requirements of Section&nbsp;12(g)&nbsp;or
15(d)&nbsp;of the Exchange Act, or (iii)&nbsp;upon a Deemed Liquidation Event, as such term is defined in the Restated Certificate, whichever
event occurs first and, as to each Investor, in accordance with <U>Subsection 4.1(e)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Additional
Covenants</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Insurance</U>.
If the Board so determines, the Company shall use its commercially reasonable efforts to obtain within ninety (90) days of the date hereof
Directors and Officers liability insurance and term &ldquo;key-person&rdquo; insurance on such individual or individuals designated by
the Board from financially sound and reputable insurers, each in an amount and on terms and conditions satisfactory to the Board, and
will use commercially reasonable efforts to cause such insurance policies to be maintained until such time as the Board determines that
such insurance should be discontinued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Employee
Agreements</U>. The Company will cause (i)&nbsp;each person now or hereafter employed by it or by any subsidiary (or engaged by the Company
or any subsidiary as a consultant/independent contractor) with access to confidential information and/or trade secrets to enter into
a nondisclosure and proprietary rights assignment agreement and (ii)&nbsp;each Key Employee to enter into a one (1)&nbsp;year noncompetition
and nonsolicitation agreement, substantially in the form attached hereto as <U>Exhibit&nbsp;A</U>. In addition, the Company shall not
materially amend, modify, terminate, waive, or otherwise alter, in whole or in part, any of the above-referenced agreements or any restricted
stock agreement between the Company and any employee, without the consent of at least seventy percent (70%) of the Preferred Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 10; Value: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Split-Segment; Name: 2 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Employee
Stock</U>. Unless otherwise approved by the Board , <FONT>including the Preferred Directors, </FONT>all
future employees and consultants of the Company who purchase, receive options to purchase, or receive awards of shares of the Company&rsquo;s
capital stock after the date hereof shall be required to execute restricted stock or option agreements, as applicable, providing for (i)&nbsp;vesting
of shares over a four (4)&nbsp;year period, with the first twenty-five percent (25%) of such shares vesting following one (1)&nbsp;year
of continued employment or service, and the remaining shares vesting in equal monthly installments over the following thirty-six (36)
months, and (ii)&nbsp;a <FONT>market stand-off provision substantially similar to that</FONT> in <FONT><U>Subsection
2.11</U>. In addition, unless otherwise approved by the Board, including </FONT>at least seventy percent (70%) <FONT>of
the Preferred Directors, the</FONT> Company shall retain a &ldquo;right of first refusal&rdquo; on employee transfers until the Company&rsquo;s
IPO and shall have the right to repurchase unvested shares at cost upon termination of employment of a holder of restricted stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Qualified
Small Business Stock</U>. The Company shall use commercially reasonable efforts to cause the shares of Preferred Stock issued pursuant
to the Purchase Agreement, as well as any shares into which such shares are converted, within the meaning of Section&nbsp;1202(f)&nbsp;of
the Internal Revenue Code (the &ldquo;<B>Code</B>&rdquo;), to constitute &ldquo;qualified small business stock&rdquo; as defined in Section&nbsp;1202(c)&nbsp;of
the Code; <U>provided, however</U>, that such requirement shall not be applicable if the Board determines, in its good-faith business
judgment, that such qualification is inconsistent with the best interests of the Company. The Company shall submit to its stockholders
(including the Investors) and to the Internal Revenue Service any reports that may be required under Section&nbsp;1202(d)(1)(C)&nbsp;of
the Code and the regulations promulgated thereunder. In addition, within twenty (20) business days after any Investor&rsquo;s written
request therefor, the Company shall, at its option, either (i)&nbsp;deliver to such Investor a written statement indicating whether (and
what portion of) such Investor&rsquo;s interest in the Company constitutes &ldquo;qualified small business stock&rdquo; as defined in
Section&nbsp;1202(c)&nbsp;of the Code or (ii)&nbsp;deliver to such Investor such factual information in the Company&rsquo;s possession
as is reasonably necessary to enable such Investor to determine whether (and what portion of) such Investor&rsquo;s interest in the Company
constitutes &ldquo;qualified small business stock&rdquo; as defined in Section&nbsp;1202(c)&nbsp;of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Matters
Requiring Investor Director Approval</U>. So long as the holders of Series&nbsp;A2 Preferred Stock, Series&nbsp;B Preferred Stock, Series&nbsp;C
Preferred Stock, Series&nbsp;D Preferred Stock and Series&nbsp;E Preferred Stock are entitled to elect at least one (1)&nbsp;Preferred
Director, the Company hereby covenants and agrees with each of the Investors that it shall not, without approval of the Board, which approval
must include the affirmative vote of at least two (2)&nbsp;of the Preferred Directors (or if there be only one (1)&nbsp;Preferred Director,
then the affirmative vote of the Preferred Director):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT>(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;enter
into any corporate strategic relationship involving the payment, contribution or assignment by the Company or to the Company of assets
greater than $100,000;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT>(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;approve,
adopt or modify the Budget or incur expenditures or expenses (or commit the Company to incur expenditures or expenses) not reflected in
the Budget for any particular fiscal year of the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT>(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;guarantee
any indebtedness except for trade accounts of the Company or any subsidiary arising in the ordinary course of business;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT>(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;make
any investment inconsistent with any investment policy approved by the Board;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT>(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;make,
or permit any subsidiary to make, any loan or advance to, or own any stock or other securities of, any subsidiary or other corporation,
partnership, or other entity unless it is wholly owned by the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT>(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;make,
or permit any subsidiary to make, any loan or advance to any Person, including, without limitation, any employee or director of the Company
or any subsidiary, except advances and similar expenditures in the ordinary course of business or under the terms of an employee stock
or option plan approved by the Board;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT>enter
into or become a party to any transaction with any director, officer or employee of the Company or any &ldquo;associate&rdquo; (as defined
in Rule&nbsp;12b-2 promulgated under the Exchange Act) of any such person;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT>make
any grants of equity compensation to employees or service providers of the Company; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT>hire
or terminate any member of senior management, at the Vice President and above levels, of the Company and approve salary, bonus and other
compensation or titles (or make changes thereto) for any such members of senior management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Board
Matters</U>. Unless otherwise determined by the vote of a majority of the directors then in office, the Board shall meet at least quarterly
in accordance with an agreed-upon schedule. The Company shall reimburse the nonemployee directors for all reasonable out-of-pocket travel
expenses incurred (consistent with the Company&rsquo;s travel policy) in connection with attending meetings of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Successor
Indemnification</U>. If the Company or any of its successors or assignees consolidates with or merges into any other Person and is not
the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall
be made so that the successors and assignees of the Company assume the obligations of the Company with respect to indemnification of members
of the Board as in effect immediately before such transaction, whether such obligations are contained in the Company&rsquo;s Bylaws, the
Restated Certificate, or elsewhere, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Indemnification
Matters</U>. The Company hereby acknowledges that one (1)&nbsp;or more of the directors nominated to serve on the Board by the Investors
(each a &ldquo;<B>Fund Director</B>&rdquo;) may have certain rights to indemnification, advancement of expenses and/or insurance provided
by one or more of the Investors and certain of their affiliates (collectively, the &ldquo;<B>Fund Indemnitors</B>&rdquo;).&nbsp; The Company
hereby agrees (a)&nbsp;that it is the indemnitor of first resort (<I>i.e.</I>, its obligations to any such Fund Director are primary and
any obligation of the Fund Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred
by such Fund Director are secondary), (b)&nbsp;that it shall be required to advance the full amount of expenses incurred by such Fund
Director and shall be liable for the full amount of all expenses, judgments, penalties, fines and amounts paid in settlement by or on
behalf of any such Fund Director to the extent legally permitted and as required by the Restated Certificate or the Company&rsquo;s Bylaws
(or any agreement between the Company and such Fund Director), without regard to any rights such Fund Director may have against the Fund
Indemnitors, and, (c)&nbsp;that it irrevocably waives, relinquishes and releases the Fund Indemnitors from any and all claims against
the Fund Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof.&nbsp; The Company further agrees
that no advancement or payment by the Fund Indemnitors on behalf of any such Fund Director with respect to any claim for which such Fund
Director has sought indemnification from the Company shall affect the foregoing and the Fund Indemnitors shall have a right of contribution
and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of such Fund Director against the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Fosun
Right to Conduct Activities</U>. The Company hereby agrees and acknowledges that Fosun (together with its affiliates) invests in numerous
portfolio companies, some of which may be deemed competitive with the Company&rsquo;s business (as currently conducted or as currently
propose to be conducted). The Company hereby agrees that, to the extent permitted under applicable law, Fosun shall not be liable to the
Company for any claim arising out of, or based upon, (i)&nbsp;the investment by Fosun in any entity competitive with the Company, or (ii)&nbsp;actions
taken by any partner, officer or other representative of Fosun to assist any such competitive company, whether or not such action was
taken as a member of the board of directors of such competitive company or otherwise, and whether or not such action has a detrimental
effect on the Company; provided, however, that the foregoing shall not relieve (x)&nbsp;any of the Investors from liability associated
with the unauthorized use or disclosure of the Company&rsquo;s confidential information obtained pursuant to this Agreement, or (y)&nbsp;any
director or officer of the Company from any liability associated with his or her fiduciary duties to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Blue
Ox and ATH Holding Right to Conduct Activities</U>.<B>&nbsp; </B>The Company hereby agrees and acknowledges that Blue Ox and ATH Holding
(together with the affiliates of each) invest in numerous portfolio companies, some of which may be deemed competitive with the Company&rsquo;s
business (as currently conducted or as currently propose to be conducted).&nbsp; The Company hereby agrees that, to the extent permitted
under applicable law, neither Blue Ox nor ATH Holding shall be liable to the Company for any claim arising out of, or based upon, (i)&nbsp;the
investment by Blue Ox or ATH Holding in any entity competitive with the Company, or (ii)&nbsp;actions taken by any partner, officer or
other representative of Blue Ox or ATH Holding&nbsp;to assist any such competitive company, whether or not such action was taken as a
member of the board of directors of such competitive company or otherwise, and whether or not such action has a detrimental effect on
the Company; <U>provided</U>, <U>however</U>, that the foregoing shall not relieve (x)&nbsp;any of the Investors from liability associated
with the unauthorized disclosure of the Company&rsquo;s confidential information obtained pursuant to this Agreement, or (y)&nbsp;any
director or officer of the Company from any liability associated with his or her fiduciary duties to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.11.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Termination
of Covenants</U>. The covenants set forth in this <U>Section&nbsp;5</U>, except for <U>Subsection 5.7</U>, shall terminate and be of no
further force or effect (i)&nbsp;immediately before the consummation of the IPO, (ii)&nbsp;when the Company first becomes subject to the
periodic reporting requirements of Section&nbsp;12(g)&nbsp;or 15(d)&nbsp;of the Exchange Act, or (iii)&nbsp;upon a Deemed Liquidation
Event, as such term is defined in the Restated Certificate, whichever event occurs first.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Successors
and Assigns</U>. <FONT>The rights under this Agreement</FONT> may <FONT>be</FONT>
assigned (<FONT>but only with all related obligations</FONT>) <FONT>by a
Holder to a transferee of</FONT> Registrable Securities <FONT>that (i)&nbsp;is an Affiliate of a Holder;
(ii)&nbsp;is a Holder&rsquo;s Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder&rsquo;s
Immediate Family Members; or (iii)&nbsp;after such transfer, holds at least ten percent (10%) of the outstanding shares of Registrable
Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations, and other recapitalizations) originally
held by such Holder; <U>provided</U>, <U>however</U>, that (x)&nbsp;the Company is, within a reasonable time after such transfer, furnished
with written notice of the name and address of such transferee and the Registrable Securities</FONT> with respect to <FONT>which
such</FONT> rights <FONT>are being transferred; and (y)&nbsp;such transferee agrees in</FONT> a written
instrument <FONT>delivered </FONT>to the Company to be bound by <FONT>and
subject to </FONT>the terms <FONT>and conditions </FONT>of this <FONT>Agreement,
including the provisions of <U>Subsection 2.11</U>. For the purposes of determining the number of shares of Registrable Securities held
by a transferee, the holdings of a transferee (1)&nbsp;that is an Affiliate or stockholder of a Holder; (2)&nbsp;who is a Holder&rsquo;s
Immediate Family Member; or (3)&nbsp;that is a trust for the benefit of an individual Holder or such Holder&rsquo;s Immediate Family Member
shall be aggregated together and with those of the transferring Holder; <U>provided further</U> that all transferees who would not qualify
individually for assignment of rights shall have a single attorney-in-fact for the purpose of exercising any rights, receiving notices,
or taking any action under this </FONT>Agreement. The terms and conditions of this Agreement inure to the benefit of and are binding upon
the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to confer
upon any party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations
or liabilities under or by reason of this Agreement, except as expressly provided herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Governing
Law</U>. This Agreement and any controversy arising out of or relating to this Agreement shall be governed by and construed in accordance
with the General Corporation Law of the State of Delaware as to matters within the scope thereof, and as to all other matters shall be
governed by and construed in accordance with the internal laws of the State of Delaware, without regard to its principles of conflicts
of laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Counterparts.</U>
This Agreement may be executed in two (2)&nbsp;or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument. <FONT>Counterparts may be delivered via facsimile, electronic
mail (including pdf</FONT> or any electronic signature complying with the U.S. federal ESIGN Act of 2000, <I>e.g.</I>, www.docusign.com<FONT>)
or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and
effective for all purposes<B>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Titles
and Subtitles</U>. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in construing
or interpreting this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Notices</U>.
All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given
upon the earlier of actual receipt or: (i)&nbsp;personal delivery to the party to be notified; (ii)&nbsp;when sent, if sent by electronic
mail or facsimile during the recipient&rsquo;s normal business hours, and if not sent during normal business hours, then on the recipient&rsquo;s
next business day; (iii)&nbsp;five (5)&nbsp;days after having been sent by registered or certified mail, return receipt requested, postage
prepaid; or (iv)&nbsp;one (1)&nbsp;<FONT>business </FONT>day after <FONT>the
business day of</FONT> deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day delivery, with written
verification of receipt. All communications shall be sent to the respective parties at their addresses as set forth on <U>Schedule A</U>
or <U>Schedule B</U> (as applicable) hereto, or to <FONT>the principal office of the Company and to the
attention of the Chief Executive Officer, in the case of the Company, or to </FONT>such email address, facsimile number, or address as
subsequently modified by written notice given in accordance with this <U>Subsection 6.5</U>. If notice is given to the Company, a copy
shall also be sent to Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111, Attn: Jonathan L. Kravetz
and if notice is given to Stockholders, a copy shall also be given to such counsel as may appear with such Investor&rsquo;s address on
the Schedule of Purchasers attached to the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Amendments
and Waivers</U>. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally
or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the holders of
a majority of the Registrable Securities then outstanding; <U>provided</U> that the Company may in its sole discretion waive compliance
with <U>Subsection <FONT>2.12(c)</FONT></U>&nbsp;(and the Company&rsquo;s failure to object promptly in
writing <FONT>after notification of</FONT> a proposed assignment allegedly in violation of <U>Subsection
<FONT>2.12(c)</FONT></U>&nbsp;shall be deemed to be a waiver)<FONT>; and
<U>provided further</U> that any provision hereof may be waived by any waiving party on such party&rsquo;s own behalf, without the consent
of any other party</FONT>. Notwithstanding the foregoing, this Agreement may not be amended or terminated and the observance of any term
hereof may not be waived with respect to any Investor without the written consent of such Investor, unless, other than with respect to
this <U>Section&nbsp;6.6</U> (which shall require the consent of the holders of a majority of the Registrable Securities then outstanding,
including Blue Ox so long as Blue Ox holds any Registrable Securities), such amendment, termination, or waiver applies to all Investors
in the same fashion (it being agreed that (x)&nbsp;a waiver of the provisions of <U>Section&nbsp;4</U> with respect to a particular transaction
shall be deemed to apply to all Investors in the same fashion if such waiver does so by its terms, notwithstanding the fact that certain
Investors may nonetheless, by agreement with the Company, purchase securities in such transaction and (y)&nbsp;any waiver, amendment or
termination of any provision or right set forth herein that specifically references an Investor (e.g. the provisions of Section&nbsp;5.9
and Section&nbsp;5.10) shall not be deemed to apply to all Investors in the same fashion). Further, this Agreement may not be amended,
and no provision hereof may be waived, in each case, in any way which would adversely affect the rights of the Key Holders hereunder in
a manner disproportionate to any adverse effect such amendment or waiver would have on the rights of the Investors hereunder, without
also the written consent of the holders of at least a majority of the Key Holder Registrable Securities held by the Key Holders. The Company
shall give prompt notice of any amendment or termination hereof or waiver hereunder to any party hereto that did not consent in writing
to such amendment, termination, or waiver. Any amendment, termination, or waiver effected in accordance with this <U>Subsection 6.6</U>
shall be binding on all parties hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to any
term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing
waiver of any such term, condition, or provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Severability</U>.
In case any one or more of the provisions contained in this Agreement is for any reason held to be invalid, illegal or unenforceable in
any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid,
illegal, or unenforceable provision shall be reformed and construed so that it will be valid, legal, and enforceable to the maximum extent
permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Aggregation
of Stock</U>. All shares of Registrable Securities held or acquired by Affiliates shall be aggregated together for the purpose of determining
the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any manner
they deem appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Additional
Investors</U>. Notwithstanding anything to the contrary contained herein, if the Company issues additional shares of Series&nbsp;C Preferred
Stock or Series&nbsp;E Preferred Stock after the date hereof, any purchaser of such shares of Preferred Stock may become a party to this
Agreement by executing and delivering an additional counterpart signature page&nbsp;to this Agreement, and thereafter shall be deemed
an &ldquo;Investor&rdquo; for all purposes hereunder. No action or consent by the Investors shall be required for such joinder to this
Agreement by such additional <FONT>Investor</FONT>, so long as such additional <FONT>Investor</FONT>
has agreed in writing to be bound by all of the obligations as an &ldquo;Investor&rdquo; hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Entire
Agreement</U>. This Agreement (including any Schedules and Exhibits hereto) constitutes the full and entire understanding and agreement
<FONT>among</FONT> the parties with respect to the subject matter hereof, and any other written or oral
agreement relating to the subject matter hereof existing between the parties is expressly canceled. Upon the effectiveness of this Agreement,
the Prior Agreement shall be deemed amended and restated and superseded and replaced in its entirety by this Agreement, and shall be of
no further force or effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.11.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Dispute
Resolution</U>. The parties (a)&nbsp;hereby irrevocably and unconditionally submit to the jurisdiction of the state courts of Delaware
and to the jurisdiction of the United States District Court for the District of Delaware for the purpose of any suit, action or other
proceeding arising out of or based upon this Agreement, (b)&nbsp;agree not to commence any suit, action or other proceeding arising out
of or based upon this Agreement except in the state courts of Delaware or the United States District Court for the District of Delaware,
and (c)&nbsp;hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding,
any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from
attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or
proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.12.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="text-transform: uppercase"><U>Waiver
of Jury Trial</U></FONT>. EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT
OF THIS AGREEMENT, THE OTHER TRANSACTION DOCUMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS
INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY&nbsp;BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS
TRANSACTION,&nbsp;INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER
COMMON LAW AND STATUTORY CLAIMS. THIS SECTION&nbsp;HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT
BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS
LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.13.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Delays
or Omissions</U>. No delay or omission to exercise any right, power, or remedy accruing to any party under this Agreement, upon any breach
or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting
party, nor shall it be construed to be a waiver of or acquiescence to any such breach or default, or to any similar breach or default
thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore
or thereafter occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative
and not alternative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.14.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Acknowledgment</U><FONT>.
The Company acknowledges that the Investors are in the business of venture capital investing and therefore review the business plans and
related proprietary information of many enterprises, including enterprises which may have products or services which compete directly
or indirectly with those of the Company. Nothing in this Agreement shall preclude or in any way restrict the Investors from investing
or participating in any particular enterprise whether or not such enterprise has products or services which compete with those of the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Remainder of Page&nbsp;Intentionally Left Blank]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
have executed this Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SERA PROGNOSTICS,&nbsp;INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Gregory C. Critchfield, MD, MS</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gregory C. Critchfield, MD, MS</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and Chief Executive Officer</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%">&nbsp;</TD>
    <TD STYLE="width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2749 E Parleys Way, Suite&nbsp;200</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">Salt Lake City, UT&nbsp; 84109</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT><B>SIGNATURE
PAGE TO FOURTH  AMENDED AND RESTATED INVESTORS&rsquo; RIGHTS AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
have executed this Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LEAD INVESTOR:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BLUE OX HEALTHCARE</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PARTNERS SP, LLC</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%">&nbsp;</TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ John A. Neczesny</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John A. Neczesny</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-indent: 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(print)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized Person</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 49%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">239 Dawson Rd.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hillsdale, NY 12529</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT><B>SIGNATURE
PAGE TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT><B>FOURTH
AMENDED AND RESTATED INVESTORS&rsquo; RIGHTS AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 3 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
have executed this Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%; font: bold 10pt Times New Roman, Times, Serif">LEAD INVESTOR:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">BXHCP SP II, LLC</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"> /s/ John A. Neczesny</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 46%">John A. Neczesny</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(print)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Authorized Person</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%">Address:</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">239 Dawson Rd.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Hillsdale, NY 12529</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURE PAGE TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOURTH AMENDED AND RESTATED INVESTORS&rsquo;
RIGHTS AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
have executed this Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%; font: bold 10pt Times New Roman, Times, Serif">INVESTOR:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">LABORATORY CORPORATION OF AMERICA HOLDINGS</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%">/s/ Megann Vaughn Watters</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 46%">Megann Vaughn Watters</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(print)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> VP</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%">Address:</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">Attn: Law Department</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">531 S Spring St.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Burlington, NC 27215</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 50%">If notice is given, a copy should also be sent to:</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%">Address:</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">Attn: Corporate Development</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">531 S Spring St.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Burlington, NC 27215</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURE PAGE TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FOURTH AMENDED AND RESTATED INVESTORS&rsquo;
RIGHTS AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
have executed this Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%; font: bold 10pt Times New Roman, Times, Serif">INVESTOR:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">DOMAIN PARTNERS VIII, L.P.</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="width: 47%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">One Palmer Square Associates</FONT>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VIII, L.L.C., its General Partner</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"> /s/ Lisa A. Kraeutler</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 46%">Lisa A. Kraeutler</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Attorney-in-Fact</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%">Address:</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">202 Carnegie Center</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Suite&nbsp;104</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Princeton, NJ 08540</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%; font: bold 10pt Times New Roman, Times, Serif">INVESTOR:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">DP VIII ASSOCIATES, L.P.</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By: </FONT></TD>
    <TD STYLE="width: 47%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">One Palmer Square Associates</FONT>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif">VIII, L.L.C., its General Partner</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"> /s/ Lisa A. Kraeutler</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 46%">Lisa A. Kraeutler</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Attorney-in-Fact</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%">Address:</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">202 Carnegie Center</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Suite&nbsp;104</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Princeton, NJ 08540</TD></TR>
  </TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURE PAGE TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FOURTH AMENDED AND RESTATED INVESTORS&rsquo;
RIGHTS AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
have executed this Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 50%">INVESTOR:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">INTERWEST PARTNERS X, L.P.</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%">By: InterWest Management Partners X, LLC, its General Partner</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%">/s/ Khaled A. Nasr</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 46%">Khaled A. Nasr</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(print)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Venture Member</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%">Address:</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">2710 Sand Hill Road</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Second Floor</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Menlo Park, CA 94025</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURE PAGE TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOURTH AMENDED AND RESTATED INVESTORS&rsquo;
RIGHTS AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
have executed this Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%; font: bold 10pt Times New Roman, Times, Serif">INVESTOR:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">CATALYST HEALTH VENTURES, L.P.</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%">By: CHV GP, LLC, its General Partner</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%">/s/ Joshua S. Phillips</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 46%">Joshua S. Phillips</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Manager</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%">Address:</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">50 Braintree Hill Office Park,</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Suite&nbsp;301</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Braintree,&nbsp;MA 02184</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%; font: bold 10pt Times New Roman, Times, Serif">INVESTOR:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">CATALYST HEALTH VENTURES (PF), L.P.</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%">By: CHV GP, LLC, its General Partner</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%">/s/ Joshua S. Phillips</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 46%">Joshua S. Phillips</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Manager</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%">Address:</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">50 Braintree Hill Office Park,</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Suite&nbsp;301</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Braintree,&nbsp;MA 02184</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURE PAGE TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FOURTH AMENDED AND RESTATED INVESTORS&rsquo;
RIGHTS AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
have executed this Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%; font: bold 10pt Times New Roman, Times, Serif">INVESTOR:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">CATALYST HEALTH VENTURES</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">FOLLOW-ON FUND L.P.</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%">By: CHV GP, LLC, its General Partner</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%">/s/ Joshua S. Phillips</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 46%">Joshua S. Phillips</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Manager</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%">Address:</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">50 Braintree Hill Office Park,</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Suite&nbsp;301</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Braintree,&nbsp;MA 02184</TD></TR>
  </TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%; font: bold 10pt Times New Roman, Times, Serif">INVESTOR:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">CHV INVESTMENTS LLC</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%">By: CHV III GP, LLC its Manager</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%">/s/ Joshua S. Phillips</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 46%">Joshua S. Phillips</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Manager</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%">Address:</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">50 Braintree Hill Office Park,</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Suite&nbsp;301</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Braintree,&nbsp;MA 02184</TD></TR>
  </TABLE>






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURE PAGE TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FOURTH AMENDED AND RESTATED INVESTORS&rsquo;
RIGHTS AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
have executed this Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%; font: bold 10pt Times New Roman, Times, Serif">INVESTOR:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">UPSTART LIFE SCIENCES CAPITAL, L.P.</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%">/s/ Dennis B. Farrar</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 46%">Dennis B. Farrar</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Managing Director</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%">Address:</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">417 Wakara Way, Suite&nbsp;3510</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Salt Lake City, UT 84108</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURE PAGE TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FOURTH AMENDED AND RESTATED INVESTORS&rsquo;
RIGHTS AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
have executed this Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%; font: bold 10pt Times New Roman, Times, Serif">INVESTOR:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">CHIONE LTD.</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"> /s/ Marcin Czernik</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 46%">Marcin Czernik</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(print)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Director</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%">Address:</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"> Simou Menardou 5, Kifisia Court</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Office 225</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">6015 Larnaca, Cyprus</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURE PAGE TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOURTH AMENDED AND RESTATED INVESTORS&rsquo;
RIGHTS AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Split-Segment; Name: 4 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
have executed this Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INVESTOR:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BILL&nbsp;&amp; MELINDA GATES FOUNDATION</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Vidya Vasu-Devan</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%">&nbsp;</TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vidya Vasu-Devan</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director, Strategic Investment Fund</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%">&nbsp;</TD>
    <TD STYLE="width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">P.O.&nbsp;Box 23350</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Seattle, WA 98102</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT><B>SIGNATURE
PAGE TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT><B>FOURTH
AMENDED AND RESTATED INVESTORS&rsquo; RIGHTS AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
have executed this Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INVESTOR:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GREGORY C. CRITCHFIELD, M.D., MS</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Gregory C. Critchfield, M.D., MS</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gregory C. Critchfield, M.D., MS</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%">&nbsp;</TD>
    <TD STYLE="width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6170 Murdock Woods</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holladay, UT 84121</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT><B>SIGNATURE
PAGE TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT><B>FOURTH
AMENDED AND RESTATED INVESTORS&rsquo; RIGHTS AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
have executed this Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INVESTOR:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ATH HOLDING COMPANY, LLC</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Vincent Scher</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%">&nbsp;</TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vincent Scher</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treasurer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address: </FONT></TD>
    <TD STYLE="width: 44%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ATH Holding Company, LLC</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c/o Anthem,&nbsp;Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">220 Virginia Avenue</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indianapolis,&nbsp;IN 46204</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT><B>SIGNATURE
PAGE TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT><B>FOURTH
AMENDED AND RESTATED INVESTORS&rsquo; RIGHTS AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>KEY HOLDERS:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GREGORY C. CRITCHFIELD, M.D.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%">&nbsp;</TD>
    <TD STYLE="width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Gregory C. Critchfield, M.D.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 48%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gregory C. Critchfield, M.D.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%">&nbsp;</TD>
    <TD STYLE="width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6170 Murdock Woods</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holladay, UT 84121</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DURLIN E. HICKOK, M.D.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%">&nbsp;</TD>
    <TD STYLE="width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 44%">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 48%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Durlin E. Hickok, M.D.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 44%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18009 Couch Market Road</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bend, OR 97703</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ANDREW A. SAUTER</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%">&nbsp;</TD>
    <TD STYLE="width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 44%">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 48%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Andrew A. Sauter</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; padding-right: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 7%; padding-right: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 44%; padding-right: 5.4pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3318 Whitehaven Dr.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Walnut Creek, CA 94598</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JAY BONIFACE, PhD</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%">&nbsp;</TD>
    <TD STYLE="width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 44%">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 48%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jay Boniface, PhD</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 44%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1020 South Douglas Street</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salt Lake City, UT 84105</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DOUGLAS C FISHER, MD</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%">&nbsp;</TD>
    <TD STYLE="width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 44%">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 48%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Douglas C Fisher, MD</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 44%; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">587 Patrol Road</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Woodside CA 94062</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT><B>SIGNATURE
PAGE TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT><B>FOURTH
AMENDED AND RESTATED INVESTORS&rsquo; RIGHTS AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Investors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">Blue Ox Healthcare Partners SP, LLC<BR>
135 East 57th St. 23rd Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">New York, NY 10022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">BXHCP SP II, LLC<BR>
135 East 57th St. 23rd Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">New York, NY 10022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">BXHCP SP III, LLC<BR>
135 East 57th St. 23rd Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">New York, NY 10022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">ATH Holding Company, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">c/o Anthem,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">220 Virginia Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Indianapolis,&nbsp;IN 46204</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Laboratory Corporation of America Holdings</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Attn: Law Department</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">531 S. Spring St.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Burlington, NC 27215</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Vaughm2@LabCorp.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">If notice is given, a copy should also be sent to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Attn: Corporate Development</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">531 S. Spring St.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Burlington, NC 27215</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">DP VIII Associates, L.P.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">202 Carnegie Center</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Suite&nbsp;104</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Princeton, NJ 08540</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(609) 683-5656</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(609) 683-4581 <I>fax</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">kraeutler@domainvc.vom</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Domain Partners VIII, L.P.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">202 Carnegie Center</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Suite&nbsp;104</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Princeton, NJ 08540</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(609) 683-5656</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(609) 683-4581 <I>fax</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">kraeutler@domainvc.vom</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Catalyst Health Ventures, L.P.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">50 Braintree Hill Office Park, Suite&nbsp;301</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Braintree, MA 02184</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(781) 228-5228</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(781) 228-5150 fax</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">jphillips@catalysthealthventures.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Catalyst Health Ventures (PF), L.P.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">50 Braintree Hill Office Park, Suite&nbsp;301</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Braintree, MA 02184</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(781) 228-5228</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(781) 228-5150 fax</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">jphillips@catalysthealthventures.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Catalyst Health Ventures Follow-On Fund L.P.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">50 Braintree Hill Office Park, Suite&nbsp;301</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Braintree, MA 02184</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(781) 228-5228</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(781) 228-5150 fax</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">jphillips@catalysthealthventures.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">CHV Investments LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">50 Braintree Hill Office Park, Suite&nbsp;301</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Braintree, MA 02184</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(781) 228-5228</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(781) 228-5150 fax</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">jphillips@catalysthealthventures.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">NI-LPT, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1 Elm Sq., Suite&nbsp;1B</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Andover, MA 01810</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">InterWest Partners X, L.P.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">2710 Sand Hill Road</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Suite&nbsp;200</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Menlo Park, CA 94025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Chione Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Simou Menardou 5, KIFISIA COURT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2<SUP>nd</SUP> Floor, Office 225</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">6015 Larnaca, Cyprus</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Osage University Partners I, L.P.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">50 Monument Road, Suite&nbsp;201<BR>
Bala Cynwyd, PA 19004</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">UpStart Life Sciences Capital, L.P.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">417 Wakara Way, Suite&nbsp;3510</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Salt Lake City, UT 84108</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(801) 505-0636</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(801) 505-0631 fax</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">denny@upstartvc.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Richard Novak Dynasty Trust</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">36 Church Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Greenwich, CT 06830</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Gregory C. Critchfield, MD, MS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">6170 Murdock Woods Place</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Holladay, UT 84121</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Trimble Trust</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">27342 Lost Colt Drive</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Laguna Hills, CA 92653</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Deer Ridge Consulting, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">P.O.&nbsp;Box 500</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">20 Johnson Drive</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Raritan, NJ&nbsp;&nbsp; 08869</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(</FONT>908)
252-7900</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(</FONT>908)
252-7904</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Reed Corry</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3316 E Shore Drive</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Seattle, WA 98112</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(206) 625-1292</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Email: reed@allegiant1.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Mintz, Levin, Cohn, Ferris, Glovsky and Popeo,
P.C.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">One Financial Center</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Boston, MA 02111</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(617) 542-6000</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(617) 542-2241 fax</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">jkravetz@mintz.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Steven Robert Garen Family Trust</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">c/o Eric Garen</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">11355 W. Olympic Blvd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Los Angeles, CA 90064</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Nicole Suzanne Garen Family Trust</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">c/o Eric Garen</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">11355 W. Olympic Blvd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Los Angeles, CA 90064</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Amos Madanes</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">1814 North Orleans St.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Chicago,&nbsp;IL 60614</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Deseret Foundation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">c/o Lori Piscopo</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">5121 S. Cottonwood St.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Murray, UT 84157</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Maurice J. McSweeney</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">c/o Foley&nbsp;&amp; Lardner</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">777 E. Wisconsin Ave.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Milwaukee, WI 53202</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Mark Fischer-Colbrie</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">21211 Rainbow Dr.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Cupertino, CA 95014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Bill and Melinda Gates Foundation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">P.O.&nbsp;Box 23350</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Seattle, WA 98102</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">2014 Exchange Place Fund A, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">c/o Goodwin Procter LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Attn: Finance Department</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">100 Northern Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Boston, MA 02210</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">2014 Exchange Place Fund B, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">c/o Goodwin Procter LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Attn: Finance Department</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">100 Northern Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Boston, MA 02210</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Stephen M. Davis</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">115 E. 87<SUP>th</SUP> Street, Apt. 39F</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">New York, NY 10128</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Kurt Fischer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">4192 Bay Beach Lane #892</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Fort Myers Beach, FL 33931</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Key Holders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Gregory C. Critchfield, MD, MS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">6170 Murdock Woods Place</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Holladay, UT 84121</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Durlin E. Hickok, M.D.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">18009 Couch Market Road</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Bend, OR 97703</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Andrew A. Sauter</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">3318 Whitehaven Dr.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Walnut Creek, CA 94598</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Jay Boniface, PhD</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">1020 Douglas Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Salt Lake City, UT 84105</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Douglas C Fisher, MD</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">587 Patrol Road</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Woodside, CA 94062</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nadia Altomare</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">29 Oliver Road</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Belmont, MA 02478</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Garrett Lam, MD</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1864 Mountain Crest Drive</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Draper, UT 84020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>Exhibit&nbsp;A</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Non-Solicitation
Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>16
<FILENAME>tm2110724d11_ex10-2.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SERA PROGNOSTICS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2011 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY
INCENTIVE PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(as amended March&nbsp;21, 2016 and August&nbsp;20,
2020)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase"><U>DEFINITIONS.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise specified
or unless the context otherwise requires, the following terms, as used in this Sera Prognostics. Inc. 2011 Employee, Director and Consultant
Equity Incentive Plan, have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Administrator</U></FONT>
means the Board of Directors, unless it has delegated power to act on its behalf to the Committee, in which case the Administrator means
the Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Affiliate</U></FONT>
means a corporation which, for purposes of Section&nbsp;424 of the Code, is a parent or subsidiary of the Company, direct or indirect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Agreement</U></FONT>
means an agreement between the Company and a Participant delivered pursuant to the Plan and pertaining to a Stock Right, in such form
as the Administrator shall approve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Board
of Directors</U></FONT> means the Board of Directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>California
Participant</U></FONT> means a Participant who resides in the State of California.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Cause</U></FONT>
means, with respect to a Participant (a)&nbsp;dishonesty with respect to the Company or any Affiliate, (b)&nbsp;insubordination, substantial
malfeasance or non-feasance of duty, (c)&nbsp;unauthorized disclosure of confidential information, (d)&nbsp;breach by a Participant of
any provision of any employment, consulting, advisory, nondisclosure, non-competition or similar agreement between the Participant and
the Company or any Affiliate, and (e)&nbsp;conduct substantially prejudicial to the business of the Company or any Affiliate; provided,
however, that any provision in an agreement between a Participant and the Company or an Affiliate, which contains a conflicting definition
of Cause for termination and which is in effect at the time of such termination, shall supersede this definition with respect to that
Participant. The determination of the Administrator as to the existence of Cause will be conclusive on the Participant and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Change
of Control</U></FONT> means the occurrence of any of the following events:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Merger/Sale
of Assets</I></FONT>. (A)&nbsp;A merger or consolidation of the Company whether or not approved by the Board of Directors, other than
a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing
to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or the parent of such
corporation) more than 50% of the total voting power represented by the voting securities of the Company or such surviving entity or parent
of such corporation, as the case may be, outstanding immediately after such merger or consolidation; or (B)&nbsp;the sale or disposition
by the Company of all or substantially all of the Company&rsquo;s assets in a transaction requiring stockholder approval. Change of Control
shall be interpreted, if applicable, in a manner, and limited to the extent necessary, so that it will not cause adverse tax consequences
under Section&nbsp;409A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Code</U></FONT>
means the United States Internal Revenue Code of 1986, as amended including any successor statute, regulation and guidance thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Committee</U></FONT>
means the committee of the Board of Directors to which the Board of Directors has delegated power to act under or pursuant to the provisions
of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Common
Stock</U></FONT> means shares of the Company&rsquo;s common stock, $0.0001 par value per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Company</U></FONT>
means Sera Prognostics,&nbsp;Inc., a Delaware corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Consultant</U></FONT>
means any natural person who is an advisor or consultant that provides bona fide services to the Company or its Affiliates, provided that
such services are not in connection with the offer or sale of securities in a capital raising transaction, and do not directly or indirectly
promote or maintain a market for the Company&rsquo;s or its Affiliates&rsquo; securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Disability</U></FONT>
or <U>Disabled</U> means permanent and total disability as defined in Section&nbsp;22(e)(3)&nbsp;of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Employee</U></FONT>
means any employee of the Company or of an Affiliate (including, without limitation, an employee who is also serving as an officer or
director of the Company or of an Affiliate), designated by the Administrator to be eligible to be granted one or more Stock Rights under
the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Exchange
Act</U></FONT> means the Securities Exchange Act of 1934, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Fair
Market Value</U></FONT> of a Share of Common Stock means:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">If
the Common Stock is listed on a national securities exchange or traded in the over-the-counter market and sales prices are regularly reported
for the Common Stock, the closing or, if not applicable, the last price of the Common Stock on the composite tape or other comparable
reporting system for the trading day on the applicable date and if such applicable date is not a trading day, the last market trading
day prior to such date;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">If
the Common Stock is not traded on a national securities exchange but is traded on the over-the-counter market, if sales prices are not
regularly reported for the Common Stock for the trading day referred to in clause&nbsp;(1), and if bid and asked prices for the Common
Stock are regularly reported, the mean between the bid and the asked price for the Common Stock at the close of trading in the over-the-counter
market for the trading day on which Common Stock was traded on the applicable date and if such applicable date is not a trading day,
the last market trading day prior to such date; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">If
the Common Stock is neither listed on a national securities exchange nor traded in the over-the-counter market, such value as the Administrator,
in good faith, shall determine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>ISO</U></FONT>
means an option intended to qualify as an incentive stock option under Section&nbsp;422 of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Non-Qualified
Option</U></FONT> means an option which is not intended to qualify as an ISO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Option</U></FONT>
means an ISO or Non-Qualified Option granted under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Participant</U></FONT>
means an Employee, director or Consultant of the Company or an Affiliate to whom one or more Stock Rights are granted under the Plan.
As used herein, &ldquo;Participant&rdquo; shall include &ldquo;Participant&rsquo;s Survivors&rdquo; where the context requires.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Plan</U></FONT>
means this Sera Prognostics,&nbsp;Inc. 2011 Employee, Director and Consultant Equity Incentive Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Securities
Act</U></FONT> means the Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Shares</U></FONT>
means shares of the Common Stock as to which Stock Rights have been or may be granted under the Plan or any shares of capital stock into
which the Shares are changed or for which they are exchanged within the provisions of Paragraph&nbsp;3 of the Plan. The Shares issued
under the Plan may be authorized and unissued shares or shares held by the Company in its treasury, or both.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Stock-Based
Award</U></FONT> means a grant by the Company under the Plan of an equity award or an equity based award which is not an Option or a Stock
Grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Stock
Grant</U></FONT> means a grant by the Company of Shares under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Stock
Right</U></FONT> means a right to Shares or the value of Shares of the Company granted pursuant to the Plan -- an ISO, a Non-Qualified
Option, a Stock Grant or a Stock-Based Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Survivor</U></FONT>
means a deceased Participant&rsquo;s legal representatives and/or any person or persons who acquired the Participant&rsquo;s rights to
a Stock Right by will or by the laws of descent and distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase"><U>PURPOSES OF THE PLAN.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Plan is intended to encourage
ownership of Shares by Employees and directors of and certain Consultants to the Company and its Affiliates in order to attract and retain
such people, to induce them to work for the benefit of the Company or of an Affiliate and to provide additional incentive for them to
promote the success of the Company or of an Affiliate. The Plan provides for the granting of ISOs, Non-Qualified Options, Stock Grants
and Stock-Based Awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase"><U>SHARES SUBJECT TO THE PLAN.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
number of Shares which may be issued from time to time pursuant to this Plan shall be the sum of: (i)&nbsp;<B>6,190,130</B> shares of
Common Stock and (ii)&nbsp;any shares of Common Stock that are represented by awards granted under the Company&rsquo;s 2008 Stock Incentive
Plan that are forfeited, expire or are cancelled without delivery of shares of Common Stock or which result in the forfeiture of shares
of Common Stock back to the Company on or after November&nbsp;8, 2011, or the equivalent of such number of Shares after the Administrator,
in its sole discretion, has interpreted the effect of any stock split, stock dividend, combination, recapitalization or similar transaction
in accordance with Paragraph 24 of this Plan; provided, however, that no more than 837 Shares shall be added to the Plan pursuant to subsection
(ii).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Notwithstanding
Subparagraph (a)&nbsp;above, on the first day of each fiscal year of the Company during the period beginning in fiscal year 2021, and
ending on the second day of fiscal year 2030, the number of Shares that may be issued from time to time pursuant to the Plan shall be
increased by an amount equal to the lesser of (i)&nbsp;4% of the number of fully diluted shares of the Company&rsquo;s Common Stock on
the immediately preceding December&nbsp;31, and (ii)&nbsp;an amount determined by the Administrator. Notwithstanding the foregoing, the
maximum number of Shares that may be issued as ISOs under the Plan shall be fifty million (50,000,000).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">If
an Option ceases to be &ldquo;outstanding&rdquo;, in whole or in part (other than by exercise), or if the Company shall reacquire (at
not more than its original issuance price) any Shares issued pursuant to a Stock Grant or Stock-Based Award, or if any Stock Right expires
or is forfeited, cancelled, or otherwise terminated or results in any Shares not being issued, the unissued or reacquired Shares which
were subject to such Stock Right shall again be available for issuance from time to time pursuant to this Plan. Notwithstanding the foregoing,
if a Stock Right is exercised, in whole or in part, by tender of Shares or if the Company or an Affiliate&rsquo;s tax withholding obligation
is satisfied by withholding Shares, the number of Shares deemed to have been issued under the Plan for purposes of the limitation set
forth in Paragraph 3(a)&nbsp;above shall be the number of Shares that were subject to the Stock Right or portion thereof, and not the
net number of Shares actually issued. However, in the case of ISOs, the foregoing provisions shall be subject to any limitations under
the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase"><U>ADMINISTRATION OF THE PLAN.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Administrator of the Plan
will be the Board of Directors, except to the extent the Board of Directors delegates its authority to the Committee, in which case the
Committee shall be the Administrator. Subject to the provisions of the Plan, the Administrator is authorized to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Interpret
the provisions of the Plan and all Stock Rights and to make all rules&nbsp;and determinations which it deems necessary or advisable for
the administration of the Plan;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Determine
which Employees, directors and Consultants shall be granted Stock Rights;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Determine
the number of Shares for which a Stock Right or Stock Rights shall be granted<B>;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Specify
the terms and conditions upon which a Stock Right or Stock Rights may be granted;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Amend
any term or condition of any outstanding Stock Right, including, without limitation, to reduce or increase the exercise price or purchase
price, accelerate the vesting schedule or extend the expiration date, provided that (i)&nbsp;such term or condition as amended is permitted
by the Plan; (ii)&nbsp;any such amendment shall not impair the rights of a Participant under any Stock Right previously granted without
such Participant&rsquo;s consent or in the event of death of the Participant the Participant&rsquo;s Survivors; and (iii)&nbsp;any such
amendment shall be made only after the Administrator determines whether such amendment would cause any adverse tax consequences to the
Participant, including, but not limited to, the annual vesting limitation contained in Section&nbsp;422(d)&nbsp;of the Code and described
in Paragraph 6(b)(iv)&nbsp;below with respect to ISOs and pursuant to Section&nbsp;409A of the Code;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Buy
out for a payment in cash or Shares, a Stock Right previously granted and/or cancel any such Stock Right and grant in substitution therefor
other Stock Rights, covering the same or a different number of Shares and having an exercise price or purchase price per share which may
be lower or higher than the exercise price or purchase price of the cancelled Stock Right, based on such terms and conditions as the Administrator
shall establish and the Participant shall accept; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Adopt
any sub-plans applicable to residents of any specified jurisdiction as it deems necessary or appropriate in order to comply with or take
advantage of any tax or other laws applicable to the Company, any Affiliate or to Participants or to otherwise facilitate the administration
of the Plan, which sub-plans may include additional restrictions or conditions applicable to Stock Rights or Shares issuable pursuant
to a Stock Right;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">provided, however, that all such interpretations,
rules, determinations, terms and conditions shall be made and prescribed in the context of not causing any adverse tax consequences under
Section&nbsp;409A of the Code and preserving the tax status under Section&nbsp;422 of the Code of those Options which are designated as
ISOs. Subject to the foregoing, the interpretation and construction by the Administrator of any provisions of the Plan or of any Stock
Right granted under it shall be final, unless otherwise determined by the Board of Directors, if the Administrator is the Committee. In
addition, if the Administrator is the Committee, the Board of Directors may take any action under the Plan that would otherwise be the
responsibility of the Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent permitted under
applicable law, the Board of Directors or the Committee may allocate all or any portion of its responsibilities and powers to any one
or more of its members and may delegate all or any portion of its responsibilities and powers to any other person selected by it. The
Board of Directors or the Committee may revoke any such allocation or delegation at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase"><U>ELIGIBILITY FOR PARTICIPATION.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Administrator will, in
its sole discretion, name the Participants in the Plan; provided, however, that each Participant must be an Employee, director or Consultant
of the Company or of an Affiliate at the time a Stock Right is granted. Notwithstanding the foregoing, the Administrator may authorize
the grant of a Stock Right to a person not then an Employee, director or Consultant of the Company or of an Affiliate; provided, however,
that the actual grant of such Stock Right shall be conditioned upon such person becoming eligible to become a Participant at or prior
to the time of the execution of the Agreement evidencing such Stock Right. ISOs may be granted only to Employees who are deemed to be
residents of the United States for tax purposes. Non-Qualified Options, Stock Grants and Stock-Based Awards may be granted to any Employee,
director or Consultant of the Company or an Affiliate. The granting of any Stock Right to any individual shall neither entitle that individual
to, nor disqualify him or her from, participation in any other grant of Stock Rights or any grant under any other benefit plan established
by the Company or any Affiliate for Employees, directors or Consultants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase"><U>TERMS AND CONDITIONS OF OPTIONS.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Option shall be set forth
in writing in an Option Agreement, duly executed by the Company and, to the extent required by law or requested by the Company, by the
Participant. The Administrator may provide that Options be granted subject to such terms and conditions, consistent with the terms and
conditions specifically required under this Plan, as the Administrator may deem appropriate including, without limitation, subsequent
approval by the shareholders of the Company of this Plan or any amendments thereto. The Option Agreements shall be subject to at least
the following terms and conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Non-Qualified
Options</U>: Each Option intended to be a Non-Qualified Option shall be subject to the terms and conditions which the Administrator determines
to be appropriate and in the best interest of the Company, subject to the following minimum standards for any such Non-Qualified Option:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)</FONT></TD><TD STYLE="text-align: justify"><U>Exercise Price</U>: Each Option Agreement shall state the exercise price (per share) of the Shares
covered by each Option, which exercise price shall be determined by the Administrator and shall be at least equal to the Fair Market Value
per share of Common Stock on the date of grant of the Option<B>.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ii)</FONT></TD><TD STYLE="text-align: justify"><U>Number of Shares</U>: Each Option Agreement shall state the number of Shares to which it pertains.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(iii)</FONT></TD><TD STYLE="text-align: justify"><U>Option Periods</U>: Each Option Agreement shall state the date or dates on which it first is exercisable
and the date after which it may no longer be exercised, and may provide that the Option rights accrue or become exercisable in installments
over a period of months or years, or upon the occurrence of certain conditions or the attainment of stated goals or events. For California
Participants, the exercise period of the Option set forth in the Option Agreement shall not be more than 120 months from the date of grant.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(iv)</FONT></TD><TD STYLE="text-align: justify"><U>Option Conditions</U>: Exercise of any Option may be conditioned upon the Participant&rsquo;s execution
of a Share purchase agreement in form satisfactory to the Administrator providing for certain protections for the Company and its other
shareholders, including requirements that:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">A.</FONT></TD><TD STYLE="text-align: justify">The Participant&rsquo;s or the Participant&rsquo;s Survivors&rsquo; right to sell or transfer the Shares
may be restricted; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">B.</FONT></TD><TD STYLE="text-align: justify">The Participant or the Participant&rsquo;s Survivors may be required to execute letters of investment
intent and must also acknowledge that the Shares will bear legends noting any applicable restrictions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(v)</FONT></TD><TD STYLE="text-align: justify"><U>Term of Option</U>: Each Option shall terminate not more than ten years from the date of the grant
or at such earlier time as the Option Agreement may provide.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>ISOs</U>:
Each Option intended to be an ISO shall be issued only to an Employee who is deemed to be a resident of the United States for tax purposes,
and shall be subject to the following terms and conditions, with such additional restrictions or changes as the Administrator determines
are appropriate but not in conflict with Section&nbsp;422 of the Code and relevant regulations and rulings of the Internal Revenue Service:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)</FONT></TD><TD STYLE="text-align: justify"><U>Minimum standards</U>: The ISO shall meet the minimum standards required of Non-Qualified Options,
as described in Paragraph 6(a)&nbsp;above, except clause (i)&nbsp;and (v)&nbsp;thereunder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ii)</FONT></TD><TD STYLE="text-align: justify"><U>Exercise Price</U>: Immediately before the ISO is granted, if the Participant owns, directly or by
reason of the applicable attribution rules&nbsp;in Section&nbsp;424(d)&nbsp;of the Code:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">A.</FONT></TD><TD STYLE="text-align: justify">10% <U>or less</U> of the total combined voting power of all classes of stock of the Company or an Affiliate,
the exercise price per share of the Shares covered by each ISO shall not be less than 100% of the Fair Market Value per share of the Common
Stock on the date of grant of the Option; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">B.</FONT></TD><TD STYLE="text-align: justify">More than 10% of the total combined voting power of all classes of stock of the Company or an Affiliate,
the exercise price per share of the Shares covered by each ISO shall not be less than 110% of the Fair Market Value per share of the Common
Stock on the date of grant of the Option.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(iii)</FONT></TD><TD STYLE="text-align: justify"><U>Term of Option</U>: For Participants who own:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">A.</FONT></TD><TD STYLE="text-align: justify">10% <U>or less</U> of the total combined voting power of all classes of stock of the Company or an Affiliate,
each ISO shall terminate not more than ten years from the date of the grant or at such earlier time as the Option Agreement may provide;
or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">B.</FONT></TD><TD STYLE="text-align: justify">More than 10% of the total combined voting power of all classes of stock of the Company or an Affiliate,
each ISO shall terminate not more than five years from the date of the grant or at such earlier time as the Option Agreement may provide.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(iv)</FONT></TD><TD STYLE="text-align: justify"><U>Limitation on Yearly Exercise</U>: The Option Agreements shall restrict the amount of ISOs which may
become exercisable in any calendar year (under this or any other ISO plan of the Company or an Affiliate) so that the aggregate Fair Market
Value (determined on the date each ISO is granted) of the stock with respect to which ISOs are exercisable for the first time by the Participant
in any calendar year does not exceed $100,000.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase"><U>TERMS AND CONDITIONS OF STOCK GRANTS.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Stock Grant to a Participant
shall state the principal terms in an Agreement duly executed by the Company and, to the extent required by law or requested by the Company,
by the Participant. For California Participants, each Stock Grant shall be issued within ten (10)&nbsp;years from the earlier of the date
the Plan is adopted or approved by the Company&rsquo;s shareholders. The Agreement shall be in a form approved by the Administrator and
shall contain terms and conditions which the Administrator determines to be appropriate and in the best interest of the Company, subject
to the following minimum standards:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
Agreement shall state the purchase price per share, if any, of the Shares covered by each Stock Grant, which purchase price shall be determined
by the Administrator but shall not be less than the minimum consideration required by the Delaware General Corporation Law, if any, on
the date of the grant of the Stock Grant;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
Agreement shall state the number of Shares to which the Stock Grant pertains; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
Agreement shall include the terms of any right of the Company to restrict or reacquire the Shares subject to the Stock Grant, including
the time and events upon which such rights shall accrue and the purchase price therefor, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase"><U>TERMS AND CONDITIONS OF OTHER STOCK-BASED AWARDS.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Administrator shall have
the right to grant other Stock-Based Awards based upon the Common Stock having such terms and conditions as the Administrator may determine,
including, without limitation, the grant of Shares based upon certain conditions, the grant of securities convertible into Shares and
the grant of stock appreciation rights, phantom stock awards or stock units. The principal terms of each Stock-Based Award shall be set
forth in an Agreement, duly executed by the Company and, to the extent required by law or requested by the Company, by the Participant.
The Agreement shall be in a form approved by the Administrator and shall contain terms and conditions which the Administrator determines
to be appropriate and in the best interest of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company intends that the
Plan and any Stock-Based Awards granted hereunder be exempt from the application of Section&nbsp;409A of the Code or meet the requirements
of paragraphs (2), (3)&nbsp;and (4)&nbsp;of subsection (a)&nbsp;of Section&nbsp;409A of the Code, to the extent applicable, and be operated
in accordance with Section&nbsp;409A so that any compensation deferred under any Stock-Based Award (and applicable investment earnings)
shall not be included in income under Section&nbsp;409A of the Code. Any ambiguities in the Plan shall be construed to effect the intent
as described in this Paragraph 8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase"><U>EXERCISE OF OPTIONS AND ISSUE OF SHARES.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An Option (or any part or
installment thereof) shall be exercised by giving written notice to the Company or its designee (in a form acceptable to the Administrator,
which may include electronic notice), together with provision for payment of the aggregate exercise price in accordance with this Paragraph
for the Shares as to which the Option is being exercised, and upon compliance with any other condition(s)&nbsp;set forth in the Option
Agreement. Such notice shall be signed by the person exercising the Option (which signature may be provided electronically in a form acceptable
to the Administrator), shall state the number of Shares with respect to which the Option is being exercised and shall contain any representation
required by the Plan or the Option Agreement. Payment of the exercise price for the Shares as to which such Option is being exercised
shall be made (a)&nbsp;in United States dollars in cash or by check, or (b)&nbsp;at the discretion of the Administrator, through delivery
of shares of Common Stock held for at least six months (if required to avoid negative accounting treatment) having a Fair Market Value
equal as of the date of the exercise to the aggregate cash exercise price for the number of Shares as to which the Option is being exercised,
or (c)&nbsp;at the discretion of the Administrator, by having the Company retain from the Shares otherwise issuable upon exercise of the
Option, a number of Shares having a Fair Market Value equal as of the date of exercise to the aggregate exercise price for the number
of Shares as to which the Option is being exercised, or (d)&nbsp;at the discretion of the Administrator (after consideration of applicable
securities, tax and accounting implications), by delivery of the grantee&rsquo;s personal recourse note bearing interest payable not less
than annually at no less than 100% of the applicable Federal rate, as defined in Section&nbsp;1274(d)&nbsp;of the Code, or (e)&nbsp;at
the discretion of the Administrator, in accordance with a cashless exercise program established with a securities brokerage firm, and
approved by the Administrator, or (f)&nbsp;at the discretion of the Administrator, by any combination of (a), (b), (c), (d)&nbsp;and (e)&nbsp;above
or (g)&nbsp;at the discretion of the Administrator, by payment of such other lawful consideration as the Administrator may determine.
Notwithstanding the foregoing, the Administrator shall accept only such payment on exercise of an ISO as is permitted by Section&nbsp;422
of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company shall then reasonably
promptly deliver the Shares as to which such Option was exercised to the Participant (or to the Participant&rsquo;s Survivors, as the
case may be). In determining what constitutes &ldquo;reasonably promptly,&rdquo; it is expressly understood that the issuance and delivery
of the Shares may be delayed by the Company in order to comply with any law or regulation (including, without limitation, state securities
or &ldquo;blue sky&rdquo; laws) which requires the Company to take any action with respect to the Shares prior to their issuance. The
Shares shall, upon delivery, be fully paid, non-assessable Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase"><U>PAYMENT IN CONNECTION WITH THE ISSUANCE OF STOCK GRANTS AND
STOCK-BASED AWARDS AND ISSUE OF SHARES.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any Stock Grant or Stock-Based
Award requiring payment of a purchase price for the Shares as to which such Stock Grant or Stock-Based Award is being granted shall be
made (a)&nbsp;in United States dollars in cash or by check, or (b)&nbsp;at the discretion of the Administrator, through delivery of shares
of Common Stock held for at least six months (if required to avoid negative accounting treatment) and having a Fair Market Value equal
as of the date of payment to the purchase price of the Stock Grant or Stock-Based Award, or (c)&nbsp;at the discretion of the Administrator
(after consideration of applicable securities, tax and accounting implications), by delivery of the grantee&rsquo;s personal recourse
note bearing interest payable not less than annually at no less than 100% of the applicable Federal rate, as defined in Section&nbsp;1274(d)&nbsp;of
the Code, or (d)&nbsp;at the discretion of the Administrator, by any combination of (a), (b)&nbsp;and (c)&nbsp;above; or (e)&nbsp;at the
discretion of the Administrator, by payment of such other lawful consideration as the Administrator may determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company shall when required
by the applicable Agreement, reasonably promptly deliver the Shares as to which such Stock Grant or Stock-Based Award was made to the
Participant (or to the Participant&rsquo;s Survivors, as the case may be), subject to any escrow provision set forth in the applicable
Agreement. In determining what constitutes &ldquo;reasonably promptly,&rdquo; it is expressly understood that the issuance and delivery
of the Shares may be delayed by the Company in order to comply with any law or regulation (including, without limitation, state securities
or &ldquo;blue sky&rdquo; laws) which requires the Company to take any action with respect to the Shares prior to their issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">11.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase"><U>RIGHTS AS A SHAREHOLDER.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No Participant to whom a Stock
Right has been granted shall have rights as a shareholder with respect to any Shares covered by such Stock Right except after due exercise
of an Option or issuance of Shares as set forth in any Agreement, tender of the aggregate exercise or purchase price, if any, for the
Shares being purchased and registration of the Shares in the Company&rsquo;s share register in the name of the Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">12.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase"><U>ASSIGNABILITY AND TRANSFERABILITY OF STOCK RIGHTS.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">By its terms, a Stock Right
granted to a Participant shall not be transferable by the Participant other than (i)&nbsp;by will or by the laws of descent and distribution,
or (ii)&nbsp;as approved by the Administrator in its discretion and set forth in the applicable Agreement provided that no Stock Right
may be transferred by a Participant for value. For California Participants, Stock Rights shall not be transferable by the Participant
other than by will or by the laws of descent and distribution, to a revocable trust, or as permitted by Rule&nbsp;701 of the Securities
Act. Notwithstanding the foregoing, an ISO transferred except in compliance with clause (i)&nbsp;above shall no longer qualify as an ISO.
The designation of a beneficiary of a Stock Right by a Participant, with the prior approval of the Administrator and in such form as the
Administrator shall prescribe, shall not be deemed a transfer prohibited by this Paragraph. Except as provided above during the Participant&rsquo;s
lifetime a Stock Right shall only be exercisable by or issued to such Participant (or his or her legal representative) and shall not be
assigned, pledged or hypothecated in any way (whether by operation of law or otherwise) and shall not be subject to execution, attachment
or similar process. Any attempted transfer, assignment, pledge, hypothecation or other disposition of any Stock Right or of any rights
granted thereunder contrary to the provisions of this Plan, or the levy of any attachment or similar process upon a Stock Right, shall
be null and void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">13.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase"><U>EFFECT ON OPTIONS OF TERMINATION OF SERVICE OTHER THAN FOR
CAUSE OR DEATH OR DISABILITY.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as otherwise provided
in a Participant&rsquo;s Option Agreement, in the event of a termination of service (whether as an Employee, director or Consultant) with
the Company or an Affiliate before the Participant has exercised an Option, the following rules&nbsp;apply:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">A
Participant who ceases to be an Employee, director or Consultant of the Company or of an Affiliate (for any reason other than termination
for Cause, Disability, or death for which events there are special rules&nbsp;in Paragraphs 14, 15, and 16, respectively), may exercise
any Option granted to him or her to the extent that the Option is exercisable on the date of such termination of service, but only within
such term as the Administrator has designated in a Participant&rsquo;s Option Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as provided in Subparagraph (c)&nbsp;below, or Paragraph 15 or 16, in no event may an Option intended to be an ISO, be exercised later
than three months after the Participant&rsquo;s termination of employment. For Options granted to California Participants, an Option must
be exercisable for at least thirty (30) days from the date of a Participant&rsquo;s termination of employment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
provisions of this Paragraph, and not the provisions of Paragraph 15 or 16, shall apply to a Participant who subsequently becomes Disabled
or dies after the termination of employment, director status or consultancy; provided, however, in the case of a Participant&rsquo;s Disability
or death within three months after the termination of employment, director status or consultancy, the Participant or the Participant&rsquo;s
Survivors may exercise the Option within one year after the date of the Participant&rsquo;s termination of service, but in no event after
the date of expiration of the term of the Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Notwithstanding
anything herein to the contrary, if subsequent to a Participant&rsquo;s termination of employment, termination of director status or termination
of consultancy, but prior to the exercise of an Option, the Administrator determines that, either prior or subsequent to the Participant&rsquo;s
termination, the Participant engaged in conduct which would constitute Cause, then such Participant shall forthwith cease to have any
right to exercise any Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">A
Participant to whom an Option has been granted under the Plan who is absent from the Company or an Affiliate because of temporary disability
(any disability other than a Disability as defined in Paragraph 1 hereof), or who is on leave of absence for any purpose, shall not, during
the period of any such absence, be deemed, by virtue of such absence alone, to have terminated such Participant&rsquo;s employment, director
status or consultancy with the Company or with an Affiliate, except as the Administrator may otherwise expressly provide; provided, however,
that, for ISOs, any leave of absence granted by the Administrator of greater than ninety days, unless pursuant to a contract or statute
that guarantees the right to reemployment, shall cause such ISO to become a Non-Qualified Option on the 181<SUP>st</SUP> day following
such leave of absence.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as required by law or as set forth in a Participant&rsquo;s Option Agreement, Options granted under the Plan shall not be affected by
any change of a Participant&rsquo;s status within or among the Company and any Affiliates, so long as the Participant continues to be
an Employee, director or Consultant of the Company or any Affiliate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase"><U>EFFECT ON OPTIONS OF TERMINATION OF SERVICE FOR CAUSE.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as otherwise provided
in a Participant&rsquo;s Option Agreement, the following rules&nbsp;apply if the Participant&rsquo;s service (whether as an Employee,
director or Consultant) with the Company or an Affiliate is terminated for Cause prior to the time that all his or her outstanding Options
have been exercised:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">All
outstanding and unexercised Options as of the time the Participant is notified his or her service is terminated for Cause will immediately
be forfeited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Cause
is not limited to events which have occurred prior to a Participant&rsquo;s termination of service, nor is it necessary that the Administrator&rsquo;s
finding of Cause occur prior to termination. If the Administrator determines, subsequent to a Participant&rsquo;s termination of service
but prior to the exercise of an Option, that either prior or subsequent to the Participant&rsquo;s termination the Participant engaged
in conduct which would constitute Cause, then the right to exercise any Option is forfeited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">15.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase"><U>EFFECT ON OPTIONS OF TERMINATION OF SERVICE FOR DISABILITY.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as otherwise provided
in a Participant&rsquo;s Option Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">A
Participant who ceases to be an Employee, director or Consultant of the Company or of an Affiliate by reason of Disability may exercise
any Option granted to such Participant:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)</FONT></TD><TD STYLE="text-align: justify">To the extent that the Option has become exercisable but has not been exercised on the date of the Participant&rsquo;s
termination of service due to Disability; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ii)</FONT></TD><TD STYLE="text-align: justify">In the event rights to exercise the Option accrue periodically, to the extent of a pro rata portion through
the date of the Participant&rsquo;s termination of service due to Disability of any additional vesting rights that would have accrued
on the next vesting date had the Participant not become Disabled. The proration shall be based upon the number of days accrued in the
current vesting period prior to the date of the Participant&rsquo;s termination of service due to Disability.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">A
Disabled Participant may exercise the Option only within the period ending one year after the date of the Participant&rsquo;s termination
of service due to Disability, notwithstanding that the Participant might have been able to exercise the Option as to some or all of the
Shares on a later date if the Participant had not been terminated due to Disability and had continued to be an Employee, director or Consultant
or, if earlier, within the originally prescribed term of the Option. For Options granted to California Participants, a Participant may
exercise such rights for at least six (6)&nbsp;months from the date of termination of service due to Disability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Administrator shall make the determination both of whether Disability has occurred and the date of its occurrence (unless a procedure
for such determination is set forth in another agreement between the Company and such Participant, in which case such procedure shall
be used for such determination). If requested, the Participant shall be examined by a physician selected or approved by the Administrator,
the cost of which examination shall be paid for by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">16.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase"><U>EFFECT ON OPTIONS OF DEATH WHILE AN EMPLOYEE, DIRECTOR OR CONSULTANT.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as otherwise provided
in a Participant&rsquo;s Option Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">In
the event of the death of a Participant while the Participant is an Employee, director or Consultant of the Company or of an Affiliate,
such Option may be exercised by the Participant&rsquo;s Survivors:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)</FONT></TD><TD STYLE="text-align: justify">To the extent that the Option has become exercisable but has not been exercised on the date of death;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ii)</FONT></TD><TD STYLE="text-align: justify">In the event rights to exercise the Option accrue periodically, to the extent of a pro rata portion through
the date of death of any additional vesting rights that would have accrued on the next vesting date had the Participant not died. The
proration shall be based upon the number of days accrued in the current vesting period prior to the Participant&rsquo;s date of death.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">If
the Participant&rsquo;s Survivors wish to exercise the Option, they must take all necessary steps to exercise the Option within one year
after the date of death of such Participant, notwithstanding that the decedent might have been able to exercise the Option as to some
or all of the Shares on a later date if he or she had not died and had continued to be an Employee, director or Consultant or, if earlier,
within the originally prescribed term of the Option. For Options granted to California Participants, the Participant&rsquo;s Survivors
must be allowed to take all necessary steps to exercise the Option for at least six (6)&nbsp;months from the date of death of such Participant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">17.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase"><U>EFFECT OF TERMINATION OF SERVICE ON STOCK GRANTS AND STOCK-BASED
AWARDS.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of a termination
of service (whether as an Employee, director or Consultant) with the Company or an Affiliate for any reason before the Participant has
accepted a Stock Grant or a Stock-Based Award and paid the purchase price, if required, such grant shall terminate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of this Paragraph
17 and Paragraph 18 below, a Participant to whom a Stock Grant has been issued under the Plan who is absent from work with the Company
or with an Affiliate because of temporary disability (any disability other than a Disability as defined in Paragraph 1 hereof), or who
is on leave of absence for any purpose, shall not, during the period of any such absence, be deemed, by virtue of such absence alone,
to have terminated such Participant&rsquo;s employment, director status or consultancy with the Company or with an Affiliate, except as
the Administrator may otherwise expressly provide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, for purposes
of this Paragraph 17 and Paragraph 18 below, any change of employment or other service within or among the Company and any Affiliates
shall not be treated as a termination of employment, director status or consultancy so long as the Participant continues to be an Employee,
director or Consultant of the Company or any Affiliate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">18.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase"><U>EFFECT ON STOCK GRANTS OF TERMINATION OF SERVICE OTHER THAN
FOR CAUSE OR DEATH OR DISABILITY.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as otherwise provided
in a Participant&rsquo;s Stock Grant Agreement, in the event of a termination of service (whether as an Employee, director or Consultant),
other than termination for Cause, Disability, or death for which events there are special rules&nbsp;in Paragraphs 19, 20, and 21, respectively,
before all forfeiture provisions or Company rights of repurchase shall have lapsed, then the Company shall have the right to cancel or
repurchase that number of Shares subject to a Stock Grant as to which the Company&rsquo;s forfeiture or repurchase rights have not lapsed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">19.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase"><U>EFFECT ON STOCK GRANTS OF TERMINATION OF SERVICE FOR CAUSE.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as otherwise provided
in a Participant&rsquo;s Stock Grant Agreement, the following rules&nbsp;apply if the Participant&rsquo;s service (whether as an Employee,
director or Consultant) with the Company or an Affiliate is terminated for Cause:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">All
Shares subject to any Stock Grant that remain subject to forfeiture provisions or as to which the Company shall have a repurchase right
shall be immediately forfeited to the Company as of the time the Participant is notified his or her service is terminated for Cause.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Cause
is not limited to events which have occurred prior to a Participant&rsquo;s termination of service, nor is it necessary that the Administrator&rsquo;s
finding of Cause occur prior to termination. If the Administrator determines, subsequent to a Participant&rsquo;s termination of service,
that either prior or subsequent to the Participant&rsquo;s termination the Participant engaged in conduct which would constitute Cause,
then all Shares subject to any Stock Grant that remained subject to forfeiture provisions or as to which the Company had a repurchase
right on the date of termination shall be immediately forfeited to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">20.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase"><U>EFFECT ON STOCK GRANTS OF TERMINATION OF SERVICE FOR DISABILITY.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as otherwise provided
in a Participant&rsquo;s Stock Grant Agreement, the following rules&nbsp;apply if a Participant ceases to be an Employee, director or
Consultant of the Company or of an Affiliate by reason of Disability: to the extent the forfeiture provisions or the Company&rsquo;s rights
of repurchase have not lapsed on the date of Disability, they shall be exercisable; provided, however, that in the event such forfeiture
provisions or rights of repurchase lapse periodically, such provisions or rights shall lapse to the extent of a pro rata portion of the
Shares subject to such Stock Grant through the date of Disability as would have lapsed had the Participant not become Disabled. The proration
shall be based upon the number of days accrued prior to the date of Disability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Administrator shall make
the determination both as to whether Disability has occurred and the date of its occurrence (unless a procedure for such determination
is set forth in another agreement between the Company and such Participant, in which case such procedure shall be used for such determination).
If requested, the Participant shall be examined by a physician selected or approved by the Administrator, the cost of which examination
shall be paid for by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">21.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase"><U>EFFECT ON STOCK GRANTS OF DEATH WHILE AN EMPLOYEE, DIRECTOR
OR CONSULTANT.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as otherwise provided
in a Participant&rsquo;s Stock Grant Agreement, the following rules&nbsp;apply in the event of the death of a Participant while the Participant
is an Employee, director or Consultant of the Company or of an Affiliate: to the extent the forfeiture provisions or the Company&rsquo;s
rights of repurchase have not lapsed on the date of death, they shall be exercisable; provided, however, that in the event such forfeiture
provisions or rights of repurchase lapse periodically, such provisions or rights shall lapse to the extent of a pro rata portion of the
Shares subject to such Stock Grant through the date of death as would have lapsed had the Participant not died. The proration shall be
based upon the number of days accrued prior to the Participant&rsquo;s date of death.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">22.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase"><U>PURCHASE FOR INVESTMENT.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless the offering and sale
of the Shares shall have been effectively registered under the Securities Act, the Company shall be under no obligation to issue Shares
under the Plan unless and until the following conditions have been fulfilled:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
person who receives a Stock Right shall warrant to the Company, prior to the receipt of Shares, that such person is acquiring such Shares
for his or her own account, for investment, and not with a view to, or for sale in connection with, the distribution of any such Shares,
in which event the person acquiring such Shares shall be bound by the provisions of the following legend (or a legend in substantially
similar form) which shall be endorsed upon the certificate evidencing the Shares issued pursuant to such exercise or such grant:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&ldquo;The shares represented by this
certificate have been taken for investment and they may not be sold or otherwise transferred by any person, including a pledgee, unless
(1)&nbsp;either (a)&nbsp;a Registration Statement with respect to such shares shall be effective under the Securities Act of 1933, as
amended, or (b)&nbsp;the Company shall have received an opinion of counsel satisfactory to it that an exemption from registration under
such Act is then available, and (2)&nbsp;there shall have been compliance with all applicable state securities laws.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">At
the discretion of the Administrator, the Company shall have received an opinion of its counsel that the Shares may be issued in compliance
with the Securities Act without registration thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">23.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase"><U>DISSOLUTION OR LIQUIDATION OF THE COMPANY.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the dissolution or liquidation
of the Company, all Options granted under this Plan which as of such date shall not have been exercised and all Stock Grants and Stock-Based
Awards which have not been accepted, to the extent required under the applicable Agreement, will terminate and become null and void; provided,
however, that if the rights of a Participant or a Participant&rsquo;s Survivors have not otherwise terminated and expired, the Participant
or the Participant&rsquo;s Survivors will have the right immediately prior to such dissolution or liquidation to exercise or accept any
Stock Right to the extent that the Stock Right is exercisable or subject to acceptance as of the date immediately prior to such dissolution
or liquidation. Upon the dissolution or liquidation of the Company, any outstanding Stock-Based Awards shall immediately terminate unless
otherwise determined by the Administrator or specifically provided in the applicable Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">24.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase"><U>ADJUSTMENTS.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the occurrence of any
of the following events, a Participant&rsquo;s rights with respect to any Stock Right granted to him or her hereunder shall be adjusted
as hereinafter provided, unless otherwise specifically provided in a Participant&rsquo;s Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Stock
Dividends and Stock Splits</U>. If (i)&nbsp;the shares of Common Stock shall be subdivided or combined into a greater or smaller number
of shares or if the Company shall issue any shares of Common Stock as a stock dividend on its outstanding Common Stock, or (ii)&nbsp;additional
shares or new or different shares or other securities of the Company or other non-cash assets are distributed with respect to such shares
of Common Stock, each Stock Right and the number of shares of Common Stock deliverable thereunder shall be appropriately increased or
decreased proportionately, and appropriate adjustments shall be made including, in the exercise or purchase price per share, to reflect
such events. The number of Shares subject to the limitations in Paragraph 3(a)&nbsp;shall also be proportionately adjusted upon the occurrence
of such events.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Corporate
Transactions</U>. If the Company is to be consolidated with or acquired by another entity in a merger, consolidation, or sale of all or
substantially all of the Company&rsquo;s assets other than a transaction to merely change the state of incorporation (a &ldquo;Corporate
Transaction&rdquo;), the Administrator or the board of directors of any entity assuming the obligations of the Company hereunder (the
 &ldquo;Successor Board&rdquo;), shall, as to outstanding Options, either (i)&nbsp;make appropriate provision for the continuation of such
Options by substituting on an equitable basis for the Shares then subject to such Options either the consideration payable with respect
to the outstanding shares of Common Stock in connection with the Corporate Transaction or securities of any successor or acquiring entity;
or (ii)&nbsp;upon written notice to the Participants, provide that such Options must be exercised (either (A)&nbsp;to the extent then
exercisable or, (B)&nbsp;at the discretion of the Administrator, any such Options being made partially or fully exercisable for purposes
of this Subparagraph), within a specified number of days of the date of such notice, at the end of which period such Options which have
not been exercised shall terminate; or (iii)&nbsp;terminate such Options in exchange for payment of an amount equal to the consideration
payable upon consummation of such Corporate Transaction to a holder of the number of shares of Common Stock into which such Option would
have been exercisable (either (A)&nbsp;to the extent then exercisable or, (B)&nbsp;at the discretion of the Administrator, any such Options
being made partially or fully exercisable for purposes of this Subparagraph) <U>less the aggregate</U> exercise price thereof. For purposes
of determining the payments to be made pursuant to Subclause (iii)&nbsp;above, in the case of a Corporate Transaction the consideration
for which, in whole or in part, is other than cash, the consideration other than cash shall be valued at the fair value thereof as determined
in good faith by the Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">With
respect to outstanding Stock Grants, the Administrator or the Successor Board, shall make appropriate provision for the continuation of
such Stock Grants on the same terms and conditions by substituting on an equitable basis for the Shares then subject to such Stock Grants
either the consideration payable with respect to the outstanding Shares of Common Stock in connection with the Corporate Transaction or
securities of any successor or acquiring entity. </FONT>In lieu of the foregoing, in connection with any Corporate Transaction, the Administrator
may provide that, upon consummation of the Corporate Transaction, each outstanding Stock Grant shall be terminated in exchange for payment
of an amount equal to the consideration payable upon consummation of such Corporate Transaction to a holder of the number of shares of
Common Stock comprising such Stock Grant (to the extent such Stock Grant is no longer subject to any forfeiture or repurchase rights then
in effect or, at the discretion of the Administrator, all forfeiture and repurchase rights being waived upon such Corporate Transaction).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In taking any of the actions
permitted under this Paragraph 24(b), the Administrator shall not be obligated by the Plan to treat all Stock Rights, all Stock Rights
held by a Participant, or all Stock Rights of the same type, identically.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Recapitalization
or Reorganization</U>. In the event of a recapitalization or reorganization of the Company other than a Corporate Transaction pursuant
to which securities of the Company or of another corporation are issued with respect to the outstanding shares of Common Stock, a Participant
upon exercising an Option or accepting a Stock Grant after the recapitalization or reorganization shall be entitled to receive for the
price paid upon such exercise or acceptance if any, the number of replacement securities which would have been received if such Option
had been exercised or Stock Grant accepted prior to such recapitalization or reorganization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Adjustments
to Stock-Based Awards</U>. Upon the happening of any of the events described in Subparagraphs (a), (b)&nbsp;or (c)&nbsp;above, any outstanding
Stock-Based Award shall be appropriately adjusted to reflect the events described in such Subparagraphs. The Administrator or the Successor
Board shall determine the specific adjustments to be made under this Paragraph 24, including, but not limited to the effect of any, Corporate
Transaction and, subject to Paragraph 4, its determination shall be conclusive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Modification
of Options</U>. Notwithstanding the foregoing, any adjustments made pursuant to Subparagraph (a), (b)&nbsp;or (c)&nbsp;above with respect
to Options shall be made only after the Administrator determines whether such adjustments would (i)&nbsp;constitute a &ldquo;modification&rdquo;
of any ISOs (as that term is defined in Section&nbsp;424(h)&nbsp;of the Code) or (ii)&nbsp;cause any adverse tax consequences for the
holders of Options, including, but not limited to, pursuant to Section&nbsp;409A of the Code. If the Administrator determines that such
adjustments made with respect to Options would constitute a modification or other adverse tax consequence, it may refrain from making
such adjustments, unless the holder of an Option specifically agrees in writing that such adjustment be made and such writing indicates
that the holder has full knowledge of the consequences of such &ldquo;modification&rdquo; on his or her income tax treatment with respect
to the Option. This paragraph shall not apply to the acceleration of the vesting of any ISO that would cause any portion of the ISO to
violate the annual vesting limitation contained in Section&nbsp;422(d)&nbsp;of the Code, as described in Paragraph 6(b)(iv).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">25.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase"><U>ISSUANCES OF SECURITIES.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as expressly provided
herein, no issuance by the Company of shares of stock of any class, or securities convertible into shares of stock of any class, shall
affect, and no adjustment by reason thereof shall be made with respect to, the number or price of shares subject to Stock Rights. Except
as expressly provided herein, no adjustments shall be made for dividends paid in cash or in property (including without limitation, securities)
of the Company prior to any issuance of Shares pursuant to a Stock Right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">26.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase"><U>FRACTIONAL SHARES.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No fractional shares shall
be issued under the Plan and the person exercising a Stock Right shall receive from the Company cash in lieu of such fractional shares
equal to the Fair Market Value thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">27.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase"><U>CONVERSION OF ISO</U></FONT><U>s <FONT STYLE="text-transform: uppercase">INTO
NON-QUALIFIED OPTIONS; TERMINATION OF ISO</FONT>s<FONT STYLE="text-transform: uppercase">.</FONT></U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Administrator, at the
written request of any Participant, may in its discretion take such actions as may be necessary to convert such Participant&rsquo;s ISOs
(or any portions thereof) that have not been exercised on the date of conversion into Non-Qualified Options at any time prior to the expiration
of such ISOs, regardless of whether the Participant is an Employee of the Company or an Affiliate at the time of such conversion. At the
time of such conversion, the Administrator (with the consent of the Participant) may impose such conditions on the exercise of the resulting
Non-Qualified Options as the Administrator in its discretion may determine, provided that such conditions shall not be inconsistent with
this Plan. Nothing in the Plan shall be deemed to give any Participant the right to have such Participant&rsquo;s ISOs converted into
Non-Qualified Options, and no such conversion shall occur until and unless the Administrator takes appropriate action. The Administrator,
with the consent of the Participant, may also terminate any portion of any ISO that has not been exercised at the time of such conversion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">28.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase"><U>WITHHOLDING.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that any federal,
state, or local income taxes, employment taxes, Federal Insurance Contributions Act (&ldquo;F.I.C.A.&rdquo;) withholdings or other amounts
are required by applicable law or governmental regulation to be withheld from the Participant&rsquo;s salary, wages or other remuneration
in connection with the issuance of a Stock Right or Shares under the Plan or for any other reason required by law, the Company may withhold
from the Participant&rsquo;s compensation, if any, or may require that the Participant advance in cash to the Company, or to any Affiliate
of the Company which employs or employed the Participant, the statutory minimum amount of such withholdings unless a different withholding
arrangement, including the use of shares of the Company&rsquo;s Common Stock or a promissory note, is authorized by the Administrator
(and permitted by law). For purposes hereof, the fair market value of the shares withheld for purposes of payroll withholding shall be
determined in the manner set forth under the definition of Fair Market Value provided in Paragraph 1 above, as of the most recent practicable
date prior to the date of exercise. If the Fair Market Value of the shares withheld is less than the amount of payroll withholdings required,
the Participant may be required to advance the difference in cash to the Company or the Affiliate employer. The Administrator in its discretion
may condition the exercise of an Option for less than the then Fair Market Value on the Participant&rsquo;s payment of such additional
withholding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">29.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase"><U>NOTICE TO COMPANY OF DISQUALIFYING DISPOSITION.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Employee who receives
an ISO must agree to notify the Company in writing immediately after the Employee makes a Disqualifying Disposition of any Shares acquired
pursuant to the exercise of an ISO. A Disqualifying Disposition is defined in Section&nbsp;424(c)&nbsp;of the Code and includes any disposition
(including any sale or gift) of such Shares before the later of (a)&nbsp;two years after the date the Employee was granted the ISO, or
(b)&nbsp;one year after the date the Employee acquired Shares by exercising the ISO, except as otherwise provided in Section&nbsp;424(c)&nbsp;of
the Code. If the Employee has died before such Shares are sold, these holding period requirements do not apply and no Disqualifying Disposition
can occur thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">30.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase"><U>TERMINATION OF THE PLAN.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Plan will terminate on November&nbsp;8, 2021, the date which is ten years from the <U>earlier</U> of the date of its adoption by the Board
of Directors and the date of its approval by the shareholders of the Company. The Plan may be terminated at an earlier date by vote of
the shareholders or the Board of Directors of the Company; provided, however, that any such earlier termination shall not affect any Agreements
executed prior to the effective date of such termination. </FONT>Termination of the Plan shall not affect any Stock Rights theretofore
granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">31.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase"><U>AMENDMENT OF THE PLAN AND AGREEMENTS.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Plan may be amended by
the shareholders of the Company. The Plan may also be amended by the Administrator, including, without limitation, to the extent necessary
to qualify any or all outstanding Stock Rights granted under the Plan or Stock Rights to be granted under the Plan for favorable federal
income tax treatment as may be afforded incentive stock options under Section&nbsp;422 of the Code (including deferral of taxation upon
exercise), and to the extent necessary to qualify the Shares issuable under the Plan for listing on any national securities exchange or
quotation in any national automated quotation system of securities dealers. Any amendment approved by the Administrator which the Administrator
determines is of a scope that requires shareholder approval shall be subject to obtaining such shareholder approval. Any modification
or amendment of the Plan shall not, without the consent of a Participant, adversely affect his or her rights under a Stock Right previously
granted to him or her. With the consent of the Participant affected, the Administrator may amend outstanding Agreements in a manner which
may be adverse to the Participant but which is not inconsistent with the Plan. In the discretion of the Administrator, outstanding Agreements
may be amended by the Administrator in a manner which is not adverse to the Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">32.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase"><U>EMPLOYMENT OR OTHER RELATIONSHIP.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nothing in this Plan or any
Agreement shall be deemed to prevent the Company or an Affiliate from terminating the employment, consultancy or director status of a
Participant, nor to prevent a Participant from terminating his or her own employment, consultancy or director status or to give any Participant
a right to be retained in employment or other service by the Company or any Affiliate for any period of time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">33.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase"><U>GOVERNING LAW.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Plan shall be construed
and enforced in accordance with the law of the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2.1
<SEQUENCE>17
<FILENAME>tm2110724d11_ex10d2-1.htm
<DESCRIPTION>EXHIBIT 10.2.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.2.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Option No.________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SERA PROGNOSTICS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Stock Option Grant Notice</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Stock Option Grant under the Company&rsquo;s</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2011 Employee, Director and Consultant Equity Incentive
Plan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify; width: 50%"><FONT STYLE="font-size: 10pt">Name and Address of Participant:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%">&nbsp;</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify; width: 50%"><FONT STYLE="font-size: 10pt">Date of Option Grant:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%">&nbsp;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: justify; width: 50%"><FONT STYLE="font-size: 10pt">Type
of Grant:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%">&nbsp;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="text-align: justify; width: 50%"><FONT STYLE="font-size: 10pt">Maximum Number of Shares for which
this Option is exercisable:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%">&nbsp;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="text-align: justify; width: 50%"><FONT STYLE="font-size: 10pt">Exercise (purchase) price per
share:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%">&nbsp;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 5%; text-align: left">6.</TD><TD STYLE="text-align: justify; width: 50%">Option Expiration Date:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%">&nbsp;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 5%; text-align: left">7.</TD><TD STYLE="text-align: justify; width: 50%">Vesting Start Date<SUP>1</SUP>:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%">&nbsp;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">8.</TD><TD STYLE="text-align: justify">Vesting Schedule: This Option shall become exercisable (and the Shares issued upon exercise shall be vested)
as follows provided the Participant is an Employee, director or Consultant of the Company or of an Affiliate on the applicable vesting
date:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[Insert Vesting Schedule - sample below]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; padding-right: 5.4pt; padding-left: 13.5pt; text-indent: -13.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[On the first anniversary of the Vesting Start Date</B></FONT></TD>
    <TD STYLE="width: 5%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 62%; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>up to ____________ Shares<SUP>2</SUP></B></FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1
</SUP></FONT>This date is only necessary if a company has decided to trigger vesting from a date that is different from the date of option
grant such as a hire date and is to be used a point of reference for future vesting only.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2
</SUP></FONT>If the agreement does not set forth a vesting schedule as to a specific number of shares and a % is used instead consider
adding the following to the end of the vesting schedule to address the potential vesting of fractional shares:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;provided that the number of shares vesting on each date shall
be rounded down to the nearest whole number, whilst the number of shares vesting on the final date shall be the remaining unvested balance
of the Shares.&rdquo;</P>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 13.5pt; text-indent: -13.5pt; width: 33%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>On the second anniversary of the Vesting Start Date</B></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; width: 5%">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; width: 62%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>an additional __________ Shares</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 13.5pt; text-indent: -13.5pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 13.5pt; text-indent: -13.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>On the third anniversary of the Vesting Start Date</B></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>an additional __________ Shares]</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing rights are cumulative
and are subject to the other terms and conditions of this Agreement and the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company and the Participant
acknowledge receipt of this Stock Option Grant Notice and agree to the terms of the Stock Option Agreement attached hereto and incorporated
by reference herein, the Company&rsquo;s 2011 Employee, Director and Consultant Equity Incentive Plan and the terms of this Option Grant
as set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif">SERA PROGNOSTICS,&nbsp;INC.</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 42%">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif">Participant</TD></TR>
  </TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SERA PROGNOSTICS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>STOCK OPTION AGREEMENT - INCORPORATED TERMS
AND CONDITIONS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AGREEMENT made as of the date
of grant set forth in the Stock Option Grant Notice by and between Sera Prognostics,&nbsp;Inc. (the &ldquo;Company&rdquo;), a Delaware
corporation, and the individual whose name appears on the Stock Option Grant Notice (the &ldquo;Participant&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company desires
to grant to the Participant an Option to purchase shares of its common stock, $0.0001 par value per share (the &ldquo;Shares&rdquo;),
under and for the purposes set forth in the Company&rsquo;s 2011 Employee, Director and Consultant Equity Incentive Plan (the &ldquo;Plan&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company and the
Participant understand and agree that any terms used and not defined herein have the same meanings as in the Plan; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company and the
Participant each intend that the Option granted herein shall be of the type set forth in the Stock Option Grant Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the mutual covenants hereinafter set forth and for other good and valuable consideration, the parties hereto agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><U>GRANT OF OPTION</U>.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Company hereby grants to
the Participant the right and option to purchase all or any part of an aggregate of the number of Shares set forth in the Stock Option
Grant Notice, on the terms and conditions and subject to all the limitations set forth herein, under United States securities and tax
laws, and in the Plan, which is incorporated herein by reference. The Participant acknowledges receipt of a copy of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><U>EXERCISE PRICE</U>.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The exercise price of the Shares
covered by the Option shall be the amount per Share set forth in the Stock Option Grant Notice, subject to adjustment, as provided in
the Plan, in the event of a stock split, reverse stock split or other events affecting the holders of Shares after the date hereof (the
 &ldquo;Exercise Price&rdquo;). Payment shall be made in accordance with Paragraph 9 of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><U>EXERCISABILITY OF OPTION</U>.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Subject to the terms and conditions
set forth in this Agreement and the Plan, the Option granted hereby shall become vested and exercisable as set forth in the Stock Option
Grant Notice and is subject to the other terms and conditions of this Agreement and the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><U>TERM OF OPTION</U>.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">This Option shall terminate
on the Option Expiration Date as specified in the Stock Option Grant Notice and, if this Option is designated in the Stock Option Grant
Notice as an ISO and the Participant owns as of the date hereof more than 10% of the total combined voting power of all classes of capital
stock of the Company or an Affiliate, such date may not be more than five years from the date of this Agreement, but shall be subject
to earlier termination as provided herein or in the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">If the Participant ceases to
be an Employee, director or Consultant of the Company or of an Affiliate for any reason other than the death or Disability of the Participant,
or termination of the Participant for Cause (the &ldquo;Termination Date&rdquo;), the Option to the extent then vested and exercisable
pursuant to Section&nbsp;3 hereof as of the Termination Date, and not previously terminated in accordance with this Agreement, may be
exercised within three months after the Termination Date, or on or prior to the Option Expiration Date as specified in the Stock Option
Grant Notice, whichever is earlier, but may not be exercised thereafter except as set forth below. In such event, the unvested portion
of the Option shall not be exercisable and shall expire and be cancelled on the Termination Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
this</FONT> Option is designated in the Stock Option Grant Notice as an ISO and the Participant ceases to be an Employee of the Company
or of an Affiliate but continues after termination of employment to provide service to the Company or an Affiliate as a director or Consultant,
this Option shall continue to vest in accordance with Section&nbsp;3 above as if this Option had not terminated until the Participant
is no longer providing services to the Company. In such case, this Option shall automatically convert and be deemed a Non-Qualified Option
as of the date that is three months from termination of the Participant's employment and this Option shall continue on the same terms
and conditions set forth herein until such Participant is no longer providing service to the Company or an Affiliate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Notwithstanding the foregoing,
in the event of the Participant&rsquo;s Disability or death within three months after the Termination Date, the Participant or the Participant&rsquo;s
Survivors may exercise the Option within one year after the Termination Date, but in no event after the Option Expiration Date as specified
in the Stock Option Grant Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">In the event the Participant&rsquo;s
service is terminated by the Company or an Affiliate for Cause, the Participant&rsquo;s right to exercise any unexercised portion of this
Option even if vested shall cease immediately as of the time the Participant is notified his or her service is terminated for Cause, and
this Option shall thereupon terminate. Notwithstanding anything herein to the contrary, if subsequent to the Participant&rsquo;s termination,
but prior to the exercise of the Option, the Administrator determines that, either prior or subsequent to the Participant&rsquo;s termination,
the Participant engaged in conduct which would constitute Cause, then the Participant shall immediately cease to have any right to exercise
the Option and this Option shall thereupon terminate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">In the event of the Disability
of the Participant, as determined in accordance with the Plan, the Option shall be exercisable within one year after the Participant&rsquo;s
termination of service due to Disability or, if earlier, on or prior to the Option Expiration Date as specified in the Stock Option Grant
Notice. In such event, the Option shall be exercisable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">to the extent that the Option has become exercisable but has not been exercised as of the date of the
Participant&rsquo;s termination of service due to Disability; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">in the event rights to exercise the Option accrue periodically, to the extent of a pro rata portion through
the date of the Participant&rsquo;s termination of service due to Disability of any additional vesting rights that would have accrued
on the next vesting date had the Participant not become Disabled. The proration shall be based upon the number of days accrued in the
current vesting period prior to the date of the Participant&rsquo;s termination of service due to Disability.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">In the event of the death of
the Participant while an Employee, director or Consultant of the Company or of an Affiliate, the Option shall be exercisable by the Participant&rsquo;s
Survivors within one year after the date of death of the Participant or, if earlier, on or prior to the Option Expiration Date as specified
in the Stock Option Grant Notice. In such event, the Option shall be exercisable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(x)</TD><TD STYLE="text-align: justify">to the extent that the Option has become exercisable but has not been exercised as of the date of death;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(y)</TD><TD STYLE="text-align: justify">in the event rights to exercise the Option accrue periodically, to the extent of a pro rata portion through
the date of death of any additional vesting rights that would have accrued on the next vesting date had the Participant not died. The
proration shall be based upon the number of days accrued in the current vesting period prior to the Participant&rsquo;s date of death.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><U>METHOD OF EXERCISING OPTION.</U></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Subject to the terms and conditions
of this Agreement, the Option may be exercised by written notice to the Company or its designee, in substantially the form of <U>Exhibit&nbsp;A</U>
attached hereto (or in such other form acceptable to the Company, which may include electronic notice). Such notice shall state the number
of Shares with respect to which the Option is being exercised and shall be signed by the person exercising the Option (which signature
may be provided electronically in a form acceptable to the Company). Payment of the Exercise Price for such Shares shall be made in accordance
with Paragraph 9 of the Plan. The Company shall deliver such Shares as soon as practicable after the notice shall be received, provided,
however, that the Company may delay issuance of such Shares until completion of any action or obtaining of any consent, which the Company
deems necessary under any applicable law (including, without limitation, state securities or &ldquo;blue sky&rdquo; laws). The Shares
as to which the Option shall have been so exercised shall be registered in the Company&rsquo;s share register in the name of the person
so exercising the Option (or, if the Option shall be exercised by the Participant and if the Participant shall so request in the notice
exercising the Option, shall be registered in the Company&rsquo;s share register in the name of the Participant and another person jointly,
with right of survivorship) and shall be delivered as provided above to or upon the written order of the person exercising the Option.
In the event the Option shall be exercised, pursuant to Section&nbsp;4 hereof, by any person other than the Participant, such notice shall
be accompanied by appropriate proof of the right of such person to exercise the Option. All Shares that shall be purchased upon the exercise
of the Option as provided herein shall be fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">6.</TD><TD STYLE="text-align: justify"><U>PARTIAL EXERCISE</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Exercise of this Option to the
extent above stated may be made in part at any time and from time to time within the above limits, except that no fractional share shall
be issued pursuant to this Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">7.</TD><TD STYLE="text-align: justify"><U>NON-ASSIGNABILITY</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Option shall not be transferable
by the Participant otherwise than by will or by the laws of descent and distribution. For California Participants, the Option shall not
be transferable other than by will, by the laws of descent and distribution, to a revocable trust or as permitted by Rule&nbsp;701 of
the Securities Act of 1933. If this Option is a Non-Qualified Option then it may also be transferred pursuant to a qualified domestic
relations order as defined by the Code or Title I of the Employee Retirement Income Security Act or the rules&nbsp;thereunder. Except
as provided above in this paragraph, the Option shall be exercisable, during the Participant&rsquo;s lifetime, only by the Participant
(or, in the event of legal incapacity or incompetency, by the Participant&rsquo;s guardian or representative) and shall not be assigned,
pledged or hypothecated in any way (whether by operation of law or otherwise) and shall not be subject to execution, attachment or similar
process. Any attempted transfer, assignment, pledge, hypothecation or other disposition of the Option or of any rights granted hereunder
contrary to the provisions of this Section&nbsp;7, or the levy of any attachment or similar process upon the Option shall be null and
void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">8.</TD><TD STYLE="text-align: justify"><U>NO RIGHTS AS STOCKHOLDER UNTIL EXERCISE</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Participant shall have no
rights as a stockholder with respect to Shares subject to this Agreement until registration of the Shares in the Company&rsquo;s share
register in the name of the Participant. Except as is expressly provided in the Plan with respect to certain changes in the capitalization
of the Company, no adjustment shall be made for dividends or similar rights for which the record date is prior to the date of such registration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">9.</TD><TD STYLE="text-align: justify"><U>ADJUSTMENTS</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Plan contains provisions
covering the treatment of Options in a number of contingencies such as stock splits and mergers. Provisions in the Plan for adjustment
with respect to stock subject to Options and the related provisions with respect to successors to the business of the Company are hereby
made applicable hereunder and are incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">10.</TD><TD><U>TAXES</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Participant acknowledges
and agrees that (i)&nbsp;any income or other taxes due from the Participant with respect to this Option or the Shares issuable upon exercise
of this Option shall be the Participant&rsquo;s responsibility; (ii)&nbsp;the Participant was free to use professional advisors of his
or her choice in connection with this Agreement, has received advice from his or her professional advisors in connection with this Agreement,
understands its meaning and import, and is entering into this Agreement freely and without coercion or duress; (iii)&nbsp;the Participant
has not received and is not relying upon any advice, representations or assurances made by or on behalf of the Company or any Affiliate
or any Employee of or counsel to the Company or any Affiliate regarding any tax or other effects or implications of the Option, the Shares
or other matters contemplated by this Agreement and (iv)&nbsp;neither the Administrator, the Company, its Affiliates, nor any of its officers
or directors, shall be held liable for any applicable costs, taxes, or penalties associated with the Option if, in fact, the Internal
Revenue Service were to determine that the Option constitutes deferred compensation under Section&nbsp;409A of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">If this Option is designated
in the Stock Option Grant Notice as a Non-Qualified Option or if the Option is an ISO and is converted into a Non-Qualified Option and
such Non-Qualified Option is exercised, the Participant agrees that the Company may withhold from the Participant&rsquo;s remuneration,
if any, the minimum statutory amount of federal, state and local withholding taxes attributable to such amount that is considered compensation
includable in such person&rsquo;s gross income. At the Company&rsquo;s discretion, the amount required to be withheld may be withheld
in cash from such remuneration, or in kind from the Shares otherwise deliverable to the Participant on exercise of the Option. The Participant
further agrees that, if the Company does not withhold an amount from the Participant&rsquo;s remuneration sufficient to satisfy the Company&rsquo;s
income tax withholding obligation, the Participant will reimburse the Company on demand, in cash, for the amount under-withheld.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">11.</TD><TD STYLE="text-align: justify"><U>PURCHASE FOR INVESTMENT</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Unless the offering and sale
of the Shares to be issued upon the particular exercise of the Option shall have been effectively registered under the Securities Act
of 1933, as now in force or hereafter amended (the &ldquo;1933 Act&rdquo;), the Company shall be under no obligation to issue the Shares
covered by such exercise unless the Company has determined that such exercise and issuance would be exempt from the registration requirements
of the 1933 Act and until the following conditions have been fulfilled:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The person(s)&nbsp;who exercise the Option shall warrant to the Company, at the time of such exercise,
that such person(s)&nbsp;are acquiring such Shares for their own respective accounts, for investment, and not with a view to, or for sale
in connection with, the distribution of any such Shares, in which event the person(s)&nbsp;acquiring such Shares shall be bound by the
provisions of the following legend which shall be endorsed upon any certificate(s)&nbsp;evidencing the Shares issued pursuant to such
exercise:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&ldquo;The shares represented by this
certificate have been taken for investment and they may not be sold or otherwise transferred by any person, including a pledgee, unless
(1)&nbsp;either (a)&nbsp;a Registration Statement with respect to such shares shall be effective under the Securities Act of 1933, as
amended, or (b)&nbsp;the Company shall have received an opinion of counsel satisfactory to it that an exemption from registration under
such Act is then available, and (2)&nbsp;there shall have been compliance with all applicable state securities laws;&rdquo; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">If
the Company so requires, the Company shall have received an opinion of its counsel that the Shares may be issued upon such particular
exercise in compliance with the 1933 Act without registration thereunder. Without limiting the generality of the foregoing, the Company
may delay issuance of the Shares until completion of any action or obtaining of any consent, which the Company deems necessary under any
applicable law (including without limitation state securities or &ldquo;blue sky&rdquo; laws).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.</TD><TD STYLE="text-align: justify"><U>RESTRICTIONS ON TRANSFER OF SHARES</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Shares acquired by the Participant pursuant to the exercise of the Option granted hereby shall not be transferred by the Participant except
as permitted herein and, if the Participant becomes a party thereto, as set forth in the Right of First Refusal and Co-Sale Agreement,
by and among the Company, the Investors and the Key Holders (each as defined therein) dated November&nbsp;8, 2011, as may be amended from
time to time (the &ldquo;Co-Sale Agreement&rdquo;). If the Participant becomes a party to the Co-Sale Agreement by executing a signature
page&nbsp;thereto and the terms of this Agreement and the Co-Sale Agreement conflict, the terms contained in the Co-Sale Agreement shall
govern and supersede any conflicting provision contained in this Section&nbsp;12.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">In
the event of the Participant&rsquo;s termination of service for any reason, the Company shall have the option, but not the obligation,
to repurchase all or any part of the Shares issued pursuant to this Agreement (including, without limitation, Shares purchased after termination
of service, Disability or death in accordance with Section&nbsp;4 hereof). In the event the Company does not, upon the termination of
service of the Participant (as described above), exercise its option pursuant to this Section&nbsp;12.2, the restrictions set forth in
the balance of this Agreement shall not thereby lapse, and the Participant for himself or herself, his or her heirs, legatees, executors,
administrators and other successors in interest, agrees that the Shares shall remain subject to such restrictions. The following provisions
shall apply to a repurchase under this Section&nbsp;12.2:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">The per share repurchase price of the Shares to be sold to the Company upon exercise of its option under
this Section&nbsp;12.2 shall be equal to the Fair Market Value of each such Share determined in accordance with the Plan as of the date
of repurchase provided, however, in the event of a termination by the Company for Cause, the per share repurchase price of the Shares
to be sold to the Company upon exercise of its option under this Section&nbsp;12.2 shall be equal to the lesser of the Exercise Price
and the Fair Market Value on the date of the repurchase.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">The Company&rsquo;s option to repurchase the Participant&rsquo;s Shares in the event of termination of
service shall be valid for a period of 12 months commencing with the date of such termination of service.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">In the event the Company shall be entitled to and shall elect to exercise its option to repurchase the
Participant&rsquo;s Shares under this Section&nbsp;12.2, the Company shall notify the Participant, or in case of death, his or her Survivor,
in writing of its intent to repurchase the Shares. Such written notice may be mailed by the Company up to and including the last day of
the time period provided for in Section&nbsp;12.2(ii)&nbsp;for exercise of the Company&rsquo;s option to repurchase.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">The written notice to the Participant shall specify the address at, and the time and date on, which payment
of the repurchase price is to be made (the &ldquo;Closing&rdquo;). The date specified shall not be less than ten days nor more than 60
days from the date of the mailing of the notice, and the Participant or his or her successor in interest with respect to the Shares shall
have no further rights as the owner thereof from and after the date specified in the notice. At the Closing, the repurchase price shall
be delivered to the Participant or his or her successor in interest and the Shares being purchased, duly endorsed for transfer, shall,
to the extent that they are not then in the possession of the Company, be delivered to the Company by the Participant or his or her successor
in interest.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.3</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">As
a condition precedent to the exercise of the Option, the Participant agrees that the Shares acquired pursuant to the exercise of the Option
may be subject to the Co-Sale Agreement and that certain Voting Agreement, by and among the Company, the Investors and the Key Holders
(each as defined therein), dated November&nbsp;8, 2011, as may be amended from time to time (the &ldquo;Voting Agreement&rdquo;) and agrees
to sign a counterpart signature page&nbsp;to the Co-Sale Agreement and the Voting Agreement if so requested by the Company. In addition,
it shall be a condition precedent to the validity of any sale or other transfer of any Shares by the Participant that the following restrictions
be complied with (except as otherwise set forth in this Section&nbsp;12):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">No Shares owned by the Participant may be sold, pledged or otherwise transferred (including by gift or
devise) to any person or entity, voluntarily, or by operation of law, except in accordance with the terms and conditions hereinafter set
forth.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">Before selling or otherwise transferring all or part of the Shares, the Participant shall give written
notice of such intention to the Company, which notice shall include the name of the proposed transferee, the proposed purchase price per
share, the terms of payment of such purchase price and all other matters relating to such sale or transfer and shall be accompanied by
a copy of the binding written agreement of the proposed transferee to purchase the Shares of the Participant. Such notice shall constitute
a binding offer by the Participant to sell to the Company such number of the Shares then held by the Participant as are proposed to be
sold in the notice at the monetary price per share designated in such notice, payable on the terms offered to the Participant by the proposed
transferee (provided, however, that the Company shall not be required to meet any non-monetary terms of the proposed transfer, including,
without limitation, delivery of other securities in exchange for the Shares proposed to be sold). The Company shall give written notice
to the Participant as to whether such offer has been accepted in whole by the Company within 60 days after its receipt of written notice
from the Participant. The Company may only accept such offer in whole and may not accept such offer in part. Such acceptance notice shall
fix a time, location and date for the Closing on such purchase (&ldquo;Closing Date&rdquo;) which shall not be less than ten nor more
than sixty days after the giving of the acceptance notice, provided, however, if any of the Shares to be sold pursuant to this Section&nbsp;12.3
have been held by the Participant for less than six months, then the Closing Date may be extended by the Company until no more than ten
days after such Shares have been held by the Participant for six months if required under applicable accounting rules&nbsp;in effect at
the time. The place for such Closing shall be at the Company&rsquo;s principal office. At such Closing, the Participant shall accept payment
as set forth herein and shall deliver to the Company in exchange therefor certificates for the number of Shares stated in the notice accompanied
by duly executed instruments of transfer.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">If the Company shall fail to accept any such offer, the Participant shall be free to sell all, but not
less than all, of the Shares set forth in his or her notice to the designated transferee at the price and terms designated in the Participant&rsquo;s
notice, provided that (i)&nbsp;such sale is consummated within six months after the giving of notice by the Participant to the Company
as aforesaid, and (ii)&nbsp;the transferee first agrees in writing to be bound by the provisions of this Section&nbsp;12 so that such
transferee (and all subsequent transferees) shall thereafter only be permitted to sell or transfer the Shares in accordance with the terms
hereof. After the expiration of such six months, the provisions of this Section&nbsp;12.3 shall again apply with respect to any proposed
voluntary transfer of the Participant&rsquo;s Shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">The restrictions on transfer contained in this Section&nbsp;12.3 shall not apply to (a)&nbsp;transfers
by the Participant to his or her spouse or children or to a trust for the benefit of his or her spouse or children, (b)&nbsp;transfers
by the Participant to his or her guardian or conservator, and (c)&nbsp;transfers by the Participant, in the event of his or her death,
to his or her executor(s)&nbsp;or administrator(s)&nbsp;or to trustee(s)&nbsp;under his or her will (collectively, &ldquo;Permitted Transferees&rdquo;);
provided however, that in any such event the Shares so transferred in the hands of each such Permitted Transferee shall remain subject
to this Agreement, and each such Permitted Transferee shall so acknowledge in writing as a condition precedent to the effectiveness of
such transfer.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">The provisions of this Section&nbsp;12.3 may be waived by the Company. Any such waiver may be unconditional
or based upon such conditions as the Company may impose.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.4</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">In
the event that the Participant or his or her successor in interest fails to deliver the Shares to be repurchased by the Company under
this Agreement, the Company may elect (a)&nbsp;to establish a segregated account in the amount of the repurchase price, such account to
be turned over to the Participant or his or her successor in interest upon delivery of such Shares, and (b)&nbsp;immediately to take such
action as is appropriate to transfer record title of such Shares from the Participant to the Company and to treat the Participant and
such Shares in all respects as if delivery of such Shares had been made as required by this Agreement. The Participant hereby irrevocably
grants the Company a power of attorney which shall be coupled with an interest for the purpose of effectuating the preceding sentence.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.5</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">If
the Company shall pay a stock dividend or declare a stock split on or with respect to any of its Common Stock, or otherwise distribute
securities of the Company to the holders of its Common Stock, the number of shares of stock or other securities of the Company issued
with respect to the shares then subject to the restrictions contained in this Agreement shall be added to the Shares subject to the Company&rsquo;s
rights to repurchase pursuant to this Agreement. If the Company shall distribute to its stockholders shares of stock of another corporation,
the shares of stock of such other corporation, distributed with respect to the Shares then subject to the restrictions contained in this
Agreement, shall be added to the Shares subject to the Company&rsquo;s rights to repurchase pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.6</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">If
the outstanding shares of Common Stock of the Company shall be subdivided into a greater number of shares or combined into a smaller number
of shares, or in the event of a reclassification of the outstanding shares of Common Stock of the Company, or if the Company shall be
a party to a merger, consolidation or capital reorganization, there shall be substituted for the Shares then subject to the restrictions
contained in this Agreement such amount and kind of securities as are issued in such subdivision, combination, reclassification, merger,
consolidation or capital reorganization in respect of the Shares subject immediately prior thereto to the Company&rsquo;s rights to repurchase
pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.7</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company shall not be required to transfer any Shares on its books which shall have been sold, assigned or otherwise transferred in violation
of this Agreement, or to treat as owner of such Shares, or to accord the right to vote as such owner or to pay dividends to, any person
or organization to which any such Shares shall have been so sold, assigned or otherwise transferred, in violation of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.8</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
provisions of Sections 12.1, 12.2 and 12.3 shall terminate upon the effective date of the registration of the Shares pursuant to the Securities
Exchange Act of 1934.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.9</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Participant agrees that in the event the Company proposes to offer for sale to the public any of its equity securities and such Participant
is requested by the Company and any underwriter engaged by the Company in connection with such offering to sign an agreement restricting
the sale or other transfer of Shares, then it will promptly sign such agreement and will not transfer, whether in privately negotiated
transactions or to the public in open market transactions or otherwise, any Shares or other securities of the Company held by him or her
during such period as is determined by the Company and the underwriters, not to exceed 180 days following the closing of the offering,
plus such additional period of time as may be required to comply with NASD Rule&nbsp;2711 or similar rules&nbsp;thereto (such period,
the &ldquo;Lock-Up Period&rdquo;). Such agreement shall be in writing and in form and substance reasonably satisfactory to the Company
and such underwriter and pursuant to customary and prevailing terms and conditions. Notwithstanding whether the Participant has signed
such an agreement, the Company may impose stop-transfer instructions with respect to the Shares or other securities of the Company subject
to the foregoing restrictions until the end of the Lock-Up Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.10</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Participant acknowledges and agrees that neither the Company, its shareholders nor its directors and officers, has any duty or obligation
to disclose to the Participant any material information regarding the business of the Company or affecting the value of the Shares before,
at the time of, or following a termination of the service of the Participant by the Company, including, without limitation, any information
concerning plans for the Company to make a public offering of its securities or to be acquired by or merged with or into another firm
or entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.11</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">All
certificates representing the Shares to be issued to the Participant pursuant to this Agreement shall have endorsed thereon a legend substantially
as follows: &ldquo;The shares represented by this certificate are subject to restrictions set forth in a Stock Option Agreement dated
_________, 201__ with this Company, a copy of which Agreement is available for inspection at the offices of the Company or will be made
available upon request.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">13.</TD><TD STYLE="text-align: justify"><U>NO OBLIGATION TO MAINTAIN RELATIONSHIP</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Participant acknowledges
that: (i)&nbsp;the Company is not by the Plan or this Option obligated to continue the Participant as an Employee, director or Consultant
of the Company or an Affiliate; (ii)&nbsp;the Plan is discretionary in nature and may be suspended or terminated by the Company at any
time; (iii)&nbsp;the grant of the Option is a one-time benefit which does not create any contractual or other right to receive future
grants of options, or benefits in lieu of options; (iv)&nbsp;all determinations with respect to any such future grants, including, but
not limited to, the times when options shall be granted, the number of shares subject to each option, the option price, and the time or
times when each option shall be exercisable, will be at the sole discretion of the Company; (v)&nbsp;the Participant&rsquo;s participation
in the Plan is voluntary; (vi)&nbsp;the value of the Option is an extraordinary item of compensation which is outside the scope of the
Participant&rsquo;s employment or consulting contract, if any; and (vii)&nbsp;the Option is not part of normal or expected compensation
for purposes of calculating any severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or
retirement benefits or similar payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">14.</TD><TD STYLE="text-align: justify"><U>IF OPTION IS INTENDED TO BE AN ISO</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">If this Option is designated
in the Stock Option Grant Notice as an ISO so that the Participant (or the Participant&rsquo;s Survivors) may qualify for the favorable
tax treatment provided to holders of Options that meet the standards of Section&nbsp;422 of the Code then any provision of this Agreement
or the Plan which conflicts with the Code so that this Option would not be deemed an ISO is null and void and any ambiguities shall be
resolved so that the Option qualifies as an ISO. The Participant should consult with the Participant&rsquo;s own tax advisors regarding
the tax effects of the Option and the requirements necessary to obtain favorable tax treatment under Section&nbsp;422 of the Code, including,
but not limited to, holding period requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notwithstanding
the foregoing, to the extent that the Option i</FONT>s designated in the Stock Option Grant Notice as an ISO and is not deemed to be
an ISO pursuant to Section&nbsp;422(d)&nbsp;of the Code because the aggregate Fair Market Value (determined as of the Date of Option
Grant) of any of the Shares with respect to which this ISO is granted becomes exercisable for the first time during any calendar year
in excess of $100,000, the portion of the Option representing such excess value shall be treated as a Non-Qualified Option and the Participant
shall be deemed to have taxable income measured by the difference between the then Fair Market Value of the Shares received upon exercise
and the price paid for such Shares pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Neither the Company nor any
Affiliate shall have any liability to the Participant, or any other party, if the Option (or any part thereof) that is intended to be
an ISO is not an ISO or for any action taken by the Administrator, including without limitation the conversion of an ISO to a Non-Qualified
Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">15.</TD><TD STYLE="text-align: justify"><U>NOTICE TO COMPANY OF DISQUALIFYING DISPOSITION OF AN ISO</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">If this Option is designated
in the Stock Option Grant Notice as an ISO then the Participant agrees to notify the Company in writing immediately after the Participant
makes a Disqualifying Disposition of any of the Shares acquired pursuant to the exercise of the ISO. A Disqualifying Disposition is defined
in Section&nbsp;424(c)&nbsp;of the Code and includes any disposition (including any sale) of such Shares before the later of (a)&nbsp;two
years after the date the Participant was granted the ISO or (b)&nbsp;one year after the date the Participant acquired Shares by exercising
the ISO, except as otherwise provided in Section&nbsp;424(c)&nbsp;of the Code. If the Participant has died before the Shares are sold,
these holding period requirements do not apply and no Disqualifying Disposition can occur thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">16.</TD><TD STYLE="text-align: justify"><U>NOTICES</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Any notices required or permitted
by the terms of this Agreement or the Plan shall be given by recognized courier service, facsimile, registered or certified mail, return
receipt requested, addressed as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If to the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Sera Prognostics,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">417 Wakara Way, Suite&nbsp;3510</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Salt Lake City, UT 84108</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Attention: Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If to the Participant at the address set forth on the Stock Option
Grant Notice</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">or to such other address or addresses of which notice in the same manner
has previously been given. Any such notice shall be deemed to have been given upon the earlier of receipt, one business day following
delivery to a recognized courier service or three business days following mailing by registered or certified mail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">17.</TD><TD STYLE="text-align: justify"><U>GOVERNING LAW</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without giving effect to the conflict
of law principles thereof. For the purpose of litigating any dispute that arises under this Agreement, the parties hereby consent to exclusive
jurisdiction in Utah and agree that such litigation shall be conducted in the state courts of Salt Lake City, Utah or the fed</FONT>eral
courts of the United States for the District of Utah.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">18.</TD><TD STYLE="text-align: justify"><U>BENEFIT OF AGREEMENT</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Subject to the provisions of
the Plan and the other provisions hereof, this Agreement shall be for the benefit of and shall be binding upon the heirs, executors, administrators,
successors and assigns of the parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">19.</TD><TD STYLE="text-align: justify"><U>ENTIRE AGREEMENT</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">This Agreement, together with
the Plan, embodies the entire agreement and understanding between the parties hereto with respect to the subject matter hereof and supersedes
all prior oral or written agreements and understandings relating to the subject matter hereof. No statement, representation, warranty,
covenant or agreement not expressly set forth in this Agreement shall affect or be used to interpret, change or restrict, the express
terms and provisions of this Agreement, provided, however, in any event, this Agreement shall be subject to and governed by the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">20.</TD><TD STYLE="text-align: justify"><U>MODIFICATIONS AND AMENDMENTS</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The terms and provisions of
this Agreement may be modified or amended as provided in the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">21.</TD><TD STYLE="text-align: justify"><U>WAIVERS AND CONSENTS</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Except as provided in the Plan,
the terms and provisions of this Agreement may be waived, or consent for the departure therefrom granted, only by written document executed
by the party entitled to the benefits of such terms or provisions. No such waiver or consent shall be deemed to be or shall constitute
a waiver or consent with respect to any other terms or provisions of this Agreement, whether or not similar. Each such waiver or consent
shall be effective only in the specific instance and for the purpose for which it was given, and shall not constitute a continuing waiver
or consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><U>DATA PRIVACY</U>.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">By entering into this Agreement,
the Participant: (i)&nbsp;authorizes the Company and each Affiliate, and any agent of the Company or any Affiliate administering the Plan
or providing Plan recordkeeping services, to disclose to the Company or any of its Affiliates such information and data as the Company
or any such Affiliate shall request in order to facilitate the grant of options and the administration of the Plan; and (ii)&nbsp;authorizes
the Company and each Affiliate to store and transmit such information in electronic form for the purposes set forth in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><U>Exhibit&nbsp;A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTICE OF EXERCISE OF STOCK OPTION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[Form&nbsp;for Unregistered Shares]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Sera Prognostics,&nbsp;Inc.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">I hereby exercise my Stock
Option to purchase __________ shares (the &ldquo;Shares&rdquo;) of the common stock, $0.0001 par value, of Sera Prognostics,&nbsp;Inc.
(the &ldquo;Company&rdquo;), at the exercise price of $_____ per share, pursuant to and subject to the terms of that certain Stock Option
Agreement between the undersigned and the Company dated ________, 201_.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">I am aware that the Shares
have not been registered under the Securities Act of 1933, as amended (the &ldquo;1933 Act&rdquo;), or any state securities laws. I understand
that the reliance by the Company on exemptions under the 1933 Act is predicated in part upon the truth and accuracy of the statements
by me in this Notice of Exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">I hereby represent and warrant
that (1)&nbsp;I have been furnished with all information which I deem necessary to evaluate the merits and risks of the purchase of the
Shares; (2)&nbsp;I have had the opportunity to ask questions concerning the Shares and the Company and all questions posed have been answered
to my satisfaction; (3)&nbsp;I have been given the opportunity to obtain any additional information I deem necessary to verify the accuracy
of any information obtained concerning the Shares and the Company; and (4)&nbsp;I have such knowledge and experience in financial and
business matters that I am able to evaluate the merits and risks of purchasing the Shares and to make an informed investment decision
relating thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">I hereby represent and warrant
that I am purchasing the Shares for my own personal account for investment and not with a view to the sale or distribution of all or any
part of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">I understand that because
the Shares have not been registered under the 1933 Act,&nbsp;I must continue to bear the economic risk of the investment for an indefinite
time and the Shares cannot be sold unless the Shares are subsequently registered under applicable federal and state securities laws or
an exemption from such registration requirements is available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">I agree that I will in no
event sell or distribute or otherwise dispose of all or any part of the Shares unless (1)&nbsp;there is an effective registration statement
under the 1933 Act and applicable state securities laws covering any such transaction involving the Shares or (2)&nbsp;the Company receives
an opinion of my legal counsel (concurred in by legal counsel for the Company) stating that such transaction is exempt from registration
or the Company otherwise satisfies itself that such transaction is exempt from registration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">I consent to the placing
of a legend on my certificate for the Shares stating that the Shares have not been registered and setting forth the restriction on transfer
contemplated hereby and to the placing of a stop transfer order on the books of the Company and with any transfer agents against the
Shares until the Shares may be legally resold or distributed without restriction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">I understand that at the
present time Rule&nbsp;144 of the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) may not be relied on for the resale or distribution
of the Shares by me. I understand that the Company has no obligation to me to register the sale of the Shares with the SEC and has not
represented to me that it will register the sale of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">I understand the terms and
restrictions on the right to dispose of the Shares set forth in the 2011 Employee, Director and Consultant Equity Incentive Plan and
the Stock Option Agreement, both of which I have carefully reviewed. I consent to the placing of a legend on my certificate for the Shares
referring to such restriction and the placing of stop transfer orders until the Shares may be transferred in accordance with the terms
of such restrictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
understand and agree that the Shares </FONT>may be subject to that certain Voting Agreement, by and among the Company, the Investors
and the Key Holders (each as defined therein), dated November&nbsp;8, 2011, as may be amended from time to time (the &ldquo;Voting Agreement&rdquo;)
and that certain Right of First Refusal and Co-Sale Agreement, by and among the Company, the Investors and the Key Holders (each as defined
therein) dated November&nbsp;8, 2011, as may be amended from time to time (the &ldquo;Co-Sale Agreement&rdquo;)<FONT STYLE="font-size: 10pt">,
and if I am not already a party to the Voting Agreement and or the Co-Sale Agreement and if the Company so requests,&nbsp;I agree to
become a party to such agreements by execution of the counterpart signature pages&nbsp;enclosed herewith. I acknowledge that I have read
and understand the Voting Agreement and the Co-Sale Agreement which sets forth certain restrictions and limitations on the Shares, including
the ability to transfer or sell them in the future. I further acknowledge and agree that to the extent the terms of Section&nbsp;12 of
the Option</FONT> Agreement conflict with the Co-Sale Agreement, the terms contained in the Co-Sale Agreement shall govern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">I have considered the Federal,
state and local income tax implications of the exercise of my Option and the purchase and subsequent sale of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">I am paying the option exercise price for the
Shares as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 25%"></TD><TD STYLE="border-bottom: Black 1pt solid; width: 50%; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify; width: 25%">&nbsp;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Please issue the Shares (check one):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Wingdings">&#168;</FONT>
to me; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-indent: -1.5in"><FONT STYLE="font-family: Wingdings">&#168;</FONT>
to me and ________________, as joint tenants with right of survivorship</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">and mail the certificate to me at the following address:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 75%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">My mailing address for shareholder communications,
if different from the address listed above is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 75%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif">Very truly yours,</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Participant (signature)</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Print Name</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Date</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Social Security Number</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><U>Exhibit&nbsp;B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>NOTICE OF EXERCISE OF STOCK OPTION</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[Form&nbsp;for Shares <U>Registered</U> in the
United States]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Sera Prognostics,&nbsp;Inc.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IMPORTANT NOTICE: This form of Notice of Exercise may only be used
at such time as the Company has filed a Registration Statement with the Securities and Exchange Commission under which the issuance of
the Shares for which this exercise is being made is registered and such Registration Statement remains effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">I hereby exercise my Stock
Option to purchase _________ shares (the &ldquo;Shares&rdquo;) of the common stock, $0.0001 par value, of Sera Prognostics,&nbsp;Inc.
(the &ldquo;Company&rdquo;), at the exercise price of $________ per share, pursuant to and subject to the terms of that Stock Option Grant
Notice dated _______________, 201_.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">I understand the nature of
the investment I am making and the financial risks thereof. I am aware that it is my responsibility to have consulted with competent tax
and legal advisors about the relevant national, state and local income tax and securities laws affecting the exercise of the Option and
the purchase and subsequent sale of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">I am paying the option exercise
price for the Shares as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 25%"></TD><TD STYLE="border-bottom: Black 1pt solid; width: 50%; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify; width: 25%">&nbsp;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Please issue the Shares (check one):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Wingdings">&#168;</FONT> to me;
or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -1in"><FONT STYLE="font-family: Wingdings">&#168;</FONT>
to me and ____________________________, as joint tenants with right of survivorship,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">at the following address:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 75%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">My mailing address for shareholder
communications, if different from the address listed above, is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 2in; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">Very truly yours,</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Participant (signature)</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Print Name</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Date</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Social Security Number</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>18
<FILENAME>tm2110724d11_ex10-5.htm
<DESCRIPTION>EXHIBIT 10.5
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.5</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Execution Version</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COMMERCIAL COLLABORATION AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Commercial Collaboration
Agreement (this &ldquo;<U>Agreement</U>&rdquo;), dated as of February 17, 2021 (the &ldquo;<U>Effective Date</U>&rdquo;), is made by and
between Anthem, Inc. and its Affiliates (as defined below) (collectively, &ldquo;Anthem&rdquo;) on the one hand, and Sera Prognostics,
Inc. (&ldquo;<U>Company</U>&rdquo;) on the other hand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WHEREAS</B>, Anthem currently participates
in Company's PRIME study, the goal of which is to determine the clinical validity of the PreTRM&reg; test;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WHEREAS</B>, at the conclusion of the PRIME
study, Anthem and Company will enter into Anthem's standard lab provider agreement, substantially in the form attached hereto as <U>Exhibit
C</U> (the &ldquo;<U>Lab Agreement</U>&rdquo;); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WHEREAS</B>, Anthem and Company desire to enter
into this Agreement relating to the delivery of, and compensation for, Testing Services (as defined below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOW THEREFORE</B>, the parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
1<BR>
ARTICLE 1 DEFINITIONS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.1</TD><TD STYLE="text-align: justify">&ldquo;<U>Affiliate</U>&rdquo; means, with respect to any person, any other Person that, directly or indirectly,
through one or more intermediaries, controls, is controlled by, or is under common control with, such person. The term &ldquo;<U>control</U>&rdquo;
means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a person,
whether through the ownership of voting securities, by contract or otherwise, and the terms &ldquo;<U>controlled</U>&rdquo; and &ldquo;<U>controlling</U>&rdquo;
have correlative meanings.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.2</TD><TD STYLE="text-align: justify">&ldquo;<U>BCBS Licensee</U>&rdquo; means any organization licensed by the Blue Cross Blue Shield Association
to use the Blue Cross and Blue Shield trademarks and names.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.3</TD><TD STYLE="text-align: justify">&ldquo;<U>Member</U>&rdquo; means any individual enrolled in, or serviced or covered by, the health benefits
products of Anthem. A &ldquo;Member&rdquo; does not include an individual participating in the PRIME study being sponsored by Anthem.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.4</TD><TD STYLE="text-align: justify">&ldquo;<U>Ordering Clinician</U>&rdquo; means a duly licensed physician specializing in obstetrics and
gynecology (OB/GYN) or family medicine (FM), or a licensed Certified Nurse Midwife (CNM).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.5</TD><TD STYLE="text-align: justify">&ldquo;<U>Payor</U>&rdquo; means any party that has contracted with Anthem to access the terms and conditions
of this Agreement, and which is responsible for payment pursuant to the terms of this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.6</TD><TD STYLE="text-align: justify">&ldquo;<U>Policies and Procedures</U>&rdquo; means the rules, policies, and procedures adopted by Anthem.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>[***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY
HARMFUL IF PUBLICLY DISCLOSED. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.7</TD><TD STYLE="text-align: justify">&ldquo;<U>Testing Services</U>&rdquo; means the offering of the PreTRM&reg; proteomic test to identify
singleton pregnant women at increased risk of spontaneous preterm birth developed by Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
2<BR>
COMPANY RESPONSIBILITIES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.1</TD><TD STYLE="text-align: justify"><U>Testing Services Capacity</U>. Company shall perform Testing Services ordered by an Ordering Clinician
and provide results in a timely manner that complies with the service level standards as set forth in the Lab Agreement, industry practices
standards, as well as all applicable laws, rules, and regulations.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.2</TD><TD STYLE="text-align: justify"><U>Services and Supplies</U>. Company will arrange for the provision of limited, non-standard, specialty
supplies, at no additional cost to Anthem, as may be necessary or desirable to facilitate the collection, transfer, and transport of specimens
from Members to Company, including but not limited to, supplies required for specimen management.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.3</TD><TD STYLE="text-align: justify"><U>Company Non-discrimination</U>. Company shall provide Testing Services to Members in a manner similar
to, and within the same time availability in which, Company provides Testing Services to any other individual, and Company will not differentiate
in the performance of Testing Services based on a Member's race, color, creed, national origin, ancestry, religion, sex, marital status,
age, disability, payment source, state of health, military service, need for health services, status as a Medicare or Medicaid beneficiary,
sexual orientation, or any other basis prohibited by law. Company shall not be required to provide any type or kind of health service
to Members that it does not customarily provide to other individuals, unless such is required by applicable law.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.4</TD><TD STYLE="text-align: justify"><U>Inability to Perform</U>. Company shall provide prompt notice to Anthem of its knowledge of any action
to restrict, suspend, or revoke Company's CLIA certification from the Centers for Medicare &amp; Medicaid Services. Additionally, Company
shall send prompt written notice to Anthem of its knowledge of any other legal, governmental, or other action involving Company which
could reasonably materially impair the ability of Company to carry out any of its obligations under this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.5</TD><TD STYLE="text-align: justify"><U>Marketing and Training</U>. Company shall develop a sales, marketing, and customer service program
and provide such training and marketing to Ordering Clinicians at the reasonable request of Anthem. Such program will include physician
office training, education, fulfillment, and support.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.6</TD><TD STYLE="text-align: justify"><U>Subcontractors</U>. Company shall give Anthem no less than 30 days' prior written notice of any subcontractors
which Company engages to assist in the offering of Testing Services. Company shall require such subcontractors to abide by the terms and
conditions of this Agreement and shall indemnify Anthem and Members for any failure of such subcontractor to comply with this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.7</TD><TD STYLE="text-align: justify"><U>Policies and Procedures</U>. Company agrees to abide by the terms of the Policies and Procedures and
to participate in, and comply with, Anthem's credentialing standards. In the event of a conflict between the terms of this Agreement and
the Policies and Procedures, the terms of this Agreement will control. Anthem shall give Company no less than 30 days' prior written notice
of any material change to the Policies and Procedures.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.8</TD><TD STYLE="text-align: justify"><U>Credentialing</U>. Company represents and warrants that it has all licenses required to provide Testing
Services in accordance with applicable laws and regulations. Company shall cooperate fully with Anthem's credentialing and recredentialing
procedures, as set forth in the Policies and Procedures. Company expressly authorizes Anthem to solicit any information regarding licensures,
registrations, certifications or accreditations, qualifications, and liability or negligence history from any source in connection with
such credentialing and recredentialing procedures for the duration of this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
3<BR>
ANTHEM RESPONSIBILITIES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.1</TD><TD STYLE="text-align: justify"><U>Purchase of Tests</U>. Anthem shall purchase the minimum number of tests as set forth in Exhibit A,
subject to earlier termination of the Agreement pursuant to <U>Section 10.2</U>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.2</TD><TD STYLE="text-align: justify"><U>Implementation of Care Management Program</U>. Anthem shall, in its sole discretion, develop appropriate
care management programs which incorporate the use of Testing Services and is targeted to patients who are stratified through use of the
PreTRM&reg; test as high risk for pre-term births. Anthem shall, in its sole discretion, implement any such care management program with
applicable Ordering Clinicians.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.3</TD><TD STYLE="text-align: justify">[***].</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.4</TD><TD STYLE="text-align: justify"><U>Inability to Perform</U>. Anthem shall provide prompt notice to Company of its knowledge of any legal,
governmental, or other action involving Anthem which Anthem reasonably believes could materially impair the ability of Anthem to carry
out some or all of its material duties and obligations under this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.5</TD><TD STYLE="text-align: justify">[***].</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.6</TD><TD STYLE="text-align: justify">[***].</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
4<BR>
COMPENSATION AND BILLING</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.1</TD><TD STYLE="text-align: justify"><U>Submission and Payment</U>. Except as otherwise provided herein, Company will submit monthly invoices
to Anthem for Testing Services at the rate per test set forth in Exhibit A (or other mutually agreed upon and documented rate) on the
5th day of each month following the month in which such services were performed. Anthem shall pay all invoices for Testing Services submitted
by Company within 45 days of receipt of the applicable invoice.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.2</TD><TD STYLE="text-align: justify"><U>Guarantee of Payment</U>. Provided that Company is not in material breach of this Agreement, and subject
to the terms and conditions herein, Anthem shall pay to Company for each of the first three ears f the Term a minimum amount per annum
equal to [***].</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
5<BR>
JOINT OPERATING COMMITTEE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.1</TD><TD STYLE="text-align: justify"><U>Joint Operating Committee</U>. A Joint Operating Committee (&ldquo;<U>JOC</U>&rdquo;) will be formed,
pursuant to the terms of this <U>Article 5</U> and the provisions set forth in <U>Exhibit B</U>, by two voting members each from Anthem
and Company. The JOC will have a chairperson. The initial chairperson shall be Nadia Altomare, to serve in such role until such time as
Ms. Altomare is no longer employed by the Company or is otherwise unable to continue in such role at any point during the term of this
Agreement, in which such case the JOC shall designate a replacement chairperson. During the term of this Agreement, Dr. Charles Kennedy,
as long as employed by or affiliated with Blue Ox, will be an ex-officio, non-voting member of the JOC. The JOC will determine details
of Anthem's and Company's collaboration, including, but not limited to:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">Overall program management;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">Anthem provider contracting support and coordination needs;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">Company's testing capacity and ramp up to meet Anthem's needs;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify">Anthem care management programs, utilization management programs, analytic support, and marketing support;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify">Company IT readiness to ensure operational capacity for the anticipated growth of the program;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">6.</TD><TD STYLE="text-align: justify">Approach to the physician offices and other end user support;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">7.</TD><TD STYLE="text-align: justify">Staffing and resources by both parties;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">8.</TD><TD STYLE="text-align: justify">Building and sharing enhanced data and analytics for current and future products and services;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">9.</TD><TD STYLE="text-align: justify">Billing process;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">10.</TD><TD STYLE="text-align: justify">[***]; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">11.</TD><TD STYLE="text-align: justify">Definition of success metrics and performance monitoring.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.2</TD><TD STYLE="text-align: justify"><U>Meetings of the JOC</U>. The JOC will establish and hold regular meetings, and any member of the JOC
may request a special meeting of the JOC in his or her discretion. Any meeting of the JOC may be held in person or via telephone or video
conference. Each member appointed by Anthem and Company will be a voting member of the JOC entitled to one vote on any matter up for a
vote at meetings of the JOC.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.3</TD><TD STYLE="text-align: justify"><U>Dispute Resolutions</U>. If the JOC reaches a deadlock on a specific issue, one executive at each of
the parties shall meet to resolve the issue in good faith. Such meeting shall occur no less than seven business days following the occurrence
of a deadlock on the JOC which at least two JOC members agree needs escalation to be resolved. Either party may take an unresolved issue
to binding arbitration pursuant to the arbitration procedures in <U>Article 11</U> to resolve a deadlock if the parties have failed to
resolve the deadlock for at least 45 days following the initial meeting of the two executives. The initial executives for purposes of
the dispute resolution under this <U>Section 5.3</U> shall be Elizabeth Canis, Anthem Vice President, Emerging Business and Partnerships,
and Gregory Critchfield, CEO of Sera Prognostics, Inc. Either party may replace such named executive for purposes of the dispute resolution
under this <U>Section 5.3</U> by written notice to the other party.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
6<BR>
CONFIDENTIALITY</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.1</TD><TD STYLE="text-align: justify"><U>Proprietary Information</U>. The parties agree that all proprietary information that either party may
receive from the other party in the performance of this Agreement is the sole property of the disclosing party. The party receiving such
information agrees to keep the information strictly confidential. Anthem specifically acknowledges and agrees that the PreTRM&reg; test
is proprietary to Company, and nothing in this Agreement construes any title, license, interest, or any other right to Anthem in or relating
to the PreTRM&reg; test. For the avoidance of doubt, the foregoing shall not be applicable to the results of the PreTRM&reg; tests, which
shall be jointly owned by the applicable Member and Anthem. Company specifically acknowledges and agrees that Anthem's Provider Agreements,
Anthem's care management program and Anthem's Policies and Procedures are proprietary to Anthem, and nothing in this Agreement construes
any title, license, interest, or any other right to Company in or relating to such. Furthermore, nothing in this Agreement confers any
title, license, interest or any other right in or to a Member's personally identifiable information (&ldquo;<U>PII</U>&rdquo;) or personal
health information (&ldquo;<U>PHI</U>&rdquo;) to Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.2</TD><TD STYLE="text-align: justify"><U>Confidentiality of Personally Identifiable Information</U>. Company and Anthem agree that all PII and
PHI related to Members is privileged and confidential. To the extent as necessary for the purposes of fulfilling the obligations set forth
in this agreement provided by law, rule, or regulation, the parties agree to keep confidential and not to disclose such information to
any third party without the prior consent of the Member.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.3</TD><TD STYLE="text-align: justify"><U>Transfer of Medical Records</U>. At the direction of Anthem, to the extent permitted by law, rule,
and regulation, Company shall share a Member's medical records with other health care providers treating the Member in a timely manner
at no cost to Anthem, the Member, or other health care provider.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.4</TD><TD STYLE="text-align: justify"><U>Survival</U>. This <U>Article 6</U> survives the termination of this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
7<BR>
INSURANCE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.1</TD><TD STYLE="text-align: justify"><U>Anthem Insurance</U>. Anthem shall self-insure or maintain insurance coverage or comprehensive general
liability and other insurances necessary and customary to insure Anthem, its agents, servants, and employees, acting within the scope
of their duties, against any claim(s) for damages arising in connection with the performance or non-performance of this Agreement by Anthem,
its agents, servants, or employees.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.2</TD><TD STYLE="text-align: justify"><U>Company Insurance</U>. Company shall self-insure or maintain general and professional liability insurance
including coverage for product liability in the amount of $[***] per occurrence and $[***] annual aggregate or such higher coverage as
may be required by law. Evidence of such coverage shall be provided to Anthem upon its prior written request. Company shall notify Anthem
no less than 10 days in advance of such policy being reduced, terminated, cancelled, or the occurrence of a lapse in coverage. Company
shall maintain such insurance for the duration of this Agreement, and thereafter, as necessary to maintain coverage for events occurring
during the term of this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
8<BR>
INDEMNIFICATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">8.1</TD><TD STYLE="text-align: justify"><U>Indemnification by Anthem</U>. Anthem agrees to indemnify Company and to hold Company harmless against
any third-party claim, action, liability, damage, and loss, including reasonable attorneys' fees and costs which arise from Anthem's fraud,
willful misconduct, or grossly negligent performance or failure to perform duties or obligations which are the responsibility of it, its
agents, employees, or representatives under this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">8.2</TD><TD STYLE="text-align: justify"><U>Indemnification by Company</U>. Company agrees to indemnify Anthem and to hold Anthem harmless against
any third-party claim, action, liability, damage, and loss, including reasonable attorneys' fees and costs which arise from Company's
fraud, willful misconduct, or grossly negligent performance or failure to perform duties or obligations which are the responsibility of
it, its agents, employees, or representatives under this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
9<BR>
RECORD ACCESS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.1</TD><TD STYLE="text-align: justify"><U>Utilization Review</U>. Company will make the Member's medical records and other PII and PHI available
to Anthem for all lawful purposes. Company will also make such records available to federal or state authorities as required by applicable
law, rule, or regulation.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.2</TD><TD STYLE="text-align: justify"><U>Books and Records</U>. Anthem shall have the right to access the books and records of Company other
than those set forth in <U>Section 9.1</U> upon no less than 30 days' prior written notice to Company. Anthem shall have the right to
inspect such books and records during normal business hours and with minimum disruption to Company's business operations. Such inspection
shall not occur more frequently than once per calendar year unless otherwise required as a result of regulatory requirements or under
applicable law. Any expenses out of the ordinary course incurred by Company in such audit shall be reimbursed by Anthem. If requested
by Company, Anthem shall give Company a summary of all findings of such audit, including any underpayments identified by the audit, within
30 days of the completion of such audit.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.3</TD><TD STYLE="text-align: justify"><U>Retention of Records</U>. Company shall maintain medical records for a period of (a) six years from
the applicable date of service, (b) in the case, of a minor, for three years after the minor achieves the age of majority or six years
from the applicable date of service, whichever is later, or (c) such longer period as required by applicable law, rule, or regulation.
This provision will survive the termination of this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
10<BR>
TERM AND TERMINATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.1</TD><TD STYLE="text-align: justify"><U>Term</U>. The initial term of this Agreement shall commence on the Effective Date and, unless earlier
terminated pursuant to <U>Section 10.2</U>, remain in effect until the later of (a) the third anniversary of the Effective Date or (b)
the date on which Anthem has consumed [***] of the PreTRM&reg; tests.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.2</TD><TD STYLE="text-align: justify"><U>Termination</U>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">This Agreement may be terminated at any time by the mutual written consent of Anthem and Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify"><U>Termination for Cause</U>. This Agreement may be terminated for cause as follows:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">If either party fails to comply with or perform when due any material term or condition of this Agreement,
the other party shall notify the defaulting arty of the default in writing, and the defaulting party will have [***] days from the date
of such notice to cure the default. If the default is not cured to the reasonable satisfaction of the non-defaulting party within such
period, the non-defaulting party may terminate this Agreement at the conclusion of the cure period.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Upon notice b Anthem to Company with no further obligations of either party: [***].</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">[***], Company shall notify Anthem of such in reasonable detail in writing, and Anthem will have 60 days
from the date of receipt of such notice to cure such impact. If the impact is not cured to the reasonable satisfaction of Company within
such period, the Company may terminate this Agreement at the conclusion of the cure period.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.3</TD><TD STYLE="text-align: justify"><U>Continuation of Care</U>. Unless otherwise set forth in this Agreement or required by applicable law
or regulation, Company shall, upon termination of this Agreement (for any reason other than those set forth in <U>Section 10.2.3(b))</U>,
continue to provide Testing Services to any Member who has, as of the date of termination, provided a specimen for a PreTRM&reg; test.
Company shall be reimbursed for such Testing Services pursuant to the terms and conditions of this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
11<BR>
DISPUTE RESOLUTION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">11.1</TD><TD STYLE="text-align: justify"><U>Dispute Resolution</U>. If any dispute arises out of or relates to this Agreement, the aggrieved party
shall provide notice to the other party of such dispute. Company and Anthem shall meet to attempt to resolve the dispute. Any dispute
shall first be submitted to (a) the JOC for resolution and then (b) the process under <U>Section 5.3</U> of this Agreement prior to submission
to binding arbitration pursuant to this <U>Section 11.1</U>. If such efforts are unsuccessful, either party may commence arbitration by
filing an arbitration demand with the American Arbitration Association (&ldquo;<U>AAA</U>&rdquo;) within 30 days of the date of the notice
of dispute. The dispute will be resolved through binding arbitration as set forth in this Article 11 in New York, New York, or another
location as mutually agreed to by the parties.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">11.2</TD><TD STYLE="text-align: justify"><U>Arbitration</U>. The arbitrator's ruling on any dispute that is brought to arbitration shall be final
and binding on the parties. The Commercial Rules relating to Payor-Provider Disputes issued by AAA will apply to any arbitration between
the parties. The cost of any arbitration will be equally borne by the parties unless the arbitrator(s) specifically instruct otherwise.
The result of any arbitration may be entered into and enforced by a court of competent jurisdiction.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">11.3</TD><TD STYLE="text-align: justify"><U>Survival</U>. This <U>Article 11</U> survives the termination of this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
12<BR>
MISCELLANEOUS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.1</TD><TD STYLE="text-align: justify"><U>Amendment</U>. This Agreement may be amended only by a written instrument duly executed by the parties
hereto. Notwithstanding the foregoing, Anthem may reasonably amend this Agreement to comply with an applicable law, rule, or regulation.
If the amendment would impose a material adverse impact on Company, then Company may terminate this Agreement on sixty (60) days' prior
written notice to Anthem by sending a termination notice within thirty (30) days after receipt of the amendment.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.2</TD><TD STYLE="text-align: justify"><U>Assignment</U>. Neither party may assign or delegate this Agreement or any part thereof (except as
otherwise expressly set forth herein) without the prior written consent of the other party.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.3</TD><TD STYLE="text-align: justify"><U>Successors and Assigns</U>. This Agreement shall be binding upon and shall inure to the benefit of
the parties hereto and their respective successors and permitted assigns.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.4</TD><TD STYLE="text-align: justify"><U>Notice</U>. Any notice required or permitted under this Agreement must be made in writing and delivered
to the address(es) set forth below (a) by hand, (b) via nationally-recognized overnight courier with proof of delivery, (c) via certified
mail, return receipt requested, or (d) via email with delivery and read receipts requested. Notice will be deemed delivered as of the
date of verified delivery. Each party may update its address(es) for notice set forth below by providing notice to the other party of
the new address.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    to Anthem:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1155
    Elm Street&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manchester,
    NH 03101&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
    Paul Eisenstat, VP Networks&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    to Company:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2749
    E Parleys Way, Suite 200&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salt
    Lake City, UT 84109&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
    Jay Moyes, Chief Financial Officer&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.5</TD><TD STYLE="text-align: justify"><U>Relationship of the Parties</U>. For the purposes of this Agreement, Anthem and Company are, and will
act at all times, as independent contractors. None of the provisions of this Agreement is intended to create, nor will be deemed or construed
to create, any relationship other than that of independent entities contracting with each other for the purposes of effectuating this
Agreement. The provisions of this Agreement will not be deemed to establish or be deemed or construed to establish any partnership, agency,
employment, agreement, or joint venture between the parties. Neither of the parties, nor any of their respective officers, directors,
employees, authorized agents, or representatives shall be construed to be the agent, employee, or representative of the other.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.6</TD><TD STYLE="text-align: justify"><U>Survival</U>. Provisions of this Agreement which, either explicitly or implicitly, apply to a party
following the termination of this Agreement will survive such termination for all purposes.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.7</TD><TD STYLE="text-align: justify"><U>Severability</U>. If any term or provision of this Agreement shall be found to be illegal, invalid
or unenforceable under applicable law, then, notwithstanding such illegality, invalidity or unenforceability, this Agreement shall remain
in full force and effect and the illegal, invalid or unenforceable term or provision shall be deemed to be deleted.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.8</TD><TD STYLE="text-align: justify"><U>Governing Law</U>. This Agreement shall be governed in all respects by the laws of the State of New
York without giving effect to the principles of conflicts of law thereof.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.9</TD><TD STYLE="text-align: justify"><U>Section Headings</U>. Section headings contained in this Agreement are inserted for convenience of
reference only, will not be deemed to be a part of this Agreement for any purpose, and shall not in any way define or affect the meaning,
construction, or scope of any of the provisions hereof.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.10</TD><TD STYLE="text-align: justify"><U>No Third-Party Beneficiaries</U>. It is the explicit intention of the parties hereto that no person
or entity other than the parties hereto is or shall be entitled to bring any action to enforce any provision of this Agreement against
either party hereto, and that the covenants, undertakings, and agreements set forth in this Agreement shall be solely for the benefit
of, and shall be enforceable only by, the parties hereto and their respective successors and assigns as permitted hereunder.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.11</TD><TD STYLE="text-align: justify"><U>Force Majeure</U>. Each party shall use all commercially reasonable efforts to perform its obligations
under this Agreement but shall be excused for failure to perform or for delay in performance hereunder due to unforeseeable circumstances
beyond its reasonable control, or which could not have been prevented by it, including, but not limited to, floods, hurricanes, earthquakes,
acts of war or terrorism, civil unrest, or embargoes.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.12</TD><TD STYLE="text-align: justify"><U>No waiver</U>. No waiver hereunder will be binding unless set forth in writing and duly executed by
the party against whom enforcement of the waiver is sought. Neither the waiver by either of the parties hereto or a breach of, or a default
under any of the provisions of this Agreement, nor the failure of either party, on one or more occasions, to enforce any of the provisions
of this Agreement or to exercise any right or privilege hereunder shall thereafter be construed as a waiver of any subsequent breach or
default of a similar nature, or as a waiver of any of such provisions, rights, or privileges hereunder.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.13</TD><TD STYLE="text-align: justify"><U>Compliance with Law</U>. Each party represents and warrants to the other party that it is in material
compliance with all applicable laws, rules, and regulations as respects its performance hereunder, and covenants that, for the duration
of this Agreement, such party will remain in material compliance with all applicable laws, rules, and regulations as respects its performance
hereunder.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.14</TD><TD STYLE="text-align: justify"><U>Cumulative Remedies</U>. The remedies provided herein are cumulative and do not preclude one party
from asserting any other rights or seeking any other remedies against the other party, or its successors or permitted assigns, pursuant
to this Agreement or as provided by applicable law. Nothing contained herein precludes a party from seeking equitable relief, where appropriate.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.15</TD><TD STYLE="text-align: justify"><U>Execution</U>. This Agreement may be executed in one or more counterparts, each of which is to be deemed
an original, and all of which, when taken together, are to be deemed one and the same instrument. Signatures to this Agreement may be
made and/or transmitted electronically, and each such signature is to be deemed an original signature for all purposes.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.16</TD><TD STYLE="text-align: justify"><U>Entire Agreement</U>. Except as expressly set forth herein, this Agreement, together with all exhibits
and appendices hereto, constitute the entire agreement between the parties hereto with respect to the subject matter contained herein
and supersedes all prior oral or written agreements, representations, statements, negotiations, understandings, and undertakings with
respect to the matters provided for herein.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.17</TD><TD STYLE="text-align: justify"><U>BCBSA Affiliation</U>. Company hereby expressly acknowledges its understanding that this Agreement
constitutes a contract between Company and Anthem, that Anthem is an independent entity operating under a license from the Blue Cross
Blue Shield Association, an Association of independent Blue Cross and Blue Shield plans (the &ldquo;<U>Association</U>&rdquo;), permitting
Anthem to use the Blue Cross and Blue Shield Service Marks, and that Anthem is not contracting as the agent of the Association. Company
acknowledges that it has no license to use the Blue Cross and/or Blue Shield names, symbols, or derivative marks (the &ldquo;<U>Brands</U>&rdquo;)
and nothing in this Agreement is to be deemed to grant a license to Company to use the Brands. Any references to the Brands made by Company
in its own materials are subject to the review and approval by Anthem pursuant to the terms of this Agreement. Company further acknowledges
and agrees that it has not entered into this Agreement based upon representations by any person other than Anthem, and that no person,
entity, or organization other than Anthem will be held accountable or liable to Company for any of Anthem's obligations to Company created
under this Agreement. This section does not create any additional obligations whatsoever on the part of Anthem other than those obligations
otherwise created under this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.18</TD><TD STYLE="text-align: justify"><U>Publicity</U>. Anthem and Company shall mutually agree on any press releases, communications, media
outreach, or similar public statements made by either party in regards to the existence and terms of this Agreement. Neither party shall
make any such public statement regarding this Agreement prior to the mutual agreement of the parties.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signatures appear on the following page</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The parties have executed
this Commercial Collaboration Agreement as of the date set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANTHEM,
    INC.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SERA
    PROGNOSTICS, INC.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Paul Marchetti</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Gregory C. Critchfield</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    &nbsp;Paul Marchetti</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    &nbsp;Gregory C. Critchfield</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    &nbsp;SVP Health Care Management</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    &nbsp;Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    &nbsp;February 17, 2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    &nbsp;February 17, 2021</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PER TEST RATES AND NUMBER OF TESTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">Rates: Anthem shall pay Company an amount per PRETRM&reg; test control to a Member equal to [***].</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify"><U>Guaranteed Tests per Year</U>: Anthem shall purchase a minimum of [***] PreTRM&reg; tests during the
term of this Agreement. The annual amounts are as follows:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">a.</TD><TD STYLE="text-align: justify">Year 1 - [***] tests</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">b.</TD><TD STYLE="text-align: justify">Year 2 - [***] tests</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">c.</TD><TD STYLE="text-align: justify">Year 3 - [***] tests</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In the event that Anthem purchases fewer
than the foregoing amount in either Year 1 or Year 2, the difference between the amount actually ordered and the guaranteed number of
tests will carry-over to the following year. For example, if Anthem orders only [***] tests in Year 1, then the guaranteed number of tests
for Year 2 will be [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify"><U>Affiliates and BCBS Licensees</U>. Any purchases made on behalf of, or distributed to, Anthem's Affiliates
or any other BCBS Licensee or one of their respective Affiliates will be credited against the guaranteed payment terms of <U>Section 4.2</U>
of the Agreement and guaranteed test volumes in Section 2 of this <U>Exhibit A</U>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: 0in">EXHIBIT B</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: 0in">[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: 0in">EXHIBIT C</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: 0in">[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 15; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>19
<FILENAME>tm2110724d11_ex10-6.htm
<DESCRIPTION>EXHIBIT 10.6
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.6</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LABORATORY SERVICES AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PRIMESTUDY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Laboratory Services Agreement (&ldquo;<B>Agreement</B>&rdquo;)
is made and entered into effective as of November&nbsp;10, 2020 (&ldquo;Effective Date&rdquo;) by and between Anthem Health Insurance
and Amerigroup Corporation, whose principal place of business is 4425 Corporation Lane Virginia Beach, VA 23462 (hereinafter referred
to collectively as &ldquo;<B>Anthem</B>&rdquo;), and Sera Prognostics,&nbsp;Inc.<B>, </B>whose principal place of business is 2749 East
Parleys Way, Suite&nbsp;200, Salt Lake City, UT 84109 (&ldquo;<B>Laboratory</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Background and Recitals</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Anthem is a sponsor and administrator
of health insurance plans that provide benefits for, among other things, laboratory analyses of samples collected from insured individuals
among the services that are covered under its plans;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Laboratory has developed the
PreTRM&reg; proteomic screening test to identify increased risks of adverse outcomes among pregnant women;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Laboratory has designed and
is sponsoring the Prematurity Risk Assessment combined with clinical Interventions for improving neonatal outcoMEs study to evaluate the
PreTRM&reg; test (the &ldquo;PRIME&rdquo; study);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Anthem and Laboratory have
agreed to collaborate on the conduct of the PRIME study, and Laboratory has entered into a Work Order with HealthCore,&nbsp;Inc. for the
purpose of managing the conduct of the PRIME study;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Anthem has agreed to compensate
Laboratory for the PreTRM&reg; tests performed pursuant to the PRIME study;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, subject to the terms
and conditions of this Agreement, the parties desire that Anthem engage Laboratory to provide certain clinical laboratory services and
related services to support Anthem&rsquo;s health insurance plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, for and in
consideration of the mutual promises and covenants set forth herein and other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>1.</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Laboratory
Responsibilities</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.1</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Services</FONT></B><FONT STYLE="font-size: 10pt">.
Subject to the terms and conditions of this Agreement, Laboratory shall provide the clinical laboratory services listed on <B>Exhibit&nbsp;A</B>,
attached hereto and incorporated herein by this reference, (the &ldquo;<B>Services</B>&rdquo;) as specifically requested by the treating
physicians or other qualified health care professionals from time-to-time for subjects enrolled in the PRIME study. All Services shall
be provided in accordance with all applicable federal, state and local laws, rules, and regulations, ordinances and licensure requirements,
and all requirements of third-party reimbursement sources (public or private), or other reimbursement sources covering laboratory services.
Laboratory shall use personnel properly licensed and qualified to perform laboratory services and shall maintain evidence of such compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I)&nbsp;IS NOT MATERIAL AND (II)&nbsp;WOULD BE COMPETITIVELY HARMFUL IF
PUBLICLY DISCLOSED.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.2</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Pricing</FONT></B><FONT STYLE="font-size: 10pt">.
The fee for each PreTRM&reg; test performed by Laboratory in accordance with the PRIME study is set out in the fee schedule attached
as <B>Exhibit&nbsp;A</B>, which is fully incorporated by reference into this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.3</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Results.
</FONT></B><FONT STYLE="font-size: 10pt">Laboratory shall provide all results of Services (&ldquo;<B>Results</B>&rdquo;) in the form of
a written report delivered to the physician or other qualified health care professional ordering each test in accordance with the PRIME
study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.4</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Processing</FONT></B><FONT STYLE="font-size: 10pt">.
Laboratory shall maintain a record of the daily intake of specimens and a system for identification of each specimen.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.5</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Support.
</FONT></B><FONT STYLE="font-size: 10pt">Laboratory shall make personnel available by telephone or electronic mail during normal business
hours to review Results, arrange for special tests as mutually agreed by the parties, and promptly communicate any new laboratory test
requisition processes to the ordering physician or other qualified health care professional.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.6</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Written
Policies</FONT></B><FONT STYLE="font-size: 10pt">. Laboratory has established written policies and procedures for detecting and preventing
fraud, waste, and abuse, and has also implemented a comprehensive compliance program and code of conduct, which complies with the standards
set forth in the OIG Compliance Program Guidance for Clinical Laboratories. Laboratory shall conduct its activities under this Agreement,
including all test orders, Services, supplies or materials provided under this Agreement, in accordance with the requirements of the applicable
federal and state laws, including those governing transportation of hazardous materials and record retention requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.7</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><FONT STYLE="font-size: 10pt">Standards,
Qualifications, and Licensure. Laboratory represents and warrants that it is, and throughout the term of this Agreement shall remain,
CLIA certified. Laboratory shall provide immediate written notice of any change to its licensure, certification or accreditation status.
Laboratory represents and warrants that any pathologist providing Services under this Agreement is qualified, credentialed, and licensed
to practice medicine as shall be required to perform Services hereunder. Laboratory represents and warrants that it and its employees
and agents who perform the Services, possess the necessary skill, education, and training, and maintain all necessary federal and state
licenses and/or certifications required to perform such Services hereunder. The Services performed hereunder shall be performed at testing
facilities that remain duly licensed clinical laboratories under applicable federal, state and local law, and are accredited by an accrediting
organization. Laboratory will provide documentation of all credentials, licenses, qualifications and accreditation required in this Agreement
to Anthem upon request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.8</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Waste</FONT></B><FONT STYLE="font-size: 10pt">.
Laboratory will be solely responsible for the disposal of any medical or other waste generated in the performance of the Services. Laboratory
shall comply with all laws and regulations applicable to such disposal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.9</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Credentialing</FONT></B><FONT STYLE="font-size: 10pt">.
Laboratory represents that it meets all applicable Anthem credentialing standards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>2.</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Billing
and Compensation by Anthem</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>2.1</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><FONT STYLE="font-size: 10pt">List
Bill Submission and Payment. Except as otherwise provided herein, Laboratory will submit monthly invoices to Anthem for Services at the
rate per test conducted in the intervention arm of the PRIME Study (not the control arm), up to a [***] tests, as set forth in Exhibit&nbsp;A
(or other mutually acceptable and documented rate) within 15 days following the month in which such services were performed. Laboratory
agrees to accept the payments at the agreed upon rate as payment in full. Each invoice shall be in the form reasonably requested by Anthem,
and include all information necessary for Anthem to process payments to Laboratory . Anthem agrees to pay Laboratory undisputed amounts
within forty-five (45) days of the receipt of any invoice; provided, however, that Anthem shall have no obligation to pay for any Services
that are not timely invoiced.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>2.2</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Hold
Harmless</FONT></B><FONT STYLE="font-size: 10pt">. Laboratory shall not, under any circumstance, including: (i)&nbsp;nonpayment of moneys
due Laboratory by Anthem, (ii)&nbsp;insolvency of Anthem, or (iii)&nbsp;breach of this Agreement, bill, charge, collect a deposit, seek
compensation, remuneration, or reimbursement from, or have any recourse against an enrolled subject, dependent of an enrolled subject,
or any persons acting on their behalf, for Services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>2.3</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Basis
of Pricing</FONT></B><FONT STYLE="font-size: 10pt">. The parties acknowledge and agree that the pricing set out in this Agreement is limited
to the tests performed under the PRIME study protocol, and may not be used to set any future reimbursement amounts for the PreTRM&reg;
test. The parties further acknowledge and agree that the aggregate services hereunder do not exceed those that are reasonable and necessary
for a legitimate business purpose, and that the compensation to be provided hereunder has not been determined in a manner that takes into
account the volume or value of any referrals or other business generated between the parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>3.</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Term&nbsp;&amp;
Termination</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>3.1</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Term</FONT></B><FONT STYLE="font-size: 10pt">.
This Agreement shall commence on the Effective Date and remain in effect until the conclusion of the PRIME study, unless otherwise terminated
as provided herein. Thereafter, this Agreement may be renewed for additional terms of one (1)&nbsp;year each upon mutual agreement of
the parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>3.2</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Termination</FONT></B><FONT STYLE="font-size: 10pt">.
Notwithstanding anything herein to the contrary, this Agreement may be terminated as follows: (i)&nbsp;by cause by either party upon the
default by the other party of any term, covenant or condition of this Agreement, where such default continues for a period of ten (10)&nbsp;days
after the defaulting party receives written notice thereof from the other party such default; (ii)&nbsp;without cause by either party
effective at any time after at least thirty (30) days prior written notice to the other party in which case the Agreement shall terminate
on the future date specified in such notice, except that no such termination without cause shall take effect prior to the first annual
anniversary of the Effective Date; (iii)&nbsp;by either party upon notice to the other party following the filing of voluntary or involuntary
bankruptcy by either party; or (iv)&nbsp;by either party immediately upon notice to the other party in the event of either party&rsquo;s
loss of license, accreditation, or certification necessary for its performance hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">4.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>Record
Retention.</B> Laboratory agrees to keep and maintain any and all records, including but not limited to medical and financial records,
for services rendered by Laboratory to Anthem as <B>may be required by federal, state, or local government laws and Anthem policies. Laboratory
shall provide a copy of such records to Anthem upon request.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>5.</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Confidential
Information</FONT></B><FONT STYLE="font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Confidential
Information is any information provided pursuant to or in furtherance of this Agreement by a Disclosing Party to a Receiving Party that
is clearly marked as &ldquo;confidential&rdquo; or that a reasonable person in like circumstances would understand to be confidential
or proprietary. &ldquo;Confidential Information&rdquo; does not include Protected Health Information, as that term is defined at 45 C.F.R.
 &sect; 160.103 and shall not apply to information that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">was known to Receiving Party at the time of disclosure hereunder, as evidenced by Receiving Party&rsquo;s
contemporaneous written or electronic records;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">becomes generally known to the public through no fault of Receiving Party or anyone doing work under its
direction pursuant to the terms of this Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">is disclosed to Receiving Party by a third person who has a right to make such disclosure without an obligation
of confidentiality to Disclosing Party; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">is developed independently by Receiving Party without use of the Disclosing party&rsquo;s Confidential
Information, as evidenced by Receiving Party&rsquo;s contemporaneous written or electronic records.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Receiving
Party shall not use Confidential Information, except in furtherance of this Agreement, or disclose Confidential Information to third parties
in a manner that is inconsistent with the terms of this Section. Except as stated herein, a Receiving Party shall restrict access to Disclosing
Party&rsquo;s Confidential Information to Receiving Party&rsquo;s employees and contractors with a need to know for the purpose of administering
or implementing this Agreement or for the purpose of providing legal, actuarial, or accounting services to Receiving Party, and only to
the extent such employees and contractors agree to be bound by confidentiality and use restrictions at least as restrictive as those set
forth herein. Receiving Party shall be responsible for any unauthorized use or disclosure of the Disclosing Party&rsquo;s Confidential
Information by any person or entity to which the Receiving Party discloses such Confidential Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Upon
termination of this Agreement, Receiving Party shall return to Disclosing Party all documents or other materials that contain Disclosing
Party&rsquo;s Confidential Information or destroy all copies thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">If
the Receiving Party is required under a final judicial or governmental order to disclose any Confidential Information received from the
Disclosing Party, the Receiving Party may disclose the Confidential Information, provided that the Receiving Party gives the Disclosing
Party sufficient prior notice to contest such order and the Receiving Party discloses only such portions of the Confidential Information
as is required by such order.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">6.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>HIPAA
Requirements</B>. Without limiting the foregoing, the parties acknowledge that each party is a &ldquo;covered entity&rdquo; as that term
is defined at 45 C.F.R. &sect; 160.103. As such, the parties agree to comply with applicable requirements of the Health Insurance Portability
and Accountability Act of 1996, as codified at 42 U.S.C. &sect; 1320d et seq. (&ldquo;HIPAA&rdquo;), the Health Information Technology
for Economic and Clinical Health Act, as each may be amended from time to time, and any current and future regulations promulgated thereunder,
including without limitation the federal privacy regulations contained at 45 C.F.R. Part&nbsp;160 and Part&nbsp;164, Subpts. A and E (the
 &ldquo;Federal Privacy Regulations&rdquo;), the federal security standards contained at 45 C.F.R. Part&nbsp;160 and Part&nbsp;164, Subpts.
A and C, the federal breach notification rules&nbsp;contained at 45 C.F.R. Part&nbsp;160 and Part&nbsp;164, Subpts. A and D, and the federal
standards for electronic transactions contained at 45 C.F.R. Parts 160 and 162, all collectively referred to herein as &ldquo;HIPAA Requirements.&rdquo;
The parties agree not to use or further disclose any Protected Health Information, as defined in the Federal Privacy Regulations, other
than as permitted by HIPAA Requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">7.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>Insurance
Coverage</B>. During the term of this Agreement, Laboratory shall maintain general and professional liability insurance including coverage
for product liability and clinical trials liability in the amount of $<B>[***]</B> per occurrence and $<B>[***]</B> annual aggregate or
such higher coverage as may be required by law. Proof of said insurance coverage shall be supplied to Anthem upon request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">8.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>Indemnification</B>.
Laboratory shall indemnify, defend, and hold Anthem, its directors, officers, agents, and employees, harmless from and against any judgments,
damages, losses, costs, and expenses (including, without limitation, reasonable attorneys&rsquo; fees) arising from, or related to, any
allegation, demand, claim, action or proceeding to the extent arising out of the Services, or Laboratory&rsquo;s breach of this Agreement
or applicable law, or Laboratory&rsquo;s negligent acts or omissions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Anthem shall indemnify, defend,
and hold Laboratory, its directors, officers, agents, and employees, harmless from and against any judgments, damages, losses, costs,
and expenses (including, without limitation, reasonable attorneys&rsquo; fees) arising from, or related to, any allegation, demand, claim,
action or proceeding to the extent arising out of the Services, or Anthem&rsquo;s breach of this Agreement or applicable law, or Anthem&rsquo;s
negligent acts or omissions, except to the extent that such judgments, damages, losses, costs and expenses were caused by Laboratory&rsquo;s
negligence, willful misconduct or failure to comply with its obligations under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">9.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>Fraud
and Abuse</B>. The parties expressly acknowledge that the compensation payable hereunder is fair market value for the items purchased
and/or the services rendered, and that nothing contained herein shall require referrals for items or services between the parties. Neither
party will knowingly or intentionally conduct itself in such a manner as to violate any federal or state law, rule&nbsp;or regulation
applicable to the items purchased or the services rendered hereunder, including but not limited to any fraud and abuse provisions relating
to the Medicare and Medicaid Programs. The parties also agree that the benefits to either party hereunder do not require, are not payment
for, and are not in any way contingent upon the admission, referral, or other arrangement for the provision of any item or service reimbursed
under any federal or state health care program, including, without limitation, Medicare or Medicaid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>10.</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Miscellaneous</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>10.1</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Assignment</FONT></B><FONT STYLE="font-size: 10pt">.
Laboratory may not assign this Agreement, or any rights or obligations hereunder, without Anthem&rsquo;s prior written consent, which
consent shall not be unreasonably withheld, delayed, or conditioned. Subject to the foregoing, this Agreement shall inure to the benefit
and be binding upon Anthem and its successors and assigns and Laboratory and its successors and assigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>10.2</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Changes
in Law</FONT></B><FONT STYLE="font-size: 10pt">. This Agreement shall be construed to be in accordance with applicable federal and state
laws. In the event there is a change in such laws, whether by statute, regulation, agency, or judicial decision that has any material
effect on any term of this Agreement, then the applicable term(s)&nbsp;of the Agreement shall be subject to renegotiation and any affected
party may request renegotiation of the affected term or terms of this Agreement, upon written notice to the other party, to remedy such
condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The parties expressly recognize
that upon request for renegotiation, each party has a duty and obligation to the other only to renegotiate the affected term(s)&nbsp;in
good faith and, further, each party expressly agrees that its consent to proposals submitted by the other party during renegotiation efforts
shall not be unreasonably withheld.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Should the parties be unable
to renegotiate the term or terms so affected so as to bring it/them into compliance with the statute, regulation, or judicial opinion
that rendered it/them unlawful or unenforceable within ten (10)&nbsp;days of the date on which notice of a desired renegotiation is given,
then either party shall be entitled, after the expiration of said ten (10)&nbsp;day period, to terminate this Agreement upon ten (10)&nbsp;additional
days written notice to the other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>10.3</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Compliance
with Laws</FONT></B><FONT STYLE="font-size: 10pt">. Laboratory warrants that it is and shall remain in compliance with all applicable
federal, state, and local laws, regulations, and standards relating, including but not limited to all laws and regulations related to
health, safety, and environmental standards, and (ii)&nbsp;all such laws related to the provision of Services purchased pursuant to this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>10.4</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Enforceability</FONT></B><FONT STYLE="font-size: 10pt">.
In the event any provision of this Agreement is found to be unenforceable or invalid, such provision shall be severable from this Agreement
and shall not</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">affect the enforceability or validity of any other provision contained
in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>10.5</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Entire
Agreement</FONT></B><FONT STYLE="font-size: 10pt">. This Agreement may be executed in one or more counterparts, all of which together
shall constitute only one Agreement. This Agreement contains the entire understanding between the parties and supersedes and terminates
any prior agreement(s)&nbsp;between the parties hereto. No amendments or additions to this Agreement shall be binding unless such amendments
or additions are in writing and signed by the parties, except as herein otherwise provided.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>10.6</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Force
Majeure</FONT></B><FONT STYLE="font-size: 10pt">. Neither party shall be liable for a delay in its performance of its obligations and
responsibilities under this Agreement due to extraordinary causes beyond its control, including, but not limited to, war, act of terrorism,
pandemics, embargo, national emergency, insurrection or riot, acts of the public enemy, fire, flood, or other natural disaster (&ldquo;Force
Majeure Event&rdquo;); provided that said party has taken reasonable measures to notify the other, in writing, of the delay. Further,
in the event either party is unable to meet its obligations hereunder because of such force majeure, and such inability continues for
a period of thirty (30) days or more, then either party may terminate this Agreement effective immediately without further obligation
to the other except as to delivery of and payment for the Services consistent with the terms of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>10.7</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Governing
Law</FONT></B><FONT STYLE="font-size: 10pt">. This Agreement and the rights and obligations of the parties hereto shall be governed by
and construed and enforced in accordance with the substantive laws of the State of Utah, without regard to its principles of conflicts
of laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>10.8</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Independent
Contractors</FONT></B><FONT STYLE="font-size: 10pt">. Each party shall be considered to be an independent party and shall not be construed
to be an agent or representative of the other party, and therefore, has no liability for the acts or omissions of the other party. In
addition, neither party, nor any of its employees, agents, or subcontractors, shall be deemed to be employees or agents of the other party.
Therefore, neither party nor any of its employees, agents, or subcontractors, shall be entitled to compensation, workers compensation,
or employee benefits of the other party by virtue of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>10.9</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Non-Solicitation.
</FONT></B><FONT STYLE="font-size: 10pt">No party may, directly or indirectly, solicit, recruit, or otherwise encourage any employee of
the other party to leave his or her employment with that other party for any reason. This restriction applies during the term and for
a period of twelve (12) months after the termination or expiration of this Agreement. The preceding sentence does not, however, prohibit
either party from: (i)&nbsp;soliciting employment by placement of general advertisements for employees on any internet site, in newspapers,
or via other media of general circulation not specifically directed at the employees of the other party; (ii)&nbsp;soliciting persons
identified through employment search firms that are not specifically directed at the employees of the other party; or (iii)&nbsp;soliciting
or hiring any person who contacts the hiring party on his or her own initiative without any prior solicitation or recruitment (other than
advertisements of the type contemplated by the preceding clauses).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>10.10</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Remedies</FONT></B><FONT STYLE="font-size: 10pt">.
In addition to those remedies provided herein, each party shall have available all remedies provided by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>10.11</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Section&nbsp;and
Other Headings</FONT></B><FONT STYLE="font-size: 10pt">. The article and other headings contained in this Agreement are for reference
purposes only and shall not affect in any way the meaning or interpretation of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>10.12</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Waiver</FONT></B><FONT STYLE="font-size: 10pt">.
The waiver of a breach of this Agreement or the failure of a party to exercise any right under this Agreement shall in no event constitute
a waiver as to any other breach, whether similar or dissimilar in nature, or prevent the exercise of any right under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>10.13</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Audit</FONT></B><FONT STYLE="font-size: 10pt">.
Anthem may, upon reasonable notice, audit any and all work or expense records of Laboratory relating to the Services provided hereunder.
Laboratory shall have the right to exclude from such inspection any of its confidential or proprietary information that is unrelated to
this Agreement, which was not otherwise provided to Anthem as a part of this Agreement. Laboratory further agrees to maintain its books
and records relating to System provided hereunder for a period of two (2)&nbsp;years from the date such work was completed, and to make
such books and records available to Anthem, during normal business hours, at any time or times within the two-year period. Any such audit
will be at Anthem&rsquo;s expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>10.14</B></FONT><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Notice</FONT></B><FONT STYLE="font-size: 10pt">.
This Agreement, including any attachments, may be amended or modified only by an instrument of equal formality signed by duly authorized
representatives of the respective parties. All notices, requests, demands, or other communications hereunder other than day-to-day communications
within the duties of the representatives shall be in writing and shall be deemed given if personally delivered or mailed to the address
set forth below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">Laboratory:</TD><TD>Sera Prognostics,&nbsp;Inc.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">2749 East Parleys Way</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Suite&nbsp;200</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Salt Lake City, UT 84109</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">Anthem:</TD><TD>Anthem Inc.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">4425 Corporation Lane</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Virginia Beach, VA 23462</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any changes in the above addresses
for notice shall be provided to the other party to this Agreement within five (5)&nbsp;days of such change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>,
the parties hereto have executed this Agreement on the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Anthem Inc.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sera Prognostics,&nbsp;Inc.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Michael Hodgins</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Gregory Critchfield</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director, Strategic Sourcing</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and CEO</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/8/2021</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/11/2020</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit&nbsp;A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Laboratory Services Fee Schedule</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7.1
<SEQUENCE>20
<FILENAME>tm2110724d11_ex10d7-1.htm
<DESCRIPTION>EXHIBIT 10.7.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.7.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Confidential</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>COMMERCIALIZATION AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Commercialization Agreement
(&ldquo;<U>Agreement</U>&rdquo;) is effective as of January 9, 2017 (&ldquo;<U>Effective Date</U>&rdquo;) and is entered into by and between
Sera Prognostics, Inc. (&ldquo;<U>Sera</U>&rdquo;), a Delaware corporation with its principal place of business at 2749 East Parleys Way,
Suite 200, Salt Lake City, Utah 84109, and Laboratory Corporation of America Holdings (&ldquo;<U>LabCorp</U>&rdquo;), a Delaware corporation
with its principal place of business at 531 South Spring Street, Burlington, North Carolina 27215. Each of Sera and LabCorp is referred
to herein as a &ldquo;<U>Party</U>&rdquo; and together as the &ldquo;<U>Parties</U>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">BACKGROUND</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">A.</TD><TD STYLE="text-align: justify">Sera is a diagnostics company that develops, commercializes, and performs a prognostic test in its CLIA-certified
laboratory referred to as the PreTRM&reg; test, which is a clinical blood test for early individualized risk assessment of spontaneous
premature birth (the &ldquo;<U>Test</U>&rdquo;).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">B.</TD><TD STYLE="text-align: justify">LabCorp provides leading-edge medical laboratory tests and services through a national network of primary
clinical laboratories and specialty testing laboratories.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">C.</TD><TD STYLE="text-align: justify">[***].</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the foregoing premises and the mutual covenants and agreements set forth herein, and for other good and valuable consideration, the
receipt and sufficiency of which are acknowledged, the Parties agree as follows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">DEFINITIONS</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Capitalized terms used herein
shall have the definitions set forth in this Article 1 or elsewhere herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Affiliate</U>&rdquo; means, with respect to a Party to this Agreement, any current or future Entity which controls, is
controlled by, or is under common control with such Party, but only for so long as such control exists. For purposes of this definition
only, &ldquo;control&rdquo; means direct or indirect ownership of at least fifty percent (50%) of the shares or other equity interests
of the subject Entity entitled to vote in the election of directors (or, in the case of an Entity that is not a corporation, for the election
of the corresponding managing authority).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Commercialize</U>&rdquo; means to advertise, market, promote, offer for sale, sell and distribute, and to accept orders,
collect fees and book revenue for sales of Tests (and &ldquo;Commercialization&rdquo; shall have the correlative meaning).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Commercially Reasonable Efforts</U>&rdquo; means the carrying out of activities using good faith commercially reasonable
and diligent efforts to achieve a goal, and using the efforts that a similarly situated company would reasonably devote to a product
of similar market potential or profit potential at a similar stage in development or product life resulting from its own research efforts,
based on conditions then prevailing and taking into account, without limitation, issues of safety and efficacy, product profile, the
competitiveness of alternative products in the marketplace, the likely timing of the product&rsquo;s entry into the market, the patent
and other proprietary position, and the status of the approval process, the commercial potential and profitability, and other relevant
scientific, medical, technical and commercial factors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL
IF PUBLICLY DISCLOSED. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Control</U>&rdquo; or &ldquo;<U>Controlled</U>&rdquo; means the possession by Sera of the ability to grant a license
or sublicense of intellectual property rights as provided for herein without violating the terms of any arrangement or agreements between
it and any third party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Entity</U>&rdquo; means a person, corporation, partnership, association, limited liability company, unincorporated organization,
firm, or other entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Field</U>&rdquo; means the prediction of a patient&rsquo;s likelihood to deliver a baby at less than thirty seven (37)
weeks of gestation. For clarity, pharmaceutical collaborations and clinical trials are outside the Field.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Legal Requirements</U>&rdquo; means any applicable national, federal, state or local law, rule, ordinance or regulation,
or formal administrative agency final guidance or published final interpretation, in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Provider</U>&rdquo; means a healthcare provider authorized and licensed to provide obstetrics services to patients within
the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Sample</U>&rdquo; means any fluid sample extracted from a Provider&rsquo;s patient as necessary to perform the Test.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<U>Territory</U>&rdquo; means the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.13<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">DISTRIBUTION RIGHTS AND OBLIGATIONS</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Independent Contractor</U>. Each Party shall perform its services under this Agreement as an independent contractor and not
as an employee or agent of the other Party or any of its parents, subsidiaries, or affiliates. Neither Party is authorized to assume or
create any obligation or responsibility, express or implied, on behalf of, or in the name of, the other Party or to bind the other Party
in any manner, except that Sera will perform all Tests that are ordered in compliance with the process described in Section 3. Without
limiting the generality of the foregoing, neither Party (a) shall have the right to enter into any contracts or commitments in the name
of, or on behalf of, the other Party, and (b) shall obligate or purport to obligate the other Party by issuing or making any warranties
or guaranties with respect to Tests to any third party that are not provided or approved in writing in advance by the other Party. Neither
Party shall be entitled to any benefits, coverages or privileges, including, without limitation, social security, unemployment, medical
or pension payments, made available to employees of the other Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.13<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.14<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.15<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.16<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">SAMPLE PROCESSING AND TESTING</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>SOPs</U>. Sera and LabCorp shall use diligent and good faith efforts to agree upon standard operating procedures for LabCorp&rsquo;s
acceptance of orders for Tests, collection, processing and shipment of Samples to Sera, and Sera&rsquo;s provision of Sera Results Reports
(defined below) (&ldquo;<U>Intercompany SOPs</U>&rdquo;) for each Test within thirty (30) days of the Effective Date. Sera acknowledges
that LabCorp is not responsible for ensuring that the collection, preservation, shipping and handling specifications established in the
Intercompany SOPs are sufficient to ensure the viability of Samples for performance of the Test. Each Intercompany SOP may only be amended
by the Parties in writing. Neither Party shall change nor deviate from an Intercompany SOP without the other Party&rsquo;s prior written
approval of the proposed change or deviation. Sera shall maintain written documentation of its own technical standard operating procedures
for its performance of the Tests (&ldquo;<U>Sera SOPs</U>&rdquo;), which shall constitute Sera&rsquo;s Confidential Information. For clarity,
the Sera SOPs shall not form part of the Intercompany SOPs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Sample Collection, Processing and Shipment by LabCorp</U>. LabCorp agrees that it will be responsible for (a) collecting Samples
at LabCorp facilities from customers who have ordered the Test; (b) procuring the supplies needed for each patient draw; (c) labeling
and processing such Samples (whether ordered in connection with other testing to be performed by LabCorp or as a standalone test); (d)
packaging the Samples; and (e) shipping the Samples to Sera&rsquo;s CLIA-certified, licensed laboratories located at 2749 Parleys Way,
Suite 200, Salt Lake City, UT 84109 (the &ldquo;<U>Licensed Facilities</U>&rdquo;) for performance of the Tests, all in accordance with
the Intercompany SOPs. Sera acknowledges that LabCorp may route samples through its regional laboratories, so long as such routing complies
with the Sera SOPs. LabCorp shall not deliver any Samples to Sera that LabCorp knows is insufficient for purposes of performing a Test.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Performance of Tests</U>. Sera will perform Tests on Samples received from LabCorp at the Licensed Facilities in accordance
with (i) the analytical, clinical and performance standards set forth on <U>Exhibit E</U> attached hereto and (ii) the Intercompany SOPs.
[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Licensed Facilities</U>. Sera shall perform the Services only at its Licensed Facilities and Sera may change the location of
the Licensed Facilities to substantially equivalent and appropriately certified, accredited, licensed laboratory facilities within the
USA upon sixty (60) days&rsquo; prior written notice to LabCorp. LabCorp&rsquo;s designated representatives may visit the Licensed Facilities
upon reasonable advance notice and during Sera&rsquo;s normal business hours to observe the performance of the Services and to verify
compliance with the Intercompany SOPs, subject to compliance with Sera&rsquo;s onsite policies and processes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Governmental Permits and Approvals</U>. Each Party will obtain and maintain all applicable professional licenses, permits, certifications,
authorizations, and approvals as may be required for the performance of its hereunder, and each Party will be solely responsible for any
fees associated with any licenses, permits, certifications, authorizations, or approvals. Sera will use commercially reasonable efforts
to obtain and receive New York Approval as soon as practicable, and will notify LabCorp promptly upon the occurrence of New York Approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Retention of Records and Samples</U>. Sera and LabCorp shall retain and preserve accurate and complete records and pertinent
Samples related to any Tests performed by Sera under this Agreement in conformity with company policies and consistent with applicable
Legal Requirements. Upon written request, each Party shall make available for review by the other all such records and preserved materials
as may be reasonably required or requested.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify">COMPENSATION</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify">CLINICAL STUDIES AND COMPLIANCE</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Compliance with Laws</U>. LabCorp and Sera each agree to perform their respective obligations under this Agreement in compliance
with all Legal Requirements and all applicable regulations, rules, and policies of third party payors that pay for the Tests. The terms
of this Agreement are intended to be in compliance with Legal Requirements applicable on the Effective Date, including, but not limited
to the federal health care anti-kickback statute (42 U.S.C. &sect; 1320a-7b), and applicable state law equivalents, as well as applicable
state law prohibitions on professional fee splitting. Should legal counsel for either Party reasonably conclude that any portion of this
Agreement is or may be in violation of such Legal Requirements, or subsequent enactments by any governmental authorities, that Party shall
give written notice and the Parties will negotiate in good faith to amend this Agreement to comply with such Legal Requirements. In the
event that the Parties are unable to agree upon such an amendment, either Party may terminate this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Privacy</U>. LabCorp and Sera each agree to protect the privacy and provide for the security of any information that relates
to a patient&rsquo;s past, present, or future physical or mental health or condition in accordance with the Health Insurance Portability
and Accountability Act of 1996, Public Law 104-191, and all regulations promulgated thereunder at 45 C.F.R. parts 160 through 164, as
amended by the federal Health Information Technology for Economic and Clinical Health Act (&ldquo;<U>HITECH Act</U>&rdquo;) and its implementing
regulations, as may be modified or amended (collectively &ldquo;<U>HIPAA</U>&rdquo;), and any other applicable federal and state laws
and regulations. The Parties acknowledge and agree that they are both &ldquo;covered entities&rdquo; providing &ldquo;treatment&rdquo;
for patients as those terms are defined under HIPAA. Both parties acknowledge that they have developed and implemented policies, procedures,
and training programs reasonably designed to protect the privacy and security of patient information in accordance with HIPAA&rsquo;s
privacy, security, and breach notification regulations. Sera shall not use any information received from LabCorp to contact a patient
directly without LabCorp&rsquo;s prior written consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Participation in Federal Health Care Programs</U>. LabCorp and Sera respectively represent, warrant and covenant to the other
that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.4.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>It, and its owners, directors, officers, agents, or employees are, as of the Effective Date, and for the remainder of the term
of this Agreement, will be, eligible to participate in the federal health care programs as defined in Section 1128B of the Social Security
Act (42 U.S.C. 1320a-7b(f)) or any state health care program as defined in Section 1128B of the Social Security Act (42 U.S.C. 1320a-7b(h)).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.4.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Neither it, nor any of its owners, directors, officers, agents, or employees has been, as of the Effective Date, nor during the
term of this Agreement, will be, sanctioned by the DHHS Office of the Inspector General as set forth in the List of Excluded Individuals/Entities
Database or excluded by the General Services Administration as set forth in Excluded Parties List System.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.4.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>It shall notify the other Party promptly in the event of any adverse action relating to its license, permit, certification or right
to receive reimbursement from any federally funded health care program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Non-Discrimination</U>. Each Party will perform its obligations hereunder in compliance with all federal and state laws prohibiting
discrimination on the basis of race, color, religion, sex, national origin, handicap, or veteran status.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">6.</TD><TD STYLE="text-align: justify">INVESTMENT</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">7.</TD><TD STYLE="text-align: justify">INDEMNIFICATION; LIMITATION OF LIABILITY AND INSURANCE.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Indemnification</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">7.1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>LabCorp will defend, indemnify and hold harmless Sera and its Affiliates, and their respective shareholders, members, partners,
directors, officers, employees, and agents (&ldquo;<U>Sera Indemnified Parties</U>&rdquo;) from and against any and all third party claims,
actions, and proceedings alleging damages, liabilities, losses, costs and/or expenses and brought against any of the Sera Indemnified
Parties to the extent arising from (a) LabCorp&rsquo;s violation of a Legal Requirement in connection with its performance of this Agreement;
(b) any negligent act or omission or intentional misconduct or omission of LabCorp in relation to its obligations under this Agreement;
(c) the breach of Section 9 by LabCorp; (d) any representations or warranties made by LabCorp in respect of Tests that are inconsistent
with, or broader than, the then-current representations and warranties published, <U>provided</U>, or approved by Sera in writing; (e)
any deviation from the results included in the Sera Results Report as compared to the results actually reported by LabCorp to the customer
(including, without limitation, any errors in reproducing the results or any information relating to the results or use or interpretation
thereof which was not included in the Sera Results Report as provided to LabCorp); (f) any Test results which are incorrect as a result
of procedures or processes or other activities within LabCorp&rsquo;s control; and (g) personal injury caused by LabCorp personnel in
their drawing, handling, storing and shipping of Samples and related patient information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">7.1.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> Sera will defend, indemnify and hold harmless LabCorp and its Affiliates, and their respective shareholders, members, partners,
directors, officers, employees, and agents (&ldquo;<U>LabCorp Indemnified Parties</U>&rdquo;) from and against any and all third party
claims, actions, and proceedings alleging damages, liabilities, losses, costs and/or expenses and brought against any of the LabCorp Indemnified
Parties to the extent arising from (a) Sera&rsquo;s violation of a Legal Requirement in connection with its performance of this Agreement;
(b) any negligent act or omission or intentional misconduct or omission of Sera in relation to its obligations under this Agreement; (c)
the breach of Section 9 by Sera; (d) any Test results (as provided by Sera to LabCorp hereunder) which (1) are incorrect as a result of
laboratory procedures or processes or other activities within Sera&rsquo;s control, or (2) are performed by Sera outside the standards
as set forth in <U>Exhibit E</U> or otherwise not in conformance with the sensitivity or specificity standards set by Sera for the Test
as of the time the Test is performed; (e) any Test tests that were not performed by Sera in accordance with Sera SOPs in effect as of
the time the test was performed; (f) any incomplete Test results as provided by Sera to LabCorp hereunder; and (g) any actual or alleged
infringement (including direct or indirect, joint or divided infringement, as the case may be) or misappropriation of any patent or other
intellectual property rights based upon the performance of the Test or based upon the Sera Mark (unless used by LabCorp other than in
strict accordance with this Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">7.1.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>A Party&rsquo;s obligations to indemnify the other Party pursuant to this Section 7.1 is conditioned upon the indemnified Party:
(i) providing the indemnifying Party with prompt written notice of such claim, action, or proceeding (although failure to provide notice
promptly shall not relieve the indemnifying Party of its obligations unless such failure materially prejudices the indemnifying Party&rsquo;s
ability to defend such claim, action or proceeding); (ii) permitting the indemnifying Party to assume and solely control the defense of
such claim, action, or proceeding and all related settlement negotiations, with counsel chosen by the indemnifying Party; and (iii) cooperating
at the indemnifying Party&rsquo;s request and expense with the defense or settlement of such claim, action, or proceeding which cooperation
must include providing reasonable assistance and information. No indemnified Party will enter into any settlement agreement for which
it will seek indemnification under this Agreement from the indemnifying Party without the prior written consent of the indemnifying Party.
Nothing herein restricts the right of a Party to participate in a claim, action, or proceeding through its own counsel and at its own
expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Limitation of Liability</U>. EXCEPT WITH RESPECT TO DAMAGES CAUSED BY FRAUD, INTENTIONAL MISCONDUCT, A BREACH OF SECTION 8 (CONFIDENTIALITY)
OR BY A PARTY&rsquo;S VIOLATION OF APPLICABLE LEGAL REQUIREMENTS, AND EXCEPT FOR AMOUNTS OWED BY A PARTY PURSUANT TO ITS INDEMNIFICATION
OBLIGATIONS IN SECTION 7.1, NEITHER PARTY WILL BE LIABLE TO THE OTHER FOR ANY INDIRECT, SPECIAL, INCIDENTAL, CONSEQUENTIAL, OR SIMILAR
LOSSES OR DAMAGES SUFFERED BY SUCH PARTY, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Insurance</U>. Each Party shall maintain in full force and effect from a third party that is rated &ldquo;A&rdquo; or &ldquo;A-&rdquo;
in Best&rsquo;s Insurance Guide, or is otherwise reasonably acceptable to the other Party, at a minimum the following insurance coverage
for its operations in the Territory:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> Automobile liability covering all vehicles owned, non-owned, hired and leased in an amount not less than $[***] per claim (combined
single limit for bodily injury and property damage).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Commercial general liability insuring against bodily injury, property damage, contractors&rsquo; completed operations and contractual
liability with a combined single limit of not less than $[***] per claim and $[***] in the aggregate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Umbrella/Excess Liability coverage of not less than $[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Insurance carried on a claims made basis shall
have a reporting tail of at least three years after the expiration or termination of this Agreement to cover all claims. This can be purchased
at termination of the Agreement. For the avoidance of doubt, any policy amounts or limitations shall not in any event be construed as
limitations on a Party&rsquo;s liability under the Agreement. After receipt of written request, each Party shall furnish the other Party
with certificates of insurance evidencing the above coverages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">8.</TD><TD STYLE="text-align: justify">CONFIDENTIALITY</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Confidentiality</U>. The Parties acknowledge that they may exchange confidential or proprietary information pursuant to this
Agreement (&ldquo;<U>Confidential Information</U>&rdquo;), whether written, verbal, or tangible. Confidential Information shall not include
information that the receiving Party can demonstrate (a) is or becomes a part of the public domain through no wrongful act or omission
of the receiving Party, (b) is or was in the receiving Party&rsquo;s lawful possession prior to receipt from the disclosing Party, as
evidenced by the receiving Party&rsquo;s records kept in the ordinary course of its business, (c) is disclosed to the receiving Party
by a third party entitled to disclose such Confidential Information, other than disclosure on behalf of the disclosing Party, or (d) was
independently developed by the receiving Party without use of or access or reference to the Confidential Information of the disclosing
Party, as evidenced by the receiving Party&rsquo;s records kept in the ordinary course of its business. Each Party agrees that, during
the term of this Agreement and thereafter, it shall not, directly or indirectly, (i) use the other Party&rsquo;s Confidential Information
for any reason other than to perform its obligations or exercise its rights under this Agreement, or (ii) disclose or otherwise make available
the other Party&rsquo;s Confidential Information to any third parties, except in either case (A) as authorized by such other Party in
writing, (B) as expressly permitted herein, or (C) to the extent required by applicable Legal Requirements, in which case it shall promptly
notify the other Party in writing of the requirement so that the other Party may seek a protective order or confidentiality treatment,
and it shall cooperate with the other Party, at the other Party&rsquo;s request and expense, in any such efforts. In no event shall Sera
use any Confidential Information of LabCorp to solicit any customers of LabCorp inside or outside the Territory during or after the term
of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Terms of Agreement</U>. Each of the Parties shall not disclose to any third party the terms of this Agreement without the prior
written consent of the other Party, except in confidence to its business or legal advisors, investors, and sources of financing, in each
case on a need-to-know basis under circumstances that reasonably ensure the confidentiality thereof, or to the extent required by law,
rule, regulation or governmental authority, including applicable rules of any securities exchange. If the terms of this Agreement are
required to be publicly disclosed by applicable Legal Requirements, the disclosing Party shall seek confidential treatment for the terms
and conditions of this Agreement to the fullest extent permitted by applicable laws, rules and regulations. Prior to seeking such confidential
treatment, the disclosing Party shall provide the other Party with a copy of the proposed disclosure showing the disclosing Party&rsquo;s
proposed redactions of the document, and shall consult with the other Party and the other Party&rsquo;s counsel and provide them with
a reasonable opportunity to request the inclusion of specified provisions or redactions in any request for confidential treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">9.</TD><TD STYLE="text-align: justify">REPRESENTATIONS AND WARRANTIES</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">9.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>By Sera</U>. Sera represents, warrants and covenants to LabCorp that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">9.1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>This Agreement is a legal and valid obligation binding upon Sera and enforceable in accordance with its terms, subject to generally
applicable Legal Requirements, and the execution, delivery and performance of this Agreement by Sera does not conflict with any agreement,
instrument or understanding to which Sera is a party or by which it is bound.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">9.1.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>No consent of, or payment to, any third party is required for Sera to grant the rights and licenses to LabCorp as set forth herein,
or for Sera to enter into this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">9.1.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Sera&rsquo;s employees who will be performing the Tests hereunder are qualified to do so, and possess the necessary skill, education,
training, and where required by any applicable Legal Requirements, Sera and its employees have the necessary federal and state licenses
or certificates, to perform such testing services. Copies of such licenses or certificates shall be provided to LabCorp upon written request,
in addition to such quality assessment information as reasonably requested by LabCorp.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">9.1.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Sera shall comply with current good laboratory practice as required by the Clinical Laboratory Improvement Amendments of 1988 under
42 USC 263a (CLIA&rsquo;88), FDA regulations for Protection of Human Subjects in Research as published in 21 CFR Parts 50, 56 and 812
and all applicable College of American Pathologists rules, regulations, orders and guidances, and the requirements with respect to current
good laboratory practices prescribed by other similar authorities in the Territory, and shall perform all its obligations under this Agreement
in a professional and workmanlike manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">9.1.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Sera shall maintain an adequate and appropriate disaster recovery plan for performance of Tests hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">9.1.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>All information and other content Sera provides to LabCorp for use in the sales, marketing and promotion of the Test shall be accurate
and not deceptive or fraudulent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">9.1.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>As of the Effective Date, neither Sera nor any of its officers, directors, employees or owners have been debarred, suspended, declared
ineligible or excluded from participation in any federal or state healthcare program and during the term of this Agreement no officer,
director or employee that has been debarred, suspended, declared ineligible or excluded from participation in any federal or state healthcare
program shall perform any services under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">9.1.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> To Sera&rsquo;s knowledge, as of the Effective Date, there is no unauthorized use, infringement or misappropriation by any third
parties of the intellectual property Controlled by Sera and used in its performance of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">9.1.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To Sera&rsquo;s knowledge, as of the Effective Date, there is no pending or threatened litigation which alleges that Test infringes
upon any third party rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">9.1.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>To Sera&rsquo;s knowledge, as of the Effective Date, there are no valid patent claims or other intellectual property rights of
a third party that would be infringed by Sera&rsquo;s performance of the Test.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">9.1.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>As of the Effective Date, Sera has not granted any licenses, authorizations or covenants-not-to-sue to any third parties with respect
to the Test in the Field in the Territory, or granted any third party the right to market, offer, perform, sell or distribute testing
services based on use of the Test in the Field in the Territory</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">9.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>By LabCorp</U>. LabCorp represents, warrants and covenants to Sera that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">9.2.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>This Agreement is a legal and valid obligation binding upon LabCorp and enforceable in accordance with its terms, subject to generally
applicable Legal Requirements, and the execution, delivery and performance of this Agreement by LabCorp does not conflict with any agreement,
instrument or understanding to which LabCorp is a party or by which it is bound.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">9.2.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>LabCorp will perform this Agreement and Commercialize Tests in compliance with all applicable federal, state, and local laws, rules,
and regulations and all applicable regulations, rules, and policies of third party payors that pay for the Tests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">9.2.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>LabCorp&rsquo;s employees who will be performing work under this Agreement are qualified to do so, and possess the necessary skill,
education, training, and where required by any applicable Legal Requirements, Sera and its employees have the necessary federal and state
licenses or certificates, to perform such work.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">9.2.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>As of the Effective Date, neither LabCorp nor any of its Affiliates or its or their officers, directors, employees or owners have
been debarred, suspended, declared ineligible or excluded from participation in any federal or state healthcare program and during the
term of this Agreement no officer, director or employee that has been debarred, suspended, declared ineligible or excluded from participation
in any federal or state healthcare program shall perform any services under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">9.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Disclaimer</U>. EXCEPT AS SPECIFIED IN THIS AGREEMENT, EACH PARTY DISCLAIMS ALL WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, WITH
RESPECT TO THE SERVICES, TESTS, THE MARKETING MATERIALS AND ITS TRADEMARKS, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE, TITLE AND NON-INFRINGEMENT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">10.</TD><TD STYLE="text-align: justify">TERM AND TERMINATION</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">10.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">10.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each Party may terminate this Agreement upon notice if the other Party: (i) makes an assignment or other arrangement for the benefit
of creditors, appoints or suffers appointment of a receiver or trustee over its property, (ii) files a petition under any bankruptcy or
insolvency act or has any such petition filed against it which is not discharged within one hundred twenty (120) days of the filing thereof,
(iii) discontinues or suspends its operations for any reason whatsoever, including loss or suspension of license or accreditation, or
(iv) is sanctioned, debarred, suspended, or excluded from any federal health care program as defined under applicable Legal Requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">10.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Effects of Expiration or Termination</U>. All licenses granted hereunder to LabCorp shall automatically terminate upon expiration
or termination of this Agreement. Upon termination of this Agreement, each Party shall immediately return to the other party all of the
other Party&rsquo;s Confidential Information in its possession or control, and LabCorp shall immediately return, at LabCorp&rsquo;s cost,
all demonstration Tests that have been provided to LabCorp by or on behalf of Sera. Notwithstanding the foregoing, each Party may retain
one copy of the Confidential Information of the other Party in its Law Department for archive purposes, and neither Party shall be required
to destroy or delete copies that have become embedded in its electronic storage systems through routine backup processes. Upon termination
or expiration of this Agreement, LabCorp agrees to cooperate with Sera in order to effect an orderly transition of LabCorp&rsquo;s responsibilities
hereunder to Sera. Upon expiration or termination of this Agreement, Sera shall complete the performance of any Tests ordered by LabCorp
prior to the date of notice of termination, and Sera shall pay LabCorp all Subcontract Fees due and payable under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">10.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Survival</U>. All rights of a Party that accrued prior to the date of expiration or termination of this Agreement shall be unaffected
by this Agreement&rsquo;s expiration or termination. Sections 2.10, 2.13, 3.11, 7.1, 7.2, 7.3, 8, 10.3, 10.4 and 11 shall survive the
termination or expiration of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">11.</TD><TD STYLE="text-align: justify">GENERAL PROVISIONS</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">11.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Affiliates</U>. LabCorp&rsquo;s Affiliates shall be permitted to exercise any of LabCorp&rsquo;s rights under this Agreement,
including without limitation, LabCorp&rsquo;s rights to accept orders for, sell, and market the Test in the Territory. In addition, Sera
is permitted to perform its obligations and exercise its rights hereunder through one or more Sera Affiliates, including, without limitation,
to perform the Test on Samples delivered hereunder. Each Party is responsible for ensuring that any Affiliates performing obligations
or exercising rights under this Agreement comply with all applicable provisions hereof, and will be fully liable for any actions or omissions
of any such Affiliates in connection therewith, including, without limitation, for any breach of any provision of this Agreement by any
such Affiliate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">11.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Force Majeure</U>. If either Party is impeded in fulfilling its undertakings in accordance with this Agreement by circumstances
beyond its reasonable control, including labor conflict, acts of God, earthquake, fire, war or terrorist attack, the impediment shall
be considered a &ldquo;Force Majeure&rdquo; condition and the Party shall be excused from liability for delays due to such reasons; <U>provided</U>,
<U>however</U>, that it notifies the other Party thereof without undue delay after such a circumstance has occurred. Upon such notification,
the Parties shall agree upon a reasonable extension of the time for performance, not to exceed an extension equal to the period the Force
Majeure condition continues to exist and a reasonable period of time thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">11.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Entire Agreement</U>. This Agreement constitutes the entire agreement between the Parties with respect to the subject matter
hereof and supersedes any and all other agreements, either oral or written, between the Parties with respect to the subject matter hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">11.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Publicity</U>. The Parties shall, upon the Effective Date, work together diligently and in good faith to prepare a joint press
release disclosing their relationship under this Agreement, and each Party may release such press release at any time after thirty (30)
days from the Effective Date. Except for such press release, and except with respect to matters disclosed therein, neither Party shall
make any media releases, public announcements and/or public disclosures relating to this Agreement or the subject matter hereof, including,
without limitation, promotional or marketing material referring to the other Party, without the other Party&rsquo;s prior written consent,
except as required by Legal Requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">11.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Implied Licenses or Rights</U>. Except as expressly set forth herein, neither Party shall have the right to use any name,
trademark or service mark of the other Party. Except as expressly set forth herein, nothing in this Agreement shall imply that either
Party has any license or right under the other Party&rsquo;s Patent Rights or other intellectual property or other propriety rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">11.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Assignment</U>. Neither Party may assign, delegate, subcontract or otherwise transfer this Agreement or any right or obligation
hereunder, in whole or part, without the prior express written consent of the other Party, except that Affiliates may exercise rights
or fulfill obligations under this Agreement as provided in Section 11.1. In addition, Sera may assign this Agreement in connection with
the sale or transfer of all or substantially all of its assets to which this Agreement relates upon written notice to LabCorp, subject
to LabCorp&rsquo;s rights under Section 10.2(e) in the event of an assignment to a competitor of LabCorp.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">11.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notice</U>. All notices, requests, and other formal or legal communications to any Party hereto must be in writing and addressed
to the receiving Party&rsquo;s address set forth below or to any other address as a Party may designate by notice hereunder, and will
either be: (i) delivered by hand, (ii) sent by recognized overnight courier, or (iii) by certified mail, return receipt requested, postage
prepaid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 25%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 1in">If to Sera:</TD>
    <TD STYLE="width: 75%; font: 10pt Times New Roman, Times, Serif; text-align: left">Sera Prognostics, Inc.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 3in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">2749 East Parleys Way, Suite 200</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 3in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Salt Lake City, Utah 84109</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 3in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Attention: Chief Financial Officer or</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif; padding-left: 3in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Chief Executive Officer</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 3in">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 1in">If to LabCorp:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Laboratory Corporation of America Holdings</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 3in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">531 South Spring Street</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 3in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Burlington, NC 27215</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 3in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Attention: Law Department</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 3in">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 1in">with a copy sent to:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Laboratory Corporation of America Holdings</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 3in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">531 South Spring Street</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 3in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Burlington, NC 27215</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 3in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Attention: Licensing/Corporate Development</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All notices, requests, and other communication
hereunder will be deemed effective: (a) if by hand, at the time of the delivery thereof to the receiving Party at the address of such
Party set forth above, (b) if sent by overnight courier, on the next business day following the day such notice is delivered to the courier
service, or (c) if sent by certified mail, five (5) business days following the day such mailing is made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">11.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Amendment/Waiver</U>. The failure of either Party to enforce any term or condition of this Agreement may not be construed as
a waiver by such Party of such term or condition, nor will a waiver of any breach of a term or condition of this Agreement on any one
occasion constitute a waiver of any subsequent breach of the same or similar term or condition. No term or provision of this Agreement
may be changed, waived, amended, or terminated except by a written agreement signed by both Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">11.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Governing Law</U>. This Agreement is governed by the laws of the State of Delaware, without regard to any conflict of laws provisions
contained therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">11.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Enforceability/Severability</U>. If any provision of this Agreement is determined to be invalid or unenforceable, such provision
will be deemed severable from the remainder of this Agreement and will not cause the invalidity or unenforceability of the remainder of
this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">11.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Headings</U>. The article, section and exhibit headings used herein are for convenience and reference only and may not be used
in the interpretation of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">11.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Counterparts</U>. This Agreement may be executed in one or more counterparts, each of which are be deemed an original, but all
of which together constitute one and the same instrument. Copies of signatures sent by facsimile transmission or in a fixed electronic
format (such as a PDF file) will be deemed to be originals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">11.13<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Interpretation</U>.
Words such as &ldquo;herein,&rdquo; &ldquo;hereof&rdquo; and &ldquo;hereunder&rdquo; refer to this Agreement as a whole and not
merely to an Article, Section or paragraph in which such words appear, unless the context otherwise requires. The singular shall
include the plural, and each masculine, feminine and neuter reference shall include and refer also to the others, unless the context
otherwise requires. The word &ldquo;or&rdquo; is used in the inclusive sense typically associated with the phrase
 &ldquo;and/or&rdquo;. The words &ldquo;include,&rdquo; &ldquo;includes&rdquo; and &ldquo;including&rdquo; shall be deemed to be
followed by the phrase &ldquo;without limitation&rdquo; and shall not be construed to limit any general statement which it follows
to the specific or similar items or matters immediately following it. The word &ldquo;will&rdquo; shall be construed to have the
same meaning and effect as the word &ldquo;shall.&rdquo; All references herein to Articles, Sections or Exhibits shall be construed
to refer to Articles, Sections and Exhibits of this Agreement, and references to this Agreement include all Exhibits hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[SIGNATURES APPEAR ON THE FOLLOWING PAGE]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the duly
authorized representatives of the Parties have executed this Agreement effective as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">SERA PROGNOSTICS, INC.</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">LABORATORY CORPORATION OF AMERICA HOLDINGS</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; width: 46%">/s/ Gregory C. Critchfield, M.D.,MS</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; width: 46%">/s/ Eric Lindblom</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Name: Gregory C. Critchfield, M.D., MS</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Name: Eric Lindblom</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Its: President and Chief Executive Officer</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Its: SVP</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: justify; text-indent: -3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: justify; text-indent: -3.5in"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: justify; text-indent: -3.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">EXHIBIT A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">EXHIBIT B</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">EXHIBIT C</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">EXHIBIT D</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">EXHIBIT E</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 19; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7.2
<SEQUENCE>21
<FILENAME>tm2110724d11_ex10d7-2.htm
<DESCRIPTION>EXHIBIT 10.7.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

                           <P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: right; margin: 0pt"><B>Exhibit 10.7.2</B></P>

<P STYLE="margin: 0pt; text-align: right">&nbsp;</P>

<P STYLE="margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>First Amendment to Commercialization Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This First Amendment to Commercialization
Agreement (&ldquo;<B>Amendment</B>&rdquo;) is made and shall be effective upon the date this Amendment is signed by both Parties (&ldquo;<B>Amendment
Date</B>&rdquo;) by and between Sera Prognostics, Inc. (&ldquo;<U>Sera</U>&rdquo;), a Delaware corporation with its principal place of
business at 2749 East Parleys Way, Suite 200, Salt Lake City, Utah 84109, and Laboratory Corporation of America Holdings (&ldquo;<U>LabCorp</U>&rdquo;),
a Delaware corporation with its principal place of business at 531 South Spring Street, Burlington, North Carolina 27215. Each of Sera
and LabCorp is referred to herein as a &ldquo;<U>Party</U>&rdquo; and together as the &ldquo;<U>Parties</U>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">BACKGROUND</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sera
and LabCorp entered into that certain Commercialization Agreement effective January 9, 2017 (&ldquo;<B>Agreement</B>&rdquo;) [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Parties wish to amend the Agreement to (i) [***], and (ii) provide for Sera to engage LabCorp to perform certain Sample collection, processing,
and shipment services; all pursuant to the terms of this Amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Capitalized
terms used but not defined in this Amendment have the meanings ascribed to them in the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the foregoing premises and the mutual covenants and agreements set forth herein, and for other good and valuable consideration, the
receipt and sufficiency of which are acknowledged, the Parties agree as follows, all of which is effective as of the Amendment Date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify"><U>Definition of Tests</U>. Paragraph A of the section entitled &ldquo;Background&rdquo; in the Agreement
is deleted in its entirety and replaced with the following:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">A</TD><TD STYLE="text-align: justify">Sera is a diagnostics company that develops, commercializes, and performs a prognostic test in its CLIA-certified
laboratory referred to as the PreTRM&reg; test, which is a clinical blood test for early individualized risk assessment of spontaneous
premature birth (as such test is currently made available by Sera and also any modified or improved versions of the test, the &ldquo;<U>Test</U>&rdquo;).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">[***]:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">C</TD><TD STYLE="text-align: justify">[***], and LabCorp wishes to accept such appointment, all as further set forth herein</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Also, Section 2.1, Section 2.2, and
Section 2.11 of the Agreement are deleted in their entirety and replaced with the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.1</TD><TD STYLE="text-align: justify">[***].</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.2</TD><TD STYLE="text-align: justify">[***].</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>[***] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY
HARMFUL IF PUBLICLY DISCLOSED. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.11</TD><TD STYLE="text-align: justify">[***].</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">[***].</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify">[***].</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify"><U>Deletion of LabCorp Duties</U>. Sections 2.12, 2.14 and 2.15 of the Agreement are deleted in their
entirety.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.</TD><TD STYLE="text-align: justify"><U>LabCorp Services</U>. New Section 2.17 is added to the Agreement as follows:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><I>2.17</I></TD><TD STYLE="text-align: justify"><I><U>LabCorp Services</U>. LabCorp shall perform Sample collection, processing, and shipment services
in support of PreTRM&reg; tests as may be requested by Sera and its other distributors from time to time in accordance with the LabCorp
terms and conditions attached hereto as <U>Schedule 1</U>, and Sera shall pay LabCorp for such services as set forth therein. [***].</I></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.</TD><TD STYLE="text-align: justify">[***].</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">8.</TD><TD STYLE="text-align: justify">[***].</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.</TD><TD STYLE="text-align: justify"><U>Miscellaneous</U>. This Amendment shall be effective from the Amendment Date and in full force and
effect until the expiration or termination of Agreement. Except as expressly provided in this Amendment, the Agreement remain unmodified
and in full force and effect.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IN WITNESS WHEREOF, the parties hereto have caused
this Amendment to be signed in duplicate by their duly authorized representatives as of the dates indicated below, to be effective on
the Amendment Date. One original of each official text of this Amendment shall be held by the parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">SERA PROGNOSTICS, INC.</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">LABORATORY CORPORATION OF AMERICA HOLDINGS</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 6%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 42%">/s/ Douglas Fisher</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 6%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 44%">/s/ Michael Minahan</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Name:</TD>
    <TD STYLE="text-align: justify">Douglas Fisher</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Name:</TD>
    <TD STYLE="text-align: justify">Michael Minahan</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Title:</TD>
    <TD STYLE="text-align: justify"> Chief Business Officer&nbsp;Title:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Title:</TD>
    <TD STYLE="text-align: justify"> SVP</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Date:</TD>
    <TD STYLE="text-align: justify">6/14/2018</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Date:</TD>
    <TD STYLE="text-align: justify">6/25/18</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SCHEDULE 1</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LABCORP TERMS AND CONDITIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Sample
Collection, Processing and Shipment by LabCorp</U>. For Non-LabCorp Test Orders, LabCorp agrees that it will (a) collect Samples at LabCorp
PSCs (defined below) from customers who have ordered the Test; (b) procure the supplies needed for each patient draw; (c) label and process
such Samples; (d) package the Samples; and (e) ship the Samples to Sera&rsquo;s Licensed Facilities for performance of such Tests, all
in accordance with the applicable portions of the Intercompany SOPs and all applicable laws, rules and regulations (the &ldquo;<U>Collection
and Processing Services</U>&rdquo;). If requested by Sera from time to time, the Parties shall review the foregoing process, and shall
work together diligently and in good faith to revise it as necessary to ensure best practices and optimal patient service. LabCorp will
also provide a test requisition form (as supplied by Sera or the applicable distributor) for each Sample. Sera acknowledges that LabCorp
may route samples through its regional laboratories, so long as such routing complies with the Sera SOPs. LabCorp shall not deliver any
Samples to Sera that LabCorp knows are insufficient for purposes of performing a Test. [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Obligations
of Sera</U>. For Non-LabCorp Test Orders, Sera agrees that it will be responsible for (a) accessioning the Samples upon receipt; (b) performing
the Test; (c) reporting the results of the Test to the applicable ordering physician; and (d) billing the client, patient or third party
payer for the Test, and collecting payment. Sera acknowledges and agrees that LabCorp does not have any obligations with respect to any
of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>LabCorp
PSCs</U>. The Collection and Processing Services may be performed by LabCorp for Non-LabCorp Test Orders at any LabCorp patient service
centers (&ldquo;<U>LabCorp PSCs</U>&rdquo;). LabCorp may modify its list of LabCorp PSCs from time to time by adding or removing LabCorp
PSCs from the listings posted when a search is conducted on the &ldquo;Find your nearest lab&rdquo; locator tool within LabCorp&rsquo;s
website, at https://www.labcorp.com/labs-and-appointments (or any successor listing, locator tool or website). For purposes of clarification,
the LabCorp PSCs covered by this Schedule 1 will not include any third party sites that have a specimen collection relationship with LabCorp,
even if included in the listing in the link above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="text-align: justify; margin: 0pt 0">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Limitation of Liability</U>. NOTWITHSTANDING ANY OTHER PROVISION
OF THIS AGREEMENT, AND EXCEPT FOR CLAIMS OR DAMAGES CAUSED BY LABCORP&rsquo;S GROSS NEGLIGENCE, INTENTIONAL MISCONDUCT OR VIOLATION OF
APPLICABLE LAWS, RULES OR REGULATIONS, AND EXCEPT FOR PERSONAL INJURY CAUSED BY LABCORP, THE LIABILITY AND OBLIGATIONS OF LABCORP, AND
THE REMEDIES OF SERA, UNDER OR IN CONNECTION WITH THE COLLECTION AND PROCESSING SERVICES MADE PURSUANT TO THIS SCHEDULE 1, SHALL BE LIMITED
TO REPEATING ANY DEFECTIVE SERVICES OR, AT THE SOLE OPTION OF LABCORP, REFUNDING THE FEES PAID WITH RESPECT TO SUCH SERVICES.</P>



<P STYLE="margin: 0pt">&nbsp;</P>



<P STYLE="margin: 0pt"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="margin: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7.3
<SEQUENCE>22
<FILENAME>tm2110724d11_ex10d7-3.htm
<DESCRIPTION>EXHIBIT 10.7.3
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.7.3&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-style: normal; font-weight: normal">CONFIDENTIAL</FONT></TD>
    <TD STYLE="text-align: right; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECOND AMENDMENT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COMMERCIALIZATION AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS Second Amendment to the
January 9, 2017 Commercialization Agreement (&ldquo;Second Amendment&rdquo;), effective as of the date this Second Amendment is signed
by both parties (the &ldquo;Effective Date&rdquo;), is made by and between Sera Prognostics, Inc. (&ldquo;Sera&rdquo;) and Laboratory
Corporation of America Holdings (&ldquo;Labcorp&rdquo;). Sera and Labcorp may be referred to herein each as a &ldquo;Party&rdquo; or collectively
as &ldquo;Parties.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RECITALS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sera
and Labcorp entered into a Commercialization Agreement having an effective date of January 9, 2017, as amended June 25, 2018 (the &ldquo;Agreement&rdquo;);
and,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Parties now wish to amend the Agreement in accordance with the terms of this Second Amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TERMS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, for good and
valuable consideration, the receipt of which is hereby acknowledged, and the mutual covenants set forth herein, the Parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section
10.1 of the Agreement is hereby amended and restated as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in">10.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Term</U>.
This Agreement will commence on the Effective Date and, unless terminated pursuant to the terms hereof, will automatically renew on each
anniversary of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
capitalized terms used in this Second Amendment and not otherwise defined herein shall have the meanings assigned them in the Agreement.
Except as expressly stated in this Second Amendment, the Agreement remains unchanged and in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the Parties
hereto have executed this Second Amendment through their authorized representatives signing below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="vertical-align: top; font-size: 10pt; font-weight: bold; text-align: left"><P STYLE="margin-top: 0; margin-bottom: 0">LABORATORY CORPORATION OF AMERICA HOLDINGS</P>
                                                                                <P STYLE="margin-left: 5pt; margin-top: 0; margin-bottom: 0"></P></TD><TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt"><B>SERA PROGNOSTICS, INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-left: 5pt; vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; width: 5%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 44%; text-align: left; padding-bottom: 1pt">/s/ Michael F. Minahan</TD><TD STYLE="vertical-align: top; width: 2%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-left: 5pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: left">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 43%; text-align: left; padding-bottom: 1pt">/s/ Douglas Fisher, MD</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-left: 5pt; vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; padding-bottom: 1pt">Michael F. Minahan</TD><TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-left: 5pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; padding-bottom: 1pt">Douglas Fisher, MD</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-left: 5pt; vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; padding-bottom: 1pt">SVP &amp; General Manager</TD><TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-left: 5pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; padding-bottom: 1pt">Chief Business Officer</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-left: 5pt; vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">Date:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-bottom: 1pt; text-align: left">1/26/2021</TD><TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-left: 5pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: left">Date:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-bottom: 1pt; text-align: left">1/25/2021</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>23
<FILENAME>tm2110724d11_ex10-8.htm
<DESCRIPTION>EXHIBIT 10.8
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.8</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="tm2110724d8_ex10-7img002.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-weight: normal">April 29, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">c/o Baker Bros. Advisors LP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">860 Washington St. &ndash; 3<SUP>rd</SUP> fl.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>Re:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IPO Participation, Board, Observer and </I></B>[***]
<B><I>Rights</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to and in consideration
of the purchase of shares of Series E Preferred Stock, par value $0.0001 per share (the &ldquo;<U>Preferred Stock</U>&rdquo;), of Sera
Prognostics, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), by Baker Bros. Advisors LP (&ldquo;<U>BBA</U>&rdquo;) and/or
one or more of its Affiliates (as defined below) (each, an &ldquo;<U>Investor</U>&rdquo; and together, the &ldquo;<U>Investors</U>&rdquo;)
pursuant to the terms and conditions of that certain Series E Preferred Stock Purchase Agreement, by and among the Company, the Investors
and the other parties named therein, dated as of February 23, 2021 (the &ldquo;<U>Purchase Agreement</U>&rdquo;), the parties to this
letter hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Public Offering Participation</I></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">a.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In the event that any Investor indicates an interest to purchase shares of the Company&rsquo;s Common Stock, par value $0.0001
per share (the &ldquo;<U>Common Stock</U>&rdquo;) in any firm commitment underwritten public offering (each, an &ldquo;<U>Offering</U>&rdquo;)
of the Company&rsquo;s capital stock prior to and including an initial public offering resulting in the listing of the Company&rsquo;s
Common Stock on a national securities exchange (a &ldquo;<U>Qualified IPO</U>&rdquo;), then, subject to compliance with all applicable
securities laws and regulations, the Company will use its commercially reasonable efforts (which must include at least three attempts,
on three dates, with at least two representatives of the managing underwriter, including the most senior underwriter personnel devoting
substantial time to the applicable Offering, both orally and in writing) to cause the managing underwriter(s) of such Offering to provide
to the Investors, on the same terms, including the price per share, and subject to the same conditions, as are applicable to the public
in such Offering, the opportunity to purchase that number of shares of capital stock of the Company being issued in such Offering equal
to their aggregate Pro Rata Share (as defined below) of the total number of shares offered for sale in such Offering (excluding shares
issuable to the underwriter(s) of the Offering upon exercise of an overallotment option to purchase additional shares) (such aggregate
Pro Rata Share, the &ldquo;<U>New Shares</U>&rdquo;). The Investors may apportion such New Shares in such proportion as they deem appropriate
among themselves and any Affiliate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">b.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The rights of the Investors to purchase shares in an Offering will be conditioned upon the completion of such Offering. The Company
may withdraw its registration statement for an Offering at any time without incurring any liability under this letter to the Investors
or any of its Affiliates. Without limiting the foregoing, the rights of the Investors described in clauses (a) through (c) of this Section
1, will terminate and be of no further force or effect upon the earliest to occur of the following: (i) the closing of a Qualified IPO;
(ii) such time as the Investors and/or their Affiliates cease to beneficially own (in the aggregate) (A) at least 75% of the Preferred
Stock purchased by the Investors (as adjusted for stock splits, recapitalizations and other similar events and including all shares of
Common Stock issued upon the conversion of the Preferred Stock to the extent still beneficially owned by the Investors), or (B) shares
or other equity securities of the Company representing at least 4% of the Company&rsquo;s outstanding voting power in an election of directors;
and (iii) the closing of a Deemed Liquidation Event (as such term is defined in the Fifth Amended and Restated Certificate of Incorporation
of the Company (the &ldquo;<U>Company Charter</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>[***] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD
BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</B></FONT>&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2110724d8_ex10-7img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">2749 East Parleys
Way - Suite 200 | Salt Lake City, Utah 84109 | Phone 801.990.0520 | Fax 801.990.064<B>0</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">c.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Investors hereby acknowledge that, despite the Company&rsquo;s use of its commercially reasonable efforts, the underwriter(s)
for the applicable Offering may determine in its or their sole discretion that it is not advisable to designate the maximum number of
shares being issued and sold in such Offering as New Shares, in which case the number of New Shares may be reduced or no New Shares may
be designated. The Investors also acknowledge that notwithstanding the terms hereof, the sale of any New Shares to any Person will only
be made in compliance with FINRA Rules 5110 and 5130 and applicable federal, state, and local laws, rules, and regulations and stock exchange
rules, regulations and listing requirements. The Company hereby acknowledges that nothing in this letter constitutes an offer or the commitment
by any Person to purchase any New Shares in any Offering. The Company and the Investors further acknowledge and agree that any New Shares
shall be excluded from and shall not be subject to the &ldquo;Market Stand-Off Agreement&rdquo; as provided in Section 2.11 of the Investor
Rights Agreement (defined below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">d.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company shall not, either directly or indirectly or by amendment, merger, consolidation or otherwise, authorize, approve, or
adopt any &ldquo;evergreen&rdquo; option plan or other equity incentive plan of the Company or any of its subsidiaries pursuant to which
the number of shares of Common Stock of the Company available for equity awards thereunder would increase automatically (without further
stockholder approval) on an annual basis by an amount that exceeds 4% of the total number of shares of Common Stock then issued and outstanding
(calculated on a fully diluted basis). The rights set forth in this clause (d) of Section 1 shall terminate and be of no further force
or effect immediately upon such time as the Investors and/or their Affiliates cease to collectively own beneficially (i) whether prior
to or after a Qualified IPO, at least 75% of the aggregate number of shares of the Preferred Stock purchased by the Investors (as adjusted
for stock splits, recapitalizations and other similar events and including all shares of Common Stock issued upon the conversion of the
Preferred Stock to the extent still beneficially owned by the Investors) or (ii) if after a Qualified IPO, at least 4% of the then-outstanding
total voting power of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Registration Rights</I></B>. [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Board Rights</I></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">a.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>From
and after the closing of a Qualified IPO, at any time (and from time to time) that the Investors and/or their Affiliates collectively
own beneficially shares or other equity securities of the Company representing at least 4% of the then-outstanding total voting power
of the Company, the Investors shall collectively be entitled to nominate one individual (an &ldquo;<U>Investor Designee</U>&rdquo;) to
serve as a director on the Board of Directors of the Company (the &ldquo;<U>Board</U>&rdquo;) <U>provided</U>, in the event that the
Investors do not exercise such right such that they nominate an Investor Designee to serve as a director immediately following the closing
of the Qualified IPO (which right must be exercised not less than twenty-one (21) days in advance of the closing of the Qualified IPO),
the Investors shall not exercise such right until after the 90th day following the closing date of the Qualified IPO). The Company shall
include the Investor Designee in the slate of nominees recommended to the Company&rsquo;s stockholders for election as directors of the
Company at each annual or special meeting of the Company&rsquo;s stockholders at which directors are to be elected and every adjournment
or postponement thereof (including, for the avoidance of doubt, every action or approval by written consent of the stockholders of the
Company or the Board in lieu of such meeting) (an &ldquo;<U>Election Meeting</U>&rdquo;). The Company will recommend, support and solicit
proxies for the election of the Investor Designee in the same manner as for all other Board members nominated for election. The Investors
will provide to the Company, in writing, the information about the Investor Designee that is reasonably required by applicable law for
inclusion in the Company&rsquo;s proxy materials for Election Meetings promptly after the Company requests such information from the
Investors, and will cause such Investor Designee to submit on a timely basis to the Company a completed and executed questionnaire in
the form that the Company provides to its outside directors generally.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">b.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>In
the event that an Investor Designee fails to be elected for any reason, or resigns from his or her seat on the Board or is removed or
otherwise ceases to be a director (whether as a result of his or her death, disability, disqualification, or otherwise), the Investors
shall be entitled to promptly designate another Investor Designee and the Company will take all necessary and desirable actions within
its control such that (i) the resulting vacancy on the Board shall not be filled pending such designation or (ii) the size of the Board
shall be increased by one and the Company will, as promptly as practicable but in no event more ten days following such designation,
take all necessary and desirable actions within its control such that such vacancy shall be filled with such successor Investor Designee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">c.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>For
so long as the Investors&rsquo; rights under this Section 3 remain in effect, the Board will not create any &ldquo;executive committee&rdquo;
of the Board, or delegate to any existing committee or subsidiary&rsquo;s governing body, responsibilities substantially similar to those
of an executive committee, without including the then-current Investor Designee, if any, thereon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">d.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Notwithstanding
the provisions of Section 3(a), the Investors shall not be entitled to designate any individual as a nominee to the Board if a majority
of the disinterested members of the Board (or the nominating committee thereof) reasonably and in good faith determine, (i) after consultation
with the Company&rsquo;s outside legal counsel and upon written advice of such counsel, that such person would not be qualified to serve
as a director of the Company under any applicable law (including requirements of fiduciary duties under applicable law), rule or regulation,
rule of the stock exchange on which the Company&rsquo;s shares are listed, the organizational documents of the Company, or any policy,
or guidelines previously approved by the Board, but only if a direct or indirect purpose of any such policy or guideline is not to obstruct
the Investors&rsquo; right to designate an individual as a nominee to the Board or its rights under this letter, or (ii) <FONT STYLE="background-color: white">that
such person is an employee or director of a competitor of the Company (<U>provided</U>, no senior employee of BBA or its Affiliates shall
be subject to exclusion pursuant to this clause (ii) as a result of such person&rsquo;s participation on any board of directors in connection
with investments by BBA or its Affiliates)</FONT>. Notwithstanding anything set forth herein to the contrary, a person&rsquo;s status
as a director, officer, employee or affiliate of any Investor or such person&rsquo;s service on the board of any other company shall
not cause such person to be deemed not qualified to serve as a director of the Company, except as required by applicable law or regulation
pursuant to clause (i) of the preceding sentence. In the event the Board (or the nominating committee thereof) does not accept an Investor
Designee as a result of such Investor Designee failing to meet the requirements set forth in this Section 3(d), the Investors shall have
the right to recommend another Investor Designee in accordance with Section 3(a). The Company shall notify the Investors of any objection
to an Investor Designee pursuant to this Section 3(d) sufficiently in advance of the date on which the proxy materials related to any
such designee are to be mailed by the Company in connection with such election of directors so as to enable the Investor to propose a
replacement Investor Designee in accordance with the terms of this letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">e.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
rights set forth in this Section 3 shall terminate and be of no further force or effect immediately upon such time as the Investors and/or
their Affiliates cease to collectively own beneficially at least 75% of the aggregate number of shares of the Preferred Stock purchased
by the Investors (as adjusted for stock splits, recapitalizations and other similar events and including all shares of Common Stock issued
upon the conversion of the Preferred Stock to the extent still beneficially owned by the Investors).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Observer Rights. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">a.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>At
any time prior to or after a Qualified IPO that an Investor Designee is not a member of the Board, the Company shall invite a single
representative of the Investors (a &ldquo;<U>BBA Observer</U>&rdquo;), as designated by the Investors from time to time, to attend and
participate in all meetings of the Board, in a nonvoting observer capacity. In this respect, the Company shall give the BBA Observer
(i) written notice of, agendas and participation details for such meetings and (ii) copies of all notices, minutes, consents, and other
materials, in each case, that it provides to the members of the Board, as applicable, at the same time and in the same manner as provided
to such members; <I>provided</I>, <I>however</I>, that the Company reserves the right to withhold any information and to exclude the
BBA Observer from any meeting or portion thereof if (1) the Board determines in good faith and based upon the advice of outside counsel
that access to such information or attendance at such meeting could (x) adversely affect the attorney-client privilege between the Company
and its counsel or (y) result in a conflict of interest, or (2) <FONT STYLE="background-color: white">the Board of Directors reasonably
determines in good faith that the BBA Observer or an Affiliate of such BBA Observer is a competitor of the Company (<U>provided</U>,
no senior employee of BBA or its Affiliates shall be subject to exclusion pursuant to this clause (2) as a result of such person&rsquo;s
participation on any board of directors in connection with investments by BBA or its Affiliates) and the Board of Directors provides
the BBA Observer advanced written notice </FONT>that access to such information or attendance at such meeting are being withheld or denied,
as the case may be, pursuant to this Section 4(a) (and the reason therefore)<FONT STYLE="background-color: white">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">b.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Except as provided in Section 4(c) below, the BBA Observer shall not, by virtue of his or her capacity as such, have or be deemed
to have, or otherwise be subject to, any duties (fiduciary or otherwise) to the Company or any of its Affiliates or subsidiaries or its
or their respective equityholders or any other Person or any duties (fiduciary or otherwise) otherwise applicable to the members of the
Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">c.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>With respect to the BBA Observer, the Company&rsquo;s obligations under this Section 4 are contingent upon such BBA Observer&rsquo;s
(i) entering into a confidentiality agreement with the Company and BBA in the form attached hereto as <U>Exhibit B</U> and (ii) agreeing,
solely in such individual&rsquo;s capacity as a BBA Observer, to be bound by the Company&rsquo;s insider trading and window policies then
in effect and applicable to members of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">d.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
rights set forth in this Section 4 shall terminate and be of no further force or effect immediately upon such time as the Investors and/or
their Affiliates cease to collectively own beneficially (i) whether prior to or after a Qualified IPO, at least 75% of the aggregate
number of shares of the Preferred Stock purchased by the Investors (as adjusted for stock splits, recapitalizations and other similar
events and including all shares of Common Stock issued upon the conversion of the Preferred Stock to the extent still beneficially owned
by the Investors) or (ii) if after a Qualified IPO, at least 4% of the then-outstanding total voting power of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>No Publicity</I></B>. [***], except that the Company may make any such disclosure if, upon the advice of counsel, there is
no alternative to such disclosure because it is required by applicable law, rule or regulation (including the rules of the SEC, FINRA
or the stock exchange on which the Common Stock is listed) [***]. [***]; <I>provided</I>, <I>however</I>, that the Company may disclose
the name of the Investors in connection with the provision of any details regarding the Purchase Agreement and the other agreements executed
by Company and the Investors in connection with the Preferred Stock financing and the transactions contemplated thereby, and to any of
its executive officers, directors, accountants, counsel, underwriters, and financial advisors with a need to know such information, provided
that such recipient agrees to abide by the foregoing confidentiality obligations or is subject to confidentiality obligations that are
substantially at least as restrictive. [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B><I>Indemnification</I></B>. The Company shall enter into a customary indemnification agreement with any Investor Designee that
is elected a member of the Board, in substantially the form as entered into between the Company and the other members of the Board in
the ordinary course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B><I>Definitions</I></B>.
When used in this letter, the following terms shall have the meanings assigned to them in this Section 8:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">a.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Affiliate</U>&rdquo;
means, with respect to any Person, any other Person directly or indirectly controlling, controlled by or under common control with such
Person, where &ldquo;control&rdquo; means the possession, directly or indirectly, of the power to direct the management and policies
of a Person whether through the ownership of voting securities or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">b.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder from time
to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">c.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Person</U>&rdquo;
means any individual, corporation, partnership, limited liability company, trust, unincorporated association, governmental entity or
other legal entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">d.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&ldquo;<U>Pro
Rata Share</U>&rdquo; means the greater of (i) 10% and (ii) the percentage determined by dividing (A) the number of shares of Common
Stock (including all shares of Common Stock issuable or issued upon conversion of the shares of the Preferred Stock and any other outstanding
securities of the Company convertible or exercisable in exchange for shares of Common Stock) collectively owned beneficially by such
Investors immediately prior to the Offering by (B) the total number of shares of outstanding Common Stock (including all shares of Common
Stock issued or issuable upon conversion of all outstanding shares of Preferred Stock, any other outstanding securities of the Company
convertible or exercisable in exchange for shares of Common Stock and all shares reserved for future issuance pursuant to any equity
incentive or similar plan) immediately prior to the Offering, in each case, excluding shares issuable to the underwriter(s) of the Offering
upon exercise of an overallotment option to purchase additional shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Amendments; Waiver; Entire Agreement</I></B>. This letter may not be amended or modified in any manner except by a written
instrument signed by the Investors and the Company. Any waiver of any term or condition shall be in writing executed by the party entitled
to waive such term or condition. Any waiver of any term or condition shall not be construed as a waiver of any subsequent breach or a
subsequent waiver of the same term or condition, or a waiver of any other term or condition of this letter. The failure of either party
to assert any of its rights hereunder shall not constitute a waiver of such rights. This letter (including the Exhibits hereto), together
with the Purchase Agreement and the other transaction documents entered into in connection therewith (including, for the avoidance of
doubt, the Investor Rights Agreement and the Fourth Amended and Restated Voting Agreement, dated as of February 23, 2021, by and between
the Company, the Investors, and the other Investors party thereto), constitutes the full and entire understanding and agreement between&nbsp;the
parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing
between the parties is expressly canceled. This letter amends, restates and supersedes in all respects the letter agreement, dated as
of March 29, 2021, by and between the Company and BBA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Assignment</I></B>. No party may assign this letter or any of its rights, interests or obligations hereunder without the
prior written consent of the other parties, and any purported assignment by a party without prior written consent of the other parties
will be null and void and not binding on such other party; <I>provided</I>, <I>however</I>, that notwithstanding the foregoing, an Investor
may assign this letter or any of its rights, interests or obligations hereunder to its Affiliates. Subject to the preceding sentence,
all of the terms, agreements, covenants, representations, warranties and obligations of this letter are binding upon, and inure to the
benefit of and are enforceable by, the parties and their respective successors and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Governing Law; Jurisdiction</I></B>. This letter shall be governed by the laws of the State of Delaware, without regard to
conflict of law principles. The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction of the state courts of the
State of Delaware and to the jurisdiction of the United States District Court for the District of Delaware for the purpose of any suit,
action or other proceeding arising out of or based upon this letter, (b) agree not to commence any suit, action or other proceeding arising
out of or based upon this letter except in the state courts of the State of Delaware or the United States District Court for the District
of Delaware, and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or
proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or
immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit,
action or proceeding is improper or that this letter or the subject matter hereof may not be enforced in or by such court.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>WAIVER OF JURY TRIAL</I></B>. EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON
OR ARISING OUT OF THIS LETTER OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF
ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS LETTER, INCLUDING, WITHOUT LIMITATION,
CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION
12 HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO
HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY
AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Notices</I></B>. All notices under this letter must be in writing and given by personal delivery, by United States Express
Mail or a nationally recognized overnight delivery service for next day delivery, or by electronic mail, as follows (or to such other
Person or address as any party may give in a notice given in accordance with the provisions hereof):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">If to the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Sera Prognostics,
Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">2749 E Parleys Way,
Suite 200</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Salt Lake City, UT
84109</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Attn: Gregory C. Critchfield,
M.D., M.S.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Email:&nbsp;&nbsp;gcritchfield@seraprognostics.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">with a copy (which
shall not constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Mintz, Levin, Cohn,
Ferris, Glovsky and Popeo, P.C.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">One Financial Center</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Boston, MA 02111</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Attn: Jonathan L.
Kravetz</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Email:&nbsp;&nbsp;&nbsp;JLKravetz@mintz.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">If to the Investors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">c/o Baker Bros. Advisors LP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">860 Washington St. &ndash; 3<SUP>rd</SUP> fl.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">New York, NY 10014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Email:&nbsp;&nbsp;&nbsp;[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">with a copy (which
shall not constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">[***]<BR>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Notice will be effective and
deemed given only as follows: (a) if given by personal delivery, up-on such personal delivery, (b) if sent for next day delivery by United
States Express Mail or overnight delivery service, on the date of delivery as confirmed by written confirmation of delivery, or (c) if
sent by electronic mail, upon acknowledgement of receipt other than by automatic means.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B><I>Equitable
Relief; Remedies</I></B>. The Company acknowledges and agrees that the Investors may be damaged irreparably and may not have an adequate
remedy at law if any provision of this letter is not performed in accordance with its specific terms or is otherwise breached. Accordingly,
in addition to any other remedy to which the Investors may be entitled, at law or in equity, the Investors will be entitled to seek an
injunction or injunctions to prevent breaches or threatened breaches of the provisions of this letter and to seek to enforce specifically
this letter and its provisions, without bond or other security being required and without any proof of actual damages. The rights, obligations
and remedies created by this letter are cumulative and in addition to any other rights, obligations or remedies otherwise available at
law or in equity. Nothing herein will be considered an election of remedies or a waiver of the right to pursue any other right or remedy
to which the Investors may be entitled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B><I>Headings;
Construction</I></B>. The section headings contained in this letter are inserted for convenience only and will not affect in any way
the meaning or interpretation of this letter. Except as otherwise expressly provided herein, the following rules of interpretation apply
hereto: (i) the singular includes the plural and vice versa; (ii) &ldquo;or&rdquo; and &ldquo;any&rdquo; are not exclusive; (iii) &ldquo;includes,&rdquo;
 &ldquo;include,&rdquo; &ldquo;included&rdquo; and &ldquo;including&rdquo; are deemed to be followed by &ldquo;without limitation&rdquo;;
and (iv) the words &ldquo;hereby,&rdquo; &ldquo;herein,&rdquo; &ldquo;hereunder,&rdquo; &ldquo;hereof&rdquo; and words of similar import
refer to this letter as a whole and not merely to the specific section or clause in which any such word appears. No presumption or burden
of proof shall arise favoring or disfavoring a party by virtue of the authorship of any provision of this letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">16.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B><I>Counterparts</I></B>.
This letter may be executed in two or more counterparts, each of which will be deemed an original but all of which together will constitute
one and the same instrument. This letter will become effective when one or more counterparts have been signed by each of the parties
and delivered to the other party, it being understood that all parties need not sign the same counterpart. The exchange of copies of
this letter and of executed signature pages by facsimile transmission or by electronic mail in &ldquo;portable document format&rdquo;
(&ldquo;.pdf&rdquo;) or by a combination of such means, will constitute effective execution and delivery of this letter as to the parties
and may be used in lieu of an original letter for all purposes. Signatures of the parties transmitted by facsimile or by .pdf shall be
deemed to be their original signatures for all purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">17.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><I>Severability</I></B>. The provisions of this letter will be deemed severable and the invalidity or unenforceability of any
provision will not affect the validity or enforceability of the other provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><I>[Signature Page Follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Very
    truly yours,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">SERA
    PROGNOSTICS, INC.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">/s/ Gregory C. Critchfield,
M.D., M.S.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Name:
    Gregory C. Critchfield, M.D., M.S.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Title:
    President and Chief Executive Officer</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.8in 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal"></FONT>&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">AGREED
    AND ACCEPTED:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Baker
    Bros. Advisors LP</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    [***]<BR> Name: [***]<BR> Title: [***]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>24
<FILENAME>tm2110724d11_ex10-9.htm
<DESCRIPTION>EXHIBIT 10.9
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

                           <P STYLE="margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 10pt"><B>Exhibit 10.9</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SERA PROGNOSTICS, INC. EMPLOYMENT AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Employment Agreement
(this &#8220;<U>Agreement</U>&#8221;) is effective for all purposes as of November 8, 2011 (the &#8220;<U>Effective Date</U>&#8221;),
by and between Sera Prognostics, Inc., a Delaware corporation (the &#8220;<U>Company</U>&#8221;), and Gregory C. Critchfield, M.D (the
 &#8220;<U>Employee</U>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the mutual covenants, conditions and undertakings set forth herein, the parties hereto hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT><U>Employment
and Duties</U>. Subject to the terms and conditions set forth in this Agreement, the Company shall employ Employee, and Employee hereby
accepts employment, as the Chairman and Chief Executive Officer of the Company, with those duties and responsibilities which are appropriate
and customary for a chief executive officer of a company similar to the Company. In such capacity, the Employee shall report to the Company&#8217;s
Board of Directors (the &#8220;<U>Board</U>&#8221;) and will be elected a member of the Board. During the term of this Agreement, the
Employee shall faithfully perform the Employee&#8217;s duties, responsibilities and obligations hereunder; subject to the understanding
that the Employee may continue to provide time to Outside Interests (as defined below), consistent with past practices, as well as additional
Outside Interests not disclosed on <U>Exhibit A</U> hereto with the Board&#8217;s consent. The Company acknowledges that the Employee
has certain outside interests, as set forth on <U>Exhibit A</U> (the &#8220;<U>Outside Interests</U>&#8221;), and agrees that the Outside
Interests shall not constitute a breach of this Agreement to the extent such interests do not materially interfere with the performance
of Employee&#8217;s duties, responsibilities and obligations under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT><U>Base
Compensation and Related Matters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Salary</U>. In consideration for the services rendered by the Employee to the Company as provided herein, the Company
shall pay the Employee an annual base salary of $300,000.00 per year (the &#8220;<U>Base Salary</U>&#8221;). The Base Salary shall be
paid according to the Company&#8217;s standard payroll policy and will be subject to applicable federal and state tax withholdings as
required by applicable law. The Base Salary may be increased but not decreased at any time by the Company&#8217;s Board or the Compensation
Committee of the Board (the &#8220;<U>Compensation Committee</U>&#8221;), in its sole discretion and the Board or the Compensation Committee
will reassess the Employee&#8217;s Base Salary annually.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT><U>Equity
Grants</U>. The Employee shall be granted as soon as practicable on or after the Effective Date, a stock option to purchase 734,900
shares of the Company&#8217;s common stock (the &#8220;<U>Option</U>&#8221;) (which option shall be issued as an incentive stock
option to the maximum extent allowed under Section 422 of the Internal Revenue Code of 1986, as amended, and the regulations
promulgated thereunder (the &#8220;<U>Code</U>&#8221;)) pursuant to the Company&#8217;s 2011 Employee, Director and Consultant
Equity Incentive Plan (the &#8220;<U>Plan</U>&#8221;). The Option shall be granted with an exercise price equal to the fair market
value of the Company&#8217;s common stock on the date of grant. Twenty-Five percent (25%) of the Option shall be vested one year
from the Effective Date and the remaining portion of such Option shall vest in equal monthly installments over a thirty-six (36)
month period commencing on the first day of the month one year following the Effective Date, subject to continued employment by the
Company. Notwithstanding the foregoing, in connection with a Change of Control (as defined in the Plan) or if a termination of the
Employee occurs within two (2) months prior thereto, then the vesting of all equity then owned by the Employee shall accelerate with
respect to one hundred percent (100%) of the unvested shares. In lieu of the Option at the request of the Employee, the Company
shall issue restricted common stock. Restricted common stock will be issued at par value. If the equity to be issued is restricted
common stock and not stock options, the number of shares of restricted common stock to be issued shall be calculated by determining
the black scholes value of the grant as if it had been issued solely as stock options and dividing such number by the then current
fair market value of the Company&#8217;s common stock so as to provide no additional benefit to the Employee for the non-payment of
the exercise price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">The Employee acknowledges and agrees that effective
as of the date of the grant of the equity as set forth in the preceding paragraph, option agreement No. SP-0040 granted by the Company
to the Employee as of April 30, 2011 shall be terminated and of no further force and effect. The Company acknowledges that any other options
previously granted to the Employee that vest based upon the Employee providing consulting services to the Company shall continue to vest
upon its terms as long as the Employee is providing services as a director, consultant or employee of the Company and that the definition
of &#8220;cause&#8221; applicable to all such option agreements shall be the definition set forth herein and not as set forth in the 2008
Stock Incentive Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Expenses</U>. The Employee will be entitled to receive prompt reimbursement for all reasonable expenses incurred by the
Employee (which are eligible for reimbursement under the Code) actually incurred by him in performing his duties; provided; however, that
such expenses are approved in accordance with the Company&#8217;s then-current policies and procedures applicable to the most senior-level
executive employees of the Company, other than the Employee, or if such policies and procedures are not in place, then as determined in
the sole discretion of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Employee Benefits</U>. The Company shall reimburse the Employee for the premium costs incurred by the Employee in maintaining
medical and dental insurance coverage for the Employee and his family until such time that the Company sponsors a group insurance plan
providing medical and dental insurance coverage for Company employees (the &#8220;<U>Health Insurance Reimbursement</U>&#8221;). The Health
Insurance Reimbursement will be paid to the Employee on the last day of each month, provided the Employee has submitted to the Company
documentary evidence establishing the Employee&#8217;s payment of such premiums to the health insurance provider. The Health Insurance
Reimbursement is intended to be provided on a qualified, tax free basis in accordance with Section 106 of the Code. In addition, the Employee
is entitled to participate in any employee benefit plans that the Company may make available to its most senior-level executive employees
generally, which may include, but not be limited to, profit sharing plans, 401(k) and cafeteria plans, or life, hospitalization, optical,
disability or other insurance plans as may be in effect, from time to time, and in accordance with rules established, from time to time,
for individual participation in such plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Vacation Days and Paid Leave</U>. The Employee will be entitled to take four (4) weeks of vacation days and paid leave
and such additional days as are provided to other senior-level executive employees of the Company, and shall be entitled to compensation
in connection therewith, in accordance with Company policy applicable to senior-level executive employees of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT><U>Facilities and Services Furnished</U>. The Company will furnish the Employee with office space and such other facilities,
furniture, equipment and services as it may determine to be reasonably necessary for the performance of the Employee&#8217;s duties as
set forth herein. It is acknowledged that as of the Effective Date, the Company is &#8220;virtual&#8221; and the Employee is using his
own home or other business office for the Company office at no expense to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT><U>Termination</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Termination by the Company</U>. The Employee&#8217;s employment hereunder may be terminated by the Company under any
of the following circumstances:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Death</U>. This Agreement shall automatically terminate upon the Employee&#8217;s death.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Disability</U>. The Board may elect to terminate the Employee&#8217;s employment in the event of Employee&#8217;s Disability
upon delivery of written notice to the Employee. For purposes of this Agreement, &#8220;Disability&#8221; shall mean any condition that,
in the reasonable, good faith judgment of a licensed physician selected by the Board, causes the Employee to be unable, after any accommodation
required by applicable law, to perform his duties, responsibilities and obligations under this Agreement for a period of at least twelve
(12) months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(iii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Cause</U>. The Board may terminate the Employee&#8217;s employment hereunder for Cause (as defined below) at any time
upon delivery of written notice to the Employee. For purposes of this Agreement, &#8220;<U>Cause</U>&#8221; shall mean (a) the conviction
of the Employee by a court of competent jurisdiction of any felony involving dishonesty, breach of trust or misappropriation or the entering
of a plea by the Employee of nolo contendre thereto; (b) the Employee&#8217;s willful failure or refusal to follow reasonable and lawful
directives of the Board, provided such failure or refusal continues after the Employee&#8217;s receipt of reasonable notice in writing
of such failure or refusal and an opportunity of not less than thirty (30) days to correct the problem; (c) a material breach by the Employee
of any of the provisions of this Agreement; or (d) the Employee&#8217;s commission of any immoral or illegal act or any gross or willful
misconduct, where a majority of the non-employee members of the Board reasonably determines that such act or misconduct has (A) seriously
undermined the ability of the Board to entrust Employee with important matters or otherwise work effectively with Employee, (B) contributed
to the Company's loss of significant revenues or business opportunities, or (C) significantly and detrimentally affected the business
or reputation of the Company or any of its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(iv)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Other Termination</U>. The Board may terminate Employee's employment with the Company at any time and for any reason,
with or without cause, subject to the provisions hereof. Employee acknowledges that Employee is, and at all times shall be, an employee
at will of the Company and nothing contained herein shall be construed to alter or affect such employee at-will status. Employee may terminate
his employment with the Company at any time, for any or no reason, subject to the provisions hereof. Inclusion under any benefit plan
or compensation arrangement will not give Employee any right or claim to any benefit hereunder except to the extent such right has become
fixed under the express terms of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT> <U>Termination by the Employee</U>. The Employee may terminate the Employee&#8217;s employment with the Company under the
following circumstances:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Voluntary Termination</U>. Employee may terminate his employment with the Company for any reason or no reason, upon delivery
of written notice to the Board at least fifteen (15) days prior to the specified termination date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Termination for Good Reason</U>. The Employee also may terminate the Employee&#8217;s employment with the Company for
 &#8220;<U>Good Reason</U>,&#8221; which shall mean for purposes of this Agreement (A) a material breach by the Company of any of the provisions
of this Agreement; (B) assignment of Employee to a role, duties or responsibilities materially inconsistent with that of a Chief Executive
Officer; (C) any circumstances caused by the Company that would require Employee to move his principal location of employment in excess
of forty-five (45) miles from Company&#8217;s current offices in Salt Lake City, Utah; or (D) an involuntary material reduction of Employee&#8217;s
then current Base Salary other than a reduction proportionately affecting all of the Company&#8217;s other senior-level executive employees.
The Employee must provide the Board with a written Notice of Termination that describes the existence of the condition the Employee believes
gives rise to Good Reason under this Section 4(b) within thirty (30) days following the initial existence of the condition. The Company
may elect to cure any condition giving rise to Good Reason within thirty (30) days of receipt of notice. The Employee&#8217;s termination
for Good Reason must, in any event, occur within the six (6) month period immediately following the initial existence of the condition
giving rise to Good Reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Effect of Termination</U>. In the event the Employee&#8217;s employment is terminated, all obligations of the Company
and the Employee under this Agreement shall cease, except that the accelerated vesting of Options set forth in Section 2(b) and the terms
of Section 5 through Section 9 shall survive such termination. Upon such termination, the Employee or the Employee&#8217;s representative
or estate shall be entitled to receive the applicable compensation, benefits and reimbursements set forth in Section 5. The Employee acknowledges
that, upon termination of the Employee&#8217;s employment, the Employee is entitled to no other compensation, severance or other benefits
other than those specifically set forth in Section 5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT><U>Compensation
and Benefits Upon Termination of Employment</U>. At all times after the Effective Date, the Employee shall be entitled to receive additional
compensation and benefits upon a termination of Employee&#8217;s employment as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT><U>Severance
Pay</U>. If, either (i) the Company terminates the Employee&#8217;s employment for any reason other than Cause, death or Disability
or (ii) the Employee terminates his employment for Good Reason; then, on the sixtieth (60<SUP>th</SUP>) day following the
termination of employment, the Company shall pay the Employee a lump sum amount equal to (i) twelve (12) months of the Base Salary
at the rate in effect at the time of the termination of employment; and (ii) a pro-rata bonus for the year in which the
Employee&#8217;s employment is terminated provided that the Company has in place a bonus plan; and (iii) any unvested equity will
immediately be forfeited and any vested stock options will be exercisable for the balance of the remaining term of the original
option grant. If, the Company terminates the Employee&#8217;s employment due to death or Disability then, on the sixtieth
(60<SUP>th</SUP>) day following the termination of employment due to death or Disability, the Company shall (i) pay the Employee a
lump sum amount equal to a pro-rata bonus for the year in which the Employee&#8217;s employment is terminated provided that the
Company has in place a bonus plan; (ii) any unvested equity will immediately be forfeited and any vested stock options will be
exercisable for the balance of the remaining term of the original option grant; and (iii) if the Company does not provide any
insurance benefits payable to the Employee or his beneficiaries, as applicable, upon his death or Disability and the Company has
previously, but not necessarily in the then applicable calendar year, achieved Ten Million Dollars in annual gross revenue in a
calendar year, then the Company shall pay the Employee a lump sum amount equal to twelve (12) months of the Base Salary at the rate
in effect at the time of the termination of employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Health Insurance</U>. If either (i) the Company terminates the Employee&#8217;s employment for any reason other than
Cause, death or Disability or (ii) the Employee terminates his employment for Good Reason, the Company will continue to provide the Health
Insurance Reimbursement until the earliest of (x) the close of the twelve (12) month period following the Employee&#8217;s termination
date, and (y) the date when the Employee becomes eligible to receive health insurance coverage in connection with new employment or self-employment.
If, as of the termination date, the Company sponsors a group insurance plan providing medical and dental insurance coverage for Company
employees, and if the Employee elects to continue his health insurance coverage under the Consolidated Omnibus Budget Reconciliation Act
(&#8220;<U>COBRA</U>&#8221;) following the termination of his employment, then the Company shall pay the Employee&#8217;s monthly premium
under COBRA until the earliest of (x) the close of the twelve (12) month period following the Employee&#8217;s termination date, (y) the
expiration of the Employee&#8217;s continuation coverage under COBRA, and (z) the date when the Employee becomes eligible to receive health
insurance coverage in connection with new employment or self-employment. If the payment of any COBRA or health insurance premiums would
otherwise violate the nondiscrimination rules or cause the reimbursement of claims to be taxable under the Patient Protection and Affordable
Care Act of 2010, together with the Health Care and Education Reconciliation Act of 2010 (collectively, the &#8220;Act&#8221;) or Section
105(h) of the Code, the Company paid premiums shall be treated as taxable payments and be subject to imputed income tax treatment to the
extent necessary to eliminate any discriminatory treatment or taxation under the Act or Section 105(h) of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>General Release</U>. Any other provision of this Agreement notwithstanding, subsections (a) and (b) above shall not apply
unless the Employee has (i) executed a general release of all claims (in a form prescribed by the Company), which must be effective and
irrevocable prior to the sixtieth (60<SUP>th</SUP>) day following the termination of employment, (ii) returned all property of the Company
in the Employee&#8217;s possession and (iii) cooperated in good faith with the Company for a transition period not to exceed sixty (60)
days to ensure an efficient transfer of the Employee&#8217;s duties and responsibilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT><U>Non-Competition;
Non-Solicitation</U>. The Employee and the Company hereby acknowledge and agree that in connection with the employment of the Employee,
the Employee has been and will be provided with trade secrets of the Company and that the Employee and the Company are entering into
this Agreement for the protection of such trade secrets. The Employee agrees to abide by the provisions set forth in this Section 6.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT><U>Non-Competition</U>.
The Employee shall not, during his employment with the Company and during the one (1) year period following the termination of his
employment with the Company (the &#8220;<U>Restrictive Period</U>&#8221;), directly or indirectly, as a manager, member, promoter,
shareholder, agent, representative, director, officer, owner, independent contractor or otherwise, or in connection with any of his
consultants, employees, agents, partners, relatives, affiliates or representatives or through any third party:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>anywhere in the United States (the &#8220;<U>Restricted Area</U>&#8221;) compete with or own, manage, operate or control
any business that directly competes in the Company&#8217;s field of interest or products in the active development pipeline of the Company
(for purposes of this paragraph, ownership of securities of not in excess of one percent (1%) of the outstanding capital stock of a public
company shall not be considered to be competition with the Company); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>anywhere in the Restricted Area, act as an employee, director, officer, manager, member, advisor, consultant, representative
or agent for any business of the type and character engaged in and competitive with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Non-Solicitation</U>. The Employee shall not, during the Restrictive Period directly or indirectly, as a manager, member,
promoter, shareholder, agent, representative, director, officer, owner, independent contractor or otherwise, or in connection with any
of his consultants, employees, agents, partners, relatives, affiliates or representatives or through any third party, solicit the employment
of or hire any current employee of the Company, or solicit a relationship with any customer of the Company, located anywhere in the Restricted
Area.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Definitions</U>. For purposes of this Section 6, the terms &#8220;compete with the Company,&#8221; &#8220;competitive
with the Company,&#8221; &#8220;field of interest&#8221; and similar terms referring to competition with the Company shall mean any business
that is engaged in identifying and commercializing biomarkers in blood samples of pregnant women which are predictive of preterm birth
and other pregnancy complications or any other anticipated business ventures of the Company which have been discussed with the Board or
amongst the senior-level executive employees as of the date of Employee&#8217;s termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT><U>Maintaining Confidential Information</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Company Confidential Information</U>. The Employee hereby agrees at all times during which he provides services as a
director, officer, employee or consultant of the Company (&#8220;<U>Employee&#8217;s Service</U>&#8221;), and thereafter to hold in strictest
confidence, and not to use, except for the benefit of the Company, any trade secrets, confidential knowledge, data or other proprietary
information relating to products, processes, know-how, formulas, developmental or experimental work, computer lists, customer lists, business
plans, financial information or other subject matter pertaining to any business of the Company or any of its clients, consultants or licensees
(collectively, &#8220;<U>Confidential Information</U>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the above,
Employee shall not have liability to the Company with regard to any Confidential Information which Employee can prove:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>was in the public domain at the time it was disclosed by the Company or has entered the public domain through no fault of
Employee;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>was
known to the Employee without restriction, at the time of disclosure, as demonstrated by files in existence at the time of disclosure;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(iii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>is disclosed with the prior written approval of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(iv)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8239;</FONT></FONT>becomes
known to Employee, without restriction, from a source other than the Company without breach of this Agreement by Employee and
otherwise not in violation of the Company&#8217;s rights; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(v)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>is disclosed pursuant to the order or requirement of a court, administrative agency, or other governmental body; provided,
however, that Employee shall provide prompt notice of such court order or requirement to the Company to enable the Company to seek a protective
order or otherwise prevent such disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Former Employer Information</U>. The Employee hereby agrees that he will not, during Employee&#8217;s Service, improperly
use or disclose any proprietary information or trade secrets of his former or concurrent employers or companies, if any, and that he will
not make available to the Company any unpublished document or any property belonging to his former or concurrent employers or companies,
if any, unless consented to in writing by said employers or companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Third-Party Information</U>. The Employee recognizes that the Company has received and in the future will receive from
third parties their confidential or proprietary information subject to a duty on the Company&#8217;s part to maintain the confidentiality
of such information and to use it only for certain limited purposes. The Employee hereby agrees, during Employee&#8217;s Service and thereafter,
to hold all such confidential or proprietary information in the strictest confidence and not to disclose it to any person, firm or corporation
(except as necessary in carrying out his work for the Company consistent with the Company&#8217;s agreement with such third party) or
to use it for the benefit of anyone other than the Company or such third party (consistent with the Company&#8217;s agreement with such
third party) without the express written authorization of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT><U>Availability
of Equitable Remedies</U>. The Employee hereby acknowledges and agrees that a breach of Section 6 or Section 7 will cause irreparable
harm and damage to the Company, that the remedy at law for the breach or threatened breach of Section 6 or Section 7 will be inadequate,
and that, in addition to all other remedies available to the Company for such breach or threatened breach (including, without limitation,
the right to recover damages), the Company will be entitled to injunctive relief for any breach or threatened breach of Section 6 or
Section 7.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT><U>Miscellaneous</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Notification of New Employer</U>. In the event that the Employee leaves the employ of the Company, he hereby grants consent
to notification by the Company to his new employer about his rights and obligations under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT><U>Severability</U>.
In the event that a court of competent jurisdiction determines that any portion of this Agreement is in violation of any statute or
public policy, then only the portions of this Agreement which violate such statute or public policy shall be stricken. All portions
of this Agreement which do not violate any statute or public policy shall continue in full force and effect. Further, any court
order striking any portion of this Agreement shall modify the stricken terms to give as much effect as possible to the intentions of
the parties under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Notices</U>. Any notices, requests or consents hereunder shall be deemed given, and any instrument delivered, three (3)
days after they have been mailed by first class mail, postage prepaid, one (1) day after they have been delivered by overnight courier,
twelve (12) hours after such notice has been sent by facsimile, or upon receipt if delivered personally, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">417 Wakara Way, Suite 3510<BR>
Salt Lake City, UT 84108</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the Employee:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">6170 Murdock Woods Place<BR>
Holladay, UT 84121</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">except that any of the foregoing may, from time
to time, by written notice to the others, designate another address or fax number which shall thereupon become his or its effective address
for the purposes of this Section 9(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Governing Law</U>. This Agreement shall be governed by the laws of the State of Utah, without giving effect to its conflict
of laws principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Successors and Assigns</U>. The rights and obligations of the Company under this Agreement shall inure to the benefit
of and shall be binding upon the successors and assigns of the Company. This Agreement is for the unique personal services of the Employee,
and the Employee shall not be entitled to assign any of the Employee&#8217;s rights or obligations hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Entire Agreement: Amendment</U>. This Agreement constitutes the entire agreement and understanding between the parties
hereto with respect to the subject matter of this Agreement, and supersedes all other prior agreements and understandings with respect
thereto including, but not limited to, the Consulting Agreement dated May 1, 2011 previously entered into by and between the Company and
the Employee. This Agreement can be amended or modified only in a writing signed by the Employee and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(g)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>No Waiver</U>. No waiver by either party at any time of any breach by the other party of, or compliance with, any condition
or provision of this Agreement to be performed by the other party shall be deemed a waiver of similar or dissimilar provisions or conditions
at the same time or any prior or subsequent time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(h)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Headings</U>. The headings herein contained are for reference only and shall not affect the meaning or interpretation
of any provision of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT> <U>Counterparts</U>. This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an
original but all of which together will constitute one and the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(j)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Costs and Expenses</U>. The Company shall reimburse all of the Employee&#8217;s reasonable costs and expenses (including,
without limitation, attorneys&#8217; fees), incurred in connection with the negotiation and preparation of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(k)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Attorneys&#8217; Fees</U>. In the event of any action at law, equity or under this Agreement to enforce or interpret
the terms of this Agreement, the prevailing party shall be entitled to reasonable attorneys&#8217; fees and court costs in addition to
any other relief to which such party may be entitled, unless the action is one in which only a prevailing plaintiff is entitled to prevailing
party fees and costs (such as a Title VII action).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(l)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Section 409A</U>. The Company intends that the cash severance payments to which the Employee is entitled on his termination
of employment pursuant to Section 5 are payable on the Employee&#8217;s Separation from Service (as defined below) and are exempt from,
or are otherwise payable in compliance with, Section 409A. The Company intends that the Company&#8217;s continued payment for the cost
of the Employee&#8217;s welfare benefits (including the payment of all COBRA administrative costs and expenses) provided by Section 5
will comply with the exception to Section 409A for reimbursements and certain other separation payments, as described in Treas. Reg. &sect;
1.409A-1(b)(9)(v)(B), to the extent such costs are taxable and subject to imputed income treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Separation from Service Defined</U>. For purposes of this Agreement, the term &#8220;<U>termination of employment</U>&#8221;
means the Employee&#8217;s &#8220;<U>Separation from Service</U>.&#8221; The term &#8220;<U>Separation from Service</U>&#8221; means (i)
the termination of the Employee&#8217;s employment with the Company and all affiliates for any reason or (ii) a permanent reduction in
the level of bona fide services the Employee provides to the Company and all affiliates to an amount that is twenty percent (20%) or less
of the average level of bona fide services the Employee provided to the Company and all affiliates in the immediately preceding thirty-six
(36) months (or the entire time period during which the Employee provided services to the Company and all affiliates if the Employee has
been providing such services for less than thirty-six (36) months), with the level of bona fide service calculated in accordance with
Treas. Reg. &sect; 1.409A-1(h)(1)(ii). Solely for purposes of determining whether an organization is an &#8220;affiliate&#8221; of the
Company, the Company will follow the rules set forth in Treas. Reg. &sect; 1.409A-1(h)(3) (which generally requires fifty percent (50%)
common ownership or control). The Employee&#8217;s employment relationship is treated as continuing while the Employee is on military
leave, sick leave, or other bona fide leave of absence (if the period of such leave does not exceed six (6) months; or, if longer, so
long as the Employee&#8217;s right to reemployment with the Company or an affiliate is provided either by statute or contract). If the
Employee&#8217;s period of leave exceeds six (6) months and his right to re-employment is not provided either by statute or by contract,
the employment relationship is deemed to terminate on the first day immediately following the expiration of such six (6) month period.
Whether a termination of employment has occurred will be determined based on all of the facts and circumstances and in accordance with
regulations issued by the United States Treasury Department pursuant to Section 409A of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT> <U>Delay in Payments</U>. Notwithstanding any provision of this Agreement to the contrary, if any of the severance payments
are subject to Section 409A and the Employee is a &#8220;<U>Specified Employee</U>&#8221; at the time of his Separation from Service,
no payments shall be made to the Employee prior to the first business day following the date which is six (6) months after the Employee&#8217;s
Separation from Service. Any amounts that would have been paid during the six (6) months following the Employee&#8217;s Separation from
Service will be paid on the first business day following the expiration of the six (6) month period without interest thereon. The Employee
may not elect the taxable year of such payment. The six (6) month delay for a Specified Employee does not apply if the Employee dies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(iii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Specified Employee Defined</U>. For purposes of this Agreement, the term &#8220;<U>Specified Employee</U>&#8221; means
certain officers and highly-compensated employees of the Company as defined in Treas. Reg. &sect; 1.409A-1(i), and as determined in accordance
with such procedures as may be adopted from time to time by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(iv)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Miscellaneous Payment Provisions</U>. If payment is not made, in whole or in part, due to a dispute between the Employee
and the Company, the payments shall be made in accordance with Treas. Reg. &sect; 1.409A-3(g), as applicable. It is intended that each
installment of the payments and benefits provided under Section 5 of this Agreement shall be treated as a separate &#8220;payment&#8221;
for purposes of Section 409A. If an expense reimbursement or provision of in-kind benefit provided pursuant to this Agreement is not exempt
from Section 409A of the Code, the following rules apply: (i) in no event shall any reimbursement be paid after the last day of the taxable
year following the taxable year in which the expense was incurred; (ii) the amount of reimbursable expenses incurred or provision of in-kind
benefits in one tax year shall not affect the expenses eligible for reimbursement or the provision of in-kind benefits in any other tax
year; and (iii) the right to reimbursement for expenses or provision of in-kind benefits is not subject to liquidation or exchange for
any other benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(v)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Ban on Acceleration or Deferral</U>. Under no circumstances may the time or schedule of any payment made or benefit provided
pursuant to this Agreement be accelerated or subject to a further deferral, except as otherwise permitted or required pursuant to regulations
and other guidance issued pursuant to Section 409A of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(vi)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>No Elections</U>. The Employee does not have any right to make any election regarding the time or form of any payment
due under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(vii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Compliant Operation and Interpretation</U>. This Agreement shall be operated in compliance with the requirements of Section
409A or an exception thereto and each provision of this Agreement shall be interpreted, to the extent possible, to comply with Section
409A or to qualify for an exception thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(m)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT><U>Dispute
Resolution; Venue</U>. The Company and the Employee shall use reasonable, good faith efforts to settle any dispute through
non-binding mediation before a mutually acceptable, neutral, third-party mediator. The mediation shall be held in Salt Lake City,
Utah and administered by the CPR Institute for Dispute Resolution (the &#8220;<U>CPR Institute</U>&#8221;) under the CPR Mediation
Procedure then in effect. Unless otherwise agreed, the parties shall jointly select a single mediator from the CPR Panels of
Distinguished Neutrals based on a list of mediator candidates supplied by the CPR Institute. If, within fourteen (14) days after
either party makes a written request for mediation under this Section 9(m)(i), the parties have not reached agreement on the
selection of a mediator, the mediator shall be selected in accordance with the CPR Mediation Procedure currently in effect. A good
faith attempt at mediation shall be a condition precedent to the commencement of litigation, but nothing in this Agreement,
including, but not limited to paragraph (ii) below, shall be deemed a condition precedent to any court action for injunction or
other interim relief pending the outcome of mediation. If the parties are unable to resolve the dispute by mediation in a timely
manner (which, in any case, shall not exceed sixty (60) days from the first notice of mediation), either party may attempt to
resolve the dispute by commencing an action (or defending or responding to such action) exclusively in the jurisdiction and venue of
the courts, whether federal or state, located in Salt Lake County, Utah.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(n)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Indemnification</U>. During the period of his employment hereunder, the Company agrees to indemnify the Employee in his
capacity as an officer and Director of the Company and, to the extent applicable, each subsidiary of the Company, all to the maximum extent
permitted under Section 145 of the Delaware General Corporation Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have executed this Agreement to be effective for all purposes as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>THE COMPANY</U>:</B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SERA PROGNOSTICS, INC.</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Mark J. Ostrowski</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Mark J. Ostrowski</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: President</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>THE EMPLOYEE</U>:</B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Gregory
    C. Critchfield, M.D.</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Gregory C. Critchfield, M.D</FONT></TD>
    </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><U>EXHIBIT A</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>OUTSIDE INTERESTS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member of the Board of Directors of the following corporations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Integrated Diagnostics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Nodality, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Metamark Genetics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Saladax Biomedical, Inc. (Chairman)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Board member of Bear Lake Watch, a non-profit corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, the Employee will, from time to time, advise various venture
capital firms on discreet, short term projects with respect to companies that are not in competition with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>25
<FILENAME>tm2110724d11_ex10-10.htm
<DESCRIPTION>EXHIBIT 10.10
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

                           <P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: right; margin: 0pt"><B>Exhibit 10.10</B></P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SERA PROGNOSTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EMPLOYMENT AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Employment Agreement
(this &ldquo;Agreement&rdquo;) is effective for all purposes as of March 24, 2020 (the &ldquo;Effective Date&rdquo;), by and between Sera
Prognostics, Inc., a Delaware corporation (the &ldquo;Company&rdquo;), and Jay M. Moyes (the &ldquo;Employee&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the mutual covenants, conditions and undertakings set forth herein, the parties hereto hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Employment
and Duties</U>. Subject to the terms and conditions set forth in this Agreement, the Company shall employ Employee, and Employee hereby
accepts employment, as the Chief Financial Officer of the Company, with those duties and responsibilities which are appropriate and customary
for a chief financial officer of a company similar to the Company. In such capacity, the Employee shall report to the Company&rsquo;s
Chief Executive Officer. During the term of this Agreement, the Employee shall faithfully perform the Employee&rsquo;s duties, responsibilities
and obligations hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Base
Compensation and Related Matters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Salary</U>.
In consideration for the services rendered by the Employee to the Company as provided herein, the Company shall pay the Employee an annual
base salary of $355,000 per year (the &ldquo;<U>Base Salary</U>&rdquo;), provided that the Employee&rsquo;s employment with the Company
remains active at a full-time rate. The Base Salary shall be paid according to the Company&rsquo;s standard payroll policy and will be
subject to applicable federal and state tax withholdings as required by applicable law. The Base Salary may be increased or decreased
at any time by the Company&rsquo;s Board of Directors (the &ldquo;<U>Board</U>&rdquo;) or the Compensation Committee of the Board in
its sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Stock
Option Grant(s) and Bonuses</U>. Subject to Board of Directors approval, the Employee shall be granted on or within thirty (30) days
after the Effective Date a hiring option to purchase 575,511 shares of the Company&rsquo;s common stock (the
 &ldquo;<U>Option</U>&rdquo;) (which option shall be issued as an incentive stock option to the maximum extent allowed under Section
422 of the Internal Revenue Code of 1986, as amended, and the regulations promulgated thereunder (the &ldquo;<U>Code</U>&rdquo;))
pursuant to the Company&rsquo;s 2011 Employee, Director and Consultant Equity Incentive Plan (the &ldquo;<U>Plan</U>&rdquo;). The
Option shall vest as to twenty-five percent (25%) of the shares subject thereto one (1) year from the Effective Date
(&ldquo;<U>Vesting Start Date</U>&rdquo;), and shall vest with respect to the remaining shares subject thereto in equal monthly
installments over an additional thirty-six (36) months thereafter commencing on the first day of the month following the Vesting
Start Date, subject to continued employment by the Company. In addition, the Option shall accelerate with respect to thirty-seven
and one-half percent (37.5%) of the outstanding unvested shares at that time then subject thereto upon a Change of Control (as
defined in the Plan) pursuant to which the Option is terminated pursuant to Section 24(b)(ii) of the Plan or cashed out pursuant to
Section 24(b)(iii) of the Plan. The Employee shall be eligible, after the Effective Date, to receive (i) additional stock options
pursuant to the Plan, and (ii) additional bonus compensation, as determined by the Board, in its sole discretion; it being the
intention of the Board to maintain Employee&rsquo;s aggregate compensation at levels appropriate and customary to those of companies
similar in industry, stage and circumstances to that of the Company. Unless otherwise approved by the Board, all future options
granted to the Employee after the Effective Date shall vest in equal monthly installments over a period of forty-eight (48) months
from the date of grant. Notwithstanding the foregoing, in the event that the Employee&rsquo;s employment with the Company is
terminated by the Company without Cause (as defined in Section 5(a)(iii) below) or by the Employee for Good Reason (as defined in
Section 5(b)(ii) below), then the vesting of all options held by the Employee at the time of the termination shall accelerate (i)
with respect to thirty-seven and one-half percent (37.5%) of the unvested shares subject thereto, or (ii) if such termination occurs
within 30 days prior to or within 12 months after a Change of Control (as defined in the Plan), with respect to one hundred percent
(100%) of the unvested shares subject thereto. You will be eligible to participate in the Company&rsquo;s Annual Incentive Plan,
which currently provides for a bonus target of 35% of your base salary, prorated for time of service, and with respect to the
calendar year ending December 31, 2020, payment will be contingent based on achievements mutually agreed by you and your
supervisor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Expenses</U>. The Employee will be entitled to receive prompt reimbursement for all reasonable expenses incurred by the Employee
(which are eligible for reimbursement under the Code) actually incurred by him in performing his duties; provided; however, that such
expenses are approved in accordance with the Company&rsquo;s then-current policies and procedures applicable to the most senior-level
executive employees of the Company, other than the Employee, or if such policies and procedures are not in place, then as determined in
the sole discretion of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Employee Benefits</U>. Upon beginning his employment with the Company, the Employee will be entitled to participate in the group
health, dental, vision, and group life insurance benefit plans, as well as the Company&rsquo;s 401(k) and Flexible Spending Account Plans
available to all Company employees. In addition, the Employee is entitled to participate in any employee benefit plans that the Company
may make available to its most senior-level executive employees generally, which may include but not be limited to, profit sharing plans,
401(k) and cafeteria plans, or life, hospitalization, optical, disability, or other insurance plans as may be in effect, from time to
time, and in accordance with rules established, from time to time, for individual participation in such plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Transition Support</U>. In the event that Employee relocates to the greater Salt Lake City, UT Wasatch Front area within twenty-four
(24) months following the Effective Date, which time period may be extended by mutual, written agreement of the parties:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
Company shall provide temporary housing support of up to $4,000 per month for six (6) months following such relocation. This temporary
housing support shall begin within a reasonable time of Employee&rsquo;s written request for temporary housing support reimbursement
and will be payable on a monthly basis thereafter in accordance with the Company&rsquo;s payroll practices; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The Company shall will reimburse up to $30,000.00 in Employee&rsquo;s relocation costs for such relocation. Should Employee&rsquo;s
documented relocation costs exceed $30,000.00, the Company may - but is not required to - reimburse those additional amounts, with said
additional reimbursement to be confirmed, in writing, by the parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Paid Time Off</U>. Upon beginning his employment with the Company, the Employee will be entitled to take five (5) weeks of
paid time off per calendar year, three (3) additional paid sick leave days per year, and shall be entitled to compensation in connection
therewith, in accordance with Company policy applicable to senior-level executive employees of the Company, as approved by the Chief
Executive Officer in its sole discretion. Neither vacation days nor paid sick leave days will roll over to the next calendar year. The
Company will pay out all unused, accrued vacation upon the Employee&rsquo;s separation from the Company. Unused, accrued paid sick leave
will not be paid out.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Facilities
and Services Furnished</U>. The Company will furnish the Employee with office space at its headquarters in Salt Lake City, Utah, and
such other facilities, furniture, equipment and services as it may determine to be reasonably necessary for the performance of the Employee&rsquo;s
duties as set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Termination</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Termination by the Company</U>. The Employee&rsquo;s employment hereunder may be terminated by the Company under any of the
following circumstances:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Death</U>.
This Agreement shall automatically terminate upon the Employee&rsquo;s death.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Disability</U>.
The Company or the Employee may elect to terminate the Employee&rsquo;s employment in the event of Employee&rsquo;s Disability upon delivery
of written notice to the Employee. For purposes of this Agreement, &ldquo;Disability&rdquo; shall mean any condition that, in the reasonable,
good faith judgment of a licensed physician selected by the Company, causes the Employee to be unable, after any accommodation required
by applicable law, to perform his duties, responsibilities and obligations under this Agreement for a period of at least twelve (12)
months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Cause</U>.
The Company may terminate the Employee&rsquo;s employment hereunder for Cause (as defined below) at any time upon delivery of written
notice to the Employee. For purposes of this Agreement, &ldquo;<U>Cause</U>&rdquo; shall mean (A) the conviction of the Employee by a
court of competent jurisdiction of any felony involving dishonesty, breach of trust or misappropriation or the entering of a plea by
the Employee of nolo contendere thereto; (B) the Employee&rsquo;s willful failure or refusal to follow reasonable and lawful directives
of the Board or the Company&rsquo;s Chief Executive Officer, provided such failure or refusal continues after the Employee&rsquo;s receipt
of reasonable notice in writing of such failure or refusal and an opportunity of not less than thirty (30) days to correct the problem;
(C) a material breach by the Employee of any of the provisions of this Agreement, with notification of such breach by the process outlined
Section 5(a)(iii)(B) above; or (D) the Employee&rsquo;s commission of any illegal act or any gross or willful misconduct, where a majority
of the non-employee members of the Board reasonably determines that such act or misconduct has (1) contributed to the Company&rsquo;s
loss of significant revenues or business opportunities, or (2) significantly and detrimentally affected the business or reputation of
the Company or any of its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Other
Termination</U>. The Company may terminate Employee&rsquo;s employment with the Company at any time and for any reason, with or
without cause, subject to the provisions hereof. Employee acknowledges that Employee is, and at all times shall be, an employee at
will of the Company and nothing contained herein shall be construed to alter or affect such employee at-will status. Employee may
terminate his employment with the Company at any time, for any or no reason, subject to the provisions hereof. Inclusion under any
benefit plan or compensation arrangement will not give Employee any right or claim to any benefit hereunder except to the extent
such right has become fixed under the express terms of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Termination by the Employee</U>. The Employee may terminate the Employee&rsquo;s employment with the Company under the following
circumstances:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Voluntary Termination</U>. Employee may terminate his employment with the Company for any reason or no reason, upon delivery
of written notice to the Company at least fifteen (15) days prior to the specified termination date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Termination
for Good Reason</U>. The Employee also may terminate the Employee&rsquo;s employment with the Company for &ldquo;<U>Good Reason</U>,&rdquo;
which shall mean for purposes of this Agreement (A) a material breach by the Company of any of the provisions of this Agreement; (B)
assignment of Employee to a role, duties or responsibilities materially inconsistent with that of a chief financial officer; (C) any
circumstances caused by the Company that would require Employee to move his principal location of employment in excess of fifty (50)
miles from the Company&rsquo;s principal business location in Salt Lake City, Utah; or (D) an involuntary material reduction of Employee&rsquo;s
then current Base Salary or target bonus opportunity other than a reduction proportionately affecting all of the Company&rsquo;s other
senior-level executive employees. The Employee must provide the Company with a written Notice of Termination that describes the existence
of the condition the Employee believes gives rise to Good Reason under this Section 5(b)(ii) within thirty (30) days following the date
on which the Employee knows or should reasonably have known of the initial existence of the condition. The Company may elect to cure
any condition giving rise to Good Reason within thirty (30) days of receipt of notice. The Employee&rsquo;s termination for Good Reason
must, in any event, occur within the six (6) month period immediately following the date on which the Employee knows or should reasonably
have known of the initial existence of the condition giving rise to Good Reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Effect of Termination</U>. In the event the Employee&rsquo;s employment is terminated, all obligations of the Company and the
Employee under this Agreement shall cease, except that the accelerated vesting of Options set forth in Section 2(b) and the terms of Section
5 through Section 9 shall survive such termination. Upon such termination, the Employee or the Employee&rsquo;s representative or estate
shall be entitled to receive the applicable compensation, benefits and reimbursements set forth in Section 5. The Employee acknowledges
that, upon termination of the Employee&rsquo;s employment, the Employee is entitled to no other compensation, severance or other benefits
other than (i) those specifically set forth in Section 6, (ii) the aggregate amount of the Employee&rsquo;s earned but unpaid Base Salary
and accrued but unpaid vacation pay through the date of such termination, (iii) any vested amounts due to the Employee pursuant to the
applicable terms of any plan, program or policy of the Company (including any life insurance or long-term disability plan) and (iv) reimbursement
of any business expenses incurred by the Employee prior to the date of termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Compensation and Benefits Upon Termination of Employment</U>. At all times after the Effective Date, the Employee shall be
entitled to receive additional compensation and benefits upon a termination of Employee&rsquo;s employment as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Severance
Pay</U>. If either (i) the Company terminates the Employee&rsquo;s employment for any reason other than Cause, death or Disability or
(ii) the Employee terminates his employment for Good Reason; then, on the sixtieth (60<SUP>th</SUP>) day following the termination of
employment, the Company shall pay the Employee a lump sum amount equal to six (6) months of the Base Salary at the rate in effect at
the time of the termination of employment. If the Company terminates the Employee&rsquo;s employment due to death or Disability and (y)
the Company does not provide any disability or life, as applicable, insurance benefits payable to the Employee or his beneficiaries,
as applicable, upon his death or Disability and (z) the Company has previously, but not necessarily in the then applicable calendar year,
achieved Ten Million Dollars in annual gross revenue in a calendar year, then, on the sixtieth (60<SUP>th</SUP>) day following the termination
of employment due to death or Disability, the Company shall pay the Employee a lump sum amount equal to six (6) months of the Base Salary
at the rate in effect at the time of the termination of employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Health
Insurance</U>. If, while participating in the Company&rsquo;s group health insurance plan(s), either (i) the Company terminates the Employee&rsquo;s
employment for any reason other than Cause, death or Disability or (ii) the Employee terminates his employment for Good Reason, and if
the Employee elects to continue his health insurance coverage under the Consolidated Omnibus Budget Reconciliation Act (&ldquo;<U>COBRA</U>&rdquo;)
following the termination of his employment, then the Company shall pay the portion of the Employee&rsquo;s monthly premium under COBRA
until the earliest of (x) the close of the twelve (12) month period following the Employee&rsquo;s termination date, (y) the expiration
of the Employee&rsquo;s continuation coverage under COBRA or (z) the date when the Employee receives health insurance coverage in connection
with new employment. If the payment of any COBRA or health insurance premiums would otherwise violate the nondiscrimination rules or
cause the reimbursement of claims to be taxable under the Patient Protection and Affordable Care Act of 2010, together with the Health
Care and Education Reconciliation Act of 2010 (collectively, the &ldquo;<U>Act</U>&rdquo;) or Section 105(h) of the Code, the Company
paid premiums shall be treated as taxable payments and be subject to imputed income tax treatment to the extent necessary to eliminate
any discriminatory treatment or taxation under the Act or Section 105(h) of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>General
Release</U>. Any other provision of this Agreement notwithstanding, subsections (a) and (b) above shall not apply unless the Employee
has (i) executed a general release of all claims (in a form prescribed by the Company), which must be effective and irrevocable prior
to the sixtieth (60<SUP>th</SUP>) day following the termination of employment, (ii) returned all property of the Company in the Employee&rsquo;s
possession and (iii) cooperated in good faith with the Company for a transition period not to exceed sixty (60) days to ensure an efficient
transfer of the Employee&rsquo;s duties and responsibilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Maintaining Confidential Information</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Company
Confidential Information</U>. The Employee hereby agrees at all times during which he provides services as a director, officer, employee
or consultant of the Company (&ldquo;<U>Employee&rsquo;s Service</U>&rdquo;), and thereafter to hold in strictest confidence, and not
to use, except for the benefit of the Company, any trade secrets, confidential knowledge, data or other proprietary information relating
to products, processes, know-how, formulas, developmental or experimental work, computer lists, customer lists, business plans, financial
information or other subject matter pertaining to any business of the Company or any of its clients, consultants or licensees (collectively
 &ldquo;<U>Confidential Information</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the above,
Employee shall not have liability to the Company with regard to any Confidential Information which Employee can prove:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>was in the public domain at the time it was disclosed by the Company or has entered the public domain through no fault of Employee;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>was known to the Employee without restriction, at the time of disclosure, as demonstrated by files in existence at the time of
disclosure;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>is
disclosed with the prior written approval of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>becomes
known to Employee, without restriction, from a source other than the Company without breach of this Agreement by Employee and otherwise
not in violation of the Company&rsquo;s rights; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>is disclosed pursuant to the order or requirement of a court, administrative agency, or other governmental body; provided, however,
that Employee shall provide prompt notice of such court order or requirement to the Company to enable the Company to seek a protective
order or otherwise prevent such disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Former Employer Information</U>. The Employee hereby agrees that he will not, during Employee&rsquo;s Service, improperly use
or disclose any proprietary information or trade secrets of his former or concurrent employers or companies, if any, and that he will
not make available to the Company any unpublished document or any property belonging to his former or concurrent employers or companies,
if any, unless consented to in writing by said employers or companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Third-Party
Information</U>. The Employee recognizes that the Company has received and in the future will receive from third parties their confidential
or proprietary information subject to a duty on the Company&rsquo;s part to maintain the confidentiality of such information and to use
it only for certain limited purposes. The Employee hereby agrees, during Employee&rsquo;s Service and thereafter, to hold all such confidential
or proprietary information in the strictest confidence and not to disclose it to any person, firm or corporation (except as necessary
in carrying out his work for the Company consistent with the Company&rsquo;s agreement with such third party) or to use it for the benefit
of anyone other than the Company or such third party (consistent with the Company&rsquo;s agreement with such third party) without the
express written authorization of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Outside Activities</U>. During the Employee&rsquo;s employment with the Company, the Employee shall not perform consulting/business
activities beyond those disclosed in Exhibit A, without prior written consent of the Company&rsquo;s Board of Directors Compensation Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Availability
of Equitable Remedies</U>. The Employee hereby acknowledges and agrees that a breach of Section 7 will cause irreparable harm and damage
to the Company, that the remedy at law for the breach or threatened breach of Section 7 will be inadequate, and that, in addition to
all other remedies available to the Company for such breach or threatened breach (including, without limitation, the right to recover
damages), the Company will be entitled to injunctive relief for any breach or threatened breach of Section 7.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Notification of New Employer</U>. In the event that the Employee leaves the employ of the Company, he hereby grants consent
to notification by the Company to his new employer about his rights and obligations under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Severability</U>. In the event that a court of competent jurisdiction determines that any portion of this Agreement is in violation
of any statute or public policy, then only the portions of this Agreement which violate such statute or public policy shall be stricken.
All portions of this Agreement which do not violate any statute or public policy shall continue in full force and effect. Further, any
court order striking any portion of this Agreement shall modify the stricken terms to give as much effect as possible to the intentions
of the parties under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Notices</U>. Any notices, requests or consents hereunder shall be deemed given, and any instrument delivered, three (3) days
after they have been mailed by first class mail, postage prepaid, one (1) day after they have been delivered by overnight courier, twelve
(12) hours after such notice has been sent by facsimile, or upon receipt if delivered personally, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><U>To the Company</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">2749 Parleys Way, Suite 200</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Salt Lake City, UT 84109</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><U>To the Employee</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">1181 E. Woodcrest Lane</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">North Salt Lake, UT 84054</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">except that any of the foregoing may, from time
to time, by written notice to the others, designate another address or fax number which shall thereupon become his or its effective address
for the purposes of this Section 9(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Governing
Law</U>. This Agreement shall be governed by the laws of the State of Utah, without giving effect to its conflict of laws principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Successors
and Assigns</U>. The rights and obligations of the Company under this Agreement shall inure to the benefit of and shall be binding upon
the successors and assigns of the Company. This Agreement is for the unique personal services of the Employee, and the Employee shall
not be entitled to assign any of the Employee&rsquo;s rights or obligations hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Entire Agreement; Amendment</U>. This Agreement constitutes the entire agreement and understanding between the parties hereto
with respect to the subject matter of this Agreement, and supersedes all other prior agreements and understandings with respect thereto.
This Agreement can be amended or modified only in a writing signed by the Employee and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>No
Waiver</U>. No waiver by either party at any time of any breach by the other party of, or compliance with, any condition or provision
of this Agreement to be performed by the other party shall be deemed a waiver of similar or dissimilar provisions or conditions at the
same time or any prior or subsequent time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Headings</U>. The headings herein contained are for reference only and shall not affect the meaning or interpretation of any
provision of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Counterparts</U>. This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original
but all of which together will constitute one and the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Costs and Expenses</U>. The Company shall reimburse all of the Employee&rsquo;s reasonable costs and expenses (including, without
limitation, attorneys&rsquo; fees), incurred in connection with the negotiation and preparation of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Attorneys&rsquo;
Fees</U>. In the event of any action at law, equity or under this Agreement to enforce or interpret the terms of this Agreement, the
prevailing party shall be entitled to reasonable attorneys&rsquo; fees and court costs in addition to any other relief to which such
party may be entitled, unless the action is one in which only a prevailing plaintiff is entitled to prevailing party fees and costs (such
as a Title VII action).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Section
409A</U>. The Company intends that the cash severance payments to which the Employee is entitled on his termination of employment pursuant
to Section 6 are payable on the Employee&rsquo;s Separation from Service (as defined below) and are exempt from, or are otherwise payable
in compliance with Section 409A. The Company intends that the Company&rsquo;s continued payment for the cost of the Employee&rsquo;s
welfare benefits (including the payment of all COBRA administrative costs and expenses) provided by Section 6 will comply with the exception
to Section 409A for reimbursements and certain other separation payments, as described in Treas. Reg. &sect; 1.409A-1(b)(9)(v)(B), to
the extent such costs are taxable and subject to imputed income treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Separation
from Service Defined</U>. For purposes of all payments of nonqualified deferred compensation subject to Section 409A to be made upon
a termination of employment under this Agreement, the term &ldquo;<U>termination of employment</U>&rdquo; means the Employee&rsquo;s
 &ldquo;<U>Separation from Service</U>.&rdquo; The term &ldquo;<U>Separation from Service</U>&rdquo; means (A) the termination of the
Employee&rsquo;s employment with the Company and all affiliates for any reason or (B)&#9; a permanent reduction in the level of bona
fide services the Employee provides to the Company and all affiliates to an amount that is twenty percent (20%) or less of the average
level of bona fide services the Employee provided to the Company and all affiliates in the immediately preceding thirty-six (36) months
(or the entire time period during which the Employee provided services to the Company and all affiliates if the Employee has been providing
such services for less than thirty-six (36) months), with the level of bona fide service calculated in accordance with Treas. Reg. &sect;
1.409A-1(h)(1)(ii). Solely for purposes of determining whether an organization is an &ldquo;<U>affiliate</U>&rdquo; of the Company, the
Company will follow the rules set forth in Treas. Reg. &sect; 1.409A-1(h)(3) (which generally requires fifty percent (50%) common ownership
or control). The Employee&rsquo;s employment relationship is treated as continuing while the Employee is on military leave, sick leave,
or other bona fide leave of absence (if the period of such leave does not exceed six (6) months; or, if longer, so long as the Employee&rsquo;s
right to reemployment with the Company or an affiliate is provided either by statute or contract). If the Employee&rsquo;s period of
leave exceeds six (6) months and his right to re-employment is not provided either by statute or by contract, the employment relationship
is deemed to terminate on the first day immediately following the expiration of such six (6) month period. Whether a termination of employment
has occurred will be determined based on all of the facts and circumstances and in accordance with regulations issued by the United States
Treasury Department pursuant to Section 409A of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Delay
in Payments</U>. Notwithstanding any provision of this Agreement to the contrary, if any of the severance payments are subject to Section
409A and the Employee is a &ldquo;<U>Specified Employee</U>&rdquo; at the time of his Separation from Service, no payments shall be made
to the Employee prior to the first business day following the date which is six (6) months after the Employee&rsquo;s Separation from
Service. Any amounts that would have been paid during the six (6) months following the Employee&rsquo;s Separation from Service will
be paid on the first business day following the expiration of the six (6) month period without interest thereon. The Employee may not
elect the taxable year of such payment. The six (6) month delay for a Specified Employee does not apply if the Employee dies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Specified
Employee Defined</U>. For purposes of this Agreement, the term &ldquo;<U>Specified Employee</U>&rdquo; means certain officers and highly-compensated
employees of the Company as defined in Treas. Reg. 1.409A-1(i), and as determined in accordance with such procedures as may be adopted
from time to time by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Miscellaneous
Payment Provisions</U>. If payment is not made, in whole or in part, due to a dispute between the Employee and the Company, the payments
shall be made in accordance with Treas. Reg. &sect; 1.409A-3(g), as applicable. It is intended that each installment of the payments
and benefits provided under Section 6 of this Agreement shall be treated as a separate &ldquo;payment&rdquo; for purposes of Section
409A. If an expense reimbursement or provision of in-kind benefit provided pursuant to this Agreement is not exempt from Section 409A
of the Code, the following rules apply: (A) in no event shall any reimbursement be paid after the last day of the taxable year following
the taxable year in which the expense was incurred; (B) the amount of reimbursable expenses incurred or provision of in-kind benefits
in one tax year shall not affect the expenses eligible for reimbursement or the provision of in-kind benefits in any other tax year;
and (C) the right to reimbursement for expenses or provision of in-kind benefits is not subject to liquidation or exchange for any other
benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Ban on Acceleration or Deferral</U>. Under no circumstances may the time or schedule of any payment made or benefit provided
pursuant to this Agreement be accelerated or subject to a further deferral, except as otherwise permitted or required pursuant to regulations
and other guidance issued pursuant to Section 409A of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Elections</U>. The Employee does not have any right to make any election regarding the time or form of any payment due under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Compliant
Operation and Interpretation</U>. This Agreement shall be operated in compliance with the requirements of Section 409A or an exception
thereto and each provision of this Agreement shall be interpreted, to the extent possible, to comply with Section 409A or to qualify
for an exception thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Dispute
Resolution; Venue</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
Company and the Employee shall use reasonable, good faith efforts to settle any dispute through non-binding mediation before a mutually-acceptable,
neutral, third-party mediator. The mediation shall be held in Salt Lake City, Utah and administered by the CPR Institute for Dispute
Resolution (the &ldquo;<U>CPR Institute</U>&rdquo;) under the CPR Mediation Procedure then in effect. Unless otherwise agreed, the parties
shall jointly select a single mediator from the CPR Panels of Distinguished Neutrals based on a list of mediator candidates supplied
by the CPR Institute. If, within fourteen (14) days after either party makes a written request for mediation under this Section 9(m)(i),
the parties have not reached agreement on the selection of a mediator, the mediator shall be selected in accordance with the CPR Mediation
Procedure currently in effect. A good faith attempt at mediation shall be a condition precedent to the commencement of litigation, but
nothing in this Agreement, including, but not limited to paragraph (ii) below, shall be deemed a condition precedent to any court action
for injunction or other interim relief pending the outcome of mediation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>If
the parties are unable to resolve the dispute by mediation in a timely manner (which, in any case, shall not exceed sixty (60) days from
the first notice of mediation), either party may attempt to resolve the dispute by commencing an action (or defending or responding to
such action) exclusively in the jurisdiction and venue of the courts, whether federal or state, located in Salt Lake County, Utah.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(n)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
Company shall, at all times, maintain Directors &amp; Officers insurance with a policy limit of least $5,000,000.00 that will cover Employee
in his capacity as an officer of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have executed this Agreement to be effective for all purposes as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>THE COMPANY</U>:</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SERA PROGNOSTICS, INC.</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 48%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Gregory C. Critchfield, M.D.</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Gregory C. Critchfield, M.D.</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Chairman, President, and CEO</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>THE EMPLOYEE</U>:</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Jay M. Moyes</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jay M. Moyes</FONT></TD>
    </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3.5in"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>EXHIBIT A</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">THE OUTSIDE INTERESTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR>
    <TD STYLE="border: Black 1pt solid; vertical-align: bottom; width: 25%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>TITLE</B></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom; width: 25%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>COMPANY NAME</B></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom; width: 22%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>HOURS PER WEEK</B></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom; width: 28%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>ACTIVITIES</B></TD></TR>
  <TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-align: center">Independent Director</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-align: center">Puma Biotechnology</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-align: center">variable</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-align: center">Board Member, <BR>
Compensation and <BR>
Audit Committees</TD></TR>
  <TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-align: center">Independent Director</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-align: center">Achieve Live <BR>
Sciences</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-align: center">variable</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-align: center">Board Member, <BR>
Compensation and <BR>
Audit Committees</TD></TR>
  <TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-align: center">Independent Director</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-align: center">BioCardia</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-align: center">variable</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-align: center">Board Member, <BR>
Compensation and <BR>
Audit Committees</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>26
<FILENAME>tm2110724d11_ex10-11.htm
<DESCRIPTION>EXHIBIT 10.11
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

                           <P STYLE="margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.11</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SERA PROGNOSTICS, INC. EMPLOYMENT AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Employment Agreement (this &ldquo;<U>Agreement</U>&rdquo;)
is effective for all purposes as of January 27, 2015 (the &ldquo;<U>Effective Date</U>&rdquo;), by and between Sera Prognostics, Inc.,
a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), and Douglas C. Fisher (the &ldquo;<U>Employee</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">NOW, THEREFORE, in consideration of the mutual
covenants, conditions and undertakings set forth herein, the parties hereto hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Employment
and Duties</U>. Subject to the terms and conditions set forth in this Agreement, the Company shall employ Employee, and Employee hereby
accepts employment, as the Chief Business Officer of the Company, with those duties and responsibilities which are appropriate and customary
for the business development leader of a company similar to the Company. In such capacity, the Employee shall report to the Company&rsquo;s
Chief Executive Officer. During the term of this Agreement, the Employee shall faithfully perform the Employee&rsquo;s duties, responsibilities
and obligations hereunder. Upon or shortly after the Effective Date, when a replacement representative to Sera&rsquo;s Board of Directors
is named by InterWest Partners, Inc., the Employee shall resign all duties and responsibilities as a Director of Sera Prognostics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Base Compensation and Related Matters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Salary</U>. In consideration for the services rendered by the Employee to the Company as provided herein, the Company shall
pay the Employee a weekly base salary of $500.00 from the Effective Date through December 31, 2015 and shall pay the Employee an annual
base salary of the average of the Company&rsquo;s non-CEO C-level employees per year beginning on January 1, 2016 (the &ldquo;<U>Base
Salary</U>&rdquo;), provided that the Employee&rsquo;s employment with the Company remains active at a full-time rate. The Base Salary
shall be paid according to the Company&rsquo;s standard payroll policy and will be subject to applicable federal and state tax withholdings
as required by applicable law. The Base Salary may be increased or decreased at any time by the Company&rsquo;s Board of Directors (the
 &ldquo;<U>Board</U>&rdquo;) or the Compensation Committee of the Board in its sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Stock
Option Grant(s) and Bonuses. The Employee shall be granted as soon as practicable on or after the Effective Date an option to
purchase 348,693 shares of the Company&rsquo;s common stock (the &ldquo;<U>Option</U>&rdquo;) (which option shall be issued as an
incentive stock option to the maximum extent allowed under Section 422 of the Internal Revenue Code of 1986, as amended, and the
regulations promulgated thereunder (the &ldquo;<U>Code</U>&rdquo;)) pursuant to the Company&rsquo;s 2011 Employee, Director and
Consultant Equity Incentive Plan (the &ldquo;<U>Plan</U>&rdquo;). The Option shall vest in equal monthly installments over a period
of forty-eight (48) months from the Effective Date, subject to continued employment by the Company. In addition, the Option shall
accelerate with respect to thirty-seven and one-half percent (37.5%) of the unvested shares then subject thereto upon a Change of
Control (as defined in the Plan) pursuant to which the Option is terminated pursuant to Section 24(b)(ii) of the Plan or cashed out
pursuant to Section 24(b)(iii) of the Plan. The Employee shall be eligible, after the Effective Date, to receive (i) additional
stock options pursuant to the Plan and (ii) additional bonus compensation, as determined by the Board, in its sole discretion; it
being the intention of the Board to maintain Employee&rsquo;s aggregate compensation at levels appropriate and customary to those of
companies similar in industry, stage and circumstances to that of the Company. Unless otherwise approved by the Board, all future
options granted to the Employee after the Effective Date shall vest in equal monthly installments over a period of forty-eight (48)
months from the date of grant. Notwithstanding the foregoing, in the event that the Employee&rsquo;s employment with the Company is
terminated by the Company without Cause (as defined in Section 4(a)(iii) below) or by the Employee for Good Reason (as defined in
Section 4(b)(ii) below), then the vesting of all options held by the Employee at the time of the termination shall accelerate (i)
with respect to thirty-seven and one-half percent (37.5%) of the unvested shares subject thereto, or (ii) if such termination occurs
within 30 days prior to or within 12 months after a Change of Control (as defined in the Plan), with respect to one hundred percent
(100%) of the unvested shares subject thereto. You will be eligible to participate in the Company&rsquo;s Annual Incentive Plan,
which currently provides for a bonus target of 30% of your base salary, and with respect to the calendar year ending December 31,
2015, you will be provided a bonus target of the average of all non-CEO C-level bonus targets, whichever is higher.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Expenses</U>.
The Employee will be entitled to receive prompt reimbursement for all reasonable expenses incurred by the Employee (which are eligible
for reimbursement under the Code) actually incurred by him in performing his duties; provided; however, that such expenses are approved
in accordance with the Company&rsquo;s then-current policies and procedures applicable to the most senior-level executive employees of
the Company, other than the Employee, or if such policies and procedures are not in place, then as determined in the sole discretion
of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Employee Benefits</U>. Upon classification as a full-time employee, the Employee will be entitled to participate in the group
health, dental, vision, and group life insurance benefit plans, as well as the Company&rsquo;s 401(k) and Flexible Spending Account Plans
available to all Company employees. In addition, the Employee is entitled to participate in any employee benefit plans that the Company
may make available to its most senior-level executive employees generally, which may include, but not be limited to, profit sharing plans,
401(k) and cafeteria plans, or life, hospitalization, optical, disability or other insurance plans as may be in effect, from time to time,
and in accordance with rules established, from time to time, for individual participation in such plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Vacation
Days and Paid Leave</U>. Upon classification as a full-time employee, the Employee will be entitled to take four (4) weeks of vacation
days, three additional personal time off days, and shall be entitled to compensation in connection therewith, in accordance with Company
policy applicable to senior-level executive employees of the Company, as approved by the Chief Executive Officer in its sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Facilities
and Services Furnished</U>. The Company will furnish the Employee with office space and such other facilities, furniture, equipment and
services as it may determine to be reasonably necessary for the performance of the Employee&rsquo;s duties as set forth herein. It is
acknowledged that as of the Effective Date, the Company is &ldquo;<U>virtual</U>&rdquo; and the Employee is using his own home for the
Company office at no expense to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Termination</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Termination
by the Company</U>. The Employee&rsquo;s employment hereunder may be terminated by the Company under any of the following circumstances:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Death</U>. This Agreement shall automatically terminate upon the Employee&rsquo;s death.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Disability</U>.
The Company may elect to terminate the Employee&rsquo;s employment in the event of Employee&rsquo;s Disability upon delivery of written
notice to the Employee. For purposes of this Agreement, &ldquo;Disability&rdquo; shall mean any condition that, in the reasonable, good
faith judgment of a licensed physician selected by the Company, causes the Employee to be unable, after any accommodation required by
applicable law, to perform his duties, responsibilities and obligations under this Agreement for a period of at least twelve (12) months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Cause</U>. The Company may terminate the Employee&rsquo;s employment hereunder for Cause (as defined below) at any time upon
delivery of written notice to the Employee. For purposes of this Agreement, &ldquo;Cause&rdquo; shall mean (A) the conviction of the Employee
by a court of competent jurisdiction of any felony involving dishonesty, breach of trust or misappropriation or the entering of a plea
by the Employee of nolo contendre thereto; (B) the Employee&rsquo;s willful failure or refusal to follow reasonable and lawful directives
of the Board or the Company&rsquo;s Chief Executive Officer, provided such failure or refusal continues after the Employee&rsquo;s receipt
of reasonable notice in writing of such failure or refusal and an opportunity of not less than thirty (30) days to correct the problem;
(C) a material breach by the Employee of any of the provisions of this Agreement; or (D) the Employee&rsquo;s commission of any immoral
or illegal act or any gross or willful misconduct, where a majority of the non-employee members of the Board reasonably determines that
such act or misconduct has (1) seriously undermined the ability of the Board to entrust Employee with important matters or otherwise work
effectively with Employee, (2) contributed to the Company&rsquo;s loss of significant revenues or business opportunities, or (3) significantly
and detrimentally affected the business or reputation of the Company or any of its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Other
Termination</U>. The Company may terminate Employee&rsquo;s employment with the Company at any time and for any reason, with or without
cause, subject to the provisions hereof. Employee acknowledges that Employee is, and at all times shall be, an employee at will of the
Company and nothing contained herein shall be construed to alter or affect such employee at-will status. Employee may terminate his employment
with the Company at any time, for any or no reason, subject to the provisions hereof. Inclusion under any benefit plan or compensation
arrangement will not give Employee any right or claim to any benefit hereunder except to the extent such right has become fixed under
the express terms of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Termination
by the Employee</U>. The Employee may terminate the Employee&rsquo;s employment with the Company under the following circumstances:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Voluntary
Termination</U>. Employee may terminate his employment with the Company for any reason or no reason, upon delivery of written notice
to the Company at least fifteen (15) days prior to the specified termination date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Termination
for Good Reason</U>. The Employee also may terminate the Employee&rsquo;s employment with the Company for &ldquo;<U>Good
Reason</U>,&rdquo; which shall mean for purposes of this Agreement (A) a material breach by the Company of any of the provisions of
this Agreement; (B) assignment of Employee to a role, duties or responsibilities materially inconsistent with that of senior
executive management; (C) any circumstances caused by the Company that would require Employee to move his principal location of
employment in excess of one hundred (100) miles from the Company&rsquo;s principal business location in Salt Lake City, Utah; or (D)
an involuntary material reduction of Employee&rsquo;s then current Base Salary other than a reduction proportionately affecting all
of the Company&rsquo;s other senior-level executive employees. The Employee must provide the Company with a written Notice of
Termination that describes the existence of the condition the Employee believes gives rise to Good Reason under this Section 4(b)
within thirty (30) days following the initial existence of the condition. The Company may elect to cure any condition giving rise to
Good Reason within thirty (30) days of receipt of notice. The Employee&rsquo;s termination for Good Reason must, in any event, occur
within the six (6) month period immediately following the initial existence of the condition giving rise to Good Reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Effect
of Termination</U>. In the event the Employee&rsquo;s employment is terminated, all obligations of the Company and the Employee under
this Agreement shall cease, except that the accelerated vesting of Options set forth in Section 2(b) and the terms of Section 5 through
Section 9 shall survive such termination. Upon such termination, the Employee or the Employee&rsquo;s representative or estate shall
be entitled to receive the applicable compensation, benefits and reimbursements set forth in Section 5. The Employee acknowledges that,
upon termination of the Employee&rsquo;s employment, the Employee is entitled to no other compensation, severance or other benefits other
than those specifically set forth in Section 5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Compensation
and Benefits Upon Termination of Employment</U>. At all times after the Effective Date, the Employee shall be entitled to receive additional
compensation and benefits upon a termination of Employee&rsquo;s employment as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Severance
Pay</U>. If either (i) the Company terminates the Employee&rsquo;s employment for any reason other than Cause, death or Disability or
(ii) the Employee terminates his employment for Good Reason; then, on the sixtieth (60th) day following the termination of employment,
the Company shall pay the Employee a lump sum amount equal to six (6) months of the Base Salary at the rate in effect at the time of
the termination of employment. If the Company terminates the Employee&rsquo;s employment due to death or Disability and (y) the Company
does not provide any insurance benefits payable to the Employee or his beneficiaries, as applicable, upon his death or Disability and
(z) the Company has previously, but not necessarily in the then applicable calendar year, achieved Ten Million Dollars in annual gross
revenue in a calendar year, then, on the sixtieth (60<SUP>th</SUP>) day following the termination of employment due to death or Disability,
the Company shall pay the Employee a lump sum amount equal to six (6) months of the Base Salary at the rate in effect at the time of
the termination of employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Health
Insurance</U>. If, while eligible to participate in the Company&rsquo;s health benefit plans, either (i) the Company terminates the Employee&rsquo;s
employment for any reason other than Cause, death or Disability or (ii) the Employee terminates his employment for Good Reason, the Company
will provide Health Insurance Reimbursement until the earliest of (x) the close of the twelve (12) month period following the Employee&rsquo;s
termination date, and (y) the date when the Employee becomes eligible to receive health insurance coverage in connection with new employment
or self-employment. If, as of the termination date, the Company continues to sponsor a group insurance plan providing medical and dental
insurance coverage for Company employees, and if the Employee elects to continue his health insurance coverage under the Consolidated
Omnibus Budget Reconciliation Act (&ldquo;<U>COBRA</U>&rdquo;) following the termination of his employment, then the Company shall pay
the portion of the Employee&rsquo;s monthly premium under COBRA until the earliest of (x) the close of the twelve (12) month period following
the Employee&rsquo;s termination date, (y) the expiration of the Employee&rsquo;s continuation coverage under COBRA or (z) the date when
the Employee becomes eligible to receive health insurance coverage in connection with new employment or self-employment. If the payment
of any COBRA or health insurance premiums would otherwise violate the nondiscrimination rules or cause the reimbursement of claims to
be taxable under the Patient Protection and Affordable Care Act of 2010, together with the Health Care and Education Reconciliation Act
of 2010 (collectively, the &ldquo;<U>Act</U>&rdquo;) or Section 105(h) of the Code, the Company paid premiums shall be treated as taxable
payments and be subject to imputed income tax treatment to the extent necessary to eliminate any discriminatory treatment or taxation
under the Act or Section 105(h) of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>General
Release</U>. Any other provision of this Agreement notwithstanding, subsections (a) and (b) above shall not apply unless the Employee
has (i) executed a general release of all claims (in a form prescribed by the Company), which must be effective and irrevocable prior
to the sixtieth (60th) day following the termination of employment, (ii) returned all property of the Company in the Employee&rsquo;s
possession and (iii) cooperated in good faith with the Company for a transition period not to exceed sixty (60) days to ensure an efficient
transfer of the Employee&rsquo;s duties and responsibilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Non-Competition;
Non-Solicitation</U>. The Employee and the Company hereby acknowledge and agree that in connection with the employment of the Employee,
the Employee has been and will be provided with trade secrets of the Company and that the Employee and the Company are entering into
this Agreement for the protection of such trade secrets. The Employee agrees to abide by the provisions set forth in this Section 6.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Non-Competition</U>. The Employee shall not, during his employment with the Company and during the one (1) year period following
the termination of his employment with the Company (the &ldquo;<U>Restrictive Period</U>&rdquo;), directly or indirectly, as a manager,
member, promoter, shareholder, agent, representative, director, officer, owner, independent contractor or otherwise, or in connection
with any of his consultants, employees, agents, partners, relatives, affiliates or representatives or through any third party:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>anywhere
in the world (the &ldquo;<U>Restricted Area</U>&rdquo;) compete with or own, manage, operate or control any business that directly competes
in the Company&rsquo;s field of interest or products in the active development pipeline of the Company (for purposes of this paragraph,
ownership of securities of not in excess of one percent (1%) of the outstanding capital stock of a public company shall not be considered
to be competition with the Company); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>anywhere
in the Restricted Area, act as an employee, director, officer, manager, member, advisor, consultant, representative or agent for any
business of the type and character engaged in and competitive with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Non-Solicitation</U>.
The Employee shall not, during the Restrictive Period directly or indirectly, as a manager, member, promoter, shareholder, agent, representative,
director, officer, owner, independent contractor or otherwise, or in connection with any of his consultants, employees, agents, partners,
relatives, affiliates or representatives or through any third party, solicit the employment of or hire any current employee of the Company,
or solicit a relationship with any customer of the Company, located anywhere in the Restricted Area.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Definitions</U>.
For purposes of this Section 6, the terms &ldquo;<U>compete with the Company</U>,&rdquo; &ldquo;<U>competitive with the Company</U>,&rdquo;
 &ldquo;<U>field of interest</U>&rdquo; and similar terms referring to competition with the Company shall mean any business that is engaged
in identifying and commercializing biomarkers in blood samples of pregnant women which are predictive of preterm birth and other pregnancy
complications or any other anticipated business ventures of the Company which have been discussed with the Board or amongst the senior-level
executive employees as of the date of Employee&rsquo;s termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Maintaining
Confidential Information</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Company
Confidential Information</U>. The Employee hereby agrees at all times during which he provides services as a director, officer, employee
or consultant of the Company (&ldquo;<U>Employee&rsquo;s Service</U>&rdquo;), and thereafter to hold in strictest confidence, and not
to use, except for the benefit of the Company, any trade secrets, confidential knowledge, data or other proprietary information relating
to products, processes, know-how, formulas, developmental or experimental work, computer lists, customer lists, business plans, financial
information or other subject matter pertaining to any business of the Company or any of its clients, consultants or licensees (collectively
 &ldquo;<U>Confidential Information</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Notwithstanding the above, Employee shall not have
liability to the Company with regard to any Confidential Information which Employee can prove:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>was in the public domain at the time it was disclosed by the Company or has entered the public domain through no fault of Employee;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>was
known to the Employee without restriction, at the time of disclosure, as demonstrated by files in existence at the time of disclosure;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>is disclosed with the prior written approval of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>becomes
known to Employee, without restriction, from a source other than the Company without breach of this Agreement by Employee and otherwise
not in violation of the Company&rsquo;s rights; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>is
disclosed pursuant to the order or requirement of a court, administrative agency, or other governmental body; provided, however, that
Employee shall provide prompt notice of such court order or requirement to the Company to enable the Company to seek a protective order
or otherwise prevent such disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Former
Employer Information</U>. The Employee hereby agrees that he will not, during Employee&rsquo;s Service, improperly use or disclose
any proprietary information or trade secrets of his former or concurrent employers or companies, if any, and that he will not make
available to the Company any unpublished document or any property belonging to his former or concurrent employers or companies, if
any, unless consented to in writing by said employers or companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Third-Party
Information</U>. The Employee recognizes that the Company has received and in the future will receive from third parties their confidential
or proprietary information subject to a duty on the Company&rsquo;s part to maintain the confidentiality of such information and to use
it only for certain limited purposes. The Employee hereby agrees, during Employee&rsquo;s Service and thereafter, to hold all such confidential
or proprietary information in the strictest confidence and not to disclose it to any person, firm or corporation (except as necessary
in carrying out his work for the Company consistent with the Company&rsquo;s agreement with such third party) or to use it for the benefit
of anyone other than the Company or such third party (consistent with the Company&rsquo;s agreement with such third party) without the
express written authorization of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Outside
Activities</U>. The Employee shall not perform consulting/business activities beyond those disclosed in Exhibit A, without prior written
consent of the Company&rsquo;s Board of Directors Compensation Committee. Following clinical validation of the Company&rsquo;s commercial
preterm predictor, the Employee shall resign his seat as a director of Sera Prognostics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Availability
of Equitable Remedies</U>. The Employee hereby acknowledges and agrees that a breach of Section 6 or Section 7 will cause irreparable
harm and damage to the Company, that the remedy at law for the breach or threatened breach of Section 6 or Section 7 will be inadequate,
and that, in addition to all other remedies available to the Company for such breach or threatened breach (including, without limitation,
the right to recover damages), the Company will be entitled to injunctive relief for any breach or threatened breach of Section 6 or
Section 7.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Notification
of New Employer</U>. In the event that the Employee leaves the employ of the Company, he hereby grants consent to notification by the
Company to his new employer about his rights and obligations under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Severability</U>.
In the event that a court of competent jurisdiction determines that any portion of this Agreement is in violation of any statute or public
policy, then only the portions of this Agreement which violate such statute or public policy shall be stricken. All portions of this
Agreement which do not violate any statute or public policy shall continue in full force and effect. Further, any court order striking
any portion of this Agreement shall modify the stricken terms to give as much effect as possible to the intentions of the parties under
this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Notices</U>. Any notices, requests or consents hereunder shall be deemed given, and any instrument delivered, three (3) days
after they have been mailed by first class mail, postage prepaid, one (1) day after they have been delivered by overnight courier, twelve
(12) hours after such notice has been sent by facsimile, or upon receipt if delivered personally, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">To the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">2749 East Parleys Way, Suite 200</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Salt Lake City, UT 84109</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">To the Employee:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">587 Patrol Road</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Woodside, CA 94062</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">except that any of the foregoing may, from time to time, by written
notice to the others, designate another address or fax number which shall thereupon become his or its effective address for the purposes
of this Section 9(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Governing
Law</U>. This Agreement shall be governed by the laws of the State of Utah, without giving effect to its conflict of laws principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Successors
and Assigns</U>. The rights and obligations of the Company under this Agreement shall inure to the benefit of and shall be binding upon
the successors and assigns of the Company. This Agreement is for the unique personal services of the Employee, and the Employee shall
not be entitled to assign any of the Employee&rsquo;s rights or obligations hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Entire
Agreement; Amendment</U>. This Agreement constitutes the entire agreement and understanding between the parties hereto with respect to
the subject matter of this Agreement, and supersedes all other prior agreements and understandings with respect thereto, including, but
not limited to, the Prior Agreement. This Agreement can be amended or modified only in a writing signed by the Employee and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>No
Waiver</U>. No waiver by either party at any time of any breach by the other party of, or compliance with, any condition or provision
of this Agreement to be performed by the other party shall be deemed a waiver of similar or dissimilar provisions or conditions at the
same time or any prior or subsequent time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Headings</U>.
The headings herein contained are for reference only and shall not affect the meaning or interpretation of any provision of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Counterparts</U>. This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original
but all of which together will constitute one and the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Costs
and Expenses</U>. The Company shall reimburse all of the Employee&rsquo;s reasonable costs and expenses (including, without limitation,
attorneys&rsquo; fees), incurred in connection with the negotiation and preparation of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Attorneys&rsquo;
Fees</U>. In the event of any action at law, equity or under this Agreement to enforce or interpret the terms of this Agreement, the
prevailing party shall be entitled to reasonable attorneys&rsquo; fees and court costs in addition to any other relief to which such
party may be entitled, unless the action is one in which only a prevailing plaintiff is entitled to prevailing party fees and costs (such
as a Title VII action).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Section 409A</U>. The Company intends that the cash severance payments to which the Employee is entitled on his termination
of employment pursuant to Section 5 are payable on the Employee&rsquo;s Separation from Service (as defined below) and are exempt from,
or are otherwise payable in compliance with Section 409A. The Company intends that the Company&rsquo;s continued payment for the cost
of the Employee&rsquo;s welfare benefits (including the payment of all COBRA administrative costs and expenses) provided by Section 5
will comply with the exception to Section 409A for reimbursements and certain other separation payments, as described in Treas. Reg.
 &sect; 1.409A-1(b)(9)(v)(B), to the extent such costs are taxable and subject to imputed income treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Separation
from Service Defined</U>. For purposes of this Agreement, the term &ldquo;<U>termination of employment</U>&rdquo; means the Employee&rsquo;s
 &ldquo;<U>Separation from Service</U>.&rdquo; The term &ldquo;<U>Separation from Service</U>&rdquo; means (A) the termination of the
Employee&rsquo;s employment with the Company and all affiliates for any reason or (B) a permanent reduction in the level of bona fide
services the Employee provides to the Company and all affiliates to an amount that is twenty percent (20%) or less of the average level
of bona fide services the Employee provided to the Company and all affiliates in the immediately preceding thirty-six (36) months (or
the entire time period during which the Employee provided services to the Company and all affiliates if the Employee has been providing
such services for less than thirty-six (36) months), with the level of bona fide service calculated in accordance with Treas. Reg. &sect;
1.409A-1(h)(1)(ii). Solely for purposes of determining whether an organization is an &ldquo;<U>affiliate</U>&rdquo; of the Company, the
Company will follow the rules set forth in Treas. Reg. &sect; 1.409A-1(h)(3) (which generally requires fifty percent (50%) common ownership
or control). The Employee&rsquo;s employment relationship is treated as continuing while the Employee is on military leave, sick leave,
or other bona fide leave of absence (if the period of such leave does not exceed six (6) months; or, if longer, so long as the Employee&rsquo;s
right to reemployment with the Company or an affiliate is provided either by statute or contract). If the Employee&rsquo;s period of
leave exceeds six (6) months and his right to re-employment is not provided either by statute or by contract, the employment relationship
is deemed to terminate on the first day immediately following the expiration of such six (6) month period. Whether a termination of employment
has occurred will be determined based on all of the facts and circumstances and in accordance with regulations issued by the United States
Treasury Department pursuant to Section 409A of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Delay
in Payments</U>. Notwithstanding any provision of this Agreement to the contrary, if any of the severance payments are subject to Section
409A and the Employee is a &ldquo;Specified Employee&rdquo; at the time of his Separation from Service, no payments shall be made to
the Employee prior to the first business day following the date which is six (6) months after the Employee&rsquo;s Separation from Service.
Any amounts that would have been paid during the six (6) months following the Employee&rsquo;s Separation from Service will be paid on
the first business day following the expiration of the six (6) month period without interest thereon. The Employee may not elect the
taxable year of such payment. The six (6) month delay for a Specified Employee does not apply if the Employee dies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Specified Employee Defined</U>. For purposes of this Agreement, the term &ldquo;Specified Employee&rdquo; means certain officers
and highly-compensated employees of the Company as defined in Treas. Reg. &sect; 1.409A-1(i), and as determined in accordance with such
procedures as may be adopted from time to time by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Miscellaneous Payment Provisions</U>. If payment is not made, in whole or in part, due to a dispute between the Employee and
the Company, the payments shall be made in accordance with Treas. Reg. &sect; 1.409A-3(g), as applicable. It is intended that each installment
of the payments and benefits provided under Section 5 of this Agreement shall be treated as a separate &ldquo;payment&rdquo; for purposes
of Section 409A. If an expense reimbursement or provision of in-kind benefit provided pursuant to this Agreement is not exempt from Section
409A of the Code, the following rules apply: (A) in no event shall any reimbursement be paid after the last day of the taxable year following
the taxable year in which the expense was incurred; (B) the amount of reimbursable expenses incurred or provision of in-kind benefits
in one tax year shall not affect the expenses eligible for reimbursement or the provision of in-kind benefits in any other tax year;
and (C) the right to reimbursement for expenses or provision of in-kind benefits is not subject to liquidation or exchange for any other
benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Ban
on Acceleration or Deferral</U>. Under no circumstances may the time or schedule of any payment made or benefit provided pursuant to
this Agreement be accelerated or subject to a further deferral, except as otherwise permitted or required pursuant to regulations and
other guidance issued pursuant to Section 409A of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>No
Elections</U>. The Employee does not have any right to make any election regarding the time or form of any payment due under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Compliant Operation and Interpretation</U>. This Agreement shall be operated in compliance with the requirements of Section
409A or an exception thereto and each provision of this Agreement shall be interpreted, to the extent possible, to comply with Section
409A or to qualify for an exception thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Dispute
Resolution; Venue</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
Company and the Employee shall use reasonable, good faith efforts to settle any dispute through non-binding mediation before a mutually-acceptable,
neutral, third-party mediator. The mediation shall be held in Salt Lake City, Utah and administered by the CPR Institute for Dispute
Resolution (the &ldquo;<U>CPR Institute</U>&rdquo;) under the CPR Mediation Procedure then in effect. Unless otherwise agreed, the parties
shall jointly select a single mediator from the CPR Panels of Distinguished Neutrals based on a list of mediator candidates supplied
by the CPR Institute. If, within fourteen (14) days after either party makes a written request for mediation under this Section 9(m)(i),
the parties have not reached agreement on the selection of a mediator, the mediator shall be selected in accordance with the CPR Mediation
Procedure currently in effect. A good faith attempt at mediation shall be a condition precedent to the commencement of litigation, but
nothing in this Agreement, including, but not limited to paragraph (ii) below, shall be deemed a condition precedent to any court action
for injunction or other interim relief pending the outcome of mediation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If the parties are unable to resolve the dispute by mediation in a timely manner (which, in any case, shall not exceed sixty (60)
days from the first notice of mediation), either party may attempt to resolve the dispute by commencing an action (or defending or responding
to such action) exclusively in the jurisdiction and venue of the courts, whether federal or state, located in Salt Lake County, Utah.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the parties hereto have executed
this Agreement to be effective for all purposes as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>THE COMPANY</U>:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SERA PROGNOSTICS, INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; width: 46%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Gregory C. Critchfield, M.D.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gregory C. Critchfield, M.D.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman, President and CEO</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>THE EMPLOYEE</U>:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Douglas C.
    Fisher</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Douglas C. Fisher, M.D.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exhibit A: Outside Activities</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consulting with InterWest
Partners involving:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Board seats at
2 companies: Obalon and Gynesonics</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Board observer
roles at 3 companies: Integrated Diagnostics, PMV Pharma, and Potenza Therapeutics</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD>Consulting for Integrated Diagnostics as their part time SVP of Corporate Development and limited time with Indi Molecular</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD>Consulting and board member for PMDI, a seed stage company developing diagnostics for prostate cancer. This will take less than 1
day per month and is primarily a non-profit entity.</TD></TR></TABLE>



<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="margin: 0pt"></P>

<!-- Field: Page; Sequence: 12; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="margin: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>27
<FILENAME>tm2110724d11_ex10-12.htm
<DESCRIPTION>EXHIBIT 10.12
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

                           <P STYLE="margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.12</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SERA PROGNOSTICS, INC. EMPLOYMENT AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Employment Agreement
(this &ldquo;<U>Agreement</U>&rdquo;) is effective for all purposes as of May 15, 2017 (the &ldquo;<U>Effective Date</U>&rdquo;), by and
between Sera Prognostics, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), and Nadia Altomare (the &ldquo;<U>Employee</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the mutual covenants, conditions and undertakings set forth herein, the parties hereto hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Employment and Duties</U>. Subject to the terms and conditions set forth in this Agreement, the Company shall employ Employee,
and Employee hereby accepts employment, as the Chief Commercial Officer of the Company, with those duties and responsibilities which are
appropriate and customary for the commercial leader of a company similar to the Company. In such capacity, the Employee shall report to
the Company&rsquo;s Chief Executive Officer. During the term of this Agreement, the Employee shall faithfully perform the Employee&rsquo;s
duties, responsibilities and obligations hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Base Compensation and Related Matters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Salary</U>. In consideration for the services rendered by the Employee to the Company as provided herein, the Company shall
pay the Employee an annual base salary of $320,000, provided that the Employee&rsquo;s employment with the Company remains active at a
full-time rate. The Base Salary shall be paid according to the Company&rsquo;s standard payroll policy and will be subject to applicable
federal and state tax withholdings as required by applicable law. The Base Salary may be increased or decreased at any time by the Company&rsquo;s
Board of Directors (the &ldquo;<U>Board</U>&rdquo;) or the Compensation Committee of the Board in its sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Stock
Option Grant(s) and Bonuses</U>. The Employee shall be granted as soon as practicable on or after the Effective Date an option to
purchase 450,000 shares of the Company&rsquo;s common stock (the &ldquo;<U>Option</U>&rdquo;) (which option shall be issued as an
incentive stock option to the maximum extent allowed under Section 422 of the Internal Revenue Code of 1986, as amended, and the
regulations promulgated thereunder (the &ldquo;<U>Code</U>&rdquo;)) pursuant to the Company&rsquo;s 2011 Employee, Director and
Consultant Equity Incentive Plan (the &ldquo;<U>Plan</U>&rdquo;). The Option shall vest as to twenty-five percent (25%) of the
shares subject thereto one (1) year from May 15, 2017 (&ldquo;<U>Vesting Start Date</U>&rdquo;), and shall vest with respect to the
remaining shares subject thereto in equal monthly installments over an additional thirty-six (36) months thereafter commencing on
the one year anniversary following the Vesting Start Date, subject to continued employment by the Company. In addition, the Option
shall accelerate with respect to thirty-seven and one-half percent (37.5%) of the unvested shares at that time then subject thereto
upon a Change of Control (as defined in the Plan) pursuant to which the Option is terminated pursuant to Section 24(b)(ii) of the
Plan or cashed out pursuant to Section 24(b)(iii) of the Plan. The Employee shall be eligible, after the Effective Date, to receive
(i) additional stock options pursuant to the Plan and (ii) additional bonus compensation, as determined by the Board, in its sole
discretion; it being the intention of the Board to maintain Employee&rsquo;s aggregate compensation at levels appropriate and
customary to those of companies similar in industry, stage and circumstances to that of the Company. Unless otherwise approved by
the Board, all future options granted to the Employee after the Effective Date shall vest in equal monthly installments over a
period of forty-eight (48) months from the date of grant. Notwithstanding the foregoing, in the event that the Employee&rsquo;s
employment with the Company is terminated by the Company without Cause (as defined in Section 4(a)(iii) below) or by the Employee
for Good Reason (as defined in Section 4(b)(ii) below), then the vesting of all options held by the Employee at the time of the
termination shall accelerate (i) with respect to thirty-seven and one-half percent (37.5%) of the unvested shares subject thereto,
or (ii) if such termination occurs within 30 days prior to or within 12 months after a Change of Control (as defined in the Plan),
with respect to one hundred percent (100%) of the unvested shares subject thereto. You will be eligible to participate in the
Company&rsquo;s Annual Incentive Plan, which currently provides for a bonus target of 40% of your base salary, prorated for time of
service, and with respect to the calendar year ending December 31, 2017, one-half of your bonus (equal to 20% of your annual base
salary earned) will be guaranteed and the remaining one-half will be contingent based upon achievements mutually agreed upon by you
and your supervisor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Expenses</U>. The Employee will be entitled to receive prompt reimbursement for all reasonable expenses incurred by the Employee
(which are eligible for reimbursement under the Code) actually incurred by her in performing her duties; provided; however, that such
expenses are approved in accordance with the Company&rsquo;s then-current policies and procedures applicable to the most senior-level
executive employees of the Company, other than the Employee, or if such policies and procedures are not in place, then as determined in
the sole discretion of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Employee Benefits</U>. Upon classification as a full-time employee, the Employee will be entitled to participate in the group
health, dental, vision, and group life insurance benefit plans, as well as the Company&rsquo;s 401(k) and Flexible Spending Account Plans
available to all Company employees. In addition, the Employee is entitled to participate in any employee benefit plans that the Company
may make available to its most senior-level executive employees generally, which may include, but not be limited to, profit sharing plans,
401(k) and cafeteria plans, or life, hospitalization, optical, disability or other insurance plans as may be in effect, from time to time,
and in accordance with rules established, from time to time, for individual participation in such plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Vacation Days and Paid Leave</U>. Upon classification as a full-time employee, the Employee will be entitled to take four (4)
weeks of vacation days, three (3) additional personal time off days, and shall be entitled to compensation in connection therewith, in
accordance with Company policy applicable to senior-level executive employees of the Company, as approved by the Chief Executive Officer
in its sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Facilities and Services Furnished</U>. The Company will furnish the Employee with office space at its headquarters in Salt Lake
City, Utah, and such other facilities, furniture, equipment and services as it may determine to be reasonably necessary for the performance
of the Employee&rsquo;s duties as set forth herein. It is acknowledged that as of the Effective Date, the Employee is using her own home
for a Company office at no expense to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination by the Company</U>. The Employee&rsquo;s employment hereunder may be terminated by the Company under any of the
following circumstances:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Death</U>. This Agreement shall automatically terminate upon the Employee&rsquo;s death.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Disability</U>. The Company may elect to terminate the Employee&rsquo;s employment in the event of Employee&rsquo;s Disability
upon delivery of written notice to the Employee. For purposes of this Agreement, &ldquo;<U>Disability</U>&rdquo; shall mean any condition
that, in the reasonable, good faith judgment of a licensed physician selected by the Company, causes the Employee to be unable, after
any accommodation required by applicable law, to perform her duties, responsibilities and obligations under this Agreement for a period
of at least twelve (12) months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Cause</U>. The Company may terminate the Employee&rsquo;s employment hereunder for Cause (as defined below) at any time upon
delivery of written notice to the Employee. For purposes of this Agreement, &ldquo;<U>Cause</U>&rdquo; shall mean (A) the conviction of
the Employee by a court of competent jurisdiction of any felony involving dishonesty, breach of trust or misappropriation or the entering
of a plea by the Employee of nolo contendre thereto; (B) the Employee&rsquo;s willful failure or refusal to follow reasonable and lawful
directives of the Board or the Company&rsquo;s Chief Executive Officer, provided such failure or refusal continues after the Employee&rsquo;s
receipt of reasonable notice in writing of such failure or refusal and an opportunity of not less than thirty (30) days to correct the
problem; (C) a material breach by the Employee of any of the provisions of this Agreement; or (D) the Employee&rsquo;s commission of any
immoral or illegal act or any gross or willful misconduct, where a majority of the non-employee members of the Board reasonably determines
that such act or misconduct has (1) seriously undermined the ability of the Board to entrust Employee with important matters or otherwise
work effectively with Employee, (2) contributed to the Company&rsquo;s loss of significant revenues or business opportunities, or (3)
significantly and detrimentally affected the business or reputation of the Company or any of its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Other Termination</U>. The Company may terminate Employee&rsquo;s employment with the Company at any time and for any reason,
with or without cause, subject to the provisions hereof. Employee acknowledges that Employee is, and at all times shall be, an employee
at will of the Company and nothing contained herein shall be construed to alter or affect such employee at-will status. Employee may terminate
her employment with the Company at any time, for any or no reason, subject to the provisions hereof. Inclusion under any benefit plan
or compensation arrangement will not give Employee any right or claim to any benefit hereunder except to the extent such right has become
fixed under the express terms of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination by the Employee</U>. The Employee may terminate the Employee&rsquo;s employment with the Company under the following
circumstances:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Voluntary Termination</U>. Employee may terminate her employment with the Company for any reason or no reason, upon delivery
of written notice to the Company at least fifteen (15) days prior to the specified termination date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Termination
for Good Reason</U>. The Employee also may terminate the Employee&rsquo;s employment with the Company for &ldquo;<U>Good
Reason</U>,&rdquo; which shall mean for purposes of this Agreement (A) a material breach by the Company of any of the provisions of
this Agreement; (B) assignment of Employee to a role, duties or responsibilities materially inconsistent with that of senior
executive management; (C) any circumstances caused by the Company that would require Employee to move her principal location of
employment in excess of one hundred (100) miles from the Company&rsquo;s principal business location in Salt Lake City, Utah; or (D)
an involuntary material reduction of Employee&rsquo;s then current Base Salary other than a reduction proportionately affecting all
of the Company&rsquo;s other senior-level executive employees. The Employee must provide the Company with a written Notice of
Termination that describes the existence of the condition the Employee believes gives rise to Good Reason under this Section 4(b)
within thirty (30) days following the initial existence of the condition. The Company may elect to cure any condition giving rise to
Good Reason within thirty (30) days of receipt of notice. The Employee&rsquo;s termination for Good Reason must, in any event, occur
within the six (6) month period immediately following the initial existence of the condition giving rise to Good Reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Effect of Termination</U>. In the event the Employee&rsquo;s employment is terminated, all obligations of the Company and the
Employee under this Agreement shall cease, except that the accelerated vesting of Options set forth in Section 2(b) and the terms of Section
5 through Section 9 shall survive such termination. Upon such termination, the Employee or the Employee&rsquo;s representative or estate
shall be entitled to receive the applicable compensation, benefits and reimbursements set forth in Section 5. The Employee acknowledges
that, upon termination of the Employee&rsquo;s employment, the Employee is entitled to no other compensation, severance or other benefits
other than those specifically set forth in Section 5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Compensation and Benefits Upon Termination of Employment</U>. At all times after the Effective Date, the Employee shall be entitled
to receive additional compensation and benefits upon a termination of Employee&rsquo;s employment as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Severance Pay</U>. If either (i) the Company terminates the Employee&rsquo;s employment for any reason other than Cause, death
or Disability or (ii) the Employee terminates her employment for Good Reason; then, on the sixtieth (60<SUP>th</SUP>) day following the
termination of employment, the Company shall pay the Employee a lump sum amount equal to six (6) months of the Base Salary at the rate
in effect at the time of the termination of employment. If the Company terminates the Employee&rsquo;s employment due to death or Disability
and (y) the Company does not provide any insurance benefits payable to the Employee or her beneficiaries, as applicable, upon her death
or Disability and (z) the Company has previously, but not necessarily in the then applicable calendar year, achieved Ten Million Dollars
in annual gross revenue in a calendar year, then, on the sixtieth (60<SUP>th</SUP>) day following the termination of employment due to
death or Disability, the Company shall pay the Employee a lump sum amount equal to six (6) months of the Base Salary at the rate in effect
at the time of the termination of employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Health
Insurance</U>. If, while eligible to participate in the Company&rsquo;s health benefit plans, either (i) the Company terminates the
Employee&rsquo;s employment for any reason other than Cause, death or Disability or (ii) the Employee terminates her employment for
Good Reason, the Company will provide Health Insurance Reimbursement until the earliest of (x) the close of the twelve (12) month
period following the Employee&rsquo;s termination date, and (y) the date when the Employee becomes eligible to receive health
insurance coverage in connection with new employment or self-employment. If, as of the termination date, the Company continues to
sponsor a group insurance plan providing medical and dental insurance coverage for Company employees, and if the Employee elects to
continue her health insurance coverage under the Consolidated Omnibus Budget Reconciliation Act (&ldquo;<U>COBRA</U>&rdquo;)
following the termination of her employment, then the Company shall pay the portion of the Employee&rsquo;s monthly premium under
COBRA until the earliest of (x) the close of the twelve (12) month period following the Employee&rsquo;s termination date, (y) the
expiration of the Employee&rsquo;s continuation coverage under COBRA or (z) the date when the Employee becomes eligible to receive
health insurance coverage in connection with new employment or self-employment. If the payment of any COBRA or health insurance
premiums would otherwise violate the nondiscrimination rules or cause the reimbursement of claims to be taxable under the Patient
Protection and Affordable Care Act of 2010, together with the Health Care and Education Reconciliation Act of 2010 (collectively,
the &ldquo;<U>Act</U>&rdquo;) or Section 105(h) of the Code, the Company paid premiums shall be treated as taxable payments and be
subject to imputed income tax treatment to the extent necessary to eliminate any discriminatory treatment or taxation under the Act
or Section 105(h) of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>General Release</U>. Any other provision of this Agreement notwithstanding, subsections (a) and (b) above shall not apply unless
the Employee has (i) executed a general release of all claims (in a form prescribed by the Company), which must be effective and irrevocable
prior to the sixtieth (60th) day following the termination of employment, (ii) returned all property of the Company in the Employee&rsquo;s
possession and (iii) cooperated in good faith with the Company for a transition period not to exceed sixty (60) days to ensure an efficient
transfer of the Employee&rsquo;s duties and responsibilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Non-Competition; Non-Solicitation</U>. The Employee and the Company hereby acknowledge and agree that in connection with the
employment of the Employee, the Employee has been and will be provided with trade secrets of the Company and that the Employee and the
Company are entering into this Agreement for the protection of such trade secrets. The Employee agrees to abide by the provisions set
forth in this <U>Section 6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Non-Competition</U>. The Employee shall not, during her employment with the Company and during the one (1) year period following
the termination of her employment with the Company (the &ldquo;<U>Restrictive Period</U>&rdquo;), directly or indirectly, as a manager,
member, promoter, shareholder, agent, representative, director, officer, owner, independent contractor or otherwise, or in connection
with any of her consultants, employees, agents, partners, relatives, affiliates or representatives or through any third party:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>anywhere in the world (the &ldquo;<U>Restricted Area</U>&rdquo;) compete with or own, manage, operate or control any business that
directly competes in the Company&rsquo;s field of interest or products in the active development pipeline of the Company (for purposes
of this paragraph, ownership of securities of not in excess of one percent (1%) of the outstanding capital stock of a public company shall
not be considered to be competition with the Company); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>anywhere in the Restricted Area, act as an employee, director, officer, manager, member, advisor, consultant, representative or
agent for any business of the type and character engaged in and competitive with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Non-Solicitation</U>.
The Employee shall not, during the Restrictive Period directly or indirectly, as a manager, member, promoter, shareholder, agent,
representative, director, officer, owner, independent contractor or otherwise, or in connection with any of her consultants,
employees, agents, partners, relatives, affiliates or representatives or through any third party, solicit the employment of or hire
any current employee of the Company, or solicit a relationship with any customer of the Company, located anywhere in the Restricted
Area.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Definitions</U>. For purposes of this <U>Section 6</U>, the terms &ldquo;<U>compete with the Company</U>,&rdquo; &ldquo;<U>competitive
with the Company</U>,&rdquo; &ldquo;f<U>ield of interest</U>&rdquo; and similar terms referring to competition with the Company shall
mean any business that is engaged in identifying and commercializing biomarkers in blood samples of pregnant women which are predictive
of preterm birth and other pregnancy complications or any other anticipated business ventures of the Company which have been discussed
with the Board or amongst the senior-level executive employees as of the date of Employee&rsquo;s termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Maintaining Confidential Information</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Company Confidential Information</U>. The Employee hereby agrees at all times during which she provides services as a director,
officer, employee or consultant of the Company (&ldquo;<U>Employee&rsquo;s Service</U>&rdquo;), and thereafter to hold in strictest confidence,
and not to use, except for the benefit of the Company, any trade secrets, confidential knowledge, data or other proprietary information
relating to products, processes, know-how, formulas, developmental or experimental work, computer lists, customer lists, business plans,
financial information or other subject matter pertaining to any business of the Company or any of its clients, consultants or licensees
(collectively &ldquo;<U>Confidential Information</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the above,
Employee shall not have liability to the Company with regard to any Confidential Information which Employee can prove:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>was in the public domain at the time it was disclosed by the Company or has entered the public domain through no fault of Employee;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>was known to the Employee without restriction, at the time of disclosure, as demonstrated by files in existence at the time of
disclosure;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>is disclosed with the prior written approval of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>becomes known to Employee, without restriction, from a source other than the Company without breach of this Agreement by Employee
and otherwise not in violation of the Company&rsquo;s rights; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>is disclosed pursuant to the order or requirement of a court, administrative agency, or other governmental body; provided, however,
that Employee shall provide prompt notice of such court order or requirement to the Company to enable the Company to seek a protective
order or otherwise prevent such disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Former
Employer Information</U>. The Employee hereby agrees that she will not, during Employee&rsquo;s Service, improperly use or disclose
any proprietary information or trade secrets of her former or concurrent employers or companies, if any, and that she will not make
available to the Company any unpublished document or any property belonging to her former or concurrent employers or companies, if
any, unless consented to in writing by said employers or companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Third-Party Information</U>. The Employee recognizes that the Company has received and in the future will receive from third
parties their confidential or proprietary information subject to a duty on the Company&rsquo;s part to maintain the confidentiality of
such information and to use it only for certain limited purposes. The Employee hereby agrees, during Employee&rsquo;s Service and thereafter,
to hold all such confidential or proprietary information in the strictest confidence and not to disclose it to any person, firm or corporation
(except as necessary in carrying out her work for the Company consistent with the Company&rsquo;s agreement with such third party) or
to use it for the benefit of anyone other than the Company or such third party (consistent with the Company&rsquo;s agreement with such
third party) without the express written authorization of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Outside Activities</U>. The Employee shall not perform consulting/business activities beyond those disclosed in <U>Exhibit A</U>,
without prior written consent of the Company&rsquo;s Board of Directors Compensation Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Availability of Equitable Remedies</U>. The Employee hereby acknowledges and agrees that a breach of Section 6 or Section 7
will cause irreparable harm and damage to the Company, that the remedy at law for the breach or threatened breach of Section 6 or Section
7 will be inadequate, and that, in addition to all other remedies available to the Company for such breach or threatened breach (including,
without limitation, the right to recover damages), the Company will be entitled to injunctive relief for any breach or threatened breach
of Section 6 or Section 7.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notification of New Employer</U>. In the event that the Employee leaves the employ of the Company, she hereby grants consent
to notification by the Company to her new employer about his rights and obligations under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Severability</U>. In the event that a court of competent jurisdiction determines that any portion of this Agreement is in violation
of any statute or public policy, then only the portions of this Agreement which violate such statute or public policy shall be stricken.
All portions of this Agreement which do not violate any statute or public policy shall continue in full force and effect. Further, any
court order striking any portion of this Agreement shall modify the stricken terms to give as much effect as possible to the intentions
of the parties under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notices</U>. Any notices, requests or consents hereunder shall be deemed given, and any instrument delivered, three (3) days
after they have been mailed by first class mail, postage prepaid, one (1) day after they have been delivered by overnight courier, twelve
(12) hours after such notice has been sent by facsimile, or upon receipt if delivered personally, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">To the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">2749 East Parleys Way, Suite 200</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Salt Lake City, UT 84109</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">To the Employee:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">29 Oliver Road</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Belmont, MA 02478</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">except that any of the foregoing may, from time
to time, by written notice to the others, designate another address or fax number which shall thereupon become her or its effective address
for the purposes of this Section 9(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Governing Law</U>. This Agreement shall be governed by the laws of the State of Utah, without giving effect to its conflict
of laws principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Successors and Assigns</U>. The rights and obligations of the Company under this Agreement shall inure to the benefit of and
shall be binding upon the successors and assigns of the Company. This Agreement is for the unique personal services of the Employee, and
the Employee shall not be entitled to assign any of the Employee&rsquo;s rights or obligations hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Entire Agreement; Amendment</U>. This Agreement constitutes the entire agreement and understanding between the parties hereto
with respect to the subject matter of this Agreement, and supersedes all other prior agreements and understandings with respect thereto,
including, but not limited to, the Prior Agreement. This Agreement can be amended or modified only in a writing signed by the Employee
and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Waiver</U>. No waiver by either party at any time of any breach by the other party of, or compliance with, any condition
or provision of this Agreement to be performed by the other party shall be deemed a waiver of similar or dissimilar provisions or conditions
at the same time or any prior or subsequent time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Headings</U>. The headings herein contained are for reference only and shall not affect the meaning or interpretation of any
provision of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Counterparts</U>. This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original
but all of which together will constitute one and the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Costs and Expenses</U>. The Company shall reimburse all of the Employee&rsquo;s reasonable costs and expenses (including, without
limitation, attorneys&rsquo; fees), incurred in connection with the negotiation and preparation of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Attorneys&rsquo; Fees</U>. In the event of any action at law, equity or under this Agreement to enforce or interpret the terms
of this Agreement, the prevailing party shall be entitled to reasonable attorneys&rsquo; fees and court costs in addition to any other
relief to which such party may be entitled, unless the action is one in which only a prevailing plaintiff is entitled to prevailing party
fees and costs (such as a Title VII action).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Section
409A</U>. The Company intends that the cash severance payments to which the Employee is entitled on her termination of employment
pursuant to Section 5 are payable on the Employee&rsquo;s Separation from Service (as defined below) and are exempt from, or are
otherwise payable in compliance with Section 409A. The Company intends that the Company&rsquo;s continued payment for the cost of
the Employee&rsquo;s welfare benefits (including the payment of all COBRA administrative costs and expenses) provided by Section 5
will comply with the exception to Section 409A for reimbursements and certain other separation payments, as described in Treas. Reg.
 &sect; 1.409A-1(b)(9)(v)(B), to the extent such costs are taxable and subject to imputed income treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Separation from Service Defined</U>. For purposes of this Agreement, the term &ldquo;<U>termination of employment</U>&rdquo;
means the Employee&rsquo;s &ldquo;<U>Separation from Service</U>.&rdquo; The term &ldquo;<U>Separation from Service</U>&rdquo; means (A)
the termination of the Employee&rsquo;s employment with the Company and all affiliates for any reason or (B) a permanent reduction in
the level of bona fide services the Employee provides to the Company and all affiliates to an amount that is twenty percent (20%) or less
of the average level of bona fide services the Employee provided to the Company and all affiliates in the immediately preceding thirty-six
(36) months (or the entire time period during which the Employee provided services to the Company and all affiliates if the Employee has
been providing such services for less than thirty-six (36) months), with the level of bona fide service calculated in accordance with
Treas. Reg. &sect; 1.409A-1(h)(1)(ii). Solely for purposes of determining whether an organization is an &ldquo;<U>affiliate</U>&rdquo;
of the Company, the Company will follow the rules set forth in Treas. Reg. &sect; 1.409A-1(h)(3) (which generally requires fifty percent
(50%) common ownership or control). The Employee&rsquo;s employment relationship is treated as continuing while the Employee is on military
leave, sick leave, or other bona fide leave of absence (if the period of such leave does not exceed six (6) months; or, if longer, so
long as the Employee&rsquo;s right to reemployment with the Company or an affiliate is provided either by statute or contract). If the
Employee&rsquo;s period of leave exceeds six (6) months and her right to re-employment is not provided either by statute or by contract,
the employment relationship is deemed to terminate on the first day immediately following the expiration of such six (6) month period.
Whether a termination of employment has occurred will be determined based on all of the facts and circumstances and in accordance with
regulations issued by the United States Treasury Department pursuant to Section 409A of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Delay in Payments</U>. Notwithstanding any provision of this Agreement to the contrary, if any of the severance payments are
subject to Section 409A and the Employee is a &ldquo;Specified Employee&rdquo; at the time of her Separation from Service, no payments
shall be made to the Employee prior to the first business day following the date which is six (6) months after the Employee&rsquo;s Separation
from Service. Any amounts that would have been paid during the six (6) months following the Employee&rsquo;s Separation from Service will
be paid on the first business day following the expiration of the six (6) month period without interest thereon. The Employee may not
elect the taxable year of such payment. The six (6) month delay for a Specified Employee does not apply if the Employee dies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Specified Employee Defined</U>. For purposes of this Agreement, the term &ldquo;<U>Specified Employee</U>&rdquo; means certain
officers and highly-compensated employees of the Company as defined in Treas. Reg. &sect; 1.409A-1(i), and as determined in accordance
with such procedures as may be adopted from time to time by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Miscellaneous
Payment Provisions</U>. If payment is not made, in whole or in part, due to a dispute between the Employee and the Company, the
payments shall be made in accordance with Treas. Reg. &sect; 1.409A-3(g), as applicable. It is intended that each installment of the
payments and benefits provided under Section 5 of this Agreement shall be treated as a separate &ldquo;payment&rdquo; for purposes
of Section 409A. If an expense reimbursement or provision of in-kind benefit provided pursuant to this Agreement is not exempt from
Section 409A of the Code, the following rules apply: (A) in no event shall any reimbursement be paid after the last day of the
taxable year following the taxable year in which the expense was incurred; (B) the amount of reimbursable expenses incurred or
provision of in-kind benefits in one tax year shall not affect the expenses eligible for reimbursement or the provision of in-kind
benefits in any other tax year; and (C) the right to reimbursement for expenses or provision of in-kind benefits is not subject to
liquidation or exchange for any other benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Ban on Acceleration or Deferral</U>. Under no circumstances may the time or schedule of any payment made or benefit provided
pursuant to this Agreement be accelerated or subject to a further deferral, except as otherwise permitted or required pursuant to regulations
and other guidance issued pursuant to Section 409A of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Elections</U>. The Employee does not have any right to make any election regarding the time or form of any payment due under
this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Compliant Operation and Interpretation</U>. This Agreement shall be operated in compliance with the requirements of Section
409A or an exception thereto and each provision of this Agreement shall be interpreted, to the extent possible, to comply with Section
409A or to qualify for an exception thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Dispute Resolution; Venue</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company and the Employee shall use reasonable, good faith efforts to settle any dispute through non-binding mediation before
a mutually-acceptable, neutral, third-party mediator. The mediation shall be held in Salt Lake City, Utah and administered by the CPR
Institute for Dispute Resolution (the &ldquo;<U>CPR Institute</U>&rdquo;) under the CPR Mediation Procedure then in effect. Unless otherwise
agreed, the parties shall jointly select a single mediator from the CPR Panels of Distinguished Neutrals based on a list of mediator candidates
supplied by the CPR Institute. If, within fourteen (14) days after either party makes a written request for mediation under this Section
9(m)(i), the parties have not reached agreement on the selection of a mediator, the mediator shall be selected in accordance with the
CPR Mediation Procedure currently in effect. A good faith attempt at mediation shall be a condition precedent to the commencement of litigation,
but nothing in this Agreement, including, but not limited to paragraph (ii) below, shall be deemed a condition precedent to any court
action for injunction or other interim relief pending the outcome of mediation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If the parties are unable to resolve the dispute by mediation in a timely manner (which, in any case, shall not exceed sixty (60)
days from the first notice of mediation), either party may attempt to resolve the dispute by commencing an action (or defending or responding
to such action) exclusively in the jurisdiction and venue of the courts, whether federal or state, located in Salt Lake County, Utah.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the parties hereto have executed
this Agreement to be effective for all purposes as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><U>THE COMPANY</U>:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">SERA PROGNOSTICS, INC.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 47%"><I>/s/ Gregory C. Critchfield</I></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Gregory C. Critchfield, M.D.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Chairman, President and CEO</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><U>THE EMPLOYEE</U>:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><I>&nbsp;</I></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><I>/s/ Nadia Altomare</I></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Nadia Altomare</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exhibit A: Outside Activities</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consulting for Abcodia
as a non-executive Board Member.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>



<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="margin: 0pt"></P>

<!-- Field: Page; Sequence: 10; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>28
<FILENAME>tm2110724d11_ex10-13.htm
<DESCRIPTION>EXHIBIT 10.13
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

                           <P STYLE="margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.13</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SERA PROGNOSTICS, INC. EMPLOYMENT AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Employment Agreement
(this &ldquo;<U>Agreement</U>&rdquo;) is effective for all purposes as of March 14, 2012 (the &ldquo;<U>Effective Date</U>&rdquo;), by
and between Sera Prognostics, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), and John J. Boniface, Ph.D. (the &ldquo;<U>Employee</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the mutual covenants, conditions and undertakings set forth herein, the parties hereto hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Employment and Duties</U>. Subject to the terms and conditions set forth in this Agreement, the Company shall employ Employee,
and Employee hereby accepts employment, as the Chief Scientific Officer of the Company, with those duties and responsibilities which are
appropriate and customary for a chief scientific officer of a company similar to the Company. In such capacity, the Employee shall report
to the Company&rsquo;s Chief Executive Officer. During the term of this Agreement, the Employee shall faithfully perform the Employee&rsquo;s
duties, responsibilities and obligations hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Base Compensation and Related Matters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Salary</U>. In consideration for the services rendered by the Employee to the Company as provided herein, the Company shall
pay the Employee an annual base salary of $225,000 per year (the &ldquo;<U>Base Salary</U>&rdquo;). The Base Salary shall be paid according
to the Company&rsquo;s standard payroll policy and will be subject to applicable federal and state tax withholdings as required by applicable
law. The Base Salary may be increased or decreased at any time by the Company&rsquo;s Board of Directors (the &ldquo;<U>Board</U>&rdquo;)
or the Compensation Committee of the Board in its sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Stock
Option Grant(s) and Bonuses</U>. The Employee shall be granted as soon as practicable on or after the Effective Date an option to
purchase 158,000 shares of the Company&rsquo;s common stock (the &ldquo;<U>Option</U>&rdquo;) (which option shall be issued as an
incentive stock option to the maximum extent allowed under Section 422 of the Internal Revenue Code of 1986, as amended, and the
regulations promulgated thereunder (the &ldquo;<U>Code</U>&rdquo;)) pursuant to the Company&rsquo;s 2011 Employee, Director and
Consultant Equity Incentive Plan (the &ldquo;<U>Plan</U>&rdquo;). The Option shall vest as to twenty-five percent (25%) of the
shares subject thereto one (1) year from November 8, 2011 (&ldquo;<U>Vesting Start Date</U>&rdquo;), and shall vest with respect to
the remaining shares subject thereto in equal monthly installments over an additional three (3) years thereafter commencing on the
first day of the month one year following the Vesting Start Date, subject to continued employment by the Company. In addition, the
Option shall accelerate with respect to thirty-seven and one-half percent (37.5%) of the unvested shares then subject thereto upon a
Change of Control (as defined in the Plan) pursuant to which the Option is terminated pursuant to Section 24(b)(ii) of the Plan or
cashed out pursuant to Section 24(b)(iii) of the Plan. The Employee shall be eligible, after the Effective Date, to receive (i)
additional stock options pursuant to the Plan, (ii) a bonus of $50,000, or such greater amount as determined by the Board in its
sole discretion, which amount shall be paid to the Employee within 15 days of the date that the Company achieves the second tranche
milestone as set forth on <U>Exhibit A</U> hereto as determined by the purchasers of the Series A2 Preferred Stock pursuant to
Section 1.2(b) of the Series A2 Purchase Agreement provided that the Employee is employed by the Company on the date the milestone
is achieved and (iii) additional bonus compensation, as determined by the Board, in its sole discretion; it being the intention of
the Board to maintain Employee&rsquo;s aggregate compensation at levels appropriate and customary to those of companies similar in
industry, stage and circumstances to that of the Company. Unless otherwise approved by the Board, all future options granted to the
Employee after the Effective Date shall vest with respect to twenty-five percent (25%) of the shares subject thereto upon the
completion of one (1) year of continuous service to the Company from the date of grant, and shall vest with respect to the remaining
shares subject thereto in equal monthly installments over an additional three (3) years thereafter. Notwithstanding the foregoing,
in the event that the Employee&rsquo;s employment with the Company is terminated by the Company without Cause (as defined in Section
4(a)(iii) below) or by the Employee for Good Reason (as defined in Section 4(b)(ii) below), then the vesting of all options held by
the Employee at the time of the termination shall accelerate (i) with respect to thirty-seven and one-half percent (37.5%) of the
unvested shares subject thereto, or (ii) if such termination occurs within 30 days prior to or within 12 months after a Change of
Control (as defined in the Plan), with respect to one hundred percent (100%) of the unvested shares subject thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Expenses</U>. The Employee will be entitled to receive prompt reimbursement for all reasonable expenses incurred by the Employee
(which are eligible for reimbursement under the Code) actually incurred by him in performing his duties; provided; however, that such
expenses are approved in accordance with the Company&rsquo;s then-current policies and procedures applicable to the most senior-level
executive employees of the Company, other than the Employee, or if such policies and procedures are not in place, then as determined in
the sole discretion of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Employee Benefits</U>. The Company shall reimburse the Employee for the premium costs incurred by the Employee in maintaining
medical and dental insurance coverage for the Employee and his family until such time that the Company sponsors a group insurance plan
providing medical and dental insurance coverage for Company employees (the &ldquo;<U>Health Insurance Reimbursement</U>&rdquo;). The Health
Insurance Reimbursement will be paid to the Employee on the last day of each month, provided the Employee has submitted to the Company
documentary evidence establishing the Employee&rsquo;s payment of such premiums to the health insurance provider. The Health Insurance
Reimbursement is intended to be provided on a qualified, tax free basis in accordance with Section 106 of the Code. In addition, the Employee
is entitled to participate in any employee benefit plans that the Company may make available to its most senior-level executive employees
generally, which may include, but not be limited to, profit sharing plans, 401(k) and cafeteria plans, or life, hospitalization, optical,
disability or other insurance plans as may be in effect, from time to time, and in accordance with rules established, from time to time,
for individual participation in such plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Vacation Days and Paid Leave</U>. The Employee will be entitled to take four (4) weeks of vacation days and paid leave, and
shall be entitled to compensation in connection therewith, in accordance with Company policy applicable to senior-level executive employees
of the Company, as approved by the Chief Executive Officer in its sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Facilities
and Services Furnished</U>. The Company will furnish the Employee with office space and such other facilities, furniture, equipment
and services as it may determine to be reasonably necessary for the performance of the Employee&rsquo;s duties as set forth herein.
It is acknowledged that as of the Effective Date, the Company is &ldquo;<U>virtual</U>&rdquo; and the Employee is using his own home
for the Company office at no expense to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination by the Company</U>. The Employee&rsquo;s employment hereunder may be terminated by the Company under any of the
following circumstances:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Death</U>. This Agreement shall automatically terminate upon the Employee&rsquo;s death.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Disability</U>. The Company may elect to terminate the Employee&rsquo;s employment in the event of Employee&rsquo;s Disability
upon delivery of written notice to the Employee. For purposes of this Agreement, &ldquo;<U>Disability</U>&rdquo; shall mean any condition
that, in the reasonable, good faith judgment of a licensed physician selected by the Company, causes the Employee to be unable, after
any accommodation required by applicable law, to perform his duties, responsibilities and obligations under this Agreement for a period
of at least twelve (12) months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Cause</U>. The Company may terminate the Employee&rsquo;s employment hereunder for Cause (as defined below) at any time upon
delivery of written notice to the Employee. For purposes of this Agreement, &ldquo;<U>Cause</U>&rdquo; shall mean (A) the conviction of
the Employee by a court of competent jurisdiction of any felony involving dishonesty, breach of trust or misappropriation or the entering
of a plea by the Employee of nolo contendre thereto; (B) the Employee&rsquo;s willful failure or refusal to follow reasonable and lawful
directives of the Board or the Company&rsquo;s Chief Executive Officer, provided such failure or refusal continues after the Employee&rsquo;s
receipt of reasonable notice in writing of such failure or refusal and an opportunity of not less than thirty (30) days to correct the
problem; (C) a material breach by the Employee of any of the provisions of this Agreement; or (D) the Employee&rsquo;s commission of any
immoral or illegal act or any gross or willful misconduct, where a majority of the non-employee members of the Board reasonably determines
that such act or misconduct has (1) seriously undermined the ability of the Board to entrust Employee with important matters or otherwise
work effectively with Employee, (2) contributed to the Company&rsquo;s loss of significant revenues or business opportunities, or (3)
significantly and detrimentally affected the business or reputation of the Company or any of its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Other Termination</U>. The Company may terminate Employee&rsquo;s employment with the Company at any time and for any reason,
with or without cause, subject to the provisions hereof. Employee acknowledges that Employee is, and at all times shall be, an employee
at will of the Company and nothing contained herein shall be construed to alter or affect such employee at-will status. Employee may terminate
his employment with the Company at any time, for any or no reason, subject to the provisions hereof. Inclusion under any benefit plan
or compensation arrangement will not give Employee any right or claim to any benefit hereunder except to the extent such right has become
fixed under the express terms of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination by the Employee</U>. The Employee may terminate the Employee&rsquo;s employment with the Company under the following
circumstances:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Voluntary Termination</U>. Employee may terminate his employment with the Company for any reason or no reason, upon delivery
of written notice to the Company at least fifteen (15) days prior to the specified termination date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination for Good Reason</U>. The Employee also may terminate the Employee&rsquo;s employment with the Company for &ldquo;<U>Good
Reason</U>,&rdquo; which shall mean for purposes of this Agreement (A) a material breach by the Company of any of the provisions of this
Agreement; (B) assignment of Employee to a role, duties or responsibilities materially inconsistent with that of senior executive management;
(C) any circumstances caused by the Company that would require Employee to move his principal location of employment in excess of one
hundred (100) miles from the Company&rsquo;s principal business location in Salt Lake City, Utah; or (D) an involuntary material reduction
of Employee&rsquo;s then current Base Salary other than a reduction proportionately affecting all of the Company&rsquo;s other senior-level
executive employees. The Employee must provide the Company with a written Notice of Termination that describes the existence of the condition
the Employee believes gives rise to Good Reason under this Section 4(b) within thirty (30) days following the initial existence of the
condition. The Company may elect to cure any condition giving rise to Good Reason within thirty (30) days of receipt of notice. The Employee&rsquo;s
termination for Good Reason must, in any event, occur within the six (6) month period immediately following the initial existence of the
condition giving rise to Good Reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Effect of Termination</U>. In the event the Employee&rsquo;s employment is terminated, all obligations of the Company and the
Employee under this Agreement shall cease, except that the accelerated vesting of Options set forth in Section 2(b) and the terms of Section
5 through Section 9 shall survive such termination. Upon such termination, the Employee or the Employee&rsquo;s representative or estate
shall be entitled to receive the applicable compensation, benefits and reimbursements set forth in Section 5. The Employee acknowledges
that, upon termination of the Employee&rsquo;s employment, the Employee is entitled to no other compensation, severance or other benefits
other than those specifically set forth in Section 5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Compensation and Benefits Upon Termination of Employment</U>. At all times after the Effective Date, the Employee shall be entitled
to receive additional compensation and benefits upon a termination of Employee&rsquo;s employment as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Severance Pay</U>. If either (i) the Company terminates the Employee&rsquo;s employment for any reason other than Cause, death
or Disability or (ii) the Employee terminates his employment for Good Reason; then, on the sixtieth (60<SUP>th</SUP>) day following the
termination of employment, the Company shall pay the Employee a lump sum amount equal to six (6) months of the Base Salary at the rate
in effect at the time of the termination of employment. If the Company terminates the Employee&rsquo;s employment due to death or Disability
and (y) the Company does not provide any insurance benefits payable to the Employee or his beneficiaries, as applicable, upon his death
or Disability and (z) the Company has previously, but not necessarily in the then applicable calendar year, achieved Ten Million Dollars
in annual gross revenue in a calendar year, then, on the sixtieth (60<SUP>th</SUP>) day following the termination of employment due to
death or Disability, the Company shall pay the Employee a lump sum amount equal to six (6) months of the Base Salary at the rate in effect
at the time of the termination of employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Health Insurance</U>. If either (i) the Company terminates the Employee&rsquo;s employment for any reason other than Cause,
death or Disability or (ii) the Employee terminates his employment for Good Reason, the Company will provide Health Insurance Reimbursement
until the earliest of (x) the close of the twelve (12) month period following the Employee&rsquo;s termination date, and (y) the date
when the Employee becomes eligible to receive health insurance coverage in connection with new employment or self-employment. If, as of
the termination date, the Company continues to sponsor a group insurance plan providing medical and dental insurance coverage for Company
employees, and if the Employee elects to continue his health insurance coverage under the Consolidated Omnibus Budget Reconciliation Act
(&ldquo;<U>COBRA</U>&rdquo;) following the termination of his employment, then the Company shall pay the portion of the Employee&rsquo;s
monthly premium under COBRA until the earliest of (x) the close of the twelve (12) month period following the Employee&rsquo;s termination
date, (y) the expiration of the Employee&rsquo;s continuation coverage under COBRA or (z) the date when the Employee becomes eligible
to receive health insurance coverage in connection with new employment or self-employment. If the payment of any COBRA or health insurance
premiums would otherwise violate the nondiscrimination rules or cause the reimbursement of claims to be taxable under the Patient Protection
and Affordable Care Act of 2010, together with the Health Care and Education Reconciliation Act of 2010 (collectively, the &ldquo;<U>Act</U>&rdquo;)
or Section 105(h) of the Code, the Company paid premiums shall be treated as taxable payments and be subject to imputed income tax treatment
to the extent necessary to eliminate any discriminatory treatment or taxation under the Act or Section 105(h) of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>General Release</U>. Any other provision of this Agreement notwithstanding, subsections (a) and (b) above shall not apply unless
the Employee has (i) executed a general release of all claims (in a form prescribed by the Company), which must be effective and irrevocable
prior to the sixtieth (60<SUP>th</SUP>) day following the termination of employment, (ii) returned all property of the Company in the
Employee&rsquo;s possession and (iii) cooperated in good faith with the Company for a transition period not to exceed sixty (60) days
to ensure an efficient transfer of the Employee&rsquo;s duties and responsibilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Non-Competition; Non-Solicitation</U>. The Employee and the Company hereby acknowledge and agree that in connection with the
employment of the Employee, the Employee has been and will be provided with trade secrets of the Company and that the Employee and the
Company are entering into this Agreement for the protection of such trade secrets. The Employee agrees to abide by the provisions set
forth in this <U>Section 6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Non-Competition</U>. The Employee shall not, during his employment with the Company and during the one (1) year period following
the termination of his employment with the Company (the &ldquo;<U>Restrictive Period</U>&rdquo;), directly or indirectly, as a manager,
member, promoter, shareholder, agent, representative, director, officer, owner, independent contractor or otherwise, or in connection
with any of his consultants, employees, agents, partners, relatives, affiliates or representatives or through any third party:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>anywhere in the United States (the &ldquo;<U>Restricted Area</U>&rdquo;) compete with or own, manage, operate or control any business
that directly competes in the Company&rsquo;s field of interest or products in the active development pipeline of the Company (for purposes
of this paragraph, ownership of securities of not in excess of one percent (1%) of the outstanding capital stock of a public company shall
not be considered to be competition with the Company); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>anywhere in the Restricted Area, act as an employee, director, officer, manager, member, advisor, consultant, representative or
agent for any business of the type and character engaged in and competitive with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Non-Solicitation</U>. The Employee shall not, during the Restrictive Period directly or indirectly, as a manager, member, promoter,
shareholder, agent, representative, director, officer, owner, independent contractor or otherwise, or in connection with any of his consultants,
employees, agents, partners, relatives, affiliates or representatives or through any third party, solicit the employment of or hire any
current employee of the Company, or solicit a relationship with any customer of the Company, located anywhere in the Restricted Area.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Definitions</U>. For purposes of this <U>Section 6</U>, the terms &ldquo;<U>compete with the Company</U>,&rdquo; &ldquo;<U>competitive
with the Company</U>,&rdquo; &ldquo;<U>field of interest</U>&rdquo; and similar terms referring to competition with the Company shall
mean any business that is engaged in identifying and commercializing biomarkers in blood samples of pregnant women which are predictive
of preterm birth and other pregnancy complications or any other anticipated business ventures of the Company which have been discussed
with the Board or amongst the senior-level executive employees as of the date of Employee&rsquo;s termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Maintaining Confidential Information</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Company Confidential Information</U>. The Employee hereby agrees at all times during which he provides services as a director,
officer, employee or consultant of the Company (&ldquo;<U>Employee&rsquo;s Service</U>&rdquo;), and thereafter to hold in strictest confidence,
and not to use, except for the benefit of the Company, any trade secrets, confidential knowledge, data or other proprietary information
relating to products, processes, know-how, formulas, developmental or experimental work, computer lists, customer lists, business plans,
financial information or other subject matter pertaining to any business of the Company or any of its clients, consultants or licensees
(collectively &ldquo;<U>Confidential Information</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the above,
Employee shall not have liability to the Company with regard to any Confidential Information which Employee can prove:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>was in the public domain at the time it was disclosed by the Company or has entered the public domain through no fault of Employee;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>was known to the Employee without restriction, at the time of disclosure, as demonstrated by files in existence at the time of
disclosure;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>is disclosed with the prior written approval of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>becomes
known to Employee, without restriction, from a source other than the Company without breach of this Agreement by Employee and otherwise
not in violation of the Company&rsquo;s rights; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>is
disclosed pursuant to the order or requirement of a court, administrative agency, or other governmental body; provided, however, that
Employee shall provide prompt notice of such court order or requirement to the Company to enable the Company to seek a protective order
or otherwise prevent such disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Former Employer Information</U>. The Employee hereby agrees that he will not, during Employee&rsquo;s Service, improperly use
or disclose any proprietary information or trade secrets of his former or concurrent employers or companies, if any, and that he will
not make available to the Company any unpublished document or any property belonging to his former or concurrent employers or companies,
if any, unless consented to in writing by said employers or companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Third-Party Information</U>. The Employee recognizes that the Company has received and in the future will receive from third
parties their confidential or proprietary information subject to a duty on the Company&rsquo;s part to maintain the confidentiality of
such information and to use it only for certain limited purposes. The Employee hereby agrees, during Employee&rsquo;s Service and thereafter,
to hold all such confidential or proprietary information in the strictest confidence and not to disclose it to any person, firm or corporation
(except as necessary in carrying out his work for the Company consistent with the Company&rsquo;s agreement with such third party) or
to use it for the benefit of anyone other than the Company or such third party (consistent with the Company&rsquo;s agreement with such
third party) without the express written authorization of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Availability of Equitable Remedies</U>. The Employee hereby acknowledges and agrees that a breach of Section 6 or Section 7
will cause irreparable harm and damage to the Company, that the remedy at law for the breach or threatened breach of Section 6 or Section
7 will be inadequate, and that, in addition to all other remedies available to the Company for such breach or threatened breach (including,
without limitation, the right to recover damages), the Company will be entitled to injunctive relief for any breach or threatened breach
of Section 6 or Section 7.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notification of New Employer</U>. In the event that the Employee leaves the employ of the Company, he hereby grants consent
to notification by the Company to his new employer about his rights and obligations under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Severability</U>. In the event that a court of competent jurisdiction determines that any portion of this Agreement is in violation
of any statute or public policy, then only the portions of this Agreement which violate such statute or public policy shall be stricken.
All portions of this Agreement which do not violate any statute or public policy shall continue in full force and effect. Further, any
court order striking any portion of this Agreement shall modify the stricken terms to give as much effect as possible to the intentions
of the parties under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notices</U>. Any notices, requests or consents hereunder shall be deemed given, and any instrument delivered, three (3) days
after they have been mailed by first class mail, postage prepaid, one (1) day after they have been delivered by overnight courier, twelve
(12) hours after such notice has been sent by facsimile, or upon receipt if delivered personally, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">To the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">2749 East Parleys Way, Suite 200</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Salt Lake City, UT 84109</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">To the Employee:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">1020 Douglas St</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">SLC, UT 84105</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">except that any of the foregoing may, from time
to time, by written notice to the others, designate another address or fax number which shall thereupon become his or its effective address
for the purposes of this Section 9(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Governing Law</U>. This Agreement shall be governed by the laws of the State of Utah, without giving effect to its conflict
of laws principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Successors and Assigns</U>. The rights and obligations of the Company under this Agreement shall inure to the benefit of and
shall be binding upon the successors and assigns of the Company. This Agreement is for the unique personal services of the Employee, and
the Employee shall not be entitled to assign any of the Employee&rsquo;s rights or obligations hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Entire Agreement; Amendment</U>. This Agreement constitutes the entire agreement and understanding between the parties hereto
with respect to the subject matter of this Agreement, and supersedes all other prior agreements and understandings with respect thereto,
including, but not limited to, the Prior Agreement. This Agreement can be amended or modified only in a writing signed by the Employee
and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Waiver</U>. No waiver by either party at any time of any breach by the other party of, or compliance with, any condition
or provision of this Agreement to be performed by the other party shall be deemed a waiver of similar or dissimilar provisions or conditions
at the same time or any prior or subsequent time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Headings</U>.
The headings herein contained are for reference only and shall not affect the meaning or interpretation of any provision of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Counterparts</U>. This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original
but all of which together will constitute one and the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Costs and Expenses</U>. The Company shall reimburse all of the Employee&rsquo;s reasonable costs and expenses (including, without
limitation, attorneys&rsquo; fees), incurred in connection with the negotiation and preparation of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Attorneys&rsquo;
Fees</U>. In the event of any action at law, equity or under this Agreement to enforce or interpret the terms of this Agreement, the
prevailing party shall be entitled to reasonable attorneys&rsquo; fees and court costs in addition to any other relief to which such
party may be entitled, unless the action is one in which only a prevailing plaintiff is entitled to prevailing party fees and costs
(such as a Title VII action).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Section 409A</U>. The Company intends that the cash severance payments to which the Employee is entitled on his termination
of employment pursuant to Section 5 are payable on the Employee&rsquo;s Separation from Service (as defined below) and are exempt from,
or are otherwise payable in compliance with Section 409A. The Company intends that the Company&rsquo;s continued payment for the cost
of the Employee&rsquo;s welfare benefits (including the payment of all COBRA administrative costs and expenses) provided by Section 5
will comply with the exception to Section 409A for reimbursements and certain other separation payments, as described in Treas. Reg. &sect;
1.409A-1(b)(9)(v)(B), to the extent such costs are taxable and subject to imputed income treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Separation from Service Defined</U>. For purposes of this Agreement, the term &ldquo;<U>termination of employment</U>&rdquo;
means the Employee&rsquo;s &ldquo;<U>Separation from Service</U>.&rdquo; The term &ldquo;<U>Separation from Service</U>&rdquo; means (A)
the termination of the Employee&rsquo;s employment with the Company and all affiliates for any reason or (B) a permanent reduction in
the level of bona fide services the Employee provides to the Company and all affiliates to an amount that is twenty percent (20%) or less
of the average level of bona fide services the Employee provided to the Company and all affiliates in the immediately preceding thirty-six
(36) months (or the entire time period during which the Employee provided services to the Company and all affiliates if the Employee has
been providing such services for less than thirty-six (36) months), with the level of bona fide service calculated in accordance with
Treas. Reg. &sect; 1.409A-1(h)(1)(ii). Solely for purposes of determining whether an organization is an &ldquo;<U>affiliate</U>&rdquo;
of the Company, the Company will follow the rules set forth in Treas. Reg. &sect; 1.409A-1(h)(3) (which generally requires fifty percent
(50%) common ownership or control). The Employee&rsquo;s employment relationship is treated as continuing while the Employee is on military
leave, sick leave, or other bona fide leave of absence (if the period of such leave does not exceed six (6) months; or, if longer, so
long as the Employee&rsquo;s right to reemployment with the Company or an affiliate is provided either by statute or contract). If the
Employee&rsquo;s period of leave exceeds six (6) months and his right to re-employment is not provided either by statute or by contract,
the employment relationship is deemed to terminate on the first day immediately following the expiration of such six (6) month period.
Whether a termination of employment has occurred will be determined based on all of the facts and circumstances and in accordance with
regulations issued by the United States Treasury Department pursuant to Section 409A of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Delay in Payments</U>. Notwithstanding any provision of this Agreement to the contrary, if any of the severance payments are
subject to Section 409A and the Employee is a &ldquo;<U>Specified Employee</U>&rdquo; at the time of his Separation from Service, no payments
shall be made to the Employee prior to the first business day following the date which is six (6) months after the Employee&rsquo;s Separation
from Service. Any amounts that would have been paid during the six (6) months following the Employee&rsquo;s Separation from Service will
be paid on the first business day following the expiration of the six (6) month period without interest thereon. The Employee may not
elect the taxable year of such payment. The six (6) month delay for a Specified Employee does not apply if the Employee dies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Specified Employee Defined</U>. For purposes of this Agreement, the term &ldquo;<U>Specified Employee</U>&rdquo; means certain
officers and highly-compensated employees of the Company as defined in Treas. Reg. &sect; 1.409A-1(i), and as determined in accordance
with such procedures as may be adopted from time to time by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Miscellaneous Payment Provisions</U>. If payment is not made, in whole or in part, due to a dispute between the Employee and
the Company, the payments shall be made in accordance with Treas. Reg. &sect; 1.409A-3(g), as applicable. It is intended that each installment
of the payments and benefits provided under Section 5 of this Agreement shall be treated as a separate &ldquo;payment&rdquo; for purposes
of Section 409A. If an expense reimbursement or provision of in-kind benefit provided pursuant to this Agreement is not exempt from Section
409A of the Code, the following rules apply: (A) in no event shall any reimbursement be paid after the last day of the taxable year following
the taxable year in which the expense was incurred; (B) the amount of reimbursable expenses incurred or provision of in-kind benefits
in one tax year shall not affect the expenses eligible for reimbursement or the provision of in-kind benefits in any other tax year; and
(C) the right to reimbursement for expenses or provision of in-kind benefits is not subject to liquidation or exchange for any other benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Ban on Acceleration or Deferral</U>. Under no circumstances may the time or schedule of any payment made or benefit provided
pursuant to this Agreement be accelerated or subject to a further deferral, except as otherwise permitted or required pursuant to regulations
and other guidance issued pursuant to Section 409A of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Elections</U>. The Employee does not have any right to make any election regarding the time or form of any payment due under
this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Compliant Operation and Interpretation</U>. This Agreement shall be operated in compliance with the requirements of Section
409A or an exception thereto and each provision of this Agreement shall be interpreted, to the extent possible, to comply with Section
409A or to qualify for an exception thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Dispute Resolution; Venue</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company and the Employee shall use reasonable, good faith efforts to settle any dispute through non-binding mediation before
a mutually-acceptable, neutral, third-party mediator. The mediation shall be held in Salt Lake City, Utah and administered by the CPR
Institute for Dispute Resolution (the &ldquo;<U>CPR Institute</U>&rdquo;) under the CPR Mediation Procedure then in effect. Unless otherwise
agreed, the parties shall jointly select a single mediator from the CPR Panels of Distinguished Neutrals based on a list of mediator candidates
supplied by the CPR Institute. If, within fourteen (14) days after either party makes a written request for mediation under this Section
9(m)(i), the parties have not reached agreement on the selection of a mediator, the mediator shall be selected in accordance with the
CPR Mediation Procedure currently in effect. A good faith attempt at mediation shall be a condition precedent to the commencement of litigation,
but nothing in this Agreement, including, but not limited to paragraph (ii) below, shall be deemed a condition precedent to any court
action for injunction or other interim relief pending the outcome of mediation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> If the parties are unable to resolve the dispute by mediation in a timely manner (which, in any case, shall not exceed sixty (60)
days from the first notice of mediation), either party may attempt to resolve the dispute by commencing an action (or defending or responding
to such action) exclusively in the jurisdiction and venue of the courts, whether federal or state, located in Salt Lake County, Utah.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have executed this Agreement to be effective for all purposes as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 50%">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 50%"><U>THE COMPANY</U>:</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 50%">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 50%">SERA PROGNOSTICS, INC.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="width: 4%">By:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 46%">/s/ Gregory C. Critchfield, M.D.</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Gregory C. Critchfield, M.D.</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Chairman, President and CEO</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 4in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 50%">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 50%"><U>THE EMPLOYEE</U>:</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 50%">&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 50%">/s/ John J. Boniface</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">John J. Boniface, Ph.D.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECOND TRANCHE MILESTONE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Second Tranche Milestone shall be the occurrence
of either one of the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) the Area Under the Curve (AUC) of the Receiver
Operator Characteristic (ROC) curve of a clinically meaningful commercial preterm birth predictor has been validated to be statistically
different from 0.5;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">OR</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) the Company&rsquo;s Board of Directors agrees
unanimously that the commercial preterm birth predictor has been successfully validated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0pt"></P>

<!-- Field: Page; Sequence: 9; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>29
<FILENAME>tm2110724d11_ex10-14.htm
<DESCRIPTION>EXHIBIT 10.14
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

                           <P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: right; margin: 0pt"><B>Exhibit 10.14</B></P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SERA PROGNOSTICS, INC. EMPLOYMENT AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Employment Agreement
(this &ldquo;<U>Agreement</U>&rdquo;) is effective for all purposes as of the start date (the &ldquo;<U>Effective Date</U>&rdquo;) of
the Offer Letter to you dated 13 June 2018, by and between Sera Prognostics, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;),
and Garrett Lam (the &ldquo;<U>Employee</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the mutual covenants, conditions and undertakings set forth herein, the parties hereto hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Employment
and Duties</U>. Subject to the terms and conditions set forth in this Agreement, the Company shall employ Employee, and Employee hereby
accepts employment, as the Chief Medical Officer of the Company, with those duties and responsibilities which are appropriate and customary
for the medical leader of a company similar to the Company. In such capacity, the Employee shall report to the Company&rsquo;s Chief
Executive Officer. During the term of this Agreement, the Employee shall faithfully perform the Employee&rsquo;s duties, responsibilities
and obligations hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Base Compensation and Related Matters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Salary</U>.
In consideration for the services rendered by the Employee to the Company as provided herein, the Company shall pay the Employee an annual
base salary of $350,000, provided that the Employee&rsquo;s employment with the Company remains active at a full-time rate. The Base
Salary shall be paid according to the Company&rsquo;s standard payroll policy and will be subject to applicable federal and state tax
withholdings as required by applicable law. The Base Salary may be increased or decreased at any time by the Company&rsquo;s Board of
Directors (the &ldquo;<U>Board</U>&rdquo;) or the Compensation Committee of the Board in its sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Stock
Option Grant(s) and Bonuses</U>. The Employee shall be granted as soon as practicable on or after the Effective Date an option to purchase
375,000 shares of the Company&rsquo;s common stock (the &ldquo;<U>Option</U>&rdquo;) (which option shall be issued as an incentive stock
option to the maximum extent allowed under Section 422 of the Internal Revenue Code of 1986, as amended, and the regulations promulgated
thereunder (the &ldquo;<U>Code</U>&rdquo;)) pursuant to the Company&rsquo;s 2011 Employee, Director and Consultant Equity Incentive Plan
(the &ldquo;Plan&rdquo;). The Option shall vest as to twenty-five percent (25%) of the shares subject thereto one (1) year from August
6, 2018 (&ldquo;<U>Vesting Start Date</U>&rdquo;), and shall vest with respect to the remaining shares subject thereto in equal monthly
installments over an additional thirty-six (36) months thereafter commencing on the sixth (6&rsquo;) day of the month one year following
the Vesting Start Date, subject to continued employment by the Company. In addition, the Option shall accelerate with respect to thirty-seven
and one-half percent (37.5%) of the outstanding unvested shares at that time then subject thereto upon a Change of Control (as defined
in the Plan) pursuant to which the Option is terminated pursuant to Section 24(b)(ii) of the Plan or cashed out pursuant to Section 24(b)(iii)
of the Plan. The Employee shall be eligible, after the Effective Date, to receive (i) additional stock options pursuant to the Plan and
(ii) additional bonus compensation, as determined by the Board, in its sole discretion; it being the intention of the Board to maintain
Employee&rsquo;s aggregate compensation at levels appropriate and customary to those of companies similar in industry, stage and circumstances
to that of the Company Unless otherwise approved by the Board, all future options granted to the Employee after the Effective Date shall
vest in equal monthly installments over a period of forty-eight (48) months from the date of grant. Notwithstanding the foregoing, in
the event that the Employee&rsquo;s employment with the Company is terminated by the Company without Cause (as defined in Section 4(a)(iii)
below) or by the Employee for Good Reason (as defined in Section 4(b)(ii) below), then the vesting of all options held by the Employee
at the time of the termination shall accelerate (i) with respect to thirty-seven and one-half percent (37.5%) of the unvested shares
subject thereto, or (ii) if such termination occurs within 30 days prior to or within 12 months after a Change of Control (as defined
in the Plan), with respect to one hundred percent (100%) of the unvested shares subject thereto. You will be eligible to participate
in the Company&rsquo;s Annual Incentive Plan, which currently provides for a bonus target of 30% of your base salary, prorated for time
of service, and with respect to the calendar year ending December 31, 2018, payment will be contingent based upon achievements mutually
agreed upon by you and your supervisor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Expenses</U>.
The Employee will be entitled to receive prompt reimbursement for all reasonable expenses incurred by the Employee (which are eligible
for reimbursement under the Code) actually incurred by him in performing his duties; provided; however, that such expenses are approved
in accordance with the Company&rsquo;s then-current policies and procedures applicable to the most senior-level executive employees of
the Company, other than the Employee, or if such policies and procedures are not in place, then as determined in the sole discretion
of the Board. <U>Employee Benefits</U>. Upon classification as a full-time employee, the Employee will be entitled to participate in
the group health, dental, vision, and group life insurance benefit plans, as well as the Company&rsquo;s 401(k) and Flexible Spending
Account Plans available to all Company employees. In addition, the Employee is entitled to participate in any employee benefit plans
that the Company may make available to its most senior-level executive employees generally, which may include, but not be limited to,
profit sharing plans, 401(k) and cafeteria plans, or life, hospitalization, optical, disability or other insurance plans as may be in
effect, from time to time, and in accordance with rules established, from time to time, for individual participation in such plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Vacation
Days and Paid Leave</U>. Upon classification as a full-time employee, the Employee will be entitled to take four (4) weeks of vacation
days, three (3) additional personal time off days, and shall be entitled to compensation in connection therewith, in accordance with
Company policy applicable to senior-level executive employees of the Company, as approved by the Chief Executive Officer in its sole
discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Facilities and Services Furnished</U>. The Company will furnish the Employee with office space at its headquarters in Salt Lake
City, Utah, and such other facilities, furniture, equipment and services as it may determine to be reasonably necessary for the performance
of the Employee&rsquo;s duties as set forth herein. It is acknowledged that as of the Effective Date, the Employee is using his own home
for a Company office at no expense to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Termination</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Termination
by the Company</U>. The Employee&rsquo;s employment hereunder may be terminated by the Company under any of the following circumstances:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Death</U>.
This Agreement shall automatically terminate upon the Employee&rsquo;s death.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Disability</U>. The Company may elect to terminate the Employee&rsquo;s employment in the event of Employee&rsquo;s Disability
upon delivery of written notice to the Employee. For purposes of this Agreement, &ldquo;<U>Disability</U>&rdquo; shall mean any condition
that, in the reasonable, good faith judgment of a licensed physician selected by the Company, causes the Employee to be unable, after
any accommodation required by applicable law, to perform his duties, responsibilities and obligations under this Agreement for a period
of at least twelve (12) <U>consecutive</U> months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Cause</U>.
The Company may terminate the Employee&rsquo;s employment hereunder for Cause (as defined below) at any time upon delivery of written
notice to the Employee. For purposes of this Agreement, &ldquo;<U>Cause</U>&rdquo; shall mean (A) the conviction of the Employee by a
court of competent jurisdiction of any felony involving dishonesty, breach of trust or misappropriation or the entering of a plea by
the Employee of nolo contendre thereto; (B) the Employee&rsquo;s willful failure or refusal to follow reasonable and lawful directives
of the Board or the Company&rsquo;s Chief Executive Officer, provided such failure or refusal continues after the Employee&rsquo;s receipt
of reasonable notice in writing of such failure or refusal and an opportunity of not less than thirty (30) days to correct the problem;
(C) a material breach by the Employee of any of the provisions of this Agreement, with notification of such breach by the process outlined
in 4.(iii).(B), above; or (D) the Employee&rsquo;s commission of any immoral or illegal act or any gross or willful misconduct, where
a majority of the non-employee members of the Board reasonably determines that such act or misconduct has (1) seriously undermined the
ability of the Board to entrust Employee with important matters or otherwise work effectively with Employee, (2) contributed to the Company&rsquo;s
loss of significant revenues or business opportunities, or (3) significantly and detrimentally affected the business or reputation of
the Company or any of its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Other
Termination</U>. The Company may terminate Employee&rsquo;s employment with the Company at any time and for any reason, with or without
cause, subject to the provisions hereof. Employee acknowledges that Employee is, and at all times shall be, an employee at will of the
Company and nothing contained herein shall be construed to alter or affect such employee at-will status. Employee may terminate his employment
with the Company at any time, for any or no reason, subject to the provisions hereof. Inclusion under any benefit plan or compensation
arrangement will not give Employee any right or claim to any benefit hereunder except to the extent such right has become fixed under
the express terms of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Termination
by the Employee</U>. The Employee may terminate the Employee&rsquo;s employment with the Company under the following circumstances:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Voluntary
Termination</U>. Employee may terminate his employment with the Company for any reason or no reason, upon delivery of written notice
to the Company at least fifteen (15) days prior to the specified termination date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Termination
for Good Reason</U>. The Employee also may terminate the Employee&rsquo;s employment with the Company for &ldquo;<U>Good Reason</U>,&rdquo;
which shall mean for purposes of this Agreement (A) a material breach by the Company of any of the provisions of this Agreement; (B)
assignment of Employee to a role, duties or responsibilities materially inconsistent with that of senior executive management; (C) any
circumstances caused by the Company that would require Employee to move his principal location of employment in excess of one hundred
(100) miles from the Company&rsquo;s principal business location in Salt Lake City, Utah; or (D) an involuntary material reduction of
Employee&rsquo;s then current Base Salary other than a reduction proportionately affecting all of the Company&rsquo;s other senior-level
executive employees. The Employee must provide the Company with a written Notice of Termination that describes the existence of the condition
the Employee believes gives rise to Good Reason under this Section 4(b) within thirty (30) days following the initial existence of the
condition. The Company may elect to cure any condition giving rise to Good Reason within thirty (30) days of receipt of notice. The Employee&rsquo;s
termination for Good Reason must, in any event, occur within the six (6) month period immediately following the initial existence of
the condition giving rise to Good Reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Effect of Termination</U>. In the event the Employee&rsquo;s employment is terminated, all obligations of the Company and the
Employee under this Agreement shall cease, except that the accelerated vesting of Options set forth in Section 2(b) and the terms of Section
5 through Section 9 shall survive such termination. Upon such termination, the Employee or the Employee&rsquo;s representative or estate
shall be entitled to receive the applicable compensation, benefits and reimbursements set forth in Section 5. The Employee acknowledges
that, upon termination of the Employee&rsquo;s employment, the Employee is entitled to no other compensation, severance or other benefits
other than those specifically set forth in Section 5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Compensation and Benefits Upon Termination of Employment</U>. At all times after the Effective Date, the Employee shall be entitled
to receive additional compensation and benefits upon a termination of Employee&rsquo;s employment as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Severance Pay</U>. If either (i) the Company terminates the Employee&rsquo;s employment for any reason other than Cause, death
or Disability or (ii) the Employee terminates his employment for Good Reason; then, on the sixtieth (60<SUP>th</SUP>) day following the
termination of employment, the Company shall pay the Employee a lump sum amount equal to six (6) months of the Base Salary at the rate
in effect at the time of the termination of employment. If the Company terminates the Employee&rsquo;s employment due to death or Disability
and (y) the Company does not provide any insurance benefits payable to the Employee or his beneficiaries, as applicable, upon his death
or Disability and (z) the Company has previously, but not necessarily in the then applicable calendar year, achieved Ten Million Dollars
in annual gross revenue in a calendar year, then, on the sixtieth (60<SUP>th</SUP>) day following the termination of employment due to
death or Disability, the Company shall pay the Employee a lump sum amount equal to six (6) months of the Base Salary at the rate in effect
at the time of the termination of employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Health
Insurance</U>. If, while eligible to participate in the Company&rsquo;s health benefit plans, either (i) the Company terminates the Employee&rsquo;s
employment for any reason other than Cause, death or Disability or (ii) the Employee terminates his employment for Good Reason, the Company
will provide Health Insurance Reimbursement until the earliest of (x) the close of the twelve (12) month period following the Employee&rsquo;s
termination date, and (y) the date when the Employee becomes eligible to receive health insurance coverage in connection with new employment
or self-employment. If, as of the termination date, the Company continues to sponsor a group insurance plan providing medical and dental
insurance coverage for Company employees, and if the Employee elects to continue his health insurance coverage under the Consolidated
Omnibus Budget Reconciliation Act (&ldquo;<U>COBRA</U>&rdquo;) following the termination of his employment, then the Company shall pay
the portion of the Employee&rsquo;s monthly premium under COBRA until the earliest of (x) the close of the twelve (12) month period following
the Employee&rsquo;s termination date, (y) the expiration of the Employee&rsquo;s continuation coverage under COBRA or (z) the date when
the Employee becomes eligible to receive health insurance coverage in connection with new employment or self-employment. If the payment
of any COBRA or health insurance premiums would otherwise violate the nondiscrimination rules or cause the reimbursement of claims to
be taxable under the Patient Protection and Affordable Care Act of 2010, together with the Health Care and Education Reconciliation Act
of 2010 (collectively, the &ldquo;<U>Act</U>&rdquo;) or Section 105(h) of the Code, the Company paid premiums shall be treated as taxable
payments and be subject to imputed income tax treatment to the extent necessary to eliminate any discriminatory treatment or taxation
under the Act or Section 105(h) of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>General
Release</U>. Any other provision of this Agreement notwithstanding, subsections (a) and (b) above shall not apply unless the Employee
has (i) executed a general release of all claims (in a form prescribed by the Company), which must be effective and irrevocable prior
to the sixtieth (60<SUP>th</SUP>) day following the termination of employment, (ii) returned all property of the Company in the Employee&rsquo;s
possession and (iii) cooperated in good faith with the Company for a transition period not to exceed sixty (60) days to ensure an efficient
transfer of the Employee&rsquo;s duties and responsibilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Non-Competition;
Non-Solicitation</U>. The Employee and the Company hereby acknowledge and agree that in connection with the employment of the Employee,
the Employee has been and will be provided with trade secrets of the Company and that the Employee and the Company are entering into
this Agreement for the protection of such trade secrets. The Employee agrees to abide by the provisions set forth in this <U>Section
6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Non-Competition</U>. The Employee shall not, during his employment with the Company and during the one (1) year period following
the termination of his employment with the Company (the &ldquo;<U>Restrictive Period</U>&rdquo;) directly or indirectly, as a manager,
member, promoter, shareholder, agent, representative, director, officer, owner, independent contractor or otherwise, or in connection
with any of his consultants, employees, agents, partners, relatives, affiliates or representatives or through any third party:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>anywhere
in the world (the &ldquo;<U>Restricted Area</U>&rdquo;) compete with or own, manage, operate or control any business that directly competes
in the Company&rsquo;s field of interest or products in the active development pipeline of the Company (for purposes of this paragraph,
ownership of securities of not in excess of one percent (1%) of the outstanding capital stock of a public company shall not be considered
to be competition with the Company); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>anywhere
in the Restricted Area, act as an employee, director, officer, manager, member, advisor, consultant, representative or agent for any
business of the type and character engaged in and competitive with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Non-Solicitation</U>.
The Employee shall not, during the Restrictive Period directly or indirectly, as a manager, member, promoter, shareholder, agent, representative,
director, officer, owner, independent contractor or otherwise, or in connection with any of his consultants, employees, agents, partners,
relatives, affiliates or representatives or through any third party, solicit the employment of or hire any current employee of the Company,
or solicit a relationship with any customer of the Company, located anywhere in the Restricted Area.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Definitions</U>.
For purposes of this <U>Section 6</U> the terms &ldquo;<U>compete with the Company.&rdquo; &ldquo;competitive with the Company,&rdquo;
 &ldquo;field of interest</U>&rdquo; and similar terms referring to competition with the Company shall mean any business that is engaged
in identifying and commercializing biomarkers in blood samples of pregnant women which are predictive of preterm birth and other pregnancy
complications or any other anticipated business ventures of the Company which have been discussed with the Board or amongst the senior-level
executive employees as of the date of Employee&rsquo;s termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Maintaining
Confidential Information</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Company
Confidential Information</U>. The Employee hereby agrees at all times during which he provides services as a director, officer, employee
or consultant of the Company (&ldquo;<U>Employee&rsquo;s Service</U>&rdquo;), and thereafter to hold in strictest confidence, and not
to use, except for the benefit of the Company, any trade secrets, confidential knowledge, data or other proprietary information relating
to products, processes, know-how, formulas, developmental or experimental work, computer lists, customer lists, business plans, financial
information or other subject matter pertaining to any business of the Company or any of its clients, consultants or licensees (collectively
 &ldquo;<U>Confidential Information</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the above,
Employee shall not have liability to the Company with regard to any Confidential Information which Employee can prove:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>was
in the public domain at the time it was disclosed by the Company or has entered the public domain through no fault of Employee;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>was
known to the Employee without restriction, at the time of disclosure, as demonstrated by files in existence at the time of disclosure;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>is disclosed with the prior written approval of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>becomes known to Employee, without restriction, from a source other than the Company without breach of this Agreement by Employee
and otherwise not in violation of the Company&rsquo;s rights; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>is
disclosed pursuant to the order or requirement of a court, administrative agency, or other governmental body; provided, however, that
Employee shall provide prompt notice of such court order or requirement to the Company to enable the Company to seek a protective order
or otherwise prevent such disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Former
Employer Information</U>. The Employee hereby agrees that he will not, during Employee&rsquo;s Service, improperly use or disclose any
proprietary information or trade secrets of his former or concurrent employers or companies, if any, and that he will not make available
to the Company any unpublished document or any property belonging to his former or concurrent employers or companies, if any, unless
consented to in writing by said employers or companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Third-Party Information</U>. The Employee recognizes that the Company has received and in the future will receive from third
parties their confidential or proprietary information subject to a duty on the Company&rsquo;s part to maintain the confidentiality of
such information and to use it only for certain limited purposes. The Employee hereby agrees, during Employee&rsquo;s Service and thereafter,
to hold all such confidential or proprietary information in the strictest confidence and not to disclose it to any person, firm or corporation
(except as necessary in carrying out his work for the Company consistent with the Company&rsquo;s agreement with such third party) or
to use it for the benefit of anyone other than the Company or such third party (consistent with the Company&rsquo;s agreement with such
third party) without the express written authorization of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Outside Activities</U>. The Employee shall not perform consulting/business activities beyond those disclosed in Exhibit A, without
prior written consent of the Company&rsquo;s Board of Directors Compensation Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Availability
of Equitable Remedies</U>. The Employee hereby acknowledges and agrees that a breach of Section 6 or Section 7 will cause irreparable
harm and damage to the Company, that the remedy at law for the breach or threatened breach of Section 6 or Section 7 will be inadequate,
and that, in addition to all other remedies available to the Company for such breach or threatened breach (including, without limitation,
the right to recover damages), the Company will be entitled to injunctive relief for any breach or threatened breach of Section 6 or
Section 7.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Notification of New Employer</U>. In the event that the Employee leaves the employ of the Company, he hereby grants consent
to notification by the Company to his new employer about his rights and obligations under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Severability</U>. In the event that a court of competent jurisdiction determines that any portion of this Agreement is in violation
of any statute or public policy, then only the portions of this Agreement which violate such statute or public policy shall be stricken.
All portions of this Agreement which do not violate any statute or public policy shall continue in full force and effect. Further, any
court order striking any portion of this Agreement shall modify the stricken terms to give as much effect as possible to the intentions
of the parties under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Notices</U>. Any notices, requests or consents hereunder shall be deemed given, and any instrument delivered, three (3) days
after they have been mailed by first class mail, postage prepaid, one (1) day after they have been delivered by overnight courier, twelve
(12) hours after such notice has been sent by facsimile, or upon receipt if delivered personally, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">To the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">2749 East Parleys Way, Suite 200</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Salt Lake City, UT 84109</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">To the Employee:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">103 South Drive</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Signal Mountain, TN 37377</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">except that any of the foregoing may, from time
to time, by written notice to the others, designate another address or fax number which shall thereupon become him or its effective address
for the purposes of this Section 9(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Governing
Law</U>. This Agreement shall be governed by the laws of the State of Utah, without giving effect to its conflict of laws principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Successors
and Assigns</U>. The rights and obligations of the Company under this Agreement shall inure to the benefit of and shall be binding upon
the successors and assigns of the Company. This Agreement is for the unique personal services of the Employee, and the Employee shall
not be entitled to assign any of the Employee&rsquo;s rights or obligations hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Entire
Agreement; Amendment</U>. This Agreement constitutes the entire agreement and understanding between the parties hereto with respect to
the subject matter of this Agreement, and supersedes all other prior agreements and understandings with respect thereto, This Agreement
can be amended or modified only in a writing signed by the Employee and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>No Waiver</U>. No waiver by either party at any time of any breach by the other party of, or compliance with, any condition
or provision of this Agreement to be performed by the other party shall be deemed a waiver of similar or dissimilar provisions or conditions
at the same time or any prior or subsequent time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Headings</U>.
The headings herein contained are for reference only and shall not affect the meaning or interpretation of any provision of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Counterparts</U>. This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original
but all of which together will constitute one and the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Costs
and Expenses</U>. The Company shall reimburse all of the Employee&rsquo;s reasonable costs and expenses (including, without limitation,
attorneys&rsquo; fees), incurred in connection with the negotiation and preparation of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Attorneys&rsquo;
Fees</U>. In the event of any action at law, equity or under this Agreement to enforce or interpret the terms of this Agreement, the
prevailing party shall be entitled to reasonable attorneys&rsquo; fees and court costs in addition to any other relief to which such
party may be entitled, unless the action is one in which only a prevailing plaintiff is entitled to prevailing party fees and costs (such
as a Title VII action).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Section
409A</U>. The Company intends that the cash severance payments to which the Employee is entitled on his termination of employment pursuant
to Section 5 are payable on the Employee&rsquo;s Separation from Service (as defined below) and are exempt from, or are otherwise payable
in compliance with Section 409A. The Company intends that the Company&rsquo;s continued payment for the cost of the Employee&rsquo;s
welfare benefits (including the payment of all COBRA administrative costs and expenses) provided by Section 5 will comply with the exception
to Section 409A for reimbursements and certain other separation payments, as described in Treas. Reg. &sect; 1.409A-1(b)(9)(v)(B), to
the extent such costs are taxable and subject to imputed income treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Separation
from Service Defined</U>. For purposes of this Agreement, the term &ldquo;<U>termination of employment</U>&rdquo; means the Employee&rsquo;s
 &ldquo;<U>Separation From Service</U>.&rdquo; The term &ldquo;Separation from Service&rdquo; means (A) the termination of the Employee&rsquo;s
employment with the Company and all affiliates for any reason or (B) a permanent reduction in the level of bona fide services the Employee
provides to the Company and all affiliates to an amount that is twenty percent (20%) or less of the average level of bona fide services
the Employee provided to the Company and all affiliates in the immediately preceding thirty-six (36) months (or the entire time period
during which the Employee provided services to the Company and all affiliates if the Employee has been providing such services for less
than thirty-six (36) months), with the level of bona fide service calculated in accordance with Treas. Reg. &sect; 1.409A-1(h)(l)(ii).
Solely for purposes of determining whether an organization is an &ldquo;<U>affiliate</U>&rdquo; of the Company, the Company will follow
the rules set forth in Treas. Reg. &sect; 1.409A-1(h)(3) (which generally requires fifty percent (50%) common ownership or control).
The Employee&rsquo;s employment relationship is treated as continuing while the Employee is on military leave, sick leave, or other bona
fide leave of absence (if the period of such leave does not exceed six (6) months; or, if longer, so long as the Employee&rsquo;s right
to reemployment with the Company or an affiliate is provided either by statute or contract). If the Employee&rsquo;s period of leave
exceeds six (6) months and his right to reemployment is not provided either by statute or by contract, the employment relationship is
deemed to terminate on the first day immediately following the expiration of such six (6) month period. Whether a termination of employment
has occurred will be determined based on all of the facts and circumstances and in accordance with regulations issued by the United States
Treasury Department pursuant to Section 409A of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Delay
in Payments</U>. Notwithstanding ally provision of this Agreement to the contrary, if any of the severance payments are subject to Section
409A and the Employee is a &ldquo;<U>Specified Employee</U>&rdquo; at the time of his Separation from Service, no payments shall be made
to the Employee prior to the first business day following the date which is six (6) months after the Employee&rsquo;s Separation from
Service. Any amounts that would have been paid during the six (6) months following the Employee&rsquo;s Separation from Service will
be paid on the first business day following the expiration of the six (6) month period without interest thereon. The Employee may not
elect the taxable year of such payment. The six (6) month delay for a Specified Employee does not apply if the Employee dies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Specified
Employee Defined</U>. For purposes of this Agreement, the term &ldquo;<U>Specified Employee</U>&rdquo; means certain officers and highly-compensated
employees of the Company as defined in Treas. Reg. &sect; 1.409A-1(i), and as determined in accordance with such procedures as may be
adopted from time to time by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Miscellaneous
Payment Provisions</U>. If payment is not made, in whole or in part, due to a dispute between the Employee and the Company, the payments
shall be made in accordance with Treas. Reg. &sect; 1.409A-3(g), as applicable. It is intended that each installment of the payments
and benefits provided under Section 5 of this Agreement shall be treated as a separate &ldquo;payment&rdquo; for purposes of Section
409A. If an expense reimbursement or provision of in-kind benefit provided pursuant to this Agreement is not exempt from Section 409A
of the Code, the following rules apply: (A) in no event shall any reimbursement be paid after the last day of the taxable year following
the taxable year in which the expense was incurred; (B) the amount of reimbursable expenses incurred or provision of in-kind benefits
in one tax year shall not affect the expenses eligible for reimbursement or the provision of in-kind benefits in any other tax year;
and (C) the right to reimbursement for expenses or provision of in-kind benefits is not subject to liquidation or exchange for any other
benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Ban on Acceleration or Deferral</U>. Under no circumstances may the time or schedule of any payment made or benefit provided
pursuant to this Agreement be accelerated or subject to a further deferral, except as otherwise permitted or required pursuant to regulations
and other guidance issued pursuant to Section 409A of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>No Elections</U>. The Employee does not have any right to make any election regarding the time or form of any payment due under
this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Compliant
Operation and Interpretation</U>. This Agreement shall be operated in compliance with the requirements of Section 409A or an exception
thereto and each provision of this Agreement shall be interpreted, to the extent possible, to comply with Section 409A or to qualify
for an exception thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Dispute
Resolution; Venue</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
Company and the Employee shall use reasonable, good faith efforts to settle any dispute through non-binding mediation before a mutually-acceptable,
neutral, third-party mediator. The mediation shall be held in Salt Lake City, Utah and administered by the CPR Institute for Dispute
Resolution (the &ldquo;<U>CPR institute</U>&rdquo;) under the CPR Mediation Procedure then in effect. Unless otherwise agreed, the parties
shall jointly select a single mediator from the CPR Panels of Distinguished Neutrals based on a list of mediator candidates supplied
by the CPR Institute. If, within fourteen (14) days after either party makes a written request for mediation under this Section 9(m)(i),
the parties have not reached agreement on the selection of a mediator, the mediator shall be selected in accordance with the CPR Mediation
Procedure currently in effect. A good faith attempt at mediation shall be a condition precedent to the commencement of litigation, but
nothing in this Agreement, including, but not limited to paragraph (ii) below, shall be deemed a condition precedent to any court action
for injunction or other interim relief pending the outcome of mediation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>If
the parties are unable to resolve the dispute by mediation in a timely manner (which, in any case, shall not exceed sixty (60) days from
the first notice of mediation), either party may attempt to resolve the dispute by commencing an action (or defending or responding to
such action) exclusively in the jurisdiction and venue of the courts, whether federal or state, located in Salt Lake County, Utah.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">==========the remainder of this page is intentionally
left blank==========</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have executed this Agreement to be effective for all purposes as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">THE COMPANY:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 50%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 48%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">SERA PROGNOSTICS, INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Gregory C. Critchfield,
    M.D.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gregory C. Critchfield, M.D.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman, President and CEO</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>THE EMPLOYEE</U>:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Garrett Lam</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Garrett Lam</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exhibit A: Outside Activities</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">1.</TD><TD STYLE="text-align: justify">Member of Clinical Innovations Medical Advisory Board</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">2.</TD><TD STYLE="text-align: justify">Complete current open cases of medico-legal consultation</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">3.</TD><TD STYLE="text-align: justify">Consulting with Illumina on NIPS</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">4.</TD><TD STYLE="text-align: justify">Consulting with Hologic on gynecological opportunities</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">5.</TD><TD STYLE="text-align: justify">Consultant for Velo biologics study on treatment of early onset
preeclampsia</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0pt"></P>

<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>30
<FILENAME>tm2110724d11_ex10-15.htm
<DESCRIPTION>EXHIBIT 10.15
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0.25in; text-indent: 0in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.15</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B><IMG SRC="tm2110724d2_ex10-12img001.jpg" ALT=""></B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">June 19, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Garrett Lam</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1864 E. Mountain Crest Drive</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Draper, UT 84020</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Re:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Separation
Agreement</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Garrett:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The purpose of this letter
agreement (the &ldquo;Agreement&rdquo;) is to set forth the terms of your separation from Sera Prognostics, Inc. (the &ldquo;Company&rdquo;),
and the entirety of the understanding between you, Garrett Lam, on the one hand and the Company on the other, with respect thereto. This
Agreement supersedes the terms of the employment agreement dated as of June 13, 2018 (the &ldquo;Employment Agreement&rdquo;) in all respects
except as to the sections 2(b), 5, 6, 7, 8 and 9 of the Employment Agreement, to the extent that those sections do not conflict with the
express terms of this Agreement (in which case the terms of this Agreement shall prevail). Payment of the Severance Pay described below
is contingent on your agreement to and compliance with the terms of this Severance Agreement. Neither this offer to you nor the Company&rsquo;s
entering into this Severance Agreement shall constitute an admission by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><U>Separation of Employment.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Your employment with the Company will end on June 19, 2020 (the &ldquo;Separation Date&rdquo;). You acknowledge and agree you will continue
to devote your full time and attention and best efforts to performing the duties assigned to you (including the transition of your responsibilities
to the individual(s) identified by the Company) and you will comply with all existing Company rules, regulations, policies and directives
through the Separation Date. You further acknowledge and agree that, from and after the Separation Date, you shall have no authority to,
and shall not, represent yourself as an employee of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Following the Separation Date, the Company will communicate your separation from the Company to internal and external parties. That communication
shall consist of the following language: &ldquo;Garrett Lam has resigned from Sera Prognostics to pursue other activities.&rdquo; The
Company&rsquo;s response to inquiries regarding your separation will be consistent with Section 4(f) below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
your separation from the Company, you will continue as a corresponding author of the Markenson et al. 2020 TREETOP publication in the
<I>American Journal of Obstetrics &amp; Gynecology Maternal Fetal Medicine </I>(</FONT>https://doi.org/10.1016/j.ajogmf.2020.100140<FONT STYLE="font-size: 10pt">),
and coordinate responses to queries with all the authors (Company and non-Company) of such paper. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="tm2110724d2_ex10-12img003.jpg" ALT="" STYLE="height: 50px; width: 850px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="text-align: justify; margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: justify; margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="text-align: justify; break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: justify; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><IMG SRC="tm2110724d2_ex10-12img001.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><U>Severance Pay.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
exchange for the mutual promises set forth in this Agreement, the Company agrees to provide severance pay to you in a lump sum of one
hundred eighty-two thousand dollars ($182,000.00) less all applicable federal, state, local and other employment-related deductions (&ldquo;the
Payment&rdquo;). The Company also will provide you with a monthly payment equivalent to your COBRA payment beginning on July 1, 2020 to
cover the cost of the continuation of your health insurance coverage through the earlier of (1) June 30, 2021 or (2) the date when you
become eligible to receive health insurance coverage in connection with new employment or self-employment (the &ldquo;COBRA Payment&rdquo;).
You will receive a Form 1099 at each taxable year&rsquo;s end for the COBRA Payments received within that taxable year. The Payment and
the COBRA Payment, together, are referred to as the &ldquo;Severance Pay.&rdquo; The Payment and the then-due COBRA Payment(s) will be
provided to you within ten (10) days of the Effective Date, which date constitutes the eighth day following the Execution Date, (as that
term is defined below). The Severance Pay, including each successive COBRA Payment, will be made by check made payable to Garrett Lam,
by sending the Severance Pay and/or COBRA Payment(s) to you via overnight mail at 1864 E. Mountain Crest Drive, Draper, UT 84020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regardless of whether
you sign this Agreement, you will have the right to continue your medical insurance pursuant to the provisions of the Consolidated Omnibus
Budget Reconciliation Act of 1985 (COBRA). You will receive your COBRA notice under separate cover. If you do not sign this agreement
and do not elect COBRA, your health insurance (if applicable) will cease on June 30, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to the
Severance Pay, and regardless of whether you sign this Agreement, you will receive payment for your accrued wages through your Separation
Date and your unused but accrued vacation pay through your Separation Date, less all applicable federal, state, local deductions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You acknowledge
and agree that the Severance Pay is not otherwise due or owing to you under any Company employment agreement (oral or written) or Company
policy or practice, including the Employment Agreement, absent your execution of this Agreement. You also agree that the Severance Pay
to be provided to you is not intended to and does not constitute a severance plan and does not confer a benefit on anyone other than the
parties. You further acknowledge that, except for the specific financial consideration set forth in this Agreement, and your final wages,
which shall be paid to you in accordance with the Company&rsquo;s regular payroll practices and applicable law following the Separation
Date (whether or not you sign this Agreement), you are not now owed and shall not in the future be entitled to any other compensation
from the Company including, without limitation, other wages, commissions, bonuses, holiday pay, paid time off or any other form of compensation
or benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="tm2110724d2_ex10-12img003.jpg" ALT="" STYLE="height: 50px; width: 850px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="text-align: justify; margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: justify; margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="text-align: justify; break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: justify; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="tm2110724d2_ex10-12img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><U>Equity.</U></B> You
acknowledge and agree that the disposition of Company equity in which you had an interest prior to the Separation Date will be fully governed
by the terms of Section 2(b) of the Employment Agreement as they apply to terminations by the Company without Cause. You and the Company
further acknowledge and agree that, at the time of the Separation Date, you owned 0 shares of common stock and had options to acquire
an additional 490,000 shares of common stock, of which options to acquire 318,750 shares of common stock remain unvested and whose vesting
will partially accelerate pursuant to Section 2(b) of the Employment Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><U>Confidentiality.</U></B>
You expressly acknowledge and agree to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;that you promptly will return to the
Company all Company documents (and any copies thereof) and property (including, without limitation, all cell phones, pagers, storage devices,
and other Company equipment) upon request, and the Company, for its part, will make reasonable accommodations to return copies of any
personal data specifically requested by you and to return your personal belongings to you within two weeks of the Separation Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;that
you promptly will relinquish to the Company all of the usernames, passwords, and contacts used by you to access all Sera and/or third
party applications for your work with the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">c)
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;that your employment with the Company created a relationship of confidence and trust
between the Company and you with respect to any information: (a) applicable to the business of the Company; or (b) applicable to the
business of any vendor, broker, client or customer of the Company, which was made known to you by the Company or by any vendor,
broker, client or customer of the Company, or learned by you in such context during the period of your employment. All such
information has commercial value in the business in which the Company is engaged and is hereinafter called &ldquo;Proprietary
Information.&rdquo; By way of illustration, but not limitation, Proprietary Information includes any and all trade secret, and
proprietary information, techniques, know&#45;how, processes, software programs, software source documents, and formulae related to
the current, future and proposed products and services of the Company, and includes, without limitation, respective information
concerning research, actual and proposed products and services, development, financial information, procurement requirements,
purchasing manufacturing, customer lists, customer databases, customer policy information, business forecasts, sales and marketing
plans and information. &ldquo;Proprietary Information&rdquo; also includes proprietary or confidential information of any third
party who disclosed such information to the Company or to you in the course of the Company&rsquo;s business. You acknowledge and
agree that all Proprietary Information is the sole property of the Company, the Company&rsquo;s assigns, and the Company&rsquo;s
customers (as applicable), and the Company, the Company&rsquo;s assigns and the Company&rsquo;s customers (as applicable) are the
sole and exclusive owner of all copyrights, trade secrets and other rights in the Proprietary Information. You assign and agree to
assign to the Company all rights, title and interest, you may have or acquired (if any) in the Proprietary Information. At all
times, both during your employment by Company and after termination of such employment, you agree that you will keep in confidence
and trust all Proprietary Information, and that you will not use or disclose any Proprietary Information or anything directly
relating to the Proprietary Information without the written consent of the Company. You understand and agree that the terms of this
Section extend to and cover disclosures or uses made of Proprietary Information online, including but not limited to social media
sites, blog posts, and any other internet-based communication or posting forum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="tm2110724d2_ex10-12img003.jpg" ALT="" STYLE="height: 50px; width: 850px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="text-align: justify; margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: justify; margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="text-align: justify; break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: justify; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="tm2110724d2_ex10-12img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;that
all information relating in any way to the negotiation of this Agreement, including the terms and amount of financial consideration provided
for in this Agreement, shall be held confidential by you and shall not be publicized or disclosed to any person (other than an immediate
family member, legal counsel or financial advisor, provided that any such individual to whom disclosure is made agrees to be bound by
these confidentiality obligations), business entity or government agency (except as mandated by state or federal law), except that nothing
in this paragraph shall prohibit you from participating in an investigation with a state or federal agency if requested by the agency
to do so;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;that
you will not make any statements that are professionally or personally disparaging about, or adverse to, the interests of the Company
(including its former or current officers, directors, employees and consultants) including, but not limited to, any statements that disparage
any person, product, service, finances, financial condition, capability or any other aspect of the business of the Company, and that you
will not engage in any conduct which could reasonably be expected to harm professionally or personally the reputation of the Company (including
its former or current officers, directors, employees and consultants); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company agrees that it shall respond to third-party inquiries regarding your employment by providing only your period of employment and
positions held and shall only verify your title and dates of employment and advise the requesting party that the Company has a policy
of not providing any additional information regarding former employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><U>Your Release of
Claims. </U></B>You hereby agree and acknowledge that, by signing this Agreement and accepting the Severance Pay, and for other good
and valuable consideration, you are waiving your right to assert any and all forms of legal claims against the Company<SUP>1</SUP>
of any kind whatsoever, whether known or unknown, arising from the beginning of time through the date you execute this Agreement
(the &ldquo;Execution Date&rdquo;). You acknowledge that as of Execution Date, you have not filed any complaints, claims, charges,
actions, grievances or arbitrations against the Company or otherwise contacted any U.S. federal, state or local governmental agency
or commission that has applicable jurisdiction to regulate the Company (each a &ldquo;Government Agency&rdquo;) regarding the
Company, except to the extent you (i) have already informed the Company in writing prior to the Execution Date, or (ii) are
permitted by law to opt against such disclosure; and further, you are not aware of any unlawful conduct in relation to the business
of the Company, except to the extent you have already informed the Company in writing prior to the Execution Date. Except as set
forth below, your waiver and release herein is intended to bar any form of legal claim, complaint or any other form of action
(jointly referred to as &ldquo;Claims&rdquo;) against the Company seeking any form of relief including, without limitation,
equitable relief (whether declaratory, injunctive or otherwise), the recovery of any damages, or any other form of monetary recovery
whatsoever (including, without limitation, back pay, front pay, compensatory damages, emotional distress damages, punitive damages,
attorneys&rsquo; fees and any other costs) against the Company, for any alleged action, inaction or circumstance existing or arising
through the Execution Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: justify; width: 25%"><DIV STYLE="text-align: justify; font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>1</SUP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of this Agreement, the Company includes Sera Prognostics, Inc. and any of its divisions, affiliates (which means all persons
and entities directly or indirectly controlling, controlled by or under common control with the Company), parents, subsidiaries and all
other related entities, and its and their former and current directors, officers, employees, trustees, agents, successors and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="tm2110724d2_ex10-12img003.jpg" ALT="" STYLE="height: 50px; width: 850px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="text-align: justify; margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: justify; margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="text-align: justify; break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: justify; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="tm2110724d2_ex10-12img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Without limiting
the foregoing general waiver and release, you specifically waive and release the Company from any Claim arising from or related to your
prior employment relationship with the Company or the termination thereof, including, without limitation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Claims under
any state or federal discrimination, fair employment practices or other employment related statute, regulation or executive order including,
but not limited to, the Utah Antidiscrimination Act, (as it may have been amended) prohibiting discrimination or harassment based upon
any protected status including, without limitation, race, national origin, age, gender, marital status, disability, veteran status or
sexual orientation. Without limitation, specifically included in this paragraph are any Claims arising under the federal Age Discrimination
in Employment Act, the Civil Rights Acts of 1866 and 1871, Title VII of the Civil Rights Act of 1964, the Civil Rights Act of 1991, the
Americans With Disabilities Act, the Age Discrimination in Employment Act, and any similar Utah or local statute.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Claims under
any other state or federal employment related statute, regulation or executive order (as they may have been amended through the Execution
Date) relating to any other terms and conditions of employment, including but not limited to the Fair Labor Standards Act and any Utah
equivalent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Claims
under any state or federal common law theory including, without limitation, wrongful discharge, breach of express or implied contract,
promissory estoppel, unjust enrichment, breach of a covenant of good faith and fair dealing, violation of public policy, defamation, interference
with contractual relations, intentional or negligent infliction of emotional distress, invasion of privacy, misrepresentation, deceit,
fraud or negligence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any other
Claim arising under state or federal law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
the foregoing, this section does not release the Company from any obligation expressly set forth in this Agreement or from any other claims
that cannot be released by law. You acknowledge and agree that, but for providing this waiver and release, you would not be receiving
the economic benefits being provided to you under the terms of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="tm2110724d2_ex10-12img003.jpg" ALT="" STYLE="height: 50px; width: 850px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="text-align: justify; margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: justify; margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="text-align: justify; break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: justify; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="tm2110724d2_ex10-12img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;It
is the Company&rsquo;s desire and intent to make certain that you fully understand the provisions and effects of this Agreement. To that
end, you have been encouraged and given the opportunity to consult with legal counsel for the purpose of reviewing the terms of this
Agreement. Also, because you are over the age of 40 consistent with the provisions of the Age Discrimination in Employment Act (&ldquo;ADEA&rdquo;),
which prohibits discrimination on the basis of age, the Company is providing you with twenty one (21) days in which to consider and accept
the terms of this Agreement by signing below and returning it to Gregory Critchfield at the addresses and/or email provided herein for
Gregory Critchfield at the Company:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Gregory Critchfield</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Chairman, President, and CEO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sera Prognostics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2749 East Parleys Way, Suite
200</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Salt Lake City, UT 84109</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">gcritchfield@seraprognostics.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>You may rescind your assent
to this Agreement if, within seven (7) days after you sign this Agreement, you deliver by hand or send by mail (certified, return receipt
and postmarked within such 7 day period) a notice of rescission to Gregory Critchfield at the Company. The eighth day following the Execution
Date is the &ldquo;Effective Date&rdquo; of this Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consistent with
the provisions of federal and state discrimination laws, nothing in this release shall be deemed to prohibit you from challenging the
validity of this release under such discrimination laws (the &ldquo;Discrimination Laws&rdquo;) or from filing a charge or complaint of
age or other employment related discrimination with the Equal Employment Opportunity Commission (&ldquo;EEOC&rdquo;) or state equivalent,
or from participating in any investigation or proceeding conducted by the EEOC or state equivalent. Further, nothing in this release or
Agreement shall be deemed to limit the Company&rsquo;s right to seek immediate dismissal of such charge or complaint on the basis that
your signing of this Agreement constitutes a full release of any individual rights under the Discrimination Laws, or to seek restitution
to the extent permitted by law of the economic benefits provided to you under this Agreement in the event that you successfully challenge
the validity of this release and prevail in any claim under the Discrimination Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><U>Entire Agreement/Modification/Waiver/Choice
of Law/Enforceability.</U></B> You acknowledge and agree that this Agreement supersedes any and all prior or contemporaneous oral and/or
written agreements between you and the Company, and sets forth the entire agreement between you and the Company, with the exception of
the sections 2(b), 5, 6, 7, 8, and 9 of the Employment Agreement shall remain in full force and effect, including the Non-Competition
and Non-Solicitation provisions of Section 6. No variations or modifications hereof shall be deemed valid unless reduced to writing and
signed by the parties hereto. The failure of the Company to seek enforcement of any provision of this Agreement in any instance or for
any period of time shall not be construed as a waiver of such provision or of the Company&rsquo;s right to seek enforcement of such provision
in the future. This Agreement shall be deemed to have been made in the State of Utah and shall be construed in accordance with the laws
of the State of Utah without giving effect to conflict of law principles. The venue for any dispute under or pertaining to this Agreement
shall be the State or Federal Courts located in Salt Lake County. The provisions of this Agreement are severable, and if for any reason
any part hereof shall be found to be unenforceable, the remaining provisions shall be enforced in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="tm2110724d2_ex10-12img003.jpg" ALT="" STYLE="height: 50px; width: 850px"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="text-align: justify; margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: justify; margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="text-align: justify; break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: justify; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="tm2110724d2_ex10-12img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><U>Cooperation.</U></B>
You agree that, with respect to any existing or future litigation or legal dispute (&ldquo;Dispute&rdquo;) involving the Company and a
third party with who you had any connection whatsoever during the time of your employment with the Company, including but not limited
to any Company employee or ex-employee asserting any employment-related claims, you will reasonably cooperate with the Company in the
defense or prosecution of that Dispute. Reasonable cooperation shall include, without limitation, providing testimony, providing assistance
to authorized Company representatives and outside counsel in preparation for trial, hearing, arbitration, mediation or any other proceeding.
You understand and agree that you may be required to travel as part of this duty of reasonable cooperation. The Company shall pay all
reasonable expenses associated with such travel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><U>No Re-hire.</U></B>
You agree you shall not be eligible for future employment or knowingly seek employment with the Company or any of its respective parents,
subsidiaries, or any entity in which any such entities hold a controlling ownership interest, either as an employee, consultant, independent
contractor, or worker of any kind paid directly by any such entity. You further agree, that upon learning that you applied for any employment
with same, you shall immediately withdraw your application. Further, you agree this forbearance to seek future employment is purely contractual
and is in no way involuntary, discriminatory, or retaliatory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><U>Tax Liabilities.</U></B>
You specifically acknowledge and agree that you are solely responsible for the tax designations of the Severance Pay. Each of the Parties
further agrees that any and all your tax liabilities that may arise out of payment of the Severance Pay will be borne exclusively and
solely by you. You further agree that, if any court, taxing authority or government entity (local, state, or federal) finds that the Severance
Pay should be subject to any further applicable taxes and related withholdings, you will be solely responsible for those applicable taxes,
withholdings, and any related interest, penalties or damages, unless such a finding is based on errors of the Company. You further agree
to indemnify the Company or its affiliates or subsidiaries for any tax liabilities, interest, penalties, or other damages or liabilities
that the Company or its affiliates or subsidiaries may be subjected to as a result of any court, taxing authority, or government entity
(local, state, or federal) finding that the Severance Pay should be subject to any further taxes and related withholdings, unless such
a finding is based on errors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>By executing this Agreement,
you are acknowledging that: (1) you have carefully read and understand the terms and effects of this Agreement, including Section 5 entitled
Release of Claims; (2) you understand that the Release of Claims in Section 5 is legally binding and by signing this Agreement, you give
up certain rights, including rights and claims under the Age Discrimination in Employment Act; (3) you have been afforded sufficient time
to understand the terms and effects of this Agreement; (4) your agreements and obligations hereunder are made voluntarily, knowingly and
without duress; and (5) neither the Company nor its agents or representatives have made any representations inconsistent with the provisions
of this Agreement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The parties agree that the
Agreement may be signed on one or more copies, each of which when signed will be deemed to be an original, and all of which together will
constitute one and the same Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="tm2110724d2_ex10-12img003.jpg" ALT="" STYLE="height: 50px; width: 850px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="text-align: justify; margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: justify; margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="text-align: justify; break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: justify; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="tm2110724d2_ex10-12img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the foregoing correctly
sets forth our understanding, please <U>sign</U>, <U>date</U> and return the enclosed copy of this Agreement to me within 21 days.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sera Prognostics, Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 3%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 47%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 48%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp; </FONT></TD>
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Gregory Critchfield</FONT></TD></TR>


<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 3%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 47%">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-left: 0.375in; width: 4%"></TD>
    <TD STYLE="text-align: justify; padding-left: 0in; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gregory Critchfield</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Its: </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman, President, and CEO</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 19, 2020</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Confirmed, Agreed and Acknowledged</B>:</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Garrett Lam</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Garrett Lam</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid">July 8, 2020&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2110724d2_ex10-12img003.jpg" ALT="" STYLE="height: 50px; width: 850px">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #7F7F7F"></P>

<!-- Field: Page; Sequence: 8; Options: Last -->
    <DIV STYLE="text-align: justify; margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: justify; margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #7F7F7F"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>31
<FILENAME>tm2110724d11_ex10-16.htm
<DESCRIPTION>EXHIBIT 10.16
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>FINAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SERA PROGNOSTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EMPLOYMENT AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Employment Agreement (this &ldquo;<U>Agreement</U>&rdquo;)
is effective for all purposes as of April 13, 2021 (the &ldquo;<U>Effective Date</U>&rdquo;), by and between Sera Prognostics, Inc., a
Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), and Benjamin Jackson (the &ldquo;<U>Employee</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NOW, THEREFORE, in consideration of the mutual
covenants, conditions and undertakings set forth herein, the parties hereto hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Employment
and Duties</U>. Subject to the terms and conditions set forth in this Agreement, the Company shall employ Employee, and Employee hereby
accepts employment, as the General Counsel of the Company, with those duties and responsibilities which are appropriate and customary
for a general counsel of a company similar to the Company. In such capacity, the Employee shall report to the Company&rsquo;s Chief Executive
Officer. During the term of this Agreement, the Employee shall faithfully perform the Employee&rsquo;s duties, responsibilities and obligations
hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Base
Compensation and Related Matters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Salary</U>.
In consideration for the services rendered by the Employee to the Company as provided herein, the Company shall pay the Employee an annual
base salary of $310,000 per year (the &ldquo;Base Salary&rdquo;), provided that the Employee&rsquo;s employment with the Company remains
active at a full-time rate. The Base Salary shall be paid according to the Company&rsquo;s standard payroll policy and will be subject
to applicable federal and state tax withholdings as required by applicable law. The Base Salary may be increased or decreased at any time
by the Company&rsquo;s Board of Directors (the &ldquo;Board&rdquo;) or the Compensation Committee of the Board in its sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Stock
Option Grant(s) and Bonuses</U>. Subject to Board of Directors approval, the Employee shall be granted as soon as practicable on or after
the Effective Date an option to purchase 404,000 shares of the Company&rsquo;s common stock (the &ldquo;Option&rdquo;) (which option shall
be issued as an incentive stock option to the maximum extent allowed under Section 422 of the Internal Revenue Code of 1986, as amended,
and the regulations promulgated thereunder (the &ldquo;Code&rdquo;)) pursuant to the Company&rsquo;s 2011 Employee, Director and Consultant
Equity Incentive Plan (the &ldquo;Plan&rdquo;). The Option shall vest as to twenty-five percent (25%) of the shares subject thereto one
(1) year from the Effective Date (&ldquo;Vesting Start Date&rdquo;), and shall vest with respect to the remaining shares subject thereto
in equal monthly installments over an additional thirty-six (36) months thereafter commencing on the first day of the month following
the Vesting Start Date, subject to continued employment by the Company. In addition, the Option shall accelerate with respect to thirty-seven
and one-half percent (37.5%) of the outstanding unvested shares at that time then subject thereto upon a Change of Control (as defined
in the Plan) pursuant to which the Option is terminated pursuant to Section 24(b)(ii) of the Plan or cashed out pursuant to Section 24(b)(iii)
of the Plan. The Employee shall be eligible, after the Effective Date, to receive (i) additional stock options pursuant to the Plan, and
(ii) additional bonus compensation, as determined by the Board, in its sole discretion; it being the intention of the Board to maintain
Employee&rsquo;s aggregate compensation at levels appropriate and customary to those of companies similar in industry, stage and circumstances
to that of the Company. Unless otherwise approved by the Board, all future options granted to the Employee after the Effective Date shall
vest in equal monthly installments over a period of forty-eight (48) months from the date of grant. Notwithstanding the foregoing, in
the event that the Employee&rsquo;s employment with the Company is terminated by the Company without Cause (as defined in Section 5(a)(iii)
below) or by the Employee for Good Reason (as defined in Section 5(b)(ii) below), then the vesting of all options held by the Employee
at the time of the termination shall accelerate (i) with respect to thirty-seven and one-half percent (37.5%) of the unvested shares subject
thereto, or (ii) if such termination occurs within 30 days prior to or within 12 months after a Change of Control (as defined in the Plan),
with respect to one hundred percent (100%) of the unvested shares subject thereto. You will be eligible to participate in the Company&rsquo;s
Annual Incentive Plan, which currently provides for a bonus target of 30% of your base salary, prorated for time of service, and with
respect to the calendar year ending December 31, 2021, payment will be contingent based on achievements mutually agreed by you and your
supervisor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Expenses</U>.
The Employee will be entitled to receive prompt reimbursement for all reasonable expenses incurred by the Employee (which are eligible
for reimbursement under the Code) actually incurred by him in performing his duties; provided; however, that such expenses are approved
in accordance with the Company&rsquo;s then-current policies and procedures applicable to the most senior-level executive employees of
the Company, other than the Employee, or if such policies and procedures are not in place, then as determined in the sole discretion of
the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Employee
Benefits</U>. Upon beginning his employment with the Company, the Employee will be entitled to participate in the group health, dental,
vision, and group life insurance benefit plans, as well as the Company&rsquo;s 401(k) and Flexible Spending Account Plans available to
all Company employees. In addition, the Employee is entitled to participate in any employee benefit plans that the Company may make available
to its most senior-level executive employees generally, which may include but not be limited to, profit sharing plans, 401(k) and cafeteria
plans, or life, hospitalization, optical, disability, or other insurance plans as may be in effect, from time to time, and in accordance
with rules established, from time to time, for individual participation in such plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Paid
Time Off</U>. Upon beginning his employment with the Company, the Employee will be entitled to take five (5) weeks of paid time off per
calendar year and shall be entitled to compensation in connection therewith, in accordance with Company policy applicable to senior-level
executive employees of the Company, as approved by the Chief Executive Officer in its sole discretion. Paid time off accrues on a semi-monthly
basis starting on date of hire. A maximum of 120 hours are allowed to roll over to the next calendar year. The Company will pay out all
unused, accrued paid time off upon the Employee&rsquo;s separation from the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Facilities
and Services Furnished</U>. The Company will furnish the Employee with office space at its headquarters in Salt Lake City, Utah, and such
other facilities, furniture, equipment and services as it may determine to be reasonably necessary for the performance of the Employee&rsquo;s
duties as set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination
by the Company</U>. The Employee&rsquo;s employment hereunder may be terminated by the Company under any of the following circumstances:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Death</U>.
This Agreement shall automatically terminate upon the Employee&rsquo;s death.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Disability</U>.
The Company may elect to terminate the Employee&rsquo;s employment in the event of Employee&rsquo;s Disability upon delivery of written
notice to the Employee. For purposes of this Agreement, &ldquo;Disability&rdquo; shall mean any condition that, in the reasonable, good
faith judgment of a licensed physician selected by the Company, causes the Employee to be unable, after any accommodation required by
applicable law, to perform his duties, responsibilities and obligations under this Agreement for a period of at least twelve (12) months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Cause</U>.
The Company may terminate the Employee&rsquo;s employment hereunder for Cause (as defined below) at any time upon delivery of written
notice to the Employee. For purposes of this Agreement, &ldquo;Cause&rdquo; shall mean (A) the conviction of the Employee by a court of
competent jurisdiction of any felony involving dishonesty, breach of trust or misappropriation or the entering of a plea by the Employee
of <I>nolo contendre</I> thereto; (B) the Employee&rsquo;s willful failure or refusal to follow reasonable and lawful directives of the
Board or the Company&rsquo;s Chief Executive Officer, provided such failure or refusal continues after the Employee&rsquo;s receipt of
reasonable notice in writing of such failure or refusal and an opportunity of not less than thirty (30) days to correct the problem; (C)
a material breach by the Employee of any of the provisions of this Agreement, with notification of such breach by the process outlined
Section 5(a)(iii)(B) above; or (D) the Employee&rsquo;s commission of any immoral or illegal act or any gross or willful misconduct, where
a majority of the non-employee members of the Board reasonably determines that such act or misconduct has (1) seriously undermined the
ability of the Board to entrust Employee with important matters or otherwise work effectively with Employee, (2) contributed to the Company&rsquo;s
loss of significant revenues or business opportunities, or (3) significantly and detrimentally affected the business or reputation of
the Company or any of its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Other
Termination</U>. The Company may terminate Employee&rsquo;s employment with the Company at any time and for any reason, with or without
cause, subject to the provisions hereof. Employee acknowledges that Employee is, and at all times shall be, an employee at will of the
Company and nothing contained herein shall be construed to alter or affect such employee at-will status. Employee may terminate his employment
with the Company at any time, for any or no reason, subject to the provisions hereof. Inclusion under any benefit plan or compensation
arrangement will not give Employee any right or claim to any benefit hereunder except to the extent such right has become fixed under
the express terms of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination
by the Employee</U>. The Employee may terminate the Employee&rsquo;s employment with the Company under the following circumstances:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Voluntary
Termination</U>. Employee may terminate his employment with the Company for any reason or no reason, upon delivery of written notice to
the Company at least fifteen (15) days prior to the specified termination date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination
for Good Reason</U>. The Employee also may terminate the Employee&rsquo;s employment with the Company for &ldquo;Good Reason,&rdquo; which
shall mean for purposes of this Agreement (A) a material breach by the Company of any of the provisions of this Agreement; (B) assignment
of Employee to a role, duties or responsibilities materially inconsistent with that of senior executive management; (C) any circumstances
caused by the Company that would require Employee to move his principal location of employment in excess of one hundred (100) miles from
the Company&rsquo;s principal business location in Salt Lake City, Utah; or (D) an involuntary material reduction of Employee&rsquo;s
then current Base Salary other than a reduction proportionately affecting all of the Company&rsquo;s other senior-level executive employees.
The Employee must provide the Company with a written Notice of Termination that describes the existence of the condition the Employee
believes gives rise to Good Reason under this Section 5(b)(ii) within thirty (30) days following the initial existence of the condition.
The Company may elect to cure any condition giving rise to Good Reason within thirty (30) days of receipt of notice. The Employee&rsquo;s
termination for Good Reason must, in any event, occur within the six (6) month period immediately following the initial existence of the
condition giving rise to Good Reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Effect
of Termination</U>. In the event the Employee&rsquo;s employment is terminated, all obligations of the Company and the Employee under
this Agreement shall cease, except that the accelerated vesting of Options set forth in Section 2(b) and the terms of Section 6 through
Section 9 shall survive such termination. Upon such termination, the Employee or the Employee&rsquo;s representative or estate shall be
entitled to receive the applicable compensation, benefits and reimbursements set forth in Section 5. The Employee acknowledges that, upon
termination of the Employee&rsquo;s employment, the Employee is entitled to no other compensation, severance or other benefits other than
those specifically set forth in Section 5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compensation
and Benefits Upon Termination of Employment</U>. At all times after the Effective Date, the Employee shall be entitled to receive additional
compensation and benefits upon a termination of Employee&rsquo;s employment as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Severance
Pay</U>. If either (i) the Company terminates the Employee&rsquo;s employment for any reason other than Cause, death or Disability or
(ii) the Employee terminates his employment for Good Reason; then, on the sixtieth (60<SUP>th</SUP>) day following the termination of
employment, the Company shall pay the Employee a lump sum amount equal to six (6) months of the Base Salary at the rate in effect at the
time of the termination of employment. If the Company terminates the Employee&rsquo;s employment due to death or Disability and (y) the
Company does not provide any disability or life, as applicable, insurance benefits payable to the Employee or his beneficiaries, as applicable,
upon his death or Disability and (z) the Company has previously, but not necessarily in the then applicable calendar year, achieved Ten
Million Dollars in annual gross revenue in a calendar year, then, on the sixtieth (60<SUP>th</SUP>) day following the termination of employment
due to death or Disability, the Company shall pay the Employee a lump sum amount equal to six (6) months of the Base Salary at the rate
in effect at the time of the termination of employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Health
Insurance</U>. If, while participating in the Company&rsquo;s group health insurance plan(s), either (i) the Company terminates the Employee&rsquo;s
employment for any reason other than Cause, death or Disability or (ii) the Employee terminates his employment for Good Reason, and if
the Employee elects to continue his health insurance coverage under the Consolidated Omnibus Budget Reconciliation Act (&ldquo;COBRA&rdquo;)
following the termination of his employment, then the Company shall pay the portion of the Employee&rsquo;s monthly premium under COBRA
until the earliest of (x) the close of the twelve (12) month period following the Employee&rsquo;s termination date, (y) the expiration
of the Employee&rsquo;s continuation coverage under COBRA or (z) the date when the Employee receives health insurance coverage in connection
with new employment. If the payment of any COBRA or health insurance premiums would otherwise violate the nondiscrimination rules or cause
the reimbursement of claims to be taxable under the Patient Protection and Affordable Care Act of 2010, together with the Health Care
and Education Reconciliation Act of 2010 (collectively, the &ldquo;Act&rdquo;) or Section 105(h) of the Code, the Company paid premiums
shall be treated as taxable payments and be subject to imputed income tax treatment to the extent necessary to eliminate any discriminatory
treatment or taxation under the Act or Section 105(h) of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>General
Release</U>. Any other provision of this Agreement notwithstanding, subsections (a) and (b) above shall not apply unless the Employee
has (i) executed a general release of all claims (in a form prescribed by the Company), which must be effective and irrevocable prior
to the sixtieth (60<SUP>th</SUP>) day following the termination of employment, (ii) returned all property of the Company in the Employee&rsquo;s
possession and (iii) cooperated in good faith with the Company for a transition period not to exceed sixty (60) days to ensure an efficient
transfer of the Employee&rsquo;s duties and responsibilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Non-Competition;
Non-Solicitation</U>. The Employee and the Company hereby acknowledge and agree that in connection with the employment of the Employee,
the Employee has been and will be provided with trade secrets of the Company and that the Employee and the Company are entering into this
Agreement for the protection of such trade secrets. The Employee agrees to abide by the provisions set forth in this Section 6.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Non-Competition</U>.
The Employee shall not, during his employment with the Company and during the one (1) year period following the termination of his employment
with the Company (the &ldquo;Restrictive Period&rdquo;) directly or indirectly, as a manager, member, promoter, shareholder, agent, representative,
director, officer, owner, independent contractor or otherwise, or in connection with any of his consultants, employees, agents, partners,
relatives, affiliates or representatives or through any third party:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;anywhere
in the world (the &ldquo;Restricted Area&rdquo;) compete with or own, manage, operate or control any business that directly competes in
the Company&rsquo;s field of interest or products in the active development pipeline of the Company (for purposes of this paragraph, ownership
of securities of not in excess of one percent (1%) of the outstanding capital stock of a public company shall not be considered to be
competition with the Company); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;anywhere
in the Restricted Area, act as an employee, director, officer, manager, member, advisor, consultant, representative or agent for any business
of the type and character engaged in and competitive with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Non-Solicitation</U>.
The Employee shall not, during the Restrictive Period directly or indirectly, as a manager, member, promoter, shareholder, agent, representative,
director, officer, owner, independent contractor or otherwise, or in connection with any of his consultants, employees, agents, partners,
relatives, affiliates or representatives or through any third party, solicit the employment of or hire any current employee of the Company,
or solicit a relationship with any customer of the Company, located anywhere in the Restricted Area.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Definitions</U>.
For purposes of this Section 6, the terms &ldquo;compete with the Company,&rdquo; &ldquo;competitive with the Company,&rdquo; &ldquo;field
of interest&rdquo; and similar terms referring to competition with the Company shall mean any business that is engaged in identifying
and commercializing biomarkers in blood samples of pregnant women which are predictive of preterm birth and other pregnancy complications
or any other anticipated business ventures of the Company which have been discussed with the Board or amongst the senior-level executive
employees as of the date of Employee&rsquo;s termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Maintaining
Confidential Information</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Company
Confidential Information</U>. The Employee hereby agrees at all times during which he provides services as a director, officer, employee
or consultant of the Company (&ldquo;Employee&rsquo;s Service&rdquo;), and thereafter to hold in strictest confidence, and not to use,
except for the benefit of the Company, any trade secrets, confidential knowledge, data or other proprietary information relating to products,
processes, know-how, formulas, developmental or experimental work, computer lists, customer lists, business plans, financial information
or other subject matter pertaining to any business of the Company or any of its clients, consultants or licensees (collectively &ldquo;Confidential
Information&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding the above, Employee shall not
have liability to the Company with regard to any Confidential Information which Employee can prove:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;was
in the public domain at the time it was disclosed by the Company or has entered the public domain through no fault of Employee;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;was
known to the Employee without restriction, at the time of disclosure, as demonstrated by files in existence at the time of disclosure;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;is
disclosed with the prior written approval of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;becomes
known to Employee, without restriction, from a source other than the Company without breach of this Agreement by Employee and otherwise
not in violation of the Company&rsquo;s rights; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;is
disclosed pursuant to the order or requirement of a court, administrative agency, or other governmental body; provided, however, that
Employee shall provide prompt notice of such court order or requirement to the Company to enable the Company to seek a protective order
or otherwise prevent such disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Former
Employer Information</U>. The Employee hereby agrees that he will not, during Employee&rsquo;s Service, improperly use or disclose any
proprietary information or trade secrets of his former or concurrent employers or companies, if any, and that he will not make available
to the Company any unpublished document or any property belonging to his former or concurrent employers or companies, if any, unless consented
to in writing by said employers or companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Third-Party
Information</U>. The Employee recognizes that the Company has received and in the future will receive from third parties their confidential
or proprietary information subject to a duty on the Company&rsquo;s part to maintain the confidentiality of such information and to use
it only for certain limited purposes. The Employee hereby agrees, during Employee&rsquo;s Service and thereafter, to hold all such confidential
or proprietary information in the strictest confidence and not to disclose it to any person, firm or corporation (except as necessary
in carrying out his work for the Company consistent with the Company&rsquo;s agreement with such third party) or to use it for the benefit
of anyone other than the Company or such third party (consistent with the Company&rsquo;s agreement with such third party) without the
express written authorization of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Outside
Activities</U>. During the Employee&rsquo;s employment with the Company, the Employee shall not perform consulting/business activities
beyond those disclosed in Exhibit A, without prior written consent of the Company&rsquo;s Board of Directors Compensation Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Availability
of Equitable Remedies</U>. The Employee hereby acknowledges and agrees that a breach of Section 6 or Section 7 will cause irreparable
harm and damage to the Company, that the remedy at law for the breach or threatened breach of Section 6 or Section 7 will be inadequate,
and that, in addition to all other remedies available to the Company for such breach or threatened breach (including, without limitation,
the right to recover damages), the Company will be entitled to injunctive relief for any breach or threatened breach of Section 6 or Section
7.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notification
of New Employer</U>. In the event that the Employee leaves the employ of the Company, he hereby grants consent to notification by the
Company to his new employer about his rights and obligations under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>.
In the event that a court of competent jurisdiction determines that any portion of this Agreement is in violation of any statute or public
policy, then only the portions of this Agreement which violate such statute or public policy shall be stricken. All portions of this Agreement
which do not violate any statute or public policy shall continue in full force and effect. Further, any court order striking any portion
of this Agreement shall modify the stricken terms to give as much effect as possible to the intentions of the parties under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>.
Any notices, requests or consents hereunder shall be deemed given, and any instrument delivered, three (3) days after they have been mailed
by first class mail, postage prepaid, one (1) day after they have been delivered by overnight courier, twelve (12) hours after such notice
has been sent by facsimile, or upon receipt if delivered personally, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>To the Company</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2749 Parleys Way, Suite 200</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Salt Lake City, UT 84109</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>To the Employee</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2863 East Oquirrh Drive</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Salt Lake City, UT 84108</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">except that any of the foregoing may, from time
to time, by written notice to the others, designate another address or fax number which shall thereupon become his or its effective address
for the purposes of this Section 9(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing
Law</U>. This Agreement shall be governed by the laws of the State of Utah, without giving effect to its conflict of laws principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors
and Assigns</U>. The rights and obligations of the Company under this Agreement shall inure to the benefit of and shall be binding upon
the successors and assigns of the Company. This Agreement is for the unique personal services of the Employee, and the Employee shall
not be entitled to assign any of the Employee&rsquo;s rights or obligations hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire
Agreement; Amendment</U>. This Agreement constitutes the entire agreement and understanding between the parties hereto with respect to
the subject matter of this Agreement, and supersedes all other prior agreements and understandings with respect thereto. This Agreement
can be amended or modified only in a writing signed by the Employee and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Waiver</U>. No waiver by either party at any time of any breach by the other party of, or compliance with, any condition or provision
of this Agreement to be performed by the other party shall be deemed a waiver of similar or dissimilar provisions or conditions at the
same time or any prior or subsequent time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Headings</U>.
The headings herein contained are for reference only and shall not affect the meaning or interpretation of any provision of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts</U>.
This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original but all of which together
will constitute one and the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Costs
and Expenses</U>. The Company shall reimburse all of the Employee&rsquo;s reasonable costs and expenses (including, without limitation,
attorneys&rsquo; fees), incurred in connection with the negotiation and preparation of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Attorneys&rsquo;
Fees</U>. In the event of any action at law, equity or under this Agreement to enforce or interpret the terms of this Agreement, the prevailing
party shall be entitled to reasonable attorneys&rsquo; fees and court costs in addition to any other relief to which such party may be
entitled, unless the action is one in which only a prevailing plaintiff is entitled to prevailing party fees and costs (such as a Title
VII action).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Section
409A</U>. The Company intends that the cash severance payments to which the Employee is entitled on his termination of employment pursuant
to Section 5 are payable on the Employee&rsquo;s Separation from Service (as defined below) and are exempt from, or are otherwise payable
in compliance with Section 409A. The Company intends that the Company&rsquo;s continued payment for the cost of the Employee&rsquo;s welfare
benefits (including the payment of all COBRA administrative costs and expenses) provided by Section 5 will comply with the exception to
Section 409A for reimbursements and certain other separation payments, as described in Treas. Reg. &sect; 1.409A-1(b)(9)(v)(B), to the
extent such costs are taxable and subject to imputed income treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Separation
from Service Defined</U>. For purposes of this Agreement, the term &ldquo;termination of employment&rdquo; means the Employee&rsquo;s
 &ldquo;Separation from Service.&rdquo; The term &ldquo;Separation from Service&rdquo; means (A) the termination of the Employee&rsquo;s
employment with the Company and all affiliates for any reason or (B) a permanent reduction in the level of bona fide services the Employee
provides to the Company and all affiliates to an amount that is twenty percent (20%) or less of the average level of bona fide services
the Employee provided to the Company and all affiliates in the immediately preceding thirty-six (36) months (or the entire time period
during which the Employee provided services to the Company and all affiliates if the Employee has been providing such services for less
than thirty-six (36) months), with the level of bona fide service calculated in accordance with Treas. Reg. &sect; 1.409A-1(h)(1)(ii).
Solely for purposes of determining whether an organization is an &ldquo;affiliate&rdquo; of the Company, the Company will follow the rules
set forth in Treas. Reg. &sect; 1.409A-1(h)(3) (which generally requires fifty percent (50%) common ownership or control). The Employee&rsquo;s
employment relationship is treated as continuing while the Employee is on military leave, sick leave, or other bona fide leave of absence
(if the period of such leave does not exceed six (6) months; or, if longer, so long as the Employee&rsquo;s right to reemployment with
the Company or an affiliate is provided either by statute or contract). If the Employee&rsquo;s period of leave exceeds six (6) months
and his right to re-employment is not provided either by statute or by contract, the employment relationship is deemed to terminate on
the first day immediately following the expiration of such six (6) month period. Whether a termination of employment has occurred will
be determined based on all of the facts and circumstances and in accordance with regulations issued by the United States Treasury Department
pursuant to Section 409A of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delay
in Payments</U>. Notwithstanding any provision of this Agreement to the contrary, if any of the severance payments are subject to Section
409A and the Employee is a &ldquo;Specified Employee&rdquo; at the time of his Separation from Service, no payments shall be made to the
Employee prior to the first business day following the date which is six (6) months after the Employee&rsquo;s Separation from Service.
Any amounts that would have been paid during the six (6) months following the Employee&rsquo;s Separation from Service will be paid on
the first business day following the expiration of the six (6) month period without interest thereon. The Employee may not elect the taxable
year of such payment. The six (6) month delay for a Specified Employee does not apply if the Employee dies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Specified
Employee Defined</U>. For purposes of this Agreement, the term &ldquo;Specified Employee&rdquo; means certain officers and highly-compensated
employees of the Company as defined in Treas. Reg. 1.409A-1(i), and as determined in accordance with such procedures as may be adopted
from time to time by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Miscellaneous
Payment Provisions</U>. If payment is not made, in whole or in part, due to a dispute between the Employee and the Company, the payments
shall be made in accordance with Treas. Reg. &sect; 1.409A-3(g), as applicable. It is intended that each installment of the payments and
benefits provided under Section 5 of this Agreement shall be treated as a separate &ldquo;payment&rdquo; for purposes of Section 409A.
If an expense reimbursement or provision of in-kind benefit provided pursuant to this Agreement is not exempt from Section 409A of the
Code, the following rules apply: (A) in no event shall any reimbursement be paid after the last day of the taxable year following the
taxable year in which the expense was incurred; (B) the amount of reimbursable expenses incurred or provision of in-kind benefits in one
tax year shall not affect the expenses eligible for reimbursement or the provision of in-kind benefits in any other tax year; and (C)
the right to reimbursement for expenses or provision of in-kind benefits is not subject to liquidation or exchange for any other benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Ban
on Acceleration or Deferral</U>. Under no circumstances may the time or schedule of any payment made or benefit provided pursuant to this
Agreement be accelerated or subject to a further deferral, except as otherwise permitted or required pursuant to regulations and other
guidance issued pursuant to Section 409A of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Elections</U>. The Employee does not have any right to make any election regarding the time or form of any payment due under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliant
Operation and Interpretation</U>. This Agreement shall be operated in compliance with the requirements of Section 409A or an exception
thereto and each provision of this Agreement shall be interpreted, to the extent possible, to comply with Section 409A or to qualify for
an exception thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Dispute
Resolution; Venue</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company and the Employee shall use reasonable, good faith efforts to settle any dispute through non-binding mediation before a mutually-acceptable,
neutral, third-party mediator. The mediation shall be held in Salt Lake City, Utah and administered by the CPR Institute for Dispute Resolution
(the &ldquo;CPR Institute&rdquo;) under the CPR Mediation Procedure then in effect. Unless otherwise agreed, the parties shall jointly
select a single mediator from the CPR Panels of Distinguished Neutrals based on a list of mediator candidates supplied by the CPR Institute.
If, within fourteen (14) days after either party makes a written request for mediation under this Section 9(m)(i), the parties have not
reached agreement on the selection of a mediator, the mediator shall be selected in accordance with the CPR Mediation Procedure currently
in effect. A good faith attempt at mediation shall be a condition precedent to the commencement of litigation, but nothing in this Agreement,
including, but not limited to paragraph (ii) below, shall be deemed a condition precedent to any court action for injunction or other
interim relief pending the outcome of mediation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the parties are unable to resolve the dispute by mediation in a timely manner (which, in any case, shall not exceed sixty (60) days from
the first notice of mediation), either party may attempt to resolve the dispute by commencing an action (or defending or responding to
such action) exclusively in the jurisdiction and venue of the courts, whether federal or state, located in Salt Lake County, Utah.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company shall, at all times, maintain Directors &amp; Officers insurance with a policy limit of least $5,000,000.00 that will cover Employee
in his capacity as an officer of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IN WITNESS WHEREOF, the parties hereto have executed
this Agreement to be effective for all purposes as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD COLSPAN="2" STYLE="text-align: justify"><U>THE COMPANY</U>:</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD COLSPAN="2" STYLE="text-align: justify">SERA PROGNOSTICS, INC.</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 3%">By:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 47%">/s/ Gregory C. Critchfield, M.D.</TD>
  <TD STYLE="text-align: justify; width: 50%">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD COLSPAN="2" STYLE="text-align: justify">Name: Gregory C. Critchfield, M.D.</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD COLSPAN="2" STYLE="text-align: justify">Title: &nbsp;&nbsp;Chairman, President, and CEO</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD COLSPAN="2" STYLE="text-align: justify"><U>THE EMPLOYEE</U>:</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: justify">/s/ Benjamin Jackson</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD COLSPAN="2" STYLE="text-align: justify">Name: Benjamin Jackson</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD COLSPAN="2" STYLE="text-align: justify">Title: &nbsp;&nbsp;General Counsel</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>EXHIBIT A</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">THE OUTSIDE INTERESTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2 5.4pt; border: Black 1pt solid; width: 20%; text-align: center"><B>TITLE</B></TD>
    <TD STYLE="padding: 2 5.4pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 25%; text-align: center"><B>COMPANY NAME</B></TD>
    <TD STYLE="padding: 2 5.4pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 23%; text-align: center"><B>HOURS PER <BR>
WEEK</B></TD>
    <TD STYLE="padding: 2 5.4pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 32%; text-align: center"><B>ACTIVITIES</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">Owner</TD>
    <TD STYLE="padding: 2 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid">TBD</TD>
    <TD STYLE="padding: 2 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&le;10</TD>
    <TD STYLE="padding: 2 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid">Writing, mostly fiction</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">Owner</TD>
    <TD STYLE="padding: 2 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid">The Ugly Dumpling</TD>
    <TD STYLE="padding: 2 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&le;10</TD>
    <TD STYLE="padding: 2 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid">Home-based food business</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 2 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 2 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 2 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 2 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 2 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 2 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 12; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in; text-indent: 0in; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>32
<FILENAME>tm2110724d11_ex10-17.htm
<DESCRIPTION>EXHIBIT 10.17
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

                           <P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: right; margin: 0pt"><B>Exhibit 10.17</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2110724d4_img01.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">July 8, 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">John Peltier</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4 West Ledge Road</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Clinton, MA 01510</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(801) 651-2964</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear John:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">It has been a great pleasure for us to speak with you and to learn
about your background and expertise. We are very pleased to offer you the position of <B>Vice President of Laboratory Operations</B> at
Sera Prognostics, Inc. (&ldquo;Sera&rdquo;). Sera is currently focused on executing the commercial launch of PreTRM&reg;, the Company's
preterm birth diagnostic test. We are very excited about having you join our team.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">So please take the next step and review the details of the verbal offer
that was extended to you:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Position Details:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4; width: 26%; padding-bottom: 4; padding-left: 5pt">Job Title:</TD>
    <TD STYLE="padding-top: 4; width: 74%; padding-bottom: 4; padding-left: 5pt">Vice President of Laboratory Operations</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4; padding-bottom: 4; padding-left: 5pt">Annual Salary:</TD>
    <TD STYLE="padding-top: 4; padding-bottom: 4; padding-left: 5pt"><B>$205,000</B>, semi-monthly paychecks to be paid on the 15th &amp; last day of each month</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4; padding-bottom: 4; padding-left: 5pt">Annual Incentive:</TD>
    <TD STYLE="padding-top: 4; padding-bottom: 4; padding-left: 5pt">Sera's Board of Directors has adopted an annual incentive plan (&ldquo;AIP&rdquo;) designed to reward the achievement of corporate objectives and individual performances. Under the AIP, you will be eligible to earn a <B>25% annual target cash incentive</B>, measured on a calendar year basis, to be prorated in 2016 based on time of service.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4; padding-bottom: 4; padding-left: 5pt">Status:</TD>
    <TD STYLE="padding-top: 4; padding-bottom: 4; padding-left: 5pt">Full-time, Exempt</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4; padding-bottom: 4; padding-left: 5pt">Anticipated Start Date:</TD>
    <TD STYLE="padding-top: 4; padding-bottom: 4; padding-left: 5pt">Anticipated Start Date: On or before September 1, 2016</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4; padding-bottom: 4; padding-left: 5pt">Reporting to:</TD>
    <TD STYLE="padding-top: 4; padding-bottom: 4; padding-left: 5pt">Greg Critchfield, CEO</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4; padding-bottom: 4; padding-left: 5pt"><B>Benefits:</B></TD>
    <TD STYLE="padding-top: 4; padding-bottom: 4; padding-left: 5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4; padding-bottom: 4; padding-left: 5pt">Insurance:</TD>
    <TD STYLE="padding-top: 4; padding-bottom: 4; padding-left: 5pt">Sera Prognostics offers major medical, dental, vision, long-term disability, term life insurance, 401(k), and a flexible spending account. You are eligible for these benefits on September 1, 2016. Benefits are effective upon your successful enrollment in the plans.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4; padding-bottom: 4; padding-left: 5pt">Paid Time Off:</TD>
    <TD STYLE="padding-top: 4; padding-bottom: 4; padding-left: 5pt">You are eligible for <B>4 weeks</B> paid time off per year (based on calendar year and prorated for the first year of employment) plus <B>3 personal days</B> per year; accruals begin with the first pay period following employment. In addition, you will receive paid time off for company recognized holidays.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2110724d4_img02.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2110724d4_img01.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4; width: 26%; padding-bottom: 4; padding-left: 5">Equity:</TD>
    <TD STYLE="padding-top: 4; width: 74%; padding-bottom: 4; padding-left: 5">You will be initially recommended to the Sera Board to be granted the option to purchase <B>175,000 shares</B> of common stock of Sera at an exercise price equal to the fair market value of the shares on the date the option is granted, subject to final approval by the Sera Board of Directors. These granted options shall have a four-year vesting schedule as follows: 25% of the shares shall vest on the one-year anniversary of your start date with Sera, and an additional 1/36th of the total shares subject to the option shall vest each month thereafter, in each case provided that you continue to be an employee, consultant or director of Sera through each applicable vesting date. The terms of this stock option grant will be governed in all respects by the terms of the Sera Prognostics 2011 Employee, Director and Consultant Equity Incentive Plan (the &ldquo;Plan&rdquo;) and the stock option agreement for the Plan, which will be provided to you after the effective date of the grant. Any future grant of stock options shall be governed by its respective Sera Prognostics Employee, Director and Consultant Equity Incentive Plan, which shall be provided to you after such a grant is awarded.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4; padding-bottom: 4; padding-left: 5">Housing:</TD>
    <TD STYLE="padding-top: 4; padding-bottom: 4; padding-left: 5">Sera will reimburse you for documented moving expenses, up to <B>$35,000</B>, involved in relocating to the Wasatch front metropolitan area. In addition, Sera will reimburse you up to <B>$6,000</B> for documented temporary housing costs incurred in the Salt Lake City area prior to your full-time relocation. Finally, Sera will also pay for <B>one</B> house-hunting trip for you and your spouse to include round-trip economy airfare and lodging.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Your employment with Sera is employment at-will. As a result, you are
free to resign at any time, with or without notice and with or without cause or reason. Similarly, Sera is free to terminate its employment
relationship with you at any time, with or without notice and with or without cause or reason. Sera's supervisors and managers have no
actual or apparent authority to change the at-will nature of your employment unless they are expressly given that authority by Sera's
CEO in writing. Any change to the at-will nature of your employment will not be valid unless it is expressed with specificity in a written
contract that is signed and dated both by you (or your authorized representative) and a properly authorized Sera representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Your offer of employment is subject to successful completion of
reference checks and a background investigation to be concluded prior to start of employment. Your employment is also contingent on
your acceptance of Sera's Confidentiality, Nondisclosure, and Inventions Assignment Agreement, which will be included with your new
hire paperwork, as well as your ability to show proof of your right to work in the United States. This proof must be provided on
your <B>first work day</B>. Please see the attached &ldquo;List of Acceptable Documents&rdquo; for acceptable 1-9 documents. We also
expect you to abide by Sera's policies and procedures as they may be adopted by Sera and in effect from time to time, and do not
contradict the terms and conditions set forth in this letter. John, we are impressed with your intellect, drive and experience. We
anticipate greatly the confirmation of your decision to accept this position and be a part of the exciting, ongoing developments at
Sera Prognostics as a member of our team. If you have any questions, please do not hesitate to talk to me.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2110724d4_img02.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2110724d4_img01.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In accepting employment with Sera, you agree to treat the details of
your compensation as sensitive and confidential information, which should be discussed within the company with only your supervisor or
Sera's human resources manager.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To confirm acceptance of this offer, please return a signed copy of
this letter to our attention by July 15, 2016 and confirming your start date as an employee on September 1, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 50%">Sincerely Yours,</TD>
    <TD STYLE="width: 50%">&nbsp;</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><I>/s/ Greg Critchfield</I></TD>
    <TD>&nbsp;</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify">Greg Critchfield</TD>
    <TD>&nbsp;</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify">Chief Executive Officer</TD>
    <TD>&nbsp;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I accept employment with Sera Prognostics on the foregoing terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="border-bottom: Black 1pt solid; width: 49%"><I>/s/ John Peltier</I></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; width: 49%">July/11/2016</TD></TR>
<TR STYLE="vertical-align: top">
<TD>John Peltier</TD>
    <TD>&nbsp;</TD>
<TD>Date</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[Acceptance page to offer letter dated July 8, 2016]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2110724d4_img02.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0pt"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.18
<SEQUENCE>33
<FILENAME>tm2110724d11_ex10-18.htm
<DESCRIPTION>EXHIBIT 10.18
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.18</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="tm2110724d8_ex10-18img001.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">June 17, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Thomas Garite, MD</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">653 Round Tree Drive</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Grand Junction, CO 81506</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Tom,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">We have greatly appreciated the consulting services that you have provided
to Sera Prognostics, Inc. (&ldquo;Sera&rdquo;) as an independent contractor under the Consulting Agreement between us dated December 1,
2018. As we have discussed with you, we are terminating that Agreement effective June 22, 2020 and are pleased to offer you employment
at Sera in the position of <B>Vice President, Clinical Sciences</B>, to start on <B>June 22, 2020</B>. We are very excited about having
you join our team in an employee capacity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">So please take the next step and review the details of this offer:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Position Details</B>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 1.38in">Job Title:</TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt"><B>Vice President, Clinical Sciences</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in">Salary:</TD><TD><B>$9,600.00 per month</B>, paid semi-monthly on the 15th &amp; last day of each month</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 1.38in">Annual Incentive:</TD>
  <TD STYLE="text-align: justify">Sera&rsquo;s Board of Directors has adopted an annual incentive plan (&ldquo;AIP&rdquo;) designed to reward the achievement of corporate
objectives and individual performances. Under the AIP, you will be eligible to earn a <B>25% annual target cash incentive based on payments
made to you as a part-time employee, and</B> measured on a calendar year basis, to be prorated in 2020 based on time of service.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -1.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in">Status:</TD><TD>Part-time, Exempt; Assuming an average of 48 hours&rsquo; work per month Anticipated Start Date: June 22, 2020</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 1.38in">Reporting to:</TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt">Gregory Critchfield, Chairman, President &amp; CEO</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Benefits</B>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in">Health/PTO:</TD><TD STYLE="text-align: justify">Since this is a part-time position, defined as working less than 30 hours per week, you will not be eligible for health benefits or
paid time off.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2110724d8_ex10-18img006.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<IMG SRC="tm2110724d8_ex10-18img002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in">Equity:</TD><TD STYLE="text-align: justify">You will be initially recommended to the Sera Board to be granted the option to purchase <B>20,000 shares</B> of common stock of Sera
at an exercise price equal to the fair market value of the shares on the date the option is granted, subject to final approval by the
Sera Board of Directors. These granted options shall have a four-year vesting schedule as follows: 25% of the shares shall vest on the
one-year anniversary of your start date with Sera, and an additional 1/36th of the total shares subject to the option shall vest each
month thereafter, in each case provided that you continue to be an employee, consultant or director of Sera through each applicable vesting
date. The terms of this stock option grant will be governed in all respects by the 2749 East Parleys Way - Suite 200 | Salt Lake City,
Utah 84109 | Phone 801.990.0520 | Fax 801.990.0640 terms of the Sera Prognostics 2011 Employee, Director and Consultant Equity Incentive
Plan (the &ldquo;Plan&rdquo;) and the stock option agreement for the Plan, which will be provided to you after the effective date of the
grant. Any future grant of stock options shall be governed by its respective Sera Prognostics Employee, Director and Consultant Equity
Incentive Plan, which shall be provided to you after such a grant is awarded.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Your employment with Sera is employment at-will. As a result, you are
free to resign at any time, with or without notice and with or without cause or reason. Similarly, Sera is free to terminate its employment
relationship with you at any time, with or without notice and with or without cause or reason. Sera&rsquo;s supervisors and managers have
no actual or apparent authority to change the at-will nature of your employment unless they are expressly given that authority by Sera&rsquo;s
CEO in writing. Any change to the at-will nature of your employment will not be valid unless it is expressed with specificity in a written
contract that is signed and dated both by you (or your authorized representative) and a properly authorized Sera representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Your offer of employment is subject to successful completion of reference
checks and a background investigation to be concluded prior to start of employment. Your employment is also contingent on your acceptance
of Sera&rsquo;s Confidentiality, Nondisclosure, and Inventions Assignment Agreement, which will be included with your new hire paperwork,
as well as your ability to show proof of your right to work in the United States. This proof must be provided on your <B>first work day</B>
and consist of either a passport or driver&rsquo;s license and Social Security card. We also expect you to abide by Sera&rsquo;s policies
and procedures as they may be adopted by Sera and in effect from time to time, and do not contradict the terms and conditions set forth
in this letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tom, we are impressed with your intellect, drive and experience. We
anticipate greatly the confirmation of your decision to accept this position and be a part of the exciting, ongoing developments at Sera
Prognostics as a member of our team. If you have any questions, please do not hesitate to contact me.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In accepting employment with Sera, you agree to treat the details of
your compensation as sensitive and confidential information, not to be discussed with anyone else within the company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2110724d8_ex10-18img007.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2110724d8_ex10-18img003.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To confirm acceptance of this offer, please return a signed copy of
this letter to our attention by <B>June 22, 2020</B> and confirming your start date as an employee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sincerely Yours,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="border-bottom: Black 1pt solid; width: 50%">/s/ Gregory C. Critchfield, MS, MD</TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gregory C. Critchfield, MS, MD</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chairman, President &amp; CEO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2110724d8_ex10-18img008.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2110724d8_ex10-18img004.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I accept employment with Sera Prognostics on the foregoing terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt; width: 30%">/s/ Thomas Garite, MD</TD>
  <TD STYLE="text-align: center; border-bottom: Black 1pt solid; padding-left: 10pt; width: 20%">6/17/20</TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 50%">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt">Thomas Garite, MD</TD>
  <TD STYLE="text-align: center; padding-left: 10pt">Date</TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 15%">Anticipated Start Date:</TD>
  <TD STYLE="text-align: center; border-bottom: Black 1pt solid; padding-left: 10pt; width: 35%">6/22/20</TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 50%">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2110724d8_ex10-18img009.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2110724d8_ex10-18img005.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0">[Acceptance page to offer letter dated June 17, 2020]</P>

<P STYLE="margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<IMG SRC="tm2110724d8_ex10-18img009.jpg" ALT=""></P>

<P STYLE="margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.18(1)
<SEQUENCE>34
<FILENAME>tm2110724d11_ex10d18-1.htm
<DESCRIPTION>EXHIBIT 10.18.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 10.18.1</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="tm2110724d8_ex10d18-1image1.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">July 1, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thomas Garite, MD</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">653 Round Tree Drive</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Grand Junction, CO 81506</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Re: <B>Amendment to Offer of Employment for Thomas
Garite, MD dated June 17, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dear Tom:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This letter is an amendment (the &ldquo;Amendment&rdquo;)
to the aforementioned Offer of Employment from Sera Prognostics, Inc. dated June 17, 2020 (the &ldquo;Offer of Employment&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Effective July 1, 2020, your salary will be
$16,000.00 per month</B>, paid semi-monthly on the 15<SUP>th</SUP> &amp; last day of each month. This is based on an assumption of an
average monthly effort of 80 hours.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All other terms, conditions and provisions of
the Offer of Employment remain unchanged by this amendment and are in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Sincerely,</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Sera Prognostics, Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-size: 10pt">/s/ Gregory Critchfield</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gregory Critchfield</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Its:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chairman, President, and CEO</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">This Amendment is accepted and agreed
    to as of the date hereof:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ Thomas Garite, MD</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Thomas Garite, MD</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt">Dated:&nbsp; </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 46%"><FONT STYLE="font-size: 10pt">7/1/20</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="tm2110724d8_ex10d18-1image2.jpg" ALT="">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.18(2)
<SEQUENCE>35
<FILENAME>tm2110724d11_ex10d18-2.htm
<DESCRIPTION>EXHIBIT 10.18.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-size: 10pt"><B>Exhibit 10.18.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="tm2110724d8_ex10d18-2img002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">July 30, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thomas Garite, MD</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">653 Round Tree Drive</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Grand Junction, CO 81506</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Re: <B>2<SUP>nd</SUP> Amendment to Offer of Employment
for Thomas Garite, MD dated June 17, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dear Tom:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This letter is the 2<SUP>nd</SUP> amendment (the
 &ldquo;2<SUP>nd</SUP> Amendment&rdquo;) to the aforementioned Offer of Employment from Sera Prognostics, Inc. dated June 17, 2020 (the
 &ldquo;Offer of Employment&rdquo;), as amended on July 1, 2020 (the 1<SUP>st</SUP> Amendment) for the purpose of a change in salary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1.5in">Equity:</TD><TD STYLE="text-align: justify">You will be initially recommended to the Sera Board to be granted the option to purchase <B>50,000 shares</B>
of common stock of Sera at an exercise price equal to the fair market value of the shares on the date the option is granted, subject to
final approval by the Sera Board of Directors. These granted options shall have a four-year vesting schedule as follows: 25% of the shares
shall vest on the one-year anniversary of your start date with Sera, and an additional 1/36th of the total shares subject to the option
shall vest each month thereafter, in each case provided that you continue to be an employee, consultant or director of Sera through each
applicable vesting date. The terms of this stock option grant will be governed in all respects by the terms of the Sera Prognostics 2011
Employee, Director and Consultant Equity Incentive Plan (the &ldquo;Plan&rdquo;) and the stock option agreement for the Plan, which will
be provided to you after the effective date of the grant. Any future grant of stock options shall be governed by its respective Sera Prognostics
Employee, Director and Consultant Equity Incentive Plan, which shall be provided to you after such a grant is awarded.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All other terms, conditions and provisions of
the Offer of Employment as amended by the 1<SUP>st</SUP> Amendment remain unchanged by this 2<SUP>nd</SUP> amendment and are in full force
and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="tm2110724d8_ex10d18-2img003.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="tm2110724d8_ex10d18-2img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 50%">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 50%">Sincerely,</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 50%"></TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 50%">Sera Prognostics, Inc.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%"></TD><TD STYLE="width: 3%; text-align: left">By:<U></U></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 47%">/s/ Gregory
                                            Critchfield</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 53%; text-align: left"></TD><TD STYLE="text-align: justify; width: 47%">Gregory Critchfield</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%"></TD><TD STYLE="width: 3%; text-align: left">Its:</TD><TD STYLE="text-align: justify; width: 47%">Chairman, President, and CEO</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Amendment is accepted and agreed to as of
the date hereof:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 50%">/s/ Thomas Garite, MD</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 50%"></TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thomas Garite, MD</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 5%">Dated:</TD><TD STYLE="border-bottom: Black 1pt solid; width: 46%; text-align: left">July 30, 2020</TD><TD STYLE="text-align: justify; width: 50%"></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="tm2110724d8_ex10d18-2img003.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.18(3)
<SEQUENCE>36
<FILENAME>tm2110724d11_ex10d18-3.htm
<DESCRIPTION>EXHIBIT 10.18.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.18.3</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;<IMG SRC="tm2110724d8_ex10d18-3img001.jpg" ALT=""></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April 28, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Thomas Garite, MD</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">653 Round Tree Drive</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Grand Junction, CO 81506</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Re:&nbsp; <B>3<SUP>rd</SUP> Amendment to Offer of Employment for Thomas Garite,
MD dated June 17, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Tom:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This letter is the 3<SUP>rd</SUP> amendment (the
 &ldquo;3<SUP>rd</SUP> Amendment&rdquo;) to the aforementioned Offer of Employment from Sera Prognostics, Inc. dated June 17, 2020 (the
 &ldquo;Offer of Employment&rdquo;), as amended on July 1, 2020 (the 1<SUP>st</SUP> Amendment) for the purpose of a change in salary and
on July 30, 2021 (the 2<SUP>nd</SUP> Amendment) for the purpose of a change in the initial number of options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 1.38in">Effective date:</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><B>January 1, 2021</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -1.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 1.38in">Annual Salary:</TD>
  <TD STYLE="text-align: justify"><B>$267,000</B>, based on an assumption of an average monthly effort of 112 hours or .65 FIE, paid semi-monthly on the 15<SUP>th</SUP>
 &amp; last day of each month.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -1.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 1.38in">Annual Incentive:</TD>
  <TD STYLE="text-align: justify">Under the annual incentive plan (&ldquo;AIP&rdquo;) you will be eligible to earn a <B>35% annual target cash incentive</B>, measured
on a calendar year basis.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All other terms, conditions, and provisions of
the Offer of Employment as amended by the 1<SUP>st </SUP>and 2<SUP>nd</SUP> Amendments remain unchanged by this 3<SUP>rd</SUP> amendment
and are in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 50%">&nbsp;</TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt">Sincerely,</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 50%">&nbsp;</TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt">Sera Prognostics, Inc.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 50%">&nbsp;</TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 3%">By:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt">/s/ Gregory Critchfield</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 50%">&nbsp;</TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 6%">&nbsp;</TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt">Gregory Critchfield</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 50%">&nbsp;</TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt">Its:</TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt">Chairman, President, and CEO</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Amendment is accepted and agreed to as of the &lsquo;hate hereof:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt; width: 45%">/s/ Thomas Garite, MD</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 50%">Dated:</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">Thomas Garite, MD</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2110724d8_ex10d18-3img002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19
<SEQUENCE>37
<FILENAME>tm2110724d11_ex10-19.htm
<DESCRIPTION>EXHIBIT 10.19
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.19</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="tm2110724d8_ex10-19img001.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">March 30,2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nichole Martin</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">810 Silver Charm Drive</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Saline, MI 48175</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Nikki,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">It has been a great pleasure for all of us to speak with you and to
learn about your background and expertise. We are very pleased to offer you the position of <B>Vice President of Quality/Regulatory</B>
at Sera Prognostics, Inc. (&ldquo;Sera&rdquo;). Sera is currently focused on executing the commercial launch of PreTRM<SUP>&reg;</SUP>,
the Company&rsquo;s preterm birth diagnostic test, and we are very excited about having you join our team.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">So please take the next step and review the detail of the verbal offer
that was extended to you:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Position Details</B>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="text-align: justify; font-size: 10pt; width: 20%"><FONT STYLE="font-size: 10pt">Job Title:</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 80%"><FONT STYLE="font-size: 10pt">Vice President of Quality/Regulatory</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">Annual Salary:</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt"><B>$265,000,</B> <FONT STYLE="font-style: normal; font-weight: normal">paid
    semi-monthly on the 15th &amp; last day of each month</FONT></FONT></TD></TR>
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="text-align: left; font-size: 10pt; vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">Annual Incentive:</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Sera&rsquo;s Board of
    Directors has adopted an annual incentive plan (&ldquo;AIP&rdquo;) designed to reward the achievement of corporate objectives and
    individual performances. Under the AIP, you will be eligible to earn a <B>25% annual target cash incentive,</B> measured on a calendar
    year basis, to be prorated in 2020 based on time of service.</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">State:</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Full-time, Exempt</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">Anticipated Start Date:</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">On or before <B>May
    26, 2020</B></FONT></TD></TR>
  <TR STYLE="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">Reporting to:</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Gregory Critchfield, Chairman, President &amp;
    CEO</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Benefits:</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="text-align: left; font-size: 10pt; vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">Insurance:</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Sera Prognostics offers major medical, dental,
    vision, short and long-term disability, term life insurance, 401(k), and a flexible spending account. You are eligible for these
    benefits on the 1st day of the month following your hire date.</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="text-align: left; font-size: 10pt; vertical-align: top">
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 10pt">Paid Time Off:</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">You are eligible for <B>4
    weeks</B> paid time off per year (based on calendar year and prorated for the first year of employment); accruals begin with the
    first pay period following employment. In addition, you will receive paid time off for 13 company recognized holidays.</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-indent: -2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-indent: -2in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-indent: -2in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2110724d8_ex10-19img002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-indent: -2in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You will be initially recommended to the Sera Board to be granted the
option to purchase <B>250,222 shares</B> of common stock of Sera at an exercise price equal to the fair market value of the shares on
the date the option is granted, subject to final approval by the Sera Board of Directors. These granted options shall have a four-year
vesting schedule as follows: 25% of the shares shall vest on the one-year anniversary of you start date with Sera, and an additional 1/36<SUP>th</SUP>
of the total share subject to the option shall vest each month thereafter, in each case provided that you continue to be an employee,
consultant or director of Sera through each applicable vesting date. The terms of this stock option grant will be governed in all respects
by the terms of the Sera Prognostics 2011 Employee, Director and Consultant Equity Incentive Plan (the &ldquo;Plan&rdquo;) and the stock
option agreement for the Plan, which will be provided to you after the effective date of the grant. And future grant of stock options
shall be governed by its respective Sera Prognostics Employee, Director and Consultant Equity Incentive Plan, which shall be provided
to you after such a grant is awarded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sign-on Bonus: A one-time sign-on bonus of <B>$5,000</B> shall be given
to you upon your hiring at Sera.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Relocation: Sera will reimburse you for documented moving expenses,
up to $30,000, involved in relocating to the Wasatch front metropolitan area. Reimbursement of moving expenses must be forfeited if you
leave the company before the 12-month anniversary of your hire date, and forgiveness of this repayment obligation will accrue at a rate
of 1/12<SUP>th</SUP> of the total amount reimbursed per month after your hire date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Your employment with Sera is employment at-will. As a result, you are
free to resign at any time, with or without notice and with or without cause or reason. Similarly, Sera is free to terminate its employment
relationship with you at any time, with or without notice and with or without cause or reason. Sera's supervisors and managers have no
actual or apparent authority to change the at-will nature of your employment unless they are expressly given that authority by Sera's
CEO in writing. Any change to the at-will nature of your employment will not be valid unless it is expressed with specificity in a written
contract that is signed and dated both by you (or your authorized representative) and a properly authorized Sera representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Your offer of employment is subject to successful completion of reference
checks and a background investigation to be concluded prior to start of employment. Your employment is also contingent on your acceptance
of Sera's Confidentiality, Nondisclosure, and Inventions Assignment Agreement, which will be included with your new hire paperwork, as
well as your ability to show proof of your right to work in the United States. This proof must be provided on your <B>first work day</B>
and consist of either a passport or driver's license and Social Security card. We also expect you to abide by Sera's policies and procedures
as they may be adopted by Sera and in effect from time to time, and do not contradict the terms and conditions set forth in this letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2110724d8_ex10-19img003.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nikki, we are impressed with your intellect, drive and experience.
We anticipate greatly the confirmation of your decision to accept this position and be a part of the exciting, ongoing developments at
Sera Prognostics as a member of our team. If you have any questions, please do not hesitate to talk to me.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In accepting employment with Sera, you agree to treat the details of
your compensation as sensitive and confidential information, which should be discussed within the company with only your supervisor or
Sera's human resources manager.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To confirm acceptance of this offer, please return a signed copy of
this letter to our attention by <B>April 2, 2020</B> and confirming your start date as an employee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sincerely Yours,</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ Gregory C. Critchfield, MS, MD</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Gregory C. Critchfield, MS, MD</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Chairman, President &amp; Chief Executive Officer</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2110724d8_ex10-19img004.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I accept employment with Sera Prognostics on the foregoing terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%"><FONT STYLE="font-size: 10pt">Start date: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 43%"><FONT STYLE="font-size: 10pt">20 May 2020</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ Nichole Martin </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">30 March 2020</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%"><FONT STYLE="font-size: 10pt">Nichole Martin</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-size: 10pt">Date</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0">[Acceptance page to offer letter dated March 30,2020]</P>

<P STYLE="margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.20
<SEQUENCE>38
<FILENAME>tm2110724d11_ex10-20.htm
<DESCRIPTION>EXHIBIT 10.20
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 10.20</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">LEASE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">by and between</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EASTLAND REGENCY, L.C.,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>a Utah limited liability company,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">as Landlord</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SERA PROGNOSTICS, INC.,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>a Delaware corporation,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">as Tenant</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGENCY OFFICE BUILDING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2749 EAST PARLEYS WAY, SUITES 200, 210, 320,
330 &amp; 340</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SALT LAKE CITY, UTAH 84109</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGENCY OFFICE BUILDING - 2749 EAST PARLEYS
WAY<BR>
SALT LAKE CITY, UTAH</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>TABLE OF CONTENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0in">&nbsp;</TD>
    <TD STYLE="text-align: right"><B>Page</B></TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0in">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0in; width: 90%">ARTICLE I.&nbsp; BASIC LEASE PROVISIONS; ENUMERATION OF EXHIBITS</TD>
    <TD STYLE="text-align: right; width: 10%">5</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 1.01.&nbsp; BASIC LEASE PROVISIONS</TD>
    <TD STYLE="text-align: right">5</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 1.02.&nbsp; SIGNIFICANCE OF A BASIC LEASE PROVISION</TD>
    <TD STYLE="text-align: right">10</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 1.03.&nbsp; ENUMERATION OF EXHIBITS</TD>
    <TD STYLE="text-align: right">10</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0in">ARTICLE II.&nbsp; GRANT AND LEASED PREMISES</TD>
    <TD STYLE="text-align: right">10</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 2.01.&nbsp; LEASED PREMISES</TD>
    <TD STYLE="text-align: right">10</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 2.02.&nbsp; EXCUSE OF LANDLORD&rsquo;S PERFORMANCE</TD>
    <TD STYLE="text-align: right">11</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 2.03.&nbsp; REVISION OF SITE PLAN</TD>
    <TD STYLE="text-align: right">11</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0in">ARTICLE III.&nbsp; RENT</TD>
    <TD STYLE="text-align: right">11</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 3.01.&nbsp; BASE MONTHLY RENT</TD>
    <TD STYLE="text-align: right">11</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 3.02.&nbsp; ESCALATIONS IN BASE MONTHLY RENT</TD>
    <TD STYLE="text-align: right">11</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 3.03.&nbsp; TENANT&rsquo;S PRO-RATA SHARE OF OPERATING EXPENSES</TD>
    <TD STYLE="text-align: right">11</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 3.04.&nbsp; OPERATING EXPENSE AUDIT</TD>
    <TD STYLE="text-align: right">14</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 3.05.&nbsp; TAXES</TD>
    <TD STYLE="text-align: right">15</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 3.06.&nbsp; PAYMENTS</TD>
    <TD STYLE="text-align: right">15</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 3.07.&nbsp; ADDITIONAL RENT</TD>
    <TD STYLE="text-align: right">15</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0in">ARTICLE IV.&nbsp; RENTAL TERM, COMMENCEMENT DATE</TD>
    <TD STYLE="text-align: right">16</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 4.01.&nbsp; RENTAL TERM</TD>
    <TD STYLE="text-align: right">16</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 4.02.&nbsp; DEFINITION OF LEASE YEAR</TD>
    <TD STYLE="text-align: right">16</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 4.03.&nbsp; RENTAL TERM COMMENCEMENT DATE AND TERMINATION DATE</TD>
    <TD STYLE="text-align: right">16</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 4.04.&nbsp; Intentionally Omitted</TD>
    <TD STYLE="text-align: right">16</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 4.05.&nbsp; END OF RENTAL TERM</TD>
    <TD STYLE="text-align: right">16</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0in">ARTICLE V.&nbsp; CONSTRUCTION OF LEASED PREMISES</TD>
    <TD STYLE="text-align: right">16</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 5.01.&nbsp; CONSTRUCTION OF LEASED PREMISES BY LANDLORD</TD>
    <TD STYLE="text-align: right">16</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 5.02.&nbsp; DELIVERY OF POSSESSION FOR TENANT&rsquo;S WORK</TD>
    <TD STYLE="text-align: right">17</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 5.03.&nbsp; CHANGES AND ADDITIONS BY LANDLORD</TD>
    <TD STYLE="text-align: right">17</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0in">ARTICLE VI.&nbsp; TENANT&rsquo;S WORK</TD>
    <TD STYLE="text-align: right">17</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 6.01.&nbsp; REMODEL OF LEASED PREMISES BY TENANT</TD>
    <TD STYLE="text-align: right">17</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 6.02.&nbsp; SETTLEMENT OF DISPUTES</TD>
    <TD STYLE="text-align: right">18</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 6.03.&nbsp; PROJECT CLOSE-OUT</TD>
    <TD STYLE="text-align: right">18</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0in">ARTICLE VII.&nbsp; PERMITTED USE</TD>
    <TD STYLE="text-align: right">20</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 7.01.&nbsp; PERMITTED USE OF LEASED PREMISES</TD>
    <TD STYLE="text-align: right">20</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 7.02.&nbsp; HAZARDOUS SUBSTANCES</TD>
    <TD STYLE="text-align: right">20</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0in">ARTICLE VIII.&nbsp; OPERATION AND MAINTENANCE OF COMMON AREAS</TD>
    <TD STYLE="text-align: right">21</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 8.01.&nbsp; CONSTRUCTION AND CONTROL OF COMMON AREAS</TD>
    <TD STYLE="text-align: right">21</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">i</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in; width: 90%">SECTION 8.02.&nbsp; LICENSE</TD>
    <TD STYLE="text-align: right; width: 10%">22</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0in">ARTICLE IX.&nbsp; ALTERATIONS, SIGNS, LOCKS &amp; KEYS</TD>
    <TD STYLE="text-align: right">22</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 9.01.&nbsp; ALTERATIONS</TD>
    <TD STYLE="text-align: right">22</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 9.02.&nbsp; REMOVAL BY TENANT</TD>
    <TD STYLE="text-align: right">22</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 9.03.&nbsp; SIGNS</TD>
    <TD STYLE="text-align: right">23</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 9.04.&nbsp; REMOVAL OF TENANT SIGNS</TD>
    <TD STYLE="text-align: right">23</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 9.05.&nbsp; COMPUTERIZED ELECTRONIC SIGNS</TD>
    <TD STYLE="text-align: right">23</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 9.06.&nbsp; LOCKS AND KEYS</TD>
    <TD STYLE="text-align: right">23</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0in">ARTICLE X.&nbsp; MAINTENANCE AND REPAIRS; ALTERATIONS; ACCESS</TD>
    <TD STYLE="text-align: right">24</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 10.01.&nbsp; LANDLORD&rsquo;S OBLIGATION FOR MAINTENANCE</TD>
    <TD STYLE="text-align: right">24</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 10.02.&nbsp; TENANT&rsquo;S OBLIGATION FOR MAINTENANCE</TD>
    <TD STYLE="text-align: right">25</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 10.03.&nbsp; SURRENDER OF LEASED PREMISES AND RIGHTS UPON TERMINATION</TD>
    <TD STYLE="text-align: right">25</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0in">ARTICLE XI.&nbsp; INSURANCE AND INDEMNITY</TD>
    <TD STYLE="text-align: right">26</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 11.01.&nbsp; TENANT&rsquo;S LIABILITY INSURANCE AND INDEMNITY</TD>
    <TD STYLE="text-align: right">26</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 11.02.&nbsp; FIRE AND CASUALTY INSURANCE</TD>
    <TD STYLE="text-align: right">27</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 11.03.&nbsp; WAIVER OF SUBROGATION</TD>
    <TD STYLE="text-align: right">27</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 11.04.&nbsp; INDEMNIFICATION</TD>
    <TD STYLE="text-align: right">28</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0in">ARTICLE XII.&nbsp; UTILITY CHARGES</TD>
    <TD STYLE="text-align: right">28</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 12.01.&nbsp; OBLIGATION OF LANDLORD</TD>
    <TD STYLE="text-align: right">28</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 12.02.&nbsp; OBLIGATIONS OF TENANT</TD>
    <TD STYLE="text-align: right">29</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 12.03.&nbsp; Intentionally Omitted</TD>
    <TD STYLE="text-align: right">30</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 12.04.&nbsp; LIMITATIONS ON LANDLORD&rsquo;S LIABILITY</TD>
    <TD STYLE="text-align: right">30</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0in">ARTICLE XIII.&nbsp; ESTOPPEL AND OFF-SET STATEMENT, ATTORNMENT AND SUBORDINATION</TD>
    <TD STYLE="text-align: right">30</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 13.01.&nbsp; ESTOPPEL OR OFF-SET STATEMENT</TD>
    <TD STYLE="text-align: right">30</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 13.02.&nbsp; ATTORNMENT</TD>
    <TD STYLE="text-align: right">30</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 13.03.&nbsp; SUBORDINATION</TD>
    <TD STYLE="text-align: right">31</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 13.04.&nbsp; MORTGAGEE SUBORDINATION</TD>
    <TD STYLE="text-align: right">31</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0in">ARTICLE XIV.&nbsp; ASSIGNMENT</TD>
    <TD STYLE="text-align: right">31</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 14.01.&nbsp; ASSIGNMENT</TD>
    <TD STYLE="text-align: right">31</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 14.02.&nbsp; Intentionally Omitted</TD>
    <TD STYLE="text-align: right">31</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 14.03.&nbsp; CONDITIONS OF CONSENT</TD>
    <TD STYLE="text-align: right">31</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 14.04.&nbsp; STANDARDS OF REASONABLENESS IN WITHHOLDING CONSENT</TD>
    <TD STYLE="text-align: right">32</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 14.05.&nbsp; DOCUMENTATION OF ASSIGNMENT</TD>
    <TD STYLE="text-align: right">32</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 14.06.&nbsp; CONTINUING LIABILITY OF TENANT</TD>
    <TD STYLE="text-align: right">32</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 14.07.&nbsp; VOIDABLE ASSIGNMENT</TD>
    <TD STYLE="text-align: right">32</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0in">ARTICLE XV.&nbsp; WASTE OR NUISANCE</TD>
    <TD STYLE="text-align: right">33</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 15.01.&nbsp; WASTE OR NUISANCE</TD>
    <TD STYLE="text-align: right">33</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0in">ARTICLE XVI.&nbsp; NOTICES</TD>
    <TD STYLE="text-align: right">33</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 16.01.&nbsp; NOTICES</TD>
    <TD STYLE="text-align: right">33</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0in">ARTICLE XVII.&nbsp; DESTRUCTION OF THE LEASED PREMISES</TD>
    <TD STYLE="text-align: right">33</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">ii</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in; width: 90%">SECTION 17.01.&nbsp; DESTRUCTION</TD>
    <TD STYLE="text-align: right; width: 10%">33</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0in">ARTICLE XVIII.&nbsp; CONDEMNATION</TD>
    <TD STYLE="text-align: right">34</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 18.01.&nbsp; CONDEMNATION</TD>
    <TD STYLE="text-align: right">34</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0in">ARTICLE XIX.&nbsp; DEFAULT OF TENANT</TD>
    <TD STYLE="text-align: right">35</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 19.01.&nbsp; DEFAULT - RIGHT TO RE-ENTER</TD>
    <TD STYLE="text-align: right">35</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 19.02.&nbsp; DEFAULT - RIGHT TO RE-LET</TD>
    <TD STYLE="text-align: right">36</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 19.03.&nbsp; LEGAL EXPENSES</TD>
    <TD STYLE="text-align: right">36</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0in">ARTICLE XX.&nbsp; BANKRUPTCY, INSOLVENCY OR RECEIVERSHIP</TD>
    <TD STYLE="text-align: right">36</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 20.01.&nbsp; ACT OF INSOLVENCY, GUARDIANSHIP, ETC</TD>
    <TD STYLE="text-align: right">36</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 20.02.&nbsp; BANKRUPTCY</TD>
    <TD STYLE="text-align: right">37</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0in">ARTICLE XXI.&nbsp; LANDLORD ACCESS</TD>
    <TD STYLE="text-align: right">37</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 21.01.&nbsp; LANDLORD ACCESS</TD>
    <TD STYLE="text-align: right">37</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0in">ARTICLE XXII.&nbsp; TENANT&rsquo;S PROPERTY AND LANDLORD&rsquo;S LIEN</TD>
    <TD STYLE="text-align: right">38</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 22.01.&nbsp; TAXES ON LEASEHOLD</TD>
    <TD STYLE="text-align: right">38</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 22.02.&nbsp; Intentionally Omitted</TD>
    <TD STYLE="text-align: right">38</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 22.03.&nbsp; Intentionally Omitted</TD>
    <TD STYLE="text-align: right">38</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 22.04.&nbsp; LANDLORD&rsquo;S LIEN</TD>
    <TD STYLE="text-align: right">38</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 22.05.&nbsp; LANDLORD&rsquo;S SUBORDINATION</TD>
    <TD STYLE="text-align: right">38</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0in">ARTICLE XXIII.&nbsp; HOLDING OVER</TD>
    <TD STYLE="text-align: right">38</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 23.01.&nbsp; HOLDING OVER</TD>
    <TD STYLE="text-align: right">38</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 23.02.&nbsp; SUCCESSORS</TD>
    <TD STYLE="text-align: right">38</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0in">ARTICLE XXIV.&nbsp; RULES AND REGULATIONS</TD>
    <TD STYLE="text-align: right">39</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 24.01.&nbsp; RULES AND REGULATIONS</TD>
    <TD STYLE="text-align: right">39</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0in">ARTICLE XXV.&nbsp; QUIET ENJOYMENT</TD>
    <TD STYLE="text-align: right">39</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 25.01.&nbsp; QUIET ENJOYMENT</TD>
    <TD STYLE="text-align: right">39</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0in">ARTICLE XXVI.&nbsp; SECURITY DEPOSIT</TD>
    <TD STYLE="text-align: right">39</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 26.01.&nbsp; SECURITY DEPOSIT</TD>
    <TD STYLE="text-align: right">39</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 26.02.&nbsp; TRANSFER OF LANDLORD&rsquo;S INTEREST IN THE SECURITY DEPOSIT</TD>
    <TD STYLE="text-align: right">40</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0in">ARTICLE XXVII.&nbsp; MISCELLANEOUS</TD>
    <TD STYLE="text-align: right">40</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 27.01.&nbsp; WAIVER</TD>
    <TD STYLE="text-align: right">40</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 27.02.&nbsp; ENTIRE LEASE AGREEMENT</TD>
    <TD STYLE="text-align: right">40</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 27.03.&nbsp; INTERPRETATION, USE OF PRONOUNS</TD>
    <TD STYLE="text-align: right">40</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 27.04.&nbsp; FORCE MAJEURE</TD>
    <TD STYLE="text-align: right">41</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 27.05.&nbsp; LOSS AND DAMAGE</TD>
    <TD STYLE="text-align: right">41</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 27.06.&nbsp; CAPTIONS AND SECTION NUMBERS</TD>
    <TD STYLE="text-align: right">41</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 27.07.&nbsp; BROKER&rsquo;S COMMISSION</TD>
    <TD STYLE="text-align: right">41</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 27.08.&nbsp; RECORDING</TD>
    <TD STYLE="text-align: right">41</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 27.09.&nbsp; CONSENT NOT UNREASONABLY WITHHELD</TD>
    <TD STYLE="text-align: right">42</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 27.10.&nbsp; Intentionally Omitted</TD>
    <TD STYLE="text-align: right">42</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 27.11.&nbsp; TIME OF ESSENCE</TD>
    <TD STYLE="text-align: right">42</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 27.12.&nbsp; ACCORD AND SATISFACTION</TD>
    <TD STYLE="text-align: right">42</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">iii</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in; width: 90%">SECTION 27.13.&nbsp; NO OPTION</TD>
    <TD STYLE="text-align: right; width: 10%">42</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 27.14.&nbsp; ANTI-DISCRIMINATION</TD>
    <TD STYLE="text-align: right">42</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 27.15.&nbsp; SEVERABILITY</TD>
    <TD STYLE="text-align: right">42</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 27.16.&nbsp; SURVIVAL OF OBLIGATIONS</TD>
    <TD STYLE="text-align: right">42</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 27.17.&nbsp; WARRANTY OF AUTHORITY</TD>
    <TD STYLE="text-align: right">43</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 27.18.&nbsp; TENANT&rsquo;S LIABILITY</TD>
    <TD STYLE="text-align: right">43</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 27.19.&nbsp; LANDLORD&rsquo;S LIABILITY</TD>
    <TD STYLE="text-align: right">43</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 27.20.&nbsp; COUNTERCLAIM AND JURY TRIAL</TD>
    <TD STYLE="text-align: right">43</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 27.21.&nbsp; TRANSFER OF LANDLORD&rsquo;S INTEREST IN THE LEASED PREMISES</TD>
    <TD STYLE="text-align: right">43</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 27.22.&nbsp; TENANT SELECTION BY LANDLORD</TD>
    <TD STYLE="text-align: right">43</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 27.23.&nbsp; DISCLOSURE OF PARTIES</TD>
    <TD STYLE="text-align: right">43</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 27.24.&nbsp; Intentionally Omitted</TD>
    <TD STYLE="text-align: right">43</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 27.25.&nbsp; EXECUTIVE ORDER CERTIFICATION</TD>
    <TD STYLE="text-align: right">44</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0in">ARTICLE XXVIII.&nbsp; ADDITIONAL PROVISIONS</TD>
    <TD STYLE="text-align: right">44</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 28.01.&nbsp; OPTION TO RENEW</TD>
    <TD STYLE="text-align: right">44</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 28.02.&nbsp; PRIOR LEASES</TD>
    <TD STYLE="text-align: right">44</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 28.03.&nbsp; FIRST RIGHT OF OFFER TO LEASE CONTIGUOUS SPACE</TD>
    <TD STYLE="text-align: right">45</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">SECTION 28.04.&nbsp; RIGHT TO TERMINATE</TD>
    <TD STYLE="text-align: right">46</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0in">EXHIBIT A&nbsp; SITE PLAN</TD>
    <TD STYLE="text-align: right">48</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0in">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0in">EXHIBIT A-1&nbsp; LEASE PLAN</TD>
    <TD STYLE="text-align: right">49</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0in">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0in">EXHIBIT B&nbsp; LEGAL DESCRIPTION</TD>
    <TD STYLE="text-align: right">51</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0in">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 0in">EXHIBIT C&nbsp; SIGN CRITERIA</TD>
    <TD STYLE="text-align: right">53</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">iv</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 2 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LEASE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(hereinafter &ldquo;<B>Lease</B>&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
I. BASIC LEASE PROVISIONS; ENUMERATION OF EXHIBITS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 1.01. </B>BASIC LEASE PROVISIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>(A)</B></TD><TD STYLE="text-align: justify"><B>EFFECTIVE DATE:</B> August 1, 2017 (&ldquo;Effective Date&rdquo;)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><B>(B)</B></TD><TD><B>LANDLORD: EASTLAND REGENCY, L.C.</B>, a Utah limited liability company (&ldquo;<B>Landlord</B>&rdquo;)</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>(C)</B></TD><TD><B>ADDRESS OF LANDLORD FOR NOTICES (Section 16.01):</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 17%">&nbsp;</TD>
    <TD STYLE="width: 77%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eastland Regency, L.C.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">do Woodbury Corporation</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn: Lease Administration</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2733 East Parleys Way, Suite 300</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salt Lake City, Utah 84109</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ref: 1603 - Sera Prognostics - Suite 200</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With a copy to:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eastland Regency, L.C.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c/o Woodbury Corporation</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn: Legal Department</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2733 East Parleys Way, Suite 300</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salt Lake City, Utah 84109</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ref: 1603 - Sera Prognostics Suite 200</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(<B>D)</B></TD><TD><B>TENANT:</B> Sera Prognostics, Inc., a Delaware corporation (&ldquo;<B>Tenant</B>&rdquo;) (Tax ID: 26-1911522)</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>(E)</B></TD><TD><B>ADDRESS OF TENANT FOR NOTICES (Section 16.01):</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 17%">&nbsp;</TD>
    <TD STYLE="width: 77%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sera Prognostics, Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn: Andy Sauter</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2749 East Parleys Way, Suite 200</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salt Lake City, Utah 84109</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With a copy to:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ballard Spahr LLP</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One Utah Center, Suite 800</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">201 South Main Street</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salt Lake City, Utah 84111</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>(F)</B></TD><TD><B>PERMITTED USE (Section 7.01):</B> General office and laboratory use, including light assembly for manufacturing of general medical
devices, and research and development (&ldquo;<B>Permitted Use</B>&rdquo;), and for no other use without the prior written consent of
Landlord.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>(G)</B></TD><TD><B>TENANT&rsquo;S TRADE NAME:</B> Sera Prognostics, Inc.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>(H)</B></TD><TD><B>BUILDING (Section 2.01):</B> REGENCY OFFICE BUILDING situated at 2749 East Parleys Way, in the City of Salt Lake, County of Salt
Lake, State of Utah (&ldquo;<B>Building</B>&rdquo;), as substantially depicted on Exhibit &ldquo;A.&rdquo;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>(I)</B></TD><TD><B>LEASED PREMISES (Section 2.01):</B> 2749 East Parleys Way, Suites 200, 210, 320, 330 &amp; 340, Salt Lake City, Utah 84109 (&ldquo;<B>Leased
Premises</B>&rdquo;), consisting of approximately 21,798 square feet of gross rentable area, as substantially depicted on Exhibit &ldquo;A-1&rdquo;.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>(J)</B></TD><TD><B>DELIVERY OF POSSESSION (Section 5.02):</B> Tenant is currently in possession of Suites 200, 320 &amp; 330 pursuant to the Prior
Leases as defined in Section 28.02(a). Suite 340 and Suite 210 shall be delivered to Tenant upon substantial completion of Landlord&rsquo;s
Work (as defined in Section 5.01). As used herein, the term &ldquo;Delivery of Possession&rdquo; (as defined in Section 5.01) shall refer
to the date on which Landlord&rsquo;s Work is substantially completed, and confirmed at a walk-thru attended by Landlord and Tenant (&ldquo;<B>Delivery
of Possession</B>&rdquo;), as certified by a notice of Delivery of Possession.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>(K)</B></TD><TD><B>RENTAL TERM, COMMENCEMENT AND EXPIRATION DATE (Sections 4.01 and 4.02):</B> The term of this Lease shall retroactively commence
on August 1, 2017 (&ldquo;<B>Rental Term Commencement Date</B>&rdquo;), and shall be for a period of five (5) full Lease Years (as defined
in Section 4.02) and five (5) months ending December 31, 2022 (&ldquo;<B>Rental Term</B>&rdquo;), as certified by a notice of Rental Term
Commencement Date.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(<B>L)</B></TD><TD><B>BASE MONTHLY RENT (Section 3.01):</B> Retroactively commencing on August 1, 2017, Tenant shall pay monthly rent in the amount of
Twenty-Nine Thousand Two Hundred Nineteen and 31/100 Dollars ($29,219.31) per month (&ldquo;<B>Base Monthly Rent</B>&rdquo;). In addition,
commencing on the date Landlord commences Landlord&rsquo;s Work in Suite 210 with all required permits in place, Tenant shall pay to Landlord
a fee of Two Thousand Four Hundred Fifty-Five and 42/100 ($2,455.42) Dollars (&ldquo;<B>210 Fee</B>&rdquo;) per calendar month, or partial
month until Delivery of Possession of Suite 210. Landlord shall provide Tenant with written notice of the date on which it commences Landlord&rsquo;s
Work in Suite 210 with all required permits in place. The 210 Fee shall be Additional Rent under this Lease.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>(M)</B></TD><TD><B>ESCALATIONS IN BASE MONTHLY RENT (Section 3.02):</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 76%; font: 10pt Times New Roman, Times, Serif; margin-right: 1.5in; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">Escalation Date</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Base Monthly Rent</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 85%; text-align: left">Commencing upon Delivery of Possession of Suite 210</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">41,034.77</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">August 1, 2018</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">42,265.82</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">August 1, 2019</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">43,533.79</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">August 1, 2020</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">44,839.80</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">August 1, 2021</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">46,185.00</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>(N)</B></TD><TD><B>LANDLORD&rsquo;S SHARE OF OPERATING EXPENSES (Section 3.03):</B> Subject to Tenant&rsquo;s reimbursement obligation, Landlord shall
pay all Operating Expenses (as defined in Section 3.03) for the calendar year 2017 (hereinafter &ldquo;<B>Base Year</B>&rdquo;) and an
amount equal to the Operating Expenses in the Base Year for each year thereafter, escalating three percent (3%) thereafter on a cumulative
basis (&ldquo;<B>Landlord&rsquo;s Share of Operating Expenses</B>&rdquo;).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 7; Options: NewSection; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>(O)</B></TD><TD><B>TENANT&rsquo;S PRO-RATA SHARE OF OPERATING EXPENSES (Section 3.03):</B> Sixty and nine thousand eight hundred ninety-three percent
(60.9893%) of all Operating Expenses in excess of Landlord&rsquo;s Share of Operating Expenses.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                                         </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>(P)</B></TD><TD><B>RESPONSIBILITY FOR UTILITIES AND SERVICES:</B> Subject to the provisions of Section 3.03, this Lease provides that the utilities
and services shall be paid by the party shown below:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 43%; padding-right: 5.4pt; padding-left: 5.4pt">Heat:</TD>
    <TD STYLE="width: 13%; padding-right: 5.4pt; padding-left: 5.4pt">Landlord</TD>
    <TD STYLE="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt">Building Insurance:</TD>
    <TD STYLE="width: 11%; padding-right: 5.4pt; padding-left: 5.4pt">Landlord</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Water:</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Landlord</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Real Property Taxes:</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Landlord</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Electricity:</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Landlord</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Common Area Maintenance:</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Landlord</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Telephone:</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Tenant</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Personal Property Taxes:</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Tenant</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Janitorial (Inside Leased Premises):</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Tenant</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Personal Property Insurance:</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Tenant</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Trash dumpster pickup</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Landlord</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">None of the utilities are separately metered except that
telephone and data services shall be contracted for directly by Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>(Q)</B></TD><TD><B>EXCESS HOUR UTILITY CHARGES AND HOURS OF OPERATION (Section 12.03):</B> Tenant shall have access to the Leased Premises twenty-four
(24) hours a day, seven (7) days per week. Standard operating hours for the Building shall be 7:00 a.m. to 6:30 p.m., Monday through Friday,
and 8:00 a.m. to 12:00 Noon on Saturday, excluding holidays (&ldquo;<B>Standard Operating Hours</B>&rdquo;). To the extent Tenant operates
during any time in excess of Standard Operating Hours, and Tenant&rsquo;s consumption of utilities increases by thirty percent (30%) or
more, then Landlord reserves the right to charge Tenant an additional charge for such after hours and/or disproportionate utility usage.
Such additional charges shall be determined and assessed by Landlord using its commercially reasonable judgement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>(R)</B></TD><TD>Intentionally Omitted.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>(S)</B></TD><TD><B>SECURITY DEPOSIT (Section 26.01): </B> A total of Seventy-Two Thousand Two Hundred and 00/100 Dollars ($72,200.00) (&ldquo;<B>Security
Deposit</B>&rdquo;), Fifty-Seven Thousand Seven Hundred and 00/100 Dollars ($57,700.00) of which is currently held by Landlord pursuant
to the Prior Leases (as defined in Section 28.02(a)) and shall now be retained as a portion of the Security Deposit for this Lease. Further,
an additional amount of Fourteen Thousand Five Hundred and 00/100 Dollars ($14,500.00), is to be delivered to Landlord upon Tenant&rsquo;s
execution of this Lease, which amount shall be held by Landlord as a portion of the Security Deposit.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>(T)</B></TD><TD>Intentionally Omitted.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>(U)</B></TD><TD>Intentionally Omitted.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 8; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>(V)</B></TD><TD><B>LANDLORD&rsquo;S WORK:</B> Landlord shall deliver Suite 210 and Suite 340 of the Leased Premises to Tenant in &ldquo;Turn-Key&rdquo;
condition in accordance with the final construction set documents approved by Landlord with plans and specifications agreed to by Landlord
and Tenant. In addition, prior to Delivery of Possession, Landlord shall replace the windows in Suite 210 at Landlord&rsquo;s sole cost
and expense. Landlord shall contribute an amount up to Four Hundred Seventy-One Thousand Two Hundred Forty-Five and 62/100 Dollars ($471,245.62)
(&ldquo;<B>Landlord&rsquo;s Construction Cost Cap</B>&rdquo;) towards Landlord&rsquo;s construction of the Leased Premises. Tenant shall
pay all costs in excess of Landlord&rsquo;s Construction Cost Cap within thirty (30) days of invoice from Landlord.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>(W)</B></TD><TD><B>TENANT&rsquo;S WORK (Section 6.01):</B> In the event Tenant wishes to remodel the Leased Premises in the future, then Tenant shall
finish the Leased Premises in accordance with plans and specifications approved by Landlord. Prior to commencement of construction, Tenant
shall submit an electronic copy of all plans to Landlord for review and approval as set forth in Section 6.01.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>(X)</B></TD><TD>Intentionally Omitted.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>(Y)</B></TD><TD><B>OPTION TO RENEW (Section 28.01):</B> Provided Tenant is not, and has not been, in default beyond any applicable cure period under
any of the terms and conditions contained herein, Tenant shall have one (1) additional consecutive five (5) year option to renew and extend
the Rental Term (&ldquo;<B>Option</B>&rdquo;) as provided herein. The Option shall only be exercised by Tenant delivering written notice
thereof to Landlord not less than one hundred eighty (180) days prior to the expiration of the Rental Term. Base Monthly Rent for the
Option period shall be as follows:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 76%; font: 10pt Times New Roman, Times, Serif; margin-right: 1.5in; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">Option Period</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Base Monthly Rent</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 85%; padding-bottom: 1pt">January 1, 2023 - December 31, 2023</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center">$</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center">47,570.55</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">January 1, 2024 - December 31, 2024</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: center">$</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: center">48,997.66</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">January 1, 2025 - December 31, 2025</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: center">$</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: center">50,467.59</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">January 1, 2026 - December 31, 2026</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: center">$</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: center">51,981.62</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">January 1, 2027 - December 31, 2027</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: center">$</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: center">53,541.07</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 9; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>(Z)</B></TD><TD><B>RIGHT OF FIRST OFFER (Section 28.03):</B> From the Effective Date of this Lease until the end of the Rental Term, Tenant shall
have an ongoing right of first offer to lease space adjacent and contiguous to the Leased Premises on the second and third floors when
such applicable space becomes available for lease as provided herein (hereinafter &ldquo;<B>First Offer Space</B>&rdquo;). For purposes
hereof, the First Offer Space (or any applicable portion thereof) shall become available for lease by Tenant immediately prior to the
first time after the Effective Date that Landlord intends to submit to a third party a bona fide proposal or letter of intent to lease
such First Offer Space (or such applicable portion thereof). Landlord shall give Tenant written notice that the First Offer Space (or
such applicable portion thereof) will or has become available for lease by Tenant and the terms (the &ldquo;<B>Offer</B>&rdquo;) upon
which Landlord is willing to rent out the First Offer Space. Tenant shall have ten (10) business days to accept the Offer by delivering
to Landlord written notice of its intent to do so. Failure of Tenant to timely deliver written notice shall be deemed a refusal by Tenant.
Should Landlord thereafter intend to offer the First Offer Space to a third party of better terms than the Offer, then Tenant shall once
again have a right of first offer and the process set forth in this Section 28.03 shall be repeated. Furthermore, if Tenant declines to
exercise its right of first offer with regard to any First Offer Space, Landlord shall have a continuing obligation to provide Tenant
with a new offer with regard to any other adjacent and continuous space during the Rental Term and with regard to the same First Offer
Space if the terms of the Offer change or more than one calendar year passes since Tenant&rsquo;s prior decline.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">In the event Tenant exercises its option to lease the First
Offer Space, Landlord and Tenant shall endeavor to execute within thirty (30) days thereafter an amendment to this Lease for such First
Offer Space upon the terms and conditions set forth in the Offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>(AA)</B></TD><TD><B>RIGHT TO TERMINATE (Section 28.04):</B> Provided Tenant is not, and has not been, in default beyond any applicable cure period
under any of the terms and provisions contained herein, Tenant shall have the one (1) time right to terminate this Lease as of December
31, 2020. To exercise such right, on or before July 1, 2020, Tenant shall provide Landlord with written notice of its intent to exercise
this right to terminate. In the event Tenant exercises this right, Tenant shall reimburse Landlord in full of any unamortized portion
of Landlord&rsquo;s Construction Cost Cap and unamortized commission payments within ten (10) days of receiving an invoice therefore from
Landlord.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Remainder of Page Intentionally Left Blank]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 1.02. SIGNIFICANCE OF A BASIC LEASE
PROVISION</B>. The foregoing provisions of Section 1.01 summarize for convenience only certain fundamental terms of this Lease delineated
more fully in the articles and sections referenced therein. In the event of a conflict between the provisions of Section 1.01 and the
balance of this Lease, the latter shall control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 1.03. ENUMERATION OF EXHIBITS</B>. The
exhibits enumerated in this Section 1.03 and attached to this Lease are incorporated in this Lease by this reference and are to be construed
as a part of this Lease. In the event of a conflict between the body of this Lease and the exhibits, the body of this Lease shall control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 94%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; margin-left: 0.5in">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 18%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXHIBIT &ldquo;A&rdquo;</FONT></TD>
    <TD STYLE="width: 82%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- SITE PLAN</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXHIBIT &ldquo;A-1&rdquo;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- LEASE PLAN</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXHIBIT &ldquo;B&rdquo;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- LEGAL DESCRIPTION</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXHIBIT &ldquo;C&rdquo;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- SIGN CRITERIA</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
II. GRANT AND LEASED PREMISES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 2.01. LEASED PREMISES</B>. In consideration
for the rent to be paid and covenants to be performed by Tenant, Landlord hereby leases to Tenant, and Tenant leases from Landlord, for
the Rental Term, and upon the terms and conditions herein set forth, the Leased Premises described in Section 1.01(1), located in the
Building referred to in Section 1.01(H). The legal description for the property on which the Building is located is attached hereto as
Exhibit &ldquo;B&rdquo;. Gross rentable area measurements herein specified are from the exterior of the perimeter walls of the Building
to the center of the interior walls.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The exterior walls and roof of the Leased Premises
and the areas beneath the Leased Premises are not demised hereunder and the use thereof, together with the right to install, maintain,
use, repair, and replace pipes, ducts, conduits, and wires leading through the Leased Premises in locations which do not materially and
adversely interfere with Tenant&rsquo;s use thereof and serving other parts of the Building or buildings, are hereby reserved to Landlord.
Landlord reserves (a) such access rights through the Leased Premises as may be reasonably necessary to enable access by Landlord to the
balance of the Building and reserved areas and elements as set forth above; and (b) the right to install or maintain meters on the Leased
Premises to monitor use of utilities. In exercising such rights, Landlord shall give Tenant forty-eight (48) hours prior notice (except
in the case of an emergency) and shall use reasonable efforts so as to not commit waste upon the Leased Premises and as far as practicable
shall not materially and adversely interfere with Tenant&rsquo;s use of the Leased Premises and shall minimize annoyance, interference
or damage to Tenant and the Leased Premises when making modifications, additions or repairs. Landlord shall not be responsible for any
damages incurred by Tenant and/or to Tenant&rsquo;s property occur during the required forty-eight (48) hour notice period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Subject to the provisions of Article VIII, Tenant
and its employees, contractors, customers, agents and invitees have the right to the non-exclusive use, in common with existing tenants
of such unreserved automobile parking spaces, driveways, footways, and other facilities designated for common use within the Building,
except that with respect to non-exclusive areas, Tenant shall cause its employees to park their cars only in areas specifically designated
from time to time by Landlord for that purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 2.02. EXCUSE OF LANDLORD&rsquo;S PERFORMANCE</B>.
Anything in this Lease to the contrary notwithstanding, providing such cause is not due to the willful act or neglect of Landlord, Landlord
shall not be deemed in default with respect to the performance of any of the terms, covenants and conditions of this Lease, if the same
shall he due to any strike, lockout, civil commotion, war-like operation, invasion, rebellion, hostilities, military or usurped power,
sabotage, governmental regulations or controls, inability to obtain any material, service or financing, act of God or other cause beyond
the control of Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 2.03. REVISION OF SITE PLAN</B>. It
is expressly agreed that the depiction of the Leased Premises, the Building and the Common Areas on Exhibit &ldquo;A&rdquo; and Exhibit
 &ldquo;A-1&rdquo; does not constitute a representation, covenant, or warranty of any kind by Landlord, and Landlord reserves the right
to change the size, location, type and number of buildings within the project, and the location, type, design and dimensions of the Common
Areas; provided, however, that no such change shall materially alter the Leased Premises or access or visibility thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
III. RENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 3.01. BASE MONTHLY RENT</B>. Tenant
agrees to pay to Landlord Base Monthly Rent in the amounts set forth in Sections 1.01(L) and 1.01(M), and 1.01(Y), if applicable, at such
place as Landlord may designate, without prior demand therefor, without offset or deduction and in advance on or before the first day
of each calendar month during the Rental Term, including any Rental Term extension or renewal thereof, commencing on the Rental Term Commencement
Date. In the event the Rental Term Commencement Date (or Delivery of Possession date for Suite 210) occurs on a day other than the first
day of a calendar month, then Base Monthly Rent to be paid on the Rental Term Commencement Date (or Delivery of Possession, as applicable)
shall include both Base Monthly Rent for the first full calendar month occurring after the Rental Term Commencement Date (or Delivery
of Possession, as applicable), plus Base Monthly Rent for the initial fractional calendar month pro-rated on a per-diem basis (based upon
a thirty (30) day month).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 3.02. ESCALATIONS IN BASE MONTHLY RENT</B>.
As set forth in Section 1.01(M).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 3.03. TENANT&rsquo;S PRO-RATA SHARE
OF OPERATING EXPENSES</B>. Tenant shall pay to Landlord as further Additional Rent (as defined in Section 3.07) the amount by which Tenant&rsquo;s
pro rata share of Landlord&rsquo;s expenses for utilities, interior and exterior Common Area (as defined in Section 8.01) maintenance,
insurance, property taxes and assessments on land and the Building, repairs, security, and Building management fees and costs (&ldquo;<B>Operating
Expense(s)</B>&rdquo;) exceed Landlord&rsquo;s Share of Operating Expenses set forth in Section 1.01(N) for the previous calendar year
 &ldquo;<B>Tenant&rsquo;s Pro-Rata Share</B>&rdquo;. For avoidance of doubt: (i) Tenant shall not incur any charges for Operating Expenses
for calendar year 2017; (ii) starting in January 2018 and continuing through the Rental Term, Tenant&rsquo;s Pro-Rata Share of Operating
Expenses shall be calculated by multiplying Tenant&rsquo;s Pro-Rata Share by the difference of Operating Expenses for the given calendar
year minus Landlord&rsquo;s Share of Operating Expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Landlord shall bill Tenant for Tenant&rsquo;s Pro-Rata
Share of Operating Expenses, if any, by April 1 of each calendar year of the Rental Term, commencing with 2019. The bill shall identify
the total Operating Expenses of the immediately prior calendar year, Landlord&rsquo;s Share of Operating Expenses and Tenant&rsquo;s Pro-Rata
Share of Operating Expenses thereof. Tenant shall pay Tenant&rsquo;s Pro-Rata Share of Operating expenses annually within thirty (30)
days following receipt of Landlord&rsquo;s invoice therefore.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Notwithstanding anything to the contrary herein,
Operating Expenses shall not include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>costs of capital repairs, capital alterations or capital replacements (except as specifically permitted herein or as amortized
in accordance with GAAP), capital improvements and equipment; except those: (i) required by laws enacted on or after the date of this
Lease, with the cost of any such improvements and equipment depreciated on a straight line basis over the useful life of the improvement
and/or equipment, or (ii) installed at the Building to reduce Operating Expenses and/or conserve energy, with the cost of any such improvements
and equipment depreciated at an annual rate reasonably calculated to equal the amount of Operating Expenses to be saved in each calendar
year throughout the Rental Term;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>costs
incurred in connection with the original construction or design of the Building or in connection with any major change in the Building,
such as adding or deleting floors or common areas, costs for the replacement of any roofs in the Building or to the correction of inherent
structural defects in the Building or to the initial malfunction of operating equipment;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>costs of the design and construction of Tenant improvements to the Leased Premises or the premises of other tenants;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>depreciation,
interest and principal payments on mortgages and other debt costs, if any and amounts paid as ground rental or as rental for the Building
by the Landlord;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>marketing costs, legal fees, space planners&rsquo; fees and advertising and promotional expenses, and brokerage fees incurred in
connection with the original development, subsequent improvement, or original or future leasing of the Building;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>costs
for which any tenant directly contracts with local providers, costs for which the Landlord is reimbursed by any tenant or occupant of
the Building or by insurance by its carrier or any tenant&rsquo;s carrier or by anyone else and expenses in connection with services
or other benefits which are not offered to the Tenant or for which the Tenant is charged directly but which are provided to another tenant
or occupant of the Building without a separate charge;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>any
bad debt loss, rent loss, or reserves for bad debts or rent loss; and reserves for capital or future operating expenses;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Landlord&rsquo;s general corporate overhead and general and administrative expenses and other costs associated with the operation
of the business of the entity which constitutes the Landlord, as the same are distinguished from the costs of operation of the Building,
including partnership or corporate accounting and legal matters, costs of defending any lawsuits with any mortgagee (except as the actions
of the Tenant may be in issue), costs of selling, syndicating, financing, mortgaging or hypothecating any of the Landlord&rsquo;s interest
in the Building, and costs incurred in connection with any disputes or proceedings, including but not limited to any disputes or proceedings
between Landlord and its employees, between Landlord and Building management, or between Landlord and other tenants or occupants;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the wages and benefits of any employee who does not devote substantially all of his or her employed time to the Building unless
such wages and benefits are prorated to reflect time spent on operating and managing the Building vis-&agrave;-vis time spent on matters
unrelated to operating and managing the Building; provided, that in no event shall Operating Expenses include wages and/or benefits attributable
to personnel above the level of on-site Building manager or on-site Building engineer or any compensation paid to clerks, attendants or
other persons in commercial concessions operated by the Landlord;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>costs, including permit, license and inspection costs, incurred with respect to the installation of tenant improvements made for
new tenants in the Building or incurred in renovating or otherwise improving, decorating, painting or redecorating vacant space for tenants
or other occupants of the Building (excluding, however, such costs relating to any common areas of the Building or parking facilities);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>overhead and profit increment paid to the Landlord or to subsidiaries or affiliates of the Landlord for services in the Building
to the extent the same unreasonably exceeds the costs of such services rendered by qualified, first-class unaffiliated third parties on
a competitive basis, which parties render services in comparable buildings;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>costs,
other than those incurred in ordinary maintenance and repair, for sculpture, paintings, fountains or other objects of art;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>costs to repair or rebuild after casualty loss (excluding deductibles under insurance policies carried by Landlord, which deductibles
shall be included in Operating Expenses and which deductibles shall not exceed Ten Thousand Dollars ($10,000.00) in any one Lease Year);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(n)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>any costs expressly excluded from Operating Expenses elsewhere in the Lease;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(o)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>rent for any office space occupied by Building management personnel to the extent the size or rental rate of such office space
exceeds the size or fair market rental value of office space occupied by management personnel of comparable buildings in the vicinity
of the Building, with adjustment where appropriate for the size of the applicable building;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(p)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>costs arising from the negligence or willful misconduct of Landlord or its agents, employees, vendors, contractors, or providers
of materials or services;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(q)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>costs incurred to comply with federal, state, county or local laws or regulations in effect as of the date of this Lease, including
but not limited to laws, regulations and building codes relating to handicap access, energy efficiency or conservation, or the removal
of hazardous material (as defined under applicable law, and defined as such as of the date of this Lease), which hazardous material is
in existence in the Building or on the Building prior to date of this Lease or is brought into the Building or onto the Building after
the date hereof by Landlord or any other tenant of the Building (excluding Tenant), and is of such a nature that a federal, state or municipal
government governmental authority, if it had knowledge of the presence of such hazardous material in the state and under the conditions
that it then exists in the Building or on the Building, would require the removal of such hazardous material or would require other remedial
or containment action with respect thereto pursuant to laws in effect as of the date of this Lease (in the event that such costs of compliance
are not paid by Landlord and are instead charged to Tenant or directly by a governmental authority, Landlord agrees that it will reimburse
Tenant for such charges);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(r)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>costs arising from Landlord&rsquo;s charitable or political contributions;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(s)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>costs
relating to the Building which are in a category of expense which was not included in Operating Expenses during the first year of the
Rental Term or any portion thereof; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(t)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>interest,
fines, late fees, collection costs, legal fees or penalties assessed as a result of Landlord&rsquo;s failure to make payments in a timely
manner or to comply with applicable laws, including regarding the payment of taxes, or to comply with the terms of any lease, mortgage,
deed of trust, ground lease, private restriction or other agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 3.04. OPERATING EXPENSE AUDIT</B>. Tenant
shall have the right, not more frequently than once every two (2) calendar years, to audit Landlord&rsquo;s general ledgers pertaining
to Operating Expenses for the prior two (2) Lease Years (the &ldquo;<B>Operating Expense Audit</B>&rdquo;). Tenant shall not be permitted
to utilize a so-called &ldquo;contingent fee&rdquo; Operating Expense auditor. Accordingly, any representative of Tenant conducting, assisting,
or having any involvement with the Operating Expense Audit shall not be permitted to have a financial stake in the outcome of the Operating
Expense Audit and Landlord shall be entitled to receive credible evidence of the same and Landlord may refuse to allow such Operating
Expense Audit in the absence of such evidence. Additionally, any representative of Tenant conducting an Operating Expense Audit shall
first sign a confidentiality agreement that provides that it shall not disclose the Operating Expense Audit, its conclusions or any information
obtained in the course of conducting the Operating Expense Audit to anyone other than Tenant and Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Landlord shall retain its general ledgers regarding
Operating Expenses for a period of at least two (2) years following the final billing for each calendar year during the Rental Term. At
any time during such two (2) year period, upon forty-five (45) days&rsquo; advance written notice to Landlord, Tenant may conduct an Operating
Expense Audit. The Operating Expense Audit shall commence on a date of which Tenant has notified Landlord not less than thirty (30) days
in advance. Tenant shall in all cases share with Landlord the conclusions of the Operating Expense Audit and any Operating Expense Audit
report. If the Operating Expense Audit discloses an overbilling, Landlord may, by written notice to Tenant within forty-five (45: days
of Landlord&rsquo;s receipt of a copy of the Operating Expense Audit, object to the conclusions or process of the Operating Expense Audit,
stating its conclusions as to whether or not there was any overbilling (and if so, the amount thereof). If Tenant disputes Landlord&rsquo;s
conclusions, Tenant shall notify Landlord and the parties shall use good faith efforts to resolve the dispute. If Landlord agrees with
the Operating Expense Audit, Landlord shall pay to Tenant the amount of the overbilling within forty-five (45) days of Landlord&rsquo;s
receipt of a copy of the Operating Expense Audit. If the Operating Expense Audit discloses an underbilling, Tenant shall pay to Landlord
the amount of the underbilling within forty-five (45) days of Tenant&rsquo;s receipt of a copy of the Operating Expense Audit or its conclusions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 3.05. TAXES</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Landlord shall pay all real property taxes and assessments which are levied against or which apply to the Building with respect
to the Leased Premises, which taxes and assessments are part of the Operating Expenses set forth in Section 3.03.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Tenant
shall pay, prior to delinquency, all taxes, assessments, charges, and fees which during the Rental Term, or any Rental Term extension
or renewal thereof, may be imposed, assessed, or levied by any governmental or public authority against or upon Tenant&rsquo;s use of
the Leased Premises or any inventory, personal property, fixtures or equipment kept or installed, or permitted to be located therein
by Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 3.06. PAYMENTS</B>. All payments of
Base Monthly Rent, Additional Rent and other payments to be made to Landlord shall be made on a timely basis and shall be payable to Landlord
or as Landlord may otherwise designate. All such payments shall be mailed or delivered to Landlord&rsquo;s principal office set forth
in Section 1.01(C), or at such other place as Landlord may designate from time to time in writing. If mailed, all payments shall be mailed
in sufficient time and with adequate postage thereon to be received in Landlord&rsquo;s account by no later than the due date for such
payment. If Tenant fails to pay any Base Monthly Rent, Additional Rent or any other amounts or charges within ten (10) days of the date
when due, Tenant shall pay interest from the due date of such past due amounts to the date of payment, both before and after judgment
at a rate equal to the greater of twelve percent (12%) per annum or two percent (2%) over the prime rate or base rate charged by Citibank
of New York at the due date of such payment; provided however, that in any case the maximum amount or rate of interest to be charged shall
not exceed the maximum non-usurious rate in accordance with applicable law. In addition, Tenant shall pay a late fee equal to four percent
(4%) of such past due amount to compensate Landlord for extra administrative, collection, processing, accounting and other costs incurred
through Tenant&rsquo;s nonpayment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 3.07. ADDITIONAL RENT</B>. Tenant shall
pay as &ldquo;<B>Additional Rent</B>&rdquo; (in addition to the aforementioned property taxes and Operating Expenses) any and all sums
of money or charges required to be paid by Tenant under this Lease whether or not the same be designated as Additional Rent. If such amounts
or charges are not paid at the time provided for in this Lease, they shall nevertheless, if not paid when due, be collectible as Additional
Rent with the next installment of Base Monthly Rent thereafter falling due hereunder, hut nothing herein contained shall be deemed to
suspend or delay the payment of any amount of money or charge at the time the same becomes due and payable hereunder, or limit any interest,
late fee or other remedy of Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
IV. RENTAL TERM, COMMENCEMENT DATE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 4.01. RENTAL TERM</B>. The initial term
of this Lease shall be for the period defined as the Rental Term in Section 1.01(K), plus the partial calendar month, if any, occurring
after the Rental Term Commencement Date if the Rental Term Commencement Date occurs other than on the first day of a calendar month.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 4.02. DEFINITION OF LEASE YEAR</B>.
The &ldquo;<B>Lease Year</B>&rdquo; shall include twelve (12) full calendar months of the Rental Term; except that the first Lease Year
shall include such twelve (12) full calendar months after the Rental Term Commencement Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 4.03. RENTAL TERM COMMENCEMENT DATE
AND TERMINATION DATE</B>. The Rental Term shall commence and continue for the term set forth in Section 1.01(K). Each of the parties hereto
agrees, upon demand of the other, to execute a Rental Term Commencement Date notice expressing the commencement, termination, and Delivery
of Possession dates of the Rental Term as soon as such dates have been determined.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 4.04. </B>Intentionally Omitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 4.05. END OF RENTAL TERM</B>. This Lease,
and the tenancy hereby created, shall terminate at the end of the Rental Term, or any Rental Term extension or renewal thereof, without
the necessity of any notice from either Landlord or Tenant to terminate the same, and Tenant hereby waives notice to vacate the Leased
Premises and agrees that I and lord shall he entitled to the benefit of all provisions of law respecting the summary recovery of possession
of the Leased Premises from Tenant holding over to the same extent as if statutory notice has been given.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
V. CONSTRUCTION OF LEASED PREMISES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 5.01. CONSTRUCTION OF LEASED PREMISES
BY LANDLORD</B>. Landlord has constructed the Building in which the Leased Premises is located and shall deliver Suite 210 and Suite 340
of the Leased Premises and convert the freezer room in Suite 200 to a conference room, all in accordance with the final construction set
documents approved by Landlord (&ldquo;<B>Landlord&rsquo;s Work</B>&rdquo;). It is understood and agreed by Tenant that no minor changes
from any plans or from Landlord&rsquo;s outline specifications made necessary during construction of the Leased Premises or the Building
shall affect or change this Lease or invalidate same. Tenant is leasing the remainder of Leased Premises in &ldquo;as is&rdquo; condition.
In addition, prior to the Delivery of Possession, Landlord shall replace the windows in Suite 210 at Landlord&rsquo;s sole cost and expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 5.02. DELIVERY OF POSSESSION FOR TENANT&rsquo;S
WORK</B>. Except as expressly stated otherwise, Landlord covenants that actual possession of Suite 210 and Suite 340 of the Leased Premises
shall be delivered to Tenant, ready for Tenant&rsquo;s Work, if any, (as defined in Section 6.01) and as set forth in Section 1.01(J).
The Leased Premises shall be deemed as ready for Tenant&rsquo;s Work when Landlord&rsquo;s Work is completed in accordance with the final
construction set documents approved by Landlord and Tenant. It is agreed that by taking possession of the Leased Premises as a tenant,
Tenant formally accepts that portion to which it has taken possession and acknowledges that such portion of the Leased Premises is in
the condition called for hereunder, except for items specifically excepted in writing at the date of occupancy as &ldquo;incomplete&rdquo;.
Except as expressly stated in this Section 5.02 and Section 5.01, Landlord covenants that actual possession of the remainder of the Leased
Premises has been delivered to Tenant in &ldquo;as is&rdquo; condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 5.03. CHANGES AND ADDITIONS BY LANDLORD</B>.
Landlord hereby reserves the right at any time, and from time to time, to make alterations or additions to, and to build additional stories
on the Building in which the Leased Premises is contained and to build adjoining the same and to modify the existing parking or other
Common Areas to accommodate additional buildings. Landlord also reserves the right to construct other buildings or improvements on the
property from time to time, on condition that if the property is expanded so as to include any additional buildings, Landlord agrees to
create or maintain a parking ratio adequate to meet local laws and ordinances, including the right to add land to the property or to erect
parking structures thereon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
VI. TENANT&rsquo;S WORK</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 6.01. REMODEL OF LEASED PREMISES BY
TENANT</B>. In the event tenant desires to remodel the Leased Premises, Tenant agrees, prior to the commencement of construction, at Tenant&rsquo;s
sole cost and expense, to provide all work of whatsoever nature in accordance with its plans and specifications, subject to Landlord&rsquo;s
prior written approval (&ldquo;<B>Tenant&rsquo;s Work</B>&rdquo;). Empty conduit extending to the Leased Premises for telephone and data
lines, from central locations in the building, shall be provided by Landlord. All terminations, crossovers, and distribution wiring from
panels to the various equipment and receptacles shall be provided by Tenant at Tenant&rsquo;s sole cost and expense. Tenant agrees to
furnish Landlord, within the time periods designated by Landlord and prior to Delivery of Possession, with a complete and detailed set
of plans and specifications drawn by a registered architect (or by some other qualified person acceptable to Landlord) setting forth and
describing Tenant&rsquo;s Work in such detail as Landlord may require and in compliance with the initial permit set drawings and the final
construction set documents approved by Landlord. If such plans and specifications are not so furnished by Tenant within the required time
periods required by Landlord, then Landlord may, at its option, in addition to other remedies Landlord may enjoy, cancel this Lease at
any time thereafter while such plans and specifications have not been so furnished. Tenant shall remit one (1) electronic copy of any
and all plans and specifications to Landlord at the following email address:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><B>drawings@woodburycorp.com.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In order for such plans and specifications to be
deemed received by Landlord for Landlord&rsquo;s approval, the email transmittal must include the following information in the subject
line: <B>1603 - Sera Prognostics - 2749 East Parleys Way, Suites 200, 210, 320, 330 &amp; 340, Salt Lake City, Utah</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Additional physical copies can be sent to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Woodbury Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Attn: Architecture</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">2733 Parleys Way, Suite 300</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Salt Lake City, Utah 84109-1662</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Ref: 1603 - Sera Prognostics</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">With a copy to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Woodbury Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Attn: Lease Administration</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">2733 Parleys Way, Suite 300</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Salt Lake City, Utah 84109-1662</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Ref: 1603 - Sera Prognostics</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">No material deviation from the final set of plans
and specifications, once submitted to and approved by Landlord, shall be made by Tenant without Landlord&rsquo;s prior written consent.
Landlord shall have the right to approve or disapprove Tenant&rsquo;s architect and contractor to be used in performing Tenant&rsquo;s
Work, and the right to require and approve insurance or bonds to be provided by Tenant or such contractors. In due course, after completion
of Tenant&rsquo;s Work, Tenant shall certify to Landlord the itemized cost of Tenant improvements and fixtures located upon the Leased
Premises. Any design costs incurred by Landlord, including space planning, preliminary and final design and engineering costs, as well
as construction permit fees, shall be part of Tenant&rsquo;s Work and shall be applied to Landlord&rsquo;s construction cost cap and/or
any additional allowance, if any. This includes any costs incurred due to Tenant requested changes, which shall include change orders
requiring extraordinary design or engineering applications. To the extent that Landlord elects to perform certain Tenant&rsquo;s Work,
Tenant shall pay Landlord for such work within ten (10) days of invoice by Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 6.02. SETTLEMENT OF DISPUTES</B>. It
is understood and agreed that any disagreement or dispute which may arise between Landlord and Tenant with reference to the work to be
performed by Landlord shall be resolved by Landlord&rsquo;s architect, whose good faith decision shall be final and binding on both Landlord
and Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 6.03. PROJECT CLOSE-OUT</B>. Where Tenant&rsquo;s
Work is performed in accordance with Section 6.01, the following procedures shall apply:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Preconstruction</U>. Prior to the commencement of construction, Tenant and Tenant&rsquo;s contractor shall participate in a
preconstruction meeting and provide all documentation requested by Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Field Inspection</U>. On completion of construction, Landlord and Tenant shall conduct an inspection of the improvements to
identify whether there are any incomplete items or other deficiencies. A punch list of such deficiencies shall be prepared. Tenant shall
make all corrections within no more than fifteen (15) days thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Required Project Closeout Information. Tenant shall provide an electronic copy of items (i) through (iii) below to Landlord at
the following email address:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><B>leaseadmin@woodburycorp.com.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In order for such plans and specifications to be
deemed received by Landlord for Landlord&rsquo;s approval, the email transmittal must include the following information in the subject
line: <B>1603 - Sera Prognostics - 2749 East Parleys Way, Suites 200, 210, 320, 330 &amp; 340, Salt Lake City, Utah</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Additional, physical copies can be sent to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Woodbury Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Attn: Architecture</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">2733 Parleys Way, Suite 300</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Salt Lake City, Utah 84109-1662</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Ref: 1603 - Sera Prognostics</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">With a copy to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Woodbury Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Attn: Lease Administration</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">2733 Parleys Way, Suite 300</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Salt Lake City, Utah 84109-1662</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Ref: 1603 - Sera Prognostics</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;As-built
drawings depicting changes to the construction documents that occurred during construction, organized according to the original construction
documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;A
list of all subcontractors and major material and equipment supplies having contracts greater than Five Thousand Dollars ($5,000.00).
The list shall include the actual final contract value of the contractor&rsquo;s and each subcontractors&rsquo; work. Also, include a
copy of contractor&rsquo;s final application for payment with a cost breakdown of the various categories of work.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Copies
of final unconditional lien waivers from Tenant&rsquo;s general contractor, each subcontractor and material supplier who have provided
materials, labor and/or services during the construction of Tenant&rsquo;s Work, and any person who has filed a preliminary lien notice
with the State&rsquo;s registry. Tenant shall include a copy of the State registry of preliminary lien notices demonstrating that all
rights to claim have been removed. In the event of disputes, reasonable evidence shall be required showing that any lien rights have been
bonded over and that the Tenant is contesting such matters in good faith and by appropriate proceedings, or upon evidence of expiration
of statute of limitation for filing mechanics liens.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
VII. PERMITTED USE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 7.01. PERMITTED USE OF LEASED PREMISES</B>.
Tenant shall use and occupy the Leased Premises during the continuance of this Lease solely for the Permitted Use set forth in Section
1.01(F) and shall not use, permit or suffer the use of the Leased Premises for any other business or purpose without the prior written
consent of Landlord. Tenant shall promptly comply with all present or future laws, ordinances, lawful orders and regulations affecting
the Leased Premises and the cleanliness, safety, occupancy and use of the Leased Premises. Tenant shall not make any use of the Leased
Premises which shall cause cancellation or an increase in the cost of any insurance policy covering the Leased Premises. Tenant shall
not keep or use on the Leased Premises any article, item, or thing which is prohibited by the standard form of fire insurance policy.
Tenant shall not commit any waste upon the Leased Premises and shall not conduct or allow any business, activity, or thing on the Leased
Premises which is an annoyance or causes damage to Landlord, to other subtenants, occupants, or users of the improvements, or to occupants
of the vicinity. Tenant shall comply with and abide by all laws, ordinances, and regulations of all municipal, county, state, and federal
authorities which are now in force or which may hereafter become effective with respect to use and occupancy of the Leased Premises. Landlord
represents that to the best of its knowledge and understanding, that upon Delivery of Possession, the Building shall comply with all currently
applicable laws, ordinances and regulations of municipal, county, state and federal authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 7.02. HAZARDOUS SUBSTANCES</B>. Tenant
shall not use, produce, store, release, dispose or handle in or about the Leased Premises or transfer to or from the Leased Premises (or
permit any other party to do such acts) any Hazardous Substance (as defined herein) except in compliance with all applicable Environmental
Laws (as defined herein). Tenant shall not construct or use any improvements, fixtures or equipment or engage in any act on or about the
Leased Premises that would require the procurement of any license or permit pursuant to any Environmental Law. Tenant shall immediately
notify Landlord of (i) the existence of any Hazardous Substance on or about the Leased Premises that may be in violation of any Environmental
Law (regardless of whether Tenant is responsible for the existence of such Hazardous Substance), (ii) any proceeding or investigation
by any governmental authority regarding the presence of any Hazardous Substance on the Leased Premises or the migration thereof to or
from any other property, (iii) all claims made or threatened by any third party against Tenant relating to any loss or injury resulting
from any Hazardous Substance, or (iv) Tenant&rsquo;s notification of the National Response Center of any release of a reportable quantity
of a Hazardous Substance in or about the Leased Premises. &ldquo;<B>Environmental Law(s)</B>&rdquo; shall mean any federal, state or local
statute, ordinance, rule, regulation or guideline pertaining to health, industrial hygiene, or the environment, including without limitation,
the federal Comprehensive Environmental Response, Compensation, and Liability Act. &ldquo;<B>Hazardous Substance(s)</B>&rdquo; shall mean
all substances, materials and wastes that are or become regulated, or classified as hazardous or toxic, under any Environmental Law. If
it is determined that any Hazardous Substance that is not legally used in the ordinary course of Tenant&rsquo;s business exists on the
Leased Premises resulting from any act of Tenant or its employees, agents, contractors, licensees, subtenants or customers, then Tenant
shall immediately take necessary action to cause the removal of such substance and shall remove such within ten (10) days after discovery.
Notwithstanding the above, if the Hazardous Substance that is not legally used in the ordinary course of Tenant&rsquo;s business is of
a nature that cannot be reasonably removed within ten (10) days Tenant shall not be in default if Tenant has commenced to cause such removal
and proceeds diligently thereafter to complete removal, except that in all cases, any Hazardous Substance must be removed within sixty
(60) days after discovery thereof. Furthermore, notwithstanding the above, if in the good faith judgment of Landlord, the existence of
such Hazardous Substance creates an emergency or is of a nature which may result in immediate physical danger to persons at the property
or the Building, Landlord may enter upon the Leased Premises and remove such Hazardous Substances and charge the cost thereof to Tenant
as Additional Rent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
VIII. OPERATION AND MAINTENANCE OF COMMON AREAS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 8.01. CONSTRUCTION AND CONTROL OF COMMON
AREAS</B>. All automobile parking areas, driveways, entrances and exits thereto, and other facilities furnished by Landlord in or near
the Building, including if any, employee parking areas, truck ways, loading docks, mail rooms or mail pickup areas, pedestrian sidewalks
and hallways, landscaped areas, retaining walls, stairways, elevators, utility rooms, restrooms and other areas and improvements provided
by Landlord for the general use in common with all tenants, their officers, agents, employees and customers (&ldquo;<B>Common Area(s)</B>&rdquo;),
shall at all times be subject to the exclusive control and management of Landlord, which Landlord shall have the right from time to time
to establish, modify and enforce reasonable rules and regulations with respect to all facilities and areas mentioned in this Section 8.01.
Landlord shall have the right to construct, maintain and operate lighting and drainage facilities on or in all such areas and improvements;
to police the same, from time to time to change the area, level, location and arrangement of parking areas and other facilities hereinabove
referred to; to restrict parking by tenants, their officers, agents and employees to employee parking areas; to close temporarily all
or any portion of such areas or facilities to such extent as may, in the opinion of counsel, be legally sufficient to prevent a dedication
thereof or the accrual of any rights to any person or the public therein; to assign &ldquo;reserved&rdquo; parking spaces for exclusive
use of certain tenants or for customer parking, to discourage non-employee and non-customer parking; and to do and perform such other
acts in and to such areas and improvements as, in the exercise of good business judgment, Landlord shall determine to be advisable with
a view toward maintaining of appropriate convenience uses, amenities, and for permitted uses by tenants, their officers, agents, employees
and customers. Landlord shall operate and maintain the Common Areas and Common Facilities (as defined herein) referred to above in such
a manner as it, in its sole discretion, shall determine from time to time to be reasonable. Without limiting the scope of such discretion,
Landlord shall have the full right and authority to employ all personnel and to make all rules and regulations pertaining to and necessary
for the proper operation, security and maintenance of the Common Areas and Common Facilities. The Building and/or property signs, traffic
control signs and other signs determined by Landlord to be in best interest of the Building shall be considered part of the Common Areas
and Common Facilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For purposes of this Article VIII, &ldquo;<B>Common
Facilities</B>&rdquo; shall mean all areas, space, equipment and special services available for the common or joint use and/or benefit
of any of the occupants of the Building or their employees, agents, servants, customers and other invitees, including without limitation,
parking areas, access roads, driveways, retaining walls, landscaped areas, truck serviceways or tunnels, loading docks, pedestrian lanes,
courts, stairs, ramps and sidewalks, comfort and first-aid stations, washrooms, restrooms, janitorial rooms, transformer vaults, electrical
rooms, sprinkler riser rooms, common equipment storage rooms, information booths, canopies, utility systems, energy management systems,
roof drains, sumps and gutters, walls and fences, and elevators and air-walkways, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 8.02. LICENSE</B>. All Common Areas
and Common Facilities not within the Leased Premises, which Tenant may be permitted to use and occupy, are to be used and occupied under
a revocable license, and if the amount of such areas be diminished, Landlord shall not be subject to any liabilities nor shall Tenant
be entitled to any compensation or diminution or abatement of rent, nor shall such diminution of such areas be deemed constructive or
actual eviction, so long as such revocations or diminutions are deemed by Landlord to serve the best interests of the Building. The term
of such revocable license shall be coterminous with this Lease and shall not be revoked or terminated during the Rental Term of this Lease.
Notwithstanding the foregoing, Landlord acknowledges that Tenant has the right, at no additional cost, to the exclusive use of four (4)
covered parking spaces. In the event that additional parking spaces in the Common Areas become available during the Rental Term, Landlord
shall offer up to two (2) additional spaces to Tenant at no additional cost before offering the parking spaces to a third (3<SUP>rd</SUP>)
party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
IX. ALTERATIONS, SIGNS, LOCKS &amp; KEYS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 9.01. ALTERATIONS</B>. Tenant shall
not make or suffer to be made any alterations or additions to the Leased Premises or any part thereof in excess of Ten Thousand Dollars
($10,000.00) per Lease Year without the prior written consent of Landlord, in Landlord&rsquo;s reasonable discretion. Any additions to,
or alterations of the Leased Premises, except movable furniture, equipment and trade fixtures, shall become a part of the realty and belong
to Landlord upon the expiration of the Rental Term, or any Rental Term extension or renewal thereof, or other termination or surrender
of the Leased Premises to Landlord. Tenant shall promptly pay all contractors and materialmen so as to minimize the possibility of a lien
attaching to the Leased Premises, and should any such lien be made or filed, Tenant shall bond against or discharge the same within ten
(10) days after written request by Landlord. Landlord reserves the right to enter the Leased Premises to post, and keep posted, notices
of non-responsibility for any such liens.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 9.02. REMOVAL BY TENANT</B>. In the
event of any Landlord-approved remodeling by Tenant, Landlord reserves title to all removed materials, building components, plumbing and
HVAC equipment, except that Tenant shall remove from the Leased Premises those items which Landlord chooses not to salvage. All new alterations,
decorations, additions and improvements paid by Tenant, if any, shall be deemed to belong to Tenant although attached to the Leased Premises.
However, none of such items (excluding personal property) may be removed from the Leased Premises and shall become the property of Landlord
upon the expiration of the Rental Term, or any Rental Term renewal or extension thereof, or other termination or surrender of the Leased
Premises to Landlord. Tenant shall not remove any of such alterations, decorations, additions and improvements, although trade fixtures
installed by Tenant may be removed if all rents due herein are paid in full and Tenant is in full compliance with all other terms and
conditions in this Lease. Furthermore, Tenant shall have no obligation to remove any Landlord&rsquo;s Work or other alterations to the
Leased Premises at the end of the Rental Term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 9.03. SIGNS</B>. Tenant shall not place
or suffer to be placed or maintained on any exterior door, wall or window of the Leased Premises, or elsewhere in the Building, any sign,
awning, marquee, decoration, lettering, attachment, canopy, advertising matter or other thing of any kind, and shall not place or maintain
any decoration, lettering or advertising matter on the glass of any window or door of the Leased Premises without first obtaining Landlord&rsquo;s
prior written approval and in Landlord&rsquo;s sole and absolute discretion, provided, however, that any Tenant signage existing in or
about the Building as of the date this Lease is executed is deemed approved by Landlord, and that Landlord shall permit Tenant to install
signage at the entrance of Suites 210 and 340 consistent with the existing signage at the exterior of Suites 200, 320 and 330. Tenant
shall maintain any such sign, awning, canopy, decoration, lettering, advertising matter or other things as may be approved in good condition
and repair at all times. Landlord may, at Tenant&rsquo;s cost, and without liability to Tenant, enter the Leased Premises and remove any
item erected in violation of this Section 9.03. Landlord has established rules and regulations governing the size, type and design of
all signs, decorations, etc., which are specifically set forth in Exhibit D.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 9.04. REMOVAL OF TENANT SIGNS</B>. At
the end of the Rental Term, or any Rental Term extension or renewal thereof, or in the event Landlord or Tenant terminates this Lease,
Tenant shall remove all signage on or within the Leased Premises within thirty (30) days of the expiration or earlier termination of this
Lease. In the event Tenant fails to remove its signage within thirty (30) days of the expiration or earlier termination of this Lease,
Tenant shall pay to Landlord a fee of Fifty Dollars ($50.00) per day for each day Tenant fails to remove its signage from the Leased Premises.
Tenant shall, at Tenant&rsquo;s sole cost and expense, repair any and all damage from the removal of any Tenant signage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 9.05. COMPUTERIZED ELECTRONIC SIGNS</B>.
Subject to the approval of the city and any other governmental agency or body having jurisdiction thereover, Landlord may revise, reconstruct
or replace any computerized electronic identification sign for the Building and/or Project (the &ldquo;<B>ID Sign</B>&rdquo;), if any,
containing an electronic message panel that permits the pre-programmed display of trade name, product and service identification, advertising,
messages and announcements (&ldquo;<B>Messages</B>&rdquo;) on a periodic and rotational basis. The ID Sign can display Messages in such
time increments as Landlord shall elect from time to time in its sole discretion. The use and operation of the ID Sign shall remain under
the exclusive control of Landlord, and shall further be subject to all applicable governmental ordinances, regulations and requirements,
including, without limitation, any restrictions deemed appropriate by the zoning administrator for the city. Notwithstanding the foregoing,
if Landlord installs an ID Sign and any Building tenants are listed thereon, Tenant shall be listed in a manner no less prominent that
other tenants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 9.06. LOCKS AND KEYS</B>. Landlord shall
have the right, but not the obligation, to install a card key system for access to the Building and covered parking area and shall issue
appropriate card keys to Tenant and Tenant&rsquo;s authorized employees. Landlord shall initially provide keys or key cards for entry
doors to the Leased Premises. From time to time, Tenant may change locks or install other locks on doors, but if Tenant does, Tenant must
provide Landlord with duplicate keys or key cards, if any, within twenty-four (24) hours after such change or installation. Tenant shall,
upon termination of this Lease, deliver to Landlord all the keys and/or key cards to the Building and the Leased Premises including any
interior offices, toilet rooms, combinations to built-in safes, etc. which shall have been furnished to or by Tenant or are in the possession
of Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
X. MAINTENANCE AND REPAIRS; ALTERATIONS; ACCESS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 10.01. LANDLORD&rsquo;S OBLIGATION FOR
MAINTENANCE</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Subject to the exception and limitations set forth in paragraph 10.02(d) herein below, Landlord shall maintain and repair: (1)
the areas outside the Leased Premises including hallways, stairways, elevators, public restrooms, if any, general landscaping, Landlord
owned parking areas, driveways and walkways; (2) the Building structure including the roof, exterior walls and foundation; and (3) all
plumbing, electrical, heating, and air conditioning systems in accordance with standards for comparable office buildings in the Salt Lake
metropolitan region. However, if the need for such repairs or maintenance results from any careless, wrongful or negligent act or omission
of Tenant, Tenant shall pay the entire cost of any such repair or maintenance including a reasonable charge to cover Landlord&rsquo;s
supervisory overhead. Landlord shall not be obligated to repair any damage or defect until Landlord has actual notice of the need for
such repair or maintenance or Landlord is in receipt of written notice from Tenant of the need of such repair and Landlord shall have
a reasonable time after receipt of such notice in which to make such repairs. Tenant shall give immediate notice to Landlord in case of
fire or accidents in the Leased Premises or in the Building of which the Leased Premises is a part or of defects therein or in any fixtures
or equipment provided by Landlord. Costs of Landlord-provided maintenance for item (2) herein shall be included as Operating Expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>Generator
Equipment</I>: Throughout the Rental Term, Landlord shall maintain, repair and replace an emergency generator and a fuel tank and connecting
equipment at the Building (but outside of the Leased Premises) to provide emergency generation to the Building, including the Leased
Premises and Tenant&rsquo;s equipment located therein (collectively, the &ldquo;<B>Generator Equipment</B>&rdquo;). Within thirty (30)
days following the Effective Date, Landlord shall deliver to Tenant documentation of the Generator Equipment&rsquo;s load relative to
the Building&rsquo;s electrical load as determined by the Landlord&rsquo;s engineer, and in the event that Landlord has actual knowledge
of any material change in such load capacity during the Rental Term, Landlord shall notify Tenant of the same. Landlord shall be responsible,
at Landlord&rsquo;s sole cost and expense, for the operation, maintenance, repair and replacement of the Generator Equipment, which shall
include maintenance testing once every six (6) calendar months. Within ten (10) days Landlord&rsquo;s receipt, Landlord shall provide
Tenant with copies of all maintenance reports and test results regarding the Generator Equipment, including without limitation, submissions
to and correspondence with any governmental agency regarding such tests. In addition, throughout the Rental Term, Landlord shall maintain,
repair and replace the uninterruptable power supply for the Building (&ldquo;<B>UPS System</B>&rdquo;), which shall include maintenance
as recommended by the manufacturer thereof and replacement of batteries as needed or at least every four (4) years. If Landlord fails
to provide such reports within the aforesaid ten (10) day period or if Tenant reasonably believes that the Generator Equipment or UPS
System is not properly maintained or adequate to provide emergency generation or power supply for the Leased Premises and Landlord fails
to remedy such matters within ten (10) days following notice from Tenant, then Tenant shall have the right to exercise self-help to effectuate
any maintenance, repairs, or replacements that Tenant finds reasonably necessary, which shall include Tenant&rsquo;s right to access
the Generator Equipment and UPS System, as applicable; provided, however, that Tenant shall be responsible for any damage or loss caused
by Tenant&rsquo;s exercise of such self-help rights and shall indemnify Landlord in connection with any third party claims related thereto.
Landlord shall reimburse Tenant for the reasonable costs incurred by Tenant in connection with such self-help exercise. Except as for
Landlord&rsquo;s obligation to reimburse Tenant for any costs Tenant incurs exercising its self-help rights in accordance with this Section
10.01(b), Landlord shall not be liable for any damages arising from or related to Landlord&rsquo;s failure to operate, maintain, repair
or replace the Generator Equipment or UPS System, including any and all damages incurred by Tenant. Landlord shall ensure that the placement
and operation of the Generator Equipment and UPS System comply with all applicable laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 10.02. TENANT&rsquo;S OBLIGATION FOR
MAINTENANCE</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Tenant shall provide its own janitorial service and keep and maintain the Leased Premises, including the interior wall surfaces
and windows, floors, floor coverings and ceilings, in a clean, sanitary and safe condition in accordance with applicable laws of the State
and in accordance with all directions, rules and regulations of the health officer, fire marshal, insurance underwriter or rating bureau
designated by Landlord, building inspector, or other proper officials of the governmental agencies having jurisdiction, at the sole cost
and expense of Tenant, and Tenant shall comply with all requirements of law, ordinance and otherwise, affecting the Leased Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Tenant shall pay, when due, all claims for labor or material furnished, for work under Sections 9.01, 9.02 and 10.02(a) hereof,
to or for Tenant at or for use in the Leased Premises, and shall bond such work to prevent assertion of claims against Landlord unless
Landlord waives such requirement in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Tenant agrees to be responsible for all furnishings, fixtures and equipment located upon the Leased Premises from time to time
and shall replace carpeting within the Leased Premises if same shall be damaged by tearing, burning, or stains resulting from spilling
anything on such carpet, reasonable wear and tear excepted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Tenant
shall be responsible for the maintenance, repair and replacement of any HVAC mini split systems for server rooms and/or any other specialty
HVAC equipment exclusively serving any lab or lab equipment of the Leased Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 10.03. SURRENDER OF LEASED PREMISES
AND RIGHTS UPON TERMINATION</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>This Lease, and the tenancy hereby created, shall cease and terminate at the end of the Rental Term hereof, or any Rental Term
extension or renewal thereof, without the necessity of any notice from either Landlord or Tenant to terminate the same, and Tenant hereby
waives notice to vacate the Leased Premises and agrees that Landlord shall be entitled to the benefit of all provisions of law respecting
summary recovery of possession of the Leased Premises from Tenant holding over to the same extent as if statutory notice has been given.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Upon
termination of this Lease at any time and for any reason whatsoever, Tenant shall surrender and deliver up the Leased Premises to Landlord
in the same condition as existed upon Delivery of Possession (as to Suite 210 and 340) and as of the Effective Date for the balance of
the Leased Premises, or as altered as provided in Section 9.01, ordinary wear and tear excepted. At the end of the Rental Term, Tenant
shall promptly remove all personal property from the Leased Premises and repair any damage caused by such removal. Subject to the terms
of this Lease, upon termination of the Rental Term, Tenant shall deliver the Leased Premises to Landlord broom clean, with no obligation
of Tenant to clean any ventilation systems or components within the interior walls of the Leased Premises. Obligations under this Lease
relating to events occurring or circumstances existing prior to the date of termination shall survive the expiration or other termination
of the Rental Term of this Lease. Liabilities accruing after the date of termination are defined in Sections 13.05, 19.01 and 19.02.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
XI. INSURANCE AND INDEMNITY</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 11.01. TENANT&rsquo;S LIABILITY INSURANCE
AND INDEMNITY</B>. Tenant shall, during the entire Rental Term, and any Rental Term extension or renewal thereof, keep in full force and
effect a policy of commercial general liability insurance with respect to the Leased Premises, with a combined single limit of not less
than Two Million Dollars ($2,000,000.00) per occurrence. The policy shall name Landlord, property manager (i.e., Woodbury Corporation)
and any other persons, firms or corporations designated by Landlord and Tenant as named &ldquo;<B>Additional Insured(s)</B>&rdquo;, and
shall contain a clause that the insurer shall not cancel or change the insurance without first giving Landlord ten (10) days prior written
notice. Such insurance shall include an endorsement permitting Landlord and property manager to recover damage suffered due to act or
omission of Tenant, notwithstanding being named as an Additional Insured party in such policies. Such insurance may be furnished by Tenant
under any blanket policy carried by it or under a separate policy therefor. The insurance shall be with an insurance company approved
by Landlord and a copy of the paid-up policy evidencing such insurance or a certificate of insurer certifying to the issuance of such
policy, and providing copies of all endorsements, shall be delivered to Landlord. If Tenant fails to provide such insurance proof of insurance
within three (3) business days of request by Landlord, Landlord may do so and charge the same to Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Tenant shall indemnify, defend and hold Landlord
harmless from and against any and all claims, actions, damages, liability and expense in connection with loss of life, personal injury
and/or damage to property arising from or out of any occurrence in, upon or at the Leased Premises or from the occupancy or use by Tenant
of the Leased Premises or any part thereof, or occasioned wholly or in part by any act or omission of Tenant, its agents, contractors,
employees, servants, sublessees, concessionaires or business invitees unless caused by the negligence of Landlord and to the extent not
covered by its casualty or liability insurance. In case Landlord shall, without fault of its part, be made a party to any litigation commenced
by or against Tenant, then Tenant shall protect and hold Landlord harmless and shall pay all costs, expenses and reasonable attorneys&rsquo;
fees incurred or paid by either in defending itself or enforcing the covenants and agreements of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Split-Segment; Name: 4 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 11.02. FIRE AND CASUALTY INSURANCE</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Subject
to the provisions of this Section 11.02, Landlord shall secure, pay for, and at all times during the Rental Term, and any Rental Term
extension or renewal thereof, maintain fire and casualty extended coverage insurance providing coverage upon the Building improvements
in an amount equal to the full insurable replacement value thereof (as determined by Landlord). Such insurance shall include twelve (12)
months rental income coverage as well as such additional endorsements as may be required by Landlord&rsquo;s lender or Landlord. All
insurance required hereunder shall be written by reputable, responsible companies licensed in the State of Utah. Tenant shall have the
right, at its request at any reasonable time, to be furnished with copies of the insurance policies then in force pursuant to this Section
11.02, together with. evidence that the premiums therefor have been paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant
agrees to maintain, at its own expense, such fire and casualty insurance coverage as Tenant may desire or require in respect to Tenant&rsquo;s
personal property, equipment, furniture, fixtures or inventory and Landlord shall have no obligation in, respect to such insurance or
losses. All property kept or stored on the Leased Premises by Tenant or with Tenant&rsquo;s permission shall be so done at Tenant&rsquo;s
sole risk and Tenant shall indemnify Landlord against and hold it harmless from any claims arising out of loss or damage to same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>Tenant shall not permit the Leased Premises to be used for any purpose which would render the insurance thereon void or cause cancellation
thereof or increase the insurance risk or increase the insurance premiums in effect just prior to the Rental Term Commencement Date of
this Lease. Tenant agrees to pay as Additional Rent the total amount of any increase in the insurance premium of Landlord over that in
effect prior to the Rental Term Commencement Date of this Lease resulting from Tenant&rsquo;s use of the Leased Premises. If Tenant installs
any electrical or other equipment which overloads the lines in the Leased Premises, Tenant shall at its own expense make whatever changes
are necessary to comply with the requirements of Landlord&rsquo;s insurance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant
shall be responsible for all glass breakage in and about the Leased Premises, unless caused by Landlord, its employees or agents, and
agrees to immediately replace all glass broken or damaged during the Rental Term, and any Rental Term extension or renewal thereof, with
glass of the same quality as that broken or damaged. Landlord may replace, at Tenant&rsquo;s expense, any broken or damaged glass if
not replaced by Tenant within five (5) days after such damage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 11.03. WAIVER OF SUBROGATION</B>. Each
party hereto does hereby remise, release and discharge the other party hereto and any officer, agent, employee or representative of such
party, of and from any liability whatsoever hereafter arising from any insurable loss, damage or injury caused by fire or other casualty
for which insurance (permitting waiver of liability and containing a waiver of subrogation) is required to be carried by the injured party
pursuant to the terms of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 28; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 11.04. INDEMNIFICATION</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Subject
to the terms and conditions set forth in Section 11.03, Tenant shall indemnify Landlord and save it harmless from and against any and
all claims, actions, damages, liability and expense in connection with loss of life, personal injury and/or damage to property arising
from or out of any occurrence in, upon or at the Leased Premises or from the occupancy or use by Tenant of the Leased Premises or any
part thereof, or occasioned wholly or in part by any act or omission of Tenant, its agents, contractors, employees, servants, sublessees,
concessionaires or business invitees to extent not covered by insurance required by Article XI. In case Landlord is, without fault on
its part, made a party to any litigation commenced by or against Tenant, then Tenant shall protect and hold Landlord harmless and shall
pay all costs, expenses and reasonable attorneys&rsquo; fees incurred or paid by Landlord in defending itself or enforcing the covenants
and agreements of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Subject
to the terms and conditions set forth in Section 11.03, to the extent not covered by the insurance required to be maintained by Tenant,
or that would not have been covered by insurance had Tenant maintained such insurance, Landlord agrees to indemnify and save harmless
Tenant in regard to third parties for damages occurring on the Common Area proximately caused by the wrongful acts or negligence of Landlord,
its contractors, agents or employees in scope of their employment, including costs of defense and reasonable attorneys&rsquo; fees incurred
in such defense. In case Tenant is, without fault on its part, made a party to litigation against Landlord as a result of such acts or
negligence which Tenant&rsquo;s insurer is not required to defend, then Landlord shall indemnify Tenant against costs of such defense
including reasonable attorneys&rsquo; fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
XII. UTILITY CHARGES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 12.01. OBLIGATION OF LANDLORD</B>. Unless
otherwise agreed in writing by the parties, during the Rental Term of this Lease Landlord shall cause to be furnished to the Leased Premises
at all times, but subject to Section 1.01 (Q) the following utilities and services, the cost and expense of which shall be included in
Operating Expenses:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Electricity,
water, gas and sewer service;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Telephone connection, but not including telephone stations and equipment (it being expressly understood and agreed that Tenant
shall be responsible for the ordering and installation of telephone lines and equipment which pertain to the Leased Premises);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Heat
and air-conditioning to such extent and to such levels as, in Landlord&rsquo;s judgment, is reasonably required for the comfortable use
and occupancy of the Leased Premises subject however to any limitations imposed by any government agency. The parties agree and understand
that the above heat and air-conditioning shall be provided to the Leased Premises at all times during the Rental Term, but subject to
Section 1.01 (Q);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 29; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Snow
removal and parking lot sweeping services for parking areas that are Common Areas of the Building;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Elevator
service;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Building
systems maintenance services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 12.02. OBLIGATIONS OF TENANT</B>. Tenant
shall arrange for and shall pay the entire cost and expense of all telephone and data installation and services, equipment and monthly
use charges, electric light bulbs (but not fluorescent bulbs used in fixtures originally installed in the Leased Premises) and all other
materials and services not expressly required to be provided and paid for pursuant to the provisions of Section 12.01. Tenant covenants
to use good faith efforts to reasonably conserve utilities by turning off lights and equipment when not in use and taking such other reasonable
actions in accordance with sound standards for energy conservation. Notwithstanding the foregoing, it is the nature of Tenant&rsquo;s
business that certain equipment remain in operation at all times, but Tenant shall be subject to the excess costs set forth Section 1.01
(Q). Additional limitations of Tenant are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant
shall not, without the written consent of Landlord, which consent shall not be unreasonably withheld, use any apparatus or device on
the Leased Premises using current in excess of 208 volts which shall in any way or to any extent increase the amount of electricity or
water usually furnished or supplied for use on the Leased Premises for the Permitted Use designated in Section 1.01(F), nor connect with
electrical current, except through existing electrical outlets in the Leased Premises, or water pipes, any apparatus or device, for the
purposes of using electric current or water;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
Tenant shall require water or electric current in excess of that usually furnished or supplied for use of the Leased Premises, or for
purposes other than those designated in Section 1.01(F), Tenant shall first procure the written consent of Landlord for the use thereof,
which consent Landlord may refuse and/or Landlord may cause a water meter or electric current meter to be installed in the Leased Premises,
so as to measure the amount of water and/or electric current consumed for any such use. The cost of such meters and of installation maintenance,
and repair thereof shall be paid for by Tenant and Tenant agrees to pay Landlord promptly upon demand by Landlord for all such water
and electric current consumed as shown by such meters, to the extent in excess of Tenant&rsquo;s Pro-Rata share of such Operating Expenses,
at the rates charged for such service by the city in which the Building is located or the local public utility, as the case may be, furnishing
the same, plus any additional expense incurred in keeping account of the water and electric current so consumed; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
and where heat generating devices are used in the Leased Premises which affect the temperature otherwise maintained by the air conditioning
system, Landlord reserves the right, after thirty (30) day notice and cure period, to install additional or supplementary air conditioning
units for the Leased Premises, and the entire cost of installing, operating, maintaining and repairing the same shall be paid by Tenant
to Landlord promptly after demand by Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 30; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 12.03. </B>Intentionally Omitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 12.04. LIMITATIONS ON LANDLORD&rsquo;S
LIABILITY</B>. Landlord shall not be liable for and Tenant shall not be entitled to terminate this Lease or to effectuate any abatement
or reduction of Base Monthly Rent by reason of Landlord&rsquo;s failure to provide or furnish any of the foregoing utilities or services
if such failure was reasonably beyond the control of Landlord. In no event shall Landlord be liable for loss or injury to persons or property,
however, arising or occurring in connection with or attributable to any failure to furnish such utilities or services even if within the
control of Landlord. Notwithstanding anything in this Section 12.04, to the contrary, if an interruption or cessation of a utility service
to the Leased Premises from a cause within the reasonable control of Landlord results in the Leased Premises being unusable by Tenant
for the conduct of Tenant&rsquo;s business, then Base Monthly Rent shall be abated commencing on that date which is seven (7) consecutive
business days following the date Tenant delivers written notice to Landlord of such interruption and continuing until either such utility
service to the Leased Premises is restored or the Leased Premises is again usable for the conduct of Tenant&rsquo;s business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
XIII. ESTOPPEL AND OFF-SET STATEMENT, ATTORNMENT<BR>
AND SUBORDINATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 13.01. ESTOPPEL OR OFF-SET STATEMENT</B>.
Tenant agrees, within ten (10) days after request therefor by Landlord, to execute in recordable form and deliver to Landlord a statement
in writing, certifying:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;that
this Lease is unmodified and in full force and effect, or if there have been modifications, stating the modifications;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
Rental Term Commencement Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;that
rent is paid currently without any off-set or defense thereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
amount of rent, if any, paid in advance; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>that there are no uncured defaults by Landlord or stating those claimed by Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 13.02. ATTORNMENT</B>. In the event
any proceedings are brought for the foreclosure of, or in the event of exercise of the power of sale under any mortgage or deed of trust
made by Landlord covering the Leased Premises, or in the event Landlord conveys in a sale all of its rights and duties in and to this
Lease and the Leased Premises, Tenant shall attorn to the purchaser upon any such foreclosure or sale and recognize such purchaser as
Landlord under this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 31; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 13.03. SUBORDINATION</B>. Tenant agrees
that this Lease shall, at the request of Landlord, be subordinate to any first mortgages or deeds of trust that may hereafter be placed
upon the Leased Premises and to any and all advances to be made thereunder; and to the interest thereon, and any Rental Term renewals,
replacements and extensions thereof, provided the mortgagees or trustees named in such mortgages or deeds of trust shall agree to recognize
this Lease in the event of foreclosure, if Tenant is not in default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 13.04. MORTGAGEE SUBORDINATION</B>.
Tenant hereby agrees that this Lease shall, if at any time requested by Landlord or any lender in respect to Landlord&rsquo;s financing
of the Building or the property in which the Leased Premises is located or any portion hereof, be made superior to any mortgage or deed
of trust that may have preceded this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
XIV. ASSIGNMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 14.01. ASSIGNMENT</B>. Tenant shall
not assign this Lease or sublet the Leased Premises, or any part thereof, without first obtaining the written consent of Landlord, which
consent shall not be unreasonably withheld. The consent of Landlord shall not relieve Tenant from continuing liability for all obligations
under this Lease. Any Assignment (as defined herein) by operation of law or if Tenant is a corporation, unincorporated association or
partnership, the transfer, assignment or hypothecation of any stock or interest in such corporation, association or partnership in the
aggregate in excess of fifty percent (50%) shall be deemed an &ldquo;<B>Assignment</B>&rdquo; within the meaning of this Section 14.01.
An Assignment consummated in violation of the provisions of this Article XIV shall be null and void and of no force or effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 14.02. </B>Intentionally Omitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 14.03. CONDITIONS OF CONSENT</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Should
consent be granted, such consent shall be subject to Tenant causing the Assignee to execute an agreement directly with Landlord undertaking
to be bound by all the terms, covenants and conditions contained in this Lease as though Assignee had originally executed this Lease
as Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Tenant
shall pay to Landlord any and all consideration received by Tenant for such Assignment to the extent such consideration exceeds the remaining
book value of Tenant&rsquo;s leasehold improvements paid for by Tenant, whether paid in lump sum or in rent exceeding Base Monthly Rent
required under this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;At
no time when Tenant is in default in the performance of any covenant of this Lease or in payment of Base Monthly Rent or any other matured
sums payable hereunder shall any Assignment be approved or permitted, nor shall the notice provision of Section 14.02 limit the right
to declare default and pursue other remedies provided for in this Lease or under the laws of the State of Utah.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 32; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 14.04. STANDARDS OF REASONABLENESS IN
WITHHOLDING CONSENT</B>. In determining whether to grant consent, Landlord may consider any statutory or common law tests including, but
not limited to, the following tests, each of which if applicable in Landlord&rsquo;s sole business judgment, shall be deemed a reasonable
ground for rejection:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Any
Assignment disapproved by Landlord&rsquo;s lender;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Any
Assignment resulting in a change of Permitted Use from that specified in Section 1.01(F);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Any
Assignment to an Assignee who lacks good reputation, successful business experience in Tenant&rsquo;s type of business and substantial
means and financial capacity adequate to conduct such a business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Any
Assignment which would breach any covenant of Landlord respecting use or exclusivity in any other lease, financing agreement or other
agreement relating to the Building:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">However, any Assignment to a parent corporation,
or to a successor corporation acquiring substantially all the assets of Tenant, and intending to operate Tenant&rsquo;s business under
the same trade name, shall be deemed reasonable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Consent by Landlord to one (1) or more Assignments
shall not constitute a waiver or consent to any subsequent Assignment nor exhaust Landlord&rsquo;s rights under this Article XIV; nor
shall acceptance of Base Monthly Rent, Additional Rent or any other payment from Assignee be deemed a waiver or consent by Landlord or
an acceptance of such Assignment. Any Assignment without such Landlord&rsquo;s consent shall be void and of no force and effect and shall
confer no estate or benefit on anyone, nor shall Landlord be required to terminate this Lease in order to invalidate such Assignment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 14.05. DOCUMENTATION OF ASSIGNMENT</B>.
Whether the documentation of any such Assignment shall be prepared by Tenant or by Landlord or its attorneys, all costs and reasonable
attorneys&rsquo; fees related to considering such Assignment shall be paid by Tenant, which fees payable to Landlord shall in no case
be more than One Thousand Dollars ($1,000.00) per Assignment considered, payable by Tenant upon demand as Additional Rent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 14.06. CONTINUING LIABILITY OF TENANT</B>.
Neither the consent of Landlord nor any otherwise permitted Assignment or subletting shall relieve Tenant from continuing liability under
this Lease, including liability for Base Monthly Rent as provided in Section 1.01(L) and 1.01(M) and any Additional Rent for which Tenant
shall remain obligated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 14.07. VOIDABLE ASSIGNMENT</B>. Any
assignment, subletting, occupancy or use without the prior written consent of Landlord shall be voidable in Landlord&rsquo;s sole and
absolute discretion and shall constitute a default under this Lease. Tenant specifically understands and agrees that at any time Tenant
is in default under the provisions of this Article XIV, Tenant shall have no right to assign or sublet Tenant&rsquo;s interest in this
Lease and Landlord shall have no obligation to give approval or disapproval under this Article XIV should Tenant attempt an assignment
or subletting while in default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 33; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
XV. WASTE OR NUISANCE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 15.01. WASTE OR NUISANCE</B>. Tenant
shall not commit or suffer to be committed any waste upon the Leased Premises, or any nuisance or other act or thing which may disturb
the quiet enjoyment of any other tenant in the Building in which the Leased Premises may be located, or elsewhere within the Building
or the Common Areas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
XVI. NOTICES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 16.01. NOTICES</B>. Except as provided
in Section 19.01, any notice, demand, request or other instrument which may be or is required to be given under this Lease shall be personally
delivered or mailed by United States certified mail, return receipt requested, postage prepaid, or via a nationally recognized overnight
courier or expedited mail service, and shall be addressed (a) if to Landlord at the address set forth in Section 1.01(C), Section 6.01
and Section 6.03, or at such other address as Landlord may designate by written notice and (b) if to Tenant at the address set forth in
Section 1.01(E) or at such other address as Tenant shall designate by written notice. Notice shall be effective on delivery unless delivery
is refused or cannot be made, in which event notice shall be effective on mailing. In order for notices to be deemed received by Landlord,
Tenant must include the details as outlined in Section 1.01(C), Section 6.01 and Section 6.03.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Notwithstanding the foregoing, any notices Landlord
is required or authorized to deliver to Tenant in order to advise Tenant of alleged violations of Tenant&rsquo;s covenants relating to
advertising, signs, parking of automobiles, hours of operation, failure of Tenant to properly maintain or repair the Leased Premises,
all as provided in, but not limited to, Articles VII, IX and X and Sections 8.01, 15.01 and 16.02, must be in writing but may be served
upon Tenant by delivering a copy of such notice to Tenant as above specified and delivering a copy of such notice to one (1) of Tenant&rsquo;s
managing employees at the Leased Premises</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
XVII. DESTRUCTION OF THE LEASED PREMISES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 17.01. DESTRUCTION</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
the Leased Premises is partially or totally destroyed by fire or other casualty insurable under standard fire insurance policies with
extended coverage endorsement so as to become partially or totally untenantable, the same shall be repaired or rebuilt as speedily as
practical under the circumstances at the expense of Landlord, unless Landlord elects not to repair or rebuild as provided in subsection
(b) of this Section 17.01. During the period required for restoration, a just and proportionate part of Base Monthly Rent, Additional
Rent and other charges payable by Tenant hereunder shall be abated until the Leased Premises is repaired or rebuilt. If Landlord does
not commence to repair or rebuild for a period equaling one hundred eighty (180) days from the date of the insurance settlement, Tenant
may terminate this Lease upon thirty (30) days&rsquo; prior written notice to Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 34; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
the Leased Premises is (i) rendered totally untenantable by reason of an occurrence described in subsection 17.01(a), or (ii) damaged
or destroyed as a result of a risk which is not insured under Landlord&rsquo;s fire insurance policies, or (iii) at least twenty percent
(20%) damaged or destroyed during the last year of the Rental Term, or (iv) if the Building is damaged in whole or in part (whether or
not the Leased Premises is damaged), to such an extent that Tenant cannot practically use the Leased Premises for its intended purpose,
then and in any such events Landlord may at its option terminate this Lease by notice in writing to Tenant within sixty (60) days after
the date of such occurrence. Unless Landlord gives such notice, this Lease shall remain in full force and effect and Landlord shall repair
such damage at its expense as expeditiously as possible under the circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
Landlord should elect or be obligated, pursuant to subsection 17.01(a), to repair or rebuild because of any damage or destruction, Landlord&rsquo;s
obligation shall be limited to the original Building and any other work or improvements which may have been originally performed or installed
at Landlord&rsquo;s expense. If the cost of performing Landlord&rsquo;s obligation exceeds the actual proceeds of insurance paid or payable
to Landlord on account of such casualty, Landlord may terminate this Lease unless Tenant, within fifteen (15) days after demand therefor,
deposits with Landlord a sum of money sufficient to pay the difference between the cost of repair and the proceeds of the insurance available
for such purpose. Tenant shall replace all work and improvements not originally installed or performed by Landlord at its expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as stated in this Article XVII, Landlord shall not be liable for any loss or damage sustained by Tenant by reason of casualties mentioned
hereinabove or any other accidental casualty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
XVIII. CONDEMNATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 18.01. CONDEMNATION</B>. As used in
this Section 18.01, the term &ldquo;<B>Condemnation Proceeding(s)</B>&rdquo; means any action or proceeding in which any interest in the
Leased Premises or the Building is taken for any public or quasi-public purpose by any lawful authority through exercise of the power
of eminent domain or right of condemnation or by purchase or otherwise in lieu thereof. If the whole of the Leased Premises is taken through
Condemnation Proceedings, this Lease shall automatically terminate as of the date possession is taken by the condemning authority. If
in excess of twenty-five percent (25%) of the Leased Premises is taken, either party hereto shall have the option to terminate this Lease
by giving the other written notice of such election at any time within thirty (30) days after the date of taking. If less than twenty-five
percent (25%) of the space is taken and Landlord determines, in Landlord&rsquo;s sole discretion, that a reasonable amount of reconstruction
thereof shall not result in the Leased Premises or the Building becoming a practical improvement reasonably suitable for use for the purpose
for which it is designed, then Landlord may elect to terminate this Lease by giving thirty (30) days written notice as provided hereinabove.
If Landlord does not commence to repair or rebuild for a period equaling one hundred eighty (180) days from the date of the insurance
settlement, Tenant may terminate this Lease upon thirty (30) days&rsquo; prior written notice to Landlord. In all other cases, or if neither
party exercises its option to terminate, this Lease shall remain in effect and the rent payable hereunder from and after the date of taking
shall be proportionately reduced in proportion to the ratio of: (i) the area contained in the Leased Premises which is capable of occupancy
after the taking; to (ii) the total area contained in the Leased Premises which was capable of occupancy prior to the taking. In the event
of any termination or rental reduction provided for in this Section 18.01, there shall be a proration of the rent payable under this Lease
and Landlord shall refund any excess theretofore paid by Tenant. Whether or not this Lease is terminated as a consequence of Condemnation
Proceedings, all damages or compensation awarded for a partial or total taking, including any sums compensating Tenant for diminution
in the value of or deprivation of its leasehold estate, shall be the sole and exclusive property of Landlord, except that Tenant shall
be entitled to any awards intended to compensate Tenant for expenses of locating and moving Tenant&rsquo;s operations to a new space.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 35; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
XIX. DEFAULT OF TENANT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 19.01. DEFAULT - RIGHT TO RE-ENTER</B>.
In the event of any failure of Tenant to pay any Base Monthly Rent, Additional Rent and other charges due hereunder within ten (10) days
after the same shall be due, or any failure by Tenant to perform any other of the terms, conditions or covenants required of Tenant by
this Lease within thirty (30) days after written notice of such default shall have been mailed to Tenant by registered mail to Tenant&rsquo;s
address as listed in Section 1.01(E) or to such address as Tenant has specified in writing, or if Tenant shall permit this Lease to be
taken under any writ of execution, then Landlord, besides other rights or remedies it may have, shall have the right to declare this Lease
terminated and the Rental Term ended and shall have the immediate right of re-entry and may remove all persons and property from the Leased
Premises. Such property may be removed and stored in a public warehouse or elsewhere at the cost of and for the account of Tenant, without
evidence of notice or resort to legal process and without being deemed guilty of trespass, or becoming liable for any loss or damage which
may be occasioned thereby. Tenant hereby waives all compensation for the forfeiture of the Rental Term or its loss of possession of the
Leased Premises in the event of the forfeiture of this Lease as provided for above. Any notice that Landlord may desire or is required
to give Tenant with reference to the foregoing provision may, in lieu of mailing, at the option of Landlord, be conspicuously posted for
ten (10) consecutive days at the main entrance to or in front of the Leased Premises, and such notice shall constitute a good, sufficient,
and lawful notice for the purpose of declaring a forfeiture of this Lease and for terminating all of the rights of Tenant hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 36; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 19.02. DEFAULT - RIGHT TO RE-LET</B>.
Should Landlord elect to re-enter, as provided herein, or should it take possession pursuant to legal proceedings or pursuant to any notice
provided for by law, it may either terminate this Lease or it may from time to time, without terminating this Lease, make such alterations
and repairs as may be necessary in order to re-let the Leased Premises and may re-let the Leased Premises, or any part thereof, for such
term or terms (which may be for a term extending beyond the Rental Term of this Lease) and at such rent or rental income and upon such
other terms and conditions as Landlord in its sole discretion may deem advisable. Upon each re-letting, all rental income received by
Landlord from such re-letting shall be applied, first, to the payment of any indebtedness other than rents due hereunder from Tenant to
Landlord; second, to the payment of any costs and expenses of such re-letting, including brokerage fees and attorneys&rsquo; fees and
costs of such alterations and repairs; third, to the payment of rents due and unpaid hereunder; and fourth, the residue, if any, shall
be held by Landlord and applied in payment of future rent as the same may become due and payable hereunder. If such rental income received
from such re-letting during any month is less than those payable during that month by Tenant hereunder, Tenant shall pay any such deficiency
immediately to Landlord. Such deficiency shall be calculated and paid monthly. No such re-entry or taking possession of the Leased Premises
by Landlord shall be construed as an election on its part to terminate this Lease unless a written notice of such intention is given to
Tenant or unless the termination thereof is decreed by a court of competent jurisdiction. Notwithstanding any such re-letting without
termination, Landlord may at any time thereafter elect to terminate this Lease for such previous breach. Should Landlord at any time terminate
this Lease for any breach, in addition to any other remedies it may have, it may recover from Tenant all damages it may incur by reason
of such breach, including the cost of recovering the Leased Premises, reasonable attorneys&rsquo; fees, and including the worth at the
time of such termination of the excess, if any, of the amount of rents and other charges equivalent to rents reserved in this Lease for
the remainder of the stated Rental Term over the then reasonable rental value of the Leased Premises for the remainder of the Rental Term,
all of which amounts shall be immediately due and payable from Tenant to Landlord. In determining the rents which would be payable by
Tenant hereunder, subsequent to default, Base Monthly Rent for each year of the unexpired Rental Term shall be equal to the average Base
Monthly Rent and Additional Rent payable by Tenant from the Rental Term Commencement Date to the time of default, or during the preceding
three (3) full calendar years, whichever is the greater amount. Notwithstanding anything to the contrary in this Lease, Landlord&rsquo;s
remedies as set forth in the Lease shall be subject to the legal doctrines of mitigation and offset. In exercising its remedies following
an event of default by Tenant, Landlord shall use commercially reasonable efforts to mitigate its damages and shall use reasonable efforts
to re-let the Leased Premises on favorable market terms</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 19.03. LEGAL EXPENSES</B>. In case of
default by either party in the performance and obligations under this Lease, the non-prevailing party shall pay all costs incurred in
enforcing this Lease, or any right arising out of the breach thereof, whether by suit or otherwise, including reasonable attorneys&rsquo;
fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
XX. BANKRUPTCY, INSOLVENCY OR RECEIVERSHIP</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 20.01. ACT OF INSOLVENCY, GUARDIANSHIP,
ETC</B>. The following shall constitute a default of this Lease by Tenant for which Landlord, at Landlord&rsquo;s option, may immediately
terminate this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
appointment of a receiver to take possession of all or substantially all of the assets of Tenant;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;A
general assignment by Tenant of its assets for the benefit of creditors;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Any
action taken or suffered by or against Tenant under any federal or state insolvency or bankruptcy act; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
appointment of a guardian, conservator, trustee, or other similar officer to take charge of all or any substantial part of Tenant&rsquo;s
property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Neither this Lease, nor any interest therein nor
any estate thereby created shall pass to any trustee, guardian, receiver or assignee for the benefit of creditors or otherwise by operation
of law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 37; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 20.02. BANKRUPTCY</B>. If Landlord shall
not be permitted to terminate this Lease as hereinabove provided because of the provisions of the United States Code relating to Bankruptcy
(&ldquo;<B>Bankruptcy Code</B>&rdquo;), then Tenant as a debtor-in-possession or any trustee for Tenant agrees promptly, within no more
than fifteen (15) days upon request by Landlord to the &ldquo;<B>Bankruptcy Court</B>&rdquo;, to assume or reject this Lease and Tenant
on behalf of itself, and any trustee agrees not to seek or request any extension or adjournment of any application to assume or reject
this Lease by Landlord with such Bankruptcy Court. In such event, Tenant or any trustee for Tenant may only assume this Lease if (a) it
cures or provides adequate assurance that the trustees shall promptly cure any default hereunder, (b) compensates or provides adequate
assurance that Tenant shall promptly compensate Landlord for any actual pecuniary loss to Landlord resulting from Tenant&rsquo;s defaults,
and (c) provides adequate assurance of performance during the fully stated Rental Term hereof of all the terms, covenants, and provisions
of this Lease to be performed by Tenant. In no event after the assumption of this Lease shall any then-existing default remain uncured
for a period in excess of the earlier of ten (10) days or the time period set forth herein. Adequate assurance of performance of this
Lease, as set forth hereinabove, shall include, without limitation, adequate assurance (1) of the source of rent reserved hereunder, (2)
that the assumption of this Lease shall not breach any provision hereunder, and (3) that business operated shall comply with the Permitted
Use covenants set forth in Sections 1.01(F) and 7.01. In the event of a filing of a petition under the Bankruptcy Code, Landlord shall
have no obligation to provide Tenant with any services or utilities as herein required, unless Tenant shall have paid and be current in
all payments of Operating Expenses, utilities or other charges therefor. Tenant shall pay all of Landlord&rsquo;s costs incurred as a
result of Tenant&rsquo;s insolvency and/or bankruptcy proceedings including, but not limited to, reasonable attorneys&rsquo; fees incurred
as a result of Landlord&rsquo;s participation in and/or monitoring of Tenant&rsquo;s insolvency proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
XXI. LANDLORD ACCESS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 21.01. LANDLORD ACCESS</B>. Except in
the case of emergency and subject to the foregoing, Landlord or Landlord&rsquo;s agent shall have the right to enter the Leased Premises
upon forty-eight (48) hours prior notice at all reasonable times to examine the same, or to show the Leased Premises to prospective purchasers
or lessees of the Building, or to make all reasonable repairs, alterations, improvements or additions as Landlord may deem necessary or
desirable, to the extent such is necessary to the structure or utility functions of the Building and does not materially adversely affect
the Leased Premises, and Landlord shall be allowed to take all material into and upon the Leased Premises that may be required therefor
without the same constituting an eviction of tenant in whole or in part, and the rents reserved shall not abate while such repairs, alterations,
improvements, or additions are being made, by reason of loss or interruption of business of Tenant, or otherwise. Landlord shall have
no liability to Tenant for any damages suffered by Tenant and/or to Tenant&rsquo;s property occur during the required forty-eight (48)
hour notice period. During the ninety (90) days prior to the expiration of the Rental Term, or any Rental Term extension or renewal thereof,
Landlord may exhibit the Leased Premises to prospective tenants and place upon the Leased Premises the usual notices &ldquo;To Let&rdquo;
or &ldquo;For Rent&rdquo; which notices Tenant shall permit to remain thereon without molestation. Notwithstanding anything to the contrary
herein, in the event that at any time during the Rental Term, Tenant notifies Landlord that any portion of the Leased Premises has been
designated for restricted entry, then Landlord agrees to abide by the restricted entry requirements as Tenant may provide. Notwithstanding
the foregoing or anything to the contrary in this Lease, neither Landlord nor any of its agents, lenders or purchasers (actual or prospective)
shall at any time during the Rental Term (i) enter any of the laboratory portions of the Leased Premises unless accompanied by a representative
of Tenant and in compliance with any reasonable gowning or other protocols required by Tenant to protect the sterile environment, or (ii)
cause any laboratory equipment to be powered down without Tenant&rsquo;s consent; provided, however, that the foregoing requirements shall
not apply in an emergency or in the event that Tenant fails to make a representative available to accompany Landlord or its agents, lenders
or purchasers (actual or prospective) upon at least forty-eight (48) hours&rsquo; notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 38; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
XXII. TENANT&rsquo;S PROPERTY AND LANDLORD&rsquo;S LIEN</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 22.01. TAXES ON LEASEHOLD</B>. Tenant
shall be responsible for and shall pay before delinquency all municipal, county and state taxes assessed during the Rental Term of this
Lease against any leasehold interest, improvements, trade fixtures or personal property of any kind, owned by or placed in, upon or about
the Leased Premises by Tenant, and taxes, levies or fees assessed on the basis of Tenant&rsquo;s occupancy thereof, including, but not
limited to, taxes measured by Base Monthly Rent and Additional Rent due from Tenant hereunder. Landlord shall have no liability to Tenant
for any damages suffered by Tenant and/or to Tenant&rsquo;s property occurring during the required forty-eight (48) hour notice period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 22.02. </B>Intentionally Omitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 22.03. </B>Intentionally Omitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 22.04. LANDLORD&rsquo;S LIEN</B>. Tenant
is advised that Utah Code Section 38-3-1 and following grants Landlord (Lessor) a lien in regard to unpaid rent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 22.05. LANDLORD&rsquo;S SUBORDINATION</B>.
Provided that Tenant is not in default hereunder, Landlord agrees to subordinate its lien on Tenant&rsquo;s personal property to that
of any bona-fide third party lender providing financing which directly benefits Tenant&rsquo;s operations in the Leased Premises. However,
Landlord shall refuse and shall otherwise not be required to subordinate its lien or priority as to Tenant&rsquo;s equipment or trade
fixtures, and Landlord shall be entitled to refuse subordination if loans are not directly related to the Leased Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
XXIII. HOLDING OVER</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 23.01. HOLDING OVER</B>. Any holding
over after the expiration of the Rental Term, or any Rental Term extension thereof, without landlord&rsquo;s approval, shall be construed
to be a tenancy-at-will and all provisions of this Lease shall be and remain in effect except that Base Monthly Rent shall be double the
amount of Base Monthly Rent (including any adjustments as provided herein) payable for the last full calendar month of the Rental Term,
including any Rental Term extension or renewal thereof, or tenancy on a month-to-month basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 23.02. SUCCESSORS</B>. All rights and
liabilities herein given to, or imposed upon, the respective parties hereto shall extend to and bind the several respective heirs, executors,
administrators, successors and assigns of such parties; and if there shall be more than one (1) tenant, they shall all be bound jointly
and severally by the terms, covenants and agreements herein. No rights, however, shall inure to the benefit of any assignee of Tenant
unless the assignment to such assignee has been approved by Landlord in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 39; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
XXIV. RULES AND REGULATIONS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 24.01. RULES AND REGULATIONS</B>. Tenant
agrees to comply with and observe all rules and regulations as established by Landlord and which are now, or which may be hereafter, prescribed
by Landlord from time to time, provided, in Landlord&rsquo;s commercially reasonable discretion, and posted in or about the Leased Premises
or otherwise brought to the notice of Tenant, both with regard to the Building as a whole and to the Leased Premises, including Common
Areas and Common Facilities. Tenant&rsquo;s failure to keep and observe such rules and regulations shall constitute a breach of the terms
of this Lease in the manner as if such rules and regulations were contained herein as covenants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
XXV. QUIET ENJOYMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 25.01. QUIET ENJOYMENT</B>. Upon payment
by Tenant of the rents herein provided, and upon the observance and performance of all the covenants, terms and conditions on Tenant&rsquo;s
part to be observed and performed, Tenant shall peaceably and quietly hold and enjoy the Leased Premises for the Rental Term, or any Rental
Term extension or renewal thereof, without hindrance or interruption by Landlord or any other person or persons lawfully or equitably
claiming by, through or under Landlord, subject, nevertheless, to the terms and conditions of this Lease and actions resulting from future
eminent domain proceedings and casualty losses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
XXVI. SECURITY DEPOSIT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 26.01. SECURITY DEPOSIT</B>. Landlord
herewith acknowledges receipt of the Security Deposit in the amount set forth in Section 1.01(S), which is to be retained as security
for the faithful performance of all the covenants, conditions and agreements of this Lease, but in no event shall Landlord be obliged
to apply the same upon rents or other charges in arrears or upon damages for Tenant&rsquo;s failure to perform such covenants, conditions
and agreements; Landlord may so apply the Security Deposit, at its option; and Landlord&rsquo;s right to the possession of the Leased
Premises for non-payment of rents or for other reasons shall not in any event be affected by reason of the fact that Landlord holds the
Security Deposit. Such sum, if not applied toward the payment of rents in arrears or toward the payment of damages suffered by Landlord
by reason of Tenant&rsquo;s breach of the covenants, conditions and agreements of this Lease, is to be returned to Tenant within thirty
(30) days following termination of the Rental Term without interest when this Lease is terminated or expired, according to these terms,
and in no event is the Security Deposit to be returned until Tenant has vacated the Leased Premises and delivered possession to Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 40; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the event that Landlord repossesses the Leased
Premises because of Tenant&rsquo;s default or because of Tenant&rsquo;s failure to carry out the covenants, conditions and agreements
of this Lease, Landlord may apply the Security Deposit toward damages as may be suffered or shall accrue thereafter by reason of Tenant&rsquo;s
default or breach. In the event of bankruptcy or other debtor-creditor proceedings against Tenant as set forth in Article XX, the Security
Deposit shall be deemed to be applied first to the payment of Base Monthly Rent, Additional Rent and other charges due to Landlord for
the earliest possible periods prior to the filing of such proceedings. Landlord shall not be obliged to keep the Security Deposit as a
separate fund, but may mix the same with its own funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 26.02. TRANSFER OF LANDLORD&rsquo;S
INTEREST IN THE SECURITY DEPOSIT</B>. Landlord may deliver the Security Deposit to the purchaser or assignee of Landlord&rsquo;s interest
in the Leased Premises and thereupon Landlord shall be discharged from any further liability with respect to the Security Deposit. Landlord
shall provide Tenant with written notice of any such transfer. This Section 26.02 shall also apply to any subsequent transfers of Landlord&rsquo;s
interest in the Leased Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
XXVII. MISCELLANEOUS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 27.01. WAIVER</B>. One (1) or more waivers
of any covenant or condition by Landlord shall not be construed as a waiver of a subsequent breach of the same covenant or condition and
the consent or approval to or of any subsequent or similar act by Tenant. The subsequent acceptance of rents hereunder by Landlord shall
not be deemed to be a waiver of any preceding breach by Tenant of any term, covenant or condition of this Lease, other than the failure
of Tenant to pay the particular rents so accepted, regardless of Landlord&rsquo;s knowledge of such preceding breach at the time of acceptance
of such rents. No breach of a covenant or condition of this Lease shall be deemed to have been waived by Landlord, unless such waiver
is in writing signed by Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 27.02. ENTIRE LEASE AGREEMENT</B>. This
Lease, the Prior Leases (as defined in Section 28.02) and the exhibits and riders, if any attached hereto or thereto and forming a part
hereof or thereof, set forth all the covenants, promises, agreements, conditions, and understandings between Landlord and Tenant concerning
the Leased Premises, and there are no covenants, promises, agreements, conditions, representations or understandings, either oral or written,
between them other than are herein set forth. No subsequent alteration, amendment, change or addition to this Lease shall be binding upon
Landlord or Tenant unless reduced to writing and signed by each party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 27.03. INTERPRETATION, USE OF PRONOUNS</B>.
Nothing contained herein shall be deemed or construed by the parties hereto, nor by any third party, as creating the relationship of principal
and agent or of partnership or of joint venture between the parties hereto, it being understood and agreed that neither the method of
computation of rent, nor any other provision contained herein, nor any acts of the parties herein, shall be deemed to create any relationship
between the parties hereto other than the relationship of Landlord and Tenant. Whenever herein the singular number is used, the same shall
include the plural, and the masculine gender shall include the feminine and neuter genders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The laws of the state where the Building is situated
shall govern the validity, performance and enforcement of this Lease. Although the printed provisions of this Lease were drawn by Landlord,
this Lease shall not be construed either for or against Landlord or Tenant, but this Lease shall be interpreted in accordance with the
general tenor of the language in an effort to reach an equitable result.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 41; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The parties agree that any deletion of language
from this Lease prior to mutual execution by Landlord and Tenant shall not be construed to have any particular meaning or to raise any
presumption or implication, including without limitation, any implication that the parties intended thereby to state the converse or opposite
of the deleted language. It is the intention of the parties hereto that, if any provision of this Lease is capable of two (2) constructions,
one (1) of which would render the provision void and one (1) of which would render the provision valid, then the provision shall have
the meaning which renders it valid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 27.04. FORCE MAJEURE</B>. In the event
that either party hereto shall be delayed or hindered in or prevented from the performance of any act required hereunder by reason of
strikes, lockouts, labor troubles, inability to procure materials, failure of power, restrictive governmental laws or regulations, riots,
insurrection, war or other reason of a like nature not the fault of the party delayed in performing work or doing acts required under
the terms of this Lease, then performance of such act shall be excused for the period of the delay and the period for the performance
of any such act shall be extended for a period equivalent to the period of such delay. The provisions of this Section 27.04 shall not
operate to excuse Tenant from prompt payment of Base Monthly Rent, Additional Rent or any other payments required by the terms of this
Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 27.05. LOSS AND DAMAGE</B>. Landlord
shall not be responsible or liable to Tenant for any loss or damage that may be occasioned by or through the acts or omissions of persons
occupying all or any part of the Leased Premises adjacent to or connected with the Leased Premises or any part of the Building of which
the Leased Premises is a part, or for any loss or damage resulting to Tenant or its property from bursting, stoppage or leaking of water,
gas sewer or steam pipes or for any damage or loss of property within the Leased Premises from any cause whatsoever.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 27.06. CAPTIONS AND SECTION NUMBERS</B>.
The captions, section numbers, article numbers and index appearing in this Lease are inserted only as a matter of convenience and in no
way define, limit, construe, or describe the scope or intent of such sections or articles of this Lease nor in any way affect this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 27.07. BROKER&rsquo;S COMMISSION</B>.
Each of the parties represents and warrants that there are no claims for brokerage commissions or finder&rsquo;s fees in connection with
the execution of this Lease, except as listed below, and each of the parties agrees to indemnify the other against, and hold it harmless
from, all liabilities arising from any such claim (including, without limitation, the cost of reasonable attorneys&rsquo; fees in connection
therewith) except as follows: Landlord has commission obligation to Woodbury Corporation. This provision in no way creates any third-party
beneficiary rights in any party, nor does it create any liability on the part of Tenant to pay any or all of the commission due Tenant&rsquo;s
broker or Landlord&rsquo;s broker.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 27.08. RECORDING</B>. Tenant shall not
record this Lease without the written consent of Landlord; however, upon the request of either party hereto, the other party shall join
in the execution of a memorandum or so-called &ldquo;short form&rdquo; of this Lease for the purposes of recordation. Such memorandum
nr short form of this Lease shall describe the parties, the Leased Premises, the Rental Term, and any Rental Term extension or renewal
thereof, any special provisions, and shall incorporate this Lease by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 42; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 27.09. CONSENT NOT UNREASONABLY WITHHELD</B>.
Landlord agrees that whenever under this Lease a provision is made for Tenant to secure the written consent of Landlord, such written
consent shall not be unreasonably withheld, except as provided in Article XIV.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 27.10. </B>Intentionally Omitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 27.11. TIME OF ESSENCE</B>. Time is
of the essence in the performance of all covenants and conditions in this Lease for which time is a factor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 27.12. ACCORD AND SATISFACTION</B>.
No payment by Tenant or receipt by Landlord of a lesser amount than the amount owing hereunder shall be deemed to be other than on account
of the earliest stipulated amount receivable from Tenant, nor shall any endorsement or statement on any check or any letter accompanying
any check or payment as rent be deemed an accord and satisfaction, and Landlord may accept such check or payment without prejudice to
Landlord&rsquo;s right to recover the balance of such rent or receivable or pursue any other remedy available under this Lease or the
law of the state wherein the Leased Premises is located.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 27.13. NO OPTION</B>. The submission
of this Lease for examination does not constitute a reservation of, or option for, the Leased Premises. This Lease becomes effective as
a lease only upon full execution and delivery thereof by Landlord and Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 27.14. ANTI-DISCRIMINATION</B>. Tenant
herein covenants by and for itself, its heirs, executors, administrators and assigns and all persons claiming under or through it, and
this Lease is made and accepted upon and subject to the following conditions: That there shall be no discrimination against or segregation
of any person or group of persons on account of race, sex, marital status, color, creed, national origin or ancestry, in the leasing,
subleasing, assigning, use, occupancy, tenure or enjoyment of the Leased Premises, nor shall Tenant itself, or any person claiming under
or through it, establish or permit any such practice or practices of discrimination or segregation with reference to the selection, location,
number, use or occupancy of tenants, lessees, sublessees, or subtenants in the Leased Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 27.15. SEVERABILITY</B>. If any term,
covenant or condition of this Lease or the application thereof to any person or circumstance shall, to any extent, be invalid or unenforceable,
the remainder of this Lease, or the application of such term, covenant or condition to persons or circumstances other than those as to
which it is held invalid or unenforceable, shall not be affected thereby and each term, covenant or condition of this Lease shall be valid
and be enforced to the fullest extent permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 27.16. SURVIVAL OF OBLIGATIONS</B>.
The provisions of this Lease, with respect to any obligation of Tenant to pay any sum owing in order to perform any act after the expiration
or early termination of this Lease, shall survive the expiration or early termination of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 43; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 27.17. WARRANTY OF AUTHORITY</B>. The
person(s) executing this Lease on behalf of Tenant hereby covenant(s) and warrant(s) as of the Effective Date that (a) Tenant is a duly
constituted entity, qualified to do business in the state where the Leased Premises is located, and (b) Tenant has paid all applicable
franchise fees and taxes, and (c) Tenant shall file when due all future forms, reports, fees, and other documents necessary to comply
with applicable laws. If Tenant is a corporation, Tenant shall furnish Landlord with such evidence as Landlord reasonably requires to
evidence the binding effect on Tenant of the execution of this Lease. The person(s) executing this Lease on behalf of Landlord hereby
covenant(s) and warrant(s) as of the Effective Date that (a) Landlord is a duly constituted entity, qualified to do business in the state
where the Leased Premises is located, and (b) Landlord has paid all applicable franchise fees and taxes, and (c) Landlord shall file when
due all future forms, reports, fees, and other documents necessary to comply with applicable laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 27.18. TENANT&rsquo;S LIABILITY</B>.
In the event there is more than one (1) Tenant hereunder, the liability of each shall be joint and several.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 27.19. LANDLORD&rsquo;S LIABILITY</B>.
Landlord&rsquo;s liability hereunder shall be limited solely to Landlord&rsquo;s interest in the Building.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 27.20. COUNTERCLAIM AND JURY TRIAL</B>.
In the event that Landlord commences any summary proceedings or action for non-payment of Base Monthly Rent, Additional Rent or other
charges provided for in this Lease, Tenant shall not interpose any non-compulsory counterclaim of any nature or description in any such
proceeding or action. Tenant and Landlord both waive a trial by jury of any or all issues arising in any action or proceeding between
the parties hereto or their successors, under or relating to this Lease, or any of its provisions. Notwithstanding the foregoing, this
provision shall not prohibit Tenant from bringing any claim it may have against Landlord in a separate and distinct proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 27.21. TRANSFER OF LANDLORD&rsquo;S
INTEREST IN THE LEASED PREMISES</B>. In the event of any transfer or transfers of Landlord&rsquo;s interest in the Leased Premises, the
transferor shall be automatically relieved of any and all obligations and liabilities on the part of Landlord accruing from and after
the date of such transfer, provided the transferee assumes such obligations and liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 27.22. TENANT SELECTION BY LANDLORD</B>.
Landlord reserves the absolute right to effect such other tenancies in the Building as Landlord, in the exercise of its sole business
judgment, shall determine to best promote the interests of the Building. Tenant does not rely on the fact, nor does Landlord represent,
that any specific tenant or number of tenants shall, during the Rental Term of this Lease, occupy any space in the Building.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 27.23. DISCLOSURE OF PARTIES</B>. Landlord
is a limited liability company, one (1) or more Managers of which is a licensed real estate broker or agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 27.24. </B>Intentionally Omitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 44; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 27.25. EXECUTIVE ORDER CERTIFICATION</B>.
For purposes of compliance with Executive Order 13224 and related regulations, Landlord and Tenant each represent and warrant that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;it
is not acting, directly or indirectly, for or on behalf of any person, group, entity, or nation named by any Executive Order, the United
States Department of Justice, or the United States Treasury department as a terrorist, &ldquo;Specially Designated National or Blocked
Person,&rdquo; or other banned or blocked person, entity, nation, or transaction (&ldquo;<B>SDN</B>&rdquo;) pursuant to any law, order,
rule or regulation that is enforced or administered by the Office of Foreign Assets Control (&ldquo;<B>OFAC</B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;it
is not engaged in this transaction, directly or indirectly on behalf of, any such person, group, entity or nation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;it
is not in violation of Presidential Executive order 13224, the USA Patriot Act, the Bank Secrecy Act, the Money Laundering Control Act
or an regulations promulgated pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Landlord agrees to defend, indemnify, and hold
harmless Tenant from and against any and all claims, damages, losses, risks, liabilities and expenses (including attorney&rsquo;s fees
and costs) arising from or related to any breach of the foregoing certification. Should Landlord, during the Rental Term of this Lease,
be designated an SDN, Tenant may, at its sole option, terminate this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Tenant agrees to defend, indemnify, and hold harmless
Landlord from and against any and all claims, damages, losses, risks, liabilities and expenses (including attorney&rsquo;s fees and costs)
arising from or related to any breach of the foregoing certification. Should Tenant, during the Rental Term of this Lease, be designated
an SDN, Landlord may, at its sole option, terminate this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
XXVIII. ADDITIONAL PROVISIONS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 28.01. OPTION TO RENEW</B>. Provided
Tenant is not, and has not been, in default beyond any applicable cure period under any of the terms and conditions contained herein,
Tenant shall have one (1) additional consecutive five (5) year option to renew and extend the Rental Term (&ldquo;Option&rsquo;) as provided
herein. The Option shall only be exercised by Tenant delivering written notice thereof to Landlord not less than one hundred eighty (180)
days prior to the expiration of the Rental Term. Base Monthly Rent for the Option period shall be as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 65%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">Option Period</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Base Monthly Rent</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 79%">January 1, 2023 - December 31, 2023</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 18%; font: 10pt Times New Roman, Times, Serif; text-align: right">47,570.55</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">January 1, 2024 - December 31, 2024</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">48,997.66</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">January 1, 2025 - December 31, 2025</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">50,467.59</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">January 1, 2026 - December 31, 2026</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">51,981.62</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">January 1, 2027 - December 31, 2027</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">53,541.07</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 28.02. PRIOR LEASES</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Landlord and Tenant previously entered into a lease for Suite 330 dated August 31, 2015; a lease for Suite 320 dated October 31,
2013; and, a lease for Suite 200 dated March 5, 2012 (collectively the &ldquo;<B>Prior Leases</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 45; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;From
and after the Effective Date of this Lease, the Prior Leases are hereby fully amended and superseded by this Lease notwithstanding anything
to the contrary in this Lease or the Prior Leases, Landlord and Tenant acknowledge and agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD>The parties hereby acknowledge and agree that there are no known outstanding obligations under the Prior Leases with regard to Tenant&rsquo;s
obligation to pay Base Monthly Rent or Additional Rent under the Prior Leases.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD>All improvements to the premises that are the subject of the Prior Leases are the property of Tenant throughout the Rental Term of
this Lease.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD>The full amount of the security deposits held by Landlord under the Prior Leases is Fifty-Seven Thousand Seven Hundred Dollars ($57,700.00),
which amount is hereby credited to the Security Deposit required under this Lease.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD>Tenant has no obligation under this Lease or the Prior Leases to contribute to any Operating Expenses incurred in calendar year 2017.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD>The Prior Leases are in effect until effectively terminated and replaced by this Lease and such Prior Leases shall be of no further
force or effect and the parties shall have no further obligations thereunder.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 28.03. FIRST RIGHT OF OFFER TO LEASE
CONTIGUOUS SPACE</B>. From the Effective Date of this Lease until the end of the Rental Term, Tenant shall have an ongoing right of first
offer to lease space adjacent and contiguous to the Leased Premises on the second and third floors when such applicable space becomes
available for lease as provided herein (hereinafter &ldquo;<B>First Offer Space</B>&rdquo;). For purposes hereof, the First Offer Space
(or any applicable portion thereof) shall become available for lease by Tenant immediately prior to the first time after the Effective
Date that Landlord intends to submit to a third party a bona fide proposal or letter of intent to lease such First Offer Space (or such
applicable portion thereof. Landlord shall give Tenant written notice that the First Offer Space (or such applicable portion thereof)
will or has become available for lease by Tenant and the terms (the &ldquo;<B>Offer</B>&rdquo;) upon which Landlord is willing to rent
out the First Offer Space. Tenant shall have ten (10) business days to accept the Offer by delivering to Landlord written notice of its
intent to do so. Failure of Tenant to timely deliver written notice shall be deemed a refusal by Tenant. Should Landlord thereafter intend
to offer the First Offer Space to a third party of better terms than the Offer, then Tenant shall once again have a right of first offer
and the process set forth in this Section 28.03 shall be repeated. Furthermore, if Tenant declines to exercise its right of first offer
with regard to any First Offer Space, Landlord shall have a continuing obligation to provide Tenant with a new offer with regard to any
other adjacent and continuous space during the Rental Term and with regard to the same First Offer Space if the terms of the Offer change
or more than one calendar year passes since Tenant&rsquo;s prior decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 46; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the event Tenant exercises its option to lease
the First Offer Space, Landlord and Tenant shall endeavor to execute within thirty (30) days thereafter an amendment to this Lease for
such First Offer Space upon the terms and conditions set forth in the Offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>SECTION 28.04. RIGHT TO TERMINATE</B>. Provided
Tenant is not, and has not been, in default beyond any applicable cure period under any of the terms and provisions contained herein,
Tenant shall have the one (1) time right to terminate this Lease as of December 31, 2020. To exercise such right, on or before July 1,
2020, Tenant shall provide Landlord with written notice of its intent to exercise this right to terminate. In the event Tenant exercises
this right, Tenant shall reimburse Landlord in full of any unamortized portion of Landlord&rsquo;s Construction Cost Cap and unamortized
commission payments within ten (10) days of receiving an invoice therefore from Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page(s) to Follow]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 47; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>, Landlord and Tenant
have executed and delivered this Lease as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SIGNATURES:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>LANDLORD</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 47%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>EASTLAND REGENCY, L.C., a Utah limited liability company</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>By:</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WOODBURY CORPORATION, a Utah corporation, Its Manager</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ <FONT STYLE="font: 10pt Times New Roman, Times, Serif">O. Randall Woodbury, President</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">O. Randall Woodbury, President</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ <FONT STYLE="font: 10pt Times New Roman, Times, Serif">W. Richards Woodbury, Chairman</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">W. Richards Woodbury, Chairman</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>TENANT</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SERA PROGNOSTICS, Inc., a Delaware corporation</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ <FONT STYLE="font: 10pt Times New Roman, Times, Serif">Andrew Sauter, CFO</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Andrew Sauter, CFO</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 48; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Split-Segment; Name: 5 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SITE PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm2110724d11_ex10-20img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 49; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT &ldquo;A-1&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LEASE PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm2110724d11_ex10-20img002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 50; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm2110724d11_ex10-20img003.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 51; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT &ldquo;B&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LEGAL DESCRIPTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The property which is the subject of this tweed
of Trust is situated in the County of Salt Lake, State of Utah, and is legally described as</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">lot 2, EASTLAND REGENCY SUBDIVISION, according
to the official plat thereof on tile and of record in the office of the Salt Lake County Recorder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Parcel 2:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Non-Exclusive Easement rights to Parcel 1. under the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Restrictions and Declaration of Easements:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 1in; text-align: left">Declarant:</TD><TD STYLE="text-align: justify">Woodbury-Morris Co., a limited partnership</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 1in; text-align: left">Dated:</TD><TD STYLE="text-align: justify">December 23, 1968</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 1in; text-align: left">Recorded:</TD><TD STYLE="text-align: justify">December 27, 1968</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 1in; text-align: left">Entry</TD><TD STYLE="text-align: justify">No.: 2271792</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 1in; text-align: left">Book/Page:</TD><TD STYLE="text-align: justify">2718/270</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">First Amendment to Restrictions and Declaration of Easements.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 1in; text-align: left">Recorded:</TD><TD STYLE="text-align: justify">May 13, 1997</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 1in; text-align: left">Entry</TD><TD STYLE="text-align: justify">No.:&#9;6643123</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 1in; text-align: left">Book/Page:</TD><TD STYLE="text-align: justify">7665/1682</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Over and across the following described Parcel:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Beginning at a point South 0&rsquo; 01 West 2000.0 feet along the Section
line and East 193.084 feet from Northwest corner of Section 21 Township 1 South, Range 1 Fast, Salt Lake Base and Meridian and running
thence Last 20.0 feet; thence North 0&deg;01 East 40.0 feet; thence last 52.8.816 feet; thence North 60 35&rsquo; 40&rdquo; Fast 40.0
feet; thence South 29&deg; 24&rsquo; 20&rdquo; Last 60.0 feet; thence South 60&deg; 35&rsquo; 40&rdquo; West 13.303 feet said point being
North 29&rsquo;&rsquo; 24&rsquo; 20&rdquo; West 735.8 feet and South 60&rsquo; 35&rsquo; 40&rdquo; West 277.97 feet from et Salt Lake
City monument; thence South 257.46 feet; thence East 45.0 feet, thence South 599.137 feet: thence North 59&rsquo; 51&rsquo; 20&rdquo;
West 140.057 feel; thence North 67&rsquo; 29&deg; 30&rdquo; West 242.38 feet; thence South 38&rdquo; 58&rsquo; West 14.6 feet to the Northerly
line of Parley&rsquo;s Way; thence North 51&rsquo; 02&rsquo; West 205.185 feet (said being North 38&rdquo; 59&rsquo; Fast 50.0 tees from
the Salt Lake City monument at the intersection of Parley&rsquo;s Way and Wilshire Drive); thence North 31&rsquo; West 170.865 feet; thence
North 467.624; feet to the point of beginning.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Parcel 3:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Easement:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 1in; text-align: left">Grantor:</TD><TD STYLE="text-align: justify">Eastland Regency Co., a Utah general partnership</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 1in; text-align: left">Dated:</TD><TD STYLE="text-align: justify">January 25, 1999</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 1in; text-align: left">Recorded:</TD><TD STYLE="text-align: justify">January 26, 1999</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 1in; text-align: left">Entry</TD><TD STYLE="text-align: justify">No.:&#9;7234315</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 1in; text-align: left">Book/Page:</TD><TD STYLE="text-align: justify">82390/0138</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Over and across the following described parcel:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 52; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1 of 1, EASTLAND REGENCY SUBDIVISION, according
to the official plat thereof on file and of record in the office of the Salt Lake County Recorder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following is shown for information purposes
only: 16-23-301-004</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This lease is subject to and together with certain
easements, rights of way, and restrictions as more particularly set forth in that certain agreement designated as RESTRICTIONS AND DECLARATION
OF EASEMENTS, dated December 23, 1968 and recorded on December 27, 1968 in Book 2718 at pages 270 - 277 inclusive as entry #2271792 which
agreement is incorporated in this Lease by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Subject to utility and other existing easements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 53; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT &ldquo;C&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGN CRITERIA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><B>A.</B></TD><TD STYLE="text-align: justify"><B>FREESTANDING PYLONS</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">None provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><B>B.</B></TD><TD STYLE="text-align: justify"><B>EXTERIOR SIGNAGE</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.</TD><TD>Tenants occupying a gross leasable of over 6,000 sq. ft. may install in a location approved by Landlord signage on the exterior of
the Building. All such signage shall be of the same type, letter style, construction, and design as described herein.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.</TD><TD>Prior to proceeding with the fabrication and installation of any exterior signage, Tenant shall submit to Landlord a sign fabrication
drawing showing the dimensions, construction details, method of attachment, location of lighting, and other pertinent information. All
sign fabrication drawings must be approved by Landlord in writing.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.</TD><TD>The wording of Tenant&rsquo;s exterior signage shall be as set forth in Section 1.01(G) of this Lease. Use of corporate logos, shields,
or crests shall be permitted.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.</TD><TD>The location of Tenant&rsquo;s sign shall be where shown on elevation page attached hereto. Multiple signs may only be provided where
specifically indicated thereon.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.</TD><TD>All signs shall be individual letter type signs constructed from sheet metal with 4&rdquo; deep painted returns matching the color
used in the exterior aluminum framing system (Duranar - Commerce Brown). No exposed fasteners shall be permitted. Signs may be illuminated
or non-illuminated at Tenant&rsquo;s option.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">a.</TD><TD>If sign is illuminated, face shall be constructed of black/white plastic. This plastic appears black at daytime, but when illuminated
appears white. Illumination is by way of white neon concealed within each letter. Backs shall be solid sheet metal or metal-ply construction.
Letter shall be set off from the face of the wall by 1&rdquo;.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">b.</TD><TD>If sign is non-illuminated, construction shall be the same as for illuminated signs except that no neon shall be installed.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">5.</TD><TD>Maximum letter size shall be 18&rdquo; high.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">6.</TD><TD>Letter style shall be selected by Landlord. Where Tenant&rsquo;s logo or trade mark utilizes a different letter style, such style
may be used only when specifically approved by Landlord.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 54; Value: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><B>C.</B></TD><TD STYLE="text-align: justify"><B>DIRECTORY SIGNAGE</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.</TD><TD>A directory of uniform design and style shall be located at the main entry identifying each suite and business therein.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.</TD><TD>Landlord shall initially design and install all directories and identifications in accordance with established criteria for the overall
project. Each business shall be identified with a uniformly sized letter and letter style.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.</TD><TD>Any subsequent changes necessary from time-to-time shall be made by Landlord at Tenant&rsquo;s expense. Such changes shall be of the
same type and quality as initially installed.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.</TD><TD>An exterior monument type directory of a design and style selected by Landlord shall be installed on the exterior of the building
near the front entry. Sign and lettering thereon shall be of sufficient size to be read by a person in a car traveling in the drive directly
in front of building. Such directory shall identify the name of each business only. Cost of lettering associated therewith shall be paid
by Tenant.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><B>D.</B></TD><TD STYLE="text-align: justify"><B>UNIT IDENTIFICATION SIGNAGE</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.</TD><TD>Each unit shall be identified by signage of a uniform style and character for the project as determined by Landlord&rsquo;s architect.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.</TD><TD>All such signage shall be located on a wall directly adjacent to the main customer entry or on the door of the Leased Premises as
determined by Landlord&rsquo;s architect. Signs shall identify the suite number and business therein.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.</TD><TD>All signs shall be provided and installed by Landlord with Tenant paying the cost of the lettering.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.</TD><TD>Sign lettering shall utilize vinyl cut-outs applied to a fiberglass or plexi-glass background. Standard size shall be approximately
7&rdquo; high by 15&rsquo; wide. Additional sign area is permitted with Tenant paying the entire cost of the sign. Listing of sub-departments,
individual professionals, or other associated entities is permitted subject to Landlord&rsquo;s architect&rsquo;s approval of the arrangement
of names, letter heights, etc.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">5.</TD><TD>Any changes required after initial installation shall be made by Landlord at Tenant&rsquo;s expense.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><B>E.</B></TD><TD STYLE="text-align: justify"><B>PARKING STALL IDENTIFICATION</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.</TD><TD>Reserved parking spaces may be designated. Reserved parking spaces shall be identified by painting &ldquo;Reserved,&rdquo; &ldquo;Business
Name Only,&rdquo; or such other mutually approved designation.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.</TD><TD>Other parking spaces may be designated for visitor or customer use only in a similar manner.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.</TD><TD>Tenant shall not permit its employees to park in spaces that are reserved or designated for specific tenants, visitors, or customers.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 55; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>39
<FILENAME>tm2110724d11_ex21-1.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 21.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">Subsidiaries of the Registrant</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">None.</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>40
<FILENAME>tm2110724d11_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Consent of Independent Registered Public Accounting
Firm</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">We consent to the reference to our firm under the caption &ldquo;Experts&rdquo;
and to the use of our report dated March 26, 2021 (except for Note 1 and paragraph 5 of Note 16, as to which the date is May 5, 2021),
in the Registration Statement (Form S-1) and related Prospectus of Sera Prognostics, Inc for the registration of shares of its common
stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Ernst &amp; Young LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Salt Lake City, Utah</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">June 11, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>tm2110724d8_ex10-7img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2110724d8_ex10-7img002.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !& 44# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BD/ )]
M:6B@"G&X*QGU//'4XR>@P.2!V_'J89%$JRQN $PQW9XX&,'J./3'J!@@J'O-
M&D09=BA<\D@!<]2<] !@G&>,DU_/W_P5$_X*/?$3X/7C_!7X"27&A^)=>EUK
M3=8^)-_I=E.-/@CTO1;Q[?X=21:^;F?4)7UBS6/Q9=>&SX;:1[V#2[B;Q!X<
MUQ8OI.%.$\YXUSB.3Y+!1E9N5234(4*<)+GK5:C3C&$$W9?;=HK>Y\%XC^(7
M#GAEPKF'%G$;J3RY3A"EAZ*4\1B:U2RHT:-*[E*=2IRQ4E"2BY*3TC9_IO\
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M;AGKC(SCUHW+C.X8ZYR,8]:5UW6]MUOVWW\M_(+"T4FY1C+ 9.!R.2 20/<
M$_0$]!1D'."..O(X^OI^-,!:*3(]1Z=1UP#C\B#]"/6E) &20 .I/ 'XT!^N
MWGZ=_D%%(2!U('U(HW*#@D \<9&>>GY]J %HI-R^H_,4;E_O#N.HZCJ/P[T;
M[:@+12;E]1^8HR/4?F* %HI,CU'KU'3UHW+ZC\Q2NNZ^]?YA9]F+12;E]1Z=
M1U]*,CU'YCOT_/!_*G==UVW6_;U\M_(!:*0LHZD#G') YSC'UR0,>IHR#P",
M^F11_P -\][>MM?34/\ A_EM?TOU%HI"RCJRC'7)%&Y<9R,>N1BBZ?5?>@VW
MT]1:*3<O]X=<=1U]/K0&4]&!^A'KC^8(^M "T4FY?[P_,49'J/S% "T4@(/0
M@_0@T;E_O#N.HZCJ/P[T!OMKZ"T4F1ZC\Q064'!8 ]<$@''K0%UW0M%)N7U'
MYCMU_+!I<CU_S_D'\J "BC(]??\  ]#^-% !2-T/T/\ *ER!U--)!!&1R#W%
M%TNH:=;6>F_R9^+W_!2_]OO2?V9_"MY\'O"<4^M_&_XE?#V[OM',D$#:+X&\
M-7]PFC'Q!XE"ZE!>WNIZJL&MMX9MM,4NLVGJUP$B$9E\'_X)@_\ !-'P9X,\
M#>#OVA/CAX:E\2_$#7-'?4/"_P -/&7AJWMM%^&L,>M,-'UEK+4&FEU?Q#K5
MKI=MK^EWMULT_3DU=TMK6*<;H_G[_@J3\"O%^D?MQ_#?X_ZA\.O%'Q#^#5SX
M9\$^(_'W_",VDVI,NF_"K6))/'&CWBV\4G]GVMUH<FB7^EK"<WUR]_'"#) ^
M/VY\(_MT_LF>-_*@T/XY^!M.N[FSTC4%T77+]_#FJV=OX@M8M0L+?6+36X[9
M[.]FM9$GBM3*LH@8SLABPY_?<QQ.)X7\,>$L-P6YU:/'%%XCC;B7#MU,54KV
MY5P=4AAYU*V'P\+J=.+I4%B5&<H.M"4H+^+LCHY3QQX_<;9SXLU>',+A?#>K
M#A/P@X6XGP_)A(9="=.N^+\)+%1AAN)ZU:4*?)6JUZ[H5*G,U"=)-?9N\%%8
MA@I4H2222#G)W'GG/+,<YR>#@UX3\??V?/ 7[1OPXN?A;\2+?4KGPIJ&KZ)K
M-_::/J<^D75V-"U"#4;6WGU"WS,]K--"([R$$"YMWDA8X=J]ETGQ%X9\00E]
M UW1==ACY9]&U6PU1(ADJ#(]A<3HHSP"Q R,=1@27&NZ!#*;>?7-(M[B-E#0
MSZG913!MP4*T;SJX)8A0-N2QVX).*_!*^-GDV+C4K5Z66U5)-4\?6IX"M&:O
M&#]GCJF"J*5Y\J3IWO)65W&_]@U\!@^(,!F&7RC',<HS2SG]4:Q=-\DXRE&4
M\*\53M[2E%.\]9)P=I:$6EZ%I^AZ1INB:5:P6&FZ1I\&D:986P:.&RTZTM([
M*QLX3&-T44%M D*;.411MP0#7YT?\%$/^"E7PH_X)Z>$/!W_  DGA'QC\5/B
MM\6=7N/#GPA^#?@"T%_XG\=:K:O;QLB3KOBTW34EF2)[V[1YIG+PA&D#*/TQ
M=P0KJ0RE<JRL2&!'4,I/4<A@<<C!K\!O^"QO[&?[1_CSXA?LO?MZ_LD0:-XR
M^-G[$%]K7B6'X/:G%)"GQ'\-W5RMY>V>B36Z2@ZO%;3:I']DF5_,@F\^TBEO
MHHXG]7(,)E^89_EJS6,)QE&<8QE5]C3G6J*2IT95]52A7Q$J-"=3F3A&M*5U
M:YPY_4Q>7Y%-Y7-TI4TI2FH\TX4E+GK55%+F;I485:J2BVW32MWI?LX?\%E?
MC)XU_:)^$'[/'[4__!.+]HS]D_4?CKXCF\+?"WQKXBBCU'PG+>KI.H:J3XC?
M4--T:\M&DM],9;&6SL]1M$F90\RH&-?/OAS_ (.#?BY\2?%GQ0\._ __ ()C
M_'OXW6GPK\<ZSX$\3:Y\--9BU^UM=9TF]6*WANF@T=1ISWL %YY6XHJ-AB<M
M7W9_P3O_ ."N?P+_ ."A>J:G\)?%_@34_@%^U%X ET[5]>^!?Q66UBU7[2GG
M6[>(/ -Y?PV]UK*6RI>B,K:6NOV4!=[JTBMS)(/YP_\ @E7_ ,%0_ O_  3]
M\7_MX^&?%'P&^/GQ?_X6%^T[XB\0Z;?_  ;\+C7])T>VL$N-,>RU8D;H-0ED
MMED1)OWCQ2H50AU8?<X#),-B\7G2CP=A*V;Y%]7H5.'/]:*\,+SSQ;I5)X?$
MRG".(]G1L^6.)ELI0E>7(OBL=GF)P=+*(_ZT55E>=*K5AGT:2GBZDJ=)3IT:
MM&$*LX*<TH2;HQM"4G+W7S'[D6__  6=^+_AO]F+]JS]ICXU?\$]OC;^SY8_
MLT:)\&[W1M$^)^I6>@?\+;N?B=XZN_!FIV7A_4KS32((? UL;3Q%J$LQ976\
M6(F,$,WAMG_P<0^,/"?A#PE\8?CK_P $R/VKOAG^SOXNL_#^H67Q>M;/1M;T
M'^PO%5D]YX8URP%P^C6=]HE[$A<R65Q<S2B:V@M(9[BYMX)/,/\ @H5_P4H\
M%_\ !0O_ ()&?\% !X)^"_QK^$3?"@?L_0ZI#\9O"-UX>_MO_A)?C-X5=1HB
MM T=X+0Z0RW3()$BDFMS*JJ>?A7QC_P64\$^,/\ @EE\+?\ @G!\._V;?C'X
MH^-_Q$_9C^$O[,7AW7O&]CH?ASX?ZIXGTSP]X8\)W_B+1M9UJXM['5+B&\TI
MM8\)W**EB]X^F7LMW!;)YC;Y;PAA<;EZJ2X#HQC4XMQN&KSABO\ <8*A&I6C
M3Y:DE*M1I3KXMUG&K7DZ:4I.,DERXSB7$X3'8>,>*:\I4\OG74)86HE5J.%;
MV*J*5&*A3JUHT81G4Y*;4KPJ.SO_ &P?!KXJ^"/CY\*_AY\:?AEK%GXC\ _$
M[PGH?COP7K&QO+NM"\4Z2=2TBXDA8EK"^A2]DTK5K,H+F!A<6ETL4J215^7/
M_!37_@L7\)_^"9GQ0_9B^''C;P5?>,V^.U[>ZEXWU"T\1:;HUS\(_A9H/B;P
M5X?NOB%K6FW23W^NR7K^)M=BT;2H'BGU6X\!>(K>-XB<GZ4_X)@?LX>)?V,?
M^"?W[-?[/7Q'UBQD\8?#?P5K5UXPNH+UIM/TK5O%/C#Q#\1=9T87]R1&=/\
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M[;.:^)P]3&QCBLS7#^'I5,%1GSWQ//1G4G24)JFO:^SDX>T^&T[/]@OV1/\
M@I^_[3_PJ^)/B'6OV8/C)\&OC#\+/BQX.^#NM? OQM'IFD^)]=^(GQ!73[S0
M(= U'69M,B@\/QP:E>ZMJ&I:W#I,5AH^AZM>S1/:VKP2^K_LM_MW6WQ\U;PG
M'=^"+O1]"^)&OZQX1\'^,=//BZRTNV\9:=\/F^+.D^%=>\-_$[POX"\:I?\
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M.,1)!&$B4)&L,<6%1;1(X0H\J-0H3 "@*OWL<7Z**D]P**** "BBB@ HHHH
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ML^L:)!)'</)#=:=J4VIV$5U=ON?SS;LO@'B/]F[Q+\/OVA?V>O!^I?$+Q?\
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MT3XP+J6K67PKT7X=RVMMHI\/:]H5I<K<:E;^&I?#ZW\R3Q3:\OQ*\#VGA?\
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/ **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>tm2110724d8_ex10-7img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2110724d8_ex10-7img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ( MT# 2(  A$! Q$!_\0
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M ,#I?\***/KD^R^Y!_9='^:7_@3#_A$_'7_0=D_\#I?\*/\ A$_'7_0=D_\
M Z7_  HHH^N3[+[D']ET?YI?^!,/^$3\=?\ 0=D_\#I?\*/^$3\=?]!V3_P.
ME_PHHH^N3[+[D']ET?YI?^!,/^$3\=?]!V3_ ,#I?\*/^$3\=?\ 0=D_\#I?
M\***/KD^R^Y!_9='^:7_ ($P_P"$3\=?]!V3_P #I?\ "C_A$_'7_0=D_P#
MZ7_"BBCZY/LON0?V71_FE_X$P_X1/QU_T'9/_ Z7_"C_ (1/QU_T'9/_  .E
M_P ***/KD^R^Y!_9='^:7_@3#_A$_'7_ $'9/_ Z7_"C_A$_'7_0=D_\#I?\
M***/KD^R^Y!_9='^:7_@3#_A$_'7_0=D_P# Z7_"C_A$_'7_ $'9/_ Z7_"B
MBCZY/LON0?V71_FE_P"!,/\ A$_'7_0=D_\  Z7_  H_X1/QU_T'9/\ P.E_
MPHHH^N3[+[D']ET?YI?^!,/^$3\=?]!V3_P.E_PH_P"$3\=?]!V3_P #I?\
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MX$P_X1/QU_T'9/\ P.E_PH_X1/QU_P!!V3_P.E_PHHH^N3[+[D']ET?YI?\
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6*SJ8B52/*TON-J&!IT9\\6V_-MG_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>tm2110724d2_ex10-12img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2110724d2_ex10-12img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !* 48# 2(  A$! Q$!_\0
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MK,UG7M/T&T,][.%./DB4@N_T'^13C%R=EN3.<81<I.R1IT5XWK_Q#U+575+
MR6$*D_ZN3YW^I'3Z"N;O1JCXNKX7C;B,2S[CD]N37H0RZ;7ONQXU7.Z<6U3B
MY6Z[(^B**P_!]]/J/A2PN+K<9BA5F;JVTD ^^0!6Y7!.+C)Q?0]BG-5(*:ZJ
MX4445)84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?Q3JB3V\23O%/+N5\XXXQZ]"#GI6]XF^(5[:^%M!_LJU!UK78D,*$9$18#)
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M_&&@>"=3UV>V@-BK7,\#;3=2X;/)QUV\9[YXH5.+?NR_ 3J22UB>PT5PN@^
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MD_R':MNBBG*<IN\G<JG3A3CRP5D%%%%26%%%% !1110 4444 %%%% !1110
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4* "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>tm2110724d2_ex10-12img003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2110724d2_ex10-12img003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  T WH# 2(  A$! Q$!_\0
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MUZBCZ_6\ON#^QL+V?WGD/_"KM<_Y^+#_ +^/_P#$T?\ "KM<_P"?BP_[^/\
M_$UZ]11]?K>7W!_8V%[/[SR'_A5VN?\ /Q8?]_'_ /B:/^%7:Y_S\6'_ '\?
M_P")KUZBCZ_6\ON#^QL+V?WGD/\ PJ[7/^?BP_[^/_\ $T?\*NUS_GXL/^_C
M_P#Q->O44?7ZWE]P?V-A>S^\\A_X5=KG_/Q8?]_'_P#B:/\ A5VN?\_%A_W\
M?_XFO7J*/K];R^X/[&PO9_>>0_\ "KM<_P"?BP_[^/\ _$T?\*NUS_GXL/\
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MVN?\_%A_W\?_ .)KUZBCZ_6\ON#^QL+V?WGD/_"KM<_Y^+#_ +^/_P#$T?\
M"KM<_P"?BP_[^/\ _$UZ]11]?K>7W!_8V%[/[SR'_A5VN?\ /Q8?]_'_ /B:
M/^%7:Y_S\6'_ '\?_P")KUZBCZ_6\ON#^QL+V?WGD/\ PJ[7/^?BP_[^/_\
M$T?\*NUS_GXL/^_C_P#Q->O44?7ZWE]P?V-A>S^\\A_X5=KG_/Q8?]_'_P#B
M:/\ A5VN?\_%A_W\?_XFO7J*/K];R^X/[&PO9_>>0_\ "KM<_P"?BP_[^/\
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M55-*:*+4Y;V<W1NXQYBQP[< *1A1DD_SI_AVRELM'B%R6:YE_>2ENNX]C]
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M/.?PI+;^NPWN5M+MOM.FW%G)-,(;>ZDB4*^"R \*3UQSC@]JM>'!CP[8 ?\
M/(5)#I\UG8""TN$$I<O)+/$7WEB23@,N.345GIM_9Z2;%=0B#(@2&9+;!3W(
M+$-^E'_  J7\,+:U,VIV4MU:F%1;[8&F13SN^50<-TYQ^-4+<R7-C8_:8+BX
MT^&XFCECV-(Q )";E&2P'0CFNBN+?4'($%]%$A4!MUON;/<@[@!^(--2PFL[
M*&VT^X2(1YR9HC)OSU)PR\YYHV YQK@1#4;.R6:VM7EMU161H_+\QMK;0<%0
M0/;K6I)96^E:WIAL85@6<O%*D8P' 4L"1W((Z]>:L_V(DEE<Q3SN\]RPDDG
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M$+YQC\,X[T_Z_$/Z_ GUV>2+0YGB<QN^Q-P."NY@I.?QJE<V-MI&HZ7+8PK
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MQP.PP /PH_K\2>GW%NBBB@84444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
7%%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>tm2110724d4_img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2110724d4_img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#*17AI9@  34T *@    @ !0$2  ,
M   !  $   $[  (    9   (5H=I  0    !   (<)R=  $    R   0D.H<
M  <   @,    2@     <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M     %)A:F5N9')A;BP@4VAY;&EN($IE;FEF80    'J'  '   (#   "((
M    '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                     %( 80!J
M &4 ;@!D '( 80!N "P ( !3 &@ >0!L &D ;@ @ $H 90!N &D 9@!A
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M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !4 8,# 2(  A$! Q$!_\0
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M4V?H9]]1_9U50YYFBS*ES\D#];R_/2@/7P?XZ_X*%_%!_P!D_P"'^J3>'_\
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MIPOM#M[BU@U*))MCO)Z?W'^Y79 \5\IA/;<EL3\1^@2Y.;W#YU_X*;_L8O\
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MR7$B6LD$-JG_ #T^1_,DD,:?\L]G^Q-_P0A\"VO[4G_!0?XV?%SQDMOJFO\
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M%_ _B[Q#I_AOXD>'[*#29;?4KA($UW8FR.>!Y'^>1T3YT^_OS7J9E4A7P_\
MLWP\\CS<LISIXC_:?BY#Z-^,7_!3+X%?L]_$*\\*^./B1H/AG7[&..6:RO$F
M21$D^X?N8YKY/_X+2?M.> _VH?\ @DWXJUKP#XDT_P 6:79^(=.M)[FS+8@D
M^T)\GS@<UUG_  5J_8S_ &;?B+X"\:?%#QM:Z')X]M]!FCTRZF\23VGVB>".
M22!/)2=$?FOSQ^'VE^5_P;L^/OGD_>?$FUD?_P E/]NJRG!P]W%QZ2B8YKF$
MX\V&E_+(]#\3_P#!-3Q##_P3]^#?[2'P+^V:/\3?">BP7^K0Z:/](U.-'?\
M?(B?ZR1$SO3_ ):1U^C?_!+#_@I3H?\ P41^"?VO;'I/C;0$2#Q!I1DY23_G
MO'ZPR=?]C[E;7_!)*W67_@FM\)(9?WT;:" ZNO\ K,N]? O_  4E_8O\5?\
M!*G]H^P_:<^ BQZ9X3^TI'XB\/6D?V>SAWO\Z2)&!_HDGM_JY/GKGG4AC*CH
MU/CN^3_Y$[*:GAZ<,1#X;>^<#^RA\0]1^$_[27[=7B'3)?LM]I>@7TD#[_\
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MX5>'Y]4\2>+O#>AZ=;\O/>:E##&/S>O!QF'K+$SA/XCZ3 UJ*PT)0^$^<O\
M@LG^P/KG[>?[-=II_A.ZAMO%GAG4!JNG),_EQW9V>7(F[M)L^X_;%?*_[#?_
M  7;U#X'ZQ8_"#]ISPSK/A'7]$V::FOS63QA$3]VAO8>H3_IO&7C?_Q^OK.U
M_P""R_P+U2VT76(M<F?PKJ7B-_#$?B.6+R]/@NOL_G;][X_=_P &_P!:YO\
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !CBBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
(* "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>tm2110724d4_img02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2110724d4_img02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  J MD# 2(  A$! Q$!_\0
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M:0!Z++,OMV?T H3X8ZJO_P"4Q/\ UIZ?5_\ RH<=)_P73_9K2(O_ ,)CK94
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M %'6NO3_ ()-?L]1N67X8Z$I;(.))^<_]M*9)_P24_9ZEX/PTT;''_+:?G
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M^;__ *Z5^&.U?_RF5_QE'7ZO_P"5#E)/^"YG[-*%A_PFVJ_+C)_X1G4^<_\
M;"G-_P %QOV:XR,^.-2/(!(\-ZE@'C_IA[_H:ZA/^"2?[/2*H'PTT7Y0 ?WL
M_P ^.Y^?K3Y?^"3/[/DQRWPUT<G& ?.GXX X_>>W^<FJOPMVQ'_E,G_C*K_\
MP_\ Y4.4;_@N/^S3L!_X3K4!EMN#X<U'/Y>14TO_  6\_9KCB+#QY>OM[+X=
MU(D_^0*Z-?\ @DM^SZO7X;Z2QQR6EF.>_P#?_P Y^E/C_P""3?[/D;#'PTT7
M"D$#S)NW_ ^_>B_"W;$?^4P_XRJW_,/_ .5#EH_^"XG[,[CGQ]>(<9^;PYJ0
MQ[?ZCK2_\/P/V: 3GQ]><$#_ )%W4N<^G[BNCD_X)(_L^/*[?\*YTQ-_79<W
M QQCC]Y^/UJ-/^"1?[/R6^P?#W3\XQO:YG8]<]W_ ,CBA?ZK=?K'_E,5^*NB
MP_WU/\C!7_@M_P#LT&$.?'UVN>S>'=2!'_D"HXO^"XW[-$@8_P#">7RA1G<W
MAS4@&YQP?(YKJ8O^"3'[/L<04_#?29< #,D\['C_ +:4A_X)+?L^%<?\*VTG
M;M"X$\X[8[/[?GGU-%^%O^HC_P ICOQ5U6'^^I_D<RO_  7$_9H9"?\ A/;T
M8.,'PYJ6?R\C_.#2Q?\ !<+]FB7(_P"$]O 1V/AW4>?I^XKI/^'2?[/7G,W_
M  K;23N_A,]Q@<YX'F?Y'%-D_P""2'[/K!0OPYTA N" ))N2.F?GY_&C_C%_
M^HC_ ,IBOQ5VP_\ Y4.;7_@N/^S*2?\ BX%T,>OA[4A_[0J6U_X+<_LU7@4K
MX^N45AG,GA_45&/Q@K?;_@D=^STZD-\-]).1@_OIQCC'!#Y'K]>>YRUO^"1?
M[/?\/PZTY1C 'VJX]<Y_UE)?ZKWU]O\ ^4P;XJZ+#_?4_P C(@_X+8?LT7$F
MU?B,<\]=#U =P/\ GA[Y^@-6+?\ X+0_LT7&_'Q-MEV#)+:1?C/T_<5HP?\
M!([]GJ!U/_"MM);8H7YIISG'<_O.3[U#+_P2!_9YDCC4?#RS18\\)>W*YR,'
M/[SG\>E+_C&.GM__ "F'-Q5VH??4_P BC'_P6F_9GF5R/B;; ( QW:1?KD'T
MS!ST_45,?^"S7[-';XGV;_-M.W2K\XYQD_N.G]*D/_!'K]GICG_A7]IG!'_'
MY<]SG_GI_D<=*;_PYX_9\SG_ (0.+ICC4+G'3'3S*7_&,_\ 3_\ \IBYN*OY
M:'WU/\A%_P""RO[-;Q;Q\3[+:,]=+O@3CT'D<U)_P^0_9I*;O^%IZ<1QTTR^
MXST_Y85"_P#P1P_9XDA1#X#7"'.1J5T"W3J?,R1Q^II8/^".7[/4'_,B1GDD
MC^T+K'/MYG^<5-N&N]?_ ,IE<W%-OAH??4_R)D_X+&_LU/,4'Q2T[(&?^0;?
M8_\ 1-)_P^/_ &:C*%'Q1TYLD#<NFWQ7)]_)Q3'_ ."/'[/;C_D0XAQM^6_N
M1D<=?WG/3.>OO40_X(W?L^ _\B0>O7^TKKD9Z<2=,<46X;ZNO_Y3%S\5=(X?
M[ZG^1/+_ ,%D?V:81EOBIIF#Z:=?''_D&FR?\%E?V:8U!_X6A9'/9=+OR1]?
MW%0K_P $;/V>XV8CP/DN<G?J=VX]>AD_R.*0_P#!&S]GUX C>"SD#&Y-1N4)
MXQGB3\?K37^K75U__*8.?%72.'^^I_D6G_X+'_LU(JG_ (6CIQW' VZ;?''U
M_<TJ?\%C/V:I.GQ3TSH#_P @Z^[_ /;&JW_#FW]GDNS?\(,06)SMU2[ P<9'
M^MZ?XTJ?\$;OV>HVR/ O\18@ZG=$<YX'[S@<]J5N&^]?_P IC4^*>L:'WU/\
MB1O^"R_[,ZHQ_P"%IZ>=JEL#3+[G'I^XY/M3V_X+'?LU(5_XNEIWSC(QIM\<
M=^?W/%,/_!'7]GHA_P#BA!\__43NN/I^\J)_^"-O[/3'CP.1A<#_ (FEW\OO
M_K.M%N&^]?\ \IAS\4_RX?[ZG^183_@L;^S7(QQ\4=.PIQN_LV^VGC/7R,8_
MJ,4__A\/^S65!_X6KI&&Z?Z#>?\ QFJK_P#!&[]GIT(_X08KD $KJEV">O\
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MQR'.O7I.?<&7!ITG_!$_]GN1\_\ "+ZLO&WY=>O1G_R)1R<,6^.O_P" T_\
M,7MN*O\ GU0_\#G_ /(F\W_!7_\ 9L7_ )JOH?3/%K=?_&J$_P""OO[-LB!E
M^*VB$'IBUN__ (U6"?\ @BA^SWY84>%]7&.<_P!OWN3_ .1:23_@B?\ L_2Q
MA?\ A&M7&T'E==O!SUS_ *S_ ".*7)PS_/7_ / :?_R0_:\57UIT/_ ZG_R)
MOK_P5^_9L9RO_"V-!R.WV>Z_^-4O_#WW]FS _P"+L:#ST_T>ZY_\A5SZ_P#!
M%#]G_HWAO6&3 &TZ[>9_/S,FFG_@B5^SYSM\-:RH/3&OWAV_G)_G%5[/A?\
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M&>2,&O&OV:;O4OB/^UMJ/B&/QC/X_P!#\,^%#H3ZVNC1:?92WEQ<PS&.W=$
MN&$< :5D=HT:1%4(2ZUD_#+QGH?AO]K[QW8:I\5]?\-:I=^,\V?@]3:?8=65
MK"R59&,EHT_[QC_!.JY3 Y#4 ?68.0/>L_Q#XMT[PH]@NH7<5HVJ7:6%H'S_
M *1.X9EC7W(5C^!K\[/AYXWEUOXLZM>:G<67P^TWQ1H?B"+7%\+Z;K-_XBT*
M)05C_M>^D+H;N,JS(JQAEVR>6QCR3TOAJ'PT?@_I,6MV?A./0?!WQ(M+6_\
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MG_$3Q?I\5UJ\5GIW@U-+NKBZTRTLY;.18=0N99[<&86IO)IY7>,?-!;CL<T
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M.M$UO4;+Q$(;/P[:_;[Z34+&YT[;:\XN4%Q&AEA)! DC#(QX!)XJ3P[^U_\
M#OQ-X.U[7HO$(M-/\+Q+<:J-1L;G3KFRC?/ENUO<1I-MDP0C!")""%W$8KYP
MOK5OV@OB2+W6/C'\/?$OA?P/X:OA>^(=%T5+73-*DFN+1[<7%P]S/;S.&L_,
M>+>@4(I9!YD9%+Q!XJN_B!\18?'&I^.?"GC[PQX"N-'.NZWH&AFQT18QJ:3C
M]\;BX$[6NT3OMD(@W@G:2V0#ZU^#OQ]\*?'O3[^X\+ZE)>_V5.+:^M[BRGL;
MNRD*!U66"=$E3<C!E+* P.1D5G0?M4^ [CXF+X177D_MQ[IK%%:UG6UDNE&6
MMENBGV=IQS^Z$A?@C;D&N$\(?'CP-??M ^)O&>G^)O#MYX6O-.T/PR=9L[L7
M%M>:I)>70AM5DC)C=Q]IB7@D@S*I(Z#AO"WQ+\-/\"/"_P .FU#3%^(FF^+[
M5)O#[31G4H)K?6OM$UV\#,7$9B22<RXVE7# _,* /;?AO^UUX"^+GB2YTKP]
MJFHWUQ:+.\DS:)?V]EB%]DA6ZEA6!MK CY7.<'&<&H_AG^V1\-_BYJNJV6B^
M)$^U:+8G5+I+^RN=-_T,<&[C-S'&);<8YFCW(./FY%>5?!_X@:/\-?B=X>\-
M^"?B_9_$3PW=S7TVKZ1+<6%[)X;M/*N+G[69[9$>*-9]D6+C<")  0R\\9XV
M^/G@S]JG2?'7B6R\0>%/$<=KX5N].\->%]/U2WO]8U>Q)2YO[A[>!S,!.EO&
MJ0@[O+CRRJTA0 'T[\(_VD?!OQTN[N#PQJ[7T]DBRR1365Q9R/$Q(2>-9XT:
M6%B"!*@:,D<,:ZR+789=:DL!O^T11+,WRG;M9F48/0\J>/\ &O'?!GQ5\)_'
M?]I'PSJO@;7='\06FA^&KY=2FT^Y646:7,MH8()% )CD)@=MC%67RVRO/'I=
MDW_%T;T9/_(,@..W^MF]_;T'U/;DQ-:4)4U'[4K/[F_T+A&][F+\7/VF_!OP
M-UJPT[Q'?ZA#?ZI#)<6UO9:1>ZC+)'&55W*VT4A50SJ,MCDUV>A:Y;^)-#M-
M1M3(;6^A2XA,L31.4=0R[D<!E."/E8 CH0#7C?Q:T/5=3_:]\)'1/%%IH%^?
M">JJ8I-.2\>:,7=B2<%E( )7G./;G(\.^,/Q7>]_:M@M[;4_[+UWPMXKT72+
MQIO&6I6^HZHDOV8R26^BQJ]J;"1965I)3C*RG(95)ZR#[?SDUYUXZ_:R\ ?#
M7QZ/#6LZ]]FU8&%9U2QN9X+ S$"+[3/'&T-MOR-OG.F<@CBO)?@/XJN+K]HB
M.VG\3ZY?_#R:\U > Y/->:#5;E=WVV.XN=SF=(29?LH=E#(LQP_DHR\?^T]X
ME@TOXM?$?[-XUT71)H)+"2]^']PT9G^)6+:$A1O7SE:5=EK']E)5FAQ*&!*
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MTC1*\JN54N@(5B.5!QG!]\#\J=15"#.*;'&L*X1549+848Y)))^I))_&G44
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>tm2110724d8_ex10-18img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2110724d8_ex10-18img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !7 ;\# 2(  A$! Q$!_\0
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MJU#8]W+Y598>+J[A1116!VA1110 4444 %%%% !1110 4444 %%%% !1110
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MP_<_:8[9(4DN&"1L54#=QR5)P<=Q6Q\=@!X/L,#_ )?U_P#1;UU%IH.G:_X
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MD=+DDKL\K^'\S:#\1?%MC:9%I!%<E8^H_=2?)^08BM?X%V2R:?K&JR'?=37
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MJ_M% &*3FY;A&"6HM%%%26(W;ZUC:QJYM(FABP;ANG?;6I=2B"VDE/1%+'Z
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7 "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>tm2110724d8_ex10-18img006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2110724d8_ex10-18img006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  L M4# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^\=KT0":2
M=5584+2D#/D%T:623Y1\I*[F..HQC/;XXO\ _@HA^R#IE[?:;??%G0K2_L+B
MYLKNVD2</:W-I(\%Q$^U2-Z2*XP#S@XZYK["O=)AOX;JVD2YB2[2:WN)$F"R
M3V\D1@$T3+(6618WPK':5.0 23C\K]7_ ."-'['FJZGJ6KW/A_Q7)/J=_>:E
M=RGQ5K"%[J]GDN;AQ$MP @>65N,# (P  37L<,4.%*E6?^L&>YQ2I)1E!TJ4
MW.=VN=6DH0CR[1UOKTUM^<>(%3Q&P.%P4N \NR7/ZRK14J6<U53BKJZO+G^%
MM74DWHW=W21]")_P4=_8Z7=YGQKT DG.1%=8(*^GED$ #OG ZGH2X?\ !1[]
MC7&#\:M Z ']W=_GQ&>_]/>OG"W_ ."+_P"Q.ZEI/#OC$MN*_)XNU,848R,/
M=%LCH>G'(R*G_P"'+G[$9_YE[QD/;_A+]1X[_P#/ROMVXZ>M?8U<L\'Y5)SE
MCO$"LY2NZF'K4:5";=KRI4DVJ<-%RPN[)/JV?FL\W^DY.;G4X/\ "&E.3O*E
MB<_Q$,13?*O=K12Y8U%9<T4[+FC9O<^B/^'CO[&G_1:_#_\ WZN__C5'_#Q[
M]C0=/C7H'X1W7_QH5\[_ /#EO]B/_H7_ !E_X6&I?_)5'_#EO]B/_H7_ !E_
MX6&I?_)51_9?@]_T$^(J_P"YJC_D3_:GTF?^B3\&_P#Q(,1^BN?0Y_X*/_L:
MX_Y+5H!X/6.ZXXXX\O\ S[U$/^"D/[&I_P":U>'A_P!LKO/X_NN/UKY]_P"'
M+?[$1_YE_P 9$?\ 8X:B?_;JD_X<L_L1=O#OC'/_ &.&H^F?^?D]N?IS4_V5
MX/+_ )B_$?\ \*Z-OOL"S7Z3*_YI'P9?F^(<3^7*_P CZ$_X>0?L:_\ 1:_#
MW_?J[_\ C=(?^"D'[&G_ $6KP\?^V5W^7^KKY[_X<M?L1_\ 0N^,/_"QU+_Y
M)I?^'+/[$7_0N^,?_"PU'_Y*I_V7X/\ _07XC_+&4O\ (:S;Z3'3A#P8_P#$
M@Q*_]L1]#1_\%'_V-3N'_"ZO#X QR([L<GV$7MCG_P#4_P#X>._L:?\ 1:_#
M_P#WZN__ (U7SPG_  1:_8A^;/AWQAVZ^,-1&>OK<_X]?S5O^"+?[$7&/#OC
M <@Y7QCJ'3!P>+H'O^M']E^#W_05XC/UQ5)O\E<EYK])EO\ Y)+P:^7$&)_-
MH^AO^'CO[&G_ $6OP_\ ]^KO_P"-4?\ #QW]C3_HM?A__OU=_P#QJOG?_ARW
M^Q'_ -"_XR_\+#4O_DJC_ARW^Q'_ -"_XR_\+#4O_DJG_9?@]_T$^(O_ (4T
M1_VI])G_ *)/P:_\2&N?1'_#QW]C/_HM?A__ +]7?_QJHC_P4@_8TW$GXT^'
M0<G_ )979[GOY7X_C7SY_P .6_V(_P#H7_&7_A8:E_\ )5'_  Y:_8B/_,N^
M,?P\7ZC_ $NJ7]E^#W_05XC+_#BZ*^_34:S7Z3*O_P 8EX-._?B'$?HFOO/H
M>/\ X*/?L;$'_B]6@#YCTBN^>!SQ%_\ 7_2FR?\ !1_]C4;0?C5X?(RW+179
MQ]W_ *99_P \]J^?$_X(M?L0X_Y%WQ?]XGGQCJ/; S_Q\]>"/;'6A_\ @BU^
MQ#\N/#OC#OT\8:B>PQ_R\^W?%+^R_![_ *"_$?U6+I7^_E)6;?29O_R2?@SO
MM_K!B;>GPVMV/H)/^"C_ .QIG'_"ZO#N,')$5V.XQ_RRY_EQ4G_#QW]C3_HM
M?A__ +]7?_QJOG?_ (<M?L1#IX>\8_\ A7ZCG\_M6:/^'+7[$?\ T+WC+_PL
M-2_^2J?]E^#W_05XC/UQ=%O\E^HWFOTF7_S27@TO3B'$-?BO^ ?1'_#QW]C3
M_HM?A_\ []7?_P :H_X>._L:?]%K\/\ _?J[_P#C5?.__#EO]B/_ *%[QE_X
M6&I?_)5'_#EO]B/_ *%_QE_X6&I?_)5/^R_![_H)\1?_  JHB_M3Z3/_ $27
M@W_XD&(/HC_AX[^QI_T6OP__ -^KO_XU1_P\=_8T_P"BU^'_ /OU=_\ QJOG
M?_ARW^Q'_P!"_P",O_"PU+_Y*H_X<M_L1_\ 0O\ C+_PL-2_^2J7]E^#W_03
MXB_^%5$/[4^DS_T27@W_ .)!B#Z%;_@H_P#L:J1_Q>KP]R,_ZJ[]?^N?],<&
MF_\ #R#]C7_HM?A[_OU=_P#QNOGL_P#!%K]B/_H7?&)]SXPU+_Y)-)_PY:_8
MC_Z%WQA_X6.I?_)-']E>#W_07XC_ "Q=&WRT'_:WTF%OPAX,OS?$&)O_ .D/
M\V?0O_#R#]C7_HM?A[_OU=__ !N@_P#!2#]C7!_XO7X>Z?\ /*['_M*OGK_A
MRU^Q'_T+OC#_ ,+'4O\ Y)H_X<M?L1_]"[XP_P#"QU+_ .2:/[*\'_\ H+\1
M_P#PKH__ "(?VM])C_HD/!C_ ,2#$_\ R!]%?\/'?V-/^BU^'_\ OU=_G_JN
M]'_#QW]C3_HM?A__ +]7?_QJOG?_ (<M?L1\?\4]XR_\+#4OT_TJC_ARW^Q'
M_P!"_P",O_"PU+_Y*H_LOP>_Z"O$7_PJHA_:GTF?^B2\&_\ Q(,0?1'_  \=
M_8T_Z+7X?_[]7?\ \:H_X>._L:?]%K\/_P#?J[_^-5\[_P##EO\ 8C_Z%_QE
M_P"%AJ7_ ,E4?\.6_P!B/_H7_&7_ (6&I?\ R53_ ++\'O\ H)\1?_"JB+^U
M/I,_]$EX-_\ B08@^B/^'CO[&G_1:_#_ /WZN_\ XU1_P\=_8T_Z+7X?_P"_
M5W_\:KYW_P"'+?[$?_0O^,O_  L-2_\ DJ@_\$6_V(\9_P"$>\9?CXQU(#\_
MM5']E^#W7%>(J_[FJ(?VI])G_HD_!O\ \2#$?Y'T.?\ @H_^QJ,_\7JT C!Z
MI=\\'C_5?Y],5%_P\@_8U' ^-/AX#_KE=8_]%@_I7SX?^"+?[$G0^'?&/N#X
MQU+_ .2?_P!5!_X(L_L1=O#OC'\?&&HC_P!N32>5>#W3%^(Z5^F*HK3T:?\
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MDU/]E>#_ /T%^(__ (5T?_D0_M;Z3'_1(>##_P"[@Q/ZP/H9?^"D'[&NX?\
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M>Z?\\[H_^TO\\U\\_P##EK]B/_H7O&7_ (6&H_\ R51_PY;_ &(_^A?\9?\
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M/\.I]%'_ (*/_L;Y/_%ZM Z_W+O^L5 _X*/_ +&V>?C5H&/=+L^_:*OGP_\
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M!_XO5H!P">4NO3C_ )9_Y]#TKY\?_@BW^Q%@'_A'?&&<@9'C#40< '()%Q[
M<Y[?C%_PY:_8C/7P]XQ_\+#4C_[=4/*_!YI/ZWXC-_\ 852O\VUJ']J_29O?
M_5+P:76W^L&*7YQ6_E\CZ"/_  4A_8U[_&GP\?\ ME='_P!IYQ^%3G_@H_\
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M,I0%O+0H7<+R0H( ';)/8\5B3ZO;6RI)?ZC%I08@QPWUS;1S7 ')$09UR3D
M8SCK727\:_9G5Y(P9 8XQ+A59W' [Y; .U>YKY^^+FH^!=+TL7/BG0FU?5+Z
MUN]+\*Z1;:7>W.K:GJCPE(4L?+A\N.<SRQ")II88-OSO*F,$]G#M_P"32_\
MDAW?:/\ X!#_ .0/4/\ A)+"&YN8;S6M/M$@D3R_/O[2$W4,X$D<L+.X!18F
M!++E6X8$C%7Y]1B6*&>'5[(P3WD$<,TES"(KB"=XP!;OO"2N=Q4,A(#< <D'
MY2\7>#X=-^"7@7PCXAT;3+[XGZWH?AOP/#<@0K=R:Q;VEM;:Y>Q37+P,]I9V
MUO=3&Z0F9XMLB1[G KQ7XLWWAGP_'I/A^]U77=)T;X07O@?3].MHK'6)/^$B
MNKFYTR_OKNTN(U$<UO;)<HD)GEW7=[!-9! JJ['LX=OQE_\ )!?RC_X!#_Y
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M1F$K M$3@=)4*D# )'S#C.:+ZUIQN5T^'6K4ZFZM&EG]HMWNFFC4&3; 61Y
MH!!_NMZD5QWA0"3Q+XZ-NIEAA\0:!-#&'*JEH/#VG2,84;"@AF8^6NW+X'&<
MGYWTO2+SX9>/]9UWQ#8Z?XKT7Q]XUMH/#?B."\6YU7P;J&I><+31;W23ONXX
M;M\B66S^T+$L09TYVURY?)U:*=63F^5/FE)MWO*\KN2NVHKI>P7\E_X!#_Y
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MBL*P22%Y7*HQ&TY*] <9)JNMPZ.C76IWBZ7ID902:C>SPQVZK(2$P[L@>0N
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M4KG3[:QUAW;4(-/M)+GRK%;EY7)\@*8@1Y97:#7OLG'EG@X0'! (/R2'GO\
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9B2TE:1V!Z!2>"QY)7^\S>E %^BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>tm2110724d8_ex10-18img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2110724d8_ex10-18img002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !7 ;\# 2(  A$! Q$!_\0
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MJU#8]W+Y598>+J[A1116!VA1110 4444 %%%% !1110 4444 %%%% !1110
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MP_<_:8[9(4DN&"1L54#=QR5)P<=Q6Q\=@!X/L,#_ )?U_P#1;UU%IH.G:_X
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MD=+DDKL\K^'\S:#\1?%MC:9%I!%<E8^H_=2?)^08BM?X%V2R:?K&JR'?=37
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MJ_M% &*3FY;A&"6HM%%%26(W;ZUC:QJYM(FABP;ANG?;6I=2B"VDE/1%+'Z
M9KE])M6U'4GO)4.Q6W\_WB<@?A7!C:LTXTJ7Q2_(Z*%.+3G+9%WP_8?*UW.K
M><S':6]/7\:L3>&;&;46O\SQW+ !GBE*$_E]*U450>!VJ2NK#4U0ARQ_X<PQ
M#C7ES27_  "K:Z?;64?EV\2QKG.%'?U^M6-@]33J*UN2HI;";?<T8I:*!ABB
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "C%%% !1110 44
M44 %%%% !1110 4444 %&*** "BBB@ HHHH **** "BBB@ HHHH ,4444 %%
M%% !1110!!>1>?:2PYQYBE<^F14&FV9L[..!MN5SG:<CK116;@G-2ZHM2?+8
MN@8I:**T("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
7 "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>tm2110724d8_ex10-18img007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2110724d8_ex10-18img007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  L M4# 2(  A$! Q$!_\0
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MH'_?NY_^-T?\/'OV-/\ HM6@?]^[G_XW7SO_ ,.6_P!B3_H7O&/_ (66I?\
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M)+P:_P#$AQ!]$G_@H_\ L:@'_B]>@'@\>7=<C'O'WJ$?\%(/V-,\?&GP\/\
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M/_A8ZE_\DT_[*\'NN+\2/EBJ+_&WZ!_:GTF7MPEX-)=O]8L2OSB?17_#Q_\
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MGOV['@_X<M?L1'KX=\8YQQCQAJ('_I0,_EFL?[+\'^F*\1UZ8JDM/FG?S[=
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M2<Q%OC3X>(B8,1Y5V!@G)  C(((^\"0"2,U O_!0C]BV.Z:\_P"%S^' 67&
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M\DT/*O!YI/ZWXCM_]A5*[\FVOT#^U?I,MW_U2\&K/I_K#BK?^DWUZZGT&?\
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M9+HE;HE9+T*ATR)E96DFV%!&B;QB) !D1D+GD@?>+# P,<U$;,!]PEF^4E0
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MWQ;LKOP#XWMO$-C:$Z=K&JK'HN@K%=WEOJ-O<V5M-F2U:T%LH8KYY88'TO\
M$JSUFZ\=_!S3[?PQH?BB:;1/%)U#1?$>HG3;5+NVT^T:2Z-Q%;7UO/>6CB0"
M-,B02._FJ.2>SAV_\FE_\D%_*/\ X!#_ .0/JC3[@W47G)=&[B(5!/;/#);N
MP)#S1R#>&BSQ@=!CDX(#II957:)BC;@JO(R+&Z\;I@_ "H,AMV!O9!GL?B+X
MP>-/B)X0NK8>!/%8\/0^"-'TO4O&/P^T#P?'KNDE;Z5Y(H[WQ;?'3K/2K2YA
M1][6XN;I$1YA:.  >9UO7OCAXAN?&N@>*_%]YX&76O#6JW?@'1_^$9L[G3-6
MM=+-C?R:GHOBW3+F:))S#,(3I.L+I>H31*T\%K-'#<-">SAV_P#)I?\ R07\
MH_\ @$/_ ) ^^YKB2!/M'VKS;16&Z<.D8"F0AG._Y#'&I4E]^W:I/\6!E1>(
M+6ZEB^P7\.HVXNQ9W5Q97-K<PPEIKB("9XW81E#;G.3@^9@'O7S-';>,+/\
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M+DZ!XBN]8OX?#SSQ^6)-4\[2-#N+AD*8MT@ACVR&Z)4]G#M^,O\ Y(+^4?\
MP&'_ ,@?>MMYDD8,DERLRL%DCW(-P=AAT^4X4(21G.>O;-*T5WEV64E$\Q"I
M906?S&5%Z8Y0*Q'4YXX)K\Y]&^//Q-T;Q5:6NK>*;KQ%X.@AT#Q%/K5[X1M?
M#SQ>&]7EBT_[5'IZS7&I/';3:A93F6>"& V(N+N>:".$Y^L/ ?C76?$&D>+O
M%BW+>(-"E\57D?A7^S4M9%O]&TE8=-GOK:Y\U+,B;5(+T1QF?#HB2[OWI19F
MJ<(2;5F[<NLM+7O]OJFNG39A=]H_^ P_^0/76N)5",/M+Q,Y2:3*J8<,59G4
M@;8PHR'!Z G'6JMAJUEJ*,+'5[/59HV*W0TR[M[B.VVG9ODVLQ!R/GC;&U\K
MGY<5P_B"YG\5^#?$-H)=2\-7^KV-[H^GW=R&BN++4Y+=H"[_ -ER7JO%%,=X
MD\P!_P"'^$'YJT'Q9J/P]U'0OAY<^$[#PIXW>'1GUC6-.*:GI?B7P^-4L=!N
M=<>>>.U>TOI+J]M+N:QN8$,KS3D3L(B[315.=/57DFE?F>RZ?%??T] OY1_\
M!A_\@?:MQ=/;F.)KQ%EEE40^;)"IG3(W")2X9CC<,@\$#@XJ=))9 71YRCE5
MB5GCSN&2YWKD/U VX!'N!S\9^)_B1XK_ .%P>&_!4<MM?POXQN] 74[;2TN#
MHB)X<@U.&2XB574K--*%PLQ:,$M@D;:\&^''C#X[>&/#DVD/XZU'Q=XC\>?&
M#Q;X4T*]'AW1K9_#5KH&DW>L-/;0:QJUE;7MM<Q0&"V$DUM+YBJ/+ <D:>SA
MV_\ )I?_ "07\H_^ 0_^0/U&O&E@@EE5YE,*M(QEDA1%* NL;,<;#*08E)X&
M\9]L!?$=O=H;G3+^*]M8G*3SPS020QS(JF6VEE#E(3$I,KRME=H(P,&O(OAS
M=>/=2^'^K0?&:W-O<VO]J0W&K:E'IEI-J'AV)65M9NXM$O-0L;%YK5I))X$O
MI?LBH&$C,<#Y\\92Q7&@?$'QSX&TZ;2?AQK*>#_"MG/9I,L&J6T&K!-4URUL
MH0TD5I.]V-/ENR(Y+C9*'(1!D5.&GNW\KR_^2Z[!?RC_ . 0_P#D#[B'B&TE
M@BN;+5;.Z@4.;RZ%W;"SA" !FEG#$1;BRB,OG?L."*LVFLPWZ)<6=_%=V3LJ
M"[M)H;B(R2$E(RT98(5A*3MNYV.#@ YKX2^+'AK1=(^.7PI\&VT*6'@+QK<:
M/9^/+6V:[MM-U06>F^);W1HP;8-!;L+JV3SV>2'S L*.S@@#T_X=K>:)\?\
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MH,?CS1/#$?B)/$/A&QO-&M[M-3U)=._L/6GL]:U+3=-O!ID5KJ]HUG+> ?\
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MXNB83#=L)H;A3YH;H<*!7OC8!Q@$'J,<$;6.#C!QE%/7KGU-3>1'_=_R/PH
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M'->QD_NX3@#$B\ <<PJ1[_+P!SR -VXY)M2*,K@8X/3T!''ISN//7H00: /
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6 ] F1@L>ZCG<S>G7K^= %^BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>tm2110724d8_ex10-18img003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2110724d8_ex10-18img003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !7 ;\# 2(  A$! Q$!_\0
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MJU#8]W+Y598>+J[A1116!VA1110 4444 %%%% !1110 4444 %%%% !1110
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MP_<_:8[9(4DN&"1L54#=QR5)P<=Q6Q\=@!X/L,#_ )?U_P#1;UU%IH.G:_X
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MD=+DDKL\K^'\S:#\1?%MC:9%I!%<E8^H_=2?)^08BM?X%V2R:?K&JR'?=37
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MJ_M% &*3FY;A&"6HM%%%26(W;ZUC:QJYM(FABP;ANG?;6I=2B"VDE/1%+'Z
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7 "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>tm2110724d8_ex10-18img008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2110724d8_ex10-18img008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  L M4# 2(  A$! Q$!_\0
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MH'_?NY_^-T?\/'OV-/\ HM6@?]^[G_XW7SO_ ,.6_P!B3_H7O&/_ (66I?\
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M)+P:_P#$AQ!]$G_@H_\ L:@'_B]>@'@\>7=<C'O'WJ$?\%(/V-,\?&GP\/\
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M/_A8ZE_\DT_[*\'NN+\2/EBJ+_&WZ!_:GTF7MPEX-)=O]8L2OSB?17_#Q_\
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MGOV['@_X<M?L1'KX=\8YQQCQAJ('_I0,_EFL?[+\'^F*\1UZ8JDM/FG?S[=
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M2<Q%OC3X>(B8,1Y5V!@G)  C(((^\"0"2,U O_!0C]BV.Z:\_P"%S^' 67&
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M\DT/*O!YI/ZWXCM_]A5*[\FVOT#^U?I,MW_U2\&K/I_K#BK?^DWUZZGT&?\
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M9+HE;HE9+T*ATR)E96DFV%!&B;QB) !D1D+GD@?>+# P,<U$;,!]PEF^4E0
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MWQ;LKOP#XWMO$-C:$Z=K&JK'HN@K%=WEOJ-O<V5M-F2U:T%LH8KYY88'TO\
M$JSUFZ\=_!S3[?PQH?BB:;1/%)U#1?$>HG3;5+NVT^T:2Z-Q%;7UO/>6CB0"
M-,B02._FJ.2>SAV_\FE_\D%_*/\ X!#_ .0/JC3[@W47G)=&[B(5!/;/#);N
MP)#S1R#>&BSQ@=!CDX(#II957:)BC;@JO(R+&Z\;I@_ "H,AMV!O9!GL?B+X
MP>-/B)X0NK8>!/%8\/0^"-'TO4O&/P^T#P?'KNDE;Z5Y(H[WQ;?'3K/2K2YA
M1][6XN;I$1YA:.  >9UO7OCAXAN?&N@>*_%]YX&76O#6JW?@'1_^$9L[G3-6
MM=+-C?R:GHOBW3+F:))S#,(3I.L+I>H31*T\%K-'#<-">SAV_P#)I?\ R07\
MH_\ @$/_ ) ^^YKB2!/M'VKS;16&Z<.D8"F0AG._Y#'&I4E]^W:I/\6!E1>(
M+6ZEB^P7\.HVXNQ9W5Q97-K<PPEIKB("9XW81E#;G.3@^9@'O7S-';>,+/\
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M+DZ!XBN]8OX?#SSQ^6)-4\[2-#N+AD*8MT@ACVR&Z)4]G#M^,O\ Y(+^4?\
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M/9^/+6V:[MM-U06>F^);W1HP;8-!;L+JV3SV>2'S L*.S@@#T_X=K>:)\?\
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MH,?CS1/#$?B)/$/A&QO-&M[M-3U)=._L/6GL]:U+3=-O!ID5KJ]HUG+> ?\
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MXNB83#=L)H;A3YH;H<*!7OC8!Q@$'J,<$;6.#C!QE%/7KGU-3>1'_=_R/PH
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M'->QD_NX3@#$B\ <<PJ1[_+P!SR -VXY)M2*,K@8X/3T!''ISN//7H00: /
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6 ] F1@L>ZCG<S>G7K^= %^BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>53
<FILENAME>tm2110724d8_ex10-18img004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2110724d8_ex10-18img004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !7 ;\# 2(  A$! Q$!_\0
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MJU#8]W+Y598>+J[A1116!VA1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 (W2LG7M632=)FN&D19=I6+/(,A!VC\ZU7.%
M)KQK4]5N_$^M)'YK>0\NR! .%4G ..YYR:Z<+0]K*[V6K/.S'%_5Z=H_%+1$
MUM'KOBV98I)&>'=N9R@55XQG@#=Q_.O1M#\.V>BP;8DWS,/GE8?,W_UJL:-I
MD>DZ;%9QDLL8ZD<DYR3^M: '.13KXASO&&D2,%E\:2]I5UFQ>U9FO07=SH]Q
M!8;1/( @+'& 2 WXXS6F12;<URQ=G<]*<5*+BRAH>G+I6E6]FAW>6F&/JW4G
M\\_G6E35&#2DX&:;=W=A"*C%170&.,?6H_-^8CC'K7#?%CQ1>^&O"J-ITGE7
M5U-Y*S8R8UVDL1[X'ZUAP?!BUGMEGU'6+V74F +3AMVUL=B>3@\@GGBJ4(VO
M)V1,IM.R5SU;S#G_ .M2A^<<5YEJ6EZUX>^%?B&TU/4I;R2)B;:X9R7\D[,#
M).>#NZFN>\%?#A/$WA.RU:XUS489)_,S&KY VNR]S_LTU"-FW(3G*Z5CV_=Q
MQUI Y]L]\&N#T#X9P>'];M]436;^X:'=B*4Y5LJ5Y_/->=Z%H/\ PEOQ-\1:
M==ZA>0Q037$JB&4]I@H'H!@T*$7]H'.2Z'T!OR>E*&R>E>'>)++Q#\+9['4M
M,UN[O=/FD\I[>Z<LN[KMP3CD \C!&#7LVF7\>IZ5:W\((BN84F0'J%901_.E
M*%K-.Z*C.[LU9EMFP,TU7+$]..N.U<K\1O$)\.>"KVYC8"[F7[/;C/)=NX^B
MY;\*\Z^#NMW6DZW=>&]0WH+F(7,"R9RK[0QX_P!I#N_X#[TU3;@Y=B95+34>
MY[EFD+$#I0#0>E9(TN)OYQQ07]*\&FT1_%/QDUG2I=0N;:%=TN8FYX"\=?>M
M?7OAQJ/A?2+G6-#\2Z@)[1#,4>3:"J\GH?0=#P>E;.DKI7U9C[5VO;0]A\S)
MXZ>N*4O@"O!/%GBVZ\2?";3-1D<QWL>I"WN'C.W<5C<@\>H*GZDUOV'PM-UH
M-EJ-GX@U*VO)[5)00YVAF0''&"!DT.E9>\P]M?X4>N!\GZ]*4MZ=:\O^%GC'
M5=4N]0\/:VXEO]/!(F8_,P5MC!CW(..>^:I^,?'&MZOXD;PIX0!6="4N+M>&
M# X8*>P7H3USP,=U[*3E9%^U5DSUKS0#R>M+O]Q7D\/P6AO5$VMZY>7=XP^=
ML9&?JV2:S]5\(^*OA[ =4\-:Q<7=C "TMK*"P"]SLS@CW&#^&:%"+=DR?:26
MK6A[2&)H+?2N9\%^+;;Q=H*7\""*=&\NX@W9\M^O7N#P0??US7'>+O'&M:MX
MD;PEX0 6Z4E+B[&,H>A SP .[>O'&,F53DVT^A;J123[GJOF<_\ UC2[Z\L@
M^#5K=H)M=UG4+ZZ8?,Q?(4]P"V2:27X:^(/#\7G>$O$UTC)RMI.V8S^!ROYB
MFXQ[D\T^VAZF)"?3C@^QIRN6[?6O&OCG<W%LF@/!/+$=TY.UR/\ GG[]JZ'X
M;^.9=:A?1]87R-:LEVN)1M:51D;L?WA_$/Q]@W2?)S(%53ERGHK$C&/6F>9C
MKQZ<&ER6'3 Q7CDMQ/\ \-'QPB:3RL?ZL,0I_P!%/;I[U,8<WR'.?+\SV,,>
M^/>@OM&YB .Y)Q7G7Q%\?W&@7%OH>B1K/K%SAN%W>4&.!A>['D\] ,UC6?PF
MU/78DO?%FOWDMV_S-"K[A'[9/ ^@P*:A[MY.PG4ULE<]>$@) &,GG%!DQQP#
M[FO(+WX6:SX;MWO?"&OWB7"G>;9GVB3'L."?8BNB^'7CYO%4,]AJ*+!J]IS(
M@X$BYQN _A(/!'O[\#AI>+N"J:VDK'>[CG!'XT,^/3CKS7B\%I>_%/QEK=O>
M:G/:Z1I<@BCMH6QN^9@"1TSA223GJ*V[;X8W7AO5K&\\.ZS=I ES&;FUD?Y7
MCW#<!VZ9[4W!+=@JC>R/30Y[C'%+NKS2\^$-I=WMQ<G7=10S2-)M5N!DDX'Y
MUY[_ ,(KGXL'PA_:U[]F YF\SY_]1YG3..O%$81E?WA2J237NGT87Q1OYKS.
MW^#]K!<Q3#7M2;RW#;2PYP>]9NF3S?\ #0>H0^:_D^4<1[CM_P!4G;IUH4$]
MF/G:T:/7@QHW'VQ7G'Q"^(-SHU[#H&A0K<:S<;1D#=Y.<8^7NQ&2/0<GK61:
M?"74M;B2Z\5>(+R:[?YFB#[PGMD\?@!BA4[*\G8/:7=DCU\N.@(S35D8]@/S
MKREOA/J>BQ>=X8\47EM,IW+ [E4;V.#C\P13O'>N^(=,T#PUH4=QY.L:MLAN
MKE6 *N BM@@<99^HQT]Z.1-KE8<[M[R/5?,]OTHWGC !_&O+/^%*V B$RZU?
MKJ();[4#SN]?7]:Z33;;5M,\/:3I.JW<ES<2W3V\]UO.[RQYCK\W7+!53/7Y
MN.<4I171C4Y=4==YF,YQ@=^W^?>E5]QQBN%L9I)K=I5BBLY$L#<FX\KRR7!^
M4K@G>F-V[/J,_>KKM'N9;[2K.\N+?[/// DCQ$Y,9902I]P3C\*EJQ<7<OT4
M44AC)!E,9KRPZ3>>&_$AU%[8R65O*7WJ. C<?H#7JK=*AEC1T*2*&5A@JPR"
M*UHUG3;7<X\7A(U^5MV<3'A\6:/)*L?VU$9U#*) R\>^1@5K07D%S&KPS1R(
MWW61L@_E52XL=,C\R>>"W7>H5V8#D=AG_/2N0U;PI;R'S]%22"1,N9"Q53_N
MGJ/J*F]%M)NWXCD\5"/-RJ7X'?[QZCZYHW#/%>/VGBW5X1%#/=R2PJ1N.[Y@
MO^]U/'KFN_TRVTG5H_M%M<-,.#DR'</KZ&C$T*]!_#==[BP>.P^*5N:TNQT:
MG)IQYID:"-54<@# )IQ.!6:.PYGQWX2C\7^'6L/,\JX1_-@D/17P1S[$$UY[
MI?CO7_ LT.B^,K"6:V4;(;Q/F? X^CCIW!^M>LZAJ]EILMK'>3I#]ID\J(N=
MH9_3/0=_KTZD57US2].UG2Y[/5(8WM64[BW&SC[P)Z$>O:M8SLN62T,9QUYH
MO4Y[QOJ%KJOPMU2^LITGM9K;?'(IX(W#^73!Y!!!KAO OQ%/A_PC9Z;_ ,(_
MJ-YY)D_?P+\KYD9N./?'X5D^%9[C_A5_C:RWN]E"R&%RI )8X/)]E0X]_>O3
MOA&<_#/2?3]\/_(SUJTHP=U?4S3<IICO#?Q!_P"$CUA-/_L'4;+*,_G3C"C'
M:O+="\3+X5^*'B2\;3[F]66>YB\NW&67,P.3[<8KZ&(]J\6^&X#?%_Q7UQ_I
M7_I0/_KU--QY96[%3C*\;LS]6UO4OC!JUMH=A;+86=N?.E\U\M_=W'@<@$X4
M9ZG)QT]QL+2'3K"WLH!B"WC6% 3T51@?H!7F'Q*\(2Z;,GC+PX#:W]DP>X\D
M8W+_ 'P!Z#.X=",Y[UTEAX_L[SX>S>)B$1K>(^;#G[LW0)[9)7'LPHG[T5R[
M!#W&^;<Y'QF__":_%/2_"R-NL+%O,N\'[QX9P?3Y<+]6-2_%O2I-*O=+\8Z:
M MS9S+'*#P#@DH3[=OR%8?@OX<W/C'3I_$5]JUW9W%W/(5>(#,@SRQ/^]G\A
M71W'P4BFA9)?$FHR X^5QN7CU&:J\8M*^Q%IR3=CTG1M2@UG2;74K5LP7,2R
M+D\C(Z'W['W%7R.*\I^$&K3V/]J>$-1^6ZTV5FB!.?E+88#V#<Y[[_:O5 2<
M@BL)Q479'1"5UJ>!2^(AX9^-6M7YLKB\!W1^5;C+\JAR/RK=USXA:SXITFYT
M?0O#%^LEXC1/-*OW4/# #H21D9SQG-,\-@']H'6_^N4G\HZ]BV#'X5M4DDUI
MT,:<6T]3P/QEX6?PG\)=+T^9E-S)J0FN"ARH<QN, ^P"CWK4C^,2Z/X:L[6+
MP_<_:8[9(4DN&"1L54#=QR5)P<=Q6Q\=@!X/L,#_ )?U_P#1;UU%IH.G:_X
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MD=+DDKL\K^'\S:#\1?%MC:9%I!%<E8^H_=2?)^08BM?X%V2R:?K&JR'?=37
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MJ_M% &*3FY;A&"6HM%%%26(W;ZUC:QJYM(FABP;ANG?;6I=2B"VDE/1%+'Z
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7 "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>54
<FILENAME>tm2110724d8_ex10-18img009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2110724d8_ex10-18img009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  L M4# 2(  A$! Q$!_\0
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MQI_T7+PM_P!^[[_XU2'_ (*0_L9GK\<?"I^L5Z?YQ5\^?\.6OV(O^@#XU_\
M"GN/_B:0_P#!%K]B/_H >-#]?%%Q_P#$FC^R_!W_ *"_$A>F.I?_ " UFWTF
MD_\ DC?!?_Q(<9_\BCZ)C_X*0?L8$'_B^/A<8.,*EXO49SCR33O^'C_[%_\
MT7'PS[8%Z!^&(*^>%_X(L?L1$'/A_P :9SS_ ,53<CT']WV]!SGTI&_X(L_L
M1$ CP_XSX88QXIN3R5(X^4]03[<_2G_9?@[_ -!?B1_X646_+[)+S;Z33;7^
MJ'@UOM_;^,M?;JK:;7W\]SZ(_P"'C_[%_P#T7'PU_P"3W_QBC_AX_P#L7_\
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MW_QBC_AX_P#L7_\ 1<?#7_D]_P#&*^=O^'+'[$O_ $+_ (T_\*FX_P#B:/\
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MM?L1?] 'QK_X5%Q_\31_PY:_8B_Z /C7_P *BX_^)H_LOP=_Z"_$?_PMI?\
MR _[6^DU_P!$;X+_ /B08S_Y$^BA_P %'_V,,#/QQ\,D^H%\ ??'D''X<4?\
M/'_V+_\ HN/AK_R>_P#C%?.W_#EG]B7J- \:8_[&FX^O/R\<4G_#EG]B7C_B
M0>-.>G_%57'H3_=] 33_ ++\'/\ H+\1_P#PLH_Y$_VI])G_ *(_P7_\/^+_
M /D3Z*_X>/\ [%__ $7'PU_Y/?\ QBC_ (>/_L7_ /1<?#7_ )/?_&*^=O\
MARQ^Q+Q_Q(/&G/ _XJFX]"?[GH#1_P .6/V)?^A?\:?^%3<?_$T_[,\'/^@O
MQ'_\*Z/^0O[4^DS_ -$?X+_^'_%__(GT3_P\?_8O_P"BX^&O_)[_ .,4?\/'
M_P!C#_HN/AK_ ,G?_C%?.W_#EC]B7_H7_&G_ (5-Q_\ $TA_X(L_L28YT#QH
M!ZCQ3<=@3V4=@><_GT)_9?@Y_P!!?B/_ .%='_(?]J?29_Z(_P &/_#_ (O_
M .1/HH_\%(/V+P#GXX>&<8/5;PYX/&#;\Y].OIS4/_#R']C <K\</"P(Z?NK
MSZ=1",>O3ID>]?/9_P""+/[$8_Y@'C;\?%%SU'N5/Z4?\.6?V),9.@>-,>O_
M  E-Q_\ $^M2\K\';Z8SQ(M_V&44O_27]^XUFWTFDG_QB'@R[_\ 508U+_TG
M\T?0G_#R/]C3_HN7A;_OW??_ !JI5_X*/_L8D#=\<O#!R <A;U>HR>D)!Z\=
M.GJ37SM_PY:_8B_Z /C7C_J:+CC_ ,=I?^'+/[$C=-!\:G''/BFX&/3^$_Y^
MM"ROP=_Z"_$?_P +:+_]M!YK])I_\T=X+K_NX,8__;3Z)_X>/_L7_P#1<?#7
M_D]_\8H_X>/_ +%__1<?#7_D]_\ &*^=O^'+'[$O_0O^-/\ PJ;C_P")H_X<
ML?L2_P#0O^-/_"IN/_B:K^S/!S_H+\1__"NC_D+^U/I,_P#1'^"__A_Q?_R)
M]$_\/'_V+_\ HN/AK_R>_P#C%!_X*/\ [&!X_P"%X^&,'CE;UNO?F$#CTX''
M/>OG;_ARQ^Q+_P!"_P"-/_"IN/\ XFC_ (<L_L2<YT#QKD>GB>Y/8'KM]Z/[
M+\''_P Q?B.O^YRC_P#(@LU^DRM?]3_!CY9_C/TBF?0/_#R#]C'J?CAX4/3G
MRKWH/?RO3\,>U6?^'D'[&'_1<?#'X+>8_#]P>/3D_4U\YG_@BU^Q(./[ \:#
MT'_"47(XZ#C9QTH'_!%C]B3J= \;?AXHNL8^FW'3_(I?V7X.]<7XD?/&4FO7
M5#>;_29=O^,0\&5_W<&-_P#D78^AW_X*0?L7ECCXX>%ATR6BO6/W5X!$ [YZ
M\CI[!K?\%'?V+)00_P <?"^<X&Y;WC!&"%:$@ GC@#L">,#Y[_X<L_L2'(&@
M>-#_ -S3<#KU_A]_6D_X<M?L1@X.@>-!USCQ1<?_ !'K1'*_!Y._USQ(\KXV
ME9>B4$U\F-YM])K1?ZG>#+M_U4&,?YI67IOMJ>\C_@HG^Q6LBR+\<O"O55("
MWPX'<A8P#DJ#@Y R.,YK1/\ P4@_8OW!?^%Y>&-W.<+>'U!(/V?C!' ]",\8
MS\[?\.6OV(^/^)!XT/U\47'_ ,2:3_ARW^Q(>3H'C0$]<>*;D=\]D'_UNW04
MWE?@[?7&>)+?GC:<K6VM>^EO^"#S7Z33_P":.\&%I_T4&,C^CO\ F?1A_P""
MD'[&'./CCX9'_ ;SUZ?\>]-_X>/_ +&'?XY>&?\ OF]'T_Y8CO7SO_PY8_8E
M'_,O^-,?]C3<?_$4W_ARU^Q)_P! #QI_X5%S[#^YV)&>O7M2_LOP<>V,\2%_
MW-4?RM^)/]J_2:U_XQ#P9TWOQ!C']WN_TSWZX_X**_L4W)#GXY>%OE!7)2_(
M!W8R2(^I(ZXR.@;&:?%_P45_8N1A(OQO\*@#)SB^SC/WL+$.A'7)X)SZ5X$/
M^"*O[$:@C^P/&F"<D?\ "47.,GO]SGIQZX':D/\ P1;_ &)N5&@>-  "!CQ/
M<#=TZG;SR">,^H''%?V7X/)*^.\2N6_PK'T6EZ+6*Z:6LNP?VM])NVG!W@Q:
M_P!K/<;^'NV_RL?0C?\ !2#]C!2"OQQ\+;B!DF.])(R>_E#I@9_#(Z$M_P"'
MD?[&G_1<O"W_ '[OO_C5?/?_  Y:_8C[Z!XUP.!_Q5%SGZ?=P!QT_7BC_ARU
M^Q%_T ?&O_A47'_Q-0\K\'?^@OQ(^>-I;=/L%?VM])K_ *(WP7?_ '<&,7W>
M[LCZ&3_@I#^QBQ^;XX^%R0#@K'>CTX),#8]>WX]I?^'D'[&'_1<?#/\ WS>?
M_(]?.O\ PY9_8D/30/&A['_BJ;@<CJ/NT?\ #EC]B7_H7_&G_A4W'_Q-/^R_
M!S_H,\2/3ZU1=OG9?D)YK])I_P#-(>#"\O\ 6'&:?^2GT5_P\@_8P_Z+EX8'
M_ ;PGMG_ )8#L?\ /:#_ (>0?L8$Y'QP\*KZ9AO2<]SD0C\.*^>S_P $6/V)
M<_\ ( \:Y'IXINL>O.%P:#_P1:_8B'_,!\:Y]#XHN!_[+Z?I[4/*_!VVF,\2
M/_"NC'_VU^FP+-OI-+;A#P8?=?ZP8W\^770^B%_X*/\ [&+ $_'/PQSZ1WP[
M^\?!XYXZY%*?^"CW[&/&/CGX8&>N5OCC\HOH>_4<5\ZG_@BS^Q("?^)!XUS_
M -C5=#^24H_X(L?L2X_Y 'C3!Z?\55<]/J5S_AT[4O[+\';*^,\2%;JL51UT
M6[26OG9:WTZ!_:GTF=_]3_!?7OG^,_6/0]_F_P""BW[%\Q!/QQ\*#;QDI?<D
MCN&C(R!WZ'.< @&FI_P4/_8LR0?CAX5/R_W;S[VY=K?ZK&5!) )Y[]B/!4_X
M(M?L1X/_ !(/&?7OXHN/;'5*<_\ P1<_8C P- \9C))_Y&FYSC'KLZ<C\>?2
MJ_LOP>>GU[Q+2TT^O4U\_LH7]K_2:OR_ZG>#"OVS_&^751_JY[]%_P %&_V+
M8@^WXX^%,XX(CO 0%4\<Q$\D$G! !S@9/*_\/(_V,\_\ER\+8]/+O<X[\^5^
MN.*^>_\ ARU^Q)VT#QKC_L:+G_X@TA_X(L_L1$8.@^-2#QC_ (2BY'TZ+W.*
M3RSP>>^+\2.MF\;2ZOI[K;[VV_$IYM])KKP;X,>O^L&,_#W3Z,_X>0?L8=OC
MCX9_[YO/_D>C_AY!^QAU_P"%X^&,?[MYC'?I *^>C_P18_8B_P"@!XT_#Q3<
M_P MG'Y"H3_P19_8C&0/#_C0 $]/%-R,<^NS/?UZ4+*_!W_H+\1__"NA_P#(
MD?VM])EV7^J'@U\\_P ;_D?1?_#Q_P#8P[_'+PQD')PMYR#@8XA]\9YZC(.*
M:W_!2']C!",_&_PP^\,P;;<GA6*@?/"2,\G@XYP0#Q7SK_PY:_8D'_, \:#(
M&?\ BJKKH<=/DY/0]C[TR3_@BY^Q$I&= \9@'H3XGN6SN..PSG<.?3< .]5'
M*O!R3M]<\2+]OKE!?BK/^OD4LX^DO2M.IPQX/8:$;\U:AGV.=6%U9<BC&[YF
M^627V3Z,_P"'D?[%_P#T6[PQ_P!\3_\ QBD/_!2/]B_&T?&[PN"WRY,<YQGO
M_J"<YQT&>?0&OG'_ (<N?L1?] 'QE_X4EW_\30/^"+O[$08 Z#XR/7 _X2:[
M4]#R"5QGOSUQ[5?]D>#JU>+\2-G_ ,QU+MIU'_K'](YZ+*O"ZHWHH2SO,E&;
M>BC)M6Y9-I2OI9L^DC_P4@_8O!(_X7EX8/)&56\Z>@'D'/'J?J.U0?\ #R#]
MB_K_ ,+P\+$<8_=7F2,#!),)Y/TXZ8%?/7_#EG]B7_H >-!NY&/%5T1P3_LX
MZCGZ=<&C_ARU^Q(#SH'C0>__  E%Q[_['8UC_9?@]TQGB0M>F,HKK_A=W_2!
M9M])J+UX/\&7_P!W!C$TWOI9:7TWV2?F?1:_\%(/V+]HQ\<?#&,=EO /P_T>
MC_AX_P#L7G_FN/AG_P G?IT\CCI7SL/^"+/[$?;0/&WX>)[C_P")II_X(L?L
M2?\ 0 \;?^%3=#] N!5+*_!RW^^>([?_ &%46_R)_M7Z33=O]4/!GYY_C7K_
M . O^NI]&?\ #Q[]B\Y ^.'AHD]<B^QCV_<]<9X&.>O(!%"3_@HC^Q:[!W^-
M_A5,,&^Y?YZA<?ZO(&,DD8]3WKP,?\$7/V)%_P"8#XTP/7Q3<GW[I^M!_P""
M+G[$FW:=!\:8ZY_X2BY!/)SD[<@>W(_*E_9?@[O'&^),6MK8RG&_KRVO\[^@
M?VK])M7MP=X+N_?B#&-Z;6]U:O1+L?1'_#R']BXE-OQQ\+;0<Y O1M7;A>1
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MMT/3UQVY-3_\/(/V,/\ HN/AG_OF\_\ D<_SKYU_X<L?L2_]"]XS/U\57/\
M1?SH_P"'+'[$O_0O^-/_  J;C_XFI65^#O7&>)'_ (5T6E_Y*E]R&\U^DSTX
M0\&$ET7$&,T]%8^BO^'D'[&'_1<?#/\ WS>?_(]'_#R#]C#_ *+CX9_[YO/_
M )'KYT/_  1:_8D'70/&G_A4W'_Q%)_PY;_8D_Z 'C3_ ,*FY_\ B*?]E^#G
M_07XD/S6+H__ "(O[4^DV_\ FD?!G_Q(,7_D>^W?_!27]C(2)$OQT\(JS+^[
M22*\=F<98 ,UN0I..@VGGGI7T?\ !SXV?"_XZZ'/XF^%_B/2_%.C6MTUG>7F
MG"11'>HP<HRR1@@A3DD ;L''S'-?G/=?\$6_V*2PBCT#Q@OF*0))/$]VVQF&
M<IA!B11RI!)&1@>OW5^S+^R]\*OV4_!MSX$^%-GJUOH]]>RZI=#5[^6_NY[M
M@%+^;(%81[0 JCC)('.#7A9U@^%*5'ER.MFM2BFG0_M3E>,5/_J(JQ48U)WY
M^5W;Y?9QNG$^ZX+QWB_CL3.AQYP9P5E^!IJ7L\PR/'/%0K)Q]V5&4[U)+GO&
M3G%M.$M$K'T[\RJN(Q*"."PRR@ 8#%-N3@]P/4 $G)5D?* %(Q@$[N@/0@9R
M>,8/MCK17Q\:M9*W*GOK[VNK_EFE]R7WW;_5K<ONJ55);).5DNB5G:R5E\BH
M=*C=65I)=K1K$J[_ /4H I/ED#AMRKR<\*,$<U$;,;SMEEPGR !ER2H !8$=
M3V;&!P2  #6U59XG+,P;@D$  9R< ]N@P#UKKYYM6<FXO=-1>CBHVMR???6]
MW>^HJE"E54%.$6J;3@GS)1:VM:4;6^?I?4HFV!/^MD7(_AP.><YP.K<'(/7K
MZT"UR1^^E&?<'^@&/USV[U=,#_\ /0]#V'<<XXZG]32^0_9\?3C],8_2L^2&
MONZ;JS:L_E):>5C565E96TM>,9/2^[E%M^KDWIOT61=(UO&\@>XE,:E_*C*B
M5P"0=NX;><9&<Y]B16'/JUM;(DNH:C#HX=@8K?4+JTBGN54 R"$/(I9CN &%
M(!(?)7-=+J$0%NZ/(I:4>5&'.%+?>QD '=@$CGH#]*^?_B[J/@+2M.2_\6:
M-7U*\M+W2_"FC0V<TVJ:IJAB*QQV!4@1W+SS1)"S%8PI#%Q2Y(]G_P"!2_\
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M,Q;"Q!$=\MC:O7&"5_,[Q6WQ,UOQKXAD^'OQ%N/ [)\5VTRYN9K+^T["]M3
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M!#B,1N8V"C )7(! P<<YX],9SBCDCV?_ (%+_P"2'?RC_P" 4_\ Y C^S!B
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GHX=@/NN#P/4]S4]C*TCN",;5R,-(>IP<[W8'\LYYS0!I4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>55
<FILENAME>tm2110724d8_ex10-18img005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2110724d8_ex10-18img005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !7 ;\# 2(  A$! Q$!_\0
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MJU#8]W+Y598>+J[A1116!VA1110 4444 %%%% !1110 4444 %%%% !1110
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MP_<_:8[9(4DN&"1L54#=QR5)P<=Q6Q\=@!X/L,#_ )?U_P#1;UU%IH.G:_X
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MD=+DDKL\K^'\S:#\1?%MC:9%I!%<E8^H_=2?)^08BM?X%V2R:?K&JR'?=37
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MJ_M% &*3FY;A&"6HM%%%26(W;ZUC:QJYM(FABP;ANG?;6I=2B"VDE/1%+'Z
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7 "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>56
<FILENAME>tm2110724d8_ex10-19img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2110724d8_ex10-19img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !I ?8# 2(  A$! Q$!_\0
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MD#%)O/I0 ^BFJ^X BD,F#TH ?130_7BC=1<!U%-+4;NE #J*;O\ :DWGTHN
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
..%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>57
<FILENAME>tm2110724d8_ex10-19img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2110724d8_ex10-19img002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !I ?8# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HI
M#UI#]: '45&Q..#56]U&WL(#+=3)$@&<L<9^E"5W9$N22NV7CT-1,0![UYUK
M'C^YEE":4=D>#EW3);Z"N;OO$6JWZA9[N3:/X1\H-=]++ZE35Z'CXC.Z%)N,
M=6CVD.#WJ0=!7AVF:M>:;>I<P3,<<,&/##O7M5E<"ZLH9UZ2(&K'$X65!J_4
MZL#F$,7=1W18HHHKF/0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $/6FL<<YI6)!X%8OB
M75_[)T>::,IY^ (U8]3D?TIQBYR45U,ZE2-.#G+9%?Q)XCATBQ;:Z/<D@)'U
MR??'3BO+;_4+S5;DRW$C2/GY0.1] *O->:MXFN%M]@?+;OD7 !/&2:[[P[X2
MMM+C$TP6:Y(P6(R![5ZL'3PD;R5Y'S=7V^9U+4](G$:/X1U#5!YA7R8#_$_4
M_A750?#W3TC EDD=\<G.*[)4"+A0 /2E(X]ZY*F.JS>CL>E0RC#TEJKGD][X
M5-MXEM].$N(;DGRVZD <FO5+"U6RL8;9"2L:[037+1:9>7WC*2_ND*6]J"L'
M/WCZ_J:[!?NBEB*TJBBF[V-,!A84I3G%6NQ:**0G! KE/2%HJ/S?F((Z4>9]
M/SI70$E%-W^U&ZF%QU%,W\]./6EW^U #J*9O]J<&STH 6BFEL#--$A)Z#\Z+
M@244F:,T7 6BF;\]OSI=U #J*9YG.*!("<<?G0M0>@^BFE\#/]: ^: '44F:
M;OZ\<TD[@/HIN_/I^=!8^E,!U%-#$]J-Q["BX#J*9YG/;\Z-_% #Z*87P>E'
MF8Z@ ?6E<!]%(#D4TO@D=AWI@/HJ/S..@SZ9I=_/2BX#Z*8&)Z"EWT .HIN_
MD#%)O/I0 ^BFJ^X BD,F#TH ?130_7BC=1<!U%-+4;NE #J*;O\ :DWGTHN
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
..%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>58
<FILENAME>tm2110724d8_ex10-19img003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2110724d8_ex10-19img003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !I ?8# 2(  A$! Q$!_\0
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MD#%)O/I0 ^BFJ^X BD,F#TH ?130_7BC=1<!U%-+4;NE #J*;O\ :DWGTHN
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
..%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>59
<FILENAME>tm2110724d8_ex10-19img004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2110724d8_ex10-19img004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !I ?8# 2(  A$! Q$!_\0
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MD#%)O/I0 ^BFJ^X BD,F#TH ?130_7BC=1<!U%-+4;NE #J*;O\ :DWGTHN
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
..%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>60
<FILENAME>tm2110724d8_ex10d18-1image1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2110724d8_ex10d18-1image1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !T > # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ -)GVH-(>E
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MG!]JL?%N[AUA?#=S W[FZ3.1Z,:TITXJ2[&$JCE&VS1[.FH690?Z7;_A(/\
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M76WQDTU(@-3TC4K6Y7AHXXPXS[$E?Y5S7C?QA-X]TV/2-&T*_91,)#+(F"<
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ML 4444P"BBBBP!1110 4444 %)FEHH 2EHHI6 ****8 :*** "BBB@ HHHH
M*3-+10 E+110 4G>EHH **** "BBB@ H-%% "44M% "4M%% !1110 4444 4
M=7F>WTV:6,@.JY!/UQ61H%B1F\EZM]P?UK=O+=;JW:%_NL.:+:!8(4C'(48R
M1BN2IA^>O&I+9+\3>-7EIN*ZDJ')I]( !2UU)61@%%%%, HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@!#2 444QCJ***0@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
JHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>61
<FILENAME>tm2110724d8_ex10d18-1image2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2110724d8_ex10d18-1image2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  L I0# 2(  A$! Q$!_\0
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M_P :ZW^SK+_GT@_[]BD_LVR_Y](/^_8HO1_E?WAR8O\ G7W?\$Y/_A9NA_\
M/.Z_[]C_ !H_X6;H?_/.Z_[]C_&NL_LZRS_QZ0?]^Q2_V=9?\^D'_?L4<U'^
M5_>')B_YU]W_  3DO^%FZ'_SSNO^_8_QH_X6;H?_ #SNO^_8_P :ZW^SK+_G
MT@_[]BC^SK+_ )](/^_8HO1_E?WAR8O^=?=_P3DO^%FZ'_SSNO\ OV/\:/\
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M@)$)7&1N''UH>X@B_P!9+&F,?>8#K_\ J/Y5SUEI5PD:13^:KP6[Q!R4V$L
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MOK>Y<QI(ID50S(#RH/2I([F-S+R0(GV,3P <9_K5"RMI;>_D+Q?NY((@&!!
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MJ>IIU% #=HH"@9]S3J* &A0.G>C8/3CTIU% #=OO1M]Z=10 W:*7;SGO2T4
H-V^E+M%+10 TKGO2@8-+10 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>62
<FILENAME>tm2110724d8_ex10d18-2img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2110724d8_ex10d18-2img002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !D @0# 2(  A$! Q$!_\0
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MBGJ?_7!OY5X9\._&6I^'-,NK>RT5[^-I=Y=3C:2,?TK:FFZ3,:C2J([GXD>
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M:OT"M&*2=CU/_A!_#.,?V-:X_P!VO/?C396UAX=TBUM8EBA2X.U%X ^4U[*
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M32@^GX4^BD @SQ2T=Z*8#2I(_I2;3_\ 6I]% #0OL/I0%P*=10 F*",BEHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% &;>6T<UW#*V0R-P1BKZJ,=!11644KW
M*DQPI:**U)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
L* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>63
<FILENAME>tm2110724d8_ex10d18-2img003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2110724d8_ex10d18-2img003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  L L<# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]\'ECCSN8
M)ZYIGFI_SV3\Q7EW[9?P,UW]H3]G[7/"6AZK#HNH:HT#17C%\1>7<Q3'(4@\
MB,KP>CFOAS_AR?\ %7_HIEE_WQ-_\57K99EV'KTG/$8A4W?9J_ZH^1S_ #W,
M<%75'"8*5>-OB32_-'Z:>:G_ #V3\Q1YJ?\ /9/S%?F7_P .3_BK_P!%,LO^
M^)O_ (JC_AR?\5?^BF67_?$W_P 57I_V)E__ $&1_P# '_F>%_K=G?\ T*I_
M^!1_R/TT\U/^>R?F*/-3_GLGYBOS+_X<G_%7_HIEE_WQ-_\ %4?\.3_BK_T4
MRR_[XF_^*H_L3+_^@R/_ ( _\P_UNSO_ *%4_P#P*/\ D?IIYJ?\]D_,4>:G
M_/9/S%?F7_PY/^*O_13++_OB;_XJC_AR?\5?^BF67_?$W_Q5']B9?_T&1_\
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MV3\Q7YE_\.3_ (J_]%,LO^^)O_BJ#_P10^*H_P":F67_ 'Q-_P#%4?V)E_\
MT&1_\ ?^8?ZWYW_T*I_^!1_R/TT\U/\ GLGYBCS4_P">R?F*_,H?\$4OBJ?^
M:F67_?$W_P 52_\ #E#XJ_\ 13++_OB;_P"*H_L3+_\ H,C_ . /_,/];\[?
M_,JG_P"!1_R/TT\U/^>R?F*/-3_GLGYBOS+_ .')_P 5?^BF67_?$W_Q5'_#
MD_XJ_P#13++_ +XF_P#BJ/[$R_\ Z#(_^ /_ ##_ %NSO_H53_\  H_Y'Z:>
M:G_/9/S%'FI_SV3\Q7YE_P##D_XJ_P#13++_ +XF_P#BJ/\ AR?\5?\ HIEE
M_P!\3?\ Q5']B9?_ -!D?_ '_F'^MV=_]"J?_@4?\C]-/-3_ )[)^8H\U/\
MGLGYBOS+_P"')_Q5_P"BF67_ 'Q-_P#%4?\ #D_XJ_\ 13++_OB;_P"*H_L3
M+_\ H,C_ . /_,/];L[_ .A5/_P*/^1^FGFI_P ]D_,4>:G_ #V3\Q7YE_\
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ME_\ #D_XJ_\ 13++_OB;_P"*H_X<G_%7_HIEE_WQ-_\ %4?V)E__ $&1_P#
M'_F'^MV=_P#0JG_X%'_(_33S4_Y[)^8J.Y\N:+:7B8'@AL'([]_\YK\S_P#A
MR?\ %7_HIEE_WQ-_\51_PY/^*O\ T4RR_P"^)O\ XJE_8F7_ /09'_P!_P"8
M?ZW9W_T*I_\ @4?\C]*]/MX[629]\2F9]YP5R2<#G '/ ZYZ#FK/FI_SV3\Q
M7YE_\.3_ (J_]%,LO^^)O_BJ/^')_P 5?^BF67_?$W_Q5/\ L3+_ /H,C_X
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M\8^\VT ;\XQVKGQ.48.%*4J6*C)]K-?J=N7\49O6Q$:5;+I0B_M732^Y'W5
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M#QT.*\D^)/CV'3?C#;:9J&OR:+IKZ!+>HRR>69;CS@@8#JVU2QVXY(K/T/\
M:(U?P/X T?4=?T<O:26]N]W=RWR0W$@=5R\=OMRQPZ94$<[^F.0-.Q[8[;)
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M<7*/<6*^++6"^F2W<H5B:R,VQ6ZKAS'T[*1T- :=CTC[9&) K?*Q (![T\2
M_P ..W/>OG:X^-NIZ1XW_P"$0O[[4+A+'6]1@DN+6$M<W=G!;VDR("H^5@;^
M!2_4B,]R*Z/Q[\96;PGHUMX/OI;V6\MX[Z2^QN^S6J2[6+!AD/+)^Z (!^64
M\;#0&G8]B6]1Y64*<H<-GMSCZ'O5CR_:O';_ ,1ZGXB?XFZFFI75K'X/G>UT
MR"(X0/%907+R2?W]\DVW!X"QKCJ:]DV^YH#3L-\OVH\OVIVWW-&WW- K#?+]
MJ/+]J=M]S1M]S0%AOE^U'E^U.V^YHV^YH"PWR_:E"4NWW-+0,**** "BBB@
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>64
<FILENAME>tm2110724d8_ex10d18-2img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2110724d8_ex10d18-2img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !D @0# 2(  A$! Q$!_\0
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MBGJ?_7!OY5X9\._&6I^'-,NK>RT5[^-I=Y=3C:2,?TK:FFZ3,:C2J([GXD>
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M:OT"M&*2=CU/_A!_#.,?V-:X_P!VO/?C396UAX=TBUM8EBA2X.U%X ^4U[*
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M32@^GX4^BD @SQ2T=Z*8#2I(_I2;3_\ 6I]% #0OL/I0%P*=10 F*",BEHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% &;>6T<UW#*V0R-P1BKZJ,=!11644KW
M*DQPI:**U)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
L* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>65
<FILENAME>tm2110724d8_ex10d18-3img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2110724d8_ex10d18-3img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !> ;T# 2(  A$! Q$!_\0
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MN,IQJX/$4\32DKJI2?-&W=-:O5-;+;6ST+V1ZBC(]??\/6OAG]O?]M_X,?\
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MBW]N^.]A_9S^,.C>)?%NFV,=SJGP]U>WN_!?Q/TJ"1$EDGB\)^+[#2]3U*S
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MG_:"_:;^ /[*W@6_^)7[0OQ5\(?"GP5%YI_MSQ#=QHVIOYTD\6GZ!H]I%?\
MB'Q3J[P7$3?V7H&CZQ<2/(S16Q)<C\-_%G_!T3_P3ST?6K[3/!/P[_:U^)^F
MV32";Q=X.^%OAFSTEX;9%VR6FD>-_B5X1UW3I9U17^S>*-#\)?Z/-;W.&,Q6
MNK"9;F&.Y7A<NS"K":3A66%E["I>,6_9U>91DDY.-[[IIV=TN3$YS@,&I?6L
M=EU*5.4HU*+Q:=>FXR:M.FHN4962?*TM_+7^F"C(]17X]_L<?\%M?^"?7[;.
MO:3X%^&_Q=N_ OQ4\1Q2G0/A+\8-"U+X=>,+RXC"B;2].N;J6/P!XHUQ"3++
MHW@[QKXHOECDCF6ZD2:**+]56G_=-/<N!;P1R+]KEFN$=4EMTD2:ZL[NVCCA
M-K(+F>:'47N4M+)8+S[3(9I8H\,7A<5E^(^K8_#5\--Z1YJ<FW-I6@[72;;2
MTE*SWV.C"YAA<PPZQ& KT,3#>5JJCRPUYIZJ]E9O6*O;YG7T5^ 7QP_X.*_^
M"?'P1^)'B3X::!%\>?VC=9\/:G=V6NWG[/GP_P!&\5>'-*U33G:PU>PM_$GC
MWXA^!+/7H],NK*5KB_\ ",6H: /-%G;3SZI::HD?JOP>_P""X_[!_P"T%\,O
MB[\4/ 7BWXB1:A\"/ACK_P 6OB7\*]:\!76E_%?2OA_X?O-'M=6U[1]!U _\
M(QXD;2M3U/3]&N8].\071LYM;5OMBK+$MQVK),W=*%9Y;C%":BTU1=GSNT+-
MM7YKQULDG)+K<Y7Q!D<:LZ,LUP49PDXRBZVL6K<R=DU=:WLWL?M117\XB?\
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MLYQBI8/#8K%XB2R^DK?V=AX4E.-H>Z[-\WN\D-6FMTC^6;_@KY'XD_X*E?\
M!6']G7_@F%\/?$=YI7@GX!:#X@\=?&/7]-M;[4X-#\1^)?#%AXN\6ZYXATFU
MV0R-X2\!1_#K0? 4DK+]J\7?%F;1)'6'4E8=U_P;?_''Q=\&/B)^U+_P2W^-
M?GZ7XZ^!OCWQ5\0/ NEW=Q/<0V<$&JQ^"?BAX4\-7%W*CK:Q^)K/0?%/AI(H
MY5OHO$WQ(U+,:N[U^8'_  1P_P""H?[)G[*OQ9_:[_:C_;(U;XB7_P"TS^TK
MXE:S@U3PIX(;Q8-(T;7M5U'QKXW+:D-6L1"/%?C);&YBL3 WE6'@6SG$S>?L
M'-_MQ?\ !4?]F:__ ."H_P"S7_P4>_8J@\?S:YX<&E1_'/0M>\)KX-D\::?X
M;GF\"^,(-/5KO4$U;4O&?PI\0W7@-]2:1?\ A$;J'0M4:+.HM(_U];*<=/#U
M>"*N&H_5:6"6+P%95:?)/B>-"&*Q+B^MZ=6%&VRG3?NK21\70S?!K$TN,L-B
M,54QM?'2R_$8?V$XN62JM*E##N2<E'V?+*JZG*VU42T5S_11MI!+$S@ AG=D
M9,[&1COB*$YRPC9$F( 'VE9L#N?)OC^"/@A\7QU/_"L?''Z>%M8Z?E7:_#WQ
MAX9\?^"?"WCWP9K-EXD\(^-_#VA^+O"WB'3+@76EZ]X<\2:39ZSH>M:;>#(O
M;'5=*O;2_M[P%A=)<"<$>9@<A^T#Q\#OC /^J8^-^1TX\,:N/_U?2OR#"0KT
M<QP4*G[NI''4X5XM74IPK0C*Z=FFG%Z-77*T]4S]=QLZ%?+L77I7J4WE\YTE
MLU&5)R2T[7<?E?K8_E:_X-5_AE\-O&G[)O[2&H^,OA]X*\6ZDGQ[AT^TOO$W
MA/0->NHK6V^&'A&ZCL8KO5-+O;F.V2>]N)H[9)O)2:XFD2#S)Y&?#_X.C?V<
M_P!GOX8_ GX!?'?P%X0\)_#GXUO\<K?P-8W'@9-,\&:UKG@S5_"?B?5]?OIM
M.TNTLXM1'A;7-$\-./$<L4DOA@^)'LFE*>)XQ7YH_P#!#[]E3_@HU\>O@9\:
M?$G[&/[:^F_LQ>"=*^).F^&_%?A'4-(BU5/%OB*?P5:75SJT\UUX.\56^D0#
M2[W1+1+B#[-=7SZ>]KNC$44C?N'X"_X(%?$+XM?&?P?\9_\ @I=^V7X^_;)N
M_ >I1W'AWX=RR:]HW@BXB6[:\N/#JW&N7UY?^&/"E_JVCZ7=^)/#OP_BT=?&
M$6D6<>I6,%M&LEQ^HYMB8Y1Q=B\UI9HE3C"-.ME;ISE&K*>#P\9)N4O9*,G*
M_*X-)<KNI)L_+<OPLL\X8P>75<L:J1JNOA\QA4Y:E*$,55:C904Y.T9+F]HD
M[[:'Y6?M.^)?%?Q8_P""Q'_!#CQA\5K+SO'GQ*_9@_X)X>*?B/8:IIBV[3>+
M]>^(OC;6?$]I<Z)<?Z'I<D>M7E\K:>_S0 #/#K7]!7_!;+]ES]F3Q7_P3D_:
M;\9^-_!'@#P5K7P[^'EQXV^'WC=- \/^'-?TOXE>&Y=OPX\.6GBC2D$[0_$#
MQ?K-G\-E\/M*6UJ3QS-;)&S-OC_"/_@N+X,^(7BK_@N)^Q9X%^$/C*'X6_%#
MQ3\-/V;?#/PW^(D6F02V_@'QK??'+XPZ3X3\61:=$+R+4(/"NHW%KJ=E:FQF
MD@L;.UMYY&FAD5/G+_@J%^S]_P %%O@+XU^!5_\ \%._V@OC'^U5^P_>_$?P
ME_PEVM?#+7##X>AO;2Y<7EG)X(O/#_AOPKH7Q"O=%D\33^$]2\46MV'2>X@\
M/ZC)>VU]#;^GB,.LPK\)8BAF&&P&'HY&L3C,-)M5<4XXO%UJE+#T5.E&I*<7
M[*/Q-K_EVX*RX85<)AJ'$>$KY=B,;F57./JN!K\[<**=#"TX5JU;DGR*,O?=
M[727O)ZGZC_\$F?VX_%/[+O_  00^*O[0/Q8M;WQ';?L]>.OBCX+^ 5KKDFL
M75GXRL=:B^'UK\-_"DMZ?]-U/1H_B[\0]6\!ZG+IH:]T?P]X?\2_V4CW/ARX
M4^1_\$<?^"7P_;ZO]3_X*E?\%!M1OOCCK'Q7\;^*]>^'/@SQO+:7NC>*'T35
MFT"3Q1XDT)%.CVFBZ#K6EZMX(\(>#K,?V+I>A>#]-?P__P 4Q/HJ/]:_\%BO
M!OP0C_X(,:&W[&CZ'+^S9X9\1_!'Q'X,N_!LPN+/4?!NL^/XM&@U6\N),:E/
MKNK>,O%$.I^+I?$0'B\^*KO65\9@>+!K&/U6_P""-?BKP5XS_P""8/[$>K>!
M3$-&LO@)X-\*7/D=_%'@6T;P/XV-QR<W'_"8^'==#\#Y0G' -?.8_-*.69!G
M&=95AY8*CGG$%?!5:LZ'MZ^7TH0IJ$).45+"NM*,IR:4.1333:7,OI,NP.(G
MGF7Y-G&(C4>7Y#1Q$9TIJ=+'XB<JCEAXSYE%>SC.G%S3J.7*_=23/LV#X!?!
M2TT-O#,'P9^%R:$QCMAH\?P\\%IIDB+!&F;G3IX$MI[58A';BUV?:T6$-EE>
M(K_+E_P6F_X)/:#^SKH4O_!2K]@5-:^!7Q9^ &K:=X_^(>B_#=;_ $J"701J
M8T[5?B'X%MH(IY/#6M>'XM7$WC#0[:&3PYXL^'>GZKIEU:W.FVOB/1/$/]?<
M/W&$8Z2'.3D]!D\]CV_+Z?"G_!3[Q!X>\,_\$]?VW-3\33Z?:Z;/^R7\?] $
MNIW1LK2ZU'Q7\.=;\-Z%H0GVG][XC\1ZEH^C1H2 7N8TSF0!ODLCS?,LOS"A
M.-2>(AB*L<-BL/.H\3"I2K5'"4Y1E=2YJ=3GY.5<LFDI-)J?U><9/EU?!SIR
MPT<%4P&&E/#5(M4W"<(RJ1IQK)1YO>:7/>^KTND?!_PI_P""O?@_QG_P2"\1
M?\%%]>L+"3QI\,_ NL>#/B'X"TN>>"RB_:0TS4]&\!Z9X02."2XU;3O#7COQ
M=XC\*:MI$DD]SXH\/_#WQ1I=RLVH:D\\\_Y8_P#!&K_@FU<?M\:CJ?\ P50_
MX*!:A<_&CQ-\5?&VNZI\)_"7B/48-9\,7<?A_6KO0KC7M5T+;-IEAX&TO5].
MU3P?X+^'=NW]E>%](\,6]CH#-X<CT9)/R[^#?A#QK+_P;5?M4^)8H-870X_V
M_O NM7TLEG]C;5-"L-%^ G@\:E9-UO-+;QQ+H5C#>=)9M/N(_P#EEFO[,/\
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M+>-BQT(Z3H.G:1KOQKO=,*:UJ^M^)+O3I&2&*S(_LH\ _LL_LY?#/PW:>$_
MOP'^%_A3P]I]O#IL>F:9X"\,QP"SL MG;I+)<Z7<7VH0[;;;'>7\S7-Q$B3-
MA#&*_ 3_ (-2_$7AZZ_8+^-/ARRGA?7],_:Z\7ZEJMI"##J=OIGB;X7?"6W\
M/:KJ$0(/V6ZG\/:CHL#X;?+HETI7$;5_4)9/&T19,*TF)61'#PI))'&SK$P
M!1G+29ZLTC-_%7F<;9GB,-FU7)<-CL=E^!RZ5/"X##49RH4Y4Z>'PLKJ<5%1
M]I.I.=_><54:NU[TO4X1RK"U\MCG&(P6 Q^,Q\L17QM>I!5JE.L\3BX.,H2Y
M^:484H*WNWY5H?S]?\%:/^"(WP1_:V^%?B;XC_L^> O#_P *?VK?!NCZCK7@
MC4/ EK!X8TGX@W%M%+>7'@[Q-:Z7;6.E6FKZ^L8L_#'B^\C:30]>;3VOI)=!
M;4H3\(_L(?\ !1;XV_MF_P#!'C]O'X1Z[J>OZG^UA^S#^S]X]\./XQ;^T;KQ
M9X_^'NN^$/%]CX;\3W5Y.!JFL?$K0=.T+7O!7BMI )_[=TK1-=OG;4M8G5?Z
M\;FX6&TF9P%VQRRD2'*&.$QB3.?59<^XXYZ5_%3_ ,&ZDL7Q'_X*8?\ !2?X
MQ?#40GX%Z[:_$R:PBAM!<VUP/B[^T5+XL^"TKQ$J+K^S_ .C>+VOH&(6.UO8
M7/\ K<CKR>OB<;PYFTLQE'$3R*IA,=A*U=JO7G)U81G@W6:4JB<+R<WS::<E
MHW.+-<+AL+Q#E"R_FH1SRGB,)B\/03H4:4>2?)BE13:IKF7*J=HZKFY_>T^X
MO^#9[4?V0_$G["-GX4\*Z-X"N_VE/"OB_P ;']H*RN+2SO/B1=1^(_%NH2^"
M=<>76U;QCJ_@"'P /"/AO3-2M@?#IU+P_K.GV@?4K'4EK]N=-_8G_9D\/?'C
M4OVB_#_PF\&:)\3O%'PR\4?"/Q;=Z)H5AI6@^-/".O>)/#7B6\B\7Z+'";#4
M;B'5O">AF.]N1)>SX6"0F*WB"_AE^WM_P0,>?Q_?_M=_\$S_ (@:W^S7^T5I
M&HW'B:'P9X5UJ\\-^']?U:&W#2OX5\2Z7-%>^ [S67B2ZO=*U+^VO"VN3RR0
MZAH\$4LYD[G_ ((S_P#!5KXV_M ?%SXA_L*?MT^';?PS^UY\'-*N;^'Q!/9V
MOA^?XBZ7X:=4\9:/KGAO15M_"UA\3M(&I:/XCTQ?!NGZ?H7C[P<WB/6X-,AU
M/X<:_/<SF^'KYKA\7Q)EN<8N>!G*G/&8/#8UPKX&M.E2BZ,<&G*3PT9T[QK1
MC&$=DERV6>4SPV58K#\-YADV#_M&'M/JV+Q>$4J..H*M5DJU3&R22KRC-1]D
MW*3M%/<_>B;X$? ](&G'P<^%T8B*S02Q^ /"4CM-$@DM)E:VTJZGWVQ*M%,'
M1D79A6.UF_CR_P"#4#P'X)\7M^WU'XP\)^%O%<FF3?LRS:==^(=&T?7+"PD>
M#]H>V:ZTA-6\.K<6$C6T4-HUA'FTBCMA+'F2XF4_VWQG=8/C:4$<R)L'EJJQ
MIY1A-N&=;5[9D:UEMU/R2P.6"NS*/XQ_^#1?_6_\%#/]_P#9>_E^T;7-DL\5
M5X:XH;S/-5+!2RF<7]>J2<_KV(J4];-).DDI*R5Y-J5U%)=F<8/"4^)N&E'+
M<IY,;.MAIQE@(^[[./,Y?$E)-W236UFGJ?UEZI\*_AKX/T7Q+KWA#X;^!?#&
MM0>'=>CM=1\/^$/#/A_58TET\>?&U_:V5I=+O;,S )Y6V4;G)*I7\I?_  :_
M?$#PI\(?V1/V^/BEXSU Z-X+^&_BW2/'OBG5S%*'L?#GA/X=>(-?UG4_LI8-
MJ4]E;6EW]F@@21=5O9;.U1 ]MO7^P/QUG_A"?%O_ &+>O=^_V-L_CT_R*_A#
M_P"".VD:WK/_  1P_P""S]EH2&;49OA]XF:VMT \RZM;+X,>+=0U[3P3S_Q,
M=(MI(0!U,?/2N[AW#5,9P]F-+$8FI7E_;>3X>5>N_:55#&553O.<Y.[IIN[N
MN:ZO\.O+G_L,!Q!@J]&G"A!Y-FE58>C'V=+GP49-.,8V454T>D?=?>YV?[#'
M[/'Q&_X. OVQ/B_^V1^UYJWB'3_V4_@QXE3PQX*^#D&MWTOA^"XU&+3]8T[X
M3^&]996L;'2-)T#3-'\2?&OQ%IFW6_&_B?Q-8:@QCL[RV=/[)_!'[*O[/'P\
M\/6_A/P3\#OA1X=\/6%I;Z98V.F>!?"T4?V"RC2&&.<W&EW=YJ%PJ)Y=]?ZE
M*]_>7*2R3C(61OPO_P"#6;Q%X/O_ /@G5XPT'1+86_B3P_\ M)>.?^$T$TWE
MZCJ][JO@[X9ZQH>O*@8,;*+PIJ'AWPXCC"^;X<N%)R0&_I<MP_END@ D2213
MB0.S#<2A<\88H5#*>@ _#AXUQ^9T\TKY5A,9BL+@LLK_ %3#4*&(>&IJE3A2
MNU*,5K.;G-2]Y^\TI-W;]+A+)\!/*:.<8C!8+%XK,:/UNK4K4UB*W-4G4]V4
M)R;O&*@FK+1)V5]/SK^+W_!,+]B/XI?$7X6_%Z_^!O@KP-\4OA'\1O!'Q1\#
M^.OAIIH\#ZR?$'P\\5Z9XPTJS\4GPO9V5MKOA:ZUS3-._MS3]8MY;26$(KSK
MN51_.G\3/$/P7\-_\'-?BR]_;?2*+X::K\*_!F@_LVW/Q-@1_AKH'B;5/A)\
M-[7PY=W7_"1?\4E%X<F\66_Q=L(8[ A1\:]8+!E=V8?VC1A@"&&.3WS_ )Z?
MX8Z5^:W_  48_P""8_[.7_!1GP7IGAWXMZ)=Z+X[\.V6I1^ OBYX4,5GXV\*
MO.CR'2%E($.M:#<3S3:I/HFIF2%);2>?3!#=W-S,>7)L[J4J\*.;X_,:U*6&
MJ83#UX8R:K8*%7ELXUG&4JT(2O)QO"]O=Y;-O;-LE=3#0Q&3X'+:-3VT<1BJ
M$\$G3Q+@]8>R]I%4>912^&6[=M4CVK]H#]C7]F;]J7X::Q\.OB]\)/ 7B#PK
MK>E3:4+K^PO#<?B#1/[16&QCF\*>*($-WX9OK5HTMIY-/)CN888[>)9F\V.7
MYL_:V^'.KIXO\6:IJ>KP6?@7XM?#C]F;P%IWB3Q!!:7G@7X6^*_V?/VB-<\?
M^(T\02>*-_@Z.Z^*V@?$.!O#T_B. >$=2U_X-66@>+I6N=?\)0R_SA:=\??^
M"E7_  ;]_%;P%\-OVC-2U3]IW_@GOKOB6T\->#M>2[/B*\\-:->6\QFL/A?K
MNMSQ>+O _P 3=#TZQO+'3/A9XRN8_!'BQK&ZL?"\]EJ?B/4]>T+^U+X?>,?#
M'Q&\#>%O'_A/6;+Q'X.\<^&-#\7>&]>TZ/S](\1^%?%>DVFL:'J&GNT4$KV6
MH:;?6]Y"T\$+NMSO6VM87CM8IS? YME+PN)GBXYGE6(YJN#QDJ[G7KT>;6=6
M#E4E"HFG"4')-^S\G9Y5C<IS26)PL,*\OS6B_9XO#0H.&&HUHQ2<*4TH1E"S
MC)-)?&[[:_E+IOP5U'QKJN@?#'PUXJM_$GC?3_VYO!7[6_Q&^-_@VYTFUT1/
M W@9/ 4T6E76C^#630?A_KWQ.\!>&K#]F7Q3\+]RR^/_  \?BG\5M0 TC5]7
M%?LEI<8BLXH0)Q]G2.VQ<7-Y>S?Z/%'#\]_?%KK4&^3F^N";FX/SWG^F&XIV
MGV=M80?9;2""V@C<[(;>,1(@95;#*.-YSN)&,@CC.:O5X>)KPQ-3VD(N*NVG
M+=WTNU9*+\EHDM-V?28+#SPM%4YS4G;6RT3N]G=W6VOWA14$HY)Y^YCCZGFH
M5(10#G^\3_7K[9KD<YJLH<B]E[-SG5<K*%D]'&VNV]U^!TN5H2DT[JI[.,5J
MY7<4FNU[O3R["71 8,WW0HSQVR<\X..>W&1WKE=:UO1]"M[C6-8U/3=+TNQA
M$][?7=R+#R+>,NW[^8[6:WR7(C)*E]W!R:\W^-7QP\*?"/1I;W5I8[G6[R$)
MH&BQ7IM[O4KL/)^[W8*64)P +ACF]</:CF(5X/\ #OX?>*?C?J-E\2_B_-<1
M^&4V7/A'X?Q)_9FEQVXR\5]J^EOG9.99)XG+-B>.WBFZ2MC\NSCQ(P6'SZ/!
M_#>&Q/$7%N87G3P]"L\1E&3X=-*6+SO$0IN&648I.4*<N>I4E:*:YU;['!<)
M>VR:7$/$.,Q61</8:LHT<52O3QN;XA:QP&5822_V^<I+EJU7*%&DFYRYN3EE
MZC!\5O$7CW4K:'X6^%[:^\*F:<7?CW7I)HM'B\N,,ATC0[$IJ7B"#YXWAN0R
M64LTDD(<-!)M_*/_ (*H_"#X>^&?@]!\3?':ZOXI^+GBKQSX;\)>'M=TU(-)
M;3=(G.I:[K=N--C4?8M'BTG1K^:P@N7:XCUN:S,C%63'[%?%/XH_#[X"^!;S
MQCXXU:P\+>&/#]J5CS<#3X[J2*'=!H^B6FT#6=6NSNBT+1U,CZE>/<I&A,+"
M/^6K]I+XQ_&_]O+QOXE\5^'?"^K:A\.?AI=Z-8>%/"NA6PU#^RC\1?$NF^$]
M"1;T CQ)XQ\5ZJMC;V4<81=,U6SU/0U ;3&9OZ>^CMX<9YF_&61<9\59QF.#
MR+@_,JV99KF53,Y9#P[5KU*7+#)L+0C-4L?1C/D]G6KRK.?-/FH1<U _B+Z:
M'BOPUE' >>^'N09#EN=\9\;Y?A\HR3A^EEM/B?B7!TN>+_MJM"I3F\*U&3<H
MX:&$A2F[QYU!RE\[?LX_&WX@?L_?%?0?'WP[6PUG7E=/#MUX<F5KG0O$>F:L
M5L+W3(%!!6:ZEMA!IDIR+"(0SNI60AO[(_@?XA\1^*_AMX3\5>-O ,WPW\4Z
MQID5WK'A"^U6/6]0T*X+M'%:WNK18349WM8X+@3A 8XIHK9ANMR3^:7_  3[
M_P""?FF?!VPTGXM?$O2[:X^)=]I3)/I&HV_VK_A'5DN[6\T_:)4QHOB"TL9(
M+'5M,BWI%>V\UPCB2>3;^PD0;R5(7:1/,!DY9E$C;=V ,;?N*O9%4<8VCZ/Q
MXS_A/BKB*7]CY%D$L1E^*K4Z_$.687!TL1C)^VG.-:6)AA(?69PAR+ZPX)S4
M/<<H\S?R_P!#KPS\3O#_ (#J9GQGQ)GT<'F?L*F7\(XW%S>"RZA.,(^SP^!G
M*7U!*497PL-(2G.ZORVU+81A7,?W6D+GG/S$#)S[X''/3KS4=V74%HW D6&;
MRT^^3.T;B ^5_$#B48XW%<<X.+$0&TGN3S[' R/;Z5+7XDFI*ZFZB>TY6<I6
MTNVHQ5].D4M-C^UM-.6/*FDU';END[=-FWT\^I^$/[:7_!72'_@GS^V7#\+/
MVC?A+XYE_99\:_#?P9K_ (4^.O@CPQ>WZ>%O&5_>:WH_B/P_XBTLR0IXFT?3
M[71+35<Z!J%CXA\(MJ\E\WAOQU:ZO9IX._-3_@JO_P %G?V+/VM?V/?''[)'
M[).N>,?VE/BA^T;-X4\!:;H^A?";XM:9%X6BB\7Z/KT^O6^F>-?"WA+6?%FM
MNVAPV7A32/!EMJ5U_;MU!XCOM3N[+3XY:_K1\=^!O!WQ#T>?PUXW\+>&_%^B
MW49\_2/%/AZP\2:9(&W*V;"\5R'8#!D"[0O&<YQXG\-?V0?V9/@_X@N/$7PO
M^ 'PF\">(+LF2;6_#/@+PWIVI[V*[GBNUA%];1G:"((F1$;<X 9Y-WTF6XKA
MV&(PV88S*\54Q^6X.6'H2PV/^KT:F(CS2AB<1!TI.5G*#E35U+V=KI2/D,[R
M_B'$4JV P6:4*6!S'&+$8B-? ?6:E/#MTU/#T9NK%034)*,[)Q<VTM#^'W_@
MKI^S5X^_9,_X) _\$H/@3\3);6S^('A_6OBS>>+;&&&.*W\*^+_B*\7Q)N/!
M:/8 W-W<^ [CQ)>^#+BX.Z?4[C0I-0N,SW+$_P!$FE_\'(?_  2A%A;"X^,_
MC>SE>"WE:#_A3GQ$NE7S[>&;]W=VNB7<%S$#(566*15;:0(QC+?MEX\^&7PZ
M^)<>G6GQ%\">#_'EOI$SW.E1>,?".F^+[32KR5?+GN[&SU;2[Z"VNKF()&^)
M% 6.,K'U$GGT7[*/[+DB+C]FSX%1A!M\H_!_P"'C+#S")4M?#QCBD<R>84)$
MF) [!2RA>Z?$67YGE.7X#/*&-Q=7!8K-L5#$83&8?!I?VG-2Y(TY82M)>R<(
MMRE4E*;3MR1=CEI\,8W+LQQN+RBK@J$,1@,/@:=/%82OBG3]BHMU926+I*?-
M)R?(HP232NVKGY-_&'_@I9^R9_P4$_X)\?\ !2^P_9;^(6N>*+KX7_L??%K_
M (3"?6O _C;P5;:4WQ!^&/Q)L?#3FZU6PL(=2^TOX9UQ!8K'(S-$"SJCNM?/
MG_!JSA_^"<OQ&;++'_PUI\1))(S D"BT;X1_!>&'[':1 ^5B&:TG8N#(RSG(
MYCS_ $%:3\#/@GX1T[Q!H?A7X._#/P[H_C73CHOC'1_#OP_\.Z%8>,-(D$]I
M_8_B6&QT.*SUK2S:ZEJ5K_9NL![%EU.Y51$9W<=E\.O '@#X;^'SX?\ ASX+
M\(>!M"EO)-4N=+\$>&="\*:)>ZM>6MHMYJXTWPY96&ER75Y'!;)/>1PM),MO
M'')(QA 7S99I@:>3XW*,+A,2HXG'9?BZ>*K8U5*M..!BU[.<8481J2J.7QKE
M44K<LM3UJ>4YC4S3+\VQF.PLZF$R_&8*MAZ6!=*E5EBXPC[2#E7J2I1@H+]V
MW/FU7,M+?S"_\' '["'CGP]/X&_X*F?LGK?>'OVB/V<KC1-;^+M[X7MH8-2\
M1^!_"LUG=Z5\3;6T<&"Y\2_#_P#LZ#3?$,%PK6M[\/-8U>ZOV&B^'-663\Z?
M^"F/_!3L_P#!57X!_L!_L;_LS>6WQ:_:9\9Z'J_Q[\#6$]\6\ _$'1]:C\">
M'?A_>S>6EGK7@#3_ !?J/BSQ^^K786]T7P?X5^%WBZ^2.;Q(43^['6=+T[6;
M:?3-4L[74-.OK62TU#3]0LH]0TR^M)5D1K?4+2Y1K66V(+Y20-N!96&PD-XC
MX5_9I_9_\"Z_IOB7PK\$/A%X3U[1GGDTKQ)X9^'G@W0-9TQ[TL+FX@U:SA6^
M6"]#>6L7S.9%F<@"0;>S!<1T(X3 T,?AXXJME5>O/"UN=4JGL:D9RIX>I+E<
MYQHU9*<9)WY4X1Y;*_E9KPSB:V/KXC+L5+"4L=AZ-+%4/9NK1E5IN$9UXPYX
MQA[6G'D<+;ZMM.QY3\"_V&/V5OA)\&OAA\+=)^"WPK\2Z;\/_ 7A#PC9^(]=
M\ >$-:UKQ!;:!X>TS38M;U75Y](O)M0U#5$MUO;N\>4-<S3M-C+AF\D_;E_X
M)Q? #]I[]EGXS_!'P]\*?A9X&\5>,O!6HQ> /%N@>!O#WAK4O#/Q)TW&L^ M
M4FUG2M.M+U-%?Q7IVCPZ]91J!JFC#4-)D=_[101?IG J1JT<8(1)& #)(I!8
M!W.Z3_6[G9F\Q/D^8H.4:JE_&)ML0++(3%)'Y3(D[&"YAN2D)G!MI"PMQOCD
MQ\@^<A&R/#CFN/\ KL<?'%UW4A7>)HR=6HY0K2G)SG=S:?/!JFTDO=C9\T;1
M7T<LGP+PGU:GA<-13I1A[M&#C&HH1BZJCRI7<E*?>\M6];_S1_\ !N%^UQK?
MQ"_9J\7?L8?%234K#XS?L9^+==\'2^'/%'VZ7Q-#\,=2UR_A\/V-U%J%SYU]
M+\+?$+^)/AKXITBSM19^"=%'@#P^\\4]GN;]_P#XY1^7\!/C&@=WV?"KQXA>
M4F2=_*\%ZC&&N;@X^U7+*BF>8$@.QAW-Y6XO\/\ P7^%_A?Q/KGC?PW\._!G
MAOQGXD37[7Q-XK\.^#_".A>+M8@\3ZI!K=ZOB3Q#8Q)J.J*]U;V<C&XEFE:6
M..?9N *>DS6=M?6UU8W$5K+:7L=S!=Q/"+VS9+GS?[4MM0M[E3;SV=U+]IA<
ML DNZ6-E&'(O&X[#8G,%C80^KVQ,,2Z+G[1J:]E*:<[1^.I&I.ZCI[2S3Y;N
M<'EE3#Y>\#6Q*KREAIX=U?9>S7O^T2FJ?/*UE-+EYOL[ZZ?RI_\ !I;_ ,F@
M_M.?]G#Z7_ZJ7P77]8*'+ 8X$TQ&1[W1Q^&?\XKS_P !?##X<_#/3;[3/AOX
M#\%?#W3=1NWNKJQ\(:!HWAVRO[F7:;FZGM-%CBMKF]N JB6\E7[5+&L$4N5M
MHB/1E$BN7.1$P7"' ,> %V@#/&06_'KVJ,ZQSS;,ZV8QO1C6J1J.ES<]^6E1
MIV<URWO[*^W6W0K)LLAE.6T<O4U6=*$H*MR>SO>I5G?DO*UO:VMS?9OU/XN_
M^"KIQ_P<B?\ !-=B,_\ $K_9-)'_ '<1\5CCN:_K#_:(^!OP]_:;^#GQ%^ _
MQ5T*V\2?#_XJ>%;KPWKMC=0P3FTA$37-IK6GIJ4;Z9:Z]X>U>/2]<\/7_P#Q
M]V.LV-CJRHXTB+;V7B7X._"GQ-XPTCQYXG^'/@+7O&>B)ID>@^,-?\)Z'JOB
M;26T>^U'4=(L]&UV[C.JV26=]JNIWMM:VLJ0+<WMU,@$T\A/IMI'Y43* 0IE
MDD4LKHY,S&:4NC*-C&>27:JY0)LVG^$=6:9N\?#A^5"G4P6)R##4J%.M"NY0
MQ,J5:553J4E&*Y6I.+@W/5<UW=Q?'E^1+!5<X=2M3Q.'SBK4K5J4\.E4IRJ4
MU3?LZSG)JRBFFHIIZJSLU_#E_P $_HM5_8_^.O[1?_!!S_@H/=O=? /]IBUU
MO3O@3XVO)!'I%WXE\;PM;^$[_P"'MQ?03:?X;T[XEBR&J>$);J-[+PC\9_ V
MDZ/HMA>ZEXLOKS1I?@3\7_VU?^#>#XG>*?@C\;OA3XR_:(_8 \3^+=4\3>&?
M'WP]T>]OM1\+S7?D)>^(_!*WMV^B>'-;U*VL[:^\0_![Q_J&C6][J$TNK:)\
M1M,?4H;CQ?\ V;>._@Q\(OB)K^F^(O'_ ,+?AQXTU_2+:TAT+Q!XO\$^%/$F
MMZ0+*[N[V"'1;_6-(O\ 5+0VUS=3W445M,L$4]Q++%&LDUR9.NU#P[H^N:1?
M:#K>E:?K.DZC$MI<:1JUC;ZAIUUIT<: 6EQI\MI:6$6!O/V9XW 7RV9V4HD?
MT%;C6%669T<1@,/4P'$&%H?VSE[<53GFU)1A+-<')4VL%*<*=)*C&/NR4VZC
MC.QX='A"IA_JWU;&UHSRS&UZN$KU5*K6G@ZBE*&$J3=12DJ<Y2:J-M-6CR>Z
MC\'K/_@Y!_X)22:!+XBNOC-\0;#69=/CNE\%7WP;^*4OBBUW"XO&L;V>R\(7
MWA7[:3?2PP:=J'B]M,T^Y5K1&T>WC%U/^1_[3W[4'[8G_!P#XDT+]F+]D#X1
M>-_@C^Q=;^*=&U;XI?%GXBV&I6NI>,8[&\.JZ3JOB1M%FOM$BTSPRFCC6;+X
M6^'_ !-XJUSQ!J;:'KB:[%JVD^']*TC^K _L#_L7G7Y?%$G[*WP!_M;[0':Z
M/PD\#W,[.0I)>%-'N@T_F$R&Y^63YPK)M0,?JOPOX8T#PGI<6A>&]'TG0]&T
M\B*QTG1=.T_2].L(A%%M@M[#3;2TM[954*0AC,F"&9RI0+P4,UX>RFH\7E&5
MU/K?L.6/UG%JM3I5^3D5515-<[AHXP=EWEHF74R;B'-*,<%FV:*6$A7YW.EA
M?95*M#G<O92DJNEXODY]=DU%['P=X3_X)^?L]:!^P[!^P FB27_P13X8:W\,
M=9#F(>(+R]U+[)K6I_$)-8WO-:>*;KQE,WQ$2[GBDF;Q?=:3JUH5L-+LA7\Q
MGP"^,G[8_P#P;R_$+QC\ _VA?A#X^_:%_80\3>,=3\3^!?BE\/+&T:^\+SWK
M0Q:GXK\/S7MUI&A:%>ZQ9V5IJ/BWX7^*O$F@:5INORZEK&C^+/#EYKUU:^+/
M[A@H''7G/^1TS[UCZWHNE>(+.XTG6-+T_5]-O(3%?:=JNGQ:CIUY;-O5K>6V
MN@;.0MD[A(K'!7<I4UY^6\08F#S)9A1CCJ6:4K8B$YNFHXKVDI?6Z349)347
M""BUI%.T[-(]3,.&J%>&#67UGEU7 1A#"553]M*G3BE>$O>IN:E)SDVVOBVT
M/PPTW_@XG_X)+W.C)KEU^T;KFBWU]937 \,7GP,^.D_B"U3R(+^:">+1_AGK
M^EO=K).T4MW!KUQI,TR.8K\1+B'\+M>_:B\/?\%-O^"\O[%?[0O[+_P^^,>M
M_"#X30?"[PAJOB?7O!.K:=;21>#/%7QB\>:]XB\RPU[7;2RT"33_ !5I4-M;
M:W%H>M1SVUV]WH-M;R6EW?\ ]==[^P#^Q9J&L'Q%<_LI_L_MJ9F,C3S_  O\
M$1EIMYD^T2&+2+E9+AG<LTK%7.%!3"@M]%>&? '@?P!IJ:)X*\(>%/!^EN)'
MET?PSI&F^&=*E@=+6RNII(M)L+*WEF2$VR1/)&)'\M8_.4",Q^I@\UR/)Z6)
MEE& Q-+$XW"XZA7A5QD)T82QM*E2J.G"-&,G9T^9IM)\UERI-OS\5DF=9KBJ
M4<UQ]"MA<)7P-3#U*>"]G5DL%*4[SG[65W4<GK?W;+>Y_'G<;$_X.[[ 1QNJ
MQV*;6,L<L<T8_P""<UV\,EOY?^K@\@Q1K&_S[XY'R5="?[-75)/+"YQ)%)&Q
M6(.8&E^[*<G[A,>"I #%>> :\W7X/_"]O'I^*/\ PKSP8_Q*8)$GQ"E\(Z'#
M\0XA'8Q^%I9V\57,)U=T?08Y+)DC9('L(HA%$&95D]6L458G0PK$XE>25$1U
M@^T7*I=7#V[.!YL<D\\CM*F5:8RKG<K5X&9XVGF=/+XSP[I/ X?#TE:JWSU<
M/*I.-;2*Y;RDI<FMK;N[/>RK*%E=3,+5EB,-F%:K6JT)4^7WZL7%MRYI7:B[
M7Y5=+[OY:/\ @L=_P3=^)WPY^)^E_P#!5C_@GLMYX7_:/^#=Z?B#\6?#_AF-
M9+GQ[H7AO3=4M=7\4:;HRG=XDNI?#L^H>$_B=X.7*>.O U_::>1&^F*'^0O^
M#2K%_+_P4)ANY+2::Z7]EM+R.1A(6E*?M&?Z+J<>US>)+)!?:;>7NW;JMKI]
M[?NP6ZW'^U&^@@G$L4Z*\<UN\$B2Q!K>2"8LMQ!,9@UM*ETF(FA=2<?,>&!'
MF'@[X/?"_P"'4VLS_#_X:> _ 4VO2:;=:NOA'PEHWA*75IM,N[ZYTX^)=1T-
M%CUMH;W4+VYMUG628/<N'RDAKW*?%^9RR/,<IQJIXRMC8933HXZ2Y:F&IY34
MG.E"2LZE9-34(\U:+II7O)V:\>?!F6K-,#F.%G4PT,-BL1BL1AHMRAB77AR.
M*=XQI66[4)7[(_C?^+_[,_[9W_!"+]KOQ[^U;^QCX&UCXW_L2?$QA/X^^%&F
M1:Q%:Z'X>.HV]QIGP_U[_A'],\3W_@W4_AY-J\T/P6^)=SX0U_2=(\+2WWA[
M7[+4-!U;6])O/U<^&W_!RE_P3!\4^%DU'QYX]^)7PI\31&X@NO!WC7X.>.]9
MU1+W3KN6UU"TM)?A5H7Q#\+M:V5Q!/;V$MQK ODMX(H];%CJ$=U:P?T'O&CP
MS0W4<<]LXD$B7$0"SQ3DF59!<!8/++R2Q"VDR?*1&9V$F:^5/%O[#/['?CG6
MI?%'C#]E[X#ZYK33_:3J]W\*?!<NH3-(Q;S;B=-)N3=S^:TCO<22B1MP#(H1
M2ZKYY@<Y]F^(,"L;B*5.$%B:-6.'JS]FE&#JVIR4Y)))OW7;K:RC%#AW&Y-7
MQ%3(<?/"8?$5JE5X6K2>(IQ]I)S<8-U(\J3D[:>B1_-'^V+_ ,%E?C3_ ,%*
M],U7]C+_ ()-_!/XQ^(4^)]O=^$_B)^T)XAT27PY8:1X$U>YL-)UF\\-3VVH
M3)X0TJ\AU%=-\6>)?%;:%XCL?#6H7R>#M/T[5C=>(M'_ $N_9:_8AU__ ()"
M?\$V_BF/@;H6E_%_]JNW\%>)OB_XTOK31-4U>P\>_$/1-,N-3TSP+HFGK/I/
MBG6/A]X<TNWNO!/@W3K*1?%5[_;]YJFCVOA[5_&&I"OVE\#?"_X??#329- ^
M''@CP?X$T=O*$FG^%O#.E:!9S,BA2SV6E6EC;27!@6*-YVB>9XTA1G801B/N
MGR?,4!Q%Y<12-+<1/$$9@W[Z;%LZ8&1"R[E!8G*.NW&OG>'AAL+EV P*H8"A
MC7BL5"=9U*N8T_=Y:-:HHKDC&,4HM1G9MMVTB=5#(L34Q6+S''8V-;%XC QP
MV$Y</[..7UHN7-7IQ]H^=RNO=]S_ !.]S^=SX0?\')'_  3S\7>"K:_^/&N_
M$']F?XMV<5DOBKX7>+OAE\2_&3:7KZPV-]J&EZ9XA\!^"KZTFTTWAN++2-1\
M?0^ -4EF69]=\/\ AR?S])M?SV_8,;7O^"D__!='QG_P4H^%/P\\3^"?V:?A
M!X:U>RT?Q;XOT6VM)?B5KA^#E[\#]'TJS%O<WD-AXDU>R\0ZAKM_:M?WKQZ'
MX.T<O.7E$$?]2/Q"_8Y_9:^+>OQ>)_B%^SM\'/%^O1W N?[5\1?#GP=?:C?D
MJ1(VH:I_95W+J<!.9%M;B5V64S2-'B8.WO?@?P;X5\!>'[3PQX)\.:#X3\+Z
M:/*TC0?#6D:;H6BV%MLCS%8Z7I=G96MI$LBLNSRC)D$LY4HJN&:9+E]#&ULH
MP-?#YECZ=6A657&*M@Z5"KS*I3CAO9Q<JCBU:JY1<=&E[J9SULHSG,\3AL/F
M^-HXC+,%4IU*+I83V&+JUJ7*X3>*523C3YH^]346I)--^\TM-5VVDZ*RND9N
MTC:,@Q")-PCCCVD@"WC"V[@!0)89/E[G^,;_ (-%_P#6_P#!0S_?_9>_E^T;
M7]GU]%OD)2)I)8K9T+E54F";S)FMK>2<&VD:YGLK6*[@D(7R-C2;596KS'P/
M\&_A5\,WUO\ X5O\-_ '@4ZS/ITVJ+X,\):1X1357T>XNI=)&OW^BPQ#6/L]
MQ>W%Q%'<I).+FYN&<!)V5?/RW-5@<JSK+UAW/^V5EO[QU;?5W@,14KOW>5NJ
MJKJ-;QY%;XK6/8Q^4/'9GDV8O$*#RFM4J^R5*ZKJI!4U'FYE[/E45KRRN[Z*
MYU?C@?\ %%>+<]O#6O\ Y_8GK^27_@U$TNSU7]GC]M&RO[6.^LK[XH^"+2\L
M[V#^T-.GM7\#:^D\,VE$[;^WO(YVL=3L"K?VE!<VMOC$1S_7X]M;S6]W;7ZQ
M26DT4\+BYAQ'/;WY/VN*=;@"W,4[NUL+5U8^2BLQ<2J1PG@7X4_#7X80:C:?
M#GX?^"O %EJ5PUQJECX,\(Z5H$E]-*=YFU)M&18+V_G<F2>]N%:YEB%JDK;8
M(6&F$SBK@\JQ^6TJ=I8[&X'&>WYVG2^I-ODY$ES<]])<T>5ZV?3+&Y%3QV:8
M+,:M5.&$P6/P;P[IW]I]>^WSN7N^S_EY)<W='\9/B/X'?M=?\&^?[5OQ$^/?
M[-7@/5/VA/V!OC%?V8\9^"K6UU.6_P##?A[1=6O[CPSH7B.?0=,\2>)M"\5_
M#&TUG48?AUX_3PKKVC^-/",_B6ZU:SF<>98_KM\.O^#E#_@EQXF\(V6I>-OB
MC\0?A7KB0B/4/"'CGX,_$/5-<T:Z262!+>?5?AGH'Q#\)SSW$*17-M)'K$9:
M&>*34(-'NGFTJQ_?JZM+6]CNH;FVBF6\B\N[M)XTO+::)D">7<VTX:T??$%5
MU=<LF%8E0*^3O$?[!O[%_C359M;\2?LM_ 75M9EG,US?W/PK\%/=3W&XN9[F
M5=(NB\[.[%GDD$AXW(JA2W;4S7+<RA36>8&>(J)6JXBCB?8U,3[TFIU;TY)S
ML^5S33?*KZ)17G1X?QN5SK5LIQ\Z,*C4J>'J4G5I45RQCRPBZB2A>+DE9).3
M2[O\9+O_ (.(O /QQ^,WPU^!/["/[.?QB^.^N^+?B;X(\&>)_B)XQ\/3>&O
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-44 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>66
<FILENAME>tm2110724d8_ex10d18-3img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2110724d8_ex10d18-3img002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  A F@# 2(  A$! Q$!_\0
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M3GU'!M\\ '\.>U.7P'X'.=OA'PRV../#^EG&.@/^C=1SD&C^V/#K_HB,T_\
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M9#>$O# SG@Z!I0/(X'_'OGCD^]*? 7@@9/\ PB/AD#('/A_2^K851DV_4DC
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M:40>"?\ GW[*&_(GM1_;'AU_T1&:?^)9C_\ YF#_ %0\=_\ HZV0?^()A_\
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M/_"EOC =I#IG3],.PH25V?Z<=H!9N!CAB""#@63_ ,%T?@C@_P#%FOC#T/\
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MR,_\4_I?7(_Z=NXP*7_A O!/_0H>&O\ PG]+]<_\^WIQ^M+^V/#K_HB,T_\
M$LQ__P S!_JAX[?]'6R#_P 03#__ #U/Q='_  71^".?^2-?&'^+_F':5Z\_
M\OO^??K44_\ P70^"7E2'_A3OQAB 4YE.G:*%BS\HD8SZ@D01"P8^8P4[0I!
MSBOVF_X0+P1V\(>&@?F_YE_2_P"\,_\ +MVZ?K2CX?\ @=CEO!_ALE<LI&@Z
M8A'&,9%L<@@D$=P>:'G'AYRRY."\UIS::C-<4XJJXR::4O9UL*Z4[-J\9JS5
M^MF72X2\=85*<I>*G#TXQG%RA+@>%-3@I+GBZE'-)58<T.9*4$VFT[6N<O\
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M/Q!U*X\3:M?V49M-#O=/LDTNQGM5N[>&YN_MIGCN9;>6.-8C&8)6=X1MZ/\
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M/@36HM%FTK5S?)XAUS5?#NC^197Q-WJ^AQZK<:G:MNA46JVL.BW\DES>&WM
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M'8V3V^I6$5G;ZQKT4,>V_(3"A*M)3]M!QESOD=K+DUMZO;6X_=>D93\_>?\
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M&LW?A".Y^(#QQW8U+6O[*ULW:V&C/K=\&F=;;21);1S2RI.\I4H#L_YI??\
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M\OG_  #_ -%"BB@!9/\ 5+_UUMO_ $<E9DOWM6_ZYQ?^BH*** %M/^0EJ?\
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M .EE_P"B15Z/_67/^^?_ $5%110!%!_Q[1_]>\/_ **BJE=_\?MK_P!=Y_\
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%BB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>67
<FILENAME>tm2110724d11_ex10-20img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2110724d11_ex10-20img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *X A$# 2(  A$! Q$!_\0
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M^>VE?]\R?XT5L[?>B@"K9%C)=@D8\\X_):N"J5A_KKSC_EX/_H*U=H ****
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M2SGI7+7/BC4-6?[+X9L3,&ZZA."($'J.[GKQD4 =)J6I66EVQN;VYC@C7N[
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M3.FFVUO\HN;Q"9I(CPA5,_>Z<Y(SVH H^%/$R:;8S:3X@DF%E*F+*&:S(D=
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MTJ:@ HHHH **** &_C12\44 4M//SWF?^?AO_05J]5.R96>[P!\LY!_(5;%
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METW3V(/?$]/&H@G(GL\'I^^J3^S+#)/V*WY_Z9+_ (4HTVQ  %G;\?\ 3,4
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M]>GT/]*DH **** "BBB@ HI,T4 5+%=KW?.=TY/Z"K8JEIPQ]J_Z[G^0JZ*
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M&4 J&]JF6@!:*** "BBB@ HHHH @;/VJ+'3:W]*GJ)@/M"'O@_TJ6@ HHHH
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M: ,#QI#<S^&KE;6$S2Y4K&."V#6,OC&[O8M6LM1T&;3Y8M-END$\N1(H^7'
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MDC@LR_SZT :XZ5'+&LL;1N,JRD'Z5(.E&* ,?0F,$4VG2$F2T<J,]"AY7'L
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M**B^"-02,*D2RW015;*A<G !]*PM#L8[_P -PV\TNG)$'^9;G#'!8\$'U[4
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M02 JR@Y&.E "6UQ'=6L5Q$VZ.5 ZD=P1FIJQ='E\J:YTZ6?S9[=B0=N"$;D
M>P!Q^%;(Z4 0W=LEY:2VTH)CE0HP'H1BJND^;]@2*8@RP_(^/:M ]*S+>4V^
ML7%HXPDP\Z-O4]&'X?+^= #-=M&NM-+Q F6!EGC ZY4AL?CC'XTVZ7^T])BN
M[<(9DQ+"W7##K6N,=N*RM.?[->W6G,S':1+%GIL;L/Q!_.@"S97$.JZ:DP7,
M<R89&ZCU4_RJ/2YE>UDM_P".WD,3@CIW'Z$57AQIFLO ?^/>\R\?HK]6'X\F
MM5%4,Y P2><"@#*TYOL&J3Z<V1&X,\)/IGYE_ D8'I6R"#TK*UJV9[>.\A4F
M>T?S$]QT8'\":T+>=+BWCF0_*Z@@4 34444 %%%!H @?BZB_W6_I4]1-S/'Q
MQ@_TJ6@ HHHH IZI#+/8O'%LW$C[_0"I+5#' B$@D#G%0ZM&LMB5:Y>W&X'>
MG7Z5/;J$@10Y? 'S'O0!+^%%&?:B@"CHX(TY 2"<M_,UH52TD :=&!TY_F:N
MT %%%% !1110 C=.*CM\^2N:D//?%,@&(5&2?>@"2BBB@"AJ5BM_#L,\L,B-
MN22-B-K=N.A^AK,EU/[&C6FM0$1[<"Y908I/][LOXUHZA;VUPJ">8PN'S$ZM
MM8$\<&J5U<ZA8L(Y[9;RQ*X:5/OK]5Z$>^?PH R/"JQGP3?B *L7F7/EA>@7
M)QBO-M)-O/\ :%S;O@;6LY<M+.W_ $SP?O8QCTZ]Z]'\)M$W@*\:!0(2UQL
MS]W)Q6+X=QH_ATW]J]E$6WRS>9&-S,.!SG/;'3M0!<\;-:RZOID+ZA%!/&N\
M)/<(J 9&24;ECC(&/6NC6#Q#(JM;7UAY!4%/W3?=QQW]*Y[QQ>BRO[61(HWE
ME39(?M)B)4D?[#9'0?C6C&ED4C<C54)0?+&V5'';VH @\0QZO#-HSZA=6CPC
M4%+"-"I^X_<FKOB74+._\,-<VEW%+ +B,&6-P54AP#S[8K%UJ.U2[TAHQJ,A
M^W*2DY&UOD?]:O:A);W'@P&"Q-E&;Q1Y4@V\^;R>,]30 V]LM/U3Q##=OKD"
M0K:&$PI* ^<J=PP?;]:ZA=9TQYA M_;-)MW;1*,[?6N2UKQ'<:/XEMK&.VA:
MT:TWM^Z.=^Y0/F],$UVJV5LLXF$*"7;M# <XZXS0 X7EL1D7$>/]X5'+J5E#
M&\LMW$D:#<S,X  JT$3'W1^5,DMH98V22)&5@0P(ZB@#!N=0M+_4;!K.XBG1
MH9R'C8,.BUE:+>>&TT2S6YU.%)O)7>IO&7!QZ;JVM1MH8-0T](8@@6*8*JC
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MF@#.GNKPP2 Z.1\IY\U>.*Q2[KH>C,L)9_M0Q'GOYAK:FNO]'D_XF<1^4_\
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MWB@EHU;;(I'?W'UXH S/"Q=O!%^TA3S&:Y+[/N[N<XSSBM'P/D^$;+G/#?\
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MMY%<$=AD G\LUHQN)(U=>0P!!]J2>%)X7BD&4=2I'L:AT_\ X\8QQA05&.F
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M% %GGU%%+QZ44 5-* &G18Z?-_,U<JCH[;M+A.,?>_\ 0C5Z@ HHHH ****
M$--B_P!4OTIQZ4R'_5+]* )**** *&HQ32Q@6]V+>;=\C%=P]\C(SQ6=?SVS
MZ>8=8M"H*E6D*Y0GV(Y_2M#4-/MM05$G+*P.49'*L#[$<U0EO;G3D:+4(6EM
M]I5+I%W C_:4=#[]* ,CPR(U^'-TL;%E$4^&/?@UI>! 5\%:8/\ IF?_ $)J
MS/#CH_PWNY(]NUX;ALJ,#H:U/ @ \$Z4 21Y1Z_[QH Z+UKGC>:C<%I+620Q
M;F4'[.#C!(_O>U="W0USNF6$EWID3"[EB DEX0XS^\:@"&5-8N;FV#;F6*;>
M0T(08"D==Q[D=JC\0F[?P]:?V@L:SG4+<$1'(QYRX_2MRUL9;0,_VF:=BIPK
MGC-9.N1ZG?>'8F^Q;[N*ZBF,$;C+*D@)P3["@!U]:ZO/JI\N. V8C&TMR2<B
MMA#>?V@RF.(683Y6#'=GZ8K.CU?5"6W:#,%XQ^^3_&F)J^L?:V#:'+Y 7@^:
MN[/YXH Z &JM])>):2FQBBDN0I\M)7*J3[D XK$NO$.HPS0QIH[AG;!#RKG\
M.:EGUW4(D#)H%W(3V61/\: *7B0W#V%L;J-%N/LTV]4;(#87H<#-0:1/XG&D
MVHAM-/:+RP%+3D''N-M1:O>W^IJ[SZ//9PP6\I:25U(.0..#[4[3X='&E0-(
M=1\SRQE4DFQGVP<4 ;6F2^('O,:C!9);8/S0REB/PVBMW KDO"US'=7MR5M;
M^ (?D^T/(01[;CBNNH H:B^HH%_L^&"4\[A+(5^G8U1%QXBQD6-EGT-P?_B:
MU9WD$B+&0"V>OTI-ES_ST3ZXH S]#-T6NS=QI'*9.0C[AT]<"GZX/]"F]3$P
M_E4FF!A+=[\%O,P2!CM3=9'^B2?]<V_I0!Y[#I=\]C$TEK.4,0'!!4\?7I71
M^!X9XFO,JZ6^%V ],\Y_I5Q=+O-2T*"UEG18GB7.QF5NGJ*TM$TMM*LC;EU=
M=^[(SZ ?TH U!TJ&YV[/FA:4?W0,FI@,55OA$8<2W)@7/WM^W]: *-\(38SY
MT^4?NVYV#T^M8\^TV.A!HFD0OR@ )(^E6[Y+'[#/C6"3Y;<?:!SQ]:S[LQKI
MF@^;<B&-3EIB0 !]30!M%+(.I;2)@>@_=K_C6K:;?( 6%H1_<8 8KFQ-I!((
M\41$=/\ CZ3_ !KH=.:%K-#!<BYC[2A@V[\10!:-9UZD#R RZ?).PZ,J@_UK
M0/2L?5&LUN%^T:LMHV/N&4+_ #H S-;CLAH]R3I,Z?*!GRUXY_WJT!%9$9_L
M6?GK^[7_ !K!UZ6Q31+EHO$BNP7A?/0[N1ZFM&-K$\?\).'/M.E '0V01;?$
M<#0+G[C #^1J<U5T[RS: Q70N4)XD#!OU%6CTH I7\DBHICM%N<GD'M6)K$L
MYTJX#:.B_+][(XY^E;.IK9F(&\NC;J. WGF+]<BN9U<Z"-,FV:T&E&-H%^26
M.>F-W- &AH*_\3><?].D0_2NFKFM").M7/\ UZQ?RKI: "D/2EI&&010!SGB
M= LVE7S#/V:\0 YZ;_DS_P"/5TE9.NHXTMW1H1Y;I)F9 R@*P/0CCIU[5IQO
MOA1\@[@#D=* 'XK,OP4U33IB@* NA<G[I8#'\JTZSM8VB*U9UW*MRA)_N\]:
M +XR<4ZD&>]+0 4444 %%%% $61YP]=M2U$5/GAN,!:EH ***#0!GZO<"ULC
M(2X&0/D.#3[!9EM\S2%RS$J<YPO89JIXC=TTY63.1(IX)'\NM:$#B2&-\YSZ
M'_"@";-%&** *6CG.EPG'][_ -"-7ZH:-G^RX=QR?F_]"-7Z "BBB@ HHHH
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M$@#J36B.@J*[0R6LJ XRIH >A! ZGBGU1TF;[1I5I*&W;XE.[UXJ]0 4444
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MG%O?$S?=LK'_ +Z/^-.%SXIQ_P >-B?^!G_&NAQ10!SWVKQ/_P! ^R_[[/\
MC574CXGO-/GMVL;-5=<$ASG^==73)?\ 4O\ [IH YS0H6AUJ:-\!ULX0P!R.
MIKIJP=/_ .1FN_\ KVB_F:WJ ,:^:0^(;")&*J4<D@>U6FL[D@ :A..><!/\
M*@N?^1DL_P#KD_\ 6M:@#.BTQ8EF432,)B2^X#DFJ?B4%/#]VJDX$6/U%;IZ
M5A^*"BZ'>LZ[HQ$0R_B* %L[2_-C;E=0('EKP4'I]*TK6.>.,B:8R.3P2 ,"
MN2LX_""V5N6MXU)C7@0R>GTKI-(&GBT(TU L&\\;2O/XT : X^E9NK7EM:0(
M;G4UL%)XD+*,_P#?7%:0Z<U1U6X:VM&=;26Y..%C )'OR: .<N-:TR:QNHXO
M%4=P_E/\@DBYX/M3+VXAM[;P]+/=K:H(R6E9A\HV#GGBL"TM+^?2YKF9=>!E
M@9CYDJ>6#CL >E79M/ELTT.99K^[+(6$*N"1\HZ T ;*^(=$S_R.4!'/_+6+
M_"NCTRX@NK".:VO%NXF^[,I!#?EQ7$+;W1C8_8O$8/G"3.8N@S\H^;I6O#X=
MN+U/M"ZOK-D)"6%N90OE\],#(% '5/\ =K#U34K"UNBEQX@2R<#_ %9>,?\
MH0I$\/3Q6RQMKFI.PD#[VEY(';Z5D:M9W,<MU$HURX:1MZRVQ3:O^RN6!]J
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MZX-7(]S1J6X. 2/2@!W-%+@>M% %+1VSI<)'3YO_ $(U?JGI@Q81_C_,U<H
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M#&JV:L$#X&>!_6@#8TUU;Q+>8(.+:/H<]S705RGAUV?6KS<#G[/&.>O>NKH
MYO7-233=>LI'C9\QL JD GK6R;V..-&E=8]_(W,!FLO5;.VO?$-E'=PK*GEM
MM#>O-9FJ>'M+O?%^FQ7%E')"+.<[23U#1X[^YH Z,:I;9QY\.<9_U@YK+UZY
M%]HUW!:R0-<-&=B^:HYR.O-8UOX/T0OK1DTN K&V(NO V#W]:@G\'Z EEHK)
MID0:6]C60Y/S+ANO- %ZP\0>)FM41/"XD,:A6*W\1&0/K6SH6N/JS7$-S8O9
M7EN^V2%F#=LY!'!K#\/:%I<'B?Q';Q6:+%%+!L3)PN8E)'7UJYX;@CA\0ZZ(
MH@L/F(H8'C..1^M '5#D=_QJIJ*7,EH5M)ECDYY89%6UZ=?QJCK$=M]B:6[G
M,,:#);=B@#F[.VUD>% 7O+<PBU)"A.0-M27"3LGAU+9UCF\LX8\_P"J5O<Z#
M)H+10WY:5;<C8A;;G'TJYJ'D+#H#W4CQPK$=SCM\@H U?LVO>8";VUVXQ@QF
MM:U698%6X96E'5E'%<J+CPV6VC591G_;(_I74V<,4%K&D+%H\95B<Y'UH F;
M&.GZ5E7D.L27!-I<VT<)Z+(A)'%:K?=-<[J@TO[:1=:A<P2$#Y$8@?R- &?X
MAMO$ T6X_P!-LRIQ_P LR.<UJ+;^(]HS>V6?^N9P:P-;.BG2I]FL7.2 /F<]
M,_[M7P^CJ<_VW>CC Q(?_B: .IM5F6W07#*TH^\4Z5-5+2S"UBIM[AYX\G$C
MG)/Z5=H 0\#-9NH37%O*DEGI8O)6^5F5T0H/<MU^E:1&015+4(KJ2("UO8[4
MY^9GCW9^G(Q0!SGB*S\0:MH.H6Q^PP0RPL N"T@..F<XS2?#6]^U^$8X^AMY
M&A'T'2K<VGV,*,VHZS=SHYP4>7*?@H&:YCX8W,%KJNM:3 ^Z"-QY#'^(+D$\
M_44 >FX%&!Z4+GFEH 3 JAK$'GZ1=Q!0VZ(\>N*T*BF020.C=&4@XH H>&KA
MKOPQI=P_WY;6-V^I45J5C>&!%%HJ6T,<B1VSM !)U^0[?Z5L YH R/$\>_0+
M@ [=IC;.?[KJ?Z5I02"6WBD!SN4'([Y%5M:3?H=^-N[_ $>0@>IVFC1VWZ)8
MMC!^SQ_GM% %^BBB@ H/2BB@"%?^/I^/X1_6IJA7/VI_]T?UJ:@ H[BBD- &
M;K98688(&PP/W@O\ZNP.)(48=QSSTK/UY1)I_?*N" !DU?@/[I,L&&.N.M $
MG/I13J* *NF+LT^)<YZ\_B:MU4TS/]G19Z\_S-6Z "BBB@ HHHH CG&87!..
M#3D&%%-G_P!2_P#NFG)]T?2@!U%%% %#4;>[EV/97 BE0YPRY5QZ&LJ:YL+^
M&:UOH5AOO+888%2QP?N-_%^!XK2U&UNYL26=V8I4Y"L-T;?4<']:S+B\L=2M
MY['4X!'=HAS&XQGCJA]* ,OP\-OPAM@20?[+R<^I2MWP>0?"6FX_YX_U-8.@
M,&^#]J23C^RP ?\ @%;O@W'_  B.F8_YY?U- &X1D$$<&O+?'(N]/N+C3;74
M)H[.2R:0QEB<%F8$ G_(KU.O+OB,3_;NP)N)T[//08=_U]* -&?X>%K.V.GW
MI21)5E*2Y\LX4C[HXS\W7J>];/A3PY>:&;MKN>&5IV!'E @#@5T5O_Q[1?[H
M_E4M &;!IABT=;$R9VC&[\<U8-IG4?M>[GRO+Q^.:M44 9[:<38W%N'_ -:Q
M.?3./\*FFM/-EM7W8\ABWUX(_K5JB@"DUB&N)YF.?-0(5],9_P :PG\%1NR'
M[?.0@"JK*K<#W-=510!0L-+BT]6*$M(YR[MU;C&*OT49Q0!FZMH\.JI&6DEA
MFB.Z*:)RK*?PZCV/%0:?H1L[[[9/>374X0QHTF!M!P3C'K@?E6P"#T(-+0!G
MC3=OV_:Y_P!+.?\ =^7;3'TQG@LH]X_T:59,^N ?\:TZ3- &!>^%UNK^YNX;
MZZM6NMOGB%L;]H"@@]0<#M6G8Z;;Z;:K;VR87^)B<LQ]6)Y)]S5VB@!!TK-U
M[2UU?2I+8OY;@AXWQG:XZ''>M.FR?ZIOH: ..T6W\2/86\C0:"$:(;3&C@].
M_&/RK4E@\1M$0(](9@/E#AR,U?T/_D!V0[^2O\JT* ./FT;Q+?Q-;72Z'!!(
M-KO;HYD [[=PQ746-JEC8P6D6?+@C6-<GLHP/Y58HH 1NE<OKNOW%CK<6FVJ
MV:RM!YYEO)-B8W;=H.>M=0>GK5.ZTZSOF7[5;QS%>A9>10!QM_J6K7UF]NTG
MAU=V.1=?_7J:;Q!JD-NTS_V R("Q"W//'8<]:Z;^P-*_Y\(?RIA\/:3NR;"$
MG/ITH LZ3>#4-+@NUC\L2KN"^E7:;&BQH$4!57@ # %.H #TJO=A/LSF2 3*
MHR$QG-6#TXJ.0,4(0@-CY21D _2@#GHY-1=V:TT"WM7 RDD[)S^"'=7($76B
M_%ZTGNVA#:A%Y(\I"%/&X^W85VWV+4C)_I^M*BYX%M&(C^)8FO/O&ZZ?8:CI
M=[:7TEYJ$4_E8D;<W)!)R !P%- 'KJD$TZH;:19HEE3[DBA@?4&IJ "F8_6G
MTE &)H91+G4K9$=2ER7?>V?OY;CTZUMBL#3D,'BW6MP?%PL,BL>GRH%-;XH
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MD'-;O@S_ )$[3/\ KE_4UB:*F/@W8(&!']DQC([_ ""MWP:FSPCIRGM'_4T
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MQO90"4<&]4#GN).*N'_D8E/_ $P_K0!SMW>:!;:C]@EU/6?-6X#,Z33E%D/
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MRA2?LT., Y_N^]9&HV1LK-K/4/&*PH[!VCDC@0MR#@#:#VH [2QAC2PMU5%
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M1V^1JT=HYXR#VQ0>M ''S:A+HWBO4)&TV\NC<11^5]GC#;L%L]2*M-<^*]0
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MM([ZSEMI@QCE4J=IP<?6KE% '#76G:SI5O#:2%M2T2)ER(UQ<*B] <</R!G
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M0JC&&'RX ^@JK;P>=H-]IJ(8Q:2-&K9ZXPV[\<G\J *-OI&JZD=1T_4-5:!
M3A;-0F0XR<[MW<XIB:3IX\/V^IK;GSK:02/YC%RVTX.<\<\=JVK9S-JECJ:
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M .A[]>*,XZUPOB*]U:-[W5=)D,BV<BPF$]P,A\?C@_0&L^X\;:_IL5M8W=C
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M5A,S:EX:G@8]9[3$JG_>.%- '69X]J4'-<[K'B:VM-#GN[:=#,D2RJC\':6
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MA?9 ?[;T+4-,Z99EWH,]R<"@#MJ3H*R-,\3:-JZ;K'4890>,!N:UL@\@Y^E
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M4444 13C**/]H?SJ0'-1S@E5Q_>'\ZD% "T444 %%%% !1110 4444 %%%%
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M,GF@!OA&.&."]6WE,L(N %D/5AY:=:Z2LW2=-&G/>!<".6;>BCL-BK_2M*@
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M3=6A8>-+>0*NH1-;R'@.F60_3HW_ ([5S[;K6G*/M=HE[".6FM>&4>I4]3[
M5'(F@>(&9/W:7;#Y@#Y5POUZ,* -Z*>.9 \4BNIZ%3D?G4U<++X<UG2)'FTF
MY+KC 1& ./\ =/R#\!FGQ>.9K&9;?5;1M^/^6:%7/T0_,_U48H [>BLW3=<T
M_5@?LEU&\BC+Q9PZ?[R]1^-7]_/UZ4 /HI ><4M !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 12G9$S8R5&?K4.FPM#81JS;BQ9\_[Q)_K4MQ_
MQ[2\\[3_ "HM/^/.'_KFO\J )J.U%!Z&@"-#^\?ZU)4,1S))QSNJ:@ HHHH
M***#0!R'DI13^?6B@#IK<?Z/%_N#^5))<P0,%EFC1B,_,P&?SHMB?LD7KL'\
MJX[Q$;63Q:D5QIAOI#;$0H;?>N<CJQ&%^I(H ZX7]F /]*@_[^"IHYHY5W1N
MKC.,J<UP[Z%<6N9Y_#VD2VW4Q0P*98_S&#^%:W@\V[6MVUK"T,!N&PC1&/'/
M]U@"* .FHHHH CF&57_>!_6GBHYB0$_WA_.I: "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "D(S2T4 (5!%,>%)/OJ' Y 89 /K4E% ''
MZO\ #?0M7N9;ETEAN)"6=XVQN.<\CO\ X5Y_+X"\1>"[V[U#2((]1)@:.*92
M5DC)/)V=#QCOVKW"F,N<^] 'BFE:CXGL;;2+/3;^XN;RZ=V5+N'"K&H(R5SU
MZ=ZVM,\5KJ^O0>']=T:,WJL0\T+8V-G@X],8/7BO36M86N1<F&,SJI59"HW
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M=.*X:34_$^E1XGMGF7IOEB#_ *0@G\ZLP>.XHU07MH\9P,D?*_\ WZ/SG\J
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MK91*.1)&2C ^O']:I'2-:LV!T[6=\8Q^[O(O,./0$%<?E7144 81U+5[9_\
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M)&7'X XIAMM7V_\ 'S#^9_PH-MJ_'^D0_FW^% $#:+?VZG['K-QN'W5N%5T
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M (W7244 <[_PCFH_]#5JW_?,'_QNF'PSJ9Z>+M8'_ (/_C==+10!S1\-ZD
M?%VL#WV0?_&Z0>&M2 _Y&_6#_P  @_\ C=.\8/*L.F1I]K*2WRI(MJX5V78_
M!R1QP/RJIKM\^C06%O9SR!(W\^X&"\GE Y(_'!% $X\-:F",^,-8_P"^+?\
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M%.\0,5\.:FP&2+24@>ORF@#,@TS69K>.7^W9/G4, (EP,CZ5*-(UO.3KS_\
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M5,DO[*)]DEW C=,-( ?YT 9/D^*_^?S1_P#P&D_^+H,/BK/_ !]Z/_X#2?\
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MPSXHN/#=T[;;J:RD.7A9?NGNP]ZVS\-]3YQ/'_WW_P#6I1\.=3'(FCX]6_\
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MU?'_ ![VN?\ >--,FLCI!:X_WC110 IEUC'%O;=?[QZ4OF:J0<06X]/F-%%
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8%_\ %444 9OV;5?^@:?^_J_XT444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>68
<FILENAME>tm2110724d11_ex10-20img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2110724d11_ex10-20img002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +Q @,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "L[5-9L])C5[MV520 50MS^ K1J"
M[C62!@0#R.WO0 ^)UEC$B'Y6&1Q4E(!CBEH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "H+LD6[$''3^=3U#= &W;/M_.@"4=:6D%+0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111F
M@!"<4QY4CC:1V5549+$\#\:S]6U2;3U7RK*6;(R9 RA$_P!XDU1CM+G6;:87
M.H-&2-I@@^7RSZ-GEORH N7'B/38(1(LXGR0N+?][M)Z9VYP/<\5IA\GD8S5
M<Z?;?9Y(!"@C<;6 &,U7T\RVY-E<,2\9_=N?XT['/J.A]Z -.BC-% !1110
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MP,36V?H?\*7RM5P/WUOG_=-:-% &<8M5R,36V/\ =-)Y6K?\]K;_ +Y-:5%
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MFL+_ ,2]I02&@(F7 SDJ<TV_U>#3V$;$/*1D)O5<#\2* *G]NZC_ -"QJ?\
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M?<@92"".".E-FB2>%XY%W*PP0?2@#A)8;H08B:\#(T:GR;A0(V#?,&S@Y8'
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MKW4+=Y-]O<0@[H)5P3D=CT/X$T ;-%)N&<=Z6@ HHHH **** "BBB@ HHHH
M**** "BBB@!&.!7'ZE):+JDL1FQ'-,!(/LN\EP%Z-G(&-O;C-=@W3CK7&WMH
MTNIWEY%Y;"&14:!I"&.0I)''&<#USCK0!UX''W3^%% )P,D#VQ10!)1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% %% ?[6E/S8,2]>F<FKH
M/ JM'<AK^6WV8*(&SZ@TT:C:&66,7$9,/^LY^[[$T 6\\UF:#_QY3_\ 7W/_
M .C&JW:WD-[")H'WQDX!VD9/XTZUAA@C=8?NF1F//<DD_J: )Z3(]:#6;J&L
M6FFR+'.7\Q]NU57.23@#\Z -"4_NG^AKG] (,MB?^H7'_.KTNM6/F2P_:%+K
M$9#L^8 #W'>L+PQJ]G>W-C%;F5G.FQ@-M^7'7K^G2@#LJR](&;6Z_P"ON?\
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M>?-*JQC'S#W/M0!;R*AN8([B(QR*"I]NGO6=_P ))I?V47#W*I&9!& W7)(
MXZ]32W/B+3[:Y6W,C22LQ4+&A;G&<'TH J:FTMI!':3CS8I)H1%+GG(=3AOP
M!P>];Y! (S6-XDN1#X=FN,*"I1P'['>/UK0:\AMK%+FYF6.,A<LQXR< #\R*
M ,C2T9=8OUNR48SLT$9_B4XRV>ASCIVYIWB%D\ZS@9"YF+*B+UW8R"#[=:O7
MTEE,D<<MQY<A!:-EX9<#)(].,]:I::96NX9[V4R/(&6W4Q[<*.K'W/\ GK0!
M8M&O=.5([YUGA _X^ ,%3Z,/3W_2M975U#*P*GH1S0RAE((R#U&.M4%B735+
M*3]F!Y4Y_=@^GX]J -&BFHZNH96!4]"*=0 4444 %%%% !1110 4444 %%%%
M "-TKF!]FCUJX%_=312M*"F_A"N!C!QCKGJ:Z=NE<5=RVZ>)I9);:2X<.JJ2
MH<)P..&XZYY ZT =H&7'6BDW*!C^E% #L#.:6BB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** ,(6TTOB"\V7DB9A0@*!Q49\*VVV=5ED'GR&63
M/5F/K6A!@ZW=<?,(UR:T: ,B'2VL[188;R94C4@<"N3T:?65LSY=]=74C2R.
MWE6J87+GUD&/UKT"7_5O]#7,^#?^/:;@ ;GZ?[YH BW:\#GS+\CT^RQ?_':J
MW%OJURR-.;UF1@RDVD9P0<@_ZWM7;TM '#&QU(3,X6Z#LI0D6D8RO?\ Y:58
MT'P^]E<IY)N;=8K81;Y(U&[YL]F/<YKL<"B@#/\ L%UC_D(R_P#? K)O_"XN
MHYF%V1,RDAF0XW>IP1735'+_ *ISCM0!Q&A^";&72+.<S2-));("[9)(Q]:F
MD\)VEK>Z7;).ZP_,H4;L\*2.]=/HP T6RP,?N5X_"J^HC_B>Z/\ [\O_ *+-
M %=?#-J#C>WYG_&C_A%;/ ^9\_[S?XUNBEH P#X6M"/O-^;?XUG'P#IYNWN/
M,D#N2QY/4C_>KL** .2MO EE:/-)!,Z-,=SGGD_]]5=B\+P1$DS,Q;N<_P#Q
M5=!10!A_\(W!CB1OU_\ BJKS^%H6B;9.R/@X;YCC\-U=)28% '$>'/#*W>@6
M<\]W([R1AF)!'\FQ4B_#G28XXXP24C8.H.[@@Y_O>M;?A/\ Y%73?^N(K9H
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M,'_?=!\0:0?^8A!_WU7'S?#^*#"+>AI6^ZOD]?UXI\?P[<Q@O=HK=P(__KT
M;'AG6]-MO#EA!/?0)*D0#KNZ&M4^(M'_ .@C;_\ ?5<?%X $ENLWVU &&>8O
M_KU77P&\TZJMRHB/ <Q#D_3- '5:QX@TF71;Z*/4(&=[>15&_J2IQ5^VUC31
M:Q ZC:9V#CSEXX^M>5ZQH TO5DL)'657QDA,<&NOB^&/AYHU+1SY(R?G'^%
M'5_VQIG_ $$;3_O^O^-)_;&F#_F(VG_?]?\ &N87X7>'5'W+@_5Q_A2'X7>'
M=V=L_P!-X_PH O\ BK5[ ^'+L1WUJS_+@"53GYA[UT%HP>TA(.044_I7F?B_
MP#HND^'+J^MTE\V/;MW-D<L!Z5NZ3:V*:':RS:5?2$0AGD64X(Q_OB@1U6HD
M&R;/9TZ?[PJM=?\ (9T\CIA_Y5GS:%I=SIHD6TF3>4.UYGR/F'^U5AO#^B_:
M8D>!O-P=G[Z3IW[T#-SM69)IKW,[M<W<KQ'@0I\J8]^Y/XT@\.:4.EN__?\
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M[@ X% &W;P"%/]H\L>N33Y)%BC+.<"DFGC@C+NP5156%3<R"><@(.4C]/<T
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M%HBIC!5AR/8UG:KJ^J6^H&UTZQ2?"AB6;%/T2YU6XO)6O[(6T97C#9RW^<T
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M:O;VT<=PL(BN%E8M'OW 9XZC'UJP8G748'"DHL+(6]#E?\*D_M*P/_+[;?\
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M0*T'BR13,FYW!V$#&,?[O7_@5 '64444 %%%% !1110 4444 %%%% !1110
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M-R59,%?;K2W/FZB@C@D,<6<LY'WO:LSPZEY=:-:Q79^1$ =@?]9C^E=$J!5
M7@#H*!GE?BZ&4>(4ARID*HJE!M%=[I=OJ<>FP)-<Q[PHSF,D_GFN-\5MGQC#
M@]2@_6O2(Q^[7Z"@#A]4U:]TCQ-*0\+LT*Y++@ 9^M;^DZIJ&I1*QMHEC((\
MX.2,_P"[@5S?B.TBOO&26\S;8VC7+9QM[YY]P#^%==H]NEO9LB3>>"Y)DX^8
M\>E $.IV-Q=V9BF"72$\QJ3'D8QUY]:\XU3PE:?VR+== 1%*J TEQ)CGT(->
MO=*YO6->N[?5AIMGI"WGR!G:2X$8&3Q@%3F@#C&\ 6$3!7TF$$\C-S)_C7.Z
MUX:MK:S6YL[ 6ZX9-R3L3]Y1GG)[^O>O2I3>2@1W5B\;-\I03J=X'3DKQ^%<
MUKRJ/#\0"%-I88ZX_>)Q[T :.D^%-9/A:VCN;B*2Y1594>27G!R 6W^GM6UI
M>A1R:%:[5\F;DMF64KU/;>.]:D&I,MI%_H-XVV%6XC'/08'/7G/T!JSIL1CT
M^%)!)N )/F'YNI/- %6'0;98<3;VE_O)-* ?PWG^=85YX2GFUFSN8[J-)H S
M1/MD;'(X.9.GM7:8%5W %]%Z[&_I0!C_ &'Q-G_D,6([X%FW'_C]5=%L/$=M
M>W_VC5[2XC>3< UH00<#@?/TKJC56R'[RZS_ ,]CW]A0!4E2\$UI]JN(6'V@
M%?+C*_PMQR35J5;XS!HIH%BSRK1$M^>[^E-U ?O;'_KX'_H#5= XH CE\TQL
M(F02=BPR/RJHT>K8^6ZM!];=O_BZOX%+B@#FM1@OU<R7-XBED$<<L,>WRR2"
M<YSUP/RI)YK^6>"W9H),,1YD4O,@]UP0"..]=&8U;.1D'J#3([2WA_U4*)_N
MJ!_*@ 3<(%#G<VWD^IKFX+>[_P"$I^U"%&4AE)^TIPIQSM$>[L.K5U##BN?L
MM+N;376E$1^S$/M9I5.TL03QL!.?=C0!O>O%<H)XIO%'EB7]_%,NY#%)C&WL
M=VW/OC\*ZS.!P.37' &?Q9EO+\E9\1A7D#APO==^,<GM0!V?-% Z44 +1110
M 4UW"(S'H.:=4-S_ ,>TN>FQOY4 /20.BL.C#(I=PKG=4N9;2UB>/4C QA!2
M%8PQ8@9IUE+? 6%Q)J*SK<;=T90 @%<GIZ&@#HJ*:I!'%.H **** "BBB@ J
MGJAQ9-S_ )P:N52U4 V9/I_@: (K+GPY;G_IT7_T 5R'@&Y2&"]+<DD84=2:
MZZR'_%.6Y_Z=%_\ 0!7)_#R!'-U,Z@LI !]* .RAA>243W'WOX5'11_C5LXQ
M]*.G\ZI2RM=R-! 2$'WY/Z"@"!"+O4+J)&_=AE+L._RCBM,* NT  #MVJC8Q
M)#=7D:+A0Z_^@"I[JZ\K"(-TK<*O^- %'Q#<I#I-RG)D:([0M.T"V6+2;65F
M,DKPH2S?0<5%J5J8M%O78EYWC.6_H*M:2PBT2RWC;B!,Y^@H N33)!&7<X J
M@XEN!]IEC) YCB_J:?#$UY*+F?A!_JX^WU-.U2$W&FW%LLX@>6-E60GE3ZT
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M"#@DYV_Y]:WN@YH&>9>(I8O[.8!E)2U EC\T$]. ?7!Q2:=*MWIEXJRJL>T
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MA5W7,'0[Q2%(,1#!NA&*N!UB@#,<*%YKFM:^V:H\<<<<JVC[N44'=QQNSV-
M' W$4/V+R[=W2/SG7R54G"Y.">.U6-&6W6.Z-S*T \@% JG:3V'(KTC0$QI
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M9&1@TUL?;(LYSL;'YB@"?M6/!J=K:7L]O<2JDDT[",8ZX"_XBM@5Q^I+I_\
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M'^B-5NJ6J%OLA"XR3CF@!(<?V*F.GV<?^@URWP]/^BW0_P!H?RKJ("?[$CR
M#]F&0.GW:Y#P%*R6]TD:DN2,>@XH [:>;R_D0;I#T6DM[?RMSNQ>5OO-_2EM
M[?RLNYW2MRS?TJ22184+.V!0!$;J)/.W''E$!OJ1G^M11(]U()YUP@YCC/;W
M/O4%LK7.H73./W*LI52.IVBM3(Y)H H:N?\ B379[>4:AMKAI;&U@MR-QA7<
M_91C^=5]?N6ET2\%N-RA#O8\ >N*N:'$D>B685<;H$+>YVB@"['&(U"J, 55
MOM2BLBD95WFD!\N-!DM4TURL9$:C=*1P@_K5"33$DG2]NI9!<ID(R,0$SV Z
M4 1Z(HFMGNG4^;)*^0PQL^8Y J3<$\/3,WR@(W>LB+Q!#HNG'SXY61KB50[-
MR3N/6LZV\21:O9/9PP2;1&[-D\T =';7J:C-&KAXX]F^-'&"W'4U7TG4[I[&
M_EE='\G)C91A2,5<LK.V#K<>9/)-&GEYD8Y4?3I6'I.HV[V5ZEO@*[D-YD@9
M4]>P_*@"R/$2VQEM8[:X>=IWQMCR,;CTI8=9A.@^7'97AW0;MPA'/'WNM9LT
MMO#;PJ8YR3<2$3!/O-S@YS531-=ACTW[(4N))#:': GJ<_E0!W[3)! A8GD
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M_P!:@!6W7QV@XMN_8O5M5"* H  X '&*50%    '856N;HQN(8AOE;H/3WH
M2:9R_D6X!D/5L<(/6I8(1#'C[SGDD]35>2X@TRU\VY<#)^9L=36!KGC2TL[9
MDLF\R=A@<<+[T 6_$GB:+18&BB(DNF!VKG[ON:Y_POH4^JWQU74P73.Y=X^^
MWK]*@\.^&I]9NO[3U,LT>[<%8_ZP_P"%>BHB00A5"I&@Z#C H D&  !T%&1Z
MUC-J%Y=R-_9T,;QJ<,\AX/TJ[IUQ-/:!KE46=25D5>@- %:TQ_;]Z?\ 86M:
MN?TBY-UXAU7L(B(_RKH!TH ****  UPOQ"D8-81AOE9P2,>CI7==JX+XA?\
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M%)9+=)7)R&<GCB@#UV"&21_/N/O?PIV4?XU;(&*\Y_X6'?#_ )<H?S-17'Q
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M!SZUU.<#)-<J;A]2\2QP38%LH?:4\Q/,*D<==K <T =6,XHHV^YHH 6BBB@
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M7\JY5<?\+,)QC_0JZT\T 9.OZ:-0T6:U6,LS@852 21SQGBN$.G)H5HI$+6
MCF^62XP-[;#GYQTY[UW'B>[DL=$>:*Z6V/F(GF$9498#GT'OVKEK'Q'J3:"T
MT3C[2)#GSVQE "<C=UX&<"@"E=_9XTTQY_LA,,2LGG%1D ;L(#].U>FQ &)3
MZ@5P.J1RZE9P7U[>F"2. O&(X=W)0@]N_H.HXKOXC^Y3G^$4 <+\8$!^'=\^
M/G1XMIQRI\Q>1^%==IL,:Z5:H% 41+QCVKDOBL'NO"O]G1X'VJ50S?W0IW?S
M&*IVGQ F@MHX19*VQ0N<]<4"/1/+C_NJ?PI&1,?=6N#_ .%BSG_EP7\S2?\
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MKTKI7.%X[USFG/=+KNRX\P\R#<RL0P)&W&>!@?G0!TU%%% !11FB@ JK?_\
M'G+GIQ_,5:JK?#=:./4C^8H IWFLPV!6.2VOG 4?-#:O(OY@8I;;6(;J<0K!
M=Q.02#-;/&"!CH6 ]:34;V$QRVCP7QZ#?#;.P!X.00*@TQFGO \LUZ[1H0OG
M6C1+SC/.,$\"@#;3\*=35&,^].H **** (YO]5)_NFL7PZ<I<_*1M8+\PQG@
M'^M;4O\ J'/HIK#L- M6M5E+W"M+\[!9FQDT ;XI/E]JRAX=L\?ZVZ_[_M0?
M#EF3GS;K_O\ M0!-J4?E8O(DW2(-K*#]]?3W]JJZ-864NG(YMXG#%CN*=<L:
M2?PM83!0TUZ ,_=N6&?KS4WAT8TA5V[1'++&HW%N%D8#D]\"@"W_ &78_P#/
MI#_WP*YGQYIUHGA.Y:.WC5@1@A?>NQKG?&A'_"-S!NA8"@#E/!!0:3:@?>^W
M$GVKTH%0."*\GT/PW_;,>U9=A5N5QP/>M[_A6\/_ #^''^[0([DNH!R1CZU1
MT5U-DYP%)GE.,^KFN.N/A]!;Q,YO6XZ +WJA/X*:VTP74CE'+ >7MY&3WH&>
MHY7UH)4CDBN!;X<P@9^V,![J!5:W\ I=2MY=RWD+P)"/O?3VH ]&X/I1\OK^
MM<+_ ,*WBQ_Q^'_OFJ\W@"-)$CCNBSL>01T'J: /0^/:DR/6N%'PWB_Y_#_W
MS44OP\MX(VD>](4<GY: .UU!U6QG)/&P]_:N7\3WL-Y;7T#W"*ENH"(&_P!8
MQ&?Q%9<7P^+P&;S6!SN12O./>K?_  KU"<M>MDGIMYH Q?AZN?%#O@_\>YZ_
M6O2II6ED-O ?G ^9O[M<QHGA9-/U*26"=FXV/+T[]!77I$D*80!<4 )! EO'
MM0<]2>Y--N+A8 ,C+,<*O<FB>9D4*BYE?A1_GM1!;"'YF.^0]6;K0 V"W8.9
M9/FE;U_AJ<D $YP.M(SA06/  R:J(K7KB1LB '*J>-Q]3[4 8_B?S+G3O,WE
M8%F3 '\7S#K[5KZ60;5MAROF-BC4[&.\LO(:/<N]3M'L12LQ?_1[8;5'WW'0
M"@"2>=C)Y$/^L/4C^$>M200K G7+'[S'O3HHEA0*OY^M-N)_*4 +EV.%7U-
M#II5A0L>O8=R:@BMV>433\OCY5Q]VG0P;<O*=TAY)/:K' ')P!SS0 56<-=,
M5W8A'7'\7M3/FO'QG%N/3JQJXH 4 8Q[4 9>KC9#:A<*!.H^E7)I_+*QQ@-*
M>@]/>JVHPK?E+5=VX'<6'1:;%HD,?(FFW=VWGF@"[!#LW%N9&^\U>8^.U_XG
M,0X)S)_[+7H%QIZ0PEA-.3T4;CR:\S\4VTUOJ:&5V+9<8)R.U F=QX8U6RM]
M M8I)<,J\\4[Q!K>G/HEW%YP9F4 ?+G/(KR][YH8HD29D('3> #4^GW@N=8O
MHV=F(L69EWYP1)%CC\30"/:;-5^PP8 _U:_RJM<64$VK02R1*S+!(@)&>"4)
M'Z"K=G_QY0?]<U_E43_\A&-L\"-A^JT#)(+:*VB6.%=B#H!4&GQ&-[S(QNN"
MP_[Y'^%7,YS[54L67S+OG/[\]_8<4 9^LF==2A^S1&64VDP5 P7/S1CJ:NZ0
M93IT/G0^5)T9=I'(^M,F!/B*S.#C[--_Z%'6ECF@!:*** *-Y8BY:.6.5X9X
ML[709QGJ".XIL%A+YBR75RTY1MR+L"@'UXJ_B@*!TH 8_"'C/'05ROAU2FK2
M*TA8*'VQ@$&'YCD-ZYZBNK8#D=<BN8\/V\D.KWIFMW0EV97)?&TXX.[CMT']
M: .GY(KGM.MEM/$4Y&]6G#,<HY#8]&(P,>@]:W;E'>WD2-]C,,!O2N>T70]1
ML]6%S=7$+J$96VR.S,3C&0>!C% '44444 -RV[&.*=110 57O#BU<X[C^8JQ
M5343MLI".Q7^8H J76LVVG7WD723)YH+K)Y99"!UY'3''7UJ]:WEO?1>;;3I
M+'G&Y&# '\*Q-562;5HR9[F)(D( AM6?<&QGYL8!X'2DT=-%&KS?9DE;450+
M)),C;PO8$D>_3WH Z,#G-+2*,4M !1110!%-Q!)_NFH[$8L+?'3RU_E4EP?]
M&E/^P?Y5'8?\@ZV_ZY+_ "% %FBBB@!#67X>4+IC '(^TSG\Y7K5-9FA?\@Y
MNW^D3_\ HUJ -.N:\<_\BX^3QYJ5TM<UXXS_ ,(V_P#UT6@"KX 0?V3.^!DR
MD9_ 5U,TZP(78\#]37)^!YXX-"G=CD"8_B<"NEB@>:07$X&1RB?W1_C0 10O
M*_GW Y'*(?X:R/$M\$\/?:-IQYRKC/\ M8KH<\$&N1\7R1KHOV:$;HUF4NQZ
M D]/K0!T)+W[F-<K;J<,W]X^E750( %&% P *2)!%&J*.%&!4=S<K%A -TC_
M '5H )[@1X506D;[J^M);6YBS)(0TK<L:2WMFC8R2-OE8\M_05.\B1(7<A5'
M4F@!))5BC+N=JCJ355(7NIEFF!$:\I&?7U-"Q-=LLT@P@.8T/\S5W(H S-<U
M0:+HMY?[/,-O&7(]<5'I^H?VUID%Q!NC26-78KVR.0#6=XWF\WPSJ%K&NXO$
M5=@,[ >_UI_AR6:X\-Z?:QVTT $"K*TD9CVG'( //XB@"2UU#5Y( \&D*D9^
MX&<#*]C3WU;4XD43:>OFOPJH^:UALM(%15X PB"FP0,)#-,0TI]ONB@#&:^U
M&T)NKJR4,P"C!SU/ %6)-1U5$=SI\2HO.YI0!BI?$!"Z9DX \Q<D]N>]68<W
M824EEB'1<XW?6@#)-UK%XP?^S$^SJ054RCY\'.>M6X-0U#[9;0SZ<8X90P:0
M.#M(!(XZ\UK@<>E4[Q#.#'$V)A\RGL".F?:@#"\5>+/["EM;:.!Y)9W"E@#M
M7VS[]*M:-J<]P\</V)8XR@<MN&<'O7,^,(I;J]TV)K:XW0OF23RVV$Y_O8QS
M72Z+,D4*$DX,"8_O&@#==Q&H8G_Z]1Q0,9C-(26(PH/\-)#$S2&:3[^.%SP*
ML'IGM0 'A?2JK*]T^TY2$=?]NGJ7GDXXA'7/5JG P, #%  JA5P!@#IBHI'+
MDQQGY^Y_NBEEEVE54$NW3VI8H_+7!.2>2: *-U,=.6V2)0QFF",S'U[U>>0(
MA=N@K&\231P)8.[  7:=?QZ5K1$S?O&&!_",=O>@!D*/-()Y01C[B^E>:>.S
M_P 3>//9G '_ 'S7J991G)P._/2O)_&LZ2ZT O*@O@C_ (#0!C@0A(A-U?Y0
MN>?RIVG6<<6LW\@R,V$FX,__ $UB[5%,56UMP Q.<D*,@BMBV@B9;J:%B9GM
M&7:22,%TX /TIB1ZO9_\>4'_ %S7^58_B&U-\_V82M&'MW#%5#_Q)VK8LLBQ
M@!X(C7^55KVV@O+M+>XA66-XF#!AD$94X_E^5(9+IMN]MIL$+N&9% R%VY_#
MM6"+/SM9\P.-RW+]80P'"]^U=':VZ6ENL$>=B#"Y/:LNWTZVN;BXF>-&EBN6
M*.1DKD+G'UQ0!8D(_P"$AM!SG[/-_..M*J$@/]MVI]()?YI5^@ HHHH ****
M &. 5.<8QS6'H]I817<LMO=>;,7?(( (R1Q[X_K6ZX!&#7(^'Q"FOWD,,IG"
M%F8LK QDGIR._MZ4 =:<@=JY/3IOM'BMY(7BE6,2*PCDB)'(Z[3GUZUUF:XW
M2=0N$UZ6S@B+QF9]Q8R'8,^XXY_"@#M,T4#ITHH 6BBB@ JIJ'_'DX/3*_\
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MJH,?O)2&-,U;Q5=M8RQFU@VG'S++Z$4Q';6PQ:Q#&,(./PJ)S_Q,HAG@Q/\
MS6N'?QWJ,*!4L;+Y0/\ 67.":P;CXC7[^(8[>>.WC@:$C;!<X8Y(Y4GJ>.@]
MZ0SU[(QQ5/3@P^TEAC=,3^@K+L-<E>PB86-Y,-N1)@-N_$=:JZ%XFEOUNF;2
M+V,K<LA#+TX% &Y+_P AZT/;R)>_NE:%8]]<M!J=M+Y$DG[B3Y4&3U2C^VI,
M9_LR].>WEF@#8HK)_ME\X_LV\'_ *3^VF ).G7OT$1H UB0 22 !U-(DB2#*
M.K#U!S7.&_CU*ZG%Q97)BMD5_)>,Y;<3SM[XV\?C2/J.EI=QS6FT7C#+QYV2
M;<@89#SW]* .C?D9KG--A']LDK?;S&#^Y\M00"QY)!R>E= 1D8/&[M6+I L8
M;^:&&*[CF+._[]6"GH#M)&".!TH VY1NC(R1QV-<GH<<D6O2(UXT[J7\S==;
M]W(VX7/&!P:ZU\A"0"V!G [U@Z5+8R:HKQPW:3.KA3*IV\-\WMU/Z4 =$.E%
M%% !1110 56O_P#CS?ZK_,59JM?<6CY]5_F* +-%%% !1110 4444 0W7%I-
M_N-_*H]-.=+M#ZPI_P"@BGW?_'G.?^F;?RIFF?\ ()L_^N"?^@B@"U1110 5
ME^'_ /D&-_U\W'_HUZU*R_#_ /R#&_Z^;C_T:] &I7,>/1GPT1_TV2NGKF/'
MG_(MG_KLE &9X*A:XTN6 C$?F99_48'%=Q'&L<:HH 51@"N5\ X_L:7_ *ZG
M^5='<7/D *H+R-PJCK_^J@"GK./+0QHLMPIS'&1][U__ %U3T!+$6_F%XS<-
MG>'QN7GICM6O!;E0TDK!I7ZGT]A7.^)8DL= C>2)'=9TR>^"U '3NZQ1EV8!
M5ZU5CC:]=995Q$.40]?J:(HVNW$DG$(^XGK[FKO;I0 8'.*J3/\ :)#;1OAN
MKD=A3IYV:3R(>9.[=E%2P6Z0(0N22<DGJ30 Z*)(8U1% 4=*CGN%@0$\L3A5
M'\1I;BX6!,G[QX '<U'! WF>?./WIZ#J%H Y7QW:D^"]7NI\F<VS!1R=HQT
MK1M/%>D?88#]I8?( /W3#D=1TK8U"V6]L;BU;!66,H<^XK$M["&^UZY\R$+;
MQ@84CAO_ *U "?\ "4:/>N2]T1;CH#&P#<]<XZ5J#7=, &+E0.W!Z5;%C:@
M?9X_^^1Q5:YCA0B&&WC:5_;A?<T 8^OZO:75HMM;7 :0NI.WJH!R3]:NVVMZ
M-;H(([E1@\Y!Y/O5ZVTRW@7F)6<\L2.IITT%I#&6>&/CI\O)- %*3Q1I$*,[
M7BC!QC!JK#XATF1A=RW8WCA5*GY1_C5^+2H)I5N;BUBW+_JUV_<JZME:KC$$
M8Q_LT <9XSUFPO=%@C@D>3=>0K\J' _>+D$X],UU4:+?0HN1Y&.2#D2#Z^E8
MNL^%K+6+I)$A6!D9%>5#M9U# XX^E;5I(;69;&:3>0N8V/5@.U %U%"@*,
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M1X\N/'KQFGZRPCLYI;HN&V$Q*B%MA]3BLFUO)KG3KIYY7*H0RK(P!7G\Q^5
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MS'+Y>\?,=LP?)R>P^[^- '2G_P"O7):;-(/$RO<_:I7?S47,#^7!R, -C!W
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MJQQ-(<X49.%)/Y#FN5T"4W&L2F.X<QHS;XSOZDY'5!C@T =A10.E% !1110
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MGMM-M]TKK'$..: ++,%7)('UJ% \LOFN<+_"O?ZFJ<6HV=RPDDN80H.47?\
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M\_2L/0])ET[4[EY)(2'Y"HX)Y_V=HP/Q/6@#HJ*** $R,XR,^E+3 JB0L.I
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M&WB*,9<]^PH >\F6\M3\V.2.U+'&L:[5'N:2.,1KZMW)[T32B)"Q!..BCJ:
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M(9>.=Q_I2&>DZ#_R K/_ *YBGZL<6+?C_(TS0/\ D!6?_7,4[6/^/$\9Y/\
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MEF2%'6XD';_KE6$/'UY#X@N1=1VT=J88\F%WD,1R>Q1<Y_#&#UH&>FU3TO\
MY!\? ZM_Z$:QK;QGITL(++=;\<XMGP?H<4WP[XJTS4+%%A-PK!RI62W=>=Q]
ML?K0!KR@'7[0]Q;RC_QY*T:RKV\AM-4MI)B54Q2#(4L>J]@#3O[?T[_GI+_W
MXD_^)H TZ*S/[?T[_GI+_P!^)/\ XFC^W].QGS)?^_$G_P 30!I9QFFY]ZYR
M^U&WU*VGEC=6@MW$925WB#.>3VR>,8Q[U6TFZ>&Z9XA!' Q56A261F)YY^<
M^G2@#KA2TB]*6@!DO^K;DCCJ*YG00T.J21202LQW8F9B1UZ#(&."/RKIW^Z:
MY_2-1>ZU::*.XDDB7.1,N"#G^#CD=>?I0!T5%%% !1110 4444 %(:6D- '!
M_$&?RKFPW&'!63;Y@+!3\OS%0ISTQ[9KK-#>231;)Y2AD,*Y*# K#\7V&H7,
MUK)8V\<H575\P^8W.,<;UP.N3D_2M_2(I(-+MHIE195C =4SM![XS0!>HHHH
M AN>;67_ '&_E3-/Q_9MKCIY*?R%/NB!:39''EM_*H]-(.EVA' \A/\ T$4
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MZ3;D(HY( ^G%5X]/N'\9&Y\Q7DBC);MPPQQUZ9K?BA,2F:YE5YB,%@N%'T%
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MX_#.NQ2>8EG+O(VGH:]2_M>$7DML8Y=T?WFQ\O3-26U^ES/-'$C$1<,YZ$T
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ML-)=PS6*[3N6T:+)&>!ER>XSQQCOGCJ:* $7ITQ2T44 %%%% !1110 4444
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M:&9]0%T=-ESN#XWK@L._3@X]* -$:=.P!&JWN/\ @'_Q-*=-G_Z"U[_Y#_\
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M:>"_%T-/G9@6PK2*0,_AGCI^- %K^P;O_H8]6_\ (/\ \;H&@W?_ $,>K?\
MD'_XW5K[?>_] R3_ +^#_"D_M"\S_P @R3_OX/\ "@#F+WP_=MXJM5;Q#J)5
MK63:<19SE>OR8*\],>G-6M+\)S:;I<-M-XBOPRDG \G:&)XV@Q\?G4EU?:B?
M%EGMT>1D%M)N<R !02O3CDYP,>]37T%Y?7]E=O92C[,6/E>8,,2, D8ZCJ*
M)AH4IEVGQ%J9D*GC,&2O?_EGTJE::!.FLWZIKNIH?+B^9?)!_B_Z9U?@-W!<
M23G3I))&4*&9QN [CIWX_*C2[NXN/$.H)+9- JQ1?,SYR?FH GT+3+C2X)DN
M+V:[:69GWR[<@'']T#TK7HP** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H/ S12$
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M6.-#T_/_ %]__6I!J/C/OH6G_P#@9_\ 6H ZJC ]*Y7^T?&?_0"T_P#\#/\
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MW&6CE&?*>(*K;L$YZMCKVK.OM4EA6QM#9Z;;O=^8S13)YJ[U; QM('(P?QH
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M)HEURV,%L<8)ST]JFOD\1I&B6KV$LCNH)E"@A,'./4G^E2K'KWDYD:VBD5@
MI"D,,'H<=2<4 /UCQO9Z/)'#);S23R(CK&H_O9QD]NAIFH>.[+3["QN9+6X9
MKR-Y(XU4Y^4@$$]CS^E)>KXG_M99+%+&2S$(!#XW!L'(R/?'ZUK3FZ&CCR3
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M ]R6/4^:N?SQ48U&_P!N1X'N!ZCSE']* .!EM9+6WN$!C",@$<:N'.<Y.=H
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>69
<FILENAME>tm2110724d11_ex10-20img003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2110724d11_ex10-20img003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *( ?(# 2(  A$! Q$!_\0
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M^E_QH^T2_P#/I+_WTO\ C6:;#72>-=B _P"O$?\ Q5)_9^O?]!Z+_P  1_\
M%4 :?GS?\^DO_?2_XT@N)2,_9)?^^E_QK,_L_7_^@_%_X #_ .*H_L_7_P#H
M/Q?^  _^*H TC<SYQ]CE_P"^E_QH^TS?\^<O_?2_XUF_V?K_ /T'X?\ P '_
M ,51_9^O_P#0>A_\ 1_\50!I_:9O^?.7_OI?\:#<R@_\>DO_ 'TO^-94EKK4
M*%Y/$$"(O+,]DH 'KDM2P0:O.@EBU^WEC/1DM%(_,-0!IFZE_P"?.7_OI?\
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MD_\ C= %HZ[:"+S"MUC/_/I)G_T&D&NV>,[;O'_7G+_\3582^)S_ ,N>C_\
M@5+_ /&Z42>)^]II!_[>I/\ XW0!9_MVR/\ #=_^ DO_ ,32C7+,KG;=?^ L
MG_Q-5O-\3_\ /GI/_@3)_P#$4WSO$V>;'2\>UR__ ,10!:_MVR_NWG_@'+_\
M32_V[9_W;O\ \ Y?_B:K&X\1#_EPT\_2Y;_XF@7/B+'S:=8_A<-_\30!8_MZ
MRY^6[X_Z<Y?_ (F@Z]9?W;O_ , Y?_B:K?:O$&?^0;9D?]?!_P *#=^( >-+
MM3]+@_X4 3GQ#9!2Q6\P/^G*7_XFD/B*P4J"MY\PR/\ 0Y?_ (FH?MGB'_H%
MVO\ X$'_  I/M?B#_H%6O_@0?\* +2:Y9R$!1<\^MK*/YK36\062RF/%T6]K
M24C]%J%+K76/SZ9:J/\ KN?\*<;K6P3C3;<_]M__ *U #QXBL2Y79>Y'_3E+
MC_T&E.O62J&8W"KTR]M( /J=O%1B\UOOI<'X3_\ UJS-?O[\:-<1W5B(DD4
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M3)-2\9S6[2L&.WE6( X'O7H27;L,_99A[''^-<;!.7\>RLT++@C@]1Q0 2^
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M8LCLW\UH Z/\**/SHH S]5 +6&3_ ,O:X^N&K0'-9VKC,FG\XQ=J?_'6K1%
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M:(K/U7_6:?\ ]?:_^@M6@* %HHHH SKHC^V;!< G9+S]-M:-9MS_ ,AS3_\
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MO7'2HXX4MY9I%QNE() &.@Q0!.S;>!][L*$3;R>6]:2-3]YOO&AW(X49;^5
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MDC7$A##"#D'LU6#M1>N *SA<RJR%T"HO4@&G_:OM$AWJRPCV^]0!84FX/<1
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MB3G\,5//;^'[C5"C7/[PS;I'+?Q'^$4T)G9)FX4#&(@!]35CY47L *10J1@
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MAGC18=_[LK 4)X Y.]L\ =A5+Q@A=;=1D?N9>GU2MVVO!<7$D?V6XCV$Y>0
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M$2 JRJ[;2/\ =S@?A6OQ&OH .E*[+'&68X51DFHQ^]8$_<ZCWH :J&5A)(,
M?=6IV8(-Q[4,0BY/2F*"YW-]WL* $53(=[=,\"J\TBQ:BI.2?*.!_P "%6V8
M*N3^54F4G4HYI!C]T448]P?Z4 68HV8^9)][L/2GS2K$A)Y/8#O22RK$N>YZ
M#U--CC);S)/O>GI0 1H6;S9/O$<#TJKJ,OEO %7=(7& *NRRK$O.<G@ 55>,
M)/"[#+LW)/;B@">*!4)=AEVZFN1T=8SXVU0R 9Y^\!CM77RR[1M49<]*YOP_
M&&U[6!*BNX<?,1TH Z1 ADW!0,#&<5%<6GG312+(R-&<\ $-]<U:     Q52
M^NS:!6"ABW YQ_0T 2\XV2[3GH0.*AEL_-3F0B0,&W ?I]*J?VG*Y5&B0$D<
M\^M79+LHJD1$DL%YX% $Z_*/F(SZUF>(--DU32WMXDC=R00LI(7]*T,2G&2H
M'I4U &=9:8D"6[OGS8H]F%8[1]*EN=/CN9!(7D1\8W(V*NT4 10J5B5222O&
M37-2MOUBV+-DB] _\<>NG93SMX-<U-"8M9LP?F)NP<_\ :@1TXI32"EH&9NJ
MG$VF^]V/_0&K2[5FZK_K]-_Z^U_] >M*@ HIN>?:G4 %%%% !1110 4C8VG/
M3'-+3)>8F&<<&@"EITT$BS>0FU5?!YSS@?TQ6/XIV_VAI6<_\M/_ &6K/AQ<
M6]RP*'=.WS*3AL  _P JK>*,G4]*&S*DR9/I]V@#I\44GS44 4+XXU33QGN_
M]*T16;? '5]/!Z_O#_*M(4 %%%% &9=?\A[3O^N<W_LM4-?"-KNA!QD>:_\
M(5?NO^0]I_\ USF_]EK/U^7R];T,E2W[U\8'L* -75G5-+N"2 -M6+3_ (\X
M?]P?RJGJ$.[3YY9.6*?=/05=M?\ CTA_W!_*@"6BBB@ IN[V-.HH ;N]JK74
MWDF-O+D?V09-6ZB?[Z<<<T 5AJ!(/^AW0QZH/\:Y#0IB?&FH,5<#>YP1@BN[
M[5PFDJ\OC2_2-MJEWW$4 =3J&I+#$WEJ['.W<!P*M6Y00+C<P(SN/>GF")83
M&$4H/X2*-JR?*N-@X../PH C=W?B'@#JQ&0145E?Q2R7$*+@6[^6QSGMUJ\0
M%7CM6'I4HN]3U4I@1B=5) Y8A0#0!KM)YA"KG!ZFG;EC![ 4_ "^@]*CVF5L
MM]P=J &A_.' 95]:>TB1IECA1WIY(49/2HPOFG)^[Z>M #5D$V&PVWT/>I&=
M8TR>!3F*HN?3M4:J7^=OP'I0!7O)ECM9)IE;RE4DJ.IJ1;J+RD<9 ;& :DN"
M@@?>H88^Z1UI(TW*K$8&.%QP* !3O.YL^PI9)UC(!R6/0#O3GD"#IR>@H2/G
M<QRW\J &I\[;FSQT!JO>ZG;V)"RL=Y!*J!UJT[[".,GL!5>6QBN WG#YV[@\
MCZ4 48-1M#<^:TVXL.<YPM6)-9LD;8)E:3L #S52YTN%5*QO*TC#Y1D<?I5R
MRTR&"%0ZAY,?,QH ;!?6Y&^2<&0]L=*ANM4@>:%+9A+)N[=!5R6*)&"1Q*7;
MC'I0MA%''A$56W;BP'4T 2*T<"!Y7 )ZDURVDZG:V_BO4;>67#W$G[H?WL D
MUO:@1>6TEM$59A@L>F,5S.IV,$&NZ&ULJH3+DMC);@YH [C>H%5[B_MK8J)I
M0A<X4'/-60!CI56XV?:K;*@G<<'TX- #_-CE4;3E>N>E0WSAH1C!P0>:R;[7
MKR#Q)'IT$$3Q$*7+=><]\\=/2MB^8^0,$C+ <?6@"%KMT0DR@ ]]M0G5%5<F
MY7CK\AK0$)\K:0"?T/X5!%"PN)@=NW:A ''K0!535XWQMNE.Y=P^0],X-2IJ
M:.<+<*3Z;#4JQ_Z21\APO11T&:E3:;H 8R%/ 'TH IMJ.UL-.HST&PUB7&H1
M#5;)Y)P0MP68[>F$:NHFAWMC')'7TYKG[J%/^$@LQM!_TG_V1J!$A\?>&58J
MVJQ@@X(V/Q^E+_PGGA@@D:M'QR?D?_"NA\I/[J_E08TQ]Q?RH&<?J/C?P]+<
MZ>JZDA*W <G8V -K#T]ZZ*ZU+99QR6X$DDY"P@\ DY(S[8!J/4[:!FL5>!'3
M[2."H('RM5C4+;[5:E$;;*#OC;/1AT_S[T <S+<Z?';M=W.KW:W(G,'G;L!'
MX^4(/E(Y'4$\]:Z+3;V2YADCGP)X)#%)M'!( .1^#"L-X(9+LRS^'9GOR021
MDP,P_BR3@=N<9XQ6YI=K);02M.%$TTAEDV]-Q '\@!^% &@#D9I:!THH ***
M* "F2C,3_0T^F2G;$YXX!/- &1X?7_1K@D?,9CE<\#@#U/8"LWQ3*4U;2%4C
M#,P/Z5IZ%L,,SQ1P(CR;L1Q[<G R3ZUF^*-IUG1_E4OYA )[9H ZC+]MN**7
M8OI10!G7P']L:<2<8$G_ ++6D.]9UZ3_ &QIX S\LA_]!K1 H 6BBB@#,NO^
M0[I_//ES?^RU5U[3[ZZN+"YL/*\RV=GQ+G!R!Z?2K=S_ ,AO3^!_JYO_ &6K
M[?</...M '.2CQ/<0^5+%IH1AAMH8'_T*NB@4I;QJ>H4 UY_HT6BK?A[B;5)
M+[[3(QD^V3^5_K& ^7?MP,8Z8XKT-<;1B@!:*** "BBB@ J"6,2.@/3GOBIZ
MBD9@Z87/6@!#;I@_>_[Z-<=H,21^,M0 S\KOWKLB[@?ZL]/6N!TV2=O%U_LC
M< R/NV]>M '<S9N$:)#@'AF%3*HC4!1Q5'[:\,7RV4H4=L=*9_:+SR +:3F(
M=2%ZF@"\<S9'(C(QGUJK8P1P7E\R+MW.I;TX4"GM?-&"3:S$ <[5Z51M+J>>
MYFD:TG6!F!7<N">* -?F0XQA/YT\D*,GI4<,N^,DQM&!V88I0/,PS#Y>RT
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MOSTI(YH$?9YJF3OD\T 3H@08 IK,6.Q>I[CM3#<+)Q$ZD=VSQ3TV(G5?<DT
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MYX7G\#5R@#$NK2VC*?:& R=J[Y3R3V'-%O;07.3"PDV'#8E)P?SJIXH1FO\
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M<_(!@'W'->ICI7ENE6$L>K6DTT#/'+-'+&SW#%HT+/L7KT&#Q[UZDGW1DYH
M6BBB@ HHHH *X;QN5;Q%X67@E;MB1[8%=S7!^-8_*\2>&IX^)/M+Y]Q@4 =V
M#1D5$%('S,,U'."L1()H L\&H9YS"T8"YWDCZ5'I[,UFI;.<G.?K4D\@C:/*
M@Y/4]J '*[F+)7!["L/4[HMJ>G1/%D^:&!'3\Z=XKUJ;0=(-]!''(5<*0X)Z
MGVJ"&2VUVPL)KO"220).'AE,>TL.@P<T =#N=?O $>U$<C/U3%<_)I]E%"6_
MM"\P #DW\G_Q55WM(4C9H[Z]P=V!]KD[#_>H Z9IRC@%" 3@4\,_]WCTKF9+
M.".>)?MMVQ9F&3=OQ^M:L>EVQ08NKMR._P!J<_UH M0W@GFD2,<1MM?(Z&I)
M)'1N$R*R-)6&#5KV.+S>OS^9,7W-GKR>*VG8*A)- #P<@&J6J/Y=@YQGD#GZ
MU<'0$53U7!L'!/<?SH N+T%<KXAMKF^\0V%G!?SV@>)CF)L=.:ZI>@^E<_J#
M(GC#3G=@ (7ZT 4F\(WXY/B?4P!URX_PIB>%M2F8_P#%2ZD$'1@PR?TKJ%0W
M!#N"$'(7U^M3LPC7G\ * .4?PE>JN3XHU4 ?[8Y_2H$\'ZA,A_XJ;554G((E
MY-=<L1=O,DY/8>E.DE6)-S?D.] '"Q>$;ZYA>23Q7K$87(PLV,U)'X'OY@'D
M\4:N0>0OG<$>]=-I<#NC2S'.YOE7TJ_-*(EX&6/1?6@#E+6R\0:-!(B744T>
M?E:7EC5Q3XJ90W^B#V(I/$L]WIVE_:X1OD##=\Q&T>V*6RUQ8--B$T<OVF1C
MB-SDD@9SGTH J7UOK]P8OM"6KE7#( .XYJZ!XHP#FSSCIBM:P8SVZ7#9WOS]
M*FDD(^2/!D(R/:@#GY9O$T04?Z(6;@*!1I.DZEI]K)YC0AF8L<#)&?2NACC"
MC+#+=VQ3;EG,9CB_UC @''W: (XI"D"(@W.1SC^=3QQ[!DG)/4U':QM# J.O
M(X+9ZT]W+-L7KW/I0 KR\[4&7_E1%%Y:GG+'J33D4(N /QIA(D.Q3@#KB@!L
MDC.YCC!SW;TKA]3MXHO$T87))F3)/>N] 5!@<"N U65I/%2A3\BSH,_@:!,]
M!%*>E(*6@9E:R[(^G,J[B+L'&<9^1Z;;:X9M3BL9K7R)98WD3=*"6"E0<#VW
M#\Q2ZYY>=/,P4Q_:QNW#C&QZH:2EG<ZA'>".U@N4$D:Q11IDH2.=V,C.!P#B
M@#I:*** "BBB@ HHHH *CE8^4Y&<[2>.M2'I5:\68V<HAV;]IP'!*T 5-%D,
MED69&5MQRS8RWN<<5E:X<^)=*&[ \V,@#ORU6O#"R_8)3*8RYD_@! Z#J/\
M/KUS5;6_F\3Z8,?=DC.<^[4 =/D4444 9UT/^)_IQ_Z93_\ LE:59US_ ,AW
M3_\ KE-_[)6C0 4444 9C_\ (PQ'_IW/\ZO3!S"^P?-M./K5%O\ D88_3[.?
M_0C6G0!P5C%KLU]9DQWD<,$JI*LT0PYW,689'W<%0,>E=XN<<]:6B@ HHHH
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M12=Z .!UNPDO/%4VR\N8!YL2XA<K_ O-:C^#I&1@->U9&;DLMPP/\Z@O-O\
MPE<HXS]IB_\ 0%KL,8'I0!PUWX9"2R1_\)AK,+Q#S&_TIB5!^IZ5*/ U^3G_
M (3'7<'_ *>#1KT]M#K=Q%=6Z3-+&HA4<$G^Z<<XK;F\000:C]B*H'R%.^55
MZ^@/6@#'/@?4,@_\)AKG'_3:E'@C4,G'B_6P.W[ZNOSTR *7K[T <@/!6H#&
M?%^MGU_>US=AIFLWOC'4-'/BG6%@M<$.)OF.1FO5,"N,T&%I/'GB*=6&$=$(
M/NE "_\ "%:CD ^+];/OYM'_  A&HX_Y'#6O^_E=D!Z]:7% '%GP1J148\9:
MV#Z^8*0^!]3./^*TUP#'/[P5VN*,4 <2O@?5%0K_ ,)KK7/^V*KV.@W-AXEA
MM;C6+J^<1%Q-<X+ >E=]BN<E;RO&2G/6W/ [T 7#8/;J&^T<CI\@J6&SN]WF
M/=L6(X&.E6HXV<B27[W4#TJ1VVCCECTH H3_ &FW4-]I+D'A=HYJ=@T-K-,Q
M)E"%C['%31Q;6+-RYZU7OVE^RR10@/(ZE0/3(H CL+QYK&)WYF8?=%78H@@+
M'[S<DUFZ!:^1IR,YW3'[Q-:,DAR4C&6/4^E '*^*;QHM(2"V+"9I=X(;!4*"
MQ.?PQ^-<_=VWV_1M.:))Y;AY&; ^]NQ][*]<5TGB*VA6SM2UM)/&96>6(';O
MPC'FJ4EJ^IZ5:C3;:6#RMP$2RX*9'7- #->M;F3PG96<B33SJ5\V0JQ9!SDD
M=3Z?C5_P+9-9Z7-FU:(N_P!]E*EP/8UM:-9-8Z9##,2TP3YV8Y)^IJTS-(?+
MC/'=O2@ =V>0QQ=/XF]*?Y:QPL%'&#D^M.1!&F%Z>M07#/+&\<7H<MZ4 $1\
MZ(*HP@ZGUJR $'' %16X$5L@R, =30Q,QVC(3N?6@!=WFY ^YZ^M/^6-.P44
M !%] *9_K6&/N=_>@!,&;J/W?IZUQ>I*!XMBQ]WSEX_ UV[,J+EB !7!W$IE
M\8(Q&%\\8S]#3$SOQ2T@I:0S,U%@E_8.S!5#MDGZ5:AO+>>39%/'(V,D*V35
M'5U9[RQ151B2^ _0\=ZR--M[G_A*K><+;K:K;2*?LL3>6S%EZMTR-K<4 =;M
M%+THHH **** "BBB@ J&X+"!R@!(&>:FJ*>(2P2(3@,,'/I0!FZ/+/-'*\N-
MK-PHQ\I]/RP?QK)UQ6;Q5I_S *K0<>OS25JZ#I]OIMBT4 AP7))B[^F>Y.,5
MF:P ?%EGQT-OC_OJ2@#J<KZT4<>E% &=)G_A(HN./L[<_C6D*S9"?^$BB7!Q
M]G//XUI"@!:*** *"#_B>SGC_CVC_P#0GJ_5"/\ Y#DQXQ]FC_\ 0GJ_0 44
M44 %%%% !1110 4444 %%%)0!Q]U_P C7-P/^/J+_P!%K77DXKC[HC_A*YO^
MOJ+_ -%K77L,_G0!S.N:?=3:JEY%;K+L0*F%!&>X:L36K*)O'<3&X@1L(RK+
MDA0 !MQ^M;'B6+4TNQ/;K+) 5 .P_,I'<"FZIKTUGKL=D%A3>Z@-)_$N 3SZ
MYXH 9XRUJ^TE[9K:X2)&SD9&2?Q[5O:%>2W^@V-W.T;230([M&P*$D9.".HK
MD_'B*+NWD6Z@MY-AY>3!(],>E=+X6\UO"NDF1][FUCW,.YVB@#9%<IX;4_\
M"6^*#V^T1#_QP5U?2N7\-@'Q1XH/_3S&/_'* .H%+0** "BBB@ K! 5O&1R
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MR: -]B;G*J2$'4^M2%%$97[J@8XKGUUC547 T.4 =!FHKG6M7*#.D2HN>>:
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M/- #J*/PHH 2N.23?XM56'2YX_[X-=B>]<7 "?%H.<_Z0?\ T&@#M!WI:**
M,VX/_%0V(_Z83?SCK2K#UB0PZG;2K*T16VF.](]Y'S1_P]ZIZ1K%Q<Z_)9&[
MEN81;B0.UN(P"21C]* .HHHHH **** "BBB@!#T_QJEJ9G73YC;A&EVD@.2
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M@!:*,T'D4 4(R/[<F'?[-'_Z$]7ZS8_^1DN.3G[+'Q_P-ZTJ "BBB@ HHHH
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MBPL=4T'[-?>>J,28Y(HV<HP!P?E!Q7.ZZ^L>'?"FE_V7-->V\:"&6:,#?\S
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M_0WK3K+A(;Q)<XZK:Q _]]/6I0 4444 %%%% !1110 4444 %(:6D[T <C:
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M-8?)$45/-C;(8+Q0!?!P<4ZLRZ?4(DWP0K(0/N#&?UJL=0U=4W-IIXZ_,O\
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MR#/_ &SC/]: .GQ[T48HH S(3GQ/>#'2TAY_X')6D:RX"?\ A*[T=OL<)_\
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MUJ$D]L""(2N,XZ;CWK6"@#@?A3J* "BBB@ HHHH 0]*JZ@TJ6,K0J6D ^4
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ML8_[]1UKT %%%% !1110 444E "T4G/I10 M,8,74@_+W%/J*<D1$C(/J.U
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MG):/T;O_ $H ]!HKFI/%KPR-&?#^L.5.-R1QD'W'STP^,B!D^'M:7_MC'_\
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MD@4M8C2:O8CS[J6"YMQ_K$BA*L@/<$L=V/H/Z5LQNLD:NARK $'U% #J***
M"BBB@ HHHH *Y6T4CQI<$[N9I/\ T3#755R=H1_PG%VN3GS')S_URBH ZO</
M6BDY]J* ,S3V#7^IX!RMP!G_ ( M9%UX,M]0U*XN)Y72&6;SO+4@Y?:HW9(X
M^Z!CGIUK8TY0MYJ9R>;GI_P!*COO$NCZ7<M;W=ZD4B@$J58X_(&@#FM2\!3Z
MU9V\$VI&VMX_-5X%A5BP,C%3N/(X(K<\)>&O^$7TR6S^UFZ,DWF;V0)@;0H&
M![**7_A-?#I_YB:?]^W_ ,*VX)8[B&.:)MT<BAD8=P>AH S]+&+_ %<[B?\
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M!ND/)/TKIM+_ ./W5>?^7O\ ]II7!^.M4O&UI[,7$B6T2@^6AP&)'>@"W?\
M@J&6 R:-?"9U&UHW8'/TQ7=:9$\&E6D,BA9(X44@>H %>+6&H76GW1GM9VC<
M$' /'0=17M>GRO<:?;3.07DB5B1TY% %;2V!O]6Z\70_]%)6G67I1S?:OQ_R
M]#_T4E:E !1110 4444 %%%% !1110 4E+534;S[#:F4(9'/RQQ@@%V/09H
MRM5O+:W\1Z<LUQ#$3')@NX4GCWKF/[2EO?B#>HEV!9B,*K"X"A0$!![@@MGI
MR/TJ>]LH-3\0QW%WJ6G?VI$&BCA:V+QH"?N%B<,P/?CZ"M[2K#3KI)(+C2K6
M&ZMSME14!7D9R#CD$<T 4H))-0NR=7N;:W8P@'[+=Y7(<D<G';VJ[>:E9?\
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MLK\T..Y^S9_]GH Z_-&:X_S_ !B"!FUQZ_9#G_T936NO&@3/^AY]!9,?_:M
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M ![1'_MU/_QR@#K:*XR;6/%41'_$N\S/]RUZ?^1*C&N>+"<?V2W_ (#?_;*
M.WHKBAK7BPGG2B/K;?\ VRE.L^+!_P PO_R7_P#ME '9GI7$ZI90O=6-WY-J
MUS8.Z&WNW"K,C @D,01GOT/0CW#VU?Q801_9@Q_UP_\ ME07%]K]T +G0H9\
M'*B2W! /KRU "V%F2+T6T$,;7=[%*L4#[E148,22!@9 /%=SFN(@U76K11'!
MH$<2=Q''M'Y U,?$>OKUT8T =CQ2UQQ\0^(< C1E/XFE'B#Q"?\ F$)GW8T
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MKXPNMN6TZ >PN7/_ +2H ZVBN57Q;<E2QTZ$ ?\ 3P__ ,:II\8RJ<'3X_\
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M*ELDX.>#6U)>:PHCB2XTYI1$9WF>)D1ES@*!N^4_[1)^E %C^T/$/_0#L_\
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MHO\ 6@"O_:NL?] +_P F?_L:/[4UC_H!?^3(_P#B:V\4<4 8G]JZN!_R _\
MR9''_CM U;4\X_L-\^TP_P *?X@\16>@6GF3R*9GR(H<\NV,X_2L;P/JUWJX
MU&XNY=[[T*J. @.>!0!L?VO?X&=%GSZ>8*!J]_QG1+CZ[UK!\)>,HKNZDTG4
MIE6]61A"Q/\ K5R3CZ@"NWS0!C-K-\/^8)='Z,M-_MJ__P"@#=_]]+6UGBER
M* ,3^VK[_H!7G_?2T?VU?8_Y -Y^:UMY%&10!C#6KPGG0[T#VV_XTHUFZYSH
MM]^ 7_&MC(I,CUH R!K<Q(']BZC[_(O'_CU+_;<@7/\ 8VI_]^D_^*K7R,>U
M&1ZT 8QU^5?^8'JI^D2?_%TW_A(),_\ ("U?_ORG_P 76T&'K2Y'K0!B_P#"
M02?] +5_^_2?_%THU^0G_D!ZL/K"G_Q=;-% &.-=D89_L75!]8D_^*I?[;<?
M\P;5/^_2_P#Q5:]&1G&>: ,G^VW(_P"0/J?_ 'Z7_P"*IIUZ0#/]AZL?I$G_
M ,56P<4F1U[4 8W_  D$O_0"U?\ [\I_\74^GZNM]<S0-97=K)&H<BX0+D$D
M#&"?2M/\:RHS_P 55<#O]BB/_C\E &I\U%&<<8-% 'G'CQL^$O$7S8(OEQ]?
M+3_&N5TWPGX?UFZ@ELM4LM@L@DML6<'[1W?);WZ5WFM73V>D>(W2P74&:\V"
M%L8YBCYY]*\NT[P/J^I1Q3M'8V<)DRMQ/+AQP 0 #@CCZ^] 'JFA:%<>'_ :
MZ==.DLL>23&<@Y?(K?UCAM-[#[8G\FK,TW29M$\')87%ZU[)&,F9L\Y;/&23
M@9QU[5I:R,_V=QG_ $Q/Y&@##M_%-Y'J#VUW9*\)G>-;Q'*Q !L!>A.?7WKG
M-<9$>SQ-;QL6G&^YF<!#YSX*HO)/7N.U2 6;>,O(:^OQ \A/DNH\O>&.0!Z=
M.QJAXET>6_>U:$'ST>4H3"64'SG^\P(_  ?C0!U4]M#9Q03I=6LBR6J++ X(
M\Y.>%)/ R2>03SUJ75_$-QI4-NEI';VEN(XLM<(6\H$D= PR  .],+^<MG;W
M,L<$\<"1B6XLP1*P Y4DG YZ&H_%%O'<,UM*?D>WB!=%3<,,W*EL@4 6]'U&
M^U&XADNC#)"LY$$\431K*NU23AF)ZDC\*UM8_P"/O3/^O@5S?A9XEG\B%+@1
MI=,%>>;S&?,:$GK@#)/ P*Z75B1=Z8 ,_OQF@#6HI!2T %%%% !5+48(+JV,
M%Q)Y:/W! /ZT_4',=A.X8@JA.16!>RVU]/H^]H)HR&+[Y< ?*/0]: ->;2K6
M[5/M@%V%SL,RJP&>N!C%,CL+:W-L?M#;;5=D:,5P.,>F<_C61<WTL7BB)(C,
MMG$!;.$7]WN<94YSVSZ5EF%(=4TVRG\FY;<_FS&Z8"8!?O,,X#>U '5+I$*R
M+-#/-&P9FRA4[MQ)/4'UJ"7PWI=RDH:)6:7S-\BXW'?G=S^-6=1_T;0+@VPR
M(X"$YZ@#CD5S.GVUY96]G<30K86[R0+Y8NVFW$L,L2<8R.,<T =!-X=LI+V:
M[3?%-*RLS(1U4Y[@]ZT;>TBM[-+6)=L2+L49S@#WKEM>U>6/6K6.V%R\,(!D
MEA :-=_'S\]-IR*7PS>WIU;^SKJ9Y#;62G+?\M,M\K$^NW&: -J;0K:3[KS1
M$F,[D(ZH05/(Z\"DO-#BO599YYI-\31.3M^=3S@\?RJQ?7TUFZ+%93W.>28P
M.*M1L98%9E*;ESM/4>U &;#HMK$K1K+))%YOFB-B"%.<_7\ZCM/#UGIZ8LY)
MK<[W;<I&1N.2.0>,UCP036'B6[.G0/.6;YHYKIE4<=LY_E6+]LOKO89+>:^=
M1&_V=;MHLGR"Q^8#GGMB@#T)+2-+E+@LS2)'L#$]1UYI+^S-];^4)YH02"3&
M0"?;D'BN-A&V*XNOMSF>WAB: B9B#P"%VYPP/3)&:Z/Q%ODT=4",QDFA4HLK
M1D@N 1N7D4 7S80/=FX=2[F$P\GC:>36:GA73;=+I88V07)#2*<.#CIPP(JO
M%*UC;ZU';R-FVB!A1G+E3L)[G)YK/N1]BE@LK:ZF^Q70C-S,TY8J2ZC&3R-P
M)'&,9XQ0!UNGV4&G6$%G;C;%"H51@=/PJU7FVH32QZM)!%'-<P6T3F)_MK1^
M7^\5=QQ][;GOGBO1+8,+:,,^]MHRWK0!+1110 4444 9^F'F]X_Y>G_I3--_
MY"&H_P#74?R-2Z<NW[7\P/\ I#'^51:=_P A#4?^NH_D: -.JU]*T%C<3(,L
MD3,/J!5@]:Y37O%VEVKW.F[Y&N'A9=RKE 2IP"<T >6:A?7.I7TMW>2[I3D9
M/\(]O2F6&HWFGO+]CN'B,J[) K'!&1V]?>JP+,S#81@G@TR,G>O'1OZBF0.6
M)3<)*#('1]RN&P0<'O\ B:]D\#ZC<ZAHA:ZD,CQOL#$=L5XX&[C^_P#T->B>
M"_$-CI6E_9KR0I)),2!CH,#K0-'?7<4LUK)'%*T4A4[77'![=17*M=79U"RC
MDU.Y1;A9()%4(?+E&"#]WTS^==?%*DT:R1L&1AD$'K6'J&S3[V658DD>==\,
M;*.)AQD'W#<^PI%%;^UI+E5LUG>">VW&\E3!*!<<<C&6R#T[$5'9W][Y,SW%
MS*(@1SA2Q9ONHO'IR<@_>'I4BO\ VH\-I]GCM[B1Q)?[!SA#PI/N2"/8&I+F
M PWDL:A0_GB[@,F LAV[67\!C\Z &K<:K"^^^CDMK?HLHG63!)P-R[!@=.]2
MMK+N3&6">1'ONG4<KDD*%![D@_3'O3KR]FO;;[,;62V4NOF37& H .?E_O'C
M';UJ@;5XI+H-(L8O8T\AG7@,C$X;ZY&/QH F-WJD2?:+B&Z2T//F"5&=1V)3
M8,>_-3M?SS-'9F9HYEF3,L0'[R)@Q#<@XY'3VIUQJ-W<6TEJ-/FBE:/:\LN!
M"H/!(;.35."U U2*\C):/,%J">C^6LAW#_OO]* +%O<:@TTW-P$W[8&D=&60
MCL0%!7H>YJ)]6FGEN;B.:9(HK:-MB,H4N7=6Y*GH5J5+N:&(+-:21""=GWGI
M+UP%ZDYS^E9-O83*NH6CPNSFTAD:-/O'=-*VWTS@^U &Y8W\C75I'YTDBW"2
M[EEQE2A X( S][^72H=.N;Q[VR,MU*R3"YW1L%P-C@+C STJM;VWV46;1136
M[&\)@A8Y9(V7YE/7"DC/?MS3K4SVK6[^2\LMF]PDD,8^<B1@RL,GD8H DNKR
M\M[6^F%U(=L:E!A?D)D93CCT I'U"1-3FM/M,X,2,5=F0AF #$$;<@8(YSSS
MZ5!?N[:9J$OE$ 11*?9O,+$>G 85/?RH;N\,NF+]G!$$MW')B0 @'.,9QR!U
MH M3S7$NGVM]]HEB5XE,JQ;<+N'WAD$FJS3ZS,1; F'RR$6X"@^>3R&'L%QG
MW/:K]C)OMI[.0(?)3:I485X\?*1^''X=JHZ8Q>31MQ.!'<<?1@!^0H Z*-"L
M:J6+$* 6/4FLJ)C_ ,)C=#TL(?\ T9)6S6/&#_PF%R3C'V"+_P!&24 :]%'/
MM10!P'BJUOKWPYXFAL%8RF\&Y8SAF7RH\@>_2O+H[*[U* 10:5>+8:=!S;^9
MRTIZG)&,DD=!_#7I7C(7+>&O$(LO.$W]HK_J20Q_=)Z&N%;PGKXU"* 7^H>7
M)8+>>:)9/E; _=_>ZT >F^&;;4K/X>V\&JN_VD)R'.64;^ ?PKH-7ZZ?W_TQ
M/Y&N9\*"\3X:P"],WVCYLF4EG_UAQG/)KIM6^_I^?^?Q/Y-0!0C\*P1:T=4^
MVW+S%]VUQ&RCV'R\?4'/O6(/$USI<9MUMHR@N)!ND+9(,C_-D#H",5WF!G..
ME<_)H-Y-8F%=4N+;+R$I$%VMEV89R-W0@'!'2@"I?WL][:VXFN8[.*XA#M&\
M/F!N3T)_J.]69?#6FZJMI<3!Y8TB4)&X#*1R>0P/K6Y';(+-()D1P$"L,9!P
M/?/ZU,JJJA5   P .U '-6>@V.@ZA:QV491)7W,H  RL:)V'HH/U)K4U/B]T
M[_KM4MT,ZA9G=C&_  SGI4&I_P#'[IQ/_/;^E &H*6F@TN: %HI,T9H 1T61
M"CJ&4C!!&0:J?V/IFT*-/M H.0!"N ?RJ[29YZT 1?9K?;M\F/&0<;1U'0U7
M.C:8Q!.GVI.2W^J7J>IZ5='-+0!'Y:"+RPB^7C&W'&*@FM+6]MQ#/%'+""#L
M9<C(Z?E5E_N-]*\[DT[Q0IC%AF.&WF+DR.6DG4C# C.,]^,?A0!W<=G:PQ&"
M.*)5*@% !R ,#]*>L,2R;UCC#[=NX* =OIGTK(TZVFENHKV6&6-A:",B4G._
M/7&<=*Y>\L_%5SH5G%:J\<MO8&&7S"=S3,NW<,'G'7F@#T0$;L9&?2ER!QFN
M3\.Z??V>K2'4!</(4 $I9BC-CYFZX&3DX J.;3;ZX\1JS0W6T3.9)A.RQM&<
M[5"@XR!@=* .J$$7F&58T$C=6 '-,2SM8&WQV\:GCD*,\#'\N*R-#T^;2_LX
MD>Y?S(55][EU5@.3R<C-9^H66I79U*W*7&-K>4ZN5#9?(P0>PH Z+^R=/$R3
MBUC61,;2JX QTXJVT:R@;UR 00".A'2N!FL?%CWUT$?R[>0R/'DEMJ;"%4\\
M')!KOH]PC7=U &: *O\ 95E_:!O?)'V@C!8,1GC'(Z&HTT/38[>6W2U3RIOO
MC).?3GJ,=O2M+'K1B@"C%I-A#$8X[:,(8S$1C.5/4'/7-74540*HPHZ"E]Z
M: %HI,T9SWH 6BDS1GC/I0!2TX@_:_:X?^E0:80;W4&R?]=W[<5-IY)^U<8Q
M<,/Y51MEFF35H[>40S-,RI)C=MXZX]: ,OQGXGDTJ$65C\UU+]YA_P LU_Q-
M>62O)+(SO"Y9SN8EN<UZ%+\.)IFWRZD)9#U=PQ)_\>J(?#)A_P OT7_?MO\
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MZ7#_ .--_L&V_P">UW_X$/\ XT44 ']A6V"#-=\_]/#_ .-']A0#.+B[&?\
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<+=W=TL\CQK$ B;0 "3Z_[1HHH U,BBBB@#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
